PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chancy, CD; Kekuda, R; Huang, W; Prasad, PD; Kuhnel, JM; Sirotnak, FM; Roon, P; Ganapathy, V; Smith, SB				Chancy, CD; Kekuda, R; Huang, W; Prasad, PD; Kuhnel, JM; Sirotnak, FM; Roon, P; Ganapathy, V; Smith, SB			Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epitheliu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; BRUSH-BORDER MEMBRANE; MOUSE SMALL-INTESTINE; APICAL MEMBRANE; BINDING PROTEIN; LEUKEMIA-CELLS; FOLIC-ACID; 5-METHYLTETRAHYDROFOLATE; IDENTIFICATION; POLARITY	The differential polarized distribution of the reduced-folate transporter (RFT-1) and folate receptor alpha (FR alpha), the two proteins involved in the transport of folate, has been characterized in normal mouse retinal pigment epithelium (RPE) and in cultured human RPE cells. RPE cells mediate the vectorial transfer of nutrients from choroidal blood to neural retina. Whereas FR alpha is known to be present in many cell types of the neural retina, in situ hybridization analysis in the present study demonstrated that RFT-1 is present only in RPE, Laser-scanning confocal microscopy using antibodies specific for RFT-1 demonstrated an apical distribution of this protein in cultured human and intact mouse RPE, which contrasts with the basolateral distribution of FR alpha in these cells, The expression of RFT-1 in the RPE cell apical membrane was confirmed by functional studies with purified apical membrane vesicles from bovine RPE, These studies, done with N-5-methyltetrahydrofolate (the predominant folate derivative in blood) and folate as substrates, have shown that RFT-1 functions in a Na+- and Cl--independent manner. The transporter is specific for folate and its analogs, A transmembrane H+ gradient influences the transport function of this protein markedly; the transport mechanism is Likely to be either folate/H+ co-transport or folate/OH- exchange. Based on the differential polarization of FR alpha and RFT-1 in RPE, we suggest that these two proteins work in a concerted manner to bring about the vectorial transfer of folate across the RPE cell layer from the choroidal blood to the neural retina. This constitutes the first report of the differential polarization of the two folate transport proteins in any polarized epithelium.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Expt Therapeut, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Smith, SB (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, CB 2820, Augusta, GA 30912 USA.			Bridges, Christy/0000-0003-1603-1445	NEI NIH HHS [EY13089] Funding Source: Medline; NICHD NIH HHS [HD33347] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R21EY013089] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONY AC, 1992, BLOOD, V79, P2807; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; BALKOVETZ DF, 1986, AM J PHYSIOL, V251, pC852, DOI 10.1152/ajpcell.1986.251.6.C852; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CHELLO PL, 1977, CANCER RES, V37, P4297; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; DEMBO M, 1984, FOLATE ANTAGONISTS T, V1, P173; Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Fei YJ, 1997, BIOCHEMISTRY-US, V36, P452, DOI 10.1021/bi962058p; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; GOLNIK KC, 1994, J NEURO-OPHTHALMOL, V14, P163; GREEN T, 1984, BIOCHEM J, V218, P75, DOI 10.1042/bj2180075; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HEWITT AT, 1997, RETINA, V1, P58; HORNE DW, 1993, AM J CLIN NUTR, V58, P80, DOI 10.1093/ajcn/58.1.80; HORNE DW, 1992, AM J PHYSIOL, V262, pG150, DOI 10.1152/ajpgi.1992.262.1.G150; Huang W, 1997, INVEST OPHTH VIS SCI, V38, P1578; JOLIN FC, 1987, MOL PHARMACOL, V35, P745; KNOX DL, 1982, RETINA-J RET VIT DIS, V2, P288, DOI 10.1097/00006982-198202040-00014; Liu F, 1997, AM J PHYSIOL-CELL PH, V273, pC1596, DOI 10.1152/ajpcell.1997.273.5.C1596; Martinasevic MK, 1996, TOXICOL APPL PHARM, V141, P373, DOI 10.1006/taap.1996.0302; Miller NR, 1996, CURR OPIN NEUROL, V9, P5, DOI 10.1097/00019052-199602000-00003; MIYAMOTO Y, 1991, INVEST OPHTH VIS SCI, V32, P2542; OKAMI T, 1990, J HISTOCHEM CYTOCHEM, V38, P1267, DOI 10.1177/38.9.2167328; OSTWALD TJ, 1980, EXP EYE RES, V3, P351; Piedrahita JA, 1999, NAT GENET, V23, P228, DOI 10.1038/13861; PRASAD PD, 1994, BBA-MOL CELL RES, V1223, P71, DOI 10.1016/0167-4889(94)90074-4; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRASAD PD, 1998, TROPHOBLAST RES, V11, P243; SELHUB J, 1981, J BIOL CHEM, V256, P4489; SELHUB J, 1984, J BIOL CHEM, V259, P6601; Seme MT, 1999, J PHARMACOL EXP THER, V289, P361; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1984, CANCER RES, V44, P5204; SIVAKAMI S, 1992, BIOCHEM J, V283, P391, DOI 10.1042/bj2830391; Smith SB, 1999, BIOCHEM BIOPH RES CO, V257, P279, DOI 10.1006/bbrc.1999.0452; Smith SB, 1999, INVEST OPHTH VIS SCI, V40, P840; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; Wolfensberger T., 1998, RETINAL PIGMENT EPIT, P103	40	107	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20676	20684		10.1074/jbc.M002328200	http://dx.doi.org/10.1074/jbc.M002328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787414	hybrid			2022-12-27	WOS:000088084500065
J	Lellek, H; Kirsten, R; Diehl, I; Apostel, F; Buck, F; Greeve, J				Lellek, H; Kirsten, R; Diehl, I; Apostel, F; Buck, F; Greeve, J			Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; MESSENGER-RNA POLYADENYLATION; TISSUE-SPECIFIC EXPRESSION; POLY(A)-BINDING PROTEIN; CATALYTIC SUBUNIT; ADENOSINE-DEAMINASE; BINDING PROTEINS; IN-VITRO; SECONDARY STRUCTURE; HEPATIC EXPRESSION	Editing of apolipoprotein B (apoB) mRNA requires the catalytic component APOBEC-1 together with "auxiliary" proteins that have not been conclusively characterized so far. Here we report the purification of these additional components of the apoB mRNA editing enzyme-complex from rat liver and the cDNA cloning of the novel APOBEC-1-stimulating protein (ASP), Two proteins copurified into the final active fraction and were characterized by peptide sequencing and mass spectrometry: KSRP, a 75-kDa protein originally described as a splicing regulating factor, and ASP, a hitherto unknown 65-kDa protein. Separation of these two proteins resulted in a reduction of APOBEC-1-stimulating activity. ASP represents a novel type of RNA-binding protein and contains three single-stranded RNA-binding domains in the amino-terminal half and a putative double-stranded RNA-binding domain at the carboxyl terminus. Purified recombinant glutathione S-transferase (GST)-ASP, but not recombinant GST-KSRP, stimulated recombinant GST-APOBEC-1 to edit apoB RNA in vitro. These data demonstrate that ASP is the second essential component of the apoB mRNA editing enzyme-complex, In rat liver, ASP is apparently associated with KSRP, which may confer stability to the editing enzyme-complex with its substrate apoB RNA serving as an additional auxiliary component.	Univ Hamburg, Krankenhaus Eppendorf, Med Kernklin & Poliklin, D-20246 Hamburg, Germany; Univ Hamburg, Krankenhaus Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Greeve, J (corresponding author), Univ Hamburg, Krankenhaus Eppendorf, Med Kernklin & Poliklin, Martinistr 52, D-20246 Hamburg, Germany.							ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Barabino SML, 1999, CELL, V99, P9, DOI 10.1016/S0092-8674(00)80057-4; BARNETT SF, 1990, METHOD ENZYMOL, V181, P293; BELOSTOTSKY DA, 1993, P NATL ACAD SCI USA, V90, P6686, DOI 10.1073/pnas.90.14.6686; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chou MY, 1999, MOL CELL BIOL, V19, P69; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENWOOD JD, 1991, BEHAV PHILOS, V19, P35; Greeve J, 1998, ARTERIOSCL THROM VAS, V18, P1079, DOI 10.1161/01.ATV.18.7.1079; Greeve J, 1999, ONCOGENE, V18, P6357, DOI 10.1038/sj.onc.1203039; Greeve J, 1996, J LIPID RES, V37, P2001; GREEVE J, 1993, J LIPID RES, V34, P1367; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Heidebrecht HJ, 1997, BLOOD, V90, P226; Hersberger M, 1999, J BIOL CHEM, V274, P34590, DOI 10.1074/jbc.274.49.34590; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hirano K, 1997, J LIPID RES, V38, P1103; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kozarsky KF, 1996, HUM GENE THER, V7, P943, DOI 10.1089/hum.1996.7.8-943; Kuehn Uwe, 1996, Journal of Molecular Biology, V256, P20; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MORITZ E, 1994, BIOL MASS SPECTROM, V23, P249; MULLERHOLTKAMP F, 1995, J MOL EVOL, V41, P467, DOI 10.1007/BF00160318; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Qian XB, 1997, J BIOL CHEM, V272, P18060, DOI 10.1074/jbc.272.29.18060; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700	67	138	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19848	19856		10.1074/jbc.M001786200	http://dx.doi.org/10.1074/jbc.M001786200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10781591	hybrid			2022-12-27	WOS:000087941300058
J	Chien, WW; Pei, L				Chien, WW; Pei, L			A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; HUMAN HOMOLOG; NUCLEOCYTOPLASMIC TRANSPORT; GENOMIC ORGANIZATION; PROTEINS; IDENTIFICATION; CLONING; PTTG; EXPRESSION; LOCATION	Pituitary tumor-transforming gene (PTTG) is a recently characterized oncogene whose expression product contains a transcriptional activation domain at the C terminus. To understand the mechanisms involved in PTTG biological functions, we used yeast two hybrid screening to identify proteins that interact with PTTG, This study reports the isolation and characterization of a novel PTTG-binding factor (PBF). PBF contains an open reading frame of 179 amino acids with a predicted molecular mass of 22 kDa. In Northern blot analyses, PBF mRNA was ubiquitously expressed in human tissues. Glutathione S-transferase pull-down and co-immunoprecipitation assays demonstrate that PBF interacts specifically with PTTG under both in vitro and in, vivo conditions. The PTTG binding domain in PBF was located within the C-terminal 30-amino acid region that contain a nuclear localization signal. Immunofluorescence and subcellular fractionation studies showed that PTTG is predominantly expressed in the cytoplasm with partial nuclear localization, whereas PBF is localized both in the cytoplasm and the nucleus. The interaction between PBF and PTTG facilitated PTTG translocation from the cytoplasm to the nucleus. Furthermore, PBF is required for transcriptional activation of basic fibroblast growth factor by PTTG, In summary, we have characterized a novel PTTG-binding protein that facilitates PTTG nuclear translocation and potentiates its transcriptional activation function.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Cedars Sinai Res Inst,Div Endocrinol & Metab, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Cedars Sinai Res Inst,Div Endocrinol & Metab, 8700 Beverly Blvd,D2019, Los Angeles, CA 90048 USA.	pei@cshs.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056608, K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56608, DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Aita VM, 1999, AM J HUM GENET, V64, P210, DOI 10.1086/302185; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Kakar SS, 1999, GENE, V240, P317, DOI 10.1016/S0378-1119(99)00446-1; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Koster M, 1999, EUR J BIOCHEM, V260, P137, DOI 10.1046/j.1432-1327.1999.00149.x; La Boissiere S, 1999, EMBO J, V18, P480; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee IA, 1999, BIOCHEM MOL BIOL INT, V47, P891; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; Pasumarthi KBS, 1997, J NEUROCHEM, V68, P898; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; SINET PM, 1994, BIOMED PHARMACOTHER, V48, P247, DOI 10.1016/0753-3322(94)90140-6; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; Yaspo ML, 1998, GENOMICS, V49, P133, DOI 10.1006/geno.1998.5217; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	27	87	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19422	19427		10.1074/jbc.M910105199	http://dx.doi.org/10.1074/jbc.M910105199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10781616	hybrid			2022-12-27	WOS:000087815900105
J	Bonen, A; Luiken, JJFP; Arumugam, Y; Glatz, JFC; Tandon, NN				Bonen, A; Luiken, JJFP; Arumugam, Y; Glatz, JFC; Tandon, NN			Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE MEMBRANE-PROTEIN; RED SKELETAL-MUSCLE; PLASMA-MEMBRANE; BINDING-PROTEIN; GLUCOSE-TRANSPORT; PALMITATE UPTAKE; GIANT VESICLES; INSULIN; EXPRESSION; HEART	We used muscle contraction, which increases fatty acid oxidation, as a model to determine whether fatty acid transport is acutely regulated by fatty acid translocase (FAT/CD36). Palmitate uptake by giant vesicles, obtained from skeletal muscle, was increased by muscle contraction. Kinetic studies indicated that muscle contraction increased V-max, but K-m remained unaltered. SulfoSN-succinimidyl oleate, a specific inhibitor of FAT/ CD36, fully blocked the contraction-induced increase in palmitate uptake. In giant vesicles from contracting muscles, plasma membrane FAT/CD36 was also increased in parallel with the increase in long chain fatty acid uptake. Further studies showed that like GLUT-4, FAT/CD36 is located in both the plasma membrane and intracellularly (endosomally). With muscle contraction, FAT/CD36 at the surface of the muscle was increased, while concomitantly, FAT/CD36 in the intracellular pool was reduced. Similar responses were observed for GLUT-4. We conclude that fatty acid uptake is subject to short term regulation by muscle contraction and involves the translocation of FAT/CD36 from intracellular stores to the sarcolemma, analogous to the regulation of glucose uptake by GLUT-4.	Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Maastricht Univ, Dept Physiol, NL-6200 MD Maastricht, Netherlands; Otsuka Amer Pharmaceut Inc, Thrombosis & Vasc Biol Lab, Rockville, MD 20850 USA	University of Waterloo; Maastricht University	Bonen, A (corresponding author), Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada.							Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; BODEN G, 1996, DIABETES, V45, P3; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; Dyck DJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE888, DOI 10.1152/ajpendo.1998.275.5.E888; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P373, DOI 10.1016/S0952-3278(97)90413-0; GLATZ JFC, 1995, PROSTAG LEUKOTR ESS, V52, P121, DOI 10.1016/0952-3278(95)90010-1; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; Gorski J, 1997, MOL CELL BIOCHEM, V166, P73, DOI 10.1023/A:1006882515938; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HARMON CM, 1992, BIOCHEM SOC T, V20, P811, DOI 10.1042/bst0200811; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Hayashi T, 1997, AM J PHYSIOL-ENDOC M, V273, pE1039, DOI 10.1152/ajpendo.1997.273.6.E1039; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; Kiens B, 1997, BIOCHEM BIOPH RES CO, V231, P463, DOI 10.1006/bbrc.1997.6118; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Luiken JJFP, 1996, EUR J BIOCHEM, V235, P564; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; McCullagh KJA, 1997, AM J PHYSIOL-ENDOC M, V273, pE239, DOI 10.1152/ajpendo.1997.273.2.E239; McCullagh KJA, 1996, AM J PHYSIOL-ENDOC M, V271, pE143, DOI 10.1152/ajpendo.1996.271.1.E143; McCullagh KJA, 1996, MOL CELL BIOCHEM, V156, P51; Newsholme Eric A., 1993, American Journal of Clinical Nutrition, V57, p738S, DOI 10.1093/ajcn/57.5.738S; Pelsers MMAL, 1999, BIOCHEM J, V337, P407, DOI 10.1042/0264-6021:3370407; PLOUG T, 1993, AM J PHYSIOL, V264, pE270, DOI 10.1152/ajpendo.1993.264.2.E270; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Roy D, 1997, AM J PHYSIOL-ENDOC M, V273, pE688, DOI 10.1152/ajpendo.1997.273.4.E688; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; TANNER LI, 1989, J BIOL CHEM, V264, P1537; TURCOTTE LP, 1991, FEBS LETT, V279, P327, DOI 10.1016/0014-5793(91)80180-B; Turcotte LP, 1997, MOL CELL BIOCHEM, V166, P153, DOI 10.1023/A:1006846907394; VANDERVUSSE GJ, 1995, J APPL PHYSIOL, V78, P1839, DOI 10.1152/jappl.1995.78.5.1839; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; VANDERVUSSE GJ, 1996, HDB PHYSIOL 12, P952; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387	49	283	291	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14501	14508		10.1074/jbc.275.19.14501	http://dx.doi.org/10.1074/jbc.275.19.14501			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799533	hybrid			2022-12-27	WOS:000087006900067
J	Ezal, CH; Marion, CD; Smith, WC				Ezal, CH; Marion, CD; Smith, WC			Primary structure requirements for Xenopus nodal-related 3 and a comparison with regions required by Xenopus nodal-related 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DIRECT NEURAL INDUCTION; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; 3-DIMENSIONAL STRUCTURE; MESODERM INDUCTION; SPEMANN ORGANIZER; RECEPTOR-BINDING; SWISS-MODEL; ACTIVIN-A	Transforming growth factor-beta superfamily members play important roles in the early development of animals, Activin and the Xenopus nodal related proteins 1, 2, and 4 induce muscle actin from Xenopus ectodermal explants, whereas the bone morphogenetic proteins 4 and 7 induce ectoderm to differentiate as epidermis. Bone morphogenetic proteins are antagonized by soluble binding proteins such as noggin and chordin, which leads to expression of neural cell adhesion molecule in animal caps. The transforming growth factor-beta superfamily member Xenopus nodal-related 3 also induces the neural cell adhesion molecule through inhibition of bone morphogenetic proteins. Therefore, whereas Xenopus nodal-related 2 and 3 share a high amount of sequence homology, they lead to very different cell fates. This study investigates the functional domains that distinguish the activities of these two factors. It was found that mutually exclusive regions of nodal-related 2 and 3 were required for activity. The central region of the mature domain is required for nodal-related 2 to induce muscle actin, whereas the N- and C-terminal ends of the mature domain are required for nodal-related 3 to induce neural cell adhesion molecule. These results help to define the minimal domains required for the unique activities of these factors.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Smith, WC (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.		Smith, W. Clay/AAQ-1589-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; CONDIE BG, 1987, DEVELOPMENT, V101, P93; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; Erter CE, 1998, DEV BIOL, V204, P361, DOI 10.1006/dbio.1998.9097; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen CS, 1997, DEVELOPMENT, V124, P483; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HOSAKA M, 1994, BIOMED RES-TOKYO, V15, P383, DOI 10.2220/biomedres.15.383; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; JONES M, 1909, DEVELOPMENT, V121, P3651; Joseph EM, 1997, DEV BIOL, V184, P367, DOI 10.1006/dbio.1997.8510; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Kofron M, 1999, DEVELOPMENT, V126, P5759; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LOPEZ AR, 1992, MOL CELL BIOL, V12, P1674, DOI 10.1128/MCB.12.4.1674; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NIEUWKOOP PD, 1994, NORMAL TABLE XENOPUS, P163; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Osada SI, 1999, DEVELOPMENT, V126, P3229; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Sambrook J., 2002, MOL CLONING LAB MANU; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Thisse C, 1999, DEVELOPMENT, V126, P229; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TOYAMA R, 1995, DEVELOPMENT, V121, P383; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	53	8	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14124	14131		10.1074/jbc.275.19.14124	http://dx.doi.org/10.1074/jbc.275.19.14124			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799488	hybrid			2022-12-27	WOS:000087006900018
J	Fillinger, S; Boschi-Muller, S; Azza, S; Dervyn, E; Branlant, G; Aymerich, S				Fillinger, S; Boschi-Muller, S; Azza, S; Dervyn, E; Branlant, G; Aymerich, S			Two glyceraldehyde-3-phosphate dehydrogenases with opposite physiological roles in a nonphotosynthetic bacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ARCHAEON PYROCOCCUS-FURIOSUS; 3 GLYCOLYTIC-ENZYMES; BACILLUS-SUBTILIS; TRIOSEPHOSPHATE ISOMERASE; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; PHOSPHOGLYCERATE KINASE; COENZYME SPECIFICITY; CARBON FLOW	Bacillus subtilis possesses two similar putative phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPDH) encoding genes, gap (renamed gapA) and gapB. A gapA mutant was unable to grow on glycolytic carbon sources, although it developed as well as the wild-type strain on gluconeogenic carbon sources. A gapB mutant showed the opposite phenotype, Purified GrapB showed a 50-fold higher GAPDHase activity with NADP(+) than with NAD(+), with K-m values of 0.86 and 5.7 mM, respectively. lacZ reporter gene fusions revealed that the gapB gene is transcribed during gluconeogenesis and repressed during glycolysis, Conversely, gapA transcription is 5-fold higher under glycolytic conditions than during gluconeogenesis. GAPDH activity assays in crude extracts of wild-type and mutant strains confirmed this differential expression pattern at the enzymatic level. Genetic analyses demonstrated that gapA transcription is repressed by the yvbQ (renamed cggR) gene product and indirectly stimulated by CcpA Thus, the same enzymatic step is catalyzed in B. subtilis by two enzymes specialized, through the regulation of their synthesis and their enzymatic characteristics, either in catabolism (GapA) or in anabolism (GapB). Such a dual enzymatic system for this step of the central carbon metabolism is described for the first time in a nonphotosynthetic eubacterium, but genomic analyses suggest that it could be a widespread feature.	INRA, CNRS, URA 1925, F-78850 Thiverval Grignon, France; Fac Sci, UHP, CNRS, UMR 7567, F-54506 Vandoeuvre Les Nancy, France; INRA, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Aymerich, S (corresponding author), INRA, CNRS, URA 1925, F-78850 Thiverval Grignon, France.	stef@platon.grignon.inra.fr		Boschi, Sandrine/0000-0001-8962-4749				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; AYMERICH S, 1986, J BACTERIOL, V166, P993, DOI 10.1128/jb.166.3.993-998.1986; BoschiMuller S, 1997, J BIOL CHEM, V272, P15106, DOI 10.1074/jbc.272.24.15106; Branny P, 1998, MICROBIOL-SGM, V144, P905, DOI 10.1099/00221287-144-4-905; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; CERFF R, 1982, METHODS CHLOROPLAST, P683; Charpentier B, 1998, J BACTERIOL, V180, P6476, DOI 10.1128/JB.180.24.6476-6483.1998; CLERMONT S, 1993, BIOCHEMISTRY-US, V32, P10178, DOI 10.1021/bi00089a038; CORBIER C, 1990, BIOCHEMISTRY-US, V29, P7101, DOI 10.1021/bi00482a022; de Graef MR, 1999, J BACTERIOL, V181, P2351, DOI 10.1128/JB.181.8.2351-2357.1999; Didierjean C, 1997, J MOL BIOL, V268, P739, DOI 10.1006/jmbi.1997.0998; Dominguez H, 1998, EUR J BIOCHEM, V254, P96, DOI 10.1046/j.1432-1327.1998.2540096.x; EIKMANNS BJ, 1992, J BACTERIOL, V174, P6076, DOI 10.1128/JB.174.19.6076-6086.1992; Garrigues C, 1997, J BACTERIOL, V179, P5282, DOI 10.1128/jb.179.17.5282-5287.1997; GueroutFleury AM, 1996, GENE, V180, P57, DOI 10.1016/S0378-1119(96)00404-0; Henkin TM, 1996, FEMS MICROBIOL LETT, V135, P9; Kaneko T, 1996, DNA Res, V3, P109; Koksharova O, 1998, PLANT MOL BIOL, V36, P183, DOI 10.1023/A:1005925732743; Kormanec J, 1997, MICROBIOL-UK, V143, P3555, DOI 10.1099/00221287-143-11-3555; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MARTIN W, 1986, EUR J BIOCHEM, V159, P323, DOI 10.1111/j.1432-1033.1986.tb09871.x; Miller JH., 1992, SHORT COURSE BACTERI, P72; Presecan-Siedel E, 1999, J BACTERIOL, V181, P6889, DOI 10.1128/JB.181.22.6889-6897.1999; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; SCHLAPFER BS, 1992, GENE, V122, P53, DOI 10.1016/0378-1119(92)90031-J; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SNOEP JL, 1990, ARCH MICROBIOL, V154, P50; Talfournier F, 1998, EUR J BIOCHEM, V252, P447, DOI 10.1046/j.1432-1327.1998.2520447.x; Tobisch S, 1999, J BACTERIOL, V181, P6996, DOI 10.1128/JB.181.22.6996-7004.1999; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van der Oost J, 1998, J BIOL CHEM, V273, P28149, DOI 10.1074/jbc.273.43.28149; VIAENE A, 1989, NUCLEIC ACIDS RES, V17, P1251, DOI 10.1093/nar/17.3.1251	33	145	159	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14031	14037		10.1074/jbc.275.19.14031	http://dx.doi.org/10.1074/jbc.275.19.14031			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799476	hybrid, Green Published			2022-12-27	WOS:000087006900006
J	Luberto, C; Yoo, DS; Suidan, HS; Bartoli, GM; Hannun, YA				Luberto, C; Yoo, DS; Suidan, HS; Bartoli, GM; Hannun, YA			Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF-INDUCED APOPTOSIS; PROTEIN-KINASE-C; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; FACTOR-ALPHA; ACID SPHINGOMYELINASE; CERAMIDE; PATHWAY	The precise role of ceramide in NF-kappa B signaling remains unclear. The recent observation of differential sphingomyelin synthase (SMS) activity in normal (low SMS) versus SV40-transformed thigh SMS) WI38 human lung fibroblasts provides an opportunity to assess the involvement of ceramide and SMS in NF-kappa B activation. Treatment of normal WI38 fibroblasts with bacterial sphingomyelinase resulted in a 4-fold elevation of ceramide and blocked NF-kappa B activation by serum stimulation. Such inhibition was not observed in SV40-transformed fibroblasts. Under regular growth conditions, after sphingomyelinase was washed out, normal WI38 did not show SM re-synthesis nor NF-kappa B activation. In SV40-WI38, on the other hand, sphingomyelinase washout induced resynthesis of SM due to the action of SMS on ceramide generated at the plasma membrane. NF-kappa B activation correlated with SM resynthesis. This activation was abrogated by D609, which inhibited SM resynthesis but not the initial formation of ceramide. The differential activity of SMS may explain the effects of ceramide in NF-kappa B signaling: in the absence of significant SIMS activity, ceramide inhibits NF-kappa B, whereas with high SMS, the conversion of the ceramide signal to a diacylglycerol signal by the action of SMS stimulates NF-kappa B. These results also suggest a role for SMS in regulating NF-kappa B.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA; Univ Cattolica Sacro Cuore, Inst Gen Pathol, I-00168 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	Medical University of South Carolina; Duke University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Rome Tor Vergata	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, POB 250780,114 Doughty St, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higuchi M, 1996, J IMMUNOL, V157, P297; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zhang P, 1997, J BIOL CHEM, V272, P9609	31	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14760	14766		10.1074/jbc.275.19.14760	http://dx.doi.org/10.1074/jbc.275.19.14760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799564	hybrid			2022-12-27	WOS:000087006900100
J	Meyer, HA; Grau, H; Kraft, R; Kostka, S; Prehn, S; Kalies, KU; Hartmann, E				Meyer, HA; Grau, H; Kraft, R; Kostka, S; Prehn, S; Kalies, KU; Hartmann, E			Mammalian Sec61 is associated with Sec62 and Sec63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE RECOGNITION; PROTEIN TRANSLOCATION; SECRETORY PROTEIN; ER MEMBRANE; POSTTRANSLATIONAL TRANSPORT; MICROSOMAL-MEMBRANES; COMPLEX; YEAST; HOMOLOG	In yeast, efficient protein transport across the endoplasmic reticulum (ER) membrane may occur co-translationally or post-translationally. The latter process is mediated by a membrane protein complex that consists of the Sec61p complex and the Sec62p-Sec63p subcomplex. In contrast, in mammalian cells protein translocation is almost exclusively co-translational. This transport depends on the Sec61 complex, which is homologous to the yeast Sec61p complex and has been identified in mammals as a ribosome-bound pore-forming membrane protein complex. We report here the existence of ribosome-free mammalian Sec61 complexes that associate with two ubiquitous proteins of the ER membrane. According to primary sequence analysis both proteins display homology to the yeast proteins Sec62p and Sec63p and are therefore named Sec62 and Sec63, respectively. The probable function of the mammalian Sec61-Sec62-Sec63 complex is discussed with respect to its abundance in ER membranes, which, in contrast to yeast ER membranes, apparently lack efficient post-translational translocation activity.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Charite, Inst Biochem, D-10115 Berlin, Germany	University of Gottingen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hartmann, E (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	ennohart@mdc-berlin.de	Hartmann, Enno/C-5687-2013					Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Daimon M, 1997, BIOCHEM BIOPH RES CO, V230, P100, DOI 10.1006/bbrc.1996.5892; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KLAPPA P, 1994, FEBS LETT, V341, P281, DOI 10.1016/0014-5793(94)80473-7; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; Ng DTW, 1996, J CELL BIOL, V132, P499, DOI 10.1083/jcb.132.4.499; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; Schroder K, 1999, EMBO J, V18, P4804, DOI 10.1093/emboj/18.17.4804; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1988, EMBO J, V7, P1763, DOI 10.1002/j.1460-2075.1988.tb03006.x; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; ZIMMERMANN R, 1990, BIOCHIMIE, V72, P95, DOI 10.1016/0300-9084(90)90134-3; ZIMMERMANN R, 1986, J BIOL CHEM, V261, P2889	47	139	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14550	14557		10.1074/jbc.275.19.14550	http://dx.doi.org/10.1074/jbc.275.19.14550			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799540	hybrid			2022-12-27	WOS:000087006900074
J	Shim, J; Park, HS; Kim, MJ; Park, J; Park, E; Cho, SG; Eom, SJ; Lee, HW; Joe, CO; Choi, EJ				Shim, J; Park, HS; Kim, MJ; Park, J; Park, E; Cho, SG; Eom, SJ; Lee, HW; Joe, CO; Choi, EJ			Rb protein down-regulates the stress-activated signals through inhibiting c-Jun N-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; CELL-DEATH; HISTONE DEACETYLASE; BINDING-PROTEINS; TYROSINE KINASE; MAP KINASES; APOPTOSIS; TRANSCRIPTION; TRANSDUCTION; JNK	The Rb protein is the product of the retinoblastoma susceptibility gene and loss of Rb function is detected in many types of human cancers. Rb plays important roles in the regulation of cell proliferation, differentiation, senescence, and apoptotic cell death. Here we show that Rb can physically interact with c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK), thereby inhibiting intracellular signals mediated by JNK/SAPK. Both in vitro binding and in vitro kinase studies suggest that a carboxyl-terminal domain of Rb containing amino acids 768-928 might be crucial for inhibiting JNK/SAPK. In comparison, Rb did not affect enzymatic activity of either extracellular signal-regulated kinase 1 or p38. Ectopically expressed Rb also abrogated the apoptotic cell death induced by ultraviolet radiation or the activation of MEKK1, an upstream kinase that can stimulate the JNK/SAPK cascade. JNK/ SAPK inhibition highlights a novel function of Rb, which may provide a new mechanism by which Rb regulates cell death. JNK/SAPK is a major protein kinase that can be stimulated in response to a variety of cellular stresses. Our results, therefore, suggest that Rb, by inhibiting JNK/SAPK, may act as a negative regulator in stress-activated intracellular signaling cascades.	Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Sungkyunkwan Univ, Sch Med, Ctr Mol Med, Samsung Biomed Res Inst, Seoul 135230, South Korea	Korea University; Korea Advanced Institute of Science & Technology (KAIST); Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center	Choi, EJ (corresponding author), Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea.	ejchoi@kuccnx.korea.ac.kr		Cho, Ssang-Goo/0000-0002-0968-7932				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GOGA A, 1995, ONCOGENE, V11, P791; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	33	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14107	14111		10.1074/jbc.275.19.14107	http://dx.doi.org/10.1074/jbc.275.19.14107			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799486	hybrid			2022-12-27	WOS:000087006900016
J	Galliano, MF; Huet, C; Frygelius, J; Polgren, A; Wewer, UM; Engvall, E				Galliano, MF; Huet, C; Frygelius, J; Polgren, A; Wewer, UM; Engvall, E			Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, alpha-actinin-2, is required for myoblast fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAM-12 MELTRIN-ALPHA; NECROSIS-FACTOR-ALPHA; METALLOPROTEASE-DISINTEGRIN; SECRETASE CLEAVAGE; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; CELL-ADHESION; FAMILY; EXPRESSION; PRECURSOR	ADAM12 belongs to the transmembrane metalloprotease ADAM ("a disintegrin and metalloprotease") family. ADAM12 has been implicated in muscle cell differentiation and fusion, but its precise function remains unknown. Here, we show that ADAM12 is dramatically up-regulated in regenerated, newly formed fibers in vivo. In C2C12 cells, ADAM12 is expressed at low levels in undifferentiated myoblasts and is transiently up-regulated at the onset of differentiation when myoblasts fuse into multinucleated myotubes, whereas other ADAMs, such as ADAMs 9, 10, 15, 17, and 19, are expressed at all stages of differentiation. Using the yeast two-hybrid screen, we found that the muscle-specific alpha-actinin-2 strongly binds to the cytoplasmic tail of ADAM12. In vitro binding assays with GST fusion proteins confirmed the specific interaction. The major binding site for alpha-actinin-2 was mapped to a short sequence in the membrane-proximal region of ADAM12 cytoplasmic tail; a second binding site was identified in the membrane-distal region. Co-immunoprecipitation experiments confirm the in vivo association of ADAM12 cytoplasmic domain with alpha-actinin-2. Overexpression of the entire cytosolic ADAM12 tail acted in a dominant negative fashion by inhibiting fusion of C2C12 cells, whereas expression of a cytosolic ADAM12 lacking the major alpha-actinin-2 binding site had no effect on cell fusion. Our results suggest that interaction of ADAM12 with alpha-actinin-2 is important for ADAM12 function.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA; Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark	Sanford Burnham Prebys Medical Discovery Institute; University of Copenhagen	Engvall, E (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bigler D, 1997, TRENDS CELL BIOL, V7, P220, DOI 10.1016/S0962-8924(97)01058-1; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; De la Porte S, 1999, INT REV CYTOL, V191, P99, DOI 10.1016/S0074-7696(08)60158-8; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Liu LA, 1999, J BIOL CHEM, V274, P38171, DOI 10.1074/jbc.274.53.38171; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlondorff J, 1999, J CELL SCI, V112, P3603; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	39	116	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13933	13939		10.1074/jbc.275.18.13933	http://dx.doi.org/10.1074/jbc.275.18.13933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788519	hybrid			2022-12-27	WOS:000086925300106
J	Hatsuzawa, K; Hirose, H; Tani, K; Yamamoto, A; Scheller, RH; Tagaya, M				Hatsuzawa, K; Hirose, H; Tani, K; Yamamoto, A; Scheller, RH; Tagaya, M			Syntaxin 18, a SNAP receptor that functions in the endoplasmic reticulum, intermediate compartment, and cis-Golgi vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLMALEIMIDE-SENSITIVE FACTOR; TRANSPORT VESICLES; COATED VESICLES; MEMBRANE-FUSION; IN-VITRO; PLASMA-MEMBRANE; MATRIX PROTEIN; LIVING CELLS; BETA-COP; T-SNARE	Members of the syntaxin family are target-soluble N-ethylmaleimide-sensitive factor-attachment protein receptors involved in vesicle docking and/or fusion within the exocytic and endocytotic pathways. By using the yeast two-hybrid system, we have identified a novel member of the syntaxin family, syntaxin 18, that binds to alpha-soluble N-ethylmaleimide-sensitive factor-attachment protein. Subcellular fractionation and immunocytochemical analysis revealed that syntaxin 18 is principally located in the endoplasmic reticulum, We examined the effect of overexpression of FLAG-tagged syntaxin 18 and a mutant lacking the N-terminal 81 amino acid residues on protein transport and organelles in the early secretory pathway. Both expressed proteins localized to the endoplasmic reticulum, and the expressed FLAG-syntaxin 18 caused remarkable aggregation of endoplasmic reticulum membranes. Although expression of the FLAG-syntaxin 18 lacking the N-terminal region produced less effect on the morphology of the endoplasmic reticulum, dispersion of the endoplasmic reticulum-Golgi intermediate compartment and cis-Golgi was elicited. Moreover, overexpression of the FLAG-syntaxin 18 mutant inhibited protein export from the endoplasmic reticulum, These results taken together suggest that syntaxin 18 functions in transport between the endoplasmic reticulum and Golgi.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan; Stanford Univ, Med Ctr, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Tokyo University of Pharmacy & Life Sciences; Kansai Medical University; Howard Hughes Medical Institute; Stanford University	Tagaya, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan.	tagaya@ls.toyaku.ac.jp						AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1069, DOI 10.1177/36.8.3292644; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; Tang BL, 1999, FEBS LETT, V446, P211, DOI 10.1016/S0014-5793(99)00195-7; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; Yamaguchi T, 1997, J BIOL CHEM, V272, P25260, DOI 10.1074/jbc.272.40.25260; Yamamoto A, 1996, J CELL SCI, V109, P1727; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	61	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13713	13720		10.1074/jbc.275.18.13713	http://dx.doi.org/10.1074/jbc.275.18.13713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788491	hybrid			2022-12-27	WOS:000086925300078
J	Sanders, SL; Weil, PA				Sanders, SL; Weil, PA			Identification of two novel TAF subunits of the yeast Saccharomyces cerevisiae TFIID complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TRANSCRIPTION IN-VIVO; HISTONE-LIKE TAFS; MOLECULAR-CLONING; GENE-EXPRESSION; SAGA; DELETION; TAF(II)S; STRAINS	Using a combination of ion exchange and immunoaffinity chromatography we have purified the general transcription initiation factor TFIID to near homogeneity from Saccharomyces cerevisiae. Yeast TFIID is composed of TBP, the TATA box binding protein, and 14 distinct TSP-associated factors (TAFs), which range in size from 17 to 150 kDa. Twelve of the TAF subunits have been previously identified, but two, TAF48p and TAF65p, are novel. TAF48p exhibits significant sequence similarity to the conserved C-terminal region of Drosophila TAF110p, human TAF130p, and human TAF105p and is encoded by a previously identified gene MPT1. TAF65p shows no significant sequence homology to any previously identified TAFp, The genes encoding TAF48p and TAF65p are single copy and essential for normal yeast cell growth. Furthermore, neither TAF48p nor TAF65p are associated with the histone acetylase Spt-Ada-Gcn5 complex or other non-TFIID TBF TAF complexes. The significance of these results in terms of TFIID structure, function, and organization is discussed.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052461, R56GM052461] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07563-09] Funding Source: Medline; NIGMS NIH HHS [GM52461] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Brachmann CB, 1998, YEAST, V14, P115; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Georgieva S, 2000, MOL CELL BIOL, V20, P1639, DOI 10.1128/MCB.20.5.1639-1648.2000; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; SIKORSKI RS, 1989, GENETICS, V122, P19; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873	41	62	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13895	13900		10.1074/jbc.275.18.13895	http://dx.doi.org/10.1074/jbc.275.18.13895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788514	hybrid			2022-12-27	WOS:000086925300101
J	Cominacini, L; Fratta Pasini, A; Garbin, U; Davoli, A; Tosetti, ML; Campagnola, M; Rigoni, A; Pastorino, AM; Lo Cascio, V; Sawamura, T				Cominacini, L; Fratta Pasini, A; Garbin, U; Davoli, A; Tosetti, ML; Campagnola, M; Rigoni, A; Pastorino, AM; Lo Cascio, V; Sawamura, T			Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappa B through an increased production of intracellular reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ADHESION MOLECULE-1; TRANSCRIPTION FACTOR; OXIDATIVE MODIFICATION; TRANSFORMING GROWTH-FACTOR-BETA-1; ANTIOXIDANTS INHIBIT; SIGNAL-TRANSDUCTION; NADPH OXIDASE; INDUCTION; EXPRESSION	In this study we examined the effect of oxidized low density lipoprotein (ox-LDL) on the intracellular production of reactive oxygen species (ROS) in bovine aortic endothelial cells (BAECs) and whether this increase occurs through its binding to the endothelial receptor lectin-like ox-LDL receptor-1 (LOX-1). Furthermore, this study also aimed to ascertain whether the binding of ox-LDL to LOX-1 is associated with NF-kappa B activation. ox-LDL induced a significant dose-dependent increase in ROS production after a 30-s incubation with BAECs (p < 0.01). ROS formation was markedly reduced in BAECs incubated with anti-LOX-1 monoclonal antibody (P < 0.001), while control nonimmune IgG produced no effect. ox-LDL induced a time- and dose-dependent significant increase in ROS formation only in CHO-K1 cells stably expressing bovine LOX-1 (p < 0.001), while no increase was present in CHO-K1 cells. The activation of the transcription factor NF-kappa B in BAECs was evident after a 5-min incubation with ox-LDL and was attenuated by anti-LOX-1 monoclonal antibody. The conclusion is that one of the pathophysiological consequences of ox-LDL binding to LOX-1 may be the activation of NF-kappa B through an increased ROS production.	Univ Verona, Dept Biomed & Surg Sci, I-37134 Verona, Italy; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Osaka 5658565, Japan	University of Verona; National Cerebral & Cardiovascular Center - Japan	Cominacini, L (corresponding author), Univ Verona, Med Osped Policlin D, Dipartimento Sci Biomed & Chirurg, I-37134 Verona, Italy.	comina@medicinad.univr.it	Sawamura, Tatsuya/E-7103-2010; cominacini, luciano/B-2775-2011					Aoyama T, 1999, BIOCHEM J, V339, P177, DOI 10.1042/0264-6021:3390177; Aoyama T, 1999, J MOL CELL CARDIOL, V31, P2101, DOI 10.1006/jmcc.1999.1041; AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BOYD HC, 1989, AM J PATHOL, V135, P815; CARLOS T, 1991, BLOOD, V77, P2266; CATHCART MK, 1989, J IMMUNOL, V142, P1963; Cominacini L, 1997, J HYPERTENS, V15, P1633, DOI 10.1097/00004872-199715120-00065; Cominacini L, 1997, FREE RADICAL BIO MED, V22, P117, DOI 10.1016/S0891-5849(96)00271-7; Cominacini L, 1998, J HYPERTENS, V16, P1913, DOI 10.1097/00004872-199816121-00010; COMINACINI L, 1991, J LIPID RES, V32, P349; Cominacini L, 1996, J LIPID MEDIAT CELL, V13, P19, DOI 10.1016/0929-7855(95)00011-9; CORSETTI JP, 1991, ANAL BIOCHEM, V195, P122, DOI 10.1016/0003-2697(91)90306-E; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JENG JR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P221, DOI 10.1016/0167-4889(93)90013-F; JORIS I, 1983, AM J PATHOL, V113, P341; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KIMURA H, 1995, ATHEROSCLEROSIS, V118, P1, DOI 10.1016/0021-9150(95)05587-M; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Maeba R, 1995, FEBS LETT, V377, P309, DOI 10.1016/0014-5793(95)01336-9; Maziere C, 1996, BIOCHEM MOL BIOL INT, V39, P1201; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Moriwaki H, 1998, ARTERIOSCL THROM VAS, V18, P1541, DOI 10.1161/01.ATV.18.10.1541; Murase T, 1998, CIRC RES, V83, P328, DOI 10.1161/01.RES.83.3.328; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; ROSENFELD ME, 1991, CIRCULATION, V83, P2137, DOI 10.1161/01.CIR.83.6.2137; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SMITH PK, 1985, ANAL BIOCHEM, V105, P293; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tsao PS, 1996, CIRCULATION, V94, P1682, DOI 10.1161/01.CIR.94.7.1682; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WIKLUND O, 1991, J LIPID RES, V32, P55; ZHOU M, 1997, ANAL BIOCHEM, V15, P162; Zulueta JJ, 1997, AM J PHYSIOL-LUNG C, V272, pL897, DOI 10.1152/ajplung.1997.272.5.L897	54	443	482	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12633	12638		10.1074/jbc.275.17.12633	http://dx.doi.org/10.1074/jbc.275.17.12633			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777555	hybrid			2022-12-27	WOS:000086762300039
J	Cruickshank, J; Shire, K; Davidson, AR; Edwards, AM; Frappier, L				Cruickshank, J; Shire, K; Davidson, AR; Edwards, AM; Frappier, L			Two domains of the Epstein-Barr virus origin DNA-binding protein, EBNA1, orchestrate sequence-specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS E2 PROTEIN; NUCLEAR ANTIGEN EBNA-1; CRYSTAL-STRUCTURE; LATENT ORIGIN; RECOGNITION; REPLICATION; PURIFICATION; ENHANCER; COMPLEX	The EBNA1 (for Epstein-Barr nuclear antigen 1) protein of Epstein-Barr virus governs the replication and partitioning of the viral genomes during latent infection by binding to specific recognition sites in the viral origin of DNA replication. The crystal structure of the DNA binding portion of the EBNA1 protein revealed that this region comprises two structural motifs; a core domain, which mediates protein dimerization and is structurally homologous to the DNA binding domain of the papillomavirus E2 protein, and a flanking domain, which mediated all the observed sequence-specific contacts. To test the possibility that the EBNA1 core domain plays a role in sequence-specific DNA binding not revealed in the crystal structure, we examined the effects of point mutations in potential hydrogen bond donors located in an cu-helix of the EBNA1 core domain whose structural homologue in E2 mediates sequence-specific DNA binding. We show that these mutations severely reduce the affinity of EBNA1 for its recognition site, and that the core domain, when expressed in the absence of the flanking domain, has sequence-specific DNA binding activity. Flanking domain residues were also found to contribute to the DNA binding activity of EBNA1, Thus, both the core and flanking domains of EBNA1 play direct roles in DNA recognition.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Frappier, L (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.			Edwards, Aled/0000-0002-4782-6016				AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; Bochkarev A, 1998, J MOL BIOL, V284, P1273, DOI 10.1006/jmbi.1998.2247; Chamberlin M J, 1992, Harvey Lect, V88, P1; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Mok YK, 1996, PROTEIN SCI, V5, P310; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; Summers H, 1997, J BIOL CHEM, V272, P26434, DOI 10.1074/jbc.272.42.26434; Yates J.L, 1996, DNA REPLICATION EUKA, P751; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Yates JL, 1996, VIROLOGY, V222, P1, DOI 10.1006/viro.1996.0392; YATES JL, 1988, CANCER CELL, V6, P197; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j	31	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22273	22277		10.1074/jbc.M001414200	http://dx.doi.org/10.1074/jbc.M001414200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801810	hybrid			2022-12-27	WOS:000088363800071
J	Gratton, JP; Fontana, J; O'Connor, DS; Garcia-Cardena, G; McCabe, TJ; Sessa, WC				Gratton, JP; Fontana, J; O'Connor, DS; Garcia-Cardena, G; McCabe, TJ; Sessa, WC			Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro - Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TYROSINE PHOSPHORYLATION; BINDING DOMAIN; CELL CAVEOLAE; IN-VIVO; PALMITOYLATION; TRANSLOCATION; CYTOSKELETON; HYPERTENSION; CHOLESTEROL	The activity of endothelial nitric-oxide synthase (eNOS) is regulated by its subcellular localization, phosphorylation and through its interaction with different proteins. The association of eNOS with caveolin-1 (Cav) is believed to maintain eNOS in an inactive state; however, increased association of eNOS to heat shock protein 90 (hsp90) is observed following activation. In this study, we investigate the relationship between caveolin and hsp90 as opposing regulatory proteins on eNOS function. Immunoprecipitation of Cav-1 from bovine lung microvascular endothelial cells shows that eNOS and hsp90 are present in the Cav-1 complex. eNOS and hsp90 from the lysate also interact with exogenous glutathione S-transferase-linked caveolin-1 (GST-Cav), and the addition of calcium-activated calmodulin (CaM) to the GST-Cav complex partially inhibited the association of eNOS and hsp90, Purified eNOS associates with GST-Cav specifically through the caveolin-scaffolding do. main (residues 82-101); however, the addition of CaM slightly, but nonstatistically, reduces eNOS binding to GST-Cav, When hsp90 is present in the binding reaction, the addition of increasing concentrations of CaM significantly displaces eNOS and hsp90 from GST-Cav. eNOS enzymatic activity is also less sensitive to inhibition by the caveolin scaffolding peptide (residues 82-101) when eNOS is prebound to hsp90, Collectively, our results show that the actions of CaM on eNOS dissociation from caveolin are facilitated in the presence of hsp90.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Mol Cardiobiol Program, New Haven, CT 06536 USA	Yale University; Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, Rm 436D,295 Congress Ave, New Haven, CT 06536 USA.	william.sessa@yale.edu	Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	NHLBI NIH HHS [R01HL51948, R01HL50974] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Czar MJ, 1996, EUR J CELL BIOL, V70, P322; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Peterson TE, 1999, CIRC RES, V85, P29; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417; Venema VJ, 1997, BIOCHEM BIOPH RES CO, V236, P155, DOI 10.1006/bbrc.1997.6921	34	262	272	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22268	22272		10.1074/jbc.M001644200	http://dx.doi.org/10.1074/jbc.M001644200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10781589	hybrid			2022-12-27	WOS:000088363800070
J	Sano, H; Chiba, H; Iwaki, D; Sohma, H; Voelker, DR; Kuroki, Y				Sano, H; Chiba, H; Iwaki, D; Sohma, H; Voelker, DR; Kuroki, Y			Surfactant proteins A and D bind CD14 by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; A-DEFICIENT MICE; SOLUBLE CD14; II CELLS; ALVEOLAR MACROPHAGES; LIPOPOLYSACCHARIDE LPS; BACTERIAL LIPOPOLYSACCHARIDES; PHOSPHOLIPID SECRETION; SPECIFICALLY BINDS; CELLULAR-RESPONSE	Surfactant proteins A (SP-A) and D (SP-D) are lung collectins that are constituents of the innate immune system of the lung. Recent evidence (Sano, H,, Sohma, H,, Muta, T., Nomura, S., Voelker, D. R., and Kuroki, Y. (1999) J. Immunol. 163, 387-395) demonstrates that SP-A modulates lipopolysaccharide (LPS)-induced cellular responses by direct interaction with CD14. In this report we examined the structural elements of the lung collectins involved in CD14 recognition and the consequences for CD14/LPS interaction. Rat SP-A and SP-D bound CD14 in a concentration-dependent manner. Mannose and EDTA inhibited SP-D binding to CD14 but did not decrease SP-A binding. The SP-A binding to CD14 was completely blocked by a monoclonal antibody that binds to the SP-A neck domain but only partially blocked by an antibody that binds to the SP-A lectin domain. SP-A but not SP-D bound to deglycosylated CD14, SP-D decreased CD14 binding to both smooth and rough LPS, whereas SP-A enhanced CD14 binding to rough LPS and inhibited binding to smooth LPS. SP-A also altered the migration profile of LPS on a sucrose density gradient in the presence of CD14. From these results, we conclude that 1) lung collectins bind CD14, 2) the SP-A neck domain and SP-D lectin domain participate in CD14 binding, 3) SP-A recognizes a peptide component and SP-D recognizes a carbohydrate moiety of CD14, and 4) lung collectins alter LPS/CD14 interactions.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Sapporo Medical University; National Jewish Health	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp			NHLBI NIH HHS [HL 45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1992, CURRENT PROTOCOLS MO; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BORRONP, 2000, AM J PHYSIOL, V278, pL840; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; FERRERO E, 1990, J IMMUNOL, V145, P331; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GRIFFISS JM, 1988, REV INFECT DIS, V10, pS287; Hailman E, 1996, J IMMUNOL, V156, P4384; HANCOCK REW, 1994, N COMP BIOC, V27, P263, DOI DOI 10.1016/S0167-7306(08)60415-9; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HAZIOT A, 1994, J IMMUNOL, V152, P5868; Honna T, 1997, BIOCHEMISTRY-US, V36, P7176, DOI 10.1021/bi962967e; Horowitz AD, 1996, AM J PHYSIOL-LUNG C, V270, pL69, DOI 10.1152/ajplung.1996.270.1.L69; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344, DOI 10.1152/ajplung.1997.272.2.L344; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114, DOI 10.1165/ajrcmb.11.1.8018334; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SIMMONS DL, 1989, BLOOD, V73, P284; Stelter F, 1996, EUR J BIOCHEM, V236, P457, DOI 10.1111/j.1432-1033.1996.00457.x; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; VANIWAARDEN JF, 1990, J BIOL CHEM, V2, P91; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	69	160	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22442	22451		10.1074/jbc.M001107200	http://dx.doi.org/10.1074/jbc.M001107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801802	hybrid			2022-12-27	WOS:000088363800093
J	Watanabe, T; Ihara, N; Itoh, T; Fujita, T; Sugimoto, Y				Watanabe, T; Ihara, N; Itoh, T; Fujita, T; Sugimoto, Y			Accelerated publication - Deletion mutation in Drosophila ma-l homologous, putative molybdopterin cofactor sulfurase gene is associated with bovine xanthinuria type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLASES; DEFICIENCY	Defective xanthine dehydrogenase (XDH) activity in humans results in xanthinuria and xanthine calculus accumulation in kidneys. Bovine xanthinuria was demonstrated in a local herd and characterized as xanthinuria type II, similar to the Drosophila ma-l mutations, which lose activities of molybdoenzymes, XDH, and aldehyde oxidase, although sulfite oxidase activity is preserved. Linkage analysis located the disease locus at the centromeric region of bovine chromosome 24, where a ma-l homologous, putative molybdopterin cofactor sulfurase gene (MCSU) has been physically mapped, We found that a deletion mutation at tyrosine 257 in MCSU is tightly associated with bovine xanthinuria type II.	Shirakawa Inst Anim Genet, Fukushima 9618061, Japan; Ohita Prefecture Livestock Expt Stn, Naoiri, Ohita 8780201, Japan		Sugimoto, Y (corresponding author), Shirakawa Inst Anim Genet, Fukushima 9618061, Japan.							Amrani L, 1999, MOL MICROBIOL, V31, P1065, DOI 10.1046/j.1365-2958.1999.01242.x; BOGAART AM, 1981, BIOCHEM GENET, V19, P929, DOI 10.1007/BF00504258; FELSTED RL, 1973, J BIOL CHEM, V248, P2580; FINNERTY V, 1979, MOL GEN GENET, V172, P37, DOI 10.1007/BF00276213; Hirano T, 1996, ANIM GENET, V27, P365, DOI 10.1111/j.1365-2052.1996.tb00980.x; Ichida K, 1997, J CLIN INVEST, V99, P2391, DOI 10.1172/JCI119421; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; Kappes SM, 1997, GENOME RES, V7, P235, DOI 10.1101/gr.7.3.235; KOJIMA T, 1984, CLIN CHIM ACTA, V137, P189; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; MIZOGUCHI H, 1997, LIVESTOCK TECHNOL, V509, P2; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; REITER S, 1990, CLIN CHIM ACTA, V187, P221, DOI 10.1016/0009-8981(90)90107-4; SIMMONDS JA, 1995, METABOLIC MOL BASES, P1781; Takeda H, 1998, ANIM GENET, V29, P216, DOI 10.1111/j.1365-2052.1998.00325.x; WADA M, 1994, NUCLEIC ACIDS RES, V22, P1651, DOI 10.1093/nar/22.9.1651; WAHL RC, 1982, J BIOL CHEM, V257, P3958	19	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21789	21792		10.1074/jbc.C000230200	http://dx.doi.org/10.1074/jbc.C000230200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801779	hybrid			2022-12-27	WOS:000088363800004
J	El Bawab, S; Roddy, P; Qian, T; Bielawska, A; Lemasters, JJ; Hannun, YA				El Bawab, S; Roddy, P; Qian, T; Bielawska, A; Lemasters, JJ; Hannun, YA			Molecular cloning and characterization of a human mitochondrial ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMYELINASE; PROTEINS; STRESS; CELLS	We have recently purified a rat brain membrane-bound nonlysosomal ceramidase (El Bawab, S,, Bielawska, A., and Y, A. Hannun (1999) J. Biol. Chem, 274, 27948-27955), Using peptide sequences obtained from the purified rat brain enzyme, we report here the cloning of the human isoform, The deduced amino acid sequence of the protein did not show any similarity with proteins of known function but was homologous to three putative proteins from Arabidospis thaliana, Mycobacterium tuberculosis, and Dictyostelium discoideum, Several blocks of amino acids were highly conserved in all of these proteins. Analysis of the protein sequence revealed the presence at the N terminus of a signal peptide followed by a putative myristoylation site and a putative mitochondrial targeting sequence. The predicted molecular mass was 84 kDa, and the isoelectric point was 6.69, in agreement with rat brain purified enzyme. Northern blot analysis of multiple human tissues showed the presence of a major band corresponding to a size of 3.5 kilobase, Analysis of this major band on the blot indicated that the enzyme is ubiquitously expressed with higher levels in kidney, skeletal muscle, and heart. The enzyme was then overexpressed in HEK 293 and MCF7 cells using the pcDNA3.1/His-ceramidase construct, and ceramidase activity (at pH 9.5) increased by 50- and 12-fold, respectively. Next, the enzyme was characterized using lysate of overexpressing cells. The results confirmed that the enzyme catalyzes the hydrolysis of ceramide in the neutral alkaline range and is independent of cations, Finally, a green fluorescent protein-ceramidase fusion protein was constructed to investigate the localization of this enzyme. The results showed that the green fluorescent protein-ceramidase fusion protein presented a mitochondrial localization pattern and colocalized with mitochondrial specific probes. These results demonstrate that this novel ceramidase is a mitochondrial enzyme, and they suggest the existence of a topologically restricted pathways of sphingolipid metabolism.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA	Medical University of South Carolina; University of North Carolina; University of North Carolina Chapel Hill	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-93707] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Sambrook J., 2002, MOL CLONING LAB MANU; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462	15	199	211	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21508	21513		10.1074/jbc.M002522200	http://dx.doi.org/10.1074/jbc.M002522200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781606	Green Published, hybrid			2022-12-27	WOS:000088230600074
J	Haddad, JJE; Olver, RE; Land, SC				Haddad, JJE; Olver, RE; Land, SC			Antioxidant/pro-oxidant equilibrium regulates HIF-1 alpha and NF-kappa B redox sensitivity - Evidence for inhibition by glutathione oxidation in alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; TRANSCRIPTION FACTOR; REACTIVE OXYGEN; LUNG INJURY; ACTIVATION; ALPHA; DIETHYLDITHIOCARBAMATE; PHOSPHORYLATION; TRANSLOCATION; SULFOXIMINE	The O-2 and redox-sensitive transcription factors hypoxia inducible factor-1 alpha (HIF-1 alpha) and nuclear factor-kappa B (NF-kappa B) are differentially regulated in the alveolar epithelium over fetal to neonatal oxygen tensions. We have used fetal alveolar type II epithelial cells to monitor their regulation in association with redox responsiveness to antioxidant pretreatment in vitro. N-Acetyl-L-cysteine, a glutathione (GSH) precursor and a potent scavenger of reactive oxygen species, induced HIF-1 alpha and ameliorated NF-kappa B nuclear abundance and DNA binding activity, respectively, in a dose-dependent manner. Analysis of variations in glutathione homeostasis at ascending Delta pO(2) regimen with N-acetyl-(L)-cysteine reveals increased GSH at the expense of the oxidized form of glutathione (GSSG;), thereby shifting GSH/GSSG into reduction equilibrium. Pyrrolidine dithiocarbamate (PDTC), which exerts both antioxidant and pro-oxidant effects, provoked a substantial increase in HIF-1 alpha nuclear abundance, with no apparent effect on its activation. PDTC reduced NF-kappa B nuclear abundance and its inhibitory effects on binding activity are dose-dependent. Assessment of glutathione homeostasis with PDTC shows increasing levels of GSSG at the expense of GSH, lowering GSH/GSSG in favor of an oxidative equilibrium. Our results indicate the hypoxic activation of HIF-1 alpha and the hyperoxic induction of NF-kappa B in the fetal epithelium is redox-sensitive and, thus, tightly regulated by the GSH/GSSG equilibrium. This highlights glutathione as a key regulatory component for determining genetic responsiveness to oxidant/antioxidant imbalance in normal lung development and pathophysiological conditions.	Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Tayside Inst Child Hlth, Ctr Res Human Dev,Oxygen Signaling Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Tayside Inst Child Hlth, Ctr Res Human Dev,Lung Membrane Transport Grp, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Land, SC (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Tayside Inst Child Hlth, Ctr Res Human Dev,Oxygen Signaling Grp, Dundee DD1 9SY, Scotland.	s.c.land@dundee.ac.uk		Land, Stephen/0000-0001-9216-5969				ATKINSON DR, 1977, CELLULARENERGY METAB; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V2, P509; BERNARD GR, 1991, AM J MED, V91, pS54, DOI 10.1016/0002-9343(91)90284-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; BRIGHAM KL, 1986, CHEST, V89, P859, DOI 10.1378/chest.89.6.859; Chabot F, 1998, EUR RESPIR J, V11, P745; Cotton RB, 1998, FETAL NEONATAL PHYSL, P1165; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DROGE W, 1994, FASEB J, V8, P1131; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; HADDAD JJ, 1999, J PHYSIOL-LONDON, V517, P91; Haddad JJE, 2000, AM J PHYSIOL-LUNG C, V278, pL492, DOI 10.1152/ajplung.2000.278.3.L492; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KELLY GS, 1998, ALTERN MED REV, V3, P144; Liu JK, 1996, FREE RADICAL RES, V24, P461, DOI 10.3109/10715769609088045; MANKHETKORN S, 1994, FREE RADICAL BIO MED, V17, P517, DOI 10.1016/0891-5849(94)90091-4; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Meister A, 1979, Ciba Found Symp, P135; MENON SD, 1993, J BIOL CHEM, V268, P26805; MOLDEUS P, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195086; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; RUSAKOW LS, 1995, J APPL PHYSIOL, V79, P1769, DOI 10.1152/jappl.1995.79.5.1769; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wild AC, 1999, BIOCHEM J, V338, P659, DOI 10.1042/0264-6021:3380659	40	211	225	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21130	21139		10.1074/jbc.M000737200	http://dx.doi.org/10.1074/jbc.M000737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801793	hybrid			2022-12-27	WOS:000088230600025
J	Yokoi, T; Ohmichi, M; Tasaka, K; Kimura, A; Kanda, Y; Hayakawa, J; Tahara, M; Hisamoto, K; Kurachi, H; Murata, Y				Yokoi, T; Ohmichi, M; Tasaka, K; Kimura, A; Kanda, Y; Hayakawa, J; Tahara, M; Hisamoto, K; Kurachi, H; Murata, Y			Activation of the luteinizing hormone beta promoter by gonadotropin-releasing hormone requires c-Jun NH2-terminal protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; TERNARY COMPLEX FACTORS; CANCER CELL-LINE; MAP KINASE; SIGNALING CASCADE; GENE-TRANSCRIPTION; 3T3 CELLS; UV-LIGHT; FACTOR-I	Regulation of the mitogen-activated protein kinase (MAPK) family by gonadotropin-releasing hormone (GnRH) in the gonadotrope cell line L beta T2 was investigated. Treatment with gonadotropin-releasing hormone agonist (GnRHa) activates extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK), Activation of ERK by GnRHa occurred within 5 min, and declined thereafter, whereas activation of JNK by GnRHa occurred with a different time frame, i.e. it was detectable at 5 min, reached a plateau at 30 min, and declined thereafter. GnRHa-induced ERK activation was dependent on protein kinase C or extracellular and intracellular Ca2+, whereas GnRHa-induced JNK activation was not dependent on protein kinase C or on extracellular or intracellular Ca2+. To determine whether a mitogen-activated protein kinase family cascade regulates rat luteinizing hormone beta (LH beta) promoter activity, we transfected the rat LH beta (-156 to +7)luciferase construct into L beta T2 cells. GnRH activated the rat LH beta promoter activity in a time-dependent manner. Neither treatment with a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, PD98059, nor cotransfection with a catalytically inactive form of a mitogen-activated protein kinase construct inhibited the induction of the rat LH beta promoter by GnRH, Furthermore, cotransfection with a dominant negative Ets had no effect on the response of the rat LH beta promoter to GnRH. On the other hand, cotransfection with either dominant negative JNK or dominant negative c-Jun significantly inhibited the induction of the rat LH beta promoter by GnRH. In addition, GnRH did not induce either the rat LH beta promoter activity in L beta T2 cells transfected stably with dominant negative c-Jun, These results suggest that GnRHa differentially activates ERK and JNK, and a JNK cascade is necessary to elicit the rat LH beta promoter activity in a c-Jun-dependent mechanism in L beta T2 cells.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Osaka 5650871, Japan	Osaka University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Osaka 5650871, Japan.	masa@gyne.med.osaka-u.acjp						Alarid ET, 1996, DEVELOPMENT, V122, P3319; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; Bost F, 1999, MOL CELL BIOL, V19, P1938; BROWN PH, 1994, ONCOGENE, V9, P791; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHANG JP, 1988, ENDOCRINOLOGY, V123, P87, DOI 10.1210/endo-123-1-87; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HERITIER AG, 1994, J NEUROENDOCRINOL, V6, P33, DOI 10.1111/j.1365-2826.1994.tb00552.x; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUCKLE WR, 1988, ENDOCR REV, V9, P387, DOI 10.1210/edrv-9-4-387; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; Kimura A, 1999, ENDOCRINOLOGY, V140, P722, DOI 10.1210/en.140.2.722; Kimura A, 1999, CANCER RES, V59, P5133; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLON PL, 1991, RECENT PROG HORM RES, V47, P69; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; NAOR Z, 1988, MOL ENDOCRINOL, V2, P512, DOI 10.1210/mend-2-6-512; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; OHMICHI M, 1997, ENDOCRINOLOGY, V138, P3130; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POTAPOVA O, 1996, CANCER RES, V56, P2800; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; REINHART J, 1992, J BIOL CHEM, V267, P21281; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sawada T, 1997, ENDOCRINOLOGY, V138, P5275, DOI 10.1210/en.138.12.5275; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; SIM PJ, 1995, MOL CELL ENDOCRINOL, V112, P257, DOI 10.1016/0303-7207(95)03616-F; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; Weck J, 1998, MOL ENDOCRINOL, V12, P451, DOI 10.1210/me.12.3.451; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WU JX, 1990, ONCOGENE, V5, P989; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	75	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21639	21647		10.1074/jbc.M910252199	http://dx.doi.org/10.1074/jbc.M910252199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10787426	hybrid			2022-12-27	WOS:000088230600090
J	Polevoda, B; Martzen, MR; Das, B; Phizicky, EM; Sherman, F				Polevoda, B; Martzen, MR; Das, B; Phizicky, EM; Sherman, F			Cytochrome c methyltransferase, Ctm1p, of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 2 HALF-SITES; SACCHAROMYCES-CEREVISIAE; CHEMICAL MODIFICATION; CRITHIDIA-ONCOPELTI; BINDING DOMAINS; DNA-BINDING; METHYLATION; ISO-1-CYTOCHROME-C; TRIMETHYLATION	Cytochromes c from plants and fungi, but not higher animals, contain methylated lysine residues at specific positions, including for example, the trimethylated lysine at position 72 in iso-1-cytochrome c of the yeast Saccharomyces cerevisiae. Testing of 6,144 strains of S. cerevisiae, each overproducing a different open reading frame fused to glutathione S-transferase, previously revealed that YHR109w was associated with an activity that methylated horse cytochrome c. me show here that this open reading frame, denoted Ctm1p, is specifically responsible for trimethylating lysine 72 of iso-1-cytochrome c. Unmethylated forms of cytochrome c but not other proteins or nucleic acids are methylated in vitro by Ctm1p produced in S. cerevisiae or Escherichia coli. Iso-1-cytochrome c purified from a ctm1-Delta strain is not trimethylated in vivo, whereas the K72R mutant form, or the trimethylated Lys-72 form of iso-1-cytochrome c, are not significantly methylated by Ctm1p in vitro. Like apo-cytochrome c, but in contrast to holocytochrome c, Ctm 1p is located in the cytosol, consistent with the view that the natural substrate is apocytochrome c. The ctm1-Delta strain lacking the methyltransferase did not exhibit any growth defect on a variety of media and growth conditions, and the unmethylated iso-1-cytochrome c was produced at the normal level and exhibited the normal activity in vivo. Ctm1p and cytochrome c were coordinately regulated during anaerobic to aerobic transition, a finding consistent with the view that this methyltransferase evolved to act on cytochrome c.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu	Polevoda, Bogdan/A-4880-2008; Das, Biswadip/P-9122-2019; Das, Biswadip/AAN-6505-2021	Das, Biswadip/0000-0002-2839-2048	NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECAM AM, 1981, EUR J BIOCHEM, V118, P295; BITAR KG, 1972, BIOCHEM J, V129, P561, DOI 10.1042/bj1290561; BROWN RH, 1973, BIOCHEM J, V131, P247, DOI 10.1042/bj1310247; BROWN RH, 1973, BIOCHEM J, V131, P253, DOI 10.1042/bj1310253; Ceesay K. J., 1991, INT J BIOCHEM, V23, P761; CEESAY KJ, 1994, INT J BIOCHEM, V26, P721, DOI 10.1016/0020-711X(94)90172-4; CERDAN ME, 1988, MOL CELL BIOL, V8, P2275, DOI 10.1128/MCB.8.6.2275; DAUM G, 1982, J BIOL CHEM, V257, P3028; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; DELANGE RJ, 1969, J BIOL CHEM, V244, P1385; DIMARIA P, 1979, J BIOL CHEM, V254, P4645; DURBAN E, 1978, J BIOL CHEM, V253, P1427; FAROOQUI J, 1980, J BIOL CHEM, V255, P4468; FAROOQUI J, 1981, J BIOL CHEM, V256, P5041; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; HAMPSEY DM, 1988, FEBS LETT, V231, P275, DOI 10.1016/0014-5793(88)80834-2; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; HOLZSCHU D, 1987, J BIOL CHEM, V262, P7125; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Z, 1994, GENE DEV, V8, P2110; LIAO HH, 1979, J BACTERIOL, V138, P853, DOI 10.1128/JB.138.3.853-860.1979; LIN D K, 1973, Nature (London), V241, P533, DOI 10.1038/241533a0; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; MEATYARD BT, 1974, PHYTOCHEMISTRY, V13, P2777, DOI 10.1016/0031-9422(74)80241-4; Moore G. R., 1990, CYTOCHROMES C EVOLUT, P115; MORGAN WT, 1972, J BIOL CHEM, V247, P6555; Nait-Kaoudjt R, 1998, EUR J BIOCHEM, V254, P111, DOI 10.1046/j.1432-1327.1998.2540111.x; NaitKaoudjt R, 1997, EUR J BIOCHEM, V244, P301, DOI 10.1111/j.1432-1033.1997.00301.x; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; NOCHUMSON S, 1977, BIOCHEM J, V165, P11, DOI 10.1042/bj1650011; Oechsner U, 1996, NUCLEIC ACIDS RES, V24, P2395, DOI 10.1093/nar/24.12.2395; PARK KS, 1987, J BIOL CHEM, V262, P14702; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; POLASTRO E, 1977, PHYTOCHEMISTRY, V16, P639, DOI 10.1016/S0031-9422(00)89221-3; POLASTRO ET, 1978, BIOCHEM BIOPH RES CO, V81, P920, DOI 10.1016/0006-291X(78)91439-0; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; RAMSHAW JAM, 1975, PHYTOCHEMISTRY, V14, P1945, DOI 10.1016/0031-9422(75)83102-5; RIEDER R, 1978, J BIOL CHEM, V253, P6045; RIEDER R, 1980, J BIOL CHEM, V255, P4732; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SMITH GM, 1980, EUR J BIOCHEM, V110, P123, DOI 10.1111/j.1432-1033.1980.tb04847.x; SPECK SH, 1979, P NATL ACAD SCI USA, V76, P155, DOI 10.1073/pnas.76.1.155; SUGENO K, 1971, J BIOCHEM-TOKYO, V70, P659, DOI 10.1093/oxfordjournals.jbchem.a129681; Takakura H, 1997, BIOCHEMISTRY-US, V36, P2642, DOI 10.1021/bi962245n; Timmerman J, 1996, J MOL BIOL, V259, P792, DOI 10.1006/jmbi.1996.0358; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yu LP, 1997, NAT STRUCT BIOL, V4, P483, DOI 10.1038/nsb0697-483	53	39	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20508	20513		10.1074/jbc.M001891200	http://dx.doi.org/10.1074/jbc.M001891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10791961	hybrid			2022-12-27	WOS:000088084500041
J	Carruthers, VB; Sherman, GD; Sibley, LD				Carruthers, VB; Sherman, GD; Sibley, LD			The Toxoplasma adhesive protein MIC2 is proteolytically processed at multiple sites by two parasite-derived proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL INVASION; PLASMODIUM-FALCIPARUM; GLIDING MOTILITY; MICRONEME DISCHARGE; SERINE-PROTEASE; GONDII; INHIBITORS; SURFACE; INVOLVEMENT; ERYTHROCYTE	MIC2 is an adhesive protein that participates in host cell invasion by the obligate intracellular parasite Toxoplasma gondii, Earlier studies established that MIC2 is secreted into the culture medium by extracellular parasites and that release is coincident with proteolytic modification. Since little is known about proteolytic processing of proteins secreted by T. gondii, we undertook this study to investigate the proteolytic events that accompany secretion of MICE. We demonstrate that the C-terminal domain of MICE is removed by a protease, termed MPP1, when MIC2 is released into the culture supernatant. Additionally, prior to release, a second protease, termed MPP2, trims the N terminus of MIC2, resulting in the release of heterogeneously sized species of MIC2. Although MPP1 activity was unaffected by any of the protease inhibitors tested, MPP2 activity was blocked by a subset of serine and cysteine protease inhibitors. These results establish that MIC2 is proteolytically modified at multiple sites by two distinct enzymes that probably operate on the parasite surface.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Johns Hopkins University; Washington University (WUSTL)	Carruthers, VB (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	vcarruth@jhsph.edu	Sibley, L. David/C-4616-2008	Carruthers, Vern/0000-0001-6859-8895	NIAID NIH HHS [R01 AI034036, AI36034] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHBAROU A, 1991, MOL BIOCHEM PARASIT, V47, P223, DOI 10.1016/0166-6851(91)90182-6; ADAMS JH, 1990, CELL, V63, P141, DOI 10.1016/0092-8674(90)90295-P; AIKAWA M, 1977, AM J PATHOL, V87, P285; BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CARRUTHERS VB, 2000, IN PRESS CELL MICROB; Conseil V, 1999, ANTIMICROB AGENTS CH, V43, P1358, DOI 10.1128/AAC.43.6.1358; DEJKRIENGKRAIKHUL PN, 1983, Z PARASITENKD, V69, P313, DOI 10.1007/BF00927873; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; Dubremetz JF, 1998, TRENDS MICROBIOL, V6, P27, DOI 10.1016/S0966-842X(97)01165-7; DUBREMETZ JF, 1980, MOL BIOCHEM PARASIT, V1, P279, DOI 10.1016/0166-6851(80)90061-4; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; Hakansson S, 1999, MOL BIOL CELL, V10, P3539, DOI 10.1091/mbc.10.11.3539; JOHNSON AM, 1991, GENE, V99, P127, DOI 10.1016/0378-1119(91)90044-C; KAWAZOE U, 1992, PARASITOLOGY, V104, P1, DOI 10.1017/S003118200006073X; KUMAR A, 1992, CELL MOL BIOL, V38, P477; NICHOLS BA, 1981, LAB INVEST, V44, P324; Ogun SA, 1996, MOL BIOCHEM PARASIT, V76, P321, DOI 10.1016/0166-6851(95)02540-5; Ortega-Barria E, 1999, J BIOL CHEM, V274, P1267, DOI 10.1074/jbc.274.3.1267; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Wan KL, 1996, MOL BIOCHEM PARASIT, V75, P179, DOI 10.1016/0166-6851(95)02524-3; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	29	144	153	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14346	14353		10.1074/jbc.275.19.14346	http://dx.doi.org/10.1074/jbc.275.19.14346			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799515				2022-12-27	WOS:000087006900047
J	Cunningham, TS; Andhare, R; Cooper, TG				Cunningham, TS; Andhare, R; Cooper, TG			Nitrogen catabolite repression of DAL80 expression depends on the relative levels of Gat1p and Ure2p production in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; REGULATED TRANSCRIPTION; PROTEIN; YEAST; BINDING; GLN3; OVEREXPRESSION; MUTANTS; VECTORS	GATA family activators (Gln3p and Gat1p) and repressors (Dal80p and Deh1p) regulate nitrogen catabolite repression (NCR)-sensitive transcription in Saccharomyces cerevisiae presumably via their competitive binding to the GATA sequences upstream of NCR-sensitive genes. Ure2p, which is not a GATA family member, inhibits Gln3p/Gat1p from functioning in the presence of good nitrogen sources. We show that NCR-sensitive DAL80 transcription can be influenced by the relative levels of GAT1 and URE2 expression. NCR, normally observed with ammonia or glutamine, is severely diminished when Gat1p is overproduced, and this inhibition is overcome by simultaneously increasing URE2 expression. Further, overproduction of Ure2p nearly eliminates NCR-sensitive transcription under derepressive growth conditions, i.e. with proline as the sole nitrogen source. Enhanced green fluorescent protein-Gat1p is nuclear when Gat1p-dependent transcription is high and cytoplasmic when it is inhibited by overproduction of Ure2p.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA.			Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BYSANI N, 1991, J BACTERIOL, V173, P4977, DOI 10.1128/jb.173.16.4977-4982.1991; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHISHOLM G, 1982, MOL CELL BIOL, V2, P1088, DOI 10.1128/MCB.2.9.1088; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Coffman JA, 1997, J BACTERIOL, V179, P3416, DOI 10.1128/jb.179.11.3416-3429.1997; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; Cooper TG, 1996, MYCOTA, V3, P139; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hardwick JS, 1999, NAT GENET, V23, P49, DOI 10.1038/14319; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KOVARI L, 1990, MOL CELL BIOL, V10, P5087, DOI 10.1128/MCB.10.10.5087; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; PARK HD, 1992, NUCLEIC ACIDS RES, V20, P1909, DOI 10.1093/nar/20.8.1909; Scott S, 2000, J BIOL CHEM, V275, P7198, DOI 10.1074/jbc.275.10.7198; SoussiBoudekou S, 1997, MOL MICROBIOL, V23, P1157, DOI 10.1046/j.1365-2958.1997.3021665.x; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X	33	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14408	14414		10.1074/jbc.275.19.14408	http://dx.doi.org/10.1074/jbc.275.19.14408			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799523	Green Accepted, hybrid			2022-12-27	WOS:000087006900056
J	Jenkins, JL; Lee, MK; Valaitis, AP; Curtiss, A; Dean, DH				Jenkins, JL; Lee, MK; Valaitis, AP; Curtiss, A; Dean, DH			Bivalent sequential binding model of a Bacillus thuringiensis toxin to gypsy moth aminopeptidase N receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; INSECTICIDAL CRYSTAL PROTEINS; AMINO-ACID-RESIDUES; DELTA-ENDOTOXIN; MANDUCA-SEXTA; CRY1AC TOXIN; DOMAIN-III; IRREVERSIBLE BINDING; HELIOTHIS-VIRESCENS; BOMBYX-MORI	Specificity for target insects of Bacillus thuringiensis insecticidal Cry toxins is largely determined by toxin affinity for insect midgut receptors. The mode of binding for one such toxin-receptor complex was investigated by extensive toxin mutagenesis, followed by realtime receptor binding analysis using an optical biosensor (BIAcore), Wild-type Cry1Ac, a three-domain, lepidopteran-specific toxin, bound purified gypsy moth (Lymantria dispar) aminopeptidase N (APN) biphasically, Site 1 displayed fast association and dissociation kinetics, while site 2 possessed slower kinetics, yet tighter affinity. We empirically determined that two Cry1Ac surface regions are involved in in vivo toxicity and APN binding. Mutations within domain III affected binding rates to APN site 1, whereas mutations in domain II affected binding rates to APN site 2, Furthermore, domain III contact is completely inhibited in the presence of N-acetylgalactosamine, indicating loss of domain III binding eliminates all APN binding. Based upon these observations, the following model is proposed. A cavity in lectin-like domain III initiates docking through recognition of an N-acetylgalactosamine moiety on L. dispar APN, Following primary docking, a higher affinity domain II binding mechanism occurs, which is critical for insecticidal activity.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; US Forest Serv, USDA, NE Res Stn, Delaware, OH 43015 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; United States Department of Agriculture (USDA); United States Forest Service	Dean, DH (corresponding author), Ohio State Univ, Dept Mol Genet, Biol Sci Bldg,484 W 12th Ave, Columbus, OH 43210 USA.	dean.10@osu.edu		Jenkins, Jeremy/0000-0001-9795-0771	NIAID NIH HHS [R01 AI29092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARONSON AI, 1986, MICROBIOL REV, V50, P1; Bravo A, 1997, J BACTERIOL, V179, P2793, DOI 10.1128/jb.179.9.2793-2801.1997; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; Carroll J, 1997, J CELL SCI, V110, P3099; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; Cooper MA, 1998, BIOCHEM J, V333, P677, DOI 10.1042/bj3330677; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; CUMMINGS CE, 1994, MOL MEMBR BIOL, V11, P87, DOI 10.3109/09687689409162225; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; de Maagd RA, 1999, MOL MICROBIOL, V31, P463, DOI 10.1046/j.1365-2958.1999.01188.x; DEAN DH, 1992, PLANT PROTEIN ENG; DeMaagd RA, 1996, APPL ENVIRON MICROB, V62, P2753, DOI 10.1128/AEM.62.8.2753-2757.1996; deMaagd RA, 1996, APPL ENVIRON MICROB, V62, P1537, DOI 10.1128/AEM.62.5.1537-1543.1996; DOW JAT, 1986, ADV INSECT PHYSIOL, V19, P187; FENG Q, 1994, BIOCHEMISTRY-US, V33, P8521, DOI 10.1021/bi00194a017; Garner KJ, 1999, INSECT BIOCHEM MOLEC, V29, P527, DOI 10.1016/S0965-1748(99)00027-2; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; GE AZ, 1991, J BIOL CHEM, V266, P17954; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARVEY WR, 1979, J EXP BIOL, V83, P293; HERRMANN MS, 1980, BIOCHIM BIOPHYS ACTA, V621, P43, DOI 10.1016/0005-2795(80)90060-4; HOFTE H, 1989, MICROBIOL REV, V53, P242; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Jenkins JL, 1999, FEBS LETT, V462, P373, DOI 10.1016/S0014-5793(99)01559-8; Joss L, 1998, ANAL BIOCHEM, V261, P203, DOI 10.1006/abio.1998.2744; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; Lee MK, 1996, BIOCHEM BIOPH RES CO, V229, P139, DOI 10.1006/bbrc.1996.1770; Lee MK, 1996, APPL ENVIRON MICROB, V62, P2845, DOI 10.1128/AEM.62.8.2845-2849.1996; LEE MK, 1995, BIOCHEM BIOPH RES CO, V216, P306, DOI 10.1006/bbrc.1995.2625; Lee MK, 1999, APPL ENVIRON MICROB, V65, P4513; LEE MK, 1992, J BIOL CHEM, V267, P3115; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LIANG YZ, 1995, J BIOL CHEM, V270, P24719, DOI 10.1074/jbc.270.42.24719; LU H, 1994, J BACTERIOL, V176, P5554, DOI 10.1128/JB.176.17.5554-5559.1994; Luo K, 1997, INSECT BIOCHEM MOLEC, V27, P735, DOI 10.1016/S0965-1748(97)00052-0; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARKEY F, 1999, BIA J, V6, P14; MASSON L, 1995, J BIOL CHEM, V270, P20309, DOI 10.1074/jbc.270.35.20309; MIDDLEBROOK JL, 1981, RECEPTOR MEDIATED BI, P95; Mirelman D, 1986, MICROBIAL LECTINS AG, P1; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; Myszka DG, 1997, BIOPHYS CHEM, V64, P127, DOI 10.1016/S0301-4622(96)02230-2; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Rajamohan F, 1996, J BIOL CHEM, V271, P2390, DOI 10.1074/jbc.271.5.2390; RAJAMOHAN F, 1995, J BACTERIOL, V177, P2276, DOI 10.1128/jb.177.9.2276-2282.1995; Rajamohan F, 1996, J BIOL CHEM, V271, P25220, DOI 10.1074/jbc.271.41.25220; Rajamohan F, 1996, P NATL ACAD SCI USA, V93, P14338, DOI 10.1073/pnas.93.25.14338; Rao VSR, 1998, J BIOMOL STRUCT DYN, V15, P853, DOI 10.1080/07391102.1998.10508207; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; Smedley DP, 1996, MICROBIOL-SGM, V142, P1617, DOI 10.1099/13500872-142-7-1617; STHILAIRE PM, 1994, BIOCHEMISTRY-US, V33, P14452, DOI 10.1021/bi00252a011; Thompson M A, 1995, Genet Eng (N Y), V17, P99; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; Valaitis AP, 1997, INSECT BIOCHEM MOLEC, V27, P529, DOI 10.1016/S0965-1748(97)00028-3; Valaitis AP, 1995, INSECT BIOCHEM MOLEC, V25, P1143, DOI 10.1016/0965-1748(95)00050-X; VALAITIS AP, 1999, SOC INV PATH 32 M IR, P76; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VONTERSCH MA, 1994, APPL ENVIRON MICROB, V60, P3711, DOI 10.1128/AEM.60.10.3711-3717.1994; WALTERS FS, 1993, BIOCHEM BIOPH RES CO, V196, P921, DOI 10.1006/bbrc.1993.2337; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WU D, 1992, J BIOL CHEM, V267, P2311; Wu SJ, 1996, J MOL BIOL, V255, P628, DOI 10.1006/jmbi.1996.0052	72	102	118	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14423	14431		10.1074/jbc.275.19.14423	http://dx.doi.org/10.1074/jbc.275.19.14423			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799525	hybrid			2022-12-27	WOS:000087006900058
J	McInnes, C; Kondejewski, LH; Hodges, RS; Sykes, BD				McInnes, C; Kondejewski, LH; Hodges, RS; Sykes, BD			Development of the structural basis for antimicrobial and hemolytic activities of peptides based on gramicidin S and design of novel analogs using NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT; ANTIBACTERIAL; HYDROPHOBICITY; ANTIBIOTICS; SENSITIVITY	The structures of 14-residue head-to-tail cyclic gramicidin S peptides have been investigated to develop the structural rationale for their antimicrobial and hemolytic profiles. The basis for these studies is G514 (cyclo(VKLKVdYPLKVKLdYP)), designed as an extension of the naturally occurring antimicrobial peptide. The structure of GS14 has been determined using NMR methods and was found to exist in a highly amphipathic antiparallel beta-sheet conformation. Systematic enantiomeric substitutions within the framework of the GS14 peptide were found to decrease the amphipathicity of this molecule. These results indicated that there was a direct correlation between the high amphipathic character and potent hemolytic activity in the diastereomers, whereas an inverse correlation existed between amphipathicity and antimicrobial function. To define the structural consequences of changing the amphipathic nature of GS14 analogs to maximize antimicrobial activity and to minimize hemolysis, NMR structures were determined in water and the membrane-mimetic solvent trifluoroethanol. The structures show that these attributes are the result of induction of the beta-sheet character in a membrane environment and the positioning of charged side chains on the hydrophobic face of the cyclic framework, thus decreasing the amphipathicity and directed hydrophobicity of these molecules. Implications for the design of more effective antimicrobials are discussed.	Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada	University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Prot Engn Network Ctr Excellence, 713 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.		McInnes, Campbell/A-6721-2009					BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; Gause GF, 1944, NATURE, V154, P703, DOI 10.1038/154703a0; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; IZUMIYA N, 1979, SYNTHETIC ASPECTS BI, P49; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Kondejewski LH, 1996, J BIOL CHEM, V271, P25261, DOI 10.1074/jbc.271.41.25261; Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; La Rocca P, 1999, BIOPHYS CHEM, V76, P145, DOI 10.1016/S0301-4622(98)00232-4; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	25	63	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14287	14294		10.1074/jbc.275.19.14287	http://dx.doi.org/10.1074/jbc.275.19.14287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799508	hybrid			2022-12-27	WOS:000087006900040
J	Takahashi, Y; Takahashi, S; Shiga, Y; Yoshimi, T; Miura, T				Takahashi, Y; Takahashi, S; Shiga, Y; Yoshimi, T; Miura, T			Hypoxic induction of prolyl 4-hydroxylase alpha(I) in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE-A; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA LEVELS; LOW-OXYGEN TENSION; INDUCIBLE FACTOR-I; RAT LUNG; PHOSPHOGLYCERATE KINASE-1; DIFFERENTIAL-DISPLAY; EXTRACELLULAR-MATRIX; RESPONSE ELEMENTS	Accumulated evidence indicates that hypoxia activates collagen synthesis in tissues. To explore the molecular mechanism of activation, we screened genes that are up-regulated or down-regulated by hypoxia, Fibroblasts isolated from fetal rat lung were cultured under hypoxia, Differential display technique showed that the mRNA level of prolyl 4-hydroxylase (PH) alpha(I), an active subunit that catalyzes the oxygen-dependent hydroxylation of proline residue in procollagen, increased 2-3-fold after an 8-h exposure to hypoxia, This elevated level was maintained over 40 h and returned to the basal level after reoxygenation, The transcription rate, protein level, and hydroxyproline content tan indicator of the prolyl hydroxylation) were all elevated by hypoxic culture. Analysis of the promotor region of PH alpha(I) gene indicated that a motif similar to hypoxia-responsive element (HRE) of hypoxia-inducible genes such as erythropoietin, was identified within a 120-base pair sequence upstream of the transcription start site. Luciferase reporter assay and mutational analysis showed that a site similar to the HRE in this motif is functionally essential to hypoxic response. Electrophoretic mobility shift assay revealed that hypoxia-inducible factor-1 was stimulated and bound to the PH alpha(I) HRE upon hypoxic challenge. Our results indicate that PHa(I), an essential enzyme for collagen synthesis, is a target gene for hypoxia-inducible factor-1.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Environm Mol Physiol, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Takahashi, Y (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Environm Mol Physiol, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.							Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arbeille P, 1997, OBSTET GYNECOL, V90, P795, DOI 10.1016/S0029-7844(97)00361-X; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BATENBURG JJ, 1988, BIOCHIM BIOPHYS ACTA, V960, P441, DOI 10.1016/0005-2760(88)90053-7; BECK I, 1991, J BIOL CHEM, V266, P15563; BERG RA, 1982, METHOD ENZYMOL, V82, P372; BRODY JS, 1992, ANNU REV PHYSIOL, V54, P351, DOI 10.1146/annurev.physiol.54.1.351; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DAVILA RM, 1995, AM J PHYSIOL-LUNG C, V268, pL309, DOI 10.1152/ajplung.1995.268.2.L309; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; DURMOWICZ AG, 1994, AM J PATHOL, V145, P1411; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; FALANGA V, 1993, J CELL PHYSIOL, V157, P408, DOI 10.1002/jcp.1041570225; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; HAY ED, 1991, COLLAGEN; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Inayama S, 1978, Keio J Med, V27, P43; ITO T, 1994, FEBS LETT, V351, P231, DOI 10.1016/0014-5793(94)00867-1; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kim SB, 1996, NEPHRON, V72, P275, DOI 10.1159/000188854; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; LEVENE CI, 1976, BIOCHIM BIOPHYS ACTA, V444, P446, DOI 10.1016/0304-4165(76)90388-3; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; OSTADAL B, 1995, PHYSIOL RES, V44, P45; Perhonen M, 1996, J APPL PHYSIOL, V80, P2226, DOI 10.1152/jappl.1996.80.6.2226; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Takahashi Y, 1997, BIOCHEM PHARMACOL, V53, P1061, DOI 10.1016/S0006-2952(97)00104-4; Takahashi Y, 1998, EUR J BIOCHEM, V254, P497, DOI 10.1046/j.1432-1327.1998.2540497.x; TAKAHASHI Y, 1997, TOXICOL APPL PHARM, V143, P288; TURTO H, 1979, ATHEROSCLEROSIS, V33, P379, DOI 10.1016/0021-9150(79)90030-3; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wasowicz M, 1998, FOLIA HISTOCHEM CYTO, V36, P3	48	143	151	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14139	14146		10.1074/jbc.275.19.14139	http://dx.doi.org/10.1074/jbc.275.19.14139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799490	hybrid			2022-12-27	WOS:000087006900020
J	Dineley, KT; Patrick, JW				Dineley, KT; Patrick, JW			Amino acid determinants of alpha 7 nicotinic acetylcholine receptor surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUNGAROTOXIN BINDING-SITES; RAT HIPPOCAMPAL INTERNEURONS; SYNAPTIC TRANSMISSION; IMMUNOCYTOCHEMICAL LOCALIZATION; CHOLINERGIC RECEPTOR; XENOPUS OOCYTES; SUBUNIT; CELLS; PROTEIN; NEURONS	Transient transfection has not been a successful method to express the alpha 7 nicotinic acetylcholine receptor such that these receptors are detected on the cell surface. This is not the case for all ligand-gated ion channels. Transient transfection with the 5-hydroxytryptamine type 3 subunit cDNA results in detectable surface receptor expression, Cell lines stably ex pressing the alpha 7 nicotinic acetylcholine receptor produce detectable, albeit variable, levels of surface receptor expression. alpha 7 nicotinic acetylcholine receptor surface expression is dependent, at least in part, on cell-specific factors, In addition to factors provided by the cells used for receptor expression, we hypothesize that the surface expression level in transfected cells is an intrinsic property of the receptor protein under study, Employing a set of alpha 7-5-hydroxytryptamine type 3 chimeric receptor subunit cDNAs, we expressed these constructs in a transient transfection system and quantified surface receptor expression. We have identified amino acids that control receptor distribution between surface and intracellular pools; surface receptor expression can be manipulated without affecting the total number of receptors, These determinants function independently of the cell line used for expression and the transfection method employed. How these surface expression determinants in the alpha 7 nicotinic acetylcholine receptor might influence synaptic efficacy is discussed.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Dineley, KT (corresponding author), Baylor Coll Med, Div Neurosci, Rm S603,1 Baylor Plaza, Houston, TX 77030 USA.	kdineley@sensor.neusc.bcm.tmc.edu			NIDA NIH HHS [F31 DA05694] Funding Source: Medline; NINDS NIH HHS [NS 13546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005694] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alkondon M, 1998, BRAIN RES, V810, P257, DOI 10.1016/S0006-8993(98)00880-4; Alkondon M, 1996, J PHARMACOL EXP THER, V278, P1460; Aramakis VB, 1998, J NEUROSCI, V18, P8485; Arroyo-Jimenez MD, 1999, J NEUROSCI, V19, P6475; BARRANTES GE, 1995, BRAIN RES, V672, P228, DOI 10.1016/0006-8993(94)01386-V; BERTRAND D, 1995, SEMIN NEUROSCI, V7, P75, DOI 10.1006/smns.1995.0010; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; Chen DN, 1997, J BIOL CHEM, V272, P24024, DOI 10.1074/jbc.272.38.24024; Chen DN, 1998, J NEUROCHEM, V70, P349; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Cooper ST, 1997, J NEUROCHEM, V68, P2140; Corringer PJ, 1998, J NEUROSCI, V18, P648; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P11548, DOI 10.1073/pnas.90.24.11548; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Frazier CJ, 1998, J NEUROSCI, V18, P8228; Frazier CJ, 1998, J NEUROSCI, V18, P1187; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; Green WN, 1998, J NEUROSCI, V18, P5555; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; HALVORSEN SW, 1995, BIOCHEM PHARMACOL, V50, P1665, DOI 10.1016/0006-2952(95)02067-5; HILL JA, 1993, J NEUROSCI, V13, P1551; JACOB MH, 1986, J CELL BIOL, V103, P205, DOI 10.1083/jcb.103.1.205; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kassner PD, 1997, J NEUROBIOL, V33, P968, DOI 10.1002/(SICI)1097-4695(199712)33:7<968::AID-NEU8>3.0.CO;2-6; KEMP G, 1985, BRAIN RES, V347, P274, DOI 10.1016/0006-8993(85)90187-8; Komourian J, 1996, BRAIN RES, V718, P37, DOI 10.1016/0006-8993(96)00024-8; Li XY, 1998, J NEUROSCI, V18, P1904; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MASON WT, 1985, NEUROSCI LETT, V59, P89, DOI 10.1016/0304-3940(85)90220-4; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; McQuiston AR, 1999, J NEUROSCI, V19, P2887; Mukerji J, 1996, J NEUROCHEM, V66, P1027; Nakayama H, 1997, NEUROSCI RES, V29, P233, DOI 10.1016/S0168-0102(97)00100-4; NEFF S, 1995, J NEUROCHEM, V64, P332; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; PATRICK J, 1977, J BIOL CHEM, V252, P8629; PENG X, 1994, MOL PHARMACOL, V45, P546; Quik M, 1996, J NEUROCHEM, V67, P145; Radcliffe KA, 1998, J NEUROSCI, V18, P7075; Rakhilin S, 1999, J CELL BIOL, V146, P203; Samuel N, 1997, NEUROSCI LETT, V222, P179, DOI 10.1016/S0304-3940(97)13377-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGUELA P, 1993, J NEUROSCI, V13, P596; SWANSON LW, 1983, P NATL ACAD SCI-BIOL, V80, P4532, DOI 10.1073/pnas.80.14.4532; Tokimasa T, 1996, J PHYSIOL-LONDON, V496, P677, DOI 10.1113/jphysiol.1996.sp021718	48	31	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13974	13985		10.1074/jbc.275.18.13974	http://dx.doi.org/10.1074/jbc.275.18.13974			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788524	hybrid			2022-12-27	WOS:000086925300112
J	Kurz, EU; Leader, KB; Kroll, DJ; Clark, M; Gieseler, F				Kurz, EU; Leader, KB; Kroll, DJ; Clark, M; Gieseler, F			Modulation of human DNA topoisomerase II alpha function by interaction with 14-3-3 epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA VIRUSES; CELL-SURFACE RECEPTOR; NUCLEAR-LOCALIZATION; 14-3-3-PROTEINS ASSOCIATE; CYTOPLASMIC LOCALIZATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; BINDING-PROTEIN; 14-3-3 PROTEIN; SHEEP BRAIN	Human DNA topoisomerase II alpha (topo II), a ubiquitous nuclear enzyme, is essential for normal and neoplastic cellular proliferation and survival. Several common anticancer drugs exert their cytotoxic effects through interaction with topo II. In experimental systems, altered topo II expression has been associated with the appearance of drug resistance. This mechanism, however, does not adequately account for clinical cases of resistance to topo II-directed drugs. Modulation by protein-protein interactions represents one mechanism of topo II regulation that has not been extensively defined. Our laboratory has identified 14-3-3 epsilon as a topo II-interacting protein. In this study, glutathione S-transferase co-precipitation, affinity column chromatography, and immunoprecipitations confirm the authenticity of these interactions. Three assays evaluate the impact of 14-3-3 epsilon on distinct topo II functional properties. Using both a modified alkaline comet assay and a DNA cleavage assay, we demonstrate that 14-3-3 epsilon negatively affects the ability of the chemotherapeutic, etoposide, to trap topo II in cleavable complexes with DNA, thereby preventing DNA strand breaks. By electrophoretic mobility shift assay, this appears to be due to reduced DNA binding activity. The association of topo II with 14-3-3 proteins does not extend to all 14-3-3 isoforms, No protein interaction or disruption of topo II function was observed with 14-3-3 sigma.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Ctr Canc, Denver, CO 80262 USA; Univ Kiel, Univ Hosp, Klin Allgemeine Innere Med, D-24105 Kiel, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; University of Kiel; Schleswig Holstein University Hospital	Kroll, DJ (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Box C238,4200 E 9th Ave, Denver, CO 80262 USA.		Gieseler, Frank/E-8386-2012; Gieseler, Frank/L-4668-2013	Gieseler, Frank/0000-0001-6409-3822; 	NATIONAL CANCER INSTITUTE [R01CA076201] Funding Source: NIH RePORTER; NCI NIH HHS [CA-76201] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; Bjergbaek L, 1999, J BIOL CHEM, V274, P26529, DOI 10.1074/jbc.274.37.26529; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DANG Q, 1994, J MOL BIOL, V243, P10, DOI 10.1006/jmbi.1994.1626; DANKS MK, 1993, CANCER RES, V53, P1373; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gantchev TG, 1998, MOL PHARMACOL, V53, P422, DOI 10.1124/mol.53.3.422; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; Gieseler F, 1999, LEUKEMIA, V13, P1859, DOI 10.1038/sj.leu.2401570; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HINDS M, 1991, CANCER RES, V51, P4729; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; KAUFMANN SH, 1994, BLOOD, V83, P517; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; Kroll DJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P175, DOI 10.1006/abbi.1997.0267; KROLL DJ, 1993, MOL ENDOCRINOL, V7, P305, DOI 10.1210/me.7.3.305; KROLL DJ, 1991, J BIOL CHEM, V266, P7967; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MCKELVEYMARTIN VJ, 1993, MUTAT RES, V288, P47, DOI 10.1016/0027-5107(93)90207-V; MIRSKI SEL, 1995, CANCER RES, V55, P2129; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; ROSEBOOM PH, 1994, DNA CELL BIOL, V13, P629, DOI 10.1089/dna.1994.13.629; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wang XQ, 1996, NUCLEIC ACIDS RES, V24, P4791, DOI 10.1093/nar/24.23.4791; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865	60	40	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13948	13954		10.1074/jbc.275.18.13948	http://dx.doi.org/10.1074/jbc.275.18.13948			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788521	hybrid			2022-12-27	WOS:000086925300108
J	Jegerschold, C; Rutherford, AW; Mattioli, TA; Crimi, M; Bassi, R				Jegerschold, C; Rutherford, AW; Mattioli, TA; Crimi, M; Bassi, R			Calcium binding to the photosystem II subunit CP29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-BAND SPECTROSCOPY; NITROCELLULOSE MEMBRANE; BIOLOGICAL-SYSTEMS; CRYSTAL-STRUCTURE; OXYGEN EVOLUTION; CHLOROPHYLL-B; CA2+ BINDING; PROTEIN; SPINACH; SITES	We have identified a Ca2+-binding site of the 29-kDa chlorophyll a/b-binding protein CP29, a light harvesting protein of photosystem II most likely involved in photoregulation. Ca-45(2+) binding studies and dot blot analyses of CP29 demonstrate that CP29 is a Ca2+-binding protein. The primary sequence of CP29 does not exhibit an obvious Ca2+-binding site therefore we have used Yb3+ replacement to analyze this site. Near-infrared Yb3+ vibronic side band fluorescence spectroscopy (Roselli, C., Boussac, A. and Mattioli, T. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12897-12901) of Yb3+-reconstituted CP29 indicated a single population of Yb3+-binding sites rich in carboxylic acids, characteristic of Ca2+-binding sites. A structural model of CP29 presents two purported extra-membranar loops which are relatively rich in carboxylic acids, one on the stromae side and one on the lumenal side. The loop on the lumenal side is adjacent to glutamic acid 166 in helix C of CP29, which is known to be the binding site for dicyclohexylcarbodiimide (Pesaresi, P., Sandona, D., Giuffra, E., and Bassi, R. (1997) FEBS Lett. 402, 151-156). Dicyclohexylcarbodiimide binding prevented Ca2+ binding, therefore we propose that the Ca2+ in CP29 is bound in the domain including the lumenal loop between helices B and C.	CEA Saclay, Dept Biol Cellulaire & Mol, Sect Bioenerget, F-91191 Gif Sur Yvette, France; CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France; Univ Verona, Fac Sci MMFFNN, I-37134 Verona, Italy	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Verona	Mattioli, TA (corresponding author), CEA Saclay, Dept Biol Cellulaire & Mol, Sect Bioenerget, F-91191 Gif Sur Yvette, France.		Rutherford, Alfred W/A-7831-2019	Rutherford, Alfred W/0000-0002-3124-154X; bassi, roberto/0000-0002-4140-8446; Jegerschold, Caroline/0000-0003-2419-6354				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P9021, DOI 10.1021/bi00028a010; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; Britt R.D, 1996, ADV PHOTOSYNTHESIS O; CHEN C, 1995, PHOTOSYNTHESIS LIGHT, V2, P329; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DAVIS DJ, 1975, BIOCHIM BIOPHYS ACTA, V387, P557, DOI 10.1016/0005-2728(75)90093-6; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; EINSPAHR H, 1984, MET IONS BIOL SYST, V17, P51; EVANS CH, 1990, BIOCHEMSITRY LANTHAN; Finn BE, 1999, ADV INORG CHEM, V46, P441; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; HAN K, 1993, PLANT CELL PHYSIOL, V34, P585; Horrocks W. D., 1982, ADV INORG BIOCHEM, P201; HORROCKS WDW, 1993, METHOD ENZYMOL, V226, P495, DOI 10.1016/0076-6879(93)26023-3; IRRGANG KD, 1991, EUR J BIOCHEM, V201, P515, DOI 10.1111/j.1432-1033.1991.tb16311.x; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; KRIEGER A, 1993, PHOTOSYNTH RES, V37, P117, DOI 10.1007/BF02187470; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUMAR VD, 1991, FEBS LETT, V283, P311, DOI 10.1016/0014-5793(91)80616-B; MACPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; NAKAMOTO K, 1963, INFRARED INORGANIC C; ONO T, 1988, FEBS LETT, V227, P147, DOI 10.1016/0014-5793(88)80886-X; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Qian M, 1999, BIOCHEMISTRY-US, V38, P6070, DOI 10.1021/bi982331i; ROSELLI C, 1994, P NATL ACAD SCI USA, V91, P12897, DOI 10.1073/pnas.91.26.12897; Roselli C, 1995, BIOSPECTROSCOPY, V1, P329, DOI 10.1002/bspy.350010504; Roselli C, 1996, P NATL ACAD SCI USA, V93, P14333, DOI 10.1073/pnas.93.25.14333; Rutherford A.W., 1992, PHOTOSYSTEMS STRUCTU, P179; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SHEN JR, 1988, BIOCHIM BIOPHYS ACTA, V936, P386, DOI 10.1016/0005-2728(88)90015-1; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; WEBBER AN, 1989, FEBS LETT, V249, P79, DOI 10.1016/0014-5793(89)80020-1; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3	43	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12781	12788		10.1074/jbc.275.17.12781	http://dx.doi.org/10.1074/jbc.275.17.12781			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777575	hybrid			2022-12-27	WOS:000086762300059
J	Schmitz, J; Weissenbach, M; Haan, S; Heinrich, PC; Schaper, F				Schmitz, J; Weissenbach, M; Haan, S; Heinrich, PC; Schaper, F			SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PHASE RESPONSE FACTOR/STAT3; KINASE JAK1; DIFFERENTIAL ACTIVATION; CYTOPLASMIC DOMAIN; STAT3 ACTIVATION; GENE-EXPRESSION; SH2 DOMAIN; RECEPTOR; CELLS	Interleukin-6 is involved in the regulation of many biological activities such as gene expression, cell proliferation, and differentiation. The control of the termination of cytokine signaling is as important as the regulation of initiation of signal transduction pathways. Three families of proteins involved in the down-regulation of cytokine signaling have been described recently: (i) SH2 domain-containing protein-tyrosine phosphatases (SHP), (ii) suppressors of cytokine signaling (SOCS), and (iii) protein inhibitors of activated STATs (PIAS). We have analyzed the interplay of two inhibitors in the signal transduction pathway of interleukin-6 and demonstrate that the tyrosine phosphatase SHP2 and SOCS3 do not act independently but are functionally linked. The activation of one inhibitor modulates the activity of the other; Inhibition of SHP2 activation leads to increased SOCS3-mRNA levels, whereas increased expression of SOCS3 results in a reduction of SHP2 phosphorylation after activation of the interleukin-6 signal transduction pathway. Furthermore, we show that tyrosine 759 in gp130 is essential for both SHP2 and SOCS3 but not for SOCS1 to exert their inhibitory activities on interleukin-6 signal transduction, Besides SHP2, SOCS3 also interacts with the Tyr(P)-759 peptide of gp130. Taken together, our results suggest differences in the function of SOCS1 and SOCS3 and a link between SHP2 and SOCS3.	Rhein Westfal TH Aachen, Sch Med, Dept Biochem, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University	Heinrich, PC (corresponding author), Rhein Westfal TH Aachen, Sch Med, Dept Biochem, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gatsios P, 1996, EUR J BIOCHEM, V241, P56, DOI 10.1111/j.1432-1033.1996.0056t.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELM MH, 1995, SCIENCE, V267, P1347; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TERSTEGEN L, 2000, IN PRESS J BIOL CHEM, V275; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	320	325	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12848	12856		10.1074/jbc.275.17.12848	http://dx.doi.org/10.1074/jbc.275.17.12848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777583	hybrid			2022-12-27	WOS:000086762300067
J	Mizutani, T; Yamada, K; Minegishi, T; Miyamoto, K				Mizutani, T; Yamada, K; Minegishi, T; Miyamoto, K			Transcriptional regulation of rat scavenger receptor class B type I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; STEROIDOGENIC FACTOR-I; BOVINE CYP11A GENE; PROTEIN STAR GENE; APOPROTEIN-A-I; SR-BI; PROMOTER ACTIVITY; BINDING PROTEIN; ADRENAL-GLAND; EXPRESSION	The scavenger receptor class B type I (SR-BI) mediates the selective transport of lipids from high density lipoprotein to cells and plays an important role in the reverse uptake of cholesterol to the liver and in the delivery of substrates for steroidogenesis in steroidogenic organs. We report here on the isolation and characterization of the upstream promoter region of the rat SR-BI gene. The transcription start site for rat SR-BI was mapped, and DNA sequence analysis revealed the presence of binding sites for the Sp1 family in the proximal 5'-flanking region. Analysis of deletion mutants with different 5' lengths revealed that the region between -121 and -90 base pairs from the transcription start site is essential for the efficient transcription of SR-BI. Both Sp1 and Sp3 bind to three GC boxes in the region (-141 to -1 base pairs) in a sequence-specific manner, Mutations in any of the GC boxes decreased efficient transcription from this promoter in MA-10 mouse Leydig tumor cells, The overexpression of Sp1 or Sp3 protein enhanced the rat SR-BI promoter activity. These results indicate that Sp1 family members of transcription factors are essential for transcription of the rat SR-BI gene.	Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan; Gunma Univ, Sch Med, Dept Obstet & Gynecol, Maebashi, Gumma 371, Japan	University of Fukui; Gunma University	Miyamoto, K (corresponding author), Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAGENBUCHLE O, 1985, J MOL BIOL, V185, P285, DOI 10.1016/0022-2836(85)90404-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kaiser UB, 1998, J BIOL CHEM, V273, P12943, DOI 10.1074/jbc.273.21.12943; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; Lopez D, 1999, ENDOCRINOLOGY, V140, P5669, DOI 10.1210/en.140.12.5669; Lopez D, 1999, ENDOCRINOLOGY, V140, P3034, DOI 10.1210/en.140.7.3034; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Xu SZ, 1997, J LIPID RES, V38, P1289; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	43	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22512	22519		10.1074/jbc.M001631200	http://dx.doi.org/10.1074/jbc.M001631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801817	hybrid			2022-12-27	WOS:000088363800101
J	Parra, KJ; Keenan, KL; Kane, PM				Parra, KJ; Keenan, KL; Kane, PM			The H subunit (Vma13p) of the yeast V-ATPase inhibits the ATPase activity of cytosolic V-1 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING SITES; SACCHAROMYCES-CEREVISIAE; NONCATALYTIC SITES; VACUOLAR MEMBRANES; KINETIC MECHANISM; POLAR LOOP; RECONSTITUTION; DOMAIN	V-ATPases are composed of a peripheral complex containing the ATP-binding sites, the V-1 sector, attached to a membrane complex containing the proton pore, the V-o sector. In vivo, free, inactive V-1 and V-o sectors exist in dynamic equilibrium with fully assembled, active V-1 V-o complexes, and this equilibrium can be perturbed by changes in carbon source. Free V-1 complexes were isolated from the cytosol of wild-type yeast cells and mutant strains lacking V-o subunit c (Vma3p) or V-1 subunit H (Vma13p). V-1 complexes from wild-type or vma3 Delta mutant cells were very similar, and contained all previously identified yeast V-1 subunits except subunit C (Vma5p). These V-1 complexes hydrolyzed CaATP but not MgATP, and CaATP hydrolysis rapidly decelerated with time. V-1 complexes from vma13 Delta cells contained all V-1 subunits except C and H, and had markedly different catalytic properties. The initial rate of CaATP hydrolysis was maintained for much longer. The complexes also hydrolyzed MgATP, but showed a rapid deceleration in hydrolysis. These results indicate that the H subunit plays an important role in silencing unproductive ATP hydrolysis by cytosolic V-1 complexes, but suggest that other mechanisms, such as product inhibition, may also play a role in silencing in vivo.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.				NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; DENG SB, 1999, J BIOL CHEM, V274, P2549; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FENG Y, 1992, J BIOL CHEM, V267, P5817; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HICKS DB, 1986, J BIOL CHEM, V261, P2896; HO MN, 1993, J BIOL CHEM, V268, P18286; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Vasilyeva E, 1998, J BIOL CHEM, V273, P23823, DOI 10.1074/jbc.273.37.23823; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; Wieczorek H, 2000, J EXP BIOL, V203, P127; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xie XS, 1996, J BIOL CHEM, V271, P30980; XIE XS, 1988, J BIOL CHEM, V263, P9859; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; Zhou ZM, 1999, J BIOL CHEM, V274, P15913, DOI 10.1074/jbc.274.22.15913	45	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21761	21767		10.1074/jbc.M002305200	http://dx.doi.org/10.1074/jbc.M002305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781598	hybrid			2022-12-27	WOS:000088230600105
J	Atienza, JM; Suh, M; Xenarios, I; Landgraf, R; Colicelli, J				Atienza, JM; Suh, M; Xenarios, I; Landgraf, R; Colicelli, J			Human ERK1 induces filamentous growth and cell wall remodeling pathways in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAP-KINASE; SIGNAL-TRANSDUCTION; PSEUDOHYPHAL DIFFERENTIATION; RESPONSE PATHWAY; CANDIDA-ALBICANS; MAMMALIAN-CELLS; FISSION YEAST; BUDDING YEAST; KSS1	Expression of an activated extracellular signal-regulated kinase 1 (ERK1) construct in yeast cells was used to examine the conservation of function among mitogen-activated protein (MAP) kinases, Sequence alignment of the human MAP kinase ERK1 with all Saccharomyces cerevisiae kinases reveals a particularly strong kinship with Kss1p (invasive growth promoting MAP kinase), Fus3p (pheromone response MAP/ERK kinase), and Mpk1p (cell wall remodeling MAP kinase), A fusion protein of constitutively active human MAP/ERK kinase 1 (MEK) and human ERK1 was introduced under regulated expression into yeast cells. The fusion protein (MEK/ERK) induced a filamentation response element promoter and led to a growth retardation effect concomitant with a morphological change resulting in elongated cells, bipolar budding, and multicell chains. Induction of filamentous growth was also observed for diploid cells following MEK/ERK expression in liquid culture. Neither haploids nor diploids, however, showed marked penetration of agar medium. These effects could be triggered by either moderate MER/ERK expression at 37 degrees C or by high level MEK/ERK expression at 30 degrees C. The combination of high level MEK/ERK expression and 37 degrees C resulted in cell death. The deleterious effects of MEK/ERK expression and high temperature were significantly mitigated by 1 M sorbitol, which also enhanced the filamentous phenotype. MEK/ERK was able to constitutively activate a cell wall maintenance reporter gene, suggesting misregulation of this pathway. In contrast, MEK/ERK effectively blocked expression from a pheromone-responsive element promoter and inhibited mating. These results are consistent with MEK/ERK promoting filamentous growth and altering the cell wall through its ability to partially mimic Kss1p and stimulate a pathway normally controlled by Mpk1p, while appearing to inhibit the normal functioning of the structurally related yeast MAP kinase Fus3p.	Univ Calif Los Angeles, DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Colicelli, J (corresponding author), Univ Calif Los Angeles, DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA.		Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031911] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31911] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Atienza JM, 1998, METHODS, V14, P35, DOI 10.1006/meth.1997.0563; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cherkasova V, 1999, GENETICS, V151, P989; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hirata D, 1998, J CELL SCI, V111, P149; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Jacoby JJ, 1998, MOL GEN GENET, V258, P148, DOI 10.1007/s004380050717; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Landgraf R, 1999, PROTEIN ENG, V12, P943, DOI 10.1093/protein/12.11.943; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lorenz MC, 1998, GENETICS, V150, P1443; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Mosch HU, 1997, GENETICS, V145, P671; Navarro-Garcia F, 1998, MICROBIOL-UK, V144, P411, DOI 10.1099/00221287-144-2-411; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Oehlen L, 1998, FEBS LETT, V429, P83, DOI 10.1016/S0014-5793(98)00568-7; Pan XW, 1999, MOL CELL BIOL, V19, P4874; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; Radcliffe PA, 1997, MICROBIOL-UK, V143, P1867, DOI 10.1099/00221287-143-6-1867; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Roemer T, 1998, J CELL SCI, V111, P479; Rose MD., 1990, METHODS YEAST GENETI; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	66	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20638	20646		10.1074/jbc.M910024199	http://dx.doi.org/10.1074/jbc.M910024199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787425	hybrid			2022-12-27	WOS:000088084500060
J	Buist, A; Blanchetot, C; Tertoolen, LGJ; den Hertog, J				Buist, A; Blanchetot, C; Tertoolen, LGJ; den Hertog, J			Identification of p130(cas) as an in vivo substrate of receptor protein-tyrosine phosphatase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM CATALYTIC DOMAINS; EPIDERMAL GROWTH-FACTOR; MEDIATED CELL-ADHESION; SRC-FAMILY KINASES; CRYSTAL-STRUCTURE; IN-VIVO; PTP-PEST; NEURONAL DIFFERENTIATION; DOWN-REGULATION; PHOSPHORYLATION	We have employed a substrate trapping strategy to identify physiological substrates of the receptor protein-tyrosine phosphatase alpha (RPTP alpha). Here we report that a substrate-trapping mutant of the RPTP alpha membrane proximal catalytic domain (D1), RPTP alpha-D1C433S, specifically bound to tyrosine-phosphorylated proteins from pervanadate-treated cells. The membrane distal catalytic domain of RPTP alpha (D2) and mutants thereof did not bind to tyrosine-phosphorylated proteins. The pattern of tyrosine-phosphorylated proteins that bound to RPTP alpha-D1-C433S varied between cell lines, but a protein of approximately 130 kDa was pulled down from every cell line. This protein was identified as p130(cas). Tyrosine-phosphorylated p130(cas) from fibronectin-stimulated NIH3T3 cells bound to RPTP alpha-D1-C433S as web, suggesting that p130(cas) is a physiological substrate of RPTP alpha. RPTP alpha dephosphorylated p130(cas) in vitro, and RPTP alpha co-localized with a subpopulation of p130(cas) to the plasma membrane. Co-transfection experiments with activated SrcY529F, p130(cas), and RPTP alpha or inactive, mutant RPTP alpha indicated that RPTP alpha dephosphorylated p130(cas) in vivo. Tyrosine-phosphorylated epidermal growth factor receptor was not dephosphorylated by RPTP alpha under these conditions, suggesting that p130(cas) is a specific substrate of RPTP alpha in living cells. In conclusion, our results provide evidence that p130(cas) is a physiological substrate of RPTP alpha in vivo.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl		Blanchetot, christophe/0000-0001-9152-9978				Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1991, CELL GROWTH DIFFER, V2, P155; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Hunter T, 1998, NAT GENET, V18, P303; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Van der Sar AM, 1999, INT J DEV BIOL, V43, P785; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; YANG Q, 1993, ADV PROTEIN PHOSPHAT, V7, P359; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	62	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20754	20761		10.1074/jbc.M001626200	http://dx.doi.org/10.1074/jbc.M001626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787408	hybrid			2022-12-27	WOS:000088084500075
J	Lam, LT; Ronchini, C; Norton, J; Capobianco, AJ; Bresnick, EH				Lam, LT; Ronchini, C; Norton, J; Capobianco, AJ; Bresnick, EH			Suppression of erythroid but not megakaryocytic differentiation of human K562 erythroleukemic cells by Notch-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BARR-VIRUS EBNA2; SIGNALING PATHWAY; BINDING-PROTEIN; DROSOPHILA-MELANOGASTER; INTRACELLULAR DOMAIN; EMBRYONIC LETHALITY; LEUKEMIA-CELLS; MICE LACKING; DNA-BINDING	The Notch signal transduction pathway is a highly conserved regulatory system that controls multiple developmental processes. We have established an erythroleukemia cell model to study how Notch regulates cell fate and erythroleukemic cell differentiation. K562 and HEL cells expressed the Notch-1 receptor and the Notch ligand Jagged-1. The stable expression of the constitutively active intracellular domain of Notch-1 (NIC-1) in K562 cells inhibited erythroid without affecting megakaryocytic maturation. Expression of antisense Notch-1 induced spontaneous erythroid maturation. Suppression of erythroid maturation by NIC-1 did not result from down-regulation of GATA-1 and TAL-1, transcription factors necessary for erythroid differentiation. Microarray gene expression analysis identified genes activated during erythroid maturation, and NIC-1 disrupted the maturation-dependent changes in the expression of these genes. These results show that NIC-1 alters the pattern of gene expression in K562 cells leading to a block in erythroid maturation and therefore suggest that Notch signaling may control the developmental potential of normal and malignant erythroid progenitor cells.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; University of Cincinnati	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 387 Med Sci,1300 Univ Ave, Madison, WI 53706 USA.	ehbresin@facstaff.wisc.edu	Ronchini, Chiara/K-3935-2013	Ronchini, Chiara/0000-0003-3908-4021; Capobianco, Anthony/0000-0002-3706-6797	NIDDK NIH HHS [DK50107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050107, R01DK050107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cornell M, 1999, GENETICS, V152, P567; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; deCelis JF, 1997, DEVELOPMENT, V124, P3241; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Gould KA, 1998, GENE EXPRESSION, V7, P87; Hadland BK, 1999, BLOOD, V94, p255A; Hamada Y, 1999, DEVELOPMENT, V126, P3415; HOFFMAN R, 1979, BLOOD, V54, P1182; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Lam LT, 1998, J BIOL CHEM, V273, P24223, DOI 10.1074/jbc.273.37.24223; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Lendahl U, 1998, BIOESSAYS, V20, P103, DOI 10.1002/(SICI)1521-1878(199802)20:2<103::AID-BIES1>3.0.CO;2-U; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; MILNER LA, 1994, BLOOD, V83, P2057; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nofziger D, 1999, DEVELOPMENT, V126, P1689; OKA C, 1995, DEVELOPMENT, V121, P3291; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Robey E, 1999, ANNU REV IMMUNOL, V17, P283, DOI 10.1146/annurev.immunol.17.1.283; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROSSON D, 1995, MOL CELL BIOL, V15, P772; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sella O, 1999, MOL CELL BIOL, V19, P5429; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Shawber C, 1996, DEVELOPMENT, V122, P3765; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SRIVASTAVA MD, 1993, LEUKEMIA RES, V17, P1063, DOI 10.1016/0145-2126(93)90164-G; STOLZ A, 1993, J BIOL CHEM, V268, P10448; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955-0674(98)80113-0; XU T, 1990, GENETICS, V126, P665; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yamamoto H, 1999, MOL CELL BIOL, V19, P3829; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	66	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19676	19684		10.1074/jbc.M002866200	http://dx.doi.org/10.1074/jbc.M002866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10783395	hybrid			2022-12-27	WOS:000087941300033
J	Bo, XN; Schoepfer, R; Burnstock, G				Bo, XN; Schoepfer, R; Burnstock, G			Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; GATED ION CHANNELS; EXTRACELLULAR ATP; ADENINE-NUCLEOTIDES; C2C12 MYOTUBES; EXPRESSION; RAT; TRIPHOSPHATE; SENSITIVITY; TERMINALS	We have cloned a new P2X ligand-gated ion channel receptor from embryonic chick skeletal muscle, which is tentatively named as chick P2X(8) (cP2X(8)) receptor. The cloned cDNA encodes a protein with 402 amino acids. Electrophysiological study of the recombinant cP2X(8) receptor expressed in Xenopus oocytes showed that 10 mu M ATP induced a fast inward current followed by rapid and long lasting desensitization in medium containing 1.8 mM Ca2+. In medium with 0.3 mM Ca2+ ATP induced a hi-phasic response as follows: a slower inward current succeeded the initial fast one. 2-Methylthio-ATP, alpha,beta-methylene-ATP, and adenosine 5'-O-(thio)triphosphate were potent agonists, whereas ADP was a very weak agonist, ATP-induced currents were blocked by 100 mu M suramin and pyridoxal phosphate 6-azophenyl-2',4'-disulfonic acid. Northern blot analysis and reverse transcription-polymerase chain reaction showed that cP2X(8) RNA transcripts were mainly expressed in skeletal muscle, brain, and heart of Day 10 chick embryos, A moderate level of expression was also detected in gizzard and retina. Whole mount in situ hybridization showed that cP2X(8) RNA transcripts were expressed mainly in neurotube, notochord, and stomach in Day 3 embryos. In Day 4 and Day 6 embryos, the cP2X(8) RNA transcripts were highly expressed in the myotome and premuscle mass. The physiological role of this receptor in the establishment of the skeletal muscle innervation will be studied.	Royal Free & Univ Coll Hosp Sch Med, Auton Neurosci Inst, London NW3 2PF, England; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Bo, XN (corresponding author), Royal Free & Univ Coll Hosp Sch Med, Auton Neurosci Inst, Rowland Hill St, London NW3 2PF, England.	x.bo@ucl.ac.uk	Bo, Xuenong/E-9845-2012	Bo, Xuenong/0000-0002-9202-3562				AKASU T, 1981, BRIT J PHARMACOL, V74, P505, DOI 10.1111/j.1476-5381.1981.tb09997.x; Bo XN, 1998, EUR J PHARMACOL, V353, P59, DOI 10.1016/S0014-2999(98)00383-5; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Collo G, 1996, J NEUROSCI, V16, P2495; EWALD DA, 1976, J MEMBRANE BIOL, V29, P47, DOI 10.1007/BF01868951; HAGGBLAD J, 1987, NEUROSCI LETT, V74, P199, DOI 10.1016/0304-3940(87)90149-2; HENNING RH, 1993, BRIT J PHARMACOL, V110, P747, DOI 10.1111/j.1476-5381.1993.tb13875.x; Henning RH, 1996, BRIT J PHARMACOL, V117, P1785, DOI 10.1111/j.1476-5381.1996.tb15355.x; HENNING RH, 1993, BRIT J PHARMACOL, V110, P133, DOI 10.1111/j.1476-5381.1993.tb13782.x; HUME RI, 1986, J NEUROSCI, V6, P681; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; KOLB HA, 1983, NATURE, V303, P621, DOI 10.1038/303621a0; Le KT, 1997, FEBS LETT, V418, P195, DOI 10.1016/S0014-5793(97)01380-X; Meyer MP, 1999, DEV DYNAM, V214, P152, DOI 10.1002/(SICI)1097-0177(199902)214:2<152::AID-AJA5>3.0.CO;2-L; Nawa G, 1998, J HUM GENET, V43, P262, DOI 10.1007/s100380050086; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Ruppelt A, 1999, PROG BRAIN RES, V120, P81; SILINSKY EM, 1975, J PHYSIOL-LONDON, V247, P145, DOI 10.1113/jphysiol.1975.sp010925; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x; THOMAS SA, 1990, J PHYSIOL-LONDON, V430, P373, DOI 10.1113/jphysiol.1990.sp018296; Urano T, 1997, CANCER RES, V57, P3281; Vulchanova L, 1997, NEUROPHARMACOLOGY, V36, P1229, DOI 10.1016/S0028-3908(97)00126-3; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Wells DG, 1995, DEV BIOL, V172, P585, DOI 10.1006/dbio.1995.8062; Xiang ZH, 1998, NEUROSCI LETT, V256, P105, DOI 10.1016/S0304-3940(98)00774-5	29	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14401	14407		10.1074/jbc.275.19.14401	http://dx.doi.org/10.1074/jbc.275.19.14401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799522	hybrid			2022-12-27	WOS:000087006900055
J	Im, DS; Heise, CE; Ancellin, N; O'Dowd, BF; Shei, GJ; Heavens, RP; Rigby, MR; Hla, T; Mandala, S; McAllister, G; George, SR; Lynch, KR				Im, DS; Heise, CE; Ancellin, N; O'Dowd, BF; Shei, GJ; Heavens, RP; Rigby, MR; Hla, T; Mandala, S; McAllister, G; George, SR; Lynch, KR			Characterization of a novel sphingosine 1-phosphate receptor, Edg-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; SPHINGOSINE-1-PHOSPHATE; CELLS; VZG-1/LP(A1)/EDG-2; DIFFERENTIATION; INVOLVEMENT; EXPRESSION; CLONING	Three G protein-coupled receptors (Edg-1, Edg-3, and Edg-5) for the lysolipid phosphoric acid mediator sphingosine 1-phosphate have been described by molecular cloning. Using a similar sequence that we found in the expressed sequence tag data base, we cloned and characterized of a fourth, high affinity, rat brain sphingosine 1-phosphate receptor, Edg-8. When HEK293T cells were co-transfected with Edg-8 and G; protein DNAs, prepared membranes showed sphingosine 1-phosphate-dependent increases in [S-35]guanosine 5'-(3-O-thio)triphosphate binding with an EC50 of 90 nM. In a rat hepatoma Rh7777 cell line that exhibits modest endogenous responses to sphingosine 1-phosphate, this lipid mediator inhibited forskolin-driven rises in cAMP by greater than 90% when the cells were transfected with Edg-8 DNA (IC50 0.7 nM). This response is blocked fully by prior treatment of cultures with pertussis toxin, thus implicating signaling through G(i/o)alpha proteins. Furthermore, Xenopus oocytes exhibit a calcium response to sphingosine 1-phosphate after injection of Edg-8 mRNA but only when oocytes are co-injected with chimeric G(q/i)alpha protein mRNA. Membranes from HEK293T and Rh7777 cell cultures expressing Edg-8 exhibited high affinity (K-D = 2 nM) binding for radiolabeled sphingosine 1-phosphate. Rat Edg-8 RNA is expressed in spleen and throughout adult rat brain where in situ hybridization revealed it to be associated with white matter. Together our data demonstrate that Edg-8 is a high affinity sphingosine 1-phosphate receptor that couples to G(i/o)alpha proteins and is expressed predominantly by oligodendrocytes and/or fibrous astrocytes in the rat brain.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; Univ Toronto, Toronto, ON M5S 2S1, Canada; Merck Res Labs, Dept Infect Dis, Rahway, NJ 07065 USA; Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	University of Virginia; University of Connecticut; University of Connecticut; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; Merck & Company; Merck & Company	Lynch, KR (corresponding author), Univ Virginia, Sch Med, Dept Pharmacol, Rm 5221,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	KRL2Z@virginia.edu	George, Susan/W-7494-2019; Hla, Timothy/G-5873-2012; George, Susan R/P-9669-2018	Hla, Timothy/0000-0001-8355-4065; IM, DONG-SOON/0000-0001-8054-8946	NIDDK NIH HHS [R01 DK4569] Funding Source: Medline; NIGMS NIH HHS [R01 GM52722, T32 GM07055] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722, T32GM007055] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Berger A, 1996, MOL PHARMACOL, V50, P451; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Edsall LC, 1997, J NEUROSCI, V17, P6952; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Glickman M, 1999, MOL CELL NEUROSCI, V14, P141, DOI 10.1006/mcne.1999.0776; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; HLA T, 1990, J BIOL CHEM, V265, P9308; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lynch KR, 1997, MOL PHARMACOL, V52, P75, DOI 10.1124/mol.52.1.75; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Masana MI, 1995, RECEPTOR CHANNEL, V3, P255; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; ODowd BF, 1996, FEBS LETT, V394, P325, DOI 10.1016/0014-5793(96)00901-5; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Retief JD, 1999, GENOME RES, V9, P373; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Weiner JA, 1998, J COMP NEUROL, V398, P587; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zhang T, 1997, CANCER RES, V57, P169; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	30	275	307	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14281	14286		10.1074/jbc.275.19.14281	http://dx.doi.org/10.1074/jbc.275.19.14281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799507	hybrid			2022-12-27	WOS:000087006900039
J	Mbalaviele, G; Abu-Amer, Y; Meng, A; Jaiswal, R; Beck, S; Pittenger, MF; Thiede, MA; Marshak, DR				Mbalaviele, G; Abu-Amer, Y; Meng, A; Jaiswal, R; Beck, S; Pittenger, MF; Thiede, MA; Marshak, DR			Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STIMULATING FACTOR GENE; MESENCHYMAL STEM-CELLS; NF-KAPPA-B; PPAR-GAMMA; BONE LOSS; DEFICIENT MICE; OXIDIZED LDL; OSTEOPROTEGERIN; LIGAND	The nuclear receptor and transcription factor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma), regulates the activity of other transcription factors in the adipogenic differentiation and inflammatory response pathways. We examined the possible function of the PPAR-gamma pathway in osteoclast (Ocl) formation from CD34(+) hematopoietic stem cells (CD34(+) HSCs), using a co-culture system comprised of human mesenchymal stem cells (hMSCs) and CD34(+) HSCs, both derived from bone marrow. Ocl formation in this co-culture system is enhanced by the addition of exogenous osteoprotegerin ligand (OPGL), an essential Ocl differentiation factor, and macrophage-colony stimulating factor (IM-CSF). The data indicate that soluble OPGL (sOPGL) and M-CSF stimulate Ocl formation in the co-cultures up to 4-fold compared with CD34(+) HSCs alone treated with sOPGL and IM-CSF. CD34(+) HSCs, but not hMSCs, express PPAR-gamma, and 15-deoxy-Delta(12,14)-prostaglandin-J2 (15d-PG-J2), a PPAR-gamma agonist, completely blocked the effects of sOPGL and M-CSF on Ocl formation and activity. The inhibitory effect of 15d-PG-J2 is specific to the Ocl lineage in both human and mouse models of osteoclastogenesis. Accordingly, parallel experiments demonstrate that sOPGL activates the NF-kappa B pathway within mouse Ocl progenitors, and this effect was abolished by 15d-PG-J2. These data establish a link between PPAR gamma and OPGL signaling within Ocl progenitors, and support a role for PPAR-gamma pathway in the modulation of osteoclastogenesis.	Osiris Therapeut Inc, Baltimore, MD 21231 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Osiris Therapeutics; Barnes-Jewish Hospital; Washington University (WUSTL); Johns Hopkins University	Mbalaviele, G (corresponding author), Osiris Therapeut Inc, 2001 Aliceanna St, Baltimore, MD 21231 USA.							Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Mbalaviele G, 1999, ENDOCRINOLOGY, V140, P3736, DOI 10.1210/endo.140.8.6880; Mbalaviele G, 1998, J CELL BIOL, V141, P1467, DOI 10.1083/jcb.141.6.1467; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; MUNDY GR, 1995, OSTEOPOROSIS, V1, P302; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAKANO Y, 1994, J BONE MINER RES, V9, P1533, DOI 10.1002/jbmr.5650091005; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; PRALLET B, 1992, J BONE MINER RES, V7, P405; Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1; RIANCHO JA, 1993, BONE MINER, V21, P53, DOI 10.1016/S0169-6009(08)80120-1; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Takahashi T, 1996, LAB INVEST, V74, P827; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; Williams RC, 1999, J DENT RES, V78, P638, DOI 10.1177/00220345990780020201; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	37	97	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14388	14393		10.1074/jbc.275.19.14388	http://dx.doi.org/10.1074/jbc.275.19.14388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799521	hybrid			2022-12-27	WOS:000087006900053
J	Svergun, DI; Nierhaus, KH				Svergun, DI; Nierhaus, KH			A map of protein-rRNA distribution in the 70 S Escherichia coli ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; SCATTERING STRUCTURAL-ANALYSIS; 1.9 ANGSTROM RESOLUTION; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; CONTRAST-VARIATION; BACILLUS-STEAROTHERMOPHILUS; CONFORMATIONAL FLEXIBILITY; CRYOELECTRON MICROSCOPY; SYNCHROTRON RADIATION	Neutron scattering exploits the enormous scattering difference between protons and deuterons. A set of 42 x-ray and neutron solution scattering curves from hybrid Escherichia coli ribosomes was obtained, where the proteins and rRNA moieties in the subunits were either protonated or deuterated in all possible combinations. This extensive data set is analyzed using a novel method. The volume defined by the cryoelectron microscopic model of Frank and co-workers (Frank, J., Zhu, J., Penczek, P., Li, Y. H., Srivastava, S., Verschoor, A., Radermacher, NI,, Grassucci, R., Lata, R. K., and Agrawal, R, K. (1995) Nature 376, 441-444) is divided into 7890 densely packed spheres of radius 0.5 nm. Simulated annealing is employed to assign each sphere to solvent, protein, or rRNA moieties to simultaneously fit all scattering curves. Twelve independent reconstructions starting from random approximations yielded reproducible results. The resulting model at a resolution of 3 nm represents the volumes occupied by rRNA and protein moieties at 95% probability threshold and displays 15 and 20 protein subvolumes in the 30 S and 50 S, respectively, connected by rRNA. 17 proteins with known atomic structure can be tentatively positioned into the protein subvolumes within the ribosome in agreement with the results from other methods. The protein-rRNA map enlarges the basis for the models of the rRNA folding and can further help to localize proteins in high-resolution crystallographic density maps.	DESY, EMBL, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Max Planck Society	Svergun, DI (corresponding author), DESY, EMBL, Notkestr 85, D-22603 Hamburg, Germany.			Svergun, Dmitri/0000-0003-0830-5696				Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Berglund H, 1997, NAT STRUCT BIOL, V4, P20, DOI 10.1038/nsb0197-20; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bocharov EV, 1996, FEBS LETT, V379, P291, DOI 10.1016/0014-5793(95)01531-0; Bocharov EV, 1998, FEBS LETT, V423, P347, DOI 10.1016/S0014-5793(98)00121-5; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; Davies C, 1998, J MOL BIOL, V279, P873, DOI 10.1006/jmbi.1998.1780; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; Davies C, 1996, STRUCTURE, V4, P1093, DOI 10.1016/S0969-2126(96)00115-3; Fedorov R, 1999, ACTA CRYSTALLOGR D, V55, P1827, DOI 10.1107/S0907444999010227; Feigin L.A., 1987, STRUCTURE ANAL SMALL; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; HOFFMAN DW, 1994, EMBO J, V13, P205, DOI 10.1002/j.1460-2075.1994.tb06250.x; INGBER L, 1993, MATH COMPUT MODEL, V18, P29, DOI 10.1016/0895-7177(93)90204-C; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Koch M H, 1979, Methods Enzymol, V59, P670; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LEBECH B, 1990, NEUTRON NEWS, V1, P7; LEIJONMARCK M, 1987, J MOL BIOL, V195, P55; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MOORE PB, 1996, RIBOSOMAL RNA STRUCT, P199; MULLER JJ, 1986, EUR BIOPHYS J BIOPHY, V13, P301, DOI 10.1007/BF00254212; Nakagawa A, 1999, EMBO J, V18, P1459, DOI 10.1093/emboj/18.6.1459; RAMAKRISHNAN V, 1986, SCIENCE, V231, P1562, DOI 10.1126/science.3513310; SCHWEDLER G, 1993, EUR J BIOCHEM, V217, P361, DOI 10.1111/j.1432-1033.1993.tb18254.x; Serdyuk I N, 1979, Methods Enzymol, V59, P750; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; Stoldt M, 1998, EMBO J, V17, P6377, DOI 10.1093/emboj/17.21.6377; STUHRMANN HB, 1965, Z PHYS CHEM NEUE FOL, V46, P247, DOI 10.1524/zpch.1965.46.3_4.247; STUHRMANN HB, 1995, NUCL INSTRUM METH A, V356, P124, DOI 10.1016/0168-9002(94)01461-2; STUHRMANN HB, 1978, J MOL BIOL, V119, P203, DOI 10.1016/0022-2836(78)90434-5; STUHRMANN HB, 1991, BIOCHIMIE, V73, P899; Svergun DI, 1997, J MOL BIOL, V271, P588, DOI 10.1006/jmbi.1997.1190; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1997, J MOL BIOL, V271, P602, DOI 10.1006/jmbi.1997.1191; SVERGUN DI, 1994, ACTA CRYSTALLOGR A, V50, P391, DOI 10.1107/S0108767393013492; Tanaka I, 1998, RNA, V4, P542, DOI 10.1017/S1355838298972004; Tocilj A, 1999, P NATL ACAD SCI USA, V96, P14252, DOI 10.1073/pnas.96.25.14252; Unge J, 1997, FEBS LETT, V411, P53, DOI 10.1016/S0014-5793(97)00611-X; Vetterling V., 1992, NUMERICAL RECIPES, V693, P59; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; Wimberly BT, 1997, STRUCTURE, V5, P1187, DOI 10.1016/S0969-2126(97)00269-4; WITTMANN HG, 1982, ANNU REV BIOCHEM, V51, P155, DOI 10.1146/annurev.bi.51.070182.001103; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6	60	79	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14432	14439		10.1074/jbc.275.19.14432	http://dx.doi.org/10.1074/jbc.275.19.14432			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799526	hybrid			2022-12-27	WOS:000087006900059
J	Hoffbuhr, KC; Davidson, E; Filiano, BA; Davidson, M; Kennaway, NG; King, MP				Hoffbuhr, KC; Davidson, E; Filiano, BA; Davidson, M; Kennaway, NG; King, MP			A pathogenic 15-base pair deletion in mitochondrial DNA-encoded cytochrome c oxidase subunit III results in the absence of functional cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; OXIDATIVE-PHOSPHORYLATION; PROTEIN-SYNTHESIS; NADH DEHYDROGENASE; LACTIC-ACIDOSIS; SKELETAL-MUSCLE; COMPLEX-III; HUMAN-CELLS; HELA-CELLS; MUTATION	A 15-base pair, in-frame, deletion (9480del15) in the mitochondrial DNA (mtDNA)-encoded cytochrome c oxidase subunit III (COX III) gene was identified previously in a patient with recurrent episodes of myoglobinuria and an isolated COX deficiency. Transmitochondrial cell lines harboring 0, 97, and 100% of the 9480del15 deletion were created by fusing human cells lacking mtDNA (rho(o) cells) with platelet and lymphocyte fractions isolated from the patient. The COX III gene mutation resulted in a severe respiratory chain defect in all mutant cell lines. Cells homoplasmic for the mutation had no detectable COX activity or respiratory ATP synthesis, and required uridine and pyruvate supplementation for growth, a phenotype similar to rho(o) cells. The cells with 97% mutated mtDNA exhibited severe reductions in both COX activity (6% of wild-type levels) and rates of ATP synthesis (9% of wild-type). The COX III polypeptide in the mutant cells, although translated at rates similar to wild-type, had reduced stability. There was no evidence for assembly of COX I, COX II, or COX III subunits in a multisubunit complex in cells homoplasmic for the mutation, thus indicating that there was no stable assembly of COX I with COX II in the absence of wild-type COX III. In contrast, the COX I and COX II subunits were assembled in cells with 97% mutated mtDNA.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	Jefferson University; Oregon Health & Science University; Columbia University	King, MP (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 308 BLSB,233 S 10th St, Philadelphia, PA 19107 USA.							Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460; BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025; BRUNORI M, 1987, EUR J BIOCHEM, V169, P1, DOI 10.1111/j.1432-1033.1987.tb13572.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Chomyn A, 1996, Methods Enzymol, V264, P334, DOI 10.1016/S0076-6879(96)64031-2; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; COSTANTINO P, 1977, J BIOL CHEM, V252, P1702; Davey GP, 1996, J NEUROCHEM, V66, P1617; DAVIS LG, 1986, BASIC METHODS MOL BI, P47; DEGOMEZPUYOU MT, 1984, J BIOL CHEM, V259, P9472; DIMAURO S, 1990, PEDIATR RES, V28, P536, DOI 10.1203/00006450-199011000-00025; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fourney R.M., 1988, FOCUS, V10, P5; Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL RE, 1990, J BIOL CHEM, V265, P16484; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jun AS, 1996, MOL CELL BIOL, V16, P771; KADENBACH B, 1986, J BIOENERG BIOMEMBR, V18, P39, DOI 10.1007/BF00743611; Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; King M P, 1996, Methods Enzymol, V264, P339, DOI 10.1016/S0076-6879(96)64032-4; King M P, 1996, Methods Enzymol, V264, P313, DOI 10.1016/S0076-6879(96)64030-0; KING MP, 1993, J BIOL CHEM, V268, P10228; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; MARIOTTINI P, 1986, J BIOL CHEM, V261, P3355; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; MILLIS AJT, 1973, BIOCHIM BIOPHYS ACTA, V292, P73, DOI 10.1016/0005-2728(73)90251-X; MIRANDA AF, 1988, TISSUE CELL, V20, P179, DOI 10.1016/0040-8166(88)90040-7; MORAES CT, 1989, BIOCHEM BIOPH RES CO, V160, P765, DOI 10.1016/0006-291X(89)92499-6; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Riistama S, 1996, BBA-BIOENERGETICS, V1275, P1, DOI 10.1016/0005-2728(96)00040-0; ROBINSON BH, 1993, BIOCHIM BIOPHYS ACTA, V1182, P231, DOI 10.1016/0925-4439(93)90064-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; SPELBRINK JN, 1994, HUM MOL GENET, V3, P1989, DOI 10.1093/hmg/3.11.1989; SUCOV HM, 1987, DEV BIOL, V120, P507, DOI 10.1016/0012-1606(87)90254-5; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VANDENBOGERT C, 1993, BIOCHIM BIOPHYS ACTA, V1144, P177, DOI 10.1016/0005-2728(93)90170-K; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; VILLANI G, 1998, J BIOL CHEM, V252, P1702; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; Weber K, 1997, AM J HUM GENET, V60, P373; Wharton DC., 1967, METHOD ENZYMOL, P245; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	55	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13994	14003		10.1074/jbc.275.18.13994	http://dx.doi.org/10.1074/jbc.275.18.13994			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788526	hybrid			2022-12-27	WOS:000086925300114
J	Leite, JF; Amoscato, AA; Cascio, M				Leite, JF; Amoscato, AA; Cascio, M			Coupled proteolytic and mass spectrometry studies indicate a novel topology for the glycine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION CHANNELS; CYSTEINE-SUBSTITUTION; FUNCTIONAL EXPRESSION; ALPHA-SUBUNIT; AMINO-ACIDS; BACTERIORHODOPSIN; IDENTIFICATION; TOPOGRAPHY; PROTEINS	Members of the heteropentameric ligand-gated ion channel superfamily rapidly mediate signaling across the synaptic cleft. Sequence analysis and limited experimental studies have yielded a topological model containing four transmembrane alpha-helices, labeled M1 to M4, and a large soluble, extracellular N-terminal domain. This model persists to date despite some recent structural studies that suggest it may be inappropriate. In this study, the topology of the glycine receptor was probed by limited proteolysis coupled to mass spectrometry, Of particular note, accessible cleavage sites within the putative M1 and M3 transmembrane helices were identified. Membrane-associated fragments within the postulated globular extracellular N-terminal domain were also observed. This report presents several key details incorporated in a new topological model and is the first direct experimental evidence that a subset of the transmembrane regions are too short to be membrane-spanning alpha-helices; rather, these regions are proposed to be a mix of alpha-helices and beta-sheets, This report is also the first to exploit the capability of mass spectrometry to probe critically the topology of a class of membrane proteins of unknown structure.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15219 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cascio, M (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15219 USA.			Amoscato, Andrew/0000-0002-1340-9150	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051911] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51911-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; Ball LE, 1998, PROTEIN SCI, V7, P758; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; CASCIO M, 1993, J BIOL CHEM, V268, P22135; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; FIMMEL S, 1989, BIOCHIM BIOPHYS ACTA, V978, P231, DOI 10.1016/0005-2736(89)90120-X; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MOORE CR, 1989, BIOCHEMISTRY-US, V28, P9184, DOI 10.1021/bi00449a034; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHRODER S, 1991, BIOCHEMISTRY-US, V30, P42, DOI 10.1021/bi00215a007; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Taylor JA, 1996, RAPID COMMUN MASS SP, V10, P679, DOI 10.1002/(SICI)1097-0231(199604)10:6<679::AID-RCM528>3.0.CO;2-Q; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; Watty A, 1998, EUR J BIOCHEM, V252, P222, DOI 10.1046/j.1432-1327.1998.2520222.x; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; XU M, 1993, J BIOL CHEM, V268, P21505	32	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13683	13689		10.1074/jbc.275.18.13683	http://dx.doi.org/10.1074/jbc.275.18.13683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788487	hybrid			2022-12-27	WOS:000086925300074
J	Bunemann, M; Meyer, T; Pott, L; Hosey, M				Bunemann, M; Meyer, T; Pott, L; Hosey, M			Novel inhibition of G beta gamma-activated potassium currents induced by M-2 muscarinic receptors via a pertussis toxin-insensitive pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNEL; PASTEURELLA-MULTOCIDA TOXIN; PROTEIN-COUPLED RECEPTORS; A(1) ADENOSINE RECEPTORS; INWARD RECTIFIER; ATRIAL MYOCYTES; XENOPUS OOCYTES; ACETYLCHOLINE-RECEPTOR; I-KACH; DESENSITIZATION	G(i) protein-coupled receptors such as the M-2 muscarinic acetylcholine receptor (mAChR) and A(1) adenosine receptor have been shown to activate (G) under bar protein-activated inwardly rectifying (K) under bar(+) channels (GIRKs) via pertussis toxin-sensitive Cf proteins in atrial myocytes and in many neuronal cells. Here we show that muscarinic M-2 receptors not only activate but also reversibly inhibit these K+ currents when stimulated with agonist for up to 2 min. The M-2 mAChR-mediated inhibition of the channel was also observed when the channels were first activated by inclusion of guanosine 5'-O-(thiotriphosphate) in the pipette. Under these conditions the M-2 mAChR-induced inhibition was quasi-irreversible, suggesting a role for G proteins in the inhibitory process. In contrast, when GIRK currents were maximally activated by co-expressing exogenous G beta gamma, the extent of acetylcholine (ACh)-induced inhibition was significantly reduced, suggesting competition between the receptor-mediated inhibition and the large pool of available G beta gamma subunits. The signaling pathway that led to the ACh-induced inhibition of GIRK channels was unaffected by pertussis toxin pretreatment. Furthermore, the internalization and agonist-induced phosphorylation of M-2 mAChn was not required because a phosphorylation- and internalization-deficient mutant of the M-2 mAChR was as potent as the wild-type counterpart. Pharmacological agents modulating various protein kinases or phosphatidylinositol 3-kinase did not affect the inhibition of GIRK currents. Furthermore, the signaling pathway that mediates GIRK current inhibition was found to be membrane-delimited because bath application of ACh did not inhibit GIRK channel activity in cell-attached patches. Other G protein-coupled receptors including M-4 mAChn and alpha(1A) adrenergic receptors also caused the inhibition, whereas other G protein-coupled receptors including A(1) and A3 adenosine receptors and alpha(2A) and alpha(2C) adrenergic receptors could not induce the inhibition. The presented results suggest the existence of a novel signaling pathway that can be activated selectively by M-2 and M-4 mAChR but not by adenosine receptors and that involves non-pertussis toxin-sensitive G proteins leading to an inhibition of G beta gamma-activated GIRK currents in a membrane-delimited fashion.	Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany	Northwestern University; Ruhr University Bochum	Hosey, M (corresponding author), Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA.		Pott, Lutz/E-5304-2011	Pott, Lutz/0000-0002-4000-4132	NHLBI NIH HHS [HL 50121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELARDINELLI L, 1983, AM J PHYSIOL, V244, pH734, DOI 10.1152/ajpheart.1983.244.5.H734; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Ciruela F, 1997, MOL PHARMACOL, V52, P788, DOI 10.1124/mol.52.5.788; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Kuzhikandathil EV, 1998, MOL CELL NEUROSCI, V12, P390, DOI 10.1006/mcne.1998.0722; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nie ZZ, 1997, MOL PHARMACOL, V52, P456, DOI 10.1124/mol.52.3.456; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Polo-Parada L, 1999, J NEUROSCI, V19, P5213; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shui Z, 1997, J PHYSIOL-LONDON, V505, P77, DOI 10.1111/j.1469-7793.1997.077bc.x; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Wilson BA, 1999, INFECT IMMUN, V67, P80, DOI 10.1128/IAI.67.1.80-87.1999; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961	40	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12537	12545		10.1074/jbc.275.17.12537	http://dx.doi.org/10.1074/jbc.275.17.12537			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777542	hybrid			2022-12-27	WOS:000086762300026
J	Tomita, S; Fujita, T; Kirino, Y; Suzuki, T				Tomita, S; Fujita, T; Kirino, Y; Suzuki, T			PDZ domain-dependent suppression of NF-kappa B/p65-induced A beta 42 production by a neuron-specific X11-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; AMYLOID PRECURSOR PROTEIN; TRANSCRIPTION FACTOR; DISEASE; RECOGNITION; SECRETION; CLEAVAGE; PEPTIDE; SITE; APP	It is widely believed that one of the causes of Alzheimer's disease (AD) is the generation and secretion of beta-amyloid (A beta) from amyloid precursor protein in the brain, Here we report that a transcription factor, NF-kappa B/ p65, induces increased secretion of amyloidogenic A beta 42 but not A beta 40. The kappa B motif-dependent production of A beta 42 was suppressed by binding of NF-kappa B/p65 to the PDZ domain of the X11-like protein (X11L), which a human homologue protein of LIN-10. The results suggest that the PDZ domain of X11L can control the ability of NF-kappa B/p65 to induce expression of protein(s) involved in A beta 42 production, The amino acids 161-163 in Rel homology domain (RHD) of NF-kappa B/p65 is important in interaction of NF-kappa B/p65 with X11L. Another subunit NF-kappa B/p50 and heterodimers of p65 and p50 do not bind to X11L. Our finding indicates NF-kappa B and X11L may, in novel way, regulate A beta production in neuronal cells. Targeting X11L by specific therapy may provide the possibility to control the progression of AD.	Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1130021, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Suzuki, T (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Suzuki, Toshiharu/B-5342-2013					Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Foletti DL, 1999, NEURON, V23, P641, DOI 10.1016/S0896-6273(01)80022-2; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Oschkinat H, 1999, NAT STRUCT BIOL, V6, P408, DOI 10.1038/8203; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Shoulson I, 1998, SCIENCE, V282, P1072, DOI 10.1126/science.282.5391.1072; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	26	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13056	13060		10.1074/jbc.C000019200	http://dx.doi.org/10.1074/jbc.C000019200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777610	hybrid			2022-12-27	WOS:000086762300094
J	Chatterjee, TK; Fisher, RA				Chatterjee, TK; Fisher, RA			Cytoplasmic, nuclear, and Golgi localization of RGS proteins - Evidence for N-terminal and RGS domain sequences as intracellular targeting motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNITS; TRANSITION-STATE; PHOSPHOLIPASE-C; FAMILY MEMBERS; GAIP; REGULATOR; RECEPTOR; MEMBRANE	RGS proteins comprise a family of proteins named for their ability to negatively (r) under bar egulate heterotrimeric (G) under bar protein (s) under bar ignaling. Biochemical studies suggest that members of this protein family act as GTPase-activating proteins for certain G alpha subunits, thereby accelerating the turn-off mechanism of G alpha and terminating signaling by both G alpha and G beta gamma subunits. In the present study, we used confocal microscopy to examine the intracellular distribution of several RGS proteins in COS-7 cells expressing RGS-green fluorescent protein (GFP) fusion proteins and in cells expressing RGS proteins endogenously. RGS2 and RGS10 accumulated in the nucleus of COS-7 cells transfected with GFP constructs of these proteins. In contrast, RGS4 and RGS16 accumulated in the cytoplasm of COS-7 transfectants, As observed in COS-7 cells, RGS4 exhibited cytoplasmic localization in mouse neuroblastoma cells, and RGS10 exhibited nuclear localization in human glioma cells. Deletion or alanine substitution of an N-terminal leucine repeat motif present in both RGS4 and RGS16, a domain identified as a nuclear export sequence in HIV Rev and other proteins, promoted nuclear localization of these proteins in COS-7 cells. In agreement with this observation, treatment of mouse neuroblastoma cells with leptomycin B to inhibit nuclear protein export by exportin1 resulted in accumulation of RGS4 in the nucleus of these cells. GFP fusions of RGS domains of RGS proteins localized in the nucleus, suggesting that nuclear localization of RGS proteins results from nuclear targeting via RGS domain sequences. RGSZ, which shares with RGS-GAIP a cysteine-rich string in its N-terminal region, localized to the Golgi complex in COS-TS cells. Deletion of the N-terminal domain of RGSZ that includes the cysteine motif promoted nuclear localization of RGSZ, None of the RGS proteins examined were localized at the plasma membrane. These results demonstrate that RGS proteins localize in the nucleus, the cytoplasm, or shuttle between the nucleus and cytoplasm as nucleo-cytoplasmic shuttle proteins. RGS proteins localize differentially within cells as a result of structural differences among these proteins that do not appear to be important determinants for their G protein-regulating activities. These findings suggest involvement of RGS proteins in more complex cellular functions than currently envisioned.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.		Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041071, R29HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; CHATTERJEE TK, 1995, METH NEUROSCI, V26, P29; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LEE BN, 1994, MOL MICROBIOL, V14, P323, DOI 10.1111/j.1365-2958.1994.tb01293.x; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tseng CC, 1998, ENDOCRINOLOGY, V139, P4470, DOI 10.1210/en.139.11.4470; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	37	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24013	24021		10.1074/jbc.M002082200	http://dx.doi.org/10.1074/jbc.M002082200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10791963	hybrid			2022-12-27	WOS:000088564200084
J	Ghosh, S; Brown, R; Jones, JCR; Ellerbroek, SM; Stack, MS				Ghosh, S; Brown, R; Jones, JCR; Ellerbroek, SM; Stack, MS			Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha(3)beta(1) integrin in oral keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; UROKINASE RECEPTOR; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; PROTEIN-KINASE; IN-VITRO; ADHESION; MIGRATION; COMPONENTS; LAMININ-5	Expression of urinary-type plasminogen activator (uPA) and its receptor (uPAR) is correlated with matrix proteolysis, cell adhesion, motility, and invasion. To evaluate the functional link between adhesion and proteolysis in gingival keratinocytes (pp126), cells were treated with immobilized integrin antibodies to induce integrin clustering Clustering of alpha(3) and beta(1) integrin subunits, but not alpha(2), alpha(5), alpha(6), or beta(4), enhanced uPA secretion. Bead-immobilized laminin-5 and collagen I, two major alpha(3)beta(1) ligands, also induced uPA expression. Coordinate regulation of the serpin plasminogen activator inhibitor 1 was also apparent; however, a net increase in uPA activity was predominant. alpha(3)beta(1) integrin clustering induced extracellular signal-regulated kinase 1/2 phosphorylation, and both uPA induction and extracellular signal-regulated kinase activation were blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059, Integrin aggregation also promoted a dramatic redistribution of uPAR on the cell surface to sites of clustered alpha(3)beta(1) integrins. Co-immunoprecipitation of beta(1) integrin with uPAR provided further evidence that protein-protein interactions between uPAR and beta(1) integrin control uPAR distribution, As a functional consequence of uPA up-regulation and uPA-mediated plasminogen activation, the globular domain of the laminin-5 alpha(3) subunit, a major pp126 matrix protein, was proteolytically processed from a 190-kDa form to a 160-kDa species, Laminin-5 containing the 160-kDa alpha(3) subunit efficiently nucleates hemidesmosome formation and reduces cell motility, Together, these data suggest that multivalent aggregation of the alpha(3)beta(1) integrin regulates proteinase expression, matrix proteolysis, and subsequent cellular behavior.	Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Obstet & Gynecol, 303 E Chicago Ave,Tarry 4-751, Chicago, IL 60611 USA.	mss130@nwu.edu	Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NIDCR NIH HHS [P01 DE12328, DE/CA 11921-04] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328, P50DE011921] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Baker SE, 1996, J CELL SCI, V109, P2509; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; GOSPODAROWICZ D, 1980, P NATL ACAD SCI-BIOL, V77, P4094, DOI 10.1073/pnas.77.7.4094; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Irigoyen JP, 1997, J BIOL CHEM, V272, P1904, DOI 10.1074/jbc.272.3.1904; JONES J, 1993, J PATHOL, V169, P235, DOI 10.1002/path.1711690210; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Plopper G, 1996, J CELL SCI, V109, P1965; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PYKE C, 1994, AM J PATHOL, V145, P782; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; STAHL A, 1994, CANCER RES, V54, P3066; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; VANWAES C, 1995, CANCER RES, V55, P5434; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xue W, 1997, CANCER RES, V57, P1682; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	46	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23869	23876		10.1074/jbc.M000935200	http://dx.doi.org/10.1074/jbc.M000935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10791952	hybrid			2022-12-27	WOS:000088564200064
J	Wang, W; Soto, H; Oldham, ER; Buchanan, ME; Homey, B; Catron, D; Jenkins, N; Copeland, NG; Gilbert, DJ; Nguyen, N; Abrams, J; Kershenovich, D; Smith, K; McClanahan, T; Vicari, AP; Zlotnik, A				Wang, W; Soto, H; Oldham, ER; Buchanan, ME; Homey, B; Catron, D; Jenkins, N; Copeland, NG; Gilbert, DJ; Nguyen, N; Abrams, J; Kershenovich, D; Smith, K; McClanahan, T; Vicari, AP; Zlotnik, A			Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CXC CHEMOKINE; PROTEIN; CELLS; LYMPHOCYTES; LYMPHOTACTIN; EXPRESSION; TECK	We report the identification and characterization of a novel CC chemokine designated CCL28 and its receptor CCR10, known previously as orphan G-protein-coupled receptor GPR2. Human and mouse CCL28 share 83% identity at the amino acid and 76% at the nucleic acid levels. We also identified the mouse homologues of CCL28 and of CCR10, which map to mouse chromosomes 13 and 11, respectively, CCL28 is expressed in a variety of human and mouse tissues, and it appears to be predominantly produced by epithelial cells. Both human and mouse CCL28 induce calcium mobilization in human and mouse CCL28 expressing transfectants. CCL28 desensitized the calcium mobilization induced in CCR10 transfectants by CCL27, indicating that these chemokines share this new chemokine receptor. In vitro, recombinant human CCL28 displays chemotactic activity for resting CD4 or CD8 T cells.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA; Schering Plough Lab Immunol Res, F-69572 Dardilly, France; NCI, Frederick Canc Res & Dev Ctr, Mammalian Genet Lab, Frederick, MD 21702 USA; Inst Nacl Nutr Salvador Zubiran, Dept Gastroenterol, Mexico City 14000, DF, Mexico	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico	Zlotnik, A (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA.		Zlotnik, Albert/C-3791-2011					BAZAN F, 1997, NATURE, V385, P640; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P267, DOI 10.1016/S0167-5699(99)01468-1; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; Hedrick JA, 1997, J IMMUNOL, V159, P1589; HEDRICK JA, 1997, J IMMUNOL, V158, P1535; Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Lefrancois L, 1997, SPRINGER SEMIN IMMUN, V18, P463, DOI 10.1007/BF00824053; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; Moser Bernhard, 1998, Science Progress, V81, P299; Pardigol A, 1998, P NATL ACAD SCI USA, V95, P6308, DOI 10.1073/pnas.95.11.6308; Rossi DL, 1999, J IMMUNOL, V162, P5490; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516; Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551; Zaballos A, 1999, J IMMUNOL, V162, P5671; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	25	215	247	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22313	22323		10.1074/jbc.M001461200	http://dx.doi.org/10.1074/jbc.M001461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10781587	hybrid			2022-12-27	WOS:000088363800077
J	Carter, NS; Drew, ME; Sanchez, M; Vasudevan, G; Landfear, SM; Ullman, B				Carter, NS; Drew, ME; Sanchez, M; Vasudevan, G; Landfear, SM; Ullman, B			Cloning of a novel inosine-guanosine transporter gene from Leishmania donovani by functional rescue of a transport-deficient mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRANSPORTER; TRYPANOSOMA-BRUCEI; PARASITE LEISHMANIA; DRUG-RESISTANCE; EXPRESSION; IDENTIFICATION; GLYCOPROTEINS; METABOLISM; ALIGNMENT; ADENOSINE	Purine transport is an indispensable nutritional function for protozoan parasites, since they are incapable of purine biosynthesis and must, therefore, acquire purines from the host milieu, Exploiting a mutant cell line (FBD5) of Leishmania donovani deficient in inosine and guanosine transport activity, the gene encoding this transporter (LdNT2) has been cloned by functional rescue of the mutant phenotype. LdNT2 encodes a polypeptide of 499 amino acids that shows substantial homology to other members of the equilibrative nucleoside transporter family. Molecular analysis revealed that LdNT2 is present as a single gene copy within the leishmanial genome and encodes a single transcript of 3 kilobase pairs. Transfection of FBD5 parasites with LdNT2 reestablished their ability to take up inosine and guanosine with a concurrent restoration of sensitivity to the inosine analog formycin B, Kinetic analyses reveal that LdNT2 is highly specific for inosine (K-m = 0.3 mu M) and guanosine (K-m = 1.7 mu M) and does not recognize other naturally occurring nucleosides, Expression of LdNT2 cRNA in Xenopus oocytes significantly augmented their ability to take up inosine and guanosine, establishing that LdNT2 by itself suffices to mediate nucleoside transport. These results authenticate genetically and biochemically that LdNT2 is a novel nucleoside transporter with an unusual and strict specificity for inosine and guanosine.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	ullmanb@ohsu.edu		Landfear, Scott/0000-0002-1643-6664	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R01AI044138, R37AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44138, AI23682, R01 AI044138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Beresford RM, 1995, P NZ PLAN P, V48, P89, DOI 10.30843/nzpp.1995.48.11498; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; Chiang CW, 1999, J BIOL CHEM, V274, P35255, DOI 10.1074/jbc.274.49.35255; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DESCOTEAUX A, 1993, METHODS MOL GENETICS, V1, P22; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; Flaspohler JA, 1997, MOL CELL BIOL, V17, P1093, DOI 10.1128/MCB.17.3.1093; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; HANSEN SEW, 1987, EUR J BIOCHEM, V168, P385, DOI 10.1111/j.1432-1033.1987.tb13431.x; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Hwang HY, 1996, J BIOL CHEM, V271, P30840, DOI 10.1074/jbc.271.48.30840; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; Madani N, 1998, P NATL ACAD SCI USA, V95, P8005, DOI 10.1073/pnas.95.14.8005; Maniatis T., 1982, MOL CLONING; MARR JJ, 1984, ANTIMICROB AGENTS CH, V25, P292, DOI 10.1128/AAC.25.2.292; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873	43	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20935	20941		10.1074/jbc.M002418200	http://dx.doi.org/10.1074/jbc.M002418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10783393	hybrid			2022-12-27	WOS:000088084500100
J	Gangurde, R; Kaushik, N; Singh, H; Modak, J				Gangurde, R; Kaushik, N; Singh, H; Modak, J			A carboxylate triad is essential for the polymerase activity of Escherichia coli DNA polymerase I (Klenow fragment) - Presence of two functional triads at the catalytic center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; DEOXYNUCLEOSIDE TRIPHOSPHATE; CRYSTAL-STRUCTURES; KINETIC MECHANISM; ION CATALYSIS; SITE; BINDING; IDENTIFICATION; RESIDUES; PYROPHOSPHATE	The catalytic roles of two essential active-site aspartates at positions 705 and 882 of Escherichia coli DNA polymerase I have been well established (Steitz, T. A. (1998) Nature 391, 231-232), We now demonstrate that the participation of at least one additional carboxylate, a glutamate at position 710 or 883, is obligatory for catalysis. This conclusion has been drawn from our investigation of the properties of single (E710D, E710A, E883D, and E883A) and double (E710D/E883D and E710A/E883A) substitutions of residues Glu(710) and Glu(883). While single substitutions of either of the glutamates resulted in some reduction in polymerase activity, the mutant enzyme with simultaneous substitution of both glutamates with alanine exhibited a nearly complete loss of activity. Interestingly, substitution with two aspartates in place of the glutamates resulted in an enzyme species that catalyzed DNA synthesis in a strictly distributive mode. Pyrophosphorolytic activity of the mutant enzymes reflected their polymerase activity profiles, with markedly reduced pyrophosphorolysis by the double mutant enzymes. Moreover, an evaluation of Mg2+ and salt optima for all mutant enzymes of Glu(710) and Glu(883) revealed significant deviations from that for the wild type, implying a possible role of these glutamates in metal coordination as well as in maintaining the structural integrity of the active site.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Modak, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.		Modak, Jayant/AAN-4989-2021; Modak, Jayant M/B-8147-2008	Modak, Jayant/0000-0001-7064-7860; Modak, Jayant M/0000-0001-7064-7860	NIGMS NIH HHS [GM 36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chowdhury K, 1996, BIOCHEMISTRY-US, V35, P16610, DOI 10.1021/bi961462l; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; Godson GN, 2000, BIOCHEMISTRY-US, V39, P332, DOI 10.1021/bi9916628; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Pritchard AE, 1999, J MOL BIOL, V285, P1067, DOI 10.1006/jmbi.1998.2352; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singh K, 1998, TRENDS BIOCHEM SCI, V23, P277, DOI 10.1016/S0968-0004(98)01250-X; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6468; YADAV PNS, 1994, J BIOL CHEM, V269, P716; Ying LI, 1998, PROTEIN SCI, V7, P1116	37	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19685	19692		10.1074/jbc.M002307200	http://dx.doi.org/10.1074/jbc.M002307200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779513	hybrid			2022-12-27	WOS:000087941300034
J	Gong, LM; Kamitani, T; Millas, S; Yeh, ETH				Gong, LM; Kamitani, T; Millas, S; Yeh, ETH			Identification of a novel isopeptidase with dual specificity for ubiquitin- and NEDD8-conjugated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; DEUBIQUITINATING ENZYMES; PROTEASOME; SENTRIN; RANGAP1; DEATH; NEDD8	Covalent conjugation of proteins by ubiquitin or ubiquitin-like molecules is an important form of post-translational modification and plays a critical role in many cellular processes. Similar to the concept of phosphorylation and dephosphorylation, these conjugates are regulated by a large number of deconjugating enzymes. Here, we report the cloning of a 2,141-base pair DNA fragment from human placenta cDNA library by a strategy that involves expressed sequence tag data base searching, polymerase chain reaction, and rapid amplification of cDNA ends. Nucleotide sequence analysis revealed that the cloned cDNA contains an open reading frame of 1,143 base pairs encoding a novel protease, USP21, which is composed of 381 residues with a calculated molecular mass of 43 kDa. The human USP21 gene is located on chromosome 1q21 and encodes a member of the ubiquitin-specific protease family with highly conserved Cys and His domains. The activity and specificity of USP21 were determined by using a COS cell expression system in vivo. We showed that USP21 is capable of removing ubiquitin from ubiquitinated proteins as expected. Furthermore, USP21 is capable of removing NEDD8 from NEDD8 conjugates but has no effect on Sentrin-1 conjugates. As expected from its biochemical activity, overexpression of USP21 has a profound growth inhibitory effect on U2OS cells. Thus, USP21 is the first ubiquitin-specific protease shown to have dual specificity for both ubiquitin and NEDD8 and may play an important role in the regulation of cell growth.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.	eyeh@heart.med.uth.tmc.edu	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NIDDK NIH HHS [DK-56298] Funding Source: Medline; NIGMS NIH HHS [GM-57502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057502] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Okura T, 1996, J IMMUNOL, V157, P4277; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; YEH ETH, 2000, IN PRESS GENE AMST; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	21	87	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14212	14216		10.1074/jbc.275.19.14212	http://dx.doi.org/10.1074/jbc.275.19.14212			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799498	hybrid			2022-12-27	WOS:000087006900029
J	Hauert, J; Patston, PA; Schapira, M				Hauert, J; Patston, PA; Schapira, M			C1 inhibitor cross-linking by tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-SYSTEM; C1-INHIBITOR; KINETICS; HEPARIN; SUBSTRATE; PROTEINS; ENZYMES; FIBRIN	C1 inhibitor, a plasma proteinase inhibitor of the serpin superfamily involved in the regulation of complement classical pathway and intrinsic blood coagulation, has been shown to bind to several components of the extracellular matrix. These reactions may be responsible for C1 inhibitor localization in the perivascular space. In the study reported here, we have examined whether C1 inhibitor could function as a substrate for plasma (factor XIIIa) or tissue transglutaminase. We made the following observations: 1) SDS-polyacrylamide gel electrophoresis and autoradiography showed that C1 inhibitor exposed to tissue transglutaminase (but not to factor XIIIa) incorporated the radioactive amine donor substrate [H-3]putrescine in a calcium-dependent manner; 2) the maximum stoichiometry for the uptake of [H-3]putrescine by C1 inhibitor was 1:1; 3) proteolytic cleavage and peptide sequencing of reduced and carboxymethylated [H-3]putrescine-C1 inhibitor identified Gln(453) (P'9) as the single amine acceptor residue; 4) studies with I-125-labeled C1 inhibitor showed that tissue transglutaminase was also able to cross-link C1 inhibitor to immobilized fibrin; and 5) C1 inhibitor cross-linked by tissue transglutaminase to immobilized fibrin had inhibitory activity against its target enzymes. Thus, tissue transglutaminase-mediated cross-linking of C1 inhibitor to fibrin or other extracellular matrix components may serve as a mechanism for covalent serpin binding and influence local regulation of the proteolytic pathways inhibited by C1 inhibitor.	CHU Vaudois, Div Hematol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Dept Med, CH-1011 Lausanne, Switzerland; Univ Illinois, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schapira, M (corresponding author), CHU Vaudois, Div Hematol, CH-1011 Lausanne, Switzerland.	marc.schapira@chuv.hospvd.ch			NHLBI NIH HHS [HL-49242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049242, R29HL049242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Davis AE, 1997, ADV EXP MED BIOL, V425, P185; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HARPEL PC, 1975, J CLIN INVEST, V55, P593, DOI 10.1172/JCI107967; He SP, 1996, J IMMUNOL, V156, P2009; He SP, 1997, FEBS LETT, V405, P42, DOI 10.1016/S0014-5793(96)01529-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNICK M, 1986, BIOCHEMISTRY-US, V25, P3890, DOI 10.1021/bi00361a023; NILSSON T, 1983, EUR J BIOCHEM, V129, P663; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Osler W, 1888, AM J MED SCI, V95, P362; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Patston PA, 1997, BIOCHEM BIOPH RES CO, V230, P597, DOI 10.1006/bbrc.1996.6010; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SCHAPIRA M, 1988, METHOD ENZYMOL, V163, P179; SIM RB, 1980, BIOCHIM BIOPHYS ACTA, V612, P433, DOI 10.1016/0005-2744(80)90126-6; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; Valnickova Z, 1998, J BIOL CHEM, V273, P27220, DOI 10.1074/jbc.273.42.27220; WEISS V, 1983, H-S Z PHYSIOL CHEM, V364, P295	26	13	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14558	14562		10.1074/jbc.275.19.14558	http://dx.doi.org/10.1074/jbc.275.19.14558			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799541	hybrid			2022-12-27	WOS:000087006900075
J	Newell, JG; Davies, M; Bateson, AN; Dunn, SMJ				Newell, JG; Davies, M; Bateson, AN; Dunn, SMJ			Tyrosine 62 of the gamma-aminobutyric acid type A receptor beta 2 subunit is an important determinant of high affinity agonist binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT GABA(A) RECEPTOR; BENZODIAZEPINE BINDING; ACETYLCHOLINE-RECEPTOR; ALPHA-SUBUNIT; H-3 FLUNITRAZEPAM; POINT MUTATIONS; A RECEPTOR; SITES; CHANNEL; LIGANDS	The gamma-aminobutyric acid type A receptor (GABA(A)R) carries both high (K-D = 10-30 nM) and low (K-D = 0.1-1.0 mu M) affinity binding sites for agonists. We have used site-directed mutagenesis to identify a specific residue in the rat beta 2 subunit that is involved in high affinity agonist binding. Tyrosine residues at positions 62 and 74 were mutated to either phenylalanine or serine and the effects on ligand binding and ion channel activation were investigated after the expression of mutant subunits with wild-type alpha 1 and gamma 2 subunits in tsA201 cells or in Xenopus oocytes. None of the mutations affected [H-3]Ro15-4513 binding or impaired allosteric interactions between the low affinity GABA and benzodiazepine sites. Although mutations at position 74 had little effect on [H-3]muscimol binding, the Y62F mutation decreased the affinity of the high affinity [H-3]muscimol binding sites by similar to 6-fold, and the Y62S mutation led to a loss of detectable high affinity binding sites. After expression in oocytes, the EC50 values for both muscimol and GABA-induced activation of Y62F and Y62S receptors were increased by 2- and 6-fold compared with the wild-type. We conclude that Tyr-62 of the beta subunit is an important determinant for high affinity agonist binding to the GABA(A) receptor.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Div Neurosci, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Psychiat, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta	Dunn, SMJ (corresponding author), Univ Alberta, Dept Pharmacol, 9-70 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	susan.dunn@ualberta.ca						AGEY MW, 1989, BIOCHEMISTRY-US, V28, P4200, DOI 10.1021/bi00436a012; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; BinIm W, 1997, BRIT J PHARMACOL, V120, P559, DOI 10.1038/sj.bjp.0700931; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Buhr A, 1997, MOL PHARMACOL, V52, P676, DOI 10.1124/mol.52.4.676; Buhr A, 1996, MOL PHARMACOL, V49, P1080; BUREAU M, 1988, BIOCHEM BIOPH RES CO, V153, P1006, DOI 10.1016/S0006-291X(88)81328-7; CASALOTTI SO, 1986, J BIOL CHEM, V261, P5013; CASH DJ, 1987, BIOCHEMISTRY-US, V26, P7526; Chang YC, 1996, J NEUROSCI, V16, P5415; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Davies M, 1998, J NEUROCHEM, V70, P2188; Davies M, 1996, NEUROPHARMACOLOGY, V35, P1199, DOI 10.1016/S0028-3908(96)00085-8; DAVIES M, 1994, CAN J PHYSL PHARM, V72, P337; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; DUNN SMJ, 1994, INT REV NEUROBIOL, V36, P51, DOI 10.1016/S0074-7742(08)60303-7; DUNN SMJ, 1983, BIOCHEMISTRY-US, V22, P2512, DOI 10.1021/bi00279a031; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; ENNA SJ, 1977, MOL PHARMACOL, V13, P442; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2199, DOI 10.1073/pnas.86.7.2199; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MOHLER H, 1978, MOL PHARMACOL, V14, P256; NAYEEM N, 1994, J NEUROCHEM, V62, P815; NEWELL JG, 2000, IN PRESS MOL BIOTECH; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLSEN RW, 1986, LIFE SCI, V39, P1969, DOI 10.1016/0024-3205(86)90320-6; OLSEN RW, 1981, MOL PHARMACOL, V19, P217; OLSEN RW, 1983, J NEUROCHEM, V41, P1653, DOI 10.1111/j.1471-4159.1983.tb00877.x; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PREGENZER JF, 1993, MOL PHARMACOL, V43, P801; SHANK RP, 1990, J NEUROCHEM, V54, P2007, DOI 10.1111/j.1471-4159.1990.tb04905.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1984, J BIOL CHEM, V259, P7219; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; TALLMAN JF, 1978, NATURE, V274, P383, DOI 10.1038/274383a0; Tanay VAMI, 1997, MOL BIOTECHNOL, V7, P217, DOI 10.1007/BF02740813; Tretter V, 1997, J NEUROSCI, V17, P2728; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537; Zezula J, 1996, EUR J PHARMACOL, V301, P207, DOI 10.1016/0014-2999(96)00066-0	56	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14198	14204		10.1074/jbc.275.19.14198	http://dx.doi.org/10.1074/jbc.275.19.14198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799496	hybrid			2022-12-27	WOS:000087006900027
J	Tatsuta, T; Shiraishi, A; Mountz, JD				Tatsuta, T; Shiraishi, A; Mountz, JD			The prodomain of caspase-1 enhances Fas-mediated apoptosis through facilitation of caspase-8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1-BETA CONVERTING-ENZYME; DOMAIN-CONTAINING RECEPTOR; ICE FAMILY PROTEASES; CELL-DEATH; MONOCLONAL-ANTIBODY; CONTAINING PROTEIN; MAMMALIAN HOMOLOG; MOLECULAR-CLONING; ADAPTER MOLECULE	Caspase-1 (interleukin-1 beta converting enzyme) is produced in the form of a latent precursor, which is cleaved to yield a prodomain in addition to the p20 and p10 subunits. It has been established that the (p20/p10)(2) heterotetramer processes the latent precursor of interleukin-1 beta into an active form during apoptosis, but the function of the residual prodomain of caspase-1 (Pro-C1) has not been established. To evaluate the involvement of Pro-C1 in apoptosis, a Pro-C1 expression vector was transfected into the HeLa cell line, which is susceptible to Fas-mediated apoptosis. Expression of recombinant Pro-C1 in HeLa cells enhanced apoptosis mediated by Fas, but not etoposide-induced apoptosis. This enhancement of Fas-mediated apoptosis was abolished by inhibitors of caspase-8 (Ile-Glu-Thr-Asp-fluoromethyl ketone) and caspase-3 (Asp-Glu-Val-Asp-aldehyde) but was only slightly diminished by an inhibitor of caspase-1 (acetyl- Tyr-Val-Ala-Asp-chloromethyl ketone). During apoptosis induced by an agonistic anti-Fas antibody, the activation of caspase-8 and caspase-3 was more pronounced and occurred more rapidly in HeLa/Pro-C1 cells than in the empty vector transfectant (HeLa/vec) cells; in contrast, caspase-1 was not activated in either HeLa/Pro-C1 or HeLa/vec cells. These results demonstrate an additional and novel function for caspase-1 in which Pro-C1 acts to enhance Fas-mediated apoptosis, most probably through facilitation of the activation of caspase-8.	Sankyo Co Ltd, Neurosci & Immunol Res Labs, Tokyo 1408710, Japan; Univ Alabama, Birmingham, AL 35294 USA; Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA	Daiichi Sankyo Company Limited; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham	Tatsuta, T (corresponding author), Sankyo Co Ltd, Neurosci & Immunol Res Labs, 1-2-58 Hiromachi, Tokyo 1408710, Japan.							Ahmad M, 1997, CANCER RES, V57, P615; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Li YG, 1997, J VIROL, V71, P1576, DOI 10.1128/JVI.71.2.1576-1582.1997; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mao PL, 1998, J BIOL CHEM, V273, P23621, DOI 10.1074/jbc.273.37.23621; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUMIMOTO SI, 1994, CELL IMMUNOL, V153, P184, DOI 10.1006/cimm.1994.1016; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tatsuta T, 1996, J IMMUNOL, V157, P3949; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14248	14254		10.1074/jbc.275.19.14248	http://dx.doi.org/10.1074/jbc.275.19.14248			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799503	hybrid			2022-12-27	WOS:000087006900034
J	del Arco, PG; Martinez-Martinez, S; Maldonado, JL; Ortega-Perez, I; Redondo, JM				del Arco, PG; Martinez-Martinez, S; Maldonado, JL; Ortega-Perez, I; Redondo, JM			A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; NF-AT; TRANSCRIPTION FACTORS; SELECTIVE ACTIVATION; GENE-EXPRESSION; FAMILY; CASCADES	Calcium signals lead to the translocation of nuclear factor of activated T cells (NFAT) from the cytoplasm to the nucleus. This process is regulated by the calcium-activated phosphatase calcineurin, which can be co-transported with NFAT to the nucleus to maintain it transcriptionally active for the duration of calcium signaling. When the calcium signal ceases, NFAT is exported to the cytoplasm, and different NFAT kinases have been reported to oppose calcineurin activities and regulate the nuclear export of NFAT, Here we show that p38 MAPK phosphorylates in vitro and interacts in vivo with NFATp, Furthermore, the activation of this pathway in HeLa cells by cotransfection with activated MKK6 and p38 counteracts the calcium-induced nuclear accumulation of NFATp but not that of NFATc, By contrast, activation of JNK or ERR pathways failed to modify the nuclear shuttling of NFATp. Consistently, activation of p38, but not the JNK MAPK pathway, results in the inhibition of NFAT p-driven transcription. In addition, the inhibition of the nuclear accumulation of NFATp by p38 appears to be mediated through the activation of NFATp nuclear export and takes place in a Leptomycin B-sensitive fashion, suggesting the involvement of the exportin CRM1 in this process. Thus, the p38 signal transduction pathway appears to play an important role in the regulation of the nuclear shuttling of NFATp and in cellular homeostasis.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Redondo, JM (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol mol Severo Ochoa, E-28049 Madrid, Spain.		Gomez-del Arco, Pablo/L-2728-2013; Redondo, Juan Miguel/H-6351-2015	Gomez-del Arco, Pablo/0000-0001-6748-7157; Redondo, Juan Miguel/0000-0001-5779-9122				Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; delArco PG, 1996, J BIOL CHEM, V271, P26335; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DeSilva DR, 1997, CELL IMMUNOL, V180, P116, DOI 10.1006/cimm.1997.1182; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU XQ, 1993, ACTA PHARM SINIC, V14, P200; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Luo C, 1996, MOL CELL BIOL, V16, P3955; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; NISHI K, 1994, J BIOL CHEM, V269, P6320; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmon RA, 1997, J IMMUNOL, V159, P5309; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	52	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13872	13878		10.1074/jbc.275.18.13872	http://dx.doi.org/10.1074/jbc.275.18.13872			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788511	hybrid			2022-12-27	WOS:000086925300098
J	Snyder, CH; Gutierrez-Cirlos, EB; Trumpower, BL				Snyder, CH; Gutierrez-Cirlos, EB; Trumpower, BL			Evidence for a concerted mechanism of ubiquinol oxidation by the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; MITOCHONDRIAL RESPIRATORY-CHAIN; PROTONMOTIVE Q-CYCLE; ELECTRON-TRANSFER; C OXIDOREDUCTASE; BOVINE HEART; DOMAIN MOVEMENT; 2FE-2S CLUSTER; SITE; UBIHYDROQUINONE	To better understand the mechanism of divergent electron transfer from ubiquinol to the iron-sulfur protein and cytochrome b(L) within the cytochrome bc(1) complex, we have examined the effects of antimycin on the presteady state reduction kinetics of the bc(1) complex in the presence or absence of endogenous ubiquinone, When ubiquinone is present, antimycin slows the rate of cytochrome c(1) reduction by similar to 10-fold but had no effect upon the rate of cytochrome c(1) reduction in bc(1) complex lacking endogenous ubiquinone, In the absence of endogenous ubiquinone cytochrome c(1), reduction was slower than when ubiquinone was present and was similar to that in the presence of ubiquinone plus antimycin, These results indicate that the low potential redox components, cytochrome b(H) and b(L) exert negative control on the rate of reduction of cytochrome c(1) and the Rieske iron-sulfur protein at center P, If electrons cannot equilibrate from cytochrome b(H) and b(L) to ubiquinone, partial reduction of the low potential components slows reduction of the high potential components. We also examined the effects of decreasing the midpoint potential of the iron-sulfur protein on the rates of cytochrome b reduction. As the midpoint potential decreased, there was a parallel decrease in the rate of b reduction, demonstrating that the rate of b reduction is dependent upon the rate of ubiquinol oxidation by the iron-sulfur protein. Together these results indicate that ubiquinol oxidation is a concerted reaction in which both the low potential and high potential redox components control ubiquinol oxidation at center P, consistent with the protonmotive Q cycle mechanism.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.		Gutiérrez, Emma/AAG-5191-2021; Gutierrez Cirlos, Emma Berta/D-4463-2011	Gutierrez Cirlos, Emma Berta/0000-0002-6672-1711	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18811, GM 20397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; BOWYER JR, 1981, J BIOL CHEM, V256, P2245; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; DEGLIESPOSTI M, 1982, FEBS LETT, V277, P49; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; MATHESON IBC, 1987, ANAL INSTRUM, V16, P345; Matsuno-Yagi A, 1999, J BIOL CHEM, V274, P9283, DOI 10.1074/jbc.274.14.9283; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 1999, J BIOENERG BIOMEMBR, V31, P235, DOI 10.1023/A:1005419712731; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	27	87	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13535	13541		10.1074/jbc.275.18.13535	http://dx.doi.org/10.1074/jbc.275.18.13535			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788468	hybrid			2022-12-27	WOS:000086925300055
J	Yamagata, A; Masui, R; Kato, R; Nakagawa, N; Ozaki, H; Sawai, H; Kuramitsu, S; Fukuyama, K				Yamagata, A; Masui, R; Kato, R; Nakagawa, N; Ozaki, H; Sawai, H; Kuramitsu, S; Fukuyama, K			Interaction of UvrA and UvrB proteins with a fluorescent single-stranded DNA - Implication for slow conformational change upon interaction of UvrB with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS HB8; NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI UVRB; CISPLATIN-DAMAGED DNA; (A)BC EXCINUCLEASE; PREINCISION COMPLEX; ATPASE ACTIVITY; RECA PROTEIN; BINDING; ENDONUCLEASE	UvrA and UvrB proteins play key roles in the damage recognition step in the nucleotide excision repair. However, the molecular mechanism of damage recognition by these proteins is still not well understood. In this work we analyzed the interaction between single-stranded DNA (ssDNA) labeled with a fluorophore tetramethylrhodamine (TMR) and Thermus thermophilus HBS UvrA (ttUvrA) and UvrB (ttUvrB) proteins. TMR-labeled ssDNA (TMR-ssDNA) as well as UV-irradiated ssDNA stimulated ATPase activity of ttUvrB more strongly than did normal ssDNA, indicating that this fluorescent ssDNA was recognized as damaged ssDNA. The addition of ttUvrA or ttUvrB enhanced the fluorescence intensity of TMR-ssDNA, and the intensity was much greater in the presence of ATP. Fluorescence titration indicated that ttUvrA has higher specificity for TMR-ssDNA than for normal ssDNA in the absence of ATP. The ttUvrB showed no specificity for TMR-ssDNA, but it took over 200 min for the fluorescence intensity of the ttUvrB-TMR-ssDNA complex to reach saturation in the presence of ATP. This time-dependent change could be separated into two phases. The first phase was rapid, whereas the second phase was slow and dependent on ATP hydrolysis. Time dependence of ATPase activity and fluorescence polarization suggested that changes other than the binding reaction occurred during the second phase. These results strongly suggest that ttUvrB binds ssDNA quickly and that a conformational change in ttUrvB-ssDNA complex occurs slowly. We also found that DNA containing a fluorophore as a lesion is useful for directly investigating the damage recognition by UvrA and UvrB.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Gunma Univ, Fac Engn, Dept Chem, Gunma 3768515, Japan; RIKEN, Inst Phys & Chem Res, Harima Inst SPring 8, Kobe, Hyogo 6795148, Japan; RIKEN, Genom Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	Osaka University; Gunma University; RIKEN; RIKEN	Kuramitsu, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp		Kato, Ryuichi/0000-0003-2087-2896				Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; FASMAN CD, 1975, CRC HDB BIOCH MOL BI, V1; FRIEDERG EC, 1995, DNA REPAIR MUTAGENES; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; Gordienko I, 1997, EMBO J, V16, P880, DOI 10.1093/emboj/16.4.880; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; KATO R, 1993, J BIOCHEM-TOKYO, V114, P926, DOI 10.1093/oxfordjournals.jbchem.a124278; Kato R, 1996, J BIOL CHEM, V271, P9612, DOI 10.1074/jbc.271.16.9612; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Mikawa T, 1998, NUCLEIC ACIDS RES, V26, P903, DOI 10.1093/nar/26.4.903; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; Nakagawa N, 1999, J BIOCHEM, V126, P986, DOI 10.1093/oxfordjournals.jbchem.a022566; Nakagawa N, 1997, J BIOL CHEM, V272, P22703, DOI 10.1074/jbc.272.36.22703; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; OZAKI H, 1995, B CHEM SOC JPN, V68, P1981, DOI 10.1246/bcsj.68.1981; Powell LM, 1998, J MOL BIOL, V283, P947, DOI 10.1006/jmbi.1998.2142; PUGH BF, 1988, J BIOL CHEM, V263, P76; Routledge MN, 1997, CARCINOGENESIS, V18, P1407, DOI 10.1093/carcin/18.7.1407; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; Shibata A, 1999, ACTA CRYSTALLOGR D, V55, P704, DOI 10.1107/S0907444998015777; SHOWDEN A, 1991, J MOL BIOL, V220, P19; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; Yamamoto N, 1996, GENE, V171, P103, DOI 10.1016/0378-1119(96)00052-2; Zou Y, 1998, J MOL BIOL, V281, P107, DOI 10.1006/jmbi.1998.1903; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	42	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13235	13242		10.1074/jbc.275.18.13235	http://dx.doi.org/10.1074/jbc.275.18.13235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788428	hybrid			2022-12-27	WOS:000086925300014
J	Bertolotto, C; Ricci, JE; Luciano, F; Mari, B; Chambard, JC; Auberger, P				Bertolotto, C; Ricci, JE; Luciano, F; Mari, B; Chambard, JC; Auberger, P			Cleavage of the serum response factor during death receptor-induced apoptosis results in an inhibition of the c-FOS promoter transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; TERNARY COMPLEX FACTORS; CELL-DEATH; GROWTH-FACTORS; FACTORS ELK-1; ICE-LIKE; ACTIVATION; SURVIVAL; PATHWAYS; PROTEINS	The c-FOS protooncogene is rapidly induced by a wide variety of extracellular stimuli including mitogenic signals. Regulation of c-FOS expression is tightly dependent on the serum response element localized within its promoter. Two transcription factors, the serum response factor (SRF) and the ternary complex factor, bind to the serum response element and play a key role in the regulation of the c-FOS promoter activity. In the present study, we show that two death effecters (CH11 and TRAIL) severely impaired the transcriptional activity of the c-FOS promoter in Jurkat T cells. This inhibition can be accounted for by the specific cleavage by caspase 3 of the SRF both in vitro and in vivo, since acetyl-DEVD-aldehyde prevented SRF cleavage and abolished the inhibitory effect of CH11 and TRAIL on the c-FOS promoter activity. Moreover, phorbol myristate acetate, a potent anti-apoptotic effector, was found to protect SRF completely from cleavage by caspase 3 and also to prevent the inhibition of the c-FOS promoter activity by death effectors. Survival factors play an essential function in the regulation of cell growth mainly by regulating the expression of immediate early gene such as c-FOS. In this line, cleavage of SRF at the onset of apoptosis could abrogate the ability of the cell to induce inappropriate survival pathways. All together, our results are consistent with a role of SRF at the interface between cell survival and death pathways.	Fac Med, INSERM, U526, F-06107 Nice 2, France; Ctr Biochim, Inst Rech Signalisat Biol Dev & Canc, CNRS, UMR 6543, F-06189 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Fac Med, INSERM, U526, 28 Ave Valombrose, F-06107 Nice 2, France.		luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; Ricci, Jean Ehrland/I-7117-2016; Bertolotto-Ballotti, Corine/O-2155-2016; AUBERGER, Patrick/G-1491-2013; Mari, Bernard/Q-5832-2019; Mari, Bernard P/F-8960-2013; Bertolotto, Corine/AAF-6634-2021; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022	luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; Ricci, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Bertolotto, Corine/0000-0001-6971-7753; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; CHAMBARD, Jean Claude/0000-0003-4722-2308				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Hasegawa J, 1996, CANCER RES, V56, P1713; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	42	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12941	12947		10.1074/jbc.275.17.12941	http://dx.doi.org/10.1074/jbc.275.17.12941			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777594	hybrid			2022-12-27	WOS:000086762300078
J	Bjergbaek, L; Kingma, P; Nielsen, IS; Wang, Y; Westergaard, O; Osheroff, N; Andersen, AH				Bjergbaek, L; Kingma, P; Nielsen, IS; Wang, Y; Westergaard, O; Osheroff, N; Andersen, AH			Communication between the ATPase and cleavage/religation domains of human topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE ANALYSIS; N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; 2-GATE MECHANISM; TRANSPORT; ENZYME; DRUGS	The DNA strand passage activity of eukaryotic topoisomerase II relies on a cascade of conformational changes triggered by ATP binding to the N-terminal domain of the enzyme. To investigate the interdomain communication between the ATPase and cleavage/religation domains of human topoisomerase II alpha, we characterized a mutant enzyme that contains a deletion at the interface between the two domains, covering amino acids 350-407. The ATPase domain retained full activity with a rate of ATP hydrolysis that was severalfold higher than normal, but the ATPase activity was unaffected by DNA. The cleavage and religation activities of the enzyme were comparable with those of the wild-type enzyme both in the absence and presence of cancer chemotherapeutic agents. However, neither ATP nor a nonhydrolyzable ATP analog stimulated cleavage complex formation, Although both conserved domains retained full activity, the mutant enzyme was unable to coordinate these activities into strand passage. Our findings suggest that the normal conformational transitions occurring in the enzyme upon ATP binding are hampered or lacking in the mutant enzyme. Consistent with this hypothesis, the enzyme displayed an abnormal clamp closing activity. In summary, the region covering amino acids 350-407 in human topoisomerase II alpha seems to be essential for correct interdomain communication and probably is involved in signaling ATP binding to the rest of the enzyme.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Aarhus University; Vanderbilt University	Andersen, AH (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Andersen, Anni/O-1162-2017; Bjergbæk, Lotte/AAW-6302-2021	Bjergbaek, Lotte/0000-0002-8233-3356; Andersen, Anni/0000-0001-7194-3258	NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Bjergbaek L, 1999, J BIOL CHEM, V274, P26529, DOI 10.1074/jbc.274.37.26529; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Caron P R, 1994, Adv Pharmacol, V29B, P271; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GOCKE E, 1983, NUCLEIC ACIDS RES, V11, P7661, DOI 10.1093/nar/11.22.7661; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen S, 1996, MOL CELL BIOL, V16, P3866; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Y, 1999, J BIOL CHEM, V274, P22839, DOI 10.1074/jbc.274.32.22839; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6	43	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13041	13048		10.1074/jbc.275.17.13041	http://dx.doi.org/10.1074/jbc.275.17.13041			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777608	hybrid			2022-12-27	WOS:000086762300092
J	Jones, JM; Morrell, JC; Gould, SJ				Jones, JM; Morrell, JC; Gould, SJ			Identification and characterization of HAOX1, HAOX2, and HAOX3, three human peroxisomal 2-hydroxy acid oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYACID OXIDASE; RAT-LIVER PEROXISOMES; GLYCOLATE OXIDASE; ZELLWEGER-SYNDROME; MOLECULAR-CLONING; DELTA(3),DELTA(2)-ENOYL-COA ISOMERASE; 2-HYDROXYPHYTANOYL-COA LYASE; BIOGENESIS DISORDERS; RENAL PEROXISOMES; REFSUM-DISEASE	Computer-based approaches identified three distinct human 2-hydroxy acid oxidase genes, HAOX1, HAOX2, and HAOX3, that encode proteins with significant sequence similarity to plant glycolate oxidase, a prototypical 2-hydroxy acid oxidase. The products of these genes are targeted to peroxisomes and have 2-hydroxy acid oxidase activities. Each gene displays a distinct tissue-specific pattern of expression, and each enzyme exhibits distinct substrate preferences, HAOX1 is expressed primarily in liver and pancreas and is most active on the two-carbon substrate, glycolate, but is also active on 2-hydroxy fatty acids, HAOX2 is expressed predominantly in liver and kidney and displays highest activity toward 2-hydroxypalmitate. HAOX3 expression was detected only in pancreas, and this enzyme displayed a preference for the medium chain substrate 2-hydroxyoctanoate. These results indicate that all three human 2-hydroxy acid oxidases are involved in the oxidation of 2-hydroxy fatty acids and may also contribute to the general pathway of fatty acid alpha-oxidation. Primary hyperoxaluria type 1 (PH1) is caused by defects in peroxisomal alanine-glyoxylate aminotransferase, the enzyme that normally eliminates intraperoxisomal glyoxylate. The presence of HAOX1 in liver and kidney peroxisomes and the ability of HAOX1 to oxidize glyoxylate to oxalate implicate HAOX1 as a mediator of PH1 pathophysiology.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	sgould@jhmi.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981] Funding Source: Medline; NIDDK NIH HHS [DK45787] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN JM, 1965, SCIENCE, V149, P1507, DOI 10.1126/science.149.3691.1507; ANGERMULLER S, 1989, PROG HISTOCHEM CYTOC, V20, P1; BAUDHUIN P, 1965, J CELL BIOL, V26, P219, DOI 10.1083/jcb.26.1.219; BELMOUDEN A, 1993, EUR J BIOCHEM, V214, P17, DOI 10.1111/j.1432-1033.1993.tb17891.x; Chang CC, 1999, J CELL SCI, V112, P1579; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CRANE DI, 1994, J BIOL CHEM, V269, P21835; Croes K, 1999, LIPIDS, V34, pS159, DOI 10.1007/BF02562273; DANPURE CJ, 1995, METABOLIC MOL BASES, P2385; DULEY JA, 1976, EUR J BIOCHEM, V63, P163, DOI 10.1111/j.1432-1033.1976.tb10219.x; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; FRY DW, 1979, BIOCHIM BIOPHYS ACTA, V568, P135, DOI 10.1016/0005-2744(79)90281-X; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; Jansen GA, 1999, BBA-MOL CELL BIOL L, V1440, P176, DOI 10.1016/S1388-1981(99)00126-2; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KISHIMOTO Y, 1979, MOL CELL BIOCHEM, V28, P93; Kohler SA, 1999, J BIOL CHEM, V274, P2401, DOI 10.1074/jbc.274.4.2401; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LE KHD, 1991, J BIOL CHEM, V266, P20877; LINDQVIST Y, 1985, P NATL ACAD SCI USA, V82, P6855, DOI 10.1073/pnas.82.20.6855; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.tb20842.x; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUMAN M, 1971, BIOCHIM BIOPHYS ACTA, V227, P500, DOI 10.1016/0005-2744(71)90003-9; SCHWAM H, 1979, BIOCHEMISTRY-US, V18, P2828, DOI 10.1021/bi00580a023; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VAMECQ J, 1988, BIOMED ENVIRON MASS, V15, P345, DOI 10.1002/bms.1200150607; Verhoeven NM, 1997, BIOCHEM BIOPH RES CO, V237, P33, DOI 10.1006/bbrc.1997.7066; Verhoeven NM, 1997, J LIPID RES, V38, P2062; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; WANDERS RJA, 1995, J INHERIT METAB DIS, V18, P201, DOI 10.1007/BF00711766; WANDERS RJA, 1994, BBA-MOL BASIS DIS, V1227, P177, DOI 10.1016/0925-4439(94)90092-2; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; Watkins PA, 1996, J LIPID RES, V37, P2288; ZAAR K, 1991, J CELL BIOL, V113, P113, DOI 10.1083/jcb.113.1.113; ZAAR K, 1991, J HISTOCHEM CYTOCHEM, V39, P801, DOI 10.1177/39.6.2033239	46	95	101	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12590	12597		10.1074/jbc.275.17.12590	http://dx.doi.org/10.1074/jbc.275.17.12590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777549	hybrid			2022-12-27	WOS:000086762300033
J	Kalluri, R; Cosgrove, D				Kalluri, R; Cosgrove, D			Assembly of type IV collagen - Insights from alpha 3(IV) collagen-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; LINKED ALPORT SYNDROME; GOODPASTURE-SYNDROME; DIFFUSE LEIOMYOMATOSIS; NONCOLLAGENOUS DOMAIN; HEREDITARY NEPHRITIS; MOLECULAR CHAPERONE; MURINE COCHLEA; CHAINS; IDENTIFICATION	Type IV collagen includes six genetically distinct polypeptides named alpha 1(IV) through alpha 6(IV). These isoforms are speculated to organize themselves into unique networks providing mammalian basement membranes specificity and inequality. Recent studies using bovine and human glomerular and testis basement membranes have shown that unique networks of collagen comprising either alpha 1 and alpha 2 chains or alpha 3, alpha 4, and alpha 5 chains can be identified. These studies have suggested that assembly of alpha 5 chain into type IV collagen network is dependent on alpha 3 expression where both chains are normally present in the tissue. In the present study, we show that in the lens and inner ear of normal mice, expression of alpha 1, alpha 2, alpha 3, alpha 4, and alpha 5 chains of type IV collagen can be detected using alpha chain-specific antibodies. In the alpha 3(IV) collagen-deficient mice, only the expression of alpha 1, alpha 2, and alpha 5 chains of type IV collagen was detectable. The non-collagenous 1 domain of alpha 5 chain was associated with alpha 1 in the non-collagenous 1 domain hexamer structure, suggesting that network incorporation of alpha 5 is possible in the absence of the alpha 3 chain in these tissues. The present study proves that expression of alpha 5 is not dependent on the expression of alpha 3 chain in these tissues and that alpha 5 chain can assemble into basement membranes in the absence of alpha 3 chain. These findings support the notion that type IV collagen assembly may be regulated by tissue-specific factors.	Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boystown Natl Res Hosp, Gene Express Lab, Omaha, NE 68010 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, DANA 563A, 330 Brookline Ave, Boston, MA 02215 USA.		Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-55001, DK-55000, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cosgrove D, 1996, HEARING RES, V100, P21, DOI 10.1016/0378-5955(96)00114-1; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; Cosgrove D, 1996, HEARING RES, V97, P54; DING J, 1994, KIDNEY INT, V46, P1504; Ferreira LR, 1996, CONNECT TISSUE RES, V33, P265, DOI 10.3109/03008209609028884; FREYTAG JW, 1976, BIOCHEM BIOPH RES CO, V72, P796; Germino G G, 1993, Curr Opin Nephrol Hypertens, V2, P430, DOI 10.1097/00041552-199305000-00011; GRUNFELD JP, 1985, KIDNEY INT, V27, P83, DOI 10.1038/ki.1985.14; GUBLER MC, 1995, KIDNEY INT, V47, P1142, DOI 10.1038/ki.1995.163; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; HUDSON B, 1991, PATHOBIOCHEMISTRY, P17; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Kahsai TZ, 1997, J BIOL CHEM, V272, P17023, DOI 10.1074/jbc.272.27.17023; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1996, P ASSOC AM PHYSICIAN, V108, P134; KALLURI R, 1994, P NATL ACAD SCI USA, V91, P6201, DOI 10.1073/pnas.91.13.6201; KALLURI R, 1995, KIDNEY INT, V47, P1199, DOI 10.1038/ki.1995.170; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; Kashtan CE, 1999, MEDICINE, V78, P338, DOI 10.1097/00005792-199909000-00005; KASHTAN CE, 1993, AM J KIDNEY DIS, V22, P627, DOI 10.1016/S0272-6386(12)80424-0; Kashtan CE, 1996, KIDNEY INT, V50, P1445, DOI 10.1038/ki.1996.459; Kashtan CE, 1998, J AM SOC NEPHROL, V9, P1736; KASHTAN CE, 1990, J LAB CLIN MED, V116, P508; KASHTAN CE, 1994, HEREDITARY NEPHRITIS, P1239; KASHTAN CE, 1997, KIDNEY INT S58, V51, pS69; KLEPPEL MM, 1992, J BIOL CHEM, V267, P4137; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Miner JH, 1999, AM J PATHOL, V154, P1633, DOI 10.1016/S0002-9440(10)65417-X; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; Nagata K, 1998, MATRIX BIOL, V16, P379, DOI 10.1016/S0945-053X(98)90011-7; Nakanishi K, 1996, J AM SOC NEPHROL, V7, P938; NAKANISHI K, 1994, KIDNEY INT, V46, P1413, DOI 10.1038/ki.1994.413; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TIMPL R, 1985, ANN NY ACAD SCI, V460, P58, DOI 10.1111/j.1749-6632.1985.tb51157.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; WEBER M, 1992, EUR J CLIN INVEST, V22, P138, DOI 10.1111/j.1365-2362.1992.tb01947.x; WEST TW, 1980, J BIOL CHEM, V255, P451; WISDOM BJ, 1992, CONNECT TISSUE RES, V27, P225, DOI 10.3109/03008209209006998; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; [No title captured]	55	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12719	12724		10.1074/jbc.275.17.12719	http://dx.doi.org/10.1074/jbc.275.17.12719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777566	hybrid			2022-12-27	WOS:000086762300050
J	Nishimiya, Y; Tsumoto, K; Shiroishi, M; Yutani, K; Kumagai, I				Nishimiya, Y; Tsumoto, K; Shiroishi, M; Yutani, K; Kumagai, I			Thermodynamic consequences of grafting enhanced affinity toward the mutated antigen onto an antibody - The case of anti-lysozyme antibody, HyHEL-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; ANTILYSOZYME MONOCLONAL-ANTIBODY; SITE-DIRECTED MUTAGENESIS; CROSS-REACTION COMPLEX; CRYSTAL-STRUCTURE; WATER-MOLECULES; HYPERVARIABLE REGIONS; PROTEIN ANTIGENS; SOMATIC MUTATION; CHICKEN LYSOZYME	In order to address the mechanism of enhancement of the affinity of an antibody toward an antigen from a thermodynamic viewpoint, anti-hen lysozyme (HEL) antibody HyHEL-10, which also recognize the mutated antigen turkey lysozyme (TEL) with reduced affinity, was examined. Grafting high affinity toward TEL onto HyHEL-10 was performed by saturation mutagenesis into four residues (Tyr(53), Ser(54), Ser(56), and Tyr(58)) in complementarity-determining region 2 of the heavy chain (CDR-H2) followed by selection with affinity for TEL. Several clones enriched have a Phe residue at site 58. Thermodynamic analyses showed that the clones selected had experienced a greater than 3-fold affinity increase toward TEL in comparison with wild-type Fv, originating from an increase in negative enthalpy change. Substitution of HyHEL-10 HTyr(58) With Phe led to the increase in negative enthalpy change and to almost identical affinity for TEL in comparison with mutants selected, indicating that mutations at other sites decrease the entropy loss despite little contribution to the affinity for TEL. These results suggest that the affinity of an antibody toward the antigen is enhanced by the increase in enthalpy change by some limited mutation, and excess entropy loss due to the mutation is decreased by other energetically neutral mutations.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Tohoku University; Osaka University	Kumagai, I (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	kmiz@mail.cc.tohoku.ac.jp	Nishimiya, Yoshiyuki/M-4173-2018	Nishimiya, Yoshiyuki/0000-0002-0701-7775; Shiroishi, Mitsunori/0000-0002-3133-157X				AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Covell DG, 1997, J MOL BIOL, V269, P281, DOI 10.1006/jmbi.1997.1028; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Harata K, 1998, PROTEINS, V30, P232; Imoto T., 1972, ENZYMES, V7, P665; Jager M, 1999, J MOL BIOL, V285, P2005, DOI 10.1006/jmbi.1998.2425; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LESCAR J, 1995, J BIOL CHEM, V270, P18067, DOI 10.1074/jbc.270.30.18067; Maenaka K, 1996, BIOCHEM BIOPH RES CO, V218, P682, DOI 10.1006/bbrc.1996.0122; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Pons J, 1999, PROTEIN SCI, V8, P958, DOI 10.1110/ps.8.5.958; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; Ueda H, 1996, NAT BIOTECHNOL, V14, P1714, DOI 10.1038/nbt1296-1714; UEDA Y, 1993, GENE, V129, P129; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xavier KA, 1998, BIOPHYS J, V74, P2036; Xavier KA, 1997, BIOPHYS J, V73, P2116, DOI 10.1016/S0006-3495(97)78242-0; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	51	21	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12813	12820		10.1074/jbc.275.17.12813	http://dx.doi.org/10.1074/jbc.275.17.12813			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777579	hybrid			2022-12-27	WOS:000086762300063
J	Yao, DY; Dore, JJE; Leof, EB				Yao, DY; Dore, JJE; Leof, EB			FKBP12 is a negative regulator of transforming growth factor-beta receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASES; TGF-BETA; I RECEPTORS; MEDIATED ENDOCYTOSIS; EXPRESSION CLONING; FAMILY; SUPERFAMILY; RESPONSES; MECHANISM; COMPLEX	Transforming growth factor-beta (TGF-beta) family polypeptides regulate cell growth and differentiation by binding to single pass serine/threonine kinases referred to as TGF-beta type I and II receptors. Although interaction screens have shown that the immunophilin FKBP12 interacts with TGF-beta type I receptors, the role of FKBP12 in TGF-beta receptor action is presently unclear. Using a chimeric TGF-beta receptor system, we have shown a specific enhancement of internalization when FKBP12 binding to the type I receptor was prevented with rapamycin. Moreover, although earlier studies demonstrated that type II receptor kinase activity was required for optimal internalization in mesenchymal cells, we found that rapamycin functioned downstream of the type II receptor kinase. Thus, rather than modulating TGF-beta signaling, our data suggest a novel role for FKBP12 as a negative regulator of TGF-beta receptor endocytosis.	Mayo Clin, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Leof, EB (corresponding author), Mayo Clin, Thorac Dis Res Unit, Guggenheim 6, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055816, R01GM054200, R37GM055816] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54200, GM55816] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Bassing CH, 1998, CELL GROWTH DIFFER, V9, P223; Bradbury FA, 1999, BIOCHEMISTRY-US, V38, P8703, DOI 10.1021/bi990169t; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; FRANZEN P, 1993, CELL, V75, P781; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	32	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13149	13154		10.1074/jbc.275.17.13149	http://dx.doi.org/10.1074/jbc.275.17.13149			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777621	hybrid			2022-12-27	WOS:000086762300105
J	Lim, CR; Kimata, Y; Ohdate, H; Kokubo, T; Kikuchi, N; Horigome, T; Kohno, K				Lim, CR; Kimata, Y; Ohdate, H; Kokubo, T; Kikuchi, N; Horigome, T; Kohno, K			The Saccharomyces cerevisiae RuvB-like protein, Tih2p, is required for cell cycle progression and RNA polymerase II-directed transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; DNA HELICASE; NUCLEAR-PORE; MOLECULAR-CLONING; FACTOR TFIIH; RAD3 GENE; O-GLCNAC; YEAST; COMPLEX; ACTIVATION	Two highly conserved RuvB-like putative DNA helicases, p47/TIP49b and p50/TIP49a, have been identified in the eukaryotes. Here, we study the function of Saccharomyces cerevisiae TIH2, which corresponds to mammalian p47/TIP49b. Tih2p is required for vegetative cell growth and localizes in the nucleus, Immunoprecipitation analysis revealed that Tih2p tightly interacts with Tih1p, the counterpart of mammalian p50/TIP49a, which has been shown to interact with the TATA-binding protein and the RNA polymerase II holoenzyme complex. Furthermore, the mutational study of the Walker A motif, which is required for nucleotide binding and hydrolysis, showed that this motif plays indispensable roles in the function of Tih2p, When a temperature-sensitive tih2 mutant, tih2-160, was incubated at the nonpermissive temperature, cells were rapidly arrested in the G(1) phase. Northern blot analysis revealed that Tih2p is required for transcription of G(1) cyclin and of several ribosomal protein genes. The similarities between the mutant phenotypes of tih2-160 and those of taf145 mutants suggest a role for TIH2 in the regulation of RNA polymerase II-directed transcription.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan; Niigata Univ, Fac Sci, Dept Biochem, Niigata 9502181, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Nara Institute of Science & Technology; Nara Institute of Science & Technology; Niigata University; Japan Science & Technology Agency (JST)	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.	kkouno@bs.aist-nara.ac.jp	Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Gohshi T, 1999, J BIOCHEM, V125, P939, DOI 10.1093/oxfordjournals.jbchem.a022372; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Holzmann K, 1998, BIOCHEM BIOPH RES CO, V252, P39, DOI 10.1006/bbrc.1998.9604; IMAI N, 1995, BIOCH LIFE SCI ADV, V14, P59; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; Kanemaki M, 1999, J BIOL CHEM, V274, P22437, DOI 10.1074/jbc.274.32.22437; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kikuchi N, 1999, J BIOCHEM, V125, P487, DOI 10.1093/oxfordjournals.jbchem.a022312; KIMATA Y, 1994, J BIOL CHEM, V269, P13497; Kimata Y, 1999, CELL STRUCT FUNCT, V24, P197, DOI 10.1247/csf.24.197; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; Leung DW, 1989, TECHNIQUE, V1, P11; LI X, 1992, CHROMOSOMA, V102, P93; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; Makino Y, 1998, BIOCHEM BIOPH RES CO, V245, P819, DOI 10.1006/bbrc.1998.8504; Makino Y, 1999, J BIOL CHEM, V274, P15329, DOI 10.1074/jbc.274.22.15329; Moore DD, 1995, GLOB MOB SURV; NAUMOVSKI L, 1986, MOL CELL BIOL, V6, P1218, DOI 10.1128/MCB.6.4.1218; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; REASON AJ, 1992, J BIOL CHEM, V267, P16911; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SIEDE W, 1994, GENETICS, V138, P271; SIKORSKI RS, 1989, GENETICS, V122, P19; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	57	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22409	22417		10.1074/jbc.M001031200	http://dx.doi.org/10.1074/jbc.M001031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10787406	hybrid			2022-12-27	WOS:000088363800089
J	Katschinski, DM; Boos, K; Schindler, SG; Fandrey, J				Katschinski, DM; Boos, K; Schindler, SG; Fandrey, J			Pivotal role of reactive oxygen species as intracellular mediators of hyperthermia-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HEAT-SHOCK PROTEINS; DNA-BINDING ACTIVITY; INDUCED CELL-DEATH; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; STRESS PROTEINS; LEUKEMIA-CELLS; NITRIC-OXIDE; HSP70	The effects of cellular antioxidant capacity on hyperthermia (HT)-induced apoptosis and production of antiapoptotic heat shock proteins (HSPs) were investigated in HL-60 cells and in HL-60AR cells that are characterized by an elevated endogenous catalase activity. Exposure of both cell lines to 43 degrees C for 1 h initiated apoptosis. Apoptosis peaked at 3-6 h after heat exposure in the HL-60 cells. Whereas HL-60AR cells were partially protected against MT-induced apoptosis at these early time points, maximal levels of apoptosis were detected later, i.e. 12-18 h after heat exposure. This differential induction of apoptosis was directly correlated to the induction of the antiapoptotic HSP27 and HSP70. In particular, in the HL-60 cells HSP27 was significantly induced at 12-18 h after exposure to 43 degrees C when apoptosis dropped. In contrast, coinciding with the late onset of apoptosis in HL-60AR cells at that time HL-60AR cells lacked a similar HSP response. In line with the higher antioxidant capacity HL-60AR cells accumulated reactive oxygen species to a lesser degree than HL-60 cells after heat treatment. Protection from MT-induced apoptosis as well as diminished heat-induced HSP27 expression was also observed after cotreatment of HL-60 cells with 43 degrees C and catalase but not with superoxide dismutase. These data emphasize the pivotal role of reactive oxygen species for HT induced pro- and antiapoptotic pathways.	Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Essen, Inst Physiol, D-45122 Essen, Germany	University of Lubeck; University of Duisburg Essen	Katschinski, DM (corresponding author), Med Univ Lubeck, Inst Physiol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.			Fandrey, Joachim/0000-0001-9585-0531				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BHALLA K, 1985, CANCER RES, V45, P3657; Bornman L, 1999, J CELL PHYSIOL, V178, P1; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIOCCA DR, 1992, CANCER RES, V52, P3648; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Flanagan SW, 1998, FEBS LETT, V431, P285, DOI 10.1016/S0014-5793(98)00779-0; Frank J, 1998, CANCER RES, V58, P2693; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Gorman AM, 1999, FEBS LETT, V445, P98, DOI 10.1016/S0014-5793(99)00094-0; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; Jornot L, 1997, FEBS LETT, V416, P381, DOI 10.1016/S0014-5793(97)01244-1; Katschinski DM, 1999, CANCER RES, V59, P3404; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LENEHAN PF, 1995, CANCER CHEMOTH PHARM, V35, P377, DOI 10.1007/s002800050250; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Li JJ, 1997, CANCER RES, V57, P1991; Malysheva IY, 1996, FEBS LETT, V391, P21, DOI 10.1016/0014-5793(96)00691-6; Matsumoto H, 1999, CANCER RES, V59, P3239; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; ROBINS HI, 1992, CLIN THERMOLOGY; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHOENIGER LO, 1994, GASTROENTEROLOGY, V106, P177, DOI 10.1016/S0016-5085(94)95209-4; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takasu T, 1998, CANCER RES, V58, P2504; TAKEUCHI A, 1995, CANCER RES, V55, P1586; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YOSHIKAWA T, 1993, CANCER RES, V53, P2326	43	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21094	21098		10.1074/jbc.M001629200	http://dx.doi.org/10.1074/jbc.M001629200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781588	hybrid			2022-12-27	WOS:000088230600020
J	Yan, LZ; Adams, ME				Yan, LZ; Adams, ME			The spider toxin omega-Aga IIIA defines a high affinity site on neuronal high voltage-activated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; TRANSMITTER RELEASE; RABBIT BRAIN; BETA-SUBUNIT; CLASS-C; CONOTOXIN	The spider toxin omega-agatoxin IIIA (omega-Aga-IIIA) is a potent inhibitor of high voltage-activated calcium currents in the mammalian brain. To establish the biochemical parameters governing its action, we radiolabeled the toxin and examined its binding to native and recombinant calcium channels. In experiments with purified rat synaptosomal membranes, both kinetic and equilibrium data demonstrate one-to-one binding of omega-Aga-IIIA to a single population of high affinity sites, with K-d = similar to 9 pm and B-max = similar to 1.4 pmol/mg protein. Partial inhibition of omega-Aga-IIIA binding by omega-conotoxins GVIA, MVIIA, and MVIIC identifies N and P/Q channels as components of this population. omega-Aga-IIIA binds to recombinant alpha(1B) and alpha(1E) calcium channels with a similar high affinity (K-d = similar to 5-9 PM) in apparent one-to-one fashion. Results from recombinant alpha(1B) binding experiments demonstrate virtually identical B-max values for omega-Aga-IIIA and omega-conotoxin MVIIA, providing further evidence for a one-to-one stoichiometry of agatoxin binding to calcium channels. The combined evidence suggests that omega-Aga-IIIA defines a unique, high affinity binding site on N-, P/Q-, and R-type calcium channels.	Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA; Univ Calif Riverside, Environm Toxicol Grad Program, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside	Adams, ME (corresponding author), Univ Calif Riverside, Dept Neurosci, 5419 Boyce Hall, Riverside, CA 92521 USA.							ADAMS ME, 1993, BIOCHEMISTRY-US, V32, P12566, DOI 10.1021/bi00210a003; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BARHANIN J, 1988, BIOCHEM BIOPH RES CO, V150, P1051, DOI 10.1016/0006-291X(88)90736-X; BOLAND LM, 1994, J NEUROSCI, V14, P5011; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; COHEN CJ, 1992, MOL PHARMACOL, V42, P947; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; DUNN SMJ, 1988, BIOCHEMISTRY-US, V27, P5275, DOI 10.1021/bi00414a049; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; ELSHOURBAGY NA, 1992, EUR J BIOCHEM, V204, P491, DOI 10.1111/j.1432-1033.1992.tb16659.x; ERTEL EA, 1994, J GEN PHYSIOL, V103, P731, DOI 10.1085/jgp.103.5.731; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; McDonough S. I., 1995, Society for Neuroscience Abstracts, V21, P339; McDonough SI, 1996, J NEUROSCI, V16, P2612; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MCENERY MW, 1993, MOL CELLULAR BIOL PH, P3; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MINTZ IM, 1994, J NEUROSCI, V14, P2844; Mori Y, 1996, JPN J PHARMACOL, V72, P83, DOI 10.1254/jjp.72.83; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Poncer JC, 1997, NEURON, V18, P463, DOI 10.1016/S0896-6273(00)81246-5; RANDALL A, 1995, J NEUROSCI, V15, P2995; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; ROCK DM, 1998, LOW VOLTAGE ACTIVATE, P279; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STOEHR SJ, 1993, NEUROSCI LETT, V161, P113, DOI 10.1016/0304-3940(93)90153-C; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; VENEMA VJ, 1992, J BIOL CHEM, V267, P2610; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; Wang G, 1999, J NEUROSCI, V19, P9235; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wu LG, 1998, P NATL ACAD SCI USA, V95, P4720, DOI 10.1073/pnas.95.8.4720; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	51	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21309	21316		10.1074/jbc.M000212200	http://dx.doi.org/10.1074/jbc.M000212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10787403	hybrid			2022-12-27	WOS:000088230600048
J	Brookes, PS; Salinas, EP; Darley-Usmar, K; Eiserich, JP; Freeman, BA; Darley-Usmar, VM; Anderson, PG				Brookes, PS; Salinas, EP; Darley-Usmar, K; Eiserich, JP; Freeman, BA; Darley-Usmar, VM; Anderson, PG			Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PEROXYNITRITE CAUSES; INHIBITS APOPTOSIS; S-NITROSYLATION; SYNTHASE; PROTEINS; NITROSATION; MECHANISMS; CASPASE-3; OXIDATION	The mitochondrial permeability transition pore (PTP) and associated release of cytochrome c are thought to be important in the apoptotic process. Nitric oxide (NO.) has been reported to inhibit apoptosis by acting on a variety of extra-mitochondrial targets. The relationship between cytochrome c release and PTP opening, and the effects of NO. are not clearly established. Nitric oxide, S-nitrosothiols and peroxynitrite are reported to variously inhibit or promote PTP opening. In this study the effects of NO. on the PTP were characterized by exposing isolated rat liver mitochondria to physiological and pathological rates of NO. released from NONOate NO. donors. Nitric oxide reversibly inhibited PTP opening with an IC50 of 11 nar NO./s, which can be readily achieved in vivo by NO. synthases. The mechanism involved mitochondrial membrane depolarization and inhibition of Ca2+ accumulation. At supraphysiological release rates (>2 mu M/s) NO. accelerated PTP opening. Substantial cytochrome c release occurred with only a 20% change in mitochondrial swelling, was an early event in the PTP, and was also inhibited by NO.. Furthermore, NO. exposure resulted in significantly lower cytochrome c release for the same degree of PTP opening. It is proposed that this pathway represents an additional mechanism underlying the antiapoptotic effects of NO..	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Anderson, PG (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.		Anderson, Peter/V-7552-2019; Freeman, Bruce A/H-9342-2012	Anderson, Peter/0000-0001-8057-9005; Brookes, Paul/0000-0002-8639-8413; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064937, R01HL058115, P60HL058418] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL58115, R01-HL64937, P6-HL58418] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balakirev MY, 1997, EUR J BIOCHEM, V246, P710, DOI 10.1111/j.1432-1033.1997.00710.x; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Borutaite V, 2000, FEBS LETT, V467, P155, DOI 10.1016/S0014-5793(00)01140-6; Bosca L, 1999, CELL SIGNAL, V11, P239, DOI 10.1016/S0898-6568(98)00064-3; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brand M. D., 1995, BIOENERGETICS, V154, P62; Brune B, 1998, BIOCHEMISTRY-MOSCOW+, V63, P817; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; ERECINSKA M, 1995, J NEUROCHEM, V65, P2699; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; Ghafourifar P, 1999, BIOL CHEM, V380, P1025, DOI 10.1515/BC.1999.127; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leist M, 1999, BIOCHEM BIOPH RES CO, V258, P215, DOI 10.1006/bbrc.1999.0491; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUI L, 1999, CELL DEATH DIFFER, V10, P937; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; *NIH, 1996, NIH8523 DHEW; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Rickwood D, 1987, MITOCHONDRIA PRACTIC, P3; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	267	280	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20474	20479		10.1074/jbc.M001077200	http://dx.doi.org/10.1074/jbc.M001077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10791954	hybrid			2022-12-27	WOS:000088084500036
J	Xian, M; Chen, XC; Liu, ZY; Wang, K; Wang, PG				Xian, M; Chen, XC; Liu, ZY; Wang, K; Wang, PG			Inhibition of papain by S-nitrosothiols - Formation of mixed disulfides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; N-NITROSOANILINES; PROTEIN THIOLS; SULFENIC ACID; ASCORBIC-ACID; SERUM-ALBUMIN; NITROSYLATION; INACTIVATION; CYSTEINE	S-Nitrosylation of protein thiols is one of the cellular regulatory mechanisms induced by NO. The cysteine protease papain has a critical thiol residue (Cys(25)). It has been demonstrated that NO or NO donors such as sodium nitroprusside and N-nitrosoaniline derivatives can reversibly inhibit this enzyme by S-NO bond formation in its active site. In this study, a different regulated mechanism of inactivation was reported using S-nitrosothiols as the NO donor. Five S-nitroso compounds, S-nitroso-N-acetyl-DL-penicillamine, S-nitrosoglutathione, S-nitrosocaptopril, glucose-S-nitroso-N-acetyl-DL-penicillamine-2, and the S-nitroso tripeptide acetyl-Phe-Gly-S-nitrosopenicillamine, exhibited different inhibitory activities toward the enzyme in a time- and concentration-dependent manner with second-order rate constants (k(i)/K-I) ranging from 8.9 to 17.2 M-1 s(-1). The inhibition of papain by S-nitrosothiol was rapidly reversed by dithiothreitol, but not by ascorbate, which could reverse the inhibition of papain by NOBF4. Incubation of the enzyme with a fluorescent S-nitroso probe (S-nitroso-5-dimethylaminonaphthalene-1-sulfonyl) resulted in the appearance of fluorescence of the protein, indicating the formation of a thiol adduct. Moreover, S-transnitrosylation in the incubation of S-nitroso inactivators with papain was excluded. These results suggest that inactivation of papain by S-nitrosothiols is due to a direct attack of the highly reactive thiolate (Cys25) in the enzyme active site on the sulfur of S-nitrosothiols to form a mixed disulfide between the inactivator and papain.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Wang, PG (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.				NIGMS NIH HHS [GM 54074] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054074, R01GM054074] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; Barnett D. J., 1994, J CHEM SOC PERK T, P1131; BARNETT DJ, 1995, J CHEM SOC P1, V2, P1279; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; CASELLI A, 1994, J BIOL CHEM, V269, P24878; FAULSTICH H, 1993, ANAL BIOCHEM, V208, P357, DOI 10.1006/abio.1993.1061; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FISCHER G, 1988, NAT PROD REP, P465; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Guo ZM, 1996, BIOORG MED CHEM LETT, V6, P573, DOI 10.1016/0960-894X(96)00073-X; Guo ZM, 1998, J AM CHEM SOC, V120, P3726, DOI 10.1021/ja974187e; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; Holmes AJ, 1998, CHEM COMMUN, P1711, DOI 10.1039/a803983f; Ignarro L., 1995, NITRIC OXIDE BIOCH M; Ishii T, 1999, BIOCHEM PHARMACOL, V58, P133, DOI 10.1016/S0006-2952(99)00060-X; KashibaIwatsuki M, 1996, FEBS LETT, V389, P149, DOI 10.1016/0014-5793(96)00560-1; KashibaIwatsuki M, 1997, J BIOCHEM-TOKYO, V122, P1208; KEILLOR JW, 1992, J AM CHEM SOC, V114, P7983, DOI 10.1021/ja00047a004; KITZ R, 1962, J BIOL CHEM, V237, P3245; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Lancaster J, 1996, NITRIC OXIDE PRINCIP; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LOSCALZO J, 1989, J PHARMACOL EXP THER, V249, P726; LOWE G, 1976, TETRAHEDRON, V32, P291, DOI 10.1016/0040-4020(76)80040-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Mohr S, 1996, J BIOL CHEM, V271, P4209; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; PADGETT CM, 1995, AM J PHYSIOL-CELL PH, V269, pC739, DOI 10.1152/ajpcell.1995.269.3.C739; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RAMACHANDRAN N, 1999, BIOCHIM BIOPHYS ACTA, P149; Ramirez J, 1996, BIOORG MED CHEM LETT, V6, P2575, DOI 10.1016/0960-894X(96)00484-2; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Richter-Addo GB, 1999, ACCOUNTS CHEM RES, V32, P529, DOI 10.1021/ar970351r; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; Scorza G, 1997, FREE RADICAL BIO MED, V22, P633, DOI 10.1016/S0891-5849(96)00378-4; Sehajpal PK, 1999, BIOCHEMISTRY-US, V38, P13407, DOI 10.1021/bi9912995; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Venturini G, 1998, BIOCHEM MOL BIOL INT, V46, P425; Venturini G, 2000, BIOCHEM BIOPH RES CO, V267, P190, DOI 10.1006/bbrc.1999.1922; Williams DLH, 1999, ACCOUNTS CHEM RES, V32, P869, DOI 10.1021/ar9800439; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Xian M, 2000, BIOCHEM BIOPH RES CO, V268, P310, DOI 10.1006/bbrc.2000.2117; Zhang H, 1996, ANAL BIOCHEM, V237, P141, DOI 10.1006/abio.1996.0212	61	77	82	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20467	20473		10.1074/jbc.M001054200	http://dx.doi.org/10.1074/jbc.M001054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779505	hybrid			2022-12-27	WOS:000088084500035
J	Zhang, ZP; Teng, CT				Zhang, ZP; Teng, CT			Estrogen receptor-related receptor alpha 1 interacts with coactivator and constitutively activates the estrogen response elements of the human lactoferrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ERR-1 ORPHAN RECEPTOR; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL LOCALIZATION; HISTONE DEACETYLASE; MOUSE; PROMOTER; EXPRESSION; BINDING	The human estrogen receptor-related receptor (ERR alpha 1, NR3B1a) was shown to bind a steroidogenic factor binding element (SFRE), TCAAGGTCATC, 26 base pairs upstream from the estrogen response element (ERE) of the human lactoferrin gene promoter, A mutation made at SFRE significantly reduced estrogen-dependent transcription from the lactoferrin ERE in human endometrial cells. In this study, we demonstrated that ERR alpha 1 binds both SFRE and ERE elements and constitutively transactivates the lactoferrin gene promoter. In DNase I footprinting protection analysis, both SFRE and ERE regions were protected by glutathione S-transferase-ERR alpha 1 fusion protein. The receptor formed two protein-DNA complexes with either SFRE or ERE in electrophoresis mobility shift assay. Homodimerization of ERR alpha 1 was confirmed with the mammalian two-hybrid system. ERR alpha 1 activates reporter constructs containing various types of estrogen response elements in endometrial and non-endometrial cells in transient transfection experiments. Overexpressing the coactivator, SRC1a or GRIP1, further enhances ERR alpha 1-induced transcriptional activity. We demonstrated that the AF2 domain of ERR alpha 1 is essential for the transactivation function and that deletion or mutation at this region abrogates the activation capability. Protein-protein interaction between the SRC1a and ERR alpha 1 C terminus was confirmed with a GST glutathione S-transferase "pull-down" assay. When comparing ERR alpha 1 and the estrogen receptor alpha (ER alpha) in many of the experiments, we found that ER alpha can also bind SFRE of the lactoferrin gene and transactivate the promoter activity in a ligand-dependent manner. The present study demonstrated that ERR alpha 1 binds similar DNA elements as ER alpha and confers its transactivation function constitutively. Therefore, ERR alpha 1 may actively modulate the estrogen response of lactoferrin gene as well as other estrogen-responsive genes.	NIEHS, Reprod & Dev Toxicol Lab, Gene Regulat Grp, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Teng, CT (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Gene Regulat Grp, NIH, POB 12233,MD E-201, Res Triangle Pk, NC 27709 USA.							Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Auwerx J, 1999, CELL, V97, P161; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; BROCK JH, 1980, ARCH DIS CHILD, V55, P417, DOI 10.1136/adc.55.6.417; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Hopfer H, 1996, BIOCHEM CELL BIOL, V74, P165, DOI 10.1139/o96-017; HUTCHENS TW, 1997, LACTOFERRIN INTERACT, P3; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; LEVAY PF, 1995, HAEMATOLOGICA, V80, P252; LIU YH, 1991, J BIOL CHEM, V266, P21880; LIU YH, 1992, MOL ENDOCRINOL, V6, P355, DOI 10.1210/me.6.3.355; Lydon John P., 1992, Gene Expression, V2, P273; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Shi HP, 1997, GENOMICS, V44, P52, DOI 10.1006/geno.1997.4850; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; Teng CT, 1999, CELL BIOCHEM BIOPHYS, V31, P49, DOI 10.1007/BF02738154; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; YANG NY, 1994, ENDOCRINE, V2, P241	60	115	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20837	20846		10.1074/jbc.M001880200	http://dx.doi.org/10.1074/jbc.M001880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779508	hybrid			2022-12-27	WOS:000088084500087
J	Yeh, CH; Wang, WC; Hsieh, TT; Huang, TF				Yeh, CH; Wang, WC; Hsieh, TT; Huang, TF			Agkistin, a snake venom-derived glycoprotein Ib antagonist, disrupts von Willebrand factor-endothelial cell interaction and inhibits angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(V)BETA(3); VONWILLEBRAND-FACTOR; ADHESION; ALPHA; APOPTOSIS; PROTEINS; DISINTEGRINS; EXPRESSION; PLATELETS; SURVIVAL	Glycoprotein (GP) Ib, an adhesion receptor expressed on both platelets and endothelial cells, mediates the binding of von Willebrand factor (VWF). Platelet GPIb plays an important role in platelet adhesion and activation, whereas the interaction of VWF and endothelial GPIb is not fully understood. We report here that agkistin, a snake venom protein, selectively blocks the interaction of vWF with human endothelial GPIb and inhibits angiogenesis in vivo. Agkistin specifically blocked hu man umbilical vein endothelial cell (HUVEC) adhesion to immobilized vWF in a concentration-dependent manner. Fluorescein isothiocyanate (FITC)-conjugated agkistin bound to HUVECs in a saturable manner. AP1, a monoclonal antibody (mAb) raised against GPIb, specifically inhibited the binding of FITC-conjugated agkistin to HUVECs in a dose-dependent manner, but other anti-integrin mAbs raised against alpha(v)beta(3), alpha(2)beta(1) and alpha(5)beta(1) did not affect this binding reaction. However, neither agkistin (2 mu g/ml) nor AP1 (40 mu g/ml) apparently reduced HUVEC viability, Both agkistin and AP1 exhibited a profound anti-angiogenic effect in vivo when assayed by using the 10-day-old embryo chick chorioallantoic membrane model. These results suggest endothelial GPIb plays a role in spontaneous angiogenesis in vivo, and the anti-angiogenic effect of agkistin may be because of disruption of the interaction of endogenous VWF with endothelial GPIb.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan	National Taiwan University; Chang Gung Memorial Hospital	Huang, TF (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1,Sec 1,Jen Ai Rd, Taipei 100, Taiwan.			Huang, Tur-Fu/0000-0001-9252-938X				Andrews RK, 1998, HISTOL HISTOPATHOL, V13, P837, DOI 10.14670/HH-13.837; Beacham DA, 1997, BLOOD, V89, P4071, DOI 10.1182/blood.V89.11.4071; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chang MC, 1998, BLOOD, V91, P1582, DOI 10.1182/blood.V91.5.1582.1582_1582_1589; CHEN YL, 1995, BIOCHEM BIOPH RES CO, V210, P472, DOI 10.1006/bbrc.1995.1684; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Feng S, 1999, BLOOD, V93, P4256, DOI 10.1182/blood.V93.12.4256.412k33_4256_4263; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Huang T. F., 1990, 11 INT C THROMB LJUB; Huang TF, 1998, CELL MOL LIFE SCI, V54, P527, DOI 10.1007/s000180050181; HUANG TF, 1994, 3 SIN JAP S COAG FIB, P79; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; Lian J, 1999, EXP CELL RES, V252, P114, DOI 10.1006/excr.1999.4612; LIU CZ, 1994, THROMB HAEMOSTASIS, V72, P919; Masood R, 1999, BLOOD, V93, P1038, DOI 10.1182/blood.V93.3.1038.403a14_1038_1044; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PENG ML, 1993, BLOOD, V81, P2321; RAJAGOPALAN V, 1992, BLOOD, V80, P153; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SADLER JE, 1991, J BIOL CHEM, V266, P18172; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Tan L, 1999, BLOOD, V93, P2605, DOI 10.1182/blood.V93.8.2605.408k18_2605_2616; WICK TM, 1993, AM J HEMATOL, V42, P284, DOI 10.1002/ajh.2830420308; Wu GX, 1997, BLOOD, V90, P2660, DOI 10.1182/blood.V90.7.2660.2660_2660_2669; Yeh CH, 1998, BLOOD, V92, P3268, DOI 10.1182/blood.V92.9.3268.421k41_3268_3276	31	29	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18615	18618		10.1074/jbc.C000234200	http://dx.doi.org/10.1074/jbc.C000234200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10779501	hybrid			2022-12-27	WOS:000087815900002
J	Coles, LS; Diamond, P; Occhiodoro, F; Vadas, MA; Shannon, MF				Coles, LS; Diamond, P; Occhiodoro, F; Vadas, MA; Shannon, MF			An ordered array of cold shock domain repressor elements across tumor necrosis factor-responsive elements of the granulocyte-macrophage colony-stimulating factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; SINGLE-STRANDED-DNA; GM-CSF PROMOTER; Y-BOX PROTEINS; BETA GENE-EXPRESSION; T-CELLS; TRANSCRIPTION FACTORS; ESCHERICHIA-COLI; YB-1; SEQUENCE	The tumor necrosis factor-alpha-responsive region of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) promoter (-114 to -31) encompasses binding sites for NF-kappa B, CBF, AP-1, ETS, and NFAT families of transcription factors. We show both here and previously that mutation of any one of these binding sites greatly reduces tumor necrosis factor-alpha induction of the GM-CSF promoter. Interspersed between these elements are sequences that when mutated lead to an increase in GM-CSF promoter activity. We have previously shown that two of these repressor elements bind proteins known as cold shock domain (CSD) factors and that overexpression of CSD proteins leads to repression of GM-CSF promoter activity in fibroblasts. CSD proteins are single strand DNA- and RNA-binding proteins that contact 5'-CCTG-3' sequences in the GM-CSF repressor elements. We show here that two newly identified repressor sequences in the proximal promoter can also bind CSD proteins. We have characterized the CSD-containing protein complexes that bind to the GM-CSF promoter and identified a novel protein related to mitochondrial single strand binding protein that forms part of one of these complexes. The four CSD-binding sites on the promoter occur in pairs on opposite strands of the DNA and appear to form an ordered array of binding elements. A similar ordered array of CSD sites are present in the promoters of the granulocyte colony-stimulating factor and interleukin-3 genes, implying a common mechanism for negative regulation of these myeloid growth factors.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Human Immunol, Adelaide, SA 5000, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2000, Australia	Institute Medical & Veterinary Science Australia; Australian National University; John Curtin School of Medical Research	Coles, LS (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Human Immunol, Frome Rd, Adelaide, SA 5000, Australia.	leeanne.coles@imvs.sa.gov.au	Vadas, Mathew/R-1378-2019					Anderson DG, 1998, CELL, V95, P975, DOI 10.1016/S0092-8674(00)81721-3; BAGOU RC, 1997, NAT MED, V3, P447; Cleavinger PJ, 1996, VIROLOGY, V222, P133, DOI 10.1006/viro.1996.0404; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; COLES LS, 1994, NUCLEIC ACIDS RES, V22, P4276, DOI 10.1093/nar/22.20.4276; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DEMETRI GD, 1991, BLOOD, V78, P2791; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HIMES SR, 1993, ONCOGENE, V8, P3189; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; JENKINS F, 1995, J IMMUNOL, V155, P1240; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; KERR D, 1994, J VIROL, V68, P7637, DOI 10.1128/JVI.68.11.7637-7643.1994; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; Kuczek E. S., 1990, MOL CELLULAR BIOL CY, P63; KUCZEK ES, 1991, J IMMUNOL, V146, P2426; KUDO S, 1995, EUR J BIOCHEM, V231, P72; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Leshkowitz D, 1996, ONCOGENE, V13, P2027; Li K, 1997, J BIOL CHEM, V272, P8686, DOI 10.1074/jbc.272.13.8686; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Liu ZY, 1997, BIOCHEMISTRY-US, V36, P14799, DOI 10.1021/bi970946u; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Maniatis T., 1982, MOL CLONING; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; Nass SJ, 1998, NAT MED, V4, P761, DOI 10.1038/nm0798-761; NIMER SD, 1995, STEM CELLS, V13, P324, DOI 10.1002/stem.5530130402; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; Ohmori M, 1996, MOL ENDOCRINOL, V10, P76, DOI 10.1210/me.10.1.76; OZER J, 1993, GENE, V133, P187, DOI 10.1016/0378-1119(93)90637-I; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; RYAN GR, 1994, MOL REPROD DEV, V39, P200; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; SAKURA H, 1988, GENE, V73, P499; Sapru MK, 1996, J BIOL CHEM, V271, P7203, DOI 10.1074/jbc.271.12.7203; Sarov-Blat L, 1998, J BIOL CHEM, V273, P5520, DOI 10.1074/jbc.273.10.5520; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; Shannon MF, 1997, CRIT REV IMMUNOL, V17, P301, DOI 10.1615/CritRevImmunol.v17.i3-4.30; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHANNON MF, 1989, LYMPHOKINE RECEPTOR, V179, P73; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SINGAL DP, 1995, GENE, V154, P299, DOI 10.1016/0378-1119(94)00861-L; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; Swamynathan SK, 1997, J VIROL, V71, P2873, DOI 10.1128/JVI.71.4.2873-2880.1997; Taylor DS, 1996, J BIOL CHEM, V271, P14020, DOI 10.1074/jbc.271.24.14020; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; Trutmann M, 1998, INT J CANCER, V77, P378, DOI 10.1002/(SICI)1097-0215(19980729)77:3<378::AID-IJC12>3.0.CO;2-4; WILLIAMSON DJ, 1988, CLIN EXP IMMUNOL, V72, P67; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yang Y. C., 1988, LYMPHOKINES, V15, P375; ZHING Z, 1996, J CLIN INVEST, V97, P1102	79	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14482	14493		10.1074/jbc.275.19.14482	http://dx.doi.org/10.1074/jbc.275.19.14482			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799531	hybrid			2022-12-27	WOS:000087006900065
J	Ueno, S; Kaieda, N; Koyama, N				Ueno, S; Kaieda, N; Koyama, N			Characterization of a P-type Na+-ATPase of a facultatively anaerobic alkaliphile, Exiguobacterium aurantiacum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALOPHILIC BACILLUS; MEMBRANE-VESICLES; PROTONMOTIVE FORCE; ACID-TRANSPORT; CYTOPLASMIC PH; SODIUM-IONS; PURIFICATION; BACTERIUM; ENERGY; MECHANISM	A facultatively anaerobic alkaliphile, Exiguobacterium aurantiacum, possesses a P-type Na+-stimulated ATPase in the membrane (Koyama, N. (1999) Curr. Microbiol. 39, 27-30). In this study, we attempted to purify and characterize the enzyme. The ATPase appears to consist of a single polypeptide with an apparent molecular mass of 100 kDa. The enzyme exhibited an optimum pH for activity at around 9. The enzyme was strongly inhibited by vanadate (50% inhibition observed at 3 mu M) and forms an acylphosphate intermediate, suggesting a P-type ATPase. The enzyme, when reconstituted into soybean phospholipid vesicles, exhibited ATP-dependent Na-22(+) uptake, which was completely inhibited by gramicidin. The reconstituted vesicles exhibited a generation of membrane potential (positive, inside). The enzyme is likely to be involved in an electrogenic transport of Na+.	Chiba Univ, Fac Sci, Dept Chem, Inage Ku, Chiba 2638522, Japan	Chiba University	Koyama, N (corresponding author), Chiba Univ, Fac Sci, Dept Chem, Inage Ku, Chiba 2638522, Japan.							COLE JS, 1973, P NATL ACAD SCI USA, V70, P3571, DOI 10.1073/pnas.70.12.3571; DAME JB, 1980, BIOCHEMISTRY-US, V19, P2931, DOI 10.1021/bi00554a018; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; GUFFANTI AA, 1978, J BIOL CHEM, V253, P708; HAROLD FM, 1972, BACTERIOL REV, V36, P172, DOI 10.1128/MMBR.36.2.172-230.1972; HEISE R, 1992, EUR J BIOCHEM, V206, P553, DOI 10.1111/j.1432-1033.1992.tb16959.x; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; KABACK HR, 1971, J BIOL CHEM, V246, P5523; Kaieda N, 1998, FEMS MICROBIOL LETT, V167, P57, DOI 10.1111/j.1574-6968.1998.tb13207.x; KOYAMA N, 1976, FEBS LETT, V72, P77, DOI 10.1016/0014-5793(76)80816-2; KOYAMA N, 1986, FEMS MICROBIOL LETT, V34, P195; KOYAMA N, 1985, BIOCHIM BIOPHYS ACTA, V812, P206, DOI 10.1016/0005-2736(85)90540-1; Koyama N, 1999, CURR MICROBIOL, V39, P27, DOI 10.1007/PL00006822; KOYAMA N, 1993, EUR J BIOCHEM, V217, P435, DOI 10.1111/j.1432-1033.1993.tb18263.x; Koyama N, 1996, ANAEROBE, V2, P123, DOI 10.1006/anae.1996.0016; KOYAMA N, 1980, ARCH BIOCHEM BIOPHYS, V199, P103, DOI 10.1016/0003-9861(80)90261-1; KRULWICH TA, 1986, J MEMBRANE BIOL, V89, P113, DOI 10.1007/BF01869707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALONEY PC, 1974, P NATL ACAD SCI USA, V71, P3896, DOI 10.1073/pnas.71.10.3896; MANDEL KG, 1980, J BIOL CHEM, V255, P7391; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; OHTA K, 1975, J GEN MICROBIOL, V86, P259, DOI 10.1099/00221287-86-2-259; SMIGAN P, 1995, FEBS LETT, V371, P119, DOI 10.1016/0014-5793(95)00866-8; SPEELMANS G, 1993, P NATL ACAD SCI USA, V90, P7975, DOI 10.1073/pnas.90.17.7975; SUGIYAMA S, 1986, BIOCHIM BIOPHYS ACTA, V852, P38, DOI 10.1016/0005-2728(86)90054-X; WAKABAYASHI K, 1988, ARCH BIOCHEM BIOPHYS, V262, P19, DOI 10.1016/0003-9861(88)90163-4	28	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14537	14540		10.1074/jbc.275.19.14537	http://dx.doi.org/10.1074/jbc.275.19.14537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799538	hybrid			2022-12-27	WOS:000087006900072
J	Wu, AM; Song, SC; Chen, YY; Gilboa-Garber, N				Wu, AM; Song, SC; Chen, YY; Gilboa-Garber, N			Defining the carbohydrate specificities of Aplysia gonad lectin exhibiting a peculiar D-galacturonic acid affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA ALPHA-1-ACID GLYCOPROTEIN; SEA HARE APLYSIA; BLOOD-GROUP; FETUIN; BINDING; UNITS; HEXASACCHARIDE; SPECTROSCOPY; PURIFICATION; AGGLUTININ	Aplysia gonad lectin (AGL), which has been shown to stimulate mitogenesis in human peripheral lymphocytes, to suppress tumor cells, and to induce neurite outgrowth and improve cell viability in cultured Aplysia neurons, exhibits a peculiar galacturonic acid/galactose specificity. The carbohydrate binding site of this lectin was characterized by enzyme-linked lectino-sorbent assay and by inhibition of AGL-glycan interactions. Examination of the lectin binding with 34 glycans revealed that it reacted strongly with the following glycoforms: most human blood group precursor (equivalent) glycoproteins (gps), two Gal alpha 1-->4Gal-containing gps, and two D-galacturonic acid (GalUA)-containing polysaccharides (pectins from apple and citrus fruits), but poorly with most human blood group A and H active and sialylated gps. Among the GalUA and mammalian saccharides tested for inhibition of AGL-glycan binding, GalUA mono- to trisaccharides were the most potent ones. They were 8.5 x 10(4) times more active than Gal and about 1.5 x 10(3) more active than the human blood group pk active disaccharide (E, Gal alpha 1-->4Gal). This disaccharide was 6, 28, and 120 times more efficient than Gal beta 1-->3GlcNAc(I), Gal beta 1-->3GalNAc(T), and Gal beta 1--> 4GlcNAc (II), respectively, and 35 and 80 times more active than melibiose (Gal alpha 1-->6Glc) and human blood group B active disaccharide (Gal alpha 1-->3Gal), respectively, showing that the decreasing order of the lectin affinity toward alpha-anomers of Gal is alpha 1-->4 > alpha 1-->6 > alpha 1-->3. From the data provided, the carbohydrate specificity of AGL can be defined as GalUA alpha 1-->4 trisaccharides to mono GalUA > branched or cluster forms of E, I, and II >> monomeric E, I, and II, whereas GalNAc is inactive.	Chang Gung Med Coll, Sch Med, Inst Mol & Cellular Biol, Glycoimmunochem Res Lab, Tao Yuan 33332, Taiwan; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Chang Gung University; Bar Ilan University	Wu, AM (corresponding author), Chang Gung Med Coll, Sch Med, Inst Mol & Cellular Biol, Glycoimmunochem Res Lab, Tao Yuan 33332, Taiwan.							ALLEN PZ, 1959, J IMMUNOL, V82, P340; Avichezer D., 1986, LECT S 14 INT CANC C, VII, P79; BEISER SM, 1952, J IMMUNOL, V68, P19; BENHAMOU N, 1988, J HISTOCHEM CYTOCHEM, V36, P1403, DOI 10.1177/36.11.3049790; Chen CP, 1998, GLYCOBIOLOGY, V8, P7, DOI 10.1093/glycob/8.1.7; CORY HT, 1974, BIOCHEM BIOPH RES CO, V61, P1289, DOI 10.1016/S0006-291X(74)80424-9; DUK M, 1994, ANAL BIOCHEM, V221, P266, DOI 10.1006/abio.1994.1410; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; Gilboa-Garber N, 1998, FEMS MICROBIOL LETT, V163, P91, DOI 10.1016/S0378-1097(98)00157-8; GILBOAGARBER N, 1984, MAR BIOL LETT, V5, P105; GILBOAGARBER N, 1985, FEBS LETT, V181, P267, DOI 10.1016/0014-5793(85)80273-8; GRAHAM ERB, 1972, GLYCOPROTEINS, P722; Herp A., 1988, Advances in Experimental Medicine and Biology, V228, P395; HOWE C, 1959, J AM CHEM SOC, V80, P6656, DOI 10.1021/ja01557a049; KABAT EA, 1948, J EXP MED, V88, P43, DOI 10.1084/jem.88.1.43; KABAT EA, 1956, BLOOD GROUP SUBSTANC, P135; LESKOWITZ S, 1954, J AM CHEM SOC, V76, P5060, DOI 10.1021/ja01649a015; LINDBERG B, 1977, CARBOHYD RES, V58, P177, DOI 10.1016/S0008-6215(00)83413-8; Lisowska E, 1996, BIOMETHODS SERIES, V7, P115; LLOYD KO, 1968, P NATL ACAD SCI USA, V61, P1470, DOI 10.1073/pnas.61.4.1470; MAISONROUGEMCAULIFFE F, 1976, ARCH BIOCHEM BIOPHYS, V175, P81, DOI 10.1016/0003-9861(76)90487-2; MORGAN WTJ, 1964, P 9 C INT SOC BLOOD, P225; MOSCHERA J, 1975, CARBOHYD RES, V40, P53, DOI 10.1016/S0008-6215(00)82668-3; NILSSON B, 1979, J BIOL CHEM, V254, P4545; SCHMID K, 1979, BIOCHIM BIOPHYS ACTA, V581, P356, DOI 10.1016/0005-2795(79)90255-1; SLOMIANY A, 1978, J BIOL CHEM, V253, P7301; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SUDAKEVITZ D, 1996, LECTINS BIOL BIOCH C, V11, P207; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P21; VICARI G, 1970, BIOCHEMISTRY-US, V9, P3414, DOI 10.1021/bi00819a020; VICARI G, 1969, J IMMUNOL, V102, P821; WIERUSZESKI JM, 1987, J BIOL CHEM, V262, P6650; WILSON MP, 1992, J NEUROBIOL, V23, P739, DOI 10.1002/neu.480230611; Wu A M, 1988, Adv Exp Med Biol, V228, P205; Wu A M, 1988, Adv Exp Med Biol, V228, P351; WU AM, 1995, LIFE SCI, V57, P1841; WU AM, 1995, BIOCHEM BIOPH RES CO, V216, P814, DOI 10.1006/bbrc.1995.2694; Wu AM, 1997, INDIAN J BIOCHEM BIO, V34, P61; WU AM, 1991, CARBOHYD RES, V213, P127, DOI 10.1016/S0008-6215(00)90604-9; WU AM, 1992, J BIOL CHEM, V267, P19130; WU AM, 1982, ARCH BIOCHEM BIOPHYS, V215, P390, DOI 10.1016/0003-9861(82)90099-6; WU AM, 1977, BIOCHEM J, V161, P37, DOI 10.1042/bj1610037; WU AM, 1984, J BIOL CHEM, V259, P7178; Wu AM, 1997, GLYCOBIOLOGY, V7, P1061, DOI 10.1093/glycob/7.8.1061; ZIPRIS D, 1987, DEV COMP IMMUNOL, V11, P501, DOI 10.1016/0145-305X(87)90039-5; ZIPRIS D, 1986, MICROBIOS, V46, P193	50	32	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14017	14024		10.1074/jbc.275.19.14017	http://dx.doi.org/10.1074/jbc.275.19.14017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799474	hybrid			2022-12-27	WOS:000087006900004
J	Zhang, H; Joseph, J; Felix, C; Kalyanaraman, B				Zhang, H; Joseph, J; Felix, C; Kalyanaraman, B			Bicarbonate enhances the hydroxylation, nitration, and peroxidation reactions catalyzed by copper, zinc superoxide dismutase - Intermediacy of carbonate anion radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; OXIDATION; PEROXYNITRITE; TYROSINE; ADDUCTS; MUTANT; ENZYME; H2O2; MYELOPEROXIDASE	The effect of bicarbonate anion (HCO3-) on the peroxidase activity of copper, zinc superoxide dismutase (SOD1) was investigated using three structurally different probes: 5,5'-dimethyl-1-pyrroline N-oxide (DMPO), tyrosine, and 2,2'-azino-bis- [3-ethylbenzothiazolinel-6-sulfonic acid (ABTS), Results indicate that HCO3- enhanced SOD/H2O2-dependent (i) hydroxylation of DMPO to DMPO-OH as measured by electron spin resonance, (ii) oxidation and nitration of tyrosine to dityrosine, nitrotyrosine, and nitrodityrosine as measured by high pressure liquid chromatography, and (iii) oxidation of ARTS to the ARTS cation radical as measured by UV-visible spectroscopy. Using oxygen-17-labeled water, it was determined that the oxygen atom present in the DMPO-OH adduct originated from H2O and not from H2O2. This result proves that neither free hydroxyl radical nor enzyme-bound hydroxyl radical was involved in the hydroxylation of DMPO. We postulate that HCO3- enhances SOD1 peroxidase activity via formation of a putative carbonate radical anion. This new and different perspective on HCO3--mediated oxidative reactions of SOD1 may help us understand the free radical mechanism of SOD1 and related mutants linked to amyotrophic lateral sclerosis.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL63119] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063119] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker DA, 1996, J AM CHEM SOC, V118, P905, DOI 10.1021/ja952895z; Becker DA, 1998, J CHEM SOC PERK T 2, P1289, DOI 10.1039/a708702k; Bhattacharjee S, 1996, J CHEM SOC PERK T 2, P2631, DOI 10.1039/p29960002631; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Clement JL, 1998, J CHEM SOC PERK T 2, P1715, DOI 10.1039/a804098b; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Hink U, 1999, FREE RADICAL BIO MED, V27, pS20; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; Jewett SL, 1999, FREE RADICAL BIO MED, V26, P905, DOI 10.1016/S0891-5849(98)00274-3; KOPPENOL WH, 1987, J PHYS CHEM-US, V91, P4429, DOI 10.1021/j100300a045; LEVINSKI AM, 1983, HARRISONS PRINCIPLES; LILIE J, 1978, RADIAT PHYS CHEM, V11, P225, DOI 10.1016/0146-5724(78)90101-2; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Malencik DA, 1996, ANAL BIOCHEM, V242, P202, DOI 10.1006/abio.1996.0454; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Sankarapandi S, 1999, J BIOL CHEM, V274, P34576, DOI 10.1074/jbc.274.49.34576; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; SATO K, 1992, J BIOL CHEM, V267, P25371; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P12912, DOI 10.1073/pnas.95.22.12912; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; Uppu RM, 1998, ARCH BIOCHEM BIOPHYS, V358, P1, DOI 10.1006/abbi.1998.0825; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099	35	101	101	3	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14038	14045		10.1074/jbc.275.19.14038	http://dx.doi.org/10.1074/jbc.275.19.14038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799477	hybrid			2022-12-27	WOS:000087006900007
J	Donaldson, IM; Friesen, JD				Donaldson, IM; Friesen, JD			Zinc stoichiometry of yeast RNA polymerase II and characterization of mutations in the zinc-binding domain of the largest subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; WHOLE-CELL EXTRACT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION INITIATION; PHENOTYPIC SELECTION; DNA; COMPONENT; INVITRO; PROTEIN; GROWTH	Atomic absorption spectroscopy demonstrated that highly purified RNA polymerase II from the yeast Saccharomyces cerevisiae binds seven zinc ions. This number agrees with the number of potential zinc-binding sites among the 12 different subunits of the enzyme and with our observation that the ninth largest subunit alone is able to bind two zinc ions. The zinc-binding motif in the largest subunit of the enzyme was investigated using mutagenic analysis. Altering any one of the six conserved residues in the zinc-binding motif conferred either a lethal or conditional phenotype, and zinc blot analysis indicated that mutant forms of the domain had a 2-fold reduction in zinc affinity. Mutations in the zinc-binding domain reduced RNA polymerase II activity in cell-free extracts, even though protein blot analysis indicated that the mutant subunit was present in excess of wild-type levels. Purification of one mutant RNA polymerase revealed a subunit profile that was wild-type like with the exception of two subunits not required for core enzyme activity (Rpb4p and Rpb7p), which were missing. Core activity of the mutant enzyme was reduced 20-fold, We conclude that mutations in the zinc-binding domain can reduce core activity without altering the association of any of the subunits required for this activity.	Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto	Friesen, JD (corresponding author), Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Donaldson, Ian/A-2867-2009	Donaldson, Ian/0000-0002-4203-8328				ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Archambault J, 1996, GENETICS, V142, P737; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; ARCHAMBAULT J, 1992, MOL GEN GENET, V232, P408, DOI 10.1007/BF00266244; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Brun I, 1997, EMBO J, V16, P5730, DOI 10.1093/emboj/16.18.5730; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHATTERJI D, 1988, CURR SCI INDIA, V57, P376; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; COLEMAN JE, 1983, ZINC ENZYMES, P219; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FALCHUK KH, 1976, BIOCHEMISTRY-US, V15, P4468, DOI 10.1021/bi00665a021; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTKE H, 1976, FEBS LETT, V65, P288, DOI 10.1016/0014-5793(76)80131-7; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Markov D, 1999, GENE DEV, V13, P2439, DOI 10.1101/gad.13.18.2439; Mayalagu S, 1997, GENE, V190, P77, DOI 10.1016/S0378-1119(96)00710-X; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; PERCIVALSMITH A, 1986, MOL CELL BIOL, V6, P2443, DOI 10.1128/MCB.6.7.2443; PETRANYI P, 1977, BIOCHEM BIOPH RES CO, V74, P1031, DOI 10.1016/0006-291X(77)91621-7; RUET A, 1980, J BIOL CHEM, V255, P6450; RUET A, 1978, EUR J BIOCHEM, V90, P325, DOI 10.1111/j.1432-1033.1978.tb12608.x; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; Sherman F, 1986, LAB COURSE MANUAL ME; SOLAIMAN D, 1984, BIOCHEMISTRY-US, V23, P6369, DOI 10.1021/bi00321a013; STRUHL K, 1987, CURRENT PROTOCOLS MO; Svetlov V, 1998, J BIOL CHEM, V273, P10827, DOI 10.1074/jbc.273.18.10827; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; TREICH I, 1991, J BIOL CHEM, V266, P21971; Treich Isabelle, 1992, Gene Expression, V2, P31; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WERNER M, 1993, J BIOL CHEM, V268, P20721; WERNER M, 1992, MOL CELL BIOL, V12, P1087, DOI 10.1128/MCB.12.3.1087; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; Woychik Nancy A., 1993, Gene Expression, V3, P77; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	57	26	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13780	13788		10.1074/jbc.275.18.13780	http://dx.doi.org/10.1074/jbc.275.18.13780			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788499	hybrid			2022-12-27	WOS:000086925300086
J	Maier, U; Babich, A; Macrez, N; Leopoldt, D; Gierschik, P; Illenberger, D; Nurnberg, B				Maier, U; Babich, A; Macrez, N; Leopoldt, D; Gierschik, P; Illenberger, D; Nurnberg, B			G beta(5)gamma(2) is a highly selective activator of phospholipid-dependent enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-COUPLED RECEPTORS; PORTAL-VEIN MYOCYTES; ADENYLYL-CYCLASE; PHOSPHOINOSITIDE 3-KINASE; ALPHA-SUBUNIT; RGS PROTEINS; C ISOZYMES; KINASE ACTIVATION; SIGNALING PATHWAY	In this study, G beta specificity in the regulation of G beta gamma-sensitive phosphoinositide 3-kinases (PI3Ks) and phospholipase C beta (PLC beta) isozymes was examined. Recombinant mammalian G beta(1-3)gamma(2) complexes purified from Sf9 membranes stimulated PI3K gamma lipid kinase activity with similar potency (10-30 nM) and efficacy, whereas transducin G beta gamma was less potent. Functionally active G beta(5)gamma(2) dimers were purified from Sf9 cell membranes following coexpression of G beta(5) and G gamma(2-His). This preparation as well as G beta(1)gamma(2-His) supported pertussis toxin-mediated ADP-ribosylation of G alpha(i1) G beta(1)gamma(2-His) Stimulated PI3K gamma lipid and protein kinase activities at nanomolar concentrations, whereas G beta(5)gamma(2-His) had no effect. Accordingly, G beta(1)gamma(2-His), but not G beta(5)gamma(2-His), significantly stimulated the lipid kinase activity of PI3K beta in the presence or absence of tyrosine-phosphorylated peptides derived from the p85-binding domain of the platelet derived-growth factor receptor. Conversely, both preparations were able to stimulate PLC beta(2) and PLC beta(1). However, G beta(1)gamma(2-His) but not G beta(5)gamma(2-His), activated PLC beta(3). Experimental evidence suggests that the mechanism of G beta(5)-dependent effector selectivity may differ between PI3K and PLC beta. In conclusion, these data indicate that G beta subunits are able to discriminate among effecters independently of G alpha due to selective protein-protein interaction.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Bordeaux 2, Lab Physiol Cellulaire & Pharmacol Mol, CNRS, UMR 5017, F-33076 Bordeaux, France; Univ Ulm, Abt Pharmacol & Toxikol, D-89081 Ulm, Germany	Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Ulm University	Nurnberg, B (corresponding author), Free Univ Berlin, Inst Pharmakol, Thoelallee 69-73, D-14195 Berlin, Germany.	bnue@zedat.fu-berlin.de		MACREZ, Nathalie/0000-0002-3844-4403; Nurnberg, Bernd/0000-0002-5995-6555				Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BOYER JL, 1994, J BIOL CHEM, V269, P2814; Brunk I, 1999, EUR J CELL BIOL, V78, P311, DOI 10.1016/S0171-9335(99)80065-X; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI AJ, 1992, EUR J BIOCHEM, V210, P521, DOI 10.1111/j.1432-1033.1992.tb17450.x; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Garcia DE, 1998, J NEUROSCI, V18, P9163; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GIERSCHIK P, 1994, METHOD ENZYMOL, V238, P181; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Kalkbrenner F, 1996, BBA-MOL CELL RES, V1314, P125, DOI 10.1016/S0167-4889(96)00072-9; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P4573; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SINKE RJ, 1995, GENOMICS, V25, P568, DOI 10.1016/0888-7543(95)80060-Y; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yan K, 1997, J BIOL CHEM, V272, P2056; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	66	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13746	13754		10.1074/jbc.275.18.13746	http://dx.doi.org/10.1074/jbc.275.18.13746			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788495	hybrid			2022-12-27	WOS:000086925300082
J	McIver, L; Baxter, RL; Campopiano, DJ				McIver, L; Baxter, RL; Campopiano, DJ			Identification of the [Fe-S] cluster-binding residues of Escherichia coli biotin synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ANAEROBIC RIBONUCLEOTIDE REDUCTASE; LYASE-ACTIVATING ENZYME; BIOB GENE-PRODUCT; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; IN-VITRO; DETHIOBIOTIN; BIOSYNTHESIS	The gene encoding Escherichia coli biotin synthase (bioB) has been expressed as a histidine fusion protein, and the protein was purified in a single step using immobilized metal affinity chromatography, The His(6)-tagged protein was fully functional in in vitro and in vivo biotin production assays. Analysis of all the published bioB sequences identified a number of conserved residues. Single point mutations, to either serine or threonine, were carried out on the four conserved (Cys-53, Cys-57, Cys-60, and Cys-188) and one non-conserved (Cys-288) cysteine residues, and the purified mutant proteins were tested both for ability to reconstitute the [2Fe-2S] clusters of the native (oxidized) dimer and enzymatic activity. The C188S mutant was insoluble. The wild-type and four of the mutant proteins were characterized by UV-visible spectroscopy, metal and sulfide analysis, and both in vitro and in vivo biotin production assays. The molecular masses of all proteins were verified using electrospray mass spectrometry. The results indicate that the His(6) tag and the C288T mutation have no effect on the activity of biotin synthase when compared with the wild-type protein. The C53S, C57S, and C60S mutant proteins, both as prepared and reconstituted, were unable to covert dethiobiotin to biotin in vitro and in vivo. We conclude that three of the conserved cysteine residues (Cys-53, Cys-57, and Cys-60), all of which lie in the highly conserved "cysteine box" motif, are crucial for [Fe-S] cluster binding, whereas Cys-188 plays a hitherto unknown structural role in biotin synthase.	Univ Edinburgh, Dept Chem, Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh	Baxter, RL (corresponding author), Univ Edinburgh, Dept Chem, Edinburgh Ctr Prot Technol, Joseph Black Bldg,Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	r.baxter@ed.ac.uk		Campopiano, Dominic/0000-0001-8573-6735				ALEXEEV D, 1994, J MOL BIOL, V235, P774, DOI 10.1006/jmbi.1994.1030; Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Baldet P, 1997, FEBS LETT, V419, P206, DOI 10.1016/S0014-5793(97)01458-0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAXTER RL, 1992, J CHEM SOC PERK T 1, P255, DOI 10.1039/p19920000255; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; Bower S, 1996, J BACTERIOL, V178, P4122, DOI 10.1128/jb.178.14.4122-4130.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Bui BTS, 1997, METHOD ENZYMOL, V279, P356; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Busby RW, 1999, J AM CHEM SOC, V121, P4706, DOI 10.1021/ja990134g; DEMOLL E, 1986, ANAL BIOCHEM, V158, P55, DOI 10.1016/0003-2697(86)90587-7; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; FAJARDOCAVAZOS P, 1993, J BACTERIOL, V175, P1735, DOI 10.1128/JB.175.6.1735-1744.1993; Flint DH, 1997, METHOD ENZYMOL, V279, P349; FLORENTIN D, 1994, CR ACAD SCI III-VIE, V317, P485; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; GLASER P, 1995, J BACTERIOL, V177, P1112, DOI 10.1128/jb.177.4.1112-1115.1995; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; HARRIS DC, 1948, QUANTITATIVE CHEM AN, P513; IFUKU O, 1994, EUR J BIOCHEM, V224, P173, DOI 10.1111/j.1432-1033.1994.tb20009.x; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; Johnson MK, 1998, PURE APPL CHEM, V70, P939, DOI 10.1351/pac199870040939; Kack H, 1999, J MOL BIOL, V291, P857, DOI 10.1006/jmbi.1999.2997; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Leuthner B, 1998, MOL MICROBIOL, V28, P615, DOI 10.1046/j.1365-2958.1998.00826.x; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; LIU ST, 1992, J BACTERIOL, V174, P5814, DOI 10.1128/jb.174.18.5814-5819.1992; Marquet A, 1998, J PHYS ORG CHEM, V11, P529, DOI 10.1002/(SICI)1099-1395(199808/09)11:8/9<529::AID-POC44>3.3.CO;2-Z; MARTI FB, 1983, THESIS EDIGENOSSISCH; McIver L, 1998, EUR J BIOCHEM, V257, P577, DOI 10.1046/j.1432-1327.1998.2570577.x; Mejean A, 1995, BIOCHEM BIOPH RES CO, V217, P1231, DOI 10.1006/bbrc.1995.2900; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier-de Choudens S, 1999, FEBS LETT, V453, P25, DOI 10.1016/S0014-5793(99)00694-8; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; PARRY RJ, 1980, TETRAHEDRON LETT, V21, P4783, DOI 10.1016/0040-4039(80)80139-0; SAKURAI N, 1993, APPL ENVIRON MICROB, V59, P2857, DOI 10.1128/AEM.59.9.2857-2863.1993; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Serebriiskii IG, 1996, GENE, V175, P15, DOI 10.1016/0378-1119(96)00114-X; SHAW DJ, 1982, NUCLEIC ACIDS RES, V10, P6119, DOI 10.1093/nar/10.19.6119; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Wu CH, 1996, GENE, V174, P251, DOI 10.1016/0378-1119(96)00090-X; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	49	30	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13888	13894		10.1074/jbc.275.18.13888	http://dx.doi.org/10.1074/jbc.275.18.13888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788513	hybrid			2022-12-27	WOS:000086925300100
J	Murata, T; Igarashi, K; Kakinuma, Y; Yamato, I				Murata, T; Igarashi, K; Kakinuma, Y; Yamato, I			Na+ binding of V-type Na+-ATPase in Enterococcus hirae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0; TRANSLOCATING ATPASE; SUBUNIT-C; PROPIONIGENIUM-MODESTUM; ENERGY TRANSDUCTION; PROTON PUMP; H+-ATPASE; F-ATPASE; SYNTHASE; F1-ATPASE	Rotation catalysis theory has been successfully applied to the molecular mechanism of the ATP synthase (F0F1-ATPase) and probably of the vacuolar ATPase. We investigated the ion binding step to Enterococcus hirae Na+-translocating V-ATPase, The kinetics of Na+ binding to purified V-ATPase suggested 6 +/- 1 Na+ bound/ enzyme molecule, with a single high affinity (Kd(Na+) = 15 +/- 5 mu M). The number of cation binding sites is consistent with the model that V-ATPase proteolipids form a rotor ring consisting of hexamers, each having one cation binding site. Release of the bound Na-22(+) from purified molecules in a chasing experiment showed two phases: a fast component (about two-thirds of the total amount of bound Na+; k(exchange) > 1.7 min(-1)) and a slow component (about one-third of the total; k(exchange) = 0.16 min(-1)), which changes to the fast component by adding ATP or ATP gamma S, This suggested that about two-thirds of the Na+ binding sites of the Na+-ATPase are readily accessible from the aqueous phase and that the slow component is important for the transport reaction.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	Tokyo University of Science; Chiba University	Murata, T (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.		Murata, Takeshi/J-6181-2017; Murata, Takeshi/F-6114-2011	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1987, J BIOL CHEM, V262, P11006; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, EMBO J, V17, P5887, DOI 10.1093/emboj/17.20.5887; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MOGI T, 1984, J BIOL CHEM, V259, P7797; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 1996, J BIOL CHEM, V271, P23661, DOI 10.1074/jbc.271.39.23661; MUROI M, 1994, BIOCHEM BIOPH RES CO, V205, P1358, DOI 10.1006/bbrc.1994.2815; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PALI T, 1995, BIOCHEMISTRY-US, V34, P9211, DOI 10.1021/bi00028a034; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Takase K, 1999, BIOSCI BIOTECH BIOCH, V63, P1125, DOI 10.1271/bbb.63.1125; VIK SB, 1994, J BIOL CHEM, V269, P30364; YAMATO I, 1983, FEBS LETT, V151, P102, DOI 10.1016/0014-5793(83)80352-4; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	33	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13415	13419		10.1074/jbc.275.18.13415	http://dx.doi.org/10.1074/jbc.275.18.13415			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788452	hybrid			2022-12-27	WOS:000086925300039
J	Nadano, D; Sato, TA				Nadano, D; Sato, TA			Caspase-3-dependent and -independent degradation of 28 S ribosomal RNA may be involved in the inhibition of protein synthesis during apoptosis initiated by death receptor engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; KINASE PKR; FAS; ACTIVATION; INACTIVATION; MECHANISMS; PROTEASES; CASPASES; PATHWAYS; FAP-1	Activation of death receptors initiates intrinsic apoptosis programs in various parts of the cell. To explore the possibility that ribosomal RNA (rRNA), essential for translation in ribosomes, is a target of pro-apoptotic proteins, rRNA was analyzed by electrophoresis in two apoptosis systems: human Jurkat cells treated with anti-Fas antibody and human U937 cells treated with tumor necrosis factor-alpha. In both systems, bands in addition to those of unmodified rRNA were detected a few hours after death receptor engagement. In both systems, the primary additional band was identical and comprised the 5'-terminal region of 28 S rRNA The degradation of 28 S rRNA was simultaneous with protein synthesis inhibition in both systems. The caspase-3 inhibitor Z-DEVD-FMK suppressed rRNA degradation and protein synthesis inhibition in Jurkat cells but not in U937 cells. Together, our data suggest that different pathways are activated in the two systems we studied, and the final steps in these pathways use very similar or identical ribonucleases to cleave 28 S rRNA. These data suggest a physiological link between rRNA degradation and inhibition of protein synthesis. In general, apoptosis execution initiated by death receptor engagement is promoted by protein synthesis inhibition. Triggered by rRNA degradation, malfunction of the protein synthesis machinery may prompt death execution.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Mol Oncol Lab, Tsukuba, Ibaraki 3050074, Japan; Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg & Pathol, Div Mol Oncol, New York, NY 10032 USA	RIKEN; Columbia University	Sato, TA (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Mol Oncol Lab, Tsukuba, Ibaraki 3050074, Japan.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; D'Alessio G., 1997, RIBONUCLEASES STRUCT; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FODSTAD O, 1977, EUR J BIOCHEM, V74, P209, DOI 10.1111/j.1432-1033.1977.tb11383.x; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GORSKI JL, 1987, J MOL EVOL, V24, P236, DOI 10.1007/BF02111237; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; NADANO D, 1993, ANAL BIOCHEM, V212, P111, DOI 10.1006/abio.1993.1299; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PEACOCK AC, 1968, BIOCHEMISTRY-US, V7, P668, DOI 10.1021/bi00842a023; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; Porse BT, 1999, CELL, V97, P423, DOI 10.1016/S0092-8674(00)80751-5; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; SABATINI DD, 1998, CELLS LAB MANUAL, V1; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SAXENA SK, 1990, J BIOL CHEM, V265, P3263; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SENIOR BW, 1970, J MOL BIOL, V53, P205, DOI 10.1016/0022-2836(70)90295-0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655; WAKEMAN JA, 1989, BIOCHEM J, V258, P49, DOI 10.1042/bj2580049; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; WETTSTEIN FO, 1963, NATURE, V197, P430, DOI 10.1038/197430a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yeh WC, 1999, IMMUNOL REV, V169, P283, DOI 10.1111/j.1600-065X.1999.tb01323.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	43	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13967	13973		10.1074/jbc.275.18.13967	http://dx.doi.org/10.1074/jbc.275.18.13967			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788523	hybrid			2022-12-27	WOS:000086925300111
J	Pena, TL; Chen, SH; Konieczny, SF; Rane, SG				Pena, TL; Chen, SH; Konieczny, SF; Rane, SG			Ras/MEK/ERK up-regulation of the fibroblast K-Ca channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; MYOBLAST DIFFERENTIATION; EPITHELIAL-CELLS; PROTEIN-KINASES; LYMPHOCYTES; GENE; RAS; TRANSCRIPTION; INHIBITOR; MEMBER	The 10T1/2-MRF4 fibroblast/myogenic cell system was used to address the following interrelated questions: whether distinct signaling pathways underlie myogenic inhibition by basic fibroblast growth factor (bFGF) and transforming growth factor (TGF)-beta; which of these pathways also up-regulates the fibroblast intermediate conductance calcium-activated potassium channel, FIK, a positive regulator of cell proliferation; and whether FIK up-regulation underlies some or all myogenic inhibitory signaling events. The results show that myogenic inhibition in 10T1/2-MRF4 cells, by both bFGF and TGF-beta, requires activation of the Ras/mitogen-activated protein (MAP) kinase/MAP kinase-ERK kinase (MEK)/ extracellular signal-regulated kinase (ERK) pathway, and resultant FIK up-regulation. We show that FIK is instrumental in MEK-dependent suppression of acetylcholine receptor channel expression but that MEK activation and FIK up-regulation are not essential to suppression of myosin heavy chain and myotube formation. These data indicate that Ras/MEK/ERK induction of FIK is pivotal to regulation of certain myogenic events by both receptor tyrosine kinases and TGF-beta receptor, and this is also the first demonstration of chronic FIK upregulation by the TGF-beta receptor family. Furthermore, the results define the physiologic signaling requirements for growth factor-stimulated FIK up-regulation, whereas previous work has concentrated on constitutive FIK up-regulation in cells stably transfected with oncoprotein signaling molecules. This study, together with earlier work showing that FIK positively regulates cell proliferation, establishes this member of the IK channel family as a multifunctional, growth factor-regulated signaling molecule.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Rane, SG (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	srane@bilbo.bio.purdue.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041115] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41115] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HUANG Y, 1994, J BIOL CHEM, V269, P31183; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KONG YF, 1995, MOL CELL BIOL, V15, P5205; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MULDER KM, 1992, J BIOL CHEM, V267, P5029; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pena TL, 1999, J MEMBRANE BIOL, V172, P249, DOI 10.1007/s002329900601; Pena TL, 1997, J BIOL CHEM, V272, P21909, DOI 10.1074/jbc.272.35.21909; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Rane SG, 1999, ADV SEC MESS PHOSPH, V33, P107; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576	22	73	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13677	13682		10.1074/jbc.275.18.13677	http://dx.doi.org/10.1074/jbc.275.18.13677			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788486	hybrid			2022-12-27	WOS:000086925300073
J	Qiu, Y; Maillett, DH; Knapp, J; Olson, JS; Riggs, AF				Qiu, Y; Maillett, DH; Knapp, J; Olson, JS; Riggs, AF			Lamprey hemoglobin - Structural basis of the Bohr effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; PETROMYZON-MARINUS; LAMPETRA-FLUVIATILIS; OXYGEN-BINDING; COOPERATIVITY; ASSOCIATION; MECHANISMS; MYOGLOBIN; LIGAND	Lampreys, among the most primitive living vertebrates, have hemoglobins (Hbs) with self-association and ligand-binding properties very different from those that characterize the alpha(2)beta(2) tetrameric Hbs of higher vertebrates. Monomeric, ligated lamprey Hb self-associates to dimers and tetramers upon deoxygenation. Dissociation to monomers upon oxygenation accounts for the cooperative binding of O-2 and its pH dependence. Honzatko and Hendrickson (Honzatko, R, B., and Hendrickson, W, A (1986) Proc. Natl. Acad. Sci, U.S.A 83, 8487-8491) proposed that the dimeric interface of the Hb resembles either the alpha(1)beta(2) interface of mammalian Hbs or the contacts in clam Hb where the E and F helices form the interface. Perutz (Perutz, M. F, (1989) Quart, Rev. Biophys. 2, 139-236) proposed a version of the clam model in which the distal histidine swings out of the heme pocket upon deoxygenation to form a bond with a carboxyl group of a second monomer, The sedimentation behavior and oxygen equilibria of nine mutants of the major Hb component, PMII, from Petromyzon marinus have been measured to test these models. The results strongly support a critical role of the E helix and the AB corner in forming the subunit interface in the dimer and rule out the alpha(1)beta(2) model The pH dependence of both the sedimentation equilibrium and the oxygen binding of the mutant E75Q indicate that Glu(75) is one of two groups responsible for the Bohr effect. Changing the distal histidine 73 to glutamine almost completely abolishes the self-association of the deoxy-Hb and causes a large increase in O-2 affinity. The recent x-ray crystallographic determination of the structure of deoxy lamprey Hb, reported after the completion of this work (Heaslet, H.A., and Royer, W, E, (1999) Structure 7, 517-526), shows that the dimer interface does involve the E helix and the AB corner, supporting the measurements and interpretations reported here.	Univ Texas, Sch Biol Sci, Neurobiol Sect, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cell Biol, Austin, TX 78712 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Keck Ctr Computat Biol, Houston, TX 77005 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Rice University; Rice University; University of Texas System; University of Texas Austin	Riggs, AF (corresponding author), Univ Texas, Sch Biol Sci, Neurobiol Sect, Austin, TX 78712 USA.	riggs@uts.cc.utexas.edu		Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [T32-GM08362, GM 35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, T32GM008362] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON AC, 1960, BIOCHIM BIOPHYS ACTA, V42, P43, DOI 10.1016/0006-3002(60)90750-2; ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; ANDERSEN ME, 1972, J BIOL CHEM, V246, P4800; ANTONINI E, 1964, ARCH BIOCHEM BIOPHYS, V105, P404, DOI 10.1016/0003-9861(64)90024-4; ATHA DH, 1979, J BIOL CHEM, V254, P2390; BARIK S, 1991, BIOTECHNIQUES, V10, P481; BEHLKE J, 1970, EUR J BIOCHEM, V15, P245, DOI 10.1111/j.1432-1033.1970.tb01001.x; BEHLKE J, 1970, FEBS LETT, V7, P177, DOI 10.1016/0014-5793(70)80150-8; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P1187; Doi Y, 1973, J Biol Chem, V248, P2354; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; EDSALL JT, 1958, BIOPHYSICAL CHEM, P452; FUJIKI H, 1970, H-S Z PHYSIOL CHEM, V351, P901; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; Heaslet HA, 1999, STRUCT FOLD DES, V7, P517, DOI 10.1016/S0969-2126(99)80068-9; HENDRICK.WA, 1968, J MOL BIOL, V33, P829, DOI 10.1016/0022-2836(68)90322-7; HOMBRADOS I, 1983, BIOCHIMIE, V65, P247, DOI 10.1016/S0300-9084(83)80276-4; HOMBRADOS I, 1987, BIOL CHEM H-S, V368, P145, DOI 10.1515/bchm3.1987.368.1.145; HOMBRADOS I, 1991, HOPPESEYLERS Z PHYSL, V372, P49; HONZATKO RB, 1986, P NATL ACAD SCI USA, V83, P8487, DOI 10.1073/pnas.83.22.8487; Hoppe-Seyer F., 1864, ARCH PATHOL ANAT PHY, V29, P233; Imai K, 1981, Methods Enzymol, V76, P438; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LANFRANCHI G, 1994, DEV BIOL, V164, P402, DOI 10.1006/dbio.1994.1210; Lankester E R, 1868, J Anat Physiol, V2, P114; Lankester E R, 1869, J Anat Physiol, V4, P119; Laue TM, 1992, BIOCH POLYM SCI, P90; LI SL, 1970, J BIOL CHEM, V245, P6149; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; NIKINMAA M, 1993, RESP PHYSIOL, V91, P283, DOI 10.1016/0034-5687(93)90106-K; NOZAKI Y, 1967, J BIOL CHEM, V242, P4731; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; Qiu Y, 1998, FASEB J, V12, pA1427; RIGGS A, 1951, J GEN PHYSIOL, V35, P23, DOI 10.1085/jgp.35.1.23; RIGGS A, 1960, J GEN PHYSIOL, V43, P737, DOI 10.1085/jgp.43.4.737; Riggs AF, 1998, J EXP BIOL, V201, P1073; RUMEN NM, 1963, ARCH BIOCHEM BIOPHYS, V103, P24, DOI 10.1016/0003-9861(63)90005-5; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shen TJ, 1997, PROTEIN ENG, V10, P1085, DOI 10.1093/protein/10.9.1085; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Svedberg T, 1933, J AM CHEM SOC, V55, P2834, DOI 10.1021/ja01334a033; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; WALD G, 1951, J GEN PHYSIOL, V35, P45, DOI 10.1085/jgp.35.1.45; WOLF HU, 1984, CLIN CHIM ACTA, V136, P95, DOI 10.1016/0009-8981(84)90251-1; WYMAN J, 1948, ADV PROTEIN CHEM, V4, P407, DOI 10.1016/S0065-3233(08)60011-X; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; ZELENIK M, 1979, H-S Z PHYSIOL CHEM, V360, P1879, DOI 10.1515/bchm2.1979.360.2.1879	49	36	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13517	13528		10.1074/jbc.275.18.13517	http://dx.doi.org/10.1074/jbc.275.18.13517			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788466	hybrid			2022-12-27	WOS:000086925300053
J	Sanchez-Alcazar, JA; Schneider, E; Martinez, MA; Carmona, P; Hernandez-Munoz, I; Siles, E; De la Torre, P; Ruiz-Cabello, J; Garcia, I; Solis-Herruzo, JA				Sanchez-Alcazar, JA; Schneider, E; Martinez, MA; Carmona, P; Hernandez-Munoz, I; Siles, E; De la Torre, P; Ruiz-Cabello, J; Garcia, I; Solis-Herruzo, JA			Tumor necrosis factor-alpha increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANOUS SUPEROXIDE-DISMUTASE; HEART-MITOCHONDRIA; INDUCED APOPTOSIS; ELECTRON-TRANSFER; CYTO-TOXICITY; DNA-DAMAGE; TNF-ALPHA; PROTON TRANSLOCATION; ENERGY TRANSDUCTION; C RELEASE	The mechanism of tumor necrosis factor alpha (TNF alpha)-induced cytotoxicity in metabolically inhibited cells is unclear, although some studies have suggested that mitochondrial dysfunction and generation of reactive oxygen species may be involved. Here we studied the effect of TNF alpha on the redox state of mitochondrial cytochromes and its involvement in the generation of reactive oxygen species in metabolically inhibited L929 cells. Treatment with TNF alpha and cycloheximide (TNF alpha/CHX) induced mitochondrial cytochrome c release, increased the steady-state reduction of cytochrome b, and decreased the steady-state reduction of cytochromes cc(1) and aa(3). TNF alpha/CHX treatment also induced lipid peroxidation, intracellular generation of reactive oxygen species, and cell death. Furthermore, as the cells died mitochondrial morphology changed from an orthodox to a hyperdense and condensed and finally to a swollen conformation. Antimycin A, a mitochondrial respiratory chain complex III inhibitor that binds to cytochrome b, blocked the formation of reactive oxygen species, suggesting that the free radicals are generated at the level of cytochrome b. Moreover, antimycin A, when added after 3 h of TNF alpha/CHX treatment, arrested the further release of cytochrome c and the cytotoxic response. We propose that the reduced cytochrome b promotes the formation of reactive oxygen species, lipid peroxidation of the cell membrane, and cell death.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Hosp Univ 12 Octubre, Ctr Invest, Madrid 28041, Spain; Hosp Univ 12 Octubre, Dept Anat Patol, Madrid 28041, Spain; Univ Complutense, Fac Farm, Unidad RNM, Dept Quim Fis 2, E-28040 Madrid, Spain; CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); State University of New York (SUNY) System; State University of New York (SUNY) Albany	Schneider, E (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Empire State Plaza, Albany, NY 12201 USA.	schneid@wadsworth.org	Ruiz-Cabello, Jesus/A-9570-2012; García-Ruiz, Inmaculada/G-8204-2015; Sanchéz-Alcázar, José A. A/L-4925-2014	Ruiz-Cabello, Jesus/0000-0001-8681-5056; García-Ruiz, Inmaculada/0000-0003-4185-8524; Sanchéz-Alcázar, José A. A/0000-0001-9705-1469; Siles Rivas, Eva/0000-0003-4192-7008	NCI NIH HHS [CA72455, CA25933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072455, R01CA025933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRANDON JR, 1972, BIOCHEMISTRY-US, V11, P1150, DOI 10.1021/bi00757a006; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CARINI R, 1992, ARCH BIOCHEM BIOPHYS, V297, P110, DOI 10.1016/0003-9861(92)90647-F; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHANCE B, 1957, METHOD ENZYMOL, V4, P273, DOI 10.1016/0076-6879(57)04060-4; Collins AR, 1999, BIOESSAYS, V21, P238, DOI 10.1002/(SICI)1521-1878(199903)21:3<238::AID-BIES8>3.0.CO;2-3; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Dinsdale D, 1999, AM J PATHOL, V155, P607, DOI 10.1016/S0002-9440(10)65156-5; DUTTON PL, 1972, BIOCHIM BIOPHYS ACTA, V267, P15, DOI 10.1016/0005-2728(72)90134-X; EADY JJ, 1995, BRIT J CANCER, V72, P1089, DOI 10.1038/bjc.1995.470; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KULL FC, 1981, CANCER RES, V41, P4885; LAIHO KU, 1975, LAB INVEST, V32, P163; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Li YZ, 1999, MOL MED, V5, P232, DOI 10.1007/BF03402120; Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; MASUMOTO N, 1990, J BIOL CHEM, V265, P22533; MATTHEWS N, 1983, BRIT J CANCER, V48, P405, DOI 10.1038/bjc.1983.205; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; NORTON WN, 1985, AM J PATHOL, V118, P387; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; ORD MJ, 1982, CELL TISSUE RES, V227, P129; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Polla BS, 1996, FREE RADICAL RES, V25, P125, DOI 10.3109/10715769609149917; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; ROBINSON G, 1977, ELECT MICROSCOPY, P326; ROBUSTELLI CG, 1991, SEMIN ONCOL, V18, P18; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RUFF MR, 1986, LYMPHOKINES, V6, P549; RUTKOWSKI JV, 1986, TOXICOLOGY, V40, P25, DOI 10.1016/0300-483X(86)90043-0; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	68	76	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13353	13361		10.1074/jbc.275.18.13353	http://dx.doi.org/10.1074/jbc.275.18.13353			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788444	hybrid			2022-12-27	WOS:000086925300030
J	Tang, H; Nishishita, T; Fitzgerald, T; Landon, EJ; Inagami, T				Tang, H; Nishishita, T; Fitzgerald, T; Landon, EJ; Inagami, T			Inhibition of AT(1) receptor internalization by concanavalin A blocks angiotensin II-induced ERK activation in vascular smooth muscle cells - Involvement of epidermal growth factor receptor proteolysis but not AT(1) receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; TYROSINE KINASE; TYPE-1 RECEPTOR; EGF RECEPTOR; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; PHOSPHOLIPASE-C; S6 KINASE; PHOSPHORYLATION; EXPRESSION	Recent studies of beta(2)-adrenergic receptor suggest that agonist-promoted receptor internalization may play an important role in extracellular signal-regulated kinase (ERK) activation by G protein-coupled receptors, In the present study, we explored the effects of angiotensin II (Ang II) type-1 receptor (AT(1)) internalization on Ang II-induced activation of ERK using the receptor internalization blocker concanavalin A (ConA) and the carboxyl terminus-truncated receptor mutants with impaired internalization. ConA inhibited AT(1) receptor internalization without affecting ligand binding to the receptor, Ang II-induced generation of second messengers, and activation of tyrosine kinases Src and Pyk2 in vascular smooth muscle cells (VSMC), ConA blocked ERK activation evoked by Ang II and the calcium ionophore A23187, Impairment of AT(1) receptor internalization by truncating the receptor carboxyl terminus did not affect Ang II-induced ERK activation. ConA induced proteolytic cleavage of the epidermal growth factor (EGF) receptor at carboxyl terminus and abolished Ang II-induced transactivation of the EGF receptor, which is critical for ERR activation by Ang II in VSMC, ConA also induced proteolysis of erbB-2 but not platelet-derived growth factor receptor. Thus, ConA blocks Ang II-induced ERR activation in VSMC through a distinct mechanism, the ConA-mediated proteolysis of the EGF receptor.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Inagami, T (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 663 Light Hall, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL-58205] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058205, R37HL058205] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; BENYA RV, 1994, J BIOL CHEM, V269, P11721; CHENG HC, 1991, J BIOL CHEM, V266, P17919; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DISABATO G, 1989, METHOD ENZYMOL, V150, P3; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; EGUCHI S, 1994, ENDOCRINOLOGY, V134, P222, DOI 10.1210/en.134.1.222; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FROST SC, 1985, J BIOL CHEM, V260, P2646; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HENIS YI, 1981, EXP CELL RES, V136, P189, DOI 10.1016/0014-4827(81)90050-1; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOMMA T, 1992, J BIOL CHEM, V267, P23129; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; INUI H, 1993, J BIOL CHEM, V268, P17045; Ishida M, 1998, CIRC RES, V82, P7; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; KAPLOWITZ PB, 1988, J CELL PHYSIOL, V136, P13, DOI 10.1002/jcp.1041360103; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TANG H, 1995, CIRC RES, V77, P239, DOI 10.1161/01.RES.77.2.239; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; THEKKUMKARA TJ, 1993, FASEB J, V7, P738; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	50	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13420	13426		10.1074/jbc.275.18.13420	http://dx.doi.org/10.1074/jbc.275.18.13420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788453	hybrid			2022-12-27	WOS:000086925300040
J	Beljaars, L; Molema, G; Schuppan, D; Geerts, A; De Bleser, PJ; Weert, B; Meijer, DKF; Poelstra, K				Beljaars, L; Molema, G; Schuppan, D; Geerts, A; De Bleser, PJ; Weert, B; Meijer, DKF; Poelstra, K			Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL LIVER FIBROSIS; MONOCLONAL-ANTIBODIES; LYSOSOMAL-ENZYMES; FIBROBLASTS; CIRRHOSIS; INTEGRINS; ADHESION; PROTEIN; MATRIX; RGD	The key pathogenic event in liver fibrosis is the activation of hepatic stellate cells (HSC). Consequently, new antifibrotic therapies are directed toward an inhibition of HSC activities. The aim of the present study was to develop a drug carrier to HSC, which would allow cell-specific delivery of antifibrotic drugs thus enhancing their effectiveness in vivo. We modified human serum albumin (HSA) with 10 cyclic peptide moieties recognizing collagen type VI receptors (C*GRGDSPC*, in which C* denotes the cyclizing cysteine residues) yielding pCVI-HSA. In vivo experiments showed preferential distribution of pCVI-HSA to both fibrotic and normal rat livers (respectively, 62 +/- 6 and 75 +/- 16% of the dose at 10 min after intravenous injection), Immunohistochemical analysis demonstrated that pCVI-HSA predominantly bound to HSC in fibrotic livers (73 +/- 14%). In contrast, endothelial cells contributed mostly to the total liver accumulation in normal rats. In vitro studies showed that pCVI-HSA specifically bound to rat HSC, in particular to the activated cells, and showed internalization of pCVI-HSA by these cells. in conclusion, pCVI-HSA may be applied as a carrier to deliver antifibrotic agents to HSC, which may strongly enhance the effectiveness and tissue selectivity of these drugs. This approach has the additional benefit that such carriers may block receptors that play a putative role in the pathogenesis of liver fibrosis.	Univ Groningen, Inst Drug Explorat, Dept Pharmacokinet & Drug Delivery, Ctr Pharm, NL-9713 AV Groningen, Netherlands; Univ Erlangen Nurnberg, Med Klin 1, D-90154 Erlangen, Germany; Free Univ Brussels, Cell Biol & Histol Lab, B-1090 Brussels, Belgium	University of Groningen; University of Erlangen Nuremberg; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Beljaars, L (corresponding author), Univ Groningen, Inst Drug Explorat, Dept Pharmacokinet & Drug Delivery, Ctr Pharm, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	L.Beljaars@farm.rug.nl	De Bleser, Pieter/AAB-2968-2021; De Bleser, Pieter/C-3489-2011	De Bleser, Pieter/0000-0003-4762-8770; Molema, Grietje/0000-0002-4147-6676; Beljaars, Leonie/0000-0003-3659-1896				ADLER S, 1993, KIDNEY INT, V44, P278, DOI 10.1038/ki.1993.242; Albrecht C, 1997, HEPATOLOGY, V26, P1553; Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; Arthur MJP, 1998, DIGESTION, V59, P376, DOI 10.1159/000007492; Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Beljaars L, 1999, HEPATOLOGY, V29, P1486, DOI 10.1002/hep.510290526; Beljaars L, 1998, J HEPATOL, V29, P579, DOI 10.1016/S0168-8278(98)80153-0; Bickel M, 1998, HEPATOLOGY, V28, P404, DOI 10.1002/hep.510280217; BRAULKE T, 1990, J BIOL CHEM, V265, P6650; Bruck R, 1997, YALE J BIOL MED, V70, P391; DANILOV YN, 1989, EXP CELL RES, V182, P186, DOI 10.1016/0014-4827(89)90290-5; Dower WJ, 1998, CURR OPIN CHEM BIOL, V2, P328, DOI 10.1016/S1367-5931(98)80005-7; ESKILD W, 1988, BIOCHIM BIOPHYS ACTA, V968, P143, DOI 10.1016/0167-4889(88)90001-8; EVERTS V, 1995, MATRIX BIOL, V14, P665, DOI 10.1016/S0945-053X(05)80030-7; Geerts A, 1998, HEPATOLOGY, V27, P590, DOI 10.1002/hep.510270238; Gerling B, 1997, NEW ENGL J MED, V336, P1611, DOI 10.1056/NEJM199705293362217; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; HARMS G, 1990, CELL TISSUE RES, V262, P35, DOI 10.1007/BF00327742; HART SL, 1994, J BIOL CHEM, V269, P12468; Horton MA, 1999, EXP NEPHROL, V7, P178; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iwamoto H, 1999, DIGEST DIS SCI, V44, P1038, DOI 10.1023/A:1026633302985; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; LOREAL O, 1992, GASTROENTEROLOGY, V102, P980, DOI 10.1016/0016-5085(92)90186-3; MARCELINO J, 1995, BBA-PROTEIN STRUCT M, V1249, P180, DOI 10.1016/0167-4838(95)00026-Q; MATHER SJ, 1987, J NUCL MED, V28, P1034; MEIJER DKF, 1995, SEMIN LIVER DIS, V15, P202, DOI 10.1055/s-2007-1007278; Meijer DKF, 1996, J CONTROL RELEASE, V39, P163, DOI 10.1016/0168-3659(95)00150-6; Meijer DKF, 1993, BIOL BARRIERS PROTEI, P339; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Olinga P, 1997, J PHARMACOL TOXICOL, V38, P59, DOI 10.1016/S1056-8719(97)00060-9; Olinga P, 1998, DRUG METAB DISPOS, V26, P5; PIERSCHBACHER MD, 1994, J CELL BIOCHEM, V56, P150, DOI 10.1002/jcb.240560205; PINZANI M, 1995, PHARMACOL THERAPEUT, V66, P387, DOI 10.1016/0163-7258(94)00072-B; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ramadori G, 1998, DIGESTION, V59, P372, DOI 10.1159/000007518; ROCHE AC, 1985, FEBS LETT, V193, P63, DOI 10.1016/0014-5793(85)80080-6; Ruhl M, 1999, EXP CELL RES, V250, P548, DOI 10.1006/excr.1999.4540; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHUPPAN D, 1985, ANAL BIOCHEM, V149, P238, DOI 10.1016/0003-2697(85)90501-9; Schuppan D, 1998, DIGESTION, V59, P385, DOI 10.1159/000007494; Soyez H, 1996, ADV DRUG DELIVER REV, V21, P81, DOI 10.1016/S0169-409X(96)00400-0; TAKAHARA T, 1995, LIVER, V15, P78; TOTH CA, 1992, HEPATOLOGY, V16, P255, DOI 10.1002/hep.1840160137; VANGOOR H, 1989, J HISTOCHEM CYTOCHEM, V37, P399, DOI 10.1177/37.3.2465338; Windmeier C, 1997, GEN PHARMACOL-VASC S, V29, P181, DOI 10.1016/S0306-3623(96)00314-X; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381	53	116	127	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12743	12751		10.1074/jbc.275.17.12743	http://dx.doi.org/10.1074/jbc.275.17.12743			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777570	hybrid			2022-12-27	WOS:000086762300054
J	Glover, RT; Angiolieri, M; Kelly, S; Monaghan, DT; Wang, JYJ; Smithgall, TE; Buller, AL				Glover, RT; Angiolieri, M; Kelly, S; Monaghan, DT; Wang, JYJ; Smithgall, TE; Buller, AL			Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NMDA RECEPTOR; SH3 DOMAIN; RAT-BRAIN; SRC-FAMILY; REGIONAL EXPRESSION; MESSENGER-RNAS; GENE-PRODUCT; CELL-CYCLE; BINDING	The COOH-terminal domain of the NR2D subunit of the NMDA receptor contains proline-rich regions that show striking homology to sequences known to bind to Src homology 3 (SH3) domains. To determine whether the proline-rich region of the NR2D subunit interacts with specific SH3 domains, in vitro SH3 domain binding assays were performed. A proline-rich fragment of the NR2D subunit (2D(866-1064)) bound to the Abl SH3 domain but not to the SH3 domains from Src, Fyn, Grb2, GAP, or phospholipase C-gamma (PLC gamma). Co-immunoprecipitation of NR2D with Abl suggests stable association of NR2D and Abl in transfected cells. The SH3 domain plays an important role in the negative regulation of Abl kinase activity. To determine whether the interaction of NR2D with the Abl SH3 domain alters Abl kinase activity, Abl was expressed alone or with NR2D in 293T cells. Autophosphorylation of Abl was readily observed when Abl was expressed alone. However, co-expression of Abl with 2D(866-1064) or full-length NR2D inhibited autophosphorylation. 2D(866-1064) did not inhibit Delta SH3 Abl, indicating a requirement for the Abl SH3 domain in the inhibitory effect, Similarly, 2D(866-1064) did not inhibit the catalytic activity of Abl-PP, which contains two point mutations in the SH2-kinase linker domain that release the negative kinase regulation by the SH3 domain. In contrast, the full-length NR2D subunit partially inhibited the autokinase activity of both Delta SH3 Abl and Abl-PP, suggesting that NR2D and Abl may interact at multiple sites. Taken together, the data in this report provide the first evidence for a novel inhibitory interaction between the NR2D subunit of the MMDA receptor and the Abl tyrosine kinase.	Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Univ Nebraska, Dept Biol, Omaha, NE 68154 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Nebraska System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Nebraska System; University of Nebraska Medical Center; University of California System; University of California San Diego	Buller, AL (corresponding author), Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA.	buller@bns.pitt.edu			NATIONAL CANCER INSTITUTE [R01CA043054, R01CA081398, R37CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81398, R37 CA043054, R01 CA043054] Funding Source: Medline; NIAAA NIH HHS [AA 00153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; BULLER AL, 1994, J NEUROSCI, V14, P5471; Buller AL, 1997, EUR J PHARMACOL, V320, P87, DOI 10.1016/S0014-2999(96)00880-1; Dunah AW, 1998, MOL PHARMACOL, V53, P429, DOI 10.1124/mol.53.3.429; Dunah AW, 1996, J NEUROCHEM, V67, P2335; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HILL KK, 1995, GENETICS, V141, P595; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HOLLMANN M, 1997, IONOTROPIC GLUTAMATE, P39; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Ko HW, 1998, J NEUROCHEM, V71, P1390; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wenzel A, 1995, NEUROREPORT, V7, P45, DOI 10.1097/00001756-199512290-00010; Wenzel A, 1996, J NEUROCHEM, V66, P1240; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	60	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12725	12729		10.1074/jbc.275.17.12725	http://dx.doi.org/10.1074/jbc.275.17.12725			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777567	hybrid			2022-12-27	WOS:000086762300051
J	Sen, CK; Khanna, S; Roy, S; Packer, L				Sen, CK; Khanna, S; Roy, S; Packer, L			Molecular basis of vitamin E action - Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTIC BONE-RESORPTION; ALPHA-LIPOIC ACID; OXIDATIVE STRESS; C-SRC; TYROSINE KINASE; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; CYSTINE UPTAKE; ANTIOXIDANT; LINE	HT4 hippocampal neuronal cells were studied to compare the efficacy of tocopherols and tocotrienol to protect against glutamate-induced death. Tocotrienols were more effective than alpha-tocopherol in preventing glutamate-induced death. Uptake of tocotrienols from the culture medium was more efficient compared with that of alpha-tocopherol. Vitamin E molecules have potent antioxidant properties. Results show that at low concentrations, tocotrienols may have protected cells by an antioxidant-independent mechanism. Examination of signal transduction pathways revealed that protein tyrosine phosphorylation processes played a central role in the execution of death. Activation of pp60(c-Src) kinase and phosphorylation of ERK were observed in response to glutamate treatment. Nanomolar amounts of cy-tocotrienol, but not alpha-tocopherol, blocked glutamate-induced death by suppressing glutamate-induced early activation of c-Src kinase. Overexpression of kinase-active c-Src sensitized cells to glutamate-induced death. Tocotrienol treatment prevented death of Src-overexpressing cells treated with glutamate. alpha-Tocotrienol did not influence activity of recombinant c-Src kinase suggesting that its mechanism of action may include regulation of SH domains. This study provides first evidence describing the molecular basis of tocotrienol action. At a concentration 4-10-fold lower than levels detected in plasma of supplemented humans, tocotrienol regulated unique signal transduction processes that were not sensitive to comparable concentrations of tocopherol.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Sen, CK (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, 1 Cyclotron Rd,Bldg 90,Rm 3031, Berkeley, CA 94720 USA.	cksen@socrates.berkeley.edu	Sen, Chandan K/A-8762-2013; Khanna, Savita/E-3378-2011; Roy, sashwati/E-3990-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM027345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; AZZI A, 1995, AM J CLIN NUTR, V62, P1337, DOI 10.1093/ajcn/62.6.1337S; BARNEKOW A, 1987, CANCER RES, V47, P235; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BELETSKY IP, 1990, J IMMUNOL METHODS, V134, P201, DOI 10.1016/0022-1759(90)90381-5; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; Borlongan C V, 1996, J Fla Med Assoc, V83, P335; BOSCOBOINIK DO, 1994, BBA-MOL CELL RES, V1224, P418, DOI 10.1016/0167-4889(94)90277-1; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; Burcham PC, 1999, MUTAGENESIS, V14, P135, DOI 10.1093/mutage/14.1.135; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363; Han D, 1997, AM J PHYSIOL-REG I, V273, pR1771, DOI 10.1152/ajpregu.1997.273.5.R1771; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Jurma OP, 1997, FREE RADICAL BIO MED, V23, P1055, DOI 10.1016/S0891-5849(97)00134-2; Kabuto H, 1998, EPILEPSIA, V39, P237, DOI 10.1111/j.1528-1157.1998.tb01367.x; KAMAT JP, 1995, NEUROSCI LETT, V195, P179, DOI 10.1016/0304-3940(95)11812-B; Karczewski JM, 1999, BIOCHEM PHARMACOL, V57, P19, DOI 10.1016/S0006-2952(98)00286-X; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Keller JN, 1998, J NEUROSCI, V18, P687; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lee JR, 1998, J IMMUNOL, V161, P1637; Levitzki A, 1996, ANTI-CANCER DRUG DES, V11, P175; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mahle C, 1997, LIFE SCI, V61, P437, DOI 10.1016/S0024-3205(97)00401-3; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MORIMOTO BH, 1990, P NATL ACAD SCI USA, V87, P3518, DOI 10.1073/pnas.87.9.3518; Murakami K, 1998, J NEUROSCI, V18, P205; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; O'Byrne D, 1999, FASEB J, V13, pA536; OKA A, 1993, J NEUROSCI, V13, P1441; Pereira CMF, 1997, FREE RADICAL BIO MED, V23, P637, DOI 10.1016/S0891-5849(97)00020-8; Roy S, 1998, FREE RADICAL BIO MED, V25, P229, DOI 10.1016/S0891-5849(98)00062-8; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1998, BIOLOGICAL OXIDANTS AND ANTIOXIDANTS: MOLECULAR MECHANISMS AND HEALTH EFFECTS, P5; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; Sen CK, 1997, FREE RADICAL BIO MED, V22, P1241, DOI 10.1016/S0891-5849(96)00552-7; SERBINOVA E, 1991, FREE RADICAL BIO MED, V10, P263, DOI 10.1016/0891-5849(91)90033-Y; Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605; STOYANOVSKY DA, 1989, BIOCHEM BIOPH RES CO, V160, P834, DOI 10.1016/0006-291X(89)92509-6; SUARNA C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P163, DOI 10.1016/0005-2760(93)90092-N; SUZUKI Y, 1993, BIOCHEMISTRY-US, V32, P10692, DOI 10.1021/bi00091a020; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Thiele JJ, 1997, FEBS LETT, V401, P167, DOI 10.1016/S0014-5793(96)01463-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tirosh O, 1999, FREE RADICAL BIO MED, V26, P1418, DOI 10.1016/S0891-5849(99)00014-3; TOMEO AC, 1995, LIPIDS, V30, P1179, DOI 10.1007/BF02536621; TRABER MG, 1995, AM J CLIN NUTR, V62, P1501; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	60	255	272	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13049	13055		10.1074/jbc.275.17.13049	http://dx.doi.org/10.1074/jbc.275.17.13049			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777609	hybrid			2022-12-27	WOS:000086762300093
J	Liu, RY; Fan, C; Liu, GQ; Olashaw, NE; Zuckerman, KS				Liu, RY; Fan, C; Liu, GQ; Olashaw, NE; Zuckerman, KS			Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha-supported proliferation of leukemia and lymphoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; AUTOCRINE PRODUCTION; FACTOR TNF; HEL CELLS; APOPTOSIS; SIGNAL; PATHWAYS	To elucidate mechanisms of tumor necrosis factor alpha (TNF-alpha)-induced proliferation of a number of human leukemia and lymphoma cell lines, we examined the role of p38 mitogen-activated protein kinase (MAPK) in TNF-alpha signaling in Mo7e and Hut-78 cells. TNF-alpha-dependent p38 MAPK activation was detected in both Mo7e and Hut-78 cells and was blocked by the p38 MAPK inhibitor, SB203580. Ablation of p38 MAPK activity by SB203580 abrogated TNF-alpha-induced Mo7e cell proliferation and TNF-alpha-dependent autocrine growth of Hut-78. As we have shown previously that activation of the nuclear factor kappa B (NF-kappa B) is also required for TNF-alpha-induced Mo7e cell proliferation, the involvement of p38 MAPK in NF-kappa B activation was assessed. SB203580 did not affect TNF-alpha-signaled nuclear translocation and DNA-binding activity of NF-kappa B, and inhibition of NF-kappa B function did not affect TNF-alpha-induced p38 MAPK activation, indicating that these events are not dependent on each other. However, SB203580 depressed the expression of TNF-kappa B-dependent genes, as monitored by a kappa B-driven reporter gene. Our findings demonstrate that activation of both p38 MAPK and NF-kappa B plays a critical role in TNF-alpha-mediated survival and proliferation of human leukemia and lymphoma cells, and p38 MAPK acts at least in part by facilitating the transcriptional activation function of NF-kappa B.	H Lee Moffitt Canc Ctr & Res Inst, Div Hematol & Med Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem Mol Biol & Anat, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Liu, RY (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Div Hematol & Med Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [P30 CA76252] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADERKA D, 1993, BLOOD, V81, P2076; AKIYAMA Y, 1992, JPN J CANCER RES, V83, P989, DOI 10.1111/j.1349-7006.1992.tb02012.x; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Birkenkamp KU, 1999, EUR CYTOKINE NETW, V10, P479; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Craxton A, 1998, J IMMUNOL, V161, P3225; DIGEL W, 1989, BLOOD, V73, P1242; Drexler HG, 1997, LEUKEMIA, V11, P541, DOI 10.1038/sj.leu.2400621; Drexler HG, 1997, LEUKEMIA, V11, P701, DOI 10.1038/sj.leu.2400633; ELBAZ O, 1994, LEUKEMIA LYMPHOMA, V12, P191, DOI 10.3109/10428199409059589; GAZDAR AF, 1980, BLOOD, V55, P409; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu RY, 1998, CANCER RES, V58, P2217; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; LIU RY, 1994, J CELL SCI, V107, P2209; LIU RY, 1996, BLOOD S1, V88, P58; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; MIURA K, 1992, LEUKEMIA RES, V16, P281, DOI 10.1016/0145-2126(92)90066-G; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wadhwa M, 1996, CYTOKINE, V8, P900, DOI 10.1006/cyto.1996.0121; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zauli G, 1998, BLOOD, V92, P472, DOI 10.1182/blood.V92.2.472.414k30_472_480	41	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21086	21093		10.1074/jbc.M001281200	http://dx.doi.org/10.1074/jbc.M001281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10783388	hybrid			2022-12-27	WOS:000088230600019
J	Munshi, C; Aarhus, R; Graeff, R; Walseth, TF; Levitt, D; Lee, HC				Munshi, C; Aarhus, R; Graeff, R; Walseth, TF; Levitt, D; Lee, HC			Identification of the enzymatic active site of CD38 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; CD8(+) T-CELLS; FUNCTIONAL EXPRESSION; ANTIGEN EXPRESSION; CRYSTAL-STRUCTURE; PICHIA-PASTORIS; CYCLASE; HYDROLYSIS; MOLECULE	CD38 is a ubiquitous protein originally identified as a lymphocyte antigen and recently also found to be a multifunctional enzyme participating in the synthesis and metabolism of two Ca2+ messengers, cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate. It is homologous to Aplysia ADP-ribosyl cyclase, where the crystal structure has been determined. Residues of CD38 corresponding to those at the active site of the Aplysia cyclase were mutagenized. Changing Glu226, which corresponded to the catalytic residue of the cyclase, to Asp, Asn, Gin, Leu, or Gly eliminated essentially all enzymatic activities of CD38, indicating it is most likely the catalytic residue. Photoaffinity labeling showed that E226G, nevertheless, retained substantial NAD binding activity. The secondary structures of these inactive mutants as measured by circular dichroism were essentially unperturbed as compared with the wild type. Other nearby residues were also investigated. The mutants D147V and E146L showed 7- and 19-fold reduction in NADase activity, respectively. The cADPR hydrolase activity of the two mutants was similarly reduced. Asp-155, on the other hand, was crucial for the GDP-ribosyl cyclase activity since its substitution with either Glu, Asn, or Gin stimulated the activity 3-15-fold, whereas other activities remained essentially unchanged. In addition to these acidic residues, two tryptophans were also important, since all enzyme activities of W125F, W125Y, W189G and W189Y were substantially reduced. This is consistent with the two tryptophans serving a substrate positioning function. A good correlation was observed when the NADase activity of all the mutants was plotted against the cADPR hydrolase activity. Homology modeling revealed all these critical residues are clustered in a pocket near the center of the CD38 molecule. The results indicate a strong structural homology between the active sites of CD38 and the Aplysia cyclase.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Physiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lee, HC (corresponding author), Univ Minnesota, Dept Pharmacol, 321 Church St SE,4-145 Jackson Hall, Minneapolis, MN 55455 USA.		Graeff, Richard Milton/B-3425-2011; Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA11806] Funding Source: Medline; NIGMS NIH HHS [GM60333] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151, DOI 10.1002/jlb.65.2.151; FRYXELL KB, 1995, PROTEIN EXPRES PURIF, V6, P329, DOI 10.1006/prep.1995.1043; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Hussain AMM, 1998, PROTEIN EXPRES PURIF, V12, P133, DOI 10.1006/prep.1997.0811; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lee HC, 1999, MOL CELL BIOCHEM, V193, P89; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 2000, J MEMBRANE BIOL, V173, P1, DOI 10.1007/s002320001001; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Liu ZY, 1996, CYTOMETRY, V26, P1; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MullerSteffner HM, 1996, J BIOL CHEM, V271, P23967, DOI 10.1074/jbc.271.39.23967; Munshi C, 1997, PROTEIN EXPRES PURIF, V11, P104, DOI 10.1006/prep.1997.0773; Munshi C, 1999, J BIOL CHEM, V274, P30770, DOI 10.1074/jbc.274.43.30770; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; TOHGO A, 1994, J BIOL CHEM, V269, P28555; Tohgo A, 1997, J BIOL CHEM, V272, P3879, DOI 10.1074/jbc.272.7.3879; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0	39	97	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21566	21571		10.1074/jbc.M909365199	http://dx.doi.org/10.1074/jbc.M909365199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781610	hybrid			2022-12-27	WOS:000088230600081
J	Sauzeau, V; Le Jeune, H; Cario-Toumaniantz, C; Smolenski, A; Lohmann, SM; Bertoglio, J; Chardin, P; Pacaud, P; Loirand, G				Sauzeau, V; Le Jeune, H; Cario-Toumaniantz, C; Smolenski, A; Lohmann, SM; Bertoglio, J; Chardin, P; Pacaud, P; Loirand, G			Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; NITRIC-OXIDE; CALCIUM SENSITIZATION; MYOSIN PHOSPHATASE; SMALL GTPASE; CELLS; TRANSDUCTION; PHOSPHORYLATION; ATHEROSCLEROSIS; PROLIFERATION	The potent vasodilator action of cyclic GMP-dependent protein kinase (cGK) involves decreasing the Ca2+ sensitivity of contraction of smooth muscle via stimulation of myosin light chain phosphatase through unknown mechanisms (Wu, X., Somlyo, A. V., and Somlyo, A. P. (1996) Biochem. Biophys. Res. Commun. 220, 658-663). Myosin light chain phosphatase activity is controlled by the small GTPase RhoA and its target Rho kinase. Here we demonstrate cGMP effects mediated by cGK that inhibit RhoA-dependent Ca2+ sensitization of contraction of blood vessels and actin cytoskeleton organization in cultured vascular myocytes. Ca2+ sensitization and actin organization were inhibited by both 8-bromo-cGMP and sodium nitroprusside (SNP). SNP also caused translocation of activated RhoA from the membrane to the cytosol, SNP-induced actin disassembly was lost in vascular myocytes in culture after successive passages but was restored by transfection of cells with cGK I. Furthermore, cGK phosphorylated RhoA in vitro, and addition of cGK I inhibited RhoA-induced Ca2+ sensitization in permeabilized smooth muscle. 8-Bromo-cGMP-induced actin disassembly was inhibited in vascular myocytes expressing RhoA(Ala-188), a mutant that could not be phosphorylated, Collectively, these results indicate that cGK phosphorylates and inhibits RhoA and suggest that the consequent inhibition of RhoA-induced Ca2+ sensitization and actin cytoskeleton organization contributes to the vasodilator action of nitric oxide.	Fac Sci, INSERM, U533, Lab Physiol Cellulaire & Mol, F-44322 Nantes 3, France; Inst Clin Biochem & Pathobiochem, Wuerzburg, Germany; INSERM, U461, F-92296 Chatenay Malabry, France; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Loirand, G (corresponding author), Fac Sci, INSERM, U533, Lab Physiol Cellulaire & Mol, 2 Rue Houssiniere,BP 92208, F-44322 Nantes 3, France.		Sauzeau, Vincent/D-3548-2015; Pacaud, Pierre/D-6392-2015; Cario-Toumaniantz, Chrystelle/D-3625-2015; Loirand, Gervaise/K-1834-2014	Loirand, Gervaise/0000-0002-2306-3931; Sauzeau, Vincent/0000-0002-6187-0312; Smolenski, Albert/0000-0001-9210-9406				Amano J, 1997, J THORAC CARDIOV SUR, V113, P19, DOI 10.1016/S0022-5223(97)70395-7; BAURIEDEL G, 1992, CIRCULATION, V85, P554, DOI 10.1161/01.CIR.85.2.554; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; FURCHGOTT RF, 1995, ANNU REV PHARMACOL, V35, P1; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; Guibert C, 1996, AM J PHYSIOL-LUNG C, V271, pL450, DOI 10.1152/ajplung.1996.271.3.L450; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNOWLES GC, 1992, J HISTOCHEM CYTOCHEM, V40, P1605, DOI 10.1177/40.10.1527379; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Loirand G, 1999, J PHYSIOL-LONDON, V516, P825, DOI 10.1111/j.1469-7793.1999.0825u.x; Loirand G, 1999, CIRCULATION, V100, P623; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oemar BS, 1998, CIRCULATION, V97, P2494, DOI 10.1161/01.CIR.97.25.2494; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; PACAUD P, 1991, J PHYSIOL-LONDON, V441, P477, DOI 10.1113/jphysiol.1991.sp018763; PACAUD P, 1995, AM J PHYSIOL-HEART C, V269, pH30, DOI 10.1152/ajpheart.1995.269.1.H30; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Somlyo AP, 1997, NATURE, V389, P908, DOI 10.1038/40002; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Stamler JS, 1999, CORONARY ARTERY DIS, V10, P273, DOI 10.1097/00019501-199907000-00001; Togashi H, 1998, AM J PHYSIOL-LUNG C, V274, pL803, DOI 10.1152/ajplung.1998.274.5.L803; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	42	476	496	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21722	21729		10.1074/jbc.M000753200	http://dx.doi.org/10.1074/jbc.M000753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10783386	hybrid			2022-12-27	WOS:000088230600100
J	Janssens, V; Van Hoof, C; De Baere, I; Merlevede, W; Goris, J				Janssens, V; Van Hoof, C; De Baere, I; Merlevede, W; Goris, J			The phosphotyrosyl phosphatase activator gene is a novel p53 target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; TATA-BINDING PROTEIN; FACTOR-KAPPA-B; DNA-BINDING; GLUCOCORTICOID RECEPTORS; P53-MEDIATED REPRESSION; CELL-LINES; TRANSCRIPTION; PROMOTER	The minimal promoter of the phosphotyrosyl phosphatase activator (PTPA) gene, encoding a regulator of protein phosphatase 2A contains two yin-yang 1 (YY1)-binding sites, positively regulating promoter activity. We now describe a role for p53 in the regulation of PTPA expression. Luciferase reporter assays in Saos-2 cells revealed that p53 could down-regulate PTPA promoter activity in a dose-dependent manner, whereas four different p53 mutants could not. The p53-responsive region mapped to the minimal promoter. Overexpression of YY1 reverses the repressive effect of p53, suggesting a functional antagonism between p53 and YY1. The latter does not involve competition for WI binding, but rather direct control of YY1 function. Inhibition of PTPA expression by endogenous p53 was demonstrated in UVB-irradiated HepG2 cells, both on the mRNA and protein level. Also basal PTPA levels are higher in p53-negative (Saos-2) versus p53-positive (HepG2, U2OS) cells, suggesting "latent" p53 can control PTPA expression as well. The higher PTPA levels in U2OS cells, programmed to overexpress constitutively a dominant-negative p53 mutant, corroborate this finding. Thus, PTPA expression is negatively regulated by p53 in normal conditions and in conditions where p53 is up-regulated, via an as yet unknown mechanism involving the negative control of YY1.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	KU Leuven	Goris, J (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Herestr 49, B-3000 Louvain, Belgium.	jozef.goris@med.kuleuven.ac.be	Janssens, Veerle/I-7059-2016	Janssens, Veerle/0000-0002-6772-8448				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bohr VA, 1999, BIOCHIMIE, V81, P155, DOI 10.1016/S0300-9084(99)80048-0; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Eckardt-Schupp F, 1999, BIOCHIMIE, V81, P161, DOI 10.1016/S0300-9084(99)80049-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARSHID M, 1992, J MED VIROL, V38, P235, DOI 10.1002/jmv.1890380402; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Iotsova V, 1996, ONCOGENE, V13, P2331; Janssens V, 1998, METH MOL B, V93, P103; Janssens V, 1999, BIOCHEM J, V344, P755, DOI 10.1042/0264-6021:3440755; JUVEN T, 1993, ONCOGENE, V8, P3411; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU X, 1995, MOL CELL BIOL, V15, P6474; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OConnor MJ, 1996, J VIROL, V70, P6529, DOI 10.1128/JVI.70.10.6529-6539.1996; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Prives C, 1999, J PATHOL, V187, P112; Ramotar D, 1998, J BIOL CHEM, V273, P21489, DOI 10.1074/jbc.273.34.21489; Ravi R, 1998, CANCER RES, V58, P4531; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Scolnick DM, 1997, CANCER RES, V57, P3693; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Van Hoof C, 1998, BIOCHEMISTRY-US, V37, P12899, DOI 10.1021/bi980496l; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; VANHOOF C, 1995, GENOMICS, V28, P261, DOI 10.1006/geno.1995.1140; VANHOOF C, 1994, ADV PROT PHOSPHATASE, V8, P301; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yonish-Rouach E, 1997, PATHOL BIOL, V45, P815	59	17	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20488	20495		10.1074/jbc.M909370199	http://dx.doi.org/10.1074/jbc.M909370199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787423	hybrid, Green Published			2022-12-27	WOS:000088084500038
J	Nietsch, HH; Roe, MW; Fiekers, JF; Moore, AL; Lidofsky, SD				Nietsch, HH; Roe, MW; Fiekers, JF; Moore, AL; Lidofsky, SD			Activation of potassium and chloride channels by tumor necrosis factor alpha - Role in liver cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INDUCED APOPTOSIS; DEPENDENT MECHANISM; RAT HEPATOCYTES; HELA-CELLS; K+; HEPATITIS; ENDOTOXIN; RECEPTOR; INVOLVEMENT	Despite abundant evidence for changes in mitochondrial membrane permeability in tumor necrosis factor (TNF)-mediated cell death, the role of plasma membrane ion channels in this process remains unclear, These studies examine the influence of TNF on ion channel opening and death in a model rat liver cell line (HTC), TNF (25 ng/ml) elicited a 2- and 5-fold increase in K+ and Cl- currents, respectively, in HTC cells. These increases occurred within 5-10 min after TNF exposure and were inhibited either by K+ or Cl- substitution or by K+ channel blockers (Ba2+, quinine, 0.1 mM each) or Cl- channel blockers (10 mu M 5-nitro-2-(3-phenylpropylamino)benzoic acid and 0.1 mm N-phenylanthranilic acid), respectively, TNF-mediated increases in K+ and Cl- currents were each inhibited by intracellular Ca2+ chelation (5 mM EGTA), ATP depletion (4 units/ml apyrase), and the protein kinase C (PKC) inhibitors chelerythrine (10 mu M) or PKC 19-36 peptide (1 mu M). In contrast, currents were not attenuated by the calmodulin kinase II 281-309 peptide (10 mu M), an inhibitor of calmodulin kinase II. In the presence of actinomycin D (1 mu M), each of the above ion channel blockers significantly delayed the progression to TNF-mediated cell death. Collectively, these data suggest that activation of K+ and Cl- channels is an early response to TNF signaling and that channel opening is Ca2+- and PRC-dependent. Our findings further suggest that K+ and Cl- channels participate in pathways leading to TNF-mediated cell death and thus represent potential therapeutic targets to attenuate liver injury from TNF.	Univ Vermont, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05401 USA; Univ Vermont, Dept Anat & Neurobiol, Burlington, VT 05401 USA	University of Vermont; University of Vermont; University of Vermont	Lidofsky, SD (corresponding author), Univ Vermont, Dept Med, Burgess 414 MFU, Burlington, VT 05401 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047849] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; Ando K, 1997, J IMMUNOL, V158, P5283; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Chan WH, 1999, J CELL PHYSIOL, V178, P397, DOI 10.1002/(SICI)1097-4652(199903)178:3<397::AID-JCP14>3.3.CO;2-U; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; Green RM, 1996, GASTROENTEROLOGY, V111, P193, DOI 10.1053/gast.1996.v111.pm8698199; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HAUSSINGER D, 1993, BIOCHEM J, V291, P355; Houzen H, 1997, J NEUROSCI RES, V50, P990, DOI 10.1002/(SICI)1097-4547(19971215)50:6<990::AID-JNR9>3.3.CO;2-8; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jones BA, 1997, AM J PHYSIOL-GASTR L, V272, pG1109, DOI 10.1152/ajpgi.1997.272.5.G1109; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Koller H, 1998, NEUROREPORT, V9, P1375; Kubitz R, 1997, GASTROENTEROLOGY, V113, P1438, DOI 10.1053/gast.1997.v113.pm9352844; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Lidofsky SD, 1997, AM J PHYSIOL-GASTR L, V273, pG849, DOI 10.1152/ajpgi.1997.273.4.G849; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; RAE JL, 1990, J MEMBRANE BIOL, V114, P29, DOI 10.1007/BF01869382; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SCHUMANN MA, 1993, J BIOL CHEM, V268, P2134; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Ventura JJ, 1999, HEPATOLOGY, V29, P849, DOI 10.1002/hep.510290339; Wang Y, 1996, J BIOL CHEM, V271, P18107, DOI 10.1074/jbc.271.30.18107; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; WHITING JF, 1995, HEPATOLOGY, V22, P1273, DOI 10.1016/0270-9139(95)90639-8; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; Wyatt TA, 1997, AM J PHYSIOL-LUNG C, V273, pL1007, DOI 10.1152/ajplung.1997.273.5.L1007; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; YIN DX, 1995, CANCER RES, V55, P4922; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114	43	101	106	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20556	20561		10.1074/jbc.M002535200	http://dx.doi.org/10.1074/jbc.M002535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10783394	hybrid			2022-12-27	WOS:000088084500049
J	Park, SK; Sedore, SA; Cronmiller, C; Hirsh, J				Park, SK; Sedore, SA; Cronmiller, C; Hirsh, J			Type II cAMP-dependent protein kinase-deficient Drosophila are viable but show developmental, circadian, and drug response phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; EGG CHAMBER FORMATION; CYCLIC-AMP SYSTEM; A MUTANT MICE; REGULATORY SUBUNIT; HIPPOCAMPAL-NEURONS; GENE-EXPRESSION; QUANTAL SIZE; OOGENESIS; CELLS	We identified a unique type II cAMP-dependent protein kinase regulatory subunit (PKA-RII) gene in Drosophila melanogaster and a severely hypomorphic if not null mutation, pka-RIIEP(2)2162. Extracts from pka-RIIEP(2)2162 flies selectively lack RII-specific autophosphorylation activity and show significantly reduced cAMP binding activity, attributable to the loss of functional PKA-RII, pka-RIIEP(2)2162 shows 2-fold increased basal PKA activity and similar to 40% of normal cAMP-inducible PKA activity. pka-RIIEP(2)2162 is fully viable but displays abnormalities of ovarian development and multiple behavioral phenotypes including arrhythmic circadian locomotor activity, decreased sensitivity to ethanol and cocaine, and a lack of sensitization to repeated cocaine exposures. These findings implicate type II PKA activity in these processes in Drosophila and imply a common role for PKA signaling in regulating responsiveness to cocaine and alcohol.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA	University of Virginia	Hirsh, J (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22903 USA.				NIDA NIH HHS [DA 27318] Funding Source: Medline; NIGMS NIH HHS [GM 27318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R24DA027318] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; BENDER LB, 1993, GENETICS, V133, P967; Brandon EP, 1998, J NEUROSCI, V18, P3639; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Cantrell AR, 1999, J NEUROSCI, V19, P5301; Cantrell AR, 1997, J NEUROSCI, V17, P7330; CARRE IA, 1992, J BIOL CHEM, V267, P2135; CARRE IA, 1993, J CELL SCI, V104, P1163; Chyb S, 1999, J NEUROSCI, V19, P8799, DOI 10.1523/JNEUROSCI.19-20-08799.1999; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davis GW, 1998, NEURON, V20, P305, DOI 10.1016/S0896-6273(00)80458-4; DAVIS RL, 1995, MOL CELL BIOCHEM, V149, P271, DOI 10.1007/BF01076588; ESKIN A, 1983, SCIENCE, V220, P82, DOI 10.1126/science.6298939; ESKIN A, 1982, P NATL ACAD SCI-BIOL, V79, P660, DOI 10.1073/pnas.79.2.660; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; FOSTER JL, 1984, J BIOL CHEM, V259, P3049; GOODE S, 1992, DEVELOPMENT, V116, P177; Goodwin SF, 1997, J NEUROSCI, V17, P8817; Inoue H, 1997, BIOCHEM BIOPH RES CO, V235, P223, DOI 10.1006/bbrc.1997.6764; Jackson SM, 1997, DEVELOPMENT, V124, P3663; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KALIVAS PW, 1995, NEUROBIOLOGY COCAINE, P81; KUMON A, 1972, J BIOL CHEM, V247, P3726; KUO JF, 1969, P NATL ACAD SCI USA, V64, P1349, DOI 10.1073/pnas.64.4.1349; LANE ME, 1995, MECH DEVELOP, V49, P191, DOI 10.1016/0925-4773(94)00317-G; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; Majercak J, 1997, MOL CELL BIOL, V17, P5915, DOI 10.1128/MCB.17.10.5915; Mayford M, 1999, TRENDS GENET, V15, P463, DOI 10.1016/S0168-9525(99)01846-6; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Muller U, 1997, J NEUROBIOL, V33, P33, DOI 10.1002/(SICI)1097-4695(199707)33:1<33::AID-NEU4>3.0.CO;2-E; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NIKAIDO SS, 1989, NEURON, V3, P609, DOI 10.1016/0896-6273(89)90271-7; OHara CM, 1996, J PHARMACOL EXP THER, V277, P186; Pandey SC, 1998, MOL NEUROBIOL, V17, P1, DOI 10.1007/BF02802021; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; Pierce RC, 1996, J PHARMACOL EXP THER, V278, P384; Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0; Pothos EN, 1998, J NEUROSCI, V18, P5575; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; WHITE FJ, 1995, NEUROBIOLOGY COCAINE, P91; XU T, 1992, DEVELOPMENT, V115, P913; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	56	101	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20588	20596		10.1074/jbc.M002460200	http://dx.doi.org/10.1074/jbc.M002460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781603	hybrid			2022-12-27	WOS:000088084500053
J	Boxrud, PD; Fay, WP; Bock, PE				Boxrud, PD; Fay, WP; Bock, PE			Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; BLOOD-COAGULATION PROTEINASES; AMINO-ACID-SEQUENCE; FLUORESCENCE PROBES; EXTINCTION COEFFICIENTS; PROTHROMBIN FRAGMENT-2; P-GUANIDINOBENZOATE; EQUIMOLAR COMPLEXES; SERINE PROTEINASES; TRYPSIN-INHIBITOR	Binding of streptokinase (SK) to plasminogen (Pg) conformationally activates the zymogen and converts both Pg and plasmin (Pm) into specific Pg activators. The interaction of SI( with Pm and its relationship to the mechanism of Pg activation were evaluated in equilibrium binding studies with active site-labeled fluorescent Pm derivatives and in kinetic studies of SK-induced changes in the catalytic specificity of Pm. SK bound to fluorescein-labeled and native Pm with dissociation constants of 11 +/- 2 pM and 12 +/- 4 pM, which represented a 1,000-10,000-fold higher affinity than determined for Pg, Stoichiometric binding of SK to native Pm was followed by generation of a two-fragment form of SK cleaved at Lys(59) (SK'), which exhibited an indistinguishable affinity for labeled Pm, while a truncated, SK55-414 species had a 120-360-fold reduced affinity. Binding of SK to native Pm was accompanied by a >50-fold enhancement in specificity for activation of Pg, which was paralleled by a surprising 2.6-10-fold loss of specificity of Pm for 8 of 11 tripeptide-pNA substrates, Further studies with Pm labeled at the active site with 2-anilinonaphthalene-6-sulfonic acid demonstrated directly that binding of SK to Pm resulted in expression of a new substrate binding exosite for Pg on the SK Pm complex. It is concluded that SK activates Pg in part by preferential binding to the active zymogen conformation. High affinity binding of SK to Pm enhances Pg substrate specificity principally through emergence of a substrate recognition exosite.	Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3321A, Nashville, TN 37232 USA; Ann Arbor Vet Affairs Hosp, Med Serv, Ann Arbor, MI 48109 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3321A, 221 Kirkland Hall, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL-02832, HL-10082, HL-56181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056181, F32HL010082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BODE W, 1992, PROTEIN SCI, V1, P426; BROCKWAY WJ, 1974, BIOCHEMISTRY-US, V13, P2063, DOI 10.1021/bi00707a010; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; COLLEN D, 1993, EUR J BIOCHEM, V216, P307, DOI 10.1111/j.1432-1033.1993.tb18147.x; COLLEN D, 1991, BLOOD, V78, P3114; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Esmon CT, 1998, NAT STRUCT BIOL, V5, P933, DOI 10.1038/2906; Fay WP, 1998, THROMB HAEMOSTASIS, V79, P985; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Haugland R., 1996, HDB FLUORESCENT PROB; HORREVOETS AJG, 1995, J BIOL CHEM, V270, P15770, DOI 10.1074/jbc.270.26.15770; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1995, BIOCHEM BIOPH RES CO, V217, P1245, DOI 10.1006/bbrc.1995.2902; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Pasternak A, 1998, BIOCHEMISTRY-US, V37, P16201, DOI 10.1021/bi980951d; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.0083l.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; Segel I.H., 1975, ENZYME KINETICS; SHI GY, 1994, BIOCHEM J, V304, P235, DOI 10.1042/bj3040235; SIEFRING GE, 1976, J BIOL CHEM, V251, P3913; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; TACHIAS K, 1995, J BIOL CHEM, V270, P18319, DOI 10.1074/jbc.270.31.18319; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1983, BIOCHIM BIOPHYS ACTA, V745, P20, DOI 10.1016/0167-4838(83)90165-6; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WOHL RC, 1978, J BIOL CHEM, V253, P1402; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110	55	58	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14579	14589		10.1074/jbc.275.19.14579	http://dx.doi.org/10.1074/jbc.275.19.14579			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799544	hybrid			2022-12-27	WOS:000087006900078
J	Oshima, Y; Joshi, BH; Puri, RK				Oshima, Y; Joshi, BH; Puri, RK			Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; RECEPTOR-GAMMA CHAIN; HUMAN GLIOMA-CELLS; HUMAN B-CELLS; PSEUDOMONAS EXOTOXIN; CHIMERIC PROTEIN; SIGNAL-TRANSDUCTION; IL-13 RECEPTOR; SARCOMA-CELLS; TUMOR-CELLS	We created a novel mutated form of human interleukin-13 (IL-13) in which a positively charged arginine (R) at position 112 was substituted to a negatively charged aspartic acid (D). This mutant, termed IL-13R112D, was expressed in Escherichia coli and purified to near homogeneity. IL-13R112D was found to be a potent IL-13 agonist with 5-10-fold improved binding affinity to IL-13 receptors compared with wild-type IL-13 (wtIL-13). The conclusion of IL-13 agonist activity was drawn on the basis of approximately 10-fold improved activity over wtIL-13 in several assays: (a) inhibition of CD14 expression in primary monocytes; (b) proliferation of TF-1 and B9 cell lines; and (c) activation of STAT6 in Epstein-Barr virus-immortalized B cells, primary monocytes, and THP-1 monocytic cell line. Furthermore, mutant IL-13R112D neutralized the cytotoxic activity of a chimeric fusion protein composed of wtIL-13 and a Pseudomonas exotoxin A (IL-13-PE38) approximately 10 times better than wtIL-13. Based on these results, it was concluded that IL-13R112D interacts with much stronger affinity than wtIL-13 on all cell types tested and that Arg-112 plays an important role in the interaction with its receptors (IL-13R). Thus, these results suggest that IL-13R112D may be a useful ligand for the study of IL-13 interaction with its receptors or, alternatively, in designing specific targeted agents for IL-13R-positive malignancies.	US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Lab Mol Tumor Biol, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Lab Mol Tumor Biol, 29 Lincoln Dr,NIH Bldg 29B,Rm 2NN10, Bethesda, MD 20892 USA.	Puri@cber.fda.gov	Oshima, Yasuo/AGN-3291-2022	Oshima, Yasuo/0000-0002-6236-6986				Alters SE, 1999, J IMMUNOTHER, V22, P229, DOI 10.1097/00002371-199905000-00005; BAMBOROUGH P, 1994, PROTEIN ENG, V7, P1077, DOI 10.1093/protein/7.9.1077; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COSENTINO G, 1995, J IMMUNOL, V155, P3145; Debinski W, 1998, INT J CANCER, V76, P547, DOI 10.1002/(SICI)1097-0215(19980518)76:4<547::AID-IJC17>3.0.CO;2-4; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Husain SR, 1997, CLIN CANCER RES, V3, P151; KITAMURA T, 1989, BLOOD, V73, P375; KREITMAN RJ, 1995, CYTOKINE, V7, P311, DOI 10.1006/cyto.1995.0039; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; Kuznetsov VA, 1999, BIOPHYS J, V77, P154, DOI 10.1016/S0006-3495(99)76879-7; LELAND P, 1995, ONCOL RES, V7, P227; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1998, INT J MOL MED, V1, P551; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Murata T, 1998, BLOOD, V91, P3884; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PURI RK, 1991, CANCER RES, V51, P3011; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; Shanafelt AB, 1998, P NATL ACAD SCI USA, V95, P9454, DOI 10.1073/pnas.95.16.9454; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	40	38	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14375	14380		10.1074/jbc.275.19.14375	http://dx.doi.org/10.1074/jbc.275.19.14375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799519	hybrid			2022-12-27	WOS:000087006900051
J	De Windt, LJ; Lim, HW; Haq, S; Force, T; Molkentin, JD				De Windt, LJ; Lim, HW; Haq, S; Force, T; Molkentin, JD			Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart - Cross-talk between cardiac hypertrophic signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; MUSCLE CELL HYPERTROPHY; GENE-EXPRESSION; CARDIOMYOCYTE HYPERTROPHY; T-LYMPHOCYTES; IN-VITRO; MICE; PHOSPHORYLATION; CYCLOSPORINE; ENDOTHELIN	Multiple intracellular signaling pathways have been shown to regulate the hypertrophic growth of cardiomyocytes, Both necessary and sufficient roles have been described for the mitogen activated protein kinase (MAPR) signaling pathway, specific protein kinase C (PKC) isoforms, and calcineurin, Here we investigate the interdependence between calcineurin, MAPK, and PKC isoforms in regulating cardiomyocyte hypertrophy using three separate approaches. Hearts from hypertrophic calcineurin transgenic mice were characterized for PKC and MAPK activation. Transgenic hearts demonstrated activation of c-Jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK1/2), but not p38 MAPK factors. Calcineurin transgenic hearts demonstrated increased activation of PKC alpha, beta(1), and theta, but not of epsilon, beta(2), or lambda. In a second approach, cultured cardiomyocytes were infected with a calcineurin adenovirus to induce hypertrophy and the effects of pharmacologic inhibitors or co-infection with a dominant negative adenovirus were examined. Calcineurin-mediated hypertrophy was prevented with PKC inhibitors, Ca2+ chelation, and attenuated with a dominant negative SEK-1 (MKK4) adenovirus, but inhibitors of ERK or p38 activation had no effect. In a third approach, we examined the activation of MAPK factors and PKC isoforms during the progression of load-induced hypertrophy in aortic banded rats with or without cyclosporine. We determined that inhibition of calcineurin activity with cyclosporine prevented PKC alpha, theta, and JNK activation, but did not affect PKC epsilon, beta, lambda, ERK1/2, or p38 activation. Collectively, these data indicate that calcineurin hypertrophic signaling is interconnected with PKC alpha, theta, and JNK in the heart, while PKC epsilon, beta, lambda, p38, and ERK1/2 are not involved in calcineurin-mediated hypertrophy.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr,Dept Med, Charlestown, MA 02129 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Massachusetts General Hospital	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	molkj0@chmcc.org	de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Molkentin, Jeffery/0000-0002-3558-6529; Force, Thomas/0000-0002-0450-8659	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050282, R55DK050282] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69562, HL-62927] Funding Source: Medline; NIDDK NIH HHS [DK50282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Asada A, 1998, J BIOL CHEM, V273, P28392, DOI 10.1074/jbc.273.43.28392; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; DeWindt LJ, 1997, J MOL CELL CARDIOL, V29, P2095, DOI 10.1006/jmcc.1997.0444; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Eble DM, 1998, J MOL CELL CARDIOL, V30, P55, DOI 10.1006/jmcc.1997.0571; Eble DM, 1998, AM J PHYSIOL-CELL PH, V274, pC1226, DOI 10.1152/ajpcell.1998.274.5.C1226; ECKEL J, 1991, J MOL CELL CARDIOL, V23, P617, DOI 10.1016/0022-2828(91)90053-O; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; Hines WA, 1999, AM J PHYSIOL-HEART C, V277, pH331, DOI 10.1152/ajpheart.1999.277.1.H331; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Li WG, 1998, BIOCHEM BIOPH RES CO, V246, P816, DOI 10.1006/bbrc.1998.8662; LIM HW, 2000, IN PRESS CIRCULATION; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MEBAZAA A, 1993, AM J PHYSIOL, V265, pH1841, DOI 10.1152/ajpheart.1993.265.5.H1841; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLER JG, 1998, SCIENCE, V282, P1007; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Paul K, 1997, CIRC RES, V81, P643; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Takeishi Y, 1999, CIRC RES, V85, P264, DOI 10.1161/01.RES.85.3.264; TAKEISHI Y, 1999, AM J PHYSIOL, V267, pH53; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Touyz RM, 1996, AM J PHYSIOL-HEART C, V270, pH857, DOI 10.1152/ajpheart.1996.270.3.H857; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; TUNG HYL, 1986, BIOCHEM BIOPH RES CO, V138, P783; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; XU YJ, 1991, CIRC RES, V69, P239, DOI 10.1161/01.RES.69.1.239; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	57	193	198	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13571	13579		10.1074/jbc.275.18.13571	http://dx.doi.org/10.1074/jbc.275.18.13571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788473	hybrid			2022-12-27	WOS:000086925300060
J	DeLeo, FR; Burritt, JB; Yu, LX; Jesaitis, AJ; Dinauer, MC; Nauseef, WM				DeLeo, FR; Burritt, JB; Yu, LX; Jesaitis, AJ; Dinauer, MC; Nauseef, WM			Processing and maturation of flavocytochrome b(558) include incorporation of heme as a prerequisite for heterodimer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL CYTOCHROME-B; RESPIRATORY-BURST OXIDASE; PHAGOCYTE NADPH OXIDASE; CELL RECEPTOR-ALPHA; SUPEROXIDE-GENERATING SYSTEM; ENDOPLASMIC-RETICULUM; CHROMOSOMAL LOCATION; CYTOSOLIC COMPONENT; MEMBRANE-PROTEIN	The phagocyte NADPH-dependent oxidase generates superoxide by reducing molecular oxygen through a transmembrane heterodimer known as flavocytochrome b(558) (flavocytochrome b), We investigated the biosynthesis of flavocytochrome b subunits gp91(phox) and p22(phox) to elucidate features of flavocytochrome b processing in myeloid cells. Although the gp91(phox) precursor, gp65, was processed to gp91(phox) within 4-8 h of chase, unassembled gp65 and p22(phox) monomers were degraded by the cytosolic proteasome, gp65 associated with p22(phox) post-translationally, within 1-4 h of chase, but prior to its modification in the Golgi complex. Moreover, p22(phox) coprecipitated with unglycosylated gp91(phox) primary translation product made in the presence of tunicamycin, suggesting that heterodimer formation does not require glycosylation, Blocking heme synthesis with succinyl acetone completely inhibited heterodimer formation, although biogenesis of gp65 and p22(phox) was unaffected, In succinyl acetone-treated cells, p22(phox) and gp65 were degraded completely by 8 h of chase, a process mediated by the cytosolic proteasome. Taken together, these data suggest that the formation of the gp65-p22(phox) heterodimer is relatively inefficient and that acquisition of heme by gp65 precedes and is required for its association with p22(phox) a process that requires neither the addition of N-linked oligosaccharides nor modification in the Golgi complex.	Vet Affairs Med Ctr, Inflammat Program, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59715 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Montana State University System; Montana State University Bozeman	Nauseef, WM (corresponding author), Univ Iowa, Dept Med, 200 Hawkins Dr, Iowa City, IA 52246 USA.	william-nauseef@uiowa.edu		Nauseef, William/0000-0003-4032-757X; Jesaitis, Algirdas/0000-0001-9001-5617; DeLeo, Frank/0000-0003-3150-2516	NHLBI NIH HHS [HL 53592] Funding Source: Medline; NIAID NIH HHS [AI07260-09, R01 AI 34879] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034879, T32AI007260] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BERENDES H, 1957, Minn Med, V40, P309; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CROSS AR, 1982, BIOCHEM J, V208, P759, DOI 10.1042/bj2080759; Dang PMC, 1999, BIOCHEMISTRY-US, V38, P5746, DOI 10.1021/bi982750f; DeLeo FR, 1998, J CLIN INVEST, V101, P2900, DOI 10.1172/JCI2649; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DOSKOW JR, 1992, IMMUNOLOGY, V77, P465; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; GEISLER C, 1989, J IMMUNOL, V143, P4069; GIRAUD A, 1992, J ENDOCRINOL, V132, P317, DOI 10.1677/joe.0.1320317; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; Heyworth PG, 1999, CURR INFLAMMAT RES, P165; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HORWITZ MS, 1969, VIROLOGY, V39, P682, DOI 10.1016/0042-6822(69)90006-3; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; KEARSE KP, 1995, IMMUNITY, V2, P391; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEARKOS CA, 1992, MOL BASIS OXIDATIVE, P45; PORTER CD, 1994, BLOOD, V84, P2767; Porter CD, 1996, BIOCHEM J, V315, P571, DOI 10.1042/bj3150571; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Rae J, 1998, AM J HUM GENET, V62, P1320, DOI 10.1086/301874; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Smith RM, 1996, J CLIN INVEST, V98, P977, DOI 10.1172/JCI118882; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; Tsuda M, 1998, HUM GENET, V103, P377, DOI 10.1007/s004390050836; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILKINSON MF, 1988, EMBO J, V7, P101, DOI 10.1002/j.1460-2075.1988.tb02788.x; WILKINSON MF, 1988, EUR J IMMUNOL, V18, P873, DOI 10.1002/eji.1830180607; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	70	131	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13986	13993		10.1074/jbc.275.18.13986	http://dx.doi.org/10.1074/jbc.275.18.13986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788525	hybrid			2022-12-27	WOS:000086925300113
J	Jianmongkol, S; Vuletich, JL; Bender, AT; Demady, DR; Osawa, Y				Jianmongkol, S; Vuletich, JL; Bender, AT; Demady, DR; Osawa, Y			Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATOR; PROSTHETIC HEME; IN-VIVO; ESCHERICHIA-COLI; L-ARGININE; INHIBITION; ISOFORMS; PROTEIN; DEGRADATION; MYOGLOBIN	It is established that aminoguanidine (AG) is a metabolism-based inactivator of the three major isoforms of nitric-oxide synthase. AG is thought to be of potential use in diseases, such as diabetes, where pathological overproduction of NO is implicated. We show here that during the inactivation of neuronal nitric-oxide synthase (nNOS) by AG that the prosthetic heme is altered, in part, to dissociable and protein-bound adducts, The protein-bound heme adduct is the result of cross-linking of the heme to residues in the oxygenase domain of nNOS. The dissociable heme product is unstable and reverts back to heme upon isolation. The alteration of the heme is concomitant with the loss in the ability to form the ferrous-CO complex of nNOS and accounts for at least two-thirds of the activity loss. Studies with [C-14]AG indicate that alteration of the protein, in part on the reductase domain of nNOS, also occurs but at low levels. Thus, heme alteration appears to be the major cause of nNOS inactivation. The elucidation of the mechanism of inactivation of nNOS will likely lead to a better understanding of the in vivo effects of NOS inhibitors such as AG.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.				NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1983, CHEM ENG NEWS, V61, P48, DOI 10.1021/cen-v061n038.p048; ATOR MA, 1987, J BIOL CHEM, V262, P14954; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; Babu BR, 1998, J BIOL CHEM, V273, P8882, DOI 10.1074/jbc.273.15.8882; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; BORNHEIM LM, 1987, MOL PHARMACOL, V32, P299; Bryk R, 1999, ARCH BIOCHEM BIOPHYS, V369, P243, DOI 10.1006/abbi.1999.1340; Bryk R, 1998, BIOCHEMISTRY-US, V37, P4844, DOI 10.1021/bi972065t; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; CORREIA MA, 1992, ARCH BIOCHEM BIOPHYS, V297, P228, DOI 10.1016/0003-9861(92)90666-K; Fast W, 1999, J AM CHEM SOC, V121, P903, DOI 10.1021/ja982318l; Feelisch M., 1996, METHODS NITRIC OXIDE; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Grant SK, 1998, BIOCHEMISTRY-US, V37, P4174, DOI 10.1021/bi972481d; Griffith OW, 1996, METHOD ENZYMOL, V268, P375; Holstad M, 1997, GEN PHARMACOL-VASC S, V29, P697, DOI 10.1016/S0306-3623(97)00012-8; KERWIN JF, 1994, MED RES REV, V14, P23, DOI 10.1002/med.2610140103; KINDT JT, 1992, J BIOL CHEM, V267, P8739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laszlo F, 1997, EUR J PHARMACOL, V334, P99, DOI 10.1016/S0014-2999(97)01163-1; LASZLO F, 1995, EUR J PHARMACOL, V272, P169, DOI 10.1016/0014-2999(94)00637-M; LUNETTA JM, 1989, MOL PHARMACOL, V35, P10; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nakatsuka M, 1998, DRUG METAB DISPOS, V26, P497; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Scott JA, 1999, J APPL PHYSIOL, V86, P1739, DOI 10.1152/jappl.1999.86.5.1739; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wolff DJ, 1996, ARCH BIOCHEM BIOPHYS, V325, P227, DOI 10.1006/abbi.1996.0028; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Wolff DJ, 1998, EUR J PHARMACOL, V350, P325, DOI 10.1016/S0014-2999(98)00267-2; YAO KQ, 1993, J BIOL CHEM, V268, P59	47	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13370	13376		10.1074/jbc.275.18.13370	http://dx.doi.org/10.1074/jbc.275.18.13370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788446	hybrid			2022-12-27	WOS:000086925300032
J	Manna, SK; Sah, NK; Aggarwal, BB				Manna, SK; Sah, NK; Aggarwal, BB			Protein tyrosine kinase p56(lck) is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-kappa B, AP-1, JNK, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; FACTOR-ALPHA; TNF-ALPHA; SIGNAL-TRANSDUCTION; SPHINGOMYELIN TURNOVER; PATHWAY; LCK; TRANSCRIPTION; INVOLVEMENT; DEGRADATION	Ceramide has been implicated as an intermediate in the signal transduction of several cytokines including tumor necrosis factor (TNF), Both ceramide and TNF activate a wide variety of cellular responses, including NF-kappa B, AP-1, JNK, and apoptosis, Whether ceramide transduces these signals through the same mechanism as TNF is not known. In the present study we investigated the role of the T cell-specific tyrosine kinase p56(lck) in ceramide- and TNF-mediated cellular responses by comparing the responses of Jurkat T cells with JCaM1 cells, isogeneic Lck-deficient T cells. Treatment with ceramide activated NF-kappa B, degraded I kappa B alpha, and induced NF-kappa B-dependent reporter gene expression in a time-dependent manner in jurkat cells but not in JCaM1 cells, suggesting the critical role of p56(lck) kinase, These effects were specific to ceramide, as activation of NF-kappa B by phorbol 12-myristate 13-acetate, lipopolysaccharide, H2O2, and TNF was minimally affected. p56(lck) was also found to be required for ceramide-induced but not TNF-induced AP-1 activation. Similarly, ceramide activated the protein kinases JNK and mitogen-activated protein kinase kinase in Jurkat cells but not in JCaM1 cells. Ceramide also induced cytotoxicity and activated caspases and reactive oxygen intermediates in Jurkat cells but not in JCaM1 cells. Ceramide activated p56(lck) activity in Jurkat cells. Moreover, the reconstitution of JCaM1 cells with p56(lck) tyrosine kinase reversed the ceramide-induced NF-kappa B activation and cytotoxicity, Overall our results demonstrate that p56(lck) plays a critical role in the activation of NF-kappa B, AP-1, JNK, and apoptosis by ceramide but has minimal or no role in activation of these responses by TNF.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@utmdacc.mda.uth.tmc.edu	Aggarwal, Bharat B/G-3388-2013					Al-Ramadi BK, 1998, P NATL ACAD SCI USA, V95, P12498, DOI 10.1073/pnas.95.21.12498; Allan-Yorke J, 1998, J VIROL, V72, P2316, DOI 10.1128/JVI.72.3.2316-2322.1998; Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; BETTS JC, 1994, J BIOL CHEM, V269, P8455; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Gerritsen ME, 1998, AM J PATHOL, V152, P505; Guo YL, 1999, AM J PHYSIOL-RENAL, V276, pF390, DOI 10.1152/ajprenal.1999.276.3.F390; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Higuchi M, 1996, J IMMUNOL, V157, P297; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JOHNS LD, 1994, J IMMUNOL, V152, P5877; Karasavvas N, 1999, CELL DEATH DIFFER, V6, P115, DOI 10.1038/sj.cdd.4400482; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM MY, 1991, J BIOL CHEM, V266, P484; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mallampalli RK, 1999, AM J PHYSIOL-LUNG C, V276, pL481, DOI 10.1152/ajplung.1999.276.3.L481; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Manna SK, 1999, J IMMUNOL, V162, P2095; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; Rouer E, 1999, ONCOGENE, V18, P4262, DOI 10.1038/sj.onc.1202720; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Weil R, 1996, CURR TOP MICROBIOL, V205, P63; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733	50	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13297	13306		10.1074/jbc.275.18.13297	http://dx.doi.org/10.1074/jbc.275.18.13297			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788436	hybrid			2022-12-27	WOS:000086925300022
J	Stradal, TB; Troxler, H; Heizmann, CW; Gimona, M				Stradal, TB; Troxler, H; Heizmann, CW; Gimona, M			Mapping the zinc ligands of S100A2 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; CALCIUM-BINDING PROTEINS; CA2+-DEPENDENT INTERACTION; CA2+-BINDING PROTEINS; MUTANT PROTEINS; BREAST-CANCER; KINASE-C; CALCYCLIN; FAMILY; CA2+	S100 family proteins are characterized by short individual N and C termini and a conserved central part, harboring two Ca2+-binding EF-hands, one of them highly conserved among EF-hand family proteins and the other characteristic for S100 proteins. In addition to Ca2+ several members of the S100 protein family, including S100A2, bind Zn2+. Two regions in the amino acid sequences of S100 proteins, namely the helices of the N-terminal EF-hand motif and the very C-terminal loop are believed to be involved in Zn2+-binding due to the presence of histidine and/or cysteine residues, Human S100A2 contains four cysteine residues, each of them located at positions that may be important for Zn2+ binding. We have now constructed and purified 10 cysteine-deficient mutants of human S100A2 by site-directed mutagenesis and investigated the contribution of the individual cysteine residues to Zn2+ binding, Here we show that Cys(1(3)) (the number in parentheses indicating the position in the sequence of S100A2) is the crucial determinant for Zn2+ binding in association with conformational changes as determined by internal tyrosine fluorescence. Solid phase Zn2+ binding assays also revealed that the C-terminal residues Cys(3(S7)) and Cys(4(94)) mediated a second type of Zn2+ binding, not associated with detectable conformational changes in the molecule. Cys(2(22)), by contrast, which is located within the first EF hand motif affected neither Ca2+ nor Zn2+ binding, and a Cys "null" mutant was entirely incapable of ligating Zn2+, These results provide new information about the mechanism and the site(s) of zinc binding in S100A2.	Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	Austrian Academy of Sciences; University of Zurich	Gimona, M (corresponding author), Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, Billrothstr 11, A-5020 Salzburg, Austria.			Stradal, Theresia/0000-0002-0352-9474				Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BECKER T, 1992, EUR J BIOCHEM, V207, P541, DOI 10.1111/j.1432-1033.1992.tb17080.x; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; FOHR UG, 1995, J BIOL CHEM, V270, P21056, DOI 10.1074/jbc.270.36.21056; Franz C, 1998, J BIOL CHEM, V273, P18826, DOI 10.1074/jbc.273.30.18826; Fritz G, 1998, BBA-MOL CELL RES, V1448, P264, DOI 10.1016/S0167-4889(98)00138-4; Garbuglia M, 1998, CELL CALCIUM, V24, P177, DOI 10.1016/S0143-4160(98)90127-0; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kordowska J, 1998, EUR J BIOCHEM, V253, P57, DOI 10.1046/j.1432-1327.1998.2530057.x; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Lesniak W, 1996, BIOCHEM BIOPH RES CO, V220, P269, DOI 10.1006/bbrc.1996.0394; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Mandinova A, 1998, J CELL SCI, V111, P2043; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Raftery MJ, 1998, J AM SOC MASS SPECTR, V9, P533, DOI 10.1016/S1044-0305(98)00020-8; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; THIEL C, 1992, J CELL SCI, V103, P733; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; Troxler H, 1999, ANAL BIOCHEM, V268, P64, DOI 10.1006/abio.1998.3015; Vallee B L, 1995, EXS, V73, P259; VOLTZ A, 1993, GENOMICS, V18, P92; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330	42	27	27	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13219	13227		10.1074/jbc.275.18.13219	http://dx.doi.org/10.1074/jbc.275.18.13219			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788426	hybrid			2022-12-27	WOS:000086925300012
J	Taniai, K; Tomita, S				Taniai, K; Tomita, S			A novel lipopolysaccharide response element in the Bombyx mori cecropin B promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALOPHORA-CECROPIA; GENE-EXPRESSION; ANTIBACTERIAL PROTEINS; SARCOPHAGA-PEREGRINA; DROSOPHILA IMMUNITY; INSECT IMMUNITY; DIPTERICIN PROMOTER; INNATE IMMUNITY; SILKWORM; CLONING	Cecropin B is one of the major antibacterial peptides in the silkworm, Bombyx mori. Transcription of the cecropin B gene (CecB) occurs rapidly after bacterial invasion. Using 235 base pairs (bp) of the CecB promoter region, a kappa B-related protein and two additional DNA-binding complexes (designated F2BPI and F4BP) were identified in nuclear extracts from immunized larval fat body by the electrophoretic mobility shift assay (EMSA) (1). Further EMSA analyses indicated that the F2BPI-binding site was CATTA, and that F2BPI translocated from the cytoplasm to the nucleus after infection. In a recently established B. mori cell line, NISES-BoMo-DZ, 235 bp of CecB promoter linked to a reporter luciferase was activated 6-fold by stimulation with lipopolysaccharide (LPS), which is a major trigger of CecB expression in larvae. Truncation of the F2BPI-binding site from the promoter reduced the activation 2-fold. Deletion of either of two kappa B motifs also reduced promoter activation 2-fold. Elimination of both the F2BPI-binding site and the kappa B motifs resulted in the complete loss of LPS inducibility. These results indicate that the F2BPI-binding site is an LPS-responsive cis-element that is necessary for full activation of CecB.	Natl Inst Sericultural & Entomol Sci, Dept Insect Physiol & Behav, Lab Biol Def, Tsukuba, Ibaraki 3058634, Japan; Natl Inst Sericultural & Entomol Sci, Dept Insect Genet & Breeding, Tsukuba, Ibaraki 3058634, Japan	National Institute of Agrobiological Sciences - Japan; National Institute of Agrobiological Sciences - Japan	Taniai, K (corresponding author), Natl Inst Sericultural & Entomol Sci, Dept Insect Physiol & Behav, Lab Biol Def, Tsukuba, Ibaraki 3058634, Japan.	taniai@nises.affrc.go.jp		Tomita, Shuichiro/0000-0002-0669-7721				BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Charlet M, 1996, EUR J BIOCHEM, V241, P699, DOI 10.1111/j.1432-1033.1996.00699.x; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; ENGSTROM Y, 1997, MOL MECH IMMUNE RESP, P213; Furukawa S, 1997, BIOCHEM BIOPH RES CO, V238, P769, DOI 10.1006/bbrc.1997.7386; Furukawa S, 1999, BIOCHEM J, V340, P265, DOI 10.1042/0264-6021:3400265; GEORGEL P, 1993, BIOCHEM BIOPH RES CO, V197, P508, DOI 10.1006/bbrc.1993.2508; Gross I, 1996, NUCLEIC ACIDS RES, V24, P1238, DOI 10.1093/nar/24.7.1238; GUDMUNDSSON GH, 1991, J BIOL CHEM, V266, P11510; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Imanishi S, 1999, APPL ENTOMOL ZOOL, V34, P259, DOI 10.1303/aez.34.259; KANAI A, 1989, FEBS LETT, V258, P199, DOI 10.1016/0014-5793(89)81652-7; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KOBAYASHI A, 1989, BIOCHIM BIOPHYS ACTA, V1009, P244, DOI 10.1016/0167-4781(89)90109-7; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KOTANI E, 1995, THESIS KYOTO I TECHN; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LINDSTROMDINNETZ I, 1995, EUR J BIOCHEM, V230, P920, DOI 10.1111/j.1432-1033.1995.tb20637.x; Mange A, 1997, J MOL BIOL, V265, P266, DOI 10.1006/jmbi.1996.0734; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; Moore DD, 1995, GLOB MOB SURV; NATORI S, 1994, CIBA F SYMP, V186, P123; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Petersen UM, 1999, EMBO J, V18, P4013, DOI 10.1093/emboj/18.14.4013; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Rao P, 1997, J IMMUNOL, V159, P3531; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; SUN SC, 1991, J BIOL CHEM, V266, P6644; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; Taniai K, 1996, BIOCHEM BIOPH RES CO, V226, P783, DOI 10.1006/bbrc.1996.1429; TANIAI K, 1995, GENE, V163, P215, DOI 10.1016/0378-1119(95)00408-X; Taniai K, 1996, BIOCHEM BIOPH RES CO, V220, P594, DOI 10.1006/bbrc.1996.0448; TESHIMA T, 1987, TETRAHEDRON, V43, P4513, DOI 10.1016/S0040-4020(01)86892-7; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; XANTHOPOULOS KG, 1988, EUR J BIOCHEM, V172, P371, DOI 10.1111/j.1432-1033.1988.tb13896.x; Yamakawa M, 1999, DEV COMP IMMUNOL, V23, P281, DOI 10.1016/S0145-305X(99)00011-7; Yamano Y, 1998, BIOSCI BIOTECH BIOCH, V62, P237, DOI 10.1271/bbb.62.237	41	18	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13179	13182		10.1074/jbc.275.18.13179	http://dx.doi.org/10.1074/jbc.275.18.13179			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788421	hybrid			2022-12-27	WOS:000086925300005
J	Vitale, N; Patton, WA; Moss, J; Vaughan, M; Lefkowitz, RJ; Premont, RT				Vitale, N; Patton, WA; Moss, J; Vaughan, M; Lefkowitz, RJ; Premont, RT			GIT proteins, a novel family of phosphatidylinositol 3,4,5-trisphosphate-stimulated GTPase-activating proteins for ARF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; NUCLEOTIDE-EXCHANGE PROTEIN; KDEL RECEPTOR; GOLGI-COMPLEX; HYDROLYSIS; DOMAIN; IDENTIFICATION; PURIFICATION; PATHWAY; BINDS	ADP-ribosylation factor (ARF) proteins are key players in numerous vesicular trafficking events ranging from the formation and fusion of vesicles in the Golgi apparatus to exocytosis and endocytosis. To complete their GTPase cycle, ARFs require a guanine nucleotide-exchange protein to catalyze replacement of GDP by GTP and a GTPase-activating protein (GAP) to accelerate hydrolysis of bound GTP. Recently numerous guanine nucleotide-exchange proteins and GAP proteins have been identified and partially characterized. Every ARF GAP protein identified to date contains a characteristic zinc finger motif. GIT1 and GIT2, two members of a new family of G protein-coupled receptor kinase-interacting proteins, also contain a putative zinc finger motif and display ARF GAP activity. Truncation of the amino-terminal region containing the zinc finger motif prevented GAP activity of GIT1, One zinc molecule was found associated per molecule of purified recombinant ARF-GAP1, GIT1, and GIT2 proteins, suggesting the zinc finger motifs of ARF GAPs are functional and should play an important role in their GAP activity. Unlike ARF-GAP1, GIT1 and GIT2 stimulate hydrolysis of GTP bound to ARF6. Accordingly we found that the phospholipid dependence of the GAP activity of ARF-GAP1 and GIT proteins was quite different, as the GIT proteins are stimulated by phosphatidylinositol 3,4,5-trisphosphate whereas ARF-GAP1 is stimulated by phosphatidylinositol 4,5-bisphosphate and diacylglycerol, These results suggest that although the mechanism of GTP hydrolysis is probably very similar in these two families of ARF GAPs, GIT proteins might specifically regulate the activity of ARF6 in cells in coordination with phosphatidylinositol 3-kinase signaling pathways.	Duke Univ, Med Ctr, Dept Med Gastroenterol, Howard Hughes Med Inst, Durham, NC 27710 USA; Ctr Neurochim, INSERM, U338, F-67084 Strasbourg, France; Duke Univ, Med Ctr, Dept Med Cardiol, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Duke University; Howard Hughes Medical Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Premont, RT (corresponding author), Duke Univ, Med Ctr, Dept Med Gastroenterol, Howard Hughes Med Inst, Box 3083, Durham, NC 27710 USA.		Vitale, Nicolas/G-5967-2014; Lefkowitz, Robert/AAW-2649-2021	Vitale, Nicolas/0000-0002-4752-4907; Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002541, Z01HL000638, Z01HL000656, Z01HL000627, R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; King FJ, 1999, MOL CELL BIOL, V19, P2330; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Moss J, 1999, MOL CELL BIOCHEM, V193, P153, DOI 10.1023/A:1006993000870; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; PREMONT RT, 2000, IN PRESS J BIOL CHEM; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359; Vitale N, 1998, J BIOL CHEM, V273, P2553, DOI 10.1074/jbc.273.5.2553	34	126	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13901	13906		10.1074/jbc.275.18.13901	http://dx.doi.org/10.1074/jbc.275.18.13901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788515	hybrid			2022-12-27	WOS:000086925300102
J	Yokoyama, K; Ohkuma, S; Taguchi, H; Yasunaga, T; Wakabayashi, T; Yoshida, M				Yokoyama, K; Ohkuma, S; Taguchi, H; Yasunaga, T; Wakabayashi, T; Yoshida, M			V-type H+-ATPase/synthase from a thermophilic eubacterium, Thermus thermophilus - Subunit structure and operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND ATPASE; VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; SULFOLOBUS-ACIDOCALDARIUS; MOLECULAR MACHINE; GENE ENCODES; VACUOLAR; PURIFICATION; SYNTHASE; BACTERIORHODOPSIN	V-type ATPase (VoV1) capable of ATP-driven H+ pumping and of H+ gradient driven ATP synthesis was isolated from a thermophilic eubacterium, Thermus thermophilus. When the enzyme was analyzed by gel electrophoresis in the presence of sodium dodecyl sulfate, it showed eight polypeptide bands of which four were subunits of V-1. We also isolated the VoV1 operon, containing nine genes in the order of atpG-I-L-E-X-F-A-B-D), which encoded proteins with molecular sizes of 13, 43, 10, 20, 35, 11, 64, 53, and 25 kDa, respectively. The last four genes were identified as those for V-1 subunits; atpA, B, D, and F encoded the A, B, gamma, and delta subunits, respectively. The first five genes, atpG-atpX, were identified as genes for the V-o subunits. The product of atpL, the proteolipid subunit, lacked a 19-amino acid presequence and, unlike V-type ATPases, contained two membrane-spanning domains rather than four. The hydrophobic 43-kDa product of atpI is the smallest member so far found of the eukaryotic 100-kDa subunit family. Its electrophoretic band overlapped with the band of the A subunit. Therefore, all the gene products were found in our purified VoV1. We isolated the A(3)B(3) subcomplex reconstituted from the isolated subunits and the A(3)B(3)gamma subcomplex from subunit-expressing Escherichia coli. Electron microscopic observation of these subcomplexes revealed that the gamma subunit of V-1 filled the central cavity of A,B, and might be central subunit, similar to the gamma subunit of F-1-ATPase.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cellular Biol, Biochem Lab, Kanazawa, Ishikawa 9200934, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan; Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 113, Japan	Kanazawa University; Tokyo Institute of Technology; University of Tokyo	Yokoyama, K (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cellular Biol, Biochem Lab, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.		Yasunaga, Takuo/C-8316-2009	Yasunaga, Takuo/0000-0002-2494-9603				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAI K, 1993, J BIOL CHEM, V268, P5649; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Crider BP, 1997, J BIOL CHEM, V272, P10721; DENDA K, 1989, J BIOL CHEM, V264, P7119; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUJIYAMA Y, 1990, FEBS LETT, V271, P111, DOI 10.1016/0014-5793(90)80384-U; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; KAGAWA Y, 1986, METHOD ENZYMOL, V126, P1; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; LAI SP, 1988, J BIOL CHEM, V263, P16731; LUBBEN M, 1989, J BACTERIOL, V171, P6106; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MURZINA NV, 1988, NUCLEIC ACIDS RES, V16, P8172, DOI 10.1093/nar/16.16.8172; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; Pitard B, 1996, EUR J BIOCHEM, V235, P769, DOI 10.1111/j.1432-1033.1996.00769.x; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; Sambrook J., 2002, MOL CLONING LAB MANU; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TAKASE K, 1994, J BIOL CHEM, V269, P11037; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Yasunaga T, 1996, J STRUCT BIOL, V116, P155, DOI 10.1006/jsbi.1996.0025; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	42	46	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13955	13961		10.1074/jbc.275.18.13955	http://dx.doi.org/10.1074/jbc.275.18.13955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788522	hybrid			2022-12-27	WOS:000086925300109
J	Boehmelt, G; Fialka, I; Brothers, G; McGinley, MD; Patterson, SD; Mo, R; Hui, CC; Chung, S; Huber, LA; Mak, TW; Iscove, NN				Boehmelt, G; Fialka, I; Brothers, G; McGinley, MD; Patterson, SD; Mo, R; Hui, CC; Chung, S; Huber, LA; Mak, TW; Iscove, NN			Cloning and characterization of the murine glucosamine-6-phosphate acetyltransferase EMeg32 - Differential expression and intracellular membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; GCN5-RELATED N-ACETYLTRANSFERASE; MITOTIC GOLGI FRAGMENTS; CELL-CYCLE; GLYCOSYL-PHOSPHATIDYLINOSITOL; GENE-EXPRESSION; ACETYLGLUCOSAMINE SYNTHESIS; SUBCELLULAR FRACTIONATION; DICTYOSTELIUM-DISCOIDEUM; ENDOPLASMIC-RETICULUM	N-Linked glycosylation is a post-translational modification occurring in many eukaryotic secreted and surface-bound proteins and has impact on diverse physiological and pathological processes. Similarly important is the generation of glycosylphosphatidylinositol linkers, which anchor membrane proteins to the cell. Both protein modifications depend on the central nucleotide sugar UDP-N-acetylglucosamine (UDP-GlcNAc). The enzymatic reactions leading to generation of nucleotide sugars are established, yet most of the respective genes still await cloning. We describe the characterization of such a gene, EMeg32, which we identified based on its differential expression in murine hematopoietic precursor cells. We further demonstrate regulated expression during embryogenesis. EMeg32 codes for a 184-amino acid protein exhibiting glucosamine-6-phosphate acetyltransferase activity. It thereby holds a key position in the pathway toward de novo UDP-GlcNAc synthesis. Surprisingly, the protein associates with the cytoplasmic side of various intracellular membranes, accumulates prior to mitosis, and copurifies with the cdc48 homolog p97/valosin-containing protein.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Inst Mol Pathol, A-1030 Vienna, Austria; Amgen Res Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Thousand Oaks, CA 91320 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Amgen; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Boehmelt, G (corresponding author), Boehringer Ingelheim Pharma KG Oncol Res, Birkendorfer Str 65, D-88397 Biberach, Germany.	guido.boehmelt@bc.boehringer-ingelheim.com	Huber, Lukas Alfons/AAM-3499-2021; Patterson, Scott/A-7404-2009	Huber, Lukas Alfons/0000-0003-1116-2120				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOEHMELT G, 1994, CELL GROWTH DIFFER, V5, P221; Boehmelt G, 1998, GENE, V207, P267, DOI 10.1016/S0378-1119(97)00648-3; BRADY G, 1995, CURR BIOL, V5, P909, DOI 10.1016/S0960-9822(95)00181-3; Brodbeck U, 1998, BIOL CHEM, V379, P1041; Cabrera-Poch N, 1998, BBA-MOL CELL RES, V1404, P139, DOI 10.1016/S0167-4889(98)00051-2; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Ding Q, 1998, DEVELOPMENT, V125, P2533; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Fialka I, 1997, ELECTROPHORESIS, V18, P2582, DOI 10.1002/elps.1150181414; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAWLEY RG, 1994, GENE THER, V1, P136; Hinderlich S, 1998, EUR J BIOCHEM, V252, P133, DOI 10.1046/j.1432-1327.1998.2520133.x; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Jones DR, 1998, INT J BIOCHEM CELL B, V30, P313, DOI 10.1016/S1357-2725(97)00144-1; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Liemann S, 1997, J MOL BIOL, V270, P79, DOI 10.1006/jmbi.1997.1091; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin RY, 1996, GENES CELLS, V1, P923, DOI 10.1046/j.1365-2443.1996.d01-215.x; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; MURRAY RK, 1990, HARPERS BIOCH, P591; NOVICK P, 1989, GENETICS, V121, P659; OIKAWA S, 1986, INT J BIOCHEM, V18, P929, DOI 10.1016/0020-711X(86)90074-1; OIKAWA S, 1985, INT J BIOCHEM, V17, P73, DOI 10.1016/0020-711X(85)90088-6; Pasquali C, 1999, J CHROMATOGR B, V722, P89, DOI 10.1016/S0378-4347(98)00314-4; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; PATTABIRAMAN TN, 1962, BIOCHIM BIOPHYS ACTA, V59, P681, DOI 10.1016/0006-3002(62)90648-0; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; POROWSKI TS, 1990, BIOCHEM MED METAB B, V44, P1, DOI 10.1016/0885-4505(90)90038-3; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; SCHACHTER H, 1978, GLYCOCONJUGATES, V2, P87; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TREVISAN M, 1995, J EXP MED, V181, P93, DOI 10.1084/jem.181.1.93; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Vessal M, 1998, COMP BIOCHEM PHYS B, V121, P379, DOI 10.1016/S0305-0491(98)10119-0; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	62	40	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12821	12832		10.1074/jbc.275.17.12821	http://dx.doi.org/10.1074/jbc.275.17.12821			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777580	hybrid			2022-12-27	WOS:000086762300064
J	Corey, MJ; Kinders, RJ; Poduje, CM; Bruce, CL; Rowley, H; Brown, LG; Hass, GM; Vessella, RL				Corey, MJ; Kinders, RJ; Poduje, CM; Bruce, CL; Rowley, H; Brown, LG; Hass, GM; Vessella, RL			Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; PROSTATE-SPECIFIC ANTIGEN; DECAY-ACCELERATING FACTOR; POLYANION BINDING-SITE; FACTOR-I; ALTERNATIVE PATHWAY; REGULATORY PROTEINS; C3 CONVERTASE; SIALIC-ACID; ACTIVATION	We have recently reported that complement factor H, a negative regulator of complement-mediated cytotoxicity, is produced and secreted by most bladder cancers. This observation was exploited in the development of the BTA stat(TM) and BTA TRAK(TM) diagnostic assays, both of which make use of two factor H-specific monoclonal antibodies in sandwich format. Here we show that both antibodies exert interesting effects on the biochemistry of complement activation in in vitro systems. Antibody X13.2 competes with C3b for association with factor H and strongly inhibits factor H/factor I-mediated cleavage of C3b, thereby evidently inactivating a negative regulator of complement; yet, the antibody strongly inhibits complement-mediated lysis as well. Conversely, antibody X52.1, which does not compete with C3b and has no effect on solution-phase cleavage of C3b, is capable of enhancing complement-mediated lysis of various cell types, including cancer cells, by over 10-fold. Our observations indicate that it is possible to deconvolute the biochemical roles of factor H in complement by means of appropriate inhibitors, a finding with potentially valuable implications for both basic research and cancer therapy.	Bion Diagnost Sci, Redmond, WA 98052 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, MJ (corresponding author), Bion Diagnost Sci, 12277 134th Ct NE, Redmond, WA 98052 USA.			Corey, Michael/0000-0002-1675-6086				ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; Austyn JM, 1993, PRINCIPLES CELLULAR; Bjorge L, 1997, INT J CANCER, V70, P14, DOI 10.1002/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9; BROWN EJ, 1983, J IMMUNOL, V131, P409; Corey E, 1997, INT J CANCER, V71, P1019, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1019::AID-IJC18>3.0.CO;2-8; Corey M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P263; Corey MJ, 1997, J IMMUNOL METHODS, V207, P43, DOI 10.1016/S0022-1759(97)00098-7; Ellis WJ, 1997, UROLOGY, V50, P882, DOI 10.1016/S0090-4295(97)00508-6; FEARON DT, 1977, J EXP MED, V146, P22, DOI 10.1084/jem.146.1.22; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FISHELSON Z, 1991, MOL IMMUNOL, V28, P545, DOI 10.1016/0161-5890(91)90169-K; FISHELSON Z, 1984, J IMMUNOL, V132, P1430; Gersuk GM, 1997, BIOCHEM BIOPH RES CO, V232, P578, DOI 10.1006/bbrc.1997.6331; Jarvis GA, 1997, INT J CANCER, V71, P1049, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7; KAWASAKI GH, 1991, Patent No. 5658754; Kinders R, 1998, CLIN CANCER RES, V4, P2511; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; MULLEREBERHARD HJ, 1972, J EXP MED, V135, P1003, DOI 10.1084/jem.135.4.1003; Niehans GA, 1996, AM J PATHOL, V149, P129; OLLERT MW, 1995, J IMMUNOL, V155, P4955; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PENN I, 1982, Current Problems in Cancer, V6, P1, DOI 10.1016/S0147-0272(82)80002-0; PENN I, 1989, CRC CRIT REV ONCOL, P27; PLATTSMI.TA, 1974, J IMMUNOL, V113, P348; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; Sarosdy MF, 1997, UROLOGY, V50, P349, DOI 10.1016/S0090-4295(97)00292-6; SCHREIBER RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P384, DOI 10.1016/0090-1229(80)90050-1; SEYA T, 1990, J IMMUNOL, V145, P238; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1993, METHOD ENZYMOL, V223, P13; Simpson KL, 1997, AM J PATHOL, V151, P1455; VANADON P, 1996, J MOL BIOL, V261, P11; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P147; VYSE TJ, 1994, GENOMICS, V24, P90, DOI 10.1006/geno.1994.1585; YAMAKAWA M, 1994, CANCER, V73, P2808, DOI 10.1002/1097-0142(19940601)73:11<2808::AID-CNCR2820731125>3.0.CO;2-P; Yamanaka HI, 1996, J IMMUNOL, V157, P1156	39	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12917	12925		10.1074/jbc.275.17.12917	http://dx.doi.org/10.1074/jbc.275.17.12917			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777591	hybrid			2022-12-27	WOS:000086762300075
J	Keefe, RG; Maley, GF; Saxl, RL; Maley, F				Keefe, RG; Maley, GF; Saxl, RL; Maley, F			A T4-phage deoxycytidylate deaminase mutant that no longer requires deoxycytidine 5 '-triphosphate for activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; EXPRESSION; SUBUNIT; PROTEIN	A deoxycytidylate (dCMP) deaminase encoded in T4-bacteriophage DNA that is induced on phage infection of Escherichia coli was shown earlier (Maley, G. F., Duceman, B. W., Wang, A. M., Martinez, J. M., and Maley, F. (1990) J. Biol. Chem. 265, 47-51) to be similar in size, properties, and amino acid composition to the T2-phage-induced deaminase. Neither enzyme is active in the absence of dCTP or its natural activator, 5-hydroxymethyl-dCTP. However, on changing the arginine (Arg) at residue 115 of the T4-deaminase to either a glutamate (R115E) or a glutamine (R115Q), the resulting mutant enzymes were active in the absence of dCTP, with each mutant possessing a turnover number or k(cat) that is about 15% that of the wild-type deaminase, When compared on the basis of specific activity, however, the mutants are about 40-50% of the wild-type (WT)-enzyme's specific activity. Molecular weight analysis on the wildtype and mutant deaminases using HPLC size exclusion chromatography revealed that the wild-type deaminase was basically a hexamer, particularly in the presence of dCTP, regardless of the extent of dilution. Under similar conditions, R115E remained a dimer, whereas R115Q and F112A varied from hexamers to dimers particularly at concentrations normally present in the assay solution. Activity measurements appear to support the conclusion that the hexameric form of the enzyme is activated by dCTP, while the dimer is not. Another feature emphasizing the difference between the WT and mutant deaminases was observed on their denaturation-renaturation in EDTA, which revealed the mutants to be restored to 50% of their original activities with the WT deaminase only marginally restored.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Maley, F (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,Box 509, Albany, NY 12201 USA.				NCI NIH HHS [CA44355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; COHEN SS, 1968, VIRUS INDUCED ENZYME, P89; FLEMING WH, 1967, J BIOL CHEM, V242, P363; Maley F, 1970, Adv Enzyme Regul, V8, P55, DOI 10.1016/0065-2571(70)90008-7; MALEY F, 1982, J BIOL CHEM, V257, P1876; MALEY F, 1972, CURR TOP CELL REGUL, V5, P177; MALEY GF, 1962, J BIOL CHEM, V237, P3311; MALEY GF, 1990, J BIOL CHEM, V265, P47; MALEY GF, 1972, J BIOL CHEM, V247, P940; MALEY GF, 1993, BIOCHIM BIOPHYS ACTA, V1162, P161, DOI 10.1016/0167-4838(93)90143-F; MALEY GF, 1972, J BIOL CHEM, V247, P931; McGaughey KM, 1996, J BIOL CHEM, V271, P23037, DOI 10.1074/jbc.271.38.23037; MCINTOSH EM, 1988, MOL CELL BIOL, V6, P1711; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MOORE JT, 1993, J BIOL CHEM, V268, P2288; MOORE JT, 1994, BIOCHEMISTRY-US, V33, P2104, DOI 10.1021/bi00174a017; SCOCCA JJ, 1969, J BIOL CHEM, V244, P3698; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	20	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12598	12602		10.1074/jbc.275.17.12598	http://dx.doi.org/10.1074/jbc.275.17.12598			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777550	hybrid			2022-12-27	WOS:000086762300034
J	Kelleher, CD; Champoux, JJ				Kelleher, CD; Champoux, JJ			RNA degradation and primer selection by Moloney murine leukemia virus reverse transcriptase contribute to the accuracy of plus strand initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HAMMERHEAD RIBOZYME CATALYSIS; SEQUENCE FEATURES IMPORTANT; DNA SYNTHESIZED INVITRO; NUCLEOCAPSID PROTEIN; POLYPURINE TRACT; H ACTIVITY; AVIAN RETROVIRUS; CLEAVAGE SPECIFICITY; CHAPERONE ACTIVITY	During reverse transcription, plus strand DNA synthesis is initiated at a purine-rich RNA primer generated by the RNase H activity of reverse transcriptase (RT). Specific initiation of plus strand synthesis from this polypurine tract (PPT) RNA is essential for the subsequent integration of the linear viral DNA product. Based on current models, it is predicted that priming from sites upstream of the PPT may be tolerated by the virus, whereas efficient extension from RNA primers located downstream from the PPT is predicted to generate dead-end products. By using hybrid duplex substrates derived from the Moloney murine leukemia virus long terminal repeat, we investigated the extent to which RNase H degrades the viral RNA during time course cleavage assays, and we tested the capacity of the polymerase activity of RT to use the resulting cleavage products as primers. We find that the majority of the RNA fragments generated by RNase H are 2-25 nucleotides in length, and only following extensive degradation are most fragments reduced to 10 nucleotides or smaller. Although extensive RNA degradation by RNase H likely eliminates many potential RNA primers, based on thermostability predictions it appears that some RNA fragments remain stably annealed to the DNA template. RNA primers generated by RNase H within the long terminal repeat sequence are found to have the capacity to initiate DNA synthesis by RT; however, the priming efficiency is significantly less than that observed with the PPT primer. We find that Moloney murine leukemia virus nucleocapsid protein reduces RNase H degradation and slightly alters the cleavage specificity of RT; however, nucleocapsid protein does not appear to enhance PPT primer utilization or suppress extension from non-PPT RNA primers.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F., 1999, CURRENT PROTOCOLS MO; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BOONE LR, 1981, J VIROL, V37, P117, DOI 10.1128/JVI.37.1.117-126.1981; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; Bowman EH, 1996, J VIROL, V70, P1687, DOI 10.1128/JVI.70.3.1687-1694.1996; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; Coffin JM, 1996, VIROLOGY, P1767; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DESGROSEILLERS L, 1982, J VIROL, V42, P326, DOI 10.1128/JVI.42.1.326-330.1982; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DINA D, 1980, J VIROL, V33, P377, DOI 10.1128/JVI.33.1.377-389.1980; ELLIS J, 1989, J VIROL, V63, P2844, DOI 10.1128/JVI.63.6.2844-2846.1989; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HONG T, 1991, J VIROL, V65, P551, DOI 10.1128/JVI.65.1.551-555.1991; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; KUNG HJ, 1981, J VIROL, V37, P127, DOI 10.1128/JVI.37.1.127-138.1981; LOBEL LI, 1989, J VIROL, V63, P2629, DOI 10.1128/JVI.63.6.2629-2637.1989; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; OYAMA F, 1989, J BIOL CHEM, V264, P18808; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RANDOLPH CA, 1993, VIROLOGY, V194, P851, DOI 10.1006/viro.1993.1329; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Robson ND, 1999, J VIROL, V73, P948, DOI 10.1128/JVI.73.2.948-957.1999; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; Stetor SR, 1999, BIOCHEMISTRY-US, V38, P3656, DOI 10.1021/bi982764l; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; TAPIERO JT, 1991, J GEN VIROL, V72, P605; TAYLOR JM, 1983, J VIROL, V48, P654, DOI 10.1128/JVI.48.3.654-659.1983; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994	65	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13061	13070		10.1074/jbc.275.17.13061	http://dx.doi.org/10.1074/jbc.275.17.13061			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777611	hybrid			2022-12-27	WOS:000086762300095
J	Moreno-Manzano, V; Ishikawa, Y; Lucio-Cazana, J; Kitamura, M				Moreno-Manzano, V; Ishikawa, Y; Lucio-Cazana, J; Kitamura, M			Selective involvement of superoxide anion, but not downstream compounds hydrogen peroxide and peroxynitrite, in tumor necrosis factor-alpha-induced apoptosis of rat mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; SIGNALING PATHWAYS; RENAL GLOMERULUS; IN-VIVO; EXPRESSION; GENERATION; DISMUTASE; DEATH; TNF	Tumor necrosis factor-alpha (TNF-alpha) induces reactive oxygen species (ROS) that serve as second messengers for intracellular signaling. Currently, precise roles of individual ROS in the actions of TNF-alpha remain to be elucidated. In this report, we investigated the roles of super-oxide anion (O-2(<(.)over bar>)) hydrogen peroxide (H2O2), and peroxynitrite (ONOO-) in TNF-alpha-triggered apoptosis of mesangial cells. Mesangial cells stimulated by TNF-alpha produced O-2(<(.)over bar>) and underwent apoptosis. The apoptosis was inhibited by transfection with manganese superoxide dismutase or treatment with a pharmacological scavenger of O-2(<(.)over bar>) Tiron. In contrast, although exogenous H2O2 induced apoptosis, TNF-alpha-triggered apoptosis was not affected either by transfection with catalase cDNA or by treatment with catalase protein or glutathione ethyl ester. Similarly, although ONOO- precursor SIN-1 induced apoptosis, treatment with a scavenger of ONOO-, uric acid, or an inhibitor of nitric oxide synthesis, N-G-nitro-L-argininemethyl ester hydrochloride, did not affect the TNF-alpha-triggered apoptosis. Like TNF-alpha-induced apoptosis, treatment with a O-2(<(.)over bar>)-releasing agent, pyrogallol, induced typical apoptosis even in the concurrent presence of scavengers for H2O2 and ONOO-. These results suggested that, in mesangial cells, TNF-alpha induces apoptosis through selective ROS. O-2(<(.)over bar>) but not H2O2 or ONOO-, was identified as the crucial mediator for the TNF-alpha-initiated, apoptotic pathway.	UCL, Univ Coll Med Sch, Dept Med, Rayne Inst, London WC1E 6JJ, England; Univ Alcala de Henares, Dept Physiol & Pharmacol, E-28871 Alcala De Henares, Spain	University of London; King's College London; University College London; Universidad de Alcala	Kitamura, M (corresponding author), UCL, Univ Coll Med Sch, Dept Med, Rayne Inst, 5 Univ St, London WC1E 6JJ, England.	m.kitamura@medicine.ucl.ac.uk	Lucio-Cazana, Francisco-Javier/B-8149-2009; Moreno, Victoria/B-4175-2014	Moreno, Victoria/0000-0002-6035-9491; Lucio-Cazana, Francisco-Javier/0000-0001-9249-8501				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hein TW, 1998, CIRC RES, V83, P404, DOI 10.1161/01.RES.83.4.404; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kitamura M, 1996, P NATL ACAD SCI USA, V93, P7387, DOI 10.1073/pnas.93.14.7387; Kitamura M, 1998, KIDNEY INT, V53, P690, DOI 10.1046/j.1523-1755.1998.00806.x; KITAMURA M, 1994, J CLIN INVEST, V94, P497, DOI 10.1172/JCI117361; Kitamura M, 1997, J IMMUNOL, V159, P1404; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; LASTER SM, 1988, J IMMUNOL, V141, P2629; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang XHS, 1996, J BIOL CHEM, V271, P31607; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xie YW, 1998, CIRC RES, V82, P891; YAMAUCHI N, 1989, CANCER RES, V49, P1671	43	122	123	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12684	12691		10.1074/jbc.275.17.12684	http://dx.doi.org/10.1074/jbc.275.17.12684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777562	hybrid			2022-12-27	WOS:000086762300046
J	Mottola, G; Jourdan, N; Castaldo, G; Malagolini, N; Lahm, A; Serafini-Cessi, F; Migliaccio, G; Bonatti, S				Mottola, G; Jourdan, N; Castaldo, G; Malagolini, N; Lahm, A; Serafini-Cessi, F; Migliaccio, G; Bonatti, S			A new determinant of endoplasmic reticulum localization is contained in the juxtamembrane region of the ectodomain of hepatitis C virus glycoprotein E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; DILYSINE-TAGGED PROTEINS; SINGLE REPORTER PROTEIN; HUMAN CD8 GLYCOPROTEIN; TRANSMEMBRANE DOMAIN; MEMBRANE-PROTEINS; SUBCELLULAR-LOCALIZATION; INTERMEDIATE COMPARTMENT; LINKED OLIGOSACCHARIDES; RECOMBINANT VACCINIA	Hepatitis C virus glycoproteins E1 and E2 do not reach the plasma membrane of the cell but accumulate intracellularly, mostly in the endoplasmic reticulum, Previous studies based on transient expression assays have shown that the transmembrane domains of both glycoproteins are sufficient to localize reporter proteins in the endoplasmic reticulum and that other localization signals may be contained in the ectodomain of El protein. To identify such signals we generated chimeric proteins between El and two reporter proteins, the human CD8 glycoprotein and the human alkaline phosphatase, and analyzed their subcellular localization in stable as well as transient transfectants. Our results showed that (i) an independent localization determinant for the endoplasmic reticulum is present in the juxtamembrane region of the ectodomain of El protein and (ii) the localization dictated by this determinant is either due to direct retention or to a recycling mechanism from the intermediate compartment/cis-Golgi complex region, which is clearly different from those previously described for other retrieval signals. These results show for the first time in mammalian cells that the localization in the endoplasmic reticulum of transmembrane protein can be determined by specific targeting signals acting in the lumen of the compartment.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Bologna, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	University of Naples Federico II; University of Bologna; Merck & Company	Migliaccio, G (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	migliaccio@irbm.it	Castaldo, Giuseppe/AAC-6782-2022; Mottola, Giovanna/Y-7540-2019	Castaldo, Giuseppe/0000-0002-4036-0874; Mottola, Giovanna/0000-0002-7541-0472				BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BONATTI S, 1989, J BIOL CHEM, V264, P12590; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Ciccaglione AR, 1998, VIROLOGY, V250, P1, DOI 10.1006/viro.1998.9380; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; Cosson P, 1997, EUR J CELL BIOL, V73, P93; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; CULLEN BR, 1992, METHOD ENZYMOL, V216, P362; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Flint M, 1999, J GEN VIROL, V80, P1943, DOI 10.1099/0022-1317-80-8-1943; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hobman TC, 1997, J VIROL, V71, P7670, DOI 10.1128/JVI.71.10.7670-7680.1997; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; LEDBETTER JA, 1985, J IMMUNOL, V135, P1819; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lotti LV, 1999, J BIOL CHEM, V274, P10413, DOI 10.1074/jbc.274.15.10413; LOW MG, 1987, BIOCHEM J, V244, P1; Martire G, 1996, J BIOL CHEM, V271, P3541; Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINICESSI F, 1993, BIOCHEM BIOPH RES CO, V194, P784, DOI 10.1006/bbrc.1993.1890; Shenkman M, 1997, P NATL ACAD SCI USA, V94, P11363, DOI 10.1073/pnas.94.21.11363; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VERDE C, 1995, EUR J CELL BIOL, V67, P267; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	60	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24070	24079		10.1074/jbc.M910400199	http://dx.doi.org/10.1074/jbc.M910400199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10783397	hybrid			2022-12-27	WOS:000088564200091
J	Ambrosetti, DC; Scholer, HR; Dailey, L; Basilico, C				Ambrosetti, DC; Scholer, HR; Dailey, L; Basilico, C			Modulation of the activity of multiple transcriptional activation domains by the DNA binding domains mediates the synergistic action of Sox2 and Oct-3 on the Fibroblast growth factor-4 enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; POU-DOMAIN; GROWTH-FACTOR-4 ENHANCER; FUNCTIONAL INTERACTION; REGULATORY ELEMENTS; MAMMALIAN EMBRYO; STEM-CELLS; PROTEIN; GENE; MOUSE	Fibroblast growth factor (FGF)-4 gene expression in the inner cell mass of the blastocyst and in EC cells requires the combined activity of two transcriptional regulators, Sox2 and Oct-3, which bind to adjacent sites on the FGF-4 enhancer DNA and synergistically activate transcription. Sox2 and Oct-3 bind cooperatively to the enhancer DNA through their DNA-binding, high mobility group and POU domains, respectively. These two domains, however, are not sufficient to activate transcription. We have analyzed a number of Sox2 and Oct-3 deletion mutants to identify the domains within each protein that contribute to the activity of the Sox2.Oct-3 complex. Within Oct-3, we have identified two activation domains, the N-terminal AD1 and the C-terminal AD2, that play a role in the activity of the Sox2.Oct-3 complex. AD1 also displays transcriptional activation functions in the absence of Sox2 while AD2 function was only detected within the Sox2.Oct-3 complex. In Sox2, we have identified three activation domains within its C terminus: R1, R2, and R3, RI and R2 can potentiate weak activation by Sox2 in the absence of Oct-3 but their deletion has no effect on the Sox2.Oct-3 complex. In contrast, R3 function is only observed when Sox2 is complexed with Oct-3. In addition, analysis of Oct-1/Oct-3 chimeras indicates that the Oct-3 homeodomain also plays a critical role in the formation of a functional Sox2.Oct-3 complex. Our results are consistent with a model in which the synergistic action of Sera and Oct-3 results from two major processes. Cooperative binding of the factors to the enhancer DNA, mediated by their binding domains, stably tethers each factor to DNA and increases the activity of intrinsic activation domains within each protein. Protein-protein and protein-DNA interactions then may lead to reciprocal conformational changes that expose latent activation domains within each protein. These findings define a mechanism that may also be utilized by other Sox.POU protein complexes in gene activation.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Univ Penn, New Bolton Ctr, Ctr Anim Transgenesis & Germ Cell Res, Kennett Sq, PA 19348 USA	New York University; University of Pennsylvania	Dailey, L (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.	dailel01@med.nyu.edu; basilc01@med.nyu.edu	, HS/AAB-4434-2019	, HS/0000-0003-2643-5136	NATIONAL CANCER INSTITUTE [R01CA078925] Funding Source: NIH RePORTER; NCI NIH HHS [CA42568, CA78925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; Fraidenraich D, 1998, DEV BIOL, V204, P197, DOI 10.1006/dbio.1998.9053; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Ma Y, 1998, MECH DEVELOP, V73, P169, DOI 10.1016/S0925-4773(98)00050-1; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6481; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Soriano NS, 1998, DEVELOPMENT, V125, P3989; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	44	136	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23387	23397		10.1074/jbc.M000932200	http://dx.doi.org/10.1074/jbc.M000932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801796	hybrid			2022-12-27	WOS:000088419400108
J	Boyd, AE; Marnett, AB; Wong, L; Taylor, P				Boyd, AE; Marnett, AB; Wong, L; Taylor, P			Probing the active center gorge of acetylcholinesterase by fluorophores linked to substituted cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL SITE; CRYSTAL-STRUCTURE; SUBSTRATE-INHIBITION; BACK DOOR; FASCICULIN; BINDING; COMPLEX; SPECIFICITY; CATALYSIS; CHOLINESTERASES	To examine the influence of individual side chains in governing rates of ligand entry into the active center gorge of acetylcholinesterase and to characterize the dynamics and immediate environment of these residues, we have conjugated reactive groups with selected charge and fluorescence characteristics to cysteines substituted by mutagenesis at specific positions on the enzyme. Insertion of side chains larger than in the native tyrosine at position 124 near the constriction point of the active site gorge confers steric hindrance to affect maximum catalytic throughput (k(cat)/K-m) and rates of diffusional entry of trifluoroketones to the active center. Smaller groups appear not to present steric constraints to entry; however, cationic side chains selectively and markedly reduce cation ligand entry through electrostatic repulsion in the gorge. The influence of side chain modification on ligand kinetics has been correlated with spectroscopic characteristics of fluorescent side chains and their capacity to influence the binding of a peptide, fasciculin, which inhibits catalysis peripherally by sealing the mouth of the gorge, Acrylodan conjugated to cysteine was substituted for tyrosine at position 124 within the gorge, for histidine 287 on the surface adjacent to the gorge and for alanine 262 on a mobile loop distal to the gorge. The 124 position reveals the most hydrophobic environment and the largest hypsochromic shift of the emission maximum with fasciculin binding. This finding likely reflects a sandwiching of the acrylodan in the complex with the tip of fasciculin loop II. An intermediate spectral shift is found for the 287 position, consistent with partial occlusion by loops II and III of fasciculin in the complex. Spectroscopic properties of the acrylodan at the 262 position are unaltered by fasciculin addition. Hence, combined spectroscopic and kinetic analyses reveal distinguishing characteristics in various regions of acetylcholinesterase that influence ligand association.	Univ Calif San Diego, Sch Med, Dept Pharmacol 0636, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol 0636, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BAZELYANSKY M, 1986, BIOCHEMISTRY-US, V25, P125, DOI 10.1021/bi00349a019; BERMAN HA, 1980, BIOCHEMISTRY-US, V19, P2226, DOI 10.1021/bi00551a036; BERMAN HA, 1978, BIOCHEMISTRY-US, V17, P1704, DOI 10.1021/bi00602a019; BERMAN JD, 1971, P NATL ACAD SCI USA, V68, P395, DOI 10.1073/pnas.68.2.395; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; CYGLER M, 1993, PROTEIN SCI, V2, P366; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FROEDE HC, 1984, J BIOL CHEM, V259, P1010; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; Hosea NA, 1996, BIOCHEMISTRY-US, V35, P10995, DOI 10.1021/bi9611220; Kenyon G L, 1977, Methods Enzymol, V47, P407; KRONMAN C, 1994, J BIOL CHEM, V269, P27819; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAKOWICZ JR, 1983, PRINCIPLES FLOURESCE; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; Lew J, 1997, J BIOL CHEM, V272, P1507, DOI 10.1074/jbc.272.3.1507; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; Velan B, 1996, FEBS LETT, V395, P22, DOI 10.1016/0014-5793(96)00995-7; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	42	26	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22401	22408		10.1074/jbc.M000606200	http://dx.doi.org/10.1074/jbc.M000606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10779503	hybrid			2022-12-27	WOS:000088363800088
J	Lerche, C; Scherer, CR; Seebohm, G; Derst, C; Wei, AD; Busch, AE; Steinmeyer, K				Lerche, C; Scherer, CR; Seebohm, G; Derst, C; Wei, AD; Busch, AE; Steinmeyer, K			Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MYOCLONUS EPILEPSY; CARDIAC-ARRHYTHMIAS; IDIOPATHIC EPILEPSY; DOMINANT DEAFNESS; K+ CHANNELS; GENE; MUTATIONS; KVLQT1; PROTEIN; JERVELL	We have isolated KCNQ5, a novel human member of the KCNQ potassium channel gene family that is differentially expressed in subregions of the brain and in skeletal muscle. When expressed in Xenopus oocytes, KCNQ5 generated voltage-dependent, slowly activating K+-selective currents that displayed a marked inward rectification at positive membrane voltages. KCNQ5 currents were insensitive to the K+ channel blocker tetraethylammonium but were strongly inhibited by the selective M-current blocker linopirdine, Upon coexpression with the structurally related KCNQ3 channel subunit, current amplitudes increased 4-5-fold Compared with homomeric KCNQ5 currents, KCNQ3/KCNQ5 currents also displayed slower activation kinetics and less inward rectification, indicating that KCNQ5 combined with KCNQ3 to form functional heteromeric channel proteins. This functional interaction between KCNQ5 and KCNQ3, a component of the M-channel, suggests that KCNQ5 may contribute to a diversity of heteromeric channels underlying native neuronal M-currents.	Aventis Pharma Deutshland GmbH, DG Cardiovasc Dis, D-65926 Frankfurt, Germany; Univ Marburg, Inst Physiol, D-35033 Marburg, Germany; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Philipps University Marburg; Washington University (WUSTL)	Steinmeyer, K (corresponding author), Aventis Pharma Deutshland GmbH, DG Cardiovasc Dis, D-65926 Frankfurt, Germany.							Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Coucke PJ, 1999, HUM MOL GENET, V8, P1321, DOI 10.1093/hmg/8.7.1321; Hadley JK, 2000, BRIT J PHARMACOL, V129, P413, DOI 10.1038/sj.bjp.0703086; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lerche H, 1999, ANN NEUROL, V46, P305, DOI 10.1002/1531-8249(199909)46:3<305::AID-ANA5>3.0.CO;2-5; Liu AW, 1996, AM J MED GENET, V63, P438; LOHRMANN E, 1995, PFLUG ARCH EUR J PHY, V429, P517, DOI 10.1007/BF00704157; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Meves H, 1999, BRIT J PHARMACOL, V127, P1213, DOI 10.1038/sj.bjp.0702642; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Pusch M, 1998, BIOPHYS J, V75, P785, DOI 10.1016/S0006-3495(98)77568-X; Sanguinetti MC, 1999, ANN NY ACAD SCI, V868, P406, DOI 10.1111/j.1749-6632.1999.tb11302.x; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Selyanko AA, 2000, J PHYSIOL-LONDON, V522, P349, DOI 10.1111/j.1469-7793.2000.t01-2-00349.x; Selyanko AA, 1999, J NEUROSCI, V19, P7742; Serratosa JM, 1999, HUM MOL GENET, V8, P345, DOI 10.1093/hmg/8.2.345; Shapiro MS, 2000, J NEUROSCI, V20, P1710; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Suessbrich H, 1999, Rev Physiol Biochem Pharmacol, V137, P191; Suessbrich H, 1996, FEBS LETT, V396, P271, DOI 10.1016/0014-5793(96)01113-1; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tinel N, 1998, FEBS LETT, V438, P171, DOI 10.1016/S0014-5793(98)01296-4; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419	42	223	234	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22395	22400		10.1074/jbc.M002378200	http://dx.doi.org/10.1074/jbc.M002378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10787416	hybrid			2022-12-27	WOS:000088363800087
J	Watanabe, K; Fujii, H; Takahashi, T; Kodama, M; Aizawa, Y; Ohta, Y; Ono, T; Hasegawa, G; Naito, M; Nakajima, T; Kamijo, Y; Gonzalez, FJ; Aoyama, T				Watanabe, K; Fujii, H; Takahashi, T; Kodama, M; Aizawa, Y; Ohta, Y; Ono, T; Hasegawa, G; Naito, M; Nakajima, T; Kamijo, Y; Gonzalez, FJ; Aoyama, T			Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; COENZYME-A DEHYDROGENASE; ENZYME GENE-EXPRESSION; PPAR-ALPHA; BETA-OXIDATION; PENTADECANOIC ACID; MOLECULAR-CLONING; KAPPA-B; RAT; MITOCHONDRIAL	The peroxisome proliferator-activated receptor alpha (PPAR alpha) is a member of the nuclear receptor superfamily and mediates the biological effects of peroxisome proliferators, To determine the physiological role of PPAR alpha in cardiac fatty acid metabolism, we examined the regulation of expression of cardiac fatty acid-metabolizing proteins using PPAR alpha-null mice. The capacity for constitutive myocardial beta-oxidation of the medium and long chain fatty acids, octanoic acid and palmitic acid, was markedly reduced in the PPAR alpha-null mice as compared with the wild-type mice, indicating that mitochondrial fatty acid catabolism is impaired in the absence of PPAR alpha. In contrast, constitutive beta-oxidation of the very long chain fatty acid, lignoceric acid, did not differ between the mice, suggesting that the constitutive expression of enzymes involved in peroxisomal beta-oxidation is independent of PPAR alpha. Indeed, PPAR alpha-null mice had normal levels of the peroxisomal beta-oxidation enzymes except the D-type bifunctional protein. At least seven mitochondrial fatty acid-metabolizing enzymes were expressed at much lower levels in the PPAR alpha-null mice, whereas other fatty acid-metabolizing enzymes were present at similar or slightly lower levels in the PPAR alpha-null, as compared with wild-type mice. Additionally, lower constitutive mRNA expression levels of fatty acid transporters were found in the PPAR alpha-null mice, suggesting a role for PPAR alpha in fatty acid transport and catabolism. Indeed, in fatty acid metabolism experiments in vivo, myocardial uptake of iodophenyl 9-methylpentadecanoic acid and its conversion to 3-methyl-nonanoic acid were reduced in the PPAR alpha-null mice. Interestingly, a decreased ATP concentration after exposure to stress, abnormal cristae of the mitochondria, abnormal caveolae, and fibrosis were observed only in the myocardium of the PPAR alpha-null mice. These cardiac abnormalities appeared to proceed in an age-dependent manner. Taken together, the results presented here indicate that PPAR alpha controls constitutive fatty acid oxidation, thus establishing a role for the receptor in cardiac fatty acid homeostasis, Furthermore, altered expression of fatty acid-metabolizing proteins seems to lead to myocardial damage and fibrosis, as inflammation and abnormal cell growth control can cause these conditions.	Niigata Coll Pharm, Dept Clin Pharmacol, Niigata 9502081, Japan; Niigata Univ, Sch Med, Dept Biochem 2, Niigata 9518510, Japan; Niigata Univ, Sch Med, Radioisotope Ctr, Niigata 9518510, Japan; Niigata Univ, Sch Med, Dept Med 1, Niigata 9518510, Japan; Niigata Univ, Sch Med, Dept Pathol 2, Niigata 9518510, Japan; Shinshu Univ, Sch Med, Dept Hyg & Med Genet, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Internal Med 2, Nagano 3908621, Japan; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Shinshu Univ, Sch Med, Dept Aging Biochem, Matsumoto, Nagano 3908621, Japan	Niigata University; Niigata University; Niigata University; Niigata University; Shinshu University; Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shinshu University	Watanabe, K (corresponding author), Niigata Coll Pharm, Dept Clin Pharmacol, Kamisin Ei Cho, Niigata 9502081, Japan.				NATIONAL CANCER INSTITUTE [ZIABC005708, Z01BC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BREMER J, 1984, FATTY ACID METABOLIS; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHOURAQUI P, 1991, J NUCL MED, V32, P447; Cox GF, 1998, J PEDIATR-US, V133, P247, DOI 10.1016/S0022-3476(98)70228-8; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; ISEMANN I, 1990, NATURE, V347, P645; KAMIJO T, 1994, J CLIN INVEST, V93, P1740, DOI 10.1172/JCI117158; Kamijo T, 1997, PEDIATR RES, V42, P569, DOI 10.1203/00006450-199711000-00002; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KNAPP FF, 1995, EUR J NUCL MED, V22, P361, DOI 10.1007/BF00941855; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lefer A M, 1987, Cardiovasc Clin, V18, P85; LEFER AM, 1985, FED PROC, V44, P275; LEFER DJ, 1987, ARCH INT PHARMACOD T, V287, P89; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; Nakajima K, 1998, NUCL MED COMMUN, V19, P839, DOI 10.1097/00006231-199809000-00004; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NAYLER WG, 1979, J MOL CELL CARDIOL, V11, P683, DOI 10.1016/0022-2828(79)90381-X; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; NIETH H, 1966, NATURE, V209, P1244, DOI 10.1038/2091244a0; Orii KE, 1996, BIOCHEM BIOPH RES CO, V219, P773, DOI 10.1006/bbrc.1996.0309; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; SAKAI K, 1995, EUR J BIOCHEM, V229, P201, DOI 10.1111/j.1432-1033.1995.tb20456.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SHINDO Y, 1978, BIOCHEM PHARMACOL, V27, P2683; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Taegtmeyer H, 1994, CURR PROB CARDIOLOGY, V19, P57; Watanabe K, 1998, Ann Nucl Med, V12, P261; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	45	255	271	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22293	22299		10.1074/jbc.M000248200	http://dx.doi.org/10.1074/jbc.M000248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801788	hybrid			2022-12-27	WOS:000088363800074
J	Unson, CG; Wu, CR; Sakmar, TP; Merrifield, RB				Unson, CG; Wu, CR; Sakmar, TP; Merrifield, RB			Selective stabilization of the high affinity binding conformation of glucagon receptor by the long splice variant of G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; PROTEIN-COUPLED RECEPTORS; ADENYLATE-CYCLASE; GS-ALPHA; SIGNAL-TRANSDUCTION; REGULATORY PROTEINS; FUSION PROTEIN; 2 FORMS; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVITY	To analyze functional differences in the interactions of the glucagon receptor (GR) with the two predominant splice variants of G alpha(s), GR was covalently linked to the short and the long forms G alpha(s)-S and G alpha(s)-L to produce the fusion proteins GR-G alpha(s)-S and GR-G alpha-L. GR-G alpha(s)-S bound glucagon with an affinity similar to that of GR, while GR-G alpha(s)-L showed a 10-fold higher affinity for glucagon. In the presence of GTP gamma S, GR-G alpha(s)-L reverted to the low affinity glucagon binding conformation. Both GR-G alpha(s)-L and GR-G alpha(s)-S were constitutively active, causing elevated basal levels of cAMP even in the absence of glucagon. A mutant GR that failed to activate G(s) (G23D1R) was fused to G alpha(s)-L. G23D1R-G alpha(s)-L bound glucagon with high affinity, but failed to elevate cAMP levels, suggesting that the mechanisms of GR-mediated G alpha(s)-L activation and G alpha(s)-L-induced high affinity glucagon binding are independent. Both GR-G alpha(s)-S and GR-G alpha(s)-L bound the antagonist desHis(1) [Nle(9),Ala(11),Ala(16)]-glucagon amide with affinities similar to GR, The antagonist displayed partial agonist activity with GR-G alpha(s)-L, but not with GR-G alpha(s)-S, Therefore, the partial agonist activity of the antagonist observed in intact cells appears to be due to GRs coupled to G alpha(s)-L. We conclude that G alpha(s)-S and G alpha(s)-L interact differently with GR and that specific coupling of GR to G alpha(s)-L may account for GTP-sensitive high affinity glucagon binding.	Rockefeller Univ, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, New York, NY USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Unson, CG (corresponding author), Rockefeller Univ, Box 294,1230 York Ave, New York, NY 10021 USA.		Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NIDDK NIH HHS [R01-DK24039] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azizeh BY, 1997, PEPTIDES, V18, P633, DOI 10.1016/S0196-9781(97)00131-9; Bertin B, 1997, RECEPTOR CHANNEL, V5, P41; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cypess AM, 1999, J BIOL CHEM, V274, P19455, DOI 10.1074/jbc.274.27.19455; CYPESS AM, 1999, PEPTIDES 1998, P722; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; HORWITZ EM, 1986, J BIOL CHEM, V261, P3670; HRUBY VJ, 1993, LIFE SCI, V52, P845, DOI 10.1016/0024-3205(93)90513-3; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JONES DT, 1990, J BIOL CHEM, V265, P2671; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LAD PM, 1977, J BIOL CHEM, V252, P5942; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; Marsh SR, 1998, MOL PHARMACOL, V53, P981; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; ODONNELL JK, 1991, MOL PHARMACOL, V39, P702; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SONNE O, 1978, J BIOL CHEM, V253, P3203; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; SUNHARA RK, 1997, SCIENCE, V278, P1943; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; UNSON CG, 1994, J BIOL CHEM, V269, P12548; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; Unson CG, 1998, J BIOL CHEM, V273, P10308, DOI 10.1074/jbc.273.17.10308; Vallejo Abbe N., 1995, P603; WALSETH TF, 1989, J BIOL CHEM, V264, P21106; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Wenzel-Seifert K, 1998, BIOCHEM J, V334, P519, DOI 10.1042/bj3340519	61	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21631	21638		10.1074/jbc.M002093200	http://dx.doi.org/10.1074/jbc.M002093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10791965	hybrid			2022-12-27	WOS:000088230600089
J	Wennemuth, G; Westenbroek, RE; Xu, T; Hille, B; Babcock, DF				Wennemuth, G; Westenbroek, RE; Xu, T; Hille, B; Babcock, DF			Ca(v)2.2 and Ca(v)2,3 (N- and R-type) Ca2+ channels in depolarization-evoked entry of Ca2+ into mouse sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; T-TYPE; SPERMATOGENIC CELLS; ACROSOME REACTION; MAMMALIAN SPERM; ZONA-PELLUCIDA; MULTIPLE TYPES; PHARMACOLOGICAL PROPERTIES; PERIPHERAL NEURONS; OMEGA-CONOTOXIN	As sperm prepare for fertilization, surface Ca2+ channels must open to initiate required, Ca2+-mediated events. However, the molecular identity and functional properties of sperm Ca2+ channels remain uncertain. Here, we use rapid local perfusion and single-cell photometry to examine the kinetics of calcium responses of mouse sperm to depolarizing stimuli. The linear rise of intracellular [Ca2+] evoked by similar to 10-s applications of an alkaline high [K+] medium directly reports activity of voltage-gated Ca2+ channels. Little response occurs if external Ca2+ is removed or if external or internal pH is elevated without depolarization. Responses are inhibited 30-40% by 30-100 mu M Ni2+ and more completely by 100-300 mu M Cd2+. They resist the dihydropyridines nitrendipine and PN200-110, but 1-10 mu M mibefradil inhibits reversibly. They also resist the venom toxins calciseptine, omega-conotoxin MVIIC, and kurtoxin, but omega-conotoxin GVIA (5 mu M) inhibits similar to 50%, GVIA also partially blocks transient, low voltage activated Ca2+ currents of patch-clamped spermatids, Differential sensitivity of sperm responses to Ni2+ and Cd2+ and partial blockade by GVIA indicate that depolarization opens at least two types of voltage-gated Ca2+ channels in epididymal sperm examined prior to capacitation. Involvement of a previously undetected Ca(V)2,2 (N-type) channel, suggested by the action of GVIA, is substantiated by immunodetection of Ca2+ channel alpha(1B) subunits in sperm and sperm extracts. Resistance to dihydropyridines, calciseptine, MVIIC, and kurtoxin indicates that Ca(V)1, Ca(V)2.1, and Ca(V)3 (L-, P/Q-, and T-type) channels contribute little to this evoked response. Partial sensitivity to 1 mu M mibefradil and an enhanced sensitivity of the GVIA-resistant component of response to Ni2+ suggest participation of a Ca(V)2.3 (R-type) channel specified by previously found alpha(1E) subunits. Our examination of depolarization-evoked Ca2+ entry indicates that mature sperm possess a larger palette of voltage-gated Ca2+ channels than previously thought. Such diversity may permit specific responses to multiple cues encountered on the path to fertilization.	Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Babcock, DF (corresponding author), Univ Washington, Sch Med, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	donner@u.washington.edu	Xu, Tao/G-5474-2010	Babcock, Donner/0000-0002-4461-4544; Wennemuth, Gunther/0000-0003-3313-2475	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629] Funding Source: NIH RePORTER; NICHD NIH HHS [U54-HD12629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1998, MOL PHARMACOL, V53, P1104; BABCOCK DF, 1987, J BIOL CHEM, V262, P15041; BABCOCK DF, 1983, P NATL ACAD SCI-BIOL, V80, P1327, DOI 10.1073/pnas.80.5.1327; BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540; Brandelli A, 1996, J ANDROL, V17, P522; Chuang RSI, 1998, NAT NEUROSCI, V1, P668, DOI 10.1038/3669; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; Ertel SI, 1997, TRENDS PHARMACOL SCI, V18, P37, DOI 10.1016/S0165-6147(96)01021-8; Espinosa F, 1999, DEV GENET, V25, P103, DOI 10.1002/(SICI)1520-6408(1999)25:2&lt;103::AID-DVG4&gt;3.0.CO;2-B; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FLORMAN HM, 1992, DEV BIOL, V152, P304, DOI 10.1016/0012-1606(92)90137-6; Goodwin LO, 1998, MOL HUM REPROD, V4, P215, DOI 10.1093/molehr/4.3.215; Goodwin LO, 1999, MOL HUM REPROD, V5, P311, DOI 10.1093/molehr/5.4.311; HAGIWARA S, 1984, J PHYSIOL-LONDON, V356, P135, DOI 10.1113/jphysiol.1984.sp015457; HELL JW, 1994, J BIOL CHEM, V269, P7390; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; Lambert RC, 1998, J NEUROSCI, V18, P8605; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lee JH, 1999, J NEUROSCI, V19, P1912; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; McDonough SI, 1996, J NEUROSCI, V16, P2612; Meir A, 1998, NEURON, V20, P341, DOI 10.1016/S0896-6273(00)80461-4; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Perez-Reyes E, 1999, CELL MOL LIFE SCI, V56, P660, DOI 10.1007/s000180050460; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Publicover SJ, 1999, HUM REPROD, V14, P873, DOI 10.1093/humrep/14.4.873; RANDALL A, 1995, J NEUROSCI, V15, P2995; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; Santi C. M., 1999, Society for Neuroscience Abstracts, V25, P197; Santi CM, 1998, J GEN PHYSIOL, V112, P33, DOI 10.1085/jgp.112.1.33; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; Shirakawa H, 1999, DEV BIOL, V208, P70, DOI 10.1006/dbio.1998.9194; Talley EM, 1999, J NEUROSCI, V19, P1895; Viana F, 1997, CELL CALCIUM, V22, P299, DOI 10.1016/S0143-4160(97)90068-3; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Westenbroek RE, 1999, DEV BIOL, V207, P457, DOI 10.1006/dbio.1998.9172; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; Yanagimachi R, 1994, MAMMALIAN FERTILIZAT, P189	47	144	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21210	21217		10.1074/jbc.M002068200	http://dx.doi.org/10.1074/jbc.M002068200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10791962	hybrid			2022-12-27	WOS:000088230600035
J	Fu, MF; Wang, CG; Reutens, AT; Wang, J; Angeletti, RH; Siconolfi-Baez, L; Ogryzko, V; Avantaggiati, ML; Pestell, RG				Fu, MF; Wang, CG; Reutens, AT; Wang, J; Angeletti, RH; Siconolfi-Baez, L; Ogryzko, V; Avantaggiati, ML; Pestell, RG			p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ADENOVIRAL ONCOPROTEIN E1A; PROSTATE-SPECIFIC ANTIGEN; HISTONE ACETYLTRANSFERASES; COACTIVATORS P300; GENE ACTIVATION; DNA-DAMAGE; IN-VIVO; CBP; PCAF	The androgen receptor (AR) is a sequence-specific DNA-binding protein that plays a key role in prostate cancer cellular proliferation by dihydrotestosterone and the induction of secondary sexual characteristics. In this study me demonstrate that the AR can be modified by acetylation in vitro and in vivo, p300 and p300/cAMP-response element-binding protein acetylated the AR at a highly conserved lysine-rich motif carboxyl-terminal to the zinc finger DNA-binding domain. [C-14]acetate-labeling experiments demonstrated that AR acetylation by p300 in cultured cells requires the same residues identified in vitro. Point mutation of the AR acetylation site (K632A/K633A) abrogated dihydrotestosterone-dependent transactivation of the AR in cultured cells. Mutation of the p300 CH3 region or the p300/cAMP-response element-binding protein histone acetylase domain reduced ligand-dependent AR function. The identification of the AR as a direct target of histone acetyltransferase co-activators has important implications for targeting inhibitors of AR function.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Roswell Park Cancer Institute	Pestell, RG (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Chanin 302, Bronx, NY 10461 USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389	NCI NIH HHS [5-P30-CA13330-26, R01CA70897, R01CA75503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897, R01CA075503, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	49	303	306	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20853	20860		10.1074/jbc.M000660200	http://dx.doi.org/10.1074/jbc.M000660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779504	hybrid			2022-12-27	WOS:000088084500089
J	Grallert, N; Rutkat, K; Buchner, J				Grallert, N; Rutkat, K; Buchner, J			Limits of protein folding inside GroE complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN ATPASE CYCLE; CRYSTAL-STRUCTURE; CITRATE SYNTHASE; HEAT-SHOCK; MECHANISM; BINDING; 2.8-ANGSTROM; POLYPEPTIDE; RESOLUTION; CATALYSIS	The GroE chaperones of Escherichia coli promote the folding of other proteins under conditions where no spontaneous folding occurs. One requirement for this reaction is the trapping of the nonnative protein inside the chaperone complex. Encapsulation may be important to prevent unfavorable intermolecular interactions during folding. We show here that, especially for oligomeric proteins, the timing of encapsulation and release is of critical importance. if this cycle is decelerated, misfolding is observed inside functional chaperone complexes.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Beissinger M, 1999, J MOL BIOL, V289, P1075, DOI 10.1006/jmbi.1999.2780; Beissinger M, 1998, BIOL CHEM, V379, P245; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; COYLE JE, 1997, FOLD DES, V2, P93; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; Fenton WA, 1997, PROTEIN SCI, V6, P743; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; Grallert H, 1999, J BIOL CHEM, V274, P20171, DOI 10.1074/jbc.274.29.20171; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; NiebaAxmann SE, 1997, J MOL BIOL, V271, P803, DOI 10.1006/jmbi.1997.1192; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; SRERE PA, 1966, J BIOL CHEM, V241, P2157; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	39	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20424	20430		10.1074/jbc.M002243200	http://dx.doi.org/10.1074/jbc.M002243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779510	hybrid			2022-12-27	WOS:000088084500029
J	Adachi, S; Amasaki, Y; Miyatake, S; Arai, N; Iwata, M				Adachi, S; Amasaki, Y; Miyatake, S; Arai, N; Iwata, M			Successive expression and activation of NFAT family members during thymocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-INDUCED APOPTOSIS; RECEPTOR SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR NFAT1; T-CELL DEVELOPMENT; POSITIVE SELECTION; NEGATIVE SELECTION; PROTEIN-KINASE; FUNCTIONAL-CHARACTERIZATION; CD4(+)CD8(+) THYMOCYTES; CALCINEURIN ACTIVATION	Differentiation of immature CD4(+)CD8(+) thymocytes to mature CD4(+) or CD8(+) T cells is induced by positive selection and appears to involve calcineurin-dependent activation of NFAT, a family of transcription factors. NFATx is predominantly expressed in CD4(+)CD8(+) thymocytes, whereas NFATp and NFATc are expressed at much lower levels in the thymus than in mature T cells. However, how or when each NFAT member is involved in the differentiation pathway is unclear. Using an in vitro model system where isolated CD4(+)CD8(+) thymocytes can survive and differentiate into semi-mature CD4-lineage T cells, we suggest that low calcineurin activity sustained for approximately 20 h is required for cell survival and differentiation. Accordingly, the DNA binding activity of NFAT slowly increased during the stimulation of 20 h to induce the differentiation. NFATx significantly contributed to the early rise, but the late increase was mostly due to NFATc activation. Meanwhile, the expression of NFATx mRNA decreased and that of NFATc mRNA increased. The DNA-binding activity of NFATp was detectable but low throughout the stimulation. NFATp became dominantly active after the semi-mature T cells differentiated into mature and activated CD4 T cells. These findings suggest that NFATx and NFATc successively play roles in T cell development.	Mitsubishi Kasei Inst Life Sci, Integrat Projects, Tokyo 1948511, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, CREST,Minato Ku, Tokyo 1080071, Japan; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA	Japan Science & Technology Agency (JST); University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Iwata, M (corresponding author), Mitsubishi Kasei Inst Life Sci, Integrat Projects, 11 Minamiooya, Tokyo 1948511, Japan.							ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Amasaki Y, 1998, J IMMUNOL, V160, P2324; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chen F, 1999, INT IMMUNOL, V11, P677, DOI 10.1093/intimm/11.5.677; Cibotti R, 1997, IMMUNITY, V6, P245, DOI 10.1016/S1074-7613(00)80327-1; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DEUSCH K, 1990, J IMMUNOL, V144, P2851; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FINE JS, 1991, J IMMUNOL, V147, P2852; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GILLILAND LK, 1991, J IMMUNOL, V146, P1759; Gomez J, 1998, ONCOGENE, V17, P1235, DOI 10.1038/sj.onc.1202049; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Iwata M, 1996, STEM CELLS, V14, P632, DOI 10.1002/stem.140632; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; JIE L, 1997, MOL BIOL CELL, V8, P157; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kuwata T, 1998, BIOCHEM BIOPH RES CO, V247, P242, DOI 10.1006/bbrc.1998.8767; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, MOL CELL BIOL, V16, P3955; Mariathasan S, 1998, J IMMUNOL, V161, P6030; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; Ohoka Y, 1997, J IMMUNOL, V158, P5707; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pan S, 1997, BIOCHEM BIOPH RES CO, V240, P314, DOI 10.1006/bbrc.1997.7381; Porritt HE, 1998, EUR J IMMUNOL, V28, P1197, DOI 10.1002/(SICI)1521-4141(199804)28:04<1197::AID-IMMU1197>3.0.CO;2-N; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rincon M, 1996, MOL CELL BIOL, V16, P1074; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shao H, 1999, J IMMUNOL, V163, P603; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Simon AK, 1996, INT IMMUNOL, V8, P1421, DOI 10.1093/intimm/8.9.1421; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; WANG CR, 1995, J EXP MED, V181, P927, DOI 10.1084/jem.181.3.927; WATANABE M, 1993, ONCOGENE, V8, P2949; WILKINSON RW, 1995, J IMMUNOL, V155, P5234; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; ZHAO Y, 1995, INT IMMUNOL, V7, P1387, DOI 10.1093/intimm/7.9.1387; ZHAO Y, 1995, J IMMUNOL, V154, P6346; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	64	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14708	14716		10.1074/jbc.275.19.14708	http://dx.doi.org/10.1074/jbc.275.19.14708			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799559	hybrid			2022-12-27	WOS:000087006900093
J	Milon, L; Meyer, P; Chiadmi, M; Munier, A; Johansson, M; Karlsson, A; Lascu, I; Capeau, J; Janin, J; Lacombe, ML				Milon, L; Meyer, P; Chiadmi, M; Munier, A; Johansson, M; Karlsson, A; Lascu, I; Capeau, J; Janin, J; Lacombe, ML			The human nm23-H4 gene product is a mitochondrial nucleoside diphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; DICTYOSTELIUM-DISCOIDEUM; NUCLEAR-LOCALIZATION; TUMOR-METASTASIS; PROTEIN; DROSOPHILA; FAMILY; CELLS; CRYSTALLOGRAPHY; APOPTOSIS	We demonstrate here the catalytic activity and subcellular localization of the Nm23-H4 protein, product of nm23-H4, a new member of the human nm23/nucleoside diphosphate (NDP) kinase gene family (Milon, L., Rousseau-Merck, M., Munier, A., Erent, M., Lascu, I., Capeau, J., and Lacombe, M. L. (1997) Hum. Genet. 99, 550-557). Nm3-H4 was synthesized in escherichia coli as the full-length protein and as a truncated form missing the N-terminal extension characteristic of mitochondrial targeting. The truncated form possesses NDP kinase activity, whereas the full-length protein is inactive, suggesting that the extension prevents enzyme folding and/or activity. X-ray crystallographic analysis was performed on active truncated Nm23-H4. Like other eukaryotic NDP kinases, it is a hexamer. Nm23-H4 naturally possesses a serine residue at position 129, equivalent to the li-pn mutation of the Drosophila NDP kinase. The x-ray structure shows that the presence of Ser(129) has local structural effects that weaken subunit interactions. Site-directed mutagenesis shows that the serine is responsible for the lability of Nm23-H4 to heat and urea treatment, because the S129P mutant is greatly stabilized. Examination of human embryonic kidney 293 cells transfected with green fluorescent protein fusions by confocal microscopy shows a specific mitochondrial localization of Nm23-H4 that was also demonstrated by Western blot analysis of subcellular fractions of these cells. Import into mitochondria is accompanied by cleavage of the N-terminal extension that results in NDP kinase activity. Submitochondrial fractionation indicates that Nm23-H4 is associated with mitochondrial membranes, possibly to the contact sites between the outer and inner membranes.	Univ Paris 06, INSERM, U402, F-75012 Paris, France; Univ Paris Sud, Lab Enzymol & Biochim Struct, CNRS, UPR 9063, F-91198 Gif Sur Yvette, France; Huddinge Univ Hosp, Karolinska Inst, Dept Clin Virol F68, S-14186 Huddinge, Sweden; Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, CNRS, UMR 5095, F-33077 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Lacombe, ML (corresponding author), Univ Paris 06, INSERM, U402, 27 Rue Chaligny, F-75012 Paris, France.	lacombe@st-antoine.inserm.fr	Janin, Joel/I-2958-2012; Karlsson, Anna/E-7945-2018; Meyer, Philippe/AAC-6038-2019	Meyer, Philippe/0000-0002-6220-0679; Karlsson, Anna/0000-0001-6843-6685				ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; Agarwal R P, 1978, Methods Enzymol, V51, P376; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHERRADI N, 1994, ENDOCRINOLOGY, V134, P1358, DOI 10.1210/en.134.3.1358; Claros MG, 1997, CURR OPIN STRUC BIOL, V7, P394, DOI 10.1016/S0959-440X(97)80057-7; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; EILERS M, 1988, PHILOS T ROY SOC B, V319, P121, DOI 10.1098/rstb.1988.0036; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gonin P, 1999, BIOCHEMISTRY-US, V38, P7265, DOI 10.1021/bi982990v; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; HERBERT E, 1955, J BIOL CHEM, V213, P923; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; JACOBUS WE, 1977, J BIOL CHEM, V252, P4232; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Kraeft SK, 1996, EXP CELL RES, V227, P63, DOI 10.1006/excr.1996.0250; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS HA, 1978, BIOCHEM J, V174, P297, DOI 10.1042/bj1740297; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth DO, 1997, J BIOL CHEM, V272, P24604, DOI 10.1074/jbc.272.39.24604; LASCU I, 1992, J BIOL CHEM, V267, P12775; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mehus JG, 1999, HUM GENET, V104, P454, DOI 10.1007/s004390050987; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MUHONEN WW, 1995, COMP BIOCHEM PHYS B, V110, P211, DOI 10.1016/0305-0491(94)00123-C; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; PEDERSEN PL, 1973, J BIOL CHEM, V248, P3956; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; PINON VPB, 1998, PHARM BIOTECH SCI TO, V3, P10; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Roussel A, 1991, SILICON GRAPHICS GEO, P81; SCHLATTNER U, 2000, IN PRESS J BIOENERG; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Struglics A, 1999, EUR J BIOCHEM, V262, P765, DOI 10.1046/j.1432-1327.1999.00432.x; TROLL H, 1993, J BIOL CHEM, V268, P25469; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457	63	114	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14264	14272		10.1074/jbc.275.19.14264	http://dx.doi.org/10.1074/jbc.275.19.14264			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799505	hybrid			2022-12-27	WOS:000087006900037
J	Perry, JM; Zhao, YD; Marletta, MA				Perry, JM; Zhao, YD; Marletta, MA			Cu2+ and Zn2+ inhibit nitric-oxide synthase through an interaction with the reductase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; ELECTRON-TRANSFER; L-ARGININE; CALMODULIN; CATALYSIS; FLAVIN; HEME; FAD; IDENTIFICATION; EXPRESSION	Cu2+ and Zn2+ inhibit all of the NADPH-dependent reactions catalyzed by neuronal nitric-oxide synthase (nNOS) including ferricytochrome c reduction, NADPH oxidation, and citrulline formation. Cu2+ and Zn2+ also inhibit ferricytochrome c reduction by the independent reductase domain. Zn2+ affects all activities of the full-length nNOS and the reductase domain to the same extent (estimated IC50 values from 9 to 31 mu M), suggesting Zn2+ occupation of a single site in the reductase domain. Citrulline formation and NADPH oxidation by the full-length nNOS and ferricytochrome c reduction by the reductase domain are affected similarly by Cu2+, with estimated IC50 values ranging from 6 to 33 mu M. However, Cu2+ inhibits ferricytochrome c reduction by the full-length nNOS 2 orders of magnitude more potently, with an estimated IC50 value of 0.12 mu M. These data suggest the possibility that Cu2+ amy interact with nNOS at two sites, one composed exclusively of the reductase domain (which is perhaps also involved in Zn2+-mediated inhibition), and another that includes components of both domains. Occupation of the second (higher affinity) site could then promote the selective inhibition of ferricytochrome c reduction in full-length nNOS. Neither the inhibition by Cu2+ nor that by Zn2+ is dependent on calmodulin.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Pharm, Div Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Marletta, MA (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Zhao, Yunde/AAC-5360-2019		NATIONAL CANCER INSTITUTE [R01CA050414] Funding Source: NIH RePORTER; NCI NIH HHS [CA50414] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BEYER WF, 1987, ANAL BIOCHEM, V161, P559, DOI 10.1016/0003-2697(87)90489-1; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FRITCHIE CJ, 1973, J BIOL CHEM, V248, P7516; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; HEVEL JM, 1992, BIOL NITRIC OXIDE, V2; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KLATT P, 1992, J BIOL CHEM, V267, P11374; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MILOS M, 1989, J INORG BIOCHEM, V36, P11, DOI 10.1016/0162-0134(89)80009-1; MULLER F, 1968, EUR J BIOCHEM, V5, P158, DOI 10.1111/j.1432-1033.1968.tb00352.x; MULLER F, 1970, EUR J BIOCHEM, V14, P185, DOI 10.1111/j.1432-1033.1970.tb00277.x; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Perry JM, 1998, CHEM BIOL, V5, P355, DOI 10.1016/S1074-5521(98)90069-2; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	36	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14070	14076		10.1074/jbc.275.19.14070	http://dx.doi.org/10.1074/jbc.275.19.14070			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799481	hybrid			2022-12-27	WOS:000087006900011
J	Ren, JS; Nichols, C; Bird, LE; Fujiwara, T; Sugimoto, H; Stuart, DI; Stammers, DK				Ren, JS; Nichols, C; Bird, LE; Fujiwara, T; Sugimoto, H; Stuart, DI; Stammers, DK			Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; INFECTION; RESISTANT; DESIGN; DERIVATIVES; REPLICATION; MORTALITY; MECHANISM	S-1153 (AG1549) is perhaps the most promising nonnucleoside inhibitor of HIV-1 reverse transcriptase currently under development as a potential anti-AIDS drug, because it has a favorable profile of resilience to many drug resistance mutations. We have determined the crystal structure of S-1153 in a complex with HIV-1 reverse transcriptase, The complex possesses some novel features, including an extensive network of hydrogen bonds involving the main chain of residues 101, 103, and 236 of the p66 reverse transcriptase subunit, Such interactions are unlikely to be disrupted by side chain mutations. The reverse transcriptase/S-1153 complex suggests different ways in which resilience to mutations in the non-nucleoside inhibitors of reverse transcriptase binding site can be achieved.	Univ Oxford, Wellcome Trust Ctr Human Genet, Struct Biol Div, Oxford OX3 7BN, England; Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, Osaka 5530002, Japan; Oxford Ctr Mol Sci, Oxford OX1 3QY, England	University of Oxford; Wellcome Centre for Human Genetics; Shionogi & Company Limited; University of Oxford	Stuart, DI (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Struct Biol Div, Roosevelt Dr, Oxford OX3 7BN, England.	dave@strubi.ox.ac.uk; daves@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Bird, Louise/0000-0002-9846-5716; Stuart, David/0000-0002-3426-4210				BALZARINI J, 1995, ANTIVIR RES, V27, P219, DOI 10.1016/0166-3542(95)00006-8; Brettle RP, 1998, INT J STD AIDS, V9, P80, DOI 10.1258/0956462981921729; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR MANUAL VERSION; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984; Esnouf RM, 1998, ACTA CRYSTALLOGR D, V54, P938, DOI 10.1107/S0907444998004284; Fujiwara T, 1998, ANTIMICROB AGENTS CH, V42, P1340, DOI 10.1128/AAC.42.6.1340; Gazzard BG, 1999, INT J CLIN PRACT, V53, P60; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c; Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLEIM JP, 1993, ANTIMICROB AGENTS CH, V37, P1659, DOI 10.1128/AAC.37.8.1659; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REN J, 2000, IN PRESS J BIOL CHEM, V275; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X; Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m; Ren JS, 1999, J MED CHEM, V42, P3845, DOI 10.1021/jm990275t; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; Schinazi R. F., 1997, International Antiviral News, V5, P129; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; STAMMERS DK, 1994, J MOL BIOL, V242, P586, DOI 10.1006/jmbi.1994.1604; YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602	32	130	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14316	14320		10.1074/jbc.275.19.14316	http://dx.doi.org/10.1074/jbc.275.19.14316			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799511	hybrid			2022-12-27	WOS:000087006900043
J	Aoki, K; Motojima, F; Taguchi, H; Yomo, T; Yoshida, M				Aoki, K; Motojima, F; Taguchi, H; Yomo, T; Yoshida, M			GroEL binds artificial proteins with random sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMODYNAMIC PARTITIONING MODEL; CHAPERONIN GROEL; BETA-LACTAMASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; SECONDARY STRUCTURES; POLYPEPTIDE BINDING; HYDROPHOBIC BINDING; ALPHA-LACTALBUMIN; CRYSTAL-STRUCTURE	Chaperonin GroEL from Escherichia coli binds to the non-native states of many unrelated proteins, and GroEL-recognizable structural features have been argued. As model substrate proteins of GroEL, we used seven artificial proteins (138 similar to 141 residues), each of which has a unique but randomly chosen amino acid sequence and no propensity to fold into a certain structure. Two of them were water-soluble, and the rest were soluble in 3 M urea. The soluble ones interacted with GroEL in a manner similar to that of a natural substrate; they stimulated the ATPase cycle of GroEL and GroEL/ GroES and inhibited GroEL-assisted folding of other protein. All seven artificial proteins were able to bind to GroEL, The results suggest that the secondary structure as well as the specific sequence motif of the substrate proteins are not necessary to be recognized by GroEL.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan	Tokyo Institute of Technology; Osaka University	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 nagatsuta, Yokohama, Kanagawa 2268503, Japan.		Taguchi, Hideki/B-6946-2009; Motojima, Fumihiro/J-2389-2014; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; Motojima, Fumihiro/0000-0003-4461-8673; taguchi, hideki/0000-0002-6612-9339				Aoki K, 1997, J BIOL CHEM, V272, P32158, DOI 10.1074/jbc.272.51.32158; Beissinger M, 1998, BIOL CHEM, V379, P245; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; Brazil BT, 1997, J BIOL CHEM, V272, P5105, DOI 10.1074/jbc.272.8.5105; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Clark AC, 1999, J MOL BIOL, V285, P1777, DOI 10.1006/jmbi.1998.2403; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Gervasoni P, 1996, P NATL ACAD SCI USA, V93, P12189, DOI 10.1073/pnas.93.22.12189; Gervasoni P, 1998, BIOCHEMISTRY-US, V37, P11660, DOI 10.1021/bi980258q; GETING MJ, 1992, NATURE, V355, P33; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; Gorovits BM, 1997, J BIOL CHEM, V272, P32; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; Hoshino M, 1996, J MOL BIOL, V262, P575, DOI 10.1006/jmbi.1996.0536; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; KUWAJIMA K, 1975, J BIOCHEM-TOKYO, V78, P205; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; Prijambada ID, 1996, FEBS LETT, V382, P21, DOI 10.1016/0014-5793(96)00123-8; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Vinckier A, 1998, BIOPHYS J, V74, P3256, DOI 10.1016/S0006-3495(98)78032-4; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yamauchi A, 1998, FEBS LETT, V421, P147, DOI 10.1016/S0014-5793(97)01552-4; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	54	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13755	13758		10.1074/jbc.275.18.13755	http://dx.doi.org/10.1074/jbc.275.18.13755			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788496	hybrid			2022-12-27	WOS:000086925300083
J	Jardim, A; Liu, W; Zheleznova, E; Ullman, B				Jardim, A; Liu, W; Zheleznova, E; Ullman, B			Peroxisomal targeting signal-1 receptor protein PEX5 from Leishmania donovani - Molecular, biochemical, and immunocytochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; TRYPANOSOMA-BRUCEI; PTS1 RECEPTOR; ORNITHINE DECARBOXYLASE; FIREFLY LUCIFERASE; ESCHERICHIA-COLI; CARBOXY TERMINUS; GLYCOSOMES; IDENTIFICATION; IMPORT	The human pathogens of the Leishmania and Trypanosoma genera compartmentalize glycolytic and other key metabolic pathways in unique subcellular microbodies called glycosomes, organelles related to the peroxisomes of mammals and yeast. The molecular machinery that carries out the specific targeting of glycosomal proteins to the organelle has not been characterized, although the bulk of glycosomal proteins contain the COOH-terminal tripeptide glycosomal peroxisomal targeting signal-1 (PTS-1) similar to the mammalian and fungal peroxisomal targeting signal. To characterize the mechanisms of glycosomal targeting, the gene encoding PEX5, designated LdPEX5, has been isolated from Leishmania donovani. LdPEX5 encodes a 625-amino acid protein with a molecular mass of 69.7 kDa. Like its homologs in yeast and humans, LdPEX5 predicts a protein with seven copies of a tetratricopeptide repeat in its COOH-terminal half proposed to mediate PTS-1 binding and three copies of a WXXX(Y/F) motif in its NH2 terminus conjectured to be essential for protein translocation into the organelle. LdPEX5 was overexpressed in Escherichia coli and purified to homogeneity for binding experiments and generation of antibodies. Recombinant LdPEX5 bound xanthine phosphoribosyltransferase (XPRT), a PTS-1 containing glycosomal protein with a K-D of 4.2 nM, but did not bind an XPRT in which the PTS-1 had been deleted. Moreover, binding studies with the COOH-terminal half of the LdPEX5 confirmed that this portion of the PEX5 protein was capable of binding the XPRT PTS-1 with an affinity of 17.3 nM. Confocal microsocopy revealed that LdPEX5 was predominantly in the cytosolic milieu, and genetic analysis implied that LdPEX5 was an essential gene.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	ullmanb@ohsu.edu		Heldwein, Ekaterina/0000-0003-3113-6958	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; ALLEN TE, 1994, MOL BIOCHEM PARASIT, V65, P233, DOI 10.1016/0166-6851(94)90075-2; BLATTNER J, 1995, FEBS LETT, V360, P310, DOI 10.1016/0014-5793(95)00128-V; BLUM JJ, 1990, J PROTOZOOL, V37, P505, DOI 10.1111/j.1550-7408.1990.tb01256.x; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Walque S, 1999, MOL BIOCHEM PARASIT, V104, P107, DOI 10.1016/S0166-6851(99)00144-9; DECKER LA, 1977, WORTHINGTON ENZYME M, P98; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Flaspohler JA, 1999, MOL BIOCHEM PARASIT, V99, P117, DOI 10.1016/S0166-6851(99)00005-5; Flaspohler JA, 1997, MOL CELL BIOL, V17, P1093, DOI 10.1128/MCB.17.3.1093; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; FUNG K, 1991, MOL BIOCHEM PARASIT, V45, P261, DOI 10.1016/0166-6851(91)90093-L; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HAMMOND DJ, 1985, J BIOL CHEM, V260, P5646; HANNAERT V, 1999, ARCH PHYSIOL BIOCHEM, V107, pB9; HANSON S, 1992, J BIOL CHEM, V267, P2350; HART DT, 1984, MOL BIOCHEM PARASIT, V13, P159, DOI 10.1016/0166-6851(84)90110-5; Heise N, 1997, MOL BIOCHEM PARASIT, V89, P61, DOI 10.1016/S0166-6851(97)00101-1; Jardim A, 1999, J BIOL CHEM, V274, P34403, DOI 10.1074/jbc.274.48.34403; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; KRASSNER S M, 1977, Acta Tropica, V34, P157; KUZOE FAS, 1993, ACTA TROP, V54, P153, DOI 10.1016/0001-706X(93)90089-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LANGFORD CK, 1992, EXP PARASITOL, V74, P360, DOI 10.1016/0014-4894(92)90161-3; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; MICHELS PAM, 1994, J BIOENERG BIOMEMBR, V26, P213, DOI 10.1007/BF00763070; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; *WHO, 1984, B WHO, V701; WIENRENGA RK, 1987, EMBO J, V6, P15; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787	54	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13637	13644		10.1074/jbc.275.18.13637	http://dx.doi.org/10.1074/jbc.275.18.13637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788481	hybrid, Green Submitted			2022-12-27	WOS:000086925300068
J	Jarmuszkiewicz, W; Almeida, AM; Vercesi, AE; Sluse, FE; Sluse-Goffart, CM				Jarmuszkiewicz, W; Almeida, AM; Vercesi, AE; Sluse, FE; Sluse-Goffart, CM			Proton re-uptake partitioning between uncoupling protein and ATP synthase during benzohydroxamic acid-resistant state 3 respiration in tomato fruit mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; PLANT-MITOCHONDRIA; MECHANISTIC STOICHIOMETRY; ALTERNATIVE OXIDASE; FATTY-ACIDS; CYCLING MECHANISM; STEADY-STATE; LOWER LIMITS; MEMBRANE	The yield of oxidative phosphorylation in isolated tomato fruit mitochondria depleted of free fatty acids remains constant when respiratory rates are decreased by a factor of 3 by the addition of n-butyl malonate. This constancy makes the determination of the contribution of the linoleic acid-induced energy-dissipating pathway by the ADP/O method possible. No decrease in membrane potential is observed in state 3 respiration with increasing concentration of n-butyl malonate, indicating that the rate of ATP synthesis is steeply dependent on membrane potential. Linoleic acid decreases the yield of oxidative phosphorylation in a concentration-dependent manner by a pure protonophoric process like that in the presence of FCCP. ADP/O measurements allow calculation of the part of respiration leading to ATP synthesis and the part of respiration sustained by the dissipative H+ re-uptake induced by linoleic acid. Respiration sustained by this energy-dissipating process remains constant at a given LA concentration until more than 50% inhibition of state 3 respiration by n-butyl malonate is achieved. The energy dissipative contribution to oxygen consumption is proposed to be equal to the protonophoric activity of plant uncoupling protein divided by the intrinsic H+/O of the cytochrome pathway. It increases with linoleic acid concentration, taking place at the expense of ADP phosphorylation without an increase in the respiration.	Univ Estadual Campinas, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil; Adam Mickiewicz Univ, Dept Bioenerget, PL-61701 Poznan, Poland; Univ Liege, Inst Chem B6, Ctr Oxygen Res & Dev, Lab Bioenerget, B-4000 Liege, Belgium	Universidade Estadual de Campinas; Adam Mickiewicz University; University of Liege	Vercesi, AE (corresponding author), Univ Estadual Campinas, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil.		de Almeida, Andrea Miyasaka/AAY-7847-2020; Vercesi, Aníbal E/C-8767-2012	Miyasaka Almeida, Andrea/0000-0002-5848-0874; Vercesi, Anibal Eugenio/0000-0001-6671-7125; Jarmuszkiewicz, Wieslawa/0000-0001-8550-8337				Almeida AM, 1999, PLANT PHYSIOL, V119, P1323, DOI 10.1104/pp.119.4.1323; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P307, DOI 10.1111/j.1432-1033.1986.tb09752.x; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BROWN GC, 1989, J BIOL CHEM, V264, P14704; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1993, MODERN TRENDS IN BIOTHERMOKINETICS, P287; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUCLU J, 1989, PHYSIOL PLANTARUM, V77, P413, DOI 10.1111/j.1399-3054.1989.tb05662.x; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P10174, DOI 10.1074/jbc.273.17.10174; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P34882, DOI 10.1074/jbc.273.52.34882; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; LUVISETTO S, 1991, J BIOL CHEM, V266, P1034; LUVISETTO S, 1994, BBA-BIOENERGETICS, V1186, P12, DOI 10.1016/0005-2728(94)90129-5; LUVISETTO S, 1987, BIOCHEMISTRY-US, V26, P7332, DOI 10.1021/bi00397a021; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; Mackenzie S, 1999, PLANT CELL, V11, P571, DOI 10.1105/tpc.11.4.571; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; MEEUSE BJD, 1975, ANNU REV PLANT PHYS, V26, P117, DOI 10.1146/annurev.pp.26.060175.001001; MOORE AL, 1993, BIOCHEM SOC T, V21, P765, DOI 10.1042/bst0210765; MURPHY MP, 1989, BIOCHIM BIOPHYS ACTA, V977, P123, DOI 10.1016/S0005-2728(89)80063-5; PIETROBON D, 1985, BIOCHEMISTRY-US, V24, P5764, DOI 10.1021/bi00342a012; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; ROUETMAYER MA, 1995, LIPIDS, V30, P739, DOI 10.1007/BF02537801; SCHONFELD P, 1989, BIOCHIM BIOPHYS ACTA, V977, P266, DOI 10.1016/S0005-2728(89)80080-5; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Sluse FE, 1998, FEBS LETT, V433, P237, DOI 10.1016/S0014-5793(98)00922-3; SLUSE FE, 1999, 28 ANN M BRAZ SOC BI; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Wagner AM, 1997, BIOSCIENCE REP, V17, P319, DOI 10.1023/A:1027388729586; WESTERHOFF HV, 1987, HTERMODYNAMICS CONTR; WOELDERS H, 1988, BIOCHIM BIOPHYS ACTA, V934, P123, DOI 10.1016/0005-2728(88)90127-2; Wojtczak L, 1998, ARCH BIOCHEM BIOPHYS, V357, P76, DOI 10.1006/abbi.1998.0777; ZORATTI M, 1982, EUR J BIOCHEM, V126, P443, DOI 10.1111/j.1432-1033.1982.tb06800.x	41	34	35	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13315	13320		10.1074/jbc.275.18.13315	http://dx.doi.org/10.1074/jbc.275.18.13315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788438	Green Published, hybrid			2022-12-27	WOS:000086925300024
J	Shao, F; Bader, MW; Jakob, U; Bardwell, JCA				Shao, F; Bader, MW; Jakob, U; Bardwell, JCA			DsbG, a protein disulfide isomerase with chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; ESCHERICHIA-COLI; IN-VIVO; CITRATE SYNTHASE; PATHWAY; SYSTEM; VITRO; HSP90	DsbG, a protein disulfide isomerase present in the periplasm of Escherichia coli, is shown to function as a molecular chaperone. Stoichiometric amounts of DsbG are sufficient to prevent the thermal aggregation of two classical chaperone substrate proteins, citrate synthase and luciferase. DsbG was also shown to interact with refolding intermediates of chemically denatured citrate synthase and prevents their aggregation in vitro. Citrate synthase reactivation experiments in the presence of DsbG suggest that DsbG binds with high affinity to early unstructured protein folding intermediates. DsbG is one of the first periplasmic proteins shown to have general chaperone activity. This ability to chaperone protein folding is likely to increase the effectiveness of DsbG as a protein disulfide isomerase.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Biomed Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.							Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Eisenberg D, 1999, SCIENCE, V285, P1021, DOI 10.1126/science.285.5430.1021; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FREEDMAN RB, 1994, CURR BIOL, V4, P93; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; STRAATEN M, 1998, FEBS LETT, V428, P255; Wang CC, 1998, ANN NY ACAD SCI, V864, P9, DOI 10.1111/j.1749-6632.1998.tb10283.x; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	32	95	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13349	13352		10.1074/jbc.275.18.13349	http://dx.doi.org/10.1074/jbc.275.18.13349			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788443	hybrid			2022-12-27	WOS:000086925300029
J	Zheng, WH; Kar, S; Quirion, R				Zheng, WH; Kar, S; Quirion, R			Stimulation of protein kinase C modulates insulin-like growth factor-1-induced Akt activation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-1 TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY DOMAIN; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; NEURONAL SURVIVAL; GLUCOSE-TRANSPORT; 3-KINASE; INHIBITOR	Activation of protein kinase C (PKC) plays an important role in the negative regulation of receptor signaling, but its effect on insulin-like growth factor-1 (IGF-1) receptor signaling remains unclear. In this study, we characterized the intracellular pathways involved in IGF-1-induced activation of Akt and evaluated the effects of the PKC activator phorbol 12-myristate 13-acetate (PMA) on the Akt activation by IGF-1. IGF-1 induced a time- and concentration-dependent activation of Akt. The effect of IGF-1 was blocked by the phosphatidylinositide 3-kinase (PI3K) inhibitors LY294002 (50 mu M) and wortmannin (0.5 mu M), but not by the MEK inhibitor PD98059 (50 mu M) or the p70 S6 kinase pathway inhibitor rapamycin (50 nM), suggesting that the stimulation of Akt by IGF-1 is mediated by the PI3K pathway. Interestingly, cotreatment with PIMA (400 nM) attenuated IGF-1-induced activation of Akt. The attenuation was blocked completely by the PKC inhibitor GO6983 (0.5 mu M), but only partially by the MEK inhibitor PD98059 (50 mu M), indicating that MAPK-dependent and -independent pathways are involved. PMA induced the activation of PKC in PC12 cells, and this induction was blocked by GO6983. These data further support the role of PKC in the effect of PMA. Moreover, PKC delta is likely involved in the action of PMA on the basis of data obtained using isoform-specific inhibitors such as rottlerin. PMA also decreased IGF-1-induced tyrosine phosphorylation of insulin receptor substrate-1 and its association with PI3K. Taken together, these results suggest, for the first time, that stimulation of PKC modulates IGF-1-induced activation of Akt.	McGill Univ, Dept Psychiat, Douglas Hosp, Res Ctr, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Pharmacol & Therapeut, Douglas Hosp, Res Ctr, Verdun, PQ H4H 1R3, Canada	McGill University; McGill University	Quirion, R (corresponding author), McGill Univ, Dept Psychiat, Douglas Hosp, Res Ctr, 6875 LaSalle Blvd, Verdun, PQ H4H 1R3, Canada.	mcou@musica.mcgil.ca	yang, chao/AAV-5929-2021					Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; delPeso L, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Dore S, 1997, TRENDS NEUROSCI, V20, P326; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Loddick SA, 1999, P NATL ACAD SCI USA, V96, P9449, DOI 10.1073/pnas.96.17.9449; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Parrizas M, 1997, J BIOL CHEM, V272, P154; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zheng WH, 1996, J NEUROCHEM, V66, P1868; ZHENG WH, 1999, SOC NEUR ABSTR, V28, P2203	64	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13377	13385		10.1074/jbc.275.18.13377	http://dx.doi.org/10.1074/jbc.275.18.13377			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788447	hybrid			2022-12-27	WOS:000086925300033
J	Kulish, D; Lee, J; Lomakin, I; Nowicka, B; Das, A; Darst, S; Normet, K; Borukhov, S				Kulish, D; Lee, J; Lomakin, I; Nowicka, B; Das, A; Darst, S; Normet, K; Borukhov, S			The functional role of basic patch, a structural element of Escherichia coli transcript cleavage factors GreA and GreB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR TFIIS; COMPLETE GENOME SEQUENCE; FACTOR-SII; TERNARY COMPLEXES; NASCENT RNA; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; IN-VITRO; GENE	The transcript cleavage factors GreA and GreB of Escherichia coli are involved in the regulation of transcription elongation. The surface charge distribution analysis of their three-dimensional structures revealed that the N-terminal domains of GreA and GreB contain a small and large basic "patch," respectively. To elucidate the functional role of basic patch, mutant Gre proteins were engineered in which the size and charge distribution of basic patch were modified and characterized biochemically. We found that Gre mutants lacking basic patch or carrying basic patch of decreased size bind to RNA polymerase and induce transcript cleavage reaction in minimally backtracked ternary elongation complex (TEC) with the same efficiency as the wild type factors, However, they exhibit substantially lower readthrough and cleavage activities toward extensively backtracked and arrested TECs and display decreased efficiency of photocross-linking to the RNA 3' terminus. Unlike wild type factors, basic patch-less Gre mutants are unable to complement the thermosensitive phenotype of GreA(-):GreB(-) E. coli strain. The large basic patch is required but not sufficient for the induction of GreB-type cleavage reaction and for the cleavage of arrested TECs, Our results demonstrate that the basic patch residues are not directly involved in the induction of transcript cleavage reaction and suggest that the primary role of basic patch is to anchor the nascent RNA in TEC, These interactions are essential for the readthrough and antiarrest activities of Gre factors and, apparently, for their in vivo functions.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA; Rockefeller Univ, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Connecticut; Rockefeller University	Borukhov, S (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave,BSB 3-27, Brooklyn, NY 11203 USA.	serbor@asan.com	Borukhov, Sergei/AAF-3195-2019	Borukhov, Sergei/0000-0002-3517-3003; Lomakin, Ivan/0000-0001-6528-5068	NIGMS NIH HHS [GM54098, GM28946] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054098, R01GM028946] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; Borukhov S, 1996, METHOD ENZYMOL, V274, P315; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FENG GH, 1994, J BIOL CHEM, V269, P22282; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAWLEY DK, 1993, CELL MOL BIOL RES, V39, P339; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Koulich D, 1998, J MOL BIOL, V276, P379, DOI 10.1006/jmbi.1997.1545; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LANGER D, 1993, NUCLEIC ACIDS RES, V21, P2251, DOI 10.1093/nar/21.9.2251; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MARKS GL, 1992, NUCLEIC ACIDS RES, V20, P3785, DOI 10.1093/nar/20.14.3785; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Polyakov A, 1998, J MOL BIOL, V281, P465, DOI 10.1006/jmbi.1998.1958; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1993, CELL MOL BIOL RES, V39, P331; REINES D, 1989, J BIOL CHEM, V264, P10799; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; Yoon H, 1998, BIOCHEMISTRY-US, V37, P12104, DOI 10.1021/bi980924n; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	60	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12789	12798		10.1074/jbc.275.17.12789	http://dx.doi.org/10.1074/jbc.275.17.12789			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777576	hybrid			2022-12-27	WOS:000086762300060
J	McGuire, JJ; Russell, CA; Balinska, M				McGuire, JJ; Russell, CA; Balinska, M			Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct - Expression in antifolate-sensitive and -resistant human cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	89th Annual Meeting of the American-Association-for-Cancer-Research	MAR 27-APR 01, 1998	NEW ORLEANS, LA	Amer Assoc Canc Res			GAMMA-GLUTAMATE SYNTHETASE; ONE-CARBON METABOLISM; MAMMALIAN-CELLS; RAT-LIVER; FOLATE METABOLISM; ESCHERICHIA-COLI; LEUKEMIA-CELLS; METHOTREXATE; GENE; POLYGLUTAMYLATION	Folylpolyglutamate synthetase (FPGS) activity in CCRF-CEM human leukemia cells was found in the cytosolic ( approximate to 67% of total) and mitochondrial ( approximate to 22%) fractions. A polyclonal antipeptide antibody (430Ab) to human FPGS specifically recognized distinct immunoreactive bands (approximate to 60 kDa) present in each subcellular fraction. Human cytosolic FPGS (hcFPGS) migrated more rapidly than mitochondrial FPGS (hmFPGS); their estimated difference in molecular mass was 1 kDa. The human K562 acute nonlymphocytic leukemia and the A253 and FaDu head and neck cancer cell lines also expressed the two FPGS isoforms, and the ratio of hcFPGS to hmFPGS protein in each cell line was similar. Since K562 and A253 cells are intrinsically resistant to pulse methotrexate (MTX) exposure relative to CCRF-CEM and FaDu cells, respectively, because of decreased MTX polyglutamate synthesis (despite having similar levels of total FPGS activity expression), these data suggest that the natural difference in drug sensitivity cannot be explained by compartmentalization of FPGS activity. Higher expression of hmFPGS relative to hcFPGS was observed in some sublines of CCRF-CEM with acquired MTX resistance suggesting that differential expression of the hmFPGS isoform may contribute to MTX resistance caused by decreased FPGS activity.	New York State Dept Hlth, Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	McGuire, JJ (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	mcguire@sc3101.med.buffalo.edu			NCI NIH HHS [CA16056, CA43500] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA043500] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABMAYR SM, 1996, CURRENT PROTOCOLS MO, V2; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GALIVAN J, 1985, P NATL ACAD SCI USA, V82, P2598, DOI 10.1073/pnas.82.9.2598; GANGJEE A, 1994, J MED CHEM, V37, P1169, DOI 10.1021/jm00034a015; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GAWTHORNE JM, 1973, BIOCHEM J, V136, P295, DOI 10.1042/bj1360295; Harlow E., 1988, ANTIBODIES LAB MANUA; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; KIM JS, 1993, J BIOL CHEM, V268, P21680; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; Longo GSA, 1997, BLOOD, V90, P1241, DOI 10.1182/blood.V90.3.1241.1241_1241_1245; LOWE KE, 1993, J BIOL CHEM, V268, P21665; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1983, ADV EXP MED BIOL, V163, P199; McGuire JJ, 1998, ONCOL RES, V10, P193; McGuire JJ, 1999, CANC DRUG DISC DEV, P339; McGuire JJ, 1997, ONCOL RES, V9, P139; MCGUIRE JJ, 1984, BIOCHEM PHARMACOL, V33, P1355, DOI 10.1016/0006-2952(84)90192-8; MCGUIRE JJ, 1989, CANCER RES, V49, P4517; MCGUIRE JJ, 1994, CANCER RES, V54, P2673; MCGUIRE JJ, 1979, CHEM BIOL PTERIDINES, P471; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PIZZORNO G, 1988, CANCER RES, V48, P2149; PIZZORNO G, 1989, CANCER RES, V49, P5275; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; SHANE B, 1989, VITAM HORM, V45, P263; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Wagner C, 1996, J NUTR, V126, pS1228, DOI 10.1093/jn/126.suppl_4.1228S; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126	40	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13012	13016		10.1074/jbc.275.17.13012	http://dx.doi.org/10.1074/jbc.275.17.13012			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	309HK	10777604	hybrid			2022-12-27	WOS:000086762300088
J	Craig, R; Larkin, A; Mingo, AM; Thuerauf, DJ; Andrews, C; McDonough, PM; Glembotski, CC				Craig, R; Larkin, A; Mingo, AM; Thuerauf, DJ; Andrews, C; McDonough, PM; Glembotski, CC			p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release - Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; LEUKEMIA INHIBITORY FACTOR; INDUCED APOPTOSIS; CELL HYPERTROPHY; TNF RECEPTOR; ALPHA; PHOSPHORYLATION; BETA; CASCADE	In cardiac myocytes, the stimulation of p38 MAPK by the MAPKK, MKK6, activates the transcription factor, NF-kappa B, and protects cells from apoptosis. In the present study in primary neonatal rat cardiac myocytes, constitutively active MKK6, MKK6(Glu), bound to I kappa B kinase (IKK)-beta and stimulated its abilities to phosphorylate I kappa B and to activate NF-kappa B. MKK6(Glu) induced NF-kappa B-dependent interleukin (IL)-6 transcription and IL-6 release in a p38-dependent manner, IL-6 protected myocardial cells against apoptosis. Like IL-6, TNF-alpha, which activates both NF-kappa B and p38, also induced p38-dependent IL-6 expression and release and protected myocytes from apoptotis. While TNF-alpha was relatively ineffective, IL-6 activated myocardial cell STAT3 by about 8-fold, indicating a probable role for this transcription factor in IL-6-mediated protection from apoptosis, TNF-alpha-mediated IL-6 induction was inhibited by a kinase-inactive form of the MAPKKK, TGF-beta activated protein kinase (Tak1), which is known to activate p38 and NF-kappa B in other cell types. Thus, by stimulating both p38 and NF-kappa B, Tak1-activating cytokines, like TNF-alpha, can induce IL-6 expression and release. Moreover, the myocyte-derived IL-6 may then function in an autocrine and/or paracrine fashion to augment myocardial cell survival during stresses that activate p38.	San Diego State Univ, SDSU Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, SDSU Heart Inst, San Diego, CA 92182 USA.	cglembotski@sunstroke.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861, P01HL046345] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56861, HL-46345] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessenko AV, 1999, LIPIDS, V34, pS75, DOI 10.1007/BF02562235; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GUILLEN I, 1995, AM J PHYSIOL-REG I, V269, pR229, DOI 10.1152/ajpregu.1995.269.2.R229; Guo DQ, 1998, J IMMUNOL, V160, P2742; Gwechenberger M, 1999, CIRCULATION, V99, P546, DOI 10.1161/01.CIR.99.4.546; Hawkins HK, 1996, AM J PATHOL, V148, P1957; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Kanda T, 1996, LIFE SCI, V58, P1705, DOI 10.1016/0024-3205(96)00150-6; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim SO, 1998, J CELL BIOCHEM, V71, P286, DOI 10.1002/(SICI)1097-4644(19981101)71:2<286::AID-JCB13>3.0.CO;2-J; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; KUKIELKA GL, 1995, CIRCULATION, V92, P1866, DOI 10.1161/01.CIR.92.7.1866; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mann Douglas L., 1996, Cytokine and Growth Factor Reviews, V7, P341, DOI 10.1016/S1359-6101(96)00043-3; Matsui H, 1996, RES COMMUN MOL PATH, V93, P149; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakano M, 1996, AM J PHYSIOL-HEART C, V270, pH1231, DOI 10.1152/ajpheart.1996.270.4.H1231; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NELSON SK, 1995, J MOL CELL CARDIOL, V27, P223, DOI 10.1016/S0022-2828(08)80021-1; NEUMANN FJ, 1995, CIRCULATION, V92, P748, DOI 10.1161/01.CIR.92.4.748; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saito S, 1999, FEBS LETT, V456, P103, DOI 10.1016/S0014-5793(99)00936-9; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamakawa T, 1999, ENDOCRINOLOGY, V140, P3562, DOI 10.1210/en.140.8.3562; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	66	283	295	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23814	23824		10.1074/jbc.M909695199	http://dx.doi.org/10.1074/jbc.M909695199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10781614	hybrid			2022-12-27	WOS:000088564200057
J	Diamant, S; Ben-Zvi, AP; Bukau, B; Goloubinoff, P				Diamant, S; Ben-Zvi, AP; Bukau, B; Goloubinoff, P			Size-dependent disaggregation of stable protein aggregates by the DnaK chaperone machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; RNA-POLYMERASE; HSP70; GRPE; GROEL; ATPASE; CLPB; MECHANISMS; DISTINCT	Classic in vitro studies show that the Hsp70 chaperone system from Escherichia coli (DnaK-DnaJ-GrpE, the DnaK system) can bind to proteins, prevent aggregation, and promote the correct refolding of chaperone-bound polypeptides into native proteins. However, little is known about how the DnaK system handles proteins that have already aggregated. In this study, glucose-6-phosphate dehydrogenase was used as a model system to generate stable populations of protein aggregates comprising controlled ranges of particle sizes. The DnaK system recognized the glucose-6-phosphate dehydrogenase aggregates as authentic substrates and specifically solubilized and refolded the protein into a native enzyme. The efficiency of disaggregation by the DnaK system was high with small aggregates, but the efficiency decreased as the size of the aggregates increased. High folding efficiency was restored by either excess DnaK or substoichiometric amounts of the chaperone ClpB. We suggest a mechanism whereby the DnaK system can readily solubilize small aggregates and refold them into active proteins. With large aggregates, however, the binding sites for the DnaK system had to be dynamically exposed with excess DnaK or the catalytic action of ClpB and ATP. Disaggregation by the DnaK machinery in the cell can solubilize early aggregates that formed accidentally during chaperone-assisted protein folding or that escaped the protection of "holding" chaperones during stress.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	Hebrew University of Jerusalem; University of Freiburg	Goloubinoff, P (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	pierre@vms.huji.ac.il	BEN-ZVI, ANAT/F-1674-2012	BEN-ZVI, ANAT/0000-0003-2477-6519; Goloubinoff, Pierre/0000-0002-4802-0807; Bukau, Bernd/0000-0003-0521-7199				Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bukau B., 1999, MOL CHAPERONES FOLDI, P3; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; Jaenicke R, 1999, MOL CHAPERONES FOLDI, P407; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mendoza JA, 1996, BIOCHEM BIOPH RES CO, V229, P271, DOI 10.1006/bbrc.1996.1791; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	31	192	195	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21107	21113		10.1074/jbc.M001293200	http://dx.doi.org/10.1074/jbc.M001293200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801805	hybrid			2022-12-27	WOS:000088230600022
J	Zhang, SJ; Cheng, HP; Zhou, YY; Wang, DJ; Zhu, WZ; Ziman, B; Spurgoen, H; Lefkowitz, RJ; Lakatta, EG; Koch, WJ; Xiao, RP				Zhang, SJ; Cheng, HP; Zhou, YY; Wang, DJ; Zhu, WZ; Ziman, B; Spurgoen, H; Lefkowitz, RJ; Lakatta, EG; Koch, WJ; Xiao, RP			Inhibition of spontaneous beta(2)-adrenergic activation rescues beta(1)-adrenergic contractile response in cardiomyocytes overexpressing beta(2)-adrenoceptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; PROTEIN-COUPLED RECEPTORS; RAT-HEART; PHOSPHOLAMBAN PHOSPHORYLATION; BETA-ADRENOCEPTOR; CARDIAC MYOCYTES; TRANSGENIC MICE; CA2+ CURRENT; DESENSITIZATION; EXPRESSION	Cardiac-specific overexpression of the human beta(2)-adrenergic receptor (AR) in transgenic mice (TG4) enhances basal cardiac function due to ligand-independent spontaneous beta(2)-AR activation. However, agonist-mediated stimulation of either beta(1)-AR or beta(2)-AR fails to further enhance contractility in TG4 ventricular myocytes. Although the lack of beta(2)-AR response has been ascribed to an efficient coupling of the receptor to pertussis toxin-sensitive G(i) proteins in addition to G(s), the contractile response to beta(1)-AR stimulation by norepinephrine and an alpha(1)-adrenergic antagonist prazosin is not restored by pertussis toxin treatment despite a G(i) protein elevation of 1.7-fold in TG4 hearts. Since beta-adrenergic receptor kinase, beta ARK1, activity remains unaltered, the unresponsiveness of beta(1)-AR is not caused by beta ARK1-mediated receptor desensitization. In contrast, pre-incubation of cells with anti-adrenergic reagents such as muscarinic receptor agonist, carbachol (10(-5) M), or a beta(2)-AR inverse agonist, ICI 118,551 (5 x 10(-7) M), to abolish spontaneous beta(2)-AR signaling, both reduce the base-line cAMP and contractility and, surprisingly, restore the beta(1)-AR contractile response. The "rescued" contractile response is completely reversed by a beta(1)-AR antagonist, CGP 20712A. Furthermore, these results from the transgenic animals are corroborated by in vitro acute gene manipulation in cultured wild type adult mouse ventricular myocytes. Adenovirus-directed overexpression of the human beta(2)-AR results in elevated baseline cAMP and contraction associated with a marked attenuation of beta(1)-AR response; carbachol pretreatment fully revives the diminished beta(1)-AR contractile response. Thus, we conclude that constitutive beta(2)-AR activation induces a heterologous desensitization of beta(1)-ARs independent of beta ARK1 and G(i) proteins; suppression of the constitutive beta(2)-AR signaling by either a beta(2)-AR inverse agonist or stimulation of the muscarinic receptor rescues the beta(1)-ARs from desensitization, permitting agonist-induced contractile response.	NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Xiao, RP (corresponding author), NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Yimei, Wang/AAE-4083-2019; Lakatta, Edward G/AAL-1447-2020; Heping, Cheng/AAE-2680-2019; Lefkowitz, Robert/AAW-2649-2021; Xiao, Rui-Ping/AAE-2629-2019	Heping, Cheng/0000-0002-9604-6702; Lakatta, Edward/0000-0002-4772-0035	NATIONAL INSTITUTE ON AGING [ZIAAG000287, Z01AG000287] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aprigliano Octavio, 1997, American Journal of Physiology, V272, pH2726; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1991, PHARMACOL REV, V43, P203; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Du XJ, 1996, AM J PHYSIOL-HEART C, V271, pH630, DOI 10.1152/ajpheart.1996.271.2.H630; ESCHENHAGEN T, 1992, MOL PHARMACOL, V42, P773; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA RC, 1994, AM J PHYSIOL, V266, pH1138, DOI 10.1152/ajpheart.1994.266.3.H1138; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Izumo S, 1998, J Card Fail, V4, P263, DOI 10.1016/S1071-9164(98)90231-7; KIUCHI K, 1993, J CLIN INVEST, V91, P907, DOI 10.1172/JCI116312; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Korzick DH, 1997, AM J PHYSIOL-HEART C, V272, pH590, DOI 10.1152/ajpheart.1997.272.1.H590; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LINDEMANN JP, 1985, J BIOL CHEM, V260, P3122; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MENDE U, 1992, N-S ARCH PHARMACOL, V345, P44; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Ping PP, 1997, AM J PHYSIOL-HEART C, V273, pH707, DOI 10.1152/ajpheart.1997.273.2.H707; PORT JD, 1990, J BIOL CHEM, V265, P14784; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Vatner DE, 1998, J CLIN INVEST, V101, P1916, DOI 10.1172/JCI1530; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1998, J CLIN INVEST, V101, P1273, DOI 10.1172/JCI1335; XIAO RP, 1994, J BIOL CHEM, V269, P19151; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Zhong HY, 1996, MOL PHARMACOL, V50, P175; Zhou YY, 1999, MOL PHARMACOL, V56, P485, DOI 10.1124/mol.56.3.485; Zhou YY, 1999, J PHYSIOL-LONDON, V521, P351, DOI 10.1111/j.1469-7793.1999.00351.x; ZHOU YY, 2000, IN PRESS AM J PHYSL	36	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21773	21779		10.1074/jbc.M909484199	http://dx.doi.org/10.1074/jbc.M909484199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10787424	hybrid			2022-12-27	WOS:000088230600107
J	Chang, A; Cheang, S; Espanel, X; Sudol, M				Chang, A; Cheang, S; Espanel, X; Sudol, M			Rsp5 WW domains interact directly with the carboxyl-terminal domain of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; PRE-MESSENGER-RNA; YES-ASSOCIATED PROTEIN; SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; INDUCED DEGRADATION; PROLYL ISOMERASE; 3'-END FORMATION; SOLID SUPPORTS; GAP1 PERMEASE	RSP5 is an essential gene in Saccharomyces cerevisiae and was recently shown to form a physical and functional complex with RNA polymerase II (RNA pol II). The amino-terminal half of Rsp5 consists of four domains: a C2 domain, which binds membrane phospholipids; and three WW domains, which are protein interaction modules that bind proline-rich Ligands, The carboxyl-terminal half of Rsp5 contains a HECT (homologous to EG-AP carboxyl terminus) domain that catalytically ligates ubiquitin to proteins and functionally classifies Rsp5 as an E3 ubiquitin-protein ligase. The C2 and WW domains are presumed to act as membrane localization and substrate recognition modules, respectively. me report that the second (and possibly third) Rsp5 WW domain mediates binding to the carboxyl-terminal domain (CTD) of the RNA pol II large subunit. The CTD comprises a heptamer (YSPTSPS) repeated 26 times and a PXY core that is critical for interaction with a specific group of WW domains. An analysis of synthetic peptides revealed a minimal CTD sequence that is sufficient to bind to the second Rsp5 WW domain (Rsp5 WW2) in vitro and in yeast two-hybrid assays. Furthermore, we found that specific "imperfect" CTD repeats can form a complex with Rsp5 WW2. In addition, we have shown that phosphorylation of this minimal CTD sequence on serine, threonine and tyrosine residues acts as a negative regulator of the Rsp5 WW2-CTD interaction. In view of the recent data pertaining to phosphorylation-driven interactions between the RNA pol II CTD and the WW domain of Ess1/Pin1, we suggest that CTD dephosphorylation may be a prerequisite for targeted RNA pol II degradation.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.			Chang, Alex/0000-0001-8584-2984	NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albert A, 1999, J CELL SCI, V112, P2493; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bensaude O, 1999, BIOCHEM CELL BIOL, V77, P249, DOI 10.1139/bcb-77-4-249; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bienkiewicz EA, 2000, J MOL BIOL, V297, P119, DOI 10.1006/jmbi.2000.3545; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; delaFuente N, 1997, FEBS LETT, V411, P308, DOI 10.1016/S0014-5793(97)00721-7; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Roberts SM, 1997, GENETICS, V147, P451; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; UESONO Y, 1994, GENE, V143, P135; Wang GL, 1999, MOL CELL BIOL, V19, P342; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Yashiroda H, 1998, GENE, V225, P39, DOI 10.1016/S0378-1119(98)00535-6; Yashiroda H, 1996, MOL CELL BIOL, V16, P3255; Zoladek T, 1997, GENETICS, V145, P595	56	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20562	20571		10.1074/jbc.M002479200	http://dx.doi.org/10.1074/jbc.M002479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781604	hybrid			2022-12-27	WOS:000088084500050
J	She, QB; Chen, NY; Dong, ZG				She, QB; Chen, NY; Dong, ZG			ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; C-JUN KINASE; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; HA-RAS; AP-1 TRANSACTIVATION; CELL-TRANSFORMATION; SIGNALING PATHWAY; ACTIVATION DOMAIN; JNK ACTIVATION	Phospholylation of the p53 tumor suppressor protein is Likely to play an important role in regulating its activity. Serine 15 phosphorylation of p53 leads to a stabilization of p53 by reducing its interaction with murine double minute 2, a negative regulatory partner, Recently, p53 was reported to be activated and phosphorylated at serine 15 following UV radiation. However, the signaling pathway that mediates UV-induced phosphorylation is less well characterized. Here, we provide evidence that UVB-induced phosphorylation of p53 at serine 15 is mediated directly by ERKs and p38 kinase. We find that in a mouse JB6 epidermal cell line, ERKs and p38 kinase form a complex with p53 following UVB radiation. Inhibition of ERKs or p38 kinase activity by the use of a dominant negative mutant of ERK2 or p38 kinase or their respective specific inhibitor, PD98059 or SB202190, results in abrogation of UVB-induced phosphorylation of p53 at serine 15. Strikingly, incubation of UVB-activated ERKs or p38 kinase immunoprecipitated complex with exogenous p53 shows serine 15 phosphorylation of both exogenous and co-precipitated endogenous p53 protein, Additionally, active recombinant ERR1/2 and p38 kinase but not JNKs are also able to phosphorylate p53 at serine 15 in vitro. Furthermore, pretreatment of cells with PD98059 or SB202190 blocks p58-dependent transcription activity but increases the level of p53 co-precipitated murine double minute. These results strongly suggest that both ERKs and p38 kinase have a direct role in UVB-induced phosphorylation of p53 at serine 15 in vivo.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			She, Qing-Bai/0000-0002-7207-0599	NCI NIH HHS [CA 77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HU MC, 1997, ONCOGENE, V415, P2277; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1999, J PATHOL, V187, P112; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rathmell WK, 1997, CANCER RES, V57, P68; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rosenberger SF, 1996, ONCOGENE, V12, P2301; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SOUSSI T, 1990, ONCOGENE, V5, P945; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	58	287	296	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20444	20449		10.1074/jbc.M001020200	http://dx.doi.org/10.1074/jbc.M001020200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781582	hybrid			2022-12-27	WOS:000088084500032
J	Du, YC; Spreitzer, RJ				Du, YC; Spreitzer, RJ			Suppressor mutations in the chloroplast-encoded large subunit improve the thermal stability of wild-type ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; SITE-DIRECTED MUTAGENESIS; PHOTOSYNTHESIS-DEFICIENT MUTANTS; REDUCED CO2/O2 SPECIFICITY; CHLAMYDOMONAS-REINHARDTII; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE/OXYGENASE; CRYSTAL-STRUCTURE; ASSEMBLY DOMAIN; OXYGENASE	A temperature-conditional, photosynthesis-deficient mutant of the green alga Chlamydomonas reinhardtii, previously recovered by genetic screening, results from a leucine 290 to phenylalanine (L290F) substitution in the chloroplast-encoded large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39), Rubisco purified from mutant cells grown at 25 degrees C has a reduction in CO2/O-2 specificity and is inactivated at lower temperatures than those that inactivate the wild-type enzyme. Second-site alanine 222 to threonine (A222T) or valine 262 to leucine (V262L) substitutions were previously isolated via genetic selection for photosynthetic ability at the 35 degrees C restrictive temperature. These intragenic suppressors improve the CO2/O-2 specificity and thermal stability of L290F Rubisco in vivo and in vitro. In the present study, directed mutagenesis and chloroplast transformation were used to create the A222T and V262L substitutions in an otherwise wild-type enzyme. Although neither substitution improves the CO2/O-2 specificity above the wild-type value, both improve the thermal stability of wild-type Rubisco in vitro. Based on the x-ray crystal structure of spinach Rubisco, large subunit residues 222, 262, and 290 are far from the active site. They surround a loop of residues in the nuclear-encoded small subunit. Interactions at this subunit interface may substantially contribute to the thermal stability of the Rubisco holoenzyme.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Spreitzer, RJ (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.							Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1990, ARCH BIOCHEM BIOPHYS, V283, P60, DOI 10.1016/0003-9861(90)90612-3; CHEN ZX, 1993, PLANT PHYSIOL, V101, P1189, DOI 10.1104/pp.101.4.1189; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; CLONEY LP, 1993, PLANT MOL BIOL, V23, P1285, DOI 10.1007/BF00042362; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; FLACHMANN R, 1992, J BIOL CHEM, V267, P10576; GATENBY AA, 1987, EUR J BIOCHEM, V168, P227, DOI 10.1111/j.1432-1033.1987.tb13409.x; HAINING RL, 1994, PHOTOSYNTH RES, V41, P349, DOI 10.1007/BF00019412; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Hong SK, 1997, J BIOL CHEM, V272, P11114; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; Kanevski I, 1999, PLANT PHYSIOL, V119, P133, DOI 10.1104/pp.119.1.133; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; Moreno J, 1999, J BIOL CHEM, V274, P26789, DOI 10.1074/jbc.274.38.26789; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; OGREN WL, 1984, ANNU REV PLANT PHYS, V35, P415, DOI 10.1146/annurev.pp.35.060184.002215; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Spreitzer RJ, 1999, PHOTOSYNTH RES, V60, P29, DOI 10.1023/A:1006240202051; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1988, PLANT PHYSIOL, V86, P773, DOI 10.1104/pp.86.3.773; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Uemura K, 1997, BIOCHEM BIOPH RES CO, V233, P568, DOI 10.1006/bbrc.1997.6497; WASMANN CC, 1989, P NATL ACAD SCI USA, V86, P1198, DOI 10.1073/pnas.86.4.1198; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY CHARLES, 1967, ANNU REV GENET, V1, P117, DOI 10.1146/annurev.ge.01.120167.001001; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	43	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19844	19847		10.1074/jbc.M002321200	http://dx.doi.org/10.1074/jbc.M002321200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779514	hybrid			2022-12-27	WOS:000087941300057
J	Frost, JA; Swantek, JL; Stippec, S; Yin, MJ; Gaynor, R; Cobb, MH				Frost, JA; Swantek, JL; Stippec, S; Yin, MJ; Gaynor, R; Cobb, MH			Stimulation of NF kappa B activity by multiple signaling pathways requires PAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; FACTOR-ALPHA; RHO-FAMILY; IKK-ALPHA; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; FACTOR RECEPTOR; ONCOGENIC RAS	The p21-activated kinase (PAK1) is a serine-threonine protein kinase that is activated by binding to the Rho family small G proteins Rac and Cdc42hs. Both Rac and Cdc42hs have been shown to regulate the activity of the transcription factor NF kappa B. Here we show that expression of active Ras, Raf-1, or Rad in fibroblasts stimulates NF kappa B in a PAK1-dependent manner and that expression of active PAK1 can stimulate NF kappa B on its own. Similarly, in macrophages activation of NF kappa B as well as transcription from the tumor necrosis factor alpha promoter depends on PAK1. In these cells lipopolysaccharide is a potent activator of PAK1 kinase activity. We also demonstrate that expression of active PAK1 stimulates the nuclear translocation of the p65 subunit of NF kappa B but does not activate the inhibitor of kappa B kinases alpha or beta. These data demonstrate that PAK1 is a crucial signaling molecule involved in NF kappa B activation by multiple stimuli.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol, 6413 Fanin, Houston, TX 77030 USA.	jfrost@farmr1.med.uth.tmc.edu		Cobb, Melanie/0000-0003-0833-5473; Frost, Jeffrey/0000-0001-9722-1536	NIGMS NIH HHS [R01 GM53032, GM18550-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018550, R01GM053032] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; HU HM, 1994, J BIOL CHEM, V269, P30069; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; LI CCH, 1994, J BIOL CHEM, V269, P30089; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Ozes ON, 1999, NATURE, V401, P82; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sharma HW, 1996, ANTICANCER RES, V16, P589; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SULCINER D, 1998, MOL BIOL CELL, V16, P7115; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	76	156	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19693	19699		10.1074/jbc.M909860199	http://dx.doi.org/10.1074/jbc.M909860199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779525	hybrid			2022-12-27	WOS:000087941300035
J	Hiraoka, N; Nakagawa, H; Ong, E; Akama, TO; Fukuda, MN; Fukuda, M				Hiraoka, N; Nakagawa, H; Ong, E; Akama, TO; Fukuda, MN; Fukuda, M			Molecular cloning and expression of two distinct human chondroitin 4-O-sulfotransferases that belong to the HNK-1 sulfotransferase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; MYELIN-ASSOCIATED GLYCOPROTEIN; CELL-ADHESION MOLECULES; HEPARAN-SULFATE; DERMATAN SULFATE; CARBOHYDRATE EPITOPE; NEURITE OUTGROWTH; L-SELECTIN; CRYSTAL-STRUCTURE	Using an expression cloning strategy, the cDNA encoding the human HNK-1 sulfotransferase (HNK-1ST) has been cloned. During this cloning we found that HNK-1ST and other Golgi-associated sulfotransferases cloned before share homologous sequences including the RDP motif (Ong, E., Yeh, J.-C., Ding, Y., Hindsgaul, O., and Fukuda, M. (1998) J. Biol. Chem, 223, 5190-5195). Using this conserved sequence in HNK-1ST as a probe, we identified two expressed sequence tags in EST data base which have 31.6 and 30.7% identity with HNK-1ST at the amino acid levels, Expression of these two full-length cDNAs failed to form HNK-1 glycan nor to add sulfate to CD34 or NCAM. Surprisingly, proteins expressed by these cDNAs transferred sulfate to the C-4 position of N-acetylgalactosamine in chondroitin and desulfated dermatan sulfate, thus we named these two enzymes, chondroitin 4-O-sulfotransferas 1 and -2 (C4ST-1 and C4ST-2). Both C4ST-1 and C4ST-2, however, did not form 4,6-di-O-sulfated N-acetylgalactosamine when chondroitin sulfate C was used as an acceptor. Moreover, analysis of S-35-labeled dermatan sulfate formed by C4ST-1 indicate that sulfation preferentially took place in GlcA-->GalNAc unit than in IdoA-->GalNAc unit, suggesting that 4-O-sulfation at N-acetylgalactosamine may precede epimerization of glucuronic acid to iduronic acid during dermatan sulfate biosynthesis, Northern analysis demonstrated that the transcript for C4ST-1 is predominantly expressed in peripheral leukocytes and hematopoietic tissues while the C4ST-2 transcript is more widely expressed in various tissues. These results indicate C4ST-1 and C4ST-2 play complementary roles in chondroitin and dermatan sulfate synthesis in different tissues.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [P01CA71932, CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932, R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ARIGA T, 1987, J BIOL CHEM, V262, P848; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GENNARINI G, 1989, J NEUROSCI RES, V22, P1, DOI 10.1002/jnr.490220102; HABUCHI H, 1973, J BIOL CHEM, V248, P6019; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; HOMANS SW, 1994, MOL GLYCOBIOLOGY, P230; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; KEIHAUER G, 1985, NATURE, V316, P728; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MALMSTRO.A, 1971, EUR J BIOCHEM, V18, P431, DOI 10.1111/j.1432-1033.1971.tb01260.x; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; OTOTANI N, 1979, CARBOHYD RES, V70, P295, DOI 10.1016/S0008-6215(00)87109-8; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; Seki N, 1997, DNA Res, V4, P345, DOI 10.1093/dnares/4.5.345; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	63	115	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20188	20196		10.1074/jbc.M002443200	http://dx.doi.org/10.1074/jbc.M002443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10781601	hybrid			2022-12-27	WOS:000087941300100
J	Chang, JY; Li, L; Canals, F; Aviles, FX				Chang, JY; Li, L; Canals, F; Aviles, FX			The unfolding pathway and conformational stability of potato carboxypeptidase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE FOLDING PATHWAY; TICK ANTICOAGULANT PEPTIDE; GROWTH FACTOR-I; DENATURED STATES; RIBONUCLEASE-A; PROTEINS; UREA; EXPRESSION; MECHANISM; COMPLEX	The unfolding and denaturation curves of potato carboxypeptidase inhibitor (PCI) were investigated using the technique of disulfide scrambling. In the presence of denaturant and thiol initiator, the native PCI denatures by shuffling its native disulfide bonds and converts to form a mixture of scrambled PCI that consists of 9 out of a possible 14 isomers. The denaturation curve is determined by the fraction of native PCI converted to scrambled isomers under increasing concentrations of denaturant. The concentration of guanidine thiocyanate, guanidine hydrochloride, and urea required to denature 50% of the native PCI was found to be 0.7, 1.45, and 8 M, respectively. The PCI unfolding curve was constructed through the analysis of structures of scrambled isomers that were denatured under increasing concentrations of denaturant. These results reveal the existence of structurally defined unfolding intermediates and a progressive expansion of the polypeptide chain. The yield of the beads-form isomer (Cys(8)-Cys(12), Cys(18)-Cys(24), and Cys(27)-Cys(34)) as a fraction of total denatured PCI was shown to be directly proportional to the strength of the denaturing condition. Furthermore, the PCI sequence was unable to fold quantitatively into a single native structure, Under physiological conditions, the scrambled isomers of PCI that constitute about 4% of the protein were in equilibrium with native PCI.	Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Autonoma Barcelona, Dept Bioquim, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental, Bellaterra 08193, Spain	University of Texas System; Autonomous University of Barcelona; Autonomous University of Barcelona	Chang, JY (corresponding author), Univ Texas, Inst Mol Med, Res Ctr Prot Chem, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rchang@imm2.imm.uth.tmc.edu	Avilés, Francesc Xavier/A-2664-2015; Aviles, Francesc Xavier/F-3482-2019	Avilés, Francesc Xavier/0000-0002-1399-6789; Aviles, Francesc Xavier/0000-0002-1399-6789				Aguzzi A, 1999, LANCET, V354, pSI22; ALEXANDRESCU AT, 1995, BIOCHEMISTRY-US, V33, P1036; Blanco-Aparicio C, 1998, J BIOL CHEM, V273, P12370, DOI 10.1074/jbc.273.20.12370; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; Bulychev A, 1999, J PROTEIN CHEM, V18, P771, DOI 10.1023/A:1020681518265; Chang JY, 1999, ANAL BIOCHEM, V268, P147, DOI 10.1006/abio.1998.3047; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1997, J BIOL CHEM, V272, P69; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1995, J BIOL CHEM, V270, P25661; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; Chang JY, 1998, BIOCHEMISTRY-US, V37, P6745, DOI 10.1021/bi9714565; CHANG JY, 1999, J BIOL CHEM, V8, P1463; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JENSEN EV, 1959, SCIENCE, V130, P1319, DOI 10.1126/science.130.3385.1319; LIEPINSH E, 1994, J AM CHEM SOC, V116, P9670, DOI 10.1021/ja00100a036; LIN SL, 1995, NAT STRUCT BIOL, V2, P835, DOI 10.1038/nsb1095-835; Mas JM, 1998, J MOL BIOL, V284, P541, DOI 10.1006/jmbi.1998.2194; MENG H, 1988, J CHROMATOGR, V443, P183, DOI 10.1016/S0021-9673(00)94792-7; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MOLINA MA, 1992, GENE, V116, P129, DOI 10.1016/0378-1119(92)90508-M; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAN H, 1995, BIOCHEMISTRY-US, V34, P13974, DOI 10.1021/bi00043a002; RASCHDORF F, 1988, BIOMED ENVIRON MASS, V16, P3, DOI 10.1002/bms.1200160102; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P25; SHORTLE D, 1993, CURR OPIN STRUC BIOL, V3, P66, DOI 10.1016/0959-440X(93)90204-X; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; Smith L. J., 1996, FOLDING DESIGN, V1, pR95; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Villanueva J, 1998, FEBS LETT, V440, P175, DOI 10.1016/S0014-5793(98)01447-1; WUTHRICH K, 1994, CURR OPIN STRUC BIOL, V4, P93, DOI 10.1016/S0959-440X(94)90065-5	41	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14205	14211		10.1074/jbc.275.19.14205	http://dx.doi.org/10.1074/jbc.275.19.14205			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799497	hybrid			2022-12-27	WOS:000087006900028
J	Mulvaney, JM; Roberson, MS				Mulvaney, JM; Roberson, MS			Divergent signaling pathways requiring discrete calcium signals mediate concurrent activation of two mitogen-activated protein kinases by gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ALPHA-T3-1 CELL-LINE; JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; ANGIOTENSIN-II; PITUITARY GONADOTROPHS; TRANSDUCTION PATHWAYS; DEPENDENT ACTIVATION; CHANNELS; CDC42	Receptors coupled to heterotrimeric G proteins are linked to activation of mitogen-activated protein kinases (MAPKs) via receptor- and cell-specific mechanisms. We have demonstrated recently that gonadotropin-releasing hormone (GnRH) receptor occupancy results in activation of extracellular signal-regulated kinase (ERK) through a mechanism requiring calcium influx through L-type calcium channels in alpha T3-1 cells and primary rat gonadotropes, Further studies were undertaken to explore the signaling mechanisms by which the GnRH receptor is coupled to activation of another member of the MAPK family, c-Jun N-terminal kinase (JNK). GnRH induces activation of the JNK cascade in a dose-, time-, and receptor-dependent manner in clonal alpha T3-1 cells and primary rat pituitary gonadotrophs, Coexpression of dominant negative Cdc42 and kinase-defective p21-activated kinase 1 and MAPK kinase 7 with JNK and ERK indicated that specific activation of JNK by GnRH appears to involve these signaling molecules. Unlike ERK activation, GnRH-stimulated JNK activity does not require activation of protein kinase C and is not blocked after chelation of extracellular calcium with EGTA. GnRH-induced JNK activity was reduced after treatment with the intracellular calcium chelator BAPTA-AM (1,2-bis (2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid acetoxymethyl eater), whereas activation of ERK was not affected. Chelation of intracellular calcium also reduced GnRH-induced activation of JNK in rat pituitary cells in primary culture. GnRH-induced induction and activation of the JNK target c-Jun was inhibited after chelation of intracellular calcium, whereas induction of c-Fos, a known target of ERK, was unaffected. Therefore, although activation of ERK by GnRH requires a specific influx of calcium through L-type calcium channels, JNK activation is independent of extracellular calcium but sensitive to chelation of intracellular calcium. Our results provide novel evidence that GnRH activates two MAPK superfamily members via strikingly divergent signaling pathways with differential sensitivity to activation of protein kinase C and mobilization of discrete pools of calcium.	Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA	Cornell University	Roberson, MS (corresponding author), Cornell Univ, Coll Vet Med, Dept Biomed Sci, T6-008A Vet Res Tower, Ithaca, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034722] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011105] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34722] Funding Source: Medline; NIMH NIH HHS [MH11105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; BOSMA MM, 1992, ENDOCRINOLOGY, V130, P3411, DOI 10.1210/en.130.6.3411; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Huang XC, 1998, ENDOCRINOLOGY, V139, P245, DOI 10.1210/en.139.1.245; IZUMI S, 1990, BIOCHEM BIOPH RES CO, V170, P359, DOI 10.1016/0006-291X(90)91282-W; Kratzmeier M, 1996, MOL CELL ENDOCRINOL, V118, P103, DOI 10.1016/0303-7207(96)03788-4; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARIAN J, 1979, MOL PHARMACOL, V16, P196; MCARDLE CA, 1992, MOL CELL NEUROSCI, V3, P124, DOI 10.1016/1044-7431(92)90016-U; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; NAOR Z, 1988, MOL ENDOCRINOL, V2, P512, DOI 10.1210/mend-2-6-512; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	35	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14182	14189		10.1074/jbc.275.19.14182	http://dx.doi.org/10.1074/jbc.275.19.14182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799494	hybrid			2022-12-27	WOS:000087006900025
J	Nuccio, ML; Ziemak, MJ; Henry, SA; Weretilnyk, EA; Hanson, AD				Nuccio, ML; Ziemak, MJ; Henry, SA; Weretilnyk, EA; Hanson, AD			cDNA cloning of phosphoethanolamine N-methyltransferase from spinach by complementation in Schizosaccharomyces pombe and characterization of the recombinant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLATED ETHANOLAMINE MOIETIES; GLYCINE BETAINE SYNTHESIS; PHOSPHATIDYLCHOLINE SYNTHESIS; CHOLINE MONOOXYGENASE; RAT-BRAIN; PLANTS; EXPRESSION; LEAVES; CARROT; GENE	The N-methylation of phosphoethanolamine is the committing step in choline biogenesis in plants and is catalyzed by S-adenosyl-L-methionine:phosphoethanolamine N-methyltransferase (PEAMT, EC 2.1.1.103). A spinach PEAMT cDNA was isolated by functional complementation of a Schizosaccharomyces pombe cho2(-) mutant and was shown to encode a protein with PEAMT activity and without ethanolamine- or phosphatidylethanolamine N-methyltransferase activity. The PEAMT cDNA specifies a 494-residue polypeptide comprising two similar, tandem methyltransferase domains, implying that PEAMT arose by gene duplication and fusion. Data base searches suggested that PEAMTs with the same tandem structure are widespread among flowering plants. Size exclusion chromatography of the recombinant enzyme indicates that it exists as a monomer, PEAMT catalyzes not only the first N-methylation of phosphoethanolamine but also the two subsequent N-methylations, yielding phosphocholine. Monomethyl- and dimethylphosphoethanolamine are detected as reaction intermediates. A truncated PEAMT lacking the C-terminal methyltransferase domain catalyzes only the first methylation. Phosphocholine inhibits both the wild type and the truncated enzyme, although the latter is less sensitive. Salinization of spinach plants increases PEAMT mRNA abundance and enzyme activity in leaves by about 16-fold, consistent with the high demand in stressed plants for choline to support glycine betaine synthesis.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	State University System of Florida; University of Florida; Carnegie Mellon University; McMaster University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@gnv.ifas.ufl.edu	Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; ANDRIAMAMPANDRY C, 1991, J NEUROCHEM, V56, P1845, DOI 10.1111/j.1471-4159.1991.tb03439.x; ARONDEL V, 1993, J BIOL CHEM, V268, P16002; BEAUDOUIN C, 1993, J NEUROCHEM, V61, P928, DOI 10.1111/j.1471-4159.1993.tb03604.x; BLIGNY R, 1990, J BIOL CHEM, V265, P1319; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; DATKO AH, 1988, PLANT PHYSIOL, V88, P854, DOI 10.1104/pp.88.3.854; DATKO AH, 1988, PLANT PHYSIOL, V88, P1338, DOI 10.1104/pp.88.4.1338; FUJIOKA M, 1992, INT J BIOCHEM, V24, P1917, DOI 10.1016/0020-711X(92)90287-B; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; HANSON AD, 1983, PLANT PHYSIOL, V71, P692, DOI 10.1104/pp.71.3.692; HONDRED D, 1987, PLANT MOL BIOL, V9, P259, DOI 10.1007/BF00166462; Huang J, 2000, PLANT PHYSIOL, V122, P747, DOI 10.1104/pp.122.3.747; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kanipes MI, 1997, BBA-LIPID LIPID MET, V1348, P134, DOI 10.1016/S0005-2760(97)00121-5; Kanipes MI, 1998, GENETICS, V150, P553; KANIPES MI, 1997, THESIS CARNEGIE MELL; LUEHRSEN KR, 1992, METHOD ENZYMOL, V216, P397; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MCNEIL SD, 2000, IN PRESS PLANT PHYSL; MUDD SH, 1989, PLANT PHYSIOL, V90, P296, DOI 10.1104/pp.90.1.296; MUDD SH, 1989, PLANT PHYSIOL, V90, P306, DOI 10.1104/pp.90.1.306; Mukherjee S, 1995, NEUROCHEM RES, V20, P1233, DOI 10.1007/BF00995388; NAIRN CJ, 1988, J MOL EVOL, V27, P133, DOI 10.1007/BF02138373; Nuccio ML, 1999, CURR OPIN PLANT BIOL, V2, P128, DOI 10.1016/S1369-5266(99)80026-0; Nuccio ML, 1998, PLANT J, V16, P487, DOI 10.1046/j.1365-313x.1998.00316.x; Rathinasabapathi B, 1997, P NATL ACAD SCI USA, V94, P3454, DOI 10.1073/pnas.94.7.3454; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; SMITH DD, 1999, PHYSIOL PLANTARUM, V108, P286; SUMMERS PS, 1993, PLANT PHYSIOL, V103, P1269, DOI 10.1104/pp.103.4.1269; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; WERETILNYK EA, 1995, PLANT PHYSIOL, V109, P1085, DOI 10.1104/pp.109.3.1085; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558	35	84	94	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14095	14101		10.1074/jbc.275.19.14095	http://dx.doi.org/10.1074/jbc.275.19.14095			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799484	hybrid			2022-12-27	WOS:000087006900014
J	Zhao, XH; Bondeva, T; Balla, T				Zhao, XH; Bondeva, T; Balla, T			Characterization of recombinant phosphatidylinositol 4-kinase beta reveals auto- and heterophosphorylation of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-KINASE SERINE KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SACCHAROMYCES-CEREVISIAE; WORTMANNIN; PI-3-KINASE; CLONING; PATHWAY; GENE	Phosphatidylinositol (PI) 4-kinases catalyze the synthesis of PI 4-phosphate, an important intermediate for the synthesis of membrane polyphosphoinositides, regulators of multiple cellular functions. Two mammalian PI 4-kinases have been cloned, a 230-kDa enzyme (alpha-form) and a 110-kDa (beta-form), both of which are inhibited by >0.1 mu M concentrations of the PI 3-kinase inhibitor, wortmannin (WT), In the present study, we created a glutathione S-transferase-PI4K beta fusion protein for expression in Escherichia coli. The purified protein was biologically active and phosphorylated PI in its 4-position with WT sensitivity and kinetic parameters that were identical to those of purified bovine brain PI4K beta, In addition to its lipid kinase activity, the enzyme exhibited autophosphorylation that was enhanced by Mn2+ ions and inhibited by WT and another PI 3-kinase inhibitor, LY 294002. The recombinant protein was unable to transphosphorylate, but its isolated C-terminal catalytic domain still displayed autophosphorylation, suggesting that the autophosphorylation site resides within the C-terminal catalytic domain of the protein and is held in position by intramolecular interactions. Autophosphorylation inhibited subsequent lipid kinase activity, which was reversed upon dephosphorylation, by protein phosphatases, PPI and PP2A(1), suggesting that it may represent a regulatory mechanism for the enzyme. Phosphorylation of endogenous or overexpressed PI4K beta was also observed in COS-7 cells; how ever, the in vivo phosphorylation of the expressed protein was only partially inhibited by WT and also occurred in a catalytically inactive form of the enzyme, indicating the presence of additional phosphorylation site(s). Successful bacterial expression of PI4K beta should aid research on the structure-function relationships of this protein as well as of other, structurally related enzymes.	NICHD, Endocrinol & Reprod Res Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Balla, T (corresponding author), NICHD, Endocrinol & Reprod Res Branch, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.			Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; HINCHLIFFE AK, 1998, BIOCHIM BIOPHYS ACTA, V1436, P87; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; LAM K, 1994, J BIOL CHEM, V269, P20648; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Uddin S, 1997, J IMMUNOL, V158, P2390; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	29	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14642	14648		10.1074/jbc.275.19.14642	http://dx.doi.org/10.1074/jbc.275.19.14642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799551	hybrid			2022-12-27	WOS:000087006900085
J	Marnett, LJ; Wright, TL; Crews, BC; Tannenbaum, SR; Marrow, JD				Marnett, LJ; Wright, TL; Crews, BC; Tannenbaum, SR; Marrow, JD			Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H SYNTHASE; IN-VIVO; LIPID-PEROXIDATION; PLATELET-FUNCTION; CYCLOOXYGENASE-2; PEROXYNITRITE; MACROPHAGES; ACTIVATION; RAT; CELLS	We investigated the effects of targeted deletion of the inducible NO synthase (iNOS) gene on the formation of prostaglandins in vivo and ex vivo. Peritoneal macrophages were obtained from control and iNOS-deficient mice, and prostaglandin E-2 (PGE(2)) was quantified after stimulation with gamma-interferon and lipopolysaccharide to induce COX-a, Total nitrate and nitrite production was completely abolished in cells from iNOS-deficient animals compared with control cells. PGE, formation by cells from MOS-deficient animals was decreased compared with cells from control animals 80% at 12 h (0.85 +/- 0.90 ng/10(6) cells versus 15.4 +/- 2.1 ng/10(6) cells, p < 0.01) and 74% at 24 h (9.4 +/- 4.3 ng/10(6) cells versus 36.8 +/- 4.1 ng/10(6) cells, p < 0.01), COX-2 protein expression was not significantly different in cells from control or knockout animals. Levels of PGE(2) in the urine of iNOS-deficient mice were decreased 78% (0.24 +/- 0.14 ng/mg of creatinine versus 1.09 +/- 0.66 ng/mg of creatinine, p < 0.01) compared with control animals. In addition, the levels of urinary F-2-isoprostanes, an index of endogenous oxidant stress, were significantly decreased in iNOS-deficient animals. In contrast, the levels of thromboxane B-2 derived from platelets allowed to aggregate ex vivo were significantly increased in iNOS-deficient mice compared with wild-type mice. These studies support the hypothesis that NO and/or NO-derived species modulate cyclooxygenase activity and eicosanoid production in vivo.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Vanderbilt University; Vanderbilt University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu			NCI NIH HHS [CA26731, CA47479] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026731, R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Curtis JF, 1996, ARCH BIOCHEM BIOPHYS, V335, P369, DOI 10.1006/abbi.1996.0518; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; DECATERINA R, 1984, AM J CARDIOL, V53, P1683; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; FRANCHI AM, 1994, P NATL ACAD SCI USA, V91, P539, DOI 10.1073/pnas.91.2.539; FROLICH JC, 1975, J CLIN INVEST, V55, P763, DOI 10.1172/JCI107987; FURLONG B, 1987, BRIT J PHARMACOL, V90, P687, DOI 10.1111/j.1476-5381.1987.tb11221.x; Goodwin DC, 1999, DRUG METAB REV, V31, P273, DOI 10.1081/DMR-100101918; Habib A, 1997, J IMMUNOL, V158, P3845; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAURAND M, 1985, J BIOL CHEM, V260, P5059; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HRYCAY EG, 1971, ARCH BIOCHEM BIOPHYS, V147, P14, DOI 10.1016/0003-9861(71)90304-3; Hughes FJ, 1999, J BIOL CHEM, V274, P1776, DOI 10.1074/jbc.274.3.1776; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lianos EA, 1998, KIDNEY INT, V53, P645, DOI 10.1046/j.1523-1755.1998.00791.x; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; MORROW JD, 1996, BIOCH PHARM, V51; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; Perkins DJ, 1999, J LEUKOCYTE BIOL, V65, P792, DOI 10.1002/jlb.65.6.792; Reckelhoff JF, 1999, AM J HYPERTENS, V12, P492, DOI 10.1016/S0895-7061(98)00264-7; Salvemini D, 1996, METHOD ENZYMOL, V269, P12; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SALVEMINI D, 1995, BRIT J PHARMACOL, V114, P1171, DOI 10.1111/j.1476-5381.1995.tb13330.x; SAUTEBIN L, 1995, BRIT J PHARMACOL, V114, P323, DOI 10.1111/j.1476-5381.1995.tb13230.x; Seibert K, 1996, BRIT J PHARMACOL, V117, P1016, DOI 10.1111/j.1476-5381.1996.tb16691.x; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; Watkins DN, 1997, BRIT J PHARMACOL, V121, P1482; Yoshimoto H, 1999, J CARDIOVASC PHARM, V33, P109, DOI 10.1097/00005344-199901000-00016; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	43	121	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13427	13430		10.1074/jbc.275.18.13427	http://dx.doi.org/10.1074/jbc.275.18.13427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788454	hybrid			2022-12-27	WOS:000086925300041
J	Chen, PF; Wu, KK				Chen, PF; Wu, KK			Characterization of the roles of the 594-645 region in human endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CATALYTIC ACTIVITY; CYTOCHROME P-450; CONTROL ELEMENT; REDUCTASE; EXPRESSION; HEME; DOMAINS; IDENTIFICATION; ISOFORMS	It has been postulated that a segment (residues 594-645) inserted in the FMN subdomain of human endothelial nitric oxide synthase (eNOS) plays a crucial role in controlling Ca2+-dependent CaM binding for eNOS activity. To investigate its functions, we expressed human eNOS in a baculovirus system with deletion of a 45-residue segment from this region (residues 594-606 and 614-645, designated as Delta 45eNOS), and characterized the purified mutant enzyme. In contrast with wild-type eNOS, Delta 45eNOS exhibited characteristics resembling inducible NOS (NOS). It contained an endogenously bound CaM, which was essential in folding and stabilizing this mutant enzyme, and retained 60% of L-citrulline formation in 5 mM EGTA. We also produced four N-terminally truncated reductase domains with or without the 45-residue segment, and either including or excluding the CaM-binding sequence. Basal cytochrome c reductase activity of reductase domains without the 45-residue segment was up to 20 fold greater than that of corresponding insert-containing domains, and higher than CaM-stimulated activity of the wild-type enzyme. A series of mutants with smaller fragment deletion in this region such as Delta 594-604, Delta 605-612, Delta 613-625, Delta 626-634, Delta 632-639, and Delta 640-645 mutants were further characterized. The crude lysate of mutants Delta 613-625 and Delta 632-639 did not show activity in the presence of Ca2+/CaM, while other four mutants had activity comparable to that of WTeNOS. The purified Delta 594-604 and Delta 605-612 proteins had a 3-5-fold higher affinity for Ca2+/CaM, but their L-citrulline forming activity was still 80% dependent upon the addition of Ca2+/CaM. Both mutants exhibited a low level of the cytochrome c and ferricyanide reductase activities, which either did not respond to (Delta 594-604) or slightly enhanced by (Delta 605-612) the exogenous CaM, In contrast, activities of Delta 626-634 and Delta 640-645 like those of WTeNOS were largely Ca2+/CaM-dependent. Thus, our findings indicate that the N-terminal half of the 594-645 segment containing residues 594-612 plays a significant role in regulating Ca2+/CaM binding.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Internal Med,Div Hematol, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Vasc Biol Res Ctr, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Chen, PF (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Internal Med,Div Hematol, 6431 Fannin,POB 20708, Houston, TX 77225 USA.	pfchen@heart.med.uth.tmc.edu	Wu, Kenneth Kun-Yu/B-1070-2010		NHLBI NIH HHS [HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; Perry JM, 1998, CHEM BIOL, V5, P355, DOI 10.1016/S1074-5521(98)90069-2; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Rafferty S, 1996, BIOCHEM BIOPH RES CO, V220, P1002, DOI 10.1006/bbrc.1996.0522; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M; STUEHR DJ, 1992, ADV ENZYMOL, V65, P287; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	41	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13155	13163		10.1074/jbc.275.17.13155	http://dx.doi.org/10.1074/jbc.275.17.13155			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777622	hybrid			2022-12-27	WOS:000086762300106
J	Francischetti, IMB; Ribeiro, JMC; Champagne, D; Andersen, J				Francischetti, IMB; Ribeiro, JMC; Champagne, D; Andersen, J			Purification, cloning, expression, and mechanism of action of a novel platelet aggregation inhibitor from the salivary gland of the blood-sucking bug, Rhodnius prolixus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ORNITHODOROS-MOUBATA; NITRIC-OXIDE; SHAPE CHANGE; TYROSINE PHOSPHORYLATION; ADENOSINE-DIPHOSPHATE; STIMULATED PLATELETS; CALCIUM MOBILIZATION; BLOODSUCKING INSECT; ADENYLATE-CYCLASE; COLLAGEN RECEPTOR	Rhodnius prolixus aggregation inhibitor 1 (RPAI-1), a 19-kDa protein isolated from the salivary gland of R. prolixus was purified by strong cation exchange and reverse-phase high performance liquid chromatographies. Based on 49 amino-terminal amino acid sequences of RPAI-1, primers were produced to generate probes to screen an R. prolixus salivary gland cDNA library. A phage containing the full-length clone of RPAI-1 codes for a mature protein of 155 amino acids. RPAI-1 shows sequence homology to triabin and pallidipin, lipocalins from Triatoma pallidipennis. The cDNA sequence was cloned in Petl17B Escherichia coli expression vector, producing an active peptide. RPAI-1 inhibits human platelet-rich plasma aggregation triggered by low concentrations of ADP, collagen, arachidonic acid, thromboxane A(2) mimetics (U46619), and very low doses of thrombin and convulxin. Here we show that ADP is the target of RPAI-1 since (i) RPAI-1 inhibits ADP-dependent large aggregation formation and secretion triggered by U46619, without affecting Ca2+ increase and shape change; (ii) ADP restored the inhibition of U46619-induced platelet aggregation by RPAI-1, (iii) PGE(1)-induced increase of cAMP (which is antagonized by U46619 in an ADP-dependent manner) was restored by RPAI-1, (iv) RPAI-1 inhibits low concentrations of ADP-mediated responses of indomethacin-treated platelets, and (v) RPAI-1 binds to ADP, as assessed by large zone chromatography. RPAI-1 affects neither integrin alpha(2)beta(1)- nor glycoprotein VI-mediated platelet responses. We conclude that RPAI-1 is the first lipocalin described that inhibits platelet aggregation by a novel mechanism, binding to ADP.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University System of Georgia; University of Georgia; University of Arizona	Ribeiro, JMC (corresponding author), Bldg 4,Rm 126,4 Ctr Dr,MSC 0425, Bethesda, MD 20892 USA.	jribeiro@nih.gov		Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810, Z01AI000810] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; Andersen H, 1999, P NATL ACAD SCI USA, V96, P11189, DOI 10.1073/pnas.96.20.11189; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BECKER HS, 1956, AM J SOCIOL, V62, P253, DOI 10.1086/222002; BEDNAR B, 1995, THROMB RES, V77, P453, DOI 10.1016/0049-3848(95)93881-Y; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CATTANEO M, 1987, BLOOD, V70, P221; Cattaneo M, 1997, THROMB HAEMOSTASIS, V77, P986; CATTANEO M, 1991, THROMB HAEMOSTASIS, V66, P694; CATTANEO M, 1992, BLOOD, V80, P2787; CHAMPAGNE DE, 1995, J BIOL CHEM, V270, P8691, DOI 10.1074/jbc.270.15.8691; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; CLAESSON HE, 1977, EUR J BIOCHEM, V76, P277, DOI 10.1111/j.1432-1033.1977.tb11593.x; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; FAILI A, 1994, BIOCHEM J, V298, P87, DOI 10.1042/bj2980087; FAILI A, 1994, BRIT J HAEMATOL, V88, P149, DOI 10.1111/j.1365-2141.1994.tb04990.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Flower DR, 1996, BIOCHEM J, V318, P1; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V353, P239, DOI 10.1006/abbi.1998.0598; Francischetti IMB, 1999, BIOCHEMISTRY-US, V38, P16678, DOI 10.1021/bi991231p; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gallet C, 1999, J BIOL CHEM, V274, P23610, DOI 10.1074/jbc.274.33.23610; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; Geiger J, 1999, ARTERIOSCL THROM VAS, V19, P2007, DOI 10.1161/01.ATV.19.8.2007; GENTRY PA, 1989, AM J VET RES, V50, P919; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HAENDLER B, 1995, BIOCHEM J, V307, P465, DOI 10.1042/bj3070465; HARSFALVI J, 1995, BLOOD, V85, P705, DOI 10.1182/blood.V85.3.705.bloodjournal853705; HAWIGER J, 1994, HEMOSTASIS THROMBOSI, P603; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; Henikoff JG, 1999, NUCLEIC ACIDS RES, V27, P226, DOI 10.1093/nar/27.1.226; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KARCZEWSKI J, 1995, BIOCHEM BIOPH RES CO, V208, P532, DOI 10.1006/bbrc.1995.1371; KARCZEWSKI J, 1994, J BIOL CHEM, V269, P6702; KELLER PM, 1993, J BIOL CHEM, V268, P5450; KINLOUGHRATHBONE RL, 1992, THROMB HAEMOSTASIS, V67, P453; KINLOUGHRATHBONE RL, 1977, THROMB HAEMOSTASIS, V37, P291; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KROLL MH, 1998, THROMBOSIS HEMORRHAG, P261; Lagrue AH, 1999, FEBS LETT, V448, P95, DOI 10.1016/S0014-5793(99)00340-3; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MALMSTEN C, 1975, P NATL ACAD SCI USA, V72, P1446, DOI 10.1073/pnas.72.4.1446; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; Martinson EA, 1998, THROMB HAEMOSTASIS, V80, P976; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORINELLI TA, 1987, AM J PHYSIOL, V253, pH1035, DOI 10.1152/ajpheart.1987.253.5.H1035; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MURRAY R, 1990, J BIOL CHEM, V265, P21670; NAKANO T, 1989, J BIOCHEM, V106, P887, DOI 10.1093/oxfordjournals.jbchem.a122947; NOESKEJUNGBLUT C, 1994, J BIOL CHEM, V269, P5050; NOESKEJUNGBLUT C, 1995, J BIOL CHEM, V270, P28629, DOI 10.1074/jbc.270.48.28629; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; PURI RN, 1995, J BIOL CHEM, V270, P24482, DOI 10.1074/jbc.270.41.24482; Ramakrishnan V, 1999, P NATL ACAD SCI USA, V96, P13336, DOI 10.1073/pnas.96.23.13336; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1981, EXPERIENTIA, V37, P384, DOI 10.1007/BF01959876; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; SAMBROOK J, 1989, NATURE, V342, P224, DOI 10.1038/342224a0; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shiraishi M, 1998, AM J VET RES, V59, P744; SIESS W, 1983, J BIOL CHEM, V258, P4683; SOSLAU G, 1993, BIOCHIM BIOPHYS ACTA, V1177, P199, DOI 10.1016/0167-4889(93)90041-M; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Valenzuela JG, 1999, BIOCHEMISTRY-US, V38, P11209, DOI 10.1021/bi990761i; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WATSON SP, 1985, BIOCHEM J, V226, P831, DOI 10.1042/bj2260831; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; YIN K, 1994, J PHARMACOL EXP THER, V270, P1192; Zhang Y, 1998, BIOCHEMISTRY-US, V37, P10681, DOI 10.1021/bi973050y	87	92	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12639	12650		10.1074/jbc.275.17.12639	http://dx.doi.org/10.1074/jbc.275.17.12639			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777556	hybrid			2022-12-27	WOS:000086762300040
J	Sander, TL; Haas, AL; Peterson, MJ; Morris, JF				Sander, TL; Haas, AL; Peterson, MJ; Morris, JF			Identification of a novel SCAN box-related protein that interacts with MZF1B - The leucine-rich scan box mediates hetero- and homoprotein associations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; KRUPPEL-ASSOCIATED BOX; TRANSCRIPTIONAL REPRESSION; BTB/POZ DOMAIN; DNA-BINDING; POZ DOMAIN; HISTONE DEACETYLASE; IMPORTIN-BETA; GENE; MZF-1	The SCAN box or (L) under bar eucine-(R) under bar ich (LeR) domain is a conserved motif found within a subfamily of C2H2 zinc finger proteins. The function of a SCAN box is unknown, but it is predicted to form alpha-helices that may be involved in protein-protein interactions. Myeloid zinc finger gene-1B (MZF1B) is an alternatively spliced human cDNA isoform of the zinc finger transcription factor, MZF1. MZF1 and MZF1B contain 13 C2H2 zinc finger motifs, but only MZF1B contains an amino-terminal SCAN box. A bone marrow cDNA library was screened for proteins interacting with the MZF1B SCAN box domain and RAZ1 (SCAN-(r) under bar elated protein (a) under bar ssociated with M (Z) under bar F1B) was identified. RAZ1 is a novel cDNA that encodes a SCAN-related domain and arginine-rich region but no zinc finger motifs. Co-immunoprecipitation assays demonstrate that the SCAN box domain of MZF1B is necessary for association with RAZ1, By yeast two-hybrid analysis, the carboxyl terminus of RAZ1 is sufficient for interaction with the MZF1B SCAN box. Furthermore, MZF1B and RAZ1 each self-associate in vitro via a SCAN box-dependent mechanism. These data provide evidence that the SCAN box is a protein interaction domain that mediates both hetero- and homoprotein associations.	Med Coll Wisconsin, Dept Pediat, Kelly Weil Lab Pediat Mol Oncol, MACC Fund Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Morris, JF (corresponding author), Med Coll Wisconsin, Dept Pediat, Kelly Weil Lab Pediat Mol Oncol, MACC Fund Res Ctr, Rm 6008,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Peterson, Michael J./A-8834-2009	Peterson, Michael J./0000-0001-9181-1009	NCI NIH HHS [CA-69141] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069141] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALABRO V, 1995, HUM GENET, V95, P18; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Chen XG, 1999, BBA-GENE STRUCT EXPR, V1444, P218, DOI 10.1016/S0167-4781(98)00273-5; CHOWDHURY K, 1992, MECH DEVELOP, V39, P129, DOI 10.1016/0925-4773(92)90040-Q; *CLONTECH, PT30241 CLONTECH, P29; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DENNY P, 1991, GENE, V106, P221, DOI 10.1016/0378-1119(91)90202-M; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dovat S, 1998, BBA-GENE STRUCT EXPR, V1442, P380, DOI 10.1016/S0167-4781(98)00167-5; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FULLER SA, 1997, CURRENT PROTOCOLS MO, V2; Galic Z, 1998, BIOCHEM MOL BIOL INT, V45, P535; *GEN COMP GROUP, WISC PACK VERS 10 0; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Gonsky R, 1997, NUCLEIC ACIDS RES, V25, P3823, DOI 10.1093/nar/25.19.3823; Guan XY, 1996, CANCER RES, V56, P3446; HROMAS R, 1991, J BIOL CHEM, V266, P14183; HROMAS R, 1995, CANCER RES, V55, P3610; Hromas R, 1996, LEUKEMIA, V10, P1049; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kurtin PJ, 1996, AM J CLIN PATHOL, V106, P680; Lee PL, 1997, GENOMICS, V43, P191, DOI 10.1006/geno.1997.4806; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Murai K, 1997, GENES CELLS, V2, P581, DOI 10.1046/j.1365-2443.1997.1430341.x; Murai K, 1998, P NATL ACAD SCI USA, V95, P3461, DOI 10.1073/pnas.95.7.3461; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NOCE T, 1992, DEV BIOL, V153, P356, DOI 10.1016/0012-1606(92)90120-6; Palmedo G, 1999, LAB INVEST, V79, P311; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Robertson KA, 1998, LEUKEMIA, V12, P690, DOI 10.1038/sj.leu.2401005; Seyfert VL, 1996, ONCOGENE, V12, P2331; TIROSVOUTIS KN, 1995, GENOMICS, V28, P485, DOI 10.1006/geno.1995.1178; Truant R, 1999, MOL CELL BIOL, V19, P1210; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Williams AJ, 1999, MOL CELL BIOL, V19, P8526; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yang XW, 1996, DEVELOPMENT, V122, P555; Yokoyama M, 1997, BBA-GENE STRUCT EXPR, V1353, P13, DOI 10.1016/S0167-4781(97)00074-2	65	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12857	12867		10.1074/jbc.275.17.12857	http://dx.doi.org/10.1074/jbc.275.17.12857			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777584	hybrid			2022-12-27	WOS:000086762300068
J	Velot, C; Srere, PA				Velot, C; Srere, PA			Reversible transdominant inhibition of a metabolic pathway - In vivo evidence of interaction between two sequential, tricarboxylic acid cycle enzymes in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; MITOCHONDRIAL MALATE-DEHYDROGENASE; CITRATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; RANDOM MUTAGENESIS; GENETIC SELECTION; PEPTIDE APTAMERS; FUSION PROTEIN; IN-VIVO; TRANSFORMATION	The enzymes of the Krebs tricarboxylic acid cycle in mitochondria are proposed to form a supramolecular complex, in which there is channeling of intermediates between enzyme active sites. While interactions have been demonstrated in vitro between most of the sequential tricarboxylic acid cycle enzymes, no direct evidence has been obtained in vivo for such interactions. We have isolated, in the Saccharomyces cerevisiae gene encoding the tricarboxylic acid cycle enzyme citrate synthase Cit1p, an "assembly mutation," i.e. a mutation that causes a tricarboxylic acid cycle deficiency without affecting the citrate synthase activity. We have shown that a 15-amino acid peptide from wild type Cit1p encompassing the mutation point inhibits the tricarboxylic acid cycle in a dominant manner, and that the inhibitory phenotype is overcome by a co-overexpression of Mdh1p, the mitochondrial malate dehydrogenase. These data provide the first direct in vivo evidence of interaction between two sequential tricarboxylic acid cycle enzymes, Cit1p and Mdh1p, and indicate that the characterization of assembly mutations by the reversible transdominant inhibition method may be a powerful way to study multienzyme complexes in their physiological context.	Dept Vet Affairs Med Ctr, Res Serv, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Velot, C (corresponding author), Vet Adm Med Ctr, 151B,4500 S Lancaster Rd, Dallas, TX 75216 USA.							Abedi MR, 1998, NUCLEIC ACIDS RES, V26, P623, DOI 10.1093/nar/26.2.623; Appling DR, 1999, METHODS, V19, P338, DOI 10.1006/meth.1999.0861; ARAGON JJ, 1991, FASEB J, V5, P2945, DOI 10.1096/fasebj.5.14.1752361; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; CHAPPELL B, 1967, BIOCH MITOCHONDRIA, P75; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; Englard S., 1969, METHOD ENZYMOL, V13, P99; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Haggie PM, 1999, J BIOL CHEM, V274, P3941, DOI 10.1074/jbc.274.7.3941; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; Jones D.P., 1988, MICROCOMPARTMENTATIO; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KISPAL G, 1989, J BIOL CHEM, V264, P11204; KISPAL G, 1991, ARCH BIOCHEM BIOPHYS, V286, P132, DOI 10.1016/0003-9861(91)90018-E; KISPAL G, 1988, J BIOL CHEM, V263, P11145; Leung DW, 1989, TECHNIQUE, V1, P11; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11692, DOI 10.1021/bi00205a004; Maniatis T., 1982, MOL CLONING LAB MANU; McCammon MT, 1996, GENETICS, V144, P57; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; Morgunov I, 1998, J BIOL CHEM, V273, P29540, DOI 10.1074/jbc.273.45.29540; MORRISON DA, 1977, J BACTERIOL, V132, P349, DOI 10.1128/JB.132.1.349-351.1977; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; OVADI J, 1995, CELL ARCHITECTURE ME; Shatalin K, 1999, BIOCHEMISTRY-US, V38, P881, DOI 10.1021/bi982195h; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Srere PA, 1997, CHANNELING INTERMEDI, P201; TYISKA RL, 1986, NATO WORKSHOP ORG CE, P177; Velot C, 1999, BIOCHEMISTRY-US, V38, P16195, DOI 10.1021/bi991695n; Velot C, 1997, BIOCHEMISTRY-US, V36, P14271, DOI 10.1021/bi972011j; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	49	44	44	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12926	12933		10.1074/jbc.275.17.12926	http://dx.doi.org/10.1074/jbc.275.17.12926			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777592	hybrid			2022-12-27	WOS:000086762300076
J	McShea, A; Samuel, T; Eppel, JT; Galloway, DA; Funk, JO				McShea, A; Samuel, T; Eppel, JT; Galloway, DA; Funk, JO			Identification of CIP-1-associated regulator of cyclin B (CARB), a novel p21-binding protein acting in the G(2) phase of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA-REPLICATION; NUCLEAR EXPORT; E7 ONCOPROTEIN; CDK INHIBITORS; P21; CENTROSOME; ARREST; PCNA; LOCALIZATION; DAMAGE	The cyclin-dependent kinase inhibitor p21(cip1) regulates cell cycle progression, DNA replication, and DNA repair by binding to specific cellular proteins through distinct amino- and carboxyl-terminal protein binding motifs, We have identified a novel human gene, CARE (CIP-1-associated regulator of cyclin B), whose product interacts with the pal carboxyl terminus. Immunocytochemical analysis demonstrates that the CARE protein is perinuclear and predominantly associated with the centrosome and mitotic spindle poles. In addition, CARE is also able to associate with cyclin El, a key regulator of mitosis. However, cyclin B1-CARB complex formation occurs preferentially in the absence of pal. Unexpectedly, overexpression of CARE is associated with a growth-inhibitory and ultimately lethal phenotype in p21(-/-) cells but not in p21(+/+) cells. These data identify a novel mechanism that may underlie the effects of p21 in the G(2)/M phases of the cell cycle.	Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, D-91052 Erlangen, Germany; Fred Hutchinson Canc Res Ctr, Program Canc Biol, Seattle, WA 98109 USA	University of Erlangen Nuremberg; Fred Hutchinson Cancer Center	Funk, JO (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, Hartmannstr 14, D-91052 Erlangen, Germany.				NATIONAL CANCER INSTITUTE [R01CA064795] Funding Source: NIH RePORTER; NCI NIH HHS [CA64795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILLY E, 1992, J CELL SCI, V101, P529; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	36	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23181	23186		10.1074/jbc.M001772200	http://dx.doi.org/10.1074/jbc.M001772200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10781590	hybrid			2022-12-27	WOS:000088419400079
J	Jing, NJ; Marchand, C; Liu, J; Mitra, R; Hogan, ME; Pommier, Y				Jing, NJ; Marchand, C; Liu, J; Mitra, R; Hogan, ME; Pommier, Y			Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAINS; DNA-BINDING DOMAIN; CATALYTIC DOMAIN; ACTIVE-SITE; I INTEGRASE; PROTEIN; CORE; MULTIMERIZATION; IDENTIFICATION	The G-tetrad-forming oligonucleotides T30177 and T30695 have been identified as potent inhibitors of human immunodeficiency virus type 1 integrase (HIV-1 IN) activity (Rando, R. F., Ojwang, J., Elbaggari, A., Reyes, G. R., Tinder, R., McGrath, M. S., and Hogan, M. E. (1995) J. Biol. Chem. 270, 1754-1760; Mazumder, A., Neamati, N., Ojwang, J. O., Sunder, S., Rando, R. F., and Pommier, Y. (1996) Biochemistry 35, 13762-13771; Jing, N., and Hogan, M. E. (1998) J. Biol. Chem. 273, 34992-34999). To understand the inhibition of HIV-1 IN activity by the G-quartet inhibitors, we have designed the oligonucleotides T40215 and T40216, composed of three and four G-quartets with stem lengths of 19 and 24 Angstrom, respectively. The fact that increasing the G-quartet stem length from 15 to 24 Angstrom kept inhibition of HIV-1 IN activity unchanged suggests that the binding interaction occurs between a GTGT loop domain of the G-quartet inhibitors and a catalytic site of HIV-1 ZN, referred to as a face-to-face interaction. Docking the NMR structure of T30695 (Jing and Hogan (1998)) into the x-ray structure of the core domain of HIV-1 IN, HIV-1 IN-(51-209) (Maignan, S., Guilloteau, J.-P., Qing, Z.-L., Clement-Mella, C., and Mikol, V. (1998) J. Mel. Biol. 282, 359-368), was performed using the GRAMM program. The statistical distributions of hydrogen bonding between HIV-1 IN and T30695 were obtained from the analyses of 1000 random docking structures. The docking results show a high probability of interaction between the GTGT loop residues of the G-quartet inhibitors and the catalytic site of HIV-1 IN, in agreement with the experimental observation.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jing, NJ (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	njing@bcm.tmc.edu	Marchand, Christophe/D-8559-2016		NIGMS NIH HHS [GM60153] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BROWN PO, 1998, INTEGRATION RETROVIR; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Este JA, 1998, MOL PHARMACOL, V53, P340, DOI 10.1124/mol.53.2.340; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Haugan IR, 1995, BIOCHEM BIOPH RES CO, V217, P802, DOI 10.1006/bbrc.1995.2843; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421; Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992; Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967; Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; Vakser IA, 1996, PROTEIN ENG, V9, P37, DOI 10.1093/protein/9.1.37; Vakser IA, 1996, PROTEIN ENG, V9, P741, DOI 10.1093/protein/9.9.741; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	40	100	104	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21460	21467		10.1074/jbc.M001436200	http://dx.doi.org/10.1074/jbc.M001436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801812	hybrid			2022-12-27	WOS:000088230600068
J	He, F; Seryshev, AB; Cowan, CW; Wensel, TG				He, F; Seryshev, AB; Cowan, CW; Wensel, TG			Multiple zinc binding sites in retinal rod cGMP phosphodiesterase, PDE6 alpha beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PHOTORECEPTOR PHOSPHODIESTERASE; CALCIUM; ACTIVATION; TRANSDUCIN; ENZYMES; CAMP; MEMBRANES; PDE10A; CA-2+	The photoreceptor cGMP phosphodiesterase (PDE6) plays a key role in vertebrate vision, but its enzymatic mechanism and the roles of metal ion co-factors have yet to be determined. We have determined the amount of endogenous Zn2+ in rod PDE6 and established a requirement for tightly bound Zn2+ in catalysis, Purified PDE6 contained 3-4-g atoms of zinc/mole, consistent with an initial content of two tightly bound Zn2+/catalytic subunit. PDE with only tightly bound Zn2+ and no free metal ions was inactive, but activity was fully restored by Mg2+, Mn2+, Co2+, or Zn2+. Mn2+, Co2+, and Zn2+ also induced aggregation and inactivation at higher concentrations and longer times. Removal of 93% of the tightly bound Zn2+ by treatment with dipicolinic acid and EDTA at pH 6.0 resulted in almost complete loss of activity in the presence of Mg2+. This activity loss was blocked almost completely by Zn2+, less potently by Co2+ and almost not at all by Mg2+, Mn2+, or Cu2+. The lost activity was restored by the addition of Zn2+, but Co2+ restored only 13% as much activity, and other metals even less. Thus tightly bound Zn2+ is required for catalysis but could also play a role in stabilizing the structure of PDE6, whereas distinct sites where Zn2+ is rapidly exchanged are likely occupied by Mg2+ under physiological conditions.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem, 1 Baylor Plaza, Houston, TX 77030 USA.		Cowan, Christopher W/I-2497-2014	Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981] Funding Source: Medline; NIDDK NIH HHS [DK07696] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADER G, 1974, EXP EYE RES, V18, P509, DOI 10.1016/0014-4835(74)90057-8; COOK NJ, 1986, BIOCHIM BIOPHYS ACTA, V883, P63, DOI 10.1016/0304-4165(86)90135-2; Cooper BF, 1997, PROTEIN SCI, V6, P1031, DOI 10.1002/pro.5560060509; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LONDESBOROUGH J, 1983, J BIOL CHEM, V258, P2966; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MCCORMICK LD, 1985, BIOPHYS J, V47, P381, DOI 10.1016/S0006-3495(85)83929-1; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; PANNBACKER RG, 1972, SCIENCE, V175, P757, DOI 10.1126/science.175.4023.757; Percival MD, 1997, BIOCHEM BIOPH RES CO, V241, P175, DOI 10.1006/bbrc.1997.7542; PILLAI R, 1994, J BIOL CHEM, V269, P30676; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SIMONS TJB, 1993, NEUROTOXICOLOGY, V14, P77; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; SRIVASTAVA D, 1995, BIOCHEM J, V308, P653, DOI 10.1042/bj3080653; STRYDOM DJ, 1994, ANAL BIOCHEM, V222, P19, DOI 10.1006/abio.1994.1448; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WENSEL TG, 1993, GTPASES BIOL, V2, P213; Xiong WH, 1998, NAT NEUROSCI, V1, P359, DOI 10.1038/nn0998_359; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	35	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20572	20577		10.1074/jbc.M000440200	http://dx.doi.org/10.1074/jbc.M000440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787404	hybrid			2022-12-27	WOS:000088084500051
J	Liu, CT; Yao, J; Mercola, D; Adamson, E				Liu, CT; Yao, J; Mercola, D; Adamson, E			The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; GROWTH-FACTOR-BETA; NGFI-A GENE; FIBROSARCOMA CELLS; PROMOTER REGION; NERVOUS-SYSTEM; HT1080 CELLS; EXPRESSION; INDUCTION; BINDING	EGR-1, a transcription factor with important functions in the regulation of growth and differentiation, is highly expressed in brain. Previous studies have shown that EGR-1 suppresses the transformed phenotype, However, the expression and role of EGR-1 in human glioblastoma cells are not yet determined. In this study, we found that the basal expression of the EGR-1 protein is undetectable, but is inducible in four human glioblastoma cell lines. To determine EGR-1 functions, we reexpressed EGR-1 in human glioblastoma U251 cells and found that the secretion of transforming growth factor-beta 1 (TGF-beta 1), plasminogen activator inhibitor-1 (PAI-1), and fibronectin (FN) was greatly enhanced. Addition of anti-TGF-beta antibodies completely inhibited the secretion of PAI-1, but had little effect on secretion of FN, indicating that PAI-1 is under the control of EGR-1-induced TGF-beta 1. An examination of the promoter of the FN gene revealed two EGR-1-binding sites between positions -75 and -52 and positions -4 and +14 that specifically bound EGR-1 in gel mobility shift experiments. Utilizing wild-type and mutant FN promoter/luciferase reporter genes, we demonstrated that EGR-1 positively regulated the activity of the FN gene. In addition, cell adhesion and migration were greatly increased in the EGR-1-expressing cells, and adhesion was reversed by addition of RGD-containing peptides, These results suggest that EGR-1 may regulate cell interaction with the extracellular matrix by coordinated induction of TGF-beta 1, FN, and PAI-1 in human glioblastoma cells.	Sydney Kimmel Canc Ctr, San Diego, CA 92121 USA; Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Liu, CT (corresponding author), Sydney Kimmel Canc Ctr, 10835 Altman row, San Diego, CA 92121 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA63783, CA67888, CA76173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067888, R01CA063783, R01CA076173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu H, 1996, CANCER RES, V56, P4541; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DER CJ, 1980, INT J CANCER, V26, P451, DOI 10.1002/ijc.2910260410; DER CJ, 1981, J CELL SCI, V52, P151; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIANCOTTI FG, 1990, CELL, V266, P8923; GIESE A, 1994, CANCER RES, V54, P3897; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kaplan IV, 1995, DEV BRAIN RES, V90, P174, DOI 10.1016/0165-3806(96)83498-5; KIM SJ, 1989, J BIOL CHEM, V264, P19373; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LEAH JD, 1993, NEUROSCIENCE, V57, P53, DOI 10.1016/0306-4522(93)90111-R; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCORMACK MA, 1992, MOL BRAIN RES, V12, P215, DOI 10.1016/0169-328X(92)90087-R; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIKAM SS, 1995, MOL CELL NEUROSCI, V6, P337, DOI 10.1006/mcne.1995.1026; Ohnishi T, 1997, CLIN EXP METASTAS, V15, P538, DOI 10.1023/A:1018422926361; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Potapova O, 1996, CANCER RES, V56, P280; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saulnier R, 1996, EXP CELL RES, V222, P360, DOI 10.1006/excr.1996.0045; SCHLINGENSIEPEN KH, 1991, NEUROSCI LETT, V122, P67, DOI 10.1016/0304-3940(91)90195-Y; Scott JN, 1998, CAN J NEUROL SCI, V25, P197, DOI 10.1017/S0317167100034016; Sottile J, 1998, J CELL SCI, V111, P2933; STEEL DM, 1989, J CELL SCI, V93, P515; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; Yau JLW, 1996, MOL BRAIN RES, V42, P354, DOI 10.1016/S0169-328X(96)00220-3	58	123	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20315	20323		10.1074/jbc.M909046199	http://dx.doi.org/10.1074/jbc.M909046199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10783396	hybrid			2022-12-27	WOS:000088084500016
J	Freise, D; Held, B; Wissenbach, U; Pfeifer, A; Trost, C; Himmerkus, N; Schweig, U; Freichel, M; Biel, M; Hofmann, F; Hoth, M; Flockerzi, V				Freise, D; Held, B; Wissenbach, U; Pfeifer, A; Trost, C; Himmerkus, N; Schweig, U; Freichel, M; Biel, M; Hofmann, F; Hoth, M; Flockerzi, V			Absence of the gamma subunit of the skeletal muscle dihydropyridine receptor increases L-type Ca2+ currents and alters channel inactivation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW CALCIUM CURRENT; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; MUSCULAR DYSGENESIS; CONTRACTION; MICE; GENE; CELLS; SEQUENCE; MOUSE	In skeletal muscle the oligomeric alpha(1S), alpha(2)/delta-1 or alpha(2)/delta-2, beta 1, and gamma 1 L-type Ca2+ channel or dihydropyridine receptor functions as a voltage sensor for excitation contraction coupling and is responsible for the L-type Ca2+ current. The gamma 1 subunit, which is tightly associated with this Ca2+ channel, is a membrane-spanning protein exclusively expressed in skeletal muscle. Previously, heterologous expression studies revealed that gamma 1 might modulate Ca2+ currents expressed by the pore subunit found in heart, alpha(1C), shifting steady state inactivation, and increasing current amplitude. To determine the role of gamma 1 assembled with the skeletal subunit composition in vivo, we used gene targeting to establish a mouse model, in which gamma 1 expression is eliminated. Comparing litter-matched mice with control mice, we found that, in contrast to heterologous expression studies, the loss of gamma 1 significantly increased the amplitude of peak dihydropyridine-sensitive I-Ca in isolated myotubes. Whereas the activation kinetics of the current remained unchanged, inactivation of the current was slowed in gamma 1-deficient myotubes and, correspondingly, steady state inactivation of I-Ca was shifted to more positive membrane potentials. These results indicate that gamma 1 decreases the amount of Ca2+ entry during stimulation of skeletal muscle.	Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Saarlandes, Inst Physiol, D-66421 Homburg, Germany	Saarland University; Technical University of Munich; Saarland University	Freise, D (corresponding author), Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany.		Tuluc, Petronel/C-2527-2011; Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052; Himmerkus, Nina/0000-0002-2910-6728; Hoth, Markus/0000-0001-7080-4643				ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DIRKSEN RT, 1995, J GEN PHYSIOL, V105, P227, DOI 10.1085/jgp.105.2.227; DULHUNTY AF, 1988, J PHYSIOL-LONDON, V399, P63; Eberst R, 1997, PFLUG ARCH EUR J PHY, V433, P633, DOI 10.1007/s004240050324; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KOTSIAS BA, 1986, AM J PHYSIOL, V250, pC40, DOI 10.1152/ajpcell.1986.250.1.C40; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lerche H, 1996, PFLUG ARCH EUR J PHY, V431, P461, DOI 10.1007/s004240050021; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P326; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OZ M, 1991, J PHARMACOL EXP THER, V257, P575; PEARSON HA, 1993, PFLUG ARCH EUR J PHY, V425, P518, DOI 10.1007/BF00374880; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; POWERS PA, 1993, J BIOL CHEM, V268, P9275; Ren DJ, 1997, J BIOL CHEM, V272, P22393, DOI 10.1074/jbc.272.36.22393; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; Wissenbach U, 1998, BIOL CHEM, V379, P45, DOI 10.1515/bchm.1998.379.1.45; Zhou JS, 1998, J BIOL CHEM, V273, P25503, DOI 10.1074/jbc.273.39.25503	44	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14476	14481		10.1074/jbc.275.19.14476	http://dx.doi.org/10.1074/jbc.275.19.14476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799530	hybrid			2022-12-27	WOS:000087006900064
J	Li, CX; Furge, KA; Cheng, QC; Albright, CF				Li, CX; Furge, KA; Cheng, QC; Albright, CF			Byr4 localizes to spindle-pole bodies in a cell cycle-regulated manner to control Cdc7 localization and septation in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SCHIZOSACCHAROMYCES-POMBE; SEPTUM FORMATION; BIPOLAR SPINDLE; DIVISION CYCLE; S-POMBE; CYTOKINESIS; KINASE; GENE; TRANSITION	Cytokinesis and septation in the fission yeast Schizosaccharomyces pombe are studied as a model for mammalian cell division. In fission yeast, septation is positively regulated by Spg1, a Ras family GTPase that localizes to spindle-pole bodies (SPBs) throughout the cell cycle. As cells enter mitosis, Spg1 accumulates in an active, GTP-bound form and binds the Cdc7 protein kinase to cause Cdc7 translocation to SPBs. Cdc7 disappears from one SPB in mid-anaphase and from the second SPB in late mitosis. Byr4 plus Cdc16 negatively regulate septation by forming a two-component GTPase-activating protein for Spg1. These results led us to hypothesize that Byr4 localization to SPBs regulated the nucleotide state of Spg1, due to its ability to form Spg1GAP activity with Cdc16 and thus the binding of Cdc7 to Spg1 at SPBs. To test this hypothesis, Byr4 localization was determined using indirect immunofluorescence. This analysis revealed that Byr4 was localized to SPBs that did not contain Cdc7. In byr4(-) mutants, Cdc7 localized to interphase SPBs and only symmetrically localized to mitotic SPBs. In contrast, Byr4 overexpression prevented Spg1 and Cdc7 localization to SPBs, These results suggest that Byr4 localization to SPBs maintains Spg1 in an inactive form, presumably by stimulating Spg1 GTPase activity with Cdc16, and that loss of Byr4 from mitotic SPBs increases the active fraction of Spg1 and thereby increases Spg1-Cdc7 binding. Byr4 localization to SPBs was decreased in spg1, cdc16, sid4, and cdc11 mutants as well as in several mutants that affect medial F-actin structures, suggesting that multiple pathways regulate Byr4 localization to SPBs.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Albright, CF (corresponding author), Dupont Pharmaceut, 500 S Ridgeway Ave, Glenolden, PA 19036 USA.	Charles.F.Albright@dupontpharma.com			NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051952] Funding Source: NIH RePORTER; NCI NIH HHS [1P30 CA68485, CA68485] Funding Source: Medline; NIGMS NIH HHS [GM51952] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; Balasubramanian MK, 1998, GENETICS, V149, P1265; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cerutti L, 1999, J CELL SCI, V112, P2313; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Gould KL, 1997, GENE DEV, V11, P2939, DOI 10.1101/gad.11.22.2939; Hagan I, 1997, J CELL SCI, V110, P1851; KEENEY JB, 1994, GENETICS, V136, P849; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Song KW, 1996, J CELL BIOL, V133, P1307, DOI 10.1083/jcb.133.6.1307	26	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14381	14387		10.1074/jbc.275.19.14381	http://dx.doi.org/10.1074/jbc.275.19.14381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799520	hybrid			2022-12-27	WOS:000087006900052
J	Klappa, P; Koivunen, P; Pirneskoski, A; Karvonen, P; Ruddock, LW; Kivirikko, KI; Freedman, RB				Klappa, P; Koivunen, P; Pirneskoski, A; Karvonen, P; Ruddock, LW; Kivirikko, KI; Freedman, RB			Mutations that destabilize the a ' domain of human protein-disulfide isomerase indirectly affect peptide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; PRESECRETORY PROTEINS; MAMMALIAN MICROSOMES; MISFOLDED PROTEINS; BETA-SUBUNIT; DOMAIN; SITE; TRANSPORT; CHAPERONE	Protein-disulfide isomerase (PDI) is a catalyst of folding of disulfide-bonded proteins and also a multifunctional polypeptide that acts as the beta-subunit in the prolyl 4-hydroxylase alpha(2)beta(2)-tetramer (P4H) and the microsomal triglyceride transfer protein alpha beta-dimer. The principal peptide-binding site of PDI is located in the b' domain, but all domains contribute to the binding of misfolded proteins, Mutations in the C-terminal part of the a' domain have significant effects on the assembly of the P4H tetramer and other functions of PDI, In this study we have addressed the question of whether these mutations in the C-terminal part of the a' domain, which affect P4H assembly, also affect peptide binding to PDI. We observed a strong correlation between P4H assembly competence and peptide binding; mutants of PDI that failed to form a functional P4H tetramer were also inactive in peptide binding. However, there was also a correlation between inactivity in these assays and indicators of conformational disruption, such as protease sensitivity. Peptide binding activity could be restored in inactive, protease-sensitive mutants by selective proteolytic removal of the mutated a' domain. Hence we propose that structural changes in the a' domain indirectly affect peptide binding to the b' domain.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90220 Oulu, Finland; Univ Oulu, Dept Biochem Med, FIN-90220 Oulu, Finland	University of Kent; University of Oulu; University of Oulu	Klappa, P (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.			Ruddock, Lloyd/0000-0002-6247-686X				CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; FREEDMAN RB, 1999, MOL CHAPERONES PROTE, P437; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KLAPPA P, 1994, FEBS LETT, V341, P281, DOI 10.1016/0014-5793(94)80473-7; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; Klappa P, 1998, EUR J BIOCHEM, V254, P63, DOI 10.1046/j.1432-1327.1998.2540063.x; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Song JL, 1997, BIOCHEM J, V328, P841, DOI 10.1042/bj3280841; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801	26	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13213	13218		10.1074/jbc.275.18.13213	http://dx.doi.org/10.1074/jbc.275.18.13213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788425	hybrid			2022-12-27	WOS:000086925300011
J	Muller, S; Berger, M; Lehembre, F; Seeler, JS; Haupt, Y; Dejean, A				Muller, S; Berger, M; Lehembre, F; Seeler, JS; Haupt, Y; Dejean, A			c-Jun and p53 activity is modulated by SUMO-1 modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED MODIFIER; NUCLEAR-PORE COMPLEX; COVALENT MODIFICATION; MDM2; PROTEIN; PHOSPHORYLATION; DEGRADATION; PML; ACTIVATION; CONJUGATION	The ubiquitin-related SUMO-1 molecule has been shown recently to modify covalently a number of cellular proteins including I kappa B alpha. SUMO-1 modification was found to antagonize I kappa B alpha ubiquitination and protect it from degradation. Here we identify the transcription factors c-Jun and p53, two well known, targets of ubiquitin, as new substrates for SUMO-1 both in vitro and in vivo. In contrast to ubiquitin, SUMO-1 preferentially targets a single lysine residue in c-Jun (Lys-229), and the abrogation of SUMO-1 modification does not compromise its ubiquitination, Activation of Jun NH2-terminal kinases, which induces a reduction in c-Jun ubiquitination, similarly decreases SUMO-1 modification. Accordingly, loss of the two major Jun NH2-terminal kinase phosphorylation sites in c-Jun, Ser-63 and Ser-73, greatly enhances conjugation by SUMO-1. A SUMO-1-deficient c-JunK229R mutant shows an increased transactivation potential on an AP-1-containing promoter compared with wild-type c-Jun, suggesting that SUMO-1 negatively regulates c-Jun activity. As with c-Jun, SUMO-1 modification of p53 is abrogated by phosphorylation but remains unaltered upon chemical damage to DNA or Mdm2-mediated ubiquitination. The SUMO-1 attachment site in p53 (Lys-386) resides within a region known to regulate the DNA binding activity of the protein. A p53 mutant, defective for SUMO-1 conjugation, shows unaltered ubiquitination but has a slightly impaired apoptotic activity, indicating that modification by SUMO-1 might be important for the full biological activity of p53, Taken together, these data provide a first link between the SUMO-1 conjugation pathway and the regulation of transcription factors.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Hebrew University of Jerusalem	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.	adejean@pasteur.fr	Dejean, Anne/L-5145-2018	Muller, Stefan/0000-0002-8792-7700; Haupt, Ygal/0000-0001-5925-0096; Seeler, Jacob-Sebastian/0000-0001-8209-8555				Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duprez E, 1999, J CELL SCI, V112, P381; Fuchs SY, 1996, ONCOGENE, V13, P1531; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KORNUC M, 1988, MOL CELL BIOL, V8, P3717, DOI 10.1128/MCB.8.9.3717; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805	36	345	352	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13321	13329		10.1074/jbc.275.18.13321	http://dx.doi.org/10.1074/jbc.275.18.13321			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788439	Green Published, hybrid			2022-12-27	WOS:000086925300025
J	Schwarzer, A; Schauf, H; Bauer, PJ				Schwarzer, A; Schauf, H; Bauer, PJ			Binding of the cGMP-gated channel to the Na/Ca-K exchanger in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; SACCULAR HAIR-CELLS; OUTER SEGMENTS; BETA-SUBUNIT; FUNCTIONAL RECONSTITUTION; PLASMA-MEMBRANE; CATION CHANNEL; PHOTOTRANSDUCTION; IDENTIFICATION; CALMODULIN	The intracellular Ca2+ concentration in rod outer segments of vertebrate photoreceptors is controlled by Ca2+ influx through cGMP-gated channels and by Ca2+ efflux driven by Na/Ca-K exchangers, Previously, we suggested that channel and exchanger are associated (Bauer, P, J,, and Drechsler, M, (1992) J, Physiol, (Lond.) 451, 109-131), This suggestion has been thoroughly examined using a variety of biochemical approaches, First, we took advantage of the fact that cGMP-gated channels bind calmodulin (CaM). Using CaM affinity chromatographic purification of the channel in 10 mM CHAPS, a significant fraction of exchanger was coeluted with the channel indicating a binding affinity between channel and exchanger. Binding of channel and exchanger was examined more directly by crosslinking of proteins in the rod outer segment membranes, Activation of the channel with cyclic 8-bromo-GMP lead to exposure of a cysteine, which allowed cross-linking of the channel to the exchanger with the thiol-specific reagent DL-1,4-bismaleimido-2,3-butanediol. Cleavage of the cross-links and electrophoretic analysis indicated that a cross-link between the alpha-subunit of the channel and the exchanger formed. Furthermore, a cross-link between two adjacent alpha-subunits of the channel was found, suggesting that the alpha-subunits of the native channel are dimerized, Further support for an interaction between alpha-subunit and exchanger was obtained by in vitro experiments. Specific binding of the exchanger to the alpha-subunit but not to the beta-subunit of the channel was observed in Western blots of purified channel incubated with purified exchanger. This study suggests that two exchanger molecules bind to one cGMP-gated channel and, more specifically, that binding of exchanger molecules occurs at the alpha-subunits, which in the native channel are dimerized, The implications of these findings regarding the possibility of local Ca2+ signaling in vertebrate photoreceptors will be discussed.	Forschungszentrum Julich, Inst Biol Informat Proc, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Bauer, PJ (corresponding author), Forschungszentrum Julich, Inst Biol Informat Proc, Postfach 1913, D-52425 Julich, Germany.	P.J.Bauer@fz-juelich.de						AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BAUER PJ, 1988, J PHYSIOL-LONDON, V401, P309, DOI 10.1113/jphysiol.1988.sp017164; Bauer PJ, 1999, AM J PHYSIOL-CELL PH, V276, pC558, DOI 10.1152/ajpcell.1999.276.3.C558; Bauer PJ, 1996, J PHYSIOL-LONDON, V494, P675, DOI 10.1113/jphysiol.1996.sp021523; BAUER PJ, 1992, J PHYSIOL-LONDON, V451, P109, DOI 10.1113/jphysiol.1992.sp019156; Borst JGG, 1996, NATURE, V383, P431, DOI 10.1038/383431a0; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; COOK NJ, 1986, J BIOL CHEM, V261, P7033; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; Detwiler P B, 1992, Curr Opin Neurobiol, V2, P433, DOI 10.1016/0959-4388(92)90176-L; FAIN GL, 1990, TRENDS NEUROSCI, V13, P378, DOI 10.1016/0166-2236(90)90023-4; Gray-Keller M, 1999, J PHYSIOL-LONDON, V519, P679, DOI 10.1111/j.1469-7793.1999.0679n.x; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MCCARTHY ST, 1994, BIOPHYS J, V67, P2076, DOI 10.1016/S0006-3495(94)80691-5; Molday RS, 1998, VISION RES, V38, P1315, DOI 10.1016/S0042-6989(97)00409-4; PAPE PC, 1995, J GEN PHYSIOL, V106, P259, DOI 10.1085/jgp.106.2.259; RATTO GM, 1988, J NEUROSCI, V8, P3240; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; ROBERTS WM, 1993, NATURE, V363, P74, DOI 10.1038/363074a0; ROBERTS WM, 1994, J NEUROSCI, V14, P3246; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; Schwarzer A, 2000, BIOPHYS J, V78, p142A; Schwarzer A, 1998, J GEN PHYSIOL, V112, p20A; STRYER L, 1991, J BIOL CHEM, V266, P10711; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Weitz D, 1998, EMBO J, V17, P2273, DOI 10.1093/emboj/17.8.2273; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	40	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13448	13454		10.1074/jbc.275.18.13448	http://dx.doi.org/10.1074/jbc.275.18.13448			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788457	hybrid, Green Published			2022-12-27	WOS:000086925300044
J	Shetty, S; Idell, S				Shetty, S; Idell, S			Post-transcriptional regulation of urokinase mRNA - Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; KINASE-C; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; MESOTHELIOMA CELLS; RICH SEQUENCES; LLC-PK1 CELLS; PHORBOL ESTER	We sought to determine if urokinase expression is regulated at the post-transcriptional level in cultured lung epithelial cells. We also sought to determine if differences in urokinase expression by cultured human lung carcinoma and non-malignant lung epithelial subtypes were attributable to post-transcriptional regulatory mechanisms. Urokinase was expressed by phenotypically diverse lung carcinoma cell lines as well as nonmalignant small airway epithelial cells and bronchial epithelial cells. Using gel mobility shift and UV crosslinking assays, we identified a 30-kDa urokinase mRNA-binding protein that selectively bound to a 66-nucleotide protein-binding fragment of urokinase mRNA. The urokinase mRNA-binding protein is found in the cytosolic but not nuclear extracts of non-malignant lung epithelial cells; whereas, it is found in the nuclear but not cytosolic extracts of selected malignant carcinoma-derived cells that express relatively large amounts of urokinase. Chimeric beta-globin/urokinase cDNA containing the urokinase mRNA-binding protein binding sequence destabilized otherwise stable beta-globin mRNA. Our results demonstrate that urokinase gene expression in lung epithelial and lung carcinoma-derived cells is regulated at the post-transcriptional level. The mechanism involves an interaction between a bs-nucleotide sequence of the urokinase mRNA 3'-untranslated region with a newly recognized urokinase mRNA-binding protein to regulate urokinase mRNA stability.	Univ Texas Hlth Ctr, Dept Specialty Care Serv, Tyler, TX 75708 USA		Shetty, S (corresponding author), Univ Texas Hlth Ctr, Dept Specialty Care Serv, 11937 US Highway 271, Tyler, TX 75708 USA.				PHS HHS [R01-62453-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKASHI M, 1991, BLOOD, V78, P2005; ALTUS MS, 1987, BIOCHEM J, V242, P387, DOI 10.1042/bj2420387; ALTUS MS, 1991, J BIOL CHEM, V266, P21190; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENDERSON BR, 1992, CANCER RES, V52, P2489; HENDERSON BR, 1992, INT J CANCER, V50, P918, DOI 10.1002/ijc.2910500617; IWAI Y, 1993, J IMMUNOL, V150, P4386; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; LEVINE BJ, 1987, P NATL ACAD SCI USA, V84, P6189, DOI 10.1073/pnas.84.17.6189; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; MAKELA TP, 1987, MOL CELL BIOL, V7, P3656; MARSHALL BC, 1992, J BIOL CHEM, V267, P11462; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shetty S, 1998, ARCH BIOCHEM BIOPHYS, V356, P265, DOI 10.1006/abbi.1998.0789; Shetty S, 1998, AM J PHYSIOL-LUNG C, V274, pL871, DOI 10.1152/ajplung.1998.274.6.L871; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	34	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13771	13779		10.1074/jbc.275.18.13771	http://dx.doi.org/10.1074/jbc.275.18.13771			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788498	hybrid			2022-12-27	WOS:000086925300085
J	Clarkson, RWE; Heeley, JL; Chapman, R; Aillet, F; Hay, RT; Wyllie, A; Watson, CJ				Clarkson, RWE; Heeley, JL; Chapman, R; Aillet, F; Hay, RT; Wyllie, A; Watson, CJ			NF-kappa B inhibits apoptosis in murine mammary epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ALPHA-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; GLAND INVOLUTION; BREAST-CANCER; GROWTH-HORMONE; HUMAN-MILK; ACTIVATION; EXPRESSION; SUPPRESSION	The transcription factor NF-kappa B is a key modulator of apoptosis in a variety of cell types, but to date this specific function of NF-kappa B has not been demonstrated in epithelia, Here, we describe the activation of NF-kappa B during post-lactational involution of the mouse mammary gland, a period of extensive apoptosis of luminal epithelial cells. Significantly, active NF-kappa B localized exclusively to nonapoptotic epithelial cells both in vivo and in the mammary epithelial cell line, KIM-2, transduced with an NF-kappa B-dependent green fluorescent protein reporter, Activation of NF-kappa B in vitro coincided with a decrease in the cytosolic repressor, I kappa B alpha. Furthermore, induction of NF-kappa B either by extracellular ligands or, more specifically, by inhibition of the I kappa B repressor with adenoviral constructs expressing antisense mRNA, resulted in enhanced survival of KIM-2 cells. Therefore, although coincident with induction of apoptosis both in vivo and in vitro, NF-kappa B appeared to exert a selective survival function in epithelial cells. This study highlights for the first time a role for NF-kappa B in modulating apoptosis in epithelium.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ St Andrews, Sch Biol, St Andrews KY16 9ST, Fife, Scotland; Western Gen Hosp, Mol Med Ctr, Sir Alistair Currie Canc Res Campaign Labs, Edinburgh EH4 2XU, Midlothian, Scotland	University of Cambridge; University of St Andrews; University of Edinburgh	Clarkson, RWE (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		Hay, Ronald/S-3233-2019; Clarkson, Richard/A-7505-2010; Hay, Ronald T/F-9338-2011; watson, Christine J/B-1431-2012	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Chapman, Rachel/0000-0001-5786-1918; clarkson, richard/0000-0001-7389-8673				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clarkson RWE, 1999, J MAMMARY GLAND BIOL, V4, P165, DOI 10.1023/A:1018725207969; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; DEJARDIN E, 1995, ONCOGENE, V11, P1835; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Goldman AS, 1996, J MAMMARY GLAND BIOL, V1, P251, DOI 10.1007/BF02018078; GORDON KE, 2000, IN PRESS BREAST CANC; Gukoyskaya AS, 1997, GASTROENTEROLOGY, V112, pA446; HARA T, 1995, PEDIATR RES, V37, P437, DOI 10.1203/00006450-199504000-00009; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hishikawa K, 1997, CIRC RES, V81, P797; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Lund LR, 1996, DEVELOPMENT, V122, P181; MAUTNER V, 1974, J GEN VIROL, V25, P325, DOI 10.1099/0022-1317-25-3-325; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SKANSENSAPHIR U, 1993, PEDIATR RES, V34, P213, DOI 10.1203/00006450-199308000-00023; Soler AP, 1999, EUR J CELL BIOL, V78, P56, DOI 10.1016/S0171-9335(99)80007-7; Soler AP, 1996, AM J PHYSIOL-RENAL, V270, pF869, DOI 10.1152/ajprenal.1996.270.5.F869; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STRANGE R, 1992, DEVELOPMENT, V115, P49; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tong LQ, 1998, J NEUROCHEM, V71, P447; Travers MT, 1996, ENDOCRINOLOGY, V137, P1530, DOI 10.1210/en.137.5.1530; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; Zandi E, 1999, MOL CELL BIOL, V19, P4547	46	102	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12737	12742		10.1074/jbc.275.17.12737	http://dx.doi.org/10.1074/jbc.275.17.12737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777569	hybrid			2022-12-27	WOS:000086762300053
J	Kuhl, M; Sheldahl, LC; Malbon, CC; Moon, RT				Kuhl, M; Sheldahl, LC; Malbon, CC; Moon, RT			Ca2+/calmodulin-dependent protein kinase II is stimulated by Wnt and frizzled homologs and promotes ventral cell fates in Xenopus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; SIGNALING PATHWAY; MESODERM INDUCTION; SYNTHETIC PEPTIDE; HOMEOBOX GENE; EMBRYOS; CALMODULIN; AXIS; EXPRESSION; CALCIUM	Wnt ligands working through Frizzled receptors have a differential ability to stimulate release of intracellular calcium (Ca2+) and activation of protein kinase C (PKC). Since targets of this Ca2+ release could play a role in Wnt signaling, we first tested the hypothesis that Ca2+/ calmodulin-dependent protein kinase II (CamKII) is activated by some Wnt and Frizzled homologs. We report that Wnt and Frizzled homologs that activate Ca2+ release and PKC also activate CamKII activity in Xenopus embryos, while Wnt and Frizzled homologs that activate beta-catenin function do not. This activation occurs within 10 min after receptor activation in a pertussis toxin-sensitive manner, concomitant with autophosphorylation of endogenous CamKII. Based on data that Wnt-5A and Wnt-11 are present maternally in Xenopus eggs, and activate CamKII, we then tested the hypothesis that CamKII participates in axis formation in the early embryo. Measurements of endogenous CamKII activity from dorsal and ventral regions of embryos revealed elevated activity on the prospective ventral side, which was suppressed by a dominant negative Xwnt-11. If this spatial bias in CamKII activity were involved in promoting ventral cell fate one might predict that elevating CamKII activity on the dorsal side would inhibit dorsal cell fates, while reducing CamKII activity on the ventral side would promote dorsal cell fates. Results obtained by expression of CamKII mutants were consistent with this prediction, revealing that CamKII contributes to a ventral cell fate.	Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Ctr Dev Biol, Seattle, WA 98195 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moon, RT (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.		Moon, Randall T/B-1743-2014; malbon, craig/ABF-3604-2020; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Sheldahl, Laird/0000-0002-3298-5436				Ault KT, 1996, DEVELOPMENT, V122, P2033; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bertwistle D, 1996, MECH DEVELOP, V57, P199, DOI 10.1016/0925-4773(96)00547-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHENG HC, 1986, J BIOL CHEM, V261, P989; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FINNEMANN S, 1995, MOL CELL BIOL, V15, P5082; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Heist EK, 1998, CELL CALCIUM, V23, P103; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Itoh K, 1999, GENE DEV, V13, P2328, DOI 10.1101/gad.13.17.2328; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kume S, 1997, SCIENCE, V278, P1940, DOI 10.1126/science.278.5345.1940; KURET J, 1985, J BIOL CHEM, V260, P6427; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	52	381	393	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12701	12711		10.1074/jbc.275.17.12701	http://dx.doi.org/10.1074/jbc.275.17.12701			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777564	hybrid			2022-12-27	WOS:000086762300048
J	Martinez, J; Ren, YG; Thuresson, AC; Hellmann, U; Astrom, J; Virtanen, A				Martinez, J; Ren, YG; Thuresson, AC; Hellmann, U; Astrom, J; Virtanen, A			A 54-kDa fragment of the poly(A)-specific ribonuclease is an oligomeric, processive, and cap-interacting poly(A)-specific 3 ' exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; POLY(A) BINDING-PROTEIN; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; MAMMALIAN-CELLS; XENOPUS OOCYTES; SYSTEM; DEADENYLATION; DEGRADATION	We have previously identified a HeLa cell 3' exonuclease specific for degrading poly(A) tails of mRNAs, Here we report on the purification and identification of a calf thymus 54-kDa polypeptide associated with a similar 3' exonuclease activity. The 54-kDa polypeptide was shown to be a fragment of the poly(A)-specific ribonuclease 74-kDa polypeptide. The native molecular mass of the nuclease activity was estimated to be 180-220 kDa, Protein/protein cross-linking revealed an oligomeric structure, most likely consisting of three subunits. The purified nuclease activity released 5'-AMP as the reaction product and degraded poly(A) in a highly processive fashion. The activity required monovalent cations and was dependent on divalent metal ions. The RNA substrate requirement was investigated, and it was found that the nuclease was highly poly(A)-specific and that only 3' end-located poly(A) was degraded by the activity. RNA substrates capped with m(7)G(5')ppp(5')G were more efficiently degraded than noncapped RNA substrates. Addition of free m7G(5')ppp(5')G cap analogue inhibited poly(A) degradation in vitro, suggesting a functional link between the RNA 5' end cap structure and poly(A) degradation at the 3' end of the RNA.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Amersham Pharmacia Biotech, SE-75125 Uppsala, Sweden	Uppsala University; Ludwig Institute for Cancer Research	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	anders.virtanen@icm.uu.se		Martinez, Javier/0000-0001-9152-7323				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BACHMANN M, 1984, FEBS LETT, V171, P25, DOI 10.1016/0014-5793(84)80453-6; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Hellman U, 1997, SPRING LAB MAN, P97; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Virtanen A, 1997, Prog Mol Subcell Biol, V18, P199; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x	40	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24222	24230		10.1074/jbc.M001705200	http://dx.doi.org/10.1074/jbc.M001705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801819	hybrid			2022-12-27	WOS:000088564200109
J	Munsterkotter, M; Barbaric, S; Horz, M				Munsterkotter, M; Barbaric, S; Horz, M			Transcriptional regulation of the yeast PHO8 promoter in comparison to the coregulated PHO5 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; POSITIONED NUCLEOSOMES; ALKALINE-PHOSPHATASE; ACID-PHOSPHATASE; FACTOR-BINDING; IN-VIVO; GENE; ACTIVATION	Expression of the PHO8 and PHO5 genes that encode a nonspecific alkaline and acid phosphatase, respectively, is regulated in response to the Pi concentration in the medium by the same transcription factors. Upon induction by phosphate starvation, both promoters undergo characteristic chromatin remodeling, yet the extent of remodeling at the PHO8 promoter is significantly lower than at PHO5. Despite the coordinate regulation of the two promoters, the PHO8 promoter is almost 10 times weaker than PHO5. Here we show that of two Pho4 binding sites that had been previously mapped at the PHO8 promoter in vitro, only the high affinity one, UASp2, is functional in vivo. Activation of the PHO8 promoter is partially Pho2-dependent. However, unlike at PHO5, Pho4 can bind strongly to its binding site in the absence of Pho2 and remodel chromatin in a Pho2-independent manner. Replacement of the inactive UASp1 element by the UASp1 element hom the PHO5 promoter results in more extensive chromatin remodeling and a concomitant a-fold increase in promoter activity. In contrast, replacement of the high affinity UASp2 site with the corresponding site from PHO5 precludes chromatin remodeling completely and as a consequence promoter activation, despite efficient binding of Pho4 to this site. Deletion of the promoter region normally covered by nucleosomes -3 and -2 results in a a-fold increase in promoter activity, further supporting a repressive role of these nucleosomes. These data show that there can be strong binding of Pho4 to a UAS element without any chromatin remodeling and promoter activation. The close correlation between promoter activity and the extent of chromatin disruption strongly suggests that the low level of PHO8 induction in comparison with PHO5 is partly due to the inability of Pho4 to achieve complete chromatin remodeling at this promoter.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Horz, M (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.		Münsterkötter, Martin/L-3436-2019; Münsterkötter, Martin/C-5288-2017	Münsterkötter, Martin/0000-0002-0044-2381; Münsterkötter, Martin/0000-0002-0044-2381				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; BARBARIC S, 1984, J BIOL CHEM, V259, P878; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Gregory PD, 1998, METHODS, V15, P295, DOI 10.1006/meth.1998.0633; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAYASHI N, 1991, MOL CELL BIOL, V11, P785, DOI 10.1128/MCB.11.2.785; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KANEKO Y, 1987, GENE, V58, P137; KANEKO Y, 1989, MOL GEN GENET, V220, P133, DOI 10.1007/BF00260867; KANEKO Y, 1985, MOL CELL BIOL, V5, P248, DOI 10.1128/MCB.5.1.248; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; OGAWA N, 1994, PHOSPHATE IN MICROORGANISMS, P56; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; ONISHI HR, 1979, J BIOL CHEM, V254, P1943; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SENGUPTA G, 1981, J CATAL, V67, P223, DOI 10.1016/0021-9517(81)90274-8; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939	38	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22678	22685		10.1074/jbc.M001409200	http://dx.doi.org/10.1074/jbc.M001409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801809	hybrid			2022-12-27	WOS:000088419400014
J	Carlier, MF; Nioche, P; Broutin-L'Hermite, I; Boujemaa, R; Le Clainche, C; Egile, C; Garbay, C; Ducruix, A; Sansonetti, P; Pantaloni, D				Carlier, MF; Nioche, P; Broutin-L'Hermite, I; Boujemaa, R; Le Clainche, C; Egile, C; Garbay, C; Ducruix, A; Sansonetti, P; Pantaloni, D			GRB2 links signaling to actin assembly by enhancing interaction of neural Wiskott-Aldrich syndrome protein (N-WASp) with actin-related protein (ARP2/3) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH3 DOMAIN; SHIGELLA-FLEXNERI; TYROSINE KINASES; FAMILY PROTEIN; DEPOLYMERIZING PROTEIN; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; MOTILITY; RECEPTOR; BINDING	Proteins of the Wiskott-Aldrich Syndrome protein (WASp) family connect signaling pathways to the actin polymerization-driven cell motility, The ubiquitous homolog of WASp, N-WASp, is a multidomain protein that interacts with the Arp2/3 complex and G-actin via its C-terminal WA domain to stimulate actin polymerization, The activity of N-WASp is enhanced by the binding of effecters like Cdc42-guanosine 5'-3-O-(thio)triphosphate, phosphatidylinositol bisphosphate, or the Shigella IcsA protein. Here we show that the SH3-SH2-SH3 adaptor Grb2 is another activator of N-WASp that stimulates actin polymerization by increasing the amount of N-WASp Arp2/3 complex, The concentration dependence of N-WASp activity, sedimentation velocity and cross-linking experiments together suggest that N-WASp is subject to self-association, and Grb2 enhances N-WASp activity by binding preferentially to its active monomeric form, Use of peptide inhibitors, mutated Grb2, and isolated SH3 domains demonstrate that the effect of Grb2 is mediated by the interaction of its C-terminal SH3 domain with the proline-rich region of N-WASp. Cdc42 and Grb2 bind simultaneously to N-WASp and enhance actin polymerization synergistically, Grb2 shortens the delay preceding the onset of Escherichia coli (IcsA) actin-based reconstituted movement. These results suggest that Grb2 may activate Arp2/3 complex-mediated actin polymerization downstream from the receptor tyrosine kinase signaling pathway.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Inst Pasteur, F-75724 Paris, France; Fac Pharm, INSERm U266, UMR CNRS 8600, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr	Broutin, Isabelle/A-2003-2017; Le Clainche, Christophe/A-4782-2015	Le Clainche, Christophe/0000-0001-5659-677X; Boujemaa-Paterski, Rajaa/0000-0001-9645-387X; Broutin, isabelle/0000-0001-9862-1232				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlier MF, 1999, CHEM BIOL, V6, pR235, DOI 10.1016/S1074-5521(99)80107-0; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; GUILLOTEAU JP, 1999, PROTEIN-STRUCT FUNCT, V25, P112; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Liu WQ, 1999, J MED CHEM, V42, P3737, DOI 10.1021/jm9911074; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Ramesh N, 1999, TRENDS CELL BIOL, V9, P15, DOI 10.1016/S0962-8924(98)01411-1; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Vaduva G, 1999, J BIOL CHEM, V274, P17103, DOI 10.1074/jbc.274.24.17103; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	57	176	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21946	21952		10.1074/jbc.M000687200	http://dx.doi.org/10.1074/jbc.M000687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10781580	hybrid			2022-12-27	WOS:000088363800028
J	Henningfeld, KA; Rastegar, S; Adler, G; Knochel, W				Henningfeld, KA; Rastegar, S; Adler, G; Knochel, W			Smad1 and Smad4 are components of the bone morphogenetic protein-4 (BMP-4)-induced transcription complex of the Xvent-2B promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATOR INHIBITOR-1 PROMOTER; XENOPUS HOMEOBOX GENE; DNA-BINDING PROTEIN; TGF-BETA; SIGNALING PATHWAY; VENTRAL MESODERM; MAD PROTEINS; ACTIVIN; COACTIVATOR	To study the mechanism of transcriptional activation of the Xenopus homeobox gene Xvent-2B, we have delineated the bone morphogenetic protein-4 (BMP-4)-responsive region between -275/-152 in the proximal pro meter. Consistent with the BMP-4 inductive nature of this region, this element exhibits transcriptional activation upon ectopic expression of Smad1 and Smad4. Electrophoretic mobility shift assays with total cellular extracts demonstrated that a DNA fragment encompassing this region was competent in the formation of a BMP-4-induced protein-DNA complex containing Smad1. Two different Smad binding regions were localized, a distal binding region for Smad1 containing two GCAT motifs and proximal AGNC binding sites for Smad4, the latter being conserved in other transforming growth factor-beta-responsive elements. Mutation of the Smad4 binding motif completely abolished transcriptional activation, whereas mutation or deletion of the Smad1 recognition sequence inhibited Smad1/Smad4 responsiveness. These results provide a functional characterization and identification of a vertebrate Smad1/Smad4 DNA response element induced by BMP-4 signaling and offers insight into the transcriptional regulation of a component essential for dorsoventral patterning in Xenopus embryos.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany; Univ Ulm, Innere Med Abt 1, D-89081 Ulm, Germany	Ulm University; Ulm University	Knochel, W (corresponding author), Univ Ulm, Biochem Abt, Albert Einstein Allee 11, D-89081 Ulm, Germany.	walter.knoechel@medizin.uni-ulm.de	Rastegar, Sepand/E-2324-2015	Rastegar, Sepand/0000-0003-4411-5646				Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Friedle H, 1998, EMBO J, V17, P2298, DOI 10.1093/emboj/17.8.2298; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladher R, 1996, DEVELOPMENT, V122, P2385; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nguyen HT, 1998, DEV BIOL, V204, P550, DOI 10.1006/dbio.1998.9081; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Papalopulu N, 1996, DEV BIOL, V174, P104, DOI 10.1006/dbio.1996.0055; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; THATCHER JD, 1999, NATURE, V126, P97; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vogel AM, 1999, MECH DEVELOP, V85, P133, DOI 10.1016/S0925-4773(99)00104-5; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	55	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21827	21835		10.1074/jbc.M000978200	http://dx.doi.org/10.1074/jbc.M000978200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10791953	hybrid			2022-12-27	WOS:000088363800012
J	Baglia, FA; Walsh, PN				Baglia, FA; Walsh, PN			RETRACTED: Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa (Retracted article. see vol 282, pg 29067, 2007)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							MOLECULAR-WEIGHT KININOGEN; BLOOD-COAGULATION FACTOR; PLASMA THROMBOPLASTIN ANTECEDENT; BINDING-SITE; HAGEMAN-FACTOR; HEAVY-CHAIN; DOMAIN; PTA; IDENTIFICATION; ABSENCE	To study the pathways for initiation of intrinsic blood coagulation, activated human platelets were compared with dextran sulfate as surfaces for factor XI activation by factor XIIa, factor XIa, or thrombin. Activated gel-filtered platelets promoted the activation of factor XI (60 nM) by thrombin (0.02-10 nM, EC50 similar to 100 pM, threshold concentration similar to 10 pM) at initial rates 2- to 5-fold greater than those obtained with dextran sulfate in the presence of either high molecular weight kininogen (45 nM) and ZnCl2 (25 mu M) or prothrombin (1.2 mu M) and CaCl2 (2 mM). The maximum rates of factor XI activation achieved in the presence of activated gel-filtered platelets were 30 nM.min(-1) with thrombin, 6 nM.min(-1) with factor XIIa and 2 nM.min(-1) with factor XIa. Values of turnover number calculated at various enzyme concentrations (0.05-1 nM) were 24-167 (mean = 86) min(-1) for thrombin, 4.6-50 (mean = 21) min(-1) for factor XIIa, and 1.3-14 (mean = 8) min(-1) for factor XIa. A physiological concentration of fibrinogen (9.0 mu M) inhibited factor XI activation by thrombin (but not by factor XIIa) in the presence of dextran sulfate but not in the presence of gel-filtered platelets. Compared with factors XIIa and XIa, thrombin is the preferred factor XI activator, and activated platelets are a relevant physiological surface for thrombin-mediated initiation of intrinsic coagulation in vivo.	Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@astro.ocis.temple.edu			NHLBI NIH HHS [HL46213, HL56914, HL56153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, P01HL056914, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAGLIA FA, 1989, BLOOD, V74, P244; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BRUNNEE T, 1993, BLOOD, V81, P580; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; LUNDBLAD RL, 1984, J BIOL CHEM, V259, P6991; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; MOVAT HZ, 1974, J LAB CLIN MED, V84, P861; NAITO K, 1991, J BIOL CHEM, V266, P7353; Oliver JA, 1999, ARTERIOSCL THROM VAS, V19, P170, DOI 10.1161/01.ATV.19.1.170; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAGNI MV, 1985, BLOOD, V65, P719; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; RATNOFF OD, 1961, J CLIN INVEST, V40, P803, DOI 10.1172/JCI104314; SAITO H, 1977, BLOOD, V50, P377; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCOTT CF, 1984, BLOOD, V63, P42; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SINHA D, 1985, J BIOL CHEM, V260, P714; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; WALSH PN, 1981, BLOOD, V57, P106	36	78	83	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20514	20519		10.1074/jbc.M000464200	http://dx.doi.org/10.1074/jbc.M000464200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781579	hybrid			2022-12-27	WOS:000088084500042
J	Kubota, H; Sakaki, Y; Ito, T				Kubota, H; Sakaki, Y; Ito, T			GI domain-mediated association of the eukaryotic initiation factor 2 alpha kinase GCN2 with its activator GCN1 is required for general amino acid control in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; PHAGOCYTE NADPH OXIDASE; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; EIF-2-ALPHA KINASE; DROSOPHILA-MELANOGASTER; TRANSLATION INITIATION; EIF2-ALPHA KINASE; HOMOLOG; EXPRESSION	In response to the starvation of a single amino acid, the budding yeast Saccharomyces cerevisiae activates numerous genes involved in various amino acid biosynthetic pathways, all of which are under the control of transcription factor GCN4. This general amino acid control response is based on de-repressed translation of GCN4 mRNA, which is induced by the activation of the eIF2 alpha kinase, GCN2. Although it is known that in vivo activation of GCN2 requires GCN1, the mode of GCN1 action remains to be elucidated at the molecular level. Here, we show that GCN2 interacts with GCN1 via the GI domain, a novel protein-binding module that occurs at the N terminus; mutations to conserved residues of this domain abolish its binding to GCN1. Furthermore, the yeast cells with GCN2 defective in interaction with GCN1 fail to display general control response. A similar phenotype is observed in cells overexpressing the GI domain of GCN2 or its target region on GCN1, Thus, GI domain-mediated association of GCN2 to GCN1 is required for general amino acid control. This finding provides the first insight into the molecular mechanism for the activation of GCN2 by GCN1.	Kanazawa Univ, Inst Canc Res, Div Genome Biol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	Kanazawa University; University of Tokyo	Ito, T (corresponding author), Kanazawa Univ, Inst Canc Res, Div Genome Biol, 13-1 Takeramachi, Kanazawa, Ishikawa 9200934, Japan.			Ito, Takashi/0000-0001-6097-2803				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; DEALDANA CRV, 1995, EMBO J, V14, P3148; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Doerks T, 1998, TRENDS GENET, V14, P248, DOI 10.1016/S0168-9525(98)01486-3; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hagiwara Y, 1997, P NATL ACAD SCI USA, V94, P9249, DOI 10.1073/pnas.94.17.9249; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1997, J BIOL CHEM, V272, P2161; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; James P, 1996, GENETICS, V144, P1425; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Olsen DS, 1998, GENETICS, V149, P1495; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Sattlegger E, 1998, J BIOL CHEM, V273, P20404, DOI 10.1074/jbc.273.32.20404; Sood R, 2000, GENETICS, V154, P787; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yamada Y, 1999, BIOCHEM BIOPH RES CO, V256, P162, DOI 10.1006/bbrc.1999.0297; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	29	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20243	20246		10.1074/jbc.C000262200	http://dx.doi.org/10.1074/jbc.C000262200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801780	hybrid			2022-12-27	WOS:000088084500004
J	Neufeld, B; Grosse-Wilde, A; Hoffmeyer, A; Jordan, BWM; Chen, PF; Dinev, D; Ludwig, S; Rapp, UR				Neufeld, B; Grosse-Wilde, A; Hoffmeyer, A; Jordan, BWM; Chen, PF; Dinev, D; Ludwig, S; Rapp, UR			Serine/threonine kinases 3pK and MAPK-activated protein kinase 2 interact with the basic helix-loop-helix transcription factor E47 and repress its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; HEAT-SHOCK; IN-VIVO; PHOSPHORYLATION; MYOD; HETERODIMERS; HOMODIMERS; DOMAIN	In the search for physiological substrates of MAPK-activated protein (MAPKAP) kinases, we identified the basic helix-loop-helix (bHLH) transcription factor E47 as an interaction partner of chromosome 3p kinase (3pK) and MAPKAP-K2 (MK2), The E2A protein E47 is known to be involved in the regulation of tissue-specific gene expression and cell differentiation. E47 is a phosphoprotein, and we identified 3pK and MK2 as E47 kinases in vitro. Furthermore, the expression of either kinase results in a repression of the transcriptional activity of E47 on an E-box containing promoter. In summary, the MAPK-activated protein kinases 3pK and MK2 were identified to form an assembly with the bHLH protein E47 suggesting that these kinases are regulators of E47 activity and E47-dependent gene expression.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Ludwig, S (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Ludwig, Stephan/0000-0003-4490-3052				ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Massari ME, 1996, MOL CELL BIOL, V16, P121; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MITSUI K, 1993, J BIOL CHEM, V268, P24415; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; WINTER B, 1993, J BIOL CHEM, V268, P9869; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	28	55	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20239	20242		10.1074/jbc.C901040199	http://dx.doi.org/10.1074/jbc.C901040199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781029	hybrid			2022-12-27	WOS:000088084500003
J	Wang, YH; Meadows, TA; Longo, N				Wang, YH; Meadows, TA; Longo, N			Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION/CARNITINE TRANSPORTER; GLUCOSE-GALACTOSE MALABSORPTION; NA+/PROLINE TRANSPORTER; ESCHERICHIA-COLI; OCTN2; COTRANSPORTER; MUTATIONS; RESIDUES; IDENTIFICATION; CATION	Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation characterized by hypoketotic hypoglycemia and skeletal and cardiac myopathy. It is caused by mutations in the sodium-dependent carnitine cotransporter OCTN2, The majority of natural mutations identified in this and other Na+/solute symporters introduce premature termination codons or impair insertion of the mutant transporter on the plasma membrane. Here we report that a missense mutation (E452K) identified in one patient with primary carnitine deficiency did not affect membrane targeting, as assessed with confocal microscopy of transporters tagged with the green fluorescent protein, but reduced carnitine transport by impairing sodium stimulation of carnitine transport. The natural mutation increased the concentration of sodium required to half-maximally stimulate carnitine transport (K-Na) from the physiological Value of 11.6 to 187 mM. Substitution of Glu(452) with glutamine (E452Q), aspartate (E452D), or alanine (E452A) caused intermediate increases in the K-Na. Carnitine transport decreased exponentially with increased K-Na. The E452K mutation is the first natural mutation in a mammalian cotransporter affecting sodium-coupled solute transfer and identifies a novel domain of the OCTN2 cotransporter involved in transmembrane sodium/solute transfer.	Emory Univ, Dept Pediat, Div Med Genet, Atlanta, GA 30322 USA	Emory University	Longo, N (corresponding author), Emory Univ, Dept Pediat, Div Med Genet, 2040 Ridgewood Dr, Atlanta, GA 30322 USA.	nl@rw.ped.emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burwinkel B, 1999, BIOCHEM BIOPH RES CO, V261, P484, DOI 10.1006/bbrc.1999.1060; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; Jung H, 1998, BBA-BIOENERGETICS, V1365, P60, DOI 10.1016/S0005-2728(98)00044-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Roe C. R., 1995, METABOLIC MOL BASES, P1501; Scaglia F, 1999, ARCH BIOCHEM BIOPHYS, V364, P99, DOI 10.1006/abbi.1999.1118; Scaglia F, 1999, SEMIN PERINATOL, V23, P152, DOI 10.1016/S0146-0005(99)80047-0; Schurmann A, 1997, BIOCHEMISTRY-US, V36, P12897, DOI 10.1021/bi971173c; Segel, 1975, ENZYME KINETICS BEHA, P274; Seth P, 1999, J BIOL CHEM, V274, P33388, DOI 10.1074/jbc.274.47.33388; Shoji Y, 1998, AM J HUM GENET, V63, P101, DOI 10.1086/301911; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Tang NLS, 1999, HUM MOL GENET, V8, P655, DOI 10.1093/hmg/8.4.655; Vaz FM, 1999, HUM GENET, V105, P157, DOI 10.1007/s004390051079; Wang YH, 2000, HUM MUTAT, V15, P238, DOI 10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; WRIGHT EM, 1984, J BIOL CHEM, V259, P4993; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, pG879, DOI 10.1152/ajpgi.1998.275.5.G879; Wright EM, 1998, ACTA PHYSIOL SCAND, V163, P257; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669	26	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20782	20786		10.1074/jbc.M000194200	http://dx.doi.org/10.1074/jbc.M000194200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10783384	hybrid			2022-12-27	WOS:000088084500079
J	Smith, JJ; Brown, TW; Eitzen, GA; Rachubinski, RA				Smith, JJ; Brown, TW; Eitzen, GA; Rachubinski, RA			Regulation of peroxisome size and number by fatty acid beta-oxidation in the yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OLEIC-ACID; HANSENULA-POLYMORPHA; ENLARGED PEROXISOMES; GIANT PEROXISOMES; CANDIDA-BOIDINII; PROTEIN; PROLIFERATION; OXIDASE; GENE	The Yarrowia lipolytica MFE2 gene encodes peroxisomal beta-oxidation multifunctional enzyme type 2 (MFE2). MFE2 is peroxisomal in a wild-type strain but is cytosolic in a strain lacking the peroxisomal targeting signal-1 (PTS1) receptor. MFE2 has a PTS1, Ala-Lys-Leu, that is essential for targeting to peroxisomes. MFE2 lacking a PTS1 can apparently oligomerize with full-length MFE2 to enable targetting to peroxisomes. Peroxisomes of an oleic acid-induced MFE2 deletion strain, mfe2-KO, are larger and more abundant than those of the wild-type strain. Under growth conditions not requiring peroxisomes, peroxisomes of mfe2-KO are larger but less abundant than those of the wild-type strain, suggesting a role for MFE2 in the regulation of peroxisome size and number. A nonfunctional version of MFE2 did not restore normal peroxisome morphology to mfe2-KO cells, indicating that their phenotype is not due to the absence of MFE2, mfe2-KO cells contain higher amounts of beta-oxidation enzymes than do wild-type cells. We also show that increasing the level of the beta-oxidation enzyme thiolase results in enlarged peroxisomes. Our results implicate peroxisomal beta-oxidation in the control of peroxisome size and number in yeast.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, 5-14 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca	Eitzen, Gary/D-3682-2009					Ausubel FM, 1988, MOL REPROD DEV; Barth G, 1997, FEMS MICROBIOL REV, V19, P219, DOI 10.1016/S0168-6445(97)00002-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chang CC, 1999, J CELL SCI, V112, P1579; DISTEL B, 1988, J CELL BIOL, V107, P1669, DOI 10.1083/jcb.107.5.1669; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Endrizzi A, 1996, CRIT REV BIOTECHNOL, V16, P301, DOI 10.3109/07388559609147424; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GODECKE A, 1989, CURR GENET, V16, P13, DOI 10.1007/BF00411078; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; Hayat MA, 1973, PRINCIPLES TECHNIQUE, V3, P237; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marshall PA, 1996, J CELL BIOL, V135, P123, DOI 10.1083/jcb.135.1.123; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; ROGGENKAMP R, 1989, MOL CELL BIOL, V9, P988, DOI 10.1128/MCB.9.3.988; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; SLOOTS JA, 1991, GENE, V105, P129, DOI 10.1016/0378-1119(91)90524-F; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VEENHUIS M, 1990, J CELL SCI, V96, P583; Wang HJJ, 1999, J BACTERIOL, V181, P5140, DOI 10.1128/JB.181.17.5140-5148.1999; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133	41	58	58	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20168	20178		10.1074/jbc.M909285199	http://dx.doi.org/10.1074/jbc.M909285199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10787422	hybrid			2022-12-27	WOS:000087941300098
J	Prabhakar, P; Cheng, V; Michel, T				Prabhakar, P; Cheng, V; Michel, T			A chimeric transmembrane domain directs endothelial nitric-oxide synthase palmitoylation and targeting to plasmalemmal caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL ACYLATION; PROTEIN; CA2+-CALMODULIN; LOCALIZATION; CALMODULIN; P75(NTR)	The endothelial nitric oxide synthase (eNOS), a key signaling protein, undergoes a series of covalent modifications, including co-translational N-myristoylation at Gly(2), as well as post-translational thiopalmitoylation at Cys(15) and Cys(26). Myristoylation of eNOS is required for the subsequent palmitoylation of the enzyme, and both acylations are required for the efficient subcellular targeting of eNOS to plasmalemmal caveolae, We constructed chimeric cDNAs encoding proteins comprised of various acylation-deficient eNOS mutants fused at their N termini to the hydrophobic transmembrane domain of the glycoprotein CD8 and characterized these constructs in transient transfection experiments in COS-7 cells. One construct (termed CD8-myr(-)eNOS) encodes a fusion protein comprised of the eNOS myristoylation deficient mutant coupled to the CD8 transmembrane domain. In biosynthetic labeling experiments using [H-3]palmitic acid, we found that the CD8-myr(-)eNOS chimera undergoes palmitoylation, Subcellular fractionation showed that the CD8-myr(-)eNOS chimera is targeted to caveolae, We also constructed and characterized a cDNA encoding the CD8 transmembrane domain fused to the palmitoylation-deficient mutant eNOS (in which Cys(15) and Cys(26) are changed to serine), This chimera (termed CD8-myr(-).palm(-)eNOS) did not undergo palmitoylation, indicating that the palmitoylation seen with the CD8.myr(-)eNOS fusion protein occurs on the same residues as in the wild-type enzyme. Importantly, the CD8-myr(-).palm(-)eNOS fusion protein remained efficiently targeted to caveolae, in contrast to the palm(-)eNOS mutant lacking the CD8 transmembrane domain, which has nominal caveolar localization. A construct encoding the CD8 transmembrane domain alone was insufficient for selective targeting to caveolae, These results indicate that membrane targeting per se, but not necessarily myristoylation, is sufficient for eNOS palmitoylation and localization to plasmalemmal caveolae, and suggest further that sequences within eNOS itself, in addition to its palmitoylation sites, facilitate the selective localization of the enzyme within caveolae.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.	michel@calvin.bwh.harvard.edu						Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Yeh DC, 1999, J BIOL CHEM, V274, P33148, DOI 10.1074/jbc.274.46.33148	25	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19416	19421		10.1074/jbc.M001952200	http://dx.doi.org/10.1074/jbc.M001952200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10787410	hybrid			2022-12-27	WOS:000087815900104
J	Goetzl, EJ; Lee, H; Azuma, T; Stossel, TP; Turck, CW; Karliner, JS				Goetzl, EJ; Lee, H; Azuma, T; Stossel, TP; Turck, CW; Karliner, JS			Gelsolin finding and cellular presentation of lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PLASMA GELSOLIN; SPHINGOSINE 1-PHOSPHATE; SERUM-ALBUMIN; BINDING; IDENTIFICATION; ASSOCIATION; APOPTOSIS; SEQUENCE; SUBTYPE	Lysophosphatidic acid (LPA) in biological fluids binds to serum albumin and other proteins that enhance its effects on cellular functions. The actin-severing protein gelsolin binds LPA with an affinity (K-d = 6 nM) similar to that of the G protein-coupled LPA receptors encoded by endothelial differentiation genes 2, 4, and 7 (Edg-2, -4, and -7 receptors) and greater than that of serum albumin (K-d = 360 nM). At concentrations of 10% or less of that in plasma, which are observed in fluids of injured tissues, purified and recombinant gelsolin augment LPA stimulation of nuclear signals and protein synthesis in rat cardiac myocytes (RCMs) that express Edg-2 and -4 receptors. At concentrations of 20% or more of that in plasma, gelsolin suppresses LPA stimulation of RCMs. The lack of effect of gelsolin on RCM responses to monoclonal anti-Edg-4 receptor antibody plus a phorbol eater without LPA attests to its specificity for LPA delivery and the absence of post-receptor effects. Inhibition of gelsolin binding and cellular delivery of LPA by L-alpha-phosphatidylinositol-4,5-bisphosphate (PIP2) and peptides constituting the two PIP2 binding domains of gelsolin suggests competition between LPA and PIP2 for the same sites. Thus, delivery of LPA to RCMs is affinity-coupled to Edg receptors by gelsolin in a PIP2-regulated process.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Vet Affairs Med Ctr, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, UB8B,Box 0711,533 Parnassus, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu		Lee, Hsinyu/0000-0002-1477-0183	NHLBI NIH HHS [HL54253, HL31809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809, R01HL054253] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen PG, 1997, FEBS LETT, V401, P89, DOI 10.1016/S0014-5793(96)01439-1; AN S, 1999, MOL PHARM, V55, P1; An SZ, 1998, J CELL BIOCHEM, P147; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BARLOW WM, 1980, BIOCHIM BIOPHYS ACTA, V620, P18, DOI 10.1016/0005-2760(80)90180-0; Dahl B, 1999, SHOCK, V12, P102, DOI 10.1097/00024382-199908000-00002; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Goetzl EJ, 1999, FASEB J, V13, pA1423; GOETZL EJ, 1999, CANCER RES, V59, P3051; GOETZL EJ, 1999, P ASS AM PHYS, V111, P1; GOETZL EJ, 1999, CANCER RES, V59, P2954; GOETZL EJ, 2000, IN PRESS ANN NY ACAD; Grinnell Frederick, 1993, Wound Repair and Regeneration, V1, P236, DOI 10.1046/j.1524-475X.1993.10409.x; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Huang S, 1997, CLIN INFECT DIS, V24, P951, DOI 10.1093/clinids/24.5.951; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LI HT, 1995, CIRCULATION, V92, P918, DOI 10.1161/01.CIR.92.4.918; Meerschaert K, 1998, EMBO J, V17, P5923, DOI 10.1093/emboj/17.20.5923; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Mounzer KC, 1999, AM J RESP CRIT CARE, V160, P1673, DOI 10.1164/ajrccm.160.5.9807137; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SPECTOR AA, 1975, J LIPID RES, V16, P165; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Suhler E, 1997, CRIT CARE MED, V25, P594, DOI 10.1097/00003246-199704000-00007; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; THUMSER AEA, 1994, BIOCHEM J, V301, P801, DOI 10.1042/bj3010801; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; Umansky SR, 1997, CELL DEATH DIFFER, V4, P608, DOI 10.1038/sj.cdd.4400282; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; YU FX, 1992, J BIOL CHEM, V267, P14616	41	108	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14573	14578		10.1074/jbc.275.19.14573	http://dx.doi.org/10.1074/jbc.275.19.14573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799543	hybrid			2022-12-27	WOS:000087006900077
J	Gonzalez-Huici, V; Lazaro, JM; Salas, M; Hermoso, JM				Gonzalez-Huici, V; Lazaro, JM; Salas, M; Hermoso, JM			Specific recognition of parental terminal protein by DNA polymerase for initiation of protein-primed DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SLIDING-BACK MECHANISM; NUCLEAR FACTOR-I; NUCLEOTIDE-SEQUENCE; FUNCTIONAL-RELATIONSHIPS; PHI-29-RELATED PHAGES; PREINITIATION COMPLEX; PHI-29; BINDING; EXPRESSION	The linear genome of Bacillus subtilis phage phi 29 has a protein covalently linked to the 5' ends, called parental terminal protein (TP), and is replicated using a free TP as primer. The initiation of phage phi 29 DNA replication requires the formation of a DNA polymerase/TP complex that recognizes the replication origins located at the genome ends. The DNA polymerase catalyzes the formation of the initiation complex TP-dAMP, and elongation proceeds coupled to strand displacement. The same mechanism is used by the related phage Nf. However, DNA polymerase and TP from phi 29 do not initiate the replication of Nf TP-DNA. To address the question of the specificity of origin recognition, we took advantage of the initiation reaction enhancement in the presence of Mn2+, allowing us to detect initiation activity in heterologous systems in which DNA polymerase, TP, and template TP-DNA are not from the same phage. Initiation was selectively stimulated when DNA polymerase and TP-DNA were from the same phage, strongly suggesting that specific recognition of origins is brought through an interaction between DNA polymerase and parental TP.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Canto Blanco, E-28049 Madrid, Spain.		Gonzalez-Huici, Victor/ABB-4680-2020; Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441; Gonzalez Huici, Victor/0000-0002-6977-1060	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BLANCO L, 1987, J VIROL, V61, P3983, DOI 10.1128/JVI.61.12.3983-3991.1987; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BRAVO A, 1994, GENE, V148, P107, DOI 10.1016/0378-1119(94)90242-9; CALDENTEY J, 1993, NUCLEIC ACIDS RES, V21, P3725, DOI 10.1093/nar/21.16.3725; de Vega M, 1998, J BIOL CHEM, V273, P28966, DOI 10.1074/jbc.273.44.28966; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; ESCARMIS C, 1982, NUCLEIC ACIDS RES, V10, P5785, DOI 10.1093/nar/10.19.5785; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; FREIRE R, 1994, EMBO J, V13, P4353, DOI 10.1002/j.1460-2075.1994.tb06755.x; Freire R, 1996, J BIOL CHEM, V271, P31000, DOI 10.1074/jbc.271.48.31000; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; HAY RT, 1996, DNA REPLICATION EUKA, P699; Illana B, 1999, J BIOL CHEM, V274, P15073, DOI 10.1074/jbc.274.21.15073; Illana B, 1996, J MOL BIOL, V264, P453, DOI 10.1006/jmbi.1996.0653; Illana B, 1998, VIROLOGY, V248, P12, DOI 10.1006/viro.1998.9276; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; KISHI T, 1993, JPN J GENET, V68, P243, DOI 10.1266/jjg.68.243; Kornberg A, 1992, DNA REPLICATION, P471; Lazaro JM, 1995, METHOD ENZYMOL, V262, P42; LEAVITT MC, 1987, NUCLEIC ACIDS RES, V15, P5251, DOI 10.1093/nar/15.13.5251; MATSUMOTO K, 1989, GENE, V84, P247; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MIZUKAMI Y, 1986, FEBS LETT, V197, P311, DOI 10.1016/0014-5793(86)80348-9; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; Pecenkova T, 1999, J MOL EVOL, V48, P197, DOI 10.1007/PL00006458; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; SALAS M, 1978, J MOL BIOL, V119, P269, DOI 10.1016/0022-2836(78)90438-2; Salas M, 1991, ANNU REV BIOCHEM, V60, P37; SALAS M, 1996, DNA REPLICATION EUKA, P131; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Truniger V, 1999, J MOL BIOL, V286, P57, DOI 10.1006/jmbi.1998.2477; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; vanLeeuwen HC, 1997, J BIOL CHEM, V272, P3398, DOI 10.1074/jbc.272.6.3398; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; YOSHIKAWA H, 1982, GENE, V17, P323; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353	48	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14678	14683		10.1074/jbc.M910058199	http://dx.doi.org/10.1074/jbc.M910058199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799555	hybrid			2022-12-27	WOS:000087006900089
J	Chang, TL; Kramer, MG; Ansari, RA; Khan, SA				Chang, TL; Kramer, MG; Ansari, RA; Khan, SA			Role of individual monomers of a dimeric initiator protein in the initiation and termination of plasmid rolling circle replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PT181 DNA INVITRO; STAPHYLOCOCCAL PLASMIDS; BACTERIAL PLASMIDS; ORIGIN RECOGNITION; REPC PROTEIN; SPECIFICITY; FAMILY; GENE; TOPOISOMERASE; ELEMENT	Plasmids of the pT181 family encode initiator proteins that act as dimers during plasmid rolling circle (RC) replication. These initiator proteins bind to the origin of replication through a sequence-specific interaction and generate a nick at the origin that acts as the primer for RC replication. Previous studies have demonstrated that the initiator proteins contain separate DNA binding and nicking-closing domains, both of which are required for plasmid replication. The tyrosine residue at position 191 of the initiator RepC protein of pT181 is known to be involved in nicking at the origin. We have generated heterodimers of RepC that consist of different combinations of wild type, DNA binding, and nicking mutant monomers to identify the role of each of the two monomers in RC replication. One monomer with DNA binding activity was sufficient for the targeting of the initiator to the origin, and the presence of Tyr-191 in one monomer was sufficient for the initiation of replication. On the other hand, a dimer consisting of one monomer defective in DNA binding and the other defective in origin nicking failed to initiate replication. Our results demonstrate that the monomer that promotes sequence-specific binding to the origin must also nick the DNA to initiate replication. Interestingly, whereas Tyr-191 of the initiator was required for nicking at the origin to initiate replication, it was dispensable for termination, suggesting that alternate amino acids in the initiator may promote termination but not initiation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Rm E 1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	Khan@pitt.edu			NIGMS NIH HHS [GM31685] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031685] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAAS PD, 1985, BIOCHIM BIOPHYS ACTA, V825, P111, DOI 10.1016/0167-4781(85)90096-X; BIRCH P, 1992, P NATL ACAD SCI USA, V89, P290, DOI 10.1073/pnas.89.1.290; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DEMPSEY LA, 1995, MOL MICROBIOL, V15, P679, DOI 10.1111/j.1365-2958.1995.tb02377.x; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; DEMPSEY LA, 1992, J BIOL CHEM, V267, P24538; GROS MF, 1987, EMBO J, V6, P3863, DOI 10.1002/j.1460-2075.1987.tb02724.x; GRUSS A, 1989, MICROBIOL REV, V53, P231, DOI 10.1128/MMBR.53.2.231-241.1989; GRUSS AD, 1987, P NATL ACAD SCI USA, V84, P2165, DOI 10.1073/pnas.84.8.2165; IORDANESCU S, 1989, MOL GEN GENET, V217, P481, DOI 10.1007/BF02464921; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; MOSCOSO M, 1995, J BACTERIOL, V177, P7041, DOI 10.1128/jb.177.24.7041-7049.1995; MURRAY RW, 1989, J BIOL CHEM, V264, P1051; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NoirotGros MF, 1996, SCIENCE, V274, P777, DOI 10.1126/science.274.5288.777; NOIROTGROS MF, 1994, EMBO J, V13, P4412, DOI 10.1002/j.1460-2075.1994.tb06761.x; NOVICK RP, 1989, ANNU REV MICROBIOL, V43, P537, DOI 10.1146/annurev.micro.43.1.537; PROJAN SJ, 1988, PLASMID, V19, P203, DOI 10.1016/0147-619X(88)90039-X; RASOOLY A, 1994, EMBO J, V13, P5245, DOI 10.1002/j.1460-2075.1994.tb06856.x; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; SOZHAMANNAN S, 1990, J BACTERIOL, V172, P4543, DOI 10.1128/jb.172.8.4543-4548.1990; THOMAS CD, 1988, BIOCHEM SOC T, V16, P758, DOI 10.1042/bst0160758; THOMAS CD, 1995, J MOL BIOL, V254, P381, DOI 10.1006/jmbi.1995.0625; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229; WANG PZ, 1992, J MOL BIOL, V223, P145, DOI 10.1016/0022-2836(92)90722-V; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x; Zhao AC, 1997, MOL MICROBIOL, V24, P535, DOI 10.1046/j.1365-2958.1997.3641730.x; Zhao AC, 1998, J BIOL CHEM, V273, P16082, DOI 10.1074/jbc.273.26.16082; ZOCK JM, 1990, J BIOL CHEM, V265, P3484	36	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13529	13534		10.1074/jbc.275.18.13529	http://dx.doi.org/10.1074/jbc.275.18.13529			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788467	hybrid			2022-12-27	WOS:000086925300054
J	Chen, JR; Capdevila, J; Harris, RC				Chen, JR; Capdevila, J; Harris, RC			Overexpression of C-terminal Src kinase blocks 14,15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXYEICOSATRIENOIC ACIDS; ARACHIDONIC-ACID; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CELL-DIVISION; PROTEIN; PP60C-SRC; CYTOCHROME-P450; EPOXYGENASE	We have previously reported that 14,15-epoxyeicosatrienoic acid (14,15-EET) is a potent mitogen for the renal epithelial cell line, LLCPKc14, This mitogenic effect is dependent upon activation of a protein-tyrosine kinase cascade that results in activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Because of suggestive evidence that 14,15-EET also activated Src in these cells, we stably transfected LLCPKc14 with an expression construct of the C-terminal Src kinase (CSK), which inhibits Src family kinase activity. In vitro Src kinase activity assays confirmed that in empty vector-transfected cells (Vector cells), 14,15-EET increased Src kinase activity, while in clones overexpressing CSK mRNA and immunoreactive protein (CSK cells), 14,15-EET-induced activation of Src was almost completely blocked (94% inhibition), Of interest, epidermal growth factor (EGF) and fetal bovine serum (FBS) also increased Src activity in Vector cells, but not in CSK cells, further confirming the ability of CSK overexpression to prevent Src activation. CSK cells failed to increase [H-3]thymidine incorporation in response to exogenous 14,15-EET. In contrast, both EGF and FBS significantly increased [H-3]thymidine incorporation in CSK cells, Immunoprecipitation with anti-phosphotyrosine antibodies and immunoblotting with an antibody against extracellular signal-regulated kinase (ERK) indicated that in CSK cells, 14,15-EET failed to activate ERK1 and ERK2; however, EGF- and FBS-induced activation of ERKs was not different from that seen in Vector cells, In Vector cells, the 14,15-EET-stimulated tyrosine phosphorylation of ERKs was blocked by pretreatment with 1 mu M PP2, a selective inhibitor of Src kinases. The present study demonstrates that 14,15-EET exerts its mitogenic effects predominantly through a Src kinase-mediated pathway, which is the most upstream signaling step determined to date in the 14,15-EET-activated tyrosine kinase cascade in renal epithelial cells.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, S 3322,MCN, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; BONVALET JP, 1987, AM J PHYSIOL, V253, pF377, DOI 10.1152/ajprenal.1987.253.3.F377; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; ENDOU H, 1983, JPN J PHARMACOL, V33, P423, DOI 10.1254/jjp.33.423; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; Graber MN, 1997, J BIOL CHEM, V272, P29546, DOI 10.1074/jbc.272.47.29546; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Hoebel BG, 1998, EUR J PHARMACOL, V346, P115, DOI 10.1016/S0014-2999(98)00118-6; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KARARA A, 1993, J BIOL CHEM, V268, P13565; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; Medhora M, 1998, INT J MOL MED, V2, P661; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Rahman M, 1997, AM J HYPERTENS, V10, P356, DOI 10.1016/S0895-7061(96)00381-0; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Weintraub NL, 1997, CIRC RES, V81, P258, DOI 10.1161/01.RES.81.2.258; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X	34	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13789	13792		10.1074/jbc.275.18.13789	http://dx.doi.org/10.1074/jbc.275.18.13789			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788500	hybrid			2022-12-27	WOS:000086925300087
J	Li, SH; Liu, XB; Ascoli, M				Li, SH; Liu, XB; Ascoli, M			p38(JAB1) binds to the intracellular precursor of the lutropin/choriogonadotropin receptor and promotes its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; METABOTROPIC GLUTAMATE RECEPTORS; EXCHANGER REGULATORY FACTOR; LEYDIG TUMOR-CELLS; CYTOPLASMIC TAIL; TRANSFECTED CELLS; BETA(2)-ADRENERGIC RECEPTOR; HORMONE RECEPTOR; INTERNALIZATION; GONADOTROPIN	Using the C-terminal tail of the rat lutropin/choriogonadotropin receptor (rLHR) as "bait" in a yeast two-hybrid screen resulted in the identification of p38(JAB1) (a protein initially identified as a co-activator of c-Jun) as a putative rLHR binding partner. More recently p38(JAB1) has been shown to promote the degradation of a cyclin-dependent kinase inhibitor and to be a component of the COP9 signalosome. Microscopic localization of an epitope-tagged p38(JAB1) expressed in 293 cells revealed a punctuated perinuclear and cytosolic localization, while cell fractionation studies showed that most of the p38(JAB1) was in a high speed supernatant, Co-transfection of 293 cells revealed that p38(JAB1) binds to the immature 68-kDa precursor of the rLHR that resides in the endoplasmic reticulum and promotes its degradation. It does not appear to interact with the cell surface rLHR, however, and it does not affect its expression, When transfected into HeLa cells, p38(JAB1) potentiates the transcriptional activity of c-Jun, but co-transfection with rLHR prevents this effect. We conclude that p38(JAB1) interacts with the rLHR precursor and promotes its degradation. These results reveal a novel protein binding partner of the rLHR and are consistent with current views of the functions of p38(JAB1).	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-319A BSB,51 Newton Rd, Iowa City, IA 52242 USA.	mario-ascoli@uiowa.edu			NCI NIH HHS [CA-40629] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Farrow KN, 1996, J BIOL CHEM, V271, P17139, DOI 10.1074/jbc.271.29.17139; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Harlow E., 1999, USING ANTIBODIES LAB; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; KAWATE N, 1994, J BIOL CHEM, V269, P30651; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Min KS, 1998, J BIOL CHEM, V273, P34911, DOI 10.1074/jbc.273.52.34911; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	46	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13386	13393		10.1074/jbc.275.18.13386	http://dx.doi.org/10.1074/jbc.275.18.13386			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788448	hybrid			2022-12-27	WOS:000086925300034
J	Lovato, MA; Hart, EA; Segura, MJR; Giner, JL; Matsuda, SPT				Lovato, MA; Hart, EA; Segura, MJR; Giner, JL; Matsuda, SPT			Functional cloning of an Arabidopsis thaliana cDNA encoding cycloeucalenol cycloisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; STEROL BIOSYNTHESIS; LANOSTEROL SYNTHASE; STRUCTURAL REQUIREMENTS; CYCLOARTENOL SYNTHASE; ENZYMATIC CLEAVAGE; MOLECULAR-CLONING; MEMBRANE-FUNCTION; YEAST; FENPROPIMORPH	Plants and certain protists use cycloeucalenol cycloisomerase (EC 5.5.1.9) to convert pentacyclic cyclopropyl sterols to conventional tetracyclic sterols. We used a novel complementation strategy to clone a cycloeucalenol cycloisomerase cDNA. Expressing an Arabidopsis thaliana cycloartenol synthase cDNA in a yeast lanosterol synthase mutant provided a sterol auxotroph that could be genetically complemented with the isomerase, We transformed this yeast strain with an Arabidopsis yeast expression library and selected sterol prototrophs to obtain a strain that accumulated biosynthetic ergosterol. The novel phenotype was conferred by an Arabidopsis cDNA that potentially encodes a 36-kDa protein. We expressed this cDNA (CP11) in Escherichia coli and showed by gas chromatography-mass spectrometry that extracts from this strain isomerized cycloeucalenol to obtusifoliol in vitro. The cDNA will be useful for obtaining heterologously expressed protein for catalytic studies and elucidating the in vivo roles of cyclopropyl sterols.	Rice Univ, Dept Chem, Houston, TX 77005 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; SUNY, Dept Chem, Syracuse, NY 13210 USA	Rice University; Rice University; State University of New York (SUNY) System; SUNY Maritime College	Matsuda, SPT (corresponding author), Rice Univ, Dept Chem, 6100 S Main St, Houston, TX 77005 USA.	matsuda@rice.edu			NIAID NIH HHS [AI41598] Funding Source: Medline; NIGMS NIH HHS [T32 GM08362] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008362] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDING C, 1974, EUR J BIOCHEM, V43, P459, DOI 10.1111/j.1432-1033.1974.tb03432.x; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENVENISTE P, 1966, PHYTOCHEMISTRY, V5, P45, DOI 10.1016/S0031-9422(00)85080-3; BENVENISTE P, 1969, EUR J BIOCHEM, V9, P526, DOI 10.1111/j.1432-1033.1969.tb00641.x; BLADOCHA M, 1983, PLANT PHYSIOL, V71, P756, DOI 10.1104/pp.71.4.756; BLOCH K, 1992, STEROIDS, V57, P378, DOI 10.1016/0039-128X(92)90081-J; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Bouvier-Nave P, 1998, EUR J BIOCHEM, V256, P88, DOI 10.1046/j.1432-1327.1998.2560088.x; BUTTKE TM, 1980, BIOCHEM BIOPH RES CO, V92, P229, DOI 10.1016/0006-291X(80)91543-0; CATTEL L, 1976, PHYTOCHEMISTRY, V15, P931, DOI 10.1016/S0031-9422(00)84373-3; Cerdon C, 1996, PHYTOCHEMISTRY, V41, P423, DOI 10.1016/0031-9422(95)00550-1; COREY EJ, 1966, J AM CHEM SOC, V88, P4750, DOI 10.1021/ja00972a056; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; EHRHARDT JD, 1967, PHYTOCHEMISTRY, V6, P815, DOI 10.1016/S0031-9422(00)86027-6; FRYBERG M, 1973, J AM CHEM SOC, V95, P5747, DOI 10.1021/ja00798a051; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Hart EA, 1999, J AM CHEM SOC, V121, P9887, DOI 10.1021/ja992589b; HARTMANNBOUILLON MA, 1978, PHYTOCHEMISTRY, V17, P1037, DOI 10.1016/S0031-9422(00)94275-4; HEINTZ R, 1974, J BIOL CHEM, V249, P4267; HEINTZ R, 1972, BIOCHEM BIOPH RES CO, V49, P820, DOI 10.1016/0006-291X(72)90484-6; HEWLINS MJE, 1969, EUR J BIOCHEM, V8, P184, DOI 10.1111/j.1432-1033.1969.tb00513.x; KHALIL IA, 1991, J AGR FOOD CHEM, V39, P404, DOI 10.1021/jf00002a036; KOTANI H, 1998, DNA RES, V5, P213; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; Lecain E, 1996, J BIOL CHEM, V271, P10866, DOI 10.1074/jbc.271.18.10866; Lees ND, 1999, CRIT REV BIOCHEM MOL, V34, P33; LIU HP, 1992, GENETICS, V132, P665; MINET M, 1992, PLANT J, V2, P417; NES WD, 1993, ARCH BIOCHEM BIOPHYS, V300, P724, DOI 10.1006/abbi.1993.1100; NES WR, 1977, BIOCH STEROIDS OTHER, P229; RAEDERSTORFF D, 1987, EUR J BIOCHEM, V164, P421, DOI 10.1111/j.1432-1033.1987.tb11074.x; RAEDERSTORFF D, 1987, EUR J BIOCHEM, V164, P427, DOI 10.1111/j.1432-1033.1987.tb11075.x; RAHIER A, 1977, PHYTOCHEMISTRY, V16, P1187, DOI 10.1016/S0031-9422(00)94357-7; RAHIER A, 1976, J CHEM SOC CHEM COMM, P287, DOI 10.1039/c39760000287; RAHIER A, 1989, EUR J BIOCHEM, V181, P615, DOI 10.1111/j.1432-1033.1989.tb14768.x; RAMGOPAL M, 1983, P NATL ACAD SCI-BIOL, V80, P712, DOI 10.1073/pnas.80.3.712; REES HH, 1968, TETRAHEDRON LETT, P723; RODRIGUEZ RJ, 1985, BIOCHIM BIOPHYS ACTA, V837, P336, DOI 10.1016/0005-2760(85)90057-8; SCHALLER H, 1991, PHYTOCHEMISTRY, V30, P2547, DOI 10.1016/0031-9422(91)85097-J; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT P, 1981, PHYTOCHEMISTRY, V20, P2153, DOI 10.1016/0031-9422(81)80105-7; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIMIZU N, 1984, J ORG CHEM, V49, P709, DOI 10.1021/jo00178a030; Venkatramesh M, 1995, ARCH BIOCHEM BIOPHYS, V324, P189, DOI 10.1006/abbi.1995.9912	51	25	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13394	13397		10.1074/jbc.275.18.13394	http://dx.doi.org/10.1074/jbc.275.18.13394			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788449	hybrid			2022-12-27	WOS:000086925300035
J	Cheema, SK; Agellon, LB				Cheema, SK; Agellon, LB			The murine and human cholesterol 7 alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; NUCLEAR RECEPTOR; BILE-ACIDS; RAT-LIVER; HYPOLIPIDEMIC DRUGS; HORMONAL-REGULATION; DOWN-REGULATION; MICE LACKING; LXR-ALPHA; EXPRESSION	We determined if fatty acids can regulate the murine Cyp7a1 and human CYP7A1 gene promoters via peroxisome proliferator-activated receptor alpha (PPAR alpha)/9-cis-retinoic acid receptor alpha (RXR alpha). In transfected cells, the murine Cyp7a1 gene promoter displayed markedly lower basal activity, but greater sensitivity to fatty acid-or WY 14,643-activated PPAR alpha/RXR alpha when compared with the human CYP7A1 gene promoter. PPAR alpha/RXR alpha can bind to a site (Site II) located within the region at nucleotides - 158 to -132 of both promoters. Mutagenesis of the human CYP7A1 Site II element abolished the response to activated PPAR alpha/RXR alpha. The murine Cyp7a1 gene promoter contains an additional PPAR/alpha RXR alpha-binding site (Site I) located within nucleotides -72 to -57. Replacement of a single residue in human CYP7A1 Site I with that found in the murine Cyp7a1 Site I sequence enabled PPAR alpha/RXR alpha binding, and this mutation resulted in reduced basal activity, but substantially improved the response to activated PPAR alpha/RXR alpha in transfected cells. We conclude that fatty acids can regulate the cyp7a gene promoter via PPAR alpha/RXR alpha. The differential response of the murine Cyp7a1 and human CYP7A1 gene promoters to PPAR alpha activators is attributable to the additional PPAR alpha/RXR alpha-binding site in the murine Cyp7a1 gene promoter.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 303, Edmonton, AB T6G 2S2, Canada; Univ Alberta, MRC, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Agellon, LB (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 303, Edmonton, AB T6G 2S2, Canada.							Agellon LB, 1997, BIOCHEM J, V328, P393; BECKER JE, 1976, ONCODEVELOPMENTAL GE, P259; BERTOLOTTI M, 1995, ARTERIOSCL THROM VAS, V15, P1064, DOI 10.1161/01.ATV.15.8.1064; Cheema SK, 1999, J NUTR, V129, P1718, DOI 10.1093/jn/129.9.1718; CHEEMA SK, 1997, J LIPID RES, V38, P157; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; CRESTANI M, 1995, J LIPID RES, V36, P2419; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOODWIN CD, 1982, J BIOL CHEM, V257, P4469; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JANTZEN JM, 1987, CELL, V10, P29; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KIRK EA, 1995, J LIPID RES, V36, P1522; Kliewer SA, 1999, RECENT PROG HORM RES, V54, P345; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEE YH, 1994, J BIOL CHEM, V269, P14681; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MIYATA KS, 1994, GENE, V148, P327, DOI 10.1016/0378-1119(94)90707-2; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; Nguyen LB, 1996, HEPATOLOGY, V24, P1468; NISHIMOTO M, 1991, J BIOL CHEM, V266, P6467; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RAEDSCH R, 1995, EUR J DRUG METAB PH, V20, P113; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUDEL L, 1994, J CLIN INVEST, V93, P2463, DOI 10.1172/JCI117255; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sambrook J., 2002, MOL CLONING LAB MANU; Schoonjans K, 1996, J LIPID RES, V37, P907; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; STAHLBERG D, 1995, HEPATOLOGY, V21, P1025, DOI 10.1016/0270-9139(95)90250-3; STAHLBERG D, 1989, J LIPID RES, V30, P953; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Stroup D, 1997, J BIOL CHEM, V272, P9833; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; Torchia EC, 1996, BIOCHEM BIOPH RES CO, V225, P128, DOI 10.1006/bbrc.1996.1141; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; VUDAC N, 1994, J BIOL CHEM, V269, P31012; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WANG DP, 1994, GENOMICS, V20, P320, DOI 10.1006/geno.1994.1177; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; XU GR, 1995, J CLIN INVEST, V95, P1497, DOI 10.1172/JCI117821; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0	60	69	71	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12530	12536		10.1074/jbc.275.17.12530	http://dx.doi.org/10.1074/jbc.275.17.12530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777541	hybrid			2022-12-27	WOS:000086762300025
J	Danilczyk, UG; Cohen-Doyle, MF; Williams, DB				Danilczyk, UG; Cohen-Doyle, MF; Williams, DB			Functional relationship between calreticulin, calnexin, and the endoplasmic reticulum luminal domain of calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MHC CLASS-I; MOLECULAR CHAPERONES CALNEXIN; N-LINKED GLYCANS; DROSOPHILA-MELANOGASTER CELLS; INTEGRAL MEMBRANE-PROTEINS; TCR-ALPHA PROTEINS; QUALITY-CONTROL; GLYCOPROTEIN GLUCOSYLTRANSFERASE; INFLUENZA HEMAGGLUTININ	Calnexin is a membrane protein of the endoplasmic reticulum (ER) that functions as a molecular chaperone and as a component of the ER quality control machinery. Calreticulin, a soluble analog of calnexin, is thought to possess similar functions, but these have not been directly demonstrated in vivo. Both proteins contain a lectin site that directs their association with newly synthesized glycoproteins. Although many glycoproteins bind to both calnexin and calreticulin, there are differences in the spectrum of glycoproteins that each binds. Using a Drosophila expression system and the mouse class I histocompatibility molecule as a model glycoprotein, we found that calreticulin does possess apparent chaperone and quality control functions, enhancing class I folding and subunit assembly, stabilizing subunits, and impeding export of assembly intermediates from the ER. Indeed, the functions of calnexin and calreticulin were largely interchangeable. We also determined that a soluble form of calnexin (residues 1-387) can functionally replace its membrane-bound counterpart. However, when calnexin was expressed as a soluble protein in L cells, the pattern of associated glycoproteins changed to resemble that of calreticulin. Conversely, membrane-anchored calreticulin bound to a similar set of glycoproteins as calnexin. Therefore, the different topological environments of calnexin and calreticulin are important in determining their distinct substrate specificities.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							Andersson H, 1996, FEBS LETT, V397, P321, DOI 10.1016/S0014-5793(96)01207-0; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Chevet E, 1999, EMBO J, V18, P3655, DOI 10.1093/emboj/18.13.3655; Christodoulou S, 1997, GENE, V191, P143, DOI 10.1016/S0378-1119(97)00025-5; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAPEL AJ, 1981, CELL, V25, P179, DOI 10.1016/0092-8674(81)90242-7; Harris MR, 1998, J IMMUNOL, V160, P5404; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Ho SC, 1999, MOL IMMUNOL, V36, P1, DOI 10.1016/S0161-5890(99)00018-8; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; SCOTT JE, 1995, J IMMUNOL, V155, P143; Smith M J, 1992, DNA Seq, V3, P247, DOI 10.3109/10425179209034025; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; Solheim JC, 1997, J IMMUNOL, V158, P2236; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Svaerke C, 1998, ACTA CHEM SCAND, V52, P942; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	65	81	84	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13089	13097		10.1074/jbc.275.17.13089	http://dx.doi.org/10.1074/jbc.275.17.13089			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777614	hybrid			2022-12-27	WOS:000086762300098
J	Gardner, AM; Martin, LA; Gardner, PR; Dou, Y; Olson, JS				Gardner, AM; Martin, LA; Gardner, PR; Dou, Y; Olson, JS			Steady-state and transient kinetics of Escherichia coli nitric-oxide dioxygenase (flavohemoglobin) - The B10 tyrosine hydroxyl is essential for dioxygen binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIC BACTERIAL HEMOGLOBIN; FLAVOHAEMOGLOBIN HMP; ALCALIGENES-EUTROPHUS; ASCARIS HEMOGLOBIN; OXIDATIVE STRESS; MYCOBACTERIUM-TUBERCULOSIS; SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; BOUND DIOXYGEN; LIGAND-BINDING	Escherichia coli expresses an inducible flavohemoglobin possessing robust NO dioxygenase activity. At 37 degrees C, the enzyme shows a maximal turnover number (V-max) of 670 s(-1) and K-m values for NADH, NO, and O-2 equal to 4.8, 0.28, and similar to 100 mu M, respectively. Individual reduction, ligand binding, and NO dioxygenation reactions were examined at 20 degrees C, where V-max is similar to 94 s(-1). Reduction by NADH occurs in two steps. NADH reduces bound FAD with a rate constant of similar to 15 mu M-1 s(-1), and heme iron is reduced by FADH(2) with a rate constant of 150 s(-1). Dioxygen binds tightly to reduced flavohemoglobin, with association and dissociation rate constants equal to 38 mu M-1 s(-1) and 0.44 s(-1), respectively, and the oxygenated flavohemoglobin dioxygenates NO to form nitrate. NO also binds reversibly to reduced flavohemoglobin in competition with O-2, dissociates slowly, and inhibits NO dioxygenase activity at [NO]/[O-2] ratios of 1:100. Replacement of the heme pocket B10 tyrosine with phenylalanine increases the O-2 dissociation rate constant similar to 80-fold, and reduces NO dioxygenase activity similar to 30-fold, demonstrating the importance of the tyrosine hydroxyl for O-2 affinity and NO scavenging activity. At 37 degrees C, V-max/K-m(NO) is 2,400 mu M-1 s(-1), demonstrating that the enzyme is extremely efficient at converting toxic NO into nitrate under physiological conditions.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Cincinnati Children's Hospital Medical Center; Rice University; Rice University	Gardner, PR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA.	gardp0@chmcc.org		Gardner, Paul/0000-0001-8189-0903; Gardner, Anne/0000-0001-7095-772X; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIGMS NIH HHS [GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; Appleby C A, 1978, Methods Enzymol, V52, P157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; Chen YP, 1996, J BIOL CHEM, V271, P4609; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Crawford MJ, 1998, J BIOL CHEM, V273, P34028, DOI 10.1074/jbc.273.51.34028; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Dickerson R.E., 1969, STRUCTURE ACTION PRO; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; ESCHENBRENNER M, 1994, BIOCHEM BIOPH RES CO, V198, P127, DOI 10.1006/bbrc.1994.1018; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Hardison R, 1999, AM SCI, V87, P126, DOI 10.1511/1999.20.809; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; Hu YM, 1999, J BACTERIOL, V181, P3486, DOI 10.1128/JB.181.11.3486-3493.1999; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; JAKOB W, 1992, ARCH BIOCHEM BIOPHYS, V292, P29, DOI 10.1016/0003-9861(92)90046-Y; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KEILIN D, 1953, NATURE, V172, P390, DOI 10.1038/172390a0; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; Lebioda L, 1999, NATURE, V401, P445, DOI 10.1038/46728; MACHEROUX P, 1998, BIOCHEM J, V1282, P7779; Membrillo-Hernandez J, 1997, FEMS MICROBIOL LETT, V155, P179, DOI 10.1111/j.1574-6968.1997.tb13875.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; ORII Y, 1992, BIOCHEM BIOPH RES CO, V187, P94, DOI 10.1016/S0006-291X(05)81463-9; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 1997, MICROBIOL-SGM, V143, P1557, DOI 10.1099/00221287-143-5-1557; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; POOLE RK, 1994, ANTON LEEUW INT J G, V65, P289, DOI 10.1007/BF00872215; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	60	131	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12581	12589		10.1074/jbc.275.17.12581	http://dx.doi.org/10.1074/jbc.275.17.12581			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777548	hybrid			2022-12-27	WOS:000086762300032
J	Ma, JX; Finley, RL; Waisman, DM; Sloane, BF				Ma, JX; Finley, RL; Waisman, DM; Sloane, BF			Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; CALCIUM-BINDING PROTEINS; LYSOSOMAL CATHEPSIN-B; EXTRACELLULAR-MATRIX; MEMBRANE ASSOCIATION; EPITHELIAL-CELLS; TYROSINE KINASE; PLASMA-MEMBRANE; S100 FAMILY; TENASCIN-C	To study potential roles of plasma membrane-associated extracellular cathepsin B in tumor cell invasion and metastasis, we used the yeast two-hybrid system to screen for proteins that interact with human procathepsin B. The annexin II light chain (p11), one of the two subunits of the annexin II tetramer, was one of the proteins identified. We have confirmed that recombinant human procathepsin B interacts with pll as well as with the annexin II tetramer in vitro. Furthermore, procathepsin B could interact with the annexin II tetramer in vivo as demonstrated by coimmunoprecipitation. Cathepsin B and the annexin II tetramer were shown by immunofluorescent staining to colocalize on the surface of human breast carcinoma and glioma cells. Taken together, our results indicate that the annexin II tetramer can serve as a binding protein for procathepsin B on the surface of tumor cells, an interaction that may facilitate tumor invasion and metastasis.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Calgary, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Calgary	Sloane, BF (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield, Detroit, MI 48201 USA.	bsloane@med.wayne.edu	Sloane, Bonnie F/A-1050-2009	Waisman, David/0000-0002-5097-9662; Finley, Russ/0000-0003-1144-6887	NATIONAL CANCER INSTITUTE [R01CA056586, R01CA036481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NCI NIH HHS [CA56586, CA36481] Funding Source: Medline; NIEHS NIH HHS [P30ES06639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; CAMPO E, 1994, AM J PATHOL, V145, P301; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; CHUONG CM, 1991, AM J PATHOL, V138, P427; DaletFumeron V, 1996, ARCH BIOCHEM BIOPHYS, V335, P351, DOI 10.1006/abbi.1996.0516; DANILOFF JK, 1989, J CELL BIOL, V108, P625, DOI 10.1083/jcb.108.2.625; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; EMMERTBUCK MR, 1992, BIOCHEM J, V282, P273; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; KREPELA E, 1995, INT J CANCER, V61, P44, DOI 10.1002/ijc.2910610109; LAH TT, 1989, CLIN EXP METASTAS, V7, P461, DOI 10.1007/BF01753666; LEE TL, 1993, J CELL SCI, V105, P167; LIGHTNER VA, 1990, J CELL SCI, V95, P263; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MA ASP, 1994, J CELL SCI, V107, P1973; MACH L, 1994, J BIOL CHEM, V269, P13036; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REMPEL SA, 1994, CANCER RES, V54, P6027; Ren WP, 1996, BIOCHEM J, V319, P793, DOI 10.1042/bj3190793; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SLOANE BF, 1994, J CELL SCI, V107, P373; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Sloane BF, 1996, NAT BIOTECHNOL, V14, P826, DOI 10.1038/nbt0796-826b; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SLY WS, 1981, METHOD CELL BIOL, V23, P191, DOI 10.1016/S0091-679X(08)61499-5; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; THIEL C, 1992, J CELL SCI, V103, P733; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WHITBY DJ, 1991, DEVELOPMENT, V112, P651; WILLINGHAM MC, 1990, FOCUS, V12, P62; WIRL G, 1990, J CELL PHYSIOL, V144, P511, DOI 10.1002/jcp.1041440320; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	75	157	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12806	12812		10.1074/jbc.275.17.12806	http://dx.doi.org/10.1074/jbc.275.17.12806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777578	hybrid			2022-12-27	WOS:000086762300062
J	Mehul, B; Bernard, D; Simonetti, L; Bernard, MA; Schmidt, R				Mehul, B; Bernard, D; Simonetti, L; Bernard, MA; Schmidt, R			Identification and cloning of a new calmodulin-like protein from human epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; BRILLIANT BLUE R-250; KERATINOCYTE CULTURES; POLYACRYLAMIDE-GEL; BINDING; CALCIUM; DIFFERENTIATION; RECOGNITION; SEPARATION; PSORIASIS	After separating by two-dimensional gel electrophoresis an extract of total proteins from human stratum corneum, two spots were extracted and analyzed for their peptide sequence, The resulting internal protein sequences provided evidence for the identification of a new calcium-binding protein. Cloning of the corresponding full-length cDNA was achieved by reverse transcriptase-polymerase chain reaction using two keratinocyte libraries, one from proliferating cultured keratinocytes and one from differentiated keratinocytes of reconstructed human epidermis. The cDNA had an open reading frame encoding a new calcium-binding protein of 146 amino acids, a member of the calmodulin family. We named this: new protein calmodulin-like skin protein (CLSP), since reverse transcriptase-polymerase chain reaction studies of CLSP expression in 10 different human tissues revealed that this protein was particularly abundant in the epidermis where its expression is directly related to keratinocyte differentiation. Expression of the cloned cDNA in Escherichia coli yielded a recombinant protein which allowed its further characterization. rCLSP is able to bind calcium, and similarly to calmodulin, exposes thereafter hydrophobic parts which most likely interact with target proteins. Epidermal proteins retained by CaM affinity column are quantitatively and qualitatively distinct from those of the rCLSP column. Sequencing of a rCLSP affinity purified protein revealed 100% identity with transglutaminase 3, a hey enzyme in terminal differentiation, indicating an important role of CLSP in this process.	LOreal, Ctr Charles Zviak, Life Sci Res, F-92583 Clichy, France	L'Oreal Group	Mehul, B (corresponding author), LOreal, Ctr Charles Zviak, Life Sci Res, 90 Rue Gen Roguet, F-92583 Clichy, France.							Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHEN HY, 1993, ANAL BIOCHEM, V212, P295, DOI 10.1006/abio.1993.1330; Cheung W Y, 1978, Adv Cyclic Nucleotide Res, V9, P233; CHEUNG WY, 1970, BIOCH BIPHYS RES COM, V38, P733; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FAIRLEY JA, 1985, J INVEST DERMATOL, V84, P195, DOI 10.1111/1523-1747.ep12264823; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KATOKA M, 1989, P NATL ACAD SCI USA, V86, P6944; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; Lee JH, 1996, J BIOL CHEM, V271, P4561; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MERRIL CR, 1986, ELECTROPHORESIS 86, P273; MIZUMOTO T, 1985, J INVEST DERMATOL, V85, P450, DOI 10.1111/1523-1747.ep12277177; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Reichert Uwe, 1993, P107; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; Tabernero L, 1997, STRUCTURE, V5, P613, DOI 10.1016/S0969-2126(97)00217-7; TSUKITA S, 1985, J CELL BIOL, V101, P2070, DOI 10.1083/jcb.101.6.2070; VANDEKERKHOF PCM, 1983, BRIT J DERMATOL, V108, P217; VANELDIK LJ, 1998, CALMODULIN SIGNAL TR; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; WATT FM, 1988, J CELL SCI, V90, P525	28	56	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12841	12847		10.1074/jbc.275.17.12841	http://dx.doi.org/10.1074/jbc.275.17.12841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777582	hybrid			2022-12-27	WOS:000086762300066
J	Goldberg, M; Peshkovsky, C; Shifteh, A; Al-Awqati, Q				Goldberg, M; Peshkovsky, C; Shifteh, A; Al-Awqati, Q			mu-protocadherin, a novel developmentally regulated protocadherin with mucin-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-CELL ADHESION; CADHERIN; EXPRESSION; APOPTOSIS; EPISIALIN; MADCAM-1; COMPLEX; CLONING; HOMOLOG	Branching morphogenesis is a central event during the development of kidneys, lungs, and other organs. We previously generated a monoclonal antibody, 3D2-E9, that inhibited branching morphogenesis and caused widespread apoptosis, We now report the purification of its antigen and cloning of its full-length cDNA. Its cDNA. encodes an integral membrane protein that contains four cadherin-like ectodomains and a thrice tandemly repeated region enriched in threonine, serine, and proline, similar to those of mucins, We thus term this protein mu-protocadherin, reflecting the hybrid nature of its extracellular region, mu-Protocadherin is expressed in two forms that are developmentally regulated, with the shorter isoform lacking the mucin-like repeats. Expression of the long isoform in heterologous cells results in adhesion of the expressing cells, suggesting that it is a new cell adhesion molecule. mu-Protocadherin contains both N and O glycosylations. It is expressed at lateral and basal surfaces of epithelia during kidney and lung development and is located in coated pits. Colocalization of mu-protocadherin with beta-catenin was noted primarily at the junction of the lateral and basal membrane. The cytoplasmic domain contains four proline-rich regions, similar to SH3 binding regions, Thus, it is likely that adhesive interactions mediated by mu-protocadherin induce signaling events that regulate branching morphogenesis.	Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Goldberg, M (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pediat, 3959 Broadway BHS Rm 724, New York, NY 10032 USA.	mg81@columbia.edu	Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NIDDK NIH HHS [DK 55388-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Cho EA, 1998, DEVELOPMENT, V125, P803; COLES HSR, 1993, DEVELOPMENT, V118, P777; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FERRARA P, 1993, TECHNIQUES PROTEIN C, V4, P379; Frohman Michael A., 1995, P381; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Goldberg MR, 1997, AM J PHYSIOL-RENAL, V272, pF79, DOI 10.1152/ajprenal.1997.272.1.F79; GOLDBERG MR, 1998, AM J RESP CRIT CARE, V157, P543; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HERZLINGER D, 1992, DEVELOPMENT, V114, P565; HUAN LJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P79, DOI 10.1016/0167-4781(92)90056-6; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Leung E, 1996, IMMUNOL CELL BIOL, V74, P490, DOI 10.1038/icb.1996.81; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Ponassi M, 1999, MECH DEVELOP, V80, P207, DOI 10.1016/S0925-4773(98)00217-2; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPICER AP, 1991, J BIOL CHEM, V266, P15099; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	33	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24622	24629		10.1074/jbc.M000234200	http://dx.doi.org/10.1074/jbc.M000234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801787	hybrid			2022-12-27	WOS:000088683300054
J	Gerber, DA; Souquere-Besse, S; Puvion, F; Dubois, MF; Bensaude, O; Cochet, C				Gerber, DA; Souquere-Besse, S; Puvion, F; Dubois, MF; Bensaude, O; Cochet, C			Heat-induced relocalization of protein kinase CK2 - Implication of CK2 in the context of cellular stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; ALPHA-SUBUNIT; BETA-SUBUNIT; II-ALPHA; CELLS; PHOSPHORYLATION; DNA; TRANSCRIPTION; PROLIFERATION; LOCALIZATION	Among various other roles described so far, protein kinase CK2 has been involved in cell cycle, proliferation, and development, Here, we show that in response to specific stresses (heat shock or UV irradiation), a pool of the cellular CK2 content relocalizes in a particular nuclear fraction, increasing the activity of the kinase there. Electron microscopic analysis shows that upon heat shock, CK2 alpha and CK2 beta subunits are both detected in similar speckle structures occurring in the interchromatin space but are differentially targeted inside the nucleolus. This CK2 relocalization process takes place in a time- and dose-dependent manner and is reversible upon recovery at 37 degrees C. Altogether, this work suggests CK2 be involved in the response to physiological stress in higher eukaryotic cells.	CENG, Lab INSERM, U244, F-38000 Grenoble, France; Inst Federat, CNRS, UPR 1983, Lab Org Fonct Noyau, F-94801 Villejuif, France; Ecole Normale Super, CNRS, UMR 8541, Lab regulat Express Genet, F-75230 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Cochet, C (corresponding author), CENG, Lab INSERM, U244, 17 Ave Martyrs, F-38000 Grenoble, France.	ccochet1@cea.fr		Bensaude, Olivier/0000-0002-0259-6608; Cochet, Claude/0000-0002-1772-4270				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; Cotto JJ, 1997, J CELL SCI, V110, P2925; DELPECH M, 1986, EUR J BIOCHEM, V160, P333, DOI 10.1111/j.1432-1033.1986.tb09976.x; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; Egyhazi E, 1999, MOL CELL BIOCHEM, V191, P149; Elefanty AG, 1996, EMBO J, V15, P319, DOI 10.1002/j.1460-2075.1996.tb00362.x; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HARLOW DL, 1988, ANTIBODIES, P313; JACKSON DA, 1994, J CELL SCI, V107, P1753; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; LASZLO A, 1992, CELL PROLIFERAT, V25, P59, DOI 10.1111/j.1365-2184.1992.tb01482.x; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; vanSteensel B, 1996, J CELL SCI, V109, P787; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; [No title captured]	37	67	67	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23919	23926		10.1074/jbc.M002697200	http://dx.doi.org/10.1074/jbc.M002697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10787418	hybrid			2022-12-27	WOS:000088564200071
J	Rizzo, MA; Shome, K; Watkins, SC; Romero, G				Rizzo, MA; Shome, K; Watkins, SC; Romero, G			The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; IN-VITRO; PHOSPHOLIPASE-D; BINDING; ENDOCYTOSIS; INSULIN; CELLS	The serine/threonine kinase Raf-1 is an essential component of the MAPK cascade. Activation of Raf-1 by extracellular signals is initiated by association with intracellular membranes. Recruitment of Raf-1 to membranes has been reported to be mediated by direct association with Res and by the phospholipase D product phosphatidic acid (PA). Here we report that insulin stimulation of HIRcB fibroblasts leads to accumulation of Res, Raf-1, phosphorylated MEK, phosphorylated MAPK, and PA on endosomal membranes, Mutations that disrupt Raf-PA interactions prevented recruitment of Raf-1 to membranes, whereas disruption of Ras-Raf interactions did not affect agonist-dependent translocation, Expression of a dominant-negative Pas mutant did not prevent insulin-dependent Raf-1 translocation, but inhibited phosphorylation of MAPK Finally, the PA-binding region of Raf-1 was sufficient to target green fluorescent protein to membranes, and its overexpression blocked recruitment of Raf-1 to membranes and disrupted insulin dependent MAPK phosphorylation, These results indicate that agonist-dependent Raf-1 translocation is primarily mediated by a direct interaction with PA and is independent of association with Ras.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Callaghan L, 1999, EUR J BIOCHEM, V265, P361; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chiariello M, 1999, FEBS LETT, V453, P20, DOI 10.1016/S0014-5793(99)00686-9; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DENT P, 1995, MOL CELL BIOL, V15, P4125; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lu KK, 1998, CELL GROWTH DIFFER, V9, P367; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mineo C, 1997, J BIOL CHEM, V272, P10345; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHEIN CH, 1989, BIOTECHNOLOGY, V7, P1141; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	269	282	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23911	23918		10.1074/jbc.M001553200	http://dx.doi.org/10.1074/jbc.M001553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801816	hybrid			2022-12-27	WOS:000088564200070
J	Feierberg, I; Luzhkov, V; Aqvist, J				Feierberg, I; Luzhkov, V; Aqvist, J			Computer simulation of primary kinetic isotope effects in the proposed rate-limiting step of the glyoxalase I catalyzed reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME CATALYSIS; TRIOSEPHOSPHATE ISOMERASE; PROTON-TRANSFER; ACTIVE-SITE; MECHANISM; DYNAMICS	The proposed rate-limiting step of the glyoxalase I catalyzed reaction is the proton abstraction from the C1 carbon of the substrate by Glu(172). Here we examine primary kinetic isotope effects and the influence of quantum dynamics on this process by computer simulations. The calculations utilize the empirical valence bond method in combination with the molecular dynamics free energy perturbation technique and path integral simulations. For the enzyme-catalyzed reaction a H/D kinetic isotope effect of 5.0 +/- 1.3 is predicted in reasonable agreement with the experimental result of about 3. Furthermore, the magnitude of quantum mechanical effects is found to be very similar for the enzyme reaction and the corresponding uncatalyzed process in solution, in agreement with other studies. The problems associated with attaining the required accuracy in order for the present approach to be useful as a diagnostic tool for the study of enzyme reactions are also discussed.	Uppsala Univ, Ctr Biomed, Dept Mol & Cell Biol, S-75124 Uppsala, Sweden; Russian Acad Sci, Inst Chem Phys Problems, Chernogolovka 142432, Moscow Region, Russia	Uppsala University; Russian Academy of Sciences; Institute of Problems of Chemical Physics of the Russian Academy of Sciences	Aqvist, J (corresponding author), Uppsala Univ, Ctr Biomed, Dept Mol & Cell Biol, Box 596, S-75124 Uppsala, Sweden.	aqvist@xray.bmc.uu.se	Luzhkov, Victor/AAE-1857-2019	Luzhkov, Victor/0000-0003-2528-4567				ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5588, DOI 10.1021/bi00670a025; Alhambra C, 1999, J AM CHEM SOC, V121, P2253, DOI 10.1021/ja9831655; ANDERSON SR, 1994, BIOCHEMISTRY-US, V33, P10545, DOI 10.1021/bi00200a041; Aqvist J, 1996, J BIOL CHEM, V271, P10010, DOI 10.1074/jbc.271.17.10010; AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; AQVIST J, 1992, J MOL STRUC-THEOCHEM, V88, P135, DOI 10.1016/0166-1280(92)87163-T; AQVIST J, 1993, CHEM REV, V93, P2523, DOI 10.1021/cr00023a010; BERNE BJ, 1986, ANNU REV PHYS CHEM, V37, P401; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; FEJERBERG I, 1999, FEBS LETT, V453, P90; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; Hwang JK, 1996, J AM CHEM SOC, V118, P11745, DOI 10.1021/ja962007f; HWANG JK, 1991, J PHYS CHEM-US, V95, P8445, DOI 10.1021/j100175a009; KALLARAKAL AT, 1995, BIOCHEMISTRY-US, V34, P2788, DOI 10.1021/bi00009a007; KING G, 1989, J CHEM PHYS, V91, P3647, DOI 10.1063/1.456845; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; LEADLAY PF, 1976, BIOCHEMISTRY-US, V15, P5617, DOI 10.1021/bi00670a029; LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997; Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(99)00012-1; Neria E, 1997, CHEM PHYS LETT, V267, P23, DOI 10.1016/S0009-2614(97)00068-7; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; SAUNDERS WH, 1985, J AM CHEM SOC, V107, P164, DOI 10.1021/ja00287a029; Schlegel HB., 2009, GAUSSIAN 09 REVISION; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597; VOTH GA, 1989, J CHEM PHYS, V91, P7749, DOI 10.1063/1.457242; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; Warshel A, 1991, COMPUTER MODELING CH	31	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22657	22662		10.1074/jbc.M000726200	http://dx.doi.org/10.1074/jbc.M000726200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801792	hybrid			2022-12-27	WOS:000088419400011
J	Sukhodolets, MV; Jin, DJ				Sukhodolets, MV; Jin, DJ			Interaction between RNA polymerase and RapA, a bacterial homolog of the SWI/SNF protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT CLEAVAGE FACTORS; ESCHERICHIA-COLI; GENE-EXPRESSION; MUTAGENESIS; GREA; RESISTANCE; HELICASES; LOCATION; BINDING; SUBUNIT	Recently, we identified a novel Escherichia coli RNA polymerase (RNAP)-associated protein, an ATPase, called RapA (Sukhodolets, M, V., and Jin, D. J. (1998) J. Biol. Chem. 273, 7018-7023), RapA is a bacterial homolog of SWI2/SNF2. We showed that RapA forms a stable complex with RNAP holoenzyme and that binding to RNAP holoenzyme stimulates the ATPase activity of RapA. We have further analyzed the interactions between purified RapA and the two forms of RNAP: core RNAP and RNAP holoenzyme, We found that RapA interacts with either form of RNAP, However, RapA exhibits higher affinity for core RNAP than for RNAP holoenzyme. Chemical cross-linking of the RNAP-RapA complex indicated that the RapA-binding sites are located at the interface between the alpha and beta' subunits of RNAP, Contrary to previously reported results (Muzzin, O,, Campbell, E., A, Xia, L., Severinova, E., Darst, S. A, and Severinov, K, (1998) J. Biol. Chem, 273, 15157-15161), our in vivo analysis of a rapA null mutant suggested that RapA is not likely to be directly involved in DNA repair.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jin, DJ (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2E14,9000 Rockville Pike, Bethesda, MD 20892 USA.	djjin@helix.nih.gov						ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgess R.R., 1987, RNA POLYM REGULATION, P3; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FENG GH, 1994, J BIOL CHEM, V269, P22282; FRIEDMAN DI, 1983, LAMBDA 2, P21; FUQUA WC, 1992, BIOTECHNIQUES, V12, P223; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GUZMAN LM, 1995, J BACTERIOL, V177, P4221; HILLEL Z, 1977, BIOCHEMISTRY-US, V16, P3334, DOI 10.1021/bi00634a008; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KOLSTO AB, 1993, J MOL BIOL, V230, P684, DOI 10.1006/jmbi.1993.1185; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Miller J.H., 1972, EXPT MOL GENETICS; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Muzzin O, 1998, J BIOL CHEM, V273, P15157, DOI 10.1074/jbc.273.24.15157; NEIGEBORN L, 1984, GENETICS, V108, P845; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; POLYAKOV A, 1988, J MOL BIOL, V281, P465; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SPARKOWSKI J, 1991, J BACTERIOL, V173, P5256, DOI 10.1128/jb.173.17.5256-5257.1991; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WITKIN EM, 1966, SCIENCE, V152, P1345, DOI 10.1126/science.152.3727.1345	32	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22090	22097		10.1074/jbc.M000056200	http://dx.doi.org/10.1074/jbc.M000056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801781	hybrid			2022-12-27	WOS:000088363800049
J	Hou, YX; Cui, LY; Riordan, JR; Chang, XB				Hou, YX; Cui, LY; Riordan, JR; Chang, XB			Allosteric interactions between the two non-equivalent nucleotide binding domains of multidrug resistance protein MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CONJUGATE EXPORT PUMP; ATPASE ACTIVITY; P-GLYCOPROTEIN; VINCRISTINE TRANSPORT; SULFONYLUREA RECEPTOR; LEUKOTRIENE C-4; GLUTATHIONE; CELLS; GENE	Membrane transporters of the adenine nucleotide binding cassette (ABC) superfamily utilize two either identical or homologous nucleotide binding domains (NBDs). Although the hydrolysis of ATP by these domains is believed to drive transport of solute, it is unknown why two rather than a single NBD is required. In the well studied P-glycoprotein multidrug transporter, the two appear to be functionally equivalent, and a strongly supported model proposes that ATP hydrolysis occurs alternately at each NBD (Senior, A. E., al-Shawi, M. H., and Urbatsch, I. L. (1995) FEBS Lett 377, 285-289), To assess how applicable this model may be to other ABC transporters, we have examined adenine nucleotide interactions with the multidrug resistance protein, MRP1, a member of a different ABC family that transports conjugated organic anions and in which sequences of the two NBDs are much less similar than in P-glycoprotein, Photoaffinity labeling experiments with 8-azido-ATP, which strongly supports transport revealed ATP binding exclusively at NBD1 and ADP trapping predominantly at NBD2, Despite this apparent asymmetry in the two domains, they are entirely interdependent as substitution of key lysine residues in the Walker A motif of either impaired both ATP binding and ADP trapping. Furthermore, the interaction of ADP at NBD2 appears to allosterically enhance the binding of ATP at NBD1. Glutathione, which supports drug transport by the protein, does not enhance ATP binding but stimulates the trapping of ADP, Thus MRP1 may employ a more complex mechanism of coupling ATP utilization to the export of agents from cells than P-glycoprotein.	Mayo Clin Scottsdale, Mayo Fdn, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Chang, XB (corresponding author), Mayo Clin Scottsdale, Mayo Fdn, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Chang XB, 1998, J BIOL CHEM, V273, P23844, DOI 10.1074/jbc.273.37.23844; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; Hipfner DR, 1996, CANCER RES, V56, P3307; Jedlitschky G, 1996, CANCER RES, V56, P988; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1	28	130	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20280	20287		10.1074/jbc.M001109200	http://dx.doi.org/10.1074/jbc.M001109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781583	hybrid			2022-12-27	WOS:000088084500011
J	Krueger, DA; Warner, EA; Dowd, DR				Krueger, DA; Warner, EA; Dowd, DR			Involvement of thyrotroph embryonic factor in calcium-mediated regulation of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LEUCINE-ZIPPER PROTEINS; TRANSCRIPTION FACTOR; DNA-BINDING; CREB; CAMP; PROMOTER; ICER; TEF; DBP	In the present study, we used an expression cloning strategy to identify transcription factors that bind specifically to a limited region of the inducible cAMP early repressor (ICER) promoter and regulate transcription. Murine thyrotroph embryonic factor (mTEF) was isolated and was shown to bind to a site located at nucleotides -117 to -108 from the transcriptional start site. Transient expression of reporter constructs containing either a consensus TEFRE or the icerTEF binding site demonstrated that TEF-dependent transcription correlated with relative binding affinities, i.e. the consensus TEFRE bound TEF more tightly and was more responsive to TEF than the icerTEFRE, Because the icerTEFRE overlapped a cAMP response element, the responsiveness of these sequences to either cAMP or Ca2+ was tested. Although TEF expression had no effect on the cAMP-regulated transcriptional response of the ICER promoter, TEF did confer calcium responsiveness to these sequences. Calcium also modestly increased the TEF-mediated transcription from a consensus TEFRE, Additional studies using Ca2+-activated kinases indicate that Ca2+/TEF/TEFRE-regulated transcription may be mediated through Ca2+/calmodulin-dependent kinase (CaMK) IV. Moreover, studies with the icerTEFRE in a CaMK IV-deficient cell line demonstrated that these cells were transcriptionally unresponsive to thapsigargin; however, responsiveness was restored by co-expression of the active CaMK IV. These studies are the first to demonstrate that TEF is a calcium-responsive transcription factor, and they suggest that there are two classes of TEF-regulated genes. One class, represented by a consensus TEFRE, is regulated by TEF in the resting cell; the second class, represented by icerTEFRE, is regulated by TEF in the calcium-activated cell.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; St Louis Univ, Hlth Sci Ctr, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Case Western Reserve University; Saint Louis University	Dowd, DR (corresponding author), Case Western Reserve Univ, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	dxd57@po.cwru.edu		Krueger, Darcy/0000-0002-7250-7391	NIAID NIH HHS [AI-35910] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hunger SP, 1996, BLOOD, V87, P4607, DOI 10.1182/blood.V87.11.4607.bloodjournal87114607; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; Johnson CM, 1997, J NEUROSCI, V17, P6189; Krueger DA, 1999, MOL ENDOCRINOL, V13, P1207, DOI 10.1210/me.13.7.1207; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Mao DL, 1998, MOL ENDOCRINOL, V12, P492, DOI 10.1210/me.12.4.492; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; Razavi R, 1998, ONCOGENE, V17, P3015, DOI 10.1038/sj.onc.1202225; ROUET P, 1992, BIOTECHNIQUES, V13, P700; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Xia ZG, 1996, J NEUROSCI, V16, P5425	28	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14524	14531		10.1074/jbc.275.19.14524	http://dx.doi.org/10.1074/jbc.275.19.14524			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799536	hybrid			2022-12-27	WOS:000087006900070
J	Nemorin, JG; Duplay, P				Nemorin, JG; Duplay, P			Evidence that Lck-mediated phosphorylation of p56(dok) and p62(dok) may play a role in CD2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; T-CELL-RECEPTOR; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; SH3 DOMAIN; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING; DOCKING PROTEIN; CROSS-LINKING	The Lck tyrosine kinase is involved in signaling by T cell surface receptors such as TCR/CD3, CD2, and CD28. As other downstream protein-tyrosine kinases are activated upon stimulation of these receptors, it is difficult to assign which tyrosine-phosphorylated proteins represent bona fide Lck substrates and which are phosphorylated by other tyrosine kinases. We have developed a system in which Lck can be activated independently of TCR/CD3. We have shown that activation of an epidermal growth factor receptor/Lck chimera leads to the specific phosphorylation of Res GTPase-activating protein (RasGAP) and two RasGAP-associated proteins, p56(dok) and p62(dok). Activation of the chimeric protein correlates with an increase in cellular Ca2+ in the absence of ZAP-70 and phospholipase C gamma 1 phosphorylation. Furthermore, we have found that p62(dok) co-immunoprecipitates with the activated epidermal growth factor receptor/LckF505 and that phosphorylated Dok proteins bind to the Src homology 2 domain of Lck in vitro. In addition, we have shown that activation via the CD2 but not the TCR/CD3 receptor leads to the phosphorylation of p56(dok) and p62(dok). Using JCaM1.6 cells, we have demonstrated that Lck is required for CD2-mediated phosphorylation of Dok proteins. We propose that phosphorylation and Src homology S-mediated association of p56(dok) and p62(dok) with Lck play a selective function in accessory receptor signal transduction mechanisms.	Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, Laval, PQ H7V 1B7, Canada	University of Quebec; Institut national de la recherche scientifique (INRS)	Duplay, P (corresponding author), Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada.	pascale_duplay@inrs-iaf.uquebec.ca						AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; Catipovic B, 1996, J BIOL CHEM, V271, P9698, DOI 10.1074/jbc.271.16.9698; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Duplay P, 1996, J BIOL CHEM, V271, P17896, DOI 10.1074/jbc.271.30.17896; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELLIS C, 1991, ONCOGENE, V6, P895; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; GOLD MR, 1993, J IMMUNOL, V150, P377; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUBERT P, 1993, J EXP MED, V178, P1587, DOI 10.1084/jem.178.5.1587; Hubert P, 1996, J IMMUNOL, V157, P4322; JIN YJ, 1990, J IMMUNOL, V144, P647; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; Lafont V, 1997, EUR J IMMUNOL, V27, P2261, DOI 10.1002/eji.1830270921; Lewis LA, 1997, J IMMUNOL, V159, P2292; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; Li S, 1998, IMMUNOL TODAY, V19, P455, DOI 10.1016/S0167-5699(98)01325-5; LORENZ U, 1994, GENE, V138, P219; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MarieCardine A, 1996, J BIOL CHEM, V271, P20734, DOI 10.1074/jbc.271.34.20734; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; OHNO H, 1991, J IMMUNOL, V146, P3742; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PERI KG, 1993, ONCOGENE, V8, P2765; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RAAB M, 1994, BIOCHEMISTRY-US, V33, P5070; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sunder-Plassmann R, 1998, J BIOL CHEM, V273, P24249, DOI 10.1074/jbc.273.37.24249; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Vuica M, 1997, J EXP MED, V186, P259, DOI 10.1084/jem.186.2.259; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607	67	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14590	14597		10.1074/jbc.275.19.14590	http://dx.doi.org/10.1074/jbc.275.19.14590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799545	hybrid			2022-12-27	WOS:000087006900079
J	Vasquez-Vivar, J; Kalyanaraman, B; Kennedy, MC				Vasquez-Vivar, J; Kalyanaraman, B; Kennedy, MC			Mitochondrial aconitase is a source of hydroxyl radical - An electron spin resonance investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; HO-CENTER-DOT; NITRIC-OXIDE; IN-VITRO; ESCHERICHIA-COLI; MAMMALIAN-CELLS; SUPEROXIDE; OXYGEN; INACTIVATION; VIVO	Mitochondrial aconitase (m-aconitase) contains a [4Fe-4S](2+) cluster in its active site that catalyzes the stereospecific dehydration-rehydration of citrate to isocitrate in the Krebs cycle. It has been proposed that the [4Fe-4S](2+) aconitase is oxidized by superoxide, generating the inactive [3Fe-4S](1+) aconitase. In this reaction, the likely products are iron(II) and hydrogen peroxide. Consequently, the inactivation of m-aconitase by superoxide may increase the formation of hydroxyl radical ((OH)-O-.) through the Fenton reaction in mitochondria. In this work, evidence for the generation of (OH)-O-. from the reaction of m-aconitase with superoxide is provided using ESR spin trapping experiments with 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide and alpha-phenyl-N-tert-butylnitrone. Formation of free (OH)-O-. was verified with the (OH)-O-. scavenger Me2SO, which forms methyl radical upon reacting with (OH)-O-.. The addition of Me2SO to incubation mixtures containing m-aconitase and xanthine/xanthine oxidase yielded methyl radical, which was detected by ESR spin trapping. Methyl radical formation was further confirmed using [C-13]Me2SO. Parallel low temperature ESR experiments demonstrated that the generation of the [3Fe-4S](1+) cluster increased with increasing additions of superoxide to m-aconitase. This reaction was reversible, as >90% of the initial aconitase activity was recovered upon treatment with glutathione and iron(II). This mechanism presents a scenario in which (OH)-O-. may be continuously generated in the mitochondria.	Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Pathol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Vasquez-Vivar, J (corresponding author), Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Pathol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jvvivar@mcw.edu			NCI NIH HHS [CA77822] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline; NIGMS NIH HHS [GM51831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Boveris A, 1973, BIOCHEM J, V156, P435; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Dykens James A., 1997, P29; Eisenstein RS, 1997, CH MICROBIOL SER, P157; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Liochev SI, 1999, FREE RADICAL BIO MED, V26, P777; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; Liochev SI, 1996, FREE RADICAL RES, V25, P369, DOI 10.3109/10715769609149059; MELLO AC, 1991, MUTAT RES, V251, P109, DOI 10.1016/0027-5107(91)90220-I; MINOTTI G, 1987, FREE RADICAL BIO MED, V3, P379, DOI 10.1016/0891-5849(87)90016-5; RUZICKA FJ, 1978, J BIOL CHEM, V253, P2514; Vasquez-Vivar J, 1999, FREE RADICAL RES, V31, P607, DOI 10.1080/10715769900301181; VILE GF, 1988, BIOCHEM PHARMACOL, V37, P2893, DOI 10.1016/0006-2952(88)90273-0; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	31	247	261	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14064	14069		10.1074/jbc.275.19.14064	http://dx.doi.org/10.1074/jbc.275.19.14064			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799480	hybrid			2022-12-27	WOS:000087006900010
J	Wu, WI; Routt, S; Bankaitis, VA; Voelker, DR				Wu, WI; Routt, S; Bankaitis, VA; Voelker, DR			A new gene involved in the transport-dependent metabolism of phosphatidylserine, PSTB2/PDR17, shares sequence similarity with the gene encoding the phosphatidylinositol/phosphatidylcholine transfer protein, SEC14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NULL ALLELE; YEAST; SYNTHASE; CLONING; DECARBOXYLASE; DNA; CREATION	A new yeast strain, designated pstB2, that is defective in the conversion of nascent phosphatidylserine (PtdSer) to phosphatidylethanolamine (PtdEtn) by PtdSer decarboxylase 2, has been isolated. The pstB2 strain requires ethanolamine for growth. Incubation of cells with [H-3]serine followed by analysis of the aminoglycerophospholipids demonstrates a 50% increase in the labeling of PtdSer and a 72% decrease in PtdEtn formation in the mutant relative to the parental strain. The PSTB2 gene was isolated by complementation, and it restores ethanolamine prototrophy and corrects the defective lipid metabolism of the pstB2 strain. The PSTB2 gene is allelic to the pleiotropic drug resistance gene, PDR17, and is homologous to SEC14, which encodes a phosphatidylinositol/phosphatidylcholine transfer protein. The protein, PstB2p, displays phosphatidylinositol but not PtdSer transfer activity, and its overexpression causes suppression of sec14 mutants. However, overexpression of the SEC14 gene fails to suppress the conditional lethality of pstB2 strains. The transport-dependent metabolism of PtdSer to PtdEtn occurs in permeabilized wild type yeast but is dramatically reduced in permeabilized pstB2 strains. Fractionation of permeabilized cells demonstrates that the pstB2 strain accumulates nascent PtdSer in the Golgi apparatus and a novel light membrane fraction, consistent with a defect in lipid transport processes that control substrate access to PtdSer decarboxylase 2.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	National Jewish Health; University of Alabama System; University of Alabama Birmingham	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA.	voelkerd@njc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044530, R01GM032453, F32GM019162, R37GM032453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19162, GM32453, GM44530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; AITKEN JF, 1990, J BIOL CHEM, V265, P4711; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; HANSON BA, 1980, J LIPID RES, V21, P309; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; OHTA A, 1981, J BIOL CHEM, V256, P2219; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; TROTTER PJ, 1994, BIOCHIM BIOPHYS ACTA, V1219, P241; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; VOELKER DR, 1994, BIOCH LIPIDS LIPOPRO, V31, P391	38	66	68	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14446	14456		10.1074/jbc.275.19.14446	http://dx.doi.org/10.1074/jbc.275.19.14446			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799527	hybrid			2022-12-27	WOS:000087006900061
J	Bothner, B; Chavez, R; Wei, J; Strupp, C; Phung, Q; Schneemann, A; Siuzdak, G				Bothner, B; Chavez, R; Wei, J; Strupp, C; Phung, Q; Schneemann, A; Siuzdak, G			Monitoring enzyme catalysis with mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; LIPOPROTEIN-LIPASE; REAL-TIME; ELECTROSPRAY; ASSAY; PROTEOLYSIS; INHIBITION; PEPTIDES; COMPLEX	Mass spectrometry is a rapid, sensitive, and accurate quantitative approach for the direst monitoring of enzyme-catalyzed reactions that does not require a chromophore or radiolabeling and thus provides a viable alternative to existing analytical techniques. In this study the proteolysis of intact viral capsid proteins, the alpha-glucosidase-catalyzed hydrolysis of p-nitrophenyl-alpha-glucopyranoside and the lipoprotein lipase-catalyzed ester hydrolysis of resorufin were examined. Matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry were used to examine the proteolysis of viral protein capsids, providing information about capsid dynamics and the stabilizing force of viral protein/RNA interactions. In addition, k(cat) and K-m values of enzyme-catalyzed hydrolysis were obtained (without the use of a chromophore), These results also demonstrate the effect an unnatural substrate can have on enzyme activity. Overall, mass spectrometry provides for efficient and quantitative analysis of enzyme-catalyzed reactions, as well as the direct observation of reaction dynamics.	Scripps Res Inst, Beckman Ctr Chem Sci, La Jolla, CA 92037 USA; Mass Consortium Corp, San Diego, CA 92121 USA	Scripps Research Institute	Siuzdak, G (corresponding author), Scripps Res Inst, Beckman Ctr Chem Sci, BCC1571,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Siuzdak, Gary/0000-0002-4749-0014	NCRR NIH HHS [S10 RR07273] Funding Source: Medline; NIGMS NIH HHS [R01 GM55775-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055775] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bothner B, 1999, NAT STRUCT BIOL, V6, P114; Bothner B, 1998, J BIOL CHEM, V273, P673, DOI 10.1074/jbc.273.2.673; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHEMNITIUS GC, 1992, ANAL BIOCHEM, V202, P16, DOI 10.1016/0003-2697(92)90199-H; GANEM B, 1991, J AM CHEM SOC, V113, P6294, DOI 10.1021/ja00016a069; Gerber SA, 1999, J AM CHEM SOC, V121, P1102, DOI 10.1021/ja982878k; GONG B, 1992, J AM CHEM SOC, V114, P1486, DOI 10.1021/ja00030a056; HSIEH FYL, 1995, ANAL BIOCHEM, V229, P20, DOI 10.1006/abio.1995.1373; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JACKSON R, 1983, ENZYMES, V16, pCH5; KATTA V, 1991, J AM CHEM SOC, V113, P8534, DOI 10.1021/ja00022a058; KOUACH M, 1994, BIOL MASS SPECTROM, V23, P283, DOI 10.1002/bms.1200230508; KREBS JF, 1995, BIOCHEMISTRY-US, V34, P720, DOI 10.1021/bi00003a002; Kriwacki RW, 1997, J CHROMATOGR A, V777, P23, DOI 10.1016/S0021-9673(97)00527-X; LEE ED, 1989, J AM CHEM SOC, V111, P4600, DOI 10.1021/ja00195a012; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; NEUMANN U, 1989, Patent No. 4847376; NEUMANN U, 1991, Patent No. 4988497; QUINN DM, 1982, BIOCHEMISTRY-US, V21, P6872, DOI 10.1021/bi00269a038; SIUZDAK G, 1994, J AM CHEM SOC, V116, P7937, DOI 10.1021/ja00096a077; Siuzdak G, 1998, J MASS SPECTROM, V33, P203, DOI 10.1002/(SICI)1096-9888(199803)33:3<203::AID-JMS653>3.0.CO;2-Q; Siuzdak G., 1996, MASS SPECTROMETRY BI; WANG CS, 1990, BIOCHIM BIOPHYS ACTA, V1043, P143, DOI 10.1016/0005-2760(90)90287-8; WASHBURN WN, 1990, J AM CHEM SOC, V112, P2040, DOI 10.1021/ja00161a082; Wu JY, 1997, CHEM BIOL, V4, P653, DOI 10.1016/S1074-5521(97)90220-9	26	101	103	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13455	13459		10.1074/jbc.275.18.13455	http://dx.doi.org/10.1074/jbc.275.18.13455			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788458	hybrid			2022-12-27	WOS:000086925300045
J	Ikegami, T; Okada, T; Hashimoto, M; Seino, S; Watanabe, T; Shirakawa, M				Ikegami, T; Okada, T; Hashimoto, M; Seino, S; Watanabe, T; Shirakawa, M			Solution structure of the chitin-binding domain of Bacillus circulans WL-12 chitinase A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REESEI CELLOBIOHYDROLASE-I; TRICHODERMA-REESEI; PROTEIN STRUCTURES; CELLULOMONAS-FIMI; CRYSTAL-STRUCTURE; ERWINIA-CHRYSANTHEMI; ENDOGLUCANASE-Z; GENE; CLONING; SYSTEM	The three-dimensional structure of the chitin-binding domain (ChBD) of chitinase A1 (ChiA1) from a Grampositive bacterium, Bacillus circulans WL-12, was determined by means of multidimensional heteronuclear NMR methods. ChiA1 is a glycosidase that hydrolyzes chitin and is composed of an N-terminal catalytic domain, two fibronectin type Iii-like domains, and C-terminal ChBD(ChiA1), (45 residues, Ala(655)-Gln(699)), which binds specifically to insoluble chitin, ChBD(ChiA1) has a compact and globular structure with the topology of a twisted beta-sandwich, This domain contains two antiparallel beta-sheets, one composed of three strands and the other of two strands. The core region formed by the hydrophobic and aromatic residues makes the overall structure rigid and compact. The overall topology of ChBD(ChiA1) is similar to that of the cellulose-binding domain (CBD) of Erwinia chrysanthemi endoglucanase Z (CBDEGZ). However, ChBD(ChiA1) lacks the three aromatic residues aligned linearly and exposed to the solvent, which probably interact with cellulose in CBDs. Therefore, the binding mechanism of a group of ChBDs including ChBD(ChiA1) may be different from that proposed for CBDs.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Niigata Univ, Fac Agr, Dept Appl Biol Chem, Niigata 9502181, Japan	Nara Institute of Science & Technology; Niigata University	Shirakawa, M (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	shira@bs.aist-nara.ac.jp	Ikegami, Takahisa/I-9626-2017	Ikegami, Takahisa/0000-0002-1429-1844				Alam MM, 1996, J FERMENT BIOENG, V82, P28, DOI 10.1016/0922-338X(96)89450-5; Boller T, 1985, CELLULAR MOL BIOL PL, P247; Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Brun E, 1997, BIOCHEMISTRY-US, V36, P16074, DOI 10.1021/bi9718494; BRUNGER AT, 1993, XPLOR 3 1 SYST XRAY; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cohen-Kupiec R, 1998, CURR OPIN BIOTECH, V9, P270, DOI 10.1016/S0958-1669(98)80058-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GLEAVE AP, 1995, FEMS MICROBIOL LETT, V131, P279, DOI [10.1111/j.1574-6968.1995.tb07788.x, 10.1016/0378-1097(95)00268-A]; GOLDSTEIN MA, 1993, J BACTERIOL, V175, P5762, DOI 10.1128/JB.175.18.5762-5768.1993; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Guntert P, 1997, Methods Mol Biol, V60, P157; HART PJ, 1995, J MOL BIOL, V248, P402, DOI 10.1006/jmbi.1995.0230; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu WD, 1996, J MAGN RESON SER B, V113, P70, DOI 10.1006/jmrb.1996.0157; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P13895, DOI 10.1021/bi961186a; Jolles P., 1999, CHITIN CHITINASES; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; Linder M, 1996, J BIOL CHEM, V271, P21268, DOI 10.1074/jbc.271.35.21268; Mattinen ML, 1997, PROTEIN SCI, V6, P294; Mattinen ML, 1997, FEBS LETT, V407, P291, DOI 10.1016/S0014-5793(97)00356-6; Mattinen ML, 1998, EUR J BIOCHEM, V256, P279, DOI 10.1046/j.1432-1327.1998.2560279.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nagy T, 1998, FEBS LETT, V429, P312, DOI 10.1016/S0014-5793(98)00625-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Perrakis A, 1997, FOLD DES, V2, P291, DOI 10.1016/S1359-0278(97)00040-0; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; SCHELTINGA ACT, 1996, J MOL BIOL, V262, P243, DOI DOI 10.1006/JMBI.1996.0510; Shiro M, 1996, BBA-GENE STRUCT EXPR, V1305, P44, DOI 10.1016/0167-4781(95)00213-8; Simpson HD, 1999, J BACTERIOL, V181, P4611, DOI 10.1128/JB.181.15.4611-4616.1999; SITRIT Y, 1995, J BACTERIOL, V177, P4187, DOI 10.1128/jb.177.14.4187-4189.1995; Suzuki K, 1998, BIOSCI BIOTECH BIOCH, V62, P128, DOI 10.1271/bbb.62.128; Suzuki K, 1999, BIOCHEM J, V343, P587, DOI 10.1042/0264-6021:3430587; TANAKA H, 1965, J BACTERIOL, V89, P1570, DOI 10.1128/JB.89.6.1570-1580.1965; Theis K, 1997, J BIOMOL NMR, V10, P403, DOI 10.1023/A:1018373601391; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; TOMME P, 1994, PROTEIN ENG, V7, P117, DOI 10.1093/protein/7.1.117; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; TSUJIBO H, 1993, J BACTERIOL, V175, P176, DOI 10.1128/JB.175.1.176-181.1993; UEDA M, 1994, J FERMENT BIOENG, V78, P205, DOI 10.1016/0922-338X(94)90291-7; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; WATANABE T, 1990, J BACTERIOL, V172, P4017, DOI 10.1128/jb.172.7.4017-4022.1990; WATANABE T, 1990, J BIOL CHEM, V265, P15659; WATANABE T, 1992, J BACTERIOL, V174, P186, DOI 10.1128/jb.174.1.186-190.1992; WEBER PL, 1996, NMR SPECTROSCOPY ITS, P187; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEINS NUCL AC; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	58	99	106	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13654	13661		10.1074/jbc.275.18.13654	http://dx.doi.org/10.1074/jbc.275.18.13654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788483	hybrid			2022-12-27	WOS:000086925300070
J	Kinsella, MG; Fischer, JW; Mason, DP; Wight, TN				Kinsella, MG; Fischer, JW; Mason, DP; Wight, TN			Retrovirally mediated expression of decorin by macrovascular endothelial cells - Effects on cellular migration and fibronectin fibrillogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; VASCULAR SMOOTH-MUSCLE; INTEGRIN ALPHA-5-BETA-1 EXPRESSION; DERMATAN SULFATE PROTEOGLYCANS; FACTOR-BETA; EXTRACELLULAR-MATRIX; TGF-BETA; CORE PROTEIN; I COLLAGEN; FIBRIL FORMATION	Decorin is a member of the widely expressed family of small leucine-rich proteoglycans. In addition to a primary role as a modulator of extracellular matrix protein fibrillogenesis, decorin can inhibit the cellular response to growth factors. Decorin expression is induced in endothelial cells during angiogenesis, but not when migration and proliferation are stimulated. Thus, decorin may support the formation of the fibrillar pericellular matrix that stabilizes the differentiated endothelial phenotype during the later stages of angiogenesis, Therefore, we tested whether constitutive decorin expression alone could modify endothelial cell migration and proliferation or affect pericellular matrix formation. To this end, replication-defective retroviral vectors were used to stably express bovine decorin, which was detected by Northern and Western blotting. The migration of endothelial cells that express decorin is significantly inhibited in both monolayer outgrowth and microchemotaxis chamber assays. The inhibition of cell migration by decorin was not accompanied by decreased proliferation. In addition, endothelial cells that express decorin assemble an extensive fibrillar fibronectin matrix more rapidly than control cells as assessed by immunocytochemical and fibronectin fibrillogenesis assays. These observations suggest that cell migration may be modulated by the influence of decorin on the assembly of the cell-associated extracellular matrix.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kinsella, MG (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramovitch R, 1998, FEBS LETT, V425, P441, DOI 10.1016/S0014-5793(98)00283-X; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BARKALOW FJ, 1994, J BIOL CHEM, V269, P3957; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collo G, 1999, J CELL SCI, V112, P569; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FOUSER L, 1991, J BIOL CHEM, V266, P18345; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; Gutierrez P, 1997, CARDIOVASC PATHOL, V6, P271, DOI 10.1016/S1054-8807(97)00001-X; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocking AM, 1998, MATRIX BIOL, V17, P1; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Kinsella MG, 1997, J BIOL CHEM, V272, P318; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KINSELLA MG, 1988, J BIOL CHEM, V263, P19222; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; Maniatis T., 1982, MOL CLONING; MANN DM, 1990, J BIOL CHEM, V265, P5317; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Podesta F, 1997, DIABETOLOGIA, V40, P879, DOI 10.1007/s001250050763; POGANY G, 1992, BIOCHEM BIOPH RES CO, V189, P165, DOI 10.1016/0006-291X(92)91539-3; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; REIDY MA, 1982, ARTERIOSCLEROSIS, V2, P216, DOI 10.1161/01.ATV.2.3.216; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; SCHWARTZ SM, 1981, ARTERIOSCLEROSIS, V1, P107, DOI 10.1161/01.ATV.1.2.107; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; THIESZEN SL, 1995, MATRIX BIOL, V14, P573, DOI 10.1016/S0945-053X(05)80006-X; TOOLE BP, 1968, ARCH BIOCHEM BIOPHYS, V128, P567, DOI 10.1016/0003-9861(68)90064-7; TOOLE BP, 1968, BIOCHEM J, V109, P857, DOI 10.1042/bj1090857; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOLKER W, 1987, EUR J CELL BIOL, V45, P72; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; WOODS A, 1992, ADV EXP MED BIOL, V313, P87; WOODS A, 1988, EXP CELL RES, V177, P272, DOI 10.1016/0014-4827(88)90461-2; Wu C, 1997, HISTOL HISTOPATHOL, V12, P233; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yoshihara T, 1997, ANTICANCER RES, V17, P833	75	73	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13924	13932		10.1074/jbc.275.18.13924	http://dx.doi.org/10.1074/jbc.275.18.13924			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788518	hybrid			2022-12-27	WOS:000086925300105
J	Rausch, JW; Bona-Le Grice, MK; Nymark-McMahon, MH; Miller, JT; Le Grice, SFJ				Rausch, JW; Bona-Le Grice, MK; Nymark-McMahon, MH; Miller, JT; Le Grice, SFJ			Interaction of p55 reverse transcriptase from the Saccharomyces cerevisiae retrotransposon Ty3 with conformationally distinct nucleic acid duplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER-BINDING-SITE; RNASE-H-DOMAIN; STRAND DNA-SYNTHESIS; ESCHERICHIA-COLI; RIBONUCLEASE-H; ANGSTROM RESOLUTION; FOOTPRINT ANALYSIS; CRYSTAL-STRUCTURE; POLYPURINE TRACT	The 55-kDa reverse transcriptase (RT) domain of the Ty3 POL3 open reading frame was purified and evaluated on conformationally distinct nucleic acid duplexes. Purified enzyme migrated as a monomer by size exclusion chromatography. Enzymatic footprinting indicate Ty3 RT protects template nucleotides +7 through -21 and primer nucleotides -1 through -24, Contrary to previous data with retroviral enzymes, a 4-base pair region of the template-primer duplex remained nuclease accessible. The C-terminal portion of Ty3 RT encodes a functional RNase H domain, although the hydrolysis profile suggests an increased spatial separation between the catalytic centers. Despite conservation of catalytically important residues in the RNase H domain, Fe2+ fails to replace Mg2+ in the RNase H catalytic center for localized generation of hydroxyl radicals, again suggesting this domain may be structurally distinct from its retroviral counterparts. RNase H Specificity was investigated using a model system challenging the enzyme to select the polypurine tract primer from within an RNA/DNA hybrid, extend this into (+) DNA, and excise the primer from nascent DNA, purified RT catalyzed each of these three steps but was almost inactive on a non-polypurine tract RNA primer. Our studies provide the first detailed characterization of the enzymatic activities of a retrotransposon reverse transcriptase.	NCI, HIV Drug Resistance Program, Div Basic Sci, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Sci Applicat Int Corp, Frederick, MD 21702 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); University of California System; University of California Irvine	Rausch, JW (corresponding author), NCI, HIV Drug Resistance Program, Div Basic Sci, Frederick Canc Res & Dev Ctr, Bldg 535, Frederick, MD 21702 USA.				NIGMS NIH HHS [GM 52263, GM33281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263, R01GM033281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BOEKE JD, 1998, RETROVIRUSES, P343; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; Burnett BP, 1997, P NATL ACAD SCI USA, V94, P7210, DOI 10.1073/pnas.94.14.7210; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; Cristofari G, 1999, J BIOL CHEM, V274, P36643, DOI 10.1074/jbc.274.51.36643; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Kashiwagi T, 1996, PROTEIN ENG, V9, P857, DOI 10.1093/protein/9.10.857; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; KEENEY JB, 1995, MOL CELL BIOL, V15, P217, DOI 10.1128/MCB.15.1.217; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; Kirchner J, 1996, J VIROL, V70, P4737, DOI 10.1128/JVI.70.7.4737-4747.1996; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lauermann V, 1997, EMBO J, V16, P6603, DOI 10.1093/emboj/16.21.6603; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; Li Y, 1997, VIROLOGY, V238, P273, DOI 10.1006/viro.1997.8837; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; Misra HS, 1998, J BIOL CHEM, V273, P9785, DOI 10.1074/jbc.273.16.9785; Nymark-McMahon MH, 1999, J VIROL, V73, P453, DOI 10.1128/JVI.73.1.453-465.1999; Perach M, 1999, VIROLOGY, V259, P176, DOI 10.1006/viro.1999.9761; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 1996, J MOL BIOL, V257, P500, DOI 10.1006/jmbi.1996.0181; SPRINGER MS, 1993, MOL BIOL EVOL, V10, P1370; Stetor SR, 1999, BIOCHEMISTRY-US, V38, P3656, DOI 10.1021/bi982764l; TAYLOR JM, 1975, J VIROL, V16, P553, DOI 10.1128/JVI.16.3.553-558.1975; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; Wilhelm M, 1997, NUCLEIC ACIDS RES, V25, P2161, DOI 10.1093/nar/25.11.2161; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; Zhang ZJ, 1998, RNA, V4, P394	55	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13879	13887		10.1074/jbc.275.18.13879	http://dx.doi.org/10.1074/jbc.275.18.13879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788512	hybrid			2022-12-27	WOS:000086925300099
J	Vaisman, A; Chaney, SG				Vaisman, A; Chaney, SG			The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; CALF THYMUS DNA; ANTICANCER DRUG CISPLATIN; HUMAN-CELLS; IN-VITRO; MUTATIONAL SPECIFICITY; REPLICATIVE BYPASS; MUTATOR PHENOTYPE; MAMMALIAN-CELLS; GAPPED DNA	DNA polymerase beta (pol beta) is the only mammalian DNA polymerase identified to date that can catalyze extensive bypass of platinum-DNA adducts in vitro. Previous studies suggest that DNA synthesis by pol beta is distributive on primed single-stranded DNA and processive on gapped DNA, The data presented in this paper provide an analysis of translesion synthesis past cisplatin- and oxaliplatin-DNA adducts by pol beta functioning in both distributive and processive modes using primer extension and steady-state kinetic experiments. Translesion synthesis past Pt-DNA adducts was greater with gapped DNA templates than with single-stranded DNA templates. In the processive mode pol beta did not discriminate between cisplatin and oxaliplatin adducts, while in the distributive mode it displayed about 2-fold increased ability for translesion synthesis past oxaliplatin compared with cisplatin adducts. The differentiation between cisplatin and oxaliplatin adducts resulted from a K-m-mediated increase in the efficiency of dCTP incorporation across from the 3'-G of oxaliplatin-GG adducts. Rates of misincorporation across platinated guanines determined by the steady-state kinetic assay were higher in reactions with primed single-stranded templates than with gapped DNA and a slight increase in the misincorporation of dTTP across from the 3'-G was found for oxaliplatin compared with cisplatin adducts.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Chaney, SG (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Vaisman, Alexandra/C-3766-2013	Vaisman, Alexandra/0000-0002-2521-1467				Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRADLEY LJN, 1993, BIOCHEMISTRY-US, V32, P982, DOI 10.1021/bi00054a031; BUBLEY GJ, 1991, MOL CARCINOGEN, V4, P397, DOI 10.1002/mc.2940040512; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; CARIELLO NF, 1992, CANCER RES, V52, P2866; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Efrati E, 1997, J BIOL CHEM, V272, P2559; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; GIBBONS GR, 1991, CARCINOGENESIS, V12, P2253, DOI 10.1093/carcin/12.12.2253; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; JOHNSON NP, 1980, CANCER RES, V40, P1463; KASHANISABET M, 1990, EUR J CANCER, V26, P383, DOI 10.1016/0277-5379(90)90238-O; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRAKER AJ, 1988, CANCER LETT, V38, P307, DOI 10.1016/0304-3835(88)90022-5; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; MAMENTA EL, 1994, CANCER RES, V54, P3500; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; PILLAIRE MJ, 1994, NUCLEIC ACIDS RES, V22, P2519, DOI 10.1093/nar/22.13.2519; Saris CP, 1996, CARCINOGENESIS, V17, P2763, DOI 10.1093/carcin/17.12.2763; SCANLON KJ, 1989, CANC INVEST, V7, P563; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; Vaisman A, 1998, CANCER RES, V58, P3579; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Woynarowski JM, 1998, MOL PHARMACOL, V54, P770, DOI 10.1124/mol.54.5.770	41	89	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13017	13025		10.1074/jbc.275.17.13017	http://dx.doi.org/10.1074/jbc.275.17.13017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777605	Green Published, hybrid			2022-12-27	WOS:000086762300089
J	Ling, L; Goeddel, DV				Ling, L; Goeddel, DV			MIP-T3, a novel protein linking tumor necrosis factor receptor-associated factor 3 to the microtubule network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOTOXIN-BETA RECEPTOR; TERMINAL KINASE; CELL-DEATH; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; CYTOPLASMIC DOMAIN; FACTOR FAMILY; TRAF FAMILY; IN-VIVO	In this study, we report the identification of a novel tumor necrosis factor receptor-associated factor 3 (TRAF3)-interacting protein designated MIP-T3. MIP-T3 is a 83-kDa protein with no significant homology to known mammalian proteins. MIP-T3 mRNA and TRAF3 mRNA are ubiquitously expressed, and TRAF3 is the only TRAF protein to interact with MIP-T3. The MIP-T3-TRAF3 interaction requires the coiled-coil TRAF-N domain of TRAF3. To our knowledge, this is the first case of a TRAF-binding protein that interacts with a single member of the TRAF family specifically through a TRAF-N coiled coil domain. MIP-T3 binds to Taxol-stabilized microtubules and to tubulin in vitro, and MIP-T3 recruits TRAF3 to microtubules when both proteins are overexpressed in HeLa cells. In a 293 cell line stably expressing CD40, TRAF3 is released from the TRAF3-MIP-T3 complex and recruited to the CD40 receptor upon CD40 ligand stimulation. MIP-T3 may provide II novel mechanism in sequestering TRAF3 to the cytoskeletal network.	Tularik Inc, S San Francisco, CA 94080 USA		Ling, L (corresponding author), Tularik Inc, 2 Corp Dr, S San Francisco, CA 94080 USA.							Aizawa S, 1997, J BIOL CHEM, V272, P2042; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Chen YD, 1996, HEMATOPATHOL MOL HEM, V10, P63; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Grammer AC, 1998, J IMMUNOL, V161, P1183; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Heald R, 1999, CURR OPIN STRUC BIOL, V9, P268, DOI 10.1016/S0959-440X(99)80037-2; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; ISHIDA TK, 1996, P NATL ACAD SCI USA, V93, P6437; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; Krajewski S, 1997, J IMMUNOL, V159, P5841; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; PIERRE P, 1994, J CELL SCI, V107, P1909; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shea TB, 1998, ADV EXP MED BIOL, V446, P181; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; WARREN WD, 1995, J IMMUNOL, V155, P5637; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	54	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23852	23860		10.1074/jbc.M001095200	http://dx.doi.org/10.1074/jbc.M001095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10791955	hybrid			2022-12-27	WOS:000088564200062
J	Ambesi, A; Miranda, M; Allen, KE; Slayman, CW				Ambesi, A; Miranda, M; Allen, KE; Slayman, CW			Stalk segment 4 of the yeast plasma membrane H+-ATPase - Mutational evidence for a role in the E-1-E-2 conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SHEEP ALPHA-1 ISOFORM; SARCOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CATION-BINDING; FUNCTIONAL CONSEQUENCES; TRANSMEMBRANE DOMAIN; SECRETORY VESICLES; CONSERVED RESIDUES; CA2+ TRANSPORT	In the P-2-type ATPases, there is growing evidence that four alpha-helical stalk segments connect the cytoplasmic part of the molecule, responsible for ATP binding and hydrolysis, to the membrane-embedded part that mediates cation transport. The present study has focused on stalk segment 4, which displays a significant degree of sequence conservation among P-2-ATPases. When site-directed mutants in this region of the yeast plasma membrane H+-ATPase were constructed and expressed in secretory vesicles, more than half of the amino acid substitutions led to a severalfold decrease in the rate of ATP hydrolysis, although they had little or no effect on the coupling between hydrolysis and transport. Strikingly, mutant ATPases bearing single substitutions of 13 consecutive residues from Ile-359 through Gly-371 were highly resistant to inorganic orthovanadate, with IC50 values at least 10-fold above those seen in the wild-type enzyme. Most of the same mutants also displayed a significant reduction in the K-m for MgATP and an increase in the pH optimum for ATP hydrolysis. Taken together, these changes in kinetic behavior point to a shift in equilibrium from the E-2 conformation of the ATPase toward the E-1 conformation. The residues from Ile-359 through Gly-371 would occupy three full turns of an alpha-helix, suggesting that this portion of stalk segment 4 may provide a conformationally active link between catalytic sites in the cytoplasm and cation-binding sites in the membrane.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Slayman, CW (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1982, J BIOL CHEM, V257, P421; Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; Dutra MB, 1998, J BIOL CHEM, V273, P17411, DOI 10.1074/jbc.273.28.17411; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fiske CH, 1925, J BIOL CHEM, V66, P375; Garnett C, 1996, BIOCHEMISTRY-US, V35, P11019, DOI 10.1021/bi960718k; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; RAO R, 1993, J BIOL CHEM, V268, P6708; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SetoYoung D, 1996, J BIOL CHEM, V271, P581, DOI 10.1074/jbc.271.1.581; Soteropoulos P, 1998, J BIOL CHEM, V273, P26426, DOI 10.1074/jbc.273.41.26426; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; ULASZEWSKI S, 1987, MOL GEN GENET, V207, P38, DOI 10.1007/BF00331488; VANDYCK L, 1990, EUR J BIOCHEM, V194, P785; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1992, J BIOL CHEM, V267, P25739; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	41	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20545	20550		10.1074/jbc.M001682200	http://dx.doi.org/10.1074/jbc.M001682200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10791959	hybrid			2022-12-27	WOS:000088084500047
J	Thanbichler, M; Bock, A; Goody, RS				Thanbichler, M; Bock, A; Goody, RS			Kinetics of the interaction of translation factor SelB from Escherichia coli with guanosine nucleotides and selenocysteine insertion sequence RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR SELB; INDUCIBLE FORMATE DEHYDROGENASE; H-RAS P21; MESSENGER-RNA; SELENOPROTEIN SYNTHESIS; OPAL UGA; PURIFICATION; PROTEIN; POLYMERASE; DOMAIN	The kinetics of the interaction of GTP and GDP with SelB, the specific translation factor for the incorporation of selenocysteine into proteins, have been investigated using the stopped-flow method. Useful signals were obtained using intrinsic (i.e. tryptophan) fluorescence, the fluorescence of methylanthraniloyl derivatives of nucleotides, or fluorescence resonance energy transfer from tryptophan to the methylanthraniloyl group. The affinities of SelB for GTP (K-d = 0.74 mu M) and GDP (K-d = 13.4 mu M) were considerably lower than those of other translation factors. Of functional significance is the fact that the rate constant for GDP release from its complex with SelB (15 s(-1)) is many orders of magnitude larger than for elongation factor Tu, explaining why a GDP/GTP exchange factor is not required for the action of SelB. In contrast, the rate of release of GTP is 2 orders of magnitude slower and not significantly faster than for elongation factor Tu. Using a fluorescently labeled 17-nucleotide RNA minihelix that represents a binding site for the protein and that is part of the fdhF selenocysteine insertion sequence element positioned immediately downstream of the UGA triplet coding for selenocysteine incorporation, the kinetics of the interaction were studied. The high affinity of the interaction (K-d similar to 1 nM) appeared to be increased even further when seleno-cysteyl-tRNA(Sec) was bound to SelB, but to be independent of the presence or nature of the guanosine nucleotide at the active site. These results suggest that the affinity of SelB for its RNA binding site is maximized when charged tRNA is bound and decreases to allow dissociation and reading of codons downstream of the selenocysteine codon after selenocysteine peptide bond formation.	Max Planck Inst Mol Physiol, D-44026 Dortmund, Germany; Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany	Max Planck Society; University of Munich	Goody, RS (corresponding author), Max Planck Inst Mol Physiol, Rheinlanddamm 201, D-44026 Dortmund, Germany.	goody@mpi-do.mpg.de	Goody, Roger S/J-8845-2014; Thanbichler, Martin/E-6035-2010	Goody, Roger S/0000-0002-0772-0444; 				BARON C, 1991, J BIOL CHEM, V266, P20375; BARON C, 1993, P NATL ACAD SCI USA, V90, P4181, DOI 10.1073/pnas.90.9.4181; BERG BL, 1991, J BIOL CHEM, V266, P22386; BERG BL, 1991, J BIOL CHEM, V266, P22380; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORCHHAMMER K, 1990, J BIOL CHEM, V265, P9346; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P1005, DOI 10.1093/nar/15.3.1005; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Huttenhofer A, 1998, BIOCHEMISTRY-US, V37, P885, DOI 10.1021/bi972298k; Huttenhofer A, 1998, COLD SPRING HARBOR M, P603; Huttenhofer A, 1996, RNA, V2, P354; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kromayer M, 1996, J MOL BIOL, V262, P413, DOI 10.1006/jmbi.1996.0525; Liu ZS, 1998, NUCLEIC ACIDS RES, V26, P896, DOI 10.1093/nar/26.4.896; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suppmann S, 1999, EMBO J, V18, P2284, DOI 10.1093/emboj/18.8.2284; WAGNER A, 1995, BIOCHEMISTRY-US, V34, P12535, DOI 10.1021/bi00039a007; WYATT JR, 1991, BIOTECHNIQUES, V11, P764	26	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20458	20466		10.1074/jbc.M002496200	http://dx.doi.org/10.1074/jbc.M002496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781605	hybrid			2022-12-27	WOS:000088084500034
J	Lauhon, CT; Kambampati, R				Lauhon, CT; Kambampati, R			The iscS gene in Escherichia coli is required for the biosynthesis of 4-thiouridine, thiamin, and NAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; NIFS-LIKE PROTEIN; AZOTOBACTER-VINELANDII; TRANSFER-RNA; SALMONELLA-TYPHIMURIUM; SELENOCYSTEINE LYASE; CLUSTER; IDENTIFICATION; PURIFICATION; CLONING	IscS, a cysteine desulfurase implicated in the repair of Fe-S clusters, was recently shown to act as a sulfurtransferase in the biosynthesis of 4-thiouridine (s(4)U) in tRNA (Kambampati, R., and Lauhon, C. T. (1999) Biochemistry 88, 16561-16568), In frame deletion of the iscS gene in Escherichia coli results in a mutant strain that lacks s(4)U in its tRNA. Assays of cell-free extracts isolated from the iscS(-) strain confirm the complete loss of tRNA sulfurtransferase activity. In addition to lacking s(4)U, the iscS(-) strain requires thiamin and nicotinic acid for growth in minimal media. The thiamin requirement can be relieved by the addition of the thiamin precursor 5-hydroxyethyl-4-methylthiazole, indicating that iscS is required specifically for thiazole biosynthesis, The growth rate of the iscS(-) strain is half that of the parent strain in rich medium, When the iscS(-) strain is switched from rich to minimal medium containing thiamin and nicotinate, growth is preceded by a considerable lag period relative to the parent strain. Addition of isoleucine results in a significant reduction in the duration of this lag phase. To examine the thiazole requirement, we have reconstituted the in vitro biosynthesis of ThiS thiocarboxylate, the ultimate sulfur donor in thiazole biosynthesis, and we show that IscS mobilizes sulfur for transfer to the C-terminal carboxylate of ThiS, ThiI, a known factor involved in both thiazole and s(4)U synthesis, stimulates this sulfur transfer step by 7-fold. Extracts from the iscS(-) strain show significantly reduced activity in the in vitro synthesis of ThiS thiocarboxylate, Transformation of the iscS(-) strain with an iscS expression plasmid complemented all of the observed phenotypic effects of the deletion mutant. Of the remaining two nifS-like genes in E, coli, neither can complement loss of iscS when each is overexpressed in the iscS(-) strain, Thus, IscS plays a significant and specific role at the top of a potentially broad sulfur transfer cascade that is required for the biosynthesis of thiamin, NAD, Fe-S clusters, and thionucleosides.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Lauhon, CT (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.	clauhon@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057002] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57002] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRELL JW, 1971, J BIOL CHEM, V246, P294; AJITKUMAR P, 1988, MICROBIOL REV, V52, P103, DOI 10.1128/MMBR.52.1.103-113.1988; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; DRACZYNSKALUSIAK B, 1992, FREE RADICAL BIO MED, V13, P689, DOI 10.1016/0891-5849(92)90042-F; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; Flint DH, 1996, J BIOL CHEM, V271, P16068; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; LIPSETT MN, 1972, J BIOL CHEM, V247, P1458; LIPSETT MN, 1978, J BACTERIOL, V135, P993, DOI 10.1128/JB.135.3.993-997.1978; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; PETES TD, 1978, GENE, V4, P37, DOI 10.1016/0378-1119(78)90013-6; RYALS J, 1982, J BACTERIOL, V151, P899, DOI 10.1128/JB.151.2.899-904.1982; Sticht H, 1998, PROG BIOPHYS MOL BIO, V70, P95, DOI 10.1016/S0079-6107(98)00027-3; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zuurmond AM, 1999, MOL GEN GENET, V260, P603, DOI 10.1007/s004380050934	38	152	160	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20096	20103		10.1074/jbc.M002680200	http://dx.doi.org/10.1074/jbc.M002680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10781607	hybrid			2022-12-27	WOS:000087941300090
J	Palmeri, D; van Zante, A; Huang, CC; Hemmerich, S; Rosen, SD				Palmeri, D; van Zante, A; Huang, CC; Hemmerich, S; Rosen, SD			Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; ADHESION MOLECULE; L-SELECTIN; LYMPHOCYTE RECIRCULATION; PROTEIN; IDENTIFICATION; RECRUITMENT; LIGANDS; CLONING	During the process of lymphocyte homing to secondary lymphoid organs, such as lymph nodes and tonsils, lymphocytes interact with and cross a specialized microvasculature, known as high endothelial venules, There is a great deal of information available about the first steps in the homing cascade, but molecular understanding of lymphocyte transmigration through the intercellular junctions of high endothelial venules is lacking. In analyzing expressed sequence tags from a cDNA library prepared from human tonsillar high endothelial cells, we have identified a cDNA encoding a novel member of the immunoglobulin superfamily, The protein, which we have termed VE-JAM ("vascular endothelial junction-associated molecule"), contains two extracellular immunoglobulin-like domains, a transmembrane domain, and a relatively short cytoplasmic tail. VE-JAM is prominently expressed on high endothelial venules but is also present on the endothelia of other vessels. Strikingly, it is highly localized to the intercellular boundaries of high endothelial cells. VE-JAM is most homologous to a recently identified molecule known as Junctional Adhesion Molecule, which is concentrated at the intercellular boundaries of both epithelial and endothelial cells. Because the Junctional Adhesion Molecule has been strongly implicated in the processes of neutrophil and monocyte transendothelial migration, an analogous function of VE-JAM during lymphocyte homing is plausible.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA; Roche Biosci, Dept Resp Dis, Palo Alto, CA 94304 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roche Holding	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	sdr@itsa.ucsf.edu		Rosen, Steven/0000-0002-6245-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM23547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEKKEVOLD ES, LAB INVEST, V79, P32799; Barclay A. N, 1997, LEUKOCYTE ANTIGEN FA; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; Chen Z, 1997, BBA-MOL BASIS DIS, V1362, P6, DOI 10.1016/S0925-4439(97)00058-6; Cines DB, 1998, BLOOD, V91, P3527; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; EPSTEIN CJ, 1990, AM J MED GENET, P31; Girard JP, 1999, AM J PATHOL, V155, P2043, DOI 10.1016/S0002-9440(10)65523-X; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Harlow E., 1988, ANTIBODIES LAB MANUA; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Izawa D, 1999, INT IMMUNOL, V11, P1989, DOI 10.1093/intimm/11.12.1989; Katevuo K, 1999, J IMMUNOL, V162, P5685; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ozaki H, 1999, J IMMUNOL, V163, P553; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Small DH, 1998, NEUROCHEM RES, V23, P795, DOI 10.1023/A:1022471729291; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; WAGNER DD, 1993, THROMB HAEMOSTASIS, V70, P105; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4	39	187	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19139	19145		10.1074/jbc.M003189200	http://dx.doi.org/10.1074/jbc.M003189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10779521	hybrid			2022-12-27	WOS:000087815900069
J	Apletalina, EV; Muller, L; Lindberg, I				Apletalina, EV; Muller, L; Lindberg, I			Mutations in the catalytic domain of prohormone convertase 2 result in decreased binding to 7B2 and loss of inhibition with 7B2 C-terminal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE POLYPEPTIDE 7B2; PROTEIN 7B2; PROPROTEIN CONVERTASES; SUBSTRATE-SPECIFICITY; SECRETORY PATHWAY; ENZYMATIC CHARACTERIZATION; RMTC-6-23 CELLS; BASIC RESIDUES; STC-1 CELLS; HUMAN FURIN	Prohormone convertases 1 (PC1) and 2 (PC2) are members of a family of subtilisin-like proprotein convertases responsible for proteolytic maturation of a number of different prohormones and proneuropeptides. Although sharing more than 50% homology in their catalytic domains, PC1 and PC2 exhibit differences in substrate specificity and susceptibility to inhibitors. In addition to these differences, PC2, unlike PC1 and other members of the family, specifically binds the neuroendocrine protein 7B2. In order to identify determinants responsible for the specific properties of the PC2 catalytic domain, we compared its primary sequence with that of other PCs. This allowed us to distinguish a PCS-specific sequence at positions 242-248. We constructed two PC2 mutants in which residues 242 and 243 and residues 242-248 were replaced with the corresponding residues of PC1. Studies of in vivo cleavage of proenkephalin, in vivo production of alpha-MSH from proopiomelanocortin, and in vitro cleavage of a PCB-specific artificial substrate by mutant PC2s did not reveal profound alterations. On the other hand, both mutant pro-PCBs exhibited a considerably reduced ability to bind to 21-kDa 7B2. In addition, inhibition of mutant PC2-(242-248) by the potent natural inhibitor 7B2 CT peptide was almost completely abolished. Taken together, our results show that residues 242-248 do not play a significant role in defining the substrate specificity of PC2 but do contribute greatly to binding 7B2 and are critical for inhibition with the 7B2 CT peptide.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@Lsumc.edu	muller, laurent/S-1990-2016; Lindberg, Iris/Q-3825-2019	muller, laurent/0000-0001-9634-4323; 	NIDA NIH HHS [R56 DA005084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703, DK 49703] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; Apletalina EV, 2000, BIOCHEM BIOPH RES CO, V267, P940, DOI 10.1006/bbrc.1999.2060; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; Barbero P, 1999, BIOCHEM BIOPH RES CO, V257, P473, DOI 10.1006/bbrc.1999.0495; Benjannet S, 1998, FEBS LETT, V428, P37, DOI 10.1016/S0014-5793(98)00480-3; BENJANNET S, 1995, FEBS LETT, V362, P151, DOI 10.1016/0014-5793(95)00228-2; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; Coates LC, 1997, J NEUROCHEM, V68, P828; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Johanning K, 1996, J NEUROCHEM, V66, P898; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; LINDBERG I, 1986, BIOCHEM BIOPH RES CO, V139, P1024, DOI 10.1016/S0006-291X(86)80280-7; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; Lindberg I., 1995, METH NEUROSCI, V23, P94; LIPKIND G, 1995, J BIOL CHEM, V270, P13277, DOI 10.1074/jbc.270.22.13277; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; Muller L, 1999, J BIOL CHEM, V274, P21471, DOI 10.1074/jbc.274.30.21471; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; PAQUET L, 1994, J BIOL CHEM, V269, P19279; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Scougall K, 1998, BIOCHEM J, V334, P531, DOI 10.1042/bj3340531; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; YI Z, 1993, J BIOL CHEM, V268, P5615; Yoon J, 1997, ENDOCRINOLOGY, V138, P3620, DOI 10.1210/en.138.9.3620; Yoon JY, 1997, J BIOL CHEM, V272, P9450; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158	58	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14667	14677		10.1074/jbc.275.19.14667	http://dx.doi.org/10.1074/jbc.275.19.14667			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799554	hybrid			2022-12-27	WOS:000087006900088
J	Bosc, DG; Graham, KC; Saulnier, RB; Zhang, CJ; Prober, D; Gietz, RD; Litchfield, DW				Bosc, DG; Graham, KC; Saulnier, RB; Zhang, CJ; Prober, D; Gietz, RD; Litchfield, DW			Identification and characterization of CKIP-1, a novel pleckstrin homology domain-containing protein that interacts with protein kinase CK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY BETA-SUBUNIT; RECEPTOR SUBSTRATE IRS-1; CASEIN KINASE-2; GROWTH-FACTOR; INSULIN-RECEPTOR; ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; SIGNALING MOLECULES; CELLULAR-REGULATION; ESCHERICHIA-COLI	The catalytic subunits of protein kinase CK2, CK2 alpha and CK2 alpha', are closely related to each other but exhibit functional specialization, To test the hypothesis that specific functions of CK2 alpha and CK2 alpha' are mediated by specific interaction partners, we used the yeast two-hybrid system to identify CK2 alpha- or CK2 alpha'-binding proteins. We report the identification and characterization of a novel CK2-interacting protein, designated CKIP-1, that interacts with CK2 alpha, but not CK2 alpha', in the yeast two-hybrid system. CKIP-1 also interacts with CK2 alpha in vitro and is co-immunoprecipitated from cell extracts with epitope-tagged CK2 alpha and an enhanced green fluorescent protein fusion protein encoding CKIP-1 (i.e. EGFP-CKIP-1) when they are co-expressed. CK2 activity is detected in anti-CKIP-1 immunoprecipitates performed with extracts from non-transfected cells indicating that CKIP-1 and CK2 interact under physiological conditions, The CKIP-1 cDNA is broadly expressed and encodes a protein with a predicted molecular weight of 46,000, EGFP-CKIP-1 is localized within the nucleus and at the plasma membrane. The plasma membrane localization is dependent on the presence of an amino-terminal pleckstrin homology domain. We postulate that CKIP-1 is a non-enzymatic regulator of one isoform of CK2 (i.e. CK2 alpha) with a potential role in targeting CK2 alpha to a particular cellular location.	Univ Western Ontario, Hlth Sci Ctr, Dept Biochem, London, ON N6A 5C1, Canada; Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada	London Health Sciences Centre; University of Manitoba; Children's Hospital Research Institute of Manitoba; Western University (University of Western Ontario); University of Manitoba	Litchfield, DW (corresponding author), Univ Western Ontario, Hlth Sci Ctr, Dept Biochem, London, ON N6A 5C1, Canada.	litchfi@julian.uwo.ca	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL K, 1995, ONCOGENE, V11, P1971; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORVERA S, 1988, J BIOL CHEM, V263, P3116; DAVLETOV B, 1993, J BIOL CHEM, V268, P6816; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; Gotz C, 1996, ONCOGENE, V13, P391; GRANDE J, 1988, FEBS LETT, V232, P130, DOI 10.1016/0014-5793(88)80401-0; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Litchfield DW, 1996, BIOCHEM CELL BIOL, V74, P541, DOI 10.1139/o96-458; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Sarrouilhe D, 1998, BBA-MOL CELL RES, V1403, P199, DOI 10.1016/S0167-4889(98)00038-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDTSPANIOL I, 1993, CELL MOL BIOL RES, V39, P761; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; Tawfic S, 1997, J CELL BIOCHEM, V64, P499; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WAGNER P, 1994, INT J ONCOL, V4, P491; WEI TQ, 1993, ARCH BIOCHEM BIOPHYS, V307, P206, DOI 10.1006/abbi.1993.1580; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	83	86	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14295	14306		10.1074/jbc.275.19.14295	http://dx.doi.org/10.1074/jbc.275.19.14295			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799509	hybrid			2022-12-27	WOS:000087006900041
J	Li, EG; Stupack, DG; Brown, SL; Klemke, R; Schlaepfer, DD; Nemerow, GR				Li, EG; Stupack, DG; Brown, SL; Klemke, R; Schlaepfer, DD; Nemerow, GR			Association of p130(CAS) with phosphatidylinositol-3-OH kinase mediates adenovirus cell entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE-PHOSPHATASE; DIRECT BINDING; GROWTH-FACTOR; PHOSPHOINOSITIDE-3-OH KINASE; SUBSTRATE P130(CAS); ALPHA(V) INTEGRINS; SH3 DOMAINS; SRC KINASE; IN-VIVO	The Crk-associated substrate, p130(CAS), has been implicated in the regulation of the actin cytoskeleton following ligation of cell integrins with the extracellular matrix. Integrin-mediated cell adhesion involves p130(CAS) association with focal adhesion kinase (p125(FAK)). Internalization/cell entry of type 2 and type 5 adenoviruses (Ad) is also mediated by alpha(v) integrins. However, expression of dominant negative forms of p125FAK does not alter virus entry, and Ad entry occurs normally in p125(FAK)-deficient fibroblasts. We now provide evidence that Ad internalization, a process which is mediated by LY,integrins, also requires p130(CAS) and phosphatidylinositol-3-OH kinase (PI 3-kinase). Ad induces p130(CAS) phosphorylation and inhibition of p130(CAS) phosphorylation by tyrphostin and genistein, or expression of the substrate domain deleted p130(CAS) blocks Ad internalization. p130(CAS) was also found to associate with the p85 subunit of PI 3-kinase through its proline-rich domain during virus internalization and expression of p130(CAS) containing a deleted proline-rich domain (PRD) inhibited adenovirus cell entry. We showed further that the RPLPSPP motif in the proline-rich region of p130(CAS) interacts with the SH3 domain of p85/PI 3-kinase. These studies reveal the molecular basis by which p130(CAS) coordinates the signaling pathways involved in integrin-mediated Ad endocytosis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Nemerow, GR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gnemerow@scripps.edu	Li, Erguang/N-7676-2019; Li, Erguang/C-2782-2013	Li, Erguang/0000-0002-3065-1336; Li, Erguang/0000-0002-3065-1336	NATIONAL EYE INSTITUTE [R01EY011431] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL054532] Funding Source: NIH RePORTER; NEI NIH HHS [EY11431] Funding Source: Medline; NHLBI NIH HHS [HL54532] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alrutz MA, 1998, P NATL ACAD SCI USA, V95, P13658, DOI 10.1073/pnas.95.23.13658; Astier A, 1997, J BIOL CHEM, V272, P228; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; ILLC D, 1995, NATURE, V377, P539; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Li E, 1998, J VIROL, V72, P8806, DOI 10.1128/JVI.72.11.8806-8812.1998; Li EG, 1998, J VIROL, V72, P2055, DOI 10.1128/JVI.72.3.2055-2061.1998; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Manie SN, 1996, BLOOD, V87, P1855; Mathias P, 1998, J VIROL, V72, P8669, DOI 10.1128/JVI.72.11.8669-8675.1998; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Nemerow GR, 1999, MICROBIOL MOL BIOL R, V63, P725, DOI 10.1128/MMBR.63.3.725-734.1999; Nojima Y, 1996, Hum Cell, V9, P169; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; PARSONS JT, 1994, J CELL SCI, P109; PATTERSON S, 1983, J GEN VIROL, V64, P1091, DOI 10.1099/0022-1317-64-5-1091; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; Wang KN, 1998, J VIROL, V72, P3455, DOI 10.1128/JVI.72.4.3455-3458.1998; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	61	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14729	14735		10.1074/jbc.275.19.14729	http://dx.doi.org/10.1074/jbc.275.19.14729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799562	hybrid			2022-12-27	WOS:000087006900096
J	Morita, YS; Acosta-Serrano, A; Buxbaum, LU; Englund, PT				Morita, YS; Acosta-Serrano, A; Buxbaum, LU; Englund, PT			Glycosyl phosphatidylinositol myristoylation in African trypanosomes - New intermediates in the pathway for fatty acid remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; CROSS-REACTING DETERMINANT; BLOOD-STREAM FORMS; PHOSPHOLIPASE-C; DEVELOPMENTAL VARIATION; BRUCEI; BIOSYNTHESIS; GLYCAN; PRECURSOR	Glycosyl phosphatidylinositol (GPI) anchors in the bloodstream form of Trypanosoma brucei are unusual in that their two fatty acids are myristate. The myristates are added in the final stages of GPI biosynthesis in a remodeling reaction. Remodeling occurs first at the sn-2 position of glycerol, involving removal of a longer fatty acid and subsequent attachment of myristate. The second myristate is then incorporated into the sn-l position, but the mechanism has been unclear due to the unavailability of a reliable cell-free system supporting complete remodeling. Here, we first refined the cell-free system (by removing Mn2+ ions), thereby allowing efficient production of the dimyristoylated GPI precursor. Using this improved system, we made three new discoveries concerning the pathway for fatty acid remodeling. First, we discovered a monomyristoylated GPI (known as glycolipid theta') as an intermediate involved in remodeling at the sn-1 position. Second, we found an alternative pathway for production of glycolipid theta, the first lyse intermediate in remodeling. The alternative pathway involves an inositol-acylated GPI known as glycolipid lyso-C'. Finally, we found that there is significant breakdown of GPIs during remodeling in the cell-free system, and we speculate that this breakdown has a regulatory role in GPI biosynthesis.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Englund, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Acosta-Serrano, Alvaro/L-5503-2015	Acosta-Serrano, Alvaro/0000-0002-2576-7959; Morita, Yasu/0000-0002-4514-9242	NIAID NIH HHS [AI21334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; BULOW R, 1989, J CELL SCI, V93, P233; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; Dang Q, 1997, TRENDS BIOCHEM SCI, V22, P317, DOI 10.1016/S0968-0004(97)01062-1; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DOERING TL, 1994, BIOCHEM J, V299, P741, DOI 10.1042/bj2990741; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LONSDALEECCLES JD, 1987, J PROTOZOOL, V34, P405, DOI 10.1111/j.1550-7408.1987.tb03201.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; NOLAN DP, 1991, EUR J BIOCHEM, V202, P411, DOI 10.1111/j.1432-1033.1991.tb16390.x; Ochatt CM, 1999, MOL BIOCHEM PARASIT, V103, P35, DOI 10.1016/S0166-6851(99)00111-5; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SHAK S, 1988, J IMMUNOL, V140, P2046; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; Werbovetz KA, 1997, MOL BIOCHEM PARASIT, V85, P1, DOI 10.1016/S0166-6851(96)02820-4; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14147	14154		10.1074/jbc.275.19.14147	http://dx.doi.org/10.1074/jbc.275.19.14147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799491	hybrid			2022-12-27	WOS:000087006900021
J	Nielsen, PK; Gho, YS; Hoffman, MP; Watanabe, H; Makino, M; Nomizu, M; Yamada, Y				Nielsen, PK; Gho, YS; Hoffman, MP; Watanabe, H; Makino, M; Nomizu, M; Yamada, Y			Identification of a major heparin and cell binding site in the LG4 module of the laminin alpha 5 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL GLOBULAR DOMAIN; DYSTROGLYCAN BINDING; SYNTHETIC PEPTIDES; BASEMENT-MEMBRANES; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; ADHESION; PERLECAN; AGRIN; MICE	The G domain of the laminin alpha chains consists of five homologous G modules (LG1-5) and has been implicated in various biological functions. In this study, we identified an active site for cell and heparin binding within the laminin alpha 5 G domain using recombinant proteins and synthetic peptides. Recombinant LG4, LG5, and LG4-5 modules were generated using a mammalian expression system. The LG4 and LG4-5 modules were highly active for cell binding, whereas the LG5 module alone showed only weak binding. Heparin inhibited cell binding to the LG4-5 module, whereas no inhibition was observed with EDTA or antibodies against the integrin beta(1) subunit. These results suggest that the LG4-5 module interacts with a cell surface receptor containing heparan sulfate but not with integrins. Solid-phase assays and surface plasmon resonance measurements demonstrated strong binding of the LG4 and LG4-5 modules to heparin with K-D values in the nanomolar range, whereas a 16-fold lower value was determined for the LG5 module. Treatment with glycosidases demonstrated that N-linked carbohydrates on the LG5 module are complex-type oligosaccharides. The LG4-5 module, devoid of N-linked carbohydrates, exhibited similar binding kinetics toward heparin. Furthermore, cell binding was unaffected by removal of N-linked glycosylation. To localize active sites on the LG4 module, various synthetic peptides were used to compete with binding of the tandem module to heparin and cells. Peptide F4 (AGQWHRVSVRWG) inhibited binding, whereas a scrambled peptide of F4 failed to compete binding. Alanine replacements demonstrated that one arginine residue within F4 was important for cell and heparin binding. Our results suggest a critical role of the LG4 module for heparan sulfate-containing receptor binding within the laminin alpha 5 chain.	NIDCR, Mol Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; NIDCR, Cell Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Hokkaido University	Yamada, Y (corresponding author), NIDCR, Mol Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Rm 405,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.							ADAC Z, 1999, J MOL BIOL, V287, P253; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; DEAN JW, 1990, J BIOL CHEM, V265, P12553; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; McDearmon EL, 1998, J BIOL CHEM, V273, P24139, DOI 10.1074/jbc.273.37.24139; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Pall EA, 1996, J BIOL CHEM, V271, P3817; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057	24	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14517	14523		10.1074/jbc.275.19.14517	http://dx.doi.org/10.1074/jbc.275.19.14517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799535	hybrid			2022-12-27	WOS:000087006900069
J	Pethe, K; Aumercier, M; Fort, E; Gatot, C; Locht, C; Menozzi, FD				Pethe, K; Aumercier, M; Fort, E; Gatot, C; Locht, C; Menozzi, FD			Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDETELLA-PERTUSSIS; COMPLEMENT RECEPTORS; SULFATE RECEPTORS; EPITHELIAL-CELLS; TUBERCULOSIS; PROTEINS; PHAGOCYTOSIS; GLYCOSAMINOGLYCANS; MICROORGANISMS; PURIFICATION	The mycobacterial adhesin heparin-binding hemagglutinin (HBHA) contains several lysine-rich repeats at its carboxyl-terminal end. Using truncated recombinant HBHA forms and hybrid proteins containing HBHA repeats grafted onto the Escherichia coli maltose-binding protein (MBP), we found that these repeats are responsible for heparin binding. Immunofluorescence microscopy studies revealed that their deletion abrogates binding of HBHA to human pneumocytes. Conversely, when fused to MBP, the HBHA repeats confer pneumocyte adherence properties to the hybrid protein. Treatment of pneumocytes with glycosaminoglycan-degrading enzymes showed that HBHA binding depends on the presence of heparan sulfate chains on the cell surface. The epitope of a monoclonal antibody that inhibits mycobacterial adherence to epithelial cells was mapped within the lysine-rich repeats, confirming their involvement in mycobacterial adherence to epithelial cells. Surface plasmon resonance analyses showed that recombinant HBHA binds to immobilized heparin with fast association kinetics (k(a) = 5.62 (+/- 0.10) x 10(5) M-1 s(-1)), whereas the dissociation kinetics were slower (k(d) = 0.015 (+/- 0.002) s(-1)), yielding a K-D value of 26 nM, Similar analyses with grafted MBP indicated similar kinetic constants, indicating that the carboxyl-terminal repeats contain the entire heparin-binding site of HBHA. The molecular characterization of the interactions of HBHA with epithelial glycosaminoglycans should help to better understand mycobacterial adherence within the lungs and may ultimately lead to new approaches for therapy or immunoprophylaxis.	Inst Pasteur Lille, Inst Biol Lille, INSERM, U447, F-59019 Lille, France; Inst Biol Lille, CNRS, Mecanismes Dev & Cancerisat, UMR 8526, F-59019 Lille, France; Comp Cell Culture Ctr SA, B-7140 Seneffe, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS)	Locht, C (corresponding author), Inst Pasteur Lille, Inst Biol Lille, INSERM, U447, 1 Rue A Calmette, F-59019 Lille, France.		Pethe, Kevin/D-4505-2011; Locht, Camille/L-3516-2018; Pethe, Kevin/F-9495-2015; Pethe, Kevin/L-1199-2013	Pethe, Kevin/0000-0003-0297-0150; Pethe, Kevin/0000-0003-0916-8873; Aumercier, Marc/0000-0002-0370-3452				BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Gagnon P., 1996, PURIFICATION TOOLS M; HANNAH JH, 1994, INFECT IMMUN, V62, P5010, DOI 10.1128/IAI.62.11.5010-5019.1994; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Maubert B, 1997, INFECT IMMUN, V65, P1251, DOI 10.1128/IAI.65.4.1251-1257.1997; Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; Menozzi FD, 1998, P NATL ACAD SCI USA, V95, P12625, DOI 10.1073/pnas.95.21.12625; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; OFEK I, 1995, ANNU REV MICROBIOL, V49, P239, DOI 10.1146/annurev.mi.49.100195.001323; PETHE K, 1999, AM SOC MICR GEN M MA; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Rostand KS, 1997, INFECT IMMUN, V65, P1; ROUSE DA, 1991, INFECT IMMUN, V59, P2595, DOI 10.1128/IAI.59.8.2595-2600.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434; STOKES RW, 1993, J IMMUNOL, V151, P7067; Su H, 1996, P NATL ACAD SCI USA, V93, P11143, DOI 10.1073/pnas.93.20.11143; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; VANPUTTEN JPM, 1995, EMBO J, V14, P21444; Wizemann TM, 1999, EMERG INFECT DIS, V5, P395, DOI 10.3201/eid0503.990310; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	39	100	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14273	14280		10.1074/jbc.275.19.14273	http://dx.doi.org/10.1074/jbc.275.19.14273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799506	hybrid			2022-12-27	WOS:000087006900038
J	Prieto, S; de la Cruz, BJ; Scheffler, IE				Prieto, S; de la Cruz, BJ; Scheffler, IE			Glucose-regulated turnover of mRNA and the influence of poly(A) tail length on half-life	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TURNOVER; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; BINDING-PROTEIN; SUCCINATE-DEHYDROGENASE; SEQUENCE ELEMENTS; DECAPPING ENZYME; ESCHERICHIA-COLI; YEAST-CELLS; EUKARYOTES	Glucose repression in Saccharomyces cerevisiae can now be seen to operate at two levels: regulation of transcription of certain genes and control of the half-life of the corresponding mRNAs (Scheffler, I. E,, de la Cruz, B. J,, and Prieto, S, (1998) Int. J, Biochem Cell Biol, 30, 1175-1193), For example, the steady state levels of SDH2 mRNA and SUC2 mRNA are significantly determined by their differential rates of turnover. A current model for the mechanism of mRNA turnover includes three distinct steps: a rate-limiting deadenylation, removal of the 5'-7-methyl-G (decapping), and 5'-3' exonuclease digestion. We have investigated the same three reactions during glucose-induced degradation of these transcripts. Our results indicate that while decapping (by Dcp1p) and 5'-3' exonuclease digestion (by Xrn1p) are obligatory steps for the rapid degradation of these mRNAs, the dependence on deadenylation is more complicated. At steady state in glycerol these transcripts have very short poly(A) tails but are nevertheless very stable; the addition of glucose causes immediate decapping and degradation without further deadenylation; in contrast, newly made SUC2 mRNA (after a shift from glucose to glycerol) has significantly longer poly(A) tails, and such transcripts are not rapidly degraded upon addition of glucose. A constitutive deadenylation reaction that is independent of the carbon source eventually makes the stability of these transcripts very sensitive to glucose. These results are interpreted in terms of a working hypothesis proposing a competition between translational initiation and decapping influenced by the carbon source. The presence of a long poly(A) tail may also affect this competition in favor of translational initiation and mRNA stabilization.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Scheffler, IE (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	ischeffler@ucsd.edu						ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; Anderson JSJ, 1996, CURR BIOL, V6, P780; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; Beretta L, 1998, J IMMUNOL, V160, P3269; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CEREGHINO GP, 1995, MOL BIOL CELL, V6, P1125, DOI 10.1091/mbc.6.9.1125; Cereghino GP, 1996, EMBO J, V15, P363, DOI 10.1002/j.1460-2075.1996.tb00366.x; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; Goldstein A, 1975, Methods Enzymol, V42, P504; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1993, BIOL YEAST SACCHAROM, V2, P193; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; MANGUS DA, 1998, METHODS COMPANION ME, V17, P28; Morrissey JP, 1999, YEAST, V15, P687, DOI 10.1002/(SICI)1097-0061(19990615)15:8<687::AID-YEA412>3.0.CO;2-L; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; NARANDA T, 1994, J BIOL CHEM, V269, P32286; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Porter D, 1997, ANAL BIOCHEM, V247, P279, DOI 10.1006/abio.1997.2059; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; RuizEchevarria MJ, 1996, TRENDS BIOCHEM SCI, V21, P433, DOI 10.1016/S0968-0004(96)10055-4; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Scheffler IE, 1998, INT J BIOCHEM CELL B, V30, P1175, DOI 10.1016/S1357-2725(98)00086-7; Sherman F., 1982, METHODS YEAST GENETI; STEVENS A, 1980, J BIOL CHEM, V255, P3080; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	58	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14155	14166		10.1074/jbc.275.19.14155	http://dx.doi.org/10.1074/jbc.275.19.14155			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799492	hybrid, Green Published			2022-12-27	WOS:000087006900022
J	Brown, AM; Kristal, BS; Effron, MS; Shestopalov, AI; Ullucci, PA; Sheu, KFR; Blass, JP; Cooper, AJL				Brown, AM; Kristal, BS; Effron, MS; Shestopalov, AI; Ullucci, PA; Sheu, KFR; Blass, JP; Cooper, AJL			Zn2+ inhibits alpha-ketoglutarate-stimulated mitochondrial respiration and the isolated alpha-ketoglutarate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ALZHEIMERS-DISEASE; PERMEABILITY TRANSITION; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; ZINC; BRAIN; CHANNELS; DEATH	Intracellular free Zn2+ is elevated in a variety of pathological conditions, including ischemia-reperfusion injury and Alzheimer's disease. Impairment of mitochondrial respiration is also associated with these pathological conditions. To test whether elevated Zn2+ and impaired respiration might be linked, respiration of isolated rat liver mitochondria was measured after addition of Zn2+. Zn2+ inhibition (K-i(app) = similar to 1 mu M) was observed for respiration stimulated by alpha-ketoglutarate at concentrations well within the range of intracellular Zn2+ reported for cultured hepatocytes, The be, complex is inhibited by Zn2+ (Link, T, A, and von Jagow, G, (1995) J. Biol. Chem, 270, 25001-25006), However, respiration stimulated by succinate (K-i(app) = similar to 6 mu M) was less sensitive to Zn2+, indicating the existence of a mitochondrial target for Zn2+ upstream from bc(1) complex. Purified pig heart cu-ketoglutarate dehydrogenase complex was strongly inhibited by Zn2+ (K-i(app) = 0 37 +/- 0.05 mu M). Glutamate dehydrogenase was more resistant (K-i(app) = 6 mu M), malate dehydrogenase was unaffected, and succinate dehydrogenase was stimulated by Zn2+, Zn2+ inhibition of alpha-ketoglutarate dehydrogenase complex required enzyme cycling and was reversed by EDTA. Reversibility was inversely related to the duration of exposure and the concentration of Zn2+. Physiological free Zn2+ may modulate hepatic mitochondrial respiration by reversible inhibition of the alpha-ketoglutarate dehydrogenase complex. In contrast, extreme or chronic elevation of intracellular Zn2+ could contribute to persistent reductions in mitochondrial respiration that have been observed in Zn2+-rich diseased tissues.	Cornell Univ, Coll Med, Burke Med Res Inst, Dementia Res Serv, White Plains, NY 10605 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; ESA Inc, Chelmsford, MA 01824 USA	Cornell University; Cornell University; Cornell University; Cornell University	Brown, AM (corresponding author), Cornell Univ, Coll Med, Burke Med Res Inst, Dementia Res Serv, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	abrown@burke.org	brown, abraham/R-8823-2019; Cooper, Arthur J.L./H-5171-2016		NIA NIH HHS [AG09014] Funding Source: Medline; NINDS NIH HHS [R01 NS038741, NS38741] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG009014] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANRAKU Y, 1975, J BIOCHEM-TOKYO, V78, P149; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; BATRA S, 1973, J CELL PHYSIOL, V82, P245, DOI 10.1002/jcp.1040820213; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Berg A, 1997, BIOL CHEM, V378, P617; BERNARD PA, 1984, BIOCHIM BIOPHYS ACTA, V766, P549, DOI 10.1016/0005-2728(84)90113-0; BLASS JP, 1976, NEW ENGL J MED, V295, P62, DOI 10.1056/NEJM197607082950202; BLASS JP, 1996, MOL MECH DEMENTIA, P91; BRIERLEY GP, 1966, BIOCHEM BIOPH RES CO, V24, P269, DOI 10.1016/0006-291X(66)90731-5; BUTTERWORTH RF, 1990, METAB BRAIN DIS, V5, P179, DOI 10.1007/BF00997071; CASH WD, 1968, ARCH BIOCHEM BIOPHYS, V128, P456, DOI 10.1016/0003-9861(68)90051-9; CASH WD, 1966, J BIOL CHEM, V241, P1745; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; CUNNANE SC, 1988, ZINC CLIN BIOCH SIGN; Danscher G, 1997, J NEUROSCI METH, V76, P53, DOI 10.1016/S0165-0270(97)00079-4; Davis M, 1997, ACT NEUR S, V70, P56; DAWSON RMC, 1986, DATA BIOCH RES, P404; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GARLAND PB, 1964, BIOCHEM J, V92, pC10, DOI 10.1042/bj0920010C; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; Gibson GE, 1998, J NEURAL TRANSM, V105, P855, DOI 10.1007/s007020050099; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; HUNTER FE, 1955, J BIOL CHEM, V216, P357; KITA K, 1984, J BIOL CHEM, V259, P3368; Kleineke JW, 1997, J PHARMACOL TOX MET, V38, P181, DOI 10.1016/S1056-8719(97)00094-4; KOBAYASHI K, 1983, J MOL CELL CARDIOL, V15, P359, DOI 10.1016/0022-2828(83)90320-6; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kristal BS, 1997, FREE RADICAL BIO MED, V22, P823, DOI 10.1016/S0891-5849(96)00428-5; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LAI JCK, 1986, J NEUROCHEM, V47, P1376, DOI 10.1111/j.1471-4159.1986.tb00768.x; LAWLIS VB, 1981, BIOCHEMISTRY-US, V20, P2512, DOI 10.1021/bi00512a023; LINK TA, 1995, J BIOL CHEM, V270, P25001, DOI 10.1074/jbc.270.42.25001; LORUSSO M, 1991, EUR J BIOCHEM, V197, P555, DOI 10.1111/j.1432-1033.1991.tb15944.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P33, DOI 10.1016/0006-3002(61)90512-1; Mastrogiacomo F, 1996, ANN NEUROL, V39, P592, DOI 10.1002/ana.410390508; MASTROGIACOMO F, 1994, ANN NEUROL, V35, P624, DOI 10.1002/ana.410350519; MASTROGIACOMO F, 1993, J NEUROCHEM, V61, P2007, DOI 10.1111/j.1471-4159.1993.tb07436.x; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Reed LJ., 1969, METHOD ENZYMOL, P55; RIGOBELLO MP, 1993, BIOCHEM BIOPH RES CO, V194, P1276, DOI 10.1006/bbrc.1993.1961; Ross GM, 1997, NAT MED, V3, P872, DOI 10.1038/nm0897-872; SARIS NEL, 1994, FEBS LETT, V356, P195, DOI 10.1016/0014-5793(94)01256-3; SCHUSTER SM, 1974, J BIOL CHEM, V249, P7159; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; TONINELLO A, 1982, FEBS LETT, V142, P63, DOI 10.1016/0014-5793(82)80220-2; Turan B, 1997, AM J PHYSIOL-HEART C, V272, pH2095, DOI 10.1152/ajpheart.1997.272.5.H2095; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WEISS RG, 1993, CIRCULATION, V87, P270, DOI 10.1161/01.CIR.87.1.270; Wudarczyk J, 1999, ARCH BIOCHEM BIOPHYS, V363, P1, DOI 10.1006/abbi.1998.1058; Zaidan E, 1997, BRAIN RES, V772, P23, DOI 10.1016/S0006-8993(97)00833-0; ZIADAN E, 1993, J CEREB BLOOD FLOW M, V13, P98; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	67	122	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13441	13447		10.1074/jbc.275.18.13441	http://dx.doi.org/10.1074/jbc.275.18.13441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788456	hybrid			2022-12-27	WOS:000086925300043
J	Ponce, J; Biton, B; Benavides, J; Avenet, P; Aragon, C				Ponce, J; Biton, B; Benavides, J; Avenet, P; Aragon, C			Transmembrane domain III plays an important role in ion binding and permeation in the glycine transporter GLYT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; SPINAL-CORD; DOPAMINE TRANSPORTER; GENE STRUCTURE; RAT-BRAIN; D-SERINE; CHANNEL; EXPRESSION; CLONING	The neuronal glycine transporter GLYT2 takes up glycine from the extracellular space by an electrogenic process where this neurotransmitter is co-transported with sodium and chloride ions. We report in this paper that tyrosine at position 289 of GLYT2a is crucial for ion coupling, glycine affinity and sodium selectivity, stressing the essential role played by this residue of transmembrane domain III in the mechanism of transport. Substitution to tryptophan (Y289W), phenylalanine (Y289F), or serine (Y289S), renders transporters unable to catalyze glycine uptake. Measurements of glycine evoked steady-state currents in transfected HEK-293 cells reveal EC50 values for glycine 17-fold (Y289F) and 45-fold (Y289S) higher than that of the wild type transporter. Sodium dependence is severely altered in tyrosine 289 mutants, both at the level of apparent affinity and cooperativity, with the more dramatic change corresponding to the less conservative substitution (Y289S), Accordingly, sodium selectivity is gradually lost in Y289F and Y289S mutants, and chloride dependence of glycine evoked currents is markedly decreased in Y289F and Y289S mutants. In the absence of three-dimensional information from these transporters, these results provide experimental evidence supporting the hypothesis of transmembrane domain III being part of a common permeation pathway for substrate and cotransported ions.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Sanofi Synthelab, CNS Res Dept, F-92290 Chatenay Malabry, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Sanofi-Aventis	Aragon, C (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.		Aragon, Carmen/K-9783-2014	Aragon, Carmen/0000-0001-8287-9386				ADAMS RH, 1995, J NEUROSCI, V15, P2524, DOI 10.1523/JNEUROSCI.15-03-02524.1995; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARAGON MC, 1987, FEBS LETT, V212, P87, DOI 10.1016/0014-5793(87)81562-4; Barker EL, 1999, J NEUROSCI, V19, P4705; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Borowsky B, 1998, J BIOL CHEM, V273, P29077, DOI 10.1074/jbc.273.44.29077; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; Cao YW, 1997, J NEUROSCI, V17, P2257; Cao YW, 1998, J NEUROSCI, V18, P7739; CASADO M, 1993, J BIOL CHEM, V268, P27313; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Galli A, 1997, J NEUROSCI, V17, P3401; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JOHNSTON GA, 1971, J NEUROCHEM, V18, P1951, DOI 10.1111/j.1471-4159.1971.tb09601.x; KANNER BI, 1994, CELL PHYSIOL BIOCHEM, V4, P174, DOI 10.1159/000154724; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIM KM, 1994, MOL PHARMACOL, V45, P608; Krystal JH, 1998, BIOL PSYCHIAT, V44, P1075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; LIU QR, 1993, J BIOL CHEM, V268, P22802; Lopez-Corcuera B, 1998, J NEUROCHEM, V71, P2211; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Nelson N, 1998, J NEUROCHEM, V71, P1785; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Ponce J, 1998, NEUROSCI LETT, V242, P25, DOI 10.1016/S0304-3940(98)00037-8; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Simpson RK, 1995, NEUROCHEM RES, V20, P1203, DOI 10.1007/BF00995384; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; Sur C, 1997, P NATL ACAD SCI USA, V94, P7639, DOI 10.1073/pnas.94.14.7639; Tsai GC, 1998, BIOL PSYCHIAT, V44, P1081, DOI 10.1016/S0006-3223(98)00279-0; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; ZAFRA F, 1995, EUR J NEUROSCI, V7, P1342, DOI 10.1111/j.1460-9568.1995.tb01125.x; ZAFRA F, 1995, J NEUROSCI, V15, P3952	52	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13856	13862		10.1074/jbc.275.18.13856	http://dx.doi.org/10.1074/jbc.275.18.13856			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788509	hybrid			2022-12-27	WOS:000086925300096
J	Zhou, ZM; Ribeiro, AA; Raetz, CRH				Zhou, ZM; Ribeiro, AA; Raetz, CRH			High-resolution NMR spectroscopy of lipid A molecules containing 4-amino-4-deoxy-L-arabinose and phosphoethanolamine substituents - Different attachment sites on lipid A molecules from NH4VO3-treated Escherichia coli versus kdsA mutants of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GRAM-NEGATIVE ENDOTOXIN; ACID-DEFICIENT MUTANT; A COMPONENT; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; POLYMYXIN RESISTANCE; CHEMICAL-STRUCTURE; PHOSPHATE GROUPS; MEMBRANE-LIPIDS	When Escherichia coli are grown on LB broth containing 25 mM NH4VO3, complex modifications to the lipid A anchor of lipopolysaccharide are induced. Six modified lipid As (EV1-EV6) have been purified. Many of these variants possess 4-amino-4-deoxy-L-arabinose (L-Ara4N) and/or phosphoethanolamine (pEtN) substituents, Here we use NMR spectroscopy to investigate the attachment sites of the L-Ara4N and pEtN moieties on underivatized, intact EV3 and EV6 and on precursors IIA and IIIA from kdsA mutants of Salmonella. CDCl3/CD3/OD/D2O (2:3:1, v/v) is shown to be a superior solvent for homo- and heteronuclear one- and two-dimensional NMR experiments, The latter were not feasible previously because available solvents caused sample decomposition. Selective inverse decoupling difference spectroscopy is used to determine the attachment sites of substituents on EV3, EV6, IIA, and IIIA. L-Ara4N is attached via a phosphodiester linkage to the 4'-phosphates of EV3 and EV6 and has the beta anomeric configuration. pEtN is attached by a pyrophosphate linkage to the 1-phosphate of EV6, The L-Ara4N and pEtN substituents of lipids IIA and IIIA are attached in the opposite manner, with L-Ara4N on the 1-phosphate of IIA and pEtN on the 4'-phosphate of IIIA. Determination of the proper attachment sites of these substituents is necessary for elucidating the enzymology of lipid A biosynthesis and for characterizing polymyxin-resistant mutants, in which L-Ara4N and pEtN substituents are greatly increased.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [R01-GM-51310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; BAX A, 1981, J MAGN RESON, V42, P164, DOI 10.1016/0022-2364(81)90022-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLL M, 1994, FEMS IMMUNOL MED MIC, V8, P329; Brade H., 1999, ENDOTOXIN HLTH DIS; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BYRD RA, 1986, J AM CHEM SOC, V108, P504, DOI 10.1021/ja00263a024; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HASE S, 1977, EUR J BIOCHEM, V75, P23, DOI 10.1111/j.1432-1033.1977.tb11500.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; LEHMANN V, 1978, EUR J BIOCHEM, V86, P487, DOI 10.1111/j.1432-1033.1978.tb12332.x; LEHMANN V, 1977, EUR J BIOCHEM, V81, P443, DOI 10.1111/j.1432-1033.1977.tb11969.x; MUHLRADT PF, 1977, EUR J BIOCHEM, V81, P193, DOI 10.1111/j.1432-1033.1977.tb11941.x; NALEWAY JJ, 1988, CARBOHYD RES, V179, P199, DOI 10.1016/0008-6215(88)84118-1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Que NLS, 1998, FASEB J, V12, pA1284; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1984, FED PROC, V43, P1567; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; THARANATHAN RN, 1978, EUR J BIOCHEM, V84, P385, DOI 10.1111/j.1432-1033.1978.tb12179.x; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	52	71	72	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13542	13551		10.1074/jbc.275.18.13542	http://dx.doi.org/10.1074/jbc.275.18.13542			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788469	hybrid			2022-12-27	WOS:000086925300056
J	Zhu, YJ; Kan, LX; Qi, C; Kanwar, YS; Yeldandi, AV; Rao, MS; Reddy, JK				Zhu, YJ; Kan, LX; Qi, C; Kanwar, YS; Yeldandi, AV; Rao, MS; Reddy, JK			Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; CO-REPRESSOR; ALPHA; GAMMA; CBP; COMPLEX	We previously isolated and identified steroid receptor coactivator-1 (SRC-1) and peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP/PPARBP) as coactivators for PPAR, using the ligand-binding domain of PPAR gamma as bait in a yeast two-hybrid screening. As part of our continuing effort to identify cofactors that influence the transcriptional activity of PPARs, we now report the isolation of a novel coactivator from mouse, designated PRIP (peroxisome proliferator-activated receptor interacting protein), a nuclear protein with 2068 amino acids and encoded by 13 exons. Northern analysis showed that PRIP mRNA is ubiquitously expressed in many tissues of adult mice. PRIP contains two LXXLL signature motifs. The amino-terminal LXYLL motif (amino acid position 892 to 896) of PRIP was found to be necessary for nuclear receptor interaction, but the second LXYLL motif (amino acid position 1496 to 1500) appeared unable to bind PPAR gamma. Deletion of the last 12 amino acids from the carboxyl terminus of PPAR gamma resulted in the abolition of the interaction between PRIP and PPAR gamma, PRIP also binds to PPAR alpha; RAR alpha; RXR alpha, ER, and TR beta 1, and this binding is increased in the presence of specific ligands. PRIP acts as a strong coactivator for PPAR gamma in the yeast and also potentiates the transcriptional activities of PPAR gamma and RXR alpha in mammalian cells. A truncated form of PRIP (amino acids 786-1132) acts as a dominant-negative repressor, suggesting that PRIP is a genuine coactivator.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@nwu.edu	kan, lixin/I-6665-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028492, R37DK028492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28492] Funding Source: Medline; NIGMS NIH HHS [R37 GM23750] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BREATHNACH R, 1978, P NATL ACAD SCI USA, V82, P8567; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IMBERT G, 1994, GENOMICS, V21, P667, DOI 10.1006/geno.1994.1335; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jain S, 1998, AM J PATHOL, V153, P349, DOI 10.1016/S0002-9440(10)65577-0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; ZHU Y, 2000, IN PRESS J BIOL CHEM, V275; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	56	158	185	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13510	13516		10.1074/jbc.275.18.13510	http://dx.doi.org/10.1074/jbc.275.18.13510			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788465	hybrid			2022-12-27	WOS:000086925300052
J	Herzig, RP; Scacco, S; Scarpulla, RC				Herzig, RP; Scacco, S; Scarpulla, RC			Sequential serum-dependent activation of CREB and NRF-1 leads to enhanced mitochondrial respiration through the induction of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-RESPONSE ELEMENT; GENE-EXPRESSION; DNA-BINDING; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; PROTEIN-KINASE; CYCLIC-AMP; NUCLEAR; TRANSCRIPTION	Progression through the cell cycle requires ATP for protein synthesis, cytoskeletal rearrangement, chromatin remodeling, and protein degradation. The mechanisms by which mammalian cells increase respiratory capacity and ATP production in preparation for cell division are largely unexplored. Here, we demonstrate that serum induction of cytochrome c mRNA and processed protein in quiescent BALB/3T3 fibroblasts is associated with a marked increase in mitochondrial respiration. Cytochrome c was induced in the absence of any increase in citrate synthase activity or in subunit IV of the cytochrome c oxidase complex mRNA or protein, indicating that the enhanced respiratory rate did not require a general increase in mitochondrial biogenesis or respiratory chain expression. Transfections with a series of cytochrome c promoter mutants showed that both nuclear respiratory factor 1 (NRF-1) and cAMP-response element-binding protein (CREB) binding sites contributed equally to induced expression by serum. Moreover, CREB and NRF-1 were phosphorylated sequentially in response to serum, and the NRF-1 phosphorylation was accompanied by an increase in its ability to trans-activate target gene expression. The results demonstrate that the differential transcriptional expression of cytochrome c, through sequential transcription factor phosphorylations, leads to enhanced mitochondrial respiratory capacity upon serum-induced entry to the cell cycle.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Univ Bari, Inst Med Biochem & Chem, I-70124 Bari, Italy	Northwestern University; Universita degli Studi di Bari Aldo Moro	Scarpulla, RC (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	rsc24@nwu.edu	Scacco, Salvatore/AAC-7406-2022	Scacco, Salvatore/0000-0003-2717-2489	NIGMS NIH HHS [GM32525-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; BOOKELMAN H, 1978, BIOCHEM MED METAB B, V19, P366, DOI 10.1016/0006-2944(78)90037-6; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHERBAS L, 1998, DROSOPHILA PRACTICAL; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DEAN DC, 1990, J BIOL CHEM, V265, P3522; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; Grossman LI, 1997, BBA-GENE STRUCT EXPR, V1352, P174, DOI 10.1016/S0167-4781(97)00025-0; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; LANOUE KF, 1984, J BIOL CHEM, V259, P4116; LAU LF, 1991, HORMONAL CONTROL GEN; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; LINDER ME, 1992, SCI AM, V267, P56; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; Marcussen M, 1996, CELL MOTIL CYTOSKEL, V35, P94, DOI 10.1002/(SICI)1097-0169(1996)35:2<94::AID-CM2>3.0.CO;2-I; Papa S, 1999, FEBS LETT, V444, P245, DOI 10.1016/S0014-5793(99)00070-8; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; PROFFITT J, 1995, GENE, V152, P173, DOI 10.1016/0378-1119(94)00701-S; SCACCO S, 2000, IN PRESS J BIOL CHEM; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SWEET S, 1995, CANCER RES, V55, P5164; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TIERCY JM, 1983, EUR J BIOCHEM, V131, P47, DOI 10.1111/j.1432-1033.1983.tb07230.x; URNESS LD, 1995, THESIS U UTAH; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	51	144	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13134	13141		10.1074/jbc.275.17.13134	http://dx.doi.org/10.1074/jbc.275.17.13134			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777619	hybrid			2022-12-27	WOS:000086762300103
J	Keely, SJ; Calandrella, SO; Barrett, KE				Keely, SJ; Calandrella, SO; Barrett, KE			Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T-84 cells is mediated by intracellular Ca2+, PYK-2, and p60(src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PANCREATIC ACINAR-CELLS; FOCAL TYROSINE KINASE; BETA-GAMMA-SUBUNITS; ANGIOTENSIN-II; CHLORIDE SECRETION; COUPLED RECEPTORS; CALCIUM CHANNELS; EPITHELIAL-CELLS; EGF RECEPTOR	Ca2+-dependent agonists, such as carbachol (CCh), stimulate epidermal growth factor receptor (EGFR) transactivation and mitogen-activated protein kinase activation in T-84 intestinal epithelial cells. This pathway constitutes an antisecretory mechanism by which CCh-stimulated chloride secretion is limited. Here, we investigated mechanisms underlying CCh-stimulated epidermal growth factor receptor (EGFR) transactivation. Thapsigargin (TG, 2 mu M) stimulated EGFR and extracellular signal-regulated kinase (ERK) phosphorylation in T-84 cells. Inhibition of either EGFR or ERK activation, with tyrphostin AG1478 (1 mu M) and PD 98059 (20 mu M), respectively, potentiated chloride secretory responses to TG, as measured by changes in short-circuit current (I-sc) across T-84 cells. CCh (100 mu M) stimulated tyrosine phosphorylation and association of the Ca2+ dependent tyrosine kinase, PYK-2, with the EGFR, which was inhibited by the Ca2+ chelator, BAPTA (20 mu M). The calmodulin inhibitor, fluphenazine (50 mu M) inhibited CCh-stimulated PYK-2 association with the EGFR and phosphorylation of EGFR and ERK, CCh also induced tyrosine phosphorylation of p60(src) and association of p60(src) with both PYK-2 and the EGFR. The Src family kinase inhibitor, PP2 (20 nM-20 mu M) attenuated CCh-stimulated EGFR and ERK phosphorylation and potentiated chloride secretory responses to CCh. We conclude that CCh-stimulated transactivation of the EGFR is mediated by a pathway involving elevations in intracellular Ca2+, calmodulin, PYK-2, and p60(src). This pathway represents a mechanism that limits CCh-stimulated chloride secretion across intestinal epithelia.	Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Keely, SJ (corresponding author), Univ Calif San Diego, Med Ctr, Div Gastroenterol, 8414,200 W Arbor Dr, San Diego, CA 92103 USA.		Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Barrett K.E.., 1999, ELECTROLYTE SECRETIO; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Cooke HJ, 1998, NEWS PHYSIOL SCI, V13, P269; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DEWAARD M, 1997, NATURE, V385, P46; DICKINSON KEJ, 1992, EUR J PHARM-MOLEC PH, V225, P291, DOI 10.1016/0922-4106(92)90102-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jeschke M, 1998, J BIOL CHEM, V273, P11354, DOI 10.1074/jbc.273.18.11354; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; OMALLEY KE, 1995, EUR J PHARMACOL, V275, P83, DOI 10.1016/0014-2999(94)00758-Y; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	54	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12619	12625		10.1074/jbc.275.17.12619	http://dx.doi.org/10.1074/jbc.275.17.12619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777553	hybrid			2022-12-27	WOS:000086762300037
J	Short, S; Tian, D; Short, ML; Jungmann, RA				Short, S; Tian, D; Short, ML; Jungmann, RA			Structural determinants for post-transcriptional stabilization of lactate dehydrogenase A mRNA by the protein kinase C signal pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; HYPOXIA-INDUCIBLE FACTOR-1; 3' UNTRANSLATED REGION; RIBONUCLEOTIDE REDUCTASE R1; EPIDERMAL GROWTH-FACTOR; CYCLIC-AMP ELEVATION; A-SUBUNIT GENE; 3'-UNTRANSLATED REGION; PHORBOL ESTER; POSTTRANSCRIPTIONAL REGULATION	Activation of protein kinase C (PKC) and protein kinase A (PKA) in rat C6 glioma cells increases the half-life of short-lived lactate dehydrogenase (LDH)-A mRNA about 5- and 8-fold, respectively. PKA and PKC act synergistically and prolong LDH-A mRNA half-life more than 21-fold. Similar effects were observed after transfection and transcription of a globin/lactate dehydrogenase minigene consisting of a beta-globin expression vector in which the 3'-untranslated region (UTR) of beta-globin had been replaced with the LDH-A 3'-UTR. Synergism was only obtained by transcription of minigenes containing the entire 3'-UTR and did not occur when truncated 3'-UTR fragments were analyzed. Additional mutational analyses showed that a 20-nucleotide region, named PKC-stabilizing region (PCSR), is responsible for mediating the stabilizing effect of PKC, Previous studies (Tian, D., Huang, D., Short, S., Short, M. L., and Jungmann, R. A. (1998) J. Biol. Chem. 273, 24861-24866) have demonstrated the existence of a cAMP-stabilizing region in LDH-A 3'-UTR. Sequence analysis of PCSR identified a 13-nucleotide AU-rich region that is common to both cAMP-stabilizing region and PCSR. These studies identify a specific PKC-responsive stabilizing element and indicate that interaction of PKA and PKC results in a potentiating effect on LDH-A mRNA stabilization.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Ctr Canc, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Jungmann, RA (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NIGMS NIH HHS [GM53115] Funding Source: Medline; NINDS NIH HHS [T32NS07140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHERN SM, 1993, J BIOL CHEM, V268, P2154; AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; AKIGUCHI I, 1993, J ENDOCRINOL, V138, P379, DOI 10.1677/joe.0.1380379; AMARA FM, 1995, CANCER RES, V55, P4503; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Boussouar F, 1999, BIOL REPROD, V61, P1139, DOI 10.1095/biolreprod61.4.1139; BOYNTON AL, 1983, BIOCHEM BIOPH RES CO, V115, P383, DOI 10.1016/0006-291X(83)91015-X; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN M, 1993, J BIOL CHEM, V268, P24138; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; FERRY RC, 1994, J BIOL CHEM, V269, P31850; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HOD Y, 1988, J BIOL CHEM, V263, P7747; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HUANG D, 1995, MOL CELL ENDOCRINOL, V108, P87, DOI 10.1016/0303-7207(94)03459-7; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; IWAI Y, 1991, J BIOL CHEM, V266, P17959; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; JUNGMANN RA, 1979, EFFECTS DRUGS CELL N, P507; Kijima K, 1996, HYPERTENSION, V27, P529, DOI 10.1161/01.HYP.27.3.529; KREIBICH G, 1970, Z KREBSFORSCH KLIN O, V74, P448, DOI 10.1007/BF00531226; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LEE C, 1979, J NATL CANCER I, V62, P193; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LI SSL, 1989, CELL BIOL INT REP, V13, P619, DOI 10.1016/0309-1651(89)90112-4; Li ZW, 1998, MOL PHARMACOL, V54, P14, DOI 10.1124/mol.54.1.14; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MORIMOTO BH, 1994, J BIOL CHEM, V269, P4065; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Pang JHS, 1996, BIOCHEM J, V319, P185, DOI 10.1042/bj3190185; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Scott W A, 1975, Methods Enzymol, V40, P273; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; SHORT ML, 1994, BIOCHEM J, V304, P391, DOI 10.1042/bj3040391; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tian D, 1998, J BIOL CHEM, V273, P28454, DOI 10.1074/jbc.273.43.28454; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAMONTANO D, 1986, J BIOL CHEM, V261, P3919; VANOOYEN A, 1979, SCIENCE, V206, P337, DOI 10.1126/science.482942; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	67	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12963	12969		10.1074/jbc.275.17.12963	http://dx.doi.org/10.1074/jbc.275.17.12963			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777597	hybrid			2022-12-27	WOS:000086762300081
J	Moon, YA; Lee, JJ; Park, SW; Ahn, YH; Kim, KS				Moon, YA; Lee, JJ; Park, SW; Ahn, YH; Kim, KS			The roles of sterol regulatory element-binding proteins in the transactivation of the rat ATP citrate-lyase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE PROMOTER; TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIATION FACTOR-1; CULTURED-CELLS; IN-VITRO; GENE; EXPRESSION; LIVER; CHOLESTEROL	ATP citrate-lyase (ACL) is a key enzyme supplying acetyl-CoA for fatty acid and cholesterol synthesis. Its expression is drastically up-regulated when an animal is fed a low fat, high carbohydrate diet after prolonged fasting. In this report, we describe the role of sterol regulatory element-binding proteins (SREBPs) in the transactivation of the rat ACL promoter. ACL promoter activity was markedly stimulated by the overexpression of SREBP-1a and, to a lesser extent, by SREBP-2 in Alexander human hepatoma cells. The promoter elements responsive to SREBPs were located within the 55-base pair sequences from -114 to -60. The gel mobility shift assay revealed four SREBP-1a binding sites in this region. Of these four elements, the -102/-94 region, immediately upstream of the inverted Y-box, and the -70/-61 region, just adjacent to Sp1 binding site, played critical roles in SREBPs-mediated stimulation. The mutation in the inverted Y-box and the coexpression of dominant negative nuclear factor-Y (NF-Y) significantly attenuated the transactivation by SREBP-1a, suggesting that NF-Y binding is a prerequisite for SREBPs to activate the ACL promoter. However, the multiple Sp1 binding sites did not affect the transactivation of the ACL promoter by SREBPs. The binding affinity of SREBP-1a to SREs of the ACL promoter also was much higher than that of SREBP-2. The transactivation potencies of the chimeric SREBPs, of which the activation domains (70 amino acids of the amino terminus) were derived from the different species of their carboxyl-terminal region, were similar to those of SREBPs corresponding to their carboxyl termini. Therefore, it is suggested that the carboxyl-terminal portions of SREBPs containing DNA binding domains are important in determining their transactivation potencies to a certain promoter.	Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Kwandong Univ, Coll Med, Dept Biochem, Kangnung 210701, Jangwon Do, South Korea	Yonsei University; Yonsei University Health System; Catholic Kwandong University	Kim, KS (corresponding author), Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, 134 Shinchon Dong, Seoul 120752, South Korea.		AHN, Yong Ho/H-6712-2017	AHN, Yong Ho/0000-0002-4133-0757; Kim, Kyung-sup/0000-0001-8483-8537; Park, Sahng Wook/0000-0002-9594-7074				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Gibson D M, 1972, Adv Enzyme Regul, V10, P187, DOI 10.1016/0065-2571(72)90014-3; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gribble AD, 1998, J MED CHEM, V41, P3582, DOI 10.1021/jm980091z; Guan GM, 1997, J BIOL CHEM, V272, P10295; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KIM KS, 1992, BIOCHEM BIOPH RES CO, V189, P264, DOI 10.1016/0006-291X(92)91553-3; KIM KS, 1994, BIOCHEM J, V302, P759, DOI 10.1042/bj3020759; KORNACKER MS, 1965, P NATL ACAD SCI USA, V54, P899, DOI 10.1073/pnas.54.3.899; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Park SW, 1997, BBA-GENE STRUCT EXPR, V1353, P236, DOI 10.1016/S0167-4781(97)00094-8; Pearce NJ, 1998, BIOCHEM J, V334, P113, DOI 10.1042/bj3340113; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WANG XD, 1993, J BIOL CHEM, V268, P14497	36	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30280	30286		10.1074/jbc.M001066200	http://dx.doi.org/10.1074/jbc.M001066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10801800	hybrid			2022-12-27	WOS:000089577900051
J	Kinashi, T; Katagiri, K; Watanabe, S; Vanhaesebroeck, B; Downward, J; Takatsu, K				Kinashi, T; Katagiri, K; Watanabe, S; Vanhaesebroeck, B; Downward, J; Takatsu, K			Distinct mechanisms of alpha(5)beta(1) integrin activation by Ha-Ras and R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MATRIX ADHESION; PHOSPHOINOSITIDE 3-KINASE; MONOCLONAL-ANTIBODY; AFFINITY MODULATION; PHOSPHOLIPASE-C; LIGAND-BINDING; FIBRONECTIN; KINASE; RECEPTOR; TRANSFORMATION	To investigate the possible roles of the Ras/Rho family members in the inside-out signals to activate integrins, we examined the ability of Ras/Rho small GTPases to stimulate avidity of alpha(5)beta(1) (VLA-5) to fibronectin in bone marrow-derived mast cells. We found that both Ha-Ras(Val-12) and R-Ras(Val-38) had strong stimulatory effects on adhesion and ligand binding activity of VLA-5 to fibronectin, However, only Ha-Ras(Val-12)-, but not R-Ras(Val-38)-induced adhesion was inhibited by wortmannin, which suggests that Ha-Ras(Val-12) is dependent on phosphatidylinositol (PI) 3-kinase on adhesion whereas R-Ras(Val-38) has another PI 3-kinase independent pathway to induce adhesion. The effector loop mutant Ha-Ras(Val-12)E37G, but not Y40C retained the ability to stimulate adhesion of mast cells to fibronectin. Consistently, PI 3-kinase p110 delta, predominantly expressed in mast cells, interacted with Ha-Ras(Val-12) E37G, but not Y40C, which was also correlated with the levels of Akt phosphorylation in mast cells. Furthermore, marked adhesion was induced by a membrane-targeted version of p110 delta, These results indicate that Ha-Ras(Val-12) activated VLA-B through PI 3-kinase p110 delta. The mutational effects of the R-Ras effector loop region on adhesion were not correlated with PI 3-kinase activities, consistent with our contention that R-Ras has a distinct pathway to modulate avidity of VLA-5.	Kyoto Univ, Grad Sch Med, Dept Mol Immunol & Allergy, Bayer Chair,Sakyo Ku, Kyoto 6068501, Japan; Univ Tokyo, Inst Med Sci, Dept Immunol, Tokyo 108, Japan; Ludwig Inst Canc Res, Cell Signalling Lab, London W1P 8BT, England; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Kyoto University; University of Tokyo; Ludwig Institute for Cancer Research; Cancer Research UK	Takatsu, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Immunol, Bayer Chair,Sakyo Ku, Kyoto 6068501, Japan.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ARROYO AG, 1993, J BIOL CHEM, V268, P9863; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FORSYTH J, 1992, METHOD ENZYMOL, V215, P311; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kinashi T, 1999, J IMMUNOL, V162, P2850; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KINASHI T, 1994, BLOOD CELLS, V20, P25; KINASHI T, 1994, BLOOD, V83, P1033; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Levesque JP, 1996, BLOOD, V88, P1168, DOI 10.1182/blood.V88.4.1168.bloodjournal8841168; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Osada M, 1999, MOL CELL BIOL, V19, P6333; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pulcinelli FM, 1998, BIOCHEM PHARMACOL, V56, P1481, DOI 10.1016/S0006-2952(98)00146-4; RODRIGUEZ VP, 1996, EMBO J, V15, P2442; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shibayama H, 1999, BLOOD, V93, P1540, DOI 10.1182/blood.V93.5.1540.405k10_1540_1548; SMYTH SS, 1993, BLOOD, V81, P2827; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SPRINGER TA, 1990, NATURE, V346, P426; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Walker EM, 1998, BIOCHEM PHARMACOL, V56, P1455, DOI 10.1016/S0006-2952(98)00256-1; Wei JY, 1997, J LEUKOCYTE BIOL, V61, P397, DOI 10.1002/jlb.61.4.397; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; ZANG Z, 1996, CELL, V85, P61	48	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22590	22596		10.1074/jbc.M000633200	http://dx.doi.org/10.1074/jbc.M000633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801791	hybrid			2022-12-27	WOS:000088363800113
J	Fujii, R; Hosoya, M; Fukusumi, S; Kawamata, Y; Habata, Y; Hinuma, S; Onda, H; Nishimura, O; Fujino, M				Fujii, R; Hosoya, M; Fukusumi, S; Kawamata, Y; Habata, Y; Hinuma, S; Onda, H; Nishimura, O; Fujino, M			Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; PROLACTIN-RELEASING PEPTIDE; GROWTH-HORMONE SECRETAGOGUE; SMALL-INTESTINE; GUINEA-PIG; GASTROINTESTINAL-TRACT; SUBSTANCE-P; RAT; IMMUNOREACTIVITY; EXPRESSION	Neuromedin U is a bioactive peptide first isolated from porcine spinal cord. In this paper, we demonstrate that neuromedin U is the cognate ligand for the orphan G protein-coupled receptor, FM-3, isolated originally as a homologue of neurotensin and growth hormone secretogogue receptors. Neuromedin Il induced specific and evident elevation of extracellular acidification rates, arachidonic acid metabolite release, and intracellular Ca2+ mobilization in Chinese hamster ovary cells expressing human FM-3. In addition, radiolabeled neuromedin Il specifically bound to membrane fractions prepared from these cells with high affinity. We subsequently analyzed the tissue distribution of neuromedin U and FM-3 mRNAs in rats using quantitative reverse transcription-polymerase chain reaction. Neuromedin U mRNA was highly expressed in the gastrointestinal tract, and the highest expression was detected in the pituitary gland. On the other hand, FM-3 mRNA was highly expressed in the small intestine and lung, suggesting that neuromedin Il plays important roles in these tissues. The identification of a specific and functional receptor for neuromedin U will facilitate studies on their physiological roles and the search for receptor agonists and antagonists.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan.			Kawamata, Yuji/0000-0001-5652-4899				AUGOOD SJ, 1988, REGUL PEPTIDES, V20, P281, DOI 10.1016/0167-0115(88)90063-8; AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; Fujii R, 1999, REGUL PEPTIDES, V83, P1, DOI 10.1016/S0167-0115(99)00028-2; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; FURNESS JB, 1989, CELL TISSUE RES, V257, P415, DOI 10.1007/BF00261844; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; Nandha KA, 1999, PEPTIDES, V20, P1203, DOI 10.1016/S0196-9781(99)00124-2; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TIMMERMANS JP, 1990, CELL TISSUE RES, V260, P367, DOI 10.1007/BF00318639; TIMMERMANS JP, 1989, CELL TISSUE RES, V258, P331, DOI 10.1007/BF00239453	30	179	198	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21068	21074		10.1074/jbc.M001546200	http://dx.doi.org/10.1074/jbc.M001546200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10783389	hybrid			2022-12-27	WOS:000088230600016
J	Yang, ZY; Wara-Aswapati, N; Chen, CM; Tsukada, J; Auron, PE				Yang, ZY; Wara-Aswapati, N; Chen, CM; Tsukada, J; Auron, PE			NF-IL6 (C/EBP beta) vigorously activates il1b gene expression via a Spi-1 (PU.1) protein-protein tether	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROINTERLEUKIN-1-BETA GENE; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; REGULATORY DOMAIN; MOLECULAR-CLONING; IL-1-BETA GENE; FAMILY MEMBERS; NUCLEAR FACTOR; T-CELLS; C-JUN	Two classes of transcription factors, ETS and bZIP, stand out as key mediators of monocyte commitment and differentiation. The ETS domain factor Spi-1 (also called PU.1) and the bZIP factor NF-IL6 (also called C/EBP beta) have been shown to be involved in the transcriptional regulation of interleukin-1 beta gene (il1b) and other monocyte-specific genes. We now show that these two factors strongly cooperate on the il1b core promoter (-59/+12) in the absence of direct NF-IL6 binding to DNA. Transient transfection assays, using mutated il1b core promoters, showed that the Spi-1, but not the NF-IL6, binding site is absolutely required for functional cooperativity, Furthermore, the NF-IL6 transactivation domain (TAD) is functionally indispensable and more critical than that of Spi-1. Additionally, TAD-deficient NF-IL6 functions as a dominant negative for Spi-1-mediated activation, suggesting the involvement of the bZIP DNA binding domain. This is supported by the demonstration of in vitro interaction between the NF-IL6 bZIP and Spi-1 winged helix-turn-helix (wHTH) DNA binding domains, arguing that NF-IL6 vigorously activates the il1b core promoter via protein-tethered transactivation mediated by Spi-1.	Harvard Univ, Sch Med, Dept Med,Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr,Div Hematol & Oncol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Auron, PE (corresponding author), Harvard Inst Med, Rm 245,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NCI NIH HHS [CA68544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; BURAS JA, 1994, J IMMUNOL, V152, P4444; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARK BD, 1988, MONOKINES OTHER NONL, P47; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAYNOR R, 1991, BLOOD, V77, P2618; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HEILAND S, 1995, MOL CELL BIOL, V15, P6623; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOLLINEDO F, 1991, EUR J BIOCHEM, V200, P483, DOI 10.1111/j.1432-1033.1991.tb16208.x; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; POLL V, 1990, CELL, V63, P643; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; SCOTT LM, 1992, BLOOD, V80, P1725; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; Wara-Aswapati N, 1999, MOL CELL BIOL, V19, P6803; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	47	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21272	21277		10.1074/jbc.M000145200	http://dx.doi.org/10.1074/jbc.M000145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801783	hybrid			2022-12-27	WOS:000088230600043
J	Zuhlke, RD; Pitt, GS; Tsien, RW; Reuter, H				Zuhlke, RD; Pitt, GS; Tsien, RW; Reuter, H			Ca2+-sensitive inactivation and facilitation of L-type Ca2+ channels both depend on specific amino acid residues in a consensus calmodulin-binding motif in the alpha(1c) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM CURRENT; VENTRICULAR MYOCYTES; PROTEIN-KINASE; SMOOTH-MUSCLE; INTRACELLULAR CALCIUM; SODIUM-CHANNELS; MAMMALIAN HEART; CELLS; ENHANCEMENT; MODULATION	L-type Ca2+ channels are unusual in displaying two opposing forms of autoregulatory feedback, Ca2+- dependent inactivation and facilitation. Previous studies suggest that both involve direct interactions between calmodulin (CaM) and a consensus CaM-binding sequence (IQ motif) in the C terminus of the channel's cu,, subunit, Here we report the functional effects of an extensive series of modifications of the IQ motif aimed at dissecting the structural determinants of the different forms of modulation. Although the combined substitution by alanine at five key positions (Ile(1624), Gln(1625) Phe(1628), Arg(1629), and Lys(1630)) abolished all Ca2+ dependence, corresponding single alanine replacements behaved similarly to the wild-type channel (77wt) in four of five cases. The mutant I1624A stood out in displaying little or no Ca2+-dependent inactivation, but clear Ca2+- and frequency-dependent facilitation. An even more pronounced tilt in favor of facilitation was seen with the double mutant I1624A/Q1625A: overt facilitation was observed even during a single depolarizing pulse, as confirmed by two-pulse experiments. Replacement of Ile1624 by 13 other amino acids produced graded and distinct patterns of change in the two forms of modulation. The extent of Ca2+-dependent facilitation was monotonically correlated with the affinity of CaM for the mutant IQ motif, determined in peptide binding experiments in vitro. Ca2+-dependent inactivation also depended on strong CaM binding to the IQ motif, but showed an additional requirement for a bulky, hydrophobic side chain at position 1624. Abolition of Ca2+-dependent modulation by IQ motif modifications mimicked and occluded the effects of overexpressing a dominant-negative CaM mutant.	Univ Bern, Inst Pharmakol, CH-3010 Bern, Switzerland; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	University of Bern; Stanford University	Zuhlke, RD (corresponding author), Univ Bern, Inst Pharmakol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.		Pitt, Geoffrey/L-4927-2019; Tuluc, Petronel/C-2527-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024067] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03743] Funding Source: Medline; NIGMS NIH HHS [GM58234] Funding Source: Medline; NINDS NIH HHS [NS24067] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Delgado C, 1999, J MOL CELL CARDIOL, V31, P1783, DOI 10.1006/jmcc.1999.1023; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FRANKENHAEUSER B, 1957, J PHYSIOL-LONDON, V137, P218, DOI 10.1113/jphysiol.1957.sp005808; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HILLE B, 1975, PHILOS T R SOC B, V270, P301, DOI 10.1098/rstb.1975.0011; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KS, 1987, P NATL ACAD SCI USA, V84, P3941, DOI 10.1073/pnas.84.11.3941; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P57, DOI 10.1113/jphysiol.1981.sp013537; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; Schuhmann K, 1997, J GEN PHYSIOL, V110, P503, DOI 10.1085/jgp.110.5.503; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; TIAHO F, 1994, J PHYSIOL-LONDON, V477, P237, DOI 10.1113/jphysiol.1994.sp020187; TSENG GN, 1988, CIRC RES, V63, P468, DOI 10.1161/01.RES.63.2.468; Victor RG, 1997, J MEMBRANE BIOL, V156, P53, DOI 10.1007/s002329900187; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; ZYGMUNT AC, 1990, J PHYSIOL-LONDON, V428, P653, DOI 10.1113/jphysiol.1990.sp018233	42	149	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21121	21129		10.1074/jbc.M002986200	http://dx.doi.org/10.1074/jbc.M002986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10779517	hybrid			2022-12-27	WOS:000088230600024
J	Tachibana, M; Siddiqi, MA; Ikegami, Y; Eshima, K; Shirota-Someya, Y; Tahara-Hanaoka, S; Koito, A; Iizuka, M; Shinohara, N				Tachibana, M; Siddiqi, MA; Ikegami, Y; Eshima, K; Shirota-Someya, Y; Tahara-Hanaoka, S; Koito, A; Iizuka, M; Shinohara, N			Coreceptor function of mutant human CD4 molecules without affinity to gp120 of human immunodeficiency virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MHC; T-CELL HYBRIDOMA; BINDING-SITE; MURINE; ANTIGEN; COMPLEX; IDENTIFICATION; DETERMINANT; EXPRESSION; FRAGMENT	Despite extensive mutational studies on the human CD4 molecule and its affinity to human immunodeficiency virus (HIV) envelope glycoprotein gp120, coreceptor functions of such mutant molecules have only been examined by indirect measurement of their affinity to class II major histocompatibility complex (MHC) molecules, In this report, coreceptor functions of mutant human CD4 molecules, which have no or reduced affinity to an HIV envelope protein, gp120, were assessed in a murine T cell receptor/class II MHC recognition system. The substitution of human C" beta strand with the murine homologous segment resulted in the loss of the coreceptor function as well as in the complete loss of gp120 binding capacity, corroborating the consensus that Phe-43 in C" beta strand plays crucial roles in both situations. However, simultaneous replacement of the C'-C" loop along with the C" beta strand by homologous murine segments rescued the coreceptor function, whereas gp120 binding capacity remained negative. Further analysis indicated that insertion of lysine be tween Gly-41 and Ser-42 can partially compensate for the coreceptor function lost by the Phe-43 --> Val mutation. Although the coreceptor function of these mutant CD4 molecules in a human T cell recognition system is yet to be determined, these observations necessitate a re-evaluation of the role played by Phe-43 in coreceptor function. Examination of the sensitivities of the mutant CD4 molecules expressed on HeLa cells to infection by a T cell-tropic HIV-1 strain indicated that only those mutants that had completely lost gp120 binding capacity were resistant to the infection, All mutants having whole C" substitution, irrespective of additional substitutions or their coreceptor functions, mere resistant to the infection.	Kitasato Univ, Sch Med, Dept Immunol, Sagamihara, Kanagawa 2288555, Japan; Mitsubishi Kasei Inst Life Sci, Dept Immunol, Machida, Tokyo 194, Japan; Mitsubishi Kasei Inst Life Sci, Dept Immunol, Machida, Tokyo 194, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan	Kitasato University; University of Tsukuba; University of Tsukuba	Shinohara, N (corresponding author), Kitasato Univ, Sch Med, Dept Immunol, 1-15-1 Kitasato, Sagamihara, Kanagawa 2288555, Japan.	nobu@med.kitasato-u.ac.jp						CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; Fleury S, 1996, J IMMUNOL, V156, P1848; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GAY D, 1988, P NATL ACAD SCI USA, V85, P5629, DOI 10.1073/pnas.85.15.5629; GLIMCHER LH, 1983, J IMMUNOL, V130, P2287; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAW YM, 1994, J EXP MED, V179, P1233, DOI 10.1084/jem.179.4.1233; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; LUCIW PA, 1984, NATURE, V312, P760, DOI 10.1038/312760a0; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; Siddiqi MA, 1997, J ACQ IMMUN DEF SYND, V14, P7, DOI 10.1097/00042560-199701010-00002; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; STAUS D, 1992, CELL, V70, P585; SUZUKI H, 1994, J IMMUNOL, V153, P4496; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VANWAUWE J, 1982, CELL IMMUNOL, V68, P181, DOI 10.1016/0008-8749(82)90101-0; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WOOD GS, 1983, J IMMUNOL, V131, P212	28	1	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20288	20294		10.1074/jbc.M001917200	http://dx.doi.org/10.1074/jbc.M001917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779509	hybrid			2022-12-27	WOS:000088084500012
J	Ariizumi, K; Shen, GL; Shikano, S; Xu, S; Ritter, R; Kumamoto, T; Edelbaum, D; Morita, A; Bergstresser, PR; Takashima, A				Ariizumi, K; Shen, GL; Shikano, S; Xu, S; Ritter, R; Kumamoto, T; Edelbaum, D; Morita, A; Bergstresser, PR; Takashima, A			Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL LANGERHANS CELLS; COLONY-STIMULATING FACTOR; EARLY ACTIVATION ANTIGEN; RECEPTOR-GAMMA-CHAIN; T-CELLS; ASIALOGLYCOPROTEIN RECEPTOR; MURINE EPIDERMIS; IN-VITRO; DOWN-REGULATION; GROWTH-FACTOR	Dendritic cells (DC) are special subsets of antigen presenting cells characterized by their potent capacity to activate immunologically naive T cells. By subtracting the mRNAs expressed by the mouse epidermus-derived DC line XS52 with the mRNAs expressed by the J774 macrophage line, we identified five novel genes that were expressed selectively by this DC line. One of these genes encoded a type II membrane-integrated polypeptide of 244 amino acids containing a putative carbohydrate recognition domain motif at the COOH-terminal end. This molecule, termed "dectin-1," was expressed abundantly at both mRNA and protein levels by the XS52 DC line, but not by non-DC lines (including the J774 macrophage line). Dectin-1 mRNA was detected predominantly in spleen and thymus (by Northern blotting) and in skin-resident DC, i.e. Langerhans cells (by reverse transcription-polymerase chain reaction). Affinity-purified antibody against dectin-1 identified a 43-kDa glycoprotein in membrane fractions isolated from the XS52 DC line and from the dectin-1 cDNA-transfected COS-1 cells. His-tagged recombinant proteins containing the extracellular domains of dectin-1 showed marked and specific binding to the surface of T cells and promoted their proliferation in the presence of anti-CD3 monoclonal antibody at suboptimal concentrations. These in vitro results suggest that dectin-1 on DC may bind to as yet undefined ligand(s) on T cells, thereby delivering T cell co-stimulatory signals. Not only do these results document the efficacy of subtractive cDNA cloning for the identification of unique genes expressed by DC, they also provide a framework for studying the physiological function of dectin-1.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Takashima, A (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	atakas@mednet.swmed.edu			NIAID NIH HHS [RI1-AI43262] Funding Source: Medline; NIAMS NIH HHS [R01-AR44189, R01-AR35068] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035068, R01AR044189] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; ARIIZUMI K, 1995, J IMMUNOL, V154, P6031; ARIIZUMI K, 1995, EUR J IMMUNOL, V25, P2137, DOI 10.1002/eji.1830250803; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bates EEM, 1999, J IMMUNOL, V163, P1973; Bhardwaj N, 1997, J EXP MED, V186, P795, DOI 10.1084/jem.186.6.795; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BIEBER T, 1992, J INVEST DERMATOL, V98, P771, DOI 10.1111/1523-1747.ep12499948; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dissen E, 1997, EUR J IMMUNOL, V27, P2080, DOI 10.1002/eji.1830270836; ELBE A, 1994, J IMMUNOL, V153, P2878; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Fanger NA, 1996, J IMMUNOL, V157, P541; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; GRANUCCI F, 1994, EUR J IMMUNOL, V24, P2522, DOI 10.1002/eji.1830241039; GRAY PW, 1986, J IMMUNOL, V137, P3644; HAMANN J, 1993, J IMMUNOL, V150, P4920; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; HEUFLER C, 1992, J EXP MED, V176, P1221, DOI 10.1084/jem.176.4.1221; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109; ISHIDOH K, 1991, J BIOL CHEM, V266, P16312; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Johnson LL, 1997, J EXP MED, V186, P1799, DOI 10.1084/jem.186.11.1799; KIJIMOTOOCHIAI S, 1994, IMMUNOL LETT, V40, P49, DOI 10.1016/0165-2478(94)90205-4; Kitajima T, 1996, J IMMUNOL, V157, P3312; KITAJIMA T, 1995, J IMMUNOL, V155, P3794; KITAJIMA T, 1995, J IMMUNOL, V155, P5190; Kitajima T, 1996, J CLIN INVEST, V98, P142, DOI 10.1172/JCI118759; KONDO H, 1994, INT ARCH ALLERGY IMM, V105, P38, DOI 10.1159/000236801; KOSZIK F, 1994, J INVEST DERMATOL, V102, P773, DOI 10.1111/1523-1747.ep12377706; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Lazetic S, 1996, J IMMUNOL, V157, P4741; LIN EY, 1993, J IMMUNOL, V151, P1979; LOEB JA, 1988, J BIOL CHEM, V263, P9752; Matsue H, 1999, J IMMUNOL, V162, P5287; MATSUE H, 1992, J INVEST DERMATOL, V99, P537, DOI 10.1111/1523-1747.ep12667296; MATSUE H, 1993, J IMMUNOL, V151, P6012; Maurer D, 1996, J IMMUNOL, V157, P607; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Mohamadzadeh M, 1996, EUR J IMMUNOL, V26, P156, DOI 10.1002/eji.1830260124; ORLOFSKY A, 1991, CELL REGUL, V2, P403, DOI 10.1091/mbc.2.5.403; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RICE KG, 1990, J BIOL CHEM, V265, P18429; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; Ross R, 1998, J INVEST DERMATOL, V110, P57, DOI 10.1046/j.1523-1747.1998.00079.x; Ross R, 1998, J IMMUNOL, V160, P3776; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SCHUHMACHERS G, 1995, J INVEST DERMATOL, V105, P225, DOI 10.1111/1523-1747.ep12317512; Shurin MR, 1996, CANCER IMMUNOL IMMUN, V43, P158, DOI 10.1007/s002620050317; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TAKASHIMA A, 1995, J IMMUNOL, V154, P5128; Timares L, 1998, P NATL ACAD SCI USA, V95, P13147, DOI 10.1073/pnas.95.22.13147; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Vremec D, 1997, J IMMUNOL, V159, P565; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; XU S, 1995, EUR J IMMUNOL, V25, P1018, DOI 10.1002/eji.1830250424; XU S, 1995, J IMMUNOL, V154, P2697; YING H, 1995, J IMMUNOL, V154, P2743; Yokota K, 1996, J IMMUNOL, V157, P1529; YUSPA SH, 1980, CANCER RES, V40, P4694	79	350	370	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20157	20167		10.1074/jbc.M909512199	http://dx.doi.org/10.1074/jbc.M909512199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779524	hybrid			2022-12-27	WOS:000087941300097
J	Huffman, KE; Levene, SD; Tesmer, VM; Shay, JW; Wright, WE				Huffman, KE; Levene, SD; Tesmer, VM; Shay, JW; Wright, WE			Telomere shortening is proportional to the size of the G-rich telomeric 3 '-overhang	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; SINGLE-STRANDED-DNA; HUMAN FIBROBLASTS; HUMAN-CHROMOSOMES; OXYTRICHA-NOVA; C-STRAND; END; REPLICATION; IMMORTALIZATION; MAINTENANCE	Most normal diploid human cells do not express telomerase activity and are unable to maintain telomere length with ongoing cell divisions. We show that the length of the single-stranded G-rich telomeric 3'-overhang is proportional to the rate of shortening in four human cell types that exhibit different rates of telomere shortening in culture. These results provide direct evidence that the size of the G-rich overhang is not fixed but subject to regulation. The potential ability to manipulate this rate has profound implications both for slowing the rate of replicative aging in normal cells and for accelerating the rate of telomere loss in cancer cells in combination with anti-telomerase therapies.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas	Wright, WE (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011; Levene, Stephen/G-3100-2010	Levene, Stephen/0000-0003-2778-5162	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047898, R01GM055871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG001228] Funding Source: NIH RePORTER; NIA NIH HHS [AG01228] Funding Source: Medline; NIGMS NIH HHS [GM55871, GM47898] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Price CM, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1216; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1999, EXP CELL RES, V251, P492, DOI 10.1006/excr.1999.4602; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1989, NUCLEIC ACIDS RES, V17, P6299, DOI 10.1093/nar/17.15.6299; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	25	199	214	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19719	19722		10.1074/jbc.M002843200	http://dx.doi.org/10.1074/jbc.M002843200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10787419	hybrid			2022-12-27	WOS:000087941300039
J	Rooney, IA; Butrovich, KD; Glass, AA; Borboroglu, S; Benedict, CA; Whitbeck, JC; Cohen, GH; Eisenberg, RJ; Ware, CF				Rooney, IA; Butrovich, KD; Glass, AA; Borboroglu, S; Benedict, CA; Whitbeck, JC; Cohen, GH; Eisenberg, RJ; Ware, CF			The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; HERPESVIRUS ENTRY MEDIATOR; SECONDARY LYMPHOID-TISSUES; TNF RECEPTOR; DEFICIENT MICE; LT-ALPHA; ABNORMAL-DEVELOPMENT; CYTOPLASMIC DOMAIN; CYTOTOXIC ACTIVITY	LIGHT is a tumor necrosis factor (TNF) ligand superfamily member, which binds two known cellular receptors, lymphotoxin-beta receptor (LT beta R) and the herpesvirus entry mediator (HveA). LIGHT is a homotrimer that activates proapoptotic and integrin-inducing pathways. Receptor binding residues via LIGHT were identified by introducing point mutations in the A' --> A" and D --> E loops of LIGHT, which altered binding to LT beta R and HveA One mutant of LIGHT exhibits selective binding to HveA and is inactive triggering cell death in HT29.14s cells or induction of ICAM-1 in fibroblasts. Studies with HveA- or LT beta R-specific antibodies further indicated that HveA does not contribute, either cooperatively or by direct signaling, to the death pathway activated by LIGHT. LT beta R, not HveA, recruits TNF receptor-associated factor-3 (TRAF3), and LIGHT-induced death is blocked by a dominant negative TRAF3 mutant. Together, these results indicate that TRAF3 recruitment propagates death signals initiated by LIGHT-LT beta R interaction and implicates a distinct biological role for LIGHT-HveA system.	La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA	La Jolla Institute for Immunology; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Ware, CF (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.				NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036731] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI03368] Funding Source: Medline; NINDS NIH HHS [NS-36731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BANKS TA, 1995, J IMMUNOL, V155, P1685; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; FORCE WR, 2000, IN PRESS J BIOL CHEM, V275; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Fu YX, 1997, J EXP MED, V185, P2111, DOI 10.1084/jem.185.12.2111; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GOH CR, 1991, PROTEIN ENG, V4, P785; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Hochman PS, 1996, J INFLAMM, V46, P220; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; ITOH N, 1993, J BIOL CHEM, V268, P10932; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Rooney I, 2000, METHOD ENZYMOL, V322, P345; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WARE CF, 1995, PATHWAYS CYTOLYSIS, P175; WilliamsAbbott L, 1997, J BIOL CHEM, V272, P19451, DOI 10.1074/jbc.272.31.19451; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	52	191	210	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14307	14315		10.1074/jbc.275.19.14307	http://dx.doi.org/10.1074/jbc.275.19.14307			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799510	hybrid			2022-12-27	WOS:000087006900042
J	Wang, JC; Stafford, JM; Scott, DK; Sutherland, C; Granner, DK				Wang, JC; Stafford, JM; Scott, DK; Sutherland, C; Granner, DK			The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; GLUCOCORTICOID RESPONSE UNIT; ACCESSORY FACTOR; GLUCOSE-METABOLISM; FACTOR-BINDING; YOUNG MODY1; PEPCK GENE; COUP-TF; IN-VIVO; TRANSCRIPTION	Glucocorticoids stimulate gluconeogenesis by increasing the rate of transcription of genes that encode gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. Previous studies have shown that hepatic nuclear factor 3 (HNF3) is required as an accessory factor for several glucocorticoid-stimulated genes, including PEPCK. Here, we show that adenovirus-mediated expression of an HNP3 beta protein with a deleted C-terminal transactivation domain (HNF3 beta Delta C) reduces the glucocorticoid-induced expression of the PEPCK and glucose-6-phosphatase genes in H4IIE hepatoma cells. Furthermore, expression of this truncated HNF3 protein results in a proportionate reduction of glucocorticoid-stimulated glucose production from lactate and pyruvate in these cells. The expression of HNF3 beta Delta N, in which the N-terminal transactivation domain is deleted, does not exhibit any of these effects. These results provide direct evidence that members of the HNF3 family are required for proper regulation of hepatic gluconeogenesis. Modulation of the function of the HNF3 family of proteins might be used to reduce the excessive hepatic production of glucose that is an important pathophysiologic feature of diabetes mellitus.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.		Wang, Jen-Chywan/AAX-4445-2020; Stafford, John/K-7763-2017	Wang, Jen-Chywan/0000-0001-6030-6886; Stafford, John/0000-0001-6527-959X; Sutherland, Calum/0000-0003-4398-7434	NIDDK NIH HHS [DK 35107, DK 20593] Funding Source: Medline; NIGMS NIH HHS [GM 07347] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, R01DK035107, P60DK020593, R37DK035107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; ROGNSTAD R, 1979, J BIOL CHEM, V254, P1875; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; VALLET V, 1995, MOL CELL BIOL, V15, P5453; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Zimmermann PL, 1997, DNA CELL BIOL, V16, P713, DOI 10.1089/dna.1997.16.713	35	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14717	14721		10.1074/jbc.275.19.14717	http://dx.doi.org/10.1074/jbc.275.19.14717			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799560	hybrid			2022-12-27	WOS:000087006900094
J	Krude, T				Krude, T			Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; AMINO-ACID MIMOSINE; S-PHASE; MAMMALIAN FIBROBLASTS; PURINE ANALOGS; FREE SYSTEM; G1 PHASE; LOCALIZATION; ROSCOVITINE; INHIBITION	Initiation of human DNA replication is investigated in vitro, using initiation-competent nuclei isolated from cells arrested in late G(1) phase by a 24-h treatment with 0.5 mM mimosine (Krude, T, (1999) Exp. Cell Res. 247, 148-159). Nuclei isolated from mimosine-arrested HeLa cells initiate semiconservative DNA replication upon incubation in cytosolic extracts from proliferating human cells. Initiation occurs in the absence and presence of a nuclear membrane. The cyclin-dependent kinase (Cdk) inhibitors roscovitine and olomoucine inhibit initiation of DNA replication, indicating a dependence of initiation on Cdk activity. Cell fractionation shows that cyclins A, E, and Cdk2 are bound to nuclei from mimosine-arrested cells. Exogenously added human cyclin A Cdk2 and cyclin E Cdk2 complexes, but not cyclin B1/Cdk1 or cyclin D2/Cdk6, can overcome inhibition of initiation by roscovitine in vitro. Depleting Cdk2 from cytosolic extract does not prevent initiation, demonstrating that cyclin Cdk2 complexes are not required in the soluble extract, but are provided by the nuclei. Initiation depends further on an essential and soluble activity present in cytosolic extracts from proliferating cells, but not from mimosine-arrested cells, acting together with nuclear cyclin/Cdk2 activity.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge; University of Cambridge	Krude, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk1@mole.bio.cam.ac.uk		Krude, Torsten/0000-0002-1842-1933				Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Harlow E., 1999, USING ANTIBODIES LAB; HOZAK P, 1994, J CELL SCI, V107, P2191; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Krude T, 1996, J CELL SCI, V109, P309; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pasero P, 1998, CURR OPIN CELL BIOL, V10, P304, DOI 10.1016/S0955-0674(98)80004-5; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; Romanowski P, 1997, TRENDS CELL BIOL, V7, P9, DOI 10.1016/S0962-8924(97)30077-4; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Tsvetkov LM, 1997, CANCER RES, V57, P2252; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WIMMEL A, 1994, ONCOGENE, V9, P995	50	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13699	13707		10.1074/jbc.275.18.13699	http://dx.doi.org/10.1074/jbc.275.18.13699			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788489	hybrid			2022-12-27	WOS:000086925300076
J	Manna, SK; Mukhopadhyay, A; Agarwal, BB				Manna, SK; Mukhopadhyay, A; Agarwal, BB			Human chorionic gonadotropin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 induced by tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD MONONUCLEAR-CELLS; BREAST-CANCER; CONSTITUTIVE ACTIVATION; MAMMARY CARCINOGENESIS; CAMP INHIBITION; MONOCYTIC CELLS; KINASE COMPLEX; FACTOR-ALPHA; BETA-HCG; IN-VITRO	Human chorionic gonadotropin (hCG) suppresses cell-mediated allogeneic reactions, viral replication, tumorigenesis, and metastasis, most of which require activation of nuclear transcription factor-kappa B (NF-kappa B) and activator protein-1 (AP-1), In the present report, we investigated the effect of hCG on NF-kappa B and AP-1 activated by tumor necrosis factor (TNF). Treatment of the CaCOV3 human ovarian cell line with hCG blocked TNF-induced activation of NF-kappa B, I kappa B alpha degradation, and NF-kappa B-dependent reporter gene transcription, hCG also blocked NF-kappa B activation induced by ceramide. The effect of hCG on NF-kappa B was mediated through inhibition of phosphorylation of I kappa B alpha. Because hCG also blocked TNF receptor-associated factor-2 and NF-kappa B-inducing kinase reporter gene expression, hCG must act at a step that causes phosphorylation of I kappa B alpha, AP-1 activation induced by TNF and ceramide was also suppressed by hCG. hCG abrogated the TNF-induced activation of mitogen-activated protein kinase kinase and c-Jun N-terminal kinase required for NF-kappa B and AP-1, respectively. Dideoxyadenosine and H-8 reversed the effect, and dibutyryl cAMP mimicked the effect, suggesting that hCG suppresses the transcription factors through cAMP-induced protein kinase A pathway. Overall, our results indicate that hCG inhibits the activation of NF-kappa B and AP-1, which may be the molecular basis by which hCG suppresses viral replication, cell proliferation, tumorigenesis, and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Agarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALVARADO MV, 1994, IN VITRO CELL DEV-AN, V30A, P4; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal V. R., 1997, CURR BIOL, V7, P94; Bonizzi G, 1997, J IMMUNOL, V159, P5264; BOURINBAIAR AS, 1992, FEBS LETT, V309, P82, DOI 10.1016/0014-5793(92)80744-2; Chaouat G, 1997, CURR TOP MICROBIOL, V222, P103; Chaouat G, 1995, HUM REPROD, V10, P55, DOI 10.1093/humrep/10.suppl_2.55; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; De SK, 1997, J CLIN INVEST, V99, P1484, DOI 10.1172/JCI119310; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HIGUCHI M, 1996, J IMMUNOL, V156, P297; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Ho HY, 1997, EUR J IMMUNOL, V27, P222, DOI 10.1002/eji.1830270133; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kachra Z, 1997, ENDOCRINOLOGY, V138, P4038, DOI 10.1210/en.138.9.4038; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Komorowski J, 1997, IMMUNOL LETT, V59, P29, DOI 10.1016/S0165-2478(97)00096-5; Komorowski J, 1997, CYTOBIOS, V92, P159; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; LIN J, 1995, MOL CELL ENDOCRINOL, V111, pR13, DOI 10.1016/0303-7207(95)03565-O; Lojun S, 1997, BIOL REPROD, V57, P1202, DOI 10.1095/biolreprod57.5.1202; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J IMMUNOL, V161, P2873; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Russo I H, 1993, Eur J Cancer Prev, V2 Suppl 3, P101; RUSSO IH, 1991, BRIT J CANCER, V64, P481, DOI 10.1038/bjc.1991.335; RUSSO IH, 1990, BRIT J CANCER, V62, P243, DOI 10.1038/bjc.1990.268; RUSSO IH, 1990, J NATL CANCER I, V82, P1286, DOI 10.1093/jnci/82.15.1286; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Srivastava P, 1998, ANTICANCER RES, V18, P4003; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	57	28	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13307	13314		10.1074/jbc.275.18.13307	http://dx.doi.org/10.1074/jbc.275.18.13307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788437	hybrid			2022-12-27	WOS:000086925300023
J	Marfatia, SM; Byron, O; Campbell, G; Liu, SC; Chishti, AH				Marfatia, SM; Byron, O; Campbell, G; Liu, SC; Chishti, AH			Human homologue of the Drosophila discs large tumor suppressor protein forms an oligomer in solution - Identification of the self-association site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE KINASE HOMOLOG; POSTSYNAPTIC DENSITY; PDZ DOMAINS; GLYCOPHORIN-C; MOLECULAR CHARACTERIZATION; CLUSTERING ACTIVITY; POTASSIUM CHANNEL; BINDING PROTEINS; PLASMA-MEMBRANE; LEUCINE ZIPPER	The human homologue of the Drosophila discs large tumor suppressor protein (hDlg), a member of the membrane-associated guanylate kinase (MAGUK) superfamily, interacts with K+ channels, N-methyl-D-aspartate receptors, calcium ATPase, adenomatous polyposis coli, and PTEN tumor suppressor proteins, and several viral oncoproteins through its PDZ domains. MAGUKs play pivotal roles in the clustering and aggregation of receptors, ion channels, and cell adhesion molecules at the synapses. To investigate the physiological basis of hDlg interactions, we examined the self-association state of full-length hDlg as well as defined segments of hDlg expressed as recombinant proteins in bacteria and insect Sf9 cells. Gel permeation chromatography of full-length hDlg revealed that the purified protein migrates as a large particle of size >440 kDa, Similar measurements of defined domains of hDlg indicated that the anomalous mobility of hDlg originated from its amino-terminal domain. Ultrastructural analysis of hDlg by low angle rotary shadow electron microscopy revealed that the full-length hDlg protein as well as its amino-terminal domain exhibits a highly flexible irregular shape. Further evaluation of the self-association state of hDlg using sedimentation equilibrium centrifugation,, matrix-assisted laser desorption/ionization mass spectrometry, and chemical crosslinking techniques confirmed that the oligomerization site of hDlg is contained within its amino-terminal domain. This unique amino-terminal domain mediates multimerization of hDlg into dimeric and tetrameric species in solution, Sedimentation velocity experiments demonstrated that the oligomerization domain exists as an elongated tetramer in solution, In vitro mutagenesis was used to demonstrate that a single cysteine residue present in the oligomerization domain of hDlg is not required for its self-association. Understanding the oligomerization status of hDlg may help to explicate the mechanism of hDlg association with multimeric K+ channels and dimeric adenomatous polyposis coli tumor suppressor protein. Our findings, therefore, begin to rationalize the role of hDlg in the clustering of membrane channels and formation of multiprotein complexes necessary for signaling and cell proliferation pathways.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med,Sect Hematol Oncol Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Anat & Cellular Biol,Sect Hematol Oncol Res, Boston, MA 02135 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; University of Glasgow	Chishti, AH (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med,Sect Hematol Oncol Res, CBR 404,736 Cambridge St, Boston, MA 02135 USA.			Byron, Olwyn/0000-0001-7857-4520	NCI NIH HHS [CA66263] Funding Source: Medline; NHLBI NIH HHS [HL60755] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chan JLK, 1997, J BIOL CHEM, V272, P146; Chishti A H, 1998, Curr Opin Hematol, V5, P116; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Hunt CA, 1996, J NEUROSCI, V16, P1380; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM H, 1977, CHEM REV, V77, P659, DOI 10.1021/cr60309a002; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kjerfve, 1988, HYDRODYNAMICS ESTUAR, P31; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Rafael JA, 1998, NEUROREPORT, V9, P2121, DOI 10.1097/00001756-199806220-00039; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Senda T, 1998, NEUROSCIENCE, V83, P857, DOI 10.1016/S0306-4522(97)00459-4; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SIEGEL DL, 1985, J CELL BIOL, V100, P775, DOI 10.1083/jcb.100.3.775; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WEAST RC, 1986, CRC HDB CHEM PHYSICS; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Wu HJ, 1998, J CELL SCI, V111, P2365; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	64	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13759	13770		10.1074/jbc.275.18.13759	http://dx.doi.org/10.1074/jbc.275.18.13759			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788497	hybrid			2022-12-27	WOS:000086925300084
J	Nelson, SA; Aris, JP; Patel, BKR; LaRochelle, WJ				Nelson, SA; Aris, JP; Patel, BKR; LaRochelle, WJ			Multiple growth factor induction of a murine early response gene that complements a lethal defect in yeast ribosome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELLS; PDGF; RNA; FIBROBLASTS; ACTIVATION; EXPRESSION; REGULATOR; COMPONENT; PROTEIN	Identification of the transcriptionally activated targets of receptor tyrosine kinases is critical to understanding biologic programs directing both normal and neoplastic growth. To elucidate these molecular processes, we identified genes induced by a potent mesenchymal mitogen, platelet-derived growth factor (PDGF), Using differential display reverse transcription-polymerase chain reaction technology, we isolated a novel growth factor-induced cDNA, San5. San5 transcript induction occurred within 60 min in NIH 3T3 fibroblasts and proceeded in the presence of cycloheximide. Maximal induction of the San5 transcript occurred between 8 and 16 h, concurrent with passage of fibroblasts through G(1). San5 message was potently induced by PDGF AA and BB and acidic and basic fibroblast growth factors, all strong activators of fibroblast proliferation, but not by epidermal growth factor and interleukin-4. In a murine hematopoietic progenitor cell line, San5 transcript induction strictly correlated with [H-3]thymidine uptake. Isolation and sequencing of the murine San5 cDNA revealed amino acid sequence homology to yeast Nop5p, a nucleolar protein required for pre-rRNA processing and ribosome assembly. Strikingly, SAN5 was able to rescue a nop5 null mutant, implicating SAN5 in the process of ribosome biogenesis. Consistent with this result, SAN5 was localized to the nucleolus in both yeast and mouse. Thus, San5 may provide a link between growth factor receptor activation and the cellular translational machinery.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Florida, Coll Med, Hlth Sci Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida	LaRochelle, WJ (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37,Rm 1E24, Bethesda, MD 20892 USA.	billr@helix.nih.gov	Nelson, Stefanie/GRN-7686-2022	Aris, John/0000-0002-6475-064X	NIGMS NIH HHS [R01 GM048586-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Betsholtz C, 1997, KIDNEY INT, V51, P1361, DOI 10.1038/ki.1997.186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dirks RPH, 1996, MOL BIOL REP, V22, P1, DOI 10.1007/BF00996300; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Rim WJH, 1998, ARCH PHARM RES, V21, P487, DOI 10.1007/BF02975363; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453	41	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13835	13841		10.1074/jbc.275.18.13835	http://dx.doi.org/10.1074/jbc.275.18.13835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788506	hybrid			2022-12-27	WOS:000086925300093
J	Riento, K; Kauppi, M; Keranen, S; Olkkonen, VM				Riento, K; Kauppi, M; Keranen, S; Olkkonen, VM			Munc18-2, a functional partner of syntaxin 3, controls apical membrane trafficking in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; CYCLIN-DEPENDENT KINASE-5; NEUROTRANSMITTER RELEASE; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; GLUT4 TRANSLOCATION; GENERAL SECRETION; 3T3-L1 ADIPOCYTES; SNARE COMPLEXES	The Sec1-related proteins bind to syntaxin family t-SNAREs with high affinity, thus controlling the interaction of syntaxins with their cognate SNARE partners. Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. We generated here a set of Munc18-2 point mutants with substitutions in conserved amino acid residues. The mutants displayed a spectrum of different syntaxin binding efficiencies. The in vitro and in vitro binding patterns were highly similar, and the association of the Munc18-2 variants with syntaxin 3 correlated well with their ability to displace SNAP-23 from syntaxin 3 complexes when overexpressed in Caco-2 cells. Even the Munc18-2 mutants that do not detectably bind syntaxin 3 were membrane associated in Caco-2 cells, suggesting that the syntaxin interaction is not the sole determinant of Sec1 protein membrane attachment, Overexpression of the wild-type Munc18-2 was shown to inhibit the apical delivery of influenza virus hemagglutinin (HA), Interestingly, mutants unable to bind syntaxin 3 behaved differently in the HA transport assay. While one of the mutants tested had no effect, one inhibited and one enhanced the apical transport of RA This implies that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction.	Natl Publ Hlth Inst, Dept Biochem, FIN-00300 Helsinki, Finland; VTT Biotechnol, FIN-02044 Vtt, Finland	Finland National Institute for Health & Welfare; VTT Technical Research Center Finland	Olkkonen, VM (corresponding author), Natl Publ Hlth Inst, Dept Biochem, Mannerheimintie 166, FIN-00300 Helsinki, Finland.			Olkkonen, Vesa/0000-0001-5553-7997				AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Bryant NJ, 1998, EUR J CELL BIOL, V76, P43, DOI 10.1016/S0171-9335(98)80016-2; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Delgrossi MH, 1997, J CELL SCI, V110, P2207; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Halachmi N, 1996, J NEUROCHEM, V66, P889; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; Lehtonen S, 1999, KIDNEY INT, V56, P815, DOI 10.1046/j.1523-1755.1999.00625.x; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OLKKONEN VM, 1994, METHOD CELL BIOL, V43, P43; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PINTO M, 1983, BIOL CELL, V47, P323; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Riento K, 1996, EUR J BIOCHEM, V239, P638, DOI 10.1111/j.1432-1033.1996.0638u.x; Riento K, 1998, J CELL SCI, V111, P2681; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SUOMALAINEN M, 1994, J VIROL, V68, P4879, DOI 10.1128/JVI.68.8.4879-4889.1994; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551	59	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13476	13483		10.1074/jbc.275.18.13476	http://dx.doi.org/10.1074/jbc.275.18.13476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788461	hybrid			2022-12-27	WOS:000086925300048
J	Shiose, A; Sumimoto, H				Shiose, A; Sumimoto, H			Arachidonic acid and phosphorylation synergistically induce a conformational change of p47(phox) to activate the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; DEPENDENT SUPEROXIDE PRODUCTION; COLONY-STIMULATING FACTOR; SRC HOMOLOGY-3 DOMAINS; HUMAN-NEUTROPHILS; SUBCELLULAR-LOCALIZATION; SUBUNIT P47(PHOX)	The superoxide-producing phagocyte NADPH oxidase can be activated by arachidonic acid (AA) or by phosphorylation of p47(phox) under cell-free conditions. The molecular mechanism underlying the activation, however, has remained largely unknown. Here we demonstrate that All at high concentrations (50-100 mu M), induces direct interaction between the oxidase factors p47(phox) and p22(phox) parallel with superoxide production. The interaction, being required for the oxidase activation, is mediated via the Src homology 3 (SH3) domains of p47(phox) (p47-(SH3)(2)), which are intramolecularly masked in a resting state. We also show that AA disrupts complexation of p47-(SH3)(2) with its intramolecular target fragment (amino acids 286-340) without affecting association of p47-(SH3)(2) with p22(phox), indicating that the disruption plays a crucial role in the induced interaction with p22(phox). Phosphorylation of p47(phox) by protein kinase C partially replaces the effects of AA; treatment of the SH3 target fragment with PKC in vitro results in a completely impaired interaction with p47-(SH3)(2), and the same treatment of the full-length p47(phox) leads to both interaction with p22(phox) and oxidase activation without AA, but to a lesser extent. Furthermore, phosphorylated p47(phox) effectively binds to p22(phox) and activates the oxidase in the presence of AA at low concentrations (1-5 mu M), where an unphosphorylated protein only slightly supports superoxide production. Thus AA, at high concentrations, fully induces the interaction of p47(phox) with p22(phox) by itself, whereas, at low concentrations, AA synergizes with phosphorylation of p47(phox) to facilitate the interaction, thereby activating the NADPH oxidase.	Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol & Struct, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol & Struct, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARK RA, 1987, J BIOL CHEM, V262, P4065; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ELY EW, 1995, BBA-LIPID LIPID MET, V1258, P135; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; Kodama T, 1999, BIOCHEM J, V337, P201, DOI 10.1042/0264-6021:3370201; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; Lopes LR, 1999, J BIOL CHEM, V274, P15533, DOI 10.1074/jbc.274.22.15533; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; OHNO Y, 1985, J BIOL CHEM, V260, P2409; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; Park JW, 1997, BIOCHEMISTRY-US, V36, P7474, DOI 10.1021/bi9700936; Park JW, 1997, J BIOL CHEM, V272, P11035; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SAKATA A, 1987, J IMMUNOL, V138, P4353; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502	50	200	204	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13793	13801		10.1074/jbc.275.18.13793	http://dx.doi.org/10.1074/jbc.275.18.13793			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788501	hybrid			2022-12-27	WOS:000086925300088
J	Ahmad, SS; Scandura, JM; Walsh, PN				Ahmad, SS; Scandura, JM; Walsh, PN			Structural and functional characterization of platelet receptor-mediated factor VIII binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-X ACTIVATION; VON-WILLEBRAND-FACTOR; PLACENTAL ANTICOAGULANT PROTEIN; PORCINE FACTOR-VIII; COAGULATION-FACTOR-VIII; INTRINSIC-FACTOR XASE; FACTOR-IXA; FACTOR-VA; VONWILLEBRAND-FACTOR; LIGHT-CHAIN	Optimal. rates of factor X (FX) activation require occupancy of receptors for factor IXa (FIXa), factor VIII (FVIII), and FX on the activated platelet surface, The presence of FVIII and FX increases 5-fold the affinity of FIXa for the surface of activated platelets, and the presence of FVIII or FVIIIa generates a high affinity, low capacity specific FX-binding site on activated platelets. We have now examined the effects of FX and active site-inhibited FIXa (EGR-FIXa) on the binding of both FVIII and FVIIIa to activated platelets and show the following: (a) von Willebrand factor inhibits FVIII binding (K-i = 0.54 nw) but not FVIIIa binding; (b) thrombin and the thrombin receptor activation peptide (SFLLRN amide) are the most potent agonists required for FVIII-binding site expression, whereas ADP is inert; (c) FVa does not compete with FVIIIa or FVIII for functional platelet-binding sites; and (d) Annexin V is a potent inhibitor of FVIIIa binding (IC50 = 10 nM) to activated platelets. The A2 domain of FVIII significantly increases the affinity and stoichiometry of FVIIIa binding to platelets and contributes to the stability of the FX-activating complex, Both FVIII and FVIIIa binding were specific, saturable, and reversible. FVIII binds to specific, high affinity receptors on activated platelets (n = 484 +/- 59; K-d = 3.7 +/- 0.31 nM) and FVIIIa interacts with an additional 300-500 sites per platelet with enhanced affinity (K-d = 1.5 +/- 0.11 nM). FVIIIa binding to activated platelets in the presence of FIXa and FX is closely coupled with rates of F-X activation. The presence of EGR-FIXa and FX increases both the number and the affinity of binding sites on activated platelets for both FVIII and FVIIIa, emphasizing the validity of a three-receptor model in the assembly of the F-X-activating complex on the platelet surface.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@astro.ocis.temple.edu		Scandura, Joseph/0000-0002-9525-143X	NHLBI NIH HHS [HL56914, HL56153, HL46213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, R01HL046213, P01HL056914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P20012; Ahmad SS, 1999, THROMB HAEMOSTASIS, P224; Ahmad SS, 1998, BLOOD, V92, p352A; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; AHMAD SS, 1994, TRENDS CARDIOVAS MED, V4, P271, DOI 10.1016/1050-1738(94)90031-0; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; Fay PJ, 1999, THROMB HAEMOSTASIS, V82, P193; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P142, DOI 10.1016/0167-4838(89)90153-2; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; JESTY J, 1990, J BIOL CHEM, V265, P17539; KANE WH, 1980, J BIOL CHEM, V255, P1170; KANE WH, 1982, J BIOL CHEM, V257, P3963; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LEE ML, 1983, THROMB RES, V30, P511, DOI 10.1016/0049-3848(83)90185-8; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; Li X, 1997, BIOCHEMISTRY-US, V36, P10760, DOI 10.1021/bi970052+; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LOLLAR P, 1987, J BIOL CHEM, V262, P17572; London F, 1996, BIOCHEMISTRY-US, V35, P16886, DOI 10.1021/bi960712v; MANN KG, 1990, BLOOD, V76, P1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1978, J CLIN INVEST, V62, P824, DOI 10.1172/JCI109194; MILETICH JP, 1979, BLOOD, V54, P1015, DOI 10.1182/blood.V54.5.1015.1015; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NESHEIM ME, 1993, THROMB HAEMOSTASIS, V70, P80; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; RODBARD D, 1984, COMPUTERS ENDOCRINOL; ROSING J, 1985, BLOOD, V65, P319; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCANDURA JM, 1995, THROMB HAEMOSTASIS, V73, P1214; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SUN J, 1993, THROMB RES, V69, P289, DOI 10.1016/0049-3848(93)90026-K; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; TRACY PB, 1979, J BIOL CHEM, V254, P354; TRACY PB, 1983, J BIOL CHEM, V258, P7264; TUDDENHAM EGD, 1982, BRIT J HAEMATOL, V52, P259, DOI 10.1111/j.1365-2141.1982.tb03888.x; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; VLOT AJ, 1995, BLOOD, V85, P3150, DOI 10.1182/blood.V85.11.3150.bloodjournal85113150; WAGENVOORD RJ, 1989, HAEMOSTASIS, V19, P196; WALSH PN, 1972, BRIT J HAEMATOL, V22, P743, DOI 10.1111/j.1365-2141.1972.tb05719.x; WALSH PN, 1978, BRIT J HAEMATOL, V40, P311, DOI 10.1111/j.1365-2141.1978.tb03667.x; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	80	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13071	13081		10.1074/jbc.275.17.13071	http://dx.doi.org/10.1074/jbc.275.17.13071			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777612	hybrid			2022-12-27	WOS:000086762300096
J	Dobashi, Y; Shoji, M; Kitagawa, M; Noguchi, T; Kameya, T				Dobashi, Y; Shoji, M; Kitagawa, M; Noguchi, T; Kameya, T			Simultaneous suppression of cdc2 and cdk2 activities induces neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEPENDENT KINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; NEURITE OUTGROWTH; BUTYROLACTONE-I; CYCLE CONTROL; EXPRESSION; LINE; PROLIFERATION	The involvement of cdc2 and cdk2 during neuronal differentiation in rat pheochromocytoma PC12 cells was examined. When PC12 cells were cultured with nerve growth factor (NGF), expression of cdc2 decreased significantly after day 5, while expression of cdk2 decreased gradually after day 7. Cells overexpressing cdc2 or cdk2 were resistant to NGF-induced differentiation and growth suppression, and maintained high cdc2 or cdk2 kinase activity, respectively, during NGF treatment. In contrast, the NGF-treated parental cells showed a marked decline in these kinase activities after day 3. When PC12 cells were treated with specific inhibitors of cdc2/cdk2 (butyrolactone-I, olomoucin), they showed marked neurite extension and up-regulation of microtubule-associated protein 2 expression. In addition, treatment with mixtures of antisense oligonucleotides for cdc2 and cdk2 resulted in down-regulation of both cdc2 and cdk2 kinase activities as well as significant neurite outgrowth and up-regulation of microtubule-associated protein 2 expression. However, neurite outgrowth was not observed in cells treated with either single antisense oligonucleotide, or antisense cdc2 + cdk4 or cdk2 + cdk4 oligonucleotide mixtures. These results suggest that simultaneous down-regulation of cdc2 and cdk2 activity is sufficient and necessary for neuronal differentiation in PC12 cells.	Kitasato Univ, Sch Med, Dept Pathol, Kanagawa 2288555, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Kitasato University; Kyushu University; Japan Science & Technology Agency (JST)	Dobashi, Y (corresponding author), Kitasato Univ, Sch Med, Dept Pathol, 1-15-1 Sagamihara, Kanagawa 2288555, Japan.	ydobashi@med.kitasato-u.ac.jp		Dobashi, Yoh/0000-0003-0507-3332				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Asiedu C, 1997, BLOOD, V90, P3430, DOI 10.1182/blood.V90.9.3430; CHO FS, 1993, BIOCHEM BIOPH RES CO, V191, P860, DOI 10.1006/bbrc.1993.1296; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dobashi Y, 1998, AM J PATHOL, V153, P963, DOI 10.1016/S0002-9440(10)65638-6; Dobashi Y, 1996, BIOCHEM BIOPH RES CO, V221, P351, DOI 10.1006/bbrc.1996.0599; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V244, P226, DOI 10.1006/bbrc.1998.8247; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Florenes VA, 1996, ONCOGENE, V13, P2447; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Katsetos CD, 1998, ANAT RECORD, V250, P351; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOTANI S, 1995, ONCOGENE, V10, P663; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QUELLE DE, 1995, ONCOGENE, V11, P635; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shoji M, 1999, AM J PATHOL, V154, P909, DOI 10.1016/S0002-9440(10)65338-2; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tang XM, 1998, J CELL BIOCHEM, V68, P128, DOI 10.1002/(SICI)1097-4644(19980101)68:1<128::AID-JCB13>3.0.CO;2-D; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	50	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12572	12580		10.1074/jbc.275.17.12572	http://dx.doi.org/10.1074/jbc.275.17.12572			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777547	hybrid			2022-12-27	WOS:000086762300031
J	Gao, M; Cui, HR; Loe, DW; Grant, CE; Almquist, KC; Cole, SPC; Deeley, RG				Gao, M; Cui, HR; Loe, DW; Grant, CE; Almquist, KC; Cole, SPC; Deeley, RG			Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; STIMULATED ATPASE ACTIVITY; ORGANIC ANION TRANSPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; LEUKOTRIENE C-4 TRANSPORT; CONJUGATE EXPORT PUMP; HAMSTER OVARY CELLS; HUMAN TUMOR-CELLS; MONOCLONAL-ANTIBODIES; MRP GENE	Multidrug Resistance Protein 1 (MRP1) transports diverse organic anionic conjugates and confers resistance to cytotoxic xenobiotics, The protein contains two nucleotide binding domains (NBDs) with features characteristic of members of the ATP-binding cassette superfamily and exhibits basal ATPase activity that can be stimulated by certain substrates. It is not known whether the two NBDs of MRP1 are functionally equivalent. To investigate this question, we have used a baculovirus dual expression vector encoding both halves of MRP1 to reconstitute an active transporter and have compared the ability of each NBD to be photoaffinity-labeled with 8-azido-[P-32]ATP and to trap 8-azido[P-32]ADP in the presence of orthovanadate. We found that NBD1 was preferentially labeled with 8-azido[P-32]ATP, while trapping of 8-azido-[P-32]ADP occurred predominantly at NBD2. Although trapping at NBD2 was dependent on co-expression of both halves of MRP1, binding of 8-azido-ATP by NBD1 remained detectable when the NH2-proximal half of MRP1 was expressed alone and when NBD1 was expressed as a soluble polypeptide. Mutation of the conserved Walker A lysine 684 or creation of an insertion mutation between Walker A and B motifs eliminated binding by NBD1 and all detectable trapping of 8-azido-ADP at NBD2. Both mutations decreased leukotriene C-4 (LTC4) transport by approximately 70%. Mutation of the NBD2 Walker A lysine 1333 eliminated trapping of 8-azido-ADP by NBD2 but, in contrast to the mutations in NBD1, essentially eliminated LTC, transport activity without affecting labeling of NBD1 with 8-azido-[P-32]ATP.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Rm A315,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				ALMQUIST KC, 1995, CANCER RES, V55, P102; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; GRANT CE, 1994, CANCER RES, V54, P357; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Heijn M, 1997, BBA-BIOMEMBRANES, V1326, P12, DOI 10.1016/S0005-2736(97)00003-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Jedlitschky G, 1996, CANCER RES, V56, P988; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1999, CANCER RES, V59, P175; KRUH GD, 1994, CANCER RES, V54, P1649; Lee K, 1998, CANCER RES, V58, P2741; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Muller M, 1996, J HEPATOL, V24, P100; Muller M, 1996, J BIOL CHEM, V271, P1877; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Priebe W, 1998, BIOCHEM BIOPH RES CO, V247, P859, DOI 10.1006/bbrc.1998.8887; RIORDAN JR, 1989, SCIENCE, V245, P1066; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAROM FJ, 1995, J BIOL CHEM, V270, P10334, DOI 10.1074/jbc.270.17.10334; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Uchiumi T, 1998, BIOCHEM BIOPH RES CO, V252, P103, DOI 10.1006/bbrc.1998.9546; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	67	158	158	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13098	13108		10.1074/jbc.275.17.13098	http://dx.doi.org/10.1074/jbc.275.17.13098			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777615	hybrid			2022-12-27	WOS:000086762300099
J	Small, KM; Forbes, SL; Rahman, FF; Bridges, KM; Liggett, SB				Small, KM; Forbes, SL; Rahman, FF; Bridges, KM; Liggett, SB			A four amino acid deletion polymorphism in the third intracellular loop of the human alpha(2C)-adrenergic receptor confers impaired coupling to multiple effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACOUSTIC STARTLE REFLEX; HUMAN BETA(2)-ADRENERGIC RECEPTOR; ALPHA-2-ADRENERGIC RECEPTORS; ALPHA(2)-ADRENERGIC RECEPTOR; GENETIC ALTERATION; PHOSPHOLIPASE-C; DOWN-REGULATION; SUBTYPE; AGONIST; EXPRESSION	The alpha(2)-adrenergic receptors (alpha(2)ARs) play a critical role in modulating neurotransmitter release in the central and peripheral sympathetic nervous systems. A polymorphism of the alpha(2C)AR subtype localized to human chromosome 4 (the pharmacologic alpha(2C)AR subtype) within an intracellular domain has been identified in normal individuals. The polymorphism (denoted De1322-325) is because of an in-frame 12-nucleic acid deletion encoding a receptor lacking Gly-Ala-Gly-Pro in the third intracellular loop. To delineate the functional consequences of this structural alteration, Chinese hamster ovary cells were permanently transfected with constructs encoding wild-type human alpha(2C)AR and the polymorphic receptor, The De1322-325 variant had decreased high affinity,agonist binding (K-H = 7.3 +/- 0.95 vel sus 3.7 +/- 0.43 nM; %R-H = 31 +/- 4 versus 49 +/- 4) compared with wild-type indicating impaired formation of the agonist-receptor-C: protein complex, The polymorphic receptor displayed markedly depressed epinephrine-promoted coupling to G(i), inhibiting adenylyl cyclase by 10 +/- 4.3% compared with 73 +/- 2.4% for wild-type alpha(2C)AR, This also was so for the endogenous ligand norepinephrine and full and partial synthetic agonists, Depressed agonist-promoted coupling to the stimulation of MAP kinase (similar to 71% impaired) and inositol phosphate production (similar to 60% impaired) was also found with the polymorphic receptor. The Del322-325 receptor was similar to 10 times more frequent in African-Americans compared with Caucasians (allele frequencies 0.381 versus 0.040). Given this significant loss of function phenotype in several signal transduction cascades and the skewed ethnic prevalence, Del322-325 represents a pharmacoethnogenetic locus and may also be the basis for interindividual variation in cardiovascular or central nervous system pathophysiology.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave,Rm 7507, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL53436] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adolfsson PI, 1998, GYNECOL OBSTET INVES, V45, P145, DOI 10.1159/000009944; Bjorklund M, 1998, MOL PHARMACOL, V54, P569; Comings DE, 1999, CLIN GENET, V55, P160, DOI 10.1034/j.1399-0004.1999.550304.x; Dorn GW, 1997, BIOCHEMISTRY-US, V36, P6415, DOI 10.1021/bi970080s; EASON MG, 1993, MOL PHARMACOL, V44, P70; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EASON MG, 1992, J BIOL CHEM, V267, P25473; FRASER CM, 1989, J BIOL CHEM, V264, P11754; Gavin KT, 1997, N-S ARCH PHARMACOL, V355, P406, DOI 10.1007/PL00004961; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; Jewell-Motz EA, 1998, BIOCHEMISTRY-US, V37, P15720, DOI 10.1021/bi980999r; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; Kumari V, 1996, PSYCHOPHARMACOLOGY, V123, P353, DOI 10.1007/BF02246646; Large V, 1997, J CLIN INVEST, V100, P3005, DOI 10.1172/JCI119854; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; MORGAN CA, 1993, PSYCHOPHARMACOLOGY, V110, P342, DOI 10.1007/BF02251291; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; Rosin DL, 1996, J COMP NEUROL, V372, P135; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Sallinen J, 1999, MOL PSYCHIATR, V4, P443, DOI 10.1038/sj.mp.4000543; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; Sallinen J, 1998, J NEUROSCI, V18, P3035; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; Shi TJS, 1999, NEUROREPORT, V10, P2835, DOI 10.1097/00001756-199909090-00025; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Tanila H, 1999, EUR J NEUROSCI, V11, P599, DOI 10.1046/j.1460-9568.1999.00464.x	38	152	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23059	23064		10.1074/jbc.M000796200	http://dx.doi.org/10.1074/jbc.M000796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801795	hybrid			2022-12-27	WOS:000088419400062
J	Zang, Q; Lu, CF; Huang, CC; Takagi, J; Springer, TA				Zang, Q; Lu, CF; Huang, CC; Takagi, J; Springer, TA			The top of the inserted-like domain of the integrin lymphocyte function-associated antigen-1 beta subunit contacts the alpha subunit beta-propeller domain near beta-sheet 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; LIGAND-BINDING REGION; I-DOMAIN; A-DOMAIN; CELL-ADHESION; MONOCLONAL-ANTIBODIES; CRITICAL RESIDUES; CRYSTAL-STRUCTURE; IMMUNE-SYSTEM; AMINO-ACIDS	We find that monoclonal antibody YTA-1 recognizes an epitope formed by a combination of the integrin alpha(L) and beta(2) subunits of LFA-1, Using human/mouse chimeras of the alpha(L) and beta(2) subunits, we determined that YTA-1 binds to the predicted inserted (I)-like domain of the beta(2) subunit and the predicted beta-propeller domain of the cu, subunit, Substitution into mouse LFA-1 of human residues Ser(302) and Arg(303) of the beta(2) subunit and Pro(78), Thr(79) Asp(80), Ile(365), and Asn(367) Of the alpha(L) subunit is sufficient to completely reconstitute YTA-1 reactivity. Antibodies that bind to epitopes that are nearby in models of the I-like and beta-propeller domains compete with YTA-1 monoclonal antibody for binding. The predicted beta-propeller domain of integrin alpha subunits contains seven beta-sheets arranged like blades of a propeller around a pseudosymmetry axis. The antigenic residues cluster on the bottom of this domain in the 1-2 loop of blade 2, and on the side of the domain in beta-strand 4 of blade 3. The I domain is inserted between these blades on the top of the beta-propeller domain. The antigenic residues in the beta subunit localize to the top of the I-like domain near the putative Mg2+ ion binding site. Thus, the I-like domain contacts the bottom or side of the beta-propeller domain near beta-sheets 2 and 3, YTA-1 preferentially reacts with activated LFA-1 and is a function-blocking antibody, suggesting that conformational movements occur near the interface it defines between the LFA-1 alpha and beta subunits.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.			Zang, Qun (Sophia)/0000-0002-6397-8896	NATIONAL CANCER INSTITUTE [R01CA031798, R37CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; GAILIT J, 1988, J BIOL CHEM, V263, P12927; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Lu CF, 1997, J IMMUNOL, V159, P268; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; OXVIG, 1999, P NATL ACAD SCI US, V96, P2215; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RANDI AM, 1994, J BIOL CHEM, V269, P12395; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; Shih DT, 1997, J CELL SCI, V110, P2619; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; SUGIE K, 1995, J IMMUNOL, V154, P1691; SUGIE K, 1995, INT IMMUNOL, V7, P763; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	56	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22202	22212		10.1074/jbc.M002883200	http://dx.doi.org/10.1074/jbc.M002883200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10781608	hybrid			2022-12-27	WOS:000088363800063
J	Lascombe, MB; Gregoire, C; Poncet, P; Tavares, GA; Rosinski-Chupin, I; Rabillon, J; Goubran-Botros, H; Mazie, JC; David, B; Alzari, PM				Lascombe, MB; Gregoire, C; Poncet, P; Tavares, GA; Rosinski-Chupin, I; Rabillon, J; Goubran-Botros, H; Mazie, JC; David, B; Alzari, PM			Crystal structure of the allergen Equ c 1 - A dimeric lipocalin with restricted IgE-reactive epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; BOVINE BETA-LACTOGLOBULIN; 3-DIMENSIONAL STRUCTURE; BIOCHEMICAL-PROPERTIES; HISTAMINE-BINDING; REFINEMENT; RESOLUTION; CLONING; CHROMATOGRAPHY; PURIFICATION	The three-dimensional structure of the major horse allergen Equ c 1 has been determined at 2.3 Angstrom resolution by x-ray crystallography. Equ c 1 displays the typical fold of lipocalins, a beta-barrel flanked by a C-terminal alpha-helix. The space between the two beta-sheets of the barrel defines an internal cavity that could serve, as in other lipocalins, for the binding and transport of small hydrophobic ligands. Equ c 1 crystallizes in a novel dimeric form, which is distinct from that observed in other lipocalin dimers and corresponds to the functional form of the allergen. Binding studies of point mutants of the allergen with specific monoclonal antibodies raised in mouse and IgE serum from horse allergic patients allowed to identify putative B cell antigenic determinants. In addition, total inhibition of IgE serum recognition by a single specific monoclonal antibody revealed the restricted nature of the IgE binding target on the molecular surface of Equ c 1.	Inst Pasteur, Unite Biochim Struct, CNRS, URA 2185,Unite Immunoallergie, F-75724 Paris 15, France; Inst Pasteur, Unite Immunoallergie, F-75724 Paris 15, France; Inst Pasteur, Biol & Genet Dev Lab, F-75724 Paris 15, France; Inst Pasteur, Lab Ingn Anticorps, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Alzari, PM (corresponding author), Inst Pasteur, Unite Biochim Struct, CNRS, URA 2185,Unite Immunoallergie, 25 & 28 Rue Docteur Roux, F-75724 Paris 15, France.	alzari@pasteur.fr	Poncet, Pascal/ABD-5096-2020	Alzari, Pedro/0000-0002-4233-1903				Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; Blanchet MA, 1996, NAT STRUCT BIOL, V3, P934, DOI 10.1038/nsb1196-934; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Botros HG, 1998, J CHROMATOGR B, V710, P57, DOI 10.1016/S0378-4347(98)00130-3; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chaudhuri BN, 1999, ACTA CRYSTALLOGR D, V55, P753, DOI 10.1107/S0907444998017211; Coles M, 1999, J MOL BIOL, V289, P139, DOI 10.1006/jmbi.1999.2755; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DANDEU JP, 1993, J CHROMATOGR-BIOMED, V621, P23, DOI 10.1016/0378-4347(93)80072-C; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; Flower DR, 1996, BIOCHEM J, V318, P1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Gregoire C, 1999, ACTA CRYSTALLOGR D, V55, P880, DOI 10.1107/S0907444998015510; Gregoire C, 1996, J BIOL CHEM, V271, P32951, DOI 10.1074/jbc.271.51.32951; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V78, P928, DOI 10.1016/0091-6749(86)90242-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Musu T, 1997, CLIN REV ALLERG IMMU, V15, P485, DOI 10.1007/BF02737743; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLSON JR, 1986, J IMMUNOL, V136, P2109; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; RIBEIRO JMC, 1994, J EXP MED, V180, P2251, DOI 10.1084/jem.180.6.2251; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Santa H, 1998, J PROTEIN CHEM, V17, P657, DOI 10.1007/BF02780967; Tegoni M, 1996, NAT STRUCT BIOL, V3, P863, DOI 10.1038/nsb1096-863; Virtanen T, 1999, IMMUNOL TODAY, V20, P398, DOI 10.1016/S0167-5699(99)01515-7; WALLS AF, 1985, J ALLERGY CLIN IMMUN, V75, P242, DOI 10.1016/0091-6749(85)90053-3; Zanotti G, 1998, ACTA CRYSTALLOGR D, V54, P1049, DOI 10.1107/S0907444998002303; Zeiler T, 1999, J IMMUNOL, V162, P1415	43	77	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21572	21577		10.1074/jbc.M002854200	http://dx.doi.org/10.1074/jbc.M002854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10787420	hybrid, Green Published			2022-12-27	WOS:000088230600082
J	Mukae, N; Yokoyama, H; Yokokura, T; Sakoyama, Y; Sakahira, H; Nagata, S				Mukae, N; Yokoyama, H; Yokokura, T; Sakoyama, Y; Sakahira, H; Nagata, S			Identification and developmental expression of inhibitor of caspase-activated DNase (ICAD) in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FRAGMENTATION FACTOR; APOPTOSIS; PROTEASES; ECDYSONE; CLEAVAGE; REAPER; DFF45; SUBUNIT; PROTEIN	DNA fragmentation, a hallmark of apoptosis, is regulated by a specific nuclease called caspase-activated DNase (CAD) and its inhibitor (ICAD). When cell lysates from Drosophila S2 cells were chemically denatured and the denatured proteins were removed after dialysis, the supernatant inhibited Drosophila CAD (dCAD). To identify the inhibitor, we tested recombinant DREP-1, which was previously identified using the Drosophila EST data base and found it also inhibited dCAD DNase. An antibody against DREP-1 inhibited the ICAD activity in the S2 cell extracts, confirming the identification of DREP-1 as a Drosophila homolog of ICAD (dICAD). The recombinant DREP-1/dICAD was cleaved at a specific site by human caspase 3 as well as by extracts prepared from S2 cells undergoing apoptosis. Biochemical fractionation and immunoprecipitation of dICAD from S2 cell extracts indicated that dICAD is complexed with dCAD in proliferating cells. The expression of the caspase-resistant form of dICAD/DREP-1 in a Drosophila neuronal cell line prevented the apoptotic DNA fragmentation. Northern hybridization and the immunohistochemical analyses revealed that the expression of the dICAD gene is developmentally regulated.	Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, B-3,2-2 Yamada-Oka, Suita, Osaka 5650871, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; Kondo T, 1997, P NATL ACAD SCI USA, V94, P11951, DOI 10.1073/pnas.94.22.11951; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; McIlroy D, 2000, GENE DEV, V14, P549; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagano M, 1998, NEUROSCI RES, V31, P113, DOI 10.1016/S0168-0102(98)00030-3; Nakagoshi H, 1998, GENE DEV, V12, P2724, DOI 10.1101/gad.12.17.2724; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UI K, 1994, IN VITRO CELL DEV-AN, V30A, P209; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yokoyama H, 2000, J BIOL CHEM, V275, P12978, DOI 10.1074/jbc.275.17.12978	39	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21402	21408		10.1074/jbc.M909611199	http://dx.doi.org/10.1074/jbc.M909611199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781612	hybrid			2022-12-27	WOS:000088230600060
J	Fan, YX; McPhie, P; Miles, EW				Fan, YX; McPhie, P; Miles, EW			Thermal repair of tryptophan synthase mutations in a regulatory intersubunit salt bridge - Evidence from arrhenius plots, absorption spectra, and primary kinetic isotope effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; ALPHA(2)BETA(2) COMPLEX REVEALS; INDUCED CONFORMATIONAL-CHANGES; SALMONELLA-TYPHIMURIUM; BIENZYME COMPLEX; BETA-SUBUNIT; ALPHA-SUBUNIT; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ACTIVE-SITE	This work is aimed at understanding how protein structure and conformation regulate activity and allosteric communication in the tryptophan synthase alpha(2)beta(2) complex from Salmonella typhimurium. Previous erystallographic and kinetic results suggest that both monovalent cations and a salt bridge between alpha subunit Asp(56) and beta subunit Lys(167) play allosteric roles. Here we show that mutation of either of these salt bridging residues produced deleterious effects that could be repaired by increased temperature in combination with CsCl or with NaCl plus an alpha subunit ligand, alpha-glycerol 3-phosphate. Arrhenius plots of the activity data under these conditions were nonlinear, The same conditions yielded temperature-dependent changes in the equilibrium distribution of enzyme-substrate intermediates and in primary kinetic isotope effects. We correlate the results with a model in which the mutant enzymes are converted by increased temperature from a low activity, "open" conformation to a high activity, "closed" conformation under certain conditions. The allosteric ligand and different monovalent cations affected the equilibrium between the open and closed forms. The results suggest that alpha subunit Asp(56) and beta subunit Lys(167) are not essential for catalysis and for allosteric communication between the alpha and beta subunits but that their mutual interaction is important in stabilization of the active, closed form of the alpha(2)beta(2) complex.	NIDDK, Sect Enzyme Struct & Funct, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Miles, EW (corresponding author), NIDDK, Sect Enzyme Struct & Funct, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,8 Ctr Dr MSC 0830, Bethesda, MD 20892 USA.	EdithM@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIHDK034002, Z01DK034002, Z01DK024942, Z01DK024140, ZIADK034002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED SA, 1991, J BIOL CHEM, V266, P21548; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P11; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 2000, IN PRESS BIOCH VITAM; Fan YX, 2000, BIOCHEMISTRY-US, V39, P4692, DOI 10.1021/bi9921586; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rowlett R, 1998, BIOCHEMISTRY-US, V37, P2961, DOI 10.1021/bi972286z; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang LH, 1997, J BIOL CHEM, V272, P7859, DOI 10.1074/jbc.272.12.7859; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG XJ, 1993, J BIOL CHEM, V268, P22269	31	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20302	20307		10.1074/jbc.M001135200	http://dx.doi.org/10.1074/jbc.M001135200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801803	hybrid			2022-12-27	WOS:000088084500014
J	Norcum, MT; Warrington, JA				Norcum, MT; Warrington, JA			Accelerated Publication - The cytokine portion of p43 occupies a central position within the eukaryotic multisynthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING POLYPEPTIDE-II; TRANSFER-RNA-SYNTHETASE; PROTEIN-PROTEIN INTERACTIONS; CELLS; APOPTOSIS; PRECURSOR	Multicellular eukaryotes contain a macromolecular assembly of nine aminoacyl-tRNA synthetase activities and three auxiliary proteins. One of these, p43, is the precursor of endothelial monocyte-activating polypeptide II (EMAP II), an inflammatory cytokine involved in apoptotic processes. As a step toward understanding this paradoxical association, the EMAP II portion of p43 has been localized within the rabbit reticulocyte multisynthetase complex. Immunoblot analysis demonstrates strong reaction of anti-EMAP II antiserum with p43, as well as cross-reactivity with isoleucyl-tRNA synthetase. Electron microscopic images of immunocomplexes show two antibody binding sites, The primary site is near the midpoint of the multisynthetase complex at the intersection of the arms with the base. This site near the lower edge of the central cleft is assigned to the C-terminal cytokine portion of p43, The secondary site of antibody binding is in the base of the particle and maps the location of isoleucyl-tRNA synthetase. These data allow refinement of the three-domain model of polypeptide distribution within the multisynthetase complex. Moreover, the central location of p43/EMAP II suggests a role for this polypeptide in optimizing normal function and in rapid disruption of essential cellular machinery when apoptosis is signaled.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Norcum, MT (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.							Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; Francklyn C, 1997, RNA, V3, P954; Gnant MFX, 1999, CANCER RES, V59, P4668; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; Norcum MT, 1999, J BIOL CHEM, V274, P12205, DOI 10.1074/jbc.274.18.12205; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; Norcum MT, 1999, FEBS LETT, V447, P217; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiner AM, 1999, SCIENCE, V284, P63, DOI 10.1126/science.284.5411.63; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	22	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17921	17924		10.1074/jbc.C000266200	http://dx.doi.org/10.1074/jbc.C000266200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10787402	hybrid			2022-12-27	WOS:000087659400002
J	Bayele, HK; Eisenthal, RS; Towner, P				Bayele, HK; Eisenthal, RS; Towner, P			Complementation of a glucose transporter mutant of Schizosaccharomyces pombe by a novel Trypanosoma brucei gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; EXPRESSION; PROTEIN; LEISHMANIA; ACID; METABOLISM; SEQUENCES; SUBSTRATE; MEMBERS; CLONING	The African trypanosome Trypanosoma brucei has a digenetic life cycle that involves the insect vector and the mammalian host. This is underscored by biochemical switches in its nutritional requirements. In the insect vector, the parasite relies on amino acid catabolism, but in the mammalian host, it derives its energy exclusively from blood glucose. Glucose transport is facilitated, and constitutes the rate-limiting step in ATP synthesis. Here, we report the cloning of a novel glucose transporter-related gene by heterologous screening of a lambda EMBL4 genomic library of T. brucei EATRO 164 using a rat liver glucose transporter cDNA clone. Genomic analysis shows that the gene is present as a single copy within the parasite genome. The gene encodes a protein with an estimated molecular mass of 55.9 kDa, which shares only segmental homology with members of the glucose transporter superfamily, Several potential post-translational modification sites including phosphorylation, N-glycosylation, and cotranslational myristoylation sites also punctuate the sequence. It is distinguished from classical transporter proteins by the absence of putative hydrophobic membrane-spanning domains. However, this protein was capable of complementing Schizosaccharomyces pombe glucose transporter mutants. The rescued phenotype conferred the ability of the cells to grow on a broad range of sugars, both monosaccharides and disaccharides. The kinetics of glucose uptake reflected those in T, brucei, In addition to complementation in yeast, we also showed that the gene enhanced glucose uptake in cultured mammalian cells.	Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England	University of Bath	Bayele, HK (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Rowland Hill St, London NW3 2PF, England.	h.bayele@rfc.ucl.ac.uk						ALVAREZ J, 1987, J BIOL CHEM, V262, P35002; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRINGAUD F, 1992, MOL BIOCHEM PARASIT, V52, P111, DOI 10.1016/0166-6851(92)90040-Q; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; CHIN JJ, 1986, J BIOL CHEM, V261, P7101; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; FRY AJ, 1993, MOL BIOCHEM PARASIT, V60, P9, DOI 10.1016/0166-6851(93)90023-Q; GRUENBERG J, 1978, EUR J BIOCHEM, V89, P461, DOI 10.1111/j.1432-1033.1978.tb12549.x; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOEVER M, 1992, ARCH MICROBIOL, V157, P191, DOI 10.1007/BF00245289; JAMES DE, 1993, J CELL SCI, V104, P607; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGFORD CK, 1992, MOL BIOCHEM PARASIT, V55, P51, DOI 10.1016/0166-6851(92)90126-5; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MICHELS PAM, 1986, J MOL EVOL, V24, P45, DOI 10.1007/BF02099950; MILBRADT B, 1994, MICROBIOL-SGM, V140, P2617, DOI 10.1099/00221287-140-10-2617; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PARSONS M, 1990, UCLA SYM BI, V130, P247; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sherman F., 1986, METHODS YEAST GENETI; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; STOCKWELL PA, 1988, TRENDS BIOCHEM SCI, V13, P332; TERKUILE BH, 1991, J BIOL CHEM, V266, P857; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VONBRAND T, 1951, BIOCH PHYSL PROTOZOA, V1, P177; ZHAO YQ, 1995, DNA CELL BIOL, V14, P359, DOI 10.1089/dna.1995.14.359	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14217	14222		10.1074/jbc.275.19.14217	http://dx.doi.org/10.1074/jbc.275.19.14217			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799499	hybrid			2022-12-27	WOS:000087006900030
J	Dallaire, F; Dupuis, S; Fiset, S; Chabot, B				Dallaire, F; Dupuis, S; Fiset, S; Chabot, B			Heterogeneous nuclear ribonucleoprotein A1 and UP1 protect mammalian telomeric repeats and modulate telomere replication in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; OXYTRICHA MACRONUCLEAR DNA; HNRNP A1; TETRAHYMENA TELOMERASE; HUMAN-CHROMOSOMES; RNA; END; SITE; YEAST; RECOGNITION	The heterogeneous nuclear ribonucleoprotein Al protein and a shortened derivative (UP1) promote telomere elongation in mammalian cells. To gain insights into the function of A1/UP1 in telomere biogenesis, we have investigated the binding properties of recombinant A1/UP1 and derivatives to single-stranded DNA oligonucleotides. Our results indicate that UP1 prefers to bind to DNA carrying single-stranded telomeric extensions at the 3' terminus. The RNA recognition motif 1 is sufficient for strong and specific binding to oligomers carrying vertebrate telomeric repeats. We find that the binding of A1/UP1 protects telomeric sequences against degradation by endo- and exonucleases. Moreover, A1/UP1 binding prevents extension by telomerase and terminal deoxynucleotidyltransferase and inhibits rNTP-dependent DNA synthesis in vitro. These observations are consistent with the hypothesis that A1/UP1 is a telomere end-binding protein that plays a role in the maintenance of long 3' overhangs.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Chabot, B (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada.		Chabot, Benoit/A-8943-2008	Chabot, Benoit/0000-0003-0994-0042				AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Blackburn EH, 1995, TELOMERES; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, EMBO J, V14, P5422, DOI 10.1002/j.1460-2075.1995.tb00226.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; FANG G, 1995, TELOMERES, P69; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; GUALBERTO A, 1995, J BIOL CHEM, V270, P4509, DOI 10.1074/jbc.270.9.4509; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; HERRICK G, 1976, J BIOL CHEM, V251, P2142; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Johnston SD, 1999, MOL CELL BIOL, V19, P923; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1992, BIOCHEMISTRY-US, V31, P10835, DOI 10.1021/bi00159a026; Reveal PM, 1997, J BIOL CHEM, V272, P11678, DOI 10.1074/jbc.272.18.11678; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; Steiner BR, 1996, P NATL ACAD SCI USA, V93, P2817, DOI 10.1073/pnas.93.7.2817; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	46	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14509	14516		10.1074/jbc.275.19.14509	http://dx.doi.org/10.1074/jbc.275.19.14509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799534	hybrid			2022-12-27	WOS:000087006900068
J	English, WR; Puente, XS; Freije, JMP; Knauper, V; Amour, A; Merryweather, A; Lopez-Otin, C; Murphy, G				English, WR; Puente, XS; Freije, JMP; Knauper, V; Amour, A; Merryweather, A; Lopez-Otin, C; Murphy, G			Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGELATINASE-A; TISSUE INHIBITORS; CATALYTIC DOMAIN; GELATINASE-A; BIOCHEMICAL-CHARACTERIZATION; IV COLLAGENASE; MT-MMPS; EXPRESSION; CELLS; IDENTIFICATION	Membrane type 4 matrix metalloproteinase (MT4-MMP) shows the least sequence homology to the other MT-MMPs, suggesting a distinct function for this protein. We have isolated a complete cDNA corresponding to the mouse homologue which includes the signal peptide and a complete pro-domain, features that were lacking from the human form originally isolated. Mouse MT4-MMP (mMT4-MMP) expressed in COS-7 cells is located at the cell surface but does not show ability to activate pro-MMP2. The pro-catalytic domain was expressed in Escherichia coli as insoluble inclusions and active enzyme recovered after refolding. Activity of the isolated catalytic domain against synthetic peptides commonly used for MMP enzyme assays could be inhibited by TIMP1, -2, and -3. The recombinant mMT4-MMP catalytic domain was also unable to activate pro-MMP2 and was very poor at hydrolyzing components of the extracellular matrix with the exception of fibrinogen and fibrin. mMT4-MMP was able to hydrolyze efficiently a peptide consisting of the pro-tumor necrosis factor alpha (TNF alpha) cleavage site, a glutathione S-transferase-proTNF alpha fusion protein, and was found to shed pro-TNF alpha when co-transfected in COS-7 cells. MT4-MMP was detected by Western blot in monocyte/macrophage cell lines which in combination with its fibrinolytic and TNF alpha-converting activity suggests a role in inflammation.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of East Anglia; University of Oviedo	English, WR (corresponding author), Univ E Anglia, Sch Biol Sci, Univ Plain, Norwich NR4 7TJ, Norfolk, England.		Puente, Xosé S./ADB-0672-2022; Freije, José M.P./A-6535-2008; López-Otín, Carlos/AAB-2106-2020	Puente, Xosé S./0000-0001-9525-1483; Freije, José M.P./0000-0002-4688-8266; López-Otín, Carlos/0000-0001-6964-1904; English, William/0000-0003-3024-2441; Knauper, Vera/0000-0002-3965-9924				Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Beckett RP, 1998, EXPERT OPIN THER PAT, V8, P259, DOI 10.1517/13543776.8.3.259; BINI A, 1999, BIOCHEMISTRY-US, V35, P13056; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kajita M, 1999, FEBS LETT, V457, P353, DOI 10.1016/S0014-5793(99)01065-0; Knauper V, 1998, BIOL EXTRAC, P199; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kolkenbrock H, 1999, BIOL CHEM, V380, P1103, DOI 10.1515/BC.1999.137; Lee ME, 1999, MOL CELLS, V9, P7; Llano E, 1999, CANCER RES, V59, P2570; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Stanton H, 1998, J CELL SCI, V111, P2789; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; Velasco G, 2000, CANCER RES, V60, P877; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619; ZARDENETA G, 1994, ANAL BIOCHEM, V223, P1, DOI 10.1006/abio.1994.1537	43	167	178	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14046	14055		10.1074/jbc.275.19.14046	http://dx.doi.org/10.1074/jbc.275.19.14046			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799478	hybrid			2022-12-27	WOS:000087006900008
J	Moskovitz, J; Poston, JM; Berlett, BS; Nosworthy, NJ; Szczepanowski, R; Stadtman, ER				Moskovitz, J; Poston, JM; Berlett, BS; Nosworthy, NJ; Szczepanowski, R; Stadtman, ER			Identification and characterization of a putative active site for peptide methionine sulfoxide reductase (MsrA) and its substrate stereospecificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; DEGRADATION; EXPRESSION; RESIDUES; GENE; RADICALS; DAMAGE	Peptide methionine sulfoxide reductases (MsrA) from many different organisms share a consensus amino acid sequence (GCFWG) that could play an important role in their active site. Site-directed single substitution of each of these amino acids except glycines in the yeast MsrA resulted in total loss of enzyme activity, Nevertheless, all the recombinant MsrA mutants and native proteins had a very similar circular dichroism spectrum. The demonstration that either treatment with iodoacetamide or replacement of the motif cysteine with serine leads to inactivation of the enzyme underscores the singular importance of cysteine residues in the activity of MsrA. The recombinant yeast MsrA was used for general characterization of the enzyme. Its K-m value was similar to the bovine MsrA and appreciably lower than the K-m of the bacterial enzyme. Also, it was shown that the enzymatic activity increased dramatically with increasing ionic strength. The recombinant yeast MsrA activity and the reduction activity of free methionine sulfoxide(s) were stereoselective toward the L-methionine S-sulfoxide and S-methyl p-tolyl sulfoxide. It was established that a methionine auxotroph yeast strain could grow on either form of L-methionine sulfoxide.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20982 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Moskovitz, J (corresponding author), NHLBI, Biochem Lab, NIH, Bethesda, MD 20982 USA.	jmosko@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000304] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROT N, 1982, ANAL BIOCHEM, V122, P291, DOI 10.1016/0003-2697(82)90283-4; BROT N, 1984, METHOD ENZYMOL, V107, P352; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; FASMAN GD, 1996, CIRCULAR DICHROISM C, P124; LAVINE TF, 1947, J BIOL CHEM, V169, P477; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MINETTI G, 1994, ITAL J BIOCHEM, V43, P273; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 1999, METHOD ENZYMOL, V300, P239; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; Moskovitz J, 1999, FASEB J, V13, pA1354; REDDY VY, 1994, J BIOL CHEM, V269, P4683; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; STADTMAN ER, 1977, P NATL ACAD SCI USA, V74, P2761, DOI 10.1073/pnas.74.7.2761; VANDER AJ, 1995, RENAL PHYSL, V5, P101; Wizemann TM, 1996, P NATL ACAD SCI USA, V93, P7985, DOI 10.1073/pnas.93.15.7985; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; YANG JT, 1986, METHOD ENZYMOL, V130, P208	22	153	156	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14167	14172		10.1074/jbc.275.19.14167	http://dx.doi.org/10.1074/jbc.275.19.14167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799493	hybrid			2022-12-27	WOS:000087006900023
J	Bae, DG; Gho, YS; Yoon, WH; Chae, CB				Bae, DG; Gho, YS; Yoon, WH; Chae, CB			Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; COMBINATORIAL LIBRARIES; CARCINOMA-CELLS; FACTOR VEGF; CANCER METASTASIS; TYROSINE KINASE; RECEPTOR; IDENTIFICATION; BINDING	Tumor angiogenesis is a critical step for the growth and metastasis of solid tumors. Vascular endothelial growth factor (VEGF) is a specific and potent angiogenic factor and contributes to the development of solid tumors by promoting tumor angiogenesis, Therefore, it is a prime therapeutic target for the development of antagonists for treatment of cancer. We identified from peptide libraries arginine-rich hexapeptides that inhibit the interaction of VEGF(165) with VEGF receptor (IC50 = 2-4 mu M). They have no effect on binding of basic fibroblast growth factor to cellular receptor. The hexapeptides inhibit the proliferation of human umbilical vein endothelial cells induced by VEGF(165) without toxicity. The peptides bind to VEGF and inhibit binding of both VEGF(165) and VEGF(121), suggesting that the peptides interact with the main body of VEGF but not the heparin-binding domain that is absent in VEGF(121). The identified peptides block the angiogenesis induced by VEGF(165) in vivo in the chick chorioallantoic membrane and the rabbit cornea. Furthermore, one of the hexapeptides, RRKRRR, blocks the growth and metastasis of VEGF-secreting HM7 human colon carcinoma cells in nude mice, Based on our results, the arginine-rich hexapeptides may be effective for the treatment of various human tumors and other angiogenesis-dependent diseases that are related to the action of VEGF and could also serve as leads for development of more effective drugs.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Chungnam Natl Univ, Coll Med, Dept Surg, Tae Jun 301130, South Korea	Pohang University of Science & Technology (POSTECH); Chungnam National University	Chae, CB (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	cbchae@postech.ac.kr	Yoon, Woong/A-2606-2016	Yoon, Woong/0000-0002-8598-3127				ASANO M, 1995, CANCER RES, V55, P5296; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FIEBICH BL, 1993, EUR J BIOCHEM, V211, P19, DOI 10.1111/j.1432-1033.1993.tb19865.x; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1974, CANCER RES, V34, P2109; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Gho YS, 1997, CANCER RES, V57, P3733; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKOB W, 1978, EXP PATHOL-JENA, V15, P241, DOI 10.1016/S0014-4908(78)80064-7; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; Mihich Enrico, 1999, Cancer Research, V59, P491; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; Park JY, 1997, ENDOCRINOLOGY, V138, P617, DOI 10.1210/en.138.2.617; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Siemeister G, 1996, BIOCHEM BIOPH RES CO, V222, P249, DOI 10.1006/bbrc.1996.0730; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Yoon WH, 1996, BIOCHEM BIOPH RES CO, V222, P694, DOI 10.1006/bbrc.1996.0806; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	53	58	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13588	13596		10.1074/jbc.275.18.13588	http://dx.doi.org/10.1074/jbc.275.18.13588			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788475	hybrid			2022-12-27	WOS:000086925300062
J	Long, CJ; Roth, MR; Tasheva, ES; Funderburgh, M; Smit, R; Conrad, GW; Funderburgh, JL				Long, CJ; Roth, MR; Tasheva, ES; Funderburgh, M; Smit, R; Conrad, GW; Funderburgh, JL			Fibroblast growth factor-2 promotes keratan sulfate proteoglycan expression by keratocytes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL STROMAL CELLS; IN-VITRO; BOVINE KERATOCYTES; SKIN FRAGILITY; CULTURES; TISSUE; LUMICAN; GLYCOSAMINOGLYCANS; BIOSYNTHESIS; PHENOTYPE	Keratocytes of the corneal stroma produce a specialized extracellular matrix responsible for corneal transparency. Corneal keratan sulfate proteoglycans (KSPG) are unique products of keratocytes that are down-regulated in corneal wounds and in vitro. This study used cultures of primary bovine keratocytes to define factors affecting KSPG expression in vitro. KSPG metabolically labeled with [S-35]sulfate decreased during the initial 2-4 days of culture in quiescent cultures with low serum concentrations (0.1%). Addition of fetal bovine serum, fibroblast growth factor-2 (FGF-2), transforming growth factor beta, or platelet derived growth factor all stimulated cell division, but only FGF-2 stimulated KSPG secretion. Combined with serum, FGF-2 also prevented serum-induced KSPG down-regulation. KSPG secretion was lost during serial subculture with or without FGF-2, Expression of KSPG core proteins (lumican, mimecan, and keratocan) was stimulated by FGF-2, and steady state mRNA pools for these proteins, particularly keratocan, were significantly increased by FGF-2 treatment. RSPG expression therefore is supported by exogenous FGF-2 and eliminated by subculture of the cells in presence of serum. FGF-2 stimulates RSPG core protein expression primarily through an increase in mRNA pools.	Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA; Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kansas State University	Funderburgh, JL (corresponding author), Univ Pittsburgh, Sch Med, Dept Ophthalmol, 203 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL EYE INSTITUTE [P30EY008098, R01EY000952, R01EY009368] Funding Source: NIH RePORTER; NEI NIH HHS [EY09368, EY08098, EY00952] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Araki M, 1998, DEV GROWTH DIFFER, V40, P167; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; Bosco L, 1997, DEVELOPMENT, V124, P421; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CINTRON C, 1977, DEV BIOL, V61, P346, DOI 10.1016/0012-1606(77)90304-9; CINTRON C, 1973, EXP EYE RES, V17, P251, DOI 10.1016/0014-4835(73)90176-0; CONRAD GW, 1974, EXP EYE RES, V18, P421, DOI 10.1016/0014-4835(74)90079-7; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; COSTER L, 1983, EXP EYE RES, V36, P517, DOI 10.1016/0014-4835(83)90045-3; DAHL IMS, 1978, EXP EYE RES, V27, P175, DOI 10.1016/0014-4835(78)90087-8; DAHL IMS, 1982, EXP EYE RES, V34, P83, DOI 10.1016/0014-4835(82)90011-2; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FINI ME, 1990, J CELL SCI, V97, P373; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Funderburgh J L, 1982, Curr Eye Res, V2, P769, DOI 10.3109/02713688209020010; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Funderburgh JL, 1998, INVEST OPHTH VIS SCI, V39, P1957; GIRARD MT, 1993, J CELL SCI, V104, P1001; GNADINGER MC, 1975, A GRAEF ARCH KLIN EX, V196, P9, DOI 10.1007/BF00410022; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; Jester JV, 1996, CORNEA, V15, P505; JOST CJ, 1991, J BIOL CHEM, V266, P13336; KLINTWORTH GK, 1981, LAB INVEST, V44, P553; LI DQ, 1995, J CELL PHYSIOL, V163, P61, DOI 10.1002/jcp.1041630108; Nakazawa K, 1998, ARCH BIOCHEM BIOPHYS, V359, P269, DOI 10.1006/abbi.1998.0897; Nakazawa K, 1996, J BIOCHEM, V120, P117; Shaw R, 1997, J NEUROSCI RES, V47, P400; WestMays JA, 1997, INVEST OPHTH VIS SCI, V38, P1367; YUE BYJ, 1976, J BIOCH, V158, P567; YUE BYJT, 1978, INVEST OPHTH VIS SCI, V17, P523	36	101	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13918	13923		10.1074/jbc.275.18.13918	http://dx.doi.org/10.1074/jbc.275.18.13918			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788517	hybrid			2022-12-27	WOS:000086925300104
J	Morimoto, T; Hasegawa, K; Kaburagi, S; Kakita, T; Wada, H; Yanazume, T; Sasayama, S				Morimoto, T; Hasegawa, K; Kaburagi, S; Kakita, T; Wada, H; Yanazume, T; Sasayama, S			Phosphorylation of GATA-4 is involved in alpha(1)-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; RAT VENTRICULAR MYOCYTES; ACTIVATED PROTEIN-KINASE; INDUCED HYPERTROPHY; BINDING PROTEIN; HEART-FAILURE; EXPRESSION; MUSCLE; CELLS; PROMOTER	The expression of endothelin-1 (ET-1) in cardiac myocytes is markedly induced during the development of heart failure in vivo and by stimulation with the ru,adrenergic agonist phenylephrine in culture. Although recent studies have suggested a role for cardiac-specific zinc finger GATA factors in the transcriptional pathways that modulate cardiac hypertrophy, it is unknown whether these factors are also involved in cardiac ET-1 transcription and if so, how these factors are modulated during this process. Using transient transfection assays in primary cardiac myocytes from neonatal rats, we show here that the GATA element in the rat ET-1 promoter was required for phenylephrine-stimulated ET-1 transcription. Cardiac GATA-1 bound the ET-1 GATA element and activated the ET-1 promoter in a sequence-specific manner. Stimulation by phenylephrine caused serine phosphorylation of GATA-4 and increased its ability to bind the ET-1 GATA element. Inhibition of the extracellularly responsive kinase cascade with PD098059 blocked the phenylephrine-induced increase in the DNA binding ability and the phosphorylation of GATA-4, These findings demonstrate that serine phosphorylation of GATA-4 is involved in alpha(1)-adrenergic agonist-responsive transcription of the ET-1 gene in cardiac myocytes and that extracellularly responsive kinase 1/2 activation plays a role upstream of GATA-4.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Kawara Cho,Shogoin, Kyoto 6068507, Japan.			Wada, Hiromichi/0000-0002-8980-224X				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Iwanaga Y, 1998, CIRCULATION, V98, P2065, DOI 10.1161/01.CIR.98.19.2065; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; Kaburagi S, 1999, CIRCULATION, V99, P292, DOI 10.1161/01.CIR.99.2.292; Kaddoura S, 1996, CIRCULATION, V93, P2068, DOI 10.1161/01.CIR.93.11.2068; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	31	122	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13721	13726		10.1074/jbc.275.18.13721	http://dx.doi.org/10.1074/jbc.275.18.13721			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788492	hybrid			2022-12-27	WOS:000086925300079
J	Roy, SK; Chiba, Y; Takeuchi, M; Jigami, Y				Roy, SK; Chiba, Y; Takeuchi, M; Jigami, Y			Characterization of yeast Yea4p, a uridine diphosphate-N-acetylglucosamine transporter localized in the endoplasmic reticulum and required for chitin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE TRANSPORTER; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; IN-VIVO; GUANOSINE DIPHOSPHATASE; SYNTHESIS INVIVO; S-CEREVISIAE; GDP-MANNOSE; CELL-WALL; GOLGI	Chitin is an essential cell wall component, synthesis of which is regulated throughout the cell cycle in the yeast Saccharomyces cerevisiae. We cloned an S, cerevisiae gene, YEA4, whose product is homologous to the Kluyueromyces lactis uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) transporter. An epitope-tagged Yea4p localized mainly in the 10,000 x g pellet (P2), suggesting endoplasmic reticulum (ER) localization. Membrane vesicles from the P2 fraction showed an 8-fold higher UDP-GlcNAc transport activity in cells harboring a multicopy YEA4 plasmid than in cells harboring vector alone, The activity distribution is identical with the protein distribution in P2, whether the gene is overexpressed or not, suggesting its native localization in P2. Immunolocalization of epitope-tagged Yea4p further revealed ER localization. The increase in transport activity due to the YEA4 overexpression is specific for UDP-GlcNAc, but not for UDP-galactose and GDP-mannose, Delta yea4-disrupted cells showed a reduced rate of UDP-GlcNAc transport, contained less chitin, and were larger and rounder in shape than the wild type cells. Our results indicate that YEA4 encodes an ER-localized UDP-GlcNAc transporter that is required for cell wall chitin synthesis in S. cerevisiae.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanagawa 2360004, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Kirin Brewery Company Limited	Jigami, Y (corresponding author), Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	jigami@nibh.go.jp	Chiba, Yasunori/L-7993-2018	Chiba, Yasunori/0000-0002-6401-5071				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; ABEIJON C, 1997, GLYCOCONJUGATE J, V14, pS128; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BOSSUYT X, 1994, EUR J BIOCHEM, V223, P981, DOI 10.1111/j.1432-1033.1994.tb19076.x; BULAWA CE, 1990, P NATL ACAD SCI USA, V87, P7424, DOI 10.1073/pnas.87.19.7424; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CABIB E, 1987, ADV ENZYMOL RAMB, V59, P59; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Chiba Y, 1998, J BIOL CHEM, V273, P26298, DOI 10.1074/jbc.273.41.26298; CHOI WJ, 1994, MOL CELL BIOL, V14, P7685, DOI 10.1128/MCB.14.12.7685; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Kainuma M, 1999, GLYCOBIOLOGY, V9, P133, DOI 10.1093/glycob/9.2.133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEALMORALES CA, 1988, P NATL ACAD SCI USA, V85, P8516, DOI 10.1073/pnas.85.22.8516; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MARTINEZ AF, 1988, BIOCHIM BIOPHYS ACTA, V946, P328, DOI 10.1016/0005-2736(88)90408-7; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; REISSIG JL, 1955, J BIOL CHEM, V217, P959; RONCERO C, 1988, J BACTERIOL, V170, P1950, DOI 10.1128/jb.170.4.1950-1954.1988; ROY SK, 1990, J GEN MICROBIOL, V136, P1967, DOI 10.1099/00221287-136-10-1967; Roy SK, 1998, J BIOL CHEM, V273, P2583, DOI 10.1074/jbc.273.5.2583; SBURLATI A, 1986, J BIOL CHEM, V261, P5147; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVERMAN SJ, 1989, YEAST, V5, P459, DOI 10.1002/yea.320050605; SPRAGUE GF, 1992, GENE EXPRESSION, P657; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Yoko-O T, 1998, EUR J BIOCHEM, V257, P630, DOI 10.1046/j.1432-1327.1998.2570630.x; Yoshida S, 1999, GLYCOBIOLOGY, V9, P53, DOI 10.1093/glycob/9.1.53; Ziman M, 1998, MOL BIOL CELL, V9, P1565, DOI 10.1091/mbc.9.6.1565; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909	45	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13580	13587		10.1074/jbc.275.18.13580	http://dx.doi.org/10.1074/jbc.275.18.13580			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788474	hybrid			2022-12-27	WOS:000086925300061
J	Konig, J; Cui, YH; Nies, AT; Keppler, D				Konig, J; Cui, YH; Nies, AT; Keppler, D			Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; FUNCTIONAL-CHARACTERIZATION; PROTEIN; IDENTIFICATION; EXPRESSION; GENE; PREDICTION; CLONING; OATP2; BRAIN	Based on sequence homology to the human organic anion transporting polypeptide 2 (OATPB; SLC21A6), we cloned a new member of the SLC21A superfamily of solute carriers, termed OATP8 (SLC21A8). The protein of 702 amino acids showed an amino acid identity of 80% with human OATPS, Based on Northern blotting, the expression of OATP8 was restricted to human liver. Cosmid clones containing the genes encoding human OATP1 (SLC21A3), OATP2 (SLC21A6), and OATP8 (SLC21AS) served to establish their genomic organization. All three genes contained 14 exons with 13 identical splice sites when transferred to the amino acid sequence. An antibody raised against the carboxyl terminus localized OATP8 to the basolateral membrane of human hepatocytes and the recombinant glyeoprotein, expressed in MDCKII cells, to the lateral membrane, Transport properties of OATP8 were studied in stably transfected MDCKII and HEH293 cells. Organic anions transported by human OATP8 included sulfobromophthalein, with a K-m of 3.3 mu M, and17 beta-glucuronosyl estradiol, with a K-m of 5.4 mu M Several bile salts were not substrates. Thus, human OATPS is a new uptake transporter in the basolateral hepatocyte membrane with an overlapping but distinct substrate specificity as compared with OATP2, which is localized to the same membrane domain.	Deutsch Krebsforschungszentrum, Div Tumor Biochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Konig, J (corresponding author), Deutsch Krebsforschungszentrum, Div Tumor Biochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Keppler, Dietrich/A-5528-2013; Nies, Anne T./D-7923-2016; Cui, Yunhai/AAP-7670-2021	Keppler, Dietrich/0000-0003-2964-2333; Nies, Anne T./0000-0001-6862-0730; Cui, Yunhai/0000-0003-4969-072X; Koenig, Joerg/0000-0001-7016-5482				Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Alpini G, 1996, GASTROENTEROLOGY, V110, P1636, DOI 10.1053/gast.1996.v110.pm8613073; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; Bossuyt X, 1996, J PHARMACOL EXP THER, V276, P891; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Cui YH, 1999, MOL PHARMACOL, V55, P929; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Eckhardt U, 1999, AM J PHYSIOL-GASTR L, V276, pG1037, DOI 10.1152/ajpgi.1999.276.4.G1037; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kakyo M, 1999, FEBS LETT, V445, P343, DOI 10.1016/S0014-5793(99)00152-0; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF326, DOI 10.1152/ajprenal.1996.270.2.F326; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Kontaxi M, 1996, J PHARMACOL EXP THER, V279, P1507; Kullak-Ublick GA, 1998, FEBS LETT, V424, P173, DOI 10.1016/S0014-5793(98)00168-9; KullakUblick GA, 1997, HEPATOLOGY, V26, P991, DOI 10.1002/hep.510260429; KullakUblick GA, 1996, J HEPATOL, V25, P985, DOI 10.1016/S0168-8278(96)80307-2; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENGER M, 1995, COMPUT METH PROG BIO, V46, P131, DOI 10.1016/0169-2607(94)01610-R; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C	29	414	429	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23161	23168		10.1074/jbc.M001448200	http://dx.doi.org/10.1074/jbc.M001448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10779507	hybrid			2022-12-27	WOS:000088419400076
J	Wu, J; Liu, SL; Zhu, JL; Norton, PA; Nojiri, S; Hoek, JB; Zern, MA				Wu, J; Liu, SL; Zhu, JL; Norton, PA; Nojiri, S; Hoek, JB; Zern, MA			Roles of tissue transglutaminase in ethanol-induced inhibition of hepatocyte proliferation and alpha 1-adrenergic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ORNITHINE DECARBOXYLASE ACTIVITY; LIVER-REGENERATION; PHOSPHOLIPASE-C; RAT HEPATOCYTES; DNA-SYNTHESIS; IN-VITRO; ACTIVATION; INTOXICATION; FIBROGENESIS	The mechanisms by which ethanol inhibits hepatocyte proliferation have been a source of some considerable investigation. Our studies have suggested a possible role for tissue transglutaminase (tTG) in this process. Others have shown that tTG has two distinctly different functions: it catalyzes protein cross-linking, which can lead to apoptosis and enhancement of extracellular matrix stability, and it can function as a G protein (G alpha(h)) Under that circumstance, we speculated that the cross-linking activity would be decreased and that it would function to enhance hepatocyte proliferation in response to adrenergic stimulation. Ethanol treatment inhibited hepatocyte proliferation and led to enhanced tTG crosslinking activity, whereas treatment of hepatocytes with an alpha 1 adrenergic agonist, phenylephrine, enhanced hepatocyte proliferation while decreasing tTG cross-linking, However, phenylephrine treatment of several hepatoma cell lines had no effect on cellular proliferation or tTG cross-linking activity, and of note, Northern blot analysis demonstrated that whereas primary hepatocytes had high levels of the alpha 1 beta adrenergic receptor (alpha 1BAR) mRNA, the hepatoma cell lines did not have this mRNA. When the Hep G(2) cell line was stably transduced with an expression vector containing the alpha 1BR cDNA, the cell line responded to phenylephrine treatment with enhanced proliferation and with decreased tTG cross-linking activity. Ethanol treatment of the alpha 1BAR-transfected cells suppressed the phospholipase C-mediated signaling pathways, as detected in the phenylephrine-induced Ca2+ response. These results suggest that phenylephrine stimulation of hepatocyte proliferation appears to be occurring through the alpha 1BAR, which is known to be coupled with the tTG G protein moiety, G alpha(h), and that tTG appears to play a significant role in either enhancing or inhibiting hepatocyte proliferation, depending on its cellular location and on whether it functions as a cross-linking enzyme or a G protein.	Univ Calif Davis, Med Ctr, Transplant Res Program, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	University of California System; University of California Davis; University of California System; University of California Davis; Jefferson University; Jefferson University	Zern, MA (corresponding author), Univ Calif Davis, Med Ctr, Transplant Res Program, 4635 2nd Ave,Suite 1001, Sacramento, CA 95817 USA.			Hoek, Jan/0000-0001-7127-4218; Norton, Pamela/0000-0003-1327-9250	NIAAA NIH HHS [AA-06386] Funding Source: Medline; NIDDK NIH HHS [DK09762, DK-41875] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041875, F32DK009762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006386] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; CARTER EA, 1985, BIOCHEM BIOPH RES CO, V128, P767, DOI 10.1016/0006-291X(85)90113-5; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIEHL AM, 1990, HEPATOLOGY, V12, P633, DOI 10.1002/hep.1840120402; DIEHL AM, 1988, HEPATOLOGY, V8, P237, DOI 10.1002/hep.1840080208; DOLYNCHUK KN, 1994, PLAST RECONSTR SURG, V93, P567, DOI 10.1097/00006534-199493030-00020; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FRIZELL E, 1995, HEPATOLOGY, V21, P847, DOI 10.1002/hep.1840210335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; Hoek JB, 1998, ALCOHOL CLIN EXP RES, V22, p224S, DOI 10.1111/j.1530-0277.1998.tb04007.x; HOUCK KA, 1989, J CELL PHYSIOL, V141, P503, DOI 10.1002/jcp.1041410308; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Katoh S, 1996, EXP CELL RES, V222, P255, DOI 10.1006/excr.1996.0032; KATOH S, 1993, ARCH BIOCHEM BIOPHYS, V303, P421, DOI 10.1006/abbi.1993.1304; Knopp J, 1997, ANN NY ACAD SCI, V827, P489, DOI 10.1111/j.1749-6632.1997.tb51859.x; KNUDSEN TB, 1996, MOL CELLULAR METHODS, P183; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Kurose I, 1997, HEPATOLOGY, V25, P368; LAMB RG, 1994, HEPATOLOGY, V19, P174, DOI 10.1016/0270-9139(94)90069-8; LEE CH, 1992, J BIOL CHEM, V267, P16044; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Saso K, 1996, ALCOHOL CLIN EXP RES, V20, pA330; SHIBLEY IA, 1995, ALCOHOL CLIN EXP RES, V19, P209, DOI 10.1111/j.1530-0277.1995.tb01494.x; TANAKA T, 1993, ALCOHOL ALCOHOLISM, V28, P41, DOI 10.1093/alcalc/28.Supplement_1B.41; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; WU DQ, 1992, J BIOL CHEM, V267, P25798; Wu J, 1998, LIVER GROWTH REPAIR, P558; YANG LJ, 1991, J BIOL CHEM, V266, P22451; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	36	39	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22213	22219		10.1074/jbc.M000091200	http://dx.doi.org/10.1074/jbc.M000091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801782	hybrid			2022-12-27	WOS:000088363800064
J	Geeves, MA; Perreault-Micale, C; Coluccio, LM				Geeves, MA; Perreault-Micale, C; Coluccio, LM			Kinetic analyses of a truncated mammalian myosin I suggest a novel isomerization event preceding nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ADP RELEASE; MOTOR PROTEIN; RAT-LIVER; ACTIN; TROPOMYOSIN; FRAGMENTS; TENSION; CALCIUM; ATPASE	MI1IQ is a complex of calmodulin and an epitope-tagged 85-kDa fragment representing the amino-terminal catalytic motor domain and the first of 6 calmodulin-binding IQ domains of the mammalian myosin I gene, rat myr-1 (130-kDa myosin I or MI130). We have determined the transient kinetic parameters that dictate the ATP hydrolysis cycle of mammalian myosin I by examining the properties of MI1IQ. Transient kinetics reveal that the affinity of MI1IQ for actin is 12 nM. The ATP-induced dissociation of actin-MI1IQ is biphasic. The fast phase is dependent upon [ATP], whereas the slow phase is not; both phases show a Ca2+ sensitivity. The fast phase is eliminated by the addition of ADP, 10 mu M being required for half-saturation of the effect in the presence of Ca2+ and 3 mu M ADP in the absence of Ca2+. The slow phase shares the same rate constant as ADP release (8 and 3 s(-1) in the presence and absence of Ca2+, respectively), but cannot be eliminated by decreasing [ADP]. We interpret these results to suggest that actin-myosin I exists in two forms in equilibrium, one of which is unable to bind nucleotide. These results also indicate that the absence of the COOH-terminal 5 calmodulin binding domains of myr-1 do not influence the kinetic properties of MI130 and that the Ca2+ sensitivity of the kinetics are in all likelihood due to Ca2+ binding to the first IQ domain.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Boston Biomed Res Inst, Watertown, MA 02472 USA	University of Kent; Boston Biomedical Research Institute	Geeves, MA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.		Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056130] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56130] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CC, 1977, J PHYSIOL-LONDON, V270, P627, DOI 10.1113/jphysiol.1977.sp011972; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; MILLAR NC, 1988, BIOCHEM J, V249, P735, DOI 10.1042/bj2490735; MOISESCU DG, 1978, J PHYSIOL-LONDON, V275, P241, DOI 10.1113/jphysiol.1978.sp012188; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Perreault-Micale C, 2000, J BIOL CHEM, V275, P21618, DOI 10.1074/jbc.M000363200; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SMITH DA, 1995, BIOPHYS J, V69, P524, DOI 10.1016/S0006-3495(95)79926-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Veigel C, 1999, BIOPHYS J, V76, pA145; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; WELLS C, 1985, NATURE, V313, P696, DOI 10.1038/313696a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105	25	58	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21624	21630		10.1074/jbc.M000342200	http://dx.doi.org/10.1074/jbc.M000342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781577	hybrid			2022-12-27	WOS:000088230600088
J	Witting, PK; Douglas, DJ; Mauk, AG				Witting, PK; Douglas, DJ; Mauk, AG			Reaction of human myoglobin and H2O2 - Involvement of a thiyl radical produced at cysteine 110	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SPERM WHALE MYOGLOBIN; HYDROGEN-PEROXIDE; ENZYME CATALYSIS; CROSS-LINKING; SPIN ADDUCTS; OXIDATION; HEMOGLOBIN; METMYOGLOBIN; ASCORBATE	The human myoglobin (Mb) sequence is similar to other mammalian Mb sequences, except for a unique cysteine at position 110. Reaction of wild-type recombinant human Mb, the C110A variant of human Mb, or horse heart Mb with H2O2 (protein/H2O2 = 1:1.2 mol/mol) resulted in formation of tryptophan peroxyl (Trp-OO.) and tyrosine phenoxyl radicals as detected by EPR spectroscopy at 77 K. For wild-type human Mb, a second radical (g similar to 2.036) was detected after decay of Trp-OO. that was not observed for the C110A variant or horse heart Mb. When the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) was included in the reaction mixture at protein/DMPO ratios less than or equal to 1:10 mol/mol, a DMPO adduct exhibiting broad absorptions was detected. Hyperfine couplings of this radical indicated a DMPO-thiyl radical. Incubation of mild-type human Mb with thiol-blocking reagents prior to reaction with peroxide inhibited DMPO adduct formation, whereas at protein/DMPO ratios greater than or equal to 1:25 mol/mol, DMPO-tyrosyl radical adducts were detected. Mass spectrometry of wild-type human Mb following reaction with H2O2 demonstrated the formation of a homodimer (mass of 34,107 +/- 5 atomic mass units) sensitive to reducing conditions. The human Mb C110A variant afforded no dimer under identical conditions. Together, these data indicate that reaction of wild-type human Mb and H2O2 differs from the corresponding reaction of other myoglobin species by formation of thiyl radicals that lead to a homodimer through intermolecular disulfide bond formation.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Mauk, AG (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Copp Bldg,2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020	Witting, Paul/0000-0003-2237-7004				BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Davies M.J., 1997, RADICAL MEDIATED PRO; DAVIES MJ, 1990, FREE RADICAL RES COM, V10, P361, DOI 10.3109/10715769009149905; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; Dean RT, 1997, BIOCHEM J, V324, P1; DETERS D, 1994, BBA-PROTEIN STRUCT M, V1208, P344, DOI 10.1016/0167-4838(94)90123-6; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; FLEMING JE, 1983, Z NATURFORSCH C, V38, P859; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; Gunther MR, 1998, BIOCHEM J, V330, P1293; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Hunter CL, 1997, BIOCHEMISTRY-US, V36, P1018, DOI 10.1021/bi961993+; Irwin JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P94, DOI 10.1006/abbi.1998.0987; KAGAN VE, 1992, J LIPID RES, V33, P385; KELMAN DJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P439, DOI 10.1006/abbi.1993.1535; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KOTAKE Y, 1994, FREE RADICAL BIO MED, V17, P215, DOI 10.1016/0891-5849(94)90077-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Lewin S, 1976, VITAMIN C ITS MOL BI; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; LYNCH SM, 1993, J LIPID RES, V34, P1745; Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a; Miller YI, 1996, ARCH BIOCHEM BIOPHYS, V326, P252, DOI 10.1006/abbi.1996.0073; Moore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731; RAGAVAN V, 1985, P NATL ACAD SCI USA, V82, P5681; RAJAGOPALAN KV, 1968, J BIOL CHEM, V243, P3784; RAO SI, 1993, J BIOL CHEM, V268, P803; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; Silvester JA, 1998, FREE RADICAL BIO MED, V24, P754, DOI 10.1016/S0891-5849(97)00327-4; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Swartz H. M., 1972, BIOL APPL ELECT SPIN; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILKS A, 1992, J BIOL CHEM, V267, P8827; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; Witting PK, 1999, CHEM RES TOXICOL, V12, P1173, DOI 10.1021/tx9900472; Witting PK, 1996, J LIPID RES, V37, P853; Witting PK, 1997, MAGN RESON CHEM, V35, P100; YEONGRENN C, 1999, J BIOL CHEM, V274, P3308	52	68	71	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20391	20398		10.1074/jbc.M000373200	http://dx.doi.org/10.1074/jbc.M000373200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779502	hybrid			2022-12-27	WOS:000088084500025
J	Lagace, TK; Storey, MK; Ridgway, ND				Lagace, TK; Storey, MK; Ridgway, ND			Regulation of phosphatidylcholine metabolism in Chinese hamster ovary cells by the sterol regulatory element-binding protein (SREBP)/SREBP cleavage-activating protein pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; COA-CHOLESTEROL ACYLTRANSFERASE; INDEPENDENT PHOSPHOLIPASE A(2); FATTY-ACID SYNTHESIS; ADIPOCYTE DETERMINATION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; CULTURED-CELLS; IDENTIFICATION; LOCALIZATION	Sterol regulation-defective (SRD) 4 cells expressing a mutant sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP D443N) and Chinese hamster ovary (CHO) cells stably expressing SCAS (CHO-SCAP) and SCAP D443N (CHO-SCAP-D443N) have increased cholesterol and fatty acid synthesis because of constitutive processing of SREBPs, We assessed whether constitutive activation of SREBPs also influenced the CDP-choline pathway for phosphatidylcholine (PtdCho) biosynthesis. Relative to control CHO 7 cells, SRD 4 cells displayed increased PtdCho synthesis and degradation as indicated by a 4-6-fold increase in [H-3]choline incorporation into PtdCho and 10-15-fold increase in intracellular [H-3]glycerophosphocholine. [H-3]Phosphocholine levels in SRD 4 cells were reduced by over 10-fold, suggesting enhanced activity of CTP:phosphocholine cytidylyltransferase alpha (CCT alpha). CHO-SCAP and CHO-SCAP D443N cells displayed modest increases in [H-3]choline incorporation into PtdCho (2-fold) and only a 2-fold reduction in [H-3]phosphocholine. Elevated PtdCho metabolism in SRD 4, compared with SCAP-overexpressing cells, was correlated with fatty acid synthesis. Inhibition of fatty acid synthesis by cerulenin resulted in almost complete normalization of PtdCho synthesis and choline metabolite profiles in SRD 4 cells, indicating that fatty acids or a fatty acid-derived metabolite was responsible for up-regulation of PtdCho synthesis. In contrast to apparent activation in vivo, CCT alpha protein, mRNA, and in vitro activity were reduced in SRD 4 cells and unchanged in SCAR transfected cells. Unlike control and SCAP transfected cells, CCT alpha in SRD 4 cells was localized by immunofluorescence to the nuclear envelope, suggesting that residual enzyme activity in these cells was in an active membrane-associated form. Translocation of CCT alpha to the nuclear envelope was reproduced by treatment of CHO 7 cells with exogenous oleate, We conclude that the SREBP/SCAP pathway regulates PtdCho synthesis via post-transcriptional activation of nuclear CCT alpha by fatty acids or a fatty acid-derived signal.	Dalhousie Univ, Clin Res Ctr, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University	Ridgway, ND (corresponding author), Dalhousie Univ, Clin Res Ctr, Atlantic Res Ctr, Rm C306,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	nridgway@is.dal.ca		Ridgway, Neale/0000-0002-0441-6228				Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL RB, 1992, METHOD ENZYMOL, V209, P267; Cullis P.R., 1996, NEW COMPREHENSIVE BI, V31, P1; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Ridgway ND, 1999, PROG LIPID RES, V38, P337, DOI 10.1016/S0163-7827(99)00007-7; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Storey MK, 1997, J LIPID RES, V38, P711; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P34; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; Yang JL, 1997, BIOCHEM J, V325, P29, DOI 10.1042/bj3250029; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	44	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14367	14374		10.1074/jbc.275.19.14367	http://dx.doi.org/10.1074/jbc.275.19.14367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799518	hybrid			2022-12-27	WOS:000087006900050
J	Cox, ME; Deeble, PD; Bissonette, EA; Parsons, SJ				Cox, ME; Deeble, PD; Bissonette, EA; Parsons, SJ			Activated 3 ',5 '-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELLS; CYCLIC-AMP; STIMULATES GROWTH; TYROSINE KINASE; CARCINOMA; MODEL; PROGRESSION; SUBUNIT; RAP1	Neuroendocrine (NE) differentiation within prostate tumors is proposed to be a contributing factor in disease progression. However, the cellular origin and molecular mechanism controlling differentiation of prostatic NE cells are unresolved. The prostate tumor cell line, LNCaP, can reversibly acquire many NE characteristics in response to treatment with beta-adrenergic receptor agonists and activators of adenylate cyclase. In this study, we demonstrate that these treatments induce protein kinase A (PKA) activation in LNCaP cells and that ectopic expression of a constitutively activated form of the PKA catalytic subunit, CI alpha, results in acquisition of NE characteristics, including the extension of neuritic processes, cessation of mitotic activity, and production of neuron-specific enolase. Forskolin-, epinephrine-, and isoproterenol-dependent NE differentiation of LNCaP cells was significantly inhibited by expressing a dominant negative mutant of the PKA regulatory subunit, RI alpha, These results demonstrate that prostatic NE differentiation in response to these agents depends on PKA activation, and this signaling pathway may provide a therapeutic target for treating advanced forms of prostate cancer.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Cox, ME (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Sch Med, Box 441, Charlottesville, VA 22908 USA.	mec8m@virginia.edu			PHS HHS [P01 40042, R21 69848, R01 76649] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAMSSON PA, 1989, PROSTATE, V14, P71, DOI 10.1002/pros.2990140109; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BOLOGNA M, 1989, CANCER, V63, P1714; Bonkhoff H, 1998, PROSTATE, P18; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COHEN RJ, 1991, BRIT J UROL, V68, P258, DOI 10.1111/j.1464-410X.1991.tb15318.x; Cox ME, 1999, CANCER RES, V59, P3821; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; di Sant'Agnese PA, 1998, PROSTATE, P74; Diaz M, 1998, PROSTATE, P32; diSantAgnese PA, 1996, CANCER, V78, P357, DOI 10.1002/(SICI)1097-0142(19960715)78:2<357::AID-CNCR27>3.0.CO;2-U; DISANTAGNESE PA, 1992, HUM PATHOL, V23, P287; DISANTAGNESE PA, 1995, CANCER, V75, P1850, DOI 10.1002/1097-0142(19950401)75:7+<1850::AID-CNCR2820751615>3.0.CO;2-4; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Gleave ME, 1998, J CELL BIOCHEM, V69, P271, DOI 10.1002/(SICI)1097-4644(19980601)69:3<271::AID-JCB5>3.0.CO;2-O; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hsu J., 1996, MULTIPLE COMP THEORY; IWAMURA M, 1994, UROLOGY, V43, P675, DOI 10.1016/0090-4295(94)90183-X; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; McVary KT, 1998, PROSTATE, P2; MURRAY KJ, 1990, BIOCHEM J, V267, P703, DOI 10.1042/bj2670703; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shen R, 1997, Urol Oncol, V3, P67, DOI 10.1016/S1078-1439(97)00039-2; TARLE M, 1994, PROSTATE, V24, P143, DOI 10.1002/pros.2990240308; THALMANN GN, 1994, CANCER RES, V54, P2577; Theodorescu D, 1997, CANCER, V80, P2109, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2109::AID-CNCR10>3.0.CO;2-2; THOMPSON T C, 1987, P239	35	99	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13812	13818		10.1074/jbc.275.18.13812	http://dx.doi.org/10.1074/jbc.275.18.13812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788503	hybrid			2022-12-27	WOS:000086925300090
J	Jiang, QS; Li, JQ; Dubroff, R; Ahn, YJ; Foskett, JK; Engelhardt, J; Kleyman, TR				Jiang, QS; Li, JQ; Dubroff, R; Ahn, YJ; Foskett, JK; Engelhardt, J; Kleyman, TR			Epithelial sodium channels regulate cystic fibrosis transmembrane conductance regulator chloride channels in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; NA+ CHANNEL; ARGININE-VASOPRESSIN; ALPHA-SUBUNITS; GAMMA-SUBUNITS; BETA-SUBUNITS; CL CHANNELS; A6 CELLS; CFTR; INHIBITION	The cystic fibrosis transmembrane conductance regulator (CFTR), in addition to its well defined Cl- channel properties, regulates other ion channels, CFTR inhibits epithelial Na+ channel (ENaC) currents in many epithelial and nonepithelial cells. Because modulation of net NaCl reabsorption has important implications in extracellular fluid volume homeostasis and airway fluid volume and composition, we investigated whether this regulation was reciprocal by examining whether ENaC regulates CFTR, Co-expression of human (h) CFTR and mouse (m) alpha beta gamma ENaC in Xenopus oocytes resulted in a significant, 3.7-fold increase in whole-cell hCFTR Cl- conductance compared with oocytes expressing hCFTR alone, The forskolin/3-isobutyl-1-methylxanthine-stimulated whole-cell conductance in hCFTR-mENaC co-injected oocytes was amiloride-insensitive, indicating an inhibition of mENaC following hCFTR activation, and it was blocked by DPC (diphenylamine-2-carboxylic acid) and was DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid)-insensitive. Enhanced hCFTR Cl- conductance was also observed when either the alpha- or beta-subunit of mENaC was co-expressed with hCFTR, but this was not seen when CFTR was co-expressed with the gamma-subunit of mENaC. Single Cl- channel analyses showed that both CFTR Cl- channel open probability and the number of CFTR Cl- channels detected per patch increased when hCFTR was co-expressed with alpha beta gamma mENaC. We conclude that in addition to acting as a regulator of ENaC, CFTR activity is regulated by ENaC.	Univ Penn, Div Renal, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Iowa, Dept Anat, Iowa City, IA 52242 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Iowa	Kleyman, TR (corresponding author), Univ Penn, Div Renal, Dept Med, 700 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.		Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268; Engelhardt, John/0000-0003-2389-9277	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; CHALFANT ML, 1993, AM J PHYSIOL, V264, pC1480, DOI 10.1152/ajpcell.1993.264.6.C1480; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; Ciampolillo F, 1996, AM J PHYSIOL-CELL PH, V271, pC1303, DOI 10.1152/ajpcell.1996.271.4.C1303; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; Cook DI, 1998, EUR J MORPHOL, V36, P67; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Farman N, 1997, AM J PHYSIOL-CELL PH, V272, pC131, DOI 10.1152/ajpcell.1997.272.1.C131; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Greger R, 1996, J MOL MED-JMM, V74, P527; Ho K, 1998, CURR OPIN NEPHROL HY, V7, P49, DOI 10.1097/00041552-199801000-00009; Ismailov II, 1996, J BIOL CHEM, V271, P4725; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Ling BN, 1997, J BIOL CHEM, V272, P594; Ma Heping, 1996, Journal of the American Society of Nephrology, V7, P1284; Mall M, 1999, AM J PHYSIOL-GASTR L, V277, pG709, DOI 10.1152/ajpgi.1999.277.3.G709; MARUNAKA Y, 1990, AM J PHYSIOL, V258, pC352, DOI 10.1152/ajpcell.1990.258.2.C352; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; NELSON WJ, 1993, PEDIATR NEPHROL, V7, P599; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; QUINTON PM, 1994, JPN J PHYSIOL, V44, pS207; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; VERREY F, 1994, J MEMBRANE BIOL, V138, P65; Wagner MC, 1999, PEDIATR NEPHROL, V13, P163, DOI 10.1007/s004670050586; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222	50	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13266	13274		10.1074/jbc.275.18.13266	http://dx.doi.org/10.1074/jbc.275.18.13266			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788432	hybrid			2022-12-27	WOS:000086925300018
J	Bren, N; Sine, SM				Bren, N; Sine, SM			Hydrophobic pairwise interactions stabilize alpha-conotoxin MI in the muscle acetylcholine receptor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERFACES; K+ CHANNEL; MOLECULAR DISSECTION; NICOTINIC RECEPTOR; MUTANT CYCLES; DELTA-SUBUNIT; GAMMA-SUBUNIT; RESIDUES; GI; IDENTIFICATION	The present work delineates pairwise interactions underlying the nanomolar affinity of alpha-conotoxin MI (CTx MI) for the alpha-delta site of the muscle acetylcholine receptor (AChR). We mutated all non-cysteine residues in CTx MI, expressed the alpha(2)beta delta(2) pentameric form of the AChR in 293 human embryonic kidney cells, and measured binding of the mutant toxins by competition against the initial rate of I-125-alpha-bungarotoxin binding. The CTx MI mutations P6G, A7V, G9S, and Y12T all decrease affinity for alpha(2)beta delta(2) pentamers by 10,000-fold. Side chains at these four positions localize to a restricted region of the known three-dimensional structure of CTx MI. Mutations of the AChR reveal major contributions to CTx MI affinity by Tyr-198 in the alpha subunit and by the selectivity determinants Ser-36, Tyr-113, and Ile-178 in the delta subunit. By using double mutant cycles analysis, we find that Tyr-12 of CTx MI interacts strongly with all three selectivity determinants in the delta subunit and that delta Ser-36 and delta Ile-178 are interdependent in stabilizing Tyr-12, We find additional strong interactions between Gly-9 and Pro-6 in CTx MI and selectivity determinants in the delta subunit, and between Ala-7 and Pro-6 and Tyr-198 in the alpha subunit. The overall results reveal the orientation of CTx MI when bound to the alpha-delta interface and show that primarily hydrophobic interactions stabilize the complex.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	sine@mayo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ANDRUE D, 1994, METHODS MOL BIOL PEP, V35, P139; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; FU DX, 1994, J BIOL CHEM, V269, P26152; Gouda H, 1997, BBA-PROTEIN STRUCT M, V1343, P327, DOI 10.1016/S0167-4838(97)00140-4; GRAY WR, 1983, J BIOL CHEM, V258, P2247; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; Guddat LW, 1996, BIOCHEMISTRY-US, V35, P11329, DOI 10.1021/bi960820h; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; KOBAYASHI Y, 1989, BIOCHEMISTRY-US, V28, P4853, DOI 10.1021/bi00437a050; Maslennikov IV, 1998, EUR J BIOCHEM, V254, P238, DOI 10.1046/j.1432-1327.1998.2540238.x; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; Prince RJ, 1999, J BIOL CHEM, V274, P19623, DOI 10.1074/jbc.274.28.19623; PRINCE RJ, 1997, NICOTINIC ACETYLCHOL, P31; Quiram PA, 1999, J BIOL CHEM, V274, P19517, DOI 10.1074/jbc.274.28.19517; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; SINE S, 1979, J BIOL CHEM, V254, P3315; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; Vallone B, 1998, P NATL ACAD SCI USA, V95, P6103, DOI 10.1073/pnas.95.11.6103	34	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12692	12700		10.1074/jbc.275.17.12692	http://dx.doi.org/10.1074/jbc.275.17.12692			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777563	hybrid			2022-12-27	WOS:000086762300047
J	Herrera, JE; Schiltz, RL; Bustin, M				Herrera, JE; Schiltz, RL; Bustin, M			The accessibility of histone H3 tails in chromatin modulates their acetylation by P300/CBP-associated factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING FORCE MICROSCOPY; NUCLEOSOMAL ARRAYS; ACETYLTRANSFERASE ACTIVITY; LINKER HISTONES; IN-VIVO; TRANSCRIPTION; PCAF; DEACETYLATION; DOMAINS; FIBERS	P300/CBP-associated factor (PCAF) is a transcriptional coactivator with intrinsic histone acetylase activity. Reversible acetylation of the core histone tails in chromatin has been linked to transcriptional regulation. Here we investigate the mechanism whereby PCAF acetylates its target in chromatin. We demonstrate that recombinant PACF preferentially acetylates the H3 tail in oligonucleosomes, as compared with nucleosome core particles. The rate of acetylation is directly related to the length of the oligonucleosomal substrate. Using a trypsin accessibility assay, we demonstrate that the rate of acetylation is also related to the accessibility of the H3 tail in uncondensed oligonucleosomes. We suggest that PCAF, and perhaps other histone acetyltransferases, acetylate chromatin templates more efficiently than core particle subunits and that this preference arises from an increased accessibility of the H3 tail in either condensed or uncondensed oligonucleosomes. Acetylation of the H3 tails by the native PCAF complex is not affected by the length of the oligonucleosomal substrate. Our results suggest that the accessibility of the H3 tail in chromatin is a major factor affecting their rate of acetylation and that component(s) in the native PCAF complex function to modify the organization of these tails in chromatin thereby enhancing their accessibility to PCAF.	NCI, Div Basic Sci, Lab Metab, Prot Sect,NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Herrera, JE (corresponding author), NCI, Div Basic Sci, Lab Metab, Prot Sect,NIH, Bldg 37 Room 3D20, Bethesda, MD 20892 USA.	herr@helix.nih.gov	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [ZIABC004496, Z01BC004496] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Dimitrov SI, 1997, METHODS, V12, P57, DOI 10.1006/meth.1997.0447; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; HARBORNE N, 1983, FEBS LETT, V155, P88, DOI 10.1016/0014-5793(83)80215-4; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Krajewski WA, 1996, BIOCHEM J, V316, P395, DOI 10.1042/bj3160395; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Moore SC, 1997, BIOCHEM BIOPH RES CO, V230, P136, DOI 10.1006/bbrc.1996.5903; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; van Holde K.E., 1988, CHROMATIN; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	32	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12994	12999		10.1074/jbc.275.17.12994	http://dx.doi.org/10.1074/jbc.275.17.12994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777601	hybrid			2022-12-27	WOS:000086762300085
J	Nakashima, N; Sharma, PM; Imamura, T; Bookstein, R; Olefsky, JM				Nakashima, N; Sharma, PM; Imamura, T; Bookstein, R; Olefsky, JM			The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; STIMULATED GLUT4 TRANSLOCATION; ACTIN FILAMENT REARRANGEMENT; RECEPTOR SUBSTRATE FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SH2 DOMAIN; PHOSPHOTYROSINE PROTEIN; GLUCOSE-TRANSPORT	PTEN is a tumor suppressor with sequence homology to protein-tyrosine phosphatases and the cytoskeleton protein tensin. PTEN is capable of dephosphorylating phosphatidylinositol 3,4,5-trisphosphate in vitro and down-regulating its levels in insulin-stimulated 293 cells. To study the role of PTEN in insulin signaling, we overexpressed PTEN in 3T3-L1 adipocytes similar to 30-fold above uninfected or control virus (green fluorescent protein)-infected cells, using an adenovirus gene transfer system. PTEN overexpression inhibited insulin-induced 2-deoxy-glucose uptake by 36%, GLUT4 translocation by 35%, and membrane ruffling by 50%, all of which are phosphatidylinositol S-kinase-dependent processes, compared with uninfected cells or cells infected with control virus. Microinjection of an anti-PTEN antibody increased basal and insulin stimulated GLUT4 translocation, suggesting that inhibition of endogenous PTEN function led to an increase In intracellular phosphatidylinositol. 3,4,S-trisphosphate levels, which stimulates GLUT4 translocation. Further, insulin-induced phosphorylation of downstream targets Akt and p70S6 kinase were also inhibited significantly by overexpression of PTEN, whereas tyrosine phosphorylation of the insulin receptor and IRS-1 or the phosphorylation of mitogen-activated protein kinase were not affected, suggesting that the Ras/mitogen-activated protein kinase pathway remains fully functional. Thus, we conclude that PTEN may regulate phosphatidylinositol 3-kinase-dependent insulin signaling pathways in 3T3-L1 adipocytes.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Vet Affairs Res Serv, La Jolla, CA 92161 USA; Canji Inc, Whittier Diabet Inst, San Diego, CA 92121 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.				PHS HHS [R01-33651] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cheney IW, 1998, CANCER RES, V58, P2331; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Davies MA, 1998, CANCER RES, V58, P5285; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Guilherme A, 1996, J BIOL CHEM, V271, P29533, DOI 10.1074/jbc.271.47.29533; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; Haruta T, 1998, ENDOCRINOLOGY, V139, P358, DOI 10.1210/en.139.1.358; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; PERESSE X, 1997, BIOCHEM BIOPH RES CO, V239, P697; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Shabram PW, 1997, HUM GENE THER, V8, P453, DOI 10.1089/hum.1997.8.4-453; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	61	140	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12889	12895		10.1074/jbc.275.17.12889	http://dx.doi.org/10.1074/jbc.275.17.12889			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777587	hybrid			2022-12-27	WOS:000086762300071
J	Tang, XW; Downes, CP; Whetton, AD; Owen-Lynch, PJ				Tang, XW; Downes, CP; Whetton, AD; Owen-Lynch, PJ			Role of phosphatidylinositol 3-kinase and specific protein kinase B isoforms in the suppression of apoptosis mediated by the Abelson protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL LINE; CHRONIC MYELOID-LEUKEMIA; NERVE GROWTH-FACTOR; BCR-ABL; PHOSPHOINOSITIDE 3-KINASE; BAD PHOSPHORYLATION; INHIBITS APOPTOSIS; SIGNALING PATHWAY; ADAPTER PROTEIN; GAMMA ISOFORMS	Leukemogenic oncogenes, such as the Abelson protein-tyrosine kinases (PTK), disrupt the normal regulation of survival, proliferation, and differentiation in hemopoietic progenitor cells. In the absence of cytokines, hemopoietic progenitor cells die by apoptosis. Abl PTKs mediate suppression of this apoptotic response leading to aberrant survival. To investigate the mechanism of Abl PTK action, we have used an interleukin-3-dependent murine mast cell line that expresses a temperature-sensitive form of the v-ABL PTK, which is active at the permissive temperature of 32 degrees C and inactive at 39 degrees C. At the permissive temperature, these cells are resistant to apoptosis induced both by the withdrawal of the hemopoietic growth factor (interleukin-3) and the addition of cytotoxic drugs. We demonstrate that v-Abl associates with and stimulates activation of phosphatidylinositol 3-kinase (PI3K) and, crucially, that this activation results in enhanced cellular levels of the mass of the second messenger phosphatidylinositol-3,4,5-trisphosphate. Activation of PI3K leads to enhanced activity of PKB and increased levels of the anti-apoptotic protein Bcl-X-L. Transfection of cells with a dominant negative PKB reduces both the Abl-stimulated PKB activity and the survival effect conferred by activation of this oncogene, Thus, PIER and PKB are required for the anti-apoptotic effects of Abl PTK.	Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; UMIST, Dept Biomol Sci, Cellular Dev Unit, Leukaemia Res Fund, Manchester M60 1QD, Lancs, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	Lancaster University; University of Manchester; University of Dundee	Owen-Lynch, PJ (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England.			WHETTON, ANTHONY D/0000-0002-1098-3878; tang, xiuwen/0000-0002-6601-1234; Owen-Lynch, Penelope Jane/0000-0002-5928-2327				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BEDI A, 1994, BLOOD, V83, P2038; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carson JP, 1999, CANCER RES, V59, P1449; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Cortez D, 1996, ONCOGENE, V13, P2589; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SPOONCER E, 1994, LEUKEMIA, V8, P620; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	42	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13142	13148		10.1074/jbc.275.17.13142	http://dx.doi.org/10.1074/jbc.275.17.13142			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777620	hybrid			2022-12-27	WOS:000086762300104
J	Wieczorek, E; Lin, ZL; Perkins, EB; Law, DJ; Merchant, JL; Zehner, ZE				Wieczorek, E; Lin, ZL; Perkins, EB; Law, DJ; Merchant, JL; Zehner, ZE			The zinc finger repressor, ZBP-89, binds to the silencer element of the human vimentin gene and complexes with the transcriptional activator, Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATIN INTERMEDIATE FILAMENTS; TUMOR-SUPPRESSOR GENE; I TAX PROTEIN; NF-KAPPA-B; NEGATIVE ELEMENT; CELL-CYCLE; EXPERIMENTAL COEXPRESSION; ANTISILENCER ELEMENT; EPITHELIAL-CELLS; MAMMALIAN-CELLS	Vimentin is a component of the eukaryotic cytoskeleton belonging to the family of intermediate filament proteins. It exhibits a complex pattern of tissue- and development-specific expression. It is also a marker of the metastatic potential of many tumor cells. Previously, the human vimentin promoter was shown to contain several regions for the binding of positive and negative acting regulatory factors. Until now, the silencer element, which shuts down vimentin synthesis in selected tissues during development, was not precisely localized; nor was its binding protein known. In vivo DMS footprinting by ligation-mediated PCR delineated the position of guanine residues important to vimentin expression. Transient transfection assays in HeLa cells of various vimentin 5'-end promoter sequences and mutants thereof precisely defined two regulatory elements, a negative element and an adjoining positive acting element. Band shift assays, UV cross-linking, and Southwestern blot analysis confirm that the silencer element specifically binds a protein. Several lines of evidence show that ZBP-89, a zinc finger, Kruppel-like repressor protein is vimentin's silencer element binding factor. Co-immunoprecipitation and DNA affinity chromatography prove that: Sp1 heterodimerizes with ZBP-89 when bound to the silencer element to yield a DNA-protein complex whose mobility is indistinguishable from that displayed by HeLa nuclear extract in band shift assays.	Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, POB 980614,Med Coll Virginia Campus, Richmond, VA 23298 USA.	Zehner@hsc.vcu.edu	Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045729, R37DK045729] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45422] Funding Source: Medline; NIDDK NIH HHS [DK-45729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chang MP, 1997, NUCLEIC ACIDS RES, V25, P4861, DOI 10.1093/nar/25.24.4861; Chen JH, 1996, ONCOGENE, V13, P1667; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chu YW, 1996, AM J PATHOL, V148, P63; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUPREY P, 1995, INT J DEV BIOL, V39, P443; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; Hendrix MJC, 1997, AM J PATHOL, V150, P483; INOSTROZA JA, 1992, CELL, V70, P477; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; John S, 1998, SCIENCE, V282, P1836, DOI 10.1126/science.282.5395.1836; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LU Q, 1994, J CELL BIOCHEM, V55, P83, DOI 10.1002/jcb.240550110; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MouraNeto V, 1996, GENE, V168, P261, DOI 10.1016/0378-1119(95)00789-X; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Ogbourne S, 1998, BIOCHEM J, V331, P1; OSBORN M, 1980, EXP CELL RES, V125, P37, DOI 10.1016/0014-4827(80)90186-X; OSBORN M, 1983, LAB INVEST, V48, P372; OSBORN M, 1982, CELL, V31, P303, DOI 10.1016/0092-8674(82)90122-2; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PAULIN D, 1990, REPROD NUTR DEV, V30, P423, DOI 10.1051/rnd:19900316; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; RITTLING SR, 1987, ANTICANCER RES, V7, P541; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SOMMERS CL, 1989, CANCER RES, V49, P4258; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; STOVER DM, 1994, CANCER RES, V54, P3092; Zemer R, 1998, GYNECOL ONCOL, V70, P410, DOI 10.1006/gyno.1998.5131	66	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12879	12888		10.1074/jbc.275.17.12879	http://dx.doi.org/10.1074/jbc.275.17.12879			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777586	hybrid			2022-12-27	WOS:000086762300070
J	Ghiselli, G; Iozzo, RV				Ghiselli, G; Iozzo, RV			Overexpression of bamacan/SMC3 causes transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE; STRUCTURAL MAINTENANCE; CHROMOSOMES SMC; CDNA CLONING; PROTEIN; COMPLEX; GENE; RECOMBINATION; COMPONENTS	Bamacan can occur in certain cell types as either a secreted proteoglycan assembled into basement membranes or as an intracellular protein known as structural maintenance of chromosome 3 (SMC3). To assess the role of this protein in tumorigenesis, we investigated whether induced overexpression of bamacan/SMC3 could transform normal fibroblasts. We generated a full-length cDNA encoding the entire mouse bamacan/SMC3 and demonstrated appropriate transcription and translation into a 146-kDa protein. AU the NIH and Balb/c 3T3 murine fibroblasts overexpressing this bamacan/SMC3 transgene generated foci of transformation and acquired anchorage-independent growth. The increased levels of bamacan/SMC3 expression achieved in the transfected fibroblasts were the same as those detected in a series of spontaneously transformed murine and human colon carcinoma cells. Moreover, a 3-4-fold overexpression of bamacan/SMC3 was detected in similar to 70% of human colon carcinoma specimens from matched pairs (n = 19, p < 0.0002) and in a cohort of intestinal tumors from Apc-deficient Min/+ mice. These results support the concept that deregulated expression of bamacan/SMC3 is involved in cell transformation.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cell Biol Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhmedov AT, 1999, J BIOL CHEM, V274, P38216, DOI 10.1074/jbc.274.53.38216; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Farr KA, 1999, EUR J BIOCHEM, V263, P14, DOI 10.1046/j.1432-1327.1999.00510.x; Ghiselli G, 1999, J BIOL CHEM, V274, P17384, DOI 10.1074/jbc.274.24.17384; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; IOZZO RV, 1987, HISTOCHEMISTRY, V88, P23, DOI 10.1007/BF00490162; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1986, J BIOL CHEM, V261, P6658; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KINZLER K, 1991, CELL, V87, P159; MCCARTHY KJ, 1989, J CELL BIOL, V109, P3187, DOI 10.1083/jcb.109.6.3187; MCCARTHY KJ, 1993, J HISTOCHEM CYTOCHEM, V41, P401, DOI 10.1177/41.3.8429203; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Stursberg S, 1999, GENE, V228, P1, DOI 10.1016/S0378-1119(99)00021-9; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433	22	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20235	20238		10.1074/jbc.C000213200	http://dx.doi.org/10.1074/jbc.C000213200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801778	hybrid			2022-12-27	WOS:000088084500002
J	Radisavljevic, Z; Avraham, H; Avraham, S				Radisavljevic, Z; Avraham, H; Avraham, S			Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/nitric oxide pathway and modulates migration of brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; NITRIC-OXIDE; TYROSINE PHOSPHORYLATION; FLK-1/KDR ACTIVATION; DEPENDENT PATHWAY; TUMOR-CELLS; PROTEIN; SYNTHASE; AKT; BARRIER	Endothelium of the cerebral blood microvessels, which constitutes the major component of the blood-brain barrier, controls leukocyte and metastatic cancer cell adhesion and trafficking into the brain parenchyma. In this study, using rat primary brain microvascular endothelial cells (BMEC), we demonstrate that the vascular endothelial growth factor (VEGF), a potent promoter of angiogenesis, up-regulates the expression of the intracellular adhesion molecule-1 (ICAM-1) through a novel pathway that includes phosphatidylinositol 3 OH-kinase (PI3K), AKT, and nitric oxide (NO), resulting in the migration of BMEC. Upon VEGF treatment, AKT is phosphorylated in a PI3K-dependent manner. AKT activation leads to NO production and release and activation-deficient AKT attenuates NO production stimulated by VEGF. Transfection of the constitutive myr-AKT construct significantly increased basal NO release in BMEC. In these cells, VEGF and the endothelium-derived NO synergistically up-regulated the expression of ICAM-1, which was mediated by the PI3K pathway. This activity was blocked by the PI3K-specific inhibitor, wortmannin, Furthermore, VEGF and NO significantly increased BmEC migration, which was mediated by the up-regulation of ICAM-1 expression and was dependent on the integrity of the PI3K/AKT/NO pathway. This effect was abolished by wortmannin, by the specific ICAM-1 antibody, by the specific inhibitor of NO synthase, N-G-L-monomethyl-arginine (L-NMMA) or by a combination of wortmannin, ICAM-1 antibody, and L-NMMA. These findings demonstrate that the angiogenic factor VEGF up-regulates ICAM-1 expression and signals to ICAM-1 as an effector molecule through the PI3K/AKT/NO pathway, which leads to brain microvessel endothelial cell, migration. These observations may contribute to a better understanding of BMEC angiogenesis and the physiological as well as pathophysiological function of the blood-brain barrier, whose integrity is crucial for normal brain function.	Harvard Univ, Sch Med,Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Sch Med,Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savrahan@caregroup.harvard.edu	Radisavljevic, Ziv/AAY-4744-2020	Radisavljevic, Ziv/0000-0003-2995-5014; Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445, R01HL051456] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson P, 1999, J IMMUNOL, V162, P2964; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; AUERBACH R, 1987, CANCER RES, V47, P1492; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; BERETA M, 1991, CELL IMMUNOL, V136, P263, DOI 10.1016/0008-8749(91)90351-B; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; BRADBURY MWB, 1993, EXP PHYSIOL, V78, P453, DOI 10.1113/expphysiol.1993.sp003698; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Etienne S, 1998, J IMMUNOL, V161, P5755; Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Freyer D, 1999, J IMMUNOL, V163, P4308; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GAMELLI RL, 1995, J TRAUMA, V39, P869, DOI 10.1097/00005373-199511000-00010; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gho YS, 1999, CANCER RES, V59, P5128; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; JANZER RC, 1993, J INHERIT METAB DIS, V16, P639, DOI 10.1007/BF00711897; Komatsu T, 1999, NITRIC OXIDE-BIOL CH, V3, P327, DOI 10.1006/niox.1999.0237; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148, DOI 10.1152/ajpcell.1999.276.5.C1148; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; NICOLSON GL, 1994, CRIT REV ONCOGENESIS, V5, P451, DOI 10.1615/CritRevOncog.v5.i5.20; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Radisavljevic Z, 1996, J LIQ CHROMATOGR R T, V19, P1061, DOI 10.1080/10826079608006302; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Weih MK, 1998, BRAIN RES PROTOC, V2, P175, DOI 10.1016/S1385-299X(97)00037-8; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; ZHANG RL, 1995, BRAIN RES, V682, P182, DOI 10.1016/0006-8993(95)00346-R	45	184	187	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20770	20774		10.1074/jbc.M002448200	http://dx.doi.org/10.1074/jbc.M002448200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787417	hybrid			2022-12-27	WOS:000088084500077
J	Kuzuyama, T; Takahashi, S; Takagi, M; Seto, H				Kuzuyama, T; Takahashi, S; Takagi, M; Seto, H			Characterization of 1-Deoxy-D-xylulose 5-phosphate reductoisomerase, an enzyme involved in isopentenyl diphosphate biosynthesis, and identification of its catalytic amino acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEVALONATE-INDEPENDENT PATHWAY; ISOPRENOID BIOSYNTHESIS; NONMEVALONATE PATHWAY; ESCHERICHIA-COLI; PHOSPHONIC ACID; 2-C-METHYL-D-ERYTHRITOL 4-PHOSPHATE; HETEROLOGOUS EXPRESSION; TERPENOID BIOSYNTHESIS; FOSMIDOMYCIN; PRECURSOR	1-Deoxy-D-xylulose 5-phosphate (DXP) reductoisomerase, which simultaneously catalyzes the intramolecular rearrangement and reduction of DXP to form 2-C-methyl-D-erythritol 4-phosphate, constitutes a key enzyme of an alternative mevalonate-independent pathway for isopentenyl diphosphate biosynthesis. The dxr gene encoding this enzyme from Escherichia coli was overexpressed as a histidine-tagged protein and characterized in detail. DNA sequencing analysis of the dxr genes from 10 E. coli dxr-deficient mutants revealed base substitution mutations at four points: two nonsense mutations and two amino acid substitutions (Gly(14) to Asp(14) and Glu(231) to Lys(231)), Diethyl pyrocarbonate treatment inactivated DXP reductoisomerase, and subsequent hydroxylamine treatment restored the activity of the diethyl pyrocarbonate-treated enzyme. To characterize these defects, we overexpressed the mutant enzymes G14D, E231K, H153Q, H209Q, and H257Q. All of these mutant enzymes except for G14D were obtained as soluble proteins. Although the purified enzyme E231K had wildtype K-m values for DXP and NADPH, the mutant enzyme had less than a 0.24% wild-type k(cat) value. K-m values of H153Q, H209Q, and H257Q for DXP increased to 3.5-, 7.6-, and 19-fold the wild-type value, respectively. These results indicate that Glu(231) of E. coli DXP reductoisomerase plays an important role(s) in the conversion of DXP to 2-C-methyl-D-erythritol 4-phosphate, and that His(153), His(209), and His(257), in part, associate with DXP binding in the enzyme molecule.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Seto, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.		Takagi, Motoki/Q-7390-2019; Takahashi, Shunji/GLT-3245-2022; Takagi, Motoki/C-9052-2009; Takahashi, Shunji/N-6921-2015	Takahashi, Shunji/0000-0003-1684-9298; Takahashi, Shunji/0000-0003-1684-9298; Kuzuyama, Tomohisa/0000-0002-7221-5858				Bouvier F, 1998, PLANT PHYSIOL, V117, P1423, DOI 10.1104/pp.117.4.1423; Duvold T, 1997, TETRAHEDRON LETT, V38, P4769, DOI 10.1016/S0040-4039(97)01045-9; Duvold T, 1997, TETRAHEDRON LETT, V38, P6181, DOI 10.1016/S0040-4039(97)01392-0; Fellermeier M, 1999, TETRAHEDRON LETT, V40, P2743, DOI 10.1016/S0040-4039(99)00361-5; IGUCHI E, 1980, J ANTIBIOT, V33, P18, DOI 10.7164/antibiotics.33.18; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; KURODA Y, 1980, J ANTIBIOT, V33, P29, DOI 10.7164/antibiotics.33.29; Kuzuyama T, 2000, J BACTERIOL, V182, P891, DOI 10.1128/JB.182.4.891-897.2000; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; Lange BM, 1999, ARCH BIOCHEM BIOPHYS, V365, P170, DOI 10.1006/abbi.1999.1168; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; OKUHARA M, 1980, J ANTIBIOT, V33, P24, DOI 10.7164/antibiotics.33.24; Proteau PJ, 1999, ORG LETT, V1, P921, DOI 10.1021/ol990839n; Radykewicz T, 2000, FEBS LETT, V465, P157, DOI 10.1016/S0014-5793(99)01743-3; Rane MJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P83, DOI 10.1006/abbi.1996.9802; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwender J, 1999, FEBS LETT, V455, P140, DOI 10.1016/S0014-5793(99)00849-2; SHIGI Y, 1989, J ANTIMICROB CHEMOTH, V24, P131, DOI 10.1093/jac/24.2.131; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	26	100	111	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19928	19932		10.1074/jbc.M001820200	http://dx.doi.org/10.1074/jbc.M001820200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10787409	hybrid			2022-12-27	WOS:000087941300068
J	Morrisey, EE; Musco, S; Chen, MYZ; Lu, MM; Leiden, JM; Parmacek, MS				Morrisey, EE; Musco, S; Chen, MYZ; Lu, MM; Leiden, JM; Parmacek, MS			The gene encoding the mitogen-responsive phosphoprotein Dab2 is differentially regulated by GATA-6 and GATA-4 in the visceral endoderm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; HEART TUBE FORMATION; CAENORHABDITIS-ELEGANS; VENTRAL MORPHOGENESIS; CELLS; FAMILY; HEMATOPOIESIS; EXPRESSION; DROSOPHILA	Gene targeting studies have demonstrated that the zinc finger transcription factor GATA-6 lies upstream in a transcriptional cascade that controls differentiation of the visceral endoderm, To understand the function of GATA-6 in the visceral endoderm and to identify genes regulated by GATA-6 in this tissue, subtractive hybridization was performed using template cDNAs derived from differentiated wild-type embryonic stem (ES) cells and GATA-6(-/-) ES cells, respectively. These analyses revealed that the gene encoding Dab2, a mitogen-responsive phosphoprotein, is differentially expressed in wild-type and GATA-6-deficient ES cells. Consistent with these findings, Dab2 is expressed in the visceral endoderm of wild-type embryos but not in the visceral endoderm of GATA-6-deficient embryos. Cotransfection experiments demonstrate that the human Dab2 promoter can be transactivated by forced expression of GATA-6 in NIH-3T3 cells. In contrast, forced expression of GATA-4 does not transactivate the human Dab2 promoter and Dab2 is expressed in the visceral endoderm of GATA-4 null embryos. Surprisingly, the specificity of GATA-6-induced transactivation of the Dab2 promoter is not mediated through its zinc finger DNA-binding domain. Taken together, these data demonstrate that the mitogen-responsive phosphoprotein Dab2 is a downstream target of GATA-6 in the visceral endoderm, Moreover, these data demonstrate that molecular mechanisms have evolved that direct, and distinguish, the functional specificity of GATA family members when they are developmentally coexpressed.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Dept Med, Boston, MA 02115 USA	University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Parmacek, MS (corresponding author), Univ Penn, Dept Med, 9123 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064632] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64632, R01 HL54115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; HAWKINS MG, 1995, J BIOL CHEM, V270, P14666, DOI 10.1074/jbc.270.24.14666; Hop C, 1997, FEBS LETT, V405, P167, DOI 10.1016/S0014-5793(97)00179-8; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Narita N, 1997, DEV BIOL, V189, P270, DOI 10.1006/dbio.1997.8684; ORKIN SH, 1992, BLOOD, V80, P575; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1998, DEV BIOL, V196, P218, DOI 10.1006/dbio.1997.8842; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1995, EXP HEMATOL, V23, P99; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zhu JW, 1998, GENE DEV, V12, P3809, DOI 10.1101/gad.12.24.3809; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	40	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19949	19954		10.1074/jbc.M001331200	http://dx.doi.org/10.1074/jbc.M001331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779506	hybrid			2022-12-27	WOS:000087941300071
J	Chen, C; Ma, JY; Lazic, A; Backovic, M; Colley, KJ				Chen, C; Ma, JY; Lazic, A; Backovic, M; Colley, KJ			Formation of insoluble oligomers correlates with ST6Gal I stable localization in the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MEMBRANE-SPANNING DOMAIN; KIN RECOGNITION; TRANSMEMBRANE DOMAINS; RETENTION SIGNAL; HELA-CELLS; APPARATUS; PROTEIN; CHOLESTEROL; CLEAVAGE	The ST6Gal I is a sialyltransferase that functions in the late Golgi to modify the N-linked oligosaccharides of glycoproteins. The ST76Gal I is expressed as two isoforms with a single amino acid difference in their catalytic domains, The STcys isoform is stably retained in the cell and is predominantly found in the Golgi, whereas the STtyr isoform is only transiently localized in the Golgi and is cleaved and secreted from a post-Golgi compartment, These two ST6Gal I isoforms were used to explore the role of the bilayer thickness mechanism and oligomerization in Golgi localization. Analysis of STcys and STtyr proteins with longer transmembrane regions suggested that the bilayer thickness mechanism is not the predominant mechanism used for ST6Gal I Golgi localization, In contrast, the formation and quantity of Triton X-100-insoluble oligomers was correlated with the stable or transient localization of the ST6Gal I isoforms in the Golgi, Nearly 100% of the STcys and only 13% of the STtyr were found as Triton-insoluble oligomers when Golgi membranes of COS-1 cells expressing these proteins were solubilized at pH 6.3, the pH of the late Golgi, In contrast, both proteins were found in the soluble fraction when these membranes were solubilized at pH 8.0, Analysis of other mutants suggested that a conformational change in the catalytic domain rather than increased disulfide bond-based cross-linking is the basis for the increased ability of STcys protein to form oligomers and the stable localization of STcys protein in the Golgi.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St M-C 536, Chicago, IL 60612 USA.		Backovic, Marija/AAX-8863-2021	Backovic, Marija/0000-0001-8814-4428	NIGMS NIH HHS [GM48134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134, R29GM048134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHEN C, 2000, IN PRESS GLYCOBIOLOG, V10; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; Fleischer S, 1974, Methods Enzymol, V31, P6; Fullekrug J, 1998, BBA-MOL CELL RES, V1404, P77, DOI 10.1016/S0167-4889(98)00048-2; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Kitazume-Kawaguchi S, 1999, GLYCOBIOLOGY, V9, P1397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma JY, 1997, J BIOL CHEM, V272, P672; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170	36	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13819	13826		10.1074/jbc.275.18.13819	http://dx.doi.org/10.1074/jbc.275.18.13819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788504	hybrid			2022-12-27	WOS:000086925300091
J	Guihard, G; Noel, J; Capiod, T				Guihard, G; Noel, J; Capiod, T			Ca2+ depletion and inositol 1,4,5-trisphosphate-evoked activation of Ca2+ entry in single guinea pig hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED HTRP3 CHANNELS; RAT-LIVER CELLS; ENDOPLASMIC-RETICULUM; ION CHANNELS; PLASMA-MEMBRANE; CALCIUM INFLUX; MAST-CELLS; RECEPTOR; CA-2+; KINETICS	Store-operated Ca2+ entry was investigated by monitoring the Ca2+-dependent K+ permeability in voltage-clamped guinea pig hepatocytes, In physiological conditions, intracellular Ca2+ stores are discharged following agonist stimulation, but depletion of this stores can be achieved using Ca2+-Mg2+-ATPase inhibitors such as 2,5-di(tert-butyl)-1,4-benzohydroquinone and thapsigargin. The effect of internal Ca2+ store depletion on Ca2+ influx was tested in single cells using inositol 1,4,5-trisphosphate (InsP(3)) release from caged InsP(3) after treatment of the cells with 2,5-di(tert-butyl)-1,4-benzohydroquinone or thapsigargin in Ca2+-free solutions. We show that the photolytic release of 1-D-myo-inositol 1,4-bisphosphate 5-phosphorothioate, a stable analog of InsP(3), and Ca2+ store depletion have additive effects to activate a high level of Ca2+ entry in single guinea pig hepatocytes, These results suggest that there is a direct functional interaction between InsP(3) receptors and Ca2+ channels in the plasma membrane, although the nature of these Ca2+ channels in hepatocytes is unclear.	Univ Paris 11, INSERM, U442, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Capiod, T (corresponding author), Univ Paris 11, INSERM, U442, Bat 443, F-91405 Orsay, France.		CAPIOD, Thierry/K-4234-2017	CAPIOD, Thierry/0000-0002-8448-7041				Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; CAPIOD T, 1989, PROC R SOC SER B-BIO, V236, P187, DOI 10.1098/rspb.1989.0020; Capiod T, 1998, J PHYSIOL-LONDON, V507, P795, DOI 10.1111/j.1469-7793.1998.795bs.x; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; Carini R, 1996, BIOCHEM BIOPH RES CO, V218, P772, DOI 10.1006/bbrc.1996.0137; COMBETTES L, 1988, J BIOL CHEM, V263, P2299; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; KEPPENS S, 1977, BIOCHIM BIOPHYS ACTA, V496, P448, DOI 10.1016/0304-4165(77)90327-0; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LUCKHOFF A, 1992, NATURE, V355, P353; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PIETRI F, 1990, CELL SIGNAL, V2, P253, DOI 10.1016/0898-6568(90)90053-D; RAPP G, 1988, PFLUGERS ARCH, V411, P204; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SAFRANY ST, 1991, MOL PHARMACOL, V39, P754; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; STRIGGOW F, 1994, EUR J BIOCHEM, V222, P229, DOI 10.1111/j.1432-1033.1994.tb18861.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WOOTTON JF, 1995, BIOPHYS J, V68, P2601, DOI 10.1016/S0006-3495(95)80444-3; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	34	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13411	13414		10.1074/jbc.275.18.13411	http://dx.doi.org/10.1074/jbc.275.18.13411			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788451	hybrid			2022-12-27	WOS:000086925300038
J	He, XD; Miginiac-Maslow, M; Sigalat, C; Keryer, E; Haraux, F				He, XD; Miginiac-Maslow, M; Sigalat, C; Keryer, E; Haraux, F			Mechanism of activation of the chloroplast ATP synthase - A kinetic study of the thiol modulation of isolated ATPase and membrane-bound ATP synthase from spinach by Escherichia coli thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; INTACT CHLOROPLASTS; DISULFIDE BOND; GAMMA-SUBUNIT; FACTOR CF1; PHOTOPHOSPHORYLATION; F1-ATPASE; ROTATION; DITHIOTHREITOL; STATE	The mechanism of thiol modulation of the chloroplast ATP synthase by Escherichia coli thioredoxin was investigated in the isolated ATPase subcomplex and in the ATP synthase complex reconstituted in bacteriorhodopsin proteoliposomes. Thiol modulation was resolved kinetically by continuously monitoring ATP hydrolysis by the isolated subcomplex and ATP synthesis by proteoliposomes, The binding rate constant of reduced thioredoxin to the oxidized ATPase subcomplex devoid of its epsilon subunit could be determined. It did not depend on the catalytic turnover. Reciprocically, the catalytic turnover did not seem to depend on thioredoxin binding. Thiol modulation by Trx of the epsilon-bearing ATPase subcomplex was slow and favored the release of epsilon. The rate constant of thioredoxin binding to the membrane-bound ATP synthase increased with the protonmotive force. It was lower in the presence of ADP than in its absence, revealing a specific effect of the ATP synthase turnover on thioredoxin-gamma subunit interaction. These findings, and more especially the comparisons between the isolated ATPase subcomplex and the ATP synthase complex, can be interpreted in the frame of the rotational catalysis hypothesis. Finally, thiol modulation changed the catalytic properties of the ATP synthase, the kinetics of which became non-Michaelian. This questions the common view about the nature of changes induced by ATP synthase thiol modulation.	CEA Saclay, Sect Bioenerget, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, Prot Membranaires Transductrices Energie URA 2096, F-91191 Gif Sur Yvette, France; Univ Paris Sud, Inst Biotechnol Plantes, CNRS, UMR 8618, F-91405 Orsay, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Haraux, F (corresponding author), CEA Saclay, Sect Bioenerget, Batiment 532, F-91191 Gif Sur Yvette, France.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; ANDRALOJC PJ, 1988, FEBS LETT, V233, P403, DOI 10.1016/0014-5793(88)80471-X; BAKKERGRUNWALD T, 1974, BIOCHIM BIOPHYS ACTA, V347, P290, DOI 10.1016/0005-2728(74)90052-8; BERGER G, 1987, J LIQ CHROMATOGR, V10, P1507, DOI 10.1080/01483918708066783; BIAUDET P, 1988, BIOCHIM BIOPHYS ACTA, V933, P487, DOI 10.1016/0005-2728(88)90084-9; BIZOUARN T, 1988, BIOCHIM BIOPHYS ACTA, V974, P104; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; DANN MS, 1992, PLANT PHYSIOL, V99, P153, DOI 10.1104/pp.99.1.153; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DUHE RJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P70, DOI 10.1016/0005-2728(90)90180-C; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FROMME P, 1987, Z NATURFORSCH C, V42, P1239; GALMICHE JM, 1990, BIOCHIMIE, V72, P25, DOI 10.1016/0300-9084(90)90169-H; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KIM CS, 1991, PHOTOCHEM PHOTOBIOL, V53, P411, DOI 10.1111/j.1751-1097.1991.tb03649.x; MIKI J, 1988, FEBS LETT, V232, P211; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MILLS JD, 1982, BIOCHIM BIOPHYS ACTA, V679, P75, DOI 10.1016/0005-2728(82)90257-2; MILLS JD, 1979, BIOCHIM BIOPHYS ACTA, V547, P455, DOI 10.1016/0005-2728(79)90026-4; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OESTERHELT D, 1974, METHOD ENZYMOL, V55, P364; Panke O, 1996, FEBS LETT, V383, P196, DOI 10.1016/0014-5793(96)00246-3; PEDERSEN PL, 1996, J BIOENERG BIOMEMBR, V28, P387; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; QUICK WP, 1987, BIOCHIM BIOPHYS ACTA, V893, P197, DOI 10.1016/0005-2728(87)90040-5; RIGAUD JL, 1995, BIOCHIM BIOPHYS ACTA, V1231, P113; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; STROTMANN H, 1990, EUR J BIOCHEM, V193, P879, DOI 10.1111/j.1432-1033.1990.tb19412.x; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	41	22	23	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13250	13258		10.1074/jbc.275.18.13250	http://dx.doi.org/10.1074/jbc.275.18.13250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788430	hybrid			2022-12-27	WOS:000086925300016
J	Lauer-Fields, JL; Tuzinski, KA; Shimokawa, K; Nagase, H; Fields, GB				Lauer-Fields, JL; Tuzinski, KA; Shimokawa, K; Nagase, H; Fields, GB			Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; HUMAN FIBROBLAST COLLAGENASE; C-TERMINAL DOMAIN; MACROPHAGE SCAVENGER RECEPTOR; SOLID-PHASE SYNTHESIS; TISSUE INHIBITOR; I COLLAGEN; MOLECULAR ARCHITECTURE; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY	The matrix metalloproteinase (MMP) family has been implicated in the process of a variety of diseases such as arthritis, atherosclerosis, and tumor cell metastasis. To study the mechanisms of MMP action on collagenous substrates, we have constructed homotrimeric triple-helical peptide (THP) models of the collagenase cleavage sites in types I and II collagen. The THPs incorporate either the alpha 1(I)772-786 or the alpha 1(II)772-783 sequence. The alpha 1(I)772-786 and alpha 1(II)772-783 THPs were hydrolyzed by MMP-1 at the Gly-Ile and Gly-Leu bonds, respectively, analogous to the bonds cleaved in corresponding native collagens. Thus, the THPs contained all necessary information to direct MMP-1 binding and proteolysis. Subsequent investigations using the alpha 1(I)772-786 THP showed hydrolysis by MMP-2, MMP-13, and a COOH-terminal domain-deleted MMP-1 (MMP-1(Delta(243-450))) but not by MMP-3 or a COOH-terminal domain-deleted MMP-3 (MMP-3(Delta(248-460))). Kinetic analyses showed a k(cat)/K-m value of 1,808 s(-1) M-1 for MMP-1 hydrolysis of alpha 1(I)772-786 THP, approximately 10-fold lower than for type I collagen. The effect is caused primarily by relative K-m values. MMP-2 and MMP-13 cleaved the THP more rapidly than MMP-1, but MMP-2 cleavage occurred at distinct multiple sites. Comparison of MMP-1 and MMP-1(Delta(243-450)) hydrolysis of alpha 1(I)772-786 THP showed that both can cleave a triple-helical substrate with a slightly higher K-m value for MMP-1(Delta(243-450)). We propose that the COOH-terminal domain of MMPs is necessary for orienting whole, native collagen molecules but may not be necessary for binding to and cleaving a THP, This proposal is consistent with the large distance between the MMP-1 catalytic and COOH-terminal domains observed by three-dimensional structural analysis and supports previous suggestions that the features of the catalytic domain contribute significantly toward enzyme specificity.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Biomed Engn, Minneapolis, MN 55455 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Imperial Coll Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England	State University System of Florida; Florida Atlantic University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Kansas; University of Kansas Medical Center; Imperial College London; University of Oxford	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.				NCI NIH HHS [CA 77402] Funding Source: Medline; NIAMS NIH HHS [AR 01929, AR 39189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189, K04AR001929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALLAN JA, 1991, J CELL SCI, V99, P789; Bella J, 1996, CONNECT TISSUE RES, V35, P401, DOI 10.3109/03008209609029218; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1985, J BIOL CHEM, V260, P6411; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Chandler S, 1996, BIOCHEM BIOPH RES CO, V228, P421, DOI 10.1006/bbrc.1996.1677; CHUNG L, 2000, IN PRESS PEPTIDES NE; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; FAN P, 1993, BIOCHEMISTRY-US, V32, P13299, DOI 10.1021/bi00211a043; Feng YB, 1996, J AM CHEM SOC, V118, P10351, DOI 10.1021/ja961260c; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1995, ANAL BIOCHEM, V231, P57, DOI 10.1006/abio.1995.1503; Fields CG, 1996, LETT PEPT SCI, V3, P3, DOI 10.1007/BF00131080; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FUNG BM, 1974, BIOPOLYMERS, V13, P1767, DOI 10.1002/bip.1974.360130910; Goodman M, 1996, J AM CHEM SOC, V118, P5156, DOI 10.1021/ja954132h; Goodman M, 1996, J AM CHEM SOC, V118, P10928, DOI 10.1021/ja961717i; Grab B, 1996, J BIOL CHEM, V271, P12234, DOI 10.1074/jbc.271.21.12234; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Holmgren SK, 1999, CHEM BIOL, V6, P63, DOI 10.1016/S1074-5521(99)80003-9; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; JELINSKI LW, 1979, J MOL BIOL, V133, P45, DOI 10.1016/0022-2836(79)90250-X; JELINSKI LW, 1980, NATURE, V284, P531, DOI 10.1038/284531a0; KHROMOVA T B, 1986, Biophysics (English Translation of Biofizika), V31, P227; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Knauss R, 1996, MAGN RESON MED, V36, P241, DOI 10.1002/mrm.1910360211; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kuznetsova N, 1998, BIOCHEMISTRY-US, V37, P11888, DOI 10.1021/bi980089+; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; LAUERFIELDS JL, 2000, IN PRESS PEPTIDES NE; LEIKIN S, 1995, NAT STRUCT BIOL, V2, P205, DOI 10.1038/nsb0395-205; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; Mielewczyk SS, 1996, BIOCHEMISTRY-US, V35, P11396, DOI 10.1021/bi960706z; MILES AJ, 1994, J BIOL CHEM, V269, P30939; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Morton LF, 1997, J BIOL CHEM, V272, P11044; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nagase H, 1996, ZINC METALLOPROTEASE, P153; NEMETHY G, 1986, BIOCHEMISTRY-US, V25, P3184, DOI 10.1021/bi00359a016; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Ottl J, 1996, FEBS LETT, V398, P31, DOI 10.1016/S0014-5793(96)01212-4; Ottl J, 1999, J AM CHEM SOC, V121, P653, DOI 10.1021/ja983456d; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STAMS T, 1994, STRUCT BIOL, V1, P119; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; Tanaka T, 1996, PROTEIN ENG, V9, P307, DOI 10.1093/protein/9.3.307; Tiktopulo EI, 1998, BIOCHEMISTRY-US, V37, P8147, DOI 10.1021/bi980360n; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1981, J BIOL CHEM, V256, P9516; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; WELGUS HG, 1985, J BIOL CHEM, V260, P1052; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1999, BIOCHEMISTRY-US, V38, P1659, DOI 10.1021/bi982315l; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656	87	105	111	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13282	13290		10.1074/jbc.275.18.13282	http://dx.doi.org/10.1074/jbc.275.18.13282			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788434	hybrid			2022-12-27	WOS:000086925300020
J	Liu, MC; Suiko, M; Sakakibara, Y				Liu, MC; Suiko, M; Sakakibara, Y			Mutational analysis of the substrate binding/catalytic domains of human M form and P form phenol sulfotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVONOL 3-SULFOTRANSFERASE; BINDING-SITE; CDNA CLONING; AMINO-ACID; SPECIFICITY; EXPRESSION; IDENTIFICATION; SULFATION; PROTEINS; SULT1A3	Human monoamine (M) form and simple phenol (P) form phenol sulfotransferases (PSTs) are greater than 93% identical in their primary sequences and yet display distinct substrate specificities and other enzymatic properties. Through the generation and characterization of a series of chimeric PSTs, we have previously demonstrated two highly variable regions within their sequences to be responsible for determining their substrate phenotypes (Sakakibara, Y,, Takami, Y,, Nakayama, T,, Suiko, M., and Liu, M.-C. (1998) J. Biol. Chem. 273, 6242-6247). By employing the site-directed mutagenesis technique, the present study aims to identify and quantitatively evaluate the specific amino acid residues critical to the substrate binding and catalysis in these two enzymes. Twelve mutated M-PSTs and seven mutated P-PSTs were generated, expressed, and purified. Enzymatic characterization showed that, of the twelve mutated M-PSTs, mutations at residues Asp-86, Glu-89, and Glu-146 resulted in a dramatic decrease in V-max/K-m with dopamine as substrate, being greater than 450 times for the DS6A/E89I/E146A mutated M-PST. With p-nitrophenol as substrate, the V-max/K-m, determined for the DS6A/E89I/E146A-mutated M-PST increased more than 25 times and approached that determined for the wild-type P-PST. These results indicated that the concerted action of the three mutated residues (D86A, E89I, and E146A) is sufficient for the conversion of the substrate phenotype of M-PST to that of P-PST, Among the mutated P-PSTs, the I89E- and A146E-mutated P-PSTs displayed considerable deviations in V-max/K-m with dopamine or p-nitrophenol as substrate. No corresponding changes, however, were detected with the opposite compound as substrate. These results indicated that, in contrast to M-PST, mutations at Ala-86, Ile-89, and Ala-146 to the corresponding residues in M-PST are not sufficient for rendering the change of P-PST substrate phenotype to that of M-PST, For both M-PSTs and P-PSTs, mutations at Lys-48 or His-108 led to the loss of sulfotransferase activities, indicating their importance in the catalytic mechanism.	Univ Texas Hlth Ctr, Biomed Res Ctr, Tyler, TX 75708 USA		Liu, MC (corresponding author), Univ Texas Hlth Ctr, Biomed Res Ctr, 11937 US Hwy 271, Tyler, TX 75708 USA.	liu@uthct.edu						Braden M, 1976, Front Oral Physiol, V2, P1; Brix LA, 1999, BIOCHEMISTRY-US, V38, P10474, DOI 10.1021/bi990795q; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Dajani R, 1998, MOL PHARMACOL, V54, P942, DOI 10.1124/mol.54.6.942; Falany C., 1993, HUMAN DRUG METABOLIS, P101; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Her C, 1998, GENOMICS, V53, P284, DOI 10.1006/geno.1998.5518; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LIU MC, 1984, P NATL ACAD SCI-BIOL, V81, P3695, DOI 10.1073/pnas.81.12.3695; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1999, BIOCHEMISTRY-US, V38, P4066, DOI 10.1021/bi982239m; Mulder G.J., 1990, CONJUGATION REACTION, P107; Sakakibara Y, 1998, J BIOL CHEM, V273, P6242, DOI 10.1074/jbc.273.11.6242; Sakakibara Y, 1997, BBA-MOL CELL RES, V1355, P102, DOI 10.1016/S0167-4889(96)00166-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tamura H, 1997, ARCH BIOCHEM BIOPHYS, V341, P309, DOI 10.1006/abbi.1997.9979; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; VERONESE ME, 1994, BIOCHEM J, V302, P497, DOI 10.1042/bj3020497; WEINSHILBOUM R, 1994, CONJUGATION DECONJUG, P45, DOI DOI 10.1007/978-3-642-78429-3; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WOOD TC, 1994, BIOCHEM BIOPH RES CO, V198, P1119, DOI 10.1006/bbrc.1994.1159; YAMAZOE Y, 1994, CHEM-BIOL INTERACT, V92, P107, DOI 10.1016/0009-2797(94)90057-4; Yanagisawa K, 1998, BIOSCI BIOTECH BIOCH, V62, P1037, DOI 10.1271/bbb.62.1037; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467	28	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13460	13464		10.1074/jbc.275.18.13460	http://dx.doi.org/10.1074/jbc.275.18.13460			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788459	hybrid			2022-12-27	WOS:000086925300046
J	Stang, E; Johannessen, LE; Knardal, SL; Madshus, IH				Stang, E; Johannessen, LE; Knardal, SL; Madshus, IH			Polyubiquitination of the epidermal growth factor receptor occurs at the plasma membrane upon ligand-induced activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; C-CBL; HORMONE RECEPTOR; INDUCED INTERNALIZATION; COATED PITS; BREFELDIN-A; RING FINGER; A431 CELLS; UBIQUITIN; ENDOCYTOSIS	We have previously shown that, although overexpression of mutant dynamin inhibits clathrin-dependent endocytosis and disrupts high affinity binding of epidermal growth factor (EGF) to the EGF receptor (EGFR), it does not inhibit ligand-induced translocation of the EGFR into clathrin-coated pits. In the present study, we demonstrate that, upon ligand binding and incubation at 37 degrees C, the EGFR was polyubiquitinated regardless of overexpression of mutant dynamin, In cells not overexpressing mutant dynamin, the EGFR was rapidly internalized and deubiquitinated, In cells being endocytosis-deficient, due to overexpression of mutant dynamin, however, the EGFR was upon prolonged chase first found in deeply invaginated coated pits, and then eventually moved out of the coated pits and back onto the smooth plasma membrane, Polyubiquitination occurred equally efficiently in cells with or without intact clathrin-dependent endocytosis, while the kinetics of ubiquitination and deubiquitination was somewhat different. We further found that the EGF-induced ubiquitination of Eps15 occurred both in the absence and presence of endocytosis with the same kinetics as polyubiquitination of the EGFR, but that the EGF-induced monoubiquitination of Eps15 was somewhat reduced upon overexpression of mutant dynamin, Our data show that EGF-induced polyubiquitination of the EGFR occurs at the plasma membrane.	Univ Oslo, Natl Hosp, Inst Pathol, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway	Stang, E (corresponding author), Univ Oslo, Natl Hosp, Inst Pathol, N-0027 Oslo, Norway.	espenst@ulrik.uio.no						BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NESTEROV A, 1994, ARCH BIOCHEM BIOPHYS, V313, P351, DOI 10.1006/abbi.1994.1398; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Skarpen E, 1998, EXP CELL RES, V243, P161, DOI 10.1006/excr.1998.4127; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	41	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13940	13947		10.1074/jbc.275.18.13940	http://dx.doi.org/10.1074/jbc.275.18.13940			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788520	hybrid			2022-12-27	WOS:000086925300107
J	Suzukawa, K; Miura, K; Mitsushita, J; Resau, J; Hirose, K; Crystal, R; Kamata, T				Suzukawa, K; Miura, K; Mitsushita, J; Resau, J; Hirose, K; Crystal, R; Kamata, T			Nerve growth factor-induced neuronal differentiation requires generation of Rac1-regulated reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; PC12 CELLS; FIBROBLASTS; SUPEROXIDE; SPECIFICITY; INVOLVEMENT; EXPRESSION	Nerve growth factor (NGF) stimulation of pheochromocytoma PC12 cells transiently increased the intracellular concentration of reactive oxygen species (ROS). This increase was blocked by the chemical antioxidant N-acetylcysteine and a flavoprotein inhibitor, diphenylene iodonium. NGF responses of PC12 cells, including neurite outgrowth, tyrosine phosphorylation, and AP-1 activation, was inhibited when ROS production was prevented by N-acetylcysteine and diphenylene iodonium. The expression of dominant negative Rac1N17 blocked induction of both ROS generation and morphological differentiation by NGF. The ROS produced appears to be H2O2, because the introduction of catalase into the cells abolished NGF-induced neurite outgrowth, ROS production, and tyrosine phosphorylation, These results suggest that the ROS, perhaps H2O2, acts as an intracellular signal mediator for NGF-induced neuronal differentiation and that NGF-stimulated ROS production is regulated by Rac1 and a flavoprotein-binding protein similar to the phagocytic NADPH oxidase.	NCI, Sci Applicat Int Corp Frederick, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; NCI, Analyt Microscopy Lab, Adv Biosci Labs,Basic Res Program, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; Cornell Univ, Med Ctr, New York, NY 10021 USA; Kureha Chem, Inst Biomed Res, Tokyo 160, Japan; Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Cornell University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Asahi 3-1-1, Nagano 3908621, Japan.		Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318; Suzukawa, Kazumi/0000-0001-9904-3905				AMES BN, 1988, IARC SCI PUBL, V89, P407; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DIAGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kamata H, 1996, NEUROSCI LETT, V212, P179, DOI 10.1016/0304-3940(96)12806-8; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MALY FE, 1989, J IMMUNOL, V142, P1260; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515	26	217	222	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13175	13178		10.1074/jbc.275.18.13175	http://dx.doi.org/10.1074/jbc.275.18.13175			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788420	hybrid			2022-12-27	WOS:000086925300004
J	Beier, F; Taylor, AC; LuValle, P				Beier, F; Taylor, AC; LuValle, P			Activating transcription factor 2 is necessary for maximal activity and serum induction of the cyclin A promoter in chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RESPONSE ELEMENT; LEUCINE ZIPPER; HERITABLE DISEASES; MOLECULAR INSIGHTS; C-FOS; BINDING; GENE; JUN; ATF-2	Endochondral bone growth is regulated through the proliferation and differentiation of growth plate chondrocytes. Mice deficient for the activating transcription factor 2 (ATF-2) gene show reduced proliferation of chondrocytes. Here we demonstrate that the cyclin A gene is a target of ATF-2 in chondrocytes. Serum stimulation of chondrogenic rat chondrosarcoma cells induces cyclin A expression. A cyclic AMP response element (CRE) is necessary for optimal activity and serum inducibility of the cyclin A promoter and confers regulation by ATF-2. Phosphorylation and activity of ATF-2 are enhanced dramatically upon serum stimulation of rat chondrosarcoma cells. Mutation of the CRE or overexpression of dominant-negative ATF-2 inhibits serum induction of the cyclin A promoter. Chondrocytes from ATF-2 deficient mice display reduced and delayed induction of cyclin A upon serum stimulation. The ATF-2-related transcription factor CRE-binding protein contributes to the activity of the cyclin A CRE in chondrocytes, whereas c-Jun and c-Fos regulate the promoter independently of the CRE. Our data suggest that the reduction in cyclin A levels in chondrocytes from ATF-2-deficient mice contributes to their phenotype of reduced chondrocyte proliferation and dwarfism.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	LuValle, P (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Beier, Frank/G-4595-2013; Beier, Frank/T-4734-2019	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Beier F, 1999, MATRIX BIOL, V18, P109, DOI 10.1016/S0945-053X(99)00009-8; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BENBROOK DM, 1990, ONCOGENE, V5, P295; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	27	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12948	12953		10.1074/jbc.275.17.12948	http://dx.doi.org/10.1074/jbc.275.17.12948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777595	hybrid			2022-12-27	WOS:000086762300079
J	Kelner, MJ; Bagnell, RD; Montoya, MA; Estes, LA; Forsberg, L; Morgenstern, R				Kelner, MJ; Bagnell, RD; Montoya, MA; Estes, LA; Forsberg, L; Morgenstern, R			Structural organization of the microsomal glutathione S-Transferase gene (MGST1) on chromosome 12p13.1-13.2 - Identification of the correct promoter region and demonstration of transcriptional regulation in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; I-HYPERSENSITIVE SITES; GAMMA-GLUTAMYL-TRANSPEPTIDASE; RAT-LIVER; INDUCIBLE EXPRESSION; DEPENDENT PROTECTION; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; SMALL-INTESTINE; MESSENGER-RNAS	The structure and regulation of the microsomal glutathione S-transferase gene (MGST1) are considerably more complex than originally perceived to be. The MGST1 gene has two alternative first exons and is located in the 12p13.1-13.2 region. Two other potential first exons were determined to be nonfunctional. The region between the functional first exons cannot direct transcription. Thus, one common promoter element directing transcription exists, and RNA splicing occurs such that only one of the first exons (containing only untranslated mRNA) is incorporated into each mRNA species with common downstream exons, MGST1 expression and regulation are therefore similar to those of other hepatic xenobiotic handling enzymes, which also produce mRNA species differing only in the 5'-untranslated regions to yield identical proteins. MGST1 was previously considered a "housekeeping" gene, as non-oxidant inducers had little effect on activity. However, the promoter region immediately upstream of the dominant first exon transcriptionally responds to oxidative stress. In this respect, MGST1 is similar to glutathione peroxidases that also transcriptionally respond to oxidative stress. The discovery that MGST1 utilizes alternative first exon splicing eliminates a problem with the first description of MGST1 cDNA in that it appeared that MGST1 expression was in violation of the ribosomal scanning model. The identification that the first exon originally noted is in fact a minor alternative first exon far downstream of the primary first exon eliminates this conundrum.	Univ Calif San Diego, Med Ctr, Dept Pathol, San Diego, CA 92103 USA; Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden	University of California System; University of California San Diego; Karolinska Institutet	Kelner, MJ (corresponding author), Univ Calif San Diego, Med Ctr, Dept Pathol, 200 W Arbor Dr, San Diego, CA 92103 USA.		Ekström, lena/E-8477-2013; Montoya, Miguel/GVT-5869-2022; Morgenstern, Ralf/GZH-0158-2022		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NIEHS NIH HHS [1 P42 ES10337] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERS MW, 1988, CRC CR REV TOXICOL, V18, P311, DOI 10.3109/10408448809037470; Andersson C, 1994, Adv Pharmacol, V27, P19, DOI 10.1016/S1054-3589(08)61028-5; ANIYA Y, 1992, ARCH BIOCHEM BIOPHYS, V296, P611, DOI 10.1016/0003-9861(92)90617-6; ANIYA Y, 1989, ARCH BIOCHEM BIOPHYS, V270, P330, DOI 10.1016/0003-9861(89)90035-0; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BERTLING WM, 1993, PCR METH APPL, V3, P95; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; Dafre AL, 1996, ARCH BIOCHEM BIOPHYS, V332, P288, DOI 10.1006/abbi.1996.0344; DAIDO A, 1994, JPN J PHARMACOL, V66, P357, DOI 10.1254/jjp.66.357; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; DEJONG JL, 1990, GENOMICS, V6, P379, DOI 10.1016/0888-7543(90)90580-N; EKSTROM L, 1999, EUR J BIOCHEM, V260, P409; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARGUS SJ, 1991, ADV EXP MED BIOL, V283, P289; HORNSBY PJ, 1985, J CELL PHYSIOL, V123, P33, DOI 10.1002/jcp.1041230106; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KELNER MJ, 1995, ARCH BIOCHEM BIOPHYS, V323, P40, DOI 10.1006/abbi.1995.0007; KELNER MJ, 1990, FREE RADICAL BIO MED, V9, P149, DOI 10.1016/0891-5849(90)90118-3; Kelner MJ, 1996, GENOMICS, V36, P100, DOI 10.1006/geno.1996.0429; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Lee SH, 1999, BBA-GENE STRUCT EXPR, V1446, P389, DOI 10.1016/S0167-4781(99)00112-8; LUNDQVIST G, 1992, BIOCHEM PHARMACOL, V43, P131, DOI 10.1016/0006-2952(92)90269-O; Luo ZH, 1996, ARCH BIOCHEM BIOPHYS, V336, P251, DOI 10.1006/abbi.1996.0555; LUQUITA MG, 1995, PHARMACOL TOXICOL, V76, P72, DOI 10.1111/j.1600-0773.1995.tb00106.x; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MASUKAWA T, 1986, BIOCHEM PHARMACOL, V35, P435, DOI 10.1016/0006-2952(86)90216-9; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; METTERS KM, 1994, J BIOL CHEM, V269, P12816; MORGENSTERN R, 1979, BIOCHEM BIOPH RES CO, V87, P657, DOI 10.1016/0006-291X(79)92009-6; MORGENSTERN R, 1982, ACTA CHEM SCAND B, V36, P255, DOI 10.3891/acta.chem.scand.36b-0255; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; Morgenstern R, 1985, REV BIOCHEM TOXICOL, V7, P67; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MOSIALOU E, 1995, ARCH BIOCHEM BIOPHYS, V320, P210, DOI 10.1016/0003-9861(95)90002-0; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; MOSIALOU E, 1993, BIOCHEM PHARMACOL, V45, P1645, DOI 10.1016/0006-2952(93)90305-G; MOSIALOU E, 1993, FEBS LETT, V315, P77, DOI 10.1016/0014-5793(93)81137-O; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; OKAMOTO T, 1994, BIOCHEMISTRY-US, V33, P11536, DOI 10.1021/bi00204a016; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REDDY CC, 1981, BIOCHEM BIOPH RES CO, V101, P970; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SANGER F, 1977, P NATL ACAD SCI USA, V74, P546; ShehinJohnson SE, 1996, DRUG METAB DISPOS, V24, P891; Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; TU CPD, 1986, J BIOL CHEM, V261, P9540; WAXMAN DJ, 1992, CANCER RES, V52, P5797	64	65	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13000	13006		10.1074/jbc.275.17.13000	http://dx.doi.org/10.1074/jbc.275.17.13000			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777602	hybrid			2022-12-27	WOS:000086762300086
J	Waterborg, JH				Waterborg, JH			Steady-state levels of histone acetylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE ACTIVITY; H4 ACETYLATION; CELL-CYCLE; YEAST; ACETYLTRANSFERASE; TRANSCRIPTION; H3; HETEROCHROMATIN; METHYLATION; COMPLEXES	The importance of control of the levels of histone acetylation for the control of gene expression in eukaryotic chromatin is being elucidated, and the yeast Saccharomyces cerevisiae has proven to be an important model system. The level of histone acetylation in yeast is the highest known. However, only acetylation of H4 has been quantified, and reports reveal loss of acetylation in histone preparations. A chaotropic guanidine-based method for histone isolation from intact wild-type cells or from a single-step nuclear preparation with butyrate preserves acetylation of all core histones. Histone H4 has an average of more than 2 acetylated lysines per molecule, distributed over 4 sites. Histones H2A, H3, and H2B have 0.2, similar to 2, and >2 acetylated lysines per molecule, respectively, distributed across 2, 5, and 6 sites. Thus, yeast nucleosomes carry, on average, 13 acetylated lysines per octamer, i.e. just above the threshold of 10-12 deduced for transcriptionally activated chromatin of animals, plants, and algae. Following M-r 100,000 ultrafiltration in 2.5% acetic acid, yeast histone H3 was purified to homogeneity by reversed-phase high pressure liquid chromatography. Other core histones were obtained at 80-95% purity.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Waterborg, JH (corresponding author), Rm 414 BSB 5007 Rockhill Rd, Kansas City, MO 64110 USA.	WaterborgJ@umkc.edu	Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634				ALONSO WR, 1986, BIOCHIM BIOPHYS ACTA, V866, P161, DOI 10.1016/0167-4781(86)90113-2; Belyaev ND, 1997, CHROMOSOMA, V106, P193, DOI 10.1007/s004120050239; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Casal M, 1996, MICROBIOL-UK, V142, P1385, DOI 10.1099/13500872-142-6-1385; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DELPINO MMS, 1994, BIOCHEM J, V303, P723, DOI 10.1042/bj3030723; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Matthews HR, 1985, ENZYMOLOGY POSTTRANS, V2, P125; MENDE LM, 1983, BIOCHEMISTRY-US, V22, P38, DOI 10.1021/bi00270a006; NELSON DA, 1982, J BIOL CHEM, V257, P1565; Olsson TGS, 1999, CURR GENET, V35, P82, DOI 10.1007/s002940050436; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suka N, 1998, COLD SPRING HARB SYM, V63, P391, DOI 10.1101/sqb.1998.63.391; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; WATERBORG JH, 1991, PLANT PHYSIOL, V96, P453, DOI 10.1104/pp.96.2.453; WATERBORG JH, 1992, PLANT MOL BIOL, V18, P181, DOI 10.1007/BF00034947; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; Waterborg JH, 1998, J BIOL CHEM, V273, P27602, DOI 10.1074/jbc.273.42.27602; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WATERBORG JH, 1995, PLANT PHYSIOL, V109, P393, DOI 10.1104/pp.109.2.393; WATERBORG JH, 1989, PLANT PHYSIOL, V90, P237, DOI 10.1104/pp.90.1.237; WATERBORG JH, 1998, PROTEIN PROTOCOLS CD; WATERBORG JH, 1999, PLANT BIOL 99 ANN M; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	49	77	81	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13007	13011		10.1074/jbc.275.17.13007	http://dx.doi.org/10.1074/jbc.275.17.13007			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777603	hybrid			2022-12-27	WOS:000086762300087
J	Millar, DS; Paul, CL; Molloy, PL; Clark, SJ				Millar, DS; Paul, CL; Molloy, PL; Clark, SJ			A distinct sequence (ATAAA)(n) separates methylated and unmethylated domains at the 5 '-end of the GSTP1 CpG island	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; ACUTE MYELOID-LEUKEMIA; DE-NOVO METHYLATION; DNA METHYLATION; GENE; EXPRESSION; CANCER; MOUSE; CELLS; HYPERMETHYLATION	What defines the boundaries between methylated and unmethylated domains in the genome is unclear. In this study we used bisulfite genomic sequencing to map the boundaries of methylation that flank the 5'- and 3' ends of the CpG island spanning the promoter region of the glutathione S-transferase (GSTP1) gene. We show that GSTP1 is expressed in a nide range of tissues including brain, lung, skeletal muscle, spleen, pancreas, bone marrow, prostate, heart, and blood and that this expression is associated with the CPG island being unmethylated, In these normal tissues a marked boundary was found to separate the methylated and unmethylated regions of the gene at the 5'-flank of the CpG island, and this boundary correlated with an (ATAAA)(19-24) repeated sequence. In contrast, the 3'-end of the CpG island was not marked by a sharp transition in methylation but by a gradual change in methylation density over about 500 base pairs. In normal tissue the sequences on either side of the 5'-boundary appear to lie in separate domains in which CpG methylation is independently controlled. These separate methylation domains are lost in all prostate cancer where GSTP1 expression is silenced and methylation extends throughout the island and spans across both the 5'- and 3'-boundary regions.	CSIRO, N Ryde, NSW 1670, Australia; Royal Prince Alfred Hosp, Kanematsu Labs, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Med, Sydney, NSW 2050, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney; University of Sydney	Clark, SJ (corresponding author), CSIRO, POB 184, N Ryde, NSW 1670, Australia.		Molloy, Peter L/H-7931-2013; Clark, Susan J/B-2272-2008; Clark, Susan J/U-7365-2019	Molloy, Peter L/0000-0002-7788-3417; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHEN H, 1992, GENOMICS, V15, P621; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARK SJ, 1995, DNA NUCLEOPROTEIN ST, P123; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MATHEW J, 1992, J CLIN PATHOL, V45, P679, DOI 10.1136/jcp.45.8.679; MEHTA R, 1994, CANCER LETT, V84, P163, DOI 10.1016/0304-3835(94)90371-9; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Melki JR, 1999, CANCER RES, V59, P3730; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; RAM TG, 1993, CANCER RES, V53, P2655; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Schmutte C, 1998, BIOL CHEM, V379, P377; Stirzaker C, 1997, CANCER RES, V57, P2229; TAMIMI Y, 1993, CANCER RES, V53, P5512; TERRIER P, 1990, AM J PATHOL, V137, P845; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728	27	61	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24893	24899		10.1074/jbc.M906538199	http://dx.doi.org/10.1074/jbc.M906538199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10779522	hybrid			2022-12-27	WOS:000088683300088
J	El-Husseini, AE; Topinka, JR; Lehrer-Graiwer, JE; Firestein, BL; Craven, SE; Aoki, C; Bredt, DS				El-Husseini, AE; Topinka, JR; Lehrer-Graiwer, JE; Firestein, BL; Craven, SE; Aoki, C; Bredt, DS			Ion channel clustering by membrane-associated guanylate kinases - Differential regulation by N-terminal lipid and metal binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-SUPPRESSOR GENE; DENSITY PROTEIN PSD-95; SIGNAL-TRANSDUCTION; SAP97; PALMITOYLATION; DOMAINS; HOMOLOG; NEURONS; SAP102	The postsynaptic density protein PSD-95 and related membrane-associated guanylate kinase (MAGUK) proteins assemble signal transduction complexes at sites of cell cell contact including synapses. Whereas PSD-95 and PSD-93 occur only at postsynaptic sites in hippocampal neurons, SAP-102 also occurs in axone. In heterologous cells, PSD-95 and PSD-93 mediate cell surface ion channel clustering, but SAP-102 and SAP-97 do not. This selective ion channel clustering activity by MAGUKs is explained by differential palmitoylation, as PSD-93 and PSD-95 are palmitoylated though SAP-97, and SAP-102 are not. Rather than being palmitoylated, we find that N-terminal cysteines from SAP-102 tightly bind to zinc. And, appending the N terminus of SAP-102 to PSD-95 results in localization of the chimera to both axone and dendrites, These data suggest that lipid modifications and heavy metal associations with the N termini of MAGUKs mediate differential functions and subcellular localizations of these synaptic scaffolds.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; NYU, Ctr Neural Sci, Dept Physiol, New York, NY 10013 USA	University of California System; University of California San Francisco; New York University	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	bredt@itsa.ucsf.edu	Aoki, Chiye/T-9405-2019	Aoki, Chiye/0000-0003-4010-9425; Firestein, Bonnie/0000-0002-1679-3565	NINDS NIH HHS [R01-NS36017] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036017] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Firestein BL, 1999, NEURON, V24, P659, DOI 10.1016/S0896-6273(00)81120-4; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; Keshet GI, 1999, J NEUROCHEM, V72, P1224, DOI 10.1046/j.1471-4159.1999.0721224.x; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Rao A, 1998, J NEUROSCI, V18, P1217; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Vallee B L, 1995, EXS, V73, P259; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	36	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23904	23910		10.1074/jbc.M909919199	http://dx.doi.org/10.1074/jbc.M909919199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10779526	hybrid			2022-12-27	WOS:000088564200069
J	Zhou, XJ; Liao, J; Meyerdierks, A; Feng, L; Naumovski, L; Bottger, EC; Omary, MB				Zhou, XJ; Liao, J; Meyerdierks, A; Feng, L; Naumovski, L; Bottger, EC; Omary, MB			Interferon-alpha induces Nmi-IFP35 heterodimeric complex formation that is affected by the phosphorylation of IFP35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN NMI; INTERMEDIATE FILAMENTS; TARGETED DISRUPTION; EPITHELIAL-CELLS; GENE; IDENTIFICATION; RESPONSES; GAMMA; STAT1; MYC	Nmi and IFP35 are interferon (IFN)-induced proteins. In cells treated with IFN-gamma, Nmi enhances the association of transcription co-activator CBP/p300 with signal transducer and activator of transcription proteins, and IFP35 forms a high molecular weight cytosolic complex of unknown constituents. Here we show that Nmi and IFP35 co-immunoprecipitate with an anti-keratin 19 antibody, which is due to cross-reaction of the antibody with Nmi, and suggests an Nmi-IFP35 physical association. In support of this, Nmi and IFP35 co-immunoprecipitate using anti-Nmi and anti-IFP35 antibodies, manifest enhanced colocalization as determined by immunofluorescence staining of IFN-treated cells, and form heterodimers as determined by chemical crosslinking. Nmi and IFP35 are primarily cytosolic proteins, and their interaction is increased after IFN-alpha treatment of cells as early as 1 h after exposure. Sucrose gradient sedimentation and size fractionation showed a shift of Nmi-IFP35 heterodimers toward a heavier fraction (100-200 kDa) in IFN-alpha-treated cells. This dynamic complex formation is reversed by pretreatment with okadaic acid. Two-dimensional gel analysis indicates that the IFN-induced complex formation correlates with IFP35 dephosphorylation. Our data demonstrate Nmi-IFP35 cytosolic localization and heterodimerization, and an IFN-alpha-regulated molecular event in which Nmi and IFP35 participate, reversibly and by a dephosphorylation dependent fashion, in a 100-200-kDa molecular complex formation.	Vet Affairs Med Ctr, Palo Alto, CA 94304 USA; Stanford Univ, Palo Alto, CA 94304 USA; Med Hsch Hannover, Inst Med Mikrobiol, D-30625 Hannover, Germany; Stanford Univ, Dept Pediat, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Stanford University	Zhou, XJ (corresponding author), Vet Affairs Med Ctr, 154J 3801 Miranda Ave, Palo Alto, CA 94304 USA.		Böttger, Erik C./F-6175-2011	Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK07056, DK47918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918, T32DK007056] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGE FC, 1994, J BIOL CHEM, V269, P1091; Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bao JX, 1996, ONCOGENE, V12, P2171; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOTTGER V, 1995, EUR J BIOCHEM, V231, P475, DOI 10.1111/j.1432-1033.1995.tb20721.x; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Kjerrulf M, 1997, IMMUNOLOGY, V92, P60, DOI 10.1046/j.1365-2567.1997.00312.x; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liao J, 1996, ELECTROPHORESIS, V17, P1671, DOI 10.1002/elps.1150171104; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyerdierks A, 1999, J HISTOCHEM CYTOCHEM, V47, P169, DOI 10.1177/002215549904700206; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Omary M B, 1998, Subcell Biochem, V31, P105; PAUL ECA, 1993, J CELL SCI, V106, P967; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang XY, 1996, BIOCHEM BIOPH RES CO, V229, P316, DOI 10.1006/bbrc.1996.1799; Weinberg WC, 1997, J INVEST DERMATOL, V109, P611, DOI 10.1111/1523-1747.ep12337539; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	32	44	45	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21364	21371		10.1074/jbc.M003177200	http://dx.doi.org/10.1074/jbc.M003177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10779520	hybrid			2022-12-27	WOS:000088230600055
J	Verdile, G; Martins, RN; Duthie, M; Holmes, E; St George-Hyslop, PH; Fraser, PE				Verdile, G; Martins, RN; Duthie, M; Holmes, E; St George-Hyslop, PH; Fraser, PE			Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; ALZHEIMERS-DISEASE; BETA-PROTEIN; GAMMA-SECRETASE; MUTANT PRESENILINS; CULTURED-CELLS; DISTINCT SITES; GENERATION; COMPLEX; PEPTIDE	Presenilin 1 (PS1) plays a pivotal role in the production of the amyloid-beta protein, which is central to the pathogenesis of Alzheimer's disease. It has been demonstrated that PS1 regulates the gamma-secretase proteolysis of the amyloid precursor protein (APP) C-terminal fragment (APP-C100), which is the final step in amyloid-beta protein production. The mechanism and detailed pathway of this PS1 activity has yet to be fully resolved, but it may be due to a presenilin-controlled trafficking of the APP fragment or possibly an inherent PS1 proteolytic activity. We have investigated the possibility of a direct interaction of PS1 and the APP-C100 within the high molecular mass presenilin complex. However, the APP-C100 is rapidly degraded, and if it forms, then any PS1-APP complex is likely to be very transitory. To circumvent this problem, we have utilized the protease inhibitor N-acetyl-leucyl-norleucinal (LLnL) and the lysosomotropic agent NH4Cl, which inhibits the turnover of the APP-C100, Under these conditions, levels of the fragment increased appreciably, and as shown by glycerol gradient analysis, the APP-C100 shifted to a higher molecular mass complex that overlapped with PS1. Immunoprecipitation studies demonstrated that a significant population of the APP-C100 co-precipitated with PS1. These findings suggest that PSI may mediate the shuttling of APP fragments and/or facilitate their presentation for gamma-secretase cleavage through a direct interaction.	Univ Western Australia, Hollywood Private Hosp, Dept Surg, Perth, WA 6009, Australia; Univ Western Australia, Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Perth, WA 6009, Australia; Univ Toronto, Ctr Res Neurodegenerat Dis, W Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, W Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Neurol, W Toronto, ON M5S 3H2, Canada	University of Western Australia; University of Western Australia; University of Toronto; University of Toronto; University of Toronto	Martins, RN (corresponding author), Univ Western Australia, Hollywood Private Hosp, Dept Surg, Perth, WA 6009, Australia.	rmartins@cyllene.uwa.edu.au		Martins, Ralph/0000-0002-4828-9363; Verdile, Giuseppe/0000-0003-2475-0124				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dumanchin C, 1999, HUM MOL GENET, V8, P1263, DOI 10.1093/hmg/8.7.1263; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Greenfield JP, 1999, J BIOL CHEM, V274, P33843, DOI 10.1074/jbc.274.48.33843; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Kim SS, 1997, J MOL NEUROSCI, V9, P49, DOI 10.1007/BF02789394; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kouchi Z, 1999, BIOCHEM BIOPH RES CO, V254, P804, DOI 10.1006/bbrc.1998.9977; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nishimura M, 1999, CLIN GENET, V55, P219, DOI 10.1034/j.1399-0004.1999.550401.x; Peraus GC, 1997, J NEUROSCI, V17, P7714; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Sudoh S, 1998, J NEUROCHEM, V71, P1535; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Trischler M, 1999, J CELL SCI, V112, P4773; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Waragai M, 1997, BIOCHEM BIOPH RES CO, V239, P480, DOI 10.1006/bbrc.1997.7488; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20794	20798		10.1074/jbc.C000208200	http://dx.doi.org/10.1074/jbc.C000208200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801777	hybrid			2022-12-27	WOS:000088084500081
J	Chivers, PT; Sauer, RT				Chivers, PT; Sauer, RT			Regulation of high affinity nickel uptake in bacteria - Ni2+-dependent interaction of NikR with wild-type and mutant operator sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; MNT-REPRESSOR; ESCHERICHIA-COLI; MET REPRESSOR; CRYSTAL-STRUCTURE; ARC REPRESSOR; RECOGNITION; RESIDUES; GENES; TRAY	Escherichia coli actively imports nickel via the ATP-dependent NikABCDE permease. NikR, a protein of the ribbon-helix-helix family of transcription factors, represses expression of the nikABCDE operon in the presence of excessive concentrations of intracellular nickel. Here, the NikR operator site is identified within the nikABCDE promoter by footprinting and mutational analyses. The operator consists of two dyad-symmetric 5'-GTATGA-3' recognition sequences separated by 16 base pairs. Mutations in the GTATGA sequences reduce NikR binding affinity in vitro and reduce repression of a P-nik-lacZ fusion in vivo. Moreover, NikR is shown to be a direct sensor of nickel ions. Strong operator binding requires the continual presence of 20-50 mu M nickel, indicating the presence of a low affinity nickel-binding site, and NikR dimers also contain two high affinity nickel-binding sites. In addition to both GTATGA sites and nickel, high affinity operator binding also requires the C-terminal domain of NikR.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399; Chivers, Peter/0000-0002-8779-1452	NIAID NIH HHS [AI-15706, AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R01AI016892, R37AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1988, MOL REPROD DEV; Baynham PJ, 1999, MOL MICROBIOL, V33, P1069, DOI 10.1046/j.1365-2958.1999.01550.x; BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BROWN BM, 1994, NAT STRUCT BIOL, V1, P164, DOI 10.1038/nsb0394-164; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; Ermler U, 1998, CURR OPIN STRUC BIOL, V8, P749, DOI 10.1016/S0959-440X(98)80095-X; FU CL, 1994, P NATL ACAD SCI USA, V91, P5099, DOI 10.1073/pnas.91.11.5099; Gomis-Ruth FX, 1998, EMBO J, V17, P7404, DOI 10.1093/emboj/17.24.7404; HE YY, 1992, NATURE, V359, P431, DOI 10.1038/359431a0; KNIGHT KL, 1989, J BIOL CHEM, V264, P13706; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Lum PL, 1999, J BIOL CHEM, V274, P19644, DOI 10.1074/jbc.274.28.19644; Maroney MJ, 1999, CURR OPIN CHEM BIOL, V3, P188, DOI 10.1016/S1367-5931(99)80032-5; Miller J. H, 1972, EXPT MOL GENETICS; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; Nooren IMA, 1999, NAT STRUCT BIOL, V6, P755; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; Ragsdale SW, 1998, CURR OPIN CHEM BIOL, V2, P208, DOI 10.1016/S1367-5931(98)80062-8; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schildbach JF, 1999, P NATL ACAD SCI USA, V96, P811, DOI 10.1073/pnas.96.3.811; SCHWARZENBACH G, 1956, HELV CHIM ACTA, V39, P1589, DOI 10.1002/hlca.19560390618; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; VERSHON AK, 1987, J MOL BIOL, V195, P311, DOI 10.1016/0022-2836(87)90652-8; WALDBURGER CD, 1995, BIOCHEMISTRY-US, V34, P13109, DOI 10.1021/bi00040a023; Wei Y, 1999, J BACTERIOL, V181, P6092, DOI 10.1128/JB.181.19.6092-6097.1999; WU LF, 1986, BIOCHIMIE, V68, P167, DOI 10.1016/S0300-9084(86)81081-1	31	136	145	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19735	19741		10.1074/jbc.M002232200	http://dx.doi.org/10.1074/jbc.M002232200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10787413	hybrid			2022-12-27	WOS:000087941300042
J	Zhou, XM; Li, JX				Zhou, XM; Li, JX			Macrophage-enriched myristoylated alanine-rich C kinase substrate and its phosphorylation is required for the phorbol ester-stimulated diffusion of beta(2) integrin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; SINGLE-PARTICLE TRACKING; PROTEIN-TYROSINE KINASE; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; LEUKOCYTE INTEGRINS; ADHESION RECEPTORS; CELL-ADHESION; I-DOMAIN; MEMBRANE	An early event of beta(2) integrin activation is the increased diffusion rate of this molecule on the cell surface, thereby providing integrin molecules with a better chance to meet the ligands, The activation of protein kinase C (PKC) stimulates integrin diffusion by releasing the cytoskeletal constraint on integrin molecules. We report here that macrophage-enriched myristoylated alanine-rich C kinase substrate (MacMARCKS), a membrane-associated PKC substrate involved in integrin activation, is required for this PKC-stimulated diffusion of integrin molecules. Using the single-particle tracking technique, we observed that the activation of PKC stimulated an 11-fold increase in the diffusion rate of beta(2) integrins in wild type J774 macrophage cells but not in those expressing mutant MacMARCKS. Further evidence is provided from a MacMARCKS-deficient cell line in which phorbol esters failed to stimulate the diffusion of integrin. Transfection of wild type MacMARCKS into these cells restored the rapid diffusion rate of the beta(2) integrins, The phosphorylation of MacMARCKS is important because transfection of a nonphosphorylatable MacMARCKS mutant or the addition of staurosporine eliminates the rapid diffusion rate of integrin. Furthermore, adding cytochalasin D bypasses the MacMARCKS deficiency and stimulates beta(2) integrin diffusion, suggesting that MacMARCKS's involvement in integrin activation is prior or at the site of cytoskeleton. Therefore, we conclude that MacMARCKS is required for releasing the cytoskeletal constraint on integrin molecules during PKC-mediated integrin activation.	Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Li, JX (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.	jxli@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ANDERSON CM, 1992, J CELL SCI, V101, P415; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BUYON JP, 1988, J IMMUNOL, V140, P3156; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GLADWIN AM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P166, DOI 10.1016/0167-4889(90)90072-L; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASHISHIAN A, 1990, ONCOGENE, V5, P1463; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Kucik DF, 1999, BIOPHYS J, V76, P314, DOI 10.1016/S0006-3495(99)77198-5; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SIMSON R, 1995, BIOPHYS J, V69, P989, DOI 10.1016/S0006-3495(95)79972-6; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Vergeres G, 1998, BIOCHEM J, V330, P5, DOI 10.1042/bj3300005; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; Wilson KM, 1996, J CELL SCI, V109, P2101; WOODS A, 1992, J CELL SCI, V101, P277; Wright S D, 1986, Methods Enzymol, V132, P204; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yue LL, 2000, CELL ADHES COMMUN, V7, P359, DOI 10.3109/15419060009109018; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	46	49	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20217	20222		10.1074/jbc.M909129199	http://dx.doi.org/10.1074/jbc.M909129199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779523	hybrid			2022-12-27	WOS:000087941300104
J	Ueda, Y; Chaudhuri, G				Ueda, Y; Chaudhuri, G			Differential expression of B1-containing transcripts in Leishmania-exposed macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; ELONGATION-FACTOR TFIIS; DOUBLE-STRANDED-RNA; PROTEIN-KINASE; MEMBRANE GLYCOPROTEIN; REPETITIVE SEQUENCES; MOLECULAR-CLONING; MESSENGER-RNAS; ALU ELEMENTS; 7SL RNA	When the parasitic protozoan Leishmania infect host macrophage cells, establishment of the infection requires alteration in the expression of genes in both the parasite and the host cells. In the early phase of infection of macrophages in vitro, Leishmania exposure affects the expression of a group of mouse macrophage genes containing the repetitive transposable element designated B1 sequence. In Leishmania-exposed macrophages compared with unexposed macrophages, small (similar to 0.5 kilobase) B1-containing RNAs (small B1-RNAs) are down-regulated, and large (1-4 kilobases) B1-containing RNAs (large B1-RNA) are up-regulated. The down-regulation of small B1-RNAs precedes the up-regulation of large B1-RNAs in Leishmania-exposed macrophages. These differential B1-containing gene expressions in Leishmania-exposed macrophages were verified using individual small-B1-RNA and large B1-RNA. The differential expressions of the B1-containing RNAs at the early phase of Leishmania-macrophage interaction may associate the establishment of the leishmanial infection.	Meharry Med Coll, Sch Med, Dept Microbiol, Nashville, TN 37208 USA; Meharry Med Coll, Sch Med, Dept Biochem, Nashville, TN 37208 USA	Meharry Medical College; Meharry Medical College	Chaudhuri, G (corresponding author), Meharry Med Coll, Sch Med, Dept Microbiol, 1005 DB Todd Jr Blvd, Nashville, TN 37208 USA.	gchaudhuri@mail.mmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008037] Funding Source: NIH RePORTER; NIAID NIH HHS [5-RO1AI42327-03, R01 AI042327-03] Funding Source: Medline; NIGMS NIH HHS [2S06GM08037-24, S06 GM008037] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALMAIN A, 1982, J MOL BIOL, V160, P163, DOI 10.1016/0022-2836(82)90173-5; Blackwell JM, 1997, PHILOS T R SOC B, V352, P1331, DOI 10.1098/rstb.1997.0118; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG DY, 1993, J BIOL CHEM, V268, P6423; CHANG DY, 1994, MOL CELL BIOL, V14, P3949, DOI 10.1128/MCB.14.6.3949; Chang DY, 1996, NUCLEIC ACIDS RES, V24, P4165, DOI 10.1093/nar/24.21.4165; Chang K. P., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P213; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1988, MOL BIOCHEM PARASIT, V27, P43, DOI 10.1016/0166-6851(88)90023-0; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; COGGINS LW, 1982, GENE, V17, P113, DOI 10.1016/0378-1119(82)90107-X; COOPER A, 1988, IMMUNOLOGY, V65, P511; Costeas PA, 1996, BBA-GENE STRUCT EXPR, V1305, P25, DOI 10.1016/0167-4781(95)00212-X; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; DASILVA RP, 1989, J IMMUNOL, V143, P617; DAVIDSON EH, 1977, DEV BIOL, V55, P69, DOI 10.1016/0012-1606(77)90320-7; DEININGER PL, 1992, TRENDS GENET, V8, P307, DOI 10.1016/0168-9525(92)90262-3; ELDER JT, 1981, NUCLEIC ACIDS RES, V9, P1171, DOI 10.1093/nar/9.5.1171; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Englander EW, 1997, MUTAT RES-DNA REPAIR, V385, P31, DOI 10.1016/S0921-8777(97)00036-0; ETGES R, 1986, J BIOL CHEM, V261, P9098; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; GALLAGHER P M, 1988, Genomics, V2, P215, DOI 10.1016/0888-7543(88)90005-5; HARADA F, 1979, NUCLEIC ACIDS RES, V7, P909, DOI 10.1093/nar/7.4.909; HEARD E, 1994, NUCLEIC ACIDS RES, V22, P1830, DOI 10.1093/nar/22.10.1830; Heard PL, 1996, J EUKARYOT MICROBIOL, V43, P409, DOI 10.1111/j.1550-7408.1996.tb05052.x; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; Huang FP, 1998, J IMMUNOL, V160, P4143; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KRAUSKOPF A, 1994, J VIROL, V68, P2741, DOI 10.1128/JVI.68.4.2741-2745.1994; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LABUDA D, 1994, J MOL EVOL, V39, P506; LABUDA D, 1991, J MOL EVOL, V32, P405, DOI 10.1007/BF02101280; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357; QUENTIN Y, 1994, GENETICA, V93, P203, DOI 10.1007/BF01435252; Racoosin EL, 1997, EXP PARASITOL, V85, P283, DOI 10.1006/expr.1996.4139; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; RUSSANOVA VR, 1995, MOL CELL BIOL, V15, P4282; RYSKOV AP, 1985, FEBS LETT, V182, P73, DOI 10.1016/0014-5793(85)81156-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; Zietkiewicz E, 1996, J MOL EVOL, V42, P66, DOI 10.1007/BF00163213	59	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19428	19432		10.1074/jbc.M001336200	http://dx.doi.org/10.1074/jbc.M001336200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10781585	hybrid, Green Accepted			2022-12-27	WOS:000087815900106
J	Busch, C; Hofmann, F; Gerhard, R; Aktories, K				Busch, C; Hofmann, F; Gerhard, R; Aktories, K			Involvement of a conserved tryptophan residue in the UDP-glucose binding of large clostridial cytotoxin glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFICILE TOXIN-B; SORDELLII LETHAL TOXIN; NOVYI ALPHA-TOXIN; RHO-PROTEINS; POLYSACCHARIDE SYNTHESIS; ACTIVE-SITE; IDENTIFICATION; GLUCOSYLATION; ENZYME; MOTIF	Large clostridial cytotoxins catalyze the glucosylation of Rho/Ras GTPases using UDP-glucose as a cosubstrate. By site-directed mutagenesis of Clostridium sordellii lethal toxin and Clostridium difficile toxin B fragments, we identified tryptophan 102, which is located in a conserved region within the catalytic domain of all clostridial cytotoxins, to be crucial for UDP-glucose binding. Exchange of Trp-102 with alanine decreased the glucosyltransferase activity by about 1,000-fold and blocked cytotoxic activity after microinjection, Replacement of Trp-102 by tyrosine caused a 100-fold reduction in enzyme activity, indicating a partial compensation of the tryptophan function by tyrosine, Decrease in glucosyltransferase and glycohydrolase activity was caused predominantly by an increase in the K-m for UDP-glucose of these mutants. The data indicate that the conserved tryptophan residue is implicated in the binding of the cosubstrate UDP-glucose by large clostridial cytotoxins. Data bank searches revealed different groups of proteins sharing the recently identified DXD motif (Busch, C., Hofmann, F., Selzer, J., Munro, J., Jeckel, D., and Aktories, K. (1998) J. Biol. Chem. 273, 19566-19572) and a conserved region defined by a tryptophan residue equivalent to Trp-102 of C. sordellii lethal toxin, From our findings, we propose a novel family of glycosyltransferases which includes both prokaryotic and eukaryotic proteins.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; Hofmann F, 1998, INFECT IMMUN, V66, P1076, DOI 10.1128/IAI.66.3.1076-1081.1998; Hofmann F, 1997, J BIOL CHEM, V272, P11074; JUST I, 1994, J BIOL CHEM, V269, P10706; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kolkman MAB, 1997, MOL MICROBIOL, V26, P197, DOI 10.1046/j.1365-2958.1997.5791940.x; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Perelle S, 1997, INFECT IMMUN, V65, P1402, DOI 10.1128/IAI.65.4.1402-1407.1997; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; VANELDERE J, 1995, MOL MICROBIOL, V15, P107; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WILSON BA, 1994, J BIOL CHEM, V269, P23296	26	57	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13228	13234		10.1074/jbc.275.18.13228	http://dx.doi.org/10.1074/jbc.275.18.13228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788427	hybrid			2022-12-27	WOS:000086925300013
J	Fredriksson, JM; Lindquist, JM; Bronnikov, GE; Nedergaard, J				Fredriksson, JM; Lindquist, JM; Bronnikov, GE; Nedergaard, J			Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; UNCOUPLING PROTEIN THERMOGENIN; C-FOS EXPRESSION; ADIPOSE-TISSUE; FAT-CELLS; HYPOXIC INDUCTION; NONSHIVERING THERMOGENESIS; TRANSCRIPTIONAL REGULATION; ADRENERGIC-RECEPTOR; MONOLAYER-CULTURE	To identify the signaling pathway that mediates the adrenergic stimulation of the expression of the gene for vascular endothelial growth factor (VEGF) during physiologically induced angiogenesis, we examined mouse brown adipocytes in primary culture. The endogenous adrenergic neurotransmitter norepinephrine (NE) iuduced VEGF expression 3-fold, in a dose- and time-dependent manner (EC50 approximate to 90 nM). Also, the hypoxia-mimicking agent cobalt, as well as serum and phorbol ester, induced VEGF expression, but the effect of NE was additive to each of these factors, implying that a separate signaling mechanism for the NE-mediated induction was activated. The NE effect was abolished by propranolol and mimicked by isoprenaline or BRL-37344 and was thus mediated via beta-adrenoreceptors. The NE-induced VEGF expression was fully cAMP mediated, an effect which was inhibited by H-89 and thus was dependent on protein kinase A activity. Involvement of other adrenergic signaling pathways (alpha(1)-adrenoreceptors, Ca2+, protein kinase C, alpha(2)-adrenoreceptors, and pertussis toxin-sensitive G(i)-proteins) was excluded. The specific inhibitor of Src tyrosine kinases, PP2, markedly reduced the stimulation by NE, which demonstrates that a cAMP-dependent Src-mediated pathway is positively connected to VEGF expression, However, inhibition of Erk1/2 MAP kinases by PD98059 was without effect. NE did not prolong VEGF mRNA half-life and its effect was thus transcriptional, and was independent of protein synthesis. These results demonstrate that adrenergic stimulation, through beta-adrenoreceptor/cAMP/protein kinase A signaling, recruits a pathway that branches off from the NE-activated Src-Erk1/2 cascade to enhance transcription of the VEGF gene.	Stockholm Univ, Arrhenius Lab F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Fredriksson, JM (corresponding author), Stockholm Univ, Arrhenius Lab F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	mf@zoofys.su.se	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010	Nedergaard, Jan/0000-0003-2070-1587				Acarregui MJ, 1999, AM J RESP CELL MOL, V20, P14, DOI 10.1165/ajrcmb.20.1.3251; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Asano A, 1997, BIOCHEM J, V328, P179, DOI 10.1042/bj3280179; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BORNER C, 1992, J BIOL CHEM, V267, P12892; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BREIER G, 1992, DEVELOPMENT, V114, P521; Bronnikov G, 1999, ENDOCRINOLOGY, V140, P4185, DOI 10.1210/en.140.9.4185; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; FOSTER DO, 1978, CAN J PHYSIOL PHARM, V56, P110, DOI 10.1139/y78-015; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FREDRIKSSON JM, 1998, ANGIOGENESIS VASCULA, P104; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JACOBSSON A, 1986, BIOSCIENCE REP, V6, P621, DOI 10.1007/BF01114756; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V220, P147, DOI 10.1006/bbrc.1996.0372; Laitinen M, 1997, ENDOCRINOLOGY, V138, P4748, DOI 10.1210/en.138.11.4748; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MOHELL N, 1989, BIOCHEM J, V261, P401, DOI 10.1042/bj2610401; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NECHAD M, 1983, EXP CELL RES, V149, P119, DOI 10.1016/0014-4827(83)90385-3; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; Nechad M., 1986, BROWN ADIPOSE TISSUE; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; Popovici RM, 1999, J CLIN ENDOCR METAB, V84, P2245, DOI 10.1210/jc.84.6.2245; Pueyo ME, 1998, EXP CELL RES, V238, P354, DOI 10.1006/excr.1997.3864; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P2165; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THONBERG H, 1994, J BIOL CHEM, V269, P33179; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tonello C, 1999, FEBS LETT, V442, P167, DOI 10.1016/S0014-5793(98)01627-5; White FC, 1995, GROWTH FACTORS, V12, P289, DOI 10.3109/08977199509028967; YAMASHITA H, 1995, CELL GROWTH DIFFER, V6, P1457; YAMASHITA H, 1994, PFLUG ARCH EUR J PHY, V428, P352, DOI 10.1007/BF00724518	68	149	159	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13802	13811		10.1074/jbc.275.18.13802	http://dx.doi.org/10.1074/jbc.275.18.13802			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788502	hybrid			2022-12-27	WOS:000086925300089
J	Josephson, K; DiGiacomo, R; Indelicato, SR; Ayo, AH; Nagabhushan, TL; Parker, MH; Walter, MR				Josephson, K; DiGiacomo, R; Indelicato, SR; Ayo, AH; Nagabhushan, TL; Parker, MH; Walter, MR			Design and analysis of an engineered human interleukin-10 monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INTERFERON RECEPTORS; IL-10 RECEPTOR; BINDING; DIMER; RESOLUTION; REVEALS; DOMAIN; CELLS; CHAIN	A monomeric form of human interleukin 10 (IL-10M1) has been engineered for detailed structure-function studies on IL-10 and its receptor complexes. Wild type IL-10 (wtIL-10) is a domain swapped dimer whose structural integrity depends on the intertwining of two peptide chains. wtIL-10 was converted to a monomeric isomer by inserting 6 amino acids into the loop connecting the swapped secondary structural elements. Characterization of IL-10M1 by mass spectroscopy, size exclusion chromatography, cross-linking, and circular dichroism shows that IL-10M1 is a stable alpha-helical monomer at physiological pH whose three-dimensional structure closely resembles one domain of wtIL-10. As previously reported, incubation of wtIL-10 with a soluble form of the IL-10R alpha (sIL-10R alpha) generates a complex that consists of 2 wtIL-10 molecules and 4 sIL-10R alpha s. In contrast, IL-10M1 forms a 1:1 complex with the sIL-10R alpha. Characterization of the interaction using isothermal titration calorimetry confirmed the 1:1 stoichiometry and yielded a dissociation constant of 30 nM with an apparent binding enthalpy of -12.2 kcal/mol. Despite forming a 1:1 complex, IL-10M1 is biologically active in cellular proliferation assays. These results indicate that the 1:1 interaction between IL-10M1 and IL-10R alpha is sufficient for recruiting the signal transducing receptor chain (IL-10R beta) into the signaling complex and eliciting IL-10 cellular responses.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Macromol Crystallog, Birmingham, AL 35294 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Walter, MR (corresponding author), Univ Alabama, Dept Microbiol, Rm 268,Basic Hlth Sci Bldg,1918 Univ Blvd, Birmingham, AL 35294 USA.				NIAID NIH HHS [AI36871] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DE WMR, 1991, J EXP MED, V174, P1209; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; EMILIE D, 1992, EUR J IMMUNOL, V22, P2937, DOI 10.1002/eji.1830221127; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; HO AS, 1994, THER IMMUNOL, V3, P173; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOWARD M, 1992, J CLIN IMMUNOL, V12, P239, DOI 10.1007/BF00918147; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Khatri VP, 1998, CANCER IMMUNOL IMMUN, V46, P239, DOI 10.1007/s002620050483; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Li J, 1997, P NATL ACAD SCI USA, V94, P6694, DOI 10.1073/pnas.94.13.6694; Liu Y, 1997, J IMMUNOL, V158, P604; LIU Y, 1994, J IMMUNOL, V152, P1821; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; RAMASWAMY R, 1999, J MOL BIOL, V1, P151; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Syto R, 1998, BIOCHEMISTRY-US, V37, P16943, DOI 10.1021/bi981555y; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WALTER MR, 1995, BIOCHEMISTRY-US, V34, P12118, DOI 10.1021/bi00038a004; WINDSOR WT, 1993, BIOCHEMISTRY-US, V32, P8807, DOI 10.1021/bi00085a011; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9	34	39	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13552	13557		10.1074/jbc.275.18.13552	http://dx.doi.org/10.1074/jbc.275.18.13552			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788470	hybrid			2022-12-27	WOS:000086925300057
J	Rader, C; Ritter, G; Nathan, S; Elia, M; Gout, I; Jungbluth, AA; Cohen, LS; Welt, S; Old, LJ; Barbas, CF				Rader, C; Ritter, G; Nathan, S; Elia, M; Gout, I; Jungbluth, AA; Cohen, LS; Welt, S; Old, LJ; Barbas, CF			The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-DISPLAY LIBRARY; HUMAN A33 ANTIGEN; HUMAN GASTROINTESTINAL EPITHELIUM; MURINE MONOCLONAL-ANTIBODIES; ADVANCED COLON-CANCER; SURFACE GLYCOPROTEIN; PHASE I/II; HUMANIZATION; FAB; EXPRESSION	The rabbit antibody repertoire, which in the form of polyclonal antibodies has been used in diagnostic applications for decades, would be an attractive source for the generation of therapeutic human antibodies. The humanization of rabbit antibodies, however, has not been reported. Here we use phage display technology to select and humanize antibodies from rabbits that were immunized with human A33 antigen which is a target antigen for the immunotherapy of colon cancer. We first selected rabbit antibodies that bind to a cell surface epitope of human A33 antigen with an affinity in the 1 nM range. For rabbit antibody humanization, we then used a selection strategy that combines grafting of the complementarity determining regions with framework fine tuning. The resulting humanized antibodies were found to retain both high specificity and affinity for human A33 antigen.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York Branch, New York, NY 10021 USA; UCL, Sch Med, Ludwig Inst Canc Res, London Branch, London W1P 8BT, England	Scripps Research Institute; Scripps Research Institute; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	Barbas, CF (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	carlos@scripps.edu	Nathan, Sheila/C-1182-2011	Nathan, Sheila/0000-0002-2132-2346; Rader, Christoph/0000-0001-9955-3454				Baca M, 1997, J BIOL CHEM, V272, P10678; BARBAS CF, 1995, NAT MED, V1, P837, DOI 10.1038/nm0895-837; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Brezinschek HP, 1998, J IMMUNOL, V160, P4762; Carter P, 1997, CURR OPIN BIOTECH, V8, P449, DOI 10.1016/S0958-1669(97)80067-5; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; Catimel B, 1997, J CHROMATOGR A, V776, P15, DOI 10.1016/S0021-9673(97)00087-3; Catimel B, 1996, J BIOL CHEM, V271, P25664, DOI 10.1074/jbc.271.41.25664; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; Foti M, 1998, J IMMUNOL METHODS, V213, P201, DOI 10.1016/S0022-1759(98)00029-5; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hudson PJ, 1999, CURR OPIN IMMUNOL, V11, P548, DOI 10.1016/S0952-7915(99)00013-8; Kabat EA, 1991, SEQUENCES PROTEINS I; KING DJ, 1995, BRIT J CANCER, V72, P1364, DOI 10.1038/bjc.1995.516; KNIGHT KL, 1994, ADV IMMUNOL, V56, P179, DOI 10.1016/S0065-2776(08)60452-6; Lang IM, 1996, GENE, V172, P295, DOI 10.1016/0378-1119(96)00021-2; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; Moritz RL, 1998, J CHROMATOGR A, V798, P91, DOI 10.1016/S0021-9673(97)01031-5; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PEDERSEN JT, 1994, J MOL BIOL, V235, P959, DOI 10.1006/jmbi.1994.1050; Presta LG, 1997, CANCER RES, V57, P4593; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; RIDDER R, 1995, BIO-TECHNOL, V13, P255, DOI 10.1038/nbt0395-255; Ritter G, 1997, BIOCHEM BIOPH RES CO, V236, P682, DOI 10.1006/bbrc.1997.6966; Roguska MA, 1996, PROTEIN ENG, V9, P895, DOI 10.1093/protein/9.10.895; ROGUSKA MA, 1994, P NATL ACAD SCI USA, V91, P969, DOI 10.1073/pnas.91.3.969; Rosok MJ, 1996, J BIOL CHEM, V271, P22611, DOI 10.1074/jbc.271.37.22611; Scott AM, 1997, CURR OPIN IMMUNOL, V9, P717, DOI 10.1016/S0952-7915(97)80054-4; SPIEKERPOLET H, 1995, P NATL ACAD SCI USA, V92, P9348, DOI 10.1073/pnas.92.20.9348; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894; Welt S, 1999, SEMIN ONCOL, V26, P683; WELT S, 1994, J CLIN ONCOL, V12, P1561, DOI 10.1200/JCO.1994.12.8.1561; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787	37	96	136	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13668	13676		10.1074/jbc.275.18.13668	http://dx.doi.org/10.1074/jbc.275.18.13668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788485	hybrid			2022-12-27	WOS:000086925300072
J	Boffa, MB; Bell, R; Stevens, WK; Nesheim, ME				Boffa, MB; Bell, R; Stevens, WK; Nesheim, ME			Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS INACTIVATION; PROCARBOXYPEPTIDASE-B; HUMAN TRYPTASE; HUMAN PLASMA; FACTOR-VIIIA; A2 SUBUNIT; IN-VIVO; CARBOXYPEPTIDASE; TAFI; THROMBOMODULIN	We have used site-directed mutagenesis and a recombinant expression system for thrombin-activable fibrinolysis inhibitor (TAFI) in order to identify the thrombin cleavage site in activated TAFI (TAFIa) and to determine the relative contribution of proteolytic cleavage and thermal instability in regulation of TAFIa activity in clots. Arg-330 of TAFIa had been proposed to be the thrombin cleavage site based on studies with trypsin, but mutation of this residue to Gin did not prevent thrombin-mediated cleavage nor did mutation to Gln of the nearby Arg-320 residue. However, mutation of Arg-302 to Gin abolished thrombin-mediated cleavage of TAFIa. All TAFIa variants were susceptible to plasmin cleavage. Interestingly, all Arg to Gin substitutions decreased the thermal stability of TAFIa, The antifibrinolytic potential of the TAFI mutants in vitro correlates with the thermal stability of their respective TAFIa species, indicating that this property plays a key role in regulating the activity if TAFIa, Incubation of TAFIa under conditions that result in complete thermal inactivation of the enzyme accelerates subsequent thrombin- and plasmin-mediated cleavage of TAFIa. Moreover, the extent of cleavage of TAFIa by thrombin does not affect the rate of decay of TAFIa activity. Collectively, these studies point to a role for the thermal instability, but not for proteolytic cleavage, of TAFIa in regulation of its activity and, thus, of its antifibrinolytic potential. Finally, we propose a model for the thermal instability of TAFIa.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca	Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46703-8] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; BORSOS T, 1961, J IMMUNOL, V87, P326; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EATON DL, 1991, J BIOL CHEM, V266, P21833; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FISHELSON Z, 1984, J IMMUNOL, V132, P1425; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; INCE EL, 1956, ORDINARY DIFFERENTIA, P133; Kabat E., 1961, EXPT IMMUNOCHEMISTRY; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; MARSHALL AG, 1978, BIOPHYSICAL CHEM, P102; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; MULLEREBERHARD HJ, 1967, J EXP MED, V125, P359, DOI 10.1084/jem.125.2.359; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; Redlitz A, 1996, CIRCULATION, V93, P1328, DOI 10.1161/01.CIR.93.7.1328; SCHECHTER NM, 1995, BIOCHEMISTRY-US, V34, P10628, DOI 10.1021/bi00033a038; SCHECHTER NM, 1993, BIOCHEMISTRY-US, V32, P2617, DOI 10.1021/bi00061a020; Selwood T, 1998, BIOCHEMISTRY-US, V37, P13174, DOI 10.1021/bi980780c; STEVENS WK, 1996, THESIS QUEENS U; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; WEILER JM, 1993, COMPLEMENT HLTH DIS, P1	30	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12868	12878		10.1074/jbc.275.17.12868	http://dx.doi.org/10.1074/jbc.275.17.12868			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777585	hybrid			2022-12-27	WOS:000086762300069
J	Corneo, B; Moshous, D; Callebaut, I; de Chasseval, R; Fischer, A; de Villartay, JP				Corneo, B; Moshous, D; Callebaut, I; de Chasseval, R; Fischer, A; de Villartay, JP			Three-dimensional clustering of human RAG2 gene mutations in severe combined immune deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; STRAND BREAK REPAIR; V(D)J RECOMBINATION; LYMPHOCYTES; SEQUENCE; REARRANGEMENT; FIBROBLASTS; BINDING; MICE	The V(D)J recombination, which leads to the somatic rearrangement of variable, diversity, and joining segments, is the mechanism accountable for the diversity of T cell receptor- and Ig-encoding genes. The products of the RAG1 and RAG2 genes are the lymphoid-specific factors responsible for the initiation of the V(D)J recombination through the generation of a DNA double strand break. RAGI or RAG2 gene inactivation in the mouse leads to abortion of the V(D)J rearrangement process, early block in both T and B cell maturation, and, ultimately, to severe combined immune deficiency (SCID). A human SCID condition is also characterized by an absence of mature T and B lymphocytes and is associated with mutations in either RAG1- or RAG2-encoding genes. Based on the predicted beta-propeller three-dimensional structure model for RAGS, we found that six out of the seven mutations described to date in T-B-SCID patients are clustered on one side of the propeller, in regions exposed to solvent. This finding reinforces the biological significance of this predicted model and suggests that RAG1 interacts with RAGS on one of the side of the scaffold formed by the beta-propeller.	Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France; Univ Paris 06, LMCP, CNRS, UMR C7590, F-75005 Paris, France; Univ Paris 07, LMCP, CNRS, UMR C7590, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	de Villartay, JP (corresponding author), Hop Necker Enfants Malad, INSERM, U429, 149 Rue Sevres, F-75015 Paris, France.		Moshous, Despina/B-7507-2017; de Villartay, jean pierre/H-9353-2017	Moshous, Despina/0000-0001-6719-3693; de Villartay, jean pierre/0000-0001-5987-0463; Corneo, Barbara/0000-0001-5189-6749				Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; ICHIHARA Y, 1992, IMMUNOL LETT, V33, P277, DOI 10.1016/0165-2478(92)90073-W; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Ramsden DA, 1997, CURR OPIN IMMUNOL, V9, P114, DOI 10.1016/S0952-7915(97)80167-7; Rieux-Laucat F, 1998, J CLIN INVEST, V102, P312, DOI 10.1172/JCI332; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schatz D G, 1997, Semin Immunol, V9, P149, DOI 10.1006/smim.1997.0068; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8	20	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12672	12675		10.1074/jbc.275.17.12672	http://dx.doi.org/10.1074/jbc.275.17.12672			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777560	hybrid			2022-12-27	WOS:000086762300044
J	Roman, LJ; Miller, RT; de la Garza, MA; Kim, JJP; Masters, BSS				Roman, LJ; Miller, RT; de la Garza, MA; Kim, JJP; Masters, BSS			The C terminus of mouse macrophage inducible nitric-oxide synthase attenuates electron flow through the flavin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; REDUCTASE; BINDING; CALMODULIN; ISOFORMS; HEME; EXPRESSION; MECHANISM; ARGININE; COMPLEX	The sequences of nitric-oxide synthase (NOS) flavin domains closely resemble that of NADPH-cytochrome P450 reductase (CPR), with the exception of a few regions. One such region is the C terminus; all NOS isoforms are 20-40 amino acids longer than CPR, forming a "tail" that is absent in CPR. To investigate its function, we removed the 21-amino acid C-terminal tail from murine macrophage inducible NOS (MOS) holoenzyme and from a flavin domain construct. Both the truncated holoenzyme and reductase domain exhibited cytochrome c reductase activities that were 7-10-fold higher than the nontruncated forms. The truncated holoenzyme catalyzed NO formation approximately 20% faster than the intact form. Using stopped-flow spectrophotometry, we demonstrated that electron transfer into and between the two flavins and from the flavin to the heme domain is 2-5-fold faster in the absence of the C-terminal tail. The heme-nitrosyl complex, formed in all NOS isoforms during NO catalysis, is 8-fold less stable in truncated iNOS. Although both CPR and intact NOS can exist in a stable, one electron-reduced semiquinone form, neither the truncated holoenzyme nor the truncated flavin domain demonstrate such a form. We propose that this C-terminal tail curls back to interact with the flavin domain in such a way as to modulate the interaction between the two flavin moieties.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Health San Antonio; Medical College of Wisconsin	Roman, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	roman@uthscsa.edu; masters@uthscsa.edu			NIGMS NIH HHS [GM52682, GM52419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052682, R01GM052419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; IGNARRO L J, 1988, P427; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BS, 1999, FLAVINS FLAVOPROTEIN, P845; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MASTERS BSS, 2000, NITRIC OXIDE; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; XIE QW, 1994, J BIOL CHEM, V269, P28500; YASUKOCHI Y, 1979, J BIOL CHEM, V254, P7097	36	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21914	21919		10.1074/jbc.M002449200	http://dx.doi.org/10.1074/jbc.M002449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10781602	hybrid			2022-12-27	WOS:000088363800024
J	Huang, CC; Zang, Q; Takagi, J; Springer, TA				Huang, CC; Zang, Q; Takagi, J; Springer, TA			Structural and functional studies with antibodies to the integrin beta 2 subunit - A model for the I-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; LEUKOCYTE ADHESION DEFICIENCY; FUNCTION-ASSOCIATED ANTIGEN-1; FUNCTION-ASSOCIATED MOLECULE-1; CELL-SURFACE EXPRESSION; LIGAND-BINDING REGION; CRYSTAL-STRUCTURE; A-DOMAIN; MONOCLONAL-ANTIBODIES; CONFORMATIONAL-CHANGES	To establish a structure and function map of the beta 2 integrin subunit, we mapped the epitopes of a panel of beta 2 monoclonal antibodies including function-blocking, nonblocking, and activating antibodies using human/mouse beta 2 subunit chimeras. Activating antibodies recognize the C-terminal half of the cysteine-rich region, residues 522-612. Antibodies that do not affect ligand binding map to residues 1-98 and residues 344-521. Monoclonal antibodies to epitopes within a predicted I-like domain (residues 104-341) strongly inhibit LFA-1-dependent adhesion. These function-blocking monoclonal antibodies were mapped to specific residues with human --> mouse knockout or mouse --> human knock-in mutations. Combinatorial epitopes involving residues distant in the sequence provide support for a specific alignment between the beta-subunit and I domains that was used to construct a three-dimensional model. Antigenic residues 133, 332, and 339 are on the first and last predicted alpha-helices of the I-like domain, which are adjacent on its "front," Other antigenic residues in beta 2 and in other integrin beta subunits are present on the front. No antigenic residues are present on the "back" of the domain, which is predicted to be in an interface with other domains, such as the alpha subunit beta-propeller domain. Most mutations in the beta 2 subunit in leukocyte adhesion deficiency are predicted to be buried in the beta 2 subunit I-like domain. Two long insertions are present relative to alpha-subunit I-domains. One is tied down to the back of the I-like domain by a disulfide bond. The other corresponds to the "specificity-determining loop" defined in beta 1 and beta 3 integrins and contains the antigenic residue Glu(175) in a disulfide-bonded loop located near the "top" of the domain.	Ctr Blood Res, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Biogen Inc, Cambridge, MA 02142 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Pfizer; Biogen	Springer, TA (corresponding author), Ctr Blood Res, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Zang, Qun (Sophia)/0000-0002-6397-8896	NATIONAL CANCER INSTITUTE [R01CA031798, R37CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BAZIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BILSLAND CAG, 1994, J LEUKOCYTE BIOL, V55, P501, DOI 10.1002/jlb.55.4.501; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DAVID V, 1991, CELL IMMUNOL, V136, P519, DOI 10.1016/0008-8749(91)90372-I; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DU XP, 1993, J BIOL CHEM, V268, P23087; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Edwards YJK, 1996, J MOL BIOL, V260, P277, DOI 10.1006/jmbi.1996.0398; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Gotoh O, 1996, J MOL BIOL, V264, P823, DOI 10.1006/jmbi.1996.0679; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES DT, 1995, PROTEINS, V23, P387, DOI 10.1002/prot.340230312; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KNAPP W, 1989, LEUCOCYTE TYPING, V4; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MIEDEMA F, 1984, EUR J IMMUNOL, V14, P518, DOI 10.1002/eji.1830140607; NELSON C, 1992, J BIOL CHEM, V267, P3351; OHASHI Y, 1992, TOHOKU J EXP MED, V167, P297, DOI 10.1620/tjem.167.297; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PEDRINACI S, 1989, HYBRIDOMA, V8, P13, DOI 10.1089/hyb.1989.8.13; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; POPE I, 1989, LEUKOCYTE TYPING, V4, P559; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shih DT, 1997, J CELL SCI, V110, P2619; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOCHEM, V121, P914; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TROWBRIDGE IS, 1981, J EXP MED, V154, P1517, DOI 10.1084/jem.154.5.1517; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wilson KS, 1998, J MOL BIOL, V276, P417; WRIGHT AH, 1995, EUR J IMMUNOL, V25, P717, DOI 10.1002/eji.1830250313; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; [No title captured]	80	86	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21514	21524		10.1074/jbc.M002286200	http://dx.doi.org/10.1074/jbc.M002286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10779511	hybrid			2022-12-27	WOS:000088230600075
J	Wilson, CM; Farmery, MR; Bulleid, NJ				Wilson, CM; Farmery, MR; Bulleid, NJ			Pivotal role of calnexin and mannose trimming in regulating the endoplasmic reticulum-associated degradation of major histocompatibility complex class I heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; MONOCLONAL-ANTIBODIES; SECRETORY PATHWAY; QUALITY-CONTROL; PROTEASOME; ER; MEMBRANE; CYTOSOL; GLYCOPROTEIN; TRANSPORT	We have established a mammalian semipermeabilized cell system that faithfully reconstitutes the proteasome-mediated degradation of major histocompatibility complex Class I heavy chain. We show that degradation required unfolding of the protein and was cytosol- and ATP-dependent and that dislocation and degradation required proteasome activity. When the interaction of heavy chain with calnexin was prevented, the rate of degradation was accelerated, suggesting that an interaction with calnexin stabilized heavy chain. Stabilization of heavy chain to degradation was also achieved either by preventing mannose trimming or by removal of the N-linked glycosylation site. This demonstrates that glycosylation and mannose trimming are required to ensure degradation of heavy chain. When degradation or mannose trimming was inhibited, heavy chain formed a prolonged interaction with immunoglobulin heavy chain binding protein, ERp57, and protein disulfide isomerase. Taken together, these results indicate that calnexin association and mannose trimming provide a mechanism to regulate the folding, assembly, and degradation of glycoproteins entering the secretory pathway.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Wilson, Cornelia/0000-0001-6584-6179; Bulleid, Neil/0000-0002-9839-5279				Allen S, 1997, BIOCHEM J, V328, P113, DOI 10.1042/bj3280113; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; STAM NJ, 1986, J IMMUNOL, V137, P2299; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	40	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21224	21232		10.1074/jbc.M000567200	http://dx.doi.org/10.1074/jbc.M000567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801790	hybrid			2022-12-27	WOS:000088230600037
J	Maeda, S; Price, GD; Badger, MR; Enomoto, C; Omata, T				Maeda, S; Price, GD; Badger, MR; Enomoto, C; Omata, T			Bicarbonate binding activity of the CmpA protein of the cyanobacterium Synechococcus sp strain PCC 7942 involved in active transport of bicarbonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE TRANSPORT; GENE-CLUSTER; CYTOPLASMIC MEMBRANE; PCC-7942; IDENTIFICATION; NITRITE; PHOTOSYNTHESIS; MECHANISM; PCC-7120; PEPTIDES	The cmpABCD operon of the cyanobacterium Synechococcus sp, strain PCC 7942 encodes an ATP-binding cassette transporter involved in HCO3- uptake. The three genes, cmpBCD, encode membrane components of an ATP-binding cassette transporter, whereas cmpA encodes a 42-kDa cytoplasmic membrane protein, which is 46.5% identical to the membrane-anchored substrate-binding protein of the nitrate/nitrite transporter. Equilibrium dialysis analysis using H14CO3-, showed that a truncated CmpA protein lacking the N-terminal 31 amino acids, expressed in Escherichia coli cells as a histidine tagged soluble protein, specifically binds inorganic carbon (CO2 or HCO3-). The addition of the recombinant CmpA protein to a buffer caused a decrease in the concentration of dissolved CO2 because of the binding of inorganic carbon to the protein. The decrease in CO2 concentration was accelerated by the addition of carbonic anhydrase, indicating that HCO3-, but not CO2, binds to the protein. Mass spectrometric measurements of the amounts of unbound and bound HCO3- in CmpA solutions containing low concentrations of inorganic carbon revealed that CmpA binds HCO3- with high affinity (K-d = 5 mu M). A similar dissociation constant was obtained by analysis of the competitive inhibition of the CmpA protein on the carboxylation of phosphoenolpyruvate by phosphoenolpyruvate carboxylase at limiting concentrations of HCO3-. These findings showed that the cmpA gene encodes the substrate-binding protein of the HCO3- transporter.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Mol Plant Physiol, Nagoya, Aichi 4648601, Japan; Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, Canberra, ACT 2601, Australia	Nagoya University; Australian National University	Omata, T (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Mol Plant Physiol, Nagoya, Aichi 4648601, Japan.	omata@agr.nagoya-u.ac.jp	Badger, Murray R/C-8153-2009; Price, G Dean/C-9505-2009	Price, G Dean/0000-0001-5906-4912; Badger, Murray/0000-0001-9428-2579				BADGER MR, 1982, PLANT PHYSIOL, V70, P517, DOI 10.1104/pp.70.2.517; BADGER MR, 1985, PLANT PHYSIOL, V77, P465, DOI 10.1104/pp.77.2.465; Cai YP, 1997, J BACTERIOL, V179, P258, DOI 10.1128/jb.179.1.258-266.1997; Frias JE, 1997, J BACTERIOL, V179, P477, DOI 10.1128/jb.179.2.477-486.1997; Harano Y, 1997, J BACTERIOL, V179, P5744, DOI 10.1128/jb.179.18.5744-5750.1997; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Kobayashi M, 1997, J BIOL CHEM, V272, P27197, DOI 10.1074/jbc.272.43.27197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane M. D., 1969, METHODS ENZYMOL, V13, P277; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; MERCHAN F, 1995, PLANT MOL BIOL, V28, P759, DOI 10.1007/BF00021199; OMATA T, 1986, PLANT PHYSIOL, V80, P525, DOI 10.1104/pp.80.2.525; OMATA T, 1990, PLANT PHYSIOL, V93, P305, DOI 10.1104/pp.93.1.305; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; Omata T, 1992, RES PHOTOSYNTHESIS, P807; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SUZUKI I, 1995, J BACTERIOL, V177, P6137, DOI 10.1128/jb.177.21.6137-6143.1995; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; UEDAN K, 1976, PLANT PHYSIOL, V57, P906, DOI 10.1104/pp.57.6.906; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; Wu QT, 1998, J BACTERIOL, V180, P1311, DOI 10.1128/JB.180.5.1311-1322.1998	30	55	58	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20551	20555		10.1074/jbc.M003034200	http://dx.doi.org/10.1074/jbc.M003034200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10779519	hybrid			2022-12-27	WOS:000088084500048
J	Knutson, A; Castano, E; Oelgeschlager, T; Roeder, RG; Westin, G				Knutson, A; Castano, E; Oelgeschlager, T; Roeder, RG; Westin, G			Downstream promoter sequences facilitate the formation of a specific transcription factor IID-promoter complex topology required for efficient transcription from the megalin/low density lipoprotein receptor-related protein 2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; PREINITIATION COMPLEX; BOX-BINDING; MAMMALIAN-CELLS; DNA-BINDING; FACTOR ATF; ACTIVATION; INITIATOR; ELEMENT	Megalin/low density lipoprotein receptor-related protein 2 (LRP-2) is an endocytic receptor expressed in highly specialized cell types such as parathyroid cells and epithelia of the kidney. Previous experiments identified a nonconsensus TATA element, with the sequence TAGAAAA, as crucial for accurate and efficient transcription from the LRP-2 promoter. Here we show that, in addition to the TAGA element, promoter sequences downstream of the transcription start site contribute significantly to transcription both in vitro and in transfected cells. Deletion and point mutational analyses reveal that the promoter region located between positions +5 and +11 (sequence TTTTGGC) is of particular importance. Complementation experiments in nuclear extracts lacking transcription factor IID (TFIID) activity show that TATA-binding protein-associated factors of TFIID are essential for the function of LRP-2 downstream promoter sequences. Interestingly, DNase I footprinting studies show that the downstream region between positions +5 and +11 does not significantly affect overall TFIID affinity to the promoter but that it profoundly affects the topology of the TFIID promoter complex not only downstream of the transcription start site, but in particular in the TATA box region. Our observations suggest a model for a novel downstream sequence function, in which TATA-binding protein-associated factor-promoter interactions downstream of the transcription start site modulate TFIID-DNA interactions in the TATA box region.	Univ Uppsala Hosp, Dept Surg, Endocrine Unit, S-75185 Uppsala, Sweden; Marie Curie Res Inst, Eukaryot Gene Regulat Lab, Surrey RH8 0TL, England; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Uppsala University; Uppsala University Hospital; Rockefeller University	Westin, G (corresponding author), Univ Uppsala Hosp, Dept Surg, Endocrine Unit, S-75185 Uppsala, Sweden.			Castano, Enrique/0000-0003-2645-9541; Oelgeschlager, Thomas/0000-0002-4086-719X				BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BESNARD F, 1991, J BIOL CHEM, V266, P18877; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; FORSBERG M, 1991, EMBO J, V10, P2543, DOI 10.1002/j.1460-2075.1991.tb07794.x; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Knutson A, 1998, DNA CELL BIOL, V17, P551, DOI 10.1089/dna.1998.17.551; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; Perier RC, 1999, NUCLEIC ACIDS RES, V27, P307, DOI 10.1093/nar/27.1.307; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sambrook J., 2002, MOL CLONING LAB MANU; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	48	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14190	14197		10.1074/jbc.275.19.14190	http://dx.doi.org/10.1074/jbc.275.19.14190			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799495	hybrid			2022-12-27	WOS:000087006900026
J	Elalamy, I; Said, FA; Singer, M; Couetil, JP; Hatmi, M				Elalamy, I; Said, FA; Singer, M; Couetil, JP; Hatmi, M			Inhibition by extracellular cAMP of phorbol 12-myristate 13-acetate-induced prostaglandin H synthase-2 expression in human pulmonary microvascular endothelial cells - Involvement of an ecto-protein kinase A activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR KAPPA-B; CYCLIC-AMP; CYCLOOXYGENASE-2 EXPRESSION; ENDOPEROXIDE SYNTHASE-2; HUMAN-PLATELETS; NUCLEAR FACTOR; TRANSCRIPTIONAL REGULATION; ENZYME IMMUNOASSAYS; ARACHIDONIC-ACID; E-2 SYNTHESIS	Exposure of human pulmonary microvascular endothelial cells (HPMECs) to phorbol 12-myristate 13-acetate (PMA) leads to the increase of prostaglandin H synthase (PGHS)-2 protein levels. Under same conditions and according to its constitutive nature, no significant variation of PGHS-1 protein was noted. The elevation of the intracellular cAMP rate is known to enhance PGHS-2 levels through a protein kinase A pathway in various cells. To determine whether the extracellular cAMP also regulates the inducible expression of PGHS, cultured HPMECs were exposed to cAMP alone or in combination with PMA. The PMA-induced PGHS-2 protein was attenuated by the extracellular cAMP, In addition, PGHS-2 activity evaluated through 6-keto-PGF1 alpha generation, which was enhanced by PMA was inhibited by extracellular cAMP. Furthermore, in HPMEC medium, PMA-induced PGHS-2 expression was accompanied by the generation of a transferable activity (TA) able to abolish platelet aggregation. This resulting TA was dependent from PGHS-2 pathway, because NS-398, a selective inhibitor of PGHS-2, suppressed its production. The inhibitory TA released by treated HPMECs was also prevented by extracellular cAMP. The specific protein kinase A (PKA) inhibitor blocked the extracellular cAMP effect on both PMA-induced 6-keto-PGF1 alpha synthesis and inhibitory TA generation, suggesting the involvement of PRA signaling at the outer surface of HPMECs, Accordingly, we established, in phosphorylation experiments, the presence of an endothelial ectoprotein kinase activity, able to phosphorylate the synthetic substrate kemptide in a cAMP-dependent mode. Reverse transcription-polymerase chain reaction analysis showed that PIMA-induced PGHS-2 mRNA was markedly reduced by extracellular cAMP. Together, these findings provide the first experimental evidence that extracellular cAMP is able to reduce HPMEC PGHS-2 expression in terms of mRNA, protein, and enzyme activity through an ecto-PKA pathway. In addition, they outline the potential role of endothelial PGHS-2 in the limitation of platelet activation during inflammatory processes.	Inst Pasteur, INSERM, U485, Unite Pharmacol Cellulaire, F-75724 Paris 15, France; Hop Broussais, Serv Chirurg Cardiothorac, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Hatmi, M (corresponding author), Inst Pasteur, INSERM, U485, Unite Pharmacol Cellulaire, 25 Rue Dr Roux, F-75724 Paris 15, France.	mhatmi@pasteur.fr						Anteby EY, 1997, J CLIN ENDOCR METAB, V82, P2289, DOI 10.1210/jc.82.7.2289; BOOYSE FM, 1976, BIOCHIM BIOPHYS ACTA, V422, P60, DOI 10.1016/0005-2744(76)90008-5; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; FEINSTEIN MB, 1983, J BIOL CHEM, V258, P1260; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; Hatmi M, 1996, J BIOL CHEM, V271, P24776, DOI 10.1074/jbc.271.40.24776; Hughes FJ, 1999, J BIOL CHEM, V274, P1776, DOI 10.1074/jbc.274.3.1776; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahboubi K, 1998, CYTOKINE, V10, P175, DOI 10.1006/cyto.1997.0235; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Minghetti L, 1997, EUR J NEUROSCI, V9, P934, DOI 10.1111/j.1460-9568.1997.tb01444.x; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Perkins DJ, 1997, PROSTAG OTH LIPID M, V54, P727, DOI 10.1016/S0090-6980(97)00144-5; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; PRADELLES P, 1990, METHOD ENZYMOL, V187, P24; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; Sipma H, 1996, BRIT J PHARMACOL, V119, P730, DOI 10.1111/j.1476-5381.1996.tb15733.x; SIROIS J, 1993, J BIOL CHEM, V268, P12199; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594; Vezza R, 1996, J BIOL CHEM, V271, P30028, DOI 10.1074/jbc.271.47.30028; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922	43	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13662	13667		10.1074/jbc.275.18.13662	http://dx.doi.org/10.1074/jbc.275.18.13662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788484	hybrid			2022-12-27	WOS:000086925300071
J	Kappler, U; Bennett, B; Rethmeier, J; Schwarz, G; Deutzmann, R; McEwan, AG; Dahl, C				Kappler, U; Bennett, B; Rethmeier, J; Schwarz, G; Deutzmann, R; McEwan, AG; Dahl, C			Sulfite : Cytochrome c oxidoreductase from Thiobacillus novellus - Purification, characterization, and molecular biology of a heterodimeric member of the sulfite oxidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC NITRATE REDUCTASE; PARACOCCUS-DENITRIFICANS; CHICKEN LIVER; XANTHINE DEHYDROGENASE; RHODOBACTER-CAPSULATUS; MOLYBDENUM COFACTOR; SULFUR OXIDATION; ESCHERICHIA-COLI; BACTERIA; PROTEINS	Direct oxidation of sulfite to sulfate occurs in various photo- and chemotrophic sulfur oxidizing microorganisms as the final step in the oxidation of reduced sulfur compounds and is catalyzed by sulfite:cytochrome c oxidoreductase (EC 1.8.2.1), Here we show that the enzyme from Thiobacillus novellus is a periplasmically located alpha beta heterodimer, consisting of a 40.6-kDa subunit containing a molybdenum cofactor and an 8.8-kDa monoheme cytochrome c(552) smbunit (midpoint redox potential, Em(8.0) = +280 mV), The organic component of the molybdenum cofactor was identified as molybdopterin contained in a 1:1 ratio to the Mo content of the enzyme. Electron paramagnetic resonance spectroscopy revealed the presence of a sulfite-inducible Mo(V) signal characteristic of sulfite:acceptor oxidoreductases. However, pH-dependent changes in the electron paramagnetic resonance signal were not detected. Kinetic studies showed that the enzyme exhibits a ping-pong mechanism involving two reactive sites. K-m values for sulfite and cytochrome c(550) were determined to be 27 and 4 mu M, respectively; the enzyme was found to be reversibly inhibited by sulfate and various buffer ions. The sorAB genes, which encode the enzyme, appear to form an operon, which is preceded by a putative extracytoplasmic function-type promoter and contains a hairpin loop termination structure downstream of sorB. While SorA exhibits significant similarities to known sequences of eukaryotic and bacterial sulfite:acceptor oxidoreductases, SorB does not appear to be closely related to any known c-type cytochromes.	Univ Bonn, Inst Mikrobiol & Biotechnol, D-53115 Bonn, Germany; CCLRC Daresbury Lab, Warrington WA4 4AD, Cheshire, England; Univ Bremen, UFT, D-28334 Bremen, Germany; Univ Bremen, Fachbereich 2, D-28334 Bremen, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Biozentrum, D-38106 Braunschweig, Germany; Univ Regensburg, Inst Biochem, D-93053 Regensburg, Germany; Univ Queensland, Dept Microbiol & Parasitol, St Lucia, Qld 4072, Australia	University of Bonn; STFC Daresbury Laboratory; University of Bremen; University of Bremen; Braunschweig University of Technology; University of Regensburg; University of Queensland	Dahl, C (corresponding author), Univ Bonn, Inst Mikrobiol & Biotechnol, Meckenheimer Allee 168, D-53115 Bonn, Germany.	chdahl@uni-bonn.de	Dahl, Christiane/H-4786-2019; Schwarz, Guenter/ABE-9643-2021; Kappler, Ulrike/A-9483-2013	Dahl, Christiane/0000-0001-8288-7546; Schwarz, Guenter/0000-0002-2118-9338; Kappler, Ulrike/0000-0002-2642-1319; McEwan, Alastair/0000-0002-2419-1003				ALLEN SH, 1952, ANAL CHEM, V7, P189; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F., 1999, CURRENT PROTOCOLS MO; BARBER MJ, 1990, J BIOL CHEM, V265, P20912; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; BRAY RC, 1983, BIOCHEM J, V211, P227, DOI 10.1042/bj2110227; Brody MS, 1999, BIOCHEMISTRY-US, V38, P6668, DOI 10.1021/bi9902539; BRUNE DC, 1989, BIOCHIM BIOPHYS ACTA, V975, P189, DOI 10.1016/S0005-2728(89)80251-8; Brune DC, 1995, ANOXYGENIC PHOTOSYNT, P847, DOI 10.1007/0-306-47954-0_39; Butler CS, 1999, BIOCHEMISTRY-US, V38, P9000, DOI 10.1021/bi990402n; CARDENAS J, 1974, ANAL BIOCHEM, V60, P372, DOI 10.1016/0003-2697(74)90244-9; CHARLES AM, 1966, BIOCHIM BIOPHYS ACTA, V128, P522; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; CLELAND WW, 1970, MECH CATALYSIS, P1; COHEN HJ, 1971, J BIOL CHEM, V246, P367; Friedrich CG, 1998, ADV MICROB PHYSIOL, V39, P235; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; GEORGE GN, 1985, J MAGN RESON, V64, P384, DOI 10.1016/0022-2364(85)90100-3; GUTTERIDGE S, 1980, BIOCHEM J, V191, P285, DOI 10.1042/bj1910285; HENIKOFF S, 1995, GENE-COMBIS, V163, pGC17, DOI 10.1016/0378-1119(95)00486-P; HEUKSHOVEN J, 1988, ELECTROPHORESIS, V9, P26; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; Hille R, 1997, J BIOL INORG CHEM, V2, P804, DOI 10.1007/s007750050199; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOSHI MS, 1994, ARCH BIOCHEM BIOPHYS, V308, P331, DOI 10.1006/abbi.1994.1047; KATAYAMA Y, 1995, MICROBIOL-UK, V141, P1469, DOI 10.1099/13500872-141-6-1469; Kelly DP, 1997, ANTON LEEUW INT J G, V71, P95, DOI 10.1023/A:1000135707181; KESSLER DL, 1974, BIOCHIM BIOPHYS ACTA, V370, P389, DOI 10.1016/0005-2744(74)90100-4; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KROGER A, 1976, EUR J BIOCHEM, V69, P497, DOI 10.1111/j.1432-1033.1976.tb10934.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMY MT, 1980, BIOCHEM J, V185, P397, DOI 10.1042/bj1850397; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; LUDWIG W, 1993, INT J SYST BACTERIOL, V43, P363, DOI 10.1099/00207713-43-2-363; MCDONNEL A, 1981, ANAL BIOCHEM, V117, P40, DOI 10.1016/0003-2697(81)90688-6; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; NANO FE, 1984, J BACTERIOL, V158, P1094, DOI 10.1128/JB.158.3.1094-1103.1984; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NORTHROP DB, 1969, J BIOL CHEM, V244, P5808; ONO H, 1984, J BIOCHEM-TOKYO, V95, P353, DOI 10.1093/oxfordjournals.jbchem.a134615; Pacheco A, 1996, INORG CHEM, V35, P7001, DOI 10.1021/ic9607806; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; Raitsimring AM, 1998, J AM CHEM SOC, V120, P11263, DOI 10.1021/ja981903j; RAJAGOPALAN KV, 1980, MOLYBDENUM MOLYBDENU, P243; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; SOUTHERLAND WM, 1983, J BACTERIOL, V156, P941, DOI 10.1128/JB.156.2.941-944.1983; Starkey RL, 1935, SOIL SCI, V39, P197, DOI 10.1097/00010694-193503000-00004; STEINMETZ MA, 1982, ARCH MICROBIOL, V131, P19, DOI 10.1007/BF00451493; SUZUKI I, 1994, METHOD ENZYMOL, V243, P447; TAKAKUWA S, 1992, ORGANIC SULFUR CHEM, P1; TAYLOR BF, 1969, J BACTERIOL, V100, P487, DOI 10.1128/JB.100.1.487-497.1969; Thomas G, 1999, FEMS MICROBIOL LETT, V174, P167, DOI 10.1111/j.1574-6968.1999.tb13564.x; Tipton K.F., 1996, ENZYMOLOGY LABFAX, P115; TOGHROL F, 1983, J BIOL CHEM, V258, P6762; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WILSON TRS, 1994, NATURE, V368, P92, DOI 10.1038/368092a0; Wodara C, 1997, J BACTERIOL, V179, P5014, DOI 10.1128/jb.179.16.5014-5023.1997; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; YAMANAKA T, 1971, J BIOCHEM-TOKYO, V70, P349, DOI 10.1093/oxfordjournals.jbchem.a129647; YAMANAKA T, 1981, PLANT CELL PHYSIOL, V22, P613	70	140	149	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13202	13212		10.1074/jbc.275.18.13202	http://dx.doi.org/10.1074/jbc.275.18.13202			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788424	hybrid, Green Submitted			2022-12-27	WOS:000086925300010
J	Short, SM; Boyer, JL; Juliano, RL				Short, SM; Boyer, JL; Juliano, RL			Integrins regulate the linkage between upstream and downstream events in G protein-coupled receptor signaling to mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR RECEPTOR; CELL LINE ECV304; MAP KINASE; TYROSINE PHOSPHORYLATION; MEDIATED ACTIVATION; DISTINCT PATHWAYS; P2 RECEPTORS; EGF RECEPTOR; PC12 CELLS	Receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs) can both activate mitogen-activated protein kinase (MAPK), a critical intermediate in the transduction of proliferative signals. Numerous observations have demonstrated that integrin-mediated cell anchorage can regulate the efficiency of signaling from RTKs to MAPK. Recently, a relationship between integrins and GPCR signaling has also emerged; however, little is understood concerning the mechanisms involved. Here, we investigate integrin regulation of GPCR signaling to MAPK, focusing on the P2Y class of GPCRs that function through activation of phospholipase C beta. P2Y receptor signaling to the downstream components mitogen-activated protein kinase kinase and MAPK is highly dependent on integrin-mediated cell anchorage. However, activation of upstream events, including inositol phosphate production and generation of calcium transients, is completely independent of cell anchorage. This indicates that integrins regulate the linkage between upstream and downstream events in this GPCR pathway, just as they do in some aspects of RTK signaling. However, the P2Y pathway does not involve cross-activation of a RTK, nor a role for She or c-Raf; thus, it is quite distinct from the classical RTK-Ras-Raf-MAPK cascade. Rather, integrin-modulated P2Y receptor stimulation of MAPK depends on calcium and on the activation of protein kinase C.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.	arjay@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054889, R01HL054889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54889] Funding Source: Medline; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Aplin AE, 1998, PHARMACOL REV, V50, P197; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Aplin AE, 1999, J CELL SCI, V112, P695; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; Boyer JL, 1997, MOL PHARMACOL, V52, P928, DOI 10.1124/mol.52.6.928; CLERK A, 1994, J BIOL CHEM, V269, P32848; Conant AR, 1998, BRIT J PHARMACOL, V125, P357, DOI 10.1038/sj.bjp.0702082; Cussac D, 1999, MOL PHARMACOL, V56, P1025, DOI 10.1124/mol.56.5.1025; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HARDEN TK, 2000, CARDIOVASCULAR BIOL; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	70	88	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12970	12977		10.1074/jbc.275.17.12970	http://dx.doi.org/10.1074/jbc.275.17.12970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777598	hybrid, Green Published			2022-12-27	WOS:000086762300082
J	Yoo, SH; So, SH; Kweon, HE; Lee, JS; Kang, MK; Jeon, CJ				Yoo, SH; So, SH; Kweon, HE; Lee, JS; Kang, MK; Jeon, CJ			Coupling of the inositol 1,4,5-trisphosphate receptor and chromogranins A and B in secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE MEMBRANE-BINDING; PH-DEPENDENT INTERACTION; TRISPHOSPHATE RECEPTOR; CONFORMATIONAL CHANGE; CALCIUM RELEASE; INTRACELLULAR STORES; ZYMOGEN GRANULES; CELLS; CA2+; PROTEIN	The secretory granules of neuroendocrine cells which contain large amounts of Ca2+ and chromogranins have been demonstrated to release Ca2+ in response to inositol. 1,4,5 trisphosphate (IP3). Moreover, chromogranin A (CG;A) has been shown to interact with several secretory granule membrane proteins, including the IP3 receptor (IP3R). To determine whether the IP(3)Rs interact directly with chromogranins A and B (CGB), two major proteins of the secretory granules, we have used purified IP3R from bovine cerebellum in the interaction study with CGA and CGB, and have shown that chromogranins A and B directly interact with the IP3R at the intravesicular pH 5.5. Immunogold cytochemical study using the IP3R and CGA antibodies indicated that IP3R-labeled gold particles were localized in the periphery of the secretory granules, indicating the presence of the IP(3)Rs on the secretory granule membrane, To determine whether the IP3R and chromogranins A and B are physically linked in the cells, bovine type 1 IP3R (IP3R-1) and CGA or CGB are co-transfected into COS-7 cells and co-immunoprecipitation was carried out. Immunoprecipitation of the cell extracts demonstrated the presence of CGA-IP3R-1 and CGB-IP3R-1 complexes, respectively, indicating the complex formation between the IP3R and chromogranins A and B in native state.	Korea Adv Inst Sci & Technol, Biomed Res Ctr, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Biomed Res Ctr, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea.							BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MATTER N, 1993, J BIOL CHEM, V268, P732; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Murphy SM, 1998, J HISTOCHEM CYTOCHEM, V46, P1261, DOI 10.1177/002215549804601106; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; SIMON JP, 1989, BIOCHEM J, V262, P1; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; Yule DI, 1997, J BIOL CHEM, V272, P9093	42	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12553	12559		10.1074/jbc.275.17.12553	http://dx.doi.org/10.1074/jbc.275.17.12553			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777544	hybrid			2022-12-27	WOS:000086762300028
J	Rajapandi, T; Greene, LE; Eisenberg, E				Rajapandi, T; Greene, LE; Eisenberg, E			The molecular chaperones Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; FUNCTIONAL HETEROCOMPLEX; RETICULOCYTE LYSATE; HSP70; MACHINERY; COMPLEX; FOLDOSOME; RECONSTITUTION; SYSTEM; DNAJ	Glucocorticoid receptors must be complexed with Hsp90 in order to bind steroids, and it has been reported that at least three other proteins, Hop, Hsc70, and a J-domain protein (either Hsp40 or Ydj1), are required for formation of active Hsp90-steroid receptor complex. In the present study, we reinvestigated activation of stripped steroid receptors isolated from either L cells or WCL2 cells. Surprisingly, we found, using highly purified proteins, that only Hsp90 and Hsc70 are required for the activation of glucocorticoid receptors in the presence of steroids; In the absence of steroids, either p23 or molybdate are also required as reported previously. Addition of Hop or Ydj1 had no affect on the rate or magnitude of the activation of the stripped receptors, and quantitative Western blots confirmed that neither Hop or Hsp40 were present in our protein preparations or in the stripped receptors. Furthermore, a truncated recombinant Hsp70 that does not bind Hop or Hsp40 was as effective as wild-type Hsp70 in activating stripped receptor. Since Hsc70 does not bind directly to Hsp90 but both proteins bind to Hop, it has been suggested that Hop acts as a bridge between Hsp90 and Hsp70. However, we found that after Hsc70 or Hsp90 bind directly to the stripped receptors, they are fully reactivated by Hsp90 or Hsc70, respectively. We, therefore, conclude that Hsp90 and Hsc70 bind independently to stripped glucocorticoid receptors and alone are sufficient to activate them to bind steroids.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Eisenberg, E (corresponding author), NHLBI, Cell Biol Lab, NIH, 9000 Rockville Pike,3 Ctr Dr,MSC 0301,Bldg 2,Room, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000516, Z01HL000516] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rajapandi T, 1998, BIOCHEMISTRY-US, V37, P7244, DOI 10.1021/bi972252r; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007	26	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22597	22604		10.1074/jbc.M002035200	http://dx.doi.org/10.1074/jbc.M002035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10781595	hybrid			2022-12-27	WOS:000088363800114
J	Brown, MA; Stenberg, LM; Persson, U; Stenflo, J				Brown, MA; Stenberg, LM; Persson, U; Stenflo, J			Identification and purification of vitamin K-dependent proteins and peptides with monoclonal antibodies specific for gamma-carboxyglutamyl (Gla) residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; LASER-INDUCED FLUORESCENCE; COAGULATION-FACTOR-XA; HUMAN FACTOR-VII; PROTHROMBIN ACTIVATOR; CAPILLARY-ELECTROPHORESIS; MEMBRANE-BINDING; CALCIUM-BINDING; ENZYME-ACTIVITY; ACID RESIDUES	Novel monoclonal antibodies that specifically recognize gamma-carboxyglutamyl (Gla) residues in proteins and peptides have been produced. As demonstrated by Western blot and time-resolved immunofluorescence assays the antibodies are pan-specific for most or all of the Gla-containing proteins tested (factors VII, IX, and X, prothrombin, protein C, protein S, growth arrest-specific protein 6, bone Gla protein, conantokin G from a cone snail, and factor Xa-like proteins from snake venom). Only the Gla-containing light chain of the two-chain proteins was bound. Decarboxylation destroyed the epitope(s) on prothrombin fragment 1, and Ca2+ strongly inhibited binding to prothrombin. In Western blot, immunofluorescence, and surface plasmon resonance assays the antibodies bound peptides conjugated to bovine serum albumin that contained either a single Gla or a tandem pair of Gla residues. Binding was maintained when the sequence surrounding the Gla residue(s) was altered. Replacement of Gla with glutamic acid resulted in a complete loss of the epitope. The utility of the antibodies was demonstrated in immunochemical methods for detecting Gla-containing proteins and in the immunopurification of a factor Xa-like protein from tiger snake venom. The amino acid sequences of the Gla domain and portions of the heavy chain of the snake protein were determined.	Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Stenflo, J (corresponding author), Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.	johan.stenflo@klkemi.mas.lu.se						BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; BORREBAECK CAK, 1981, J BIOL CHEM, V256, P4723; Britz-Mckibbin P, 1999, ANAL CHEM, V71, P1633, DOI 10.1021/ac981241g; CAIRNS JR, 1991, ANAL BIOCHEM, V199, P93, DOI 10.1016/0003-2697(91)90274-W; CHEUNG WF, 1995, THROMB RES, V80, P419, DOI 10.1016/0049-3848(95)00194-V; CHEUNG WF, 1995, THROMB RES, V79, P199, DOI 10.1016/0049-3848(95)00105-Z; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; COPPOLA R, 1992, THROMB RES, V68, P269, DOI 10.1016/0049-3848(92)90084-N; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; DOWD P, 1995, ANNU REV NUTR, V15, P419, DOI 10.1146/annurev.nu.15.070195.002223; FERNLUND P, 1975, J BIOL CHEM, V250, P6125; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; Gillis S, 1997, PROTEIN SCI, V6, P185; HAUSCHKA PV, 1979, BIOCHEMISTRY-US, V18, P4992, DOI 10.1021/bi00589a029; JIE KSG, 1995, ANAL BIOCHEM, V224, P163, DOI 10.1006/abio.1995.1023; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; Joseph JS, 1999, BLOOD, V94, P621, DOI 10.1182/blood.V94.2.621.414k25_621_631; Kelleher RL, 1999, ANAL CHEM, V71, P4250, DOI 10.1021/ac990684x; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE L, 1989, J IMMUNOL METHODS, V124, P239, DOI 10.1016/0022-1759(89)90360-8; LEWIS RM, 1983, BIOCHEMISTRY-US, V22, P948, DOI 10.1021/bi00273a037; MANN KG, 1990, VITAMIN K DEPENDENT, P71; MARCOVINA S, 1989, THROMB HAEMOSTASIS, V62, P708; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P20; NELSESTUEN GL, 1972, J BIOL CHEM, V247, P8176; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PRICE PA, 1984, METHOD ENZYMOL, V107, P548; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16621, DOI 10.1074/jbc.271.28.16621; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; PUCCETTI PM, 1991, THROMB HAEMOSTASIS, V65, P1199; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Shanahan CM, 1998, CRIT REV EUKAR GENE, V8, P357, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.60; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1973, BIOCHEM BIOPH RES CO, V50, P98, DOI 10.1016/0006-291X(73)91069-3; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; STOCKER K, 1994, TOXICON, V32, P1227, DOI 10.1016/0041-0101(94)90352-2; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANS G, 1985, J BIOL CHEM, V260, P9366; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; Vo HC, 1999, FEBS LETT, V445, P256, DOI 10.1016/S0014-5793(99)00131-3; WAKABAYASHI K, 1986, J BIOL CHEM, V261, P1097; Wojcik EGC, 1998, BBA-PROTEIN STRUCT M, V1382, P91, DOI 10.1016/S0167-4838(97)00149-0; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; Yan SB, 1996, J MOL RECOGNIT, V9, P211	56	43	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19795	19802		10.1074/jbc.M002298200	http://dx.doi.org/10.1074/jbc.M002298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779512	hybrid			2022-12-27	WOS:000087941300050
J	Faruqi, TR; Weiss, EJ; Shapiro, MJ; Huang, W; Coughlin, SR				Faruqi, TR; Weiss, EJ; Shapiro, MJ; Huang, W; Coughlin, SR			Structure-function analysis of protease-activated receptor 4 tethered ligand peptides - Determinants of specificity and utility in assays of receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBIN RECEPTOR; PROTEOLYTIC MECHANISM; MOLECULAR-CLONING; MOUSE PLATELETS; G-PROTEINS; CELLS; EXPRESSION; MICE; ANTAGONIST; CLEAVAGE	Thrombin activates protease-activated receptors (PARs) by specific cleavage of their amino-terminal exodomains to unmask a tethered ligand that binds intramolecularly to the body of the receptor to effect transmembrane signaling. Peptides that mimic such ligands are valuable as agonists for probing PAR function, but the tethered ligand peptide for PAR4, GYPGRF, lacks potency and is of limited utility. In a structure-activity analysis of PARI peptides, AYPGKF was similar to 10-fold more potent than GYPGKF and, unlike GYPGKF, elicited PAR4-mediated responses comparable in magnitude to those elicited by thrombin, AYPGKF was relatively specific for PARA in part due to the tyrosine at position 2; substitution of phenylalanine or p-fluorophenylalanine at this position produced peptides that activated both PAR1 and PAR4. Because human platelets express both PAR1 and PAR4, it might be desirable to inhibit both receptors, Identifying a single agonist for both receptors raises the possibility that a single antagonist for both receptors might be developed. The AYPGKF peptide is a useful new tool for probing PAR4 function. For example, AYPGKF activated and desensitized PARA in platelets and, like thrombin, triggered phosphoinositide hydrolysis but not inhibition of adenylyl cyclase in PAR4-expressing cells. The latter shows that, unlike PAR1, PARA couples to G(q) and not G(i).	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, HSE 1355,Box 0130,513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907, R01HL059202] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07731, HL44907, HL59202] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; BLANK JL, 1993, J BIOL CHEM, V268, P25184; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; COLLER BS, 1992, BIOCHEMISTRY-US, V31, P11713, DOI 10.1021/bi00162a007; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; COUGHLIN SR, 1995, Patent No. 5759994; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Ishihara H, 1998, BLOOD, V91, P4152, DOI 10.1182/blood.V91.11.4152.411k22_4152_4157; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Sage S.O., 1996, PRACT APPROACH SER, P67; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Seiler SM, 1996, MOL PHARMACOL, V49, P190; SEILER SM, 1995, BIOCHEM PHARMACOL, V49, P519, DOI 10.1016/0006-2952(94)00473-Y; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	33	162	173	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19728	19734		10.1074/jbc.M909960199	http://dx.doi.org/10.1074/jbc.M909960199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10779527	hybrid			2022-12-27	WOS:000087941300041
J	Szczesna-Skorupa, E; Kemper, B				Szczesna-Skorupa, E; Kemper, B			Endoplasmic reticulum retention determinants in the transmembrane and linker domains of cytochrome P4502C1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL ALDEHYDE DEHYDROGENASE; EARLY SECRETORY PATHWAY; SIGNAL-ANCHOR; GOLGI LOCALIZATION; RECYCLING PATHWAY; PROTEIN RETENTION; PLASMA-MEMBRANE; COAT PROTEINS; AMINO-ACIDS; RETRIEVAL	The cytochrome P450 2C1 N-terminal signal anchor sequence mediates direct retention of the protein in the endoplasmic reticulum and consists of a hydrophobic transmembrane domain, residues 3-20, followed by a hydrophilic linker, residues 21-28, Fusions of the N-terminal 21 or 28 amino acids of P450 2C1 to green fluorescent protein resulted in endoplasmic reticulum localization of the chimera in transfected cells. Disruption of microtubules by nocodazole treatment resulted in redistribution into a punctate pattern for the 1-21, but not for the 1-28, chimera indicating that the linker was preventing transport from the endoplasmic reticulum but was not required for retrieval to the endoplasmic reticulum from the pre-Golgi compartment, In the 1-28 chimera, mutations of residues 21-23 (KQS) in the linker resulted in redistribution of the chimera after nocodazole treatment. Mutations in the transmembrane domain affected both direct retention in the endoplasmic reticulum and retrieval from the pre-Golgi compartment, and although structural requirements for each process are distinct, in both cases the arrangement of amino acids and distribution of hydrophobicity are critical. In contrast, the linker region exhibits a sequence-specific requirement for direct retention in the endoplasmic reticulum.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35897] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KS, 1993, J BIOL CHEM, V268, P18726; Amarneh BA, 1996, MOL CELL ENDOCRINOL, V119, P69, DOI 10.1016/0303-7207(96)03796-3; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Boehm J, 1997, J CELL SCI, V110, P991; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; Chen CD, 1997, J BIOL CHEM, V272, P22891, DOI 10.1074/jbc.272.36.22891; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Eliasson E, 1996, MOL PHARMACOL, V50, P573; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; Masaki R, 1996, J BIOL CHEM, V271, P16939, DOI 10.1074/jbc.271.28.16939; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Massaad MJ, 1999, EUR J CELL BIOL, V78, P435, DOI 10.1016/S0171-9335(99)80070-3; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; NEVE EP, 1996, ARCH BIOCHEM BIOPHYS, V333, P27; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NISHIKAWA S, 1993, P NATL ACAD SCI USA, V90, P8179, DOI 10.1073/pnas.90.17.8179; Orci L, 1996, P NATL ACAD SCI USA, V93, P8968, DOI 10.1073/pnas.93.17.8968; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; Talmud P, 1996, PROTEIN ENG, V9, P317, DOI 10.1093/protein/9.4.317; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	47	42	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19409	19415		10.1074/jbc.M002394200	http://dx.doi.org/10.1074/jbc.M002394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10781599	hybrid			2022-12-27	WOS:000087815900103
J	Benson, MD; Bargeon, JL; Xiao, GZ; Thomas, PE; Kim, A; Cui, YQ; Franceschi, RT				Benson, MD; Bargeon, JL; Xiao, GZ; Thomas, PE; Kim, A; Cui, YQ; Franceschi, RT			Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; CELL-LINE; OSTEOCALCIN PROMOTER; DEFICIENT MICE; MC3T3-E1 CELLS; MESSENGER-RNA; ASCORBIC-ACID; TATA BOX; DIFFERENTIATION; TRANSCRIPTION	Bone sialoprotein is a 70-kDa extracellular matrix component that is intimately associated with biomineralization, yet the cis-acting elements of the Bsp gene that restrict its expression to mineralizing cells remain uncharacterized. To identify such elements, we analyzed a 2472-base pair fragment of the murine promoter that directs osteoblast-selective expression of a luciferase reporter gene and found that the region between -338 and -178 relative to the transcriptional start is crucial for its osteoblast-selective activity. We identified an element within this region that binds a protein complex in the nuclear extracts of osteoblastic cells and is required for its transcriptional activity. Introduction of a mutation that disrupts a homeodomain binding site within this sequence eliminates both its in vitro binding and nearly all of the osteoblastic-selective activity of the 2472-base pair promoter. We further found that the Dlx5 homeoprotein, which is able to regulate the osteoblast-specific osteocalcin promoter, can bind this element and stimulate its enhancer activity when overexpressed in COS7 cells. These data represent the first description of an osteoblast-specific element within the bone sialoprotein promoter and demonstrate its regulation by a member of a family of factors known to be involved in skeletogenesis.	Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Franceschi, RT (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	rennyf@umich.edu	Benson, M. Douglas/L-9125-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012211, R56DE011723] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NIDCR NIH HHS [DE 11723, DE12211] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acampora D, 1999, DEVELOPMENT, V126, P3795; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHEN JK, 1992, J BONE MINER RES, V7, P987; Chen JK, 1996, J BONE MINER RES, V11, P654; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFRANCO DJ, 1992, ENDOCRINOLOGY, V131, P114, DOI 10.1210/en.131.1.114; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; FRANCESCHI RT, 1992, J BONE MINER RES, V7, pS218; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goldberg HA, 1996, CONNECT TISSUE RES, V35, P385, DOI 10.3109/03008209609029216; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Kerr JM, 1997, CALCIFIED TISSUE INT, V60, P276, DOI 10.1007/s002239900229; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; OGATA Y, 1995, EUR J BIOCHEM, V230, P183; Ogata Y, 1997, J CELL BIOCHEM, V65, P501, DOI 10.1002/(SICI)1097-4644(19970615)65:4<501::AID-JCB6>3.0.CO;2-S; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Thomas BL, 1997, DEVELOPMENT, V124, P4811; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; YOUNG MF, 1994, MAMM GENOME, V5, P108, DOI 10.1007/BF00292337	45	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13907	13917		10.1074/jbc.275.18.13907	http://dx.doi.org/10.1074/jbc.275.18.13907			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788516	hybrid			2022-12-27	WOS:000086925300103
J	de Haan, G; Chusacultanachai, S; Mao, CJ; Katzenellenbogen, BS; Shapiro, DJ				de Haan, G; Chusacultanachai, S; Mao, CJ; Katzenellenbogen, BS; Shapiro, DJ			Estrogen receptor-KRAB chimeras are potent ligand-dependent repressors of estrogen-regulated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; HORMONE-INDEPENDENT TRANSACTIVATION; RNA-POLYMERASE-II; RESPONSE ELEMENT; TRANSCRIPTION ACTIVATION; BREAST-CANCER; IN-VIVO; ENHANCED AFFINITY; NUCLEAR RECEPTORS; PS2 GENE	As an approach to targeted repression of genes of interest, we describe the development of human estrogen receptor (ER) alpha-KRAB repressor domain chimeras that are potent ligand-dependent repressors of the transcription of estrogen response element (ERE)-containing promoters and analyze their mechanisms of action. Repression by the KRAB domain was dominant over transactivation mediated by ER AF1 and AF2. An ERE and an ER ligand (estrogen or antiestrogen) were required for repression. Studies with several promoters and cell lines demonstrated that the presence of EREs, rather than the capacity for estrogen induction, determines the potential for repression of a gene by the KRAB-ER alpha-KRAB (HERK) chimera. A single consensus ERE was sufficient for repression, but the KERK chimera was unable to suppress transcription from the imperfect ERE in the native pS2 promoter. We recently reported mutations that enhance binding of a steroid receptor DNA-binding domain to the ERE. Introducing these mutations into wild-type ER enhanced transactivation from the pS2 ERE. Insertion of these mutations into KERK created the novel repressor KERK-3M, which is a potent repressor of both ER-induced and basal transcription on a promoter containing the pS2 ERE. These modified ER-KRAB chimeras should prove useful as new tools for the functional analysis and repression of ER-regulated genes.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 413 RAL,600 S Mathews Ave, Urbana, IL 61801 USA.		de Haan, Gerald/D-2081-2015	de Haan, Gerald/0000-0001-9706-0138	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060514] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60514] Funding Source: Medline; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barkhem T, 1997, J STEROID BIOCHEM, V62, P53, DOI 10.1016/S0960-0760(97)00017-4; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BROCK ML, 1983, J BIOL CHEM, V258, P5449; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Cheskis BJ, 1997, J BIOL CHEM, V272, P11384; Chien PY, 1999, MOL ENDOCRINOL, V13, P2122, DOI 10.1210/me.13.12.2122; Chusacultanachai S, 1999, J BIOL CHEM, V274, P23591, DOI 10.1074/jbc.274.33.23591; Clarke R, 1996, TRENDS ENDOCRIN MET, V7, P291, DOI 10.1016/S1043-2760(96)00127-0; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; DICKSON RB, 1997, CANC PRINCIPLES PRAC, V1, P1541; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; INCE BA, 1993, J BIOL CHEM, V268, P14026; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; KATZENELLNBOGEN JA, 1997, MOL ENDOCRINOL, V10, P119; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIPPMAN ME, 1987, J CELL BIOCHEM, V35, P1, DOI 10.1002/jcb.240350102; Ma ZQ, 1999, J STEROID BIOCHEM, V69, P155, DOI 10.1016/S0960-0760(98)00154-X; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MALOY S, 1994, METH MOL G, V3, P205; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mattick S, 1997, J STEROID BIOCHEM, V60, P285, DOI 10.1016/S0960-0760(96)00198-7; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; PENGUE G, 1995, J VIROL, V69, P6577, DOI 10.1128/JVI.69.10.6577-6580.1995; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; RIO MC, 1990, CANCER CELL-MON REV, V2, P269; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P4197, DOI 10.1021/bi00180a012; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; THIESEN H-J, 1990, New Biologist, V2, P363; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; XING H, 1993, J BIOL CHEM, V268, P23227; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457	58	19	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13493	13501		10.1074/jbc.275.18.13493	http://dx.doi.org/10.1074/jbc.275.18.13493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788463	hybrid			2022-12-27	WOS:000086925300050
J	Bell, SD; Jackson, SP				Bell, SD; Jackson, SP			The role of transcription factor B in transcription initiation and promoter clearance in the archaeon Sulfolobus acidocaldarius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; START SITE SELECTION; TATA-BINDING PROTEIN; FACTOR-TFIIB; FUNCTIONAL DOMAINS; PREINITIATION COMPLEX; FACTOR REQUIREMENTS; SHIBATAE; HOMOLOG; YEAST	Mechanisms of transcription initiation appear to be remarkably conserved between archaea and eucaryotes, For instance, there is homology between archaeal and eucaryotic basal transcription factors. Also, the archaeal RNA polymerase (RNAP) resembles eucaryotic nuclear RNAPs in subunit composition and at the amino acid sequence level. Here, we examine the role of transcription factor B, the archaeal homologue of eucaryotic transcription factor IIB, in transcription initiation. We show that the N-terminal region of transcription factor B is required for RNAP recruitment. Furthermore, we reveal that mutation of a conserved residue immediately C-terminal of the N-terminal zinc ribbon motif abrogates transcription on certain promoters. Finally, we identify the promoter sequences responsive to this mutation and demonstrate that the effect of the mutation is to block a late stage in transcription initiation, following formation of the promoter open complex.	Wellcome Trust, Cambridge CB2 1QR, England; Canc Res Campaign, Inst Canc & Dev Biol, Cambridge CB2 1QR, England	Wellcome Trust Sanger Institute; CRUK Cambridge Institute	Jackson, SP (corresponding author), Wellcome Trust, Tennis Court Rd, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Bell, Stephen/0000-0002-8474-6592				Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, COLD SPRING HARB SYM, V63, P41, DOI 10.1101/sqb.1998.63.41; Bell SD, 1998, P NATL ACAD SCI USA, V95, P15218, DOI 10.1073/pnas.95.26.15218; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Conaway JW, 1998, COLD SPRING HARB SYM, V63, P357, DOI 10.1101/sqb.1998.63.357; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PAVIN JD, 1993, CELL, V73, P533; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; QURESHI SA, 1995, NUCLEIC ACIDS RES, V23, P1775, DOI 10.1093/nar/23.10.1775; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P6077, DOI 10.1073/pnas.92.13.6077; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	28	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12934	12940		10.1074/jbc.275.17.12934	http://dx.doi.org/10.1074/jbc.275.17.12934			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777593	hybrid			2022-12-27	WOS:000086762300077
J	Su, L; David, M				Su, L; David, M			Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor - Selective inhibition of STAT3 and STAT5 by piceatannol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; TYROSINE KINASE; TRANSCRIPTION FACTOR; CELL LINE; ACTIVATION; PROTEIN; BINDING; TYK2; REQUIRES; DOMAINS	Interferon-alpha (IFN alpha) can activate several members of the signal transducers and activator of transcription (STAT) transcription factor family, a process that requires the tyrosine kinases Jak1 and Tyk2. Here we provide evidence that IFN alpha-mediated activation of various STAT proteins is regulated by distinct mechanisms. Piceatannol, previously reported as a Syk/ZAP70-specific kinase inhibitor, selectively inhibits the tyrosine phosphorylation of STAT3 and STAT5, but not of STAT1 and STATE. This inhibition is paralleled by the loss of Jak1 and IFNAR1 tyrosine phosphorylation in response to IFN alpha, whereas Tyk2 and IFNAR2 tyrosine phosphorylation is unaffected. Last, the IFN alpha-induced serine phosphorylation of STAT1 and STAT3 is not inhibited by piceatannol but is sensitive to the Src kinase-specific inhibitor PP2. Thus, our results not only demonstrate that the IFN alpha/beta receptor utilizes distinct mechanisms to trigger the tyrosine phosphorylation of specific STAT proteins, but they also indicate a diverging pathway that leads to the serine phosphorylation of STAT1 and STAT3.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, UCSD Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.			Su, Leon/0000-0001-7654-9997	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA80105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Peters JD, 1996, J BIOL CHEM, V271, P4755; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; VELAZQUEZ L, 1992, CELL, V70, P31; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	34	115	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12661	12666		10.1074/jbc.275.17.12661	http://dx.doi.org/10.1074/jbc.275.17.12661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777558	hybrid			2022-12-27	WOS:000086762300042
J	Aharoni, A; Weiner, L; Ottolenghi, M; Sheves, M				Aharoni, A; Weiner, L; Ottolenghi, M; Sheves, M			Bacteriorhodpsin experiences light-induced conformational alterations in nonisomerizable C-13=C-14 pigments - A study with EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON CRYSTALLOGRAPHY; PROTEIN-STRUCTURE; SPIN; DYNAMICS; CHROMOPHORE; PHOTOCYCLE; MUTANTS; EVENTS; PHOTOISOMERIZATION	The mechanism by which bacteriorhodopsin is activated following light absorption is not completely clear. We have detected protein conformational alterations following light absorption by retinal-based chromophores in the bacteriorhodopsin binding site by monitoring the rate of reduction-oxidation reactions of covalently attached spin labels, using EPR spectroscopy. It was found that the reduction reaction with hydroxylamine is light-catalyzed in the A103C-labeled pigment but not in E74C or M163C. The reaction is light-catalyzed even when isomerization of the C-13=C-14 bond of the retinal chromophore is prevented. The reverse oxidation reaction with molecular oxygen is effective only in apomembrane derived from the mutant A103C. This reaction is light-accelerated following light absorption of the retinal oxime, which occupies the binding site. The light-induced acceleration is evident also in "locked" bacteriorhodopsin in which isomerization around the C-13=C-14 bond is prevented. It is evident that the chromophore-protein covalent bond is not a prerequisite for protein response. In contrast to the case of the retinal oxime, a reduced C=N bond A103C-labeled pigment did not exhibit acceleration of the oxidation reaction following light absorption. Acceleration was observed, however, following substitution of the polyene by groups that modify the excited state charge delocalization. It is suggested that protein conformational alterations are induced by charge redistribution along the retinal polyene following light absorption.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Serv, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem	Ottolenghi, M (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.		Lev, Weiner/GZK-4484-2022	Aharoni, Amir/0000-0003-2701-6996				AKHTAR M, 1968, BIOCHEM J, V110, P693, DOI 10.1042/bj1100693; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BECHER B, 1977, BIOPHYS J, V19, P285, DOI 10.1016/S0006-3495(77)85588-4; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P2101, DOI 10.1073/pnas.92.6.2101; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FAN J, 1983, J AM CHEM SOC, V105, P5162; FEIX YV, 1998, SPIN LABELING, P251; FREEDMAN KA, 1986, J AM CHEM SOC, V108, P1245, DOI 10.1021/ja00266a020; FRIEDMAN N, 1994, BIOCHEMISTRY-US, V33, P1971, DOI 10.1021/bi00174a001; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Lanyi JK, 1999, INT REV CYTOL, V187, P161, DOI 10.1016/S0074-7696(08)62418-3; LEWIS A, 1978, P NATL ACAD SCI USA, V75, P549, DOI 10.1073/pnas.75.2.549; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; NETTLETON DO, 1989, ARCH BIOCHEM BIOPHYS, V271, P414, DOI 10.1016/0003-9861(89)90291-9; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTOLENGHI M, 1995, ISR J CHEM, V35, P193; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Pfeiffer M, 1999, J MOL BIOL, V287, P163, DOI 10.1006/jmbi.1998.2593; Rink T, 1997, BIOPHYS J, V73, P983, DOI 10.1016/S0006-3495(97)78131-1; ROOZEN MJGW, 1990, J PHYS CHEM-US, V94, P7326, DOI 10.1021/j100381a068; Rousso I, 1997, P NATL ACAD SCI USA, V94, P7937, DOI 10.1073/pnas.94.15.7937; Rousso I, 1998, BIOPHYS J, V75, P413, DOI 10.1016/S0006-3495(98)77526-5; Rousso I, 1996, J AM CHEM SOC, V118, P11299, DOI 10.1021/ja960404k; SALEM L, 1975, NATURE, V258, P526, DOI 10.1038/258526a0; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; SHEVES M, 1985, BIOCHEMISTRY-US, V24, P1260, DOI 10.1021/bi00326a031; STEINHOFF HJ, 1995, BIOPHYS CHEM, V56, P89, DOI 10.1016/0301-4622(95)00019-T; STEINHOFF HJ, 1994, SCIENCE, V266, P105, DOI 10.1126/science.7939627; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; Xu D, 1996, BIOPHYS J, V70, P453, DOI 10.1016/S0006-3495(96)79588-7	40	24	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21010	21016		10.1074/jbc.M001208200	http://dx.doi.org/10.1074/jbc.M001208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801804	hybrid			2022-12-27	WOS:000088230600008
J	Fukuyama, K; Yoshida, M; Yamashita, A; Deyama, T; Baba, M; Suzuki, A; Mohri, H; Ikezawa, Z; Nakajima, H; Hirai, S; Ohno, S				Fukuyama, K; Yoshida, M; Yamashita, A; Deyama, T; Baba, M; Suzuki, A; Mohri, H; Ikezawa, Z; Nakajima, H; Hirai, S; Ohno, S			MAPK upstream kinase (MUK)-binding inhibitory protein, a negative regulator of MUK/dual leucine zipper-bearing kinase/leucine zipper protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED LINEAGE KINASE-2; SIGNAL-TRANSDUCTION; DIFFERENTIAL ACTIVATION; MOLECULAR-CLONING; BINDING-PROTEINS; CELL-DEATH; ZPK GENE; JNK; APOPTOSIS; PATHWAYS	Mitogen-activated protein kinase upstream kinase/dual leucine zipper-bearing kinase/leucine-zipper protein kinase (MUK/DLK/ZPK) is a MAPKKK class protein kinase that induces JNK/SAPK activation. We report here a protein named MBIP that binds to MUK/DLK/ZPK. MUK-binding inhibitory protein (MBIP) contains two tandemly orientated leucine-zipper-like motifs with a cluster of basic amino acids located between the two motifs. MBIP interacts with one of the two leucine-zipper-like motifs of MUK/DLK/ZPK and inhibits the activity of MUK/DLK/ZPK to induce JNK/SAPK activation. Notably, no similar effect was observed with another JNK/SAPK-inducing MAPKKK, COT/Tp1-2, showing the specificity of MBIP action. Furthermore, the overexpression of MBIP partially inhibits the activation of JNK by 0.3 M sorbitol in 293T cells. Taken together, these observations indicate that MBIP can function as a regulator of MUK/DLK/ZPK, a finding that may provide a clue to understanding the molecular mechanism of JNK/SAPK activation by hyperosmotic stress.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Yokohama City University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	sh3312@med.yokohama-cu.ac.jp	Ohno, Shigeo/B-1768-2010; Baba, Masaya/L-7490-2013; Baba, Masaya/ABE-4893-2020	Ohno, Shigeo/0000-0002-1294-5269; Baba, Masaya/0000-0002-5308-6683; 				Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Douziech M, 1999, J HISTOCHEM CYTOCHEM, V47, P1287, DOI 10.1177/002215549904701008; Douziech M, 1998, BIOCHEM BIOPH RES CO, V249, P927, DOI 10.1006/bbrc.1998.9249; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Rasmussen RK, 1998, ELECTROPHORESIS, V19, P809, DOI 10.1002/elps.1150190535; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	45	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21247	21254		10.1074/jbc.M001488200	http://dx.doi.org/10.1074/jbc.M001488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801814	hybrid			2022-12-27	WOS:000088230600040
J	Park, WY; Park, JS; Cho, KA; Kim, DI; Ko, YG; Seo, JS; Park, SC				Park, WY; Park, JS; Cho, KA; Kim, DI; Ko, YG; Seo, JS; Park, SC			Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MAP KINASE CASCADE; PLASMA-MEMBRANE; IN-VIVO; SCAFFOLDING DOMAIN; HUMAN-FIBROBLASTS; GENE FAMILY; MDCK CELLS; EXPRESSION; DIFFERENTIATION	Senescent human diploid fibroblasts do not respond to growth factors like epidermal growth factor (EGF), although they have a normal level of receptors and downstream signaling molecules. To examine the mechanism of signaling attenuation, we investigated Erk activation after EGF stimulation in senescent cells. Senescent cells did not phosphorylate Erk-1/2 after EGF stimulation, whereas young cells did, In those senescent cells, we found an increased level of caveolin proteins and strong interactions between caveolin-1 and EGF receptor. Electron microscopic analysis demonstrated an increased number of caveolae structures in senescent cells. More interestingly, brain, spleen, and lung from 26-month-old rats showed substantial increases of caveolin proteins. However, in the case of p53-induced senescence, caveolin-1 was not induced, and EGF stimulation phosphorylated Erk-1/2 as much as young control cells. Finally, we overexpressed caveolin-1 in young human diploid fibroblasts in which the activation of Erk-1/2 upon EGF stimulation was significantly suppressed. These results suggest that the unresponsiveness of senescent fibroblasts to EGF stimulation mag be due to the overexpression of caveolins, which seems to be independent of growth arrest and other aging phenotypes.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea	Seoul National University (SNU)	Park, SC (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem, Chongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.		park, woongyang/D-5727-2012; Seo, Jeong-Sun/J-2763-2012					ALVAREZ E, 1993, MECH AGEING DEV, V71, P1, DOI 10.1016/0047-6374(93)90030-U; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; COHEN BM, 1985, LIFE SCI, V37, P1403, DOI 10.1016/0024-3205(85)90079-7; CONET J, 1997, J BIOL CHEM, V272, P30429; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1995, AM J PATHOL, V147, P1; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Kitano S, 1998, J CELL PHYSIOL, V176, P32, DOI 10.1002/(SICI)1097-4652(199807)176:1<32::AID-JCP4>3.0.CO;2-9; Ko YG, 1999, J IMMUNOL, V162, P7217; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311; Munoz P, 1996, J BIOL CHEM, V271, P8133, DOI 10.1074/jbc.271.14.8133; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park SC, 1999, J GERONTOL A-BIOL, V54, pB78, DOI 10.1093/gerona/54.2.B78; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; Ribault D, 1998, MECH AGEING DEV, V100, P25, DOI 10.1016/S0047-6374(97)00115-2; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SEVERS NJ, 1988, J CELL SCI, V90, P341; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359	41	184	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20847	20852		10.1074/jbc.M908162199	http://dx.doi.org/10.1074/jbc.M908162199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781609	hybrid			2022-12-27	WOS:000088084500088
J	Svensson, EC; Huggins, GS; Dardik, FB; Polk, CE; Leiden, JM				Svensson, EC; Huggins, GS; Dardik, FB; Polk, CE; Leiden, JM			A functionally conserved N-terminal domain of the friend of GATA-2 (FOG-2) protein represses GATA4-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; HEART TUBE FORMATION; GENE-EXPRESSION; VENTRAL MORPHOGENESIS; ENDOTHELIAL-CELLS; BINDING PROTEIN; ENCODING GENE; CO-REPRESSOR; FAMILY; COFACTOR	GATA4 is a transcriptional activator of cardiac-restricted promoters and is required for normal cardiac morphogenesis. Friend of GATA-2 (FOG-2) is a multizine finger protein that associates with GATA4 and represses GATA4-dependent transcription. To better understand the transcriptional repressor activity of FOG-2 we performed a functional analysis of the FOG-2 protein. The results demonstrated that 1) zinc fingers 1 and 6 of FOG-2 are each capable of interacting with evolutionarily conserved motifs within the N-terminal zinc finger of mammalian GATA proteins, 2) a nuclear localization signal (RKRRK) (amino acids 736-740) is required to program nuclear targeting of FOG-2, and 3) FOG-2 can interact with the transcriptional co-repressor, C-terminal-binding protein-2 via a conserved sequence motif in FOG-2 (PIDLS). Surprisingly, however, this interaction with C-terminal-binding protein-2 is not required for FOG-2-mediated repression of GATA4-dependent transcription. instead, we have identified a novel N-terminal domain of FOG-2 (amino acids 1-247) that is both necessary and sufficient to repress GATA4-dependent transcription. This N-terminal repressor domain is functionally conserved in the related protein, Friend of GATA1, Taken together, these results define a set of evolutionarily conserved mechanisms by which FOG proteins repress GATA-dependent transcription and thereby form the foundation for genetic studies designed to elucidate the role of FOG-2 in cardiac development.	Harvard Univ, Sch Publ Hlth, Lab Cardiovasc Biol, Boston, MA 02115 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Chicago; Harvard University; Harvard Medical School	Leiden, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Lab Cardiovasc Biol, Bldg 2,Rm 117,677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL54592, R01 HL054592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Cubadda Y, 1997, GENE DEV, V11, P3083, DOI 10.1101/gad.11.22.3083; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854	38	99	102	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20762	20769		10.1074/jbc.M001522200	http://dx.doi.org/10.1074/jbc.M001522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801815	hybrid			2022-12-27	WOS:000088084500076
J	Koo, LS; Tschirret-Guth, RA; Straub, WE; Moenne-Loccoz, P; Loehr, TM; de Montellano, PRO				Koo, LS; Tschirret-Guth, RA; Straub, WE; Moenne-Loccoz, P; Loehr, TM; de Montellano, PRO			The active site of the thermophilic CYP119 from Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN; SUBSTRATE-BINDING; LIGAND-BINDING; REDOX EQUILIBRIA; SPIN TRANSITION; P2 GENOME; CYTOCHROME-P450; MUTAGENESIS; DETERMINANTS; SPECIFICITY	CYP119 from Sulfolobus solfataricus, the first thermophilic cytochrome P450, is stable at up to 85 degrees C. UV-visible and resonance Raman show the enzyme is in the low spin state and only modestly shifts to the high spin state at higher temperatures. Styrene only causes a small spin state shift, but T-1 NMR studies confirm that styrene is bound in the active site. CYP119 catalyzes the H2O2-dependent epoxidation of styrene, cis-beta-methylstyrene, and cis-stilbene with retention of stereochemistry. This catalytic activity is stable to preincubation at 80 degrees C for 90 min. Site-specific mutagenesis shows that Thr-213 is catalytically important and Thr-214 helps to control the iron spin state. Topological analysis by reaction with aryldiazenes shows that Thr-213 lies above pyrrole rings A and B and is close to the iron atom, whereas Thr-214 is some distance away. CYP119 is very slowly reduced by putidaredoxin and putidaredoxin reductase, but these proteins support catalytic turnover of the Thr-214 mutants. Protein melting curves indicate that the thermal stability of CYP119 does not depend on the iron spin state or the active site architecture defined by the threonine residues. Independence of thermal stability from active site structural factors should facilitate the engineering of novel thermostable catalysts.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.			MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468, R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34468, GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTINI I, 1986, NMR PARAMAGNETIC MOL, P47; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Charlebois RL, 1996, FEBS LETT, V389, P88, DOI 10.1016/0014-5793(96)00525-X; DEMONTELLANO PRO, 1995, BIOCHIMIE, V77, P581, DOI 10.1016/0300-9084(96)88174-0; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P473; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P575; DEROSA M, 1975, J GEN MICROBIOL, V86, P156, DOI 10.1099/00221287-86-1-156; DWEK RA, 1973, NUCL MAGN RESON, P11; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; FRUETEL JA, 1994, J BIOL CHEM, V269, P28815; Green MT, 1998, J AM CHEM SOC, V120, P10772, DOI 10.1021/ja980994h; HAHN EL, 1950, PHYS REV, V77, P297, DOI 10.1103/PhysRev.77.297.2; HARRIS D, 1993, J AM CHEM SOC, V115, P8775, DOI 10.1021/ja00072a034; HUANG PKC, 1968, J AM CHEM SOC, V90, P2354, DOI 10.1021/ja01011a027; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JARDETZKY O, 1981, NMR MOL BIOL, P69; KERTES AS, 1989, SOLUBILITY DATA SERI, V38, P1; KOO LS, 1997, FASEB J, V9, pA813; LANGE R, 1979, EUR J BIOCHEM, V94, P485, DOI 10.1111/j.1432-1033.1979.tb12916.x; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; LUZ Z, 1964, J CHEM PHYS, V40, P2686, DOI 10.1063/1.1725581; MARDEN MC, 1982, EUR J BIOCHEM, V129, P111, DOI 10.1111/j.1432-1033.1982.tb07028.x; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; MODI S, 1995, BIOCHEMISTRY-US, V34, P8982, DOI 10.1021/bi00028a006; NASTAINZCYK W, 1975, EUR J BIOCHEM, V60, P615, DOI 10.1111/j.1432-1033.1975.tb21039.x; Nickerson DP, 1997, FEBS LETT, V405, P153, DOI 10.1016/S0014-5793(97)00174-9; Okamoto N, 1998, BIOCHEMISTRY-US, V37, P8839, DOI 10.1021/bi980469v; PoliScaife S, 1997, BIOCHEMISTRY-US, V36, P12672, DOI 10.1021/bi970527x; SASS M, 1977, J MAGN RESON, V25, P263, DOI 10.1016/0022-2364(77)90021-X; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; Sensen CW, 1998, EXTREMOPHILES, V2, P305, DOI 10.1007/s007920050073; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Smith G, 1998, BIOCHEM J, V331, P783, DOI 10.1042/bj3310783; SOLOMON I, 1956, J CHEM PHYS, V25, P261, DOI 10.1063/1.1742867; SONO M, 1982, J BIOL CHEM, V257, P8308; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; SWIFT TJ, 1962, J CHEM PHYS, V37, P307, DOI 10.1063/1.1701321; Truan G, 1998, ARCH BIOCHEM BIOPHYS, V349, P53, DOI 10.1006/abbi.1997.0400; TSCHIRRETGUTH R, 2000, IN PRESS J BIOL INOR; Vaz ADN, 1998, P NATL ACAD SCI USA, V95, P3555, DOI 10.1073/pnas.95.7.3555; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Wright RL, 1996, FEBS LETT, V384, P235, DOI 10.1016/0014-5793(96)00322-5; YU NT, 1986, METHOD ENZYMOL, V130, P350; [No title captured]	47	83	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14112	14123		10.1074/jbc.275.19.14112	http://dx.doi.org/10.1074/jbc.275.19.14112			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799487	hybrid			2022-12-27	WOS:000087006900017
J	Porat, A; Sagiv, Y; Elazar, Z				Porat, A; Sagiv, Y; Elazar, Z			A 56-kDa selenium-binding protein participates in intra-Golgi protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; VESICULAR TRANSPORT; VESICLE DOCKING; IN-VITRO; BIOCHEMICAL REQUIREMENTS; SNARE COMPLEX; MEDIAL GOLGI; MOUSE-LIVER	Transport of proteins between intracellular membrane compartments is a highly regulated process that depends on several cytosolic factors. By using the well characterized intra-Golgi cell-free transport assay, we purified from bovine brain cytosol a 56-kDa protein that shows a significant transport activity. Partial sequencing of four tryptic peptides obtained from the 56-kDa protein revealed its identity to a cytosolic protein previously characterized as a selenium-binding protein, SBP56. Recombinant SBP56 expressed in Escherichia coli exhibited transport activity when added to the cell-free intra-Golgi transport. Affinity purified anti-SBP56 polyclonal antibodies specifically inhibited intra-Golgi transport in vitro. Although SBP56 is predominantly localized in the cytosol, a significant amount is associated with membranes. Subcellular fractionation showed that this protein is peripherally associated with the Golgi membrane. The experiments presented in this study indicate that SBP56 participates in late stages of intra-Golgi protein transport.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							ANTONY C, 1992, J CELL SCI, V103, P785; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BANSAL MP, 1989, CARCINOGENESIS, V10, P541, DOI 10.1093/carcin/10.3.541; BANSAL MP, 1990, CARCINOGENESIS, V11, P2071, DOI 10.1093/carcin/11.11.2071; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mayer T, 1996, J BIOL CHEM, V271, P16097, DOI 10.1074/jbc.271.27.16097; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Paul KS, 1998, FEBS LETT, V431, P91, DOI 10.1016/S0014-5793(98)00722-4; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Sheetz MP, 1999, EUR J BIOCHEM, V262, P19, DOI 10.1046/j.1432-1327.1999.00340.x; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Walter DM, 1998, J BIOL CHEM, V273, P29565, DOI 10.1074/jbc.273.45.29565; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yang MH, 1998, CANCER RES, V58, P3150	59	95	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14457	14465		10.1074/jbc.275.19.14457	http://dx.doi.org/10.1074/jbc.275.19.14457			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799528	hybrid			2022-12-27	WOS:000087006900062
J	Tanahashi, N; Murakami, Y; Minami, Y; Shimbara, N; Hendil, KB; Tanaka, K				Tanahashi, N; Murakami, Y; Minami, Y; Shimbara, N; Hendil, KB; Tanaka, K			Hybrid proteasomes - Induction by interferon-gamma and contribution to ATP-dependent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; 26S PROTEASOME; ACTIVATOR PA28; ORNITHINE DECARBOXYLASE; ANTIGEN PRESENTATION; PROTEIN ACTIVATOR; BINDING; PURIFICATION; REGULATOR; PA700	Eukaryotic cells contain various types of proteasomes. Core 20 S proteasomes (abbreviated 20 S below) have two binding sites for the regulatory particles, PA700 and PA28. PA700-20 S-PA700 complexes are known as 26 S proteasomes and are ATP-dependent machines that degrade cell proteins. PA28 is found both in previously described complexes of the type PA28-20 S-PA28 and in complexes that also contain PA700, as PA700-20 S-PA28. We refer to the latter as "hybrid proteasomes." The relative amounts of the various types of proteasomes in HeLa extracts were determined by a combination of immunoprecipitation and immunoblotting. Hybrid proteasomes accounted for about a fourth of all proteasomes in the extracts. Association of PA28 and proteasomes proved to be ATP-dependent. Hybrid proteasomes catalyzed ATP-dependent degradation of ornithine decarboxylase (ODC) without ubiquitinylation, as do 26 S proteasomes. In contrast, the homo-PA28 complex (PA28-20 S-PA28) was incapable of degrading ODC. Intriguingly, a major immunomodulatory cytokine, interferon-gamma, appreciably enhanced the ODC degradation in HeLa and SW620 cells through induction of the hybrid proteasome, which may also be responsible for the immunological processing of intracellular antigens. Taken together, we report here for the first time the existence of two types of ATP-dependent proteases, the 26 S proteasome and the hybrid proteasome, which appear to share the ATP-dependent proteolytic pathway in mammalian cells.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Bunkyo Ku, Tokyo 1138613, Japan; Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 1058461, Japan; Oita Med Univ, Dept Biochem, Oita 8795593, Japan; UP Sci Inc, Dept Res, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen, Denmark	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Jikei University; Oita University; University of Copenhagen	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	tanakak@rinshoken.or.jp						Adams GM, 1997, J MOL BIOL, V273, P646, DOI 10.1006/jmbi.1997.1334; AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062; Shimbara N, 1997, GENES CELLS, V2, P785, DOI 10.1046/j.1365-2443.1997.1610359.x; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Tanaka K, 1998, IMMUNOL REV, V163, P161; TANAKA K, 1997, CELL BIOL LAB HDB, P129; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+	39	290	299	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14336	14345		10.1074/jbc.275.19.14336	http://dx.doi.org/10.1074/jbc.275.19.14336			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799514	hybrid			2022-12-27	WOS:000087006900046
J	Turner, MD; Arvan, P				Turner, MD; Arvan, P			Protein traffic from the secretory pathway to the endosomal system in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; SYNTHESIZED LYSOSOMAL-ENZYMES; MANNOSE 6-PHOSPHATE RECEPTORS; CONSTITUTIVE-LIKE SECRETION; GRANULE CONTENT PROTEINS; ADP-RIBOSYLATION FACTOR; DISULFIDE-BONDED LOOP; AP-1 ADAPTER COMPLEX; SEMLIKI FOREST VIRUS; BREFELDIN-A	Constitutive-like secretion involves vesicular trafficking corresponding kinetically and biochemically with a post-trans-Golgi network (TGN) origin. In pancreatic beta-cells, the budding of AP-1/clathrin-coated vesicles, a portion of which is derived from immature secretory granules, has been hypothesized to initiate constitutive-like trafficking. However, similar to 30 min after release of a 20 degrees C intracellular transport block in pancreatic beta-cells (to synchronize protein egress from the TGN), addition of brefeldin A (BFA) (which inhibits AP-1 recruitment) was reported not to block subsequent constitutive-like secretion. To further explore post-TGN trafficking in pancreatic beta-cell lines, we have followed the fate of pulse-labeled procathepsin B (ProB, a lysosomal pro-enyzme) after postpulse wortmannin treatment or the BFA treatment described above. We find that continuous wortmannin treatment allows ProB to reach immature secretory granules but inhibits its egress from maturing granules. Remarkably, BFA treatment causes augmented unstimulated secretion of newly synthesized ProB that is not paralleled by insulin. This effect requires a delay of 25-35 min after release from the 20 degrees C block. Further, when ProB delivery to endosomes is inhibited, its BFA-augmented secretion is eliminated. We hypothesize that the constitutive-like pathway involves an endosomal intermediate.	Albert Einstein Coll Med, Ctr Diabet, Div Endocrinol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Albert Einstein Coll Med, Ctr Diabet, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Turner, Mark/A-4178-2009	Turner, Mark/0000-0001-7175-1053	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Castle AM, 1997, J CELL BIOL, V138, P45, DOI 10.1083/jcb.138.1.45; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeLisle RC, 1996, EUR J CELL BIOL, V71, P62; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Dumermuth E, 1998, METHODS, V16, P188, DOI 10.1006/meth.1998.0666; EFRAT S, 1991, J BIOL CHEM, V266, P11141; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; FEDDE KN, 1988, J CELL BIOCHEM, V37, P233, DOI 10.1002/jcb.240370210; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; Han P, 1999, J BIOL CHEM, V274, P22337, DOI 10.1074/jbc.274.32.22337; Harsay E, 1998, MOL BIOL CELL, V9, p208A; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HUANG XF, 1994, J BIOL CHEM, V269, P20838; KIELIAN M, 1990, J VIROL, V64, P4614, DOI 10.1128/JVI.64.10.4614-4624.1990; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; Lewin DA, 1998, FEBS LETT, V435, P263, DOI 10.1016/S0014-5793(98)01083-7; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; NEERMANARBEZ M, 1993, J BIOL CHEM, V268, P16248; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1984, J CELL BIOL, V99, P2187, DOI 10.1083/jcb.99.6.2187; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; Rindler MJ, 1998, J BIOL CHEM, V273, P31180, DOI 10.1074/jbc.273.47.31180; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VARRO A, 1994, J BIOL CHEM, V269, P20764; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273	68	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14025	14030		10.1074/jbc.275.19.14025	http://dx.doi.org/10.1074/jbc.275.19.14025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799475	hybrid			2022-12-27	WOS:000087006900005
J	Watson, EL; Jacobson, KL; Singh, JC; Idzerda, R; Ott, SM; DiJulio, DH; Wong, ST; Storm, DR				Watson, EL; Jacobson, KL; Singh, JC; Idzerda, R; Ott, SM; DiJulio, DH; Wong, ST; Storm, DR			The type 8 adenylyl cyclase is critical for Ca2+ stimulation of cAMP accumulation in mouse parotid acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CARDIAC RYANODINE RECEPTOR; CALCIUM CHANNELS; BINDING SITES; SMOOTH-MUSCLE; NCB-20 CELLS; IN-VIVO; CALMODULIN; ENTRY	Capacitative Ca2+ entry stimulates cAMP synthesis in mouse parotid acini, suggesting that one of the Ca2+-sensitive adenylyl cyclases (AC1 or AC8) may play an important role in the regulation of parotid function (Watson, E. L., Wu, Z., Jacobson, K. L., Storm, D. R., Singh, J. C., and Ott, S. M. (1998) Am. J. Physiol. 274, C557-C565). To evaluate the role of AC1 and AC8 in Ca2+ stimulation of cAMP synthesis in parotid cells, acini were isolated from AC1 mutant (AC1-KO) and AC8 mutant (AC8-KO) mice and analyzed for Ca2+ stimulation of intracellular cAMP levels. Although Ca2+ stimulation of intracellular cAMP levels in acini from AC1-KO mice was indistinguishable from wild type mice, acini from AC8-KO mice showed no Ca2+-stimulated cAMP accumulation. This indicates that AC8, but not AC1, plays a major role in coupling Ca2+ signals to cAMP synthesis in parotid acini. Interestingly, treatment of acini from AC8-KO mice with agents, i.e. carbachol and thapsigargin that increase intracellular Ca2+, lowered cAMP levels. This decrease was dependent upon Ca2+ influx and independent of phosphodiesterase activation. Immunoblot analysis revealed that AC5/6 and AC3 are expressed in parotid glands. Inhibition of calmodulin (CaM) kinase II with KN-62, or inclusion of the CaM inhibitor, calmidazolium, did not prevent agonist-induced inhibition of stimulated cAMP accumulation. In vitro studies revealed that Ca2+, independently of CaM, inhibited isoproterenol-stimulated AC. Data suggest that agonist augmentation of stimulated cAMP levels is due to activation of AC8 in mouse parotid acini, and strongly support a role for AC5/6 in the inhibition of stimulated cAMP levels.	Univ Washington, Dept Oral Biol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Watson, EL (corresponding author), Univ Washington, Dept Oral Biol, Box 357132, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-05249] Funding Source: Medline; NINDS NIH HHS [NS-20498] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ammer H, 1997, MOL PHARMACOL, V52, P993, DOI 10.1124/mol.52.6.993; Antoni F A, 1998, Adv Second Messenger Phosphoprotein Res, V32, P153; Basavappa S, 1999, BIOCHEM BIOPH RES CO, V254, P699, DOI 10.1006/bbrc.1998.9997; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; DEHAYE JP, 1993, AM J PHYSIOL, V265, pC1356, DOI 10.1152/ajpcell.1993.265.5.C1356; DiJulio DH, 1997, J BIOL CHEM, V272, P15687, DOI 10.1074/jbc.272.25.15687; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Gailly P, 1998, CELL CALCIUM, V24, P293, DOI 10.1016/S0143-4160(98)90053-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; HIRST RA, 1995, BIOCHEM PHARMACOL, V49, P1633, DOI 10.1016/0006-2952(95)00075-B; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; Holen I, 1996, EUR J BIOCHEM, V236, P163, DOI 10.1111/j.1432-1033.1996.00163.x; HORN VJ, 1989, FEBS LETT, V258, P13, DOI 10.1016/0014-5793(89)81604-7; HUGHES AR, 1989, CELL CALCIUM, V10, P519, DOI 10.1016/0143-4160(89)90013-4; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kawabe J, 1996, FEBS LETT, V384, P273, DOI 10.1016/0014-5793(96)00331-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matifat F, 1997, BIOCHEM J, V322, P267, DOI 10.1042/bj3220267; Mons N, 1998, LIFE SCI, V62, P1647, DOI 10.1016/S0024-3205(98)00122-2; Murthy KS, 1998, MOL PHARMACOL, V54, P122, DOI 10.1124/mol.54.1.122; Ozawa T, 1998, BIOCHEM BIOPH RES CO, V246, P422, DOI 10.1006/bbrc.1998.8636; PIASCIK MT, 1986, AM J PHYSIOL, V250, pC642, DOI 10.1152/ajpcell.1986.250.4.C642; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; Sambrook J., 2002, MOL CLONING LAB MANU; STEINER AL, 1972, J BIOL CHEM, V247, P1106; Takahashi H, 1998, ARCH DERMATOL RES, V290, P407, DOI 10.1007/s004030050327; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tojyo Y, 1998, EUR J PHARMACOL, V360, P73, DOI 10.1016/S0014-2999(98)00651-7; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Towbin H, 1992, Biotechnology, V24, P145; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; WATSON EL, 1985, LIFE SCI, V37, P2531, DOI 10.1016/0024-3205(85)90611-3; WATSON EL, 1993, AM J PHYSIOL, V265, pC1061; Watson EL, 1998, AM J PHYSIOL-CELL PH, V274, pC557, DOI 10.1152/ajpcell.1998.274.3.C557; WATSON EL, 1990, MOL PHARMACOL, V38, P547; WATSON EL, 1979, AM J PHYSIOL, V236, pC233, DOI 10.1152/ajpcell.1979.236.5.C233; WATSON EL, 1993, CELL SIGNAL, V5, P583, DOI 10.1016/0898-6568(93)90053-O; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; Xia Z., 1996, REGULATORY PROPERTIE; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; Yoshimura K, 1998, BBA-MOL CELL RES, V1402, P171, DOI 10.1016/S0167-4889(98)00007-X; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZHANG GY, 1993, MOL CELL BIOCHEM, V122, P159, DOI 10.1007/BF01076100; Zhang Z, 1998, EUR J MORPHOL, V36, P219	69	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14691	14699		10.1074/jbc.275.19.14691	http://dx.doi.org/10.1074/jbc.275.19.14691			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799557	hybrid			2022-12-27	WOS:000087006900091
J	Handschin, C; Meyer, UA				Handschin, C; Meyer, UA			A conserved nuclear receptor consensus sequence (DR-4) mediates transcriptional activation of the chicken CYP2H1 gene by phenobarbital in a hepatoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ENHANCER MODULE; MOUSE PRIMARY HEPATOCYTES; CIS-ACTING ELEMENT; 5'-FLANKING REGION; CYP2B10 GENE; PROTEIN-PHOSPHORYLATION; CYTOCHROME-P450 GENES; INDUCTION; EXPRESSION; CAR	Phenobarbital-responsive DNA elements were identified in the 5'-flanking region of the chicken CYP2H1 gene by in reporter gene assays in a chicken hepatoma cell line (leghorn male hepatoma (LMH)), A 264-base pair (bp) enhancer sequence (phenobarbital-responsive unit (PBRU)) responded to phenobarbital and a variety of phenobarbital-type inducers. Analysis of putative transcription factor binding sites within the 264-bp element revealed a nuclear receptor half-site repeat (DR-4) neighboring a putative nuclear factor-1 site. This motif resembles phenobarbital response elements in the flanking regions of three phenobarbital-inducible genes, rat CYP2B2, mouse Cyp2b10 and human CYP2B6. Activation of the 264-bp element was eliminated after site-directed mutagenesis of the DR-4 hexamer half-sites. Evidence for evolutionary conservation of this recognition site was indicated by activation in LMH cells of a mouse Cyp2b10 phenobarbital-responsive enhancer by the same spectrum of inducers that activate the CYP2H1 264-bp PBRU. Inhibition of this activation by okadaic acid may explain the reported inhibitory effects on induction of CYP2B1/2 and Cyp2b10 by this phosphatase inhibitor. We show that this inhibition occurs directly on the 264-bp PBRU, whereas the proximal promoter of CYP2H1 is induced by okadaic acid in reporter gene assays. These experiments exploit the unique phenobarbital inducibility of the hepatoma-derived cell line LMH.	Univ Basel, Bioctr, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Meyer, UA (corresponding author), Univ Basel, Bioctr, Dept Pharmacol Neurobiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Urs-A.Meyer@unibas.ch	Handschin, Christoph/E-6886-2015	Handschin, Christoph/0000-0003-0603-1097				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Barwick JL, 1996, MOL PHARMACOL, V50, P10; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burt DW, 1999, NATURE, V402, P411, DOI 10.1038/46555; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Dogra SC, 1998, CLIN EXP PHARMACOL P, V25, P1, DOI 10.1111/j.1440-1681.1998.tb02135.x; Dogra SC, 1997, DNA CELL BIOL, V16, P1407, DOI 10.1089/dna.1997.16.1407; Dogra SC, 1999, MOL PHARMACOL, V55, P14, DOI 10.1124/mol.55.1.14; Frueh FW, 1997, MOL PHARMACOL, V51, P363; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; Galisteo M, 1999, J PHARMACOL EXP THER, V290, P1270; Ganem LG, 1999, TOXICOL APPL PHARM, V155, P32, DOI 10.1006/taap.1998.8599; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; HAHN CN, 1991, J BIOL CHEM, V266, P17031; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huss JM, 1996, P NATL ACAD SCI USA, V93, P4666, DOI 10.1073/pnas.93.10.4666; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kawamura A, 1999, BIOCHEM BIOPH RES CO, V264, P530, DOI 10.1006/bbrc.1999.1544; Kemper B, 1998, PROG NUCLEIC ACID RE, V61, P25, DOI 10.1016/S0079-6603(08)60824-7; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MATTSCHOSS LA, 1986, J BIOL CHEM, V261, P9438; Morgan ET, 1998, DRUG METAB DISPOS, V26, P1232; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nirodi CS, 1996, ARCH BIOCHEM BIOPHYS, V331, P79, DOI 10.1006/abbi.1996.0285; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; Ourlin JC, 2000, ARCH BIOCHEM BIOPHYS, V373, P375, DOI 10.1006/abbi.1999.1566; Posti K, 1999, EUR J BIOCHEM, V264, P19, DOI 10.1046/j.1432-1327.1999.00539.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; Ramsden R, 1999, GENE, V228, P169, DOI 10.1016/S0378-1119(98)00612-X; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351	52	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13362	13369		10.1074/jbc.275.18.13362	http://dx.doi.org/10.1074/jbc.275.18.13362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788445	Green Accepted, hybrid			2022-12-27	WOS:000086925300031
J	Schubert, KM; Scheid, MP; Duronio, V				Schubert, KM; Scheid, MP; Duronio, V			Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTOR; BAD PHOSPHORYLATION; INDUCED APOPTOSIS; CELL-SURVIVAL; MAP KINASE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE-3-OH KINASE	The second messenger ceramide (N-alkylsphingosine) has been implicated in a host of cellular processes including growth arrest and apoptosis, Ceramide has been reported to have effects on both protein kinases and phosphatases and may constitute an important component of stress response in various tissues. We have examined in detail the relationship between ceramide signaling and the activation of an important signaling pathway, phosphatidylinositol (PI) 3-kinase and its downstream target, protein kinase B (PKB). PKB activation was observed following stimulation of cells with the cytokine granulocyte-macrophage colony-stimulating factor. Addition of cell-permeable ceramide analogs, C-2- or C-6-ceramide, caused a partial loss (50-60%) of PKB activation. This reduction was not a result of decreased PI(3,4,5)P-3 or PI(3,4)P-2 generation by PI 3-kinase. Two residues of PKB (threonine 308 and serine 473) require phosphorylation for maximal PKB activation. Serine 473 phosphorylation was consistently reduced by treatment with ceramide, whereas threonine 308 phosphorylation remained unaffected. In further experiments, ceramide appeared to accelerate serine 473 dephosphorylation, suggesting the activation of a phosphatase. Consistent with this, the reduction in serine 473 phosphorylation was inhibited by the phosphatase inhibitors okadaic acid and calyculin A. Surprisingly, threonine 308 phosphorylation was abolished in cells treated with these inhibitors, revealing a novel mechanism of regulation of threonine 308 phosphorylation, These results demonstrate that PI 3-kinase-dependent kinase 2-catalyzed phosphorylation of serine 473 is the principal target of a ceramide-activated phosphatase.	Vancouver Hosp, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6H 3Z6, Canada	University of British Columbia; University of British Columbia	Duronio, V (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC V6H 3Z6, Canada.	vduronio@vanhosp.bc.ca						Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Coffer PJ, 1998, BIOCHEM J, V335, P1; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Laurenz JC, 1996, BBA-LIPID LIPID MET, V1299, P146, DOI 10.1016/0005-2760(95)00202-2; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Saba JD, 1996, PHILOS T ROY SOC B, V351, P233, DOI 10.1098/rstb.1996.0021; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	53	211	222	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13330	13335		10.1074/jbc.275.18.13330	http://dx.doi.org/10.1074/jbc.275.18.13330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788440	hybrid			2022-12-27	WOS:000086925300026
J	Jang, MH; Scrutton, NS; Hille, R				Jang, MH; Scrutton, NS; Hille, R			Formation of W(3)A(1) electron-transferring flavoprotein (ETF) hydroquinone in the trimethylamine dehydrogenase center dot ETF protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; BACTERIUM W3A1; METHYLOPHILUS-METHYLOTROPHUS; PARACOCCUS-DENITRIFICANS; 3-DIMENSIONAL STRUCTURE; XANTHINE-OXIDASE; PIG-KIDNEY; PURIFICATION; EXPRESSION; RESOLUTION	The electron-transferring flavoprotein (ETF) from Methylophilus methylotrophus (sp. W(3)A(1)) exhibits unusual oxidation-reduction properties and can only be reduced to the level of the semiquinone under most circumstances (including turnover with its physiological reductant, trimethylamine dehydrogenase (TMADH), or reaction with strong reducing reagents such as sodium dithionite). In the present study, we demonstrate that ETF can be reduced fully to its hydroquinone form both enzymatically and chemically when it is in complex with TMADH. Quantitative titration of the TMADH ETF protein complex with sodium dithionite shows that a total of five electrons are taken up by the system, indicating that full reduction of ETF occurs within the complex. The results indicate that the oxidation-reduction properties of ETF are perturbed upon binding to TMADH, a conclusion further supported by the observation of a spectral change upon formation of the TMADH ETF complex that is due to a change in the environment of the FAD of ETF. The results are discussed in the context of ETF undergoing a conformational change during formation of the TMADH ETF electron transfer complex, which modulates the spectral and oxidation-reduction properties of ETF such that full reduction of the protein can take place.	Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University System of Ohio; Ohio State University; University of Leicester	Hille, R (corresponding author), Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58481] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; BARBER MJ, 1988, BIOCHEM J, V256, P657, DOI 10.1042/bj2560657; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; CHEN DW, 1994, J BIOL CHEM, V269, P32120; Chohan KK, 1998, PROTEIN PEPTIDE LETT, V5, P231; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; FRERMAN FE, 1987, BIOCHEM SOC T, V16, P416; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; GORELICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830, DOI 10.1021/bi00345a015; GORELICK RJ, 1982, BIOCHEMISTRY-US, V21, P6936, DOI 10.1021/bi00269a049; HALL CL, 1980, J BIOL CHEM, V255, P3591; HILLE R, 1984, J BIOL CHEM, V259, P1570; HUANG LX, 1995, J BIOL CHEM, V270, P23958, DOI 10.1074/jbc.270.41.23958; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; HUSAIN M, 1990, METHOD ENZYMOL, V188, P309; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; IKEDA Y, 1986, J CLIN INVEST, V78, P997, DOI 10.1172/JCI112691; JANG MH, 1999, IN PRESS J BIOL CHEM; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; NAGY J, 1979, J BIOL CHEM, V254, P2684; OLSON JS, 1974, J BIOL CHEM, V249, P4363; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; Roberts DL, 1999, BIOCHEMISTRY-US, V38, P1977, DOI 10.1021/bi9820917; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; Scrutton NS, 1999, BIOCHEM SOC T, V27, P196, DOI 10.1042/bst0270196; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	38	19	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12546	12552		10.1074/jbc.275.17.12546	http://dx.doi.org/10.1074/jbc.275.17.12546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777543	hybrid			2022-12-27	WOS:000086762300027
J	Li, JR; Yang, SF; Billiar, TR				Li, JR; Yang, SF; Billiar, TR			Cyclic nucleotides suppress tumor necrosis factor alpha-mediated apoptosis by inhibiting caspase activation and cytochrome c release in primary hepatocytes via a mechanism independent of Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PROGRAMMED CELL-DEATH; NITRIC-OXIDE PRODUCTION; NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SYMPATHETIC NEURONS; S-NITROSYLATION; PC12 CELLS; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION	Cyclic nucleotides have been previously shown to modulate cell death processes in many cell types; however, the mechanisms by which cyclic nucleotides regulate apoptosis are unclear. In this study, we demonstrated that cAMP as well as cGMP analogs suppressed tumor necrosis factor alpha (TNF alpha) plus actinomycin D (ActD)-induced apoptosis in a dose-dependent manner in cultured primary hepatocytes. Furthermore, forskolin, which increases intracellular cAMP levels, also effectively suppressed TNF alpha+ActD-induced apoptosis. Activation of multiple caspases was suppressed in cells exposed to TNF alpha+ActD in the presence of cAMP or cGMP analogs. TNF alpha+ActD-induced cytochrome c release from mitochondria was also inhibited by cAMP or cGMP, reinforcing our conclusion that cyclic nucleotides interfere with the early signaling events of TNF alpha-mediated apoptosis, We evaluated the possibility that cAMP and cGMP inhibit apoptosis by activating the serine/threonine kinase Akt, which is known to promote cell survival. Both cAMP- and cGMP-elevating agents led to marked increases in Akt activation that was inhibited by the phosphatidylinositol 3'-kinase inhibitors, LY294002 and wortmannin. However, complete inhibition of cyclic nucleotide-induced Akt activation had little effect on cyclic nucleotide-mediated cell survival, indicating the existence of other survival pathways. Interestingly, the specific inhibitor of protein kinase A (PKA), KT5720, blocked cGMP-mediated protection but only partially prevented the anti-apoptotic effect of cAMP, indicating that both PKA-dependent and -independent mechanisms are involved in cAMP-mediated suppression of apoptosis signaling. Our data suggest that multiple survival signaling pathways coexist in cells and that cyclic nucleotides delay apoptosis by interfering with apoptosis signaling by both PKA-dependent and -independent mechanisms.	Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, W1503 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	jianrong@pitt.edu	Li, Jianrong/C-4126-2011	Li, Jianrong/0000-0002-8232-9322	NIGMS NIH HHS [GM-44100, GM19866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044100, R01GM044100, R29GM044100] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barge RMY, 1997, BBA-MOL CELL RES, V1355, P141, DOI 10.1016/S0167-4889(96)00130-9; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carson JP, 1999, CANCER RES, V59, P1449; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1999, J NEUROCHEM, V73, P466, DOI 10.1046/j.1471-4159.1999.0730466.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Estevez AG, 1998, J NEUROSCI, V18, P3708; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Bermejo L, 1998, J CELL SCI, V111, P637; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; JIANG H, 1992, BIOCHEM CELL BIOL, V70, P1283, DOI 10.1139/o92-175; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LEIST M, 1994, J IMMUNOL, V153, P1778; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Murad F, 1996, JAMA-J AM MED ASSOC, V276, P1189, DOI 10.1001/jama.276.14.1189; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Polte T, 1998, BIOCHEM BIOPH RES CO, V251, P460, DOI 10.1006/bbrc.1998.9486; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Walton M, 1999, J NEUROCHEM, V73, P1836; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	66	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13026	13034		10.1074/jbc.275.17.13026	http://dx.doi.org/10.1074/jbc.275.17.13026			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777606	hybrid			2022-12-27	WOS:000086762300090
J	Yokoyama, H; Mukae, N; Sakahira, H; Okawa, K; Iwamatsu, A; Nagata, S				Yokoyama, H; Mukae, N; Sakahira, H; Okawa, K; Iwamatsu, A; Nagata, S			A novel activation mechanism of caspase-activated DNase from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FRAGMENTATION FACTOR; CYSTEINE PROTEASE; CRYSTAL-STRUCTURE; C-ELEGANS; APOPTOSIS; INHIBITOR; ICAD; CARBOXYMETHYLATION; SUBUNIT	Caspase activated DNase (CAD) is an enzyme that cleaves chromosomal DNA in apoptotic cells. Here, we identified a DNase in Drosophila Schneider cells that can be activated by caspase 3, and purified it as a complex of two subunits (p32 and p20). Using primers based on the amino acid sequence of the purified proteins, a cDNA coding for Drosophila CAD (dCAD) was cloned. The polypeptide encoded by the cDNA contained 450 amino acids with a calculated M-r of 52,057, and showed significant homology with human and mouse CAD (22% identity). Mammalian CADs carry a nuclear localization signal at the C terminus. In contrast, dCAD lacked the corresponding sequence, and the purified dCAD did not cause DNA fragmentation in nuclei in a cell-free system. When dCAD was co-expressed in COS cells with Drosophila inhibitor of CAD (dICAD), a 52-kDa dCAD was produced as a heterotetrameric complex with dICAD. When the complex was treated with human caspase 3 or Drosophila caspase (drICE), the dICAD was cleaved, and released from dCAD. In addition, dCAD was also cleaved by these caspases, and behaved as a (p32)(2)(p20)(2) complex in gel filtration. When a Drosophila neuronal cell line was induced to apoptosis by treatment with a kinase inhibitor, both dCAD and dICAD were cleaved. These results indicated that unlike mammalian CAD, Drosophila CAD must be cleaved by caspases to be activated.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan; Kirin Brewery Co Ltd, Cent Lab Key Technol, Yokohama, Kanagawa 2360004, Japan	Osaka University; Japan Science & Technology Agency (JST); Kirin Brewery Company Limited	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka,B 3, Osaka 5650871, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; ITO K, 1994, ARCH BIOCHEM BIOPHYS, V313, P126, DOI 10.1006/abbi.1994.1368; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Murai K, 1998, P NATL ACAD SCI USA, V95, P3461, DOI 10.1073/pnas.95.7.3461; Nagano M, 1998, NEUROSCI RES, V31, P113, DOI 10.1016/S0168-0102(98)00030-3; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	44	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12978	12986		10.1074/jbc.275.17.12978	http://dx.doi.org/10.1074/jbc.275.17.12978			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777599	hybrid			2022-12-27	WOS:000086762300083
J	Fujimoto, H; Tadano-Aritomi, K; Tokumasu, A; Ito, K; Hikita, T; Suzuki, K; Ishizuka, I				Fujimoto, H; Tadano-Aritomi, K; Tokumasu, A; Ito, K; Hikita, T; Suzuki, K; Ishizuka, I			Requirement of seminolipid in spermatogenesis revealed by UDP-galactose : ceramide galactosyltransferase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION MASS-SPECTROMETRY; GERM-CELL; MOLECULAR-CLONING; MOUSE; GENE; GALACTOCEREBROSIDE; MEMBRANE; MEIOSIS; PROTEIN; SULFOGLYCOLIPIDS	Although seminolipid has long been suspected to play an essential role in spermatogenesis because of its uniquely abundant and temporally regulated expression in the spermatocytes, direct experimental evidence has been lacking. We have tested the hypothesis by examining the testis of the UDP-galactose:ceramide galactosyltransferase-deficient mouse, which is incapable of synthesizing seminolipid. Spermatogenesis in homozygous affected males is arrested at the late pachytene stage and the spermatogenic cells degenerate through the apoptotic process. This stage closely follows the phase of rapid seminolipid synthesis in the wild-type mouse. These observations not only provide the first experimental evidence that seminolipid is indeed essential for normal spermatogenesis but also support the broader concept that cell surface glycolipids are important in cellular differentiation and cell-to-cell interaction.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan; Univ N Carolina, Sch Med, Dept Neurol, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Ctr Neurosci, Chapel Hill, NC 27599 USA	Teikyo University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Fujimoto, H (corresponding author), Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD03110] Funding Source: Medline; NINDS NIH HHS [R01-NS24289] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Bosio A, 1998, J NEUROCHEM, V70, P308; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; de Rooij DG, 1999, BIOL REPROD, V61, P842, DOI 10.1095/biolreprod61.3.842; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Drabent B, 1996, HISTOCHEM CELL BIOL, V106, P247; Ezoe T, 2000, J NEUROSCI RES, V59, P170, DOI 10.1002/(SICI)1097-4547(20000115)59:2<170::AID-JNR3>3.0.CO;2-G; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HAKOMORI S, 2000, ENCYC LIFE SCI; HANDA S, 1974, J BIOCHEM-TOKYO, V75, P77, DOI 10.1093/oxfordjournals.jbchem.a130385; Hirahara Y, 2000, EUR J BIOCHEM, V267, P1909, DOI 10.1046/j.1432-1327.2000.01139.x; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; IIDA N, 1989, J BIOL CHEM, V264, P5974; ISHIZUKA I, 1973, J BIOCHEM-TOKYO, V73, P77; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; ISHIZUKA I, 1985, NEW COMPREHENSIVE BI, V10, P101; JEGOU B, 1993, INT REV CYTOL, V147, P25, DOI 10.1016/S0074-7696(08)60766-4; Klink A, 1997, MAMM GENOME, V8, P376, DOI 10.1007/s003359900638; KORNBLATT MJ, 1974, CAN J BIOCHEM CELL B, V52, P689, DOI 10.1139/o74-098; KURODA H, 1989, J CELL PHYSIOL, V139, P329, DOI 10.1002/jcp.1041390215; KUSHI Y, 1985, J BIOCHEM-TOKYO, V97, P419, DOI 10.1093/oxfordjournals.jbchem.a135076; LINGWOOD C, 1981, J CELL BIOL, V89, P621, DOI 10.1083/jcb.89.3.621; LINGWOOD CA, 1986, BIOCHEM CELL BIOL, V64, P984, DOI 10.1139/o86-131; LINGWOOD CA, 1985, J CELL SCI, V75, P329; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; Sweeney C, 1996, DEVELOPMENT, V122, P53; TADANOARITOMI K, 1995, CARBOHYD RES, V273, P41, DOI 10.1016/0008-6215(95)00106-4; TAKI T, 1995, ANAL BIOCHEM, V225, P24, DOI 10.1006/abio.1995.1102; Tsunekawa N, 1999, MOL REPROD DEV, V52, P383, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;383::AID-MRD7&gt;3.0.CO;2-Z; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; WATANABE D, 1994, J BIOL CHEM, V269, P7744	37	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22623	22626		10.1074/jbc.C000200200	http://dx.doi.org/10.1074/jbc.C000200200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801776	hybrid			2022-12-27	WOS:000088419400005
J	O'Shea, SM; Harrison, NL				O'Shea, SM; Harrison, NL			Arg-274 and Leu-277 of the gamma-aminobutyric acid type A receptor alpha(2) subunit define agonist efficacy and potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT GABA(A) RECEPTOR; CHANNEL-LINING RESIDUES; GLYCINE RECEPTORS; BENZODIAZEPINE PHARMACOLOGY; ACETYLCHOLINE-RECEPTORS; XENOPUS OOCYTES; BINDING-SITE; AMINO-ACIDS; IDENTIFICATION; HYPEREKPLEXIA	Alanine-scanning mutagenesis and the whole cell voltage clamp technique were used to investigate the function of the extracellular loop between the second and third transmembrane domains (TM2-TM3) of the gamma-aminobutyric acid type A receptor (GABA(A)-R). A conserved arginine residue in the TM2-TM3 loop of the GABA(A)-R alpha(2) subunit was mutated to alanine, and the mutant alpha(2)(R274A) was co-expressed with wild-type beta(1) and gamma(2S) subunits in human embryonic kidney (HEIK) 293 cells. The GABA EC50 was increased by about 27-fold in the mutant receptor relative to receptors containing a wildtype alpha(2) subunit. Similarly, the GABA EC50 at alpha(2) (L277A)-beta(1 gamma)Y(2S) and alpha(2) (K279A)beta(1)gamma(2S) GABA(A)-R combinations was increased by 51- and 4-fold, respectively. The alpha(2)(R274A) or a,(L277A) mutations also reduced the maximal response of piperidine-4-sulfonic acid relative to GABA by converting piperidine 4-sulfonic acid into a weak partial agonist at the GABA(A)-R. Based on these results, we propose that alpha(2)(Arg-274) and alpha(2)(Leu-277) are crucial to the efficient transduction of agonist binding into channel gating at the GABA(A)-R.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, CV Starr Lab Mol Neuropharmacol, New York, NY 10021 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Dept Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA	Cornell University; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Harrison, NL (corresponding author), Cornell Univ, Weill Med Coll, Dept Anesthesiol, CV Starr Lab Mol Neuropharmacol, 525 E 68th St, New York, NY 10021 USA.				NIDA NIH HHS [DA07255] Funding Source: Medline; NIGMS NIH HHS [GM45129, GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007255] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; DOWNIE DL, 1995, BRIT J PHARMACOL, V114, P1641, DOI 10.1111/j.1476-5381.1995.tb14952.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EBERT B, 1994, MOL PHARMACOL, V46, P957; HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970; Johnston GAR, 1996, PHARMACOL THERAPEUT, V69, P173, DOI 10.1016/0163-7258(95)02043-8; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; Krasowski MD, 1997, NEUROPHARMACOLOGY, V36, P941, DOI 10.1016/S0028-3908(97)00074-9; KROGSGAARDLARSEN P, 1981, J NEUROCHEM, V37, P401, DOI 10.1111/j.1471-4159.1981.tb00469.x; KROGSGAARDLARSEN P, 1980, J NEUROCHEM, V34, P756, DOI 10.1111/j.1471-4159.1980.tb11211.x; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LAUBE B, 1995, NEUROREPORT, V6, P897, DOI 10.1097/00001756-199504190-00018; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; O'Shea SM, 2000, BRAIN RES, V852, P344, DOI 10.1016/S0006-8993(99)02151-4; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RAJENDRA S, 1995, TRENDS NEUROSCI, V18, P80; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Tretter V, 1997, J NEUROSCI, V17, P2728; Vafa B, 1998, INT REV NEUROBIOL, V42, P285, DOI 10.1016/S0074-7742(08)60613-3; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhou M, 1999, P NATL ACAD SCI USA, V96, P10466, DOI 10.1073/pnas.96.18.10466	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22764	22768		10.1074/jbc.M001299200	http://dx.doi.org/10.1074/jbc.M001299200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801806	hybrid			2022-12-27	WOS:000088419400025
J	Santhamma, KR; Sen, I				Santhamma, KR; Sen, I			Specific cellular proteins associate with angiotensin-converting enzyme and regulate its intracellular transport and cleavage-secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; AMYLOID PRECURSOR PROTEIN; FACTOR-ALPHA PRECURSOR; BINDING-PROTEIN; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; DEFICIENT MICE; MESSENGER-RNAS; METALLOPROTEASE; TRANSCRIPTION	Angiotensin-converting enzyme (ACE) is an extensively glycosylated type I ectoprotein anchored in the plasma membrane by a hydrophobic transmembrane domain. In tissue culture as well as in vivo, the extracellular domain of ACE is released into the culture medium by a regulated proteolytic cleavage. To identify the cellular proteins that regulate ACE processing and cleavage-secretion, ACE-bound proteins were purified by affinity chromatography and characterized by microsequencing and Western blotting. One protein was identified as ribophorin and another as immunoglobulin-binding protein (BiP), a chaperone. Metabolic labeling and immunoprecipitation of ACE confirmed its interaction with BiP. Overexpression of BiP inhibited ACE secretion, an effect accentuated by the expression of an enzymatically inactive mutant BiP, This inhibition was caused by the retention of ACE precursors by BiP in the endoplasmic reticulum, as revealed by immunoprecipitation and immunofluorescence experiments. However, treatment with a phorbol ester, phorbol 12-myristate 13-acetate, enhanced ACE secretion even from cells overexpressing BiP. Western blot analysis of ACE-associated proteins with antibodies to protein kinase C (PRC) revealed the presence of its specific isozymes. Treatment with phorbol 12-myristate 13-acetate caused marked reduction in ACE association of selective PKC species. Thus, our studies have identified PKC and BiP as two proteins that directly interact with ACE and modulate its cell-surface expression and cleavage secretion.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, I (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL54297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELDENT V, 1993, J BIOL CHEM, V268, P26428; Ehlers M R, 1991, Protein Expr Purif, V2, P1, DOI 10.1016/1046-5928(91)90001-Y; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUBERT C, 1991, J BIOL CHEM, V266, P15377; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Ramchandran R, 1996, AM J PHYSIOL-HEART C, V271, pH744, DOI 10.1152/ajpheart.1996.271.2.H744; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WEI L, 1991, J BIOL CHEM, V266, P5540; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23253	23258		10.1074/jbc.M000593200	http://dx.doi.org/10.1074/jbc.M000593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10783385	hybrid			2022-12-27	WOS:000088419400090
J	Wagner, BA; Buettner, GR; Oberley, LW; Darby, CJ; Burns, CP				Wagner, BA; Buettner, GR; Oberley, LW; Darby, CJ; Burns, CP			Myeloperoxidase is involved in H2O2-induced apoptosis of HL-60 human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOPEROXIDASE-CATALYZED OXIDATION; ACUTE PROMYELOCYTIC LEUKEMIA; HYDROGEN-PEROXIDE; RADICAL GENERATION; IONIZING-RADIATION; PROTEIN-KINASE; INTACT-CELLS; NITRITE NO2; DNA DAMAGE; ACTIVATION	We examined the mechanism of H2O2-induced cytotoxicity and its relationship to oxidation in human leukemia cells. The HL-60 promyelocytic leukemia cell line was sensitive to H2O2, and at concentrations up to about 20-25 mu M, the killing was mediated by apoptosis, There was limited evidence of lipid peroxidation, suggesting that the effects of H2O2 do not involve hydroxyl radical. When HL-60 cells were exposed to H2O2 in the presence of the spin trap alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN), we detected a 12-line electron paramagnetic resonance spectrum assigned to the POBN/POBN. N-centered spin adduct previously described in peroxidase-containing cell-free systems. Generation of this radical by HL-60 cells had the same H2O2 concentration dependence as initiation of apoptosis, In contrast, studies with the K562 human erythroleukemia cell line, which is often used for comparison with the HL-60, and with high passaged HL-60 cells (spent HL-60) studied under the same conditions failed to generate POBN., Cellular levels of antioxidant enzymes superoxide dismutase, glutathione peroxidase, and catalase did not explain the differences between these cell lines. Interestingly, the K562 and spent HL-60 cells, which did not generate the radical, also failed to undergo H2O2-induced apoptosis, Based on this we reasoned that the difference in H2O2-induced apoptosis might be due to the enzyme myeloperoxidase. Only the apoptosis-manifesting HL-60 cells contained appreciable immunoreactive protein or enzymatic activity of this cellular enzyme. When HL-60 cells were incubated with methimazole or 4-aminobenzoic acid hydrazide, which are inhibitors of myeloperoxidase, they no longer underwent H2O2-induced apoptosis, Hypochlorous acid stimulated apoptosis in both HL-60 and spent HL-60 cells, indicating that another oxidant generated by myeloperoxidase induces apoptosis and that it may be the direct mediator of H2O2-induced apoptosis, Taken together these observations indicate that H2O2-induced apoptosis in the HL-60 human leukemia cell is mediated by myeloperoxidase and is linked to a non-Fenton oxidative event marked by POBN..	Univ Iowa, Coll Med, Free Radical & Radiat Biol Grad Program, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Free Radical & Radiat Biol Grad Program, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Ctr Canc, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Burns, CP (corresponding author), Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA.	c-burns@uiowa.edu		Buettner, Garry/0000-0002-5594-1903	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARRICK BA, 1985, J CLIN INVEST, V76, P567, DOI 10.1172/JCI112008; BANDYOPADHYAY U, 1993, BIOCHEM J, V296, P79, DOI 10.1042/bj2960079; Bertling CJ, 1996, PHOTOCHEM PHOTOBIOL, V64, P137, DOI 10.1111/j.1751-1097.1996.tb02433.x; BOREK C, 1986, P NATL ACAD SCI USA, V83, P1490, DOI 10.1073/pnas.83.5.1490; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BUETTNER GR, 1990, FREE RADICAL RES COM, V10, P5, DOI 10.3109/10715769009145927; BUETTNER GR, 1985, CANCER LETT, V25, P297, DOI 10.1016/S0304-3835(15)30009-4; CACERESDITTMAR G, 1995, PHOTOCHEM PHOTOBIOL, V62, P176, DOI 10.1111/j.1751-1097.1995.tb05255.x; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; CHRIST M, 1993, IMMUNOLOGY, V78, P455; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROUTE F, 1982, INT J RADIAT BIOL, V41, P209, DOI 10.1080/09553008214550221; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DiPietrantonio AM, 1999, BIOCHEM BIOPH RES CO, V255, P477, DOI 10.1006/bbrc.1999.0208; DOERGE DR, 1995, XENOBIOTICA, V25, P761, DOI 10.3109/00498259509061891; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Fabisiak JP, 1998, BIOCHEMISTRY-US, V37, P13781, DOI 10.1021/bi9808262; FARBER JL, 1990, LAB INVEST, V62, P670; GALLAGHER R, 1979, BLOOD, V54, P713; GALLIN EK, 1987, BLOOD, V70, P694; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Halliwell B., 1989, FREE RADICAL BIO MED, P86; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansson M, 1996, J IMMUNOL, V156, P42; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kakeya H, 1998, CANCER RES, V58, P4888; Kasai T, 1998, J IMMUNOL, V161, P6469; KOMIYAMA T, 1986, J PHARMACOBIO-DYNAM, V9, P651, DOI 10.1248/bpb1978.9.651; KOSTKA P, 1989, LIPIDS, V24, P545, DOI 10.1007/BF02535136; Kravtsov VD, 1998, BLOOD, V92, P968; KRINSKY NI, 1981, THROMB HAEMOSTASIS, V45, P116; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb NJ, 1999, CRIT CARE MED, V27, P1738, DOI 10.1097/00003246-199909000-00007; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; Lundqvist-Gustafsson H, 1999, J LEUKOCYTE BIOL, V65, P196, DOI 10.1002/jlb.65.2.196; Mansat V, 1997, CANCER RES, V57, P5300; MCCORMICK ML, 1995, J BIOL CHEM, V270, P29265, DOI 10.1074/jbc.270.49.29265; MELLO AC, 1984, BIOCHEM J, V218, P273, DOI 10.1042/bj2180273; MENEGHINI R, 1980, BIOCHIM BIOPHYS ACTA, V608, P167, DOI 10.1016/0005-2787(80)90144-6; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORIKAWA K, 1985, CANCER RES, V45, P3482; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; NORTH JA, 1992, J BIOL CHEM, V267, P5743; Otero G, 1997, CARCINOGENESIS, V18, P1569, DOI 10.1093/carcin/18.8.1569; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; PINCEMAIL J, 1988, EXPERIENTIA, V44, P450, DOI 10.1007/BF01940544; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; RESZKA K, 1988, PHOTOCHEM PHOTOBIOL, V47, P625, DOI 10.1111/j.1751-1097.1988.tb02758.x; Reszka KJ, 1997, CHEM RES TOXICOL, V10, P1325, DOI 10.1021/tx970039q; Reszka KJ, 1998, FREE RADICAL BIO MED, V25, P208, DOI 10.1016/S0891-5849(98)00058-6; Reszka KJ, 1999, FREE RADICAL BIO MED, V26, P669, DOI 10.1016/S0891-5849(98)00244-5; Robinson S, 1998, FEBS LETT, V430, P297, DOI 10.1016/S0014-5793(98)00679-6; SANGEETHA P, 1990, FREE RADICAL BIO MED, V8, P15, DOI 10.1016/0891-5849(90)90139-A; Saran M, 1997, INT J RADIAT BIOL, V72, P745, DOI 10.1080/095530097142906; Saran M, 1997, RADIAT RES, V147, P70, DOI 10.2307/3579445; SATO K, 1995, J INVEST DERMATOL, V105, P608, DOI 10.1111/1523-1747.ep12323724; SMITH ST, 1988, INT J RADIAT BIOL, V53, P829, DOI 10.1080/09553008814551161; SOHAL RS, 1993, BIOCHEM BIOPH RES CO, V196, P7, DOI 10.1006/bbrc.1993.2208; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; TAUROG A, 1989, ENDOCRINOLOGY, V124, P30, DOI 10.1210/endo-124-1-30; TUTTLE SW, 1994, INT J RADIAT ONCOL, V29, P357, DOI 10.1016/0360-3016(94)90289-5; WAGNER BA, 1993, CANCER RES, V53, P711; Wagner BA, 1998, CANCER RES, V58, P2809; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Witenberg B, 1999, BIOCHEM PHARMACOL, V57, P823, DOI 10.1016/S0006-2952(98)00351-7; Yamada K, 1997, ANTICANCER RES, V17, P2041; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	87	83	89	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22461	22469		10.1074/jbc.M001434200	http://dx.doi.org/10.1074/jbc.M001434200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801811	Green Submitted, hybrid			2022-12-27	WOS:000088363800095
J	Abe, Y; Matsumoto, S; Kito, K; Ueda, N				Abe, Y; Matsumoto, S; Kito, K; Ueda, N			Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; KILLING ACTIVITY; LAK CELLS; LYMPHOTOXIN; PROLIFERATION; INTERLEUKIN-2; COMPLEX; CASCADE; MEMBER; FAMILY	A novel protein kinase, TOPK (T-LAK cell-originated protein kinase), was isolated from a lymphokine-activated killer T (T-LAK) cell subtraction cDNA fragment library. The open reading frame of the TOPK gene encodes a protein of 322 amino acids, possessing a protein kinase domain profile. The cap site analysis of the 5'-end of TOPK mRNA revealed two forms, a major full-length form and a minor spliced form at the 5'-site, both encoding the same protein. A BLAST homology search and phylogenetic analysis indicated that TOPK is related to dual specific mitogen-activated protein kinase kinase (MAPKK). The transfection of the TOPK gene to COS-7 cells up-regulated a phosphorylation of p38 MAPK but not ERK1/2 or SAPK/JNK. Gel precipitation study indicated that TOPK protein can be associated with p38 in vitro. Tissue distribution of TOPK mRNA expression was specific for the testis, T-LAK cells, activated lymphoid cells, and lymphoid tumors. On the other hand, deactivated T-LAK, cells did not show TOPK mRNA expression. These data suggest that TOPK is a newly identified member of a novel MEK3/6-related MAPKK that may be enrolled in the activation of lymphoid cells and support testicular functions.	Ehime Univ, Sch Med, Dept Pathol 1, Shigenobu, Ehime 7910295, Japan	Ehime University	Abe, Y (corresponding author), Ehime Univ, Sch Med, Dept Pathol 1, Shigenobu, Ehime 7910295, Japan.	yasuhito@m.ehime-u.ac.jp						ABE Y, 1993, LYMPHOKINE CYTOK RES, V12, P279; ABE Y, 1991, JPN J CANCER RES, V82, P23, DOI 10.1111/j.1349-7006.1991.tb01740.x; ABE Y, 1992, LYMPHOKINE CYTOK RES, V11, P115; Becker W, 1996, BBA-MOL CELL RES, V1312, P63, DOI 10.1016/0167-4889(96)00036-5; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Butch ER, 1996, J BIOL CHEM, V271, P4230; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Craxton A, 1998, J IMMUNOL, V161, P3225; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; HORIUCHI A, 1994, CLIN EXP IMMUNOL, V96, P152; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448; Kueng P, 1997, J CELL BIOL, V139, P1851, DOI 10.1083/jcb.139.7.1851; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MIYAKE M, 1992, EUR J IMMUNOL, V22, P2147, DOI 10.1002/eji.1830220828; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Murga C, 1999, TRENDS ENDOCRIN MET, V10, P122, DOI 10.1016/S1043-2760(98)00131-3; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Schafer PH, 1999, J IMMUNOL, V162, P659; Schafer PH, 1999, J IMMUNOL, V162, P7110; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Spitzer JH, 1999, CELL IMMUNOL, V194, P205, DOI 10.1006/cimm.1999.1511; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Zhang J, 1999, J IMMUNOL, V162, P3819	31	165	185	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21525	21531		10.1074/jbc.M909629199	http://dx.doi.org/10.1074/jbc.M909629199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781613	hybrid			2022-12-27	WOS:000088230600076
J	Edelman, DB; Meech, R; Jones, FS				Edelman, DB; Meech, R; Jones, FS			The homeodomain protein Barx2 contains activator and repressor domains and interacts with members of the CREB family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; HOX HOMEOBOX GENES; TRANSCRIPTION FACTORS; EXPRESSION PATTERNS; CRYSTAL-STRUCTURE; DNA INTERACTIONS; HOMEOTIC GENES; NERVOUS-SYSTEM; BODY PLANS; BINDING	Barx1 and Barx2 are homeodomain proteins originally identified using regulatory elements of genes encoding certain cell adhesion molecules (CAMs). In the present study, we characterize regions of Barx2 that bind to regulatory elements of genes encoding three CAMs, L1, neuron-glia CAIM (Ng-CAM), and neural CAM (N-CAM), and identify domains of Barx2 that regulate N-CAM transcription. The homeodomain of Barx2 was sufficient for binding to homeodomain binding sites (HBS) from all three CAM genes. The presence of a 17-amino acid Barx basic region resulted in a 2-fold decrease in binding to HBS sequences from the Ng-CAM and L1 genes, whereas it led to a 6.5-fold increase in binding to the HBS from the N-CAM promoter. Thus, the Barx basic region influences the strength and specificity of Barx2 binding to DNA In co-transfection experiments, Barx2 repressed N-CAM promoter activity. A 24-residue N-terminal region of Barx2 was essential for repression. When this region was absent, Barx2 activated the N-CAM promoter. A 63-residue C-terminal domain was required for this activation, In GST pull-down experiments, Barx2 bound to proteins of the CREB family, CREB1 and ATF2. Overall, these findings provide a framework for understanding developmental and physiological contexts that influence repressor or activator functions of Barx2.	Scripps Res Inst, Dept Neurobiol SBR14, La Jolla, CA 92037 USA; Inst Neurosci, San Diego, CA 92121 USA	Scripps Research Institute	Jones, FS (corresponding author), Scripps Res Inst, Dept Neurobiol SBR14, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Meech, Robyn/0000-0002-6831-0801				AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; Castelli-Gair J, 1998, INT J DEV BIOL, V42, P437; Chan RL, 1998, BBA-GENE STRUCT EXPR, V1442, P1, DOI 10.1016/S0167-4781(98)00119-5; DEBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Edelman GM, 1998, BRAIN RES REV, V26, P337, DOI 10.1016/S0165-0173(97)00034-9; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; HOEY T, 1988, NATURE, V332, P428; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRUMLAUF R, 1993, J NEUROBIOL, V24, P1328, DOI 10.1002/neu.480241006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; Mitsiadis TA, 1998, EUR J ORAL SCI, V106, P112, DOI 10.1111/j.1600-0722.1998.tb02161.x; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Saito T, 1998, DEV BIOL, V199, P216, DOI 10.1006/dbio.1998.8889; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1983, CELL, V85, P428; Smith DM, 1999, MECH DEVELOP, V80, P203, DOI 10.1016/S0925-4773(98)00216-0; TISSIERSETA JP, 1995, MECH DEVELOP, V51, P3, DOI 10.1016/0925-4773(94)00343-L; Tucker AS, 1998, SCIENCE, V282, P1136, DOI 10.1126/science.282.5391.1136; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wang YB, 1996, P NATL ACAD SCI USA, V93, P1892, DOI 10.1073/pnas.93.5.1892; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLPERT L, 1994, DEV GENET, V15, P485, DOI 10.1002/dvg.1020150607; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; Yuan D, 1996, J BIOL CHEM, V271, P21660, DOI 10.1074/jbc.271.35.21660	47	25	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21737	21745		10.1074/jbc.M909998199	http://dx.doi.org/10.1074/jbc.M909998199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781615	hybrid			2022-12-27	WOS:000088230600102
J	Tarcsa, E; Szymanska, G; Lecker, S; O'Connor, CM; Goldberg, AL				Tarcsa, E; Szymanska, G; Lecker, S; O'Connor, CM; Goldberg, AL			Ca2+-free calmodulin and calmodulin damaged by in vitro aging are selectively degraded by 26 S proteasomes without ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ISOASPARTYL RESIDUES; END RULE PATHWAY; PROTEIN-DEGRADATION; VERTEBRATE CALMODULIN; IN-VITRO; CARBOXYL METHYLATION; ANTIGEN PRESENTATION; DEPENDENT PROTEASES; ABNORMAL PROTEINS; PROTEOLYSIS	The ubiquitin-proteasome pathway is believed to selectively degrade post-synthetically damaged proteins in eukaryotic cells. To study this process we used calmodulin (CaM) as a substrate because of its importance in cell regulation and because it acquires isoaspartyl residues in its Ca2+-binding regions both in vivo and after in vitro "aging" (incubation for 2 weeks without Ca2+). When microinjected into Xenopus oocytes, in vitro aged CaM was degraded much faster than native CaM by a proteasome-dependent process. Similarly, in HeLa cell extracts aged CaM was degraded at a higher rate, even though it was not conjugated to ubiquitin more rapidly than the native species. Ca2+ stimulated the ubiquitination of both species, but inhibited their degradation. Thus, for CaM, ubiquitination and proteolysis appear to be dissociated. Accordingly, purified muscle 26 S proteasomes could degrade aged CaM and native Ca2+-free (apo) CaM without ubiquitination. Addition of Ca2+ dramatically reduced degradation of the native molecules but only slightly reduced the breakdown of the aged species. Thus, upon Ca2+ binding, native CaM assumes a non-degradable conformation, which most of the age-damaged species cannot assume. Thus, flexible conformations, as may arise from age-induced damage or the absence of ligands, can promote degradation directly by the proteasome without ubiquitination.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA	Harvard University; Harvard Medical School; Boston College	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave,Bldg C1-415, Boston, MA 02115 USA.		O'Connor, Clare/A-1679-2010	O'Connor, Clare/0000-0002-7201-647X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008109] Funding Source: NIH RePORTER; NIA NIH HHS [AG08109] Funding Source: Medline; NIDDK NIH HHS [DK02707] Funding Source: Medline; NIGMS NIH HHS [GM46147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CHAFOULEAS JG, 1981, P NATL ACAD SCI-BIOL, V78, P996, DOI 10.1073/pnas.78.2.996; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DESROSIERS RR, 1990, J BIOL CHEM, V265, P21368; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; Ferrington DA, 1997, BIOCHEM BIOPH RES CO, V237, P163, DOI 10.1006/bbrc.1997.7105; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GREGORI L, 1987, J BIOL CHEM, V262, P2562; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Laub M, 1997, BBA-MOL CELL RES, V1357, P173, DOI 10.1016/S0167-4889(97)00017-7; Laub M, 1998, EUR J BIOCHEM, V255, P422, DOI 10.1046/j.1432-1327.1998.2550422.x; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; OCONNOR CM, 1984, P NATL ACAD SCI-BIOL, V81, P7757, DOI 10.1073/pnas.81.24.7757; OTA IM, 1990, ARCH BIOCHEM BIOPHYS, V279, P320, DOI 10.1016/0003-9861(90)90498-N; OTA IM, 1989, J BIOL CHEM, V264, P54; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; Sambrook J., 2002, MOL CLONING LAB MANU; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Szymanska G, 1998, J BIOL CHEM, V273, P28516, DOI 10.1074/jbc.273.43.28516; Szymanska G, 1997, ANAL BIOCHEM, V252, P96, DOI 10.1006/abio.1997.2319; TANAKA K, 1983, J CELL BIOL, V96, P1580, DOI 10.1083/jcb.96.6.1580; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; ZIEGENHAGEN R, 1988, BIOL CHEM H-S, V369, P1317, DOI 10.1515/bchm3.1988.369.2.1317	50	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20295	20301		10.1074/jbc.M001555200	http://dx.doi.org/10.1074/jbc.M001555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10791958	hybrid			2022-12-27	WOS:000088084500013
J	Cuajungco, MP; Goldstein, LE; Nunomura, A; Smith, MA; Lim, JT; Atwood, CS; Huang, XD; Farrag, YW; Perry, G; Bush, AI				Cuajungco, MP; Goldstein, LE; Nunomura, A; Smith, MA; Lim, JT; Atwood, CS; Huang, XD; Farrag, YW; Perry, G; Bush, AI			Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of A beta by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENILE PLAQUES; PROTEIN; AGGREGATION; DEPOSITION; ISOFORMS; PEPTIDE; NEURONS; DAMAGE; CORTEX; MICE	A beta binds Zn2+, Cu2+ and Fe3+ in vitro, and these metals are markedly elevated in the neocortex and especially enriched in amyloid plaque deposits of individuals with Alzheimer's disease (AD). Zn2+ precipitates A beta in vitro, and Cu2+ interaction with A beta promotes its neurotoxicity, correlating with metal reduction and the cell-free generation of H2O2 (A beta 1-42 > A beta 1-40 > ratA beta 1-40). Because Zn2+ is redox-inert, we studied the possibility that it may play an inhibitory role in H2O2-mediated A beta toxicity. In competition to the cytotoxic potentiation caused by coincubation with Cu2+, Zn2+ rescued primary cortical and human embryonic kidney 293 cells that were exposed to A beta 1-42, correlating with the effect of Zn2+ in suppressing Cu2+-dependent H2O2 formation from A beta 1-42. Since plaques contain exceptionally high concentrations of Zn2+, we examined the relationship between oxidation (8-OH guanosine) levels in AD-affected tissue and histological amyloid burden and found a significant negative correlation. These data suggest a protective role for Zn2+ in AD, where plaques form as the result of a more robust Zn2+ antioxidant response to the underlying oxidative attack.	Massachusetts Gen Hosp, Lab Oxidat Biol, Genet Aging Unit, Charlestown, MA 02129 USA; Univ Auckland, Sch Med, Dept Psychiat & Behav Sci, Auckland, New Zealand; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Asahikawa Med Coll, Dept Psychiat & Neurol, Asahikawa, Hokkaido 0788510, Japan	Harvard University; Massachusetts General Hospital; University of Auckland; Case Western Reserve University; Asahikawa Medical College	Bush, AI (corresponding author), Massachusetts Gen Hosp, Lab Oxidat Biol, Genet Aging Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	, Craig/AAB-3963-2022; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Cuajungco, Math/B-2647-2008; Perry, George/A-8611-2009; Smith, Mark A/A-9053-2009	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Cuajungco, Math/0000-0003-0749-9564; Perry, George/0000-0002-6547-0172; Goldstein, Lee/0000-0001-8419-9800	NIA NIH HHS [R01-AG09287, R29 AG-12686] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012686, R01AG009287] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; ATWOOD CS, 2000, IN PRESS J NEUROCHEM; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CAMPBELL EB, 1991, ANAL BIOCHEM, V194, P268, DOI 10.1016/0003-2697(91)90229-M; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Du YS, 1997, J NEUROCHEM, V69, P299; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moir RD, 1999, BIOCHEMISTRY-US, V38, P4595, DOI 10.1021/bi982437d; Nunomura A, 1999, J NEUROSCI, V19, P1959; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Smith MA, 1997, J NEUROSCI, V17, P2653; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009	30	350	369	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19439	19442		10.1074/jbc.C000165200	http://dx.doi.org/10.1074/jbc.C000165200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10801774	hybrid			2022-12-27	WOS:000087941300002
J	Bock, BC; Vacratsis, PO; Qamirani, E; Gallo, KA				Bock, BC; Vacratsis, PO; Qamirani, E; Gallo, KA			Cdc42-induced activation of the mixed-lineage kinase SPRK in vivo - Requirement of the Cdc42/Rac interactive binding motif and changes in phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; PROTEIN-KINASE; RAS TRANSFORMATION; RHO-GTPASES; RAPID PHOSPHORYLATION; P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; RAT-1 FIBROBLASTS; FOCAL COMPLEXES; ALPHA-PAK	Src homology 3 domain (SH3)-containing proline-rich protein kinase (SPRK)/mixed-lineage kinase (MLK)-3 is a serine/threonine kinase that upon overexpression in mammalian cells activates the c-Jun NH2-terminal kinase pathway. The mechanisms by which SPRK activity is regulated are not well understood. The small Rho family GTPases, Rac and Cdc42, have been shown to bind and modulate the activities of signaling proteins, including SPRK, which contain Cdc42/Rac interactive binding motifs. Coexpression of SPRK and activated Cdc42 increases SPRKs activity. SPRKs Cdc42/Rac interactive binding-like motif contains six of the eight consensus residues. Using a site-directed mutagenesis approach, we show that SPRK contains a functional Cdc42/Rac interactive binding motif that is required for SPRKs association with and activation by Cdc42. However, experiments using a SPRK variant that lacks the COOH-terminal zipper region/basic stretch suggest that this region may also contribute to Cdc42 binding. Unlike the PAK family of protein kinases, we find that the activation of SPRK by Cdc42 cannot be recapitulated in an in vitro system using purified, recombinant proteins. Comparative phosphopeptide mapping demonstrates that coexpression of activated Cdc42 with SPRK alters the in vivo serine/threonine phosphorylation pattern of SPRK suggesting that the mechanism by which Cdc42 increases SPRKs catalytic activity involves a change in the in vivo phosphorylation of SPRK. This is, to the best of our knowledge, the first demonstrated example of a Cdc42-mediated change in the in vivo phosphorylation of a protein kinase. These studies suggest an additional component or cellular environment is required for SPRK activation by Cdc42.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 108 Giltner Hall, E Lansing, MI 48824 USA.	gallo@psl.msu.edu			NATIONAL CANCER INSTITUTE [R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA76306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BACKLUND PS, 1993, BIOCHEM BIOPH RES CO, V196, P534, DOI 10.1006/bbrc.1993.2283; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; EZOE K, 1994, ONCOGENE, V9, P935; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; GORMAN C, 1990, DNA CLONING PRACTICA, P143; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART MJ, 1990, J BIOL CHEM, V265, P5990; Hartkamp J, 1999, CANCER RES, V59, P2195; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; ING YL, 1994, ONCOGENE, V9, P1745; KANAKURA Y, 1991, BLOOD, V77, P243; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAMAKI T, 1992, CANCER RES, V52, P566; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	66	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14231	14241		10.1074/jbc.275.19.14231	http://dx.doi.org/10.1074/jbc.275.19.14231			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799501	Green Submitted, hybrid			2022-12-27	WOS:000087006900032
J	Dam, TK; Roy, R; Das, SK; Oscarson, S; Brewer, CF				Dam, TK; Roy, R; Das, SK; Oscarson, S; Brewer, CF			Binding of multivalent carbohydrates to concanavalin A and Dioclea grandiflora lectin - Thermodynamic analysis of the "multivalency effect"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE TRIMANNOSIDE; TITRATION MICROCALORIMETRY; OLIGOSACCHARIDES; RECOGNITION; SPECIFICITIES; DERIVATIVES; COMPLEXES; PROTEINS; FEATURES	Binding of a series of synthetic multivalent carbohydrate analogs to the Man/Glc-specific lectins concanavalin A and Dioclea grandiflora lectin was investigated by isothermal titration microcalorimetry. Dimeric analogs possessing terminal alpha-D-mannopyranoside residues, and di-, tri-, and tetrameric analogs possessing terminal 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside residues, which is the core trimannoside of asparagine-linked carbohydrates, were selected in order to compare the effects of low and high affinity analogs, respectively. Experimental conditions were found that prevented precipitation of the carbohydrate-lectin cross-linked complexes during the isothermal titration microcalorimetry experiments. The results show that the value of n, the number of binding sites on each monomer of the lectins, is inversely proportional to the number of binding epitopes (valency) of each carbohydrate. Hence, n values close to 1.0, 0.50, and 0.25 were observed for the binding of mono-, di-, and tetravalent sugars, respectively, to the two lectins, Importantly, differences in the functional valency of a triantennary analog for concanavalin A and D. grandiflora lectin are observed. The enthalpy of binding, Delta H, is observed to be directly proportional to the number of binding epitopes in the higher affinity analogs. For example, Delta H of a tetravalent trimannoside analog is nearly four times greater than that of the corresponding monovalent analog. Increases in K-a values of the multivalent carbohydrates relative to monovalent analogs, known as the "multivalency effect," are shown to be due to more positive entropy (T Delta S) contributions to binding of the former sugars, A general thermodynamic model for distinguishing binding of multivalent ligands to a single receptor with multiple, equal subsites versus binding to separate receptor molecules is given.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Stockholm Univ, Dept Organ Chem, S-10691 Stockholm, Sweden; Univ Ottawa, Dept Chem, Ottawa, ON K1N 6N5, Canada	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stockholm University; University of Ottawa	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Oscarson, Stefan/0000-0002-8273-4918	NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016054, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BREWER CF, 1996, CHEMTRACTS BIOCH MOL, V6, P165; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; Chervenak MC, 1996, BIOORGAN MED CHEM, V4, P1963, DOI 10.1016/S0968-0896(96)00178-2; Dam TK, 1998, J BIOL CHEM, V273, P32826, DOI 10.1074/jbc.273.49.32826; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; DRICKAMER K, 1995, NAT STRUCT BIOL, V2, P437, DOI 10.1038/nsb0695-437; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; GUNTHER GR, 1973, P NATL ACAD SCI USA, V70, P1012, DOI 10.1073/pnas.70.4.1012; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; HUET M, 1975, EUR J BIOCHEM, V59, P627, DOI 10.1111/j.1432-1033.1975.tb02491.x; Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEE YC, 1983, J BIOL CHEM, V258, P199; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MCKENZIE GH, 1972, BIOCHIM BIOPHYS ACTA, V263, P283, DOI 10.1016/0005-2795(72)90081-5; MOREIRA RA, 1983, PLANTA, V158, P63, DOI 10.1007/BF00395404; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Olsen LR, 1997, BIOCHEMISTRY-US, V36, P15073, DOI 10.1021/bi971828+; Page D, 1997, GLYCOCONJUGATE J, V14, P345, DOI 10.1023/A:1018522712250; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; Rao JH, 1998, SCIENCE, V280, P708, DOI 10.1126/science.280.5364.708; Roy R, 1998, GLYCOCONJUGATE J, V15, P251, DOI 10.1023/A:1006945028547; Roy R, 1996, CURR OPIN STRUC BIOL, V6, P692, DOI 10.1016/S0959-440X(96)80037-6; Roy R, 1999, PURE APPL CHEM, V71, P565, DOI 10.1351/pac199971040565; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SAHA SK, 1994, CARBOHYD RES, V254, P157; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Weatherman RV, 1996, BIOCHEMISTRY-US, V35, P3619, DOI 10.1021/bi951916z; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WITCZAK ZJ, 1997, CARBOHYDRATES DRUG D, P1; Wong CH, 1999, ACCOUNTS CHEM RES, V32, P376, DOI 10.1021/ar960237t; Zanini D, 1997, BIOCONJUGATE CHEM, V8, P187, DOI 10.1021/bc970005u	38	197	204	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14223	14230		10.1074/jbc.275.19.14223	http://dx.doi.org/10.1074/jbc.275.19.14223			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799500	hybrid, Green Submitted			2022-12-27	WOS:000087006900031
J	Doedens, JR; Black, RA				Doedens, JR; Black, RA			Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; L-SELECTIN; TNF RECEPTOR; GROWTH-FACTOR; METALLOPROTEASE-DISINTEGRIN; STRUCTURAL REQUIREMENTS; SECRETASE CLEAVAGE; BINDING-PROTEIN; T-LYMPHOCYTES; IL-6 RECEPTOR	The extracellular domains of many proteins, including growth factors, cytokines, receptors, and adhesion molecules, are proteolytically released from cells, a process termed "shedding." Tumor necrosis factor-alpha converting enzyme (TACE/ADAM-17) is a metalloprotease-disintegrin that sheds tumor necrosis factor-alpha and other proteins. To study the regulation of TACE-mediated shedding, we examined the effects of stimulation of cells on TACE localization and expression. Immunofluorescence microscopy revealed a punctate distribution of TACE on the surface of untreated cells, and stimulation of monocytic cells with lipopolysaccharide did not affect TACE staining. Phorbol 12-myristate 13-acetate (PMA), a potent inducer of shedding, decreased cell-surface staining for TACE. Surface biotinylation experiments confirmed and extended this observation; PMA decreased the half-life of surface-biotinylated TACE without increasing the turnover of total cell-surface proteins. Soluble fragments of TACE were not detected in the medium of cells that had down-regulated TACE, and TACE was not down-regulated when endocytosis was inhibited. Antibody uptake experiments suggested that cell-surface TACE was internalized in response to PMA. Surprisingly, a metalloprotease inhibitor prevented the PMA-induced turnover of TACE. Thus, PIMA activates shedding and causes the down-regulation of a major "sheddase," suggesting that induced shedding may be regulated by a mechanism that decreases the amount of active TACE on the cell surface.	Immunex Corp, Dept Res Adm, Seattle, WA 98101 USA	Immunex Corporation	Doedens, JR (corresponding author), Immunex Corp, Dept Res Adm, 51 Univ St, Seattle, WA 98101 USA.							Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Buccione R, 1996, J BIOL CHEM, V271, P3523; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	49	151	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14598	14607		10.1074/jbc.275.19.14598	http://dx.doi.org/10.1074/jbc.275.19.14598			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799546	hybrid			2022-12-27	WOS:000087006900080
J	Elefant, F; Cooke, NE; Liebhaber, SK				Elefant, F; Cooke, NE; Liebhaber, SK			Targeted recruitment of histone acetyltransferase activity to a locus control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; CREB-BINDING-PROTEIN; HYPERSENSITIVE SITE-I; TRANSCRIPTIONAL REPRESSION; TRANSGENIC MICE; CHROMATIN STRUCTURE; PHYSICAL LINKAGE; NUCLEOSOME CORE; YEAST GCN5P; ACETYLATION	Locus control regions (LCRs) are capable of activating target genes over substantial distances and establishing autonomously regulated chromatin domains. The basis for this action is poorly defined. Human growth hormone gene (hGH-N) expression is activated by an LCR marked by a series of DNase I-hypersensitive sites (HSI-III and HSV) in pituitary chromatin, These HSs are located between -15 and -32 kilobases (kb) relative to the hGH transcription start site. To establish a mechanistic basis for hGH LCR function, we carried out acetylation mapping of core histones H3 and H4 in chromatin encompassing the hGH cluster. These studies revealed that the entire LCR was selectively enriched for acetylation in chromatin isolated from a human pituitary somatotrope adenoma and in pituitaries of mice transgenic for the hGH locus, but not in hepatic or erythroid cells. Quantification of histone modification in the pituitary revealed a dramatic peak at HSI/II, the major pituitary-specific hGH LCR determinant (-15 kb), with gradually decreasing levels of modification extending from this site in both 5'- and 3'-directions. The 5'-border of the acetylated domain coincided with the 5' most hGH LCR element, HSV (-34 kb); and the 3'-border included the expressed hGH-N gene, but did not extend farther 3' into the placenta-specific region of the gene cluster. These data support a model of LCR function involving targeted recruitment and subsequent spreading of histone acetyltransferase activity to encompass and activate a remote target gene.	Univ Penn, Sch Med, Dept Genet & Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Liebhaber, SK (corresponding author), Univ Penn, Sch Med, Dept Genet & Med, Rm 428,Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	liebhaber@mail.med.upenn.edu			NICHD NIH HHS [HD25147] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bennani-Baiti IM, 1998, GENOMICS, V48, P258, DOI 10.1006/geno.1997.5171; Bennani-Baiti IM, 1998, P NATL ACAD SCI USA, V95, P10655, DOI 10.1073/pnas.95.18.10655; BENNANIBAITI IM, 1995, GENOMICS, V29, P647, DOI 10.1006/geno.1995.9954; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; CraneRobinson C, 1997, METHODS, V12, P48, DOI 10.1006/meth.1997.0446; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GINDER G, 1989, METHODS HEMATOL, V20, P111; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hampsey M, 1997, TRENDS GENET, V13, P427, DOI 10.1016/S0168-9525(97)01292-4; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1233, DOI 10.1210/me.11.9.1233; JONES BK, 1995, MOL CELL BIOL, V15, P7010; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCWILLIAMS D, 1980, ENDOCRINOLOGY, V107, P761, DOI 10.1210/endo-107-3-761; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NACHTIGAL MW, 1993, J BIOL CHEM, V268, P8473; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; ONeill LP, 1996, METHOD ENZYMOL, V274, P189; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rhodes D, 1997, NATURE, V389, P231, DOI 10.1038/38386; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Shewchuk BM, 1999, J BIOL CHEM, V274, P35725, DOI 10.1074/jbc.274.50.35725; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Su YH, 2000, J BIOL CHEM, V275, P7902, DOI 10.1074/jbc.275.11.7902; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	66	71	73	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13827	13834		10.1074/jbc.275.18.13827	http://dx.doi.org/10.1074/jbc.275.18.13827			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788505	hybrid			2022-12-27	WOS:000086925300092
J	Gonzalez-Blasco, G; Sanz-Aparicio, J; Gonzalez, B; Hermoso, JA; Polaina, J				Gonzalez-Blasco, G; Sanz-Aparicio, J; Gonzalez, B; Hermoso, JA; Polaina, J			Directed evolution of beta-glucosidase A from Paenibacillus polymyxa to thermal resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GLUTAMATE-DEHYDROGENASE; GLYCOSYL HYDROLASES; THERMOTOGA-MARITIMA; BACILLUS-POLYMYXA; RANDOM MUTAGENESIS; HIGH-TEMPERATURES; ENZYME STABILITY; KEY ROLE	The beta-glucosidase encoded by the bglA gene from Paenibacillus polymyxa has a half-life time of 15 min at 35 degrees C and no detectable activity at 55 degrees C, We have isolated random mutations that enhance the thermoresistance of the enzyme. Following a directed evolution strategy, we have combined some of the isolated mutations to obtain a beta-glucosidase with a half-life of 12 min at 65 degrees C, in the range of resistance of thermophilic enzymes. No significant alteration of the kinetic parameters of the enzyme was observed. One of the mutants isolated in the screening for thermoresistant beta-glucosidase had the same resistance to denaturation as the wild type. This mutation caused the accumulation of enzyme in E. coli, probably due to its lower turnover. The structural changes responsible for the properties of the mutant enzymes have been analyzed. The putative causes increasing thermoresistance are as follows: the formation of an extra salt bridge, the replacement of an Asn residue exposed to the solvent, stabilization of the hydrophobic core, and stabilization of the quaternary structure of the protein.	CSIC, Inst Agroquim & Tecnol Alimentos, E-46980 Valencia, Spain; CSIC, Inst Quim Fis Rocasolano, CMBE, Dept Cristalog, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Polaina, J (corresponding author), CSIC, Inst Agroquim & Tecnol Alimentos, Apartado Correos 73, E-46100 Valencia, Spain.		Hermoso, Juan/J-3433-2012; Gonzalez, Beatriz/M-1219-2014; Polaina, Julio/H-4498-2012; Sanz-Aparicio, Julia/F-6201-2013	Hermoso, Juan/0000-0002-1862-8950; Gonzalez, Beatriz/0000-0002-0710-0202; Sanz-Aparicio, Julia/0000-0002-6849-8621; Polaina, Julio/0000-0001-9912-0640				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Burlacu-Miron S, 1998, J BIOL CHEM, V273, P19102, DOI 10.1074/jbc.273.30.19102; Daniel RM, 1996, BIOCHEM J, V317, P1, DOI 10.1042/bj3170001; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawamura S, 1998, J BIOL CHEM, V273, P19982, DOI 10.1074/jbc.273.32.19982; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; Lebbink JHG, 1998, J MOL BIOL, V280, P287, DOI 10.1006/jmbi.1998.1870; LIAO XB, 1990, GENE, V88, P107, DOI 10.1016/0378-1119(90)90066-Z; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; LOPEZCAMACHO C, 1993, MUTAT RES, V301, P73, DOI 10.1016/0165-7992(93)90027-S; LopezCamacho C, 1996, BIOCHEM J, V314, P833, DOI 10.1042/bj3140833; MacedoRibeiro S, 1996, STRUCTURE, V4, P1291, DOI 10.1016/S0969-2126(96)00137-2; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Querol E, 1996, PROTEIN ENG, V9, P265, DOI 10.1093/protein/9.3.265; Salminen T, 1996, PROTEIN SCI, V5, P1014; Sanz-Aparicio J, 1998, PROTEINS, V33, P567, DOI 10.1002/(SICI)1097-0134(19981201)33:4<567::AID-PROT9>3.0.CO;2-U; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Vieille C, 1996, TRENDS BIOTECHNOL, V14, P183, DOI 10.1016/0167-7799(96)10026-3; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; Zhang XJ, 1995, PROTEIN ENG, V8, P1017, DOI 10.1093/protein/8.10.1017	35	64	68	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13708	13712		10.1074/jbc.275.18.13708	http://dx.doi.org/10.1074/jbc.275.18.13708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788490	hybrid			2022-12-27	WOS:000086925300077
J	Ichikawa, H; Kroos, L				Ichikawa, H; Kroos, L			Combined action of two transcription factors regulates genes encoding spore coat proteins of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL SIGMA-FACTOR; RNA-POLYMERASE; REPRESSES TRANSCRIPTION; MYXOCOCCUS-XANTHUS; SPORULATION GENE; SPATIAL CONTROL; SWITCH PROTEIN; PROMOTER; EXPRESSION; REGION	During sporulation of Bacillus subtilis, spore coat proteins encoded by cot genes are expressed in the mother cell and deposited on the forespore, Transcription of the cotB, cotC, and cotX genes by sigma(K) RNA polymerase is activated by a small, DNA-binding protein called GerE, The promoter region of each of these genes has two GerE binding sites. 5' deletions that eliminated the more upstream GerE site decreased expression of lacZ fused to cotB and cotX by approximately 80% and 60%, respectively but had no effect on cotC-lacZ expression. The cotC-lacZ fusion was expressed later during sporulation than the other two fusions, Primer extension analysis confirmed that cotB mRNA increases first during sporulation, followed by cotX and cotC mRNAs over a 2-h period. In vitro transcription experiments suggest that the differential pattern of cot gene expression results from the combined action of GerE and another transcription factor, SpoIIID. A low concentration of GerE activated cotB transcription by sigma(K) RNA polymerase, whereas a higher concentration was needed to activate transcription of cotX or cotC, SpoIIID at low concentration repressed cotC transcription, whereas a higher concentration only partially repressed cotX transcription and had little effect on cotB transcription. DNase I foot-printing showed that SpoIIID binds strongly to two sites in the cotC promoter region, binds weakly to one site in the cotX promoter, and does not bind specifically to cotB, We propose that late in sporulation the rising level of GerE and the falling level of SpoIIID, together with the position and affinity of binding sites for these transcription factors in cot gene promoters, dictates the timing and level of spore coat protein synthesis, ensuring optimal assembly of the protein shell on the forespore surface.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Kroos, L (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.				NIGMS NIH HHS [GM43585] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043585, R01GM043585] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brandner JP, 1998, J BACTERIOL, V180, P1995, DOI 10.1128/JB.180.8.1995-2004.1998; CARTER HL, 1986, P NATL ACAD SCI USA, V83, P9438, DOI 10.1073/pnas.83.24.9438; CUTTING S, 1989, J MOL BIOL, V207, P393, DOI 10.1016/0022-2836(89)90262-3; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; Fisseha M, 1996, J BACTERIOL, V178, P2539, DOI 10.1128/jb.178.9.2539-2550.1996; HALBERG R, 1994, J MOL BIOL, V243, P425, DOI 10.1006/jmbi.1994.1670; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; HALBERG R, 1995, J BACTERIOL, V177, P1888, DOI 10.1128/jb.177.7.1888-1891.1995; Harwood C.R., 1990, MOL BIOL METHODS BAC; Ichikawa H, 1999, J BIOL CHEM, V274, P8322, DOI 10.1074/jbc.274.12.8322; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; JONES CH, 1992, J BACTERIOL, V174, P6815, DOI 10.1128/JB.174.21.6815-6821.1992; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; KENNEY TJ, 1991, J BACTERIOL, V173, P3282, DOI 10.1128/jb.173.11.3282-3290.1991; Kroos L, 1999, MOL MICROBIOL, V31, P1285, DOI 10.1046/j.1365-2958.1999.01214.x; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUNKEL B, 1988, J BACTERIOL, V170, P3513, DOI 10.1128/jb.170.8.3513-3522.1988; KUNKEL B, 1989, GENE DEV, V3, P1735, DOI 10.1101/gad.3.11.1735; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Miller J. H, 1972, EXPT MOL GENETICS; OKE V, 1993, J BACTERIOL, V175, P7341, DOI 10.1128/JB.175.22.7341-7347.1993; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; ROELS S, 1992, J BACTERIOL, V174, P575, DOI 10.1128/jb.174.2.575-585.1992; STEVENS CM, 1990, MOL MICROBIOL, V4, P543, DOI 10.1111/j.1365-2958.1990.tb00622.x; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; Wade KH, 1999, J BACTERIOL, V181, P4365, DOI 10.1128/JB.181.14.4365-4373.1999; Zhang B, 1997, J BACTERIOL, V179, P972, DOI 10.1128/jb.179.3.972-975.1997; Zhang B, 1999, J BACTERIOL, V181, P4081, DOI 10.1128/JB.181.13.4081-4088.1999; Zhang B, 1997, J BACTERIOL, V179, P6138, DOI 10.1128/jb.179.19.6138-6144.1997; ZHANG J, 1993, J BACTERIOL, V175, P3757, DOI 10.1128/JB.175.12.3757-3766.1993; ZHANG JK, 1994, J MOL BIOL, V240, P405, DOI 10.1006/jmbi.1994.1456; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P; ZHOU YH, 1994, J MOL BIOL, V243, P603, DOI 10.1016/0022-2836(94)90035-3; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	39	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13849	13855		10.1074/jbc.275.18.13849	http://dx.doi.org/10.1074/jbc.275.18.13849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788508	hybrid			2022-12-27	WOS:000086925300095
J	Kang, YJ; Zhou, ZX; Wang, GW; Buridi, A; Klein, JB				Kang, YJ; Zhou, ZX; Wang, GW; Buridi, A; Klein, JB			Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEONATAL MOUSE CARDIOMYOCYTES; LIPID-PEROXIDATION; MAP KINASE; ANTHRACYCLINE CARDIOTOXICITY; RADICAL FORMATION; ADRIAMYCIN; HEART; STRESS; RATS; PREVENTION	Cardiomyopathy induced by doxorubicin (DOX) has long been a major impediment of clinical applications of this effective anticancer agent. Previous studies have shown that cardiac-specific metallothionein (MT)-overexpressing transgenic mice are highly resistant to DOX-induced cardiotoxicity. To investigate cellular and molecular mechanisms by which MT participates in this cytoprotection, transgenic mice containing high levels of cardiac MT and non-transgenic controls were treated intraperitoneally with DOX at a single dose of 15 mg/kg and sacrificed on the 4th day after treatment. Myocardial apoptosis was detected by a terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay and confirmed by electron microscopy of immunogold staining of apoptotic nuclei. Dual staining of cardiac ly-sarcomeric actin using an immunohistochemical method further identified apoptotic myocytes. Apoptosis was significantly inhibited in the transgenic myocardium. The anti-apoptotic effect of MT was further revealed in primary cultures of neonatal mouse cardiomyocytes. Furthermore, DOX activated p38 mitogen-activated protein kinase (MAPK), which was critically involved in the apoptotic process, as demonstrated by inhibition of DOX-induced apoptosis by a p38-specific inhibitor, SB203580. Both DOX-induced p38 MAPK activation and apoptosis were dramatically inhibited in the transgenic cardiomyocytes. The results thus demonstrate that DOX induces apoptosis in cardiomyocytes both in vivo and in vitro and MT suppresses this effect through at least in part inhibition of p38 MAPK activation.	Univ Louisville, Dept Med, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; Jewish Hosp, Heart & Lung Inst, Louisville, KY 40292 USA; Vet Affairs Med Ctr, Louisville, KY 40292 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kang, YJ (corresponding author), Univ Louisville, Sch Med, Dept Med, 511 S Floyd St,MDR 530, Louisville, KY 40202 USA.	yjkang01@athena.louisville.edu	Klein, Jon/B-9833-2013		NATIONAL CANCER INSTITUTE [R29CA068125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059225] Funding Source: NIH RePORTER; NCI NIH HHS [CA68125] Funding Source: Medline; NHLBI NIH HHS [HL59225] Funding Source: Medline; NIAAA NIH HHS [R21 AA013601] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Azmi S, 1997, CANCER LETT, V111, P225, DOI 10.1016/S0304-3835(96)04539-9; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BASSER RL, 1993, CANCER TREAT REV, V19, P57, DOI 10.1016/0305-7372(93)90027-O; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Cece R, 1996, LAB INVEST, V75, P601; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; EATON DL, 1991, METHOD ENZYMOL, V205, P83; EGORIN MJ, 1974, CANCER RES, V34, P2243; FERRANS VJ, 1978, CANCER TREAT REP, V62, P955; GIANNI L, 1985, J BIOL CHEM, V260, P6820; GUTTERIDGE JMC, 1984, BIOCHEM PHARMACOL, V33, P1725, DOI 10.1016/0006-2952(84)90340-X; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HASINOFF BB, 1989, AGENTS ACTIONS, V26, P378, DOI 10.1007/BF01967305; Imondi AR, 1996, CANCER RES, V56, P4200; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kang Y. J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P192; Kang YJ, 1999, AM J PHYSIOL-HEART C, V276, pH993, DOI 10.1152/ajpheart.1999.276.3.H993; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE HJ, 1995, INT J PHARM, V121, P1, DOI 10.1016/0378-5173(94)00414-Z; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Miura T, 1997, LIFE SCI, V60, pPL301; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NAGANUMA A, 1988, JPN J CANCER RES, V79, P406, DOI 10.1111/j.1349-7006.1988.tb01605.x; NAMIKAWA K, 1993, YAKUGAKU ZASSHI, V113, P591, DOI 10.1248/yakushi1947.113.8_591; Rane MJ, 1997, J IMMUNOL, V159, P5070; SATO M, 1992, RES COMMUN CHEM PATH, V75, P159; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SATOH M, 1988, CANCER CHEMOTH PHARM, V21, P176; SATOH M, 1988, TOXICOLOGY, V53, P231; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Wang GW, 1999, J PHARMACOL EXP THER, V288, P938; Wang GW, 1999, AM J PHYSIOL-HEART C, V276, pH167, DOI 10.1152/ajpheart.1999.276.1.H167; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; YAMASHITA N, 1994, J CLIN INVEST, V94, P2193, DOI 10.1172/JCI117580; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang J, 1996, J MOL CELL CARDIOL, V28, P1931, DOI 10.1006/jmcc.1996.0186	46	178	189	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13690	13698		10.1074/jbc.275.18.13690	http://dx.doi.org/10.1074/jbc.275.18.13690			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788488	hybrid			2022-12-27	WOS:000086925300075
J	Motterlini, R; Foresti, R; Bassi, R; Calabrese, V; Clark, JE; Green, CJ				Motterlini, R; Foresti, R; Bassi, R; Calabrese, V; Clark, JE; Green, CJ			Endothelial heme oxygenase-1 induction by hypoxia - Modulation by inducible nitric-oxide synthase and S-nitrosothiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; GENE-EXPRESSION; GLUTATHIONE DEPLETION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; RELAXING FACTOR; MESSENGER-RNA; UVA RADIATION; CELLS; RAT	The stress protein heme oxygenase-1 (HO-1) is induced in endothelial cells exposed to nitric oxide (NO)releasing agents, and this process is finely modulated by thiols (Foresti, R,, Clark, J, E,, Green, C, J,, and Motterlini Il, (1997) J. Biol, Chem, 272, 18411-18417), Here, we report that up-regulation of HO-1 in aortic endothelial cells by severe hypoxic conditions (pO(2) less than or equal to 2 mm Hg) is preceded by increased inducible NO synthase and NO synthase activity. This effect is accompanied by oxidation of intracellular glutathione and formation of S-nitrosothiols, Incubation of cells with a selective inhibitor of inducible NO synthase (S-(2-aminoethyl)-isothiourea) or a NO scavenger ([2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide]) significantly attenuated the increase in heme oxygenase activity caused by reduced oxygen availability. A series of antioxidant agents did not prevent the elevation in heme oxygenase activity by hypoxia; however, the precursor of glutathione synthesis and thiol donor, N-acetylcysteine, completely abolished HO-1 induction. We also found that the hypoxia-mediated increase in endothelial heme oxygenase activity was potentiated by the presence of S-nitrosoglutathione. These results indicate that intracellular interaction of thiols with NO is an important determinant in the mechanism leading to HO-1 induction by reduced oxygen levels. We suggest that in addition to oxidative stress, HO-1 gene expression can be regulated by redox reactions involving NO and S-nitrosothiols (nitrosative stress), emphasizing a versatile role for the heme oxygenase pathway in the cellular adaptation to a variety of stressful conditions.	Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow HA1 3UJ, Middx, England; Univ Catania, Fac Med, Dept Biochem, I-95125 Catania, Italy	Imperial College London; University of Catania	Motterlini, R (corresponding author), Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow HA1 3UJ, Middx, England.	r.motterlini@ic.ac.uk	Motterlini, Roberto/Q-1890-2019; Calabrese, Vittorio/AAC-8157-2021; Motterlini, Roberto/G-2489-2013	Motterlini, Roberto/0000-0003-2684-2612; Calabrese, Vittorio/0000-0002-0478-985X; Motterlini, Roberto/0000-0003-2684-2612; foresti, roberta/0000-0002-0836-7937				Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; ABRAHAMSE AF, 1988, FAM PLANN PERSPECT, V20, P13, DOI 10.2307/2135591; ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Borger DR, 1998, AM J PHYSIOL-HEART C, V274, pH965, DOI 10.1152/ajpheart.1998.274.3.H965; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Calabrese V, 1998, FREE RADICAL BIO MED, V24, P1159, DOI 10.1016/S0891-5849(97)00441-3; Caudill TK, 1998, AM J PHYSIOL-REG I, V275, pR1025, DOI 10.1152/ajpregu.1998.275.4.R1025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Clark JE, 1997, BIOCHEM BIOPH RES CO, V241, P215, DOI 10.1006/bbrc.1997.7742; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; delaTorre A, 1998, SURGERY, V124, P137, DOI 10.1016/S0039-6060(98)70113-8; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DING Y, 1999, EUR J BIOCHEM, V264, P854; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Immenschuh S, 1999, J HEPATOL, V30, P61, DOI 10.1016/S0168-8278(99)80008-7; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kaur H, 1999, FREE RADICAL BIO MED, V27, pS78; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIKUCHI K, 1993, ANAL CHEM, V65, P1794, DOI 10.1021/ac00061a025; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MCQUILLAN LP, 1995, AM J PHYSIOL, V267, pH1921; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Motterlini R, 1996, BIOCHEM BIOPH RES CO, V225, P167, DOI 10.1006/bbrc.1996.1148; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Motterlini R, 1998, CIRC RES, V83, P568, DOI 10.1161/01.RES.83.5.568; MOTTERLINI R, 1996, AM J PHYSIOL, V20, pH107; Oguro T, 1997, J PHARMACOL EXP THER, V280, P1455; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Phelan MW, 1996, J CELL PHYSIOL, V167, P469, DOI 10.1002/(SICI)1097-4652(199606)167:3<469::AID-JCP11>3.3.CO;2-C; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RIZZARDINI M, 1994, BIOCHEM J, V304, P477, DOI 10.1042/bj3040477; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Vesely MJJ, 1999, FEBS LETT, V458, P257, DOI 10.1016/S0014-5793(99)01129-1; Vesely MJJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1087, DOI 10.1152/ajpcell.1998.275.4.C1087; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	59	233	246	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13613	13620		10.1074/jbc.275.18.13613	http://dx.doi.org/10.1074/jbc.275.18.13613			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788478	hybrid			2022-12-27	WOS:000086925300065
J	Wann, ER; Gurusiddappa, S; Hook, M				Wann, ER; Gurusiddappa, S; Hook, M			The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; STREPTOCOCCUS-PYOGENES; NUCLEOTIDE-SEQUENCE; EPITHELIAL-CELLS; SURFACE-PROTEINS; MULTIPLE BINDING; ADHERENCE; GENE; EXPRESSION; VIRULENCE	Staphylococcus aureus is an important pathogen capable of causing a wide spectrum of diseases in humans and animals, This bacterium expresses a variety of virulence factors that participate in the process of infection. These include MSCRAMMs ((m) under bar icrobial (s) under bar urface (c) under bar omponents (r) under bar ecognizing (a) under bar dhesive (m) under bar atrix (m) under bar olecules) that mediate the adherence of the bacteria to host extracellular matrix components, such as collagen, fibronectin (Fn), and fibrinogen (Fg), Two Fn-binding MSCRAMMs, FnbpA and FnbpB, have been previously identified. The Fn binding activity has been localized to the similar to 40-amino acid residue D repeats in the C-terminal part of these proteins. However, no biological activity has yet been attributed to the N-terminal A regions of these proteins. These regions exhibit substantial amino acid sequence identity to the A regions of other staphylococcal MSCRAMMs, including ClfA, ClfB, and SdrG (Fbe), all of which bind Fg. This raises the question of whether the Fn-binding MSCRAMMs can also bind specifically to Fg, In this report, we show that a recombinant form of the A region of FnbpA does specifically recognize Fg. We localize the binding site in Fg for recombinant FnbpA to the gamma-chain, in particular to the C-terminal residues of this polypeptide, the site also recognized by ClfA. In addition, we demonstrate that recombinant FnbpA can compete with ClfA for binding to both immobilized and soluble Fg. By the use of surface plasmon resonance spectroscopy and fluorescence polarization, we determine the dissociation equilibrium constant for the interaction of recombinant FnbpA with intact immobilized Fg and with a synthetic C-terminal gamma-chain peptide, respectively. Finally, by overexpressing FnbpA in a mutant strain of S. aureus that lacks the expression of both ClfA and ClfB, we show that native FnbpA can mediate the interaction of S. aureus with soluble Fg.	Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Biochem & Biophys, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wann, ER (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624, R56AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x; COURTNEY HS, 1994, INFECT IMMUN, V62, P3937, DOI 10.1128/IAI.62.9.3937-3946.1994; Dziewanowska K, 1999, INFECT IMMUN, V67, P4673, DOI 10.1128/IAI.67.9.4673-4678.1999; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Flock JI, 1996, INFECT IMMUN, V64, P1876, DOI 10.1128/IAI.64.5.1876-1878.1996; Foster TJ, 1998, METHOD MICROBIOL, V27, P433; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; HETTASCH JM, 1992, THROMB HAEMOSTASIS, V68, P701; HOMONYLOMCGAVIN M, 1993, INFECT IMMUN, V61, P2479; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; Katerov V, 1998, MICROBIOL-UK, V144, P119, DOI 10.1099/00221287-144-1-119; KUYPERS JM, 1989, INFECT IMMUN, V57, P2306, DOI 10.1128/IAI.57.8.2306-2312.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammers A, 1999, FEMS MICROBIOL LETT, V180, P103, DOI 10.1111/j.1574-6968.1999.tb08783.x; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; McGavin MJ, 1997, INFECT IMMUN, V65, P2621, DOI 10.1128/IAI.65.7.2621-2628.1997; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666-2673.1998; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; Palma M, 1996, INFECT IMMUN, V64, P5284, DOI 10.1128/IAI.64.12.5284-5289.1996; Palma M, 1998, J BIOL CHEM, V273, P13177, DOI 10.1074/jbc.273.21.13177; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Peacock SJ, 1999, MICROBIOL-SGM, V145, P3477, DOI 10.1099/00221287-145-12-3477; PHONIMDAENG P, 1990, MOL MICROBIOL, V4, P393, DOI 10.1111/j.1365-2958.1990.tb00606.x; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; RUPP ME, 1997, STAPHYLOCOCCI HUMAN, P379; Sambrook J., 2002, MOL CLONING LAB MANU; SaraviaOtten P, 1997, J BACTERIOL, V179, P5259, DOI 10.1128/jb.179.17.5259-5263.1997; Sawai T, 1997, INFECT IMMUN, V65, P466, DOI 10.1128/IAI.65.2.466-471.1997; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P135; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SHERERTZ RJ, 1993, J INFECT DIS, V167, P98, DOI 10.1093/infdis/167.1.98; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; TONHAT H, 1997, J BIOL CHEM, V272, P22285; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331	51	228	238	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13863	13871		10.1074/jbc.275.18.13863	http://dx.doi.org/10.1074/jbc.275.18.13863			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788510	hybrid			2022-12-27	WOS:000086925300097
J	Liu, Y; Li, HC; Tanaka, K; Tsumaki, N; Yamada, Y				Liu, Y; Li, HC; Tanaka, K; Tsumaki, N; Yamada, Y			Identification of an enhancer sequence within the first intron required for cartilage-specific transcription of the alpha 2(XI) collagen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; SRY-RELATED GENE; AUTOSOMAL SEX REVERSAL; II COLLAGEN; CAMPOMELIC DYSPLASIA; RAT CHONDROSARCOMA; FIBRILLAR COLLAGEN; MOUSE EMBRYOS; XI COLLAGEN; CELL-LINE	Type XI collagen, a heterotrimer composed of alpha 1(XI), alpha 2(XI) and alpha 3(XI), is primarily synthesized by chondrocytes in cartilage and is also present in some other tissues. Type XI collagen plays a critical role in collagen fibril formation and skeletal morphogenesis. We investigated a tissue-specific transcriptional enhancer in the first intron of the alpha 2(XI) collagen gene (Col11a2). Transient transfection assays using reporter gene constructs revealed that a 60-base pair (bp) segment within intron 1 increased promoter activity of Col11a2 in rat chondro-sarcoma cells but not in either BalB/3T3 cells or undifferentiated ATDC5 cells, suggesting that it contained cell tape-specific enhancer activity. In transgenic mice, this 60-bp fragment was also able to target beta-galactosidase expression to cartilage including the limbs and axial skeleton, with similar localization specificity as the full-length intron 1 fragment. Competition experiments in gel shift assays using mutated oligonucleotides showed that recombinant Sox9 bound to a 7-bp sequence, CT-CAAAG, within the 60-bp segment. Anti-Sox9 antibodies supershifted the complex of the 60-bp segment with recombinant Sox9 or with rat chondrosarcoma cell extracts, confirming the binding of Sox9 to the enhancer. Moreover, a site-specific mutation within the 7-bp segment resulted in essentially complete loss of the enhancer activity in chondrosarcoma cells and transgenic mice. These results suggest that the 7-bp sequence within intron 1 plays a critical role in the cartilage-specific enhancer activity of Col11a2 through Sox9-mediated transcriptional activation.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, Y (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Rm 405, Bethesda, MD 20892 USA.		Tanaka, Kazuhiro/Q-7387-2019	Tanaka, Kazuhiro/0000-0002-5138-8952; Tsumaki, Noriyuki/0000-0002-0520-3654				Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BERNARD M, 1988, J BIOL CHEM, V263, P17159; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Hogan B, 1994, MANIPULATING MOUSE E; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; KIMURA T, 1989, J BIOL CHEM, V264, P13910; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li SW, 1998, MATRIX BIOL, V17, P213, DOI 10.1016/S0945-053X(98)90060-9; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Liu Y, 1997, J BIOL CHEM, V272, P29880, DOI 10.1074/jbc.272.47.29880; MATSUKI Y, 1995, J DENT RES, V74, P307, DOI 10.1177/00220345950740010401; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SMITH GN, 1985, J BIOL CHEM, V260, P761; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Sugimoto M, 1998, CELL TISSUE RES, V292, P325, DOI 10.1007/s004410051063; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5	35	78	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12712	12718		10.1074/jbc.275.17.12712	http://dx.doi.org/10.1074/jbc.275.17.12712			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777565	hybrid			2022-12-27	WOS:000086762300049
J	Mundell, SJ; Benovic, JL				Mundell, SJ; Benovic, JL			Selective regulation of endogenous G protein-coupled receptors by arrestins in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; SOMATOSTATIN RECEPTOR; HOMOLOGOUS DESENSITIZATION; DISTINCT MECHANISMS; PLASMA-MEMBRANE; INTERNALIZATION; RESENSITIZATION; PHOSPHORYLATION	Arrestins play an important role in regulating desensitization and trafficking of G protein-coupled receptors (GPCRs). However, limited insight into the specificity of arrestin-mediated regulation of GPCRs is currently avail able. Recently, we used an antisense strategy to reduce arrestin levels in HEK293 cells and characterize the role of arrestins on endogenous G(s)-coupled receptors (Mundell, S. J., Loudon, R. B., and Benovic, J. L. (1999) Biochemistry 38, 8723-8732). Here, we characterized GPCRs coupled to either G(q) (M-1 muscarinic acetylcholine receptor (M(1)AchR) and P2y(1) and P2y(2) purinergic receptors) or G(i) (somatostatin and AT1 angiotensin receptors) in wild type and arrestin antisense HEK293 cells. The agonist-specific desensitization of the M(1)Ach and somatostatin receptors was significantly attenuated in antisense-expressing cells, whereas desensitization of P2y(1) and P2y(2) purinergic and AT1 angiotensin receptors was unaffected by reduced arrestin levels. To further examine arrestin/ GPCR specificity, we studied the effects of endogenous GPCR activation on the redistribution of arrestin-a epitope tagged with the green fluorescent protein (arrestin-2-GFP). These studies revealed a receptor-specific movement of arrestin-2-GFP that mirrored the arrestin-receptor specificity observed in the antisense cells. Thus, agonist-induced activation of endogenous beta(2)-adrenergic, prostaglandin E-2, M(1)Ach, and somatostatin receptors induced arrestin-2-GFP redistribution to early endosomes, whereas P2y(1) and P2y(2) purinergic and AT1 angiotensin receptor activation did not. Thus, endogenous arrestins mediate the regulation of selective G(q)- and G(i)-coupled receptors in HEK293 cells.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47417] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; Balmforth AJ, 1997, BRIT J PHARMACOL, V122, P1469, DOI 10.1038/sj.bjp.0701522; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; FERGUSON SSG, 1996, SCIENCE, V271, P383; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heringdorf DMZ, 1998, EUR J PHARMACOL, V354, P113, DOI 10.1016/S0014-2999(98)00436-1; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PALMER TM, 1994, MOL PHARMACOL, V45, P1082; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WILKINSON GF, 1994, MOL PHARMACOL, V45, P731; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	39	83	85	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12900	12908		10.1074/jbc.275.17.12900	http://dx.doi.org/10.1074/jbc.275.17.12900			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777589	hybrid			2022-12-27	WOS:000086762300073
J	Board, PG; Coggan, M; Chelvanayagam, G; Easteal, S; Jermiin, LS; Schulte, GK; Danley, DE; Hoth, LR; Griffor, MC; Kamath, AV; Rosner, MH; Chrunyk, BA; Perregaux, DE; Gabel, CA; Geoghegan, KF; Pandit, J				Board, PG; Coggan, M; Chelvanayagam, G; Easteal, S; Jermiin, LS; Schulte, GK; Danley, DE; Hoth, LR; Griffor, MC; Kamath, AV; Rosner, MH; Chrunyk, BA; Perregaux, DE; Gabel, CA; Geoghegan, KF; Pandit, J			Identification, characterization, and crystal structure of the omega class glutathione transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEHYDROASCORBATE REDUCTASE; SULFATE-BINDING POCKET; S-TRANSFERASE; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; DICHLOROACETIC-ACID; RESPIRATORY BURST; RAT-LIVER; MU-CLASS; EXPRESSION	A new class of glutathione transferases has been discovered by analysis of the expressed sequence tag data base and sequence alignment, Glutathione S-transferases (GSTs) of the new class, named Omega, exist in several mammalian species and Caenorhabditis elegans, In humans, GSTO 1-1 is expressed in most tissues and exhibits glutathione-dependent thiol transferase and dehydroascorbate reductase activities characteristic of the glutaredoxins, The structure of GSTO 1-1 has been determined at 2.0-Angstrom resolution and has a characteristic GST fold (Protein Data Bank entry code leem). The Omega class GSTs exhibit an unusual N-terminal extension that abuts the C terminus to form a novel structural unit. Unlike other mammalian GSTs, GSTO 1-1 appears to have an active site cysteine that can form a disulfide bond with glutathione,	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Human Genet Grp, Canberra, ACT 2601, Australia; Univ Sydney, Australian Genom Informat Ctr, Sydney, NSW 2006, Australia; Pfizer Global Res & Dev, Groton, CT 06340 USA	Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research; University of Sydney; Pfizer	Pandit, J (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, GPO Box 4, Canberra, ACT 2601, Australia.		Jermiin, Lars Sommer/C-2458-2009; Jermiin, Lars Sommer/AAQ-7033-2020	Jermiin, Lars Sommer/0000-0002-9619-3809; Jermiin, Lars Sommer/0000-0002-9619-3809; Easteal, Simon/0000-0002-0462-502X; Pandit, Jayvardhan/0000-0001-6128-7779				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADACHI J, 1996, MOLPHY VERSION 2 3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; AXELSSON K, 1978, BIOCHEMISTRY-US, V17, P2978, DOI 10.1021/bi00608a006; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Board PG, 1997, BIOCHEM J, V328, P929; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; Board PG, 1998, BIOCHEM J, V330, P827; BRUGNER AT, 1996, XPLOR VERSION 3 1; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Dal Monte M, 1998, BIOCHEM J, V334, P57; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Flanagan JU, 1999, PROTEIN SCI, V8, P2205, DOI 10.1110/ps.8.10.2205; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HALL AG, 1994, CANCER RES, V54, P5251; Hanson SRA, 1999, J BIOL CHEM, V274, P4735, DOI 10.1074/jbc.274.8.4735; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ishikawa T, 1998, J BIOL CHEM, V273, P28708, DOI 10.1074/jbc.273.44.28708; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; Menegon A, 1998, LANCET, V352, P1344, DOI 10.1016/S0140-6736(98)03453-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paolicchi A, 1996, ARCH BIOCHEM BIOPHYS, V333, P489, DOI 10.1006/abbi.1996.0419; Patskovsky YV, 2000, J BIOL CHEM, V275, P3296, DOI 10.1074/jbc.275.5.3296; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; Retief JD, 1999, GENOME RES, V9, P373; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; SEKINE Y, 1995, EXP EYE RES, V60, P159, DOI 10.1016/S0014-4835(95)80006-9; Seres T, 1996, J IMMUNOL, V156, P1973; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; THOMASSLAYTER B, 1994, HUM ECOL, V22, P467, DOI 10.1007/BF02169389; TONG L, 1993, J APPL CRYSTALLOGR, V26, P15, DOI 10.1107/S0021889892007295; Tong Z, 1998, CHEM RES TOXICOL, V11, P1332, DOI 10.1021/tx980144f; Tong Z, 1998, BIOCHEM J, V331, P371, DOI 10.1042/bj3310371; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Washburn MP, 1999, BIOCHEM BIOPH RES CO, V257, P567, DOI 10.1006/bbrc.1999.0508; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; Whittington AT, 1999, BIOCHEM J, V337, P141, DOI 10.1042/0264-6021:3370141; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x; [No title captured]	61	559	592	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24798	24806		10.1074/jbc.M001706200	http://dx.doi.org/10.1074/jbc.M001706200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10783391	hybrid			2022-12-27	WOS:000088683300077
J	Massaad, C; Paradon, M; Jacques, C; Salvat, C; Bereziat, G; Berenbaum, F; Olivier, JL				Massaad, C; Paradon, M; Jacques, C; Salvat, C; Bereziat, G; Berenbaum, F; Olivier, JL			Induction of secreted type IIA phospholipase A(2) gene transcription by interleukin-1 beta - Role of C/EBP factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; ALPHA-1-ACID GLYCOPROTEIN GENE; RABBIT ARTICULAR CHONDROCYTES; RAT MESANGIAL CELLS; NUCLEAR FACTOR-I; BETA-ISOFORM; RESPONSE ELEMENTS; BINDING-PROTEIN	Secreted type IIA phospholipase A(2), which is involved in arachidonic acid release, is abundantly produced by chondrocytes and secreted in the synovial fluids of patients affected by rheumatoid arthritis. Transfection experiments showed that interleukin-1 beta stimulates the phospholipase A(2) [-1614; +20] promoter activity by 6-7-fold and that the [-210; -176] fragment is critical for this stimulation. CAAT enhancer-binding protein (C/EBP) beta and C/EBP delta transcription factors bind to this element as shown by bandshift experiments. Interleukin-1 beta increased the levels of C/EBP delta mRNA as soon as 2 h and up to 24 h without affecting those of C/EBP delta, Higher amounts of C/EBP delta proteins correlate with the stimulation of C/EBP delta mRNA Mutations or 5' deletions in the upstream [-247; -210] region reduced by 2-fold the basal and interleukin-1 beta-stimulated transcription activities. Two types of factors bind to overlapping sequences on this fragment: NF1-like proteins and the glucocorticoid receptor. The glucocorticoid receptor is responsible for a moderate stimulation of the promoter activity by dexamethasone and may interact with C/EBP factors to achieve a full transcription activity in basal conditions and in the presence of interleukin-1 beta. A [-114; -85] proximal regulatory element forms three complexes in bandshift experiments, the slowest mobility one involving the Sp1 zinc finger factor. Mutation of this sequence reduced to 2-fold the stimulation of the promoter activity by interleukin-1 beta or the C/EBP factors. Induction of the transcription of secreted type IIA phospholipase A(2) gene by interleukin-1 beta in chondrocytes absolutely requires C/EBP beta and C/EBP delta factors but does not involve NF-kappa B.	Univ Paris 06, CNRS, UPRESA 7079, UFR St Antoine, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Olivier, JL (corresponding author), Univ Paris 06, CNRS, UPRESA 7079, UFR St Antoine, 7 Quai St Bernard, F-75252 Paris 05, France.	olivier@ccr.jussieu.fr	Olivier, Jean luc/AAQ-2721-2021; Berenbaum, Francis/AAO-5690-2020	Berenbaum, Francis/0000-0001-8252-7815; JACQUES, Claire/0000-0002-2741-5340				Alaaeddine N, 1999, ARTHRITIS RHEUM-US, V42, P710, DOI 10.1002/1529-0131(199904)42:4<710::AID-ANR14>3.0.CO;2-4; ALAM T, 1992, J BIOL CHEM, V267, P5021; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BECK CA, 1993, ENDOCRINOLOGY, V133, P728, DOI 10.1210/en.133.2.728; BERENBAUM F, 1994, FEBS LETT, V340, P51, DOI 10.1016/0014-5793(94)80171-1; Berenbaum F, 1996, EXP CELL RES, V222, P379, DOI 10.1006/excr.1996.0047; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; DelMonaco M, 1997, J INVEST DERMATOL, V108, P938, DOI 10.1111/1523-1747.ep12295241; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; Fan QS, 1997, MOL CELL BIOL, V17, P4238, DOI 10.1128/MCB.17.8.4238; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; GARLATTI M, 1994, MOL CELL BIOL, V14, P8007, DOI 10.1128/MCB.14.12.8007; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; Haselmann J, 1997, CYTOKINE, V9, P199, DOI 10.1006/cyto.1996.0154; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; INGRASSIA R, 1994, DNA CELL BIOL, V13, P615, DOI 10.1089/dna.1994.13.615; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Khare S, 1996, J MED VIROL, V50, P254, DOI 10.1002/(SICI)1096-9071(199611)50:3<254::AID-JMV8>3.0.CO;2-8; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2524, DOI 10.1172/JCI116861; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lamas M, 1997, CYTOKINE, V9, P973, DOI 10.1006/cyto.1997.0248; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; Lin MKS, 1996, J RHEUMATOL, V23, P1162; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Margerie D, 1997, OSTEOARTHR CARTILAGE, V5, P129, DOI 10.1016/S1063-4584(97)80006-4; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; Massaad C, 1997, MOL PHARMACOL, V51, P285, DOI 10.1124/mol.51.2.285; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOUDGIL VK, 1991, BIOCHEM BIOPH RES CO, V174, P1239, DOI 10.1016/0006-291X(91)91554-P; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; OLIVIER JL, 1994, BIOCHEMISTRY-US, V33, P7134, DOI 10.1021/bi00189a017; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Paradon M, 1998, EUR J BIOCHEM, V258, P113, DOI 10.1046/j.1432-1327.1998.2580113.x; PEKKI A, 1992, J STEROID BIOCHEM, V41, P753, DOI 10.1016/0960-0760(92)90417-H; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAMJI DP, 1994, BIOCHEM SOC T, V22, pS338; ROSSINI GP, 1994, J STEROID BIOCHEM, V48, P517; ROZANSKY DJ, 1994, J CLIN INVEST, V94, P2357, DOI 10.1172/JCI117601; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WINKLER J, 1997, PHOSPHALIPASE A, V2; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123	69	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22686	22694		10.1074/jbc.M001250200	http://dx.doi.org/10.1074/jbc.M001250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10791956	hybrid			2022-12-27	WOS:000088419400015
J	Taylor, CV; Taupenot, L; Mahata, SK; Mahata, M; Wu, HJ; Yasothornsrikul, S; Toneff, T; Caporale, C; Jiang, QJ; Parmer, RJ; Hook, VYH; O'Connor, DT				Taylor, CV; Taupenot, L; Mahata, SK; Mahata, M; Wu, HJ; Yasothornsrikul, S; Toneff, T; Caporale, C; Jiang, QJ; Parmer, RJ; Hook, VYH; O'Connor, DT			Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A - Determination of proteolytic cleavage sites in hormone storage granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-DERIVED PEPTIDE; PARATHYROID CELL SECRETION; PROHORMONE CONVERTASES; CHROMAFFIN GRANULES; PROTEINS; FRAGMENT; VESICLES; CALCIUM; PANCREASTATIN; PURIFICATION	The catestatin fragment of chromogranin A is an inhibitor of catecholamine release, but its occurrence in vivo has not yet been verified, nor have its precise cleavage sites been established. Here we found extensive processing of catestatin in chromogranin A, as judged by catestatin radioimmunoassay of size-fractionated chromaffin granules. On mass spectrometry, a major catestatin form was bovine chromogranin A(332-364); identity of the peptide was confirmed by diagnostic Met(346) oxidation. Further analysis revealed two additional forms: bovine chromogranin A(332-364) and A(343-362). Synthetic longer (chromogranin A(332-364)) and shorter (chromogranin A(344-364)) versions of catestatin each inhibited catecholamine release from chromaffin cells, with superior potency for the shorter version (IC50 similar to 2.01 versus similar to 0.35 mu M). Radioimmunoassay demonstrated catestatin release from the regulated secretory pathway in chromaffin cells. Human catestatin was cleaved in pheochromocytoma chromaffin granules, with the major form, human chromogranin A(340-372), bounded by dibasic sites. We conclude that catestatin is cleaved extensively in vivo, and the peptide is released by exocytosis, In chromaffin granules, the major form of catestatin is cleaved at dibasic sites, while smaller carboxyl-terminal forms also occur, Knowledge of cleavage sites of catestatin from chromogranin A may provide a useful starting point in analysis of the relationship between structure and function for this peptide.	Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Ctr Genet Mol, San Diego, CA 92161 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	O'Connor, DT (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	doconnor@ucsd.edu	Mahata, Sushil/AAF-8781-2021	Taupenot, Laurent/0000-0003-2316-3825				AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; Beynon R.J., 1989, PROTEOLYTIC ENZYMES; Caporale C, 1996, COMPUT APPL BIOSCI, V12, P81; CURRY WJ, 1992, FEBS LETT, V301, P319, DOI 10.1016/0014-5793(92)80266-J; DREES BM, 1994, ENDOCRINOLOGY, V134, P2057, DOI 10.1210/en.134.5.2057; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; Eskeland NL, 1996, J CLIN INVEST, V98, P148, DOI 10.1172/JCI118760; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Fricker L D, 1991, NIDA Res Monogr, V111, P171; GILL BM, 1992, NEUROPEPTIDES, V21, P105, DOI 10.1016/0143-4179(92)90521-W; GRANT G, 1992, SYNTHETIC PEPTIDES U, P382; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; Hook VYH, 1999, ENDOCRINOLOGY, V140, P3744, DOI 10.1210/en.140.8.3744; Hook VYH, 1996, ARCH BIOCHEM BIOPHYS, V328, P107, DOI 10.1006/abbi.1996.0149; HOOK VYH, 1990, LIFE SCI, V47, P1135, DOI 10.1016/0024-3205(90)90173-O; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HWANG SR, 1995, FEBS LETT, V368, P471, DOI 10.1016/0014-5793(95)00709-I; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; Kanno T, 1998, BIOMED RES-TOKYO, V19, P411, DOI 10.2220/biomedres.19.411; Kennedy BP, 1998, PEPTIDES, V19, P1241, DOI 10.1016/S0196-9781(98)00086-2; KIRCHMAIR R, 1995, BIOCHEM J, V310, P331, DOI 10.1042/bj3100331; Laslop A, 1998, J NEUROCHEM, V70, P374; Mahata M, 1996, HYPERTENSION, V28, P414, DOI 10.1161/01.HYP.28.3.414; Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Nagasawa S, 1998, BIOMED RES-TOKYO, V19, P407, DOI 10.2220/biomedres.19.407; Nakane H, 1998, BIOMED RES-TOKYO, V19, P401, DOI 10.2220/biomedres.19.401; Nishikawa Y, 1998, BIOMED RES-TOKYO, V19, P237, DOI 10.2220/biomedres.19.237; OCONNOR DT, 1984, HYPERTENSION, V6, P2, DOI 10.1161/01.HYP.6.1.2; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; OCONNOR DT, 1982, CLIN EXP HYPERTENS, V4, P563, DOI 10.3109/10641968209061599; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheibani N, 1999, PREP BIOCHEM BIOTECH, V29, P77, DOI 10.1080/10826069908544695; SIGAFOOS J, 1993, J ANAT, V183, P253; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIUZDAK G, 1996, MASS SPECTROMETRY BI, P161; Smith B J, 1984, Methods Mol Biol, V1, P41, DOI 10.1385/0-89603-062-8:41; SYVERSEN U, 1992, NEUROPEPTIDES, V22, P235, DOI 10.1016/0143-4179(92)90052-X; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; TAUPENOT L, 1995, REGUL PEPTIDES, V56, P71, DOI 10.1016/0167-0115(95)00008-Y; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Udupi V, 1999, REGUL PEPTIDES, V83, P123, DOI 10.1016/S0167-0115(99)00061-0; Urata H, 1996, AM J HYPERTENS, V9, P277, DOI 10.1016/0895-7061(95)00349-5; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Yasothornsrikul S, 1998, J NEUROCHEM, V70, P153	50	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22905	22915		10.1074/jbc.M001232200	http://dx.doi.org/10.1074/jbc.M001232200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10781584	hybrid			2022-12-27	WOS:000088419400043
J	Tridandapani, S; Lyden, TW; Smith, JL; Carter, JE; Coggeshall, KM; Anderson, CL				Tridandapani, S; Lyden, TW; Smith, JL; Carter, JE; Coggeshall, KM; Anderson, CL			The adapter protein LAT enhances Fc gamma receptor-mediated signal transduction in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-E RECEPTOR; TYROSINE PHOSPHORYLATION; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; ANTIGEN RECEPTOR; MEMBRANE DOMAINS; CROSS-LINKING; IGE RECEPTOR; LIPID RAFTS	Fc gamma R clustering in monocytes initiates a cascade of signaling events that culminate in biological responses such as phagocytosis, production of inflammatory cytokines, and generation of reactive oxygen species. We have identified and determined the function of the adapter protein linker of activation of T cell (LAT) in Fc gamma R-mediated signaling and function. Clustering of Fc gamma Rs on the human monocytic cell line, THP-1, induces phosphorylation of a major 36-kDa protein which immunoreacts with anti-LAT antisera, Our data indicate that although both the 36-kDa and 38-kDa isoforms of LAT are expressed in THP-1 and U937 human monocytic cells, Fc gamma R clustering induces phosphorylation of the 36-kDa isoform only. Co-immunoprecipitation experiments revealed a constitutive association of p36 LAT with both Fc gamma RI and Fc gamma RIIa immunoprecipitates, and an activation-induced association of LAT with PLC gamma 1, Grb2, and the p85 subunit of phosphatidylinositol 3-kinase. Transient transfection experiments in COS-7 cells indicated that overexpression of a wild type but not a dominant-negative LAT, that is incapable of binding to p85, enhances phagocytosis by Fc gamma RI. Furthermore, bone marrow-derived macrophages from LAT-deficient mice displayed reduced phagocytic efficiency in comparison to the macrophages from wild-type mice. Thus, we conclude that p36 LAT serves to enhance Fc gamma R-induced signal transduction in myeloid cells.	Ohio State Univ, Coll Med, Davis Res Ctr 2054, Dept Internal Med, Columbus, OH 43210 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20877 USA; Oklahoma Med Res Fdn, Dept Immunobiol & Canc, Oklahoma City, OK 73104 USA	University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oklahoma Medical Research Foundation	Anderson, CL (corresponding author), Ohio State Univ, Coll Med, Davis Res Ctr 2054, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.	anderson.48@osu.edu			NCI NIH HHS [CA44983] Funding Source: Medline; NICHD NIH HHS [HD35121] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Duchemin AM, 1997, J IMMUNOL, V158, P865; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jevremovic D, 1999, J IMMUNOL, V162, P2453; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KUMAR G, 1995, BIOCHEM J, V307, P215, DOI 10.1042/bj3070215; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; METZGER H, 1992, J IMMUNOL, V149, P1477; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sanchez-Mejorada G, 1998, J LEUKOCYTE BIOL, V63, P521, DOI 10.1002/jlb.63.5.521; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHEN ZH, 1994, J IMMUNOL, V152, P3017; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	47	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20480	20487		10.1074/jbc.M909462199	http://dx.doi.org/10.1074/jbc.M909462199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781611	hybrid			2022-12-27	WOS:000088084500037
J	Morisco, C; Zebrowski, D; Condorelli, G; Tsichlis, P; Vatner, SF; Sadoshima, J				Morisco, C; Zebrowski, D; Condorelli, G; Tsichlis, P; Vatner, SF; Sadoshima, J			The Akt-glycogen synthase kinase 3 beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROMOTES CELL-SURVIVAL; N-TERMINAL KINASES; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; CARDIOMYOCYTE HYPERTROPHY; VENTRICULAR MYOCYTES; COUPLED RECEPTORS; IN-VIVO; PHOSPHORYLATION	We examined the mechanism of atrial natriuretic factor (ANF) transcription by isoproterenol (ISO), an agonist for the beta-adrenergic receptor (beta AR), in cardiac myocytes. ISO only modestly activated members of the mitogen-activated protein kinase family. ISO-induced ANF transcription was not affected by inhibition of mitogen-activated protein kinases, whereas it was significantly inhibited by KN93, an inhibitor of Ca2+/calmodulin-dependent kinase (CaM kinase II). Production of 3'-phosphorylated phosphatidylinositides (3 phosphoinositides) was also required for ISO-induced ANF transcription. ISO caused phosphorylation (Ser-473) and activation of Akt through CaM kinase II- and 3 phosphoinositides-dependent mechanisms. Constitutively active Akt increased myocyte surface area, total protein content, and ANF expression, whereas dominant negative Akt blocked ISO-stimulated ANF transcription. ISO caused Ser-9 phosphorylation and decreased activities of GSK3 beta. Overexpression of GSK3 beta inhibited ANF transcription, which was reversed by ISO. ISO failed to reverse the inhibitory effect of GSK3 beta(S9A), an Akt-insensitive mutant. Kinase-inactive GSK3 beta increased ANF transcription. Cyclosporin A partially inhibited ISO-stimulated ANF transcription, indicating that calcineurin only partially mediates ANF transcription. These results suggest that both CaM kinase II and 3 phosphoinositides mediate beta AR-induced Akt activation and ANF transcription in cardiac myocytes. Furthermore, beta AR-stimulated ANF transcription is predominantly mediated by activation of Akt and subsequent phosphorylation/inhibition of GSK3 beta.	Penn State Univ, Coll Med, Dept Mol Cellular Physiol, Weis Ctr Res, Danville, PA 17822 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Jefferson University	Sadoshima, J (corresponding author), Penn State Univ, Coll Med, Dept Mol Cellular Physiol, Weis Ctr Res, 100N Acad Ave, Danville, PA 17822 USA.	Jsadoshima@psghs.edu	Zebrowski, David C/R-6178-2016; Condorelli, Gianluigi/Q-6736-2017	MORISCO, Carmine/0000-0002-2158-6317; Sadoshima, Junichi/0000-0003-3724-4132; Condorelli, Gianluigi/0000-0003-0481-6843				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOLUYT MO, 1995, AM J PHYSIOL-HEART C, V269, pH638; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montessuit C, 1999, J BIOL CHEM, V274, P9006, DOI 10.1074/jbc.274.13.9006; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; PINSON A, 1993, J MOL CELL CARDIOL, V25, P477, DOI 10.1006/jmcc.1993.1053; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sugden PH, 1998, ADV ENZYME REGUL, V38, P87, DOI 10.1016/S0065-2571(97)00010-1; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Yamazaki T, 1997, CIRCULATION, V95, P1260; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	70	218	228	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14466	14475		10.1074/jbc.275.19.14466	http://dx.doi.org/10.1074/jbc.275.19.14466			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799529	hybrid			2022-12-27	WOS:000087006900063
J	Roman, J; Gimenez, A; Lluis, JM; Gasso, M; Rubio, M; Caballeria, J; Pares, A; Rodes, J; Fernandez-Checa, JC				Roman, J; Gimenez, A; Lluis, JM; Gasso, M; Rubio, M; Caballeria, J; Pares, A; Rodes, J; Fernandez-Checa, JC			Enhanced DNA binding and activation of transcription factors NF-kappa B and AP-1 by acetaldehyde in HEPG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA(2)(I) COLLAGEN PROMOTER; KINASE-C ACTIVATION; GENE-TRANSCRIPTION; LIPID-PEROXIDATION; MITOCHONDRIAL GLUTATHIONE; OXIDATIVE STRESS; REDOX REGULATION; RAT HEPATOCYTES; STELLATE CELLS	Because transcription factors NF-kappa B and activator protein-1 (AP-1) are known to regulate gene expression, we have analyzed the role of acetaldehyde in the activation of NF-kappa B and AP-1 in HepG2 cells. Binding activity and transactivation of NF-kappa B and AP-1 were determined by gel retardation assays and transfection of a luciferase reporter construct controlled by kappa B and AP-1 binding sites, respectively. Acetaldehyde enhanced the DNA binding of NF-kappa B and AP-1 by 1 and 4 h, respectively, increasing the kappa B- and AP-1-dependent luciferase expression. Supershift assays revealed the presence of NF-kappa B heterodimers p65/p50 and p50/p52, whereas nuclear c-Jun levels correlated with the DNA binding of AP-1. The enhanced binding of NF-kappa B to DNA by acetaldehyde in intact cells was accompanied by the proteolytic degradation of I kappa B-alpha. However, the addition of acetaldehyde to cytostolic extracts from untreated Hep G2 cells did not affect the DNA binding of AP-1 but activated the NF-kappa B heterodimer p65/p50 in the absence of I kappa B-alpha degradation. Preincubation of HepG2 cells with protein kinase C inhibitors abolished the enhanced DNA binding of NF-kappa B and AP-1 caused by acetaldehyde. Hence, these findings uncover a previously unrecognized role for acetaldehyde in the activation of NF-kappa B and AP-1, which may be of relevance in the alcohol-induced liver disease.	CSIC, Inst Malalt Digest, Liver Unit, Barcelona 08036, Spain; CSIC, Inst Invest Biomed August Pi Suner, Barcelona 08036, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Fernandez-Checa, JC (corresponding author), Hosp Clin & Prov Barcelona, Liver Unit, Villarroel 170, Barcelona, Spain.		Pares, Albert/M-6268-2019; Pares, Albert/G-1328-2011; Fernández-Checa, José Carlos/L-8342-2014	Pares, Albert/0000-0002-5413-9687; Pares, Albert/0000-0002-5413-9687; Fernández-Checa, José Carlos/0000-0003-3422-2990	NIAAA NIH HHS [AA11999-01, AA 09526] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009526, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Anania FA, 1999, ALCOHOL CLIN EXP RES, V23, P279; ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; Anania FA, 1996, ARCH BIOCHEM BIOPHYS, V331, P187, DOI 10.1006/abbi.1996.0297; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASHAK KG, 1991, ALCOHOL CLIN EXP RES, V15, P45; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BRACH MA, 1993, MOL CELL BIOL, V13, P4824; BRENNER DA, 1987, J BIOL CHEM, V262, P17690; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; CLEMENS DL, 1995, ARCH BIOCHEM BIOPHYS, V321, P311, DOI 10.1006/abbi.1995.1400; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HONCHEL R, 1992, ALCOHOL CLIN EXP RES, V16, P665, DOI 10.1111/j.1530-0277.1992.tb00656.x; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jokelainen K, 1998, BIOCHEM BIOPH RES CO, V253, P834, DOI 10.1006/bbrc.1998.9863; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; LIEBER CS, 1994, GASTROENTEROLOGY, V106, P1085, DOI 10.1016/0016-5085(94)90772-2; Lindros KO, 1999, LAB INVEST, V79, P799; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miao K, 1997, ARCH BIOCHEM BIOPHYS, V341, P140, DOI 10.1006/abbi.1997.9948; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; NIEMELA O, 1991, J CLIN INVEST, V87, P1367, DOI 10.1172/JCI115141; NIEMELA O, 1995, HEPATOLOGY, V22, P1208, DOI 10.1016/0270-9139(95)90630-4; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; PARES A, 1994, HEPATOLOGY, V19, P498, DOI 10.1016/0270-9139(94)90030-2; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Roman J, 1999, HEPATOLOGY, V30, P1473, DOI 10.1002/hep.510300623; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAW S, 1981, J LAB CLIN MED, V98, P417; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	48	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14684	14690		10.1074/jbc.275.19.14684	http://dx.doi.org/10.1074/jbc.275.19.14684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799556	hybrid			2022-12-27	WOS:000087006900090
J	Cunnick, JM; Dorsey, JF; Munoz-Antonia, T; Mei, L; Wu, J				Cunnick, JM; Dorsey, JF; Munoz-Antonia, T; Mei, L; Wu, J			Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; TYROSINE-PHOSPHATASE; SPHINGOSINE 1-PHOSPHATE; SIGNAL-TRANSDUCTION; RAS ACTIVATION; SH2 DOMAINS; PH DOMAIN; INSULIN; GAB1; PHOSPHORYLATION	Grb2-associated binder-1 (Gab1) is a multisite docking protein containing a pleckstrin homology (PH) domain, multiple potential tyrosine phosphorylation sites, and several proline-rich sequences. Gab1 becomes tyrosine-phosphorylated in cells stimulated with growth factors, cytokines, and ligands for G protein-coupled receptors, A major Gab1-binding protein detected in cells treated with extracellular stimuli is the tyrosine phosphatase, SHP2. Although the role of SHP2-Gab1 interaction in cell signaling has not yet been characterized, SHP2 is known to mediate mitogen-activated protein (MAP) kinase activation induced by the epidermal growth factor (EGF), However, the mechanism by which the SHP2 phosphatase exerts a positive signaling role remains obscure. In this study, we prepared Gab1 mutants lacking the SHP2 binding site (Gab1Y627F), the phosphatidylinositol 3-kinase (PI3K) binding sites (Gab1 Delta PI3K), and the PH domain (Gab1 Delta PH). Expression of Gab1Y627F blocked the extracellular signal-regulated kinase-2 (ERK2) activation by lysophosphatidic acid (LPA) and EGF, Conversely, expression of the wild-type Gab1 in HEK293 cells augmented the LPA receptor Edg2-mediated ERK2 activation. Whereas the PH domain was required for Gab1 mediation of ERR2 activation by LPA, it was not essential for EGF-induced ERK2 activation. Expression of Gab1 Delta PI3K had no apparent effect on ERK2 activation by LPA and EGF in the cells that we have examined. These results establish a role for Gab1 in the LPA-induced MAP kinase pathway and clearly demonstrate that Gab1-SHP2 interaction is essential for ERK2 activation by LPA and EGF. These findings also suggest that the positive role of SHP2 in the MAP kinase pathway depends on its interaction with Gab1.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program MRC 3057E, Tampa, FL 33612 USA; Univ S Florida, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Birmingham	Wu, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program MRC 3057E, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wu@moffitt.usf.edu	Cunnick, Jess/F-1715-2018; Mei, Lin/G-8755-2012; Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NATIONAL CANCER INSTITUTE [R01CA077467, R29CA077467, R56CA077467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062] Funding Source: NIH RePORTER; NCI NIH HHS [CA77467, R29 CA077467] Funding Source: Medline; NINDS NIH HHS [NS39401, NS34062] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICHER JA, 1995, J BIOL CHEM, V270, P11707; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	116	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13842	13848		10.1074/jbc.275.18.13842	http://dx.doi.org/10.1074/jbc.275.18.13842			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788507	hybrid			2022-12-27	WOS:000086925300094
J	O'Brien, PJ; Prevost, N; Molino, M; Hollinger, MK; Woolkalis, MJ; Woulfe, DS; Brass, LF				O'Brien, PJ; Prevost, N; Molino, M; Hollinger, MK; Woolkalis, MJ; Woulfe, DS; Brass, LF			Thrombin responses in human endothelial cells - Contributions from receptors other than Par1 include the transactivation of Par2 by thrombin-cleaved Par1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; TETHERED-LIGAND-RECEPTOR; MOLECULAR-CLONING; PLATELET ACTIVATION; GENE; INTERNALIZATION; EXPRESSION; FAMILY; ANTAGONISTS; CONTAINS	The recent identification of two new thrombin receptors, PAR3 and PAR4, led us to re-examine the basis for endothelial cell responses to thrombin, Human umbilical vein endothelial cells (HUVEC) are known to express PAR1 and the trypsin/tryptase receptor, PAR2, Northern blots detected both of those receptors and, to a lesser extent, PAR3, but PAR4 message was undetectable and there was no response to PAR4 agonist peptides. To determine whether PAR3 or any other receptor contributes to thrombin signaling in HUVEC, PAR1 cleavage was blocked with two selective antibodies and PAR1 activation was inhibited with the antagonist, BMS200261. The antibodies completely inhibited HUVEC responses to thrombin, but BMS200261 was only partly effective, even though separate studies established that the antagonist completely inhibits PAR1 signaling at the concentrations used. Since peptides mimicking the PAR1 tethered ligand domain can also activate PAR2, we asked whether the remaining thrombin response in the presence of the antagonist could be due in part to the intermolecular transactivation of PAR2 by cleaved PAR1, Evidence that transactivation can occur was obtained in COS-7 cells co-expressing PAR2 and a variant of PAR1 that can be cleaved, but not signal. There was a substantial response to thrombin only in cells expressing both receptors, Conversely, in HUVEC, complete blockade of the thrombin response by the PAR1 antagonist occurred only when signaling through PAR2 was also blocked. From these observations we conclude that 1) PAR1 is the predominant thrombin receptor expressed in HUVEC and cleavage of PAR1 is required for endothelial cell responses to thrombin; 2) although PAR3 may be expressed, there is still no evidence that it mediates thrombin responses; 3) PAR4 is not expressed on HUVEC; and 4) transactivation of PAR2 by cleaved PAR1 can contribute to endothelial cell responses to thrombin, particularly when signaling through PAR1 is blocked. Such transactivation may limit the effectiveness of PAR1 antagonists, which compete with the tethered ligand domain rather than preventing PAR1 cleavage.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy; Thomas Jefferson Univ, Dept Physiol, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Jefferson University	Brass, LF (corresponding author), Univ Penn, Dept Med, Rm 913 BRB 2,421 Curie Blvd, Philadelphia, PA 19104 USA.	brass@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052132, R01HL052132, P01HL040387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40387, HL-52132] Funding Source: Medline; NIDDK NIH HHS [DK-19525] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; ARCHIPOFF G, 1999, BIOCHEM J, V273, P679; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; CHEN J, 1994, J BIOL CHEM, V269, P16041; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001; GREAVES M, 1978, BIOCHIM BIOPHYS ACTA, V516, P193, DOI 10.1016/0304-419X(78)90008-2; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Maniatis T., 1982, MOL CLONING; MARSTON E, 1995, NAT RESOUR ENV ISS, V3, P1; May MJ, 1998, AM J PHYSIOL-CELL PH, V274, pC789, DOI 10.1152/ajpcell.1998.274.3.C789; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Molino M, 1997, J BIOL CHEM, V272, P11133; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; Ramachandran R, 1997, THROMB HAEMOSTASIS, V78, P1119; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; Schussler O, 1996, J BIOL CHEM, V271, P26473, DOI 10.1074/jbc.271.43.26473; Seiler SM, 1996, MOL PHARMACOL, V49, P190; Seiler SM, 1996, SEMIN THROMB HEMOST, V22, P223, DOI 10.1055/s-2007-999012; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; STORCK J, 1995, THROMB RES, V77, P249, DOI 10.1016/0049-3848(95)91612-O; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	53	265	274	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13502	13509		10.1074/jbc.275.18.13502	http://dx.doi.org/10.1074/jbc.275.18.13502			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788464	hybrid			2022-12-27	WOS:000086925300051
J	Zhu, XJ; Boman, AL; Kuai, J; Cieplak, W; Kahn, RA				Zhu, XJ; Boman, AL; Kuai, J; Cieplak, W; Kahn, RA			Effectors increase the affinity of ADP-ribosylation factor for GTP to increase binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; PHOSPHOLIPASE-D; SACCHAROMYCES-CEREVISIAE; CHOLERA-TOXIN; ARF PROTEINS; ADENYLATE-CYCLASE; STRUCTURAL BASIS; GOLGI MEMBRANES; AMINO-TERMINUS; ACTIVE-SITE	The stoichiometry of the binding of GTP to ADP-ribosylation factor (ARF) proteins, normally quite low at similar to 0.05 mol/mol protein, was found to increase to a maximum of 1 mol/mol in the presence of effecters. The mechanism of this action was found to result from the ability of these effecters to increase the affinity of ARF for activating guanine nucleotide triphosphates. The existence of a conformation of ARF with low affinity (>100 mu M) for GTP is proposed. The actions of effecters to increase the equilibrium binding of GTP is interpreted as evidence that these same effecters interact with and modulate the affinity of the inactive ARF for GTP. A new model for these interactions among ARF, effecters, and GTP is proposed, and a preliminary test in cells is supportive of these observations with relevance to signaling in cells.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@bimcore.emory.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Boman AL, 1999, CELL MOTIL CYTOSKEL, V44, P119, DOI 10.1002/(SICI)1097-0169(199910)44:2<119::AID-CM4>3.3.CO;2-3; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cieplak W, 1995, J BIOL CHEM, V270, P30545, DOI 10.1074/jbc.270.51.30545; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Losonczi JA, 1998, BIOCHEMISTRY-US, V37, P706, DOI 10.1021/bi9717791; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MOSS J, 1991, MOL MICROBIOL, V5, P2621, DOI 10.1111/j.1365-2958.1991.tb01971.x; Moss J, 1999, MOL CELL BIOCHEM, V193, P153, DOI 10.1023/A:1006993000870; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; TERUI T, 1994, J BIOL CHEM, V269, P28130; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; Williger BT, 1999, FEBS LETT, V454, P85, DOI 10.1016/S0014-5793(99)00771-1; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792	48	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13465	13475		10.1074/jbc.275.18.13465	http://dx.doi.org/10.1074/jbc.275.18.13465			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788460	hybrid			2022-12-27	WOS:000086925300047
J	Caffrey, JJ; Safrany, ST; Yang, XN; Shears, SB				Caffrey, JJ; Safrany, ST; Yang, XN; Shears, SB			Discovery of molecular and catalytic diversity among human diphosphoinositol-polyphosphate phosphohydrolases - An expanding Nudt family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL HEXAKISPHOSPHATE KINASE; DIADENOSINE POLYPHOSPHATES; SACCHAROMYCES-CEREVISIAE; PROTEIN; PENTAKISPHOSPHATE; TETRAKISPHOSPHATE; TURNOVER; SITE; HYDROLASES; MUTATIONS	The turnover of the "high energy" diphosphoinositol polyphosphates by Ca2+- and cyclic nucleotide-modulated enzymes is considered a regulatory, molecular switching activity. Target processes may include intracellular trafficking. Following our earlier identification of a prototype human (d) under bar iphospho (i) under bar nositol-(p) under bar olyphosphate phosphohydrolase (hDIPP1), we now describe new 21-kDa human isoforms, hDIPP2 alpha and hDIPP2 beta, distinguished from each other solely by hDIPP2 beta possessing one additional amino acid (Gln(86)). Candidate DIPP2 alpha and DIPP2 beta homologues in rat and mouse were also identified. The rank order for catalytic activity is hDIPP1 > hDIPP2 alpha > hDIPP2 beta. Differential expression of hDIPP isoforms may provide flexibility in response times of the molecular switches. The 76% identity between hDIPP1 and the hDIPP2s includes conservation of an emerging signature sequence, namely, a Nudt (MutT) motif with a GX(2)GX(6)G carboxy extension. Northern and Western analyses indicate expression of hDIPP2s is broad but atypically controlled; these proteins are translated from multiple mRNAs that differ in the length of the 3'-untranslated region because of utilization of an array of alternative (canonical and noncanonical) polyadenylation signals. Thus, cells can recruit sophisticated molecular processes to regulate diphosphoinositol polyphosphate turnover.			Caffrey, JJ (corresponding author), NIEHS, Inositide Signaling Grp, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	caffrey@niehs.nih.gov	Shears, Stephen B/C-6335-2019; Safrany, Stephen/AAX-3332-2020	Shears, Stephen B/0000-0001-7309-8916; Safrany, Stephen/0000-0002-9592-4112	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albanese V, 1998, GENOMICS, V47, P414, DOI 10.1006/geno.1997.5130; Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Costeas PA, 1996, BBA-GENE STRUCT EXPR, V1305, P25, DOI 10.1016/0167-4781(95)00212-X; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Gaudon C, 1999, EMBO J, V18, P2229, DOI 10.1093/emboj/18.8.2229; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; HERVE D, 1995, MOL BRAIN RES, V32, P125, DOI 10.1016/0169-328X(95)00070-9; Holden CP, 1996, J NEUROCHEM, V67, P574; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Jovanovic A, 1998, FEBS LETT, V423, P314, DOI 10.1016/S0014-5793(98)00114-8; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Michell RH, 1997, ESSAYS BIOCHEM, V32, P31; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Seki N, 1997, DNA Res, V4, P345, DOI 10.1093/dnares/4.5.345; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SINDHWANI R, 1994, J BIOL CHEM, V269, P3272; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Yamaguchi Y, 1996, J BIOL CHEM, V271, P27838, DOI 10.1074/jbc.271.44.27838; Yang XN, 1999, J BIOL CHEM, V274, P35434, DOI 10.1074/jbc.274.50.35434; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	32	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12730	12736		10.1074/jbc.275.17.12730	http://dx.doi.org/10.1074/jbc.275.17.12730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777568	hybrid			2022-12-27	WOS:000086762300052
J	Chen, HJ; Hwong, CL; Wang, CH; Hwang, JL				Chen, HJ; Hwong, CL; Wang, CH; Hwang, JL			Degradation of DNA topoisomerase I by a novel trypsin-like serine protease in proliferating human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG CAMPTOTHECIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; ESCHERICHIA-COLI; 13S CONDENSIN; KINASE-C; TRANSCRIPTION; PHOSPHORYLATION; UBIQUITIN; CELLS	DNA topoisomerase I (Topo I) contributes to various important biological functions, and its activity is therefore likely regulated in response to different physiological conditions. Increases in both the synthesis and degradation of Topo I were previously shown to accompany phytohemagglutinin stimulation of proliferation in human peripheral T lymphocytes. The mechanism of this degradation of Topo I has now been investigated with both in vivo and in vitro assays. The activity of a nuclear protease that specifically degrades Topo I was induced in proliferating T lymphocytes. The full-length Topo I protein (100 kDa) was sequentially degraded to 97- and 82-kDa fragments both in vivo and in vitro. The initial site of proteolytic cleavage was mapped to the NH2-terminal region of the enzyme. The degradation of Topo I in vitro was inhibited by aprotinin or soybean trypsin inhibitor, suggesting that the enzyme responsible is a trypsin-like serine protease. Furthermore, Topo I degradation by this protease was Mg2+-dependent. The Topo I-specific protease activity induced during T lymphocytes proliferation was not detected in jurkat (human T cell leukemia) cells and various other tested human cancer cell lines, possibly explaining why the abundance of Topo I is increased in tumor cells.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Inst Biochem, Taipei 112, Taiwan; Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Taipei 105, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital	Hwang, JL (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.							ARAD G, 1976, CELL, V8, P95, DOI 10.1016/0092-8674(76)90190-2; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; CARDELLINI E, 1993, BIOCHEM J, V291, P303, DOI 10.1042/bj2910303; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; Chen HJ, 1999, EUR J BIOCHEM, V265, P367, DOI 10.1046/j.1432-1327.1999.00741.x; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DARPA P, 1995, EXP CELL RES, V217, P125, DOI 10.1006/excr.1995.1071; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FERNANDEZBEROS ME, 1992, J BACTERIOL, V174, P7059, DOI 10.1128/JB.174.21.7059-7062.1992; Fu Q, 1999, MOL PHARMACOL, V55, P677; Giaccone G, 1995, BBA-GENE STRUCT EXPR, V1264, P337, DOI 10.1016/0167-4781(95)00171-9; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; GRAYZEL AI, 1975, CELL IMMUNOL, V18, P210, DOI 10.1016/0008-8749(75)90049-0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRABAYASHI N, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P436; HIRSCHHORN R, 1969, NATURE, V222, P1247, DOI 10.1038/2221247a0; HUSAIN I, 1994, CANCER RES, V54, P539; HWONG CL, 1993, J BIOL CHEM, V268, P18982; Kato GJ, 1999, HUM MUTAT, V13, P87, DOI 10.1002/(SICI)1098-1004(1999)13:2<87::AID-HUMU1>3.0.CO;2-K; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; KOHNO H, 1986, J BIOL CHEM, V261, P744; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MULLER S, 1995, BIOESSAYS, V17, P677, DOI 10.1002/bies.950170804; OSADA H, 1986, BIOCHEM J, V23, P459; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1996, SEMIN ONCOL, V23, P3; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; ROWINSKY EK, 1994, J CLIN ONCOL, V12, P2193, DOI 10.1200/JCO.1994.12.10.2193; RYAN JW, 1992, BIOCHIM BIOPHYS ACTA, V1119, P140, DOI 10.1016/0167-4838(92)90384-P; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SAMUELS DS, 1992, J BIOL CHEM, V267, P11156; SAMUELS DS, 1994, BBA-MOL CELL RES, V1223, P77, DOI 10.1016/0167-4889(94)90075-2; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Shykind BM, 1997, GENE DEV, V11, P397, DOI 10.1101/gad.11.3.397; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; VANDERZEE AGJ, 1991, CANCER RES, V51, P5915; WANG JC, 1993, CURR OPIN GENET DEV, V3, P764, DOI 10.1016/S0959-437X(05)80096-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Zhu J, 1996, MOL CELL BIOL, V16, P1805	58	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13109	13117		10.1074/jbc.275.17.13109	http://dx.doi.org/10.1074/jbc.275.17.13109			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777616	hybrid			2022-12-27	WOS:000086762300100
J	Fuchs, SY; Tappin, I; Ronai, Z				Fuchs, SY; Tappin, I; Ronai, Z			Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; UBIQUITIN-DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION PATHWAY; C-JUN; DNA-BINDING; RESPONSE ELEMENT; EXPRESSION; FAMILY; DOMAIN; CELLS	Trans-activation of the activating transcription factor-2 (ATF2) in response to cellular stress requires the N-terminal phosphorylation of ATF2 by stress-activated protein kinases (SAPK). In this study, we investigated the role of ATF2 phosphorylation in the maintenance of ATF2 stability. Activation of SAPK by forced expression of Delta MEKK1 increased overall ATF2 ubiquitination, presumably because of the enhanced dimerization of ATF2. Treatment of Delta MEKK1-expressing cells with okadaic acid led to the increase in N-terminal phosphorylation, protection from ubiquitination, and accumulation of exogenously expressed ATF2, indicating the role of protein phosphatases in balancing the effects of stress kinases. Analysis of ubiquitination and degradation of the constitutively dimerized ATF2 mutant (ATF2(Delta 150-248)) showed that activation of JNK or p38 kinase renders ATF2 resistant to ubiquitination and degradation. This effect is mediated by JNKp38-dependent phosphorylation of ATF2 at Thr-69 and Thr-71, because the phosphorylation-deficient mutant (ATF2(Delta 150-248-T69A,T71A)) was not protected from ubiquitination and degradation by the activation of SAPK, Treatment of cells with okadaic acid elevated the tumor necrosis factor alpha-induced ATF2 level and the extent of its specific N-terminal phosphorylation. Cycloheximide, which activates SAPK, while inhibiting protein synthesis, stabilized endogenous ATF2. However, treatment of cells with the high dose of SB203580, which inhibits JNK and p38 kinase, resulted in efficient degradation of ATF2 in cells exposed to cycloheximide. This degradation was abrogated by cotreatment with the proteasome inhibitor MG132. Our findings suggest that N-terminal phosphorylation of ATF2 dimers protect ATF2 from ubiquitination and degradation. We propose the hypothesis that the balance between SAPK and protein phosphatases affects the duration and magnitude of ATF2 transcriptional output because of the effect on substrate recognition for ubiquitination and degradation.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; Prives C, 1999, J PATHOL, V187, P112; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vrana JA, 1999, RADIAT RES, V151, P559, DOI 10.2307/3580032; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	33	98	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12560	12564		10.1074/jbc.275.17.12560	http://dx.doi.org/10.1074/jbc.275.17.12560			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777545	hybrid			2022-12-27	WOS:000086762300029
J	Salomons, FA; Kiel, JAKW; Faber, KN; Veenhuis, M; van der Klei, IJ				Salomons, FA; Kiel, JAKW; Faber, KN; Veenhuis, M; van der Klei, IJ			Overproduction of Pex5p stimulates import of alcohol oxidase and dihydroxyacetone synthase in a Hansenula polymorpha pex14 null mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL TARGETING SIGNAL; PROTEIN-IMPORT; SACCHAROMYCES-CEREVISIAE; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE; PICHIA-PASTORIS; GENE ENCODES; YEAST; BIOGENESIS; MEMBRANE	Hansenula polymorpha Delta pex14 cells are affected in peroxisomal matrix protein import and lack normal peroxisomes. Instead, they contain peroxisomal membrane remnants, which harbor a very small amount of the major peroxisomal matrix enzymes alcohol oxidase (AO) and dihydroxyacetone synthase (DHAS). The bulk of these proteins is, however, mislocated in the cytosol, Here, we show that in Delta pex14 cells overproduction of the PTS1 receptor, Pex5p, leads to enhanced import of the PTS1 proteins AO and DHAS but not of the PTS2 protein amine oxidase. The import of the PTS1 protein catalase (CAT) was not stimulated by Pex5p overproduction. The difference in import behavior of AO and CAT was not related to their PTS1, since green fluorescent protein fused to the PTS1 of either AO or CAT were both not imported in Delta pex14 cells overproducing Pex5p. When produced in a wild type control strain, both proteins were normally imported into peroxisomes. In Delta pex14 cells overproducing Pex5p, Pex5P had a dual location and was localized in the cytosol and bound to the outer surface of the peroxisomal membrane. Our results indicate that binding of Pex5p to the peroxisomal membrane and import of certain PTS1 proteins can proceed in the absence of Pex14p.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	van der Klei, IJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	I.J.van.der.Klei@biol.rug.nl	van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Baerends RJS, 1997, YEAST, V13, P1449, DOI 10.1002/(SICI)1097-0061(199712)13:15<1449::AID-YEA191>3.0.CO;2-Q; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; BRODSKY JL, 1998, PROTEIN TARGETING TR, P169; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DIDION T, 1992, FEBS LETT, V303, P113, DOI 10.1016/0014-5793(92)80500-G; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; EVERS ME, 1994, MOL BIOL CELL, V5, P829, DOI 10.1091/mbc.5.8.829; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HANSEN H, 1992, MOL GEN GENET, V235, P269, DOI 10.1007/BF00279370; HOVIUS R, 1998, PROTEIN TARGETING TR, P231; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Kiel JAKW, 1999, YEAST, V15, P1059, DOI 10.1002/(SICI)1097-0061(199908)15:11<1059::AID-YEA434>3.0.CO;2-I; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luck H, 1963, METHODS ENZYMATIC AN, P885; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Sakai Y, 1996, J CELL BIOL, V134, P37, DOI 10.1083/jcb.134.1.37; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; van der Klei IJ, 1998, CURR GENET, V34, P1, DOI 10.1007/s002940050360; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; vanderKlei IJ, 1996, ANN NY ACAD SCI, V804, P47; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VERDUYN C, 1984, J MICROBIOL METH, V2, P15, DOI 10.1016/0167-7012(84)90027-7; Waterham HR, 1997, J CELL BIOL, V139, P1419, DOI 10.1083/jcb.139.6.1419; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Will GK, 1999, MOL CELL BIOL, V19, P2265; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	54	68	69	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12603	12611		10.1074/jbc.275.17.12603	http://dx.doi.org/10.1074/jbc.275.17.12603			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777551	hybrid, Green Published			2022-12-27	WOS:000086762300035
J	Breitschopf, K; Zeiher, AM; Dimmeler, S				Breitschopf, K; Zeiher, AM; Dimmeler, S			Ubiquitin-mediated degradation of the proapoptotic active form of bid - A functional consequence on apoptosis induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL-PROMOTING PROTEINS; CYTOCHROME-C RELEASE; BCL-X-L; CELL-DEATH; PROTEASOME PATHWAY; STRUCTURAL BASIS; INTERACTS; FAMILY; BAX; MITOCHONDRIA	Under basal conditions, the proapoptotic protein Bid is a long-lived protein. Pro-apoptotic stimuli such as tumor necrosis factor-alpha (TNF alpha) or Fas induce its caspase-8-mediated cleavage into two fragments. The COOH-terminal cleavage fragment of Bid (tBid) becomes localized to mitochondrial membranes and triggers the release of cytochrome c. Here we show that tBid is ubiquitinated and subsequently degraded by the 26 S proteasome. Degradation of tBid is significantly inhibited by the proteasome inhibitors MG-132 and lactacystin. In contrast, caspase-specific or lysosomal inhibitors do not affect tBid stability. Furthermore, mutation of the putative ubiquitin acceptor sites within tBid results in a stabilized protein as assessed by pulse-chase analysis. To address whether tBid degradation might be regulated by interaction with other Bcl-2-like proteins, cotransfection studies were performed. However, neither the presence of proapoptotic Bax nor antiapoptotic Bcl-2 or Bcl-XL affected tBid degradation. Finally, we determined the functional role of tBid degradation. Overexpression of stabilized tBid proteins significantly enhanced cytochrome c release and subsequent apoptosis induction approximately 2-fold compared with wild type tBid. Similarly, tBid-induced apoptosis was considerably amplified by inhibition of tBid degradation using the proteasome-specific inhibitor MG-132. Thus, proteasomal degradation of tBid limits the extent of apoptosis in living cells.	Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de		Dimmeler, Stefanie/0000-0002-1045-2436				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOYD JM, 1995, ONCOGENE, V11, P1921; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GAIEWSKI TF, 1996, CELL, V87, P589; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	36	174	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21648	21652		10.1074/jbc.M001083200	http://dx.doi.org/10.1074/jbc.M001083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801801	hybrid			2022-12-27	WOS:000088230600091
J	Wei, Y; Bloom, P; Gu, RM; Wang, WH				Wei, Y; Bloom, P; Gu, RM; Wang, WH			Protein-tyrosine phosphatase reduces the number of apical small conductance K+ channels in the rat cortical collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FACTOR RECEPTOR; CELLS; PHOSPHORYLATION; MEMBRANE; KINASES; TUBULE; SRC; INTERNALIZATION; FIBROBLASTS	Previous studies have demonstrated that an increase in the activity of protein-tyrosine kinase (PTK) is involved in the down-regulation of the activity of apical small conductance K+ (SK) channels in the cortical collecting duet (CCD) from rats on a K+-deficient diet (1), We used the patch clamp technique to investigate the role of protein-tyrosine phosphatase (PTP) in the regulation of the activity of SK channels in the CCD from rats on a high K+ diet. Western blot analysis indicated that PTP-1D is expressed in the renal cortex. Application of 1 mu M phenylarsine oxide (PAO) or 1 mM benzylphosphonic acid, agents that inhibit PTP, reversibly reduced channel activity by 95%. Pretreatment of CCDs with PAO for 30 min decreased the mean NPo reversibly from control value 3.20 to 0.40. Addition of 1 mu M herbimycin A, an inhibitor of PTK, had no significant effect on channel activity in the CCDs from rats on a high K+ diet. However, herbimycin A abolished the inhibitory effect of PAO, indicating that the effect of PAO is the result of interaction between PTK and PTP. Addition of brefeldin A, an agent that blocks protein trafficking from Golgi complex to the membrane, had no effect on channel activity. Moreover, application of colchicine, a microtubule inhibitor, or paclitaxel, a microtubule stabilizer, had no effect on channel activity. In contrast, PAO still reduced channel activity in the presence of brefeldin A, colchicine, or paclitaxel. Furthermore, the effect of PAO on channel activity was absent when the tubules were bathed in 16% sucrose-containing bath solution or treated with concanavalin A. We conclude that PTP is involved in the regulation of the activity of SR channels and that inhibition of PTP may facilitate the internalization of the SK channels.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047402, R29DK047402] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47402] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; BEGUM N, 1994, AM J PHYSIOL, V267, pE14, DOI 10.1152/ajpendo.1994.267.1.E14; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Frindt G, 1998, AM J PHYSIOL-RENAL, V274, pF525, DOI 10.1152/ajprenal.1998.274.3.F525; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Giebisch G, 1996, KIDNEY INT, V49, P1624, DOI 10.1038/ki.1996.236; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; LING BN, 1991, KIDNEY INT, V40, P441, DOI 10.1038/ki.1991.231; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; PACHA J, 1991, AM J PHYSIOL, V261, pF696, DOI 10.1152/ajprenal.1991.261.4.F696; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Pasquet JM, 1998, BIOCHEM J, V333, P591, DOI 10.1042/bj3330591; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; SCHLATTER E, 1992, PFLUG ARCH EUR J PHY, V420, P39, DOI 10.1007/BF00378639; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; STANTON B, 1987, J CLIN INVEST, V79, P198, DOI 10.1172/JCI112783; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Yamaji Y, 1997, AM J PHYSIOL-CELL PH, V272, pC886, DOI 10.1152/ajpcell.1997.272.3.C886	35	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20502	20507		10.1074/jbc.M000783200	http://dx.doi.org/10.1074/jbc.M000783200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787405	hybrid			2022-12-27	WOS:000088084500040
J	Boyer, LA; Logie, C; Bonte, E; Becker, PB; Wade, PA; Wolffe, AP; Wu, C; Imbalzano, AN; Peterson, CL				Boyer, LA; Logie, C; Bonte, E; Becker, PB; Wade, PA; Wolffe, AP; Wu, C; Imbalzano, AN; Peterson, CL			Functional delineation of three groups of the ATP-dependent family of chromatin remodeling enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; SWI-SNF COMPLEX; HISTONE DEACETYLASE; CORE PARTICLE; IN-VITRO; DNA; DROSOPHILA; PROTEIN; ISWI; BINDING	ATP-dependent chromatin remodeling enzymes antagonize the inhibitory effects of chromatin. We com pare six different remodeling complexes: ySWI/SNF, yRSC, hSWI/SNF, xMi-2, dCHRAC, and dNURF. We find that each complex uses similar amounts of ATP to remodel nucleosomal arrays at nearly identical rates. We also perform assays with arrays reconstituted with hyperacetylated or trypsinized histones and isolated histone (H3/H4)(2) tetramers. The results define three groups of the ATP-dependent family of remodeling enzymes. In addition we investigate the ability of an acidic activator to recruit remodeling complexes to nucleosomal arrays. We propose that ATP-dependent chromatin remodeling enzymes share a common reaction mechanism and that a key distinction between complexes is in their mode of regulation or recruitment.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Adolf Butenandt Inst, D-80336 Munich, Germany; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Munich; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Biotech 2,Suite 301, Worcester, MA 01605 USA.		Wade, Paul A/D-2374-2019; Logie, Colin/L-9833-2019; Logie, Colin/A-1528-2010	Wade, Paul A/0000-0002-6042-357X; Logie, Colin/0000-0002-8534-6582; Logie, Colin/0000-0002-8534-6582; Becker, Peter/0000-0001-7186-0372	NIGMS NIH HHS [R01 GM049650, R01 GM056244, GM49650, R37 GM049650, GM56244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244, R01GM049650, R37GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Boyer LA, 2000, J BIOL CHEM, V275, P11545, DOI 10.1074/jbc.275.16.11545; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Logie C, 1999, METHOD ENZYMOL, V304, P726; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WOLFFE AP, 1994, CURR BIOL, V4, P525, DOI 10.1016/S0960-9822(00)00114-7; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	59	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18864	18870		10.1074/jbc.M002810200	http://dx.doi.org/10.1074/jbc.M002810200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10779516	hybrid, Green Published			2022-12-27	WOS:000087815900035
J	Bulik, DA; van Ophem, P; Manning, JM; Shen, ZJ; Newburg, DS; Jarroll, EL				Bulik, DA; van Ophem, P; Manning, JM; Shen, ZJ; Newburg, DS; Jarroll, EL			UDP-N-acetylglucosamine pyrophosphorylase, a key enzyme in encysting Giardia, is allosterically regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LAMBLIA; GENE; URIDYLTRANSFERASE; IDENTIFICATION; PURIFICATION; CARBOHYDRATE; ISOMERASE; CLONING; CYSTS	Giardia synthesizes UDP-GalNAc during cyst wall formation (encystment) via a pathway of inducible enzymes similar to that used to synthesize chitin or peptidoglycan and that includes the UTP-requiring UDP-N-acetylglucosamine pyrophosphorylase. Although it has never been reported as a regulatory enzyme in any system studied to date, kinetic data including Hill plots demonstrate clearly that UDP-N-acetylglucosamine pyrophosphorylase activity, purified from encysting Giardia, is allosterically activated anabolically by physiological levels of glucosamine 6-phosphate (3 mu M). Capillary electrophoresis demonstrates that within 24 h after trophozoites are induced to encyst, the level of glucosamine g-phosphate increases 3-fold over that of non-encysting cells and that by 48 h into encystment the level of glucosamine 6-phosphate has decreased to non-encysting levels or below. UDP-N-acetylglucosamine pyrophosphorylase protein is present constitutively in encysting as well as non-encysting cells. UDP-N-acetylglucosamine pyrophosphorylase immunoaffinity purified from encysting and non-encysting cells exhibited the same molecular weight, amino acid composition, and circular dichroism spectra, Moreover, regardless of whether the enzyme came from encysting or nonencysting cells, the change in its circular dichroism spectra and up to a 6-fold increase in its specific activity anabolically were due to its activation with glucosamine 6-phosphate. Thus, the data support the idea that UDP-N-acetylglucosamine pyrophosphorylase is a major regulatory point in amino sugar synthesis in encysting Giardia and that its allosteric anabolic activation may shift the equilibrium of this pathway toward UDP-GalNAc synthesis.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Shriver Ctr, Program Glycobiol, Waltham, MA 02460 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA	Northeastern University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Jarroll, EL (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.							[Anonymous], 1995, PARASIT PROTOZ; BENSON RL, 1970, J BIOL CHEM, V245, P2219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulik DA, 1998, MOL BIOCHEM PARASIT, V95, P135, DOI 10.1016/S0166-6851(98)00076-0; CABIB E, 1991, ENCY PLANT PHYSL, P395; ENGHOFER E, 1980, DEV BIOL, V78, P63, DOI 10.1016/0012-1606(80)90318-8; Erlandsen SL, 1996, J EUKARYOT MICROBIOL, V43, P416, DOI 10.1111/j.1550-7408.1996.tb05053.x; Feely D.E., 1984, P3; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOVEJENSEN B, 1992, J BACTERIOL, V174, P6852, DOI 10.1128/JB.174.21.6852-6856.1992; JARROLL EL, 1995, FOLIA PARASIT, V42, P81; KAWAI H, 1976, J FERMENT TECHNOL, V54, P463; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; LINDMARK DG, 1988, EXP PARASITOL, V65, P141, DOI 10.1016/0014-4894(88)90116-6; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; MACECHKO PT, 1992, MOL BIOCHEM PARASIT, V56, P301, DOI 10.1016/0166-6851(92)90179-N; MANNING P, 1992, J PROTOZOOL, V39, P290, DOI 10.1111/j.1550-7408.1992.tb01317.x; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; NOLTMANN E, 1972, ENZYMES, P314; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V54, P273, DOI 10.1016/0006-3002(61)90366-3; SCHUPP DG, 1988, GASTROENTEROLOGY, V95, P1; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STANELONI RJ, 1982, CRC CR REV BIOCH MOL, V12, P289, DOI 10.1080/10409238209104422; Steimle PA, 1997, MOL BIOCHEM PARASIT, V84, P149, DOI 10.1016/S0166-6851(96)02790-9; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147; ULRICH J, 1995, J BACTERIOL, V177, P6902; Van Keulen H, 1998, J EUKARYOT MICROBIOL, V45, P637, DOI 10.1111/j.1550-7408.1998.tb04560.x; VOGLER AP, 1989, J BACTERIOL, V171, P6586, DOI 10.1128/jb.171.12.6586-6592.1989; WHITE RJ, 1968, BIOCHEM J, V106, P847, DOI 10.1042/bj1060847; YAMAMOTO K, 1979, CAN J MICROBIOL, V25, P1381, DOI 10.1139/m79-216	35	36	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14722	14728		10.1074/jbc.275.19.14722	http://dx.doi.org/10.1074/jbc.275.19.14722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799561	hybrid			2022-12-27	WOS:000087006900095
J	Gomes, XV; Gary, SL; Burgers, PMJ				Gomes, XV; Gary, SL; Burgers, PMJ			Overproduction in Escherichia coli and characterization of yeast replication factor C lacking the ligase homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; BASE EXCISION-REPAIR; LARGE SUBUNIT P140; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; MOLECULAR-CLONING; AUXILIARY PROTEIN; COMPLEX-FORMATION; TRANSFER-RNA	Eukaryotic replication factor C (RF-C) is a heteropentameric complex that is required to load the replication clamp proliferating cell nuclear antigen onto primed DNA. Saccharomyces cerevisiae RF-C is encoded by the genes RFC1-RFC5. The RFC1 gene was cloned under control of the strong inducible bacteriophage T7 promoter, yet induction did not yield detectable Rfc1p. However, a truncated form of RFC1 deleted for the coding region for amino acids 3-273, rfc1-Delta N, did allow overproduction. The other four RFC genes were cloned into the latter plasmid to yield a single plasmid that overproduced RF-C to moderate levels. Overproduction of the complex was further enhanced when the Escherichia coli argU gene encoding the rare arginine tRNA was also overproduced. The enzyme thus produced in E. coli was purified to homogeneity through three column steps, including a proliferating cell nuclear antigen affinity column. This enzyme, as well as the enzyme purified from yeast, is prone to aggregation and inactivation, and therefore, light scattering was used to determine conditions stabilizing the enzyme and preventing aggregation. Broad-range carrier ampholytes at about 0.05% were found to be most effective. In some assays, the Rfc1-Delta N containing RF-C from E, coli showed an increased activity compared with the full-length enzyme from yeast, likely because the latter enzyme exhibits significant nonspecific binding to single-stranded DNA. Replacement of RFC1 by rfc1-Delta N in yeast shows essentially no phenotype with regard to DNA replication, damage susceptibility, telomere length maintenance, and intrachromosomal recombination.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021		NIGMS NIH HHS [R01 GM032431, GM32431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AK, 1996, MOL CELL BIOL, V16, P4614; Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; Beckwith WH, 1998, BIOCHEMISTRY-US, V37, P3711, DOI 10.1021/bi972777j; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; Gary SL, 1995, NUCLEIC ACIDS RES, V23, P4986, DOI 10.1093/nar/23.24.4986; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; Kaiser C., 1994, METHODS YEAST GENETI; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; McAlear MA, 1996, GENETICS, V142, P65; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; SIKORSKI RS, 1989, GENETICS, V122, P19; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SPANJAARD RA, 1990, NUCLEIC ACIDS RES, V18, P5031, DOI 10.1093/nar/18.17.5031; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uchiumi F, 1999, BIOCHEM BIOPH RES CO, V258, P482, DOI 10.1006/bbrc.1999.0589; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Xie YL, 1999, GENETICS, V151, P499; YODER BL, 1991, J BIOL CHEM, V266, P22689	48	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14541	14549		10.1074/jbc.275.19.14541	http://dx.doi.org/10.1074/jbc.275.19.14541			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799539	hybrid			2022-12-27	WOS:000087006900073
J	Kolodziej, SJ; Hudmon, A; Waxham, MN; Stoops, JK				Kolodziej, SJ; Hudmon, A; Waxham, MN; Stoops, JK			Three-dimensional reconstructions of calcium/calmodulin dependent (CaM) kinase II alpha and truncated CaM kinase II alpha reveal a unique organization for its structural core and functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; HUMAN ALPHA(2)-MACROGLOBULIN; CA-2+-INDEPENDENT ACTIVITY; CRYOELECTRON MICROSCOPY; MUTANT MICE; CALMODULIN; AUTOPHOSPHORYLATION	Studies of the structural organization of calcium/ calmodulin-dependent protein kinase II alpha (CaM KII alpha) and truncated CaM KII alpha by three-dimensional electron microscopy and protein engineering show that the structures consist of 12 subunits that are organized in two stacked hexameric rings with 622 symmetry. The body of CaM KII alpha is gear-shaped, consisting of six slanted flanges, and has six foot-like processes attached by narrow appendages to both ends of the flanges, Truncated CaM KII alpha that lacks functional domains has a structure that is very similar to the body of CaM KII alpha. Thus, the functional domains reside in the foot-like processes, and the association domain comprises the gear-shaped core. The ribbon diagram of the bilobate structure of CaM KI fits nicely in the envelope of the foot-like component and indicates that the crevice between the two lobes comprising the functional domains is near the middle portion of the foot. The clustering of the functional domains provides a favorable arrangement for the autophosphorylation reaction, and the unusual arrangement of the catalytic domain on extended tethers appears to be significant for the remarkable functional diversity of CaM KII alpha in cellular regulation.	Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Neurobiol & Anat, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Stoops, JK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA.	James.K.Stoops@uth.tmc.edu		Waxham, M. Neal/0000-0003-4801-1190	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026086, T32NS007373, R56NS026086] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 07373, NS 26086] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brocke L, 1999, J BIOL CHEM, V274, P22713, DOI 10.1074/jbc.274.32.22713; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BURGIN KE, 1990, J NEUROSCI, V10, P1788; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1985, NEW METHODOLOGIES ST, P36; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GONZALEZ RC, 1987, DIGITAL IMAGE PROCES, P170; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; Kolodziej SJ, 1998, J STRUCT BIOL, V123, P124, DOI 10.1006/jsbi.1998.4027; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Qazi U, 1998, J BIOL CHEM, V273, P8987, DOI 10.1074/jbc.273.15.8987; Qazi U, 1999, J BIOL CHEM, V274, P8137, DOI 10.1074/jbc.274.12.8137; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x; ZHOU ZH, 1995, NAT STRUCT BIOL, V2, P1026, DOI 10.1038/nsb1195-1026	49	133	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14354	14359		10.1074/jbc.275.19.14354	http://dx.doi.org/10.1074/jbc.275.19.14354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799516	hybrid			2022-12-27	WOS:000087006900048
J	Low, BC; Seow, KT; Guy, GR				Low, BC; Seow, KT; Guy, GR			Evidence for a novel Cdc42GAP domain at the carboxyl terminus of BNIP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; CRYSTAL-STRUCTURE; CONSERVED ARGININE; BINDING DOMAIN; GENE-PRODUCT; RAS; COMPLEX; GAPS	We recently identified BNIP-2, a previously cloned Bcl-2- and E1B-associated protein, as a putative substrate of the FGF receptor tyrosine kinase and showed that it possesses GTPase-activating activity toward Cdc42 despite the lack of homology to previously described catalytic domains of GTPase-activating proteins (GAPs). BNIP-2 contains many arginine residues at the carboxyl terminus, which includes the region of homology to the noncatalytic domain of Cdc42GAP, termed BNIP-2 and Cdc42GAP homology (BCH) domain. Using BNIP-2 glutathione S-transferase recombinants, it was found that its BCH bound Cdc42, and contributed the GAP activity. This domain was predicted to fold into cw-helical bundles similar to the topology of the catalytic GAP domain of Cdc42GAP. Alignment of exposed arginine residues in this domain helped to identify Arg-235 and Arg-238 as good candidates for catalysis. Arg-238 matched well to the arginine "finger" required for enhanced GTP hydrolysis in homodimerized Cdc42. Site-directed mutagenesis confirmed that an R235K or R238K mutation severely impaired the BNIP-2 GAP activity without affecting its binding to Cdc42. From deletion studies, a region adjacent to the arginine patch ((EYV290)-E-288 on BNIP-2) and the Switch I and Rho family-specific "Insert" region on Cdc42 are involved in the binding. The results indicate that the BCH domain of BNIP-2 represents a novel GAP domain that employs an arginine patch motif similar to that of the Cdc42-homodimer.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbgg@imcb.nus.edu.sg	Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; AHMED S, 1994, J BIOL CHEM, V269, P17642; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Al-Mulla F, 1999, J PATHOL, V187, P433, DOI 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bax B, 1998, NATURE, V392, P447, DOI 10.1038/33040; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Calmels TPG, 1998, FEBS LETT, V426, P205, DOI 10.1016/S0014-5793(98)00331-7; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 1999, BRIT J CANCER, V80, P25; Hillig RC, 1999, MOL CELL, V3, P781, DOI 10.1016/S1097-2765(01)80010-1; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Leonard DA, 1998, J BIOL CHEM, V273, P16210, DOI 10.1074/jbc.273.26.16210; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morcos P, 1996, MOL CELL BIOL, V16, P2496; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Rittinger K, 1998, NATURE, V392, P448, DOI 10.1038/33043; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sermon BA, 1998, J BIOL CHEM, V273, P9480, DOI 10.1074/jbc.273.16.9480; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609	54	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14415	14422		10.1074/jbc.275.19.14415	http://dx.doi.org/10.1074/jbc.275.19.14415			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799524	hybrid			2022-12-27	WOS:000087006900057
J	Mechling, DE; Bachinger, HP				Mechling, DE; Bachinger, HP			The collagen-like peptide (GER)(15)GPCCG forms pH-dependent covalently linked triple helical trimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL DOMAIN; GLY-X-Y; ELECTROSTATIC INTERACTIONS; MODEL PEPTIDES; STABILITY; PROTEIN; CONFORMATION; PREFERENCES; MOLECULE; RESIDUES	A collagen-like peptide with the sequence (GER)(15) GPCCG was synthesized to study the formation of a triple helix in the absence of proline residues. This peptide can form a triple helix at acidic and basic pH, but is insoluble around neutral pH. The formation of a triple helix can be used to covalently oxidize the cysteine residues into a disulfide knot. Three disulfide bonds are formed between the three chains as has been found at the carboxyl-terminal end of the type III collagen triple helix. This is a new method to covalently link collagenlike peptides with a stereochemistry that occurs in nature. The peptide undergoes a reversible, cooperative triple helix reversible arrow coil transition with a transition midpoint (T-m) of 17 to 20 degrees C at acidic pH and 32 to 37 degrees C at basic pH. At acidic pH there was little influence of the T-m on the salt concentration of the buffer. At basic pH increasing the salt concentration reduced the T-m to values comparable to the stability at acidic pH. These experiments show that the tripeptide unit GER which occurs frequently in collagen sequences can form a triple helical structure in the absence of more typical collagen-like tripeptide units and that charge-charge interactions play a role in the stabilization of the triple helix of this peptide.	Oregon Hlth Sci Univ, Shriners Hosp Crippled Children, Res Dept, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Bachinger, HP (corresponding author), Oregon Hlth Sci Univ, Shriners Hosp Crippled Children, Res Dept, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BERG RA, 1970, J BIOL CHEM, V245, P5759; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BURJANADZE TV, 1982, BIOPOLYMERS, V21, P1489, DOI 10.1002/bip.360210803; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Dames SA, 1999, FEBS LETT, V446, P75, DOI 10.1016/S0014-5793(99)00186-6; DICK YP, 1966, ARCH BIOCHEM BIOPHYS, V117, P466, DOI 10.1016/0003-9861(66)90436-X; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; FIELDS CG, 1995, ANAL BIOCHEM, V231, P57, DOI 10.1006/abio.1995.1503; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FIETZEK PP, 1975, MOL CELL BIOCHEM, V8, P141, DOI 10.1007/BF01792765; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; GLANVILLE RW, 1976, H-S Z PHYSIOL CHEM, V357, P1663; Goodman M, 1996, J AM CHEM SOC, V118, P5156, DOI 10.1021/ja954132h; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Holmgren SK, 1999, CHEM BIOL, V6, P63, DOI 10.1016/S1074-5521(99)80003-9; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; JOSSE J, 1964, J MOL BIOL, V9, P269, DOI 10.1016/S0022-2836(64)80207-2; KATZ EP, 1990, BIOPOLYMERS, V29, P791, DOI 10.1002/bip.360290413; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; LAMBERT N, 1983, BIOCHEM J, V213, P213; LEIKIN S, 1995, NAT STRUCT BIOL, V2, P205, DOI 10.1038/nsb0395-205; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; RIPAMONTI A, 1980, BIOPOLYMERS, V19, P965, DOI 10.1002/bip.1980.360190503; ROTH W, 1980, BIOPOLYMERS, V19, P1909, DOI 10.1002/bip.1980.360191017; SALEM G, 1975, FEBS LETT, V51, P94, DOI 10.1016/0014-5793(75)80861-1; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023	35	31	35	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14532	14536		10.1074/jbc.275.19.14532	http://dx.doi.org/10.1074/jbc.275.19.14532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799537	hybrid			2022-12-27	WOS:000087006900071
J	Scholz, G; Cartledge, K; Dunn, AR				Scholz, G; Cartledge, K; Dunn, AR			Hck enhances the adherence of lipopolysaccharide-stimulated macrophages via Cbl and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TOLL-LIKE RECEPTOR-2; INTEGRIN SIGNALING PATHWAY; CELL ANTIGEN RECEPTOR; C-CBL; BACTERIAL LIPOPOLYSACCHARIDE; IN-VIVO; PROTOONCOGENE PRODUCT; SH3 DOMAIN; ADAPTER PROTEINS	Src family tyrosine kinases have previously been proposed to mediate some of the biological effects of lipopolysaccharide on macrophages, Accordingly, we have sought to identify substrates of Src family kinases in lipopolysaccharide-stimulated macrophages. Stimulation of Bac1.2F5 macrophage cells with lipopolysaccharide was found to induce gradual and persistent tyrosine phosphorylation of Cbl in an Src family kinase-dependent manner. Immunoprecipitation experiments revealed that Cbl associates with Hck in Bac1.2F5 cells, while expression of an activated form of Hck in Bac1.2F5 cells induces tyrosine phosphorylation of Cbl in the absence of lipopolysaccharide stimulation. The Src homology 3 domain of Hck can directly bind Cbl, and this interaction is important for phosphorylation of Chi. Association of the p85 subunit of phosphatidylinositol (PI) 3-kinase with Cbl is enhanced following lipopolysaccharide stimulation of Bac1.2F5 cells, and transient expression experiments indicate that phosphorylation of Cbl by Hck can facilitate the association of p85 with Cbl, Lipopolysaccharide treatment also stimulates the partial translocation of lick to the cytoskeleton of Bac1.2F5 cells. Notably, lipopolysaccharide enhances the adherence of Bac1.2F5 cells, an effect that is dependent on the activity of Src family kinases and PI 3-kinase. Thus, we postulate that Hck enhances the adherence of lipopolysaccharide-stimulated macrophages, at least in part, via Cbl and PI 3-kinase.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Mol Biol Lab, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Scholz, G (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Mol Biol Lab, POB 2008, Melbourne, Vic 3050, Australia.	Glen.Scholz@ludwig.edu.au		Scholz, Glen/0000-0003-2722-6344				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Auger M. J., 1992, MACROPHAGE, P1; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BOULET I, 1992, ONCOGENE, V7, P703; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUSCHER D, 1993, ONCOGENE, V8, P3323; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GENG Y, 1993, J IMMUNOL, V151, P6692; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Heine H, 1999, J IMMUNOL, V162, P6971; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Horita DA, 1998, J MOL BIOL, V278, P253, DOI 10.1006/jmbi.1998.1690; Hoshino K, 1999, J IMMUNOL, V162, P3749; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; NOVOTNEY M, 1991, BIOCHEMISTRY-US, V30, P5597, DOI 10.1021/bi00236a037; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; REIMANN T, 1994, J IMMUNOL, V153, P5740; Ribon V, 1996, MOL CELL BIOL, V16, P45; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14615	14623		10.1074/jbc.275.19.14615	http://dx.doi.org/10.1074/jbc.275.19.14615			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799548	hybrid			2022-12-27	WOS:000087006900082
J	Monestier, M; Decker, P; Briand, JP; Gabriel, JL; Muller, S				Monestier, M; Decker, P; Briand, JP; Gabriel, JL; Muller, S			Molecular and structural properties of three autoimmune IgG monoclonal antibodies to histone H2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; 3-DIMENSIONAL STRUCTURE; ANTIGEN COMPLEX; NUCLEOSOME; AUTOANTIBODIES; REGION; MICE; DNA; SPECIFICITIES; AUTOANTIGENS	In systemic autoimmune diseases such as lupus the immune system produces autoantibodies to nuclear antigens including DNA and histone molecules. In the present study, we describe three monoclonal IgG antibodies that have been obtained from lupus-prone MRL/ lpr mice. These three antibodies react with the amino terminus of histone H2B, a region of the molecule that is accessible in chromatin, Using a series of overlapping H2B synthetic peptides and structural analogues, we have mapped the different epitopes recognized by these antibodies. We have also sequenced the combining sites (variable regions) of the antibodies and modeled their interactions with the corresponding epitopes. Overall, the data suggest that the mechanisms of interaction with antigen are different for each of the three antibodies, even though they all react with the amino-terminal domain of the histone H2B molecule. The results also suggest that the binding between these antibodies and histone H2B is different from that between most antibodies and conventional protein antigens since the heavy chain complementarity-determining region 3 appears to play only a limited role in the three antibodies tested. The study of the interaction between self-antigens and spontaneously occurring autoantibodies may help us elucidate the mechanisms driving the expansion of self-reactive lymphocytes.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67000 Strasbourg, France	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Monestier, M (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.		Muller, Sylviane/J-5319-2014; Decker, Patrice/AAD-8624-2022	Decker, Patrice/0000-0002-8155-2792	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026665, R29AI026665] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26665] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BARAKAT S, 1990, CLIN EXP IMMUNOL, V81, P256; Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545; BRIAND JP, 1995, J BIOL CHEM, V270, P20686, DOI 10.1074/jbc.270.35.20686; Burlingame RW, 1996, MOL BIOL REP, V23, P159, DOI 10.1007/BF00351164; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GABRIEL JL, 1993, P NATL ACAD SCI USA, V90, P4186, DOI 10.1073/pnas.90.9.4186; GELIEBTER J, 1987, FOCUS, V9, P5; HARDIN JA, 1983, P NATL ACAD SCI-BIOL, V80, P7410, DOI 10.1073/pnas.80.24.7410; Hasegawa M, 1998, ANN RHEUM DIS, V57, P470, DOI 10.1136/ard.57.8.470; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1991, SEQUENCES PROTEINS I; Kingery BD, 1996, BIOTECHNOL SOFTW J, V13, P20; Mandal C, 1996, NAT BIOTECHNOL, V14, P323, DOI 10.1038/nbt0396-323; Monestier M, 1997, MOL IMMUNOL, V34, P39, DOI 10.1016/S0161-5890(96)00111-3; Monestier M, 1997, METHODS, V11, P36, DOI 10.1006/meth.1996.0385; MONESTIER M, 1991, EUR J IMMUNOL, V21, P1725, DOI 10.1002/eji.1830210721; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; MONESTIER M, 1992, RHEUM DIS CLIN N AM, V18, P415; Monestier M, 1996, MOL IMMUNOL, V33, P89, DOI 10.1016/0161-5890(95)00115-8; MULLER S, 1985, BIOCHIM BIOPHYS ACTA, V827, P235, DOI 10.1016/0167-4838(85)90208-0; NEIMARK J, 1993, PEPTIDE RES, V6, P219; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PORTANOVA JP, 1990, J IMMUNOL, V144, P4633; Quesnel A, 1998, J PEPT RES, V52, P107; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Stemmer C, 1996, J BIOL CHEM, V271, P21257, DOI 10.1074/jbc.271.35.21257; Stemmer C, 1997, J MOL BIOL, V273, P52, DOI 10.1006/jmbi.1997.1270; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; van Holde KE., 1989, SPRINGER SERIES MOL; Williams WM, 1996, CLIN EXP IMMUNOL, V104, P18, DOI 10.1046/j.1365-2249.1996.d01-633.x; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	36	24	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13558	13563		10.1074/jbc.275.18.13558	http://dx.doi.org/10.1074/jbc.275.18.13558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788471	hybrid			2022-12-27	WOS:000086925300058
J	Tang, BL; Zhang, T; Low, DYH; Wong, ET; Horstmann, H; Hong, WJ				Tang, BL; Zhang, T; Low, DYH; Wong, ET; Horstmann, H; Hong, WJ			Mammalian homologues of yeast Sec31p - An ubiquitously expressed form is localized to endoplasmic reticulum (ER) exit sites and is essential for ER-Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; INTERMEDIATE COMPARTMENT; SUBUNIT INTERACTIONS; VESICLE FORMATION; SEC13P COMPLEX; COAT PROTEINS; COPII; SEC24P; RECONSTITUTION; APPARATUS	The yeast coat protein II (COPII) is responsible for vesicle budding from the endoplasmic reticulum (ER), Mammalian functional homologues for all yeast COPII components, except for Sec31p, have been reported. We have cloned a mammalian cDNA whose product (Sec31A) is about 26% identical to Saccharomyces cerevisiae Sec31p, Data base searches also revealed another partial sequence encoding a polypeptide (Sec31B) that is 40% identical to Sec31A Northern analysis revealed that Sec31A transcripts are ubiquitously and abundantly expressed, while Sec31B transcripts are particularly enriched in the testis and thymus, but present in very low levels in other tissues. Sec31A is localized to vesicular structures that scatter throughout the cell but are concentrated at the perinuclear region. The structures marked by Sec31A contain Sec13, a component of COPII that is well characterized to mark the ER exit sites. Immunoelectron microscopy revealed that Sec31A colocalizes with Sec13 in structures with extensive vesicular-tubular profiles. Antibodies raised against a C-terminal portion of Sec31A co-precipitate Sec13 and inhibit ER-Golgi transport of temperature-arrested vesicular stomatitis G protein in a semi-intact cell assay. Cytosol immunodepleted of Sec31A failed to support vesicular stomatitis G protein transport, which can be rescued by a high molecular weight fraction of the cytosol containing both Sec31A and Sec13, We conclude that Sec31A represents a functional mammalian homologue of yeast Sec31p.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Tang, BL (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010; Tang, Bor Luen/E-4548-2012	Tang, Bor Luen/0000-0002-1925-636X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P137; HARAKUGE SO, 1994, J CELL BIOL, V124, P8883; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; KAISER CA, 1990, CELL, V61, P23; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shugrue CA, 1999, J CELL SCI, V112, P4547; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Tang BL, 1999, BIOCHEM BIOPH RES CO, V258, P679, DOI 10.1006/bbrc.1999.0574; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Tani K, 1999, FEBS LETT, V447, P247, DOI 10.1016/S0014-5793(99)00303-8; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	48	71	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13597	13604		10.1074/jbc.275.18.13597	http://dx.doi.org/10.1074/jbc.275.18.13597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788476	hybrid			2022-12-27	WOS:000086925300063
J	Herrington, J; Diakonova, M; Rui, L; Gunter, DR; Carter-Su, C				Herrington, J; Diakonova, M; Rui, L; Gunter, DR; Carter-Su, C			SH2-B is required for growth hormone-induced actin reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; BINDING PROTEIN RAC; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; PHOSPHORYLATION; IDENTIFICATION; DOMAIN	The Src homology-2 (SH2) domain-containing protein SH2-B beta is a substrate of the growth hormone (GH) receptor-associated tyrosine kinase JAK2. Here we tested whether SH2-B beta is involved in GH regulation of the actin cytoskeleton. Based on cell fractionation and confocal microscopy, we find SH2-B beta present at the plasma membrane and in the cytosol. SH2-B beta colocalized with filamentous actin in GH and platelet-derived growth factor (PDGF)-induced membrane ruffles. To test if SH2-B beta is required for actin reorganization, we transiently overexpressed wild-type or mutant SH2-B beta in 3T3-F442A cells and assayed for GH- and PDGF-induced membrane ruffling and fluid phase pinocytosis. Overexpression of wild-type SH2-B beta enhanced ruffling and pinocytosis produced by submaximal GH but not sub-maximal PDGF. Point mutant SH2-B beta (R555E) and truncation mutant Delta C555, both lacking a functional SH2 domain, inhibited membrane ruffling and pinocytosis induced by GH and PDGF. Mutant Delta N504, which possesses a functional SH2 domain and enhances JAK2 kinase activity in overexpression systems, also inhibited GH stimulated membrane ruffling. Delta N504 failed to inhibit GH-induced nuclear localization of Stat5B, indicating JAK2 is active in these cells. Taken together, these results show that SH2-B beta is required for GH-induced actin reorganization by a mechanism discrete from the action of SH2-B beta as a stimulator of JAK2 kinase activity.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 6804 Med Sci 2,1301 Catherine St, Ann Arbor, MI 48109 USA.			Diakonova, Maria/0000-0002-4554-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK054222, P60DK020572, P30DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-54222, DK-20572, R01 DK034171, R01-DK-34171, R01 DK054222] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRUNK U, 1976, EXP CELL RES, V103, P295, DOI 10.1016/0014-4827(76)90266-4; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; Goh ELK, 1998, ENDOCRINOLOGY, V139, P4364, DOI 10.1210/en.139.10.4364; Goh ELK, 1997, ENDOCRINOLOGY, V138, P3207, DOI 10.1210/en.138.8.3207; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MERILAINEN J, 1993, J CELL SCI, V105, P647; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; OHLSSON C, 1992, P NATL ACAD SCI USA, V89, P9826, DOI 10.1073/pnas.89.20.9826; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; RUI L, 2000, IN PRESS MOL CELL BI; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WABITSCH M, 1993, HORM RES, V40, P5, DOI 10.1159/000183760; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WIEDERMANN CJ, 1993, BLOOD, V82, P954; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	53	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13126	13133		10.1074/jbc.275.17.13126	http://dx.doi.org/10.1074/jbc.275.17.13126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777618	hybrid			2022-12-27	WOS:000086762300102
J	Martin, G; Poirier, H; Hennuyer, N; Crombie, D; Fruchart, JC; Heyman, RA; Besnard, P; Auwerx, J				Martin, G; Poirier, H; Hennuyer, N; Crombie, D; Fruchart, JC; Heyman, RA; Besnard, P; Auwerx, J			Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA ACTIVATORS; BINDING-PROTEIN; PREADIPOCYTE DIFFERENTIATION; LIPOPROTEIN-LIPASE; RXR HETERODIMERS; NUCLEAR RECEPTOR; RAT-LIVER; EXPRESSION; ALPHA; ADIPOCYTES	The intracellular fatty acid content of insulin-sensitive target tissues determines in part their insulin sensitivity. Uptake of fatty acids into cells is a controlled process determined in part by a regulated import/export system that is controlled at least by two key groups of proteins, i.e. the fatty acid transport protein (FATP) and acyl-CoA synthetase (ACS), which facilitate, respectively, the transport of fatty acids across the cell membrane and catalyze their esterification to prevent their efflux, Previously it was shown that the expression of the FATP-1 and ACS genes was controlled by insulin and by peroxisome proliferator-activated receptor (PPAR) agonists in liver or in adipose tissue. The aim of this investigation was to determine the effects of retinoic acid derivatives on the expression of FATP-1 and ACS. In several cultured cell lines, it was shown that the expression of both the FATP-1 and ACS mRNAs was specifically induced at the transcriptional level by selective retinoid X receptor (RXR) but not by retinoic acid receptor (RAR) ligands, This effect was most pronounced in hepatoma cell lines. A similar induction of FATP-1 and ACS mRNA levels was also observed in vivo in Zucker diabetic fatty rats treated with the RXR agonist, LGD1069 (4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra- hydro-2-naphthyl)ethenyl]benzoic acid). Through the use of heterodimer-selective compounds, it was demonstrated that the modulatory effect of these rexinoids on FATP-1 and ACS gene expression was mediated through activation of RXR in the context of the PPAR-RXR heterodimer. The observation that both RXR and PPAR agonists can stimulate the transcription of genes implicated in lipid metabolism, suggest that rexinoids may also act as lipid-modifying agents and support a role of the permissive PPAR-RXR heterodimer in the control of insulin sensitivity.	Inst Pasteur, INSERM, U325, Dept Atherosclerose, F-59019 Lille, France; Univ Bourgogne, Ecole Natl Super Biol Appl Nutr & Alimentat, CESG,CNRS,EP1777, Lab Physiol Nutr, F-21000 Dijon, France; Ligand Pharmaceut Inc, San Diego, CA 92121 USA; Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; Ligand Pharmaceuticals; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), Inst Pasteur, INSERM, U325, Dept Atherosclerose, 1 Rue Prof Calmette, F-59019 Lille, France.	auwerx@igbmc.u-strasbg.fr	Auwerx, Johan/ABE-9307-2021	Auwerx, Johan/0000-0002-5065-5393; HENNUYER, Nathalie/0000-0003-0303-7258				ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; HERTZ R, 1992, BIOCHEM J, V281, P41, DOI 10.1042/bj2810041; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin G, 1998, INT CONGR SER, V1155, P35; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MeunierDurmort C, 1996, BIOCHEM J, V319, P483, DOI 10.1042/bj3190483; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; Poirier H, 1997, FEBS LETT, V412, P480, DOI 10.1016/S0014-5793(97)00830-2; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; ZHOU SL, 1995, P SOC EXP BIOL MED, V208, P263	34	67	85	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12612	12618		10.1074/jbc.275.17.12612	http://dx.doi.org/10.1074/jbc.275.17.12612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777552	hybrid			2022-12-27	WOS:000086762300036
J	Perez-Sanchez, C; Gomez-Ferreria, MA; de la Fuente, CA; Granadino, B; Velasco, G; Esteban-Gamboa, A; Rey-Campos, J				Perez-Sanchez, C; Gomez-Ferreria, MA; de la Fuente, CA; Granadino, B; Velasco, G; Esteban-Gamboa, A; Rey-Campos, J			FHX, a novel fork head factor with a dual DNA binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HNF3; WINGED HELIX PROTEINS; CAENORHABDITIS-ELEGANS; FAMILY MEMBER; GENE; EXPRESSION; DOMAIN; ACTIVATION; PROMOTER; SEQUENCE	The HNF3/fork head family includes a large number of transcription factors that share a structurally related DNA binding domain. Bork head factors have been shown to play important roles both during development and in the adult. We now describe the cloning of a novel mammalian fork head factor that we have named FHX ((f) under bar ork head (h) under bar omologous (X) under bar (FHX), which is expressed in many adult tissues. In the embryo, FHX expression showed a very early onset during the cleavage stages of preimplantation development. Polymerase chain reaction-assisted site selection experiments showed that FHX bound DNA with a dual sequence specificity. Sites recognized by FHX could be classified into two different types according to their sequences. Binding of FHX to sequences of each type appeared to occur independently, Our data suggest that either different regions of the fork head domain or different molecular forms of this domain could be involved in binding of FHX to each type of site. In transfection assays, FHX was capable of activating transcription from promoters containing FHX sites of either type.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Oviedo	Rey-Campos, J (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		goenechea, begoña granadino/Y-4694-2019; Velasco, Gloria/AAS-5842-2021	Velasco, Gloria/0000-0001-8032-5056; granadino, begona/0000-0002-0144-8638				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; ARENZANA N, 1995, BIOCHEM J, V308, P613, DOI 10.1042/bj3080613; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Brody SL, 1997, GENOMICS, V45, P509, DOI 10.1006/geno.1997.4970; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; HACKETT BP, 1995, P NATL ACAD SCI USA, V92, P4249, DOI 10.1073/pnas.92.10.4249; Hellqvist M, 1998, J BIOL CHEM, V273, P23335, DOI 10.1074/jbc.273.36.23335; Iida K, 1997, DEVELOPMENT, V124, P4627; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; MartinezHackert E, 1997, J MOL BIOL, V269, P301, DOI 10.1006/jmbi.1997.1065; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ortiz L, 1997, J BIOL CHEM, V272, P23334, DOI 10.1074/jbc.272.37.23334; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wehr R, 1997, DEVELOPMENT, V124, P4447; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	47	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12909	12916		10.1074/jbc.275.17.12909	http://dx.doi.org/10.1074/jbc.275.17.12909			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777590	hybrid, Green Published			2022-12-27	WOS:000086762300074
J	Patterson, JH; McConville, MJ; Haites, RE; Coppel, RL; Billman-Jacobe, H				Patterson, JH; McConville, MJ; Haites, RE; Coppel, RL; Billman-Jacobe, H			Identification of a methyltransferase from Mycobacterium smegmatis involved in glycopeptidolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC GENE-CLUSTER; STREPTOMYCES-AVERMITILIS; AVIUM; EXPRESSION; COMPLEX; PATHOGENICITY; ORGANIZATION; CONSTRUCTION; AVERMECTIN; VARIANTS	Glycopeptidolipids (GPLs) are major components of the cell walls of several species of mycobacteria. We have isolated a transposon mutant of Mycobacterium smegmatis that is unable to synthesize mature GPLs and that displays a rough colony morphology. The disrupted gene, mtf1, shares a high degree of homology with several S-adenoslmethionine-dependent methyltransferases. The enzyme encoded by mtf1 is required for the methylation of a single rhamnose residue that forms part of the conserved GPL core structure. This conclusion is supported by the finding that (a) the mutant synthesized only GPLs with undermethylated (either mono- or nonmethylated instead of di- or trimethylated) rhamnose residues; (b) complementation of the mutant with a wild-type copy of mtf1 restored high levels of synthesis of GPLs containing di- and trimethylated rhamnose; and (c) S-adenosylmethionine-dependent methylation of rhamnosylated GPLs could be detected in cell lysates of wild-type cells and mtf1-complemented mutant cells, but not in mutant cells lacking intact mtf1. Structural analysis of wild-type and mutant GPLs suggests that disruption of mtf1 specifically inhibits addition of O-methyl groups to the 3 (or 2)-position of the rhamnose, In the absence of 3-O-methylation, further methylation of GPL rhamnose is apparently inhibited, and overall GPL synthesis is down-regulated by 90%.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia	University of Melbourne; Monash University	Billman-Jacobe, H (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Royal Parade, Parkville, Vic 3052, Australia.		Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124; Billman-Jacobe, Helen/0000-0001-5713-4657				ANDERBERG RJ, 1995, BIOTECHNIQUES, V18, P217; Aspinall GO, 1995, ADV CARBOHYD CHEM BI, V51, P169, DOI 10.1016/S0065-2318(08)60194-8; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; BELISLE JT, 1993, J BIOL CHEM, V268, P10517; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; BillmanJacobe H, 1996, FEMS MICROBIOL LETT, V144, P47, DOI 10.1016/0378-1097(96)00336-9; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAFFE M, 1983, BIOCHIM BIOPHYS ACTA, V751, P439, DOI 10.1016/0005-2760(83)90304-1; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; Eckstein TM, 1998, J BACTERIOL, V180, P5567, DOI 10.1128/JB.180.21.5567-5573.1998; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fouces R, 1999, MICROBIOL-UK, V145, P855, DOI 10.1099/13500872-145-4-855; GRAY GR, 1972, METHOD ENZYMOL, V35, P90; GUILHOT C, 1994, J BACTERIOL, V176, P535, DOI 10.1128/JB.176.2.535-539.1994; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; Ikeda H, 1999, P NATL ACAD SCI USA, V96, P9509, DOI 10.1073/pnas.96.17.9509; ILTON M, 1971, P NATL ACAD SCI USA, V68, P87, DOI 10.1073/pnas.68.1.87; INOUYE M, 1994, GENE, V141, P121; Kansal RG, 1998, MICROB PATHOGENESIS, V25, P203, DOI 10.1006/mpat.1998.0227; MACNEIL T, 1993, J BACTERIOL, V175, P2552, DOI 10.1128/JB.175.9.2552-2563.1993; Mao YQ, 1999, CHEM BIOL, V6, P251, DOI 10.1016/S1074-5521(99)80040-4; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILLS JA, 1994, J BACTERIOL, V176, P4803, DOI 10.1128/jb.176.16.4803-4808.1994; Parish T, 1998, METH MOL B, V101, P77, DOI 10.1385/0-89603-471-2:77; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RADFORD AJ, 1991, PLASMID, V25, P149, DOI 10.1016/0147-619X(91)90029-V; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER WB, 1970, AM REV RESPIR DIS, V102, P499; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233	33	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24900	24906		10.1074/jbc.M000147200	http://dx.doi.org/10.1074/jbc.M000147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801784	hybrid			2022-12-27	WOS:000088683300089
J	Wang, YJ; Gregory, RB; Barritt, GJ				Wang, YJ; Gregory, RB; Barritt, GJ			Regulation of F-actin and endoplasmic reticulum organization by the trimeric G-protein G(12) in rat hepatocytes - Implication for the activation of store-operated Ca2+ inflow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; LEUKEMIA HL-60 CELLS; GTP-BINDING PROTEIN; PERTUSSIS-TOXIN; PLASMA-MEMBRANE; SUBCELLULAR-DISTRIBUTION; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; ADP-RIBOSYLATION; RECEPTOR	The roles of the heterotrimeric G-protein, G(i2), in regulating the actin cytoskeleton and the activation of store-operated Ca2+ channels in rat hepatocytes were investigated. G alpha(i2) was principally associated with the plasma membrane and microsomes. Both F-actin and G alpha(i2) were detected by Western blot analysis in a purified plasma membrane preparation, the supernatant and pellet obtained by treating the plasma membrane with Triton X-100, and after depolymerization and repolymerization of F-actin in the Triton X-100-insoluble pellet. Actin in the Triton X-100-soluble supernatant coprecipitated with G alpha(i2) using either anti-G alpha(i2) or antiactin antibodies. The principally cortical location of F-actin in hepatocytes cultured for 0.5 h changed to a pericanalicular distribution over a further 3.5 h, Some G alpha(i2) co-localized with F-actin at the plasma membrane. Pretreatment with pertussis toxin ADP-ribosylated 70-80% of G alpha(i2) in the plasma membrane and microsomes, prevented the redistribution of F-actin, caused redistribution and fragmentation of the endoplasmic reticulum, and inhibited vasopressin-stimulated Ca2+ inflow. It is concluded that (i) a significant portion of hepatocyte G alpha(i2) associates with, and regulates the arrangement of, cortical F-actin and the endoplasmic reticulum and (ii) either or both of these regulatory roles are likely to be required for normal vasopressin activation of Ca2+ inflow.	Flinders Univ S Australia, Fac Hlth Sci, Sch Med, Dept Biochem Med, Adelaide, SA 5001, Australia	Flinders University South Australia	Barritt, GJ (corresponding author), Flinders Univ S Australia, Fac Hlth Sci, Sch Med, Dept Biochem Med, GPO 2100, Adelaide, SA 5001, Australia.	Greg.Barritt@flinders.edu.au						Aronson N N Jr, 1974, Methods Enzymol, V31, P90; ARTERBURN LM, 1995, HEPATOLOGY, V22, P175, DOI 10.1002/hep.1840220128; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRY MN, 1991, LABORATORY TECHNIQUE, V21, P15; BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; BERVEN LA, 1995, J BIOL CHEM, V270, P25893, DOI 10.1074/jbc.270.43.25893; BOHM M, 1993, BIOCHEM PHARMACOL, V46, P2145, DOI 10.1016/0006-2952(93)90603-T; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadrin M, 1996, J CELL BIOCHEM, V62, P334, DOI 10.1002/(SICI)1097-4644(199609)62:3<334::AID-JCB4>3.0.CO;2-S; FERNANDO KC, 1994, BIOCHEM J, V303, P351, DOI 10.1042/bj3030351; Fernando KC, 1997, BIOCHEM J, V328, P463; Fierro L, 1999, PFLUG ARCH EUR J PHY, V437, P547, DOI 10.1007/s004240050816; FRENCH SW, 1993, MOL CELL BIOL LIVER, P143; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; GRIFFITHS SL, 1990, EUR J BIOCHEM, V193, P367, DOI 10.1111/j.1432-1033.1990.tb19348.x; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; Heringdorf DMZ, 1996, EUR J BIOCHEM, V235, P670, DOI 10.1111/j.1432-1033.1996.00670.x; HINTON RH, 1997, SUBCELLULAR FRACTION, P42; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KOMATSU M, 1995, ENDOCRINOLOGY, V136, P1857, DOI 10.1210/en.136.5.1857; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; LAOMMLI UK, 1970, NATURE, V227, P680; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MORRIS NJ, 1994, BIOCHEM J, V301, P693, DOI 10.1042/bj3010693; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PHILLIPS MJ, 1981, J CELL BIOL, V91, P524, DOI 10.1083/jcb.91.2.524; POBINER BF, 1991, MOL PHARMACOL, V40, P156; PRPIC V, 1984, J BIOL CHEM, V259, P1382; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; Saltarelli D, 1999, CELL SIGNAL, V11, P415, DOI 10.1016/S0898-6568(99)00012-1; Sarndahl E, 1996, J BIOL CHEM, V271, P15267; SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791; SHETH B, 1991, BIOCHEM J, V275, P809, DOI 10.1042/bj2750809; THIBAULT N, 1992, TOXICOLOGY, V73, P269, DOI 10.1016/0300-483X(92)90069-Q; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueda H, 1997, J CELL SCI, V110, P1503; Watanabe H, 1998, FASEB J, V12, P341, DOI 10.1096/fasebj.12.3.341; Wieland T, 1996, EUR J BIOCHEM, V239, P752, DOI 10.1111/j.1432-1033.1996.0752u.x; WU YN, 1992, J BIOL CHEM, V267, P8396; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	48	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22229	22237		10.1074/jbc.M001563200	http://dx.doi.org/10.1074/jbc.M001563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10787407	hybrid			2022-12-27	WOS:000088363800066
J	Fukuhara, S; Marinissen, MJ; Chiariello, M; Gutkind, JS				Fukuhara, S; Marinissen, MJ; Chiariello, M; Gutkind, JS			Signaling from G protein-coupled receptors to ERK5/big MAPK 1 involves G alpha(q) and G alpha(12/13) families of heterotrimeric G proteins - Evidence for the existence of a novel Ras and Rho-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATION; GENE-EXPRESSION; INVOLVEMENT; THROMBIN	The regulation of gene expression by cell surface receptors often involves the stimulation of signaling pathways including one or more members of the MAPK superfamily of serine-threonine kinases. Upon their activation in the cytosol, MAPKs can translocate to the nucleus and affect the activity of a variety of transcription factors. Recently, it has been observed that a novel member of the MAPK superfamily, ERK5, can be potently activated by transforming G protein-coupled receptors (GPCRs) and that ERK5 participates in the regulation of c-jun expression through the activation of MEF2 transcription factors. How cell surface receptors, including GPCRs, stimulate ERK5 is still poorly understood. In this study, we have used transiently transfected COS-7 cells to begin delineating the biochemical route linking GPCRs to ERK5. We show that receptors that can couple to the Gq and G(12/13) families of heterotrimeric G proteins, mi and thrombin receptors, respectively, but not those coupled to G(i), such as m2 receptors, are able to regulate the activity of ERK5. To investigate which heterotrimeric G proteins signal to ERK5, we used a chimeric system by which G alpha(q)- and G alpha(13)-mediated signaling pathways can be conditionally activated upon ligand stimulation. Using this system, as well as the expression of activated forms of G protein subunits, we show that the G alpha(q) and G alpha(12/13) families of heterotrimeric G proteins, but not the G alpha(i), G alpha(s), and beta gamma subunits, are able to regulate ERK5. Furthermore, we provide evidence that the stimulation of ERK5 by GPCRs involves a novel signaling pathway, which is distinct from those regulated by Ras and Rho GTPases.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Rm 212,Bldg 30,30 Convent Dr, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Chiariello, Mario/O-3642-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Chiariello, Mario/0000-0001-8434-5177	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe MK, 1999, MOL CELL BIOL, V19, P1301; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyata Y, 1999, GENES CELLS, V4, P299, DOI 10.1046/j.1365-2443.1999.00261.x; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	48	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21730	21736		10.1074/jbc.M002410200	http://dx.doi.org/10.1074/jbc.M002410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781600	hybrid			2022-12-27	WOS:000088230600101
J	Yang, BL; Cao, L; Kiani, C; Lee, V; Zhang, Y; Adams, ME; Yang, BB				Yang, BL; Cao, L; Kiani, C; Lee, V; Zhang, Y; Adams, ME; Yang, BB			Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PG-M; CELL-ADHESION; LINK PROTEIN; CDNA CLONING; AGGRECAN; CHONDROGENESIS; PROLIFERATION; CARTILAGE; BRAIN	The large aggregating chondroitin sulfate proteoglycans, including aggrecan, versican (PG-M), neurocan, and brevican, are characterized by N-terminal and C-terminal globular (or selectin-like) domains known as the G1 and G3 domains, respectively, For this study, we generated a series of expression constructs containing various combinations of chicken versican/PG-M domains and a leading peptide of link protein in order to examine the roles of the G1 and G3 domains in versican function, In transfection studies, we observed that the presence of the G1 domain was sufficient to inhibit product secretion, while the G3 domain enhanced this process, We also demonstrated that the G1 domain inhibited the attachment of glycosaminoglycan chains to the core proteins, while the G3 domain enhanced this process. Further studies revealed that inhibition of secretion by G1 was mediated by its two tandem repeats, while G3's promotion of glycosaminoglycan chain attachment was apparently dependent on G3's complement-binding protein (CBP)-like motif, The modulatory effects of these two molecular domains may contribute to versican's biological activities.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BLOCK JA, 1991, J BONE JOINT SURG AM, V73A, P647, DOI 10.2106/00004623-199173050-00002; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Cao L, 1999, EXP CELL RES, V246, P527, DOI 10.1006/excr.1998.4335; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LI H, 1993, J BIOL CHEM, V268, P23504; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; NASO MF, 1994, J BIOL CHEM, V269, P32999; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; VERTEL BM, 1993, J CELL SCI, V104, P939; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YANG B, 1994, ANAL BIOCHEM, V228, P299; YANG BB, 1997, MATRIX BIOL, V16, P537; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	35	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21255	21261		10.1074/jbc.M001443200	http://dx.doi.org/10.1074/jbc.M001443200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801813	hybrid			2022-12-27	WOS:000088230600041
J	Lu, D; Kussie, P; Pytowski, B; Persaud, K; Bohlen, P; Witte, L; Zhu, ZP				Lu, D; Kussie, P; Pytowski, B; Persaud, K; Bohlen, P; Witte, L; Zhu, ZP			Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; STEM-CELL FACTOR; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LIGAND-BINDING; SIGNAL-TRANSDUCTION; KINASE; VEGF; FLT-1; ANGIOGENESIS	The kinase domain receptor (KDR) of vascular endothelial growth factor (VEGF) is the main human receptor responsible for the angiogenic activity of VEGF. The extracellular region of KDR is comprised of seven immunoglobulin-like domains, of which the first three have been shown to be required for ligand binding. We have previously described antibodies directed against the extracellular region of KDR, including MAB383 and MAB664, which were shown to block the binding of VEGF to the receptor and to inhibit both VEGF-induced mitogenesis of human endothelial cells in vitro and tumor growth in vivo. Here we generated a series of KDR deletion mutants consisting of truncated extracellular regions and mapped out the domain(s) responsible for binding to VEGF and the neutralizing anti-KDR antibodies. All neutralizing antibodies were found to require domain 3 for efficient binding. Alanine-scanning mutagenesis of domain 3 identified two different sets of five residues, Ile(256), Asp(257), Glu(261), Leu(313) and Thr(315) and Tyr(262), Pro(263), Ser(264), Ser(265), and Lys(266), that were critical for binding to MAB383 and MAB664, respectively. Combination of alanine mutations affecting both MAB383 and MAB664 binding resulted in a variant that also lost binding to VEGF. These results suggest that the residues within this region of domain 3 are critical for VEGF binding. Our studies provide a basis for the mechanism of action of our anti-KDR antibodies and establish a functional foundation for the development of other classes of antagonists to the receptor.	ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Prot Chem, New York, NY 10014 USA; ImClone Syst Inc, Dept Res, New York, NY 10014 USA	Eli Lilly; Eli Lilly; Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Mol & Cell Biol, 180 Varick St, New York, NY 10014 USA.	zhenping@imclone.com						Barleon B, 1997, J BIOL CHEM, V272, P10382; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BROWN F, 1997, REGULATION ANGIOGENE, P233; Cabilly S, 1998, METH MOL B, V87, P175; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCH AE, 1994, J IMMUNOL, V152, P4149; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; Lu D, 1999, J IMMUNOL METHODS, V230, P159, DOI 10.1016/S0022-1759(99)00135-0; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; Zhu ZP, 1999, INVEST NEW DRUG, V17, P195, DOI 10.1023/A:1006314501634	36	66	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14321	14330		10.1074/jbc.275.19.14321	http://dx.doi.org/10.1074/jbc.275.19.14321			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799512	hybrid			2022-12-27	WOS:000087006900044
J	Wittstock, U; Halkier, BA				Wittstock, U; Halkier, BA			Cytochrome P450CYP79A2 from Arabidopsis thaliana L. catalyzes the conversion of L-phenylalanine to phenylacetaldoxime in the biosynthesis of benzylglucosinolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYPHENYLACETALDEHYDE OXIME; CYANOGENIC GLUCOSIDE DHURRIN; BICOLOR L MOENCH; ESCHERICHIA-COLI; GLUCOSINOLATE BIOSYNTHESIS; IN-VITRO; THIOHYDROXIMATE GLUCOSYLTRANSFERASE; TROPAEOLUM-MAJUS; L SEEDLINGS; AMINO-ACID	Glucosinolates are natural plant products gaining increasing interest as cancer-preventing agents and crop protectants. Similar to cyanogenic glucosides, glucosinolates are derived from amino acids and have aldoximes as intermediates. We report cloning and characterization of cytochrome P450 CYP79A2 involved in aldoxime formation in the glucosinolate-producing Arabidopsis thaliana L. The CYP79A2 cDNA was cloned by polymerase chain reaction, and CYP79A2 was functionally expressed in Escherichia coli. Characterization of the recombinant protein shows that CYP79A2 is an N-hydroxylase converting L-phenylalanine into phenylacetaldoxime, the precursor of benzylglucosinolate. Transgenic A. thaliana constitutively expressing CYP79A2 accumulate high levels of benzylglucosinolate. CYP79A2 expressed in E. coli has a K-m of 6.7 mu mol liter(-1) for L-phenylalanine. Neither L-tyrosine, L-tryptophan, L-methionine, nor DL-homophenylalanine are metabolized by CYP79A2, indicating that the enzyme has a narrow substrate specificity. CYP79A2 is the first enzyme shown to catalyze the conversion of an amino acid to the aldoxime in the biosynthesis of glucosinolates. Our data provide the first conclusive evidence that evolutionarily conserved cytochromes P450 catalyze this step common for the biosynthetic pathways of glucosinolates and cyanogenic glucosides. This strongly indicates that the biosynthesis of glucosinolates has evolved based on a cyanogenic predisposition.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol, DK-1871 Frederiksberg, Denmark	University of Copenhagen; University of Copenhagen	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.		Halkier, Barbara A/H-3196-2014	Halkier, Barbara A/0000-0002-3742-702X; Wittstock, Ute/0000-0002-0914-8453				Andersen MD, 2000, J BIOL CHEM, V275, P1966, DOI 10.1074/jbc.275.3.1966; [Anonymous], 1988, ACS SYM SER; Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BENNETT R, 1993, PLANT PHYSIOL, V102, P1307, DOI 10.1104/pp.102.4.1307; Bennett RN, 1996, PLANT CELL ENVIRON, V19, P801, DOI 10.1111/j.1365-3040.1996.tb00417.x; Bennett RN, 1997, PHYTOCHEMISTRY, V45, P59, DOI 10.1016/S0031-9422(96)00787-X; Bennett RN, 1997, PLANT PHYSIOL, V114, P1283, DOI 10.1104/pp.114.4.1283; BENNETT RN, 1995, PLANT PHYSIOL, V109, P299, DOI 10.1104/pp.109.1.299; Brown PD, 1995, J AGR FOOD CHEM, V43, P3070, DOI 10.1021/jf00060a015; Buchner R., 1987, GLUCOSINOLATES RAPES, P50, DOI DOI 10.1007/978-94-009-3615-7; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DALESSIO JM, 1992, FOCUS, V14, P76; DellaPenna D, 1999, SCIENCE, V285, P375, DOI 10.1126/science.285.5426.375; Du LC, 1996, PLANT PHYSIOL, V111, P831, DOI 10.1104/pp.111.3.831; Du LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/pnas.92.26.12505; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GLENDENING TM, 1988, PLANT PHYSIOL, V86, P319, DOI 10.1104/pp.86.2.319; GUO LK, 1994, PHYTOCHEMISTRY, V36, P1133, DOI 10.1016/S0031-9422(00)89626-0; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; Halkier BA, 1997, TRENDS PLANT SCI, V2, P425, DOI 10.1016/S1360-1385(97)01128-X; HAUGHN GW, 1991, PLANT PHYSIOL, V97, P217, DOI 10.1104/pp.97.1.217; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; HOGGE LR, 1988, J CHROMATOGR SCI, V26, P551, DOI 10.1093/chromsci/26.11.551; IMAI Y, 1967, EUR J BIOCHEM, V1, P419, DOI 10.1111/j.1432-1033.1967.tb00090.x; JAIN JC, 1990, PHYTOCHEMISTRY, V29, P1425, DOI 10.1016/0031-9422(90)80094-W; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KOCH B, 1992, ARCH BIOCHEM BIOPHYS, V292, P141, DOI 10.1016/0003-9861(92)90062-2; KOCH BM, 1995, ARCH BIOCHEM BIOPHYS, V323, P177; LUDWIGMULLER J, 1988, PHYSIOL PLANTARUM, V74, P240, DOI 10.1111/j.1399-3054.1988.tb00627.x; Manici LM, 1997, J AGR FOOD CHEM, V45, P2768, DOI 10.1021/jf9608635; MATSUO M, 1968, CHEM PHARM BULL, V16, P1128; Nastruzzi C, 1996, J AGR FOOD CHEM, V44, P1014, DOI 10.1021/jf9503523; NIELSEN JS, 2000, IN PRESS PLANT PHYSL; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OMURA T, 1964, J BIOL CHEM, V239, P2370; PAQUETTE SM, 2000, IN PRESS DNA CELL BI; PINTAO AM, 1995, PLANTA MED, V61, P233, DOI 10.1055/s-2006-958062; REED DW, 1993, ARCH BIOCHEM BIOPHYS, V305, P526, DOI 10.1006/abbi.1993.1456; Rodman JE, 1996, SYST BOT, V21, P289, DOI 10.2307/2419660; SAUPE SG, 1981, PHYTOCHEMISTRY ANGIO, P81; SIBBESEN O, 1995, J BIOL CHEM, V270, P3506, DOI 10.1074/jbc.270.8.3506; Sorensen H., 1990, CANOLA RAPESEED PROD, P149; STADLER E, 1978, ENTOMOL EXP APPL, V24, P711, DOI 10.1007/BF02385127; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; Yun CH, 1997, J BIOL CHEM, V272, P19725, DOI 10.1074/jbc.272.32.19725; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399	53	190	206	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14659	14666		10.1074/jbc.275.19.14659	http://dx.doi.org/10.1074/jbc.275.19.14659			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799553	hybrid			2022-12-27	WOS:000087006900087
J	Paul, A; Torrie, LJ; McLaren, GJ; Kennedy, C; Gould, GW; Plevin, R				Paul, A; Torrie, LJ; McLaren, GJ; Kennedy, C; Gould, GW; Plevin, R			P2Y receptor-mediated inhibition of tumor necrosis factor alpha-stimulated stress-activated protein kinase activity in EAhy926 endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NUCLEOTIDE RECEPTORS; TYROSINE KINASE; GROWTH-FACTOR; MAP KINASE; COUPLED RECEPTORS; DNA-SYNTHESIS; UTP; ATP; PHOSPHATASE	In the EAhy926 endothelial cell line, UTP, ATP, and forskolin, but not UDP and epidermal growth factor, inhibited tumor necrosis factor alpha (TNF alpha)- and sorbitol stimulation of the stress-activated protein kinases, JNK, and p38 mitogen-activated protein (MAP) kinase, and MAPKAP kinase-2, the downstream target of p38 MAP kinase. In NCT2544 keratinocytes, UTP and a proteinase-activated receptor-a agonist caused similar inhibition, but in 13121N1 cells, transfected with the human P2Y(2) or P2Y(4) receptor, UTP stimulated JNK and p38 MAP kinase activities. This suggests that the effects mediated by P2Y receptors are cell-specific. The inhibitory effects of UTP were not due to induction of MAP kinase phosphatase-1, but were manifest upstream in the pathway at the level, of MEK-4. The inhibitory effect of UTP was insensitive to the MEK-1 inhibitor PD 098059, changes in intracellular Ca2+ levels, or pertussis toxin, Acute phorbol 12-myristate 13-acetate pretreatment also inhibited TNF alpha-stimulated SAP kinase activity, while chronic pretreatment reversed the effects of UTP. Furthermore, the protein kinase C inhibitors Ro318220 and Go6983 reversed the inhibitory action of UTP, but GF109203X was ineffective. These results indicate a novel mechanism of cross-talk regulation between P2Y receptors and TNF alpha-stimulated SAP kinase pathways in endothelial cells, mediated by Ca2+-independent isoforms of protein kinase C.	Univ Strathclyde, Strathclude Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Dept Biochem, Glasgow G12 8QQ, Lanark, Scotland	University of Strathclyde; University of Glasgow	Plevin, R (corresponding author), Univ Strathclyde, Strathclude Inst Biomed Sci, Dept Physiol & Pharmacol, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.	r.plevin@strath.ac.uk		Plevin, Robin/0000-0002-7849-1220; Kennedy, Charles/0000-0001-9661-5437; Gould, Gwyn/0000-0001-6571-2875; Paul, Andrew/0000-0001-5775-2332				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; BOEYNAEMS JM, 1990, TRENDS PHARMACOL SCI, V11, P34, DOI 10.1016/0165-6147(90)90039-B; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Erlinge D, 1996, BRIT J PHARMACOL, V118, P1028, DOI 10.1111/j.1476-5381.1996.tb15502.x; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Graham A, 1996, BRIT J PHARMACOL, V117, P1341, DOI 10.1111/j.1476-5381.1996.tb16734.x; Graham A, 1996, BIOCHEM J, V315, P563, DOI 10.1042/bj3150563; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HARDEN TK, 1998, CARDIOVASCULAR BIOL, P181; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Huwiler A, 1997, BRIT J PHARMACOL, V120, P807, DOI 10.1038/sj.bjp.0700979; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Kennedy C, 1999, BRIT J PHARMACOL, V126; Kennedy C, 1998, DEV CARDIOVASC MED, V209, P243; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; MALARKEY K, 1995, BRIT J PHARMACOL, V116, P2267, DOI 10.1111/j.1476-5381.1995.tb15063.x; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MITA D, 1997, AM J PHYSIOL, V273, pL1276; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; PURKISS JR, 1994, BRIT J PHARMACOL, V111, P723, DOI 10.1111/j.1476-5381.1994.tb14797.x; Satterwhite CM, 1999, AM J PHYSIOL-HEART C, V276, pH1091, DOI 10.1152/ajpheart.1999.276.3.H1091; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANDAELE P, 1992, CIRC RES, V70, P82, DOI 10.1161/01.RES.70.1.82; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	45	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13243	13249		10.1074/jbc.275.18.13243	http://dx.doi.org/10.1074/jbc.275.18.13243			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788429	hybrid			2022-12-27	WOS:000086925300015
J	Bald, D; Noji, H; Stumpp, MT; Yoshida, M; Hisabori, T				Bald, D; Noji, H; Stumpp, MT; Yoshida, M; Hisabori, T			ATPase activity of a highly stable alpha(3)beta(3)gamma subcomplex of thermophilic F-1 can be regulated by the introduced regulatory region of gamma subunit of chloroplast F-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; COUPLING FACTOR-I; EPSILON-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; THIOL MODULATION; DISULFIDE BOND; H+-ATPASE; ENDOGENOUS INHIBITOR; BETA-SUBUNITS; WILD-TYPE	A mutant F-1-ATPase alpha(3)beta(3)gamma subcomplex from the thermophilic Bacillus PS3 was constructed, in which 111 amino acid residues (Val(92) to Phe(202)) from the central region of the gamma subunit were replaced by the 148 amino acid residues of the homologous region from spinach chloroplast F-1-ATPase gamma subunit, including the regulatory stretch, and were designated as alpha(3)beta(3)gamma((TCT)) (Thermophilic-Chloroplast-Thermophilic). By the insertion of this regulatory region into the gamma subunit of thermophilic F-1, we could confer the thiol modulation property to the thermophilic alpha(3)beta(3)gamma subcomplex. The overexpressed alpha(3)beta(3)gamma((TCT)) was easily purified in large scale, and the ATP hydrolyzing activity of the obtained complex was shown to increase up to 3-fold upon treatment with chloroplast thioredoxin-f and dithiothreitol. No loss of thermostability compared with the wild type subcomplex was found, and activation by dithiothreitol was functional at temperatures up to 80 degrees C. alpha(3)beta(3)gamma((TCT)) was inhibited by the epsilon subunit from chloroplast F-1-ATPase but not by the one from the thermophilic F-1-ATPase, indicating that the introduced amino acid residues from chloroplast F-1-gamma subunit are important for functional interaction with the epsilon subunit.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Teikyo Biotechnol Ctr, CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CRECZYNSKIPASA TB, 1994, FEBS LETT, V350, P195, DOI 10.1016/0014-5793(94)00762-4; CRUZ JA, 1995, PLANT PHYSIOL, V109, P1379, DOI 10.1104/pp.109.4.1379; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Hisabori T, 1998, J BIOL CHEM, V273, P15901, DOI 10.1074/jbc.273.26.15901; Hisabori T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1711; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Krenn BE, 1995, BIOCHEM SOC T, V23, P757, DOI 10.1042/bst0230757; KUKI M, 1988, J BIOL CHEM, V263, P17437; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; Ross SA, 1996, J BIOENERG BIOMEMBR, V28, P49; ROSS SA, 1995, J BIOL CHEM, V270, P9813, DOI 10.1074/jbc.270.17.9813; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; Stiggall D L, 1979, Methods Enzymol, V55, P308; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; WERNERGRUNE S, 1994, MOL GEN GENET, V244, P144; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	50	22	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12757	12762		10.1074/jbc.275.17.12757	http://dx.doi.org/10.1074/jbc.275.17.12757			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777572	hybrid			2022-12-27	WOS:000086762300056
J	Buensuceso, CS; O'Toole, TE				Buensuceso, CS; O'Toole, TE			The association of CRKII with C3G can be regulated by integrins and defines a novel means to regulate the mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; NERVE GROWTH-FACTOR; MAP KINASE; CYTOPLASMIC DOMAINS; TYROSINE PHOSPHORYLATION; MEDIATED ACTIVATION; RAS ACTIVATION; PC12 CELLS; RAP1; ADHESION	In studies to define mechanisms of ERK activation in Chinese hamster ovary cells, we have observed an inverse correlation between CRKII-C3G complex formation and ERK activity. That is, we were able to coprecipitate the guanine nucleotide exchange factor C3G with the adaptor protein CRKII in lysates from suspended cells that had low ERK activity, but we could not do so or could do so less efficiently in lysates of adherent cells with increased ERK activity. Consistent with the presence of a functional CRKII-C3G complex, we detected more GTP-loaded RAP1 in suspension than adherent lysates, Overexpression of cDNAs encoding B-RAF, CRKII W109L, and PTP1B C215S activated ERK in suspension cells, the latter two constructs also disrupting CRKII-C3G complex formation. Finally, we have also observed that certain integrin alpha subunit cytoplasmic splice variants differentially regulate ERK1/2 but also in a manner that correlated with levels of a CRKII-C3G complex. Thus, these data suggest the involvement of integrins in an ERK suppression pathway mediated by CRKII-C3G complex formation and downstream signaling from activated RAP1.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	O'Toole, TE (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,CVN231-VB2, La Jolla, CA 92037 USA.		O'Toole, Timothy/I-4172-2013; O'Toole, Timothy/G-9169-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053620] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53620] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SHAW LM, 1995, J BIOL CHEM, V270, P23648, DOI 10.1074/jbc.270.40.23648; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	43	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13118	13125		10.1074/jbc.275.17.13118	http://dx.doi.org/10.1074/jbc.275.17.13118			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777617	hybrid			2022-12-27	WOS:000086762300101
J	Ma, Q; Renzelli, AJ; Baldwin, KT; Antonini, JM				Ma, Q; Renzelli, AJ; Baldwin, KT; Antonini, JM			Superinduction of CYP1A1 gene expression - Regulation of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of Ah receptor by cycloheximide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; PROTEIN-DNA INTERACTIONS; MOUSE HEPATOMA-CELLS; TRANSCRIPTIONAL ENHANCER; AROMATIC-HYDROCARBONS; NUCLEAR TRANSLOCATOR; CYTOCHROME P4501A1; DIOXIN RECEPTOR; MICE LACKING; 1C1C7 CELLS	Cycloheximide superinduces the transcription of CYP1A1 in the presence of an agonist for the Ah receptor (AhR). To investigate the molecular target for "superinduction," we analyzed the agonist-induced degradation of AhR. Whereas 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent agonist of AhR, induces a rapid reduction of the AhR protein, cycloheximide blocks the downregulation of steady state AhR. Analyses of the turnover of AhR reveal that cycloheximide blocks the shortening of the half-life of AhR by TCDD, Blocking of the TCDD-induced AhR degradation requires inhibition of protein synthesis, because (a) cycloheximide inhibits protein synthesis at the concentration at which it causes superinduction and inhibition of AhR degradation; and (b) puromycin, an inhibitor of protein synthesis by mimicking aminoacyl-tRNA, also blocks the TCDD-induced AhR degradation. The blocking of the TCDD-induced AhR degradation correlates with the superinduction of CYP1A1 gene expression in a time- and dose-dependent manner. Furthermore, cycloheximide is shown to increase the accumulation of the TCDD-activated AhR and the functional AhR Amt complex in nucleus. Collectively, our results reveal a mechanism of superinduction by cycloheximide by enhancing the stability of agonist-activated AhR, The finding that inhibition of protein synthesis blocks the TCDD-induced AhR turnover implicates a cycloheximide-sensitive, labile factor (designated as (A) under bar hR (d) under bar egradation (p) under bar romoting (f) under bar actor, or ADPF) in controlling the removal of agonist-activated AhR in nucleus.	Ctr Dis Control & Prevent, NIOSH, Pathol & Physiol Res Branch,Hlth Effects Lab Div,, NIH, Morgantown, WV 26505 USA; Ctr Dis Control & Prevent, NIOSH, Mol Toxicol lab,Toxicol & Mol Biol Branch, NIH, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA	Ma, Q (corresponding author), Ctr Dis Control & Prevent, NIOSH, Pathol & Physiol Res Branch,Hlth Effects Lab Div,, NIH, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.							AGAWAL ML, 1998, J BIOL CHEM, V273, P1; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Calvert GM, 1999, OCCUP ENVIRON MED, V56, P270, DOI 10.1136/oem.56.4.270; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHEN JD, 1995, MOL MED, V1, P141; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CONNEY AH, 1982, CANCER RES, V42, P4875; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; KLAWANS HL, 1987, ACTA NEUROL SCAND, V2, P255; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; LUSTER M, 1979, ANN NY ACAD SCI, V31, P473; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1997, J BIOL CHEM, V272, P8878; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; OLIVER RM, 1975, BRIT J IND MED, V32, P49; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND A, 1984, BIOL MECHANISMS DIOX, V18; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Sambrook J., 2002, MOL CLONING LAB MANU; SassoneCorsi P, 1997, NATURE, V389, P443, DOI 10.1038/38904; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	53	78	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12676	12683		10.1074/jbc.275.17.12676	http://dx.doi.org/10.1074/jbc.275.17.12676			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777561	hybrid			2022-12-27	WOS:000086762300045
J	Mitta, G; Vandenbulcke, F; Hubert, F; Salzet, M; Roch, P				Mitta, G; Vandenbulcke, F; Hubert, F; Salzet, M; Roch, P			Involvement of mytilins in mussel antimicrobial defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSESHOE-CRAB HEMOCYTES; CRASSOSTREA-GIGAS; INNATE IMMUNITY; INSECT IMMUNITY; PEPTIDES; EDULIS; GALLOPROVINCIALIS; SEQUENCE; BINDING; FAMILY	Four cationic peptides were purified from mussel (Mytilus galloprovincialis) hemocytes, A combination of Edman degradation and mass spectrometry of plasma revealed (i) a previously characterized molecule, mytilin B (Charlet, M., Chernysh, S., Philippe, H., Hetrut, C., Hoffmann, J., and Bulet, P. (1996) J. Biol. Chem. 271, 21808-21813) and (ii) three new isoforms, mytilin C, D, and G1. The four molecules exhibited complementary antimicrobial properties. The cDNA sequence coding for the mytilin B precursor was obtained from a hemocyte cDNA library, This precursor contains a putative signal peptide of 22 residues, a processing peptide sequence of 34 amino acids, and a C-terminal extension of 48 residues rich in acidic residues. Distribution of mytilin B mRNA and of the corresponding peptide in various mussel tissues revealed that mytilins are synthesized and stared in a specific hemocyte subtype. Furthermore, in an experimental model of infection, we showed (i) a recruitment of hemocytes containing mytilins toward the injection site within hours following bacterial challenge, (ii) that mytilins probably play a prominent role in Billing intracellular bacteria after phagocytosis, and (ii) later an increase of mytilin-like material occurred in the plasma suggesting a secondary systemic role.	Univ Montpellier 2, DRIM, UMR 5098, IFREMER, F-34095 Montpellier, France; Univ Sci & Tech Lille Flandres Artois, Ctr Biol Cellulaire, Lab Endocrinol Annelides, Grp Neuroimmun Hirudinees,UPRES A CNRS, F-59655 Villeneuve Dascq, France	Ifremer; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Roch, P (corresponding author), Univ Montpellier 2, DRIM, UMR 5098, IFREMER, CC 80,Pl Eugene Bataillon, F-34095 Montpellier, France.	proch@ifremer.fr	MITTA, Guillaume/A-6489-2010; Salzet, Michel/A-7675-2011	Salzet, Michel/0000-0003-4318-0817; Vandenbulcke, Franck/0000-0002-9735-1784; mitta, guillaume/0000-0003-1188-1467				ANGUIANOBELTRAN C, 1996, THESIS CICESE ENSENA; BACHERE E, 1988, DEV COMP IMMUNOL, V12, P549, DOI 10.1016/0145-305X(88)90071-7; BACHERE E, 1991, DIS AQUAT ORGAN, V11, P173, DOI 10.3354/dao011173; BAYNE CJ, 1990, BIOSCIENCE, V40, P723, DOI 10.2307/1311504; BULET P, 1991, J BIOL CHEM, V266, P24520; BURNS CD, 1979, AQUACULTURE, V16, P193, DOI 10.1016/0044-8486(79)90107-8; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; CHENG TC, 1979, J INVERTEBR PATHOL, V33, P204, DOI 10.1016/0022-2011(79)90154-X; CHINAIN M, 1988, DIS AQUAT ORGAN, V5, P215, DOI 10.3354/dao005215; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; FRIEBEL B, 1995, COMP BIOCHEM PHYS A, V112, P81, DOI 10.1016/0300-9629(95)00086-M; Ganz T, 1997, Curr Opin Hematol, V4, P53; GAUTHIER JD, 1995, J INVERTEBR PATHOL, V66, P156, DOI 10.1006/jipa.1995.1079; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hubert F, 1997, BBA-MOL BASIS DIS, V1361, P29, DOI 10.1016/S0925-4439(97)00013-6; Hubert F, 1996, EUR J BIOCHEM, V240, P302, DOI 10.1111/j.1432-1033.1996.0302h.x; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kenchington E, 1995, CAN J FISH AQUAT SCI, V52, P2613, DOI 10.1139/f95-850; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; LEIPPE M, 1988, DEV COMP IMMUNOL, V12, P297, DOI 10.1016/0145-305X(88)90006-7; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Morvan A, 1997, J INVERTEBR PATHOL, V69, P177, DOI 10.1006/jipa.1996.4642; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; PIPE RK, 1990, HISTOCHEM J, V22, P595, DOI 10.1007/BF01072941; PIPE RK, 1990, CELL TISSUE RES, V261, P261, DOI 10.1007/BF00318667; RENWRANTZ L, 1985, DEV COMP IMMUNOL, V9, P203, DOI 10.1016/0145-305X(85)90111-9; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; Sugumar G, 1998, DIS AQUAT ORGAN, V33, P111, DOI 10.3354/dao033111	33	156	182	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12954	12962		10.1074/jbc.275.17.12954	http://dx.doi.org/10.1074/jbc.275.17.12954			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777596	hybrid			2022-12-27	WOS:000086762300080
J	Roy, SK; Wachira, SJ; Xiao, WH; Hu, JB; Kalvakolanu, DV				Roy, SK; Wachira, SJ; Xiao, WH; Hu, JB; Kalvakolanu, DV			CCAAT/enhancer-binding protein-beta regulates interferon-induced transcription through a novel element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C/EBP-BETA; TARGETED DISRUPTION; GAMMA-INTERFERON; GENE-TRANSCRIPTION; ALPHA-INTERFERON; INDUCTION; CELLS; DIFFERENTIATION; MICE	We have described previously a novel interferon (IFN)-responsive cia-acting enhancer element called gamma-IFN-activated transcriptional element (GATE). GATE is distinct from the known IFN-stimulated elements and binds to novel transacting factors. To identify the gamma-IFN-responsive transacting factors that interact with GATE, we have screened a cDNA expression library derived from IFN-gamma-stimulated murine macrophage cell line and isolated three different cDNAs. Among these is a gene coding for the pleiotropic transcription factor, CCAAT/ enhancer-binding protein-beta (C/EBP-beta). We report here that the gene for C/EBP-beta binds to GATE and induces gene expression. A mutant C/EBP-beta interferes with the IFN-gamma-stimulated transcription of the ISGF3 gamma (p48) promoter. Other members of the C/EBP family do not cause these effects. Interestingly, the expression of C/EBP-beta, not the other members of its family, is induced by IFN-gamma. These studies thus identify a novel role for C/EBP-beta in the IFN-signaling pathways.	Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA.		Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326	NCI NIH HHS [CA71401, CA 78282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRIGGS RC, 1994, BLOOD, V83, P2153; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Chen XN, 1997, BLOOD, V90, P156; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Kalvakolanu DV, 1999, TRENDS MICROBIOL, V7, P166, DOI 10.1016/S0966-842X(99)01476-6; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEWIS JA, 1989, J VIROL, V63, P4569, DOI 10.1128/JVI.63.11.4569-4578.1989; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SEN GC, 1997, TRANSCRIPTIONAL REGU; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880	42	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12626	12632		10.1074/jbc.275.17.12626	http://dx.doi.org/10.1074/jbc.275.17.12626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777554	hybrid			2022-12-27	WOS:000086762300038
J	Vasudevan, S; Roberts, JR; McClintock, RA; Dent, JA; Celikel, R; Ware, J; Varughese, KI; Ruggeri, ZM				Vasudevan, S; Roberts, JR; McClintock, RA; Dent, JA; Celikel, R; Ware, J; Varughese, KI; Ruggeri, ZM			Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR BINDING; PLATELET-AGGREGATION; IX COMPLEX; CRYSTAL-STRUCTURE; IDENTIFICATION; BOTROCETIN; RISTOCETIN; RESIDUES; RECEPTOR; FRAGMENT	Binding of the von Willebrand factor (vWF) A1 domain to the glycoprotein (GP) Ib-IX-V complex mediates platelet adhesion to reactive substrates under high shear stress conditions, a key event in hemostasis and thrombosis. We have now used the known three-dimensional structure of the A1 domain to model the interaction with the GP Ib alpha sequence 271-279, which has previously been implicated in ligand binding: Docking procedures suggested that A1 domain residues in strand beta 3 and preceding loop (residues 559-566) as well as in helix alpha 3 (residues 594-603) interact with Asp residues 272, 274, 277 and sulfated Tyr residues 278 and 279 in GP Ib alpha. To verify this model, 14 mutant A1 domain fragments containing single or multiple side chain substitutions were tested for their ability to mediate platelet adhesion under flow. Each of the vWF residues Tyr(565), GlU(596), and Lys(599) proved to be strictly required for A1 domain function, which, in agreement with previous findings, was also dependent on Gly(561). Moreover, an accessory functional role was apparent for a group of positively charged residues, including Arg at positions 629, 632, 636 and Lye at positions 643 and 645, possibly acting in concert. There was, however, no evidence from the model that these residues directly participate in forming the complex with GP Ib alpha. These results provide a partial model of the vWF-GP Ib alpha interaction linked to the manifestation of functional activity in platelet adhesion.	Scripps Res Inst, Res Inst,Dept Mol & Expt Med, Roon Res Ctr Arteriosclerosis & Thrombosis, Div Expt Hemostasis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Ruggeri, ZM (corresponding author), Scripps Res Inst, Res Inst,Dept Mol & Expt Med, Roon Res Ctr Arteriosclerosis & Thrombosis, Div Expt Hemostasis & Thrombosis, MEM-175,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL-42846, HL-48728, HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL048728, R01HL042846, R37HL042846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; BADIMON L, 1998, VONWILLEBRAND FACTOR, P225; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; BRUNGER AT, 1996, X PLOR CRYSTALLOGRPA; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CELIKEL R, 1997, BLOOD CELL MOL DIS, V23, P124; CLAMP JR, 1971, IMMUNOCHEMISTRY, V8, P871; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; Goto S, 1999, CIRCULATION, V99, P608, DOI 10.1161/01.CIR.99.5.608; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; MURATA M, 1991, J BIOL CHEM, V266, P15474; NICHOLS WC, 1998, THROMBOSIS HEMORRHAG, P729; PRIOR CP, 1993, BIO-TECHNOL, V11, P709, DOI 10.1038/nbt0693-709; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; READ MS, 1989, BLOOD, V74, P1031; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; RUGGERI ZM, 1998, VONWILLEBRAND FACTOR, P79; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1990, J BIOL CHEM, V265, P274; Ware J, 1998, THROMB HAEMOSTASIS, V79, P466	45	37	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12763	12768		10.1074/jbc.275.17.12763	http://dx.doi.org/10.1074/jbc.275.17.12763			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777573	hybrid			2022-12-27	WOS:000086762300057
J	Davydov, IV; Varshavsky, A				Davydov, IV; Varshavsky, A			RGS4 is arginylated and degraded by the N-end rule pathway in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PROTEIN TRANSFERASE; YEAST METHIONINE AMINOPEPTIDASE; MUSCLE-SPECIFIC CALPAIN; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; UBIQUITIN SYSTEM; ALPHA-SUBUNIT; DEGRADATION; PROTEASOME; ACTIVATION	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. We used an expression-cloning screen to search for mouse proteins that are degraded by the ubiquitia/proteasome-dependent N-end rule pathway in a reticulocyte lysate. One substrate thus identified was RGS4, a member of the RGS family of GTPase-activating proteins that downregulate specific G proteins. A determinant of the RGS4 degradation signal (degron) was located at the N terminus of RGS4, because converting cysteine 2 to either glycine, alanine, or valine completely stabilized RGS4. Radiochemical sequencing indicated that the N-terminal methionine of the lysate-produced RGS4 was replaced with arginine. Since N-terminal arginine is a destabilizing residue not encoded by RGS4 mRNA, we conclude that the degron of RGS4 is generated through the removal of N-terminal methionine and enzymatic arginylation of the resulting N-terminal cysteine. RGS16, another member of the RGS family, was also found to be an N-end rule substrate. RGS4 that was transiently expressed in mouse L cells was short-lived in these cells. However, the targeting of RGS4 for degradation in this in vivo setting involved primarily another degron, because N-terminal variants of RGS4 that were stable in reticulocyte lysate remained unstable in L cells.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Varshavsky, A (corresponding author), CALTECH, Div Biol, 147-75,1200 E Calif Blvd, Pasadena, CA 91125 USA.				NIDDK NIH HHS [DK39520] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R37DK039520, R56DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0; BAKER RT, 1991, P NATL ACAD SCI USA, V87, P2374; BALZI E, 1990, J BIOL CHEM, V265, P7464; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; COOK RK, 1991, J BIOL CHEM, V266, P16825; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Elce JS, 1997, J BIOL CHEM, V272, P11268; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Grigoryev S, 1996, J BIOL CHEM, V271, P28521, DOI 10.1074/jbc.271.45.28521; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V30, P280; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; LEMM JA, 1994, EMBO J, V13, P2295; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; LI J, 1995, BIOCHEMISTRY-US, V34, P15829, DOI 10.1021/bi00048a028; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; Sijts AJAM, 1997, J BIOL CHEM, V272, P19261, DOI 10.1074/jbc.272.31.19261; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STEWART A, 1995, TRENDS GENETICS NOME; STEWART AE, 1995, J BIOL CHEM, V270, P25, DOI 10.1074/jbc.270.1.25; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Taban CH, 1996, EXPERIENTIA, V52, P865, DOI 10.1007/BF01938871; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074-5521(99)80129-X; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Walker KW, 1999, J BIOL CHEM, V274, P13403, DOI 10.1074/jbc.274.19.13403; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WEBB EC, 1992, ENZYME NOMENCLATURE, P527; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wieland T, 1997, J BIOL CHEM, V272, P8853; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	74	121	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22931	22941		10.1074/jbc.M001605200	http://dx.doi.org/10.1074/jbc.M001605200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10783390	Green Accepted, hybrid			2022-12-27	WOS:000088419400046
J	Cervin, MA; Spiegelman, GB				Cervin, MA; Spiegelman, GB			A role for Asp(75) in domain interactions in the Bacillus subtilis response regulator SpoOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; SPOIIG PROMOTER; STIMULATES TRANSCRIPTION; SIGMA(F) ACTIVITY; DEDUCED PRODUCT; SPO0A PROTEIN; ABRB GENE	Spo0A is a two-domain response regulator required for sporulation initiation in Bacillus subtilis, Studies on response regulators have focused on the activity of each domain, but very little is known about the mechanism by which the regulatory domain inhibits the activator domain. In this study, we created a single amino acid substitution in the regulatory domain, D75S, which resulted in a dramatic decrease in sporulation in vivo, In vitro studies with the purified Spo0AD75S protein demonstrated that phosphorylation and DNA binding were comparable with wild type Spo0A. However, the mutant was unable to stimulate transcription by sigma(A)-RNA polymerase from the Spo0A-dependent spoIIG operon promoter, We suggest that the amino acid Asp(75) and/or the region within which it resides, the alpha 3-beta 4 loop, are involved in the inhibitory interaction between the regulatory and activator domains of Spo0A.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Spiegelman, GB (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	spie@interchange.ubc.ca						Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; Baikalov I, 1998, BIOCHEMISTRY-US, V37, P3665, DOI 10.1021/bi972365a; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BALDUS JM, 1994, J BACTERIOL, V176, P296, DOI 10.1128/JB.176.2.296-306.1994; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BRISSETTE RE, 1991, J BACTERIOL, V173, P3749, DOI 10.1128/JB.173.12.3749-3755.1991; Buckner CM, 1998, J BACTERIOL, V180, P4987, DOI 10.1128/JB.180.18.4987-4990.1998; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Cervin MA, 1999, MOL MICROBIOL, V31, P597, DOI 10.1046/j.1365-2958.1999.01200.x; Da Re S, 1999, MOL MICROBIOL, V34, P504, DOI 10.1046/j.1365-2958.1999.01614.x; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DOBINSON KF, 1987, BIOCHEMISTRY-US, V26, P8206, DOI 10.1021/bi00399a028; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; Errington J, 1996, PHILOS T ROY SOC B, V351, P537, DOI 10.1098/rstb.1996.0052; Feher VA, 1998, FEBS LETT, V425, P1, DOI 10.1016/S0014-5793(98)00182-3; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; Greene EA, 1996, J BIOL CHEM, V271, P11455, DOI 10.1074/jbc.271.19.11455; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; Hatt JK, 1998, J BACTERIOL, V180, P3584, DOI 10.1128/JB.180.14.3584-3591.1998; Hoch J.A., 1995, 2 COMPONENT SIGNAL T, DOI [10.1128/9781555818319, DOI 10.1128/9781555818319]; HOCH JA, 1985, J BACTERIOL, V161, P552, DOI 10.1128/JB.161.2.552-555.1985; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; HOCH JA, 1993, ADV MICROB PHYSIOL, V35, P111, DOI 10.1016/S0065-2911(08)60098-3; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Jiang M, 1999, MOL MICROBIOL, V33, P389, DOI 10.1046/j.1365-2958.1999.01481.x; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Madhusudan, 1997, BIOCHEMISTRY-US, V36, P12739, DOI 10.1021/bi971276v; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RODENBURG KW, 1994, PROTEIN ENG, V7, P905, DOI 10.1093/protein/7.7.905; Rowe-Magnus DA, 1998, P NATL ACAD SCI USA, V95, P5305, DOI 10.1073/pnas.95.9.5305; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SATOLA S, 1991, P NATL ACAD SCI USA, V88, P4533, DOI 10.1073/pnas.88.10.4533; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; Schyns G, 1997, J BACTERIOL, V179, P5605, DOI 10.1128/jb.179.17.5605-5608.1997; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; TRACH KA, 1985, P NATL ACAD SCI USA, V82, P7260, DOI 10.1073/pnas.82.21.7260; Tzeng YL, 1997, J MOL BIOL, V272, P200, DOI 10.1006/jmbi.1997.1226; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996	54	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22025	22030		10.1074/jbc.M000211200	http://dx.doi.org/10.1074/jbc.M000211200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801786	hybrid			2022-12-27	WOS:000088363800040
J	Cherest, H; Thomas, D; Surdin-Kerjan, Y				Cherest, H; Thomas, D; Surdin-Kerjan, Y			Polyglutamylation of folate coenzymes is necessary for methionine biosynthesis and maintenance of intact mitochondrial genome in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; TRANSFER-RNA-SYNTHETASES; CHINESE-HAMSTER CELLS; ONE-CARBON METABOLISM; FOLYLPOLYGLUTAMATE SYNTHETASE; GENETIC-ANALYSIS; SHUTTLE VECTORS; YEAST; MUTANTS; COMPARTMENTATION	One-carbon metabolism is essential to provide activated one-carbon units in the biosynthesis of methionine, purines, and thymidylate. The major forms of folates in vivo are polyglutamylated derivatives. In organisms that synthesize folate coenzymes de novo, the addition of the glutamyl side chains is achieved by the action of two enzymes, dihydrofolate synthetase and folylpolyglutamate synthetase. We report here the characterization and molecular analysis of the two glutamate-adding enzymes of Saccharomyces cerevisiae. We show that dihydrofolate synthetase catalyzing the binding of the first glutamyl side chain to dihydropteroate yielding dihydrofolate is encoded by the YMR113w gene that we propose to rename FOL3. Mutant cells bearing a fol3 mutation require folinic acid for growth and have no dihydrofolate synthetase activity. We show also that folylpolyglutamate synthetase, which catalyzes the extention of the glutamate chains of the folate coenzymes, is encoded by the MET7 gene. Folylpolyglutamate synthetase activity is required for methionine synthesis and for maintenance of mitochondrial DNA. We have tested whether two folylpolyglutamate synthetases could be encoded by the MET7 gene, by the use of alternative initiation codons. Our results show that the loss of mitochondrial functions in met7 mutant cells is not because of the absence of a mitochondrial folylpolyglutamate synthetase.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Surdin-Kerjan, Y (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.							APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; BOGNAR AL, 1986, METHOD ENZYMOL, V122, P349; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHEREST H, 1992, GENETICS, V130, P51; CHIU MI, 1992, GENETICS, V132, P987; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; ELLIS SR, 1988, MOL CELL BIOL, V9, P1611; FOO SK, 1982, J BIOL CHEM, V257, P13587; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GEORGE S, 1987, BIOCHEMISTRY-US, V26, P522, DOI 10.1021/bi00376a026; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; Higgins D G, 1994, Methods Mol Biol, V25, P307; Imeson HC, 1997, METHOD ENZYMOL, V281, P141; Iwai K, 1980, Methods Enzymol, V66, P581; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; LITTLE JG, 1979, MOL GEN GENET, V168, P141, DOI 10.1007/BF00431440; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSELOT M, 1975, MOL GEN GENET, V139, P121, DOI 10.1007/BF00264692; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCDONALD D, 1995, PHYTOCHEMISTRY, V38, P327, DOI 10.1016/0031-9422(94)00615-Z; McNeil JB, 1996, GENETICS, V142, P371; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1995, EUR J BIOCHEM, V230, P582; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; WHITFIELD CD, 1970, J BIOL CHEM, V245, P390; WILLIAMSON DH, 1971, MOL GEN GENET, V111, P209, DOI 10.1007/BF00433106; WINTERSBERGER U, 1973, MOL GEN GENET, V126, P61, DOI 10.1007/BF00333482; WU M, 1987, J BIOL CHEM, V262, P12275	50	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14056	14063		10.1074/jbc.275.19.14056	http://dx.doi.org/10.1074/jbc.275.19.14056			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799479	hybrid			2022-12-27	WOS:000087006900009
J	Shea, ME; Hiasa, H				Shea, ME; Hiasa, H			Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT STRUCTURE; II TOPOISOMERASE; STRAND CLEAVAGE; NALIDIXIC-ACID; GYRASE; IV; ENZYME; REPLICATION; MECHANISM; PURIFICATION	Quinolone antibacterial drugs target both DNA gyrase (Gyr) and topoisomerase IV (Topo IV) and form topoisomerase-quinolone-DNA ternary complexes. The formation of ternary complexes results in the inhibition of DNA replication and leads to the generation of double-strand breaks and subsequent cell death. Here, we have studied the consequences of collisions between the UvrD helicase and the ternary complexes formed with either Gyr, Topo IV, or a mutant Gyr, Gyr (A59), which does not wrap the DNA strand around itself. We show (i) that Gyr-norfloxacin (Norf)-DNA and Topo IV-Norf-DNA, but not Gyr (A59)-Norf-DNA, ternary complexes inhibit the UvrD-catalyzed strand-displacement activity, (ii) that a single-strand break is generated at small portions of the ternary complexes upon their collisions with UvrD, and (iii) that the majority of Topo IV-Norf-DNA ternary complexes become nonreversible when UvrD collides with the Topo IV-Norf-DNA ternary complexes, whereas the majority of Gyr-Norf-DNA ternary complexes remain reversible after their collision with the UvrD helicase. These results indicated that different DNA repair mechanisms might be involved in the repair of Gyr-Norf-DNA and Topo IV-Norf-DNA ternary complexes.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Shea, ME (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59465-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 1980, MECH STUDIES DNA REP, P809; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P191; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Shea ME, 1999, J BIOL CHEM, V274, P22747, DOI 10.1074/jbc.274.32.22747; SMITH JT, 1984, FORTSCHR ANTIMIKROB, V493, P3; Strumberg D, 1999, J BIOL CHEM, V274, P7292, DOI 10.1074/jbc.274.11.7292; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; ULLSPERGER JC, 1995, NUCL ACIDS MOL BIOL, P115; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	33	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14649	14658		10.1074/jbc.275.19.14649	http://dx.doi.org/10.1074/jbc.275.19.14649			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799552	hybrid			2022-12-27	WOS:000087006900086
J	Corbacho, AM; Nava, G; Eiserich, JP; Noris, G; Macotela, Y; Struman, I; de la Escalera, GM; Freeman, BA; Clapp, C				Corbacho, AM; Nava, G; Eiserich, JP; Noris, G; Macotela, Y; Struman, I; de la Escalera, GM; Freeman, BA; Clapp, C			Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; GROWTH-HORMONE; RAT LUNG; ANGIOGENESIS; FRAGMENT; EXPRESSION; INHIBITOR; RECEPTOR; INTERLEUKIN-1-BETA	Prolactin (PRL), originally associated with milk secretion, is now known to possess a wide variety of biological actions and diverse sites of production beyond the pituitary, Proteolytic cleavage is a common post-translational modification that can either activate precursor proteins or confer upon the peptide fragment unique biological actions not exerted by the parent molecule. Recent studies have demonstrated that the 16-kDa N-terminal proteolytic cleavage product of PRL (16K-PRL) acts as a potent inhibitor of angiogenesis. Despite previous demonstrations of 16K-PRL production in vivo, biological functions beyond its antiangiogenic actions remain unknown. Here we show that 16K-PRL, but not full-length PRL, acts to promote the expression of the inducible isoform of nitric oxide synthase (iNOS) and nitric oxide ((NO)-N-.) production by pulmonary fibroblasts and alveolar type II cells with potency comparable with the proinflammatory cytokines interleukin-1 beta, interferon gamma, and tumor necrosis factor alpha. The differential effect of 16K-PRL versus PRL occurs through a receptor distinct from known PRL receptors. Additionally, pulmonary fibroblasts express the PRL gene and endogenously produce 16K-PRL, suggesting that this pathway may serve both autocrine and paracrine roles in the regulation of (NO)-N-. production. These results reveal that proteolytic cleavage of PRL confers upon this classical hormone potent iNOS inducing activity, suggesting its role in inflammatory/immune processes.	Univ Nacl Autonoma Mexico, Ctr Neurobiol, Juriquilla Queretaro 76001, Qro, Mexico; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Mol Genet, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Univ Liege, Lab Biol Mol & Genie Genet, B-4000 Sart Tilman Par Liege, Belgium	Universidad Nacional Autonoma de Mexico; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Liege	Clapp, C (corresponding author), Univ Nacl Autonoma Mexico, Ctr Neurobiol, Campus Juriquilla,Apartado Postal 1-1141, Juriquilla Queretaro 76001, Qro, Mexico.	clapp@servidor.unam.mx	Freeman, Bruce A/H-9342-2012	struman, ingrid/0000-0003-2550-3707; Martinez de la Escalera, Gonzalo/0000-0002-4309-3476	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058115, P60HL058418] Funding Source: NIH RePORTER; NHLBI NIH HHS [P6-HL58418, R01-HL58115, R01-HL6493] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; Chikanza IC, 1999, ANN NY ACAD SCI, V876, P119, DOI 10.1111/j.1749-6632.1999.tb07629.x; Clapp C, 1998, J ENDOCRINOL, V158, P137, DOI 10.1677/joe.0.1580137; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CLAPP C, 1992, ENDOCRINOLOGY, V130, P1380, DOI 10.1210/en.130.3.1380; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; FERRARA N, 1991, ENDOCRINOLOGY, V129, P896, DOI 10.1210/endo-129-2-896; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; GUTIERREZ HH, 1995, AM J PHYSIOL-LUNG C, V268, pL501, DOI 10.1152/ajplung.1995.268.3.L501; IMAI T, 1994, J CLIN INVEST, V93, P543, DOI 10.1172/JCI117005; JORENS PG, 1992, EUR J PHARMACOL, V224, P7, DOI 10.1016/0014-2999(92)94811-9; Meli R, 1997, LIFE SCI, V61, P1395, DOI 10.1016/S0024-3205(97)00685-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moss ML, 1997, J NEUROIMMUNOL, V72, P127, DOI 10.1016/S0165-5728(96)00180-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Raso GM, 1999, J NEUROCHEM, V73, P2272, DOI 10.1046/j.1471-4159.1999.0732272.x; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; Struman I, 1999, P NATL ACAD SCI USA, V96, P1246, DOI 10.1073/pnas.96.4.1246; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Torner L, 1999, J ENDOCRINOL, V161, P423, DOI 10.1677/joe.0.1610423; TORNER L, 1995, ENDOCRINOLOGY, V136, P5454, DOI 10.1210/en.136.12.5454; TRAVO P, 1980, BLOOD VESSELS, V17, P110; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1	32	40	42	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13183	13186		10.1074/jbc.275.18.13183	http://dx.doi.org/10.1074/jbc.275.18.13183			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788422	hybrid			2022-12-27	WOS:000086925300006
J	Mireau, H; Cosset, A; Marechal-Drouard, L; Fox, TD; Small, ID; Dietrich, A				Mireau, H; Cosset, A; Marechal-Drouard, L; Fox, TD; Small, ID; Dietrich, A			Expression of Arabidopsis thaliana mitochondrial alanyl-tRNA synthetase is not sufficient to trigger mitochondrial import of tRNA(Ala) in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; FUNCTIONAL TRANSFER-RNAS; SACCHAROMYCES-CEREVISIAE; PLANT-MITOCHONDRIA; TRANSLATIONAL ACTIVATION; LEISHMANIA MITOCHONDRIA; 5'-UNTRANSLATED LEADER; TRYPANOSOMA-BRUCEI; TRANSGENIC PLANTS; SHUTTLE VECTORS	It has often been suggested that precursors to mitochondrial aminoacyl-tRNA synthetases are likely carriers for mitochondrial import of tRNAs in those organisms where this process occurs. In plants, it has been shown that mutation of U-70 to C-70 in Arabidopsis thaliana tRN(Ala)(UGC) blocks aminoacylation and also prevents import of the tRNA into mitochondria. This suggests that interaction of tRNA(Ala) with alanyl-tRNA synthetase (AlaRS) is necessary for import to occur. To test whether this interaction is sufficient to drive import, we co-expressed A. thaliana tRNA(Ala)(UGC) and the precursor to the A. thaliana mitochondrial AlaRS in Saccharomyces cerevisiae, The A. thaliana enzyme and its cognate tRNA were correctly expressed in yeast in vivo. However, although the plant AlaRS was efficiently imported into mitochondria in the transformed strains, we found no evidence for import of the A. thaliana tRNA(Ala) nor of the endogenous cytosolic tRNA(Ala) isoacceptors, We conclude that at least one other factor besides the mitochondrial AlaRS precursor must be involved in mitochondrial import of tRNA(Ala) in plants.	INRA, Genet & Ameliorat Plantes Stn, F-78026 Versailles, France; CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cornell University	Mireau, H (corresponding author), INRA, Genet & Ameliorat Plantes Stn, Route St Cyr, F-78026 Versailles, France.		Small, Ian D/C-1168-2008; Small, Ian/AAR-5506-2021; Drouard, Laurence/D-2385-2010	Small, Ian D/0000-0001-5300-1216; Small, Ian/0000-0001-5300-1216; Drouard, Laurence/0000-0001-6537-524X; Mireau, Hakim/0000-0002-2299-5139; Fox, Thomas/0000-0001-7629-3661	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029362] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNEIRO VTC, 1994, PLANT MOL BIOL, V26, P1843, DOI 10.1007/BF00019497; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHIU MI, 1992, GENETICS, V132, P987; Dietrich A, 1996, PLANT J, V10, P913, DOI 10.1046/j.1365-313X.1996.10050913.x; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; Dietrich A, 1996, BIOCHIMIE, V78, P518, DOI 10.1016/0300-9084(96)84758-4; Dunstan HM, 1997, GENETICS, V147, P87; Entelis NS, 1998, P NATL ACAD SCI USA, V95, P2838, DOI 10.1073/pnas.95.6.2838; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GREEN GA, 1987, PLANT MOL BIOL, V10, P13, DOI 10.1007/BF00014182; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MarechalDrouard L, 1995, METHOD ENZYMOL, V260, P310, DOI 10.1016/0076-6879(95)60148-1; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MARTIN RP, 1979, BIOCHEMISTRY-US, V18, P4600, DOI 10.1021/bi00588a021; MINET M, 1992, PLANT J, V2, P417; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; Mukherjee S, 1999, J BIOL CHEM, V274, P31249, DOI 10.1074/jbc.274.44.31249; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; Nabholz CE, 1997, P NATL ACAD SCI USA, V94, P7903, DOI 10.1073/pnas.94.15.7903; Nabholz CE, 1999, MOL BIOL CELL, V10, P2547, DOI 10.1091/mbc.10.8.2547; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Rusconi CP, 1996, GENE DEV, V10, P2870, DOI 10.1101/gad.10.22.2870; Schneider Andre, 1994, Trends in Cell Biology, V4, P282, DOI 10.1016/0962-8924(94)90218-6; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; SUYAMA Y, 1967, BIOCHEMISTRY-US, V6, P2829, DOI 10.1021/bi00861a025; SUYAMA Y, 1976, GENETICS BIOGENESIS, P763; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; TARASSOV IA, 1992, NUCLEIC ACIDS RES, V20, P1277, DOI 10.1093/nar/20.6.1277; THORSNESS PE, 1993, GENETICS, V134, P21; WIESENBERGER G, 1995, MOL CELL BIOL, V15, P3291	39	13	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13291	13296		10.1074/jbc.275.18.13291	http://dx.doi.org/10.1074/jbc.275.18.13291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788435	Green Published, hybrid			2022-12-27	WOS:000086925300021
J	Vann, LR; Twitty, S; Spiegel, S; Milstien, S				Vann, LR; Twitty, S; Spiegel, S; Milstien, S			Divergence in regulation of nitric-oxide synthase and its cofactor tetrahydrobiopterin by tumor necrosis factor-alpha - Ceramide potentiates nitric oxide synthesis without affecting GTP cyclohydrolase I activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; VASCULAR SMOOTH-MUSCLE; VEIN ENDOTHELIAL-CELLS; GENE-EXPRESSION; PROINFLAMMATORY CYTOKINES; INDUCED APOPTOSIS; BINDING SITES; GLIAL-CELLS; ACTIVATION; INDUCTION	Synthesis of 6(R)-5,6,7,8-tetrahydrobiopterin (BH4), a required cofactor for inducible nitric-oxide synthase (iNOS) activity, is usually coordinately regulated with iNOS expression. In C6 glioma cells, tumor necrosis factor-cu (TNF-cu) concomitantly potentiated the stimulation of nitric oxide (NO) and BH4 production induced by IFN-gamma and interleukin-1 beta. Expression of both iNOS and GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme in the BH4 biosynthetic pathway, was also markedly increased, as were their activities and protein levels. Ceramide, a sphingolipid metabolite, may mediate some of the actions of TNF-alpha. Indeed, we found that bacterial sphingomyelinase, which hydrolyzes sphingomyelin and increases endogenous ceramide, or the cell permeable ceramide analogue, C-2-ceramide, but not C-2-dihydroceramide (N-acetylsphinganine), significantly mimicked the effects of TNF-alpha on NO production and iNOS expression and activity in C6 cells. Surprisingly, although TNF-alpha increased BH4 synthesis and GTPCH activity, neither BH4 nor GTPCH expression was affected by C-2-ceramide or sphingomyelinase in IFN-gamma- and interleukin-1 beta-stimulated cells. It is likely that increased BH4 levels results from increased GTPCH protein and activity in vivo rather than from reduced turnover of BH4, because the GTPCH inhibitor, 2,4-diamino-6-hydroxypyrimidine, blocked cytokine-stimulated BH4 accumulation. Moreover, expression of the GTPCH feedback regulatory protein, which if decreased might increase GTPCH activity, was not affected by TNF-alpha or ceramide. Treatment with the antioxidant pyrrolidine dithiocarbamate, which is known to inhibit NF-kappa B and sphingomyelinase in C6 cells, or with the peptide SN-50, which blocks translocation of NF-kappa B to the nucleus, inhibited TNF-alpha-dependent iNOS mRNA expression without affecting GTPCH mRNA levels. This is the first demonstration that cytokine-stimulated iNOS and GTPCH expression, and therefore NO and BH4 biosynthesis, may be regulated by discrete pathways. As BH4 is also a cofactor for the aromatic amino acid hydroxylases, discovery of distinct mechanisms for regulation of BH4 and NO has important implications for its specific functions.	NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Georgetown University	Milstien, S (corresponding author), NIMH, Lab Cellular & Mol Regulat, NIH, Bldg 36,Rm 2A-11, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 1996, MOL PHARMACOL, V49, P149; Anastasiadis PZ, 1997, EUR J NEUROSCI, V9, P1831, DOI 10.1111/j.1460-9568.1997.tb00749.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETTS JC, 1994, J BIOL CHEM, V269, P8455; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DSa C, 1996, MOL BRAIN RES, V41, P105, DOI 10.1016/0169-328X(96)00073-3; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; Hattori Y, 1997, J MOL CELL CARDIOL, V29, P1585, DOI 10.1006/jmcc.1997.0396; Hattori Y, 1996, EUR J PHARMACOL, V296, P107, DOI 10.1016/0014-2999(95)00675-3; Higuchi M, 1996, J IMMUNOL, V157, P297; Kapatos G, 2000, J BIOL CHEM, V275, P5947, DOI 10.1074/jbc.275.8.5947; Katsuyama K, 1998, ENDOCRINOLOGY, V139, P4506, DOI 10.1210/en.139.11.4506; Katusic ZS, 1998, ARTERIOSCL THROM VAS, V18, P27, DOI 10.1161/01.ATV.18.1.27; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; KOSARHASHEMI B, 1993, ADV EXP MED BIOL, V338, P93; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MILSTIEN S, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P505; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; MILSTIEN S, 1987, UNCONJUGATED PTERINS, P49; MUHL H, 1994, KIDNEY INT, V46, P1302, DOI 10.1038/ki.1994.398; NICHOL CA, 1983, P NATL ACAD SCI-BIOL, V80, P1546, DOI 10.1073/pnas.80.6.1546; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SAKAI N, 1995, J NEUROCHEM, V65, P895; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimoji M, 1999, J NEUROCHEM, V72, P757, DOI 10.1046/j.1471-4159.1999.0720757.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; SPIEGEL S, 1996, GROW FACT CYTOK  A&B, V1, P537; Steinmetz MO, 1998, J MOL BIOL, V279, P189, DOI 10.1006/jmbi.1998.1649; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Togari A, 1998, FEBS LETT, V428, P212, DOI 10.1016/S0014-5793(98)00531-6; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Werner ER, 1998, P SOC EXP BIOL MED, V219, P171; WERNER ER, 1991, PATHOBIOLOGY, V59, P276, DOI 10.1159/000163662; Witter K, 1996, GENE, V171, P285, DOI 10.1016/0378-1119(95)00886-1; XIE QW, 1994, J BIOL CHEM, V269, P4705; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zhang HF, 1998, BIOCHEM PHARMACOL, V55, P1873, DOI 10.1016/S0006-2952(98)00078-1	57	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13275	13281		10.1074/jbc.275.18.13275	http://dx.doi.org/10.1074/jbc.275.18.13275			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788433	hybrid			2022-12-27	WOS:000086925300019
J	Molloy, CA; May, FEB; Westley, BR				Molloy, CA; May, FEB; Westley, BR			Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING-PROTEINS; FACTOR-I RECEPTORS; GROWTH-FACTOR; SH2 DOMAINS; IGF-I; IRS-1; CARCINOMA; GENE; OVEREXPRESSION; TAMOXIFEN	Estrogens can stimulate the proliferation of estrogen-responsive breast cancer cells by increasing their proliferative response to insulin-like growth factors. The mechanism underlying the increased proliferation could involve the induction of components of the insulin-like growth factor signal transduction pathway by estrogen, In this study we have examined the regulation of the expression of insulin receptor substrate-1, a major intracellular substrate of the type I insulin-like growth factor receptor tyrosine kinase, Estradiol increased insulin receptor substrate-1 mRNA and protein levels at concentrations consistent with a mechanism involving the estrogen receptor. Insulin receptor substrate-1 was not induced significantly by the antiestrogens tamoxifen and ICI 182,780, but they inhibited the induction of insulin receptor substrate-1 by estradiol. Analysis of tyrosine-phosphorylated insulin receptor substrate-1 showed that the highest levels were found in cells stimulated by estradiol and insulin-like growth factor-I, whereas low levels were found in the absence of estradiol irrespective of whether type I insulin-like growth factor ligands were present. Insulin receptor substrate-2, -3, and -4 were not induced by estradiol. These results suggest that estrogens and antiestrogens may regulate cell proliferation by controlling insulin receptor substrate-1 expression, thereby amplifying or attenuating signaling through the insulin-like growth factor signal transduction pathway.	Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Westley, BR (corresponding author), Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							ALTSCHULER D, 1994, MOL ENDOCRINOL, V8, P1139, DOI 10.1210/me.8.9.1139; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; BONNETERRE J, 1990, CANCER RES, V50, P6931; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CULLEN KJ, 1992, BREAST CANCER RES TR, V22, P21, DOI 10.1007/BF01833330; DALY RJ, 1994, ONCOGENE, V9, P2723; Daws MR, 1996, ENDOCRINOLOGY, V137, P1177, DOI 10.1210/en.137.4.1177; DEFRIEND DJ, 1994, CANCER RES, V54, P408; ENGEL LW, 1978, CANCER RES, V38, P3352; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; FIGUEROA JA, 1992, BREAST CANCER RES TR, V22, P81, DOI 10.1007/BF01833336; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FURLANETTO RW, 1984, CANCER RES, V44, P2122; Guvakova MA, 1997, CANCER RES, V57, P2606; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; HEALICON RM, 1993, INT J CANCER, V53, P388, DOI 10.1002/ijc.2910530308; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; LASFARGUES EY, 1958, J NATL CANCER I, V21, P1131; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MAY FEB, 1988, J BIOL CHEM, V263, P12901; MAY FEB, 1987, J BIOL CHEM, V262, P15894; MILAZZO G, 1992, CANCER RES, V52, P3924; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PEYRAT JP, 1990, J STEROID BIOCHEM, V37, P823, DOI 10.1016/0960-0760(90)90426-L; PEYRAT JP, 1992, BREAST CANC RES TREA, V22, P56; Rocha RL, 1997, CLIN CANCER RES, V3, P103; SIMON WE, 1984, JNCI-J NATL CANCER I, V73, P313, DOI 10.1093/jnci/73.2.313; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; THORSEN T, 1992, J STEROID BIOCHEM, V41, P537, DOI 10.1016/0960-0760(92)90379-W; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; WESTLEY BR, 1994, J STEROID BIOCHEM, V51, P1, DOI 10.1016/0960-0760(94)90109-0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YEE D, 1991, BREAST CANCER RES TR, V18, P3, DOI 10.1007/BF01975437; YEE D, 1988, CANCER RES, V48, P6691; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	50	117	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12565	12571		10.1074/jbc.275.17.12565	http://dx.doi.org/10.1074/jbc.275.17.12565			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777546	hybrid			2022-12-27	WOS:000086762300030
J	Liu, SC; Ginsberg, MH				Liu, SC; Ginsberg, MH			Paxillin binding to a conserved sequence motif in the alpha(4) integrin cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; ASSOCIATION; PP125(FAK); ACTIVATION; MODULATION; AFFINITY; KINASE; ROLES	alpha(4)beta(1) integrin-mediated cell adhesion results in increased cell migration, reduced cell spreading, and focal adhesion formation relative to other beta(1) integrins. Paxillin, a signaling adapter protein, binds tightly to the alpha(4) cytoplasmic domain and is implicated in alpha(4) integrin signaling. We now report the mapping of a paxillin-binding site in the alpha(4) cytoplasmic domain and an assessment of its role in the alpha(4) tail-specific integrin functions. By using truncation mutants and a peptide competition assay, we found that a region of 9 amino acid residues (Glu(983)-Tyr(991)) within the alpha(4) cytoplasmic domain contains a minimal sequence sufficient for paxillin binding. Alanine scanning of this region implicated Tyr(991) and Glu(983) as critical residues. The role of these residues was confirmed by introducing these Ala substitutions into the full-length alpha(4) tail sequence. Y991A or E983A substitution disrupted the interaction of alpha(4) integrins with paxillin. These same two point mutations reversed the effects of the alpha(4) tail on cell spreading. The key features of the identified paxillin-binding sequence are present in all cr,integrins sequenced to date, including that from Xenopus laevis. The maintenance of this sequence motif suggests that paxillin binding is an evolutionarily conserved function of alpha(4) integrins.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009922] Funding Source: NIH RePORTER; NHLBI NIH HHS [IF32HL09922-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN YP, 1994, BLOOD, V84, P1857; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Hagmann J, 1998, J CELL SCI, V111, P2181; Hemler M E, 1995, Curr Opin Hematol, V2, P61; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Newton RA, 1997, J LEUKOCYTE BIOL, V61, P422, DOI 10.1002/jlb.61.4.422; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; WOOD CK, 1994, J CELL SCI, V107, P709; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	26	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22736	22742		10.1074/jbc.M000388200	http://dx.doi.org/10.1074/jbc.M000388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10781578	hybrid			2022-12-27	WOS:000088419400021
J	Shao, JY; Sheng, HM; DuBois, RN; Beauchamp, RD				Shao, JY; Sheng, HM; DuBois, RN; Beauchamp, RD			Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR GENE; C-K-RAS; P53; OVEREXPRESSION; EXPRESSION; INHIBITION; PROTEIN; CANCER	The cellular responses to activated Ras vary depending on cell type. Normal cells are often induced into pathways that lead to cell growth arrest, senescence, and/or apoptosis in response to activated Ras expression. These are important protective anti-tumorigenic responses that restrict the propagation of cells bearing activated oncogenes. Here we show that induction of Ha-Ras(Val-12) in Rat-1 fibroblasts resulted in G(1) growth arrest and apoptosis with loss of viable cells that is accompanied by a marked decrease in cyclin D1 levels via increased ubiquitin-proteasome-dependent cyclin D1 turnover. This is in contrast with a rat intestinal epithelial cell line in which induction of Ha-Ras(Val-12) results in transformation associated with sustained proliferation and increased levels of cyclin D1, that is not accompanied by anoikis or apoptosis. Expression of the cyclin D1 mutant (T286A) that contains an alanine for threonine 286 substitution and is resistant to ubiquitin-proteasome degradation in the Ha.Ras(Val-12) expressing Rat-1 cells resulted in a sustained transformed phenotype with no accumulation of cells in G(1). Inhibition of mitogen-activated protein kinase (MEK1/2) pathway partially reversed the Ras-mediated decrease in cyclin D1. Induction of Ha-Ras(Val-12) resulted in activation of Akt kinase and inactivation of glycogen-synthase-3 beta kinase that are associated with reduction of cyclin D1 protein. These results suggest that has-mediated cyclin D1 degradation in Rat-1 cells appears to be partially dependent on activation of mitogen-activated protein kinase pathway and independent of glycogen-synthase-3 beta kinase pathway.	Vanderbilt Univ, Med Ctr, Vanterbilt Ingram Canc Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanterbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanterbilt Ingram Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Med Ctr, Vanterbilt Ingram Canc Ctr, Dept Surg, 21st Ave S,MCN D-5230, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020	Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA-69457] Funding Source: Medline; NIDDK NIH HHS [DK-47297, DK-52334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R01DK052334, R37DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1996, ONCOGENE, V12, P1903; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BATES S, 1994, ONCOGENE, V9, P1633; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOS JL, 1989, CANCER RES, V49, P4682; COLEMAN WB, 1994, CARCINOGENESIS, V15, P1005, DOI 10.1093/carcin/15.5.1005; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FILMUS J, 1992, ONCOGENE, V7, P521; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GILLETT C, 1994, CANCER RES, V54, P1812; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KANDA Y, 1994, INT J CANCER, V58, P291, DOI 10.1002/ijc.2910580224; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1993, CELL, V73, P1069; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Willens S, 1996, J AM PODIAT MED ASSN, V86, P463; Winston JT, 1996, ONCOGENE, V12, P127; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zhang T, 1997, CANCER RES, V57, P169; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	48	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22916	22924		10.1074/jbc.M002235200	http://dx.doi.org/10.1074/jbc.M002235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10781597	hybrid			2022-12-27	WOS:000088419400044
J	Collado, M; Medema, RH; Garcia-Cao, I; Dubuisson, MLN; Barradas, M; Glassford, J; Rivas, C; Burgering, BMT; Serrano, M; Lam, EWF				Collado, M; Medema, RH; Garcia-Cao, I; Dubuisson, MLN; Barradas, M; Glassford, J; Rivas, C; Burgering, BMT; Serrano, M; Lam, EWF			Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE ARREST; FORKHEAD TRANSCRIPTION FACTOR; P53 TUMOR SUPPRESSION; PHOSPHATIDYLINOSITOL 4-KINASE; REPLICATIVE SENESCENCE; INK4A LOCUS; IN-VIVO; DEPENDENT KINASES; GENE-PRODUCT	A senescence-like growth arrest is induced in mouse primary embryo fibroblasts by inhibitors of phosphoinositide 3-kinase (PI3K), We observed that senescence like growth arrest is correlated with an increase in p27(Kip1) but that down-regulation of other cyclin-dependent kinase (CDK) inhibitors, including p15(INK4b) p16(INK4a), p19 (INK4d), and p21(Cip1) as well as other negative cell cycle regulators such as p53 and p19(ARF), implies that this senescence-related growth arrest is independent of the activity of p53, p19(ARF), p16(INK4a),and p21(Cip1) which are associated with replicative senescence. The p27(Kip1) binds to the cyclin/CDK2 complexes and causes a decrease in CDK2 kinase activity. We demonstrated that ectopic expression of p27(Kip1) can induce permanent cell cycle arrest and a senescence-like phenotype in wildtype mouse embryo fibroblasts, We also obtained results suggesting that the kinase inhibitors LY294002 and Wortmannin arrest cell growth and induce a senescence-like phenotype, at least partially, through inhibition of PI3K and protein kinase B/Akt, activation of the forkhead protein AFX, and up-regulation of p27(Kip1)-expression. In summary, these observations taken together suggest that p27(Kip1) is an important mediator of the permanent cell cycle arrest induced by PI3K inhibitors Our data suggest that repression of CDK2 activity by p27(Kip1) is required for the PI3K-induced senescence, yet mouse embryo fibroblasts derived from p27(Kip1-/-) mice entered cell cycle arrest after treatment with LY294002, We show that this is due to a compensatory mechanism by which p130 functionally substitutes for the loss of p27(Kip1). This is the first description that p130 may have a role in inhibiting CDK activity during senescence.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Royal Postgrad Med Sch, Dept Haematol, London, England; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain; Univ Utrecht, Med Ctr, Jordan Lab G03 647, Dept Haematol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Physiol Chem Lab, NL-3584 CX Utrecht, Netherlands	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Utrecht University; Utrecht University	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Serrano, Manuel/H-2634-2015; Collado, Manuel/K-8140-2014; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Rivas, Carmen/L-3162-2017; Rivas, Carmen/AAB-6278-2019; Lam, Eric W-F/AAW-8566-2020	Serrano, Manuel/0000-0001-7177-9312; Collado, Manuel/0000-0002-0330-0880; Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199; Lam, Eric W-F/0000-0003-1274-3576; Medema, Rene/0000-0002-6754-0381				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Good LF, 1996, J CELL PHYSIOL, V168, P580, DOI 10.1002/(SICI)1097-4652(199609)168:3<580::AID-JCP10>3.0.CO;2-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanazawa Shinichiro, 1994, Kobe Journal of Medical Sciences, V40, P165; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Stein GH, 1999, MOL CELL BIOL, V19, P2109; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tresini M, 1998, CANCER RES, V58, P1; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wynford-Thomas D, 1999, J PATHOL, V187, P100; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	67	223	231	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21960	21968		10.1074/jbc.M000759200	http://dx.doi.org/10.1074/jbc.M000759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10791951	hybrid			2022-12-27	WOS:000088363800030
J	Hsu, CC; Davis, KM; Jin, H; Foos, T; Floor, E; Chen, WQ; Tyburski, JB; Yang, CY; Schloss, JV; Wu, JY				Hsu, CC; Davis, KM; Jin, H; Foos, T; Floor, E; Chen, WQ; Tyburski, JB; Yang, CY; Schloss, JV; Wu, JY			Association of L-glutamic acid decarboxylase to the 70-kDa heat shock protein as a potential anchoring mechanism to synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEIN; BRAIN; HSC70; PHOSPHORYLATION; PURIFICATION; DOMAIN; FORM; ACTIVATION	Recently we have reported that the membrane-associated form of the gamma-aminobutyric acid-synthesizing enzyme, L-glutamate decarboxylase (MGAD), is regulated by the vesicular proton gradient (Hsu, C. C,, Thomas, C., Chen, W., Davis, K. M., Foes, T., Chen, J. L., Wu, E., Floor, E., Schloss, J. V., and Wu, J. Y. (1999) J. Biol. Chem. 274, 24366-24371). In this report, several lines of evidence are presented to indicate that L-glutamate decarboxylase (GAD) can become membrane-associated to synaptic vesicles first through complex formation with the heat shock protein 70 family, specifically heat shock cognate 76 (HSC70), followed by interaction with cysteine string protein (CSP), an integral protein of the synaptic vesicle. The first Line of evidence comes from purification of MGAD in which HSC70, as identified from amino acid sequencing, co-purified with GAD. Second, in reconstitution studies, HSC70 was found to form complex with GAD,, as shown by gel mobility shift in non-denaturing gradient gel electrophoresis. Third, in immunoprecipitation studies, again, HSC70 was co-immunoprecipitated with GAD by a GAD(65)-specific monoclonal antibody. Fourth, HSC70 and CSP were co-purified with GAD by specific anti-GAD immunoaffinity columns. Furthermore, studies here suggest that both GrAD(65) and GAD(67) are associated with synaptic vesicles along with HSC70 and CSP. Eased on these findings, a model is proposed to link anchorage of MGAD to synaptic vesicles in relation to its role in gamma-aminobutyric acid neurotransmission.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	University of Kansas; University of Kansas; Baylor College of Medicine; Academia Sinica - Taiwan	Wu, JY (corresponding author), Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.	jywu@ukans.edu		Schloss, John/0000-0002-6586-7508				BAO J, 1995, J BIOL CHEM, V270, P6464, DOI 10.1074/jbc.270.12.6464; Bao Jun, 1994, Journal of Biomedical Science, V1, P237, DOI 10.1007/BF02253308; BLACK MM, 1991, J NEUROSCI, V11, P1163; Boice JA, 1997, J BIOL CHEM, V272, P24825, DOI 10.1074/jbc.272.40.24825; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; CHANG YC, 1988, J NEUROSCI, V8, P2123; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; CHRISTGAU S, 1991, J BIOL CHEM, V266, P23516; Davis KM, 2000, BIOCHEM BIOPH RES CO, V267, P777, DOI 10.1006/bbrc.1999.2038; DIRKX R, 1995, J BIOL CHEM, V270, P2241, DOI 10.1074/jbc.270.5.2241; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; FLOOR E, 1995, J NEUROCHEM, V64, P689; FLOOR E, 1989, J NEUROCHEM, V52, P1433, DOI 10.1111/j.1471-4159.1989.tb09190.x; FONNUM F, 1968, BIOCHEM J, V106, P401, DOI 10.1042/bj1060401; GU ZW, 1993, J PROTEIN CHEM, V12, P585, DOI 10.1007/BF01025123; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Hsu CC, 1999, J BIOL CHEM, V274, P24366, DOI 10.1074/jbc.274.34.24366; Kanaani J, 1999, J BIOL CHEM, V274, P37200, DOI 10.1074/jbc.274.52.37200; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN DL, 1982, J NEUROCHEM, V39, P1001, DOI 10.1111/j.1471-4159.1982.tb11489.x; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; NATHAN B, 1994, J BIOL CHEM, V269, P7249; NATHAN B, 1994, P NATL ACAD SCI USA, V91, P242, DOI 10.1073/pnas.91.1.242; NATHAN B, 1994, BRAIN RES, V642, P297, DOI 10.1016/0006-8993(94)90934-2; ROBERTS EUGENE, 1968, BRAIN RES, V8, P1, DOI 10.1016/0006-8993(68)90170-4; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; TSANG TC, 1993, FEBS LETT, V323, P1, DOI 10.1016/0014-5793(93)81435-3; WANG Y, 1994, NEUROSCI LETT, V180, P175, DOI 10.1016/0304-3940(94)90515-0; WESTHEAD EW, 1987, ANN NY ACAD SCI, V493, P92, DOI 10.1111/j.1749-6632.1987.tb27186.x; WU JY, 1986, BRAIN RES, V373, P1, DOI 10.1016/0006-8993(86)90309-4; WU JY, 1982, P NATL ACAD SCI-BIOL, V79, P4270, DOI 10.1073/pnas.79.14.4270; WU JY, 1981, RES METHODS NEUROCHE, V5, P129	37	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20822	20828		10.1074/jbc.M001403200	http://dx.doi.org/10.1074/jbc.M001403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781586	hybrid			2022-12-27	WOS:000088084500085
J	Trumbo, TA; Maurer, MC				Trumbo, TA; Maurer, MC			Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; PRO-ARG CHLOROMETHYLKETONE; HUMAN ALPHA-THROMBIN; PLASMA FACTOR-XIII; MYOCARDIAL-INFARCTION; BLOOD-COAGULATION; HUMAN-FIBRINOGEN; THROMBOLYTIC THERAPY; COMMON POLYMORPHISM; VENOUS THROMBOSIS	the blood coagulation cascade, thrombin cleaves fibrinopeptides A and B from fibrinogen revealing sites for fibrin polymerization that lead to insoluble clot formation. Factor XIII stabilizes this clot by catalyzing the formation of intermolecular cross-links in the fibrin network, Thrombin activates the Factor XIII a(2) dimer by cleaving the Factor XIII activation peptide segment at the Arg(37)-Gly(38) peptide bond. Using a high performance liquid chromatography assay, the kinetic constants K-m, k(cat), and k(cat)/K-m mere determined for thrombin hydrolysis of fibrinogen A alpha-(7-20), Factor XIII activation peptide-(28-41), and Factor XIII activation peptide-(28-41) with a Val(34) to Leu substitution. This Val to Leu mutation has been correlated with protection from myocardial infarction, In the absence of fibrin, the Factor XIII activation peptide-(28-41) exhibits a 10-fold lower k(cat)/K-m value than fibrinogen A alpha-(7-20). With the Factor XIII V34L mutation, decreases in K-m and increases in k(cat) produce a 6-fold increase in k(cat)/K-m relative to the wild-type Factor XIII sequence. A review of the x-ray crystal structures of known substrates and inhibitors of thrombin leads to a hypothesis that the new Leu generates a peptide with more extensive interactions with the surface of thrombin. As a result, the Factor XIII V34L is proposed to be susceptible to wasteful conversion of zymogen to activated enzyme. Premature depletion may provide cardioprotective effects.	Univ Louisville, Dept Chem, Louisville, KY 40292 USA	University of Louisville	Maurer, MC (corresponding author), Univ Louisville, Dept Chem, Louisville, KY 40292 USA.							Anwar R, 1999, BRIT J HAEMATOL, V107, P468, DOI 10.1046/j.1365-2141.1999.01648.x; Anwar R, 1999, BLOOD, V93, P897, DOI 10.1182/blood.V93.3.897.403k02_897_905; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Catto AJ, 1998, STROKE, V29, P813, DOI 10.1161/01.STR.29.4.813; Catto AJ, 1999, BLOOD, V93, P906, DOI 10.1182/blood.V93.3.906.403k24_906_908; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535; FEAR JD, 1983, THROMB HAEMOSTASIS, V49, P102; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P676; GREENBERG CS, 1987, BLOOD, V69, P867; HALKIER T, 1991, MECH BLOOD COAGULATI, P3; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; Kangsadalampai S, 1998, BLOOD, V92, P2766, DOI 10.1182/blood.V92.8.2766.420k26_2766_2770; Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P862; Kohler HP, 1999, THROMB HAEMOSTASIS, V81, P511; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250; Kohler HP, 1999, QJM-INT J MED, V92, P67, DOI 10.1093/qjmed/92.2.67; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MARSH HC, 1982, BIOCHEMISTRY-US, V21, P6167, DOI 10.1021/bi00267a022; MARSH HC, 1983, BIOCHEMISTRY-US, V22, P4170, DOI 10.1021/bi00287a002; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MARY A, 1988, BIOCHIM BIOPHYS ACTA, V966, P328, DOI 10.1016/0304-4165(88)90082-7; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Maurer MC, 1998, BIOCHEMISTRY-US, V37, P5888, DOI 10.1021/bi972538w; McCormack LJ, 1998, THROMB HAEMOSTASIS, V80, P523; Muszbek L, 1999, THROMB RES, V94, P271, DOI 10.1016/S0049-3848(99)00023-7; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NI F, 1995, J MOL BIOL, V252, P656, DOI 10.1006/jmbi.1995.0527; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1992, BIOCHEMISTRY-US, V31, P11551, DOI 10.1021/bi00161a037; ONUNDARSON PT, 1993, THROMB HAEMOSTASIS, V70, P998; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SCHERAGA HA, 1983, ANN NY ACAD SCI, V408, P330, DOI 10.1111/j.1749-6632.1983.tb23255.x; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wartiovaara U, 1999, ATHEROSCLEROSIS, V142, P295, DOI 10.1016/S0021-9150(98)00241-X; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P5410, DOI 10.1021/bi00591a024; WINZOR DJ, 1964, ARCH BIOCHEM BIOPHYS, V104, P202, DOI 10.1016/S0003-9861(64)80004-7; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	53	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20627	20631		10.1074/jbc.M000209200	http://dx.doi.org/10.1074/jbc.M000209200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801785	hybrid			2022-12-27	WOS:000088084500058
J	Banks, AS; Davis, SM; Bates, SH; Myers, MG				Banks, AS; Davis, SM; Bates, SH; Myers, MG			Activation of downstream signals by the long form of the leptin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; ERYTHROPOIETIN RECEPTOR; OB-R; EXTRACELLULAR DOMAIN; CYTOKINE RECEPTORS; GROWTH-FACTOR; DB/DB MICE; PROTEIN; KINASE; TRANSDUCTION	The adipocyte-derived hormone leptin signals the status of body energy stores by activating the long form of the leptin receptor (LRb). Activation of LRb results in the activation of the associated Jak2 tyrosine kinase and the transmission of downstream phosphotyrosine-dependent signals. We have investigated the signaling function of mutant LRb intracellular domains under the control of the extracellular erythropoietin (Epo) receptor. By using this system, we confirm that two tyrosine residues in the intracellular domain of murine LRb become phosphorylated to mediate LRb signaling; Tyr(985) controls the tyrosine phosphorylation of SHP-8, and Tyr(1138) controls STAT3 activation. We furthermore investigated the mechanisms by which LRb controls downstream ERK activation and c-fos and SOCS3 message accumulation. Tyr(985)-mediated recruitment of SHP-8 does not alter tyrosine phosphorylation of Jak2 or STAT3 but results in GRB-2 binding to tyrosine-phosphorylated SHP-2 and is required for the majority of ERK activation during LRb signaling. Tyr(985) and ERK activation similarly mediate c-fos mRNA accumulation. In contrast, SOCS3 mRNA accumulation requires Tyr(1138)-mediated STAT3 activation. Thus, the two LRb tyrosine residues that are phosphorylated during receptor activation mediate distinct signaling pathways as follows: SHP-2 binding to Tyr(985) positively regulates the ERK --> c-fos pathway, and STAT3 binding to Tyr(1138) mediates the inhibitory SOCS3 pathway.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Myers, MG (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02130 USA.	martin.myers@joslin.harvard.edu	Banks, Alexander/B-4832-2012	Banks, Alexander/0000-0003-1787-6925	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK056731, R01DK056731] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 56731] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bittorf T, 1997, CELL SIGNAL, V9, P85, DOI 10.1016/S0898-6568(96)00121-0; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Morton NM, 1999, J MOL ENDOCRINOL, V22, P173, DOI 10.1677/jme.0.0220173; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Nakashima K, 1997, FEBS LETT, V401, P49, DOI 10.1016/S0014-5793(96)01430-5; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Symes A, 1997, J BIOL CHEM, V272, P9648; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; White DW, 1997, P NATL ACAD SCI USA, V94, P10657, DOI 10.1073/pnas.94.20.10657; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Yoshimura A, 1998, Curr Opin Hematol, V5, P171, DOI 10.1097/00062752-199805000-00004; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	67	603	634	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14563	14572		10.1074/jbc.275.19.14563	http://dx.doi.org/10.1074/jbc.275.19.14563			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799542	hybrid			2022-12-27	WOS:000087006900076
J	Rajan, DP; Huang, W; Kekuda, R; George, RL; Wang, J; Conway, SJ; Devoe, LD; Leibach, FH; Prasad, PD; Ganapathy, V				Rajan, DP; Huang, W; Kekuda, R; George, RL; Wang, J; Conway, SJ; Devoe, LD; Leibach, FH; Prasad, PD; Ganapathy, V			Differential influence of the 4F2 heavy chain and the protein related to b(0,+) amino acid transport on substrate affinity of the heteromeric b(0,+) amino acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; CANDIDATE GENE; CLONING; EXPRESSION; IDENTIFICATION; GLYCOPROTEIN; HETERODIMERS; CYSTINURIA; 4F2HC/CD98; MEMBERS	We provide evidence here that b(o,+) amino acid transporter (b(o,+)AT) interacts with 4F2 heavy chain (4F2hc) as well as with the protein related to b(o'+) amino acid transporter (rBAT) to constitute functionally competent b(o,+)-like amino acid transport systems. This evidence has been obtained by co-expression of b(o,+)AT and 4F2hc or b(o,+)AT and rBAT in human retinal pigment epithelial cells and in COS-l cells. The ability to interact with 4F2hc and rBAT is demonstrable with mouse b(o,+)AT as well as with human b(o,+)AT. Even though both the 4F2hc.b(o,+)AT complex and the rBAT.b(o,+)AT complex exhibit substrate specificity that is characteristic of system b(o,+), these two complexes differ significantly in substrate affinity. The 4F2hc.b(o,+) AT complex has higher substrate affinity than the rBAT.b(o,+)AT complex. In situ hybridization studies demonstrate that the regional distribution pattern of mRNA in the kidney is identical for b(o,+)AT and 4F2hc. The pattern of rBAT mRNA expression is different from that of b(o,+)AT mRNA and 4F2hc mRNA, but there are regions in the kidney where b(o,+)AT mRNA expression overlaps with rBAT mRNA expression as well as with 4F2hc mRNA expression.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Physiol & Endocrinol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 33347] Funding Source: Medline; NIDA NIH HHS [DA 10045] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; GANAPATHY V, 1999, TXB GASTROENTEROLOGY, P456; Huang W, 1997, INVEST OPHTH VIS SCI, V38, P1578; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kekuda R, 1997, AM J PHYSIOL-GASTR L, V272, pG1463, DOI 10.1152/ajpgi.1997.272.6.G1463; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1997, BIOCHEM J, V328, P657, DOI 10.1042/bj3280657; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Seth P, 1997, BIOCHEM BIOPH RES CO, V241, P535, DOI 10.1006/bbrc.1997.7840; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776	22	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14331	14335		10.1074/jbc.275.19.14331	http://dx.doi.org/10.1074/jbc.275.19.14331			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799513	hybrid			2022-12-27	WOS:000087006900045
J	Wang, XT; McCullough, KD; Franke, TF; Holbrook, NJ				Wang, XT; McCullough, KD; Franke, TF; Holbrook, NJ			Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; INSULIN-LIKE GROWTH-FACTOR-1; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAY; INDUCED APOPTOSIS; HEAT-SHOCK; C-AKT; TRANSCRIPTION FACTOR	The serine/threonine kinase Akt (also known as protein kinase B) is activated in response to various stimuli by a mechanism involving phosphoinositide 3-kinase (PI3-K). Akt provides a survival signal that protects cells from apoptosis induced by growth factor withdrawal, but its function in other forms of stress is less clear. Here we investigated the role of PI3-K/Akt during the cellular response to oxidant injury. H2O2 treatment elevated Akt activity in multiple cell types in a time- (5-30 min) and dose (400 mu M-2 mM)-dependent manner. Expression of a dominant negative mutant of p85 (regulatory component of PI3-K) and treatment with inhibitors of PB-K (wortmannin and LY294002) prevented H2O2-induced Akt activation. Akt activation by H2O2 also depended on epidermal growth factor receptor (EGFR) signaling; H2O2 treatment led to EGFR phosphorylation, and inhibition of EGFR activation prevented Akt activation by H2O2. As H2O2 causes apoptosis of HeLa cells, we investigated whether alterations of PI3-K/Akt signaling would affect this response. Wortmannin and LY294002 treatment significantly enhanced H2O2-induced apoptosis, whereas expression of exogenous myristoylated Akt tan activated form) inhibited cell death. Constitutive expression of v-Akt likewise enhanced survival of H2O2-treated NHH3T3 cells. These results suggest that H2O2 activates Akt via an EGFR/PI3-K-dependent pathway and that elevated Akt activity confers protection against oxidative stress-induced apoptosis.	NIA, Biol Chem Lab, Cell Stress & Aging Sec, Baltimore, MD 21224 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Columbia University	Holbrook, NJ (corresponding author), NIA, Biol Chem Lab, Cell Stress & Aging Sec, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	nikki-holbrook@nih.gov						Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BELLACOSA A, 1993, ONCOGENE, V8, P745; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Goldkorn T, 1998, J CELL SCI, V111, P3209; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Parrizas M, 1997, J BIOL CHEM, V272, P154; Rao GN, 1996, ONCOGENE, V13, P713; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zanella CL, 1996, CANCER RES, V56, P5334; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	52	387	403	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14624	14631		10.1074/jbc.275.19.14624	http://dx.doi.org/10.1074/jbc.275.19.14624			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799549	hybrid			2022-12-27	WOS:000087006900083
J	Alexiev, U; Mollaaghababa, R; Khorana, HG; Heyn, MP				Alexiev, U; Mollaaghababa, R; Khorana, HG; Heyn, MP			Evidence for long range allosteric interactions between the extracellular and cytoplasmic parts of bacteriorhodopsin from the mutant R82A and its second site revertant R82A/G231C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-BLUE TRANSITION; PH-INDICATOR DYES; PROTON RELEASE; SCHIFF-BASE; PURPLE MEMBRANE; REPROTONATION SWITCH; ARGININE RESIDUES; M-INTERMEDIATE; ASPARTIC-ACID; SURFACE	Evidence is presented for long range interactions between the extracellular and cytoplasmic parts of the heptahelical membrane protein bacteriorhodopsin in the mutant R82A and its second site revertant R82A/ G231C, (i) In the double mutants R82A/G72C and R82A/ A160C, with the cysteine mutation on the extracellular or cytoplasmic surface, respectively, the photocycle is the same as in the single mutant R82A with an accelerated deprotonation of the Schiff base and a reversed order of proton release and uptake. Proton release and uptake kinetics were measured directly at either surface by using the unique cysteine residue as attachment site for the pH indicator fluorescein. Whereas in wild type proton uptake on the cytoplasmic surface occurs during the M-decay (tau similar to 8 ms), in R82A it occurs already during the first phase of the M-rise (tau < 1 mu s). (ii) The introduction of a second mutation at the cytoplasmic surface in position 231 (helix G) restores wild type ground state absorption properties, kinetics of photocycle and of proton release, and uptake in the mutant R82A/G231C, In addition, kinetic HID isotope effects provide evidence that the proton release mechanism in R82A/G231C and in wild type is similar. These results suggest the existence of long range interactions between the cytoplasmic and extracellular surface domains of bacteriorhodopsin mediated by salt bridges and hydrogen-bonded networks between helices C (Arg-82) and G (Asp-212 and Gly-231). Such long range interactions are expected to be of functional significance for activation and signal transduction in heptahelical G-protein-coupled receptors.	Free Univ Berlin, Dept Phys, Biophys Grp, Arnimallee 14, D-14195 Berlin, Germany; MIT, Dept Biol, Cambridge, MA 02139 USA	Free University of Berlin; Massachusetts Institute of Technology (MIT)	Alexiev, U (corresponding author), Free Univ Berlin, Dept Phys, Biophys Grp, Arnimallee 14, D-14195 Berlin, Germany.		Alexiev, Ulrike/L-8478-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXIEV U, 1995, P NATL ACAD SCI USA, V92, P372, DOI 10.1073/pnas.92.2.372; ALEXIEV U, 1994, BIOCHEMISTRY-US, V33, P13693, DOI 10.1021/bi00250a020; ALEXIEV U, 1994, BIOCHEMISTRY-US, V33, P298, DOI 10.1021/bi00167a039; Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; BALASHOV SP, 1993, BIOCHEMISTRY-US, V32, P10331, DOI 10.1021/bi00090a008; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, BIOCHEMISTRY-US, V34, P12903, DOI 10.1021/bi00039a053; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; Chizhov I, 1996, BIOPHYS J, V71, P2329, DOI 10.1016/S0006-3495(96)79475-4; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; Dickopf S, 1997, BIOPHYS J, V73, P3171, DOI 10.1016/S0006-3495(97)78343-7; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FERSHT A, 1985, ENZYME STRUCTURE MEC, P263; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GUTMAN M, 1995, BBA-BIOENERGETICS, V1231, P123, DOI 10.1016/0005-2728(95)00074-S; Hatanaka M, 1996, BIOCHEMISTRY-US, V35, P6308, DOI 10.1021/bi952973v; HEBERLE J, 1992, P NATL ACAD SCI USA, V89, P5996, DOI 10.1073/pnas.89.13.5996; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; leCoutre J, 1996, FEBS LETT, V398, P333, DOI 10.1016/S0014-5793(96)01254-9; LIAO MJ, 1983, J BIOL CHEM, V258, P9949; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MARTI T, 1991, J BIOL CHEM, V266, P18674; METZ G, 1992, FEBS LETT, V303, P237, DOI 10.1016/0014-5793(92)80528-O; Moltke S, 1995, ISR J CHEM, V35, P401; MOWERY P, 1979, J MOL BIOL, V12, P88; MRABET NT, 1992, BIOCHEMISTRY-US, V31, P2239, DOI 10.1021/bi00123a005; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Richter HT, 1996, BIOCHEMISTRY-US, V35, P4054, DOI 10.1021/bi952883q; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; Scharnagl C, 1996, CHEM PHYS, V212, P231, DOI 10.1016/S0301-0104(96)00192-9; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; SCHERRER P, 1994, BIOCHEMISTRY-US, V33, P13684, DOI 10.1021/bi00250a019; SCHERRER P, 1992, COLLOQ INSE, V221, P205; SEBBAN P, 1995, BIOCHEMISTRY-US, V34, P8390, DOI 10.1021/bi00026a021; STERN LJ, 1989, J BIOL CHEM, V264, P14202; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SZUNDI I, 1989, BIOPHYS J, V56, P369, DOI 10.1016/S0006-3495(89)82683-9; Thomas EA, 1997, P NATL ACAD SCI USA, V94, P14115, DOI 10.1073/pnas.94.25.14115; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010	48	23	25	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13431	13440		10.1074/jbc.275.18.13431	http://dx.doi.org/10.1074/jbc.275.18.13431			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788455	hybrid			2022-12-27	WOS:000086925300042
J	Day, IS; Miller, C; Golovkin, M; Reddy, ASN				Day, IS; Miller, C; Golovkin, M; Reddy, ASN			Interaction of a kinesin-like calmodulin-binding protein with a protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAINS; HEAVY-CHAIN; CHROMOSOME SEGREGATION; SIGNAL-TRANSDUCTION; CONSERVED FEATURES; MOTOR PROTEINS; PEA-SEEDLINGS; MAP KINASE; IN-VIVO; CENP-E	Kinesin-like calmodulin-binding protein (KCBP) is a novel member of the kinesin superfamily that is involved in cell division and trichome morphogenesis. KCBP is unique among all known kinesins in having a myosin tail homology-4 region in the N-terminal tail and a calmodulin-binding region following the motor domain. Calcium, through calmodulin, has been shown to negatively regulate the interaction of KCBP with microtubules, Here we have used the yeast two-hybrid system to identify the proteins that interact with the tail region of KCBP. A protein kinase (KCBP-interacting protein kinase (KIPK)) was found to interact specifically with the tail region of KCBP, KIPK is related to a group of protein kinases specific to plants that has an additional sequence between subdomains VII and VIII of the conserved C-terminal catalytic domain and an extensive N-terminal region. The catalytic domain alone of KIPK interacted weakly with the N-terminal KCBP protein but strongly with full-length KCBP, whereas the noncatalytic region did not interact with either protein. The interaction of KCBP with KIPK was confirmed using coprecipitation assays. Using bacterially expressed full-length and truncated proteins, we have shown that the catalytic domain is capable of phosphorylating itself. The association of KIPK with KCBP suggests regulation of KCBP or KCBP-associated proteins by phosphorylation and/or that KCBP is involved in targeting KIPK to its proper cellular location.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	reddy@lamar.colostate.edu		Reddy, Anireddy/0000-0002-4038-4091				BIERMANN B, 1990, PLANT PHYSIOL, V94, P1609, DOI 10.1104/pp.94.4.1609; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; Bowser J, 1997, PLANT J, V12, P1429, DOI 10.1046/j.1365-313x.1997.12061429.x; Chandok MR, 1996, MOL GEN GENET, V251, P599, DOI 10.1007/BF02173650; Day IS, 1998, PLANT MOL BIOL, V36, P451, DOI 10.1023/A:1005959311462; Deavours BE, 1998, CELL MOTIL CYTOSKEL, V40, P408, DOI 10.1002/(SICI)1097-0169(1998)40:4<408::AID-CM8>3.0.CO;2-6; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; Golovkin M, 1998, PLANT CELL, V10, P1637, DOI 10.1105/tpc.10.10.1637; GOODSON HV, 1994, J CELL SCI, V107, P1875; HAIMO LT, 1995, TRENDS CELL BIOL, V5, P165, DOI 10.1016/S0962-8924(00)88981-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hardie DG, 1999, ANNU REV PLANT PHYS, V50, P97, DOI 10.1146/annurev.arplant.50.1.97; HAYASHIDA N, 1993, GENE, V124, P251, DOI 10.1016/0378-1119(93)90401-N; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; Kao YL, 2000, BIOCHEM BIOPH RES CO, V267, P201, DOI 10.1006/bbrc.1999.1896; Khanna R, 1999, PLANT MOL BIOL, V39, P231, DOI 10.1023/A:1006154203639; Krishnakumar S, 1999, DEVELOPMENT, V126, P3079; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; Kuo WN, 1995, BIOCHEM MOL BIOL INT, V37, P423; LAWTON MA, 1989, P NATL ACAD SCI USA, V86, P3140, DOI 10.1073/pnas.86.9.3140; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIN X, 1991, P NATL ACAD SCI USA, V88, P6951, DOI 10.1073/pnas.88.16.6951; Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Meyer RC, 1996, PLANT SCI, V118, P71, DOI 10.1016/0168-9452(96)04426-3; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Narasimhulu SB, 1997, PLANT J, V12, P1139, DOI 10.1046/j.1365-313X.1997.12051139.x; Narasimhulu SB, 1998, PLANT CELL, V10, P957, DOI 10.1105/tpc.10.6.957; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; REDDY AS, 2000, IN PRESS SIGNAL TRAN; Reddy ASN, 1996, PLANT J, V10, P9, DOI 10.1046/j.1365-313X.1996.10010009.x; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; REDDY ASN, 1994, BIOCHEM BIOPH RES CO, V199, P1089, DOI 10.1006/bbrc.1994.1342; REDDY ASN, 2000, IN PRESS INT REV CYT; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; Reddy VS, 1999, BIOINFORMATICS, V15, P1055; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Robertson A M, 1997, Prog Cell Cycle Res, V3, P59; Rogers GC, 1999, J MOL BIOL, V294, P1, DOI 10.1006/jmbi.1999.3249; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; Schneider S, 1996, BIOTECHNIQUES, V20, P960; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; Smirnova EA, 1998, CELL MOTIL CYTOSKEL, V41, P271, DOI 10.1002/(SICI)1097-0169(1998)41:3<271::AID-CM8>3.3.CO;2-N; Sokolova M, 1997, FEBS LETT, V400, P201, DOI 10.1016/S0014-5793(96)01380-4; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STEARNS ME, 1990, BIOCHEM CELL BIOL, V68, P436, DOI 10.1139/o90-061; STONE JM, 1995, PLANT PHYSIOL, V108, P451, DOI 10.1104/pp.108.2.451; Thaler C D, 1996, Int Rev Cytol, V164, P269; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; VanderHoeven PCJ, 1996, PLANT PHYSIOL, V111, P857, DOI 10.1104/pp.111.3.857; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; Vos JW, 1999, MOL BIOL CELL, V10, p373A; Wang W, 1996, PLANT MOL BIOL, V31, P87, DOI 10.1007/BF00020609; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	79	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13737	13745		10.1074/jbc.275.18.13737	http://dx.doi.org/10.1074/jbc.275.18.13737			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788494	hybrid			2022-12-27	WOS:000086925300081
J	Kilpelainen, I; Kaksonen, M; Kinnunen, T; Avikainen, H; Fath, M; Linhardt, RJ; Raulo, E; Rauvala, H				Kilpelainen, I; Kaksonen, M; Kinnunen, T; Avikainen, H; Fath, M; Linhardt, RJ; Raulo, E; Rauvala, H			Heparin-binding growth-associated molecule contains two heparin-binding beta-sheet domains that are homologous to the thrombospondin type I repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; MELANOMA CELL-ADHESION; N-SYNDECAN SYNDECAN-3; TRIPLE-RESONANCE NMR; CHEMICAL-SHIFT INDEX; HB-GAM; NEURITE OUTGROWTH; CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; BIOLOGICAL-ACTIVITIES	Heparin-binding growth-associated molecule (HB-GAM) is an extracellular matrix-associated protein implicated in the development and plasticity of neuronal connections of brain. Binding to cell surface heparan sulfate is indispensable for the biological activity of HB-GAM, In the present paper we have studied the structure of recombinant HB-GAIM using heteronuclear NMR. These studies show that HB-GARI contains two beta-sheet domains connected by a flexible linker. Both of these domains contain three antiparallel beta-strands, In addition to this domain structure, HB-GAM contains the Nand C-terminal lysine-rich sequences that lack a detectable structure and appear to form random coils. Studies using CD and NMR spectroscopy suggest that HB-GAIM undergoes a conformational change upon binding to heparin, and that the binding occurs primarily to the beta-sheet domains of the protein. Search of sequence data bases shows that the beta-sheet domains of HB-GAM are homologous to the thrombospondin type I repeat (TSR), Sequence comparisions show that the beta-sheet structures found previously in midkine, a protein homologous with HB-GAM, also correspond to the TSR motif, We suggest that the TSR sequence motif found in various extracellular proteins defines a beta-sheet structure similar to that found in HB-GAM and midkine, In addition to the apparent structural similarity, a similarity in biological functions is suggested by the occurrence of the TSR sequence motif in a wide variety of proteins that mediate cell-to-extracellular matrix and cell-to-cell interactions, in which the TSR domain mediates specific cell surface binding.	Univ Helsinki, Inst Biotechnol, NMR Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, Mol Neurobiol Lab, FIN-00014 Helsinki, Finland; Univ Iowa, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA	University of Helsinki; University of Helsinki; University of Iowa; University of Iowa	Kilpelainen, I (corresponding author), Univ Helsinki, Inst Biotechnol, NMR Lab, POB 56, FIN-00014 Helsinki, Finland.	ilkka.kilpelainen@helsinki.fi		Kinnunen, Dr Tarja K/0000-0001-5630-2233; Rauvala, Heikki/0000-0001-7809-9811; Fath, Melissa/0000-0002-7272-2120; Raulo, Erkki/0000-0001-9113-3770; Kaksonen, Marko/0000-0003-3645-7689				Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Fath M, 1999, FEBS LETT, V454, P105, DOI 10.1016/S0014-5793(99)00785-1; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Lauri SE, 1999, J NEUROSCI, V19, P1226; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Naitza S, 1998, PARASITOL TODAY, V14, P479, DOI 10.1016/S0169-4758(98)01346-5; NOLO R, 1995, NEUROSCI LETT, V191, P39, DOI 10.1016/0304-3940(94)11551-1; PENG HB, 1995, J NEUROSCI, V15, P3027; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Rauvala H, 1997, PROG NEUROBIOL, V52, P127, DOI 10.1016/S0301-0082(97)00007-5; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; Sawitzky D, 1996, MED MICROBIOL IMMUN, V184, P155, DOI 10.1007/BF02456129; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	50	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13564	13570		10.1074/jbc.275.18.13564	http://dx.doi.org/10.1074/jbc.275.18.13564			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788472	hybrid			2022-12-27	WOS:000086925300059
J	Semenov, AY; Vassiliev, IR; van der Est, A; Mamedov, MD; Zybailov, B; Shen, GZ; Stehlik, D; Diner, BA; Chitnis, PR; Golbeck, JH				Semenov, AY; Vassiliev, IR; van der Est, A; Mamedov, MD; Zybailov, B; Shen, GZ; Stehlik, D; Diner, BA; Chitnis, PR; Golbeck, JH			Recruitment of a foreign quinone into the A(1) site of photosystem I - Altered kinetics of electron transfer in phylloquinone biosynthetic pathway mutants studied by time-resolved optical, EPR, and electrometric techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; PHOTOSYNTHETIC REACTION CENTERS; CLUSTER F-B; RESONANCE SPECTROSCOPY; PARAMAGNETIC-RESONANCE; SPIN POLARIZATION; ROOM-TEMPERATURE; 2 PHYLLOQUINONES; TRANSIENT EPR; ACCEPTOR	Interruption of the menA or menB gene in Synechocystis sp, PCC 6803 results in the incorporation of a foreign quinone, termed Q, into the A, site of photosystem I with a number of experimental indicators identifying Q as plastoquinone-9, A global multiexponential analysis of time-resolved optical spectra in the blue region shows the following three kinetic components: 1) a 3-ms lifetime in the absence of methyl viologen that represents charge recombination between P700(+) and an FeS- cluster; 2) a 750-mu s lifetime that represents electron donation from an FeS- cluster to methyl viologen; and 3) an similar to 15-mu s lifetime that represents an electrochromic shift of a carotenoid pigment. Room temperature direct detection transient EPR studies of forward electron trans fer show a spectrum of P700(+) Q(-) during the lifetime of the spin polarization and give no evidence of a significant population of P700(+) FeS- for t less than or equal to 2-3 mu s. The UV difference spectrum measured 5 mu s after a flash shows a maximum at 315 nm, a crossover at 280 nm, and a minimum at 255 nm as well as a shoulder at 290-295 nm, all of which are characteristic of the plastoquinone-9 anion radical, Kinetic measurements that monitor Q at 315 nm show a major phase of forward electron transfer to the FeS clusters with a lifetime of similar to 15 mu s, which matches the electrochromic shift at 485 nm of the carotenoid, as well as an minor phase with a lifetime of similar to 250 mu s. Electrometric measurements show similar biphasic kinetics, The slower kinetic phase can be detected using time-resolved EPR spectroscopy and has a spectrum characteristic of a semiquinone anion radical. We estimate the redox potential of plastoquinone-9 in the A(1) site to be more oxidizing than phylloquinone so that electron transfer from Q(-) to F-X is thermodynamically unfavorable in the menA and menB mutants.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; DuPont Co Inc, Expt Stn, Cent Res & Dev, Wilmington, DE 19980 USA; Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Lomonosov Moscow State University; Brock University; Free University of Berlin; DuPont; Iowa State University	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	JHG5@psu.edu	Mamedov, Mahir/X-7600-2018; Semenov, Alexey Yu/G-2759-2014	Semenov, Alexey Yu/0000-0003-1035-0381; Zybailov, Boris/0000-0003-2432-9145				BENASSON R, 1973, BIOCHIM BIOPHYS ACTA, V325, P175; BIGGINS J, 1990, BIOCHEMISTRY-US, V29, P7259, DOI 10.1021/bi00483a014; BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; BOCK CH, 1989, FEBS LETT, V247, P91, DOI 10.1016/0014-5793(89)81247-5; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; CHAMOROVSKY SK, 1982, PHOTOBIOCH PHOTOBIOP, V4, P195; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Diner BA, 1998, METHOD ENZYMOL, V297, P337; Franke JE, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P75; Golbeck JH, 1999, PHOTOSYNTH RES, V61, P107, DOI 10.1023/A:1006281802710; GUTMANN V, 1976, COORDIN CHEM REV, V18, P225, DOI 10.1016/S0010-8545(00)82045-7; IWAKI M, 1994, PLANT CELL PHYSIOL, V35, P983; JAWORSKI JS, 1979, J ELECTROANAL CHEM, V105, P329, DOI 10.1016/S0022-0728(79)80126-6; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Kandrashkin YE, 1998, APPL MAGN RESON, V15, P417, DOI 10.1007/BF03162027; Klukas O, 1999, J BIOL CHEM, V274, P7361, DOI 10.1074/jbc.274.11.7361; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; Mamedov MD, 1996, J BIOENERG BIOMEMBR, V28, P517, DOI 10.1007/BF02110441; Mamedova AA, 1999, FEBS LETT, V462, P421, DOI 10.1016/S0014-5793(99)01570-7; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PRINCE RC, 1986, METHOD ENZYMOL, V125, P109; PRINCE RC, 1983, FEBS LETT, V160, P273, DOI 10.1016/0014-5793(83)80981-8; RUSTANDI RR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P311, DOI 10.1016/0005-2728(92)90087-I; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; SETIF P, 1990, CURRENT RES PHOTOSYN, V2, P539; Shinkarev VP, 2000, BIOPHYS J, V78, P363, DOI 10.1016/S0006-3495(00)76599-4; SIECKMAN I, 1991, FEBS LETT, V284, P98, DOI 10.1016/0014-5793(91)80771-T; van der Est A, 1998, BBA-BIOENERGETICS, V1409, P87, DOI 10.1016/S0005-2728(98)00152-2; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; VANGORKOM HJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P439, DOI 10.1016/0005-2728(74)90081-4; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; VOS MH, 1988, BIOCHIM BIOPHYS ACTA, V934, P293, DOI 10.1016/0005-2728(88)90089-8; VOS MH, 1990, BIOPHYS J, V58, P1547, DOI 10.1016/S0006-3495(90)82499-1; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	40	77	85	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23429	23438		10.1074/jbc.M000508200	http://dx.doi.org/10.1074/jbc.M000508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801789	hybrid			2022-12-27	WOS:000088564200006
J	Winchester, SK; Selvamurugan, N; D'Alonzo, RC; Partridge, NC				Winchester, SK; Selvamurugan, N; D'Alonzo, RC; Partridge, NC			Developmental regulation of collagenase-3 mRNA in normal, differentiating osteoblasts through the activator protein-1 and the runt domain binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE CELL-CULTURES; GROWTH-FACTOR-I; PARATHYROID-HORMONE; MATRIX METALLOPROTEINASE-13; OSTEOCALCIN GENE; HYPERTROPHIC CHONDROCYTES; INTERSTITIAL COLLAGENASE; BREAST CARCINOMAS; FIBROBLAST-GROWTH; RAT OSTEOBLASTS	Collagenase-3 mRNA is initially detectable when osteoblasts cease proliferation, increasing during differentiation and mineralization. We showed that this developmental expression is due to an increase in collagenase-3 gene transcription. Mutation of either the activator protein-1 or the runt domain binding site decreased collagenase-3 promoter activity, demonstrating that these sites are responsible for collagenase-3 gene transcription. The activator protein-1 and runt domain binding sites bind members of the activator protein-1 and core-binding factor family of transcription factors, respectively. We identified core-binding factor al binding to the runt domain binding site and JunD in addition to a Fos-related antigen binding to the activator protein-1 site. Overexpression of both c-Fos and c-Jun in osteoblasts or core-binding factor al increased collagenase-3 promoter activity. Furthermore, overexpression of c-Fos, c-Jun, and core-binding factor al synergistically increased collagenase-3 promoter activity. Mutation of either the activator protein-1 or the runt domain binding site resulted in the inability of c-Fos and c-Jun or core-binding factor al to increase collagenase-3 promoter activity, suggesting that there is cooperative interaction between the sites and the proteins. Overexpression of Fra-2 and JunD repressed core-binding factor al-induced collagenase-3 promoter activity. Our results suggest that members of the activator protein-1 and core-binding factor families, binding to the activator protein-1 and runt domain binding sites are responsible for the developmental regulation of collagenase-3 gene expression in osteoblasts.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Selvamurugan, Nagarajan/P-7894-2016	Selvamurugan, Nagarajan/0000-0003-3713-1920; Partridge, Nicola/0000-0002-5406-4814	NIDDK NIH HHS [DK48109, DK47420, R01 DK047420] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047420, R01DK048109, R01DK047420] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CURRAN T, 1987, ONCOGENE, V2, P79; Delany AM, 1996, ENDOCRINOLOGY, V137, P4665, DOI 10.1210/en.137.11.4665; DELANY AM, 1995, ENDOCRINOLOGY, V136, P4776, DOI 10.1210/en.136.11.4776; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GARDNER K, 1994, J BIOL CHEM, V269, P32963; Gazzerro E, 1999, ENDOCRINOLOGY, V140, P562, DOI 10.1210/en.140.2.562; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, AM J PATHOL, V151, P499; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; REZZONICO R, 1995, ONCOGENE, V11, P1069; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Rydziel S, 1997, J CELL BIOCHEM, V67, P176, DOI 10.1002/(SICI)1097-4644(19971101)67:2<176::AID-JCB3>3.0.CO;2-U; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; StahleBackdahl M, 1997, LAB INVEST, V76, P717; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Varghese S, 1997, ENDOCRINOLOGY, V138, P1035, DOI 10.1210/en.138.3.1035; Wang HL, 1996, ONCOGENE, V13, P2639; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097-4652(199912)181:3<479::AID-JCP12>3.0.CO;2-D; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; [No title captured]	57	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23310	23318		10.1074/jbc.M003004200	http://dx.doi.org/10.1074/jbc.M003004200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10779518	hybrid			2022-12-27	WOS:000088419400098
J	Drees, B; Friederich, E; Fradelizi, J; Louvard, D; Beckerle, MC; Grolsteyn, RM				Drees, B; Friederich, E; Fradelizi, J; Louvard, D; Beckerle, MC; Grolsteyn, RM			Characterization of the interaction between zyxin and members of the ena/vasodilator-stimulated phosphoprotein family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTILITY; HOST-CELL ACTIN; PROLINE-RICH REGION; LISTERIA-MONOCYTOGENES; FOCAL-ADHESION; CYTOSKELETAL DYNAMICS; OWN CYTOSKELETON; MAMMALIAN-CELLS; SURFACE PROTEIN; ENA/VASP FAMILY	Zyxin contains a proline-rich N-terminal domain that is similar to the C-terminal domain in the ActA protein of the bacteria, Listeria monocytogenes. We screened the entire amino acid sequence of human zyxin for Mena-interacting peptides and found that, as with ActA, proline-rich sequences were the sole zyxin sequences capable of binding to Ena/vasodilator-stimulated phosphoprotein (VASP) family members in vitro. From this information, we tested zyxin mutants in which the proline-rich sequences were altered. The reduction in Mena/VASP binding was confirmed by peptide tests, immunoprecipitation, and ectopic expression of zyxin variants at the surface of mitochondria. By transfection assays we showed that zyxin interaction with Mena/VASP in vivo enhances the production of actin-rich structures at the apical surface of cells. Microinjection into cells of peptides corresponding to the first proline-rich sequence of zyxin caused the loss of Mena/VASP from focal contacts. Furthermore, these peptides reduced the degree of spreading of cells replated after trypsinization, We conclude that zyxin and proteins that harbor similar proline-rich repeats contribute to the positioning of Mena/VASP proteins. The positioning of Ena/VASP family members appears to be important when the actin cytoskeleton is reorganized, such as during spreading.	Univ Utah, Dept Biol, Huntsman Canc Inst, Salt Lake City, UT 84103 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Grolsteyn, RM (corresponding author), Inst Curie, CNRS, UMR144, 26 Rue Ulm, F-75248 Paris 05, France.	golsteyn@curie.fr						Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; ASHAR HR, 1995, CELL, V82, P57; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BEREITERHAHN J, 1990, J CELL SCI, V96, P171; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Fradelizi J, 1999, BIOTECHNIQUES, V26, P484; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Golsteyn RM, 1997, J CELL SCI, V110, P1893; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MATTHIAS PD, 1982, EMBO J, V1, P1207, DOI 10.1002/j.1460-2075.1982.tb00014.x; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; Sechi AS, 1997, J CELL BIOL, V137, P155, DOI 10.1083/jcb.137.1.155; SMALL JV, 1978, NATURE, V272, P638, DOI 10.1038/272638a0; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1992, J CELL BIOL, V118, P71, DOI 10.1083/jcb.118.1.71; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; Zeile WL, 1998, P NATL ACAD SCI USA, V95, P13917, DOI 10.1073/pnas.95.23.13917; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	61	133	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22503	22511		10.1074/jbc.M001698200	http://dx.doi.org/10.1074/jbc.M001698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801818	hybrid			2022-12-27	WOS:000088363800100
J	Sato, K; Homma, M				Sato, K; Homma, M			Multimeric structure of PomA, a component of the Na+-driven polar flagellar motor of Vibrio alginolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE CHANNEL COMPONENTS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TORQUE GENERATION; ALKALOPHILIC BACILLUS; CYTOPLASMIC MEMBRANE; AMILORIDE ANALOG; PROTEIN; ROTATION; GENE	Four integral membrane proteins, PomA, PomB, MotX, and MotY, are thought to be directly involved in torque generation of the Na+-driven polar flagellar motor of Vibrio alginolyticus. Our previous study showed that PomA and PomB form a complex, which catalyzes sodium influx in response to a potassium diffusion potential. PomA forms a stable dimer when expressed in a PomB null mutant. To explore the possible functional dependence of PomA domains in adjacent subunits, we prepared a series of PomA dimer fusions containing different combinations of wild-type or mutant subunits, Introduction of the mutation P199L, which completely inactivates flagellar rotation, into either the first or the second half of the dimer abolished motility. The P199L mutation in monomeric PomA also altered the PomA-PomB interaction. PomA dimer with the P199L mutation even in one subunit also had no ability to interact with PomB, indicating that the both subunits in the dimer are required for the functional interaction between PomA and PomB, Flagellar rotation by wild-type PomA dimer was completely inactivated by phenamil, a sodium channel blocker. However, activity was retained in the presence of phenamil when either half of the dimer was replaced with a phenamil-resistant subunit, indicating that both subunits must bind phenamil for motility to be fully inhibited. These observations demonstrate that both halves of the PomA dimer function together to generate the torque for flagellar rotation.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Sato, K (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.							Asai Y, 1997, J BACTERIOL, V179, P5104, DOI 10.1128/jb.179.16.5104-5110.1997; Asai Y, 1999, J BACTERIOL, V181, P6332, DOI 10.1128/JB.181.20.6332-6338.1999; Atsumi T, 1996, J BACTERIOL, V178, P5024, DOI 10.1128/jb.178.16.5024-5026.1996; ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; BERG HC, 1995, BIOPHYS J, V68, pS163; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1991, J BACTERIOL, V173, P4049, DOI 10.1128/jb.173.13.4049-4055.1991; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Braun TF, 1999, J BACTERIOL, V181, P3542, DOI 10.1128/JB.181.11.3542-3551.1999; CHUN SY, 1988, SCIENCE, V239, P276, DOI 10.1126/science.2447650; DEAN GE, 1984, J BACTERIOL, V159, P991, DOI 10.1128/JB.159.3.991-999.1984; DEMOT R, 1994, MOL MICROBIOL, V12, P333; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; GARZA AG, 1995, P NATL ACAD SCI USA, V92, P1970, DOI 10.1073/pnas.92.6.1970; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; Kojima S, 1999, MICROBIOL-UK, V145, P1759, DOI 10.1099/13500872-145-7-1759; Kojima S, 1999, J MOL BIOL, V285, P1537, DOI 10.1006/jmbi.1998.2377; KOSTER W, 1990, MOL GEN GENET, V223, P379; Lloyd SA, 1999, NATURE, V400, P472, DOI 10.1038/22794; Lloyd SA, 1996, J BACTERIOL, V178, P223, DOI 10.1128/jb.178.1.223-231.1996; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; MCCARTER LL, 1994, J BACTERIOL, V176, P4219, DOI 10.1128/jb.176.14.4219-4225.1994; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Muramoto K, 1998, MOL MICROBIOL, V29, P1191, DOI 10.1046/j.1365-2958.1998.00998.x; MURAMOTO K, 1995, J MOL BIOL, V251, P50, DOI 10.1006/jmbi.1995.0415; Okunishi I, 1996, J BACTERIOL, V178, P2409, DOI 10.1128/jb.178.8.2409-2415.1996; OOSAWA K, 1994, J BACTERIOL, V176, P3683, DOI 10.1128/JB.176.12.3683-3691.1994; Park Y, 1999, EMBO J, V18, P4149, DOI 10.1093/emboj/18.15.4149; Sato K, 2000, J BIOL CHEM, V275, P5718, DOI 10.1074/jbc.275.8.5718; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STADER J, 1986, J BACTERIOL, V166, P244, DOI 10.1128/jb.166.1.244-252.1986; STOLZ B, 1991, J BACTERIOL, V173, P7033, DOI 10.1128/jb.173.21.7033-7037.1991; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; Yorimitsu T, 1999, J BACTERIOL, V181, P5103, DOI 10.1128/JB.181.16.5103-5106.1999; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431; Zhou JD, 1997, J MOL BIOL, V273, P428, DOI 10.1006/jmbi.1997.1316; Zhou JD, 1998, P NATL ACAD SCI USA, V95, P6436, DOI 10.1073/pnas.95.11.6436	43	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20223	20228		10.1074/jbc.M002236200	http://dx.doi.org/10.1074/jbc.M002236200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10783392	hybrid			2022-12-27	WOS:000087941300105
J	Sandholzer, U; von Figura, H; Pohlmann, R				Sandholzer, U; von Figura, H; Pohlmann, R			Function and properties of chimeric MPR 46-MPR 300 mannose 6-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; LYSOSOMAL ACID-PHOSPHATASE; CYTOPLASMIC TAIL; MANNOSE-6-PHOSPHATE RECEPTORS; BOVINE LIVER; AMINO-ACIDS; RAPID INTERNALIZATION; TARGETED DISRUPTION; LIGAND INTERACTIONS; CARBOXYL-TERMINUS	The two known mannose 6-phosphate receptors (MPR 46 and MPR 300) mediate the transport of mannose 6-phosphate-containing lysosomal proteins to lysosomes. Endocytosis of extracellular mannose g-phosphate ligands can only be mediated by MPR 300. Neither type of MPR appears to be sufficient for targetting the full complement of lysosomal enzymes to lysosomes. The complements of lysosomal enzymes transported by either of the two receptors are distinct but largely overlapping. Chimeric receptors were constructed in which the transmembrane and cytoplasmic domains of the two receptors were systematically exchanged. After expression of the chimeric receptors in cells lacking endogenous MPRs the binding of ligands, the subcellular distribution and the sorting efficiency for lysosomal enzymes were analyzed. All chimeras were functional, and their subcellular distribution was similar to that of wild type MPRs. The ability to endocytose lysosomal enzymes was restricted to receptors with the lumenal domain of MPR 300. The efficiency to sort lysosomal enzymes correlated with the lumenal and cytoplasmic domains of MPR 300. In contrast to the wild type receptors, a significant fraction of most of the chimeric receptors was misrouted to lysosomes, indicating that the signals determining the routing of MPRs have been fitted for the parent receptor polypeptides.	Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Gottingen, Biochem Abt 2, D-37075 Gottingen, Germany	University of Munster; University of Gottingen	Pohlmann, R (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.							ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BLEEKEMOLEN JE, 1988, EUR J CELL BIOL, V47, P366; BRESCIANI R, 1992, EUR J CELL BIOL, V58, P57; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLAIRMONT KB, 1991, J BIOL CHEM, V266, P12131; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; Dittmer F, 1999, BIOCHEM J, V340, P729, DOI 10.1042/0264-6021:3400729; FILSON AJ, 1993, DEVELOPMENT, V118, P731; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GIESELMANN V, 1984, H-S Z PHYSIOL CHEM, V365, P651, DOI 10.1515/bchm2.1984.365.1.651; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1994, EUR J BIOCHEM, V224, P685, DOI 10.1111/j.1432-1033.1994.00685.x; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; MA ZM, 1991, J BIOL CHEM, V266, P10589; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; POHLMANN R, 1996, BIOMEMBR, V4, P223; PORTER MT, 1969, P NATL ACAD SCI USA, V62, P887, DOI 10.1073/pnas.62.3.887; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SAHAGIAN GG, 1981, P NATL ACAD SCI-BIOL, V78, P4289, DOI 10.1073/pnas.78.7.4289; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WENK J, 1991, BIOCHEM INT, V23, P723; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	63	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14132	14138		10.1074/jbc.275.19.14132	http://dx.doi.org/10.1074/jbc.275.19.14132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799489	hybrid			2022-12-27	WOS:000087006900019
J	Sun, F; Hug, MJ; Bradbury, NA; Frizzell, RA				Sun, F; Hug, MJ; Bradbury, NA; Frizzell, RA			Protein kinase A associates with cystic fibrosis transmembrane conductance regulator via an interaction with ezrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; ANCHORING PROTEIN; A-KINASE; SUBUNIT RII; PHOSPHORYLATION; DOMAIN; BINDING; CYTOSKELETON; EXPRESSION; EXCHANGER	The cystic fibrosis transmembrane conductance regulator (CFTR) is an epithelial Cl- channel whose activity is controlled by cAMP-dependent protein kinase (PKA)mediated phosphorylation. We found that CFTR immunoprecipitates from Calu-3 airway cells contain endogenous PKA, which is capable of phosphorylating CFTR. This phosphorylation is stimulated by cAMP and inhibited by the PKA inhibitory peptide. The endogenous PKA that co-precipitates with CFTR could also phosphorylate the PKA substrate peptide, Leu-Arg-Arg-Ala-Ser-Leu-Gly (kemptide), Both the catalytic and type II regulatory subunits of PKA are identified by immunoblotting CFTR immunoprecipitates, demonstrating that the endogenous kinase associated with CFTR is PKA, type II (PKA II). Phosphorylation reactions mediated by CFTR-associated PKA II are inhibited by Ht31 peptide but not by the control peptide Ht31P, indicating that a protein kinase A anchoring protein (AKAP) is responsible for the association between PKA and CFTR, Ezrin may function as this AKAP, since it is expressed in Calu-3 and T84 epithelia, ezrin binds RII in overlay assays, and RII is immunoprecipitated with ezrin from Calu-3 cells. Whole-cell patch clamp of Calu-3 cells shows that Ht31 peptide reduces cAMP-stimulated CFTR Cl- current, but Ht31P does not. Taken together, these data demonstrate that PRA II is linked physically and functionally to CFTR by an AKAP interaction, and they suggest that ezrin serves as an AKAP for PHA-mediated phosphorylation of CFTR,	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.				NIDDK NIH HHS [DK56490] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FRANCK Z, 1993, J CELL SCI, V105, P219; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hanrahan JW, 1996, J EXP ZOOL, V275, P283; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Johnson CM, 1997, J NEUROSCI, V17, P6189; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; NAIRN AC, 1996, PEDIATR PULM, V13, P12; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Singh AE, 1998, AM J PHYSIOL-CELL PH, V275, pC562, DOI 10.1152/ajpcell.1998.275.2.C562; SUN F, 1999, PEDIATR PULM, V19, P165; Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204	45	128	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14360	14366		10.1074/jbc.275.19.14360	http://dx.doi.org/10.1074/jbc.275.19.14360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799517	hybrid			2022-12-27	WOS:000087006900049
J	de Mena, IR; Lefai, E; Garesse, R; Kaguni, LS				de Mena, IR; Lefai, E; Garesse, R; Kaguni, LS			Regulation of mitochondrial single-stranded DNA-binding protein gene expression links nuclear and mitochondrial DNA replication in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; XENOPUS-LAEVIS; ATP SYNTHASE; STRUCTURAL ORGANIZATION; POLYMERASE-GAMMA; ALPHA-SUBUNIT; ANTIGEN GENE; PROMOTER; EMBRYOS; SEQUENCE	The structural organization of the Drosophila melanogaster gene encoding mitochondrial single-stranded DNA-binding protein (mtSSB) has been determined and its pattern of expression evaluated during Drosophila development. The D, melanogaster mtSSB gene contains four exons and three small introns, The transcriptional initiation site is located 22 nucleotides upstream from the initiator translation codon in adults, whereas several initiation sites are found in embryos. No consensus TATA or CAAT sequences are located at canonical positions, although an AT-rich sequence was identified flanking the major transcriptional initiation site. Northern analyses indicated that the mtSSB transcript is present at variable levels throughout development, In situ hybridization analysis shows that maternally deposited mtSSB mRNA is distributed homogeneously in the early embryo, whereas de novo transcript is produced specifically at an elevated level in the developing midgut, Transfection assays in cultured Schneider cells with promoter region deletion constructs revealed that the proximal 230 nucleotides contain cis-acting elements required for efficient gene expression. Putative transcription factor binding sites clustered within this region include two Drosophila DNA replication-related elements (DRE) and a single putative E2F binding site. Deletion and base substitution mutagenesis of the DRE sites demonstrated that they are required for efficient promoter activity, and gel electrophoretic mobility shift analyses showed that DRE binding factor (DREF) binds to these sites, Our data suggest strongly that the Drosophila mtSSB gene is regulated by the DRE/DREF system, This finding represents a first link between nuclear and mitochondrial DNA replication.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Madrid 28028, Spain	Michigan State University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.		Lefai, Etienne/L-7961-2019; Garesse, Rafael/F-3836-2012; Lefai, Etienne/E-9615-2019	Lefai, Etienne/0000-0002-3042-7801; Lefai, Etienne/0000-0002-3042-7801	NHLBI NIH HHS [HL59656] Funding Source: Medline; NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; BARAT M, 1985, EXP CELL RES, V157, P207, DOI 10.1016/0014-4827(85)90163-6; BERTAZZONI U, 1977, EUR J BIOCHEM, V81, P237, DOI 10.1111/j.1432-1033.1977.tb11945.x; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOLDEN A, 1977, J BIOL CHEM, V252, P3351; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; Champagne AM, 1997, GENE, V184, P65, DOI 10.1016/S0378-1119(96)00574-4; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; de Mena IR, 1999, J BIOL CHEM, V274, P37321, DOI 10.1074/jbc.274.52.37321; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FALSON P, 1991, J BIOL CHEM, V266, P287; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; FEGER G, 1995, EMBO J, V14, P5387, DOI 10.1002/j.1460-2075.1995.tb00223.x; FOE VE, 1989, DEVELOPMENT, V107, P1; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; Gupta S, 1998, GENE, V212, P269, DOI 10.1016/S0378-1119(98)00148-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; HUBSCHER U, 1977, EUR J BIOCHEM, V81, P249, DOI 10.1111/j.1432-1033.1977.tb11946.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Li K, 1997, J BIOL CHEM, V272, P8686, DOI 10.1074/jbc.272.13.8686; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; Pena P, 1995, BIOCHEM J, V312, P887, DOI 10.1042/bj3120887; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; RUBENSTEIN JLR, 1977, CELL, V12, P471, DOI 10.1016/0092-8674(77)90123-4; Sambrook J., 2002, MOL CLONING LAB MANU; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Skaer H, 1996, EXP NEPHROL, V4, P119; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Talamillo A, 1998, MOL BIOL REP, V25, P87, DOI 10.1023/A:1006868306735; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; TREISMAN JE, 1995, GENE DEV, V9, P1709, DOI 10.1101/gad.9.14.1709; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1981, J BIOL CHEM, V256, P2772; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	57	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13628	13636		10.1074/jbc.275.18.13628	http://dx.doi.org/10.1074/jbc.275.18.13628			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788480				2022-12-27	WOS:000086925300067
J	Schwake, M; Pusch, M; Kharkovets, T; Jentsch, TJ				Schwake, M; Pusch, M; Kharkovets, T; Jentsch, TJ			Surface expression and single channel properties of KCNQ2/KCNQ3, M-type K+ channels involved in epilepsy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; POTASSIUM M-CHANNEL; FUNCTIONAL EXPRESSION; IDIOPATHIC EPILEPSY; CARDIAC-ARRHYTHMIAS; CHLORIDE CHANNEL; GENE; MUTATION; KCNQ2; CONDUCTANCE	Mutations in either KCNQ2 or KCNQ3 underlie benign familial neonatal convulsions (BFNC), an inherited epilepsy. The corresponding proteins are co-expressed in broad regions of the brain and associate to heteromeric K+ channels. These channels mediate M-type currents that regulate neuronal excitability. We investigated the basis for the increase in currents seen after co-expressing these subunits in Xenopus oocytes, Noise analysis and single channel recordings revealed a conductance of approximate to 18 pS for KCNQ2 and approximate to 7 pS for KCNQ3, Different conductance levels (ranging from 8 to 22 pS) were seen upon co-expression, Their weighted average is close to that obtained by noise analysis (16 pS), The open probability of heteromeric channels was not increased significantly. Co-expression of both subunits increased the surface expression of KCNQ2 and KCNQ3 by factors of 5 and >10, respectively. A KCNQ2 mutant associated with BFNC that has a truncated cytoplasmic carboxyl terminus did not reach the surface and failed to stimulate KCNQ3 surface expression. By contrast, several BFNC-associated missense mutations in KCNQ2 or KCNQ3 did not alter their surface expression. Thus, the increase in currents seen upon co-expressing KCNQ2 and KCNQ3 is predominantly due to an increase in surface expression, which is dependent on an intact carboxyl terminus.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany; Ist Cibernet & Biofis, I-16149 Genoa, Italy	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de	Schwake, Michael/F-5381-2010	Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553; Schwake, Michael/0000-0002-4173-2166	Telethon [1079] Funding Source: Medline	Telethon(Fondazione Telethon)		Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Meves H, 1999, BRIT J PHARMACOL, V127, P1213, DOI 10.1038/sj.bjp.0702642; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PUSCH M, 1994, BIOPHYS J, V66, P149, DOI 10.1016/S0006-3495(94)80753-2; Pusch M, 1998, PFLUG ARCH EUR J PHY, V437, P172, DOI 10.1007/s004240050765; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Selyanko AA, 1998, J PHYSIOL-LONDON, V510, P71, DOI 10.1111/j.1469-7793.1998.071bz.x; SELYANKO AA, 1993, J PHYSIOL-LONDON, V472, P711, DOI 10.1113/jphysiol.1993.sp019968; SELYANKO AA, 1992, P ROY SOC B-BIOL SCI, V250, P119, DOI 10.1098/rspb.1992.0139; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; Selyanko AA, 1999, J NEUROSCI, V19, P7742; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Tinel N, 1998, FEBS LETT, V438, P171, DOI 10.1016/S0014-5793(98)01296-4; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	27	138	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13343	13348		10.1074/jbc.275.18.13343	http://dx.doi.org/10.1074/jbc.275.18.13343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788442	hybrid, Green Published			2022-12-27	WOS:000086925300028
J	Sullivan, DA; Cohen, JB				Sullivan, DA; Cohen, JB			Mapping the agonist binding site of the nicotinic acetylcholine receptor - Orientation requirements for activation by covalent agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN BINDING; CHANNEL-LINING RESIDUES; GAMMA-SUBUNIT; DELTA-SUBUNIT; AMINO-ACIDS; M2 SEGMENT; CURARIFORM ANTAGONISTS; SCANNING MUTAGENESIS; CONSERVED TYROSINES; LIGAND-BINDING	To characterize the structural requirements for ligand orientation compatible with activation of the Torpedo nicotinic acetylcholine receptor (nAChR), we used Cys mutagenesis in conjunction with sulfhydryl-reactive reagents to tether primary or quaternary amines at defined positions within the agonist binding site of nAChRs containing mutant alpha- or gamma-subunits expressed in Xenopus oocytes, 4-(N-Maleimido)benzyltrimethylammonium and 2-aminoethylmethanethiosulfonate acted as irreversible antagonists when tethered at alpha Y93C, alpha Y198C, or gamma E57C, as well as at alpha N94C (2-aminoethylmethanethiosulfonate only), [2-(Trimethylammonium)ethyl]-methanethiosulfonate (MTSET), which attaches thiocholine to binding site Cys, also acted as an irreversible antagonist when tethered at alpha Y93C, alpha N94C, or gamma E57C. However, MTSET modification of alpha Y198C resulted in prolonged activation of the nAChR not reversible by washing but inhibitable by subsequent exposure to non competitive antagonists. Modification of alpha Y198C (or any of the other positions tested) by [(trimethylammonium)methyl]methanethiosulfonate resulted only in irreversible inhibition, while modification of alpha Y198C by [3-(trimethylammonium)propyl]methanethiosulfonate resulted in irreversible activation of nAChR, but at lower efficacy than by MTSET, Thus changing the length of the tethering arm by less than 1 Angstrom in either direction markedly effects the ability of the covalent trimethylammonium to activate the nAChR, and agonist activation depends on a very selective orientation of the quaternary ammonium within the agonist binding site.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19522] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Akk G, 1996, BIOPHYS J, V70, P2652, DOI 10.1016/S0006-3495(96)79834-X; Akk G, 1999, BIOPHYS J, V76, P207, DOI 10.1016/S0006-3495(99)77190-0; AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Boileau AJ, 1999, J NEUROSCI, V19, P4847; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; CHABALA LD, 1986, J PHYSIOL-LONDON, V379, P83, DOI 10.1113/jphysiol.1986.sp016242; CHARNET P, 1990, NEURON, V2, P87; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; CORRINGER PJ, 2000, IN PRESS ANN REV PHA; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FU DX, 1994, J BIOL CHEM, V269, P26152; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; GALZI JL, 1990, J BIOL CHEM, V265, P10430; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; Karlin A, 1998, METHOD ENZYMOL, V293, P123; OGDEN DC, 1985, PROC R SOC SER B-BIO, V225, P329, DOI 10.1098/rspb.1985.0065; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; Osaka H, 1998, J BIOL CHEM, V273, P12758, DOI 10.1074/jbc.273.21.12758; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; SINE SM, 1991, J BIOL CHEM, V266, P19369; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Spura A, 1999, BIOCHEMISTRY-US, V38, P4912, DOI 10.1021/bi982656z; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; Zhou M, 1999, P NATL ACAD SCI USA, V96, P10466, DOI 10.1073/pnas.96.18.10466	43	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12651	12660		10.1074/jbc.275.17.12651	http://dx.doi.org/10.1074/jbc.275.17.12651			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777557	hybrid			2022-12-27	WOS:000086762300041
J	Poujol, N; Wurtz, JM; Tahiri, B; Lumbroso, S; Nicolas, JC; Moras, D; Sultan, C				Poujol, N; Wurtz, JM; Tahiri, B; Lumbroso, S; Nicolas, JC; Moras, D; Sultan, C			Specific recognition of androgens by their nuclear receptor - A structure-function study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; THYROID-HORMONE RECEPTOR; CRYSTAL-STRUCTURE; GENE; ANTAGONISM; GAMMA; INSENSITIVITY; SUPERFAMILY; MUTATIONS; CANCER	Androgens, like progestins, are 3-ketosteroids with structural differences restricted to the 17 beta substituent in the steroid D-ring. To better understand the specific recognition of ligands by the human androgen receptor (hAR), a homology model of the ligand-binding domain (LBD) was constructed based on the progesterone receptor LBD crystal structure. Several mutants of residues potentially involved in the specific recognition of ligands in the hAR were constructed and tested for their ability to bind agonists. Their transactivation capacity in response to agonist (R1881) and antagonists (cyproterone acetate, hydroxyflutamide, and ICI 176344) was also measured. Substitution of His(874) by alanine, only marginally impairs the ligand-binding and transactivation capacity of the hAR receptor. In contrast, mutations of Thr(877) and, to a greater extent, Asn(705) perturb ligand recognition, alter transactivation efficiency, and broaden receptor specificity. Interestingly, the N705A mutant acquires progesterone receptor (PR) properties for agonist ligands but, unlike wild type AR and PR, loses the capacity to repress transactivation with nonsteroidal antagonists. Models of the hAR LBD complexes with several ligands are presented, which suggests new directions for drug design.	INSERM, U439, F-34090 Montpellier, France; Hop Lapeyronie, Lab Hormol Dev & Reprod, F-34295 Montpellier, France; Hop A de Villeneuve, F-34295 Montpellier, France; Inst Genet & Biol Mol & Cellaire, Struct Biol Lab, F-67404 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Sultan, C (corresponding author), INSERM, U439, F-34090 Montpellier, France.		Wurtz, Jean-Marie/P-4652-2016; Lumbroso, Serge/AFS-0438-2022	Wurtz, Jean-Marie/0000-0003-2963-8617; 				BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BROWN TR, 1992, 7 ANN M END SOC, P428; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; DEBELLIS A, 1992, MOL ENDOCRINOL, V6, P1909, DOI 10.1210/me.6.11.1909; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gottlieb B, 1998, NUCLEIC ACIDS RES, V26, P234, DOI 10.1093/nar/26.1.234; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; Hamann LG, 1998, J MED CHEM, V41, P623, DOI 10.1021/jm970699s; HIORT O, 1994, EUR J PEDIATR, V153, P317, DOI 10.1007/BF01956409; HUMM AW, 1990, ARCH PHARM, V323, P83, DOI 10.1002/ardp.19903230206; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Letz M, 1999, BBA-PROTEIN STRUCT M, V1429, P391, DOI 10.1016/S0167-4838(98)00249-0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Poujol N, 1997, MOL CELL ENDOCRINOL, V130, P43, DOI 10.1016/S0303-7207(97)00072-5; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RISSTALPERS C, 1993, BIOCHEM BIOPH RES CO, V196, P173, DOI 10.1006/bbrc.1993.2231; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; VEDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893	37	106	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24022	24031		10.1074/jbc.M001999200	http://dx.doi.org/10.1074/jbc.M001999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10787411	hybrid			2022-12-27	WOS:000088564200085
J	Wastl, J; Maier, UG				Wastl, J; Maier, UG			Transport of proteins into cryptomonads complex plastids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST IMPORT; DIATOM PLASTIDS; PRECURSOR; CYANELLES; BINDING; ALGAE; GENE	Complex plastids, found in many alga groups, are surrounded by three or four membranes. Therefore, proteins of the complex plastids, which are encoded in the cell nucleus, must cross three or four membranes during transport to the plastid. To study this process we have developed a method for isolating transport-competent two membrane-bound plastids derived from the complex plastids of the cryptophyte Guillardia theta. This in vitro protein import system provides the first non-heterologous system for studying the import of proteins into four-membrane complex plastids. We use our import system as well as canine microsomes to demonstrate in the case of cryptomonads how nuclear proteins pass the first nucleomorph-encoded proteins the third and fourth membrane and discuss the potential mechanisms for protein transport across the second membrane.	Univ Marburg, Dept Appl Cell & Mol Biol, D-35032 Marburg, Germany	Philipps University Marburg	Maier, UG (corresponding author), Univ Marburg, Dept Appl Cell & Mol Biol, Karl von Frisch Str, D-35032 Marburg, Germany.	maier@mailer.uni-marburg.de	Wastl, Juergen/C-6876-2016	Wastl, Juergen/0000-0001-7757-8001				Apt KE, 1996, MOL GEN GENET, V252, P572, DOI 10.1007/s004380050264; BHAYA D, 1991, MOL GEN GENET, V229, P400, DOI 10.1007/BF00267462; Bonk M, 1997, EUR J BIOCHEM, V247, P942, DOI 10.1111/j.1432-1033.1997.00942.x; Cavalier-Smith T, 1999, J EUKARYOT MICROBIOL, V46, P347, DOI 10.1111/j.1550-7408.1999.tb04614.x; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Delwiche CF, 1997, PLANT SYST EVOL, P53; Fraunholz MJ, 1998, MOL GEN GENET, V260, P207, DOI 10.1007/s004380050887; GIBBS SP, 1979, J CELL SCI, V35, P253; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; Gilson PR, 1997, CURR OPIN GENET DEV, V7, P800, DOI 10.1016/S0959-437X(97)80043-3; Jakowitsch J, 1996, FEBS LETT, V381, P153, DOI 10.1016/0014-5793(96)00102-0; Lang M, 1998, J BIOL CHEM, V273, P30973, DOI 10.1074/jbc.273.47.30973; LIAUD MF, 1997, J MOL EVOL S1, V44, P28; May T, 1999, FEBS LETT, V452, P52, DOI 10.1016/S0014-5793(99)00527-X; McFadden GI, 1997, TRENDS GENET, V13, P46, DOI 10.1016/S0168-9525(97)01010-X; MULLER SB, 1994, CURR GENET, V26, P410, DOI 10.1007/BF00309927; ORTIZ W, 1980, PLANT PHYSIOL, V66, P291, DOI 10.1104/pp.66.2.291; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Sulli C, 1996, PLANT CELL, V8, P43; SULLI C, 1995, J BIOL CHEM, V270, P13084, DOI 10.1074/jbc.270.22.13084; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; Wastl J, 1999, J MOL EVOL, V48, P112, DOI 10.1007/PL00006438; Wittpoth C, 1998, PLANTA, V206, P79, DOI 10.1007/s004250050376; Zauner S, 2000, P NATL ACAD SCI USA, V97, P200, DOI 10.1073/pnas.97.1.200	26	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23194	23198		10.1074/jbc.M003125200	http://dx.doi.org/10.1074/jbc.M003125200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10787421	hybrid			2022-12-27	WOS:000088419400081
J	Hirosaki, T; Mizushima, H; Tsubota, Y; Moriyama, K; Miyazaki, K				Hirosaki, T; Mizushima, H; Tsubota, Y; Moriyama, K; Miyazaki, K			Structural requirement of carboxyl-terminal globular domains of laminin alpha 3 chain for promotion of rapid cell adhesion and migration by laminin-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; GASTRIC-CARCINOMA CELLS; BASEMENT-MEMBRANES; PLASMINOGEN-ACTIVATOR; EPIDERMAL JUNCTION; EPITHELIAL-CELLS; HEPARIN-BINDING; SCATTER FACTOR; GAMMA-2 CHAIN; HUMAN TISSUES	The basement membrane protein laminin-5, a heterotrimer of laminin alpha 3, beta 3, and gamma 2 chains, potently promotes cellular adhesion and motility, It has been supposed that the carboxyl-terminal globular region of the alpha 3 chain consisting of five distinct domains (G1 to G5) is important for its interaction with integrins, To clarify the function of each G domain, we transfected cDNAs for the full-length (wild type (WT)) and five deletion derivatives (Delta Gs) of the a3 chain into human fibrosarcoma cell line HT1080, which expressed and secreted the laminin beta 3 and gamma 2 chains but not the alpha 3 chain. The transfectants with the alpha 3 chain cDNAs lacking G5 (Delta G(5)), G4-5 (Delta G(4-5)), G3-5 (Delta G(3-5)), and G2-5 (Delta G(2-5)) secreted laminin-5 variants at levels comparable to that with WT cDNA However, the transfectant with the cDNA without any G domains (Delta G(1-5)) secreted little laminin-5, suggesting that the G domains are essential for the efficient assembly and secretion of the heterotrimer alpha 3 beta 3 gamma 2, The transfectants with WT, Delta G(5), and Delta G(4-5) cDNAs survived in serum-free medium longer than those with Delta G(3-5), Delta G(2-5), and Delta G(1-5) cDNAs, The transfectants with WT, Delta G(5), and Delta G(4-5) cDNAs secreted apparently the same size of laminin-5, which lacked G4 and G5 due to proteolytic cleavage between G3 and G4, and these laminin-5 forms potently promoted integrin alpha(3)beta(1)-dependent cell adhesion and migration, However, the laminin-5 forms of Delta G(3-5) and Delta G(2-5) hardly promoted the cell adhesion and motility, These findings demonstrate that the G3 domain, but not the G4 and G5 domains, of the alpha 3 chain is essential for the potent promotion of cell adhesion and motility bg laminin-5.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 642-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.							ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; Aumailley M, 1999, MATRIX BIOL, V18, P19, DOI 10.1016/S0945-053X(98)00004-3; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; GEE SH, 1993, J BIOL CHEM, V268, P14972; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GRORGESLABOUESS.E, 1996, NAT GENET, V13, P370; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Koshikawa N, 1999, CANCER RES, V59, P5596; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miyata S, 1998, CLIN EXP METASTAS, V16, P613, DOI 10.1023/A:1006576313979; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Pattaramalai S, 1996, EXP CELL RES, V222, P281, DOI 10.1006/excr.1996.0036; PETERS BP, 1985, J BIOL CHEM, V260, P4732; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; PYKE C, 1995, CANCER RES, V55, P4132; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1988, BIOCHIM BIOPHYS ACTA, V942, P45, DOI 10.1016/0005-2736(88)90273-8; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189	37	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22495	22502		10.1074/jbc.M001326200	http://dx.doi.org/10.1074/jbc.M001326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801807	hybrid			2022-12-27	WOS:000088363800099
J	Li, DQ; Clark, CC; Myers, JC				Li, DQ; Clark, CC; Myers, JC			Basement membrane zone type XV collagen is a disulfide-bonded chondroitin sulfate proteoglycan in human tissues and cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON-INTRON ORGANIZATION; TRIPLE-HELICAL REGION; XVIII COLLAGEN; ALPHA-1 CHAIN; IX COLLAGEN; EXTRACELLULAR-MATRIX; CORRESPONDING GENE; EXPRESSION; CARTILAGE; PROTEINS	Type XV collagen has a widespread distribution in human tissues, but a nearly restricted localization in basement membrane zones. The alpha 1(XV) chain contains a highly interrupted collagenous region of 577 residues, and noncollagenous amino- and carboxyl-terminal domains of 530 and 256 residues, respectively. Cysteines are present in each domain and consensus sequences for O-linked glycosaminoglycans are situated in the amino terminus and in two large, noncollagenous interruptions, We now report that type XV collagen is a chondroitin sulfate proteoglycan in human tissues and cultured cells, and that the alpha chains are covalently linked by interchain disulfide bonds only between the two cysteines in the collagenous region. Western blotting of tissue extracts revealed a diffuse smear with a mean size greater than or equal to 400 kDa, which after chondroitinase digestion resolved into a 250-kDa band in umbilical cord, and 250-and 225-kDa bands in placenta, lung, colon, and skeletal muscle. The latter two bands were also directly visualized by alcian blue/silver staining of a purified placenta extract. In a human rhabdomyosarcoma cell line, almost all of the newly synthesized type XV collagen was secreted into the medium and upon chondroitinase digestion just the 250-kDa alpha chain was generated. Chondroitinase plus collagenase digestion of tissue and medium proteins followed by Western blotting using domain-specific antibodies revealed a 135-kDa amino-terminal fragment containing glycosaminoglycan chains and a 27-kDa fragment representing the intact carboxyl terminus. However, a truncated carboxyl peptide of similar to 8-kDa was also evident in tissue extracts containing the 225-kDa form. Our data suggest that the 225-kDa form arises from differential carboxyl cleavage of the 250-kDa form, and could explain the similar to 19-kDa endostatin-related fragments (John, H,, Preissner, K. T., Forssmann, W,-G,, and Standker, L, (1999) Biochemistry 38, 10217-10224), which may be liberated from the alpha 1(XV) chain.	Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 805, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Myers, JC (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 805, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Sawant, Kirti V/H-3778-2013		NIAMS NIH HHS [AR07490, AR44549] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007490, R01AR044549] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi E, 1997, INT REV CYTOL, V173, P73; Amenta PS, 2000, HUM PATHOL, V31, P359, DOI 10.1016/S0046-8177(00)80251-8; AYAD S, 1991, BIOCHEM J, V278, P441, DOI 10.1042/bj2780441; BOURDON MA, 1990, EXTRACELLULAR MATRIX, P157; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BYERS S, 1987, J BIOL CHEM, V262, P9166; CLARK CC, 1987, J BIOL CHEM, V262, P10229; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; Hagg PM, 1997, AM J PATHOL, V150, P2075; Hagg PM, 1998, J BIOL CHEM, V273, P17824, DOI 10.1074/jbc.273.28.17824; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; HARDINGHAM TE, 1986, RHEUMATOLOGY, V10, P148; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P305; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; John H, 1999, BIOCHEMISTRY-US, V38, P10217, DOI 10.1021/bi990787+; JUST M, 1991, J BIOL CHEM, V266, P17326; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KIVIRIKKO S, 1994, J BIOL CHEM, V269, P4773; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KOCH M, 1992, EUR J BIOCHEM, V207, P847, DOI 10.1111/j.1432-1033.1992.tb17116.x; KRIEG T, 1979, FEBS LETT, V104, P405, DOI 10.1016/0014-5793(79)80863-7; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; MURAGAKI Y, 1994, J BIOL CHEM, V269, P4042; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; MYERS JC, 1992, P NATL ACAD SCI USA, V89, P10144, DOI 10.1073/pnas.89.21.10144; MYERS JC, 1994, J BIOL CHEM, V269, P18549; Myers JC, 1996, CELL TISSUE RES, V286, P493, DOI 10.1007/s004410050719; Myers JC, 1997, AM J PATHOL, V151, P1729; Myers JC, 1999, EXP CELL RES, V253, P587, DOI 10.1006/excr.1999.4642; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PETERKOFSKY B, 1982, METHOD ENZYMOL, V82, P453; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; Rehn M, 1996, SEMIN CELL DEV BIOL, V7, P673, DOI 10.1006/scdb.1996.0082; REHN M, 1994, J BIOL CHEM, V269, P13929; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; Reichenberger E, 1996, SEMIN CELL DEV BIOL, V7, P631, DOI 10.1006/scdb.1996.0077; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; VAHERI A, 1978, P NATL ACAD SCI USA, V75, P4944, DOI 10.1073/pnas.75.10.4944; vanderRest M, 1996, SEMIN CELL DEV BIOL, V7, P639, DOI 10.1006/scdb.1996.0078; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; WATT SL, 1992, J BIOL CHEM, V267, P20093	48	83	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22339	22347		10.1074/jbc.M000519200	http://dx.doi.org/10.1074/jbc.M000519200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10791950	hybrid			2022-12-27	WOS:000088363800080
J	Spura, A; Riel, RU; Freedman, ND; Agrawal, S; Seto, C; Hawrot, E				Spura, A; Riel, RU; Freedman, ND; Agrawal, S; Seto, C; Hawrot, E			Biotinylation of substituted cysteines in the nicotinic acetylcholine receptor reveals distinct binding modes for alpha-bungarotoxin and erabutoxin a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; TORPEDO-CALIFORNICA; AMINO-ACIDS; TRANSMEMBRANE TOPOLOGY; DELTA-SUBUNIT; RAT-BRAIN; RESIDUES; COMPLEX	Although previous results indicate that cu-subunit residues Trp(187), Val(186), Phe(189), Tyr(190), and Pro(194) Of the mouse nicotinic acetylcholine receptor are solvent-accessible and are in a position to contribute to the alpha-bungarotoxin (alpha-Bgtx) binding site (Spura, A. Russin, T. S., Freedman, N. D., Grant, M., McLaughlin, J. T., and Hawrot, E. (1999) Biochemistry 38, 4912-4921), little is known about the accessibility of other residues within this region. By determining second-order rate constants for the reaction of cysteine mutants at alpha 184-alpha 197 with the thiol-specific biotin derivative (+) -biotinyl-3-maleimidopropionamidyl-3,6-dioxaoctanediamine, we now show that only very subtle differences in reactivity (similar to 10-fold) are detectable, arguing that the entire region is solvent-exposed. Importantly, biotinylation in the presence of saturating concentrations of the long neurotoxin alpha-Bgtx is significantly retarded for positions alpha W187C, alpha F189C, and reduced wild-type receptors (alpha Cys(192) and alpha Cys(193)), further emphasizing their major contribution to the alpha-Bgtx binding site. Interestingly, although biotinylation of position alpha V188C is not affected by the presence of alpha-Bgtx, erabutoxin a, which is a member of the short neurotoxin family, inhibits biotinylation at position alpha V188C, but not at alpha W187C or alpha F189C, Taken together, these results indicate that short and long neurotoxins establish interactions with distinct amino acids on the nicotinic acetylcholine receptor.	Brown Univ, Div Biol & Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA	Brown University; Brown University	Hawrot, E (corresponding author), Brown Univ, Div Biol & Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.	edward_hawrot@brown.edu	Freedman, Neal David/B-9741-2015	Freedman, Neal David/0000-0003-0074-1098	NIGMS NIH HHS [GM32629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANAND R, 1993, BIOCHEMISTRY-US, V32, P9975, DOI 10.1021/bi00089a013; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BECKER JM, 1971, P NATL ACAD SCI USA, V68, P2604, DOI 10.1073/pnas.68.10.2604; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Boileau AJ, 1999, J NEUROSCI, V19, P4847; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; CHASE BA, 1987, NEUROSCIENCE, V3, P959; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CRIADO M, 1986, BIOCHEMISTRY-US, V25, P2839, DOI 10.1021/bi00358a015; CURRIER SF, 1977, BIOCHEMISTRY-US, V16, P1944, DOI 10.1021/bi00628a029; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; Gallivan JP, 1997, CHEM BIOL, V4, P739, DOI 10.1016/S1074-5521(97)90312-4; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KELLER SH, 1995, J BIOL CHEM, V270, P4165, DOI 10.1074/jbc.270.8.4165; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENTZ TL, 1988, INT REV NEUROBIOL, V29, P117, DOI 10.1016/S0074-7742(08)60085-9; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MCLAUGHLIN JT, 1995, BIOCHEM J, V310, P765, DOI 10.1042/bj3100765; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; OTERO AD, 1984, BIOCHEMISTRY-US, V23, P2321, DOI 10.1021/bi00306a001; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; PEDEMONTE CH, 1990, P NATL ACAD SCI USA, V87, P9789, DOI 10.1073/pnas.87.24.9789; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; SAEDI MS, 1990, FEBS LETT, V267, P55, DOI 10.1016/0014-5793(90)80286-R; Schelte P, 2000, BIOCONJUGATE CHEM, V11, P118, DOI 10.1021/bc990122k; Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u; SINE S, 1979, J BIOL CHEM, V254, P3315; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1981, J BIOL CHEM, V256, P6692; Spura A, 1999, BIOCHEMISTRY-US, V38, P4912, DOI 10.1021/bi982656z; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; WHITE SH, 1994, MEMBRANE STRUCTURE M; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	49	19	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22452	22460		10.1074/jbc.M001283200	http://dx.doi.org/10.1074/jbc.M001283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10791957	hybrid			2022-12-27	WOS:000088363800094
J	Emmerich, NPN; Nussbaum, AK; Stevanovic, S; Priemer, M; Toes, REM; Rammensee, HG; Schild, H				Emmerich, NPN; Nussbaum, AK; Stevanovic, S; Priemer, M; Toes, REM; Rammensee, HG; Schild, H			The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ANTIGEN PRESENTATION; ORNITHINE DECARBOXYLASE; ENDOPLASMIC-RETICULUM; REGULATORY PARTICLE; DISULFIDE-ISOMERASE; BETA-SUBUNITS; CELL-PROTEINS; C-FOS; DEGRADATION	Intracellular protein degradation is a major source of short antigenic peptides that can be presented on the cell surface in the context of major histocompatibility class I molecules for recognition by cytotoxic T lymphocytes. The capacity of the most important cytosolic protease, the 20 S proteasome, to generate peptide fragments with an average length of 7-8 amino acid residues has been thoroughly investigated. It has been shown that the cleavage products are not randomly generated, but originate from the commitment of the catalytically active subunits to complex recognition motifs in the primary amino acid sequence. The role of the even larger 26 S proteasome is less well defined, however. It has been demonstrated that the 26 S proteasome can bind and degrade ubiquitin-tagged proteins and minigene translation products in vivo and in vitro, but the nature of the degradation products remains elusive. In this study, we present the first analysis of cleavage products from in vitro digestion of the unmodified model substrate beta-casein with both the 26 S and 20 S proteasome. The data we obtained show that 26 S and 20 S proteasomes generate overlapping, but at the same time substantially different, sets of fragments by following very similar instructions.	Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany; Leiden Univ, Med Ctr, Dept Immunohematol & Bloodbank, NL-2300 RC Leiden, Netherlands	Eberhard Karls University of Tubingen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schild, H (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.			Toes, Rene/0000-0002-9618-6414				Anton LC, 1998, J IMMUNOL, V160, P4859; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BenShahar S, 1997, J BIOL CHEM, V272, P21060, DOI 10.1074/jbc.272.34.21060; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; COX JH, 1995, J IMMUNOL, V154, P511; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; Dick TP, 1998, EUR J IMMUNOL, V28, P2478, DOI 10.1002/(SICI)1521-4141(199808)28:08<2478::AID-IMMU2478>3.3.CO;2-L; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; KUEHN L, 1989, BIOCHIM BIOPHYS ACTA, V991, P263, DOI 10.1016/0304-4165(89)90114-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammert E, 1997, EUR J IMMUNOL, V27, P1685, DOI 10.1002/eji.1830270714; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; Michalek MT, 1996, J IMMUNOL, V157, P617; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; RAMMENSEE H, 1999, MHC LIGANDS PEPTIDE; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N; Tobery T, 1999, J IMMUNOL, V162, P639; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; [No title captured]	48	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21140	21148		10.1074/jbc.M000740200	http://dx.doi.org/10.1074/jbc.M000740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801794	hybrid			2022-12-27	WOS:000088230600026
J	Feinberg, H; Park-Snyder, S; Kolatkar, AR; Heise, CT; Taylor, ME; Weis, WI				Feinberg, H; Park-Snyder, S; Kolatkar, AR; Heise, CT; Taylor, ME; Weis, WI			Structure of a C-type carbohydrate recognition domain from the macrophage mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; CRYSTAL-STRUCTURE; ANIMAL LECTINS; LIGAND-BINDING; RAT-LIVER; OLIGOSACCHARIDES; MUTAGENESIS; TETRANECTIN; MECHANISM; SYSTEM	The mannose receptor of macrophages and liver endothelium mediates clearance of pathogenic organisms and potentially harmful glycoconjugates. The extracellular portion of the receptor includes eight C-type carbohydrate recognition domains (CRDs), of which one, CRD-4, shows detectable binding to monosaccharide ligands, We have determined the crystal structure of CRD-4, Although the basic C-type lectin fold is preserved, a loop extends away from the core of the domain to form a domain-swapped dimer in the crystal. Of the two Ca2+ sites, only the principal site known to mediate carbohydrate binding in other C-type lectins is occupied. This site is altered in a way that makes sugar binding impossible in the mode observed in other C-type lectins, The structure is likely to represent an endosomal form of the domain formed when Ca2+ is lost from the auxiliary calcium site, The structure suggests a mechanism for endosomal ligand release in which the auxiliary calcium site serves as a pH sensor. Acid pH-induced removal of this Ca2+ results in conformational rearrangements of the receptor, rendering it unable to bind carbohydrate ligands.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Stanford University; University of Oxford	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg,299 Campus Dr W, Stanford, CA 94305 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Taylor, Maureen/0000-0001-8300-4987	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Hitchen PG, 1998, BIOCHEM J, V333, P601, DOI 10.1042/bj3330601; IOBST ST, 1994, J BIOL CHEM, V269, P15505; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; LOEB JA, 1988, J BIOL CHEM, V263, P9752; Mizuno H, 1997, NAT STRUCT BIOL, V4, P438, DOI 10.1038/nsb0697-438; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TAYLOR ME, 1997, GLYCOBIOLOGY, V7, P5; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693	40	99	110	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21539	21548		10.1074/jbc.M002366200	http://dx.doi.org/10.1074/jbc.M002366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10779515	hybrid			2022-12-27	WOS:000088230600078
J	Kitagawa, H; Fujita, M; Ito, N; Sugahara, K				Kitagawa, H; Fujita, M; Ito, N; Sugahara, K			Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; HEPARAN-SULFATE; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; 6-SULFOTRANSFERASE; PROTEOGLYCANS; GENE; SPECIFICITIES; CARTILAGE; PROTEIN	A novel human chondroitin 6-O-sulfotransferase, designated C6ST-2, was identified by BLAST analysis of expressed sequence tag using the sequence of a previously described human chondroitin 6-O-sulfotransferase (C6ST-1) as a probe. The new cDNA sequence revealed an open reading frame coding for a protein of 486 amino acids with a type II transmembrane protein topology. The amino acid sequence displayed 24% identity to the human C6ST-1, and the highest sequence identity was found in the COOH-terminal catalytic domain. The expression of a soluble recombinant form of the protein in COS-l cells produced an active sulfotransferase with marked specificity for polymer chondroitin. In contrast, keratan sulfate and oligosaccharides containing the Gal beta 1-4GlcNAc sequence, which are good acceptor substrates for the C6ST-1, hardly served as accepters. The identification of the reaction product indicated that the enzyme is a novel chondroitin 6-O-sulfotransferase (C6ST-2) that mainly transfers sulfate to N-acetylgalactosamine. The coding region of C6ST-2 was contained in a single exon and localized to chromosome Xp11, Northern blot analysis of human brain poly(A)(+) RNA revealed a single transcript of 2.4 kilobase pairs. Reverse transcription-polymerase chain reaction analysis showed that C6ST-2 is developmentally regulated in various tissues with expression persisting through adulthood in the spleen. Thus, we demonstrated the redundancy in chondroitin 6-O-sulfotransferases capable of forming chondroitin 6-sulfate, which is important for understanding the mechanisms leading to specific changes in the sulfation profile of chondroitin sulfate chains in various tissues during development and malignant transformation.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.		Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bowman KG, 1999, CHEM BIOL, V6, pR9, DOI 10.1016/S1074-5521(99)80014-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Gladwin AJ, 1996, GENOMICS, V32, P471, DOI 10.1006/geno.1996.0145; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Humphries DE, 1998, BIOCHEM J, V332, P303, DOI 10.1042/bj3320303; INEROT S, 1983, COLLAGEN REL RES, V3, P245; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Mazany KD, 1998, BBA-MOL BASIS DIS, V1407, P92, DOI 10.1016/S0925-4439(98)00028-3; MOURAO PAS, 1981, BIOCHEM BIOPH RES CO, V98, P388, DOI 10.1016/0006-291X(81)90852-4; POOLE AR, 1986, BIOCHEM J, V236, P1; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; TOLEDO SPA, 1978, AM J MED GENET, V2, P385, DOI 10.1002/ajmg.1320020408; Tsutsumi K, 1998, FEBS LETT, V441, P235, DOI 10.1016/S0014-5793(98)01532-4; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; UCHIMURA K, 1999, GLYCOCONJ J, V16, pS13	31	74	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21075	21080		10.1074/jbc.M002101200	http://dx.doi.org/10.1074/jbc.M002101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10781596	hybrid			2022-12-27	WOS:000088230600017
J	Hong, Y; Maeda, Y; Watanabe, R; Inoue, N; Ohishi, K; Kinoshita, T				Hong, Y; Maeda, Y; Watanabe, R; Inoue, N; Ohishi, K; Kinoshita, T			Requirement of PIG-F and PIG-O for transferring phosphoethanolamine to the third mannose in glycosylphosphatidylinositol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOL-PHOSPHATE-MANNOSE; GPI-ANCHOR SYNTHESIS; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; FIRST STEP; BIOSYNTHESIS; PROTEIN; GENE; HOMOLOG	Many eukaryotic proteins are anchored by glycosylphosphatidylinositol (GPI) to the cell surface membrane. The GPI anchor is linked to proteins by an amide bond formed between the carboxyl terminus and phosphoethanolamine attached to the third mannose. Here, we report the roles of two mammalian genes involved in transfer of phosphoethanolamine to the third mannose in GPI. We cloned a mouse gene termed Pig-o that encodes a 1101-amino acid PIG-O protein bearing regions conserved in various phosphodiesterases. Pig-o knockout F9 embryonal carcinoma cells expressed very little GPI-anchored proteins and accumulated the same major GPI intermediate as the mouse class F mutant cell, which is defective in transferring phosphoethanolamine to the third mannose due to mutant Pig-f gene. PIG-O and PIG-F proteins associate with each other, and the stability of PIG-O was dependent upon PIG-F. However, the class F cell is completely deficient in the surface expression of GPI-anchored proteins. A minor GPI intermediate seen in Pig-o knockout but not class F cells had more than three mannoses with phosphoethanolamines on the first and third mannoses, suggesting that this GPI may account for the low expression of GPI-anchored proteins. Therefore, mammalian cells have redundant activities in transferring phosphoethanolamine to the third mannose, both of which require PIG-F.	Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009	Watanabe, Reika/0000-0002-7427-7702				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Hong Y, 1999, J BIOL CHEM, V274, P18582, DOI 10.1074/jbc.274.26.18582; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; INOUE N, 1993, J BIOL CHEM, V268, P6882; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 1996, GENOMICS, V34, P340, DOI 10.1006/geno.1996.0296; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schultz C, 1998, TRENDS PLANT SCI, V3, P426, DOI 10.1016/S1360-1385(98)01328-4; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Tomita S, 1998, J BIOL CHEM, V273, P9249, DOI 10.1074/jbc.273.15.9249; Tujioka H, 1998, BIOCHEM BIOPH RES CO, V251, P737, DOI 10.1006/bbrc.1998.9542; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEDA E, 1993, J BIOL CHEM, V268, P9998; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; Zhang NS, 1999, YEAST, V15, P1287, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1287::AID-YEA458>3.0.CO;2-S	41	63	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20911	20919		10.1074/jbc.M001913200	http://dx.doi.org/10.1074/jbc.M001913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781593	hybrid			2022-12-27	WOS:000088084500097
J	Kim, KI; Baek, SH; Jeon, YJ; Nishimori, S; Suzuki, T; Uchida, S; Shimbara, N; Saitoh, H; Tanaka, K; Chung, CH				Kim, KI; Baek, SH; Jeon, YJ; Nishimori, S; Suzuki, T; Uchida, S; Shimbara, N; Saitoh, H; Tanaka, K; Chung, CH			A new SUMO-1-specific protease, SUSP1, that is highly expressed in reproductive organs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; CHICK SKELETAL-MUSCLE; SUMO-1; YEAST; CONJUGATION; DEGRADATION; MODIFIER; P53	A full-length cDNA encoding a SUlMO-1-specific protease, named SUSP1, was identified and cloned for the first time from the human brain. Nucleotide sequence analysis of the cDNA containing an open reading flame of 3336 base pairs revealed that the protease consists of 1112 amino acids with a calculated molecular mass of 126,116 Da. Like yeast Ulp1, SUSP1 is a cysteine protease containing the well conserved His/Asp/Cys catalytic triad. SUSP1 expressed in Escherichia coli cells efficiently released SUMO-1 from SUMO-1 . beta-galactosidase fusion but not from other ubiquitin-like protein fusions, including Smt3 . beta-galactosidase, suggesting its role in the generation of matured SUMO-1 specifically from its precursors. Interestingly, reproductive organs, such as testis, ovary, and prostate, contained much higher amounts of SUSP1 mRNA than colon and peripheral blood leukocyte, whereas other tissues, such as heart and spleen, had little or none. In addition, confocal microscopy using green fluorescent protein SUSP1 fusion showed that SUSP1 is exclusively localized to the cytoplasm of NIH3T3 and HeLa cells. These results suggest that SUSP1 may play a role in the regulation of SUMO-1-mediated cellular processes particularly related to reproduction.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea; Univ Tokyo, Branch Hosp, Dept Internal Med, Tokyo 1128688, Japan; Tokyo Metropolitan Inst Med Sci, Japan Sci & Technol Corp, CREST, Tokyo 1138613, Japan; Sumitomo Elect Ind Ltd, Dept Biomed Res & Dev, Yokohama, Kanagawa 2448588, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	Seoul National University (SNU); Seoul National University (SNU); University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; Sumitomo Electric Industries; Northwell Health	Chung, CH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.		KIM, KEUN IL/D-2959-2011	Jeon, Young Joo/0000-0003-1004-5336; Suzuki, Toshiaki/0000-0002-0650-6251				Baek SH, 1997, J BIOL CHEM, V272, P25560, DOI 10.1074/jbc.272.41.25560; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanaka K, 1998, MOL CELLS, V8, P503; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766	23	128	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14102	14106		10.1074/jbc.275.19.14102	http://dx.doi.org/10.1074/jbc.275.19.14102			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799485	hybrid			2022-12-27	WOS:000087006900015
J	Reddy, P; Slack, JL; Davis, R; Cerretti, DP; Kozlosky, CJ; Blanton, RA; Shows, D; Peschon, JJ; Black, RA				Reddy, P; Slack, JL; Davis, R; Cerretti, DP; Kozlosky, CJ; Blanton, RA; Shows, D; Peschon, JJ; Black, RA			Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR; DISINTEGRIN-METALLOPROTEASE; SECRETASE CLEAVAGE; FACTOR RECEPTOR; CELL-SURFACE; INHIBITOR; IDENTIFICATION; ECTODOMAIN; ADHESION	Many membrane-bound proteins, including cytokines, receptors, and growth factors, are proteolytically cleaved to release a soluble form of their extracellular domain. The tumor necrosis factor (TNF)-alpha converting enzyme (TACE/ADAM-17) is a transmembrane metalloproteinase responsible for the proteolytic release or "shedding" of several cell-surface proteins, including TNF and p75 TNFR. We established a TACE-reconstitution system using TACE-deficient cells co-transfected with TACE and substrate cDNAs to study TACE function and regulation. Using the TACE-reconstitution system, we identified two additional substrates of TACE, interleukin (IL)-1R-II and p55 TNFR. Using truncations and chimeric constructs of TACE and another ADAM family member, ADAM-10, we studied the function of the different domains of TACE in three shedding activities. We found that TACE must be expressed with its membrane-anchoring domain for phorbol ester-stimulated shedding of TMF, p75 TNFR, and IL-1R-II, but that the cytoplasmic domain is not required for the shedding of these substrates. The catalytic domain of ADAM-10 could not be functionally substituted for that of TACE. IL-1R-II shedding required the cysteine-rich domain of TACE as well as the catalytic domain, whereas TNF and p75 TNFR shedding required only the tethered TACE catalytic domain.	Immunex Corp, Dept Cell Sci, Seattle, WA 98101 USA; Immunex Corp, Dept Biochem, Seattle, WA 98101 USA; Immunex Corp, Dept Mol Biol, Seattle, WA 98101 USA; Immunex Corp, Dept Mol Immunol, Seattle, WA 98101 USA; Immunex Corp, Dept Res Adm, Seattle, WA 98101 USA	Immunex Corporation; Immunex Corporation; Immunex Corporation; Immunex Corporation; Immunex Corporation	Reddy, P (corresponding author), Immunex Corp, Dept Cell Sci, 51 Univ St, Seattle, WA 98101 USA.							Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cerretti DP, 1999, CYTOKINE, V11, P541, DOI 10.1006/cyto.1998.0466; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P87; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; OVERELL RW, 1988, MOL CELL BIOL, V8, P1803, DOI 10.1128/MCB.8.4.1803; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0	38	420	438	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14608	14614		10.1074/jbc.275.19.14608	http://dx.doi.org/10.1074/jbc.275.19.14608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799547	hybrid			2022-12-27	WOS:000087006900081
J	Breyton, C				Breyton, C			Conformational changes in the cytochrome b(6)f complex induced by inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST RIESKE PROTEIN; 8 ANGSTROM RESOLUTION; OPEN READING FRAME; ELECTRON CRYSTALLOGRAPHY; PROJECTION STRUCTURE; BACTERIORHODOPSIN PHOTOCYCLE; CHLAMYDOMONAS-REINHARDTII; RHODOBACTER-SPHAEROIDES; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE	Binding of stigmatellin, an inhibitor of the Q(o) site of the bc-type complexes, has been shown to induce large conformational changes of the Rieske protein in the respiratory bc(1) complex (Kim, H., Xia, D., Yu, C. A., Xia, J. Z., Kachurin, A. M., Zhang, L., Yu, L., and Deisenhofer, J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8026-8033; Iwata, S., Lee, J. W., Okada, K., Lee, J. K., Iwata, M., Rasmussen, B., Link, T. A., Ramaswamy, S., and clap, B. K. (1998) Science 281, 64-71; Zhang, Z., Huang, L., Shulmeister, V. M., Chi, Y. I., Kim, K. K., Hung, L. W., Crofts, A. R., Berry, E. A., and Kim, S. a (1998) Nature 392, 677-684). Such a movement seems necessary to shuttle electrons from the membrane-soluble quinol to the extramembrane heme of cytochrome c(1). To see whether similar changes occur in the related photosynthetic b(6)f complex, we have studied the effect of the binding of stigmatellin to the eukaryotic b(6)f complex by electron crystallography. Comparison of projection maps of thin three-dimensional crystals prepared with or without stigmatellin, and either negatively stained or embedded in glucose, reveals a similar type of movement to that observed in the bc(1) complex and suggests also the occurrence of conformational changes in the transmembrane region.	Max Planck Inst Biophys, Dept Biol Struct, D-60528 Frankfurt, Germany	Max Planck Society	Breyton, C (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.	breyton@mpibp-frankfurt.mpg.de						ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbagallo RP, 1999, BIOCHEMISTRY-US, V38, P12814, DOI 10.1021/bi990424+; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; Bulllough PA, 1999, J MOL BIOL, V286, P1663, DOI 10.1006/jmbi.1999.2570; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1987, LIGHT REACTIONS, P447; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROFTS AR, 1998, 11 INT C PHOT, V3, P1481; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; Furbacher P. N., 1996, P221; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; Gohlke U, 1997, EMBO J, V16, P1181, DOI 10.1093/emboj/16.6.1181; GRIGORIEFF N, 1995, J MOL BIOL, V254, P404, DOI 10.1006/jmbi.1995.0627; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; Hauska G., 1996, OXYGENIC PHOTOSYNTHE, P377; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hendrickson FM, 1998, BIOPHYS J, V75, P1446, DOI 10.1016/S0006-3495(98)74063-9; HOFLE G, 1984, LIEBIGS ANN CHEM, P1883; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Joliot P, 1998, BIOCHEMISTRY-US, V37, P10404, DOI 10.1021/bi980546m; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUHLBRANDT W, 1982, ULTRAMICROSCOPY, V7, P221, DOI 10.1016/0304-3991(82)90169-3; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; Rhee KH, 1998, NATURE, V396, P283, DOI 10.1038/24421; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; Schoepp B, 2000, J BIOL CHEM, V275, P5275, DOI 10.1074/jbc.275.8.5275; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Walz T, 1998, J STRUCT BIOL, V121, P142, DOI 10.1006/jsbi.1998.3945; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WIDGER WR, 1991, MOL BIOL PLASTIDS PH, P149; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Wollman F. A., 1998, MOL BIOL CHLOROPLAST, P459; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yeager M, 1999, Methods Enzymol, V294, P135; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961; Zito F, 1998, BIOCHEMISTRY-US, V37, P10395, DOI 10.1021/bi980238o	67	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13195	13201		10.1074/jbc.275.18.13195	http://dx.doi.org/10.1074/jbc.275.18.13195			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788423	hybrid			2022-12-27	WOS:000086925300009
J	Kim, Y; Han, JM; Han, BR; Lee, KA; Kim, JH; Lee, BD; Jang, IH; Suh, PG; Ryu, SH				Kim, Y; Han, JM; Han, BR; Lee, KA; Kim, JH; Lee, BD; Jang, IH; Suh, PG; Ryu, SH			Phospholipase D1 is phosphorylated and activated by protein kinase C in caveolin-enriched microdomains within the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; CELL-SURFACE; ALPHA; RHOA; STIMULATION; FAMILY; RAT	Activities of phospholipase D (PLD) in diverse subcellular organelles have been identified but the details of regulatory mechanisms in such locations are unknown. Protein kinase C (PKC) is a major regulator of PLD. Serine 2, threonine 147, and serine 561 residues of phospholipase D1 (PLD1) were determined as sites of phosphorylation by PKC (Kim, Y., Dan, J. M., Park, J. B., Lee, S. D., Oh, Y. S., Chung, C., Lee, T. G., Kim, J. H., Park, S, K., Yoo, J. S., Suh, P. G., Ryu, S. H. (1999) Biochemistry 38, 10344-10351), In our present study, a triple mutation of these phosphorylation sites diminished markedly phorbol 12-myristate 13-acetate (PMA)-induced PLD1 activity in COS-7 cells. We looked at the location of the PLD1 phosphorylation by PKC by observing PMA induced band shifts and by use of anti-phospho-PLD1 monoclonal antibody. The shifted PMA-induced proteins and the immunoreactivity of the anti-phospho-PLD1 antibody were mainly found in the caveolin-enriched membrane (CEM) fraction. Depletion of cellular cholesterol led to a loss of this compartmentalization of phosphorylated PLD1 in the GEM. Replacement of the cellular cholesterol led to the restoration of phosphorylated PLD1 in the CEM. Immunocytochemical studies of COS-7 cells revealed that PLD1 was localized in the plasma membrane as well as in the vesicular structures in the cytoplasm, but the phosphorylation of PLD1 occurred only in the plasma membrane. Our results, therefore, show that phosphorylation, and thereby activation, of PLD1 by PKC occurs in the caveolin and cholesterol-enriched low density domain of the plasma membrane in COS-7 cells.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010	Kim, Yong/0000-0002-1387-2962; Jang, Il Ho/0000-0002-0820-3035; Han, Jung Min/0000-0003-3372-7575; Ryu, Sung Ho/0000-0003-0913-3048				BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; Banno Y, 1997, J BIOL CHEM, V272, P5208, DOI 10.1074/jbc.272.8.5208; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HALLOW E, 1988, ANTIBODIES LAB MANUA, P139; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; LEE YH, 1994, J BIOL CHEM, V269, P26842; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Roth MG, 1999, CHEM PHYS LIPIDS, V98, P141, DOI 10.1016/S0009-3084(99)00026-2; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singer WD, 1996, J BIOL CHEM, V271, P4504; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	33	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13621	13627		10.1074/jbc.275.18.13621	http://dx.doi.org/10.1074/jbc.275.18.13621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788479	hybrid			2022-12-27	WOS:000086925300066
J	Fernandez-Chacon, R; Achiriloaie, M; Janz, R; Albanesi, JP; Sudhof, TC				Fernandez-Chacon, R; Achiriloaie, M; Janz, R; Albanesi, JP; Sudhof, TC			SCAMP1 function in endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER MEMBRANE-PROTEINS; COATED VESICLE FORMATION; HOMOLOGY DOMAIN; SYNAPTOTAGMIN-I; HIGH-AFFINITY; AP-2 SUBUNIT; EPS15; EH; RECEPTOR; DYNAMIN	Secretory carrier membrane proteins (SCAMPs) are ubiquitous components of recycling vesicles that shuttle between the plasma membrane, endosomes, and the trans-Golgi complex. SCAMPs contain multiple N-terminal NPF repeats and four highly conserved transmembrane regions. NPF repeats often interact with EH domain proteins that function in budding of transport vesicles from the plasma membrane or the Golgi complex. We now show that the NPF repeats of SCAMP1 bind to two ER domain proteins, intersectin 1, which is involved in endocytic budding at the plasma membrane, and gamma-synergin, which may mediate the budding of vesicles in the trans-Golgi complex. Expression of SCAMP1 lacking the N-terminal NPF repeats potently inhibited transferrin uptake by endocytosis, Our data suggest that one of the functions of SCAMPs is to participate in endocytosis via a mechanism which may involve the recruitment of clathrin coats to the plasma membrane and the trans-Golgi network.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015	Janz, Roger/0000-0002-9872-0596; Fernandez-Chacon, Rafael/0000-0002-9845-9885	NIGMS NIH HHS [R01-GM55562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; Bauerfeind R, 1996, J NEUROCYTOL, V25, P701, DOI 10.1007/BF02284836; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Fernandez-Chacon R, 1999, J BIOL CHEM, V274, P32551, DOI 10.1074/jbc.274.46.32551; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Iannolo G, 1997, CANCER RES, V57, P240; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kobayashi T, 1998, SEMIN CELL DEV BIOL, V9, P517, DOI 10.1006/scdb.1998.0257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Seaman MNJ, 1996, J BIOL CHEM, V271, P25446, DOI 10.1074/jbc.271.41.25446; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Singleton DR, 1997, J CELL SCI, V110, P2099; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wu TT, 1998, MOL BIOL CELL, V9, P1661, DOI 10.1091/mbc.9.7.1661; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12752	12756		10.1074/jbc.275.17.12752	http://dx.doi.org/10.1074/jbc.275.17.12752			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777571	hybrid			2022-12-27	WOS:000086762300055
J	Ikari, Y; Fujikawa, K; Yee, KO; Schwartz, SM				Ikari, Y; Fujikawa, K; Yee, KO; Schwartz, SM			alpha(1)-Proteinase inhibitor, alpha(1)-antichymotrypsin, or alpha(2)-macroglobulin is required for vascular smooth muscle cell spreading in three-dimensional fibrin gel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; PERMEABILITY FACTOR; ENDOTHELIAL-CELLS; BOVINE PLASMA; GROWTH-FACTOR; IN-VITRO; OSTEOPONTIN; MATRIX; VITRONECTIN; EXPRESSION	It is assumed that vitronectin and other adhesion molecules induce cell spreading. We found that vascular smooth muscle cells require unidentified plasma components besides adhesion molecules to spread in fibrin gel, a likely provisional matrix at wound sites. By purification, the plasma components were found to be alpha(1)-proteinase Inhibitor, alpha(1)-antichymotrypsin, and alpha(2)-macroglobulin. The chemically inactivated alpha(1)-proteinase inhibitor and alpha(2)-macroglobulin lose the spreading activity, indicating that these proteins function as proteinase inhibitors but not as adhesion molecules. Not only antiintegrin (alpha(nu)beta(3) and alpha(5)beta(1)) antibodies but also anti-fibronectin antibodies inhibit the cell spreading. The spreading occurs without the addition of fibronectin and integrins, suggesting that cells produce these molecules. In the absence of the proteinase inhibitors, Western blot analysis shows that the fibronectin is degraded in fibrin gel, while it is intact in the presence of the inhibitors. Thus, the proteinase inhibitors prevent adhesion molecules such as fibronectin from being degraded by a cell-derived proteinase(s) and thus play a role in cell spreading.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Dept Mol & Cellular Biol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Ikari, Y (corresponding author), Mitsui Mem Hosp, Div Cardiol, Chiyoda Ku, 1 Kanda Izumi Cho, Tokyo 1018634, Japan.				NHLBI NIH HHS [HL03174] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARNES DW, 1983, P NATL ACAD SCI-BIOL, V80, P1362, DOI 10.1073/pnas.80.5.1362; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BROWN LF, 1993, AM J PATHOL, V142, P273; COSTANTINI V, 1992, CANCER METAST REV, V11, P283, DOI 10.1007/BF01307183; Courtman DW, 1998, CIRC RES, V82, P996, DOI 10.1161/01.RES.82.9.996; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; GOURKUN OV, 1997, BLOOD, V89, P4407; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HIGASHIYAMA M, 1995, CANCER-AM CANCER SOC, V76, P1368, DOI 10.1002/1097-0142(19951015)76:8<1368::AID-CNCR2820760812>3.0.CO;2-N; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Liaw L, 1998, J CLIN INVEST, V101, P1468; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MONTESANO R, 1987, J CELL PHYSIOL, V132, P509, DOI 10.1002/jcp.1041320313; NAGASAWA S, 1970, J BIOCHEM-TOKYO, V67, P809, DOI 10.1093/oxfordjournals.jbchem.a129313; Nagase H, 1997, BIOL CHEM, V378, P151; ONEILL C, 1986, CELL, V44, P489, DOI 10.1016/0092-8674(86)90470-8; PEREZREYES N, 1992, P NATL ACAD SCI USA, V89, P1224, DOI 10.1073/pnas.89.4.1224; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Planus E, 1997, J CELL SCI, V110, P1091; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; SCHWARTZ SM, 1996, J HYPERTENS        S, V14, P71; SINHA D, 1994, J BIOCHEM, V115, P387, DOI 10.1093/oxfordjournals.jbchem.a124348; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; STARKEY PM, 1983, ANN NY ACAD SCI, V421, P112, DOI 10.1111/j.1749-6632.1983.tb18097.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; Yee KO, 1998, CIRC RES, V83, P241, DOI 10.1161/01.RES.83.3.241; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426	42	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12799	12805		10.1074/jbc.275.17.12799	http://dx.doi.org/10.1074/jbc.275.17.12799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777577	hybrid			2022-12-27	WOS:000086762300061
J	Keri, RA; Bachmann, DJ; Behrooz, A; Herr, BD; Ameduri, RK; Quirk, CC; Nilson, JH				Keri, RA; Bachmann, DJ; Behrooz, A; Herr, BD; Ameduri, RK; Quirk, CC; Nilson, JH			An NF-Y binding site is important for basal, but not gonadotropin-releasing hormone-stimulated, expression of the luteinizing hormone beta subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; GROWTH-RESPONSE PROTEIN-1; ORPHAN NUCLEAR RECEPTOR; TRANSGENIC MICE; PROMOTER; TRANSCRIPTION; PITUITARY; ELEMENTS; SYNERGY; ACTS	Regulated synthesis of luteinizing hormone (LH) re quires coordinated transcriptional control of the alpha and LH beta subunits in pituitary gonadotropes. Several cis-acting elements and trans-acting factors have been defined for control of the LH beta promoter through heterologous cell culture models. In this report, we describe the identification of bipartite NF-Y (CBF/CP1) binding sites within the proximal bovine LH beta promoter. When multimerized, one of these sites activates the heterologous, minimal HSV thymidine kinase promoter in the gonadotrope-derived cell line alpha T3-1. The functional role of the promoter-distal site in regulating the full-length bovine LH beta promoter was assessed in vivo using transgenic mice harboring a mutant promoter linked to the chloramphenicol acetyltransferase reporter gene. While this element is important for conferring high level activity of the LH beta promoter in pituitary, it does not appear to be essential for mediating gonadotropin-releasing hormone (GnRH) regulation. This is the first characterization of a cia-acting element within this GnRH-dependent promoter that is restricted to regulating basal expression and not GnRH-induced activity.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Nilson, JH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd, Cleveland, OH 44106 USA.		Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009843, R01DK028559] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28559, DK09843] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BOKAR JA, 1989, MOL CELL BIOL, V9, P51130; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; FALLEST PC, 1995, BIOL REPROD, V53, P103, DOI 10.1095/biolreprod53.1.103; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; Halvorson LM, 1999, MOL ENDOCRINOL, V13, P106, DOI 10.1210/me.13.1.106; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JACKSON SM, 1995, MOL ENDOCRINOL, V9, P278, DOI 10.1210/me.9.3.278; Kaiser UB, 1998, J BIOL CHEM, V273, P12943, DOI 10.1074/jbc.273.21.12943; Kaiser UB, 1998, ENDOCRINOLOGY, V139, P2443, DOI 10.1210/en.139.5.2443; KAY TWH, 1992, MOL ENDOCRINOL, V6, P1767, DOI 10.1210/me.6.11.1767; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Luisi B., 1995, DNA PROTEIN STRUCTUR, P1; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; McNeilly JR, 1996, J ENDOCRINOL, V151, P481, DOI 10.1677/joe.0.1510481; Murakami Y, 1997, BBA-GENE STRUCT EXPR, V1352, P311, DOI 10.1016/S0167-4781(97)00032-8; QUINN PG, 1993, J BIOL CHEM, V268, P16999; SAADE G, 1989, ENDOCRINOLOGY, V124, P1744, DOI 10.1210/endo-124-4-1744; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; TURCO E, 1990, IMMUNOGENETICS, V32, P117; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Weck J, 1998, MOL ENDOCRINOL, V12, P451, DOI 10.1210/me.12.3.451; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P1497, DOI 10.1210/me.13.9.1497; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	42	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13082	13088		10.1074/jbc.275.17.13082	http://dx.doi.org/10.1074/jbc.275.17.13082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777613	hybrid			2022-12-27	WOS:000086762300097
J	Bylund, J; Hidestrand, M; Ingelman-Sundberg, M; Oliw, EH				Bylund, J; Hidestrand, M; Ingelman-Sundberg, M; Oliw, EH			Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW HYDROXYLATORS; OMEGA-HYDROXYLASE; YEAST-CELLS; BIOSYNTHESIS; EXPRESSION; CYTOCHROME-P450; SPERMATOZOA; RECEPTOR; PLASMA; ENZYME	A novel cytochrome P450, CYP4F8, was recently cloned from human seminal vesicles. CYP4F8 was expressed in yeast. Recombinant CYP4F8 oxygenated arachidonic acid to (18R)-hydroxyarachidonate, whereas prostaglandin (PG) D-2, PGE(1), PGE(2), PGF(2 alpha), and leukotriene B-4 appeared to be poor substrates. Three stable PGH, analogues, 9,11-epoxymethano-PGH(2) (U-44069), 11,9-epoxymethano-PGH(2) (U-46619), and 9,11-diazo-18-deoxy-PGH(2) (U-51605) were rapidly metabolized by omega 2- and omega 3-hydroxylation, U-44069 was oxygenated with a V-max of similar to 260 pmol min(-1) pmol P450(-1) and a K-m of similar to 7 mu M. PGH(2) decomposes mainly to PGE(2) in buffer and to PGF(2 alpha) by reduction with SnCl2. CYP4F8 metabolized PGH(2) to 19-hydroxy-PGH(2), which decomposed to 19-hydrsxy-PGE(2) in buffer and could be reduced to 19-hydroxy-PGF(2 alpha) with SnCl2. 18-Hydroxy metabolites were also formed (similar to 17%). PGH(1) was metabolized to 19- and 18-hydroxy-PGH(1) in the same way. Microsomes of human seminal vesicles oxygenated arachidonate, U-44069, U-46619, U-51605, and PGH(2), similar to CYP4F8, (19R)-Hydroxy-PGE(1) and (19R)-hydroxy-PGE(2) are the main prostaglandins of human seminal fluid. We propose that they are formed by CYP4F8-catalyzed omega 2-hydroxylation of PGH, and PGH, in the seminal vesicles and isomerization to (19R)-hydroxy-PGE by PGE synthase. CYP4F8 is the first described hydroxylase with specificity and catalytic competence for prostaglandin endoperoxides.	Uppsala Univ, Dept Pharmaceut Biosci, Uppsala Biomed Ctr, Div Biochem Pharmacol, SE-75124 Uppsala, Sweden; Karolinska Inst, Inst Environm Med, Div Mol Toxicol, SE-17177 Stockholm, Sweden	Uppsala University; Karolinska Institutet	Bylund, J (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Uppsala Biomed Ctr, Div Biochem Pharmacol, POB 591,Husargatan 3,Entrance C 2, SE-75124 Uppsala, Sweden.		Ingelman-Sundberg, Magnus/ABD-9302-2021	Oliw, Ernst/0000-0002-7986-8130				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bylund J, 1998, ANAL BIOCHEM, V265, P55, DOI 10.1006/abio.1998.2897; Bylund J, 1999, BIOCHEM BIOPH RES CO, V261, P169, DOI 10.1006/bbrc.1999.1011; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Denison FC, 1999, MOL HUM REPROD, V5, P220, DOI 10.1093/molehr/5.3.220; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HECKER M, 1989, J BIOL CHEM, V264, P141; INGELMANSUNDBERG M, 1980, BIOCHIM BIOPHYS ACTA, V599, P417, DOI 10.1016/0005-2736(80)90188-1; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kelly RW, 1999, INT J ANDROL, V22, P2; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; KRYNETSKI EY, 1995, PHARMACOGENETICS, V5, P103, DOI 10.1097/00008571-199504000-00007; Kupker W, 2000, FERTIL STERIL, V73, P453, DOI 10.1016/S0015-0282(99)00564-6; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; OLIW EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P295, DOI 10.1016/0005-2760(88)90294-9; OLIW EH, 1988, J BIOL CHEM, V263, P7222; OLIW EH, 1988, PROSTAGLANDINS, V35, P523, DOI 10.1016/0090-6980(88)90028-7; OLIW EH, 1987, ARCH BIOCHEM BIOPHYS, V258, P272, DOI 10.1016/0003-9861(87)90345-6; OLIW EH, 1986, J BIOL CHEM, V261, P2675; OLIW EH, 1989, J BIOL CHEM, V264, P17845; OLIW EH, 1991, BIOCHIM BIOPHYS ACTA, V1086, P287, DOI 10.1016/0005-2760(91)90172-E; Oscarson M, 1997, MOL PHARMACOL, V52, P1034, DOI 10.1124/mol.52.6.1034; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POURIAN MR, 1995, ANDROLOGIA, V27, P71; RAAIJMAKERS JGAM, 1977, J CHROMATOGR, V138, P355, DOI 10.1016/S0021-9673(00)94971-9; Schaefer M, 1998, P NATL ACAD SCI USA, V95, P3008, DOI 10.1073/pnas.95.6.3008; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; TAYLOR PL, 1974, NATURE, V250, P665, DOI 10.1038/250665a0; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; Von Wachenfeldt Claes, 1995, P183	33	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21844	21849		10.1074/jbc.M001712200	http://dx.doi.org/10.1074/jbc.M001712200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10791960	hybrid			2022-12-27	WOS:000088363800014
J	Magalon, A; Bock, A				Magalon, A; Bock, A			Analysis of the HypC-HycE complex, a key intermediate in the assembly of the metal center of the Escherichia coli hydrogenase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SITE-SPECIFIC MUTAGENESIS; POLYMERASE CHAIN-REACTION; MUTATIONAL ANALYSIS; LARGE SUBUNIT; ACTIVE-SITE; DESULFOVIBRIO-BACULATUS; AZOTOBACTER-VINELANDII; ALCALIGENES-EUTROPHUS; NICKEL INCORPORATION	The formation of a complex between the specific chaperone-type protein HypC and the precursor form of the large subunit HycE in the maturation pathway of hydrogenase 3 from Escherichia coli has been studied by targeted replacement of amino acids in both proteins. HypC and its homologs contain the motif MC(L/I/V)(G/A)(L/I/V)P at the amino terminus, from which the methionine residue is post-translationally removed. The exchange of the cysteine residue led to complete loss of the ability to interact with the precursor form of HycE, but replacement of the proline residue had no effect. Site-directed replacement of the conserved cysteine residues in HycE involved in nickel binding was also performed, Exchange of Cys(241) resulted in the inability of the HycE variant to interact with HypC and to incorporate nickel. The variants of HycE in which Cys(244) and Cys(531) were replaced by alanine residues were unable to incorporate nickel, although the mutated proteins could interact with HypC. Intriguingly, the precursor of HycE in which the Cys(534) residue was exchanged could form the complex with HypC, could incorporate nickel, and was C-terminally processed, but it delivered an inactive enzyme. Our findings are in favor of a model in which binding of HypC masks Cys(241); Cys(244) and Cys(531) bind the iron and nickel moieties, respectively; and C534 closes the bridge between the two metals after C-terminal processing has taken place.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany	University of Munich	Magalon, A (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.	Axel.Magalon@lrz.uni-muenchen.de		Magalon, Axel/0000-0002-3375-738X				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Binder U, 1996, ARCH MICROBIOL, V165, P69, DOI 10.1007/s002030050299; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P199, DOI 10.1016/0167-4781(92)90077-D; CHEN LY, 1993, J BIOL CHEM, V268, P18710; COLBEAU A, 1993, MOL MICROBIOL, V8, P15, DOI 10.1111/j.1365-2958.1993.tb01199.x; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; DERNEDDE J, 1993, ARCH MICROBIOL, V159, P545, DOI 10.1007/BF00249034; Drapal N, 1998, BIOCHEMISTRY-US, V37, P2941, DOI 10.1021/bi9720078; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; EIDSNESS MK, 1989, P NATL ACAD SCI USA, V86, P147, DOI 10.1073/pnas.86.1.147; Fritsche E, 1999, J MOL BIOL, V288, P989, DOI 10.1006/jmbi.1999.2719; HE SH, 1989, J BIOL CHEM, V264, P2678; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; JONES DH, 1991, BIOTECHNIQUES, V10, P62; Kaneko T, 1996, DNA Res, V3, P109; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; Maier T, 1996, ADV INORG BIOCHEM, P173; Maier T, 1996, BIOCHEMISTRY-US, V35, P10089, DOI 10.1021/bi960567l; Massanz C, 1999, BIOCHEMISTRY-US, V38, P14330, DOI 10.1021/bi9908080; MENON NK, 1991, J BACTERIOL, V173, P4851, DOI 10.1128/jb.173.15.4851-4861.1991; MENON NK, 1994, J BACTERIOL, V176, P4416, DOI 10.1128/jb.176.14.4416-4423.1994; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PRZYBYLA AE, 1992, FEMS MICROBIOL LETT, V88, P109, DOI 10.1016/0378-1097(92)90687-J; REY L, 1993, MOL MICROBIOL, V8, P471, DOI 10.1111/j.1365-2958.1993.tb01591.x; ROSSMANN R, 1995, EUR J BIOCHEM, V227, P545, DOI 10.1111/j.1432-1033.1995.tb20422.x; ROSSMANN R, 1994, EUR J BIOCHEM, V220, P377, DOI 10.1111/j.1432-1033.1994.tb18634.x; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Theodoratou E, 2000, ARCH MICROBIOL, V173, P110, DOI 10.1007/s002039900116; Theodoratou E, 2000, EUR J BIOCHEM, V267, P1995, DOI 10.1046/j.1432-1327.2000.01202.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243	41	74	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21114	21120		10.1074/jbc.M000987200	http://dx.doi.org/10.1074/jbc.M000987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10783387	hybrid			2022-12-27	WOS:000088230600023
J	Anghel, SI; Perly, V; Melancon, G; Barsalou, A; Chagnon, S; Rosenauer, A; Miller, WH; Mader, S				Anghel, SI; Perly, V; Melancon, G; Barsalou, A; Chagnon, S; Rosenauer, A; Miller, WH; Mader, S			Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; RESPONSE ELEMENTS; RETINOIC ACID; COACTIVATOR; TAMOXIFEN; TRANSACTIVATION; CONTAINS	dThe antagonist activity of antiestrogens is due to the presence of a long carbon side chain at positions 7 alpha or 11 beta or equivalent on their steroid or steroid-like skeletons. These side chains establish hydrophobic interactions with amino acids of the estrogen receptor alpha (ER alpha) ligand binding domain. In addition, a hydrogen bond formed between amino acid Asp-351 and the tertiary amine present at the end of the side chain of partial antiestrogens is considered to be crucial for their antiestrogenicity. Here, we have investigated the role of Asp-351 in antiestrogen action in transiently transfected HeLa and MDA-MB-231 cells. Our results indicate that disruption of the negative charge at position 351 does not increase the agonist activity of partial antiestrogens and thus that the hydrogen bond with the antiestrogen side chain is not determinant in positioning the side chain in an antagonist position. The negative charge at position 351 was not required for transcriptional activity in the presence of hormone, but its presence was necessary for basal activity of the wild-type receptor and constitutive activities of mutants L536P and Y537A, suggesting a role of Asp-351 in stabilizing the active conformation of ER alpha, This stabilizing role of Asp-351 could be due to interaction of Asp-351 with the amide group of the peptide bond between Leu-539 and Leu-540 in helix 12 observed in the active conformation of the ER alpha ligand binding domain.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada	Universite de Montreal; Lady Davis Institute; McGill University; McGill University	Mader, S (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.							Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Barsalou A, 1998, J BIOL CHEM, V273, P17138, DOI 10.1074/jbc.273.27.17138; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CATHERINE WH, 1997, MOL ENDOCRINOL, V9, P1053; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JORDAN VC, 1982, MOL CELL ENDOCRINOL, V27, P291, DOI 10.1016/0303-7207(82)90095-8; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; LEDNICER D, 1967, J MED CHEM, V10, P78, DOI 10.1021/jm00313a016; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Levenson AS, 1998, CANCER RES, V58, P1872; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MADER S, 1993, J BIOL CHEM, V268, P591; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROBERTSON DW, 1982, J MED CHEM, V25, P167, DOI 10.1021/jm00344a015; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WOLF DM, 1994, BREAST CANCER RES TR, V31, P129, DOI 10.1007/BF00689683; WOLF DM, 1994, BREAST CANCER RES TR, V31, P117, DOI 10.1007/BF00689682; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	42	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20867	20872		10.1074/jbc.M002098200	http://dx.doi.org/10.1074/jbc.M002098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10787412	hybrid			2022-12-27	WOS:000088084500091
J	Lim, RWL; Halpain, S				Lim, RWL; Halpain, S			Regulated association of microtubule-associated protein 2 (MAP2) with Src and Grb2: Evidence for MAP2 as a scaffolding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; TAU-PROTEIN; BIDIRECTIONAL CONTROL; GLUTAMATE RECEPTORS; DENDRITIC SPINES; ACTIN-FILAMENTS; TERMINAL DOMAIN; PHOSPHATASE 2A; BINDING MOTIF	Microtubule-associated protein 2 (MAP2) and tan, which is involved in Alzheimer's disease, are major cytoskeletal proteins in neurons. These proteins are involved in microtubule assembly and stability, To further characterize MAP2, we took a strategy of identifying potential MAP2 binding partners. The low molecular weight MAP2c protein has 11 PXXP motifs that are conserved across species, and these PXXP motifs could be potential ligands for Src homology 3 (SH3) domains. We tested for MAP2 interaction with SH3 domain-containing proteins. All neuronal MAP2 isoforms bound specifically to the SH3 domains of c-Src and Grb2 in an in vitro glutathione S-transferase-SH3 pull-down assay. Interactions between endogenous proteins were confirmed by co-immunoprecipitation using brain lysate, All three proteins were also found co-expressed in neuronal cell bodies and dendrites. Surprisingly, the SH3 domain-binding site was mapped to the microtubule-binding domain that contains no PXXP motif. Src bound primarily the soluble, non-microtubule-associated MAP2c in vitro. This specific MAP2/SH3 domain interaction was inhibited by phosphorylation of MAP2c by the mitogen-activated protein kinase extracellular signal-regulated kinase 2 but not by protein kinase A. This phosphorylation-regulated association of MAP2 with proteins of intracellular signal transduction pathways suggests a possible link between cellular signaling and neuronal cytoskeleton, with MAP2 perhaps acting as a molecular scaffold upon which cytoskeleton-modifying proteins assemble and dissociate in response to neuronal activity.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Halpain, S (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shelley@scripps.edu			NIMH NIH HHS [R01 MH050861, MH 50861] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH050861, R01MH050861] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIYAMA T, 1986, J BIOL CHEM, V261, P5648; AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; AOKI C, 1985, J NEUROSCI, V5, P2465; BERLING B, 1994, EUR J CELL BIOL, V64, P120; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DOLL T, 1990, NUCLEIC ACIDS RES, V18, P361, DOI 10.1093/nar/18.2.361; Gamblin TC, 1996, BIOCHEMISTRY-US, V35, P12576, DOI 10.1021/bi961135d; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; GOEDERT M, 1995, BIOCHEM SOC T, V23, P80, DOI 10.1042/bst0230080; GOLDENRING JR, 1985, J NEUROCHEM, V45, P900, DOI 10.1111/j.1471-4159.1985.tb04078.x; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; GRIFFITH LM, 1978, J CELL BIOL, V78, P958, DOI 10.1083/jcb.78.3.958; Halpain S, 1998, J NEUROSCI, V18, P9835; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Jiang WG, 1995, BIOCHEM BIOPH RES CO, V217, P1062, DOI 10.1006/bbrc.1995.2877; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; KADOWAKI T, 1985, J BIOL CHEM, V260, P4016; KOTANI S, 1985, J BIOL CHEM, V260, P779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee G, 1998, J CELL SCI, V111, P3167; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; LUNDQVIST G, 1992, BIOCHIM BIOPHYS ACTA, V1159, P103, DOI 10.1016/0167-4838(92)90081-N; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Matsushita M, 1998, BIOCHEM BIOPH RES CO, V245, P337, DOI 10.1006/bbrc.1998.8420; MATTEN WT, 1990, J CELL BIOL, V111, P1959, DOI 10.1083/jcb.111.5.1959; MATUS A, 1986, NEUROSCIENCE, V17, P371, DOI 10.1016/0306-4522(86)90253-8; MONTORO RJ, 1993, NEUROSCIENCE, V54, P859, DOI 10.1016/0306-4522(93)90580-9; MORALES M, 1989, CELL TISSUE RES, V256, P447; NISHIDA E, 1987, J BIOL CHEM, V262, P16200; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Philpot BD, 1997, J NEUROSCI, V17, P9596; Quinlan EM, 1996, NEURON, V16, P357, DOI 10.1016/S0896-6273(00)80053-7; Quinlan EM, 1996, J NEUROSCI, V16, P7627; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SAMBROOK J, 1989, MOL CLONING LAB MANA; Sanchez C, 1996, EUR J BIOCHEM, V241, P765, DOI 10.1111/j.1432-1033.1996.00765.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTILARO RF, 1986, BIOCHEMISTRY-US, V25, P2003, DOI 10.1021/bi00356a025; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGER A, 1992, J CELL SCI, V102, P601; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUYAMA S, 1987, J BIOL CHEM, V262, P10886; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529	74	68	70	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20578	20587		10.1074/jbc.M001887200	http://dx.doi.org/10.1074/jbc.M001887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781592	hybrid			2022-12-27	WOS:000088084500052
J	Munger, SD; Gleeson, RA; Aldrich, HC; Rust, NC; Ache, BW; Greenberg, RM				Munger, SD; Gleeson, RA; Aldrich, HC; Rust, NC; Ache, BW; Greenberg, RM			Characterization of a phosphoinositide-mediated odor transduction pathway reveals plasma membrane localization of an inositol 1,4,5-trisphosphate receptor in lobster olfactory receptor neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CATION CHANNEL; SIGNAL TRANSDUCTION; CYCLIC NUCLEOTIDE; G-PROTEINS; CALCIUM; DROSOPHILA; DISTINCT; TRANSPORT; DIVERSITY; ROLES	The role of phosphoinositide signaling in olfactory transduction is still being resolved. Compelling functional evidence for the transduction of odor signals via phosphoinositide pathways in olfactory transduction comes from invertebrate olfactory systems, in particular lobster olfactory receptor neurons. We now provide molecular evidence for two components of the phosphoinositide signaling pathway in lobster olfactory receptor neurons, a G protein alpha subunit of the G(q) family and an inositol 1,4,5-trisphosphate-gated channel or an inositol 1,4,5 trisphosphate (IP3) receptor. Both proteins localize to the site of olfactory transduction, the outer dendrite of the olfactory receptor neurons. Furthermore, the IP3 receptor localizes to membranes in the ciliary transduction compartment of these cells at both the light microscopic and electron microscopic levels. Given the absence of intracellular organelles in the sub-micron diameter olfactory cilia, this finding indicates that the IP3 receptor is associated with the plasma membrane and provides the first definitive evidence for plasma membrane localization of an IP3R in neurons. The association of the IP3 receptor with the plasma membrane may be a novel mechanism for regulating intracellular cations in restricted cellular compartments of neurons.	Univ Florida, Whitney Lab, St Augustine, FL 32086 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32610 USA; Univ Florida, Dept Zool, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Munger, SD (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, Hlth Sci Facil, Rm 232,685 W Baltimore St, Baltimore, MD 21201 USA.				NIDCD NIH HHS [DC01655] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001655] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BOEKHOFF I, 1994, J NEUROSCI, V14, P3304; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Camus G, 1998, EUR J NEUROSCI, V10, P839, DOI 10.1046/j.1460-9568.1998.00091.x; CIDARREGUI A, 1995, J NEUROSCI, V15, P4259; CUNNINGHAM AM, 1993, NEUROSCIENCE, V57, P339, DOI 10.1016/0306-4522(93)90067-P; FADOOL DA, 1995, CHEM SENSES, V20, P489, DOI 10.1093/chemse/20.5.489; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; Gold GH, 1999, ANNU REV PHYSIOL, V61, P857, DOI 10.1146/annurev.physiol.61.1.857; GRUNERT U, 1988, CELL TISSUE RES, V251, P95, DOI 10.1007/BF00215452; HATT H, 1994, P NATL ACAD SCI USA, V91, P6264, DOI 10.1073/pnas.91.14.6264; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kume S, 1997, DEV BIOL, V182, P228, DOI 10.1006/dbio.1996.8479; McClintock TS, 1997, J NEUROCHEM, V68, P2248; MCDOWELL EM, 1976, ARCH PATHOL LAB MED, V100, P405; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Minke B, 1996, CURR OPIN NEUROBIOL, V6, P459, DOI 10.1016/S0959-4388(96)80050-X; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Restrepo D, 1996, J NEUROBIOL, V30, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schandar M, 1998, J BIOL CHEM, V273, P16669, DOI 10.1074/jbc.273.27.16669; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; SEOK JH, 1992, J BIOL CHEM, V267, P15893; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sinha M, 1999, GENE, V233, P271, DOI 10.1016/S0378-1119(99)00158-4; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; Ueda H, 1996, J NEUROSCI, V16, P2891; Wang TL, 1999, J NEUROSCI, V19, P4221; Xu FQ, 1999, J NEUROSCI, V19, P4881; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929; Zhainazarov AB, 1998, J NEUROPHYSIOL, V79, P1349, DOI 10.1152/jn.1998.79.3.1349	39	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20450	20457		10.1074/jbc.M001989200	http://dx.doi.org/10.1074/jbc.M001989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781594	hybrid			2022-12-27	WOS:000088084500033
J	Nakano, K; Yamauchi, J; Nakagawa, K; Itoh, H; Kitamura, N				Nakano, K; Yamauchi, J; Nakagawa, K; Itoh, H; Kitamura, N			NESK, a member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is expressed during the late stages of embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-RELATED PROTEIN-KINASE; KAPPA-B; SIGNALING PATHWAY; BETA-GAMMA; JNK; CLONING; CASCADE; DOMAIN; HPK1; NIK	The c-Jun N-terminal kinase (JNK) signaling pathway plays a crucial role in cellular responses stimulated by stress-inducing agents and proinflammatory cytokines. The group I germinal center kinase family members selectively activate the JNK pathway. In this study, we have isolated a mouse cDNA encoding a protein kinase homologous to Nck-interacting kinase (MK), a member of the group I germinal center kinase family. This protein kinase is expressed during the late stages of embryogenesis, but not in adult tissues, and thus named NESK (NIK-like embryo-specific kinase). NESK selectively activated the JNK pathway when overexpressed in HEK 293 cells but did not stimulate the p38 kinase or extracellular signal-regulated kinase (ERK) pathways. NESK-induced JNK activation was inhibited by the dominant negative mutants of MEKK1 and MKK4. Tumor necrosis factor (TNF)-alpha or TNF receptor-associated factor 2 (TRAF2) stimulated the NESK activity. Furthermore, the dominant negative NESK mutant inhibited the JNK activation induced by TNF-alpha or TRAF2. These results suggest that NESK, a novel activator of the JNK pathway, functions in coupling TRAF2 to the MEKK1 --> MKK4 --> JNK kinase cascade during the late stages of mammalian embryogenesis.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	nkitamur@bio.titech.ac.jp						Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; HATZ P, 1994, J BIOL CHEM, V269, P16802; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kanai-Azuma M, 1999, MECH DEVELOP, V89, P155, DOI 10.1016/S0925-4773(99)00193-8; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kurioka K, 1998, BBA-GENE STRUCT EXPR, V1443, P275, DOI 10.1016/S0167-4781(98)00224-3; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	26	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20533	20539		10.1074/jbc.M001009200	http://dx.doi.org/10.1074/jbc.M001009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801798	hybrid			2022-12-27	WOS:000088084500045
J	Sviridov, D; Hoang, A; Sawyer, WH; Fidge, NH				Sviridov, D; Hoang, A; Sawyer, WH; Fidge, NH			Identification of a sequence of apolipoprotein A-I associated with the activation of lecithin : cholesterol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN SKIN FIBROBLASTS; CELLULAR CHOLESTEROL; INTRACELLULAR CHOLESTEROL; MICELLAR COMPLEXES; AMPHIPATHIC HELIX; APOA-I; EFFLUX; BINDING; PLASMA	We aimed to distinguish between the effects of mutations in apoA-I on the requirements for the secondary structure and a specific amino acid sequence for lecithin:cholesterol acyltransferase (LCAT) activation. Several mutants were constructed targeting region 140-150: (i) two mutations affecting alpha-helical structure, deletion of amino acids 140-150 and substitution of Ala(143) for proline; (ii) two mutations not affecting alpha-helical structure, substitution of Val(149) for arginine and substitution of amino acids 63-73 for sequence 140-150; and (iii) a mutation in a similar region away from the target area, deletion of amino acids 63-73. All mutations affecting region 140-150 resulted in a 4-42-fold reduction in LCAT activation. Three mutations, apoA-I(Delta 140-150), apoA-I(P143A), and apoA-I(140-150 --> 63-73), affected both the apparent V-max and K-m, whereas the mutation apoA-I(R140V) affected only the V-max. The mutation apoA-I(Delta 63-73) caused only a 5-fold increase in the K-m. All mutants, except apoA-I(P143A) and apoA-I(Delta 63-73), were active in phospholipid binding assay. All mutants, except apoA-I(P143A), formed normal discoidal complexes with phospholipid, The mutation apoA-I(Delta 63-73) caused a significant reduction in the stability of apoA-I phospholipid complexes in denaturation experiments. Combined, our results strongly suggest that although the correct conformation and orientation of apoA-I in the complex with lipids are crucial for activation of LCAT, when these conditions are fulfilled, activation also strongly depends on the sequence that includes amino acids 140-150.	Baker Med Res Inst, Melbourne, Vic 8008, Australia; Univ Melbourne, Dept Biochem, Parkville, Vic 3052, Australia	Baker Heart and Diabetes Institute; University of Melbourne	Sviridov, D (corresponding author), Baker Med Res Inst, POB 6492,St Kilda Rd, Melbourne, Vic 8008, Australia.	Dmitri.Sviridov@Baker.edu.au	Sviridov, Dmitri/E-7943-2010					Ashby DT, 1998, ARTERIOSCL THROM VAS, V18, P1450, DOI 10.1161/01.ATV.18.9.1450; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V834, P188, DOI 10.1016/0005-2760(85)90155-9; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Dhoest A, 1997, J BIOL CHEM, V272, P15967, DOI 10.1074/jbc.272.25.15967; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1972, BIOCHIM BIOPHYS ACTA, V270, P513, DOI 10.1016/0005-2760(72)90116-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Frank PG, 1998, BIOCHEMISTRY-US, V37, P13902, DOI 10.1021/bi981205b; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1989, J BIOL CHEM, V264, P4818; Labeur C, 1997, ARTERIOSCL THROM VAS, V17, P580, DOI 10.1161/01.ATV.17.3.580; LIANG HQ, 1994, J LIPID RES, V35, P1187; Lindholm EM, 1998, BIOCHEMISTRY-US, V37, P4863, DOI 10.1021/bi972888i; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MENG QH, 1993, J BIOL CHEM, V268, P16966; Miettinen HE, 1997, ARTERIOSCL THROM VAS, V17, P83, DOI 10.1161/01.ATV.17.1.83; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; OIKAWA S, 1993, BIOCHIM BIOPHYS ACTA, V1165, P327, DOI 10.1016/0005-2760(93)90144-X; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Oram JF, 1996, J LIPID RES, V37, P2473; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; Pussinen PJ, 1998, J LIPID RES, V39, P152; Pyle LE, 1997, ANAL BIOCHEM, V253, P253, DOI 10.1006/abio.1997.2371; Pyle LE, 1996, BIOCHEMISTRY-US, V35, P12046, DOI 10.1021/bi9609073; Sasahara T, 1997, J LIPID RES, V38, P600; SEGREST JP, 1992, J LIPID RES, V33, P141; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; Sviridov D, 1999, PROTEIN EXPRES PURIF, V17, P231, DOI 10.1006/prep.1999.1114; SVIRIDOV D, 1995, J LIPID RES, V36, P1887; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; SVIRIDOV DD, 1992, FEBS LETT, V303, P202, DOI 10.1016/0014-5793(92)80519-M; Uboldi P, 1996, J LIPID RES, V37, P2557; UTERMANN G, 1984, EUR J BIOCHEM, V144, P325, DOI 10.1111/j.1432-1033.1984.tb08467.x; VADIVELOO PK, 1993, BIOCHEMISTRY-US, V32, P9480, DOI 10.1021/bi00087a028; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	49	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19707	19712		10.1074/jbc.M000962200	http://dx.doi.org/10.1074/jbc.M000962200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10781581	hybrid			2022-12-27	WOS:000087941300037
J	Liu, YF; Dorow, D; Marshall, J				Liu, YF; Dorow, D; Marshall, J			Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE-2; INTRANUCLEAR INCLUSIONS; CELLULAR-LOCALIZATION; STRIATAL NEURONS; PROTEIN-KINASE; DISEASE; EXPRESSION; APOPTOSIS; PATHWAY; JNK	We previously reported that expression of polyglutamine expanded huntingtin induces apoptosis via c-Jun amino-terminal kinase (JNK) activation in HN33 cells (Liu, Y. F. (1998) J. Biol. Chem. 273, 28873-28822), Extending this study, we now demonstrate a role of mixed-lineage kinase 2 (MLK2), a JNK activator, in polyglutamine-expanded huntingtin-mediated neuronal toxicity. We find that normal huntingtin interacts with MLK2, whereas the polyglutamine expansion interferes with this interaction. Similar to the expression of polyglutamine-expanded huntingtin, expression of MLK2 also induces JNK activation and apoptosis in HN33 cells. Go-expression of dominant negative MLK2 significantly attenuates neuronal apoptosis induced by the mutated huntingtin, Furthermore, over-expression of the N terminus of normal huntingtin partially rescues the neuronal toxicity induced by MLK2, Our results suggest that activation of MLK2-mediated signaling cascades may be partially involved in neuronal death induced by polyglutamine-expanded huntingtin.	Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Peter MacCallum Canc Inst, Trecowthick Res Ctr, Melbourne, Vic 3000, Australia; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Northeastern University; Peter Maccallum Cancer Center; Brown University	Liu, YF (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, 312 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.							DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; Eilers A, 1998, J NEUROSCI, V18, P1713; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; Fusco FR, 1999, J NEUROSCI, V19, P1189; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Phelan DR, 1999, MOL REPROD DEV, V52, P135, DOI 10.1002/(SICI)1098-2795(199902)52:2&lt;135::AID-MRD3&gt;3.0.CO;2-N; SANCHEZ I, 1994, NATURE, V380, P75; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104	26	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19035	19040		10.1074/jbc.C000180200	http://dx.doi.org/10.1074/jbc.C000180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10801775	hybrid			2022-12-27	WOS:000087815900056
J	Bailey, A; Mueller, E; Bowyer, P				Bailey, A; Mueller, E; Bowyer, P			Ornithine decarboxylase of Stagonospora (Septoria) nodorum is required for virulence toward wheat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DL-ALPHA-DIFLUOROMETHYLORNITHINE; FUNGICIDAL ACTIVITY; POLYAMINE BIOSYNTHESIS; LEISHMANIA-DONOVANI; FILAMENTOUS FUNGI; USTILAGO-MAYDIS; HYGROMYCIN-B; GENE; TRANSFORMATION; RESISTANCE	A knockout strain of Stagonospora (Septoria) nodorum lacking the single ornithine decarboxylase (ODC) allele has been created by targeted gene replacement. A central region of the S. nodorum ODC gene was isolated by polymerase chain reaction using degenerate oligonucleotides and used to probe a lambda genomic library. The gene was sequenced and the encoded ODC protein sequence was shown to be similar to those from other fungi. The functionality of the S. nodorum ODC was confirmed by complementation of an Aspergillus nidulans mutant (puA) strain devoid of ODC activity, restoring growth in the absence of exogenous polyamines. Sporulation of the transformants was reduced suggesting abberant regulation of the S. nodorum gene in A. nidulans. Transformation-mediated gene replacement was used to create strains which were auxotrophic for putrescine and lack ODC coding sequences. Pathogenicity studies on these mutants showed that they are greatly reduced in virulence compared with non-disrupted transformants. This confirms that the strains carrying an ODC disruption cannot obtain sufficient polyamines from the host plant for normal growth and, thus, that fungal ODC may be a suitable target for chemical intervention.	Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; University of Bristol	Bowyer, P (corresponding author), Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England.			bowyer, paul/0000-0002-1083-9286; Bailey, Andy/0000-0002-7594-3703				Bacchi C.J., 1987, P317; BENEDIKZ PW, 1981, T BRIT MYCOL SOC, V77, P667, DOI 10.1016/S0007-1536(81)80126-X; BIMBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; CARROLL AM, 1994, FUNGAL GENET NEWSL, V41, P23; COOLEY RN, 1988, CURR GENET, V13, P383, DOI 10.1007/BF00365659; Davis RL., 1996, MYCOTA, V3, P347; DEGRAAFF LH, 1989, THESIS AGR U WAGENIN; FONZI WA, 1987, J BIOL CHEM, V262, P10127; *GEN COMP GROUP, 1994, WISC PACK VERS 8; GIFFIN BF, 1986, J PROTOZOOL, V33, P238, DOI 10.1111/j.1550-7408.1986.tb05599.x; GILLIN FD, 1983, J PROTOZOOL, V31, P161; GuevaraOlvera L, 1997, MICROBIOL-UK, V143, P2237, DOI 10.1099/00221287-143-7-2237; GURR SJ, 1988, GENE STRUCTURE EUKAR, P93; GuzmandePena D, 1997, FUNGAL GENET BIOL, V21, P198, DOI 10.1006/fgbi.1996.0945; HAVIS ND, 1994, PESTIC SCI, V41, P71, DOI 10.1002/ps.2780410112; HAVIS ND, 1994, PESTIC SCI, V41, P61, DOI 10.1002/ps.2780410111; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; Hynes MJ, 1996, J GENET, V75, P297, DOI 10.1007/BF02966310; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; Kumar A, 1997, TRENDS PLANT SCI, V2, P124, DOI 10.1016/S1360-1385(97)01013-3; Mackintosh CA, 1997, J PHYTOPATHOL, V145, P43, DOI 10.1111/j.1439-0434.1997.tb00340.x; Mattern I.E., 1988, FUNGAL GENET NEWSL, V35, P25, DOI DOI 10.4148/1941-4765.1533; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; Michael AJ, 1996, BIOCHEM J, V314, P241, DOI 10.1042/bj3140241; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PITKIN J, 1994, ARCH BIOCHEM BIOPHYS, V315, P153, DOI 10.1006/abbi.1994.1484; PUNT PJ, 1992, METHOD ENZYMOL, V216, P447; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH TA, 1992, MYCOL RES, V96, P395, DOI 10.1016/S0953-7562(09)80959-3; SNEATH PHA, 1955, NATURE, V175, P818, DOI 10.1038/175818a0; SPECHT CA, 1982, ANAL BIOCHEM, V119, P158, DOI 10.1016/0003-2697(82)90680-7; STEVENS L, 1976, BIOCHEM J, V158, P235, DOI 10.1042/bj1580235; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; WALTERS DR, 1995, MYCOL RES, V99, P129, DOI 10.1016/S0953-7562(09)80876-9; WEST HM, 1989, MYCOL RES, V92, P453, DOI 10.1016/S0953-7562(89)80190-X; WILLIAMS LJ, 1992, MOL CELL BIOL, V12, P347, DOI 10.1128/MCB.12.1.347; ZAPPIA V, 1988, ADV EXP MED BIOL, V250, P1	41	40	42	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14242	14247		10.1074/jbc.275.19.14242	http://dx.doi.org/10.1074/jbc.275.19.14242			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799502	hybrid			2022-12-27	WOS:000087006900033
J	Hara, KY; Noji, H; Bald, D; Yasuda, R; Kinosita, K; Yoshida, M				Hara, KY; Noji, H; Bald, D; Yasuda, R; Kinosita, K; Yoshida, M			The role of the DELSEED motif of the beta subunit in rotation of F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; ATP SYNTHASE; GAMMA-SUBUNIT; EPSILON-SUBUNITS; WILD-TYPE; EXPRESSION; COMPLEX; SITE	F-1-ATPase is a rotary motor protein, and ATP hydrolysis generates torque at the interface between the gamma subunit, a rotor shaft, and the alpha(3)beta(3) substructure, a stator ring. The region of conserved acidic "DELSEED" motif of the beta subunit has a contact with gamma subunit and has been assumed to be involved in torque generation. Using the thermophilic alpha(3)beta(3)gamma complex in which the corresponding sequence is DELSDED, we replaced each residue and all five acidic residues in this sequence with alanine. In addition, each of two conserved residues at the counterpart contact position of gamma subunit was also replaced. Surprisingly, all of these mutants rotated with as much torque as the wild-type. We conclude that side chains of the DELSEED motif of the beta subunit do not have a direct role in torque generation.	Teikyo Univ, Biotechnol Res Ctr 3F, CREST, Genet Programming Team 13,Miyamae Ku, Kawasaki, Kanagawa 216000, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan	Japan Science & Technology Agency (JST); Teikyo University; Tokyo Institute of Technology; Keio University	Yoshida, M (corresponding author), Teikyo Univ, Biotechnol Res Ctr 3F, CREST, Genet Programming Team 13,Miyamae Ku, Nogawa 907, Kawasaki, Kanagawa 216000, Japan.	myoshida@res.titech.ac.jp	Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Kagawa Y, 1996, J BIOENERG BIOMEMBR, V28, P421, DOI 10.1007/BF02113984; KAGAWA Y, 1966, J BIOL CHEM, V241, P2467; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; Ren H, 1999, J BIOL CHEM, V274, P31366, DOI 10.1074/jbc.274.44.31366; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	30	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14260	14263		10.1074/jbc.275.19.14260	http://dx.doi.org/10.1074/jbc.275.19.14260			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799504	hybrid			2022-12-27	WOS:000087006900036
J	Mirmira, RG; Watada, H; German, MS				Mirmira, RG; Watada, H; German, MS			beta-cell differentiation factor Nkx6.1 contains distinct DNA binding interference and transcriptional repression domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEINS; INSULIN GENE; PANCREATIC DEVELOPMENT; ENGRAILED HOMEODOMAIN; SEQUENCE RECOGNITION; CRYSTAL-STRUCTURE; ISLET CELLS; SPECIFICITY; COMPLEX; IDENTIFICATION	beta-Cell differentiation factor Nkx6.1 is a homeodomain protein expressed in developing and mature beta-cells in the pancreatic islets of Langerhans, To understand how it contributes to beta-cell development and function, we characterized its DNA binding and transactivation properties. A single copy of the homeodomain of Nkx6.1 binds to a strictly conserved 8-base pair DNA consensus sequence, TTAATTAC; even minor variations to this consensus reduce DNA binding affinity significantly. Full-length Nkx6.1, however, has markedly reduced DNA binding affinity due to an acidic domain at the carboxyl end of the molecule that functions as a mobile binding interference domain capable of interrupting the interaction between DNA and DNA binding domains of the helix-turn-helix type. When expressed in fibroblast cell. lines, Nkx6.1 represses transcription through isolated Nkx6.1 binding sites; in beta-cell lines, Nkx6.1 specifically represses the intact insulin promoter through TAAT-containing sequences. In Gal4 one-hybrid fusion studies, transcriptional repression maps to a discreet region within the amino terminus. Our findings suggest a model in which Nkx6.1, regulated by interactions through its carboxyl terminus, directs the repression of specific genes in developing and mature beta-cells.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075; Watada, Hirotaka/0000-0001-5961-1816	NIDDK NIH HHS [R01 DK021344, DK21344] Funding Source: Medline; PHS HHS [K08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK021344, R37DK021344, R01DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Awatramani R, 1997, J NEUROSCI, V17, P6657; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Draganescu A, 1998, J MOL BIOL, V276, P529, DOI 10.1006/jmbi.1997.1567; DRAGANESCU A, 1995, J MOL BIOL, V250, P595, DOI 10.1006/jmbi.1995.0401; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jorgensen MC, 1999, FEBS LETT, V461, P287, DOI 10.1016/S0014-5793(99)01436-2; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; Ogbourne S, 1998, BIOCHEM J, V331, P1; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANDER M, 1998, KEYST S VERT DEV STE; Smith SB, 1999, MOL CELL BIOL, V19, P8272; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; TREISMAN J, 1989, CELL, V59, P553; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263	47	50	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14743	14751		10.1074/jbc.275.19.14743	http://dx.doi.org/10.1074/jbc.275.19.14743			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799563	hybrid			2022-12-27	WOS:000087006900098
J	Bourbouloux, A; Shahi, P; Chakladar, A; Delrot, S; Bachhawat, AH				Bourbouloux, A; Shahi, P; Chakladar, A; Delrot, S; Bachhawat, AH			Hgt1p, a high affinity glutathione transporter from the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED GLUTATHIONE; SCHIZOSACCHAROMYCES-POMBE; GENE; EXPRESSION; PROTEIN; MUTANTS; IDENTIFICATION; BIOSYNTHESIS; ALIGNMENT; SYSTEMS	A high affinity glutathione transporter has been identified, cloned, and characterized from the yeast Saccharomyces cerevisiae, This transporter, Hgt1p, represents the first high affinity glutathione transporter to be described from any system so far. The strategy for the identification involved investigating candidate glutathione transporters from the yeast genome sequence project followed by genetic and physiological investigations. This approach revealed HGT1 (open reading frame YJL212c) as encoding a high affinity glutathione transporter. Yeast strains deleted in HGT1 did not show any detectable plasma membrane glutathione transport, and hgt1 Delta disruptants were non-viable in a glutathione biosynthetic mutant (gsh1 Delta) background. The glutathione repressible transport activity observed in wild type cells was also absent in the hgt1 Delta strains. The transporter was cloned and kinetic studies indicated that Hgt1p had a high affinity for glutathione (K-m = 54 mu M)) and was not sensitive to competition by amino acids, dipeptides, or other tripeptides. Significant inhibition was observed, however, with oxidized glutathione and glutathione conjugates, The transporter reveals a novel class of transporters that has homologues in other yeasts and plants but with no apparent homologues in either Escherichia coli or in higher eukaryotes other than plants.	Inst Microbiol Technol, Chandigarh 160036, India; Univ Poitiers, UFR Sci, Lab Physiol & Biochim Vegetales, ESA CNRS 6161, F-86022 Poitiers, France	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Bachhawat, AH (corresponding author), Inst Microbiol Technol, Sector 39-A, Chandigarh 160036, India.			Delrot, Serge/0000-0001-9602-0441				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Brachmann CB, 1998, YEAST, V14, P115; Chaudhuri B, 1997, GENETICS, V145, P75; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Iantomasi T, 1997, BBA-BIOMEMBRANES, V1330, P274; Jamai A, 1996, PLANT PHYSIOL, V111, P1145, DOI 10.1104/pp.111.4.1145; Kaiser C., 1994, METHODS YEAST GENETI; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee TK, 1997, YALE J BIOL MED, V70, P287; Li LQ, 1997, YALE J BIOL MED, V70, P301; LISKOWSKY T, 1993, CURR GENET, V23, P408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu SC, 1996, J CLIN INVEST, V97, P1488, DOI 10.1172/JCI118571; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; Lubkowitz MA, 1997, MICROBIOL-UK, V143, P387, DOI 10.1099/00221287-143-2-387; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miyake T, 1998, BIOSCI BIOTECH BIOCH, V62, P1858, DOI 10.1271/bbb.62.1858; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; OHTAKE Y, 1990, AGR BIOL CHEM TOKYO, V54, P3145, DOI 10.1080/00021369.1990.10870487; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; Rappa G, 1997, CANCER RES, V57, P5232; Rebbeor JF, 1998, J BIOL CHEM, V273, P33449, DOI 10.1074/jbc.273.50.33449; SATO S, 1994, CURR GENET, V26, P31, DOI 10.1007/BF00326301; Sherrill C, 1998, J BACTERIOL, V180, P1454, DOI 10.1128/JB.180.6.1454-1459.1998; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YI JR, 1995, P NATL ACAD SCI USA, V92, P1495, DOI 10.1073/pnas.92.5.1495	36	145	157	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13259	13265		10.1074/jbc.275.18.13259	http://dx.doi.org/10.1074/jbc.275.18.13259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788431	hybrid			2022-12-27	WOS:000086925300017
J	Gong, XM; Peng, T; Yakhnin, A; Zolkiewski, M; Quinn, J; Yeaman, SJ; Roche, TE				Gong, XM; Peng, T; Yakhnin, A; Zolkiewski, M; Quinn, J; Yeaman, SJ; Roche, TE			Specificity determinants for the pyruvate dehydrogenase component reaction mapped with mutated and prosthetic group modified lipoyl domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOAMIDE DEHYDROGENASE; AZOTOBACTER-VINELANDII; MULTIENZYME COMPLEXES; NUCLEOTIDE-SEQUENCE; DIHYDROLIPOYL ACETYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; REDUCTIVE ACYLATION; ESCHERICHIA-COLI; PURIFICATION; EXPRESSION	Efficient catalysis in the second step of the pyruvate dehydrogenase (E1) component reaction requires a lipoyl group to be attached to a lipoyl domain that displays appropriately positioned specificity residues. As substrates, the human dihydrolipoyl acetyltransferase provides an N-terminal (L1) and an inner (L2) lipoyl domain. We evaluated the specificity requirements for the E1 reaction with 27 mutant L2 (including four substitutions for the lipoylated lysine, Lys(173)), with three analogs substituted for the lipoyl group on Lys(173), and with selected ii mutants. Besides Lys(173) mutants, only E170Q mutation prevented lipoylation. Based on analysis of the structural stability of mutants by differential scanning calorimetry, alanine substitutions of residues with aromatic side chains in terminal regions outside the folded portion of the L2 domain significantly decreased the stability of mutant L2, suggesting specific interactions of these terminal regions with the folded domain. E1 reaction rates were markedly reduced by the following substitutions in the L2 domain (equivalent site-L1): L140A, S141A (S14A-L1), T143A, E162A, D172N, and E179A (E52A-L1), These mutants gave diverse changes in kinetic parameters. These residues are spread over >24 Angstrom on one side of the L2 structure, supporting extensive contact between E1 and L2 domain. Alignment of over 40 lipoyl domain sequences supports Ser(141), Thr(143), and Glu(179) serving as specificity residues for use by E1 from eukaryotic sources. Extensive interactions of the lipoyl-lysine prosthetic group within the active site are supported by the limited inhibition of E1 acetylation of native L2 by L2 domains altered either by mutation of Lys(173) Or enzymatic addition of lipoate analogs to Lys(173). Thus, efficient use by mammalian E1 of cognate lipoyl domains derives from unique surface residues with critical interactions contributed by the universal lipoyl-lysine prosthetic group, key specificity residues, and some conserved residues, particularly Asp(172) adjacent to Lys(173).	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Kansas State University; Newcastle University - UK	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, Willard Hall, Manhattan, KS 66506 USA.	bchter@ksu.edu	Quinn, Janet/AAR-9957-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; BERG A, 1995, EUR J BIOCHEM, V234, P148, DOI 10.1111/j.1432-1033.1995.148_c.x; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; FREY PA, 1989, ANN NY ACAD SCI, V573, P21, DOI 10.1111/j.1749-6632.1989.tb14984.x; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GRAHAM LD, 1990, FEBS LETT, V262, P241, DOI 10.1016/0014-5793(90)80200-3; Howard MJ, 1998, GASTROENTEROLOGY, V115, P139, DOI 10.1016/S0016-5085(98)70375-0; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; OTULAKOWSKI G, 1988, SOMAT CELL MOLEC GEN, V14, P411, DOI 10.1007/BF01534650; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Quinn J, 1997, METHOD ENZYMOL, V279, P193; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; Roche T. E., 1996, CHANNELING INTERMEDI, P115; ROCHE TE, 1993, BIOCHEMISTRY-US, V32, P5629, DOI 10.1021/bi00072a019; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130	33	15	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13645	13653		10.1074/jbc.275.18.13645	http://dx.doi.org/10.1074/jbc.275.18.13645			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788482	hybrid			2022-12-27	WOS:000086925300069
J	Howard, PW; Maurer, RA				Howard, PW; Maurer, RA			Identification of a conserved protein that interacts with specific LIM homeodomain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; PATHWAY; DOMAINS; FAMILY; PURIFICATION; ACTIVATION; PROMOTER; SYSTEM; LHX3	Lhx3, a member of the LIM homeodomain family of transcription factors, is required for development of the pituitary and is implicated in the transcription of pituitary-specific hormone genes. In this report we describe a novel gene product, SLB, that selectively interacts with Lhx3 and the closely related LIM factor, Lhx4. The SLB cDNA encodes a 1749-residue protein that contains seven WD40 repeats near the amino terminus and a putative nuclear localization signal and does not contain other recognizable motifs. SLB is expressed in a tissue-specific manner with the highest concentrations of SLB mRNA in the testis and pituitary cells. We demonstrate that SLB specifically binds to Lhx3 and Lhx4 with high affinity both in vitro and in vivo. SLB has much lower affinity or no detectable affinity for other LIM domains, An expression vector for a fragment of SLB containing the LIM-interaction domain was shown to reduce expression of Lhx3-responsive reporter genes. The ability of the LIM-interacting domain of SLB to alter reporter gene activity as well as the tissue-specific expression and the specificity of SLB binding to LIM factors suggest a possible role in modulating the transcriptional activity of specific LIM factors.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Maurer, RA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; Dawid IB, 1998, TRENDS GENET, V14, P480, DOI 10.1016/S0168-9525(98)01615-1; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Girardin SE, 1998, FEBS LETT, V431, P333, DOI 10.1016/S0014-5793(98)00787-X; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOWARD PW, 1994, J BIOL CHEM, V268, P28662; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; Meier BC, 1999, MOL CELL ENDOCRINOL, V147, P65, DOI 10.1016/S0303-7207(98)00213-5; Milan M, 1999, MOL CELL, V4, P267, DOI 10.1016/S1097-2765(00)80374-3; MORCILLO P, 1997, GENE DEV, V11, P2720; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; van Meyel DJ, 1999, MOL CELL, V4, P259, DOI 10.1016/S1097-2765(00)80373-1	33	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13336	13342		10.1074/jbc.275.18.13336	http://dx.doi.org/10.1074/jbc.275.18.13336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788441	hybrid			2022-12-27	WOS:000086925300027
J	Fellows, J; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ				Fellows, J; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ			The Elp2 subunit of elongator and elongating RNA polymerase II holoenzyme is a WD40 repeat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; MEDIATOR; YEAST; DNA; METABOLISM; COMPLEX; DOMAIN	A novel yeast gene, ELP2, is shown to encode the 90-kDa subunit of the Elongator complex and elongating RNA polymerase II holoenzyme. ELP2 encodes a protein with eight WD40 repeats, and cells lacking the gene display typical elp phenotypes, such as temperature and salt sensitivity. Generally, different combinations of double and triple ELP gene deletions cause the same phenotypes as single ELP1, ELP2, or ELP3 deletion, providing genetic evidence that the ELP gene products work together in a complex.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Svejstrup, JQ (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Blanche Ln, S Mimms EN6 3LD, Herts, England.			Svejstrup, Jesper/0000-0003-4964-6147; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	23	53	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12896	12899		10.1074/jbc.275.17.12896	http://dx.doi.org/10.1074/jbc.275.17.12896			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777588	hybrid			2022-12-27	WOS:000086762300072
J	Frolov, A; Petrescu, A; Atshaves, BP; So, PTC; Gratton, E; Serrero, G; Schroeder, F				Frolov, A; Petrescu, A; Atshaves, BP; So, PTC; Gratton, E; Serrero, G; Schroeder, F			High density lipoprotein-mediated cholesterol uptake and targeting to lipid droplets in intact L-cell fibroblasts - A single- and multiphoton fluorescence approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; DIFFERENTIATION-RELATED PROTEIN; FATTY-ACID; SCAVENGER RECEPTOR; CLASS-B; PHYSICAL-PROPERTIES; PLASMA-MEMBRANES; BINDING PROTEIN; ANIMAL-CELLS; IN-VIVO	Fluorescent sterols, dehydroergosterol and NBD-cholesterol, were used to examine high density lipoprotein-mediated cholesterol uptake and intracellular targeting in L-cell fibroblasts. The uptake, but not esterification or targeting to lipid droplets, of these sterols differed >100-fold, suggesting significant differences in uptake pathways. NBD cholesterol uptake kinetics and lipoprotein specificity reflected high density lipoprotein-mediated sterol uptake via the scavenger receptor B1. Fluorescence energy transfer showed an average intermolecular distance of 26 (A) over dot between the two fluorescent sterols in L-cells. Indirect immunofluorescence revealed that both fluorescent sterols localized to L-cell lipid droplets, the surface of which contained adipose differentiation-related protein. This lipid droplet-specific protein specifically bound NBD-cholesterol with high affinity (K-d = 2 nM) at a single site. Thus, NBD-cholesterol and dehydroergosterol were useful fluorescent probes of sterol uptake and intracellular sterol targeting. NBD-cholesterol more selectively probed high density lipoprotein-mediated uptake and rapid intracellular targeting of sterol to lipid droplets. Targeting of sterol to lipid droplets was correlated with the presence of adipose differentiation related protein, a lipid droplet-specific protein shown for the first time to bind unesterified sterol with high affinity.	Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Texas Vet Med Ctr, Dept Pathobiol, College Stn, TX 77843 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; Univ Illinois, Dept Phys, Fluorescence Dynam Lab, Urbana, IL 61801 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Massachusetts Institute of Technology (MIT); University of Illinois System; University of Illinois Urbana-Champaign; University System of Maryland; University of Maryland Baltimore	Schroeder, F (corresponding author), Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu			NCRR NIH HHS [5P41RR03155] Funding Source: Medline; NIDDK NIH HHS [DK41463] Funding Source: Medline; NIGMS NIH HHS [GM 31561] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003155] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; BERGERON R, 1982, ANAL BIOCHEM, V119, P128, DOI 10.1016/0003-2697(82)90675-3; BERGERON RJ, 1982, J LIPID RES, V23, P391; BILLHEIMER JT, 1990, ADV CHOLESTEROL RES, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasaemle DL, 1997, J LIPID RES, V38, P2249; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Fielding CJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P273; Fielding CJ, 1997, J LIPID RES, V38, P1503; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; FORSTER TH., 1967, COMPREHENSIVE BIOCH, P61; FOWLER SD, 1985, J HISTOCHEM CYTOCHEM, V33, P833, DOI 10.1177/33.8.4020099; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; HALE JE, 1982, EUR J BIOCHEM, V122, P649; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Loura LMS, 1997, BIOPHYS J, V72, P2226, DOI 10.1016/S0006-3495(97)78866-0; Maiti S, 1997, SCIENCE, V275, P530, DOI 10.1126/science.275.5299.530; Masters BR, 1997, BIOPHYS J, V72, P2405, DOI 10.1016/S0006-3495(97)78886-6; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; NEMECZ G, 1988, BIOCHIM BIOPHYS ACTA, V943, P511, DOI 10.1016/0005-2736(88)90384-7; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48, DOI 10.1152/ajpheart.1995.268.1.H48; SCHROEDER F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P183, DOI 10.1016/0005-2736(91)90185-B; SCHROEDER F, 1984, PROG LIPID RES, V23, P97, DOI 10.1016/0163-7827(84)90009-2; SCHROEDER F, 1979, J BIOL CHEM, V254, P2456; SCHROEDER F, 1987, BIOCHEMISTRY-US, V26, P2441, DOI 10.1021/bi00383a007; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1979, FEBS LETT, V97, P233, DOI 10.1016/0014-5793(79)80091-5; SCHROEDER F, 1976, J BIOL CHEM, V251, P6739; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SCHROEDER F, 1985, SUBCELLULAR BIOCH, P51; Smart EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P253; SMITH RJM, 1974, BIOCHEM J, V137, P413, DOI 10.1042/bj1370413; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; SO PTC, 1996, FLUORESCENCE IMAGING, P351; Sparrow CP, 1999, J LIPID RES, V40, P1747; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139	61	112	113	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12769	12780		10.1074/jbc.275.17.12769	http://dx.doi.org/10.1074/jbc.275.17.12769			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777574	hybrid			2022-12-27	WOS:000086762300058
J	Xie, P; Browning, DD; Hay, N; Mackman, N; Ye, RD				Xie, P; Browning, DD; Hay, N; Mackman, N; Ye, RD			Activation of NF-kappa B by bradykinin through a G alpha(q)-and G beta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN EPITHELIAL-CELLS; SERUM RESPONSE FACTOR; GENE-EXPRESSION; IKK-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; THROMBIN RECEPTOR; RGS PROTEINS; P115 RHOGEF; KINASE IKK	Recent work has suggested a role for the serine/threonine kinase Akt and I kappa B kinases (IKKs) in nuclear factor (NF)-kappa B activation. In this study, the involvement of these components in NF-kappa B activation through a G protein-coupled pathway was examined using transfected HeLa cells that express the BE-type bradykinin (BK) receptor. The function of IKK2, and to a lesser extent, IKK1, was suggested by BK-induced activation of their kinase activities and by the ability of their dominant negative mutants to inhibit BK-induced NF-kappa B activation. BK-induced NF-kappa B activation and IKK2 activity were markedly inhibited by RGS3T, a regulator of G protein signaling that inhibits G alpha(q), and by two G beta gamma scavengers. Go-expression of G alpha q potentiated BK-induced NF-kappa B activation, whereas co-expression of either an activated G alpha q(Q209L) or G beta(1)gamma(2) induced IKK2 activity and NF-kappa B activation without BK stimulation. BK-induced NF-kappa B activation was partially blocked by LY294002 and by a dominant negative mutant of phosphoinositide 3-kinase (PI3K), suggesting that PI3K is a downstream effector of G alpha(q) and G beta(1)gamma(2) for NF-kappa B activation. Furthermore, BK could activate the PI8K downstream kinase Akt, whereas a catalytically inactive mutant of Akt inhibited BK-induced NF-kappa B activation. Taken together, these findings suggest that BK utilizes a signaling pathway that involves G alpha(q), G beta(1)gamma(2), PI3K1 Akt, and IKK for NF-kappa B activation.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Scripps Research Institute	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 So Wolcott Ave,MC868, Chicago, IL 60612 USA.	yer@uic.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040176, R56AI040176] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hsu MH, 1999, BLOOD, V93, P3241, DOI 10.1182/blood.V93.10.3241.410k02_3241_3249; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; Lieb K, 1997, J IMMUNOL, V159, P4952; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARI B, 1994, J BIOL CHEM, V269, P8517; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rahman A, 1999, J IMMUNOL, V162, P5466; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Todisco A, 1999, BIOCHEM BIOPH RES CO, V261, P877, DOI 10.1006/bbrc.1999.1141; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; Ye RD, 1996, GENE EXPRESSION, V5, P205; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	62	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24907	24914		10.1074/jbc.M001051200	http://dx.doi.org/10.1074/jbc.M001051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801799	hybrid			2022-12-27	WOS:000088683300090
J	Booden, MA; Sakaguchi, DS; Buss, JE				Booden, MA; Sakaguchi, DS; Buss, JE			Mutation of Ha-Ras C terminus changes effector pathway utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INOSITOL POLYPHOSPHATE 4-PHOSPHATASE; PLASMA-MEMBRANE LOCALIZATION; PHOSPHOINOSITIDE 3-KINASE; PC12 CELLS; INCREASING COMPLEXITY; ACTIN ORGANIZATION; POLYBASIC DOMAIN; ACTIVATE RAF-1; ZINC-FINGER	In PC12 cells, Ha-Ras modulates multiple effector proteins that induce neuronal differentiation. To regulate these pathways Ha-nas must be located at the plasma membrane, a process normally requiring attachment of farnesyl and palmitate lipids to the C terminus. Ext61L, a constitutively activated and palmitoylated Ha-Res that lacks a farnesyl group, induced neurites with more actin cytoskeletal changes and lamellipodia than were induced by farnesylated Ha-Ras61L, Ext61L-triggered neurite outgrowth was prevented easily by co-expressing inhibitory Rho, Cdc42, or p21-activated kinase but required increased amounts of inhibitory Rac, Compared with Ha-Ras61L, Ext61L caused a-fold greater Rac GTP binding and phosphatidylinositol 3-kinase activity in membranes, a hyperactivation that explained the numerous lamellipodia and ineffectiveness of Rac(N17), In contrast, Ext61L activated B-Raf kinase and ERK phosphorylation more poorly than Ha-Ras61L, Thus, accentuated differentiation by Ext61L apparently results from heightened activation of one Ras effector (phosphatidylinositol 3-kinase) and suboptimal activation of another (B-Raf). This surprising unbalanced effector activation, without changes in the designated Res effector domain, indicates the Ext61L C-terminal alternations are a new way to influence Ha-Res-effector utilization and suggest a broader role of the lipidated C terminus in Ha-Res biological functions.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Iowa State Univ Sci & Technol, Dept Zool Genet, Ames, IA 50011 USA; Iowa State Univ Sci & Technol, Signal Transduct Training Grp, Ames, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University	Buss, JE (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, 3212 Mol Biol Bldg, Ames, IA 50011 USA.	jbuss@iastate.edu		Buss, Janice/0000-0002-8086-265X; Sakaguchi, Donald/0000-0003-4537-0972				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Coats SG, 1999, BIOCHEMISTRY-US, V38, P12926, DOI 10.1021/bi9909290; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Denisov G, 1998, BIOPHYS J, V74, P731, DOI 10.1016/S0006-3495(98)73998-0; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Okada T, 1999, MOL CELL BIOL, V19, P6057; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Willumsen BM, 1996, ONCOGENE, V13, P1901; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23559	23568		10.1074/jbc.M001368200	http://dx.doi.org/10.1074/jbc.M001368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801808	hybrid			2022-12-27	WOS:000088564200022
J	Yao, PM; Tabas, I				Yao, PM; Tabas, I			Free cholesterol loading of macrophages induces apoptosis involving the Fas pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FOAM CELL NECROSIS; ACYL-COENZYME-A; ATHEROSCLEROTIC LESIONS; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MEMBRANE-FUNCTION; UP-REGULATION; LIPID CORE; LIGAND	Macrophage death is an important feature of atherosclerosis, but the cellular mechanism for this process is largely unknown. There is increasing interest in cellular free cholesterol (FC) excess as an inducer of lesional macrophage death because macrophages accumulate large amounts of FC in vitro, and FC loading of macrophages in culture causes cell death. In this study, a cell culture model was used to explore the cellular mechanisms involved in the initial stages of FC-induced macrophage death. After 9 h of FC loading, some of the macrophages exhibited externalization of phosphatidylserine and DNA fragmentation, indicative of an apoptotic mechanism. Incubation of the cells with Z-DEVD-fluoromethylketone blocked these events, indicating dependence upon effector caspases, Macrophages from mice with mutations in either Fas or Fas ligand (FasL) demonstrated substantial resistance to FC-induced apoptosis, and FC-induced death in wild-type macrophages was blocked by an anti-Fast antibody. FC loading had no effect on the expression of cell-surface Fas but caused a small yet reproducible increase in cell-surface Fast. To determine the physiological significance of this finding, unloaded and FC-loaded Fas-deficient macrophages, which can only present Fast, were compared for their ability to induce apoptosis in secondarily added Fas-bearing macrophages. The FC-loaded macrophages were much more potent inducers of apoptosis than the unloaded macrophages, and this effect was almost completely blocked by an inhibitory anti-Fast antibody, In summary, during the early stages of FC loading of macrophages, a fraction of cells exhibited biochemical changes that are indicative of apoptosis. An important part of this event is BC-induced activation of Fast that leads to Fas-mediated apoptosis, In light of recent in vivo findings that show that apoptotic macrophages in atherosclerotic lesions express both Fas and Fast, we present a cellular model of Fas-mediated death in lesional foam cells.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BAURIEDEL G, 1999, CIRCULATION, V96, P190; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Brenner C, 1998, EXP GERONTOL, V33, P543; Cai WJ, 1997, ATHEROSCLEROSIS, V131, P177, DOI 10.1016/S0021-9150(97)06099-1; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Darzynkiewicz Z, 1998, Hum Cell, V11, P3; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fazio S, 1999, CIRCULATION, V100, P613; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Geng YJ, 1998, CIRCULATION, V98, P48; GERRITY RG, 1981, AM J PATHOL, V103, P191; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hagimoto N, 1997, AM J RESP CELL MOL, V17, P272, DOI 10.1165/ajrcmb.17.3.2893; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; Hegyi L, 1996, J PATHOL, V180, P423, DOI 10.1002/(SICI)1096-9896(199612)180:4<423::AID-PATH677>3.0.CO;2-1; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; KHAN M, 1999, 13 ANN C FREE COMM B, V3; Kiener PA, 1997, J IMMUNOL, V159, P1594; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Krammer P H, 1999, Adv Immunol, V71, P163; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lopez-Collazo E, 1998, J INTERF CYTOK RES, V18, P461, DOI 10.1089/jir.1998.18.461; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MartinezLorenzo MJ, 1996, IMMUNOLOGY, V89, P511, DOI 10.1046/j.1365-2567.1996.d01-782.x; McConkey DJ, 1998, TOXICOL LETT, V99, P157, DOI 10.1016/S0378-4274(98)00155-6; Mitchinson MJ, 1996, CURR OPIN LIPIDOL, V7, P324, DOI 10.1097/00041433-199610000-00011; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PAPAHADJOPOULOS D, 1974, J THEOR BIOL, V43, P329, DOI 10.1016/S0022-5193(74)80064-0; RAPP JH, 1983, J LIPID RES, V24, P1329; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Schneider DB, 2000, ARTERIOSCL THROM VAS, V20, P298, DOI 10.1161/01.ATV.20.2.298; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabas I, 1997, TRENDS CARDIOVAS MED, V7, P256, DOI 10.1016/S1050-1738(97)00086-8; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; Yeh WC, 1999, IMMUNOL REV, V169, P283, DOI 10.1111/j.1600-065X.1999.tb01323.x	60	154	161	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23807	23813		10.1074/jbc.M002087200	http://dx.doi.org/10.1074/jbc.M002087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10791964	hybrid			2022-12-27	WOS:000088564200056
J	O'Neill, T; Dwyer, AJ; Ziv, Y; Chan, DW; Lees-Miller, SP; Abraham, RH; Lai, JH; Hill, D; Shiloh, Y; Cantley, LC; Rathbun, GA				O'Neill, T; Dwyer, AJ; Ziv, Y; Chan, DW; Lees-Miller, SP; Abraham, RH; Lai, JH; Hill, D; Shiloh, Y; Cantley, LC; Rathbun, GA			Utilization of oriented peptide libraries to identify substrate motifs selected by ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA GENE; NIJMEGEN BREAKAGE SYNDROME; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; 3-KINASE RELATED KINASES; DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; V(D)J RECOMBINATION; IONIZING-RADIATION	The ataxia telangiectasia mutated (ATM) gene encodes a serine/threonine protein kinase that plays a critical role in genomic surveillance and development. Here, we use a peptide library approach to define the in vitro substrate specificity of ATM kinase activity. The peptide library analysis identified an optimal sequence with a central core motif of LSQE that is preferentially phosphorylated by ATM. The contributions of the amino acids surrounding serine in the LSQE motif were assessed by utilizing specific peptide libraries or individual peptide substrates. All amino acids comprising the LSQE sequence were critical for maximum peptide substrate suitability for ATM. The DNA-dependent protein kinase (DNA-PK), a Ser/Thr kinase related to ATM and important in DNA repair, was compared with ATM in terms of peptide substrate selectivity. DNA-PK was found to be unique in its preference of neighboring amino acids to the phosphorylated serine. Peptide library analyses defined a preferred amino acid motif for ATM that permits clear distinctions between ATM and DNA-PK kinase activity. Data base searches using the library-derived ATM sequence identified previously characterized substrates of ATM, as well as novel candidate substrate targets that may function downstream in ATM-directed signaling pathways.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Ctr Blood Res, Boston, MA 02115 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Biol Chem, Calgary, AB T2N 1N4, Canada; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Harvard Univ, Beth Israel Deaconess Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Oncogene Sci Inc, Cambridge, MA 02142 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Tel Aviv University; Sackler Faculty of Medicine; University of Calgary; University of Calgary; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rathbun, GA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Lees-Miller, Susan/0000-0001-5809-2516	NIGMS NIH HHS [GM57018, GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, R01GM057018] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chapman CR, 1999, MOL BIOL CELL, V10, P3223, DOI 10.1091/mbc.10.10.3223; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kuljis RO, 1999, BRAIN RES, V842, P351, DOI 10.1016/S0006-8993(99)01813-2; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Mayo LD, 1997, CANCER RES, V57, P5013; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	65	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22719	22727		10.1074/jbc.M001002200	http://dx.doi.org/10.1074/jbc.M001002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801797	hybrid			2022-12-27	WOS:000088419400019
J	Vollmer, W; Tomasz, A				Vollmer, W; Tomasz, A			The pgdA gene encodes for a peptidoglycan N-acetylglucosamine deacetylase in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEICHOIC-ACID; GLUCOSAMINE RESIDUES; ESCHERICHIA-COLI; LYSOZYME; SUSCEPTIBILITY; RESISTANCE; AUTOLYSIS; VARIANTS; CLONING	Analytical work on the fractionation of the glycan strands of Streptococcus pneumoniae cell wall has led to the observation that an unusually high proportion of hexosamine units (over 80% of the glucosamine and 10% of the muramic acid residues) was not N-acetylated, explaining the resistance of the peptidoglycan to the hydrolytic action of lysozyme, a muramidase that cleaves in the glycan backbone. A gene, pgdA, was identified as encoding for the peptidoglycan N-acetylglucosamine deacetylase A with amino acid sequence similarity to fungal chitin deacetylases and rhizobial NodB chitooligosaccharide deacetylases. Pneumococci in which pgdA was inactivated by insertion duplication mutagenesis produced fully N-acetylated glycan and became hypersensitive to exogenous lysozyme in the stationary phase of growth. The pgdA gene may contribute to pneumococcal virulence by providing protection against host lysozyme, which is known to accumulate in high concentrations at infection sites.	Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA	Rockefeller University	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA.			Tomasz, Alexander/0000-0003-1520-1983	NIAID NIH HHS [AI37275] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037275] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANO K, 1977, EUR J BIOCHEM, V76, P299, DOI 10.1111/j.1432-1033.1977.tb11596.x; ARAKI Y, 1971, BIOCHEM BIOPH RES CO, V45, P751, DOI 10.1016/0006-291X(71)90481-5; Atrih A, 1999, J BACTERIOL, V181, P3956, DOI 10.1128/JB.181.13.3956-3966.1999; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BERCOVICI B, 1975, SURG GYNECOL OBSTET, V141, P885; BRENNER M, 1969, THIN LAYER CHROMATOG, P730; CHEN JD, 1988, GENE, V64, P155, DOI 10.1016/0378-1119(88)90489-1; COTTAGNOUD P, 1993, J INFECT DIS, V167, P684, DOI 10.1093/infdis/167.3.684; DISTLER JJ, 1960, J BIOL CHEM, V235, P2538; DUPONT C, 1991, J BACTERIOL, V173, P4318, DOI 10.1128/JB.173.14.4318-4324.1991; Fischer W, 1997, MICROB DRUG RESIST, V3, P309, DOI 10.1089/mdr.1997.3.309; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; Garcia P, 1999, MOL MICROBIOL, V31, P1275, DOI 10.1046/j.1365-2958.1999.01238.x; GARCIABUSTOS JF, 1988, J BACTERIOL, V170, P2143, DOI 10.1128/jb.170.5.2143-2147.1988; GARCIABUSTOS JF, 1987, J BACTERIOL, V169, P447, DOI 10.1128/jb.169.2.447-453.1987; Hakenbeck R, 1998, J BACTERIOL, V180, P1831, DOI 10.1128/JB.180.7.1831-1840.1998; HAKENBECK R, 1978, ANTIMICROB AGENTS CH, V13, P302, DOI 10.1128/AAC.13.2.302; HAYASHI H, 1973, BIOCHEM BIOPH RES CO, V50, P641, DOI 10.1016/0006-291X(73)91292-8; HAYASHI H, 1973, J BACTERIOL, V113, P592, DOI 10.1128/JB.113.2.592-598.1973; HEYMANN H, 1964, J BIOL CHEM, V239, P2981; HOELTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; HORNE DS, 1993, J BACTERIOL, V175, P1717, DOI 10.1128/JB.175.6.1717-1722.1993; KLOCKARS M, 1978, ACTA MED SCAND, V203, P71; KUSSER W, 1980, EUR J BIOCHEM, V103, P277, DOI 10.1111/j.1432-1033.1980.tb04312.x; LACKS S, 1966, GENETICS, V53, P207; Morrison DA, 1997, MICROB DRUG RESIST, V3, P27, DOI 10.1089/mdr.1997.3.27; NONOMURA N, 1991, ANN OTO RHINOL LARYN, V100, P236, DOI 10.1177/000348949110000313; OHNO N, 1982, CARBOHYD RES, V107, P152, DOI 10.1016/S0008-6215(00)80785-5; PERI KG, 1990, BIOCHEM CELL BIOL, V68, P123, DOI 10.1139/o90-017; ROSEMAN S, 1957, J BIOL CHEM, V226, P115; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZPUELLES JM, 1986, EUR J BIOCHEM, V158, P289, DOI 10.1111/j.1432-1033.1986.tb09749.x; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; Severin A, 1997, MICROB DRUG RESIST, V3, P391, DOI 10.1089/mdr.1997.3.391; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; THOMASHOW MF, 1978, J BACTERIOL, V135, P1008, DOI 10.1128/JB.135.3.1008-1014.1978; TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694; TOMASZ A, 1964, BACTERIOL P, V64, P29; VANDAM JEG, 1990, ANTON LEEUW INT J G, V58, P1; WESTMACOTT D, 1979, J GEN MICROBIOL, V115, P1; ZIPPERLE GF, 1984, CAN J MICROBIOL, V30, P553, DOI 10.1139/m84-083	42	198	208	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20496	20501		10.1074/jbc.M910189199	http://dx.doi.org/10.1074/jbc.M910189199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10781617	hybrid			2022-12-27	WOS:000088084500039
J	Widmann, M; Christen, P				Widmann, M; Christen, P			Comparison of folding rates of homologous prokaryotic and eukaryotic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; PROLINE ISOMERIZATION; MECHANISM; PHOSPHORYLATION; KINETICS; MUTANTS; CHICKEN	The rate of polypeptide chain elongation is up to one order of magnitude faster in prokaryotic cells than in eukaryotes. Were we report that the rates of in vitro refolding of orthologous prokaryotic and eukaryotic proteins correlate with their differential rates of biosynthesis. The mitochondrial and cytosolic aspartate aminotransferases of chicken and aspartate aminotransferase of Escherichia coli show pairwise sequence identities of 41-48% and nearly identical three-dimensional structures. Nevertheless, the prokaryotic enzyme refolded 6 times faster (at 25 degrees C) than the eukaryotic isoenzymes after denaturation in 6 M guanidine hydrochloride. Prokaryotic malate dehydrogenase and lactate dehydrogenase also renatured faster than their orthologous eukaryotic counterparts, suggesting that evolutionary pressure has adapted the rate of folding to the rate of elongation of polypeptide chains.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	christen@biocfebs.unizh.ch						ANDERSSON DI, 1982, MOL GEN GENET, V187, P467, DOI 10.1007/BF00332630; Birolo L, 1999, BIOCHEMISTRY-US, V38, P905, DOI 10.1021/bi981467d; CAMPBELL D, 1990, BIOL SPECTROSCOPY, P102; CHENG HN, 1977, BIOPOLYMERS, V16, P1465, DOI 10.1002/bip.1977.360160707; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; DINTZIS HM, 1961, P NATL ACAD SCI USA, V47, P247, DOI 10.1073/pnas.47.3.247; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Fersht A. R., 1998, STRUCTURE MECH PROTE, P540; FINK AL, 1988, FEBS LETT, V236, P190, DOI 10.1016/0014-5793(88)80312-0; GEHRING H, 1978, J BIOL CHEM, V253, P3158; GOUSTIN AS, 1982, BIOCHIM BIOPHYS ACTA, V699, P22, DOI 10.1016/0167-4781(82)90167-1; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JANSONIUS JN, 1985, TRANSAMINASES, P110; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MUI PW, 1985, BIOCHEMISTRY-US, V24, P4481, DOI 10.1021/bi00337a033; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; SCHLEIF R, 1973, J BACTERIOL, V115, P9, DOI 10.1128/JB.115.1.9-14.1973; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; Schmid FX, 1998, MOL CHAPERONES LIFE, P361; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; VACCA RA, 1995, EUR J BIOCHEM, V227, P481, DOI 10.1111/j.1432-1033.1995.tb20413.x; Widmann M, 1995, FEBS LETT, V377, P481, DOI 10.1016/0014-5793(95)01406-3; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	28	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18619	18622		10.1074/jbc.C000156200	http://dx.doi.org/10.1074/jbc.C000156200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10781576	hybrid			2022-12-27	WOS:000087815900003
J	Cascardo, JCM; Almeida, RS; Buzeli, RAA; Carolino, SMB; Otoni, WC; Fontes, EPB				Cascardo, JCM; Almeida, RS; Buzeli, RAA; Carolino, SMB; Otoni, WC; Fontes, EPB			The phosphorylation state and expression of soybean BiP isoforms are differentially regulated following abiotic stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; DEFECTIVE SIGNAL PEPTIDE; BINDING-PROTEIN HOMOLOG; HEAT-SHOCK PROTEINS; IMMUNIZED HENS; PLANT-CELLS; TRANSPORT; FLOURY-2; ELECTROPHORESIS; OVEREXPRESSION	The mammalian BiP is regulated by phosphorylation, and it is generally accepted that its unmodified form constitutes the biologically active species. In fact, the glycosylation inhibitor tunicamycin induces dephosphorylation of mammalian BiP, The stress-induced phosphorylation state of plant BiP has not been examined, Here, we demonstrated that soybean BiP exists in interconvertible phosphorylated and nonphosphorylated forms, and the equilibrium can be shift to either direction in response to different stimuli. In contrast to tunicamycin treatment, water stress condition stimulated phosphorylation of BiP species in soybean cultured cells and stressed leaves. Despite their phosphorylation state, we demonstrated that BiP isoforms from water-stressed leaves exhibit protein binding activity, suggesting that plant BiP functional regulation may differ from other eukaryotic BiPs, We also compared the induction of the soybean BiP gene family, which consists of at least four members designated soyBiPA, soyBiPB, soyBiPC, and soyBiPD, by tunicamycin and osmotic stress. Although all soybean BiP genes were induced by tunicamycin, just the soyBiPA RNA was upregulated by osmotic stress. In addition, these stresses promoted BiP induction with different kinetics and acted synergistically to increase BiP accumulation. These results suggest that the soybean BiP gene family is differentially regulated by abiotic stresses through distinct signaling pathways.	Univ Fed Vicosa, Inst Biotecnol Aplicado Agropecuaria, Dept Bioquim & Biol Mol, BIOAGRO,DBB, BR-36571000 Vicosa, MG, Brazil; Univ Fed Vicosa, Inst Biotecnol Aplicado Agropecuaria, Dept Biol Vegetal, BR-36571000 Vicosa, MG, Brazil	Universidade Federal de Vicosa; Universidade Federal de Vicosa	Fontes, EPB (corresponding author), Univ Fed Vicosa, Inst Biotecnol Aplicado Agropecuaria, Dept Bioquim & Biol Mol, BIOAGRO,DBB, Av PH Rolfs S-N, BR-36571000 Vicosa, MG, Brazil.		Festucci Buselli, Reginaldo/B-6305-2009; Almeida, Raul/A-8770-2008; Otoni, Wagner C/D-6439-2013; Fontes, Elizabeth/K-3159-2012	Festucci Buselli, Reginaldo/0000-0002-4648-8836; Otoni, Wagner C/0000-0002-9614-9373; Fontes, Elizabeth/0000-0002-7986-1369				Anderson JV, 1994, PLANT PHYSL ROCKV, V104, P1395; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOSTON RS, 1991, PLANT CELL, V3, P497, DOI 10.1105/tpc.3.5.497; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CAROLINO SMB, 1997, THESIS U FEDERAL VIC; CARROLL SB, 1983, J BIOL CHEM, V258, P24; Catski J., 1974, METHODS STUDYING PLA, P136; CHRISPEELS MJ, 1983, PLANTA, V158, P140, DOI 10.1007/BF00397707; COLEMAN CE, 1995, P NATL ACAD SCI USA, V92, P6828, DOI 10.1073/pnas.92.15.6828; DAMICO L, 1992, PLANT J, V2, P443; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; Denecke J, 1996, PLANT PHYSIOL BIOCH, V34, P197; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Figueiredo Jose E. F., 1997, Revista Brasileira de Fisiologia Vegetal, V9, P103; FINER JJ, 1988, PLANT CELL TISS ORG, V15, P125, DOI 10.1007/BF00035754; FONTES EBP, 1991, PLANT CELL, V3, P483, DOI 10.1105/tpc.3.5.483; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Galili G, 1998, PLANT MOL BIOL, V38, P1, DOI 10.1023/A:1006011919671; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gillikin JW, 1997, PLANT PHYSIOL, V114, P345, DOI 10.1104/pp.114.1.345; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HELM KW, 1993, MOL CELL BIOL, V13, P238, DOI 10.1128/MCB.13.1.238; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; KALINSKI A, 1995, PLANTA, V195, P611, DOI 10.1007/BF00195722; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Koizumi N, 1999, PLANT PHYSIOL, V121, P353, DOI 10.1104/pp.121.2.353; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leborgne-Castel N, 1999, PLANT CELL, V11, P459, DOI 10.1105/tpc.11.3.459; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Li XH, 1998, PLANT CELL, V10, P119, DOI 10.1105/tpc.10.1.119; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEDRAZZINI E, 1994, PLANT J, V5, P103, DOI 10.1046/j.1365-313X.1994.5010103.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POLSON A, 1985, IMMUNOL INVEST, V14, P323, DOI 10.3109/08820138509022667; RIPP KG, 1988, PLANT PHYSIOL, V88, P1435, DOI 10.1104/pp.88.4.1435; Sambrook J., 2002, MOL CLONING LAB MANU; SHAMU CE, 1997, CURR BIOL, V7, P67; Wrobel RL, 1997, GENE, V204, P105, DOI 10.1016/S0378-1119(97)00529-5	46	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14494	14500		10.1074/jbc.275.19.14494	http://dx.doi.org/10.1074/jbc.275.19.14494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799532	Green Published, hybrid			2022-12-27	WOS:000087006900066
J	Eckmann, L; Smith, JR; Housley, MP; Dwinell, MB; Kagnoff, MF				Eckmann, L; Smith, JR; Housley, MP; Dwinell, MB; Kagnoff, MF			Analysis by high density cDNA arrays of altered gene expression in human intestinal epithelial cells in response to infection with the invasive enteric bacteria Salmonella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OLIGONUCLEOTIDE ARRAYS; REGULATED EXPRESSION; BARRIER FUNCTION; NITRIC-OXIDE; ACTIVIN-A; T-CELLS; TYPHIMURIUM; INTERLEUKIN-8; INFLAMMATION	Many clinically important enteric: pathogens initiate disease by invading and passing through the intestinal epithelium, a process accompanied by increased epithelial expression of proinflammatory cytokines. To further define the role intestinal epithelial cells play in initiating and modulating the host response to infection with invasive bacteria, hybrid selection on high density cDNA arrays was used to characterize the mRNA expression profile of similar to 4,300 genes in human intestinal epithelial cells after infection with the prototypic invasive bacteria, Salmonella. Selected findings were further evaluated by reverse transcription-polymerase chain reaction, Northern blot analysis, and protein assays. Epithelial infection with Salmonella significantly up-regulated mRNA expression of a relatively small fraction of all genes tested. Of these, several cytokines (granulocyte colony-stimulating factor, inhibin A, Epstein-Barr virus-induced gene 3, interleukin-8, macrophage inflammatory protein-2 alpha), kinases (TKT, Eck, HEK), transcription factors (interferon regulatory factor-1), and HLA class I were the most prominent. Furthermore, the transcription factor NF-kappa B is shown to be important for inducible mRNA expression for a broad group of genes tested. These findings expand the repertoire of known epithelial cell responses to infection with an invasive enteric pathogen. The results also show that evaluation of mRNA expression profiles by cDNA array analysis is a powerful approach to characterizing and understanding host-pathogen interactions.	Univ Calif San Diego, Dept Med 0623D, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Eckmann, L (corresponding author), Univ Calif San Diego, Dept Med 0623D, 9500 Gilman Dr, La Jolla, CA 92093 USA.	leckmann@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35108] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DELERMA B, 1999, EUR J IMMUNOL, V29, P499; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; ECKMANN L, 1994, J BIOL CHEM, V269, P33102; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Elewaut D, 1999, J IMMUNOL, V163, P1457; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hartung T, 1998, MED MICROBIOL IMMUN, V187, P61, DOI 10.1007/s004300050075; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Hobbie S, 1997, J IMMUNOL, V159, P5550; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JEPSON MA, 1995, INFECT IMMUN, V63, P356, DOI 10.1128/IAI.63.1.356-359.1995; Jobin C, 1998, J IMMUNOL, V160, P410; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kaufmann SHE, 1999, IMMUNOL LETT, V65, P81, DOI 10.1016/S0165-2478(98)00128-X; KAWAMURA N, 1995, DIGEST DIS SCI, V40, P2280, DOI 10.1007/BF02209018; Keskinen P, 1997, IMMUNOLOGY, V91, P421, DOI 10.1046/j.1365-2567.1997.00258.x; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Munz B, 1999, J ENDOCRINOL, V161, P187, DOI 10.1677/joe.0.1610187; NAUCIEL C, 1990, J IMMUNOL, V145, P1265; Nusing RM, 1999, BRIT J PHARMACOL, V127, P919, DOI 10.1038/sj.bjp.0702626; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Salzman AL, 1998, GASTROENTEROLOGY, V114, P93, DOI 10.1016/S0016-5085(98)70637-7; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Witthoft T, 1998, AM J PHYSIOL-GASTR L, V275, pG564, DOI 10.1152/ajpgi.1998.275.3.G564; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	37	154	159	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14084	14094		10.1074/jbc.275.19.14084	http://dx.doi.org/10.1074/jbc.275.19.14084			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799483	hybrid			2022-12-27	WOS:000087006900013
J	Kawahara, M; Kuroda, Y; Arispe, N; Rojas, E				Kawahara, M; Kuroda, Y; Arispe, N; Rojas, E			Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETES-MELLITUS; PRECURSOR PROTEIN; BILAYER-MEMBRANES; DISEASE; CHANNELS; GENE; NEUROTOXICITY; CHOLESTEROL; PEPTIDES; CULTURES	A growing number of reports suggest that elevated levels of extracellular Alzheimer's beta-amyloid protein alter the homeostasis of free [Ca2+](i) in different cell types of the mammalian brain. In line with these results, we have previously shown that A beta P[1-40] forms cation-selective channels (Ca2+ included) across artificial planar bilayers formed from acidic phospholipids and across excised membrane patches from immortalized hypothalamic GnRH neurons (GT1-7 cells), suggesting that the nonregulated Ca2+-influx through these spontaneously formed "amyloid channels" may provide a mechanism to explain its toxicity (1), We have now found and report here that the application of A beta P[1-40] to GT1-7 neurons consistently elevates [Ca2+](i) levels. We also found that human islet amylin and the prion protein fragment (PrP106-126), peptides that acquire beta-pleated sheet conformation in water solutions and have been reported to form ion channels across planar bilayer membranes, also increase cytosolic free calcium in GT1-7 neurons. Searching for protective agents, we found that soluble cholesterol, known to decrease the fluidity of the cell membrane, inhibits A beta P[1-40]-evoked [Ca2+](i) rise. These results suggest that unregulated Ca2+ entry across amyloid channels may be a common mechanism causing cell death, not only in diseases of the third age, including Alzheimer's disease and type 2 diabetes mellitus, but also in prion-induced diseases.	Univ Chile, Fac Med, Inst Biomed Sci, Santiago, Chile; Tokyo Metropolitan Inst Neurosci, Dept Mol & Cellular Neurobiol, Fuchu, Tokyo 1838526, Japan; Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20892 USA	Universidad de Chile; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Uniformed Services University of the Health Sciences - USA	Rojas, E (corresponding author), Univ Chile, Fac Med, Inst Biomed Sci, Independencia 1027,Casilla 70005,Correo 7, Santiago, Chile.							ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; COOPER GJS, 1989, BIOCHIM BIOPHYS ACTA, V1014, P247, DOI 10.1016/0167-4889(89)90220-6; COOPER GJS, 1988, P NATL ACAD SCI USA, V85, P7763, DOI 10.1073/pnas.85.20.7763; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; FORLONI G, 1993, NEUROREPORT, V4, P506; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; Fujii G, 1997, BIOCHEMISTRY-US, V36, P4959, DOI 10.1021/bi962894z; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; Lin MX, 1997, J BIOL CHEM, V272, P44; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; Lundbaek JA, 1996, BIOCHEMISTRY-US, V35, P3825, DOI 10.1021/bi952250b; MALOUF AT, 1992, NEUROBIOL AGING, V13, P543, DOI 10.1016/0197-4580(92)90054-2; MATSON MP, 1992, J NEUROSCI, V12, P376; MAY PC, 1993, J NEUROCHEM, V61, P2330, DOI 10.1111/j.1471-4159.1993.tb07480.x; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; MOORE CX, 1991, BIOCHEM BIOPH RES CO, V179, P1, DOI 10.1016/0006-291X(91)91325-7; Muller WE, 1998, AMYLOID, V5, P10, DOI 10.3109/13506129809007284; MURAMOTO T, 1992, BRAIN RES, V599, P309, DOI 10.1016/0006-8993(92)90406-Y; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SLOTTE JP, 1994, CURR TOP MEMBR, V40, P483, DOI 10.1016/S0070-2161(08)60993-4; Spergel DJ, 1996, NEUROENDOCRINOLOGY, V63, P101, DOI 10.1159/000126946; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Tucker HM, 1998, J NEUROCHEM, V71, P506; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	41	264	273	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14077	14083		10.1074/jbc.275.19.14077	http://dx.doi.org/10.1074/jbc.275.19.14077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799482	hybrid			2022-12-27	WOS:000087006900012
J	Pendurthi, UR; Allen, KE; Ezban, M; Rao, LVM				Pendurthi, UR; Allen, KE; Ezban, M; Rao, LVM			Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa center dot tissue factor-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; IMMEDIATE-EARLY GENE; COAGULATION-FACTOR-X; CANINE KIDNEY-CELLS; FACTOR PATHWAY; BLOOD-COAGULATION; ENDOTHELIAL-CELLS; UP-REGULATION; IN-SITU; BINDING	Extracellular interactions of plasma clotting factor VIIa (FVIIa) with tissue factor (TF) on cell surfaces trigger the intracellular signaling events. At present, it is unclear how these signals influence phenotype, To elucidate this, we have used cDNA microarray technology to examine changes in transcriptional program in human fibroblasts in response to exposure to FVIIa. cDNA microarrays revealed that FVIIa binding to TF up-regulated the expression of Cyr61 and CTGF (connective tissue growth factor), the genes that encode extracellular matrix signaling proteins Cyr61 and CTGF, respectively. Northern blot analysis confirmed that FVIIa binding to TF markedly increased the expression of Cyr61 and CTGF in a time- and dose-dependent manner. FVIIa catalytic activity is required for the gene induction, In addition to FVIIa, thrombin also induced the expression of Cyr61 and CTGF, Hirudin abolished the thrombin-induced expression of these mRNAs but not the FVIIa-induced expression. FVIIa-induced expression of Cyr61 appears not to involve the currently known protease-activated receptors (PARs), whereas thrombin-induced expression involves the activation of PAR1 and possibly an additional PAR. Various intracellular signaling pathway inhibitors exhibited different inhibitory pattern on FVIIa and thrombin-induced up-regulation of Cyr61. Cyr61 and CTGF could act as downstream mediators of FVIIa TF in affecting various biological processes.	Univ Texas Hlth Ctr, Dept Mol Biol, Tyler, TX 75708 USA; Univ Texas Hlth Ctr, Dept Biochem, Tyler, TX 75708 USA; Novo Nordisk AS Hlth Care Discovery, Tissue Factor Factor VII Res, DK-2760 Malov, Denmark	Novo Nordisk	Pendurthi, UR (corresponding author), Univ Texas Hlth Ctr, Dept Mol Biol, US Highway 271, Tyler, TX 75708 USA.							Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Coughlin SR, 1999, THROMB HAEMOSTASIS, V82, P353; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kamikubo Y, 1997, FEBS LETT, V407, P116, DOI 10.1016/S0014-5793(97)00312-8; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; Masuda M, 1996, EUR J IMMUNOL, V26, P2529, DOI 10.1002/eji.1830261037; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PETERSEN LC, 2000, IN PRESS THROMB HAEM; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Prydz H, 1999, THROMB HAEMOSTASIS, V82, P183; Rao LVM, 1996, BLOOD, V87, P3738, DOI 10.1182/blood.V87.9.3738.bloodjournal8793738; RAO LVM, 1992, THROMB HAEMOSTASIS, V67, P654; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Ruf W, 1999, THROMB HAEMOSTASIS, V82, P175; Ruf W, 1996, Curr Opin Hematol, V3, P379; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; Sato Y, 1997, THROMB HAEMOSTASIS, V78, P1138; Shoji M, 1998, AM J PATHOL, V152, P399; Siegbahn A, 1999, THROMB HAEMOSTASIS, P505; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Sorensen BB, 1998, BLOOD COAGUL FIBRIN, V9, pS67; Taniguchi T, 1998, CANCER RES, V58, P4461; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	53	147	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14632	14641		10.1074/jbc.275.19.14632	http://dx.doi.org/10.1074/jbc.275.19.14632			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799550	hybrid			2022-12-27	WOS:000087006900084
J	Venkateswaran, A; Repa, JJ; Lobaccaro, JMA; Bronson, A; Mangelsdorf, DJ; Edwards, PA				Venkateswaran, A; Repa, JJ; Lobaccaro, JMA; Bronson, A; Mangelsdorf, DJ; Edwards, PA			Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages - A transcriptional role for specific oxysterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR LXR-ALPHA; DROSOPHILA WHITE GENE; PEROXISOMAL MEMBRANE-PROTEIN; RESISTANCE P-GLYCOPROTEINS; COLONY-STIMULATING FACTOR; MULTIDRUG-RESISTANCE; NUCLEAR RECEPTOR; MOLECULAR-CLONING; RESPONSE PATHWAY; APOLIPOPROTEIN-E	To identify genes that are transcriptionally activated when human macrophages accumulate excess lipids, we employed the mRNA differential display technique using RNA isolated from human monocyte-macrophages incubated in the absence or presence of acetylated low density lipoprotein and sterols (cholesterol and 25-hydroxycholesterol). These studies identified a mRNA whose levels were highly induced in lipid-loaded macrophages, The mRNA encoded the human White protein, a member of the ATP-binding cassette (ABC) transporter superfamily of proteins. The mRNA levels of ABC8, the murine homolog of the human white gene, were also induced when a murine macrophage cell line, RAW264.7, was incubated with acetylated low density lipoprotein and sterols. Additional studies demonstrated that white/ ABC8 mRNA levels were induced by specific oxysterols that included 25-, 20(S)-, and 22(R)-hydroxycholesterol, and by a retinoid X receptor-specific ligand, Furthermore, the oxysterol-mediated induction of ABC8 expression in mouse peritoneal macrophages was dependent on the presence of the nuclear oxysterol receptors, liver X receptors (LXRs). Macrophages derived from mice lacking both LXR alpha and LXR beta failed to up-regulate the expression of ABCS following incubation with 22(R)-hydroxycholesterol. Oxysterol-dependent induction of white/ABC8 mRNA was blocked by actinomycin D but not by cycloheximide treatment of cells. We conclude that the white and ABC8 genes are primary response genes that are transcriptionally activated by specific oxysterols and that this induction is mediated by the LXR subfamily of nuclear hormone receptors, These data strongly support the hypothesis that white/ABC8 has a role in cellular sterol homeostasis.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.		Lobaccaro, Jean-Marc/Q-3926-2019; Lobaccaro, Jean-Marc A./U-1928-2019	Lobaccaro, Jean-Marc/0000-0001-9890-2392; Repa, Joyce/0000-0001-5740-1954; Mangelsdorf, David/0000-0002-4355-0796	NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1998, CANCER RES, V58, P5337; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; AMBUDKAR SV, 1998, METHODS ENZYMOLOGY, V292; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVERMAN N, 1995, HUM MOL GENET, V4, P1791, DOI 10.1093/hmg/4.suppl_1.1791; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; Chen HM, 1996, AM J HUM GENET, V59, P66; Childs S, 1994, Important Adv Oncol, P21; Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; EWART GD, 1994, J BIOL CHEM, V269, P10370; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; GERRITY RG, 1981, AM J PATHOL, V103, P181; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kuwana H, 1996, BBA-GENE STRUCT EXPR, V1309, P47, DOI 10.1016/S0167-4781(96)00137-6; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; MAZZONE T, 1989, J LIPID RES, V30, P1055; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; Miyake K, 1999, CANCER RES, V59, P8; MONTELL I, 1992, BIOCHEM GENET, V30, P61, DOI 10.1007/BF00554428; MORGAN CJ, 1993, TRANSPLANTATION, V56, P437, DOI 10.1097/00007890-199308000-00036; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; Qiao JH, 1997, AM J PATHOL, V150, P1687; REMALEY AT, 1995, J LIPID RES, V36, P308; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Savary S, 1996, MAMM GENOME, V7, P673, DOI 10.1007/s003359900203; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Shani N, 1996, P NATL ACAD SCI USA, V93, P11901, DOI 10.1073/pnas.93.21.11901; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307	61	340	358	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14700	14707		10.1074/jbc.275.19.14700	http://dx.doi.org/10.1074/jbc.275.19.14700			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799558	hybrid			2022-12-27	WOS:000087006900092
J	Fajloun, Z; Ferrat, G; Carlier, E; Fathallah, M; Lecomte, C; Sandoz, G; di Luccio, E; Mabrouk, K; Legros, C; Darbon, H; Rochat, H; Sabatier, JM; De Waard, M				Fajloun, Z; Ferrat, G; Carlier, E; Fathallah, M; Lecomte, C; Sandoz, G; di Luccio, E; Mabrouk, K; Legros, C; Darbon, H; Rochat, H; Sabatier, JM; De Waard, M			Synthesis, H-1 NMR structure, and activity of a three-disulfide-bridged maurotoxin analog designed to restore the consensus motif of scorpion toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; POTASSIUM CHANNELS; HIGH-AFFINITY; CHARYBDOTOXIN; SPECTROSCOPY; OOCYTES; MAURUS; VENOM	Maurotoxin (MTX) is a 34-residue toxin that has been isolated from the venom of the chactidae scorpion Scorpio maurus palmatus, The toxin displays an exceptionally wide range of pharmacological activity since it binds onto small conductance Ca2+-activated K+ channels and also blocks Ky channels (Shaker, Kv1.2 and Kv1.3). MIX possesses 53-68% sequence identity with HsTx1 and Pi1, two other Kf channel short chain scorpion toxins cross-linked by four disulfide bridges. These three toxins differ from other K+/Cl-/Na+ channel scorpion toxins cross-linked by either three or four disulfide bridges by the presence of an extra half-cystine residue in the middle of a consensus sequence generally associated with the formation of an alpha/beta scaffold (an alpha-helix connected to an antiparallel beta-sheet by two disulfide bridges). Because MTX exhibits an uncommon disulfide bridge organization among known scorpion toxins (C1-C5, C2-C6, C3-C4, and C7-C8 instead of C1-C4, C2-C5, and C3-C6 for three-disulfide-bridged toxins or C1-C5, C2-C6, C3-C7, and C4-C8 for four-disulfide-bridged toxins), we designed and chemically synthesized an MTX analog with three instead of four disulfide bridges ([Abu(19),Abu(34)]MTX and in which the entire consensus motif of scorpion toxins was restored by the substitution of the two half-cystines in positions 19 and 34 (corresponding to C4 and C8) by two isosteric alpha-aminobutyrate (Abu) derivatives. The three-dimensional structure of [Abu(19),Abu(34)]MTX in solution was solved by H-1 NMR, This analog adopts the alpha/beta scaffold with now conventional half-cystine pairings connecting C1-C5, C2-C6, and C3-C7 (with C4 and C8 replaced by Abu derivatives). This novel arrangement in half-cystine pairings that concerns the last disulfide bridge results mainly in a reorientation of the alpha-helix regarding the beta-sheet structure. In vivo, [Abu(19),Abu(34)]MTX remains lethal in mice as assessed by intracerebroventricular injection of the peptide (LD50 value of 0.25 mu g/mouse). The structural variations are also accompanied by changes in the pharmacological selectivity of the peptide, suggesting that the organization pattern of disulfide bridges should affect the three-dimensional presentation of certain key residues critical to the blockage of K+ channel subtypes.	Fac Med Nord, IFR Jean Roche, INSERM, U464,Lab Neurobiol Canaux Ion, F-13916 Marseille 20, France; Fac Med Nord, IFR Jean Roche, CNRS, UMR 6560,Lab Biochim, F-13916 Marseille 20, France; CNRS, UPR 9039, F-13402 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	De Waard, M (corresponding author), Fac Med Nord, IFR Jean Roche, INSERM, U464,Lab Neurobiol Canaux Ion, Blvd Pierre Dramard, F-13916 Marseille 20, France.	dewaard.m@jean-roche.univ-mrs.fr	Legros, Christian/K-1346-2015; Fajloun, Ziad/AAO-8595-2021; di Luccio, Eric/Z-5388-2019; sandoz, guillaume/AAI-9236-2020; De Waard, Michel/G-7406-2014	sandoz, guillaume/0000-0003-1251-0852; De Waard, Michel/0000-0002-2782-9615; SABATIER, Jean-Marc/0000-0002-9040-5647; LEGROS, Christian/0000-0002-3346-7059				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Blanc E, 1997, PROTEINS, V29, P321, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;321::AID-PROT6&gt;3.0.CO;2-D; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Darbon H, 1999, PERSPECT DRUG DISCOV, V16, P41; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; GRAY EG, 1962, J ANAT, V96, P79; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lebrun B, 1997, BIOCHEM J, V328, P321, DOI 10.1042/bj3280321; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; OlamendiPortugal T, 1996, BIOCHEM J, V315, P977, DOI 10.1042/bj3150977; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Possani LD, 1999, PERSPECT DRUG DISCOV, V16, P15; SABATIER JM, 1999, HDB TOXINOLOGY ANIMA, P198; SEAGAR MJ, 1984, J BIOL CHEM, V259, P1491	21	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13605	13612		10.1074/jbc.275.18.13605	http://dx.doi.org/10.1074/jbc.275.18.13605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788477	hybrid			2022-12-27	WOS:000086925300064
J	Maccarrone, M; Bari, M; Lorenzon, T; Bisogno, T; Di Marzo, V; Finazzi-Agro, A				Maccarrone, M; Bari, M; Lorenzon, T; Bisogno, T; Di Marzo, V; Finazzi-Agro, A			Anandamide uptake by human endothelial cells and its regulation by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA K562 CELLS; CANNABINOID RECEPTOR; MESENTERIC VASODILATION; S-NITROSOTHIOLS; MESSENGER-RNA; 2-ARACHIDONOYLGLYCEROL; INHIBITION; ENDOCANNABINOIDS; TRANSPORT; SYNTHASE	Anandamide (AEA) has vasodilator activity, which can be terminated by cellular re-uptake and degradation. Here we investigated the presence and regulation of the AEA transporter in human umbelical vein endothelial cells (HUVECs), HUVECs take up AEA by facilitated transport (apparent K-m = 190 +/- 10 nM and V-max = 45 +/- 3 pmol min(-1) . mg(-1) protein), which is inhibited by alpha-linolenoyl-vanillyl-amide and N-(4-hydroxyphenyl) arachidonoylamide, and stimulated up to 2.2-fold by nitric oxide (NO) donors. The NO scavenger hydroxocobalamin abolishes the latter effect, which is instead enhanced by superoxide anions but inhibited by superoxide dismutase and N-acetylcysteine, a precursor of glutathione synthesis. Peroxynitrite (ONOO-) causes a 4-fold activation of AEA transport into cells. The HUVEC AEA transporter contributes to the termination of a typical type 1 cannabinoid receptor (CB1) -mediated action of AEA i.e. the inhibition of forskolin-stimulated adenylyl cyclase, because NO/ONOO- donors and alpha-linolenoyl-vanillyl-amide/N-(4-hydroxyphenyl)-arachidonoylamide were found to attenuate and enhance, respectively, this effect of AEA. Consistently, activation of CB, cannabinoid receptors by either AEA or the cannabinoid HU-210 caused a stimulation of HUVEC inducible NO synthase activity and expression up to 2.9- and 2.6-fold, respectively. Also these effects are regulated by the AEA transporter, HU-210 enhanced AEA uptake by HOVECs in a fashion sensitive to the NO synthase inhibitor N omega-nitro-L-arginine methyl ester, These findings suggest a NO-mediated regulatory loop between CB1 cannabinoid receptors and AEA transporter.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco Felice Napoli, Napoli, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Finazzi-Agro, A (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	Finazzi@uniroma2.it	Di Marzo, Vincenzo/AAD-7742-2019; Bisogno, Tiziana/B-7891-2015	Di Marzo, Vincenzo/0000-0002-1490-3070; 				Bauer J A, 1995, Adv Pharmacol, V34, P361; BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Beltramo M, 1999, EUR J PHARMACOL, V364, P75, DOI 10.1016/S0014-2999(98)00821-8; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; CALIGNANO A, 1997, EUR J PHARMACOL, V337, P1; Chaytor AT, 1999, J PHYSIOL-LONDON, V520, P539, DOI 10.1111/j.1469-7793.1999.00539.x; Cho MM, 1999, AM J PHYSIOL-CELL PH, V276, pC337; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Di Marzo V, 1998, BIOCHEM J, V331, P15; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Fimiani C, 1999, PROSTAG OTH LIPID M, V57, P23, DOI 10.1016/S0090-6980(98)00068-9; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fleming I, 1999, BRIT J PHARMACOL, V126, P949, DOI 10.1038/sj.bjp.0702381; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Halliwell B, 1999, FREE RADICAL BIO MED, P73; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Jarai Z, 2000, HYPERTENSION, V35, P679, DOI 10.1161/01.HYP.35.2.679; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kelm M, 1997, J BIOL CHEM, V272, P9922; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Maccarrone M, 1996, EUR J BIOCHEM, V241, P297, DOI 10.1111/j.1432-1033.1996.0297t.x; Maccarrone M, 1998, FEBS LETT, V434, P421, DOI 10.1016/S0014-5793(98)01026-6; Maccarrone M, 1999, ANAL BIOCHEM, V267, P314, DOI 10.1006/abio.1998.2964; Maccarrone M, 1999, FEBS LETT, V447, P277, DOI 10.1016/S0014-5793(99)00308-7; Maccarrone M, 1998, J BIOL CHEM, V273, P32332, DOI 10.1074/jbc.273.48.32332; McCulloch AI, 1998, BRIT J PHARMACOL, V123, P1700, DOI 10.1038/sj.bjp.0701781; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Mombouli JV, 1997, TRENDS PHARMACOL SCI, V18, P252, DOI 10.1016/S0165-6147(97)90633-7; Pestonjamasp VK, 1998, BBA-LIPID LIPID MET, V1394, P249, DOI 10.1016/S0005-2760(98)00110-6; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; PLANE F, 1998, BRIT J PHARMACOL, V121, P1509; Randall MD, 1996, BIOCHEM BIOPH RES CO, V229, P114, DOI 10.1006/bbrc.1996.1766; Randall MD, 1998, TRENDS PHARMACOL SCI, V19, P55, DOI 10.1016/S0165-6147(97)01161-9; Schena M, 1999, AM J HYPERTENS, V12, P388; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Shivachar AC, 1996, BIOCHEM PHARMACOL, V51, P669, DOI 10.1016/S0006-2952(95)02248-1; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Ueda N, 1999, FEBS LETT, V454, P267, DOI 10.1016/S0014-5793(99)00820-0; Upchurch G R Jr, 1995, Adv Pharmacol, V34, P343; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Wagner JA, 1998, J MOL MED-JMM, V76, P824, DOI 10.1007/s001090050287; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	58	161	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13484	13492		10.1074/jbc.275.18.13484	http://dx.doi.org/10.1074/jbc.275.18.13484			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788462	hybrid			2022-12-27	WOS:000086925300049
J	Petaja-Repo, UE; Hogue, M; Laperriere, A; Walker, P; Bouvier, M				Petaja-Repo, UE; Hogue, M; Laperriere, A; Walker, P; Bouvier, M			Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; O-LINKED GLYCOSYLATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; CYCLOPHILIN HOMOLOG NINAA; BETA-ADRENERGIC-RECEPTOR; INTRACELLULAR RETENTION; ADENYLATE-CYCLASE; BREFELDIN-A; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; FUNCTIONAL EXPRESSION	Synthesis and maturation of G protein-coupled receptors are complex events that require an intricate combination of processes that include protein folding, posttranslational modifications, and transport through distinct cellular compartments. Relatively little is known about the nature and kinetics of specific steps involved in these processes. Here, the human delta opioid receptor expressed in human embryonic kidney 293S cells is used as a model to delineate these steps and to establish the kinetics of receptor synthesis, glycosylation, and transport. We found that the receptor is synthesized as a core-glycosylated M-r 45,000 precursor that is converted to the fully mature M-r 55,000 receptor with a half-time of about 120 min. In addition to trimming and processing of two N-linked oligosaccharides, maturation involves addition of O-glycans containing N-acetylgalactosamine, galactose, and sialic acid. In contrast to N-glycosylation, which is initiated co-translationally and is completed when the protein reaches the trans-Golgi network, O-glycosylation was found to occur only after the receptor exits from the endoplasmic reticulum (ER) and was terminated as early as the trans-Golgi cisternae, Once the carbohydrates are fully processed and the receptor reaches the trans-Golgi network, it is transported to the cell surface in about 10 min. The exit from the ER was found to be the limiting step in overall processing of the receptor. This indicates that early events in the folding of the receptor are probably rate-limiting and that receptor folding intermediates are retained in the ER until they can adopt the correct conformation. The overall low efficiency of receptor maturation, less than 50% of the precursor being processed to the fully glycosylated protein, further suggests that only a fraction of the synthesized receptors attain properly folded conformation that allows exit from the ER. This indicates that folding and ER export are key events in control of receptor cell surface expression. Whether or not the low efficiency of the ER export is a general feature among G protein-coupled receptors remains to be investigated.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; AstraZeneca R&D Montreal, St Laurent, PQ H4A 1Z9, Canada	Universite de Montreal; AstraZeneca	Bouvier, M (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.		Petäjä-Repo, Ulla/AAV-6115-2021; Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dhawan BN, 1996, PHARMACOL REV, V48, P567; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HEIN L, 1994, J BIOL CHEM, V269, P27719; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; Jaquette J, 1997, ENDOCRINOLOGY, V138, P85, DOI 10.1210/en.138.1.85; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KNAPP RJ, 1994, LIFE SCI, V54, pPL463, DOI 10.1016/0024-3205(94)90138-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latronico AC, 1998, MOL ENDOCRINOL, V12, P442, DOI 10.1210/me.12.3.442; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PILLER V, 1990, J BIOL CHEM, V265, P9264; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; Quock RM, 1999, PHARMACOL REV, V51, P503; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rottger S, 1998, J CELL SCI, V111, P45; ROZELL TG, 1995, MOL ENDOCRINOL, V9, P1727; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; Sadeghi HM, 1997, J RECEPT SIGNAL TR R, V17, P433, DOI 10.3109/10799899709036619; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; SIMONIN F, 1994, MOL PHARMACOL, V46, P1015; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; Valiquette M, 1996, J BIOL CHEM, V271, P18789, DOI 10.1074/jbc.271.31.18789; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; VON ZM, 1993, J BIOL CHEM, V268, P763; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; WARD CL, 1994, J BIOL CHEM, V269, P25710; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	72	252	256	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13727	13736		10.1074/jbc.275.18.13727	http://dx.doi.org/10.1074/jbc.275.18.13727			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788493	Green Published, hybrid			2022-12-27	WOS:000086925300080
J	Prieto-Alamo, MJ; Jurado, J; Gallardo-Madueno, R; Monje-Casas, F; Holmgren, A; Pueyo, C				Prieto-Alamo, MJ; Jurado, J; Gallardo-Madueno, R; Monje-Casas, F; Holmgren, A; Pueyo, C			Transcriptional regulation of glutaredoxin and thioredoxin pathways and related enzymes in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CYTOPLASM; DISULFIDE BOND FORMATION; IN-VIVO TRANSCRIPTION; RIBONUCLEOTIDE REDUCTASE; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; 2FE-2S CENTERS; OXYR; SOXR; PROTEIN	We examined the in vivo expression of up to 16 genes encoding for components of both glutaredoxin and thioredoxin systems and for members of the OxyR and SoxRS regulons, We demonstrated that grxA (Grx1) transcription is triggered in bacteria lacking Trx1 (trxA) and GSH (gshA) in an OxyR-dependent manner. We also indicated that, unlike OxyR, SoxR is not constitutively activated in the oxidizing environment of trxA gshA mutants. We discovered that the lack of Trx1 plus GSH increases the steady-state levels of Trx reductase (trxB) and Trx2 (trxC) transcripts. This increase and the trxB and trxC up-regulation caused by the constitutive oxyR2 allele indicate that OxyR also plays a role in the regulation of the thioredoxin pathway. On the contrary, no change in the expression of genes for Trx1, Grx2, and Grx3 was observed, Transcription of nrdAB (RRase) was not induced by oxidative stress yet was induced by hydroxyurea (RRase inhibitor). Induction level was as the enhanced nrdAB basal expression of trxA grxA mutants, indicating that RRase operation without Trx1 and Grx1 must lead to disturbances sensed as those caused by hydroxyurea, We also demonstrated an inverse relation between nrdAB expression and that of genes coding for components of both glutaredoxin (grxA, gorA) and thioredoxin (trxB, trxC) systems.	Univ Cordoba, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain; Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Universidad de Cordoba; Karolinska Institutet	Pueyo, C (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Avda Medina Azahara S-N, E-14071 Cordoba, Spain.		Carpio, Juan Jurado/K-7808-2014; Prieto-Alamo, Maria Jose/K-6141-2014; Monje-Casas, Fernando/M-3062-2014; Pueyo, Carmen/B-4509-2016	Carpio, Juan Jurado/0000-0003-1701-8496; Prieto-Alamo, Maria Jose/0000-0002-8164-032X; Monje-Casas, Fernando/0000-0002-3587-2373; Pueyo, Carmen/0000-0002-2624-2011				ABRIL N, 1992, ENVIRON MOL MUTAGEN, V19, P288, DOI 10.1002/em.2850190405; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; Bradley TM, 1997, NUCLEIC ACIDS RES, V25, P1469, DOI 10.1093/nar/25.8.1469; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; COUSINOU M, 2000, IN PRESS SCI TOTAL E; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Ding HG, 1998, BIOCHEMISTRY-US, V37, P17280, DOI 10.1021/bi980532g; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; Gallardo-Madueno R, 1998, J BIOL CHEM, V273, P18382, DOI 10.1074/jbc.273.29.18382; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; Kobayashi K, 1999, FEBS LETT, V451, P227, DOI 10.1016/S0014-5793(99)00565-7; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; Lee HS, 1998, FREE RADICAL BIO MED, V24, P1193, DOI 10.1016/S0891-5849(97)00427-9; Liochev SI, 1999, J BIOL CHEM, V274, P9479, DOI 10.1074/jbc.274.14.9479; Mannervik B., 1983, FUNCTIONS GLUTATHION, P385; Michan C, 1999, J BACTERIOL, V181, P2759; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULDER GJ, 1988, GLUTATHIONE CONJUGAT, P357; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; PROVENCE DL, 1994, METHODS GEN MOL BACT, P343; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; SINHA NK, 1972, J BACTERIOL, V112, P1321, DOI 10.1128/JB.112.3.1321-1334.1972; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 1999, J BACTERIOL, V181, P4639, DOI 10.1128/JB.181.15.4639-4643.1999	45	107	114	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13398	13405		10.1074/jbc.275.18.13398	http://dx.doi.org/10.1074/jbc.275.18.13398			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10788450	hybrid			2022-12-27	WOS:000086925300036
J	Eshel, R; Zanin, A; Sagi-Assif, O; Meshel, T; Smorodinsky, NI; Dwir, O; Alon, R; Brakenhoff, R; van Dongen, G; Witz, IP				Eshel, R; Zanin, A; Sagi-Assif, O; Meshel, T; Smorodinsky, NI; Dwir, O; Alon, R; Brakenhoff, R; van Dongen, G; Witz, IP			The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; SURFACE; PROTEIN; CANCER; FAMILY; FUCOSE; BIOSYNTHESIS	By differential display we demonstrated that antibody-mediated ligation of the GPI-linked protein product of E48, a newly discovered human Ly-6 gene, upregulates the expression of the FX enzyme in 3 lines of head and neck squamous carcinoma cells. FX is responsible for the last step in the synthesis of GDP-L-fucose, The up-regulation of FX was E48 ligand-specific. 22AWT head and neck squamous carcinoma cells expressing high levels of E48 expressed significantly higher levels of FX than the E48 antisense transfected 22AWT cells (8-3 cells). The former cells also expressed higher levels of two major fucosylated glycans (the selectin ligand, Sialyl Lewis a, and VIM-2) than the E48 antisense transfectants, Conversely, transfection of cells from the 14CWT line expressing very low levels of E48 with E48 cDNA caused an up-regulated expression of FX and of the two fucosylated glycans in the 14C-CMV16 transfectants, Moreover, the expression levels of Sialyl Lewis a was significantly up-regulated on HNSCC upon ligation of E48 by anti-E48 antibodies. The functional significance of the E48-mediated up-regulation of Sialyl Lewis a was demonstrated in rolling experiments on E-selectin bearing surfaces under physiological conditions of shear flow and on tumor necrosis factor cu activated human umbilical venous endothelial cells. Only high E48/ FX/Sialyl Lewis a expressing 14C-CMV16 cells could roll on purified E-selectin or establish E-selectin dependent rolling on the activated human umbilical venous endothelial cells. Low E48/FX/Sialyl Lewis a expressing 14CWT cells did not roll. These results show that E48 controls the expression of the FX enzyme and of certain fucosylated E-selectin ligands by HNSCC, E48 may thus function as a key regulator of the adhesiveness of these tumor cells to inflamed vessel walls expressing E-selectin.	Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Res Canc Dev & Prevent, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Alec & Myra Marmot Hybridoma Unit, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, IL-76100 Rehovot, Israel; Free Univ Amsterdam Hosp, Dept Otolaryngol Head & Neck Surg, NL-1007 MB Amsterdam, Netherlands	Tel Aviv University; Tel Aviv University; Tel Aviv University; Weizmann Institute of Science; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Witz, IP (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.		ALON, RONEN/GRX-6987-2022; Brakenhoff, Ruud/D-3960-2009	Alon, Ronen/0000-0001-9161-6369				BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; Brakenhoff RH, 1997, J IMMUNOL, V159, P4879; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DEBREE R, 1995, CLIN CANCER RES, V1, P277; DEFLORA A, 1977, BIOCHIM BIOPHYS ACTA, V500, P109, DOI 10.1016/0304-4165(77)90051-4; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Etzioni A, 1993, Immunodeficiency, V4, P307; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; GERRETSEN M, 1994, CELL BIOPHYS, V24-5, P135, DOI 10.1007/BF02789224; GUMLEY TP, 1995, IMMUNOL CELL BIOL, V73, P277, DOI 10.1038/icb.1995.45; HANSEN HJ, 1993, CANCER, V71, P3478, DOI 10.1002/1097-0142(19930601)71:11<3478::AID-CNCR2820711104>3.0.CO;2-A; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; Kimura Y, 1997, GENOMICS, V41, P477, DOI 10.1006/geno.1997.4680; Kniep B, 1996, J BIOCHEM-TOKYO, V119, P456; KONG RKM, 1993, ARCH BIOCHEM BIOPHYS, V300, P677, DOI 10.1006/abbi.1993.1094; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITEPLO RG, 1984, INT J CANCER, V33, P669, DOI 10.1002/ijc.2910330518; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mao M, 1996, P NATL ACAD SCI USA, V93, P5910, DOI 10.1073/pnas.93.12.5910; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; QUAK JJ, 1990, AM J PATHOL, V136, P191; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; Sambrook J., 2002, MOL CLONING LAB MANU; SHEVACH EM, 1989, IMMUNOL TODAY, V10, P195, DOI 10.1016/0167-5699(89)90324-1; SHIRAHAMA T, 1993, CANCER, V72, P1329, DOI 10.1002/1097-0142(19930815)72:4<1329::AID-CNCR2820720430>3.0.CO;2-6; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Sugita Y, 1995, IMMUNOTECHNOLOGY, V1, P157, DOI 10.1016/1380-2933(95)00018-6; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; SUN J, 1995, P NALT ACAD SCI US, V92, P7524; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YAFFE EA, 1973, J CLIN INVEST, V52, P2745	39	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12833	12840		10.1074/jbc.275.17.12833	http://dx.doi.org/10.1074/jbc.275.17.12833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777581	hybrid			2022-12-27	WOS:000086762300065
J	Mochizuki, N; Ohba, Y; Kobayashi, S; Otsuka, N; Graybiel, AM; Tanaka, S; Matsuda, M				Mochizuki, N; Ohba, Y; Kobayashi, S; Otsuka, N; Graybiel, AM; Tanaka, S; Matsuda, M			Crk activation of JNK via C3G and R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; EXCHANGE PROTEIN C3G; N-TERMINAL KINASE; SIGNALING PATHWAY; PHOSPHOINOSITIDE 3-KINASE; INTEGRIN ACTIVATION; BINDING PROTEINS; EPITHELIAL-CELLS; RAP1; EXPRESSION	v-crk is an oncogene identified originally in CT10 chicken tumor virus. C3G, a guanine nucleotide exchange factor (GEF) for Rap1 and R-Ras, is postulated to transduce the oncogenic signal of v-Crk to c-Jun kinase (JNK). We have found that R-Ras, but not Rap1, mediates JNK activation by v-Crk in 293T and NIH 3T3 cells. Constitutively activated R-Ras, R-Ras(Val-38), but not Rap1(Val-12) activated JNK, as did the constitutively active H-Ras(Val-12) or Bac1(Val-12). v-Crk activation of JNK was inhibited by a dominant-negative mutant of R-Ras, R-Ras(Asn-43). JNK activation by R-Ras(Val-38) was inhibited by a dominant-negative mutant of mixed lineage kinase 3. Among six GEFs for Res-family G proteins, mSos1, Ras-GRF, C3G, CalDAG-GEFI, Ras-GRP/CalDAG-GEFII, and Epac/cAMP-GEFI, GEFs for either H-Ras or R-Ras activated JNK and c-Jun-dependent transcription. CalDAG-GEFI and Epac/cAMP-GEFI, both of which are GEFs specific for Rap1, did not activate JNK or c-Jun-dependent transcription. These results demonstrate that R-Ras, but not Rap1, is the downstream effector of C3G to stimulate JNK, Finally, we found that expression of the dominant-negative R-Ras mutant induced flat reversion of NIH 3T3 cells transformed by v-Crk, suggesting that R-Ras-dependent JNK activation is critical for the transformation by v-Crk.	Int Med Ctr japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; Massachusetts Institute of Technology (MIT); Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr japan, Res Inst, Dept Pathol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.		Ohba, Yusuke/E-7944-2011; Tanaka, Shinya/D-3586-2011	Graybiel, Ann/0000-0002-4326-7720; Matsuda, Michiyuki/0000-0002-5876-9969				Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COX AD, 1994, ONCOGENE, V9, P3281; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Ling P, 1999, MOL CELL BIOL, V19, P1359; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; REY I, 1994, ONCOGENE, V9, P685; SAEZ R, 1994, ONCOGENE, V9, P2977; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	45	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12667	12671		10.1074/jbc.275.17.12667	http://dx.doi.org/10.1074/jbc.275.17.12667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777559	hybrid			2022-12-27	WOS:000086762300043
J	Rajendran, VM; Sangan, P; Geibel, J; Binder, HJ				Rajendran, VM; Sangan, P; Geibel, J; Binder, HJ			Ouabain-sensitive H,K-ATPase functions as Na,H-ATPase in apical membranes of rat distal colon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; PROXIMAL COLON; POTASSIUM-DEPLETION; ALPHA-SUBUNIT; ION-TRANSPORT; K+-ATPASE; SODIUM; H+,K+-ATPASE; EXPRESSION; ALDOSTERONE	Na,K-ATPase activity has been identified in the apical membrane of rat distal colon, whereas ouabain-sensitive and ouabain-insensitive H,K-ATPase activities are localized solely to apical membranes. This study was designed to determine whether apical membrane Na,K-ATPase represented contamination of basolateral membranes or an alternate mode of H,K-ATPase expression. An antibody directed against the H,K-ATPase alpha subunit (HKc alpha) inhibited apical Na,K-ATPase activity by 92% but did not alter basolateral membrane Na,K- ATPase activity. Two distinct H,K-ATPase isoforms exist; one of which, the ouabain-insensitive HKc alpha, has been cloned. Because dietary sodium depletion markedly increases ouabain-insensitive active potassium absorption and HKc alpha mRNA and protein expression, Na,K-ATPase and H,K-ATPase activities and protein expression were determined in apical membranes from control and sodium-depleted rats. Sodium depletion substantially increased ouabain-insensitive H,K-ATPase activity and HKc alpha protein expression by 109-250% but increased ouabain-sensitive Na,K-ATPase and H,K-ATPase activities by only 30% and 42%, respectively. These studies suggest that apical membrane Na,K-ATPase activity is an alternate mode of ouabain-sensitive H,K-ATPase and does not solely represent basolateral membrane contamination.	Yale Univ, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Dept Surg, New Haven, CT 06520 USA	Yale University; Yale University	Binder, HJ (corresponding author), Yale Univ, Dept Internal Med, POB 208019, New Haven, CT 06520 USA.	henry.binder@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018777] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18777-19, R01 DK018777] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIBER J, 1983, BIOCHIM BIOPHYS ACTA, V735, P1, DOI 10.1016/0005-2736(83)90255-9; Binder HJ, 1999, SEMIN NEPHROL, V19, P405; BROSIUS FC, 1995, AM J PHYSIOL-RENAL, V269, pF461, DOI 10.1152/ajprenal.1995.269.4.F461; Codina J, 1999, J BIOL CHEM, V274, P19693, DOI 10.1074/jbc.274.28.19693; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FOSTER ES, 1986, J CLIN INVEST, V77, P228, DOI 10.1172/JCI112281; HALEVY J, 1986, GASTROENTEROLOGY, V91, P1227, DOI 10.1016/S0016-5085(86)80021-X; HAYASHI M, 1987, AM J PHYSIOL, V252, pF447, DOI 10.1152/ajprenal.1987.252.3.F447; HAYASHI M, 1987, AM J PHYSIOL, V252, pF437, DOI 10.1152/ajprenal.1987.252.3.F437; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; JAISSER F, 1993, AM J PHYSIOL, V265, pC1080, DOI 10.1152/ajpcell.1993.265.4.C1080; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; KINNE R, 1978, BIOCH NEPHROLOGY, P178; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; PANDIYAN V, 1992, GASTROENTEROLOGY, V102, P1846, DOI 10.1016/0016-5085(92)90304-H; Rajendran VM, 1998, AM J PHYSIOL-GASTR L, V274, pG424, DOI 10.1152/ajpgi.1998.274.2.G424; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; Rajendran VM, 1998, GASTROENTEROLOGY, V114, pA408, DOI 10.1016/S0016-5085(98)81652-1; Rajendran VM, 1999, GASTROENTEROLOGY, V116, pA921; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; Sangan P, 2000, AM J PHYSIOL-CELL PH, V278, pC182, DOI 10.1152/ajpcell.2000.278.1.C182; Sangan P, 1999, AM J PHYSIOL-CELL PH, V276, pC350, DOI 10.1152/ajpcell.1999.276.2.C350; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SHULL GE, 1986, J BIOL CHEM, V261, P6788; STIEGER B, 1986, J MEMBRANE BIOL, V91, P19, DOI 10.1007/BF01870211; SWEIRY JH, 1989, J CLIN INVEST, V83, P844, DOI 10.1172/JCI113967; TURNAMIAN SG, 1989, J CLIN INVEST, V84, P1924, DOI 10.1172/JCI114380; TURNAMIAN SG, 1990, AM J PHYSIOL, V258, pG492, DOI 10.1152/ajpgi.1990.258.3.G492; VANWHY SK, 1992, AM J PHYSIOL, V263, pF75	37	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					13035	13040		10.1074/jbc.275.17.13035	http://dx.doi.org/10.1074/jbc.275.17.13035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777607	hybrid			2022-12-27	WOS:000086762300091
J	Tebo, JM; Datta, S; Kishore, R; Kolosov, M; Major, JA; Ohmori, Y; Hamilton, TA				Tebo, JM; Datta, S; Kishore, R; Kolosov, M; Major, JA; Ohmori, Y; Hamilton, TA			Interleukin-1-mediated stabilization of mouse KC mRNA depends on sequences in both 5 '- and 3 '-untranslated regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA DEGRADATION; NF-KAPPA-B; AU-RICH ELEMENT; SIGNAL-TRANSDUCTION PATHWAYS; CELL-DERIVED LYMPHOKINES; GENE-EXPRESSION; FACTOR-ALPHA; BINDING PROTEIN; FACTOR RECEPTOR	mRNA transcribed from the mouse KC chemokine gene accumulated to significantly higher levels in multiple cell types after treatment with interleukin 1 alpha (IL-1 alpha) as compared with tumor necrosis factor-alpha (TNF alpha). Although TNF alpha and IL-1 alpha both signaled the activation of nuclear factor kappa B and enhanced transcription of the KC gene with equal potency, only IL-1 alpha treatment resulted in stabilization of KC mnNA. Nucleotide sequences that confer sensitivity for IL-1 alpha-mediated mRNA stabilization were identified within the 5'- and 3'-untranslated regions (UTRs) of KC mRNA using transient transfection of chimeric plasmids containing specific portions of KC mRNA linked to the chloramphenicol acetyltransferase (CAT) gene. When plasmids containing either the 3'- or 5'-UTR of KC mRNA were used, the half-life of CAT mRNA was unaltered either in untreated or IL-1 alpha-stimulated cells. In contrast, CAT mRNA transcribed from plasmids that contained both the 5'- and 3'-UTRs of the KC mRNA decayed more rapidly than control CAT mRNA, and this enhanced decay was prevented in cells treated with IL-1 alpha. A cluster of four overlapping AUUUA motifs within the 3'-UTR was required, whereas the 5'-UTR region exhibited orientation dependence. These findings indicate that cooperative function of the two nucleotide sequences involves a distinct signaling pathway used by IL-1 alpha but not TNF alpha.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, TA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hameltt@ccf.org		Ohmori, Yoshihiro/0000-0002-6069-357X; Hamilton, Thomas/0000-0002-9817-242X	NCI NIH HHS [CA39621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams DO., 1992, INFLAMMATION BASIC P, P637; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEUTLER B, 1995, J INVEST MED, V43, P227; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; HALL DJ, 1989, J CELL PHYSIOL, V141, P154, DOI 10.1002/jcp.1041410123; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; INTRONA M, 1987, J IMMUNOL, V138, P3891; Jobin C, 1999, J IMMUNOL, V162, P4447; KASAMA T, 1994, J IMMUNOL, V152, P3559; Kim HS, 1998, J LEUKOCYTE BIOL, V64, P33, DOI 10.1002/jlb.64.1.33; Kishore R, 1999, J IMMUNOL, V162, P2457; LE JM, 1987, LAB INVEST, V56, P234; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NATHAN CF, 1995, TXB RHEUMATOLOGY, P144; NG SB, 1994, J BIOL CHEM, V269, P19021; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OHMORI Y, 1995, J IMMUNOL, V155, P3593; OHMORI Y, 1994, J IMMUNOL, V153, P2204; OHMORI Y, 1993, AM J PATHOL, V142, P861; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1994, PHARMACOL THERAPEUT, V63, P235, DOI 10.1016/0163-7258(94)90026-4; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN XY, 1989, J CELL PHYSIOL, V140, P44, DOI 10.1002/jcp.1041400106; SHEN XY, 1990, BIOCHEM BIOPH RES CO, V2, P145; Sherry B, 1992, Cytokines, V4, P117; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; Tebo JM, 1998, BLOOD, V92, P4742, DOI 10.1182/blood.V92.12.4742.424k26_4742_4749; VILCEK J, 1991, J BIOL CHEM, V266, P7313; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YANG L, 1994, J BIOL CHEM, V269, P32732; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	67	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2000	275	17					12987	12993		10.1074/jbc.275.17.12987	http://dx.doi.org/10.1074/jbc.275.17.12987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309HK	10777600	hybrid			2022-12-27	WOS:000086762300084
